Selegiline	0	B-Chemical
-	7	O
induced	3	O
postural	5	B-Disease
hypotension	5	I-Disease
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
:	9	O
a	5	O
longitudinal	5	O
study	9	O
on	5	O
the	5	O
effects	9	O
of	5	O
drug	5	O
withdrawal	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
The	5	O
United	9	O
Kingdom	2	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
Disease	2	I-Disease
Research	2	O
Group	9	O
(	9	O
UKPDRG	_	O
)	9	O
trial	5	O
found	9	O
an	5	O
increased	9	O
mortality	5	O
in	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
randomized	5	O
to	5	O
receive	5	O
10	9	O
mg	0	O
selegiline	0	B-Chemical
per	9	O
day	9	O
and	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
compared	9	O
with	5	O
those	5	O
taking	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
alone	9	O
.	9	O

Recently	9	O
,	9	O
we	5	O
found	9	O
that	5	O
therapy	5	O
with	5	O
selegiline	0	B-Chemical
and	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
was	9	O
associated	9	O
with	5	O
selective	9	O
systolic	5	B-Disease
orthostatic	5	I-Disease
hypotension	5	I-Disease
which	5	O
was	9	O
abolished	3	O
by	9	O
withdrawal	5	O
of	5	O
selegiline	0	B-Chemical
.	9	O

This	5	O
unwanted	5	O
effect	9	O
on	5	O
postural	5	O
blood	9	O
pressure	5	O
was	9	O
not	5	O
the	5	O
result	9	O
of	5	O
underlying	5	O
autonomic	5	O
failure	5	O
.	9	O

The	5	O
aims	5	O
of	5	O
this	5	O
study	9	O
were	9	O
to	5	O
confirm	9	O
our	5	O
previous	9	O
findings	9	O
in	5	O
a	5	O
separate	9	O
cohort	9	O
of	5	O
patients	5	O
and	5	O
to	5	O
determine	9	O
the	5	O
time	5	O
course	5	O
of	5	O
the	5	O
cardiovascular	5	O
consequences	5	O
of	5	O
stopping	5	O
selegiline	0	B-Chemical
in	5	O
the	5	O
expectation	5	O
that	5	O
this	5	O
might	9	O
shed	9	O
light	9	O
on	5	O
the	5	O
mechanisms	9	O
by	9	O
which	5	O
the	5	O
drug	5	O
causes	9	O
orthostatic	5	B-Disease
hypotension	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
The	5	O
cardiovascular	5	O
responses	5	O
to	5	O
standing	5	O
and	5	O
head	5	O
-	7	O
up	5	O
tilt	5	O
were	9	O
studied	9	O
repeatedly	5	O
in	5	O
PD	9	B-Disease
patients	5	O
receiving	9	O
selegiline	0	B-Chemical
and	5	O
as	5	O
the	5	O
drug	5	O
was	9	O
withdrawn	9	O
.	9	O

RESULTS	9	O
:	9	O
Head	2	O
-	7	O
up	5	O
tilt	5	O
caused	9	O
systolic	5	B-Disease
orthostatic	5	I-Disease
hypotension	5	I-Disease
which	5	O
was	9	O
marked	9	O
in	5	O
six	9	O
of	5	O
20	9	O
PD	9	B-Disease
patients	5	O
on	5	O
selegiline	0	B-Chemical
,	9	O
one	5	O
of	5	O
whom	5	O
lost	9	O
consciousness	5	O
with	5	O
unrecordable	5	O
blood	9	O
pressures	5	O
.	9	O

A	9	O
lesser	9	O
degree	5	O
of	5	O
orthostatic	5	B-Disease
hypotension	5	I-Disease
occurred	9	O
with	5	O
standing	5	O
.	9	O

Orthostatic	5	B-Disease
hypotension	5	I-Disease
was	9	O
ameliorated	9	O
4	9	O
days	9	O
after	9	O
withdrawal	5	O
of	5	O
selegiline	0	B-Chemical
and	5	O
totally	9	O
abolished	3	O
7	9	O
days	9	O
after	9	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
.	9	O

Stopping	5	O
selegiline	0	B-Chemical
also	9	O
significantly	9	O
reduced	9	B-Disease
the	5	I-Disease
supine	5	I-Disease
systolic	5	I-Disease
and	5	I-Disease
diastolic	5	I-Disease
blood	9	I-Disease
pressures	5	I-Disease
consistent	9	O
with	5	O
a	5	O
previously	9	O
undescribed	4	O
supine	5	O
pressor	5	O
action	5	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
study	9	O
confirms	9	O
our	5	O
previous	9	O
finding	9	O
that	5	O
selegiline	0	B-Chemical
in	5	O
combination	9	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
is	5	O
associated	9	O
with	5	O
selective	9	O
orthostatic	5	B-Disease
hypotension	5	I-Disease
.	9	O

The	5	O
possibilities	5	O
that	5	O
these	5	O
cardiovascular	5	O
findings	9	O
might	9	O
be	5	O
the	5	O
result	9	O
of	5	O
non	9	O
-	7	O
selective	9	O
inhibition	3	O
of	5	O
monoamine	0	O
oxidase	0	O
or	5	O
of	5	O
amphetamine	5	B-Chemical
and	5	O
metamphetamine	5	B-Chemical
are	5	O
discussed	5	O
.	9	O

Further	9	O
studies	9	O
on	5	O
effects	9	O
of	5	O
irrigation	5	O
solutions	0	O
on	5	O
rat	3	O
bladders	9	O
.	9	O

Further	9	O
studies	9	O
on	5	O
the	5	O
effects	9	O
of	5	O
certain	5	O
irrigating	5	O
fluids	5	O
on	5	O
the	5	O
rat	3	O
bladder	9	O
for	5	O
18	7	O
hours	9	O
are	5	O
reported	9	O
.	9	O

The	5	O
results	9	O
have	5	O
shown	9	O
that	5	O
the	5	O
degradation	9	O
product	9	O
p	7	B-Chemical
-	7	I-Chemical
choloroaniline	_	I-Chemical
is	5	O
not	5	O
a	5	O
significant	9	O
factor	9	O
in	5	O
chlorhexidine	0	B-Chemical
-	7	I-Chemical
digluconate	0	I-Chemical
associated	9	O
erosive	5	O
cystitis	9	B-Disease
.	9	O

A	9	O
high	9	O
percentage	9	O
of	5	O
kanamycin	1	B-Chemical
-	7	O
colistin	0	B-Chemical
and	5	O
povidone	0	B-Chemical
-	7	I-Chemical
iodine	0	I-Chemical
irrigations	5	O
were	9	O
associated	9	O
with	5	O
erosive	5	O
cystitis	9	B-Disease
and	5	O
suggested	9	O
a	5	O
possible	5	O
complication	5	O
with	5	O
human	3	O
usage	9	O
.	9	O

Picloxydine	_	B-Chemical
irrigations	5	O
appeared	9	O
to	5	O
have	5	O
a	5	O
lower	9	O
incidence	5	O
of	5	O
erosive	5	O
cystitis	9	B-Disease
but	9	O
further	9	O
studies	9	O
would	5	O
have	5	O
to	5	O
be	5	O
performed	9	O
before	9	O
it	5	O
could	9	O
be	5	O
recommended	5	O
for	5	O
use	5	O
in	5	O
urological	5	O
procedures	5	O
.	9	O

Effects	9	O
of	5	O
tetrandrine	0	B-Chemical
and	5	O
fangchinoline	3	B-Chemical
on	5	O
experimental	5	O
thrombosis	5	B-Disease
in	5	O
mice	3	O
and	5	O
human	3	O
platelet	9	B-Disease
aggregation	9	I-Disease
.	9	O

Tetrandrine	0	B-Chemical
(	9	O
TET	9	B-Chemical
)	9	O
and	5	O
fangchinoline	3	B-Chemical
(	9	O
FAN	2	B-Chemical
)	9	O
are	5	O
two	5	O
naturally	9	O
occurring	9	O
analogues	0	O
with	5	O
a	5	O
bisbenzylisoquinoline	0	B-Chemical
structure	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
investigate	9	O
the	5	O
effects	9	O
of	5	O
TET	9	B-Chemical
and	5	O
FAN	2	B-Chemical
on	5	O
the	5	O
experimental	5	O
thrombosis	5	B-Disease
induced	3	O
by	9	O
collagen	3	O
plus	9	O
epinephrine	0	B-Chemical
(	9	O
EP	9	B-Chemical
)	9	O
in	5	O
mice	3	O
,	9	O
and	5	O
platelet	9	B-Disease
aggregation	9	I-Disease
and	5	O
blood	9	B-Disease
coagulation	5	I-Disease
in	5	O
vitro	3	O
.	9	O

In	9	O
the	5	O
in	5	O
vivo	3	O
study	9	O
,	9	O
the	5	O
administration	9	O
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
of	5	O
TET	9	B-Chemical
and	5	O
FAN	2	B-Chemical
in	5	O
mice	3	O
showed	9	O
the	5	O
inhibition	3	O
of	5	O
thrombosis	5	B-Disease
by	9	O
55	7	O
%	9	O
and	5	O
35	9	O
%	9	O
,	9	O
respectively	9	O
,	9	O
while	9	O
acetylsalicylic	0	B-Chemical
acid	0	I-Chemical
(	9	O
ASA	9	B-Chemical
,	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
,	9	O
a	5	O
positive	9	O
control	9	O
,	9	O
showed	9	O
only	9	O
30	9	O
%	9	O
inhibition	3	O
.	9	O

In	9	O
the	5	O
vitro	3	O
human	3	O
platelet	9	B-Disease
aggregations	9	I-Disease
induced	3	O
by	9	O
the	5	O
agonists	3	O
used	5	O
in	5	O
tests	5	O
,	9	O
TET	9	B-Chemical
and	5	O
FAN	2	B-Chemical
showed	9	O
the	5	O
inhibitions	9	O
dose	9	O
dependently	3	O
.	9	O

In	9	O
addition	9	O
,	9	O
neither	9	O
TET	9	B-Chemical
nor	9	O
FAN	2	B-Chemical
showed	9	O
any	5	O
anticoagulation	5	O
activities	9	O
in	5	O
the	5	O
measurement	5	O
of	5	O
the	5	O
activated	3	O
partial	9	O
thromboplastin	5	O
time	5	O
(	9	O
APTT	5	O
)	9	O
,	9	O
prothrombin	9	O
time	5	O
(	9	O
PT	9	O
)	9	O
and	5	O
thrombin	0	O
time	5	O
(	9	O
TT	7	O
)	9	O
using	9	O
human	3	O
-	7	O
citrated	0	O
plasma	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
antithrombosis	5	O
of	5	O
TET	9	B-Chemical
and	5	O
FAN	2	B-Chemical
in	5	O
mice	3	O
may	5	O
be	5	O
mainly	9	O
related	9	O
to	5	O
the	5	O
antiplatelet	5	O
aggregation	9	O
activities	9	O
.	9	O

Angioedema	5	B-Disease
due	5	O
to	5	O
ACE	9	B-Chemical
inhibitors	3	I-Chemical
:	9	O
common	5	O
and	5	O
inadequately	5	O
diagnosed	5	O
.	9	O

The	5	O
estimated	5	O
incidence	5	O
of	5	O
angioedema	5	B-Disease
during	5	O
angiotensin	9	B-Chemical
-	7	I-Chemical
converting	9	I-Chemical
enzyme	0	I-Chemical
(	9	I-Chemical
ACE	9	I-Chemical
)	9	I-Chemical
inhibitor	3	I-Chemical
treatment	9	O
is	5	O
between	5	O
1	9	O
and	5	O
7	9	O
per	9	O
thousand	5	O
patients	5	O
.	9	O

This	5	O
potentially	5	O
serious	5	O
adverse	5	O
effect	9	O
is	5	O
often	5	O
preceded	9	O
by	9	O
minor	9	O
manifestations	5	O
that	5	O
may	5	O
serve	5	O
as	5	O
a	5	O
warning	5	O
.	9	O

Cocaine	5	B-Chemical
-	7	O
induced	3	O
mood	5	B-Disease
disorder	5	I-Disease
:	9	O
prevalence	5	O
rates	5	O
and	5	O
psychiatric	5	B-Disease
symptoms	5	O
in	5	O
an	5	O
outpatient	5	O
cocaine	5	B-Chemical
-	7	O
dependent	9	O
sample	9	O
.	9	O

This	5	O
paper	5	O
attempts	5	O
to	5	O
examine	9	O
and	5	O
compare	9	O
prevalence	5	O
rates	5	O
and	5	O
symptom	5	O
patterns	5	O
of	5	O
DSM	4	O
substance	5	O
-	7	O
induced	3	O
and	5	O
other	5	O
mood	5	B-Disease
disorders	5	I-Disease
.	9	O

243	7	O
cocaine	5	B-Chemical
-	7	O
dependent	9	O
outpatients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
mood	5	B-Disease
disorder	5	I-Disease
(	9	O
CIMD	3	B-Disease
)	9	O
,	9	O
other	5	O
mood	5	B-Disease
disorders	5	I-Disease
,	9	O
or	5	O
no	9	O
mood	5	B-Disease
disorder	5	I-Disease
were	9	O
compared	9	O
on	5	O
measures	5	O
of	5	O
psychiatric	5	B-Disease
symptoms	5	O
.	9	O

The	5	O
prevalence	5	O
rate	9	O
for	5	O
CIMD	3	B-Disease
was	9	O
12	9	O
%	9	O
at	9	O
baseline	5	O
.	9	O

Introduction	5	O
of	5	O
the	5	O
DSM	4	O
-	7	O
IV	9	O
diagnosis	5	O
of	5	O
CIMD	3	B-Disease
did	9	O
not	5	O
substantially	9	O
affect	9	O
rates	5	O
of	5	O
the	5	O
other	5	O
depressive	5	B-Disease
disorders	5	I-Disease
.	9	O

Patients	5	O
with	5	O
CIMD	3	B-Disease
had	9	O
symptom	5	O
severity	5	O
levels	3	O
between	5	O
those	5	O
of	5	O
patients	5	O
with	5	O
and	5	O
without	9	O
a	5	O
mood	5	B-Disease
disorder	5	I-Disease
.	9	O

These	5	O
findings	9	O
suggest	9	O
some	5	O
validity	5	O
for	5	O
the	5	O
new	5	O
DSM	4	O
-	7	O
IV	9	O
diagnosis	5	O
of	5	O
CIMD	3	B-Disease
,	9	O
but	9	O
also	9	O
suggest	9	O
that	5	O
it	5	O
requires	5	O
further	9	O
specification	5	O
and	5	O
replication	9	O
.	9	O

Effect	0	O
of	5	O
fucoidan	0	B-Chemical
treatment	9	O
on	5	O
collagenase	0	O
-	7	O
induced	3	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
in	5	O
rats	9	O
.	9	O

Inflammatory	9	O
cells	3	O
are	5	O
postulated	9	O
to	5	O
mediate	3	O
some	5	O
of	5	O
the	5	O
brain	5	B-Disease
damage	9	I-Disease
following	9	O
ischemic	9	B-Disease
stroke	5	I-Disease
.	9	O

Intracerebral	5	B-Disease
hemorrhage	5	I-Disease
is	5	O
associated	9	O
with	5	O
more	5	O
inflammation	9	B-Disease
than	5	O
ischemic	9	B-Disease
stroke	5	I-Disease
.	9	O

We	9	O
tested	9	O
the	5	O
sulfated	0	O
polysaccharide	0	O
fucoidan	0	B-Chemical
,	9	O
which	5	O
has	9	O
been	9	O
reported	9	O
to	5	O
reduce	5	O
inflammatory	3	O
brain	5	B-Disease
damage	9	I-Disease
,	9	O
in	5	O
a	5	O
rat	3	O
model	5	O
of	5	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
induced	3	O
by	9	O
injection	9	O
of	5	O
bacterial	9	O
collagenase	0	O
into	9	O
the	5	O
caudate	5	O
nucleus	9	O
.	9	O

Rats	9	O
were	9	O
treated	3	O
with	5	O
seven	9	O
day	9	O
intravenous	0	O
infusion	0	O
of	5	O
fucoidan	0	B-Chemical
(	9	O
30	9	O
micrograms	0	O
h	0	O
-	7	O
1	9	O
)	9	O
or	5	O
vehicle	3	O
.	9	O

The	5	O
hematoma	5	B-Disease
was	9	O
assessed	9	O
in	5	O
vivo	3	O
by	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
.	9	O

Motor	5	O
behavior	5	O
,	9	O
passive	5	O
avoidance	5	O
,	9	O
and	5	O
skilled	5	O
forelimb	5	O
function	9	O
were	9	O
tested	9	O
repeatedly	5	O
for	5	O
six	9	O
weeks	9	O
.	9	O

Fucoidan	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
exhibited	9	O
evidence	9	O
of	5	O
impaired	9	B-Disease
blood	9	I-Disease
clotting	5	I-Disease
and	5	O
hemodilution	5	B-Disease
,	9	O
had	9	O
larger	5	O
hematomas	5	B-Disease
,	9	O
and	5	O
tended	5	O
to	5	O
have	5	O
less	5	O
inflammation	9	B-Disease
in	5	O
the	5	O
vicinity	9	O
of	5	O
the	5	O
hematoma	5	B-Disease
after	9	O
three	9	O
days	9	O
.	9	O

They	5	O
showed	9	O
significantly	9	O
more	5	O
rapid	5	O
improvement	5	O
of	5	O
motor	5	O
function	9	O
in	5	O
the	5	O
first	9	O
week	9	O
following	9	O
hemorrhage	5	B-Disease
and	5	O
better	5	O
memory	5	O
retention	9	O
in	5	O
the	5	O
passive	5	O
avoidance	5	O
test	5	O
.	9	O

Acute	5	O
white	9	B-Disease
matter	5	I-Disease
edema	5	I-Disease
and	5	O
eventual	5	O
neuronal	3	B-Disease
loss	9	I-Disease
in	5	O
the	5	O
striatum	9	O
adjacent	9	O
to	5	O
the	5	O
hematoma	5	B-Disease
did	9	O
not	5	O
differ	9	O
between	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

Investigation	9	O
of	5	O
more	5	O
specific	9	O
anti	3	O
-	7	O
inflammatory	3	O
agents	5	O
and	5	O
hemodiluting	9	O
agents	5	O
are	5	O
warranted	9	O
in	5	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
.	9	O

Recurarization	_	O
in	5	O
the	5	O
recovery	9	O
room	9	O
.	9	O

A	9	O
case	5	O
of	5	O
recurarization	5	O
in	5	O
the	5	O
recovery	9	O
room	9	O
is	5	O
reported	9	O
.	9	O

Accumulation	9	O
of	5	O
atracurium	0	B-Chemical
in	5	O
the	5	O
intravenous	0	O
line	9	O
led	9	O
to	5	O
recurarization	5	O
after	9	O
flushing	5	O
the	5	O
line	9	O
in	5	O
the	5	O
recovery	9	O
room	9	O
.	9	O

A	9	O
respiratory	5	B-Disease
arrest	3	I-Disease
with	5	O
severe	5	O
desaturation	5	B-Disease
and	5	O
bradycardia	5	B-Disease
occurred	9	O
.	9	O

Circumstances	5	O
leading	9	O
to	5	O
this	5	O
event	5	O
and	5	O
the	5	O
mechanisms	9	O
enabling	5	O
a	5	O
neuromuscular	5	B-Disease
blockade	3	I-Disease
to	5	O
occur	5	O
,	9	O
following	9	O
the	5	O
administration	9	O
of	5	O
a	5	O
small	9	O
dose	9	O
of	5	O
relaxant	0	O
,	9	O
are	5	O
discussed	5	O
.	9	O

The	5	O
haemodynamic	5	O
effects	9	O
of	5	O
propofol	0	B-Chemical
in	5	O
combination	9	O
with	5	O
ephedrine	0	B-Chemical
in	5	O
elderly	5	O
patients	5	O
(	9	O
ASA	9	O
groups	9	O
3	9	O
and	5	O
4	9	O
)	9	O
.	9	O

The	5	O
marked	9	O
vasodilator	0	O
and	5	O
negative	9	O
inotropic	5	O
effects	9	O
of	5	O
propofol	0	B-Chemical
are	5	O
disadvantages	5	O
in	5	O
frail	5	O
elderly	5	O
patients	5	O
.	9	O

We	9	O
investigated	9	O
the	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
adding	0	O
different	9	O
doses	0	O
of	5	O
ephedrine	0	B-Chemical
to	5	O
propofol	0	B-Chemical
in	5	O
order	5	O
to	5	O
obtund	5	O
the	5	O
hypotensive	5	B-Disease
response	9	O
.	9	O

The	5	O
haemodynamic	5	O
effects	9	O
of	5	O
adding	0	O
15	9	O
,	9	O
20	9	O
or	5	O
25	9	O
mg	0	O
of	5	O
ephedrine	0	B-Chemical
to	5	O
200	0	O
mg	0	O
of	5	O
propofol	0	B-Chemical
were	9	O
compared	9	O
to	5	O
control	9	O
in	5	O
40	9	O
ASA	9	O
3	9	O
/	9	O
4	9	O
patients	5	O
over	5	O
60	9	O
years	5	O
presenting	5	O
for	5	O
genito	5	O
-	7	O
urinary	9	O
surgery	5	O
.	9	O

The	5	O
addition	9	O
of	5	O
ephedrine	0	B-Chemical
to	5	O
propofol	0	B-Chemical
appears	9	O
to	5	O
be	5	O
an	5	O
effective	5	O
method	5	O
of	5	O
obtunding	5	O
the	5	O
hypotensive	5	B-Disease
response	9	O
to	5	O
propofol	0	B-Chemical
at	9	O
all	5	O
doses	0	O
used	5	O
in	5	O
this	5	O
study	9	O
.	9	O

However	9	O
,	9	O
marked	9	O
tachycardia	5	B-Disease
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
ephedrine	0	B-Chemical
in	5	O
combination	9	O
with	5	O
propofol	0	B-Chemical
occurred	9	O
in	5	O
the	5	O
majority	9	O
of	5	O
patients	5	O
,	9	O
occasionally	5	O
reaching	5	O
high	9	O
levels	3	O
in	5	O
individual	5	O
patients	5	O
.	9	O

Due	5	O
to	5	O
the	5	O
risk	5	O
of	5	O
this	5	O
tachycardia	5	B-Disease
inducing	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
,	9	O
we	5	O
would	5	O
not	5	O
recommend	5	O
the	5	O
use	5	O
in	5	O
elderly	5	O
patients	5	O
of	5	O
any	5	O
of	5	O
the	5	O
ephedrine	0	B-Chemical
/	9	O
propofol	0	B-Chemical
/	9	O
mixtures	0	O
studied	9	O
.	9	O

Gemcitabine	0	B-Chemical
plus	9	O
vinorelbine	0	B-Chemical
in	5	O
nonsmall	3	B-Disease
cell	3	I-Disease
lung	9	I-Disease
carcinoma	3	I-Disease
patients	5	O
age	5	O
70	9	O
years	5	O
or	5	O
older	5	O
or	5	O
patients	5	O
who	5	O
cannot	5	O
receive	5	O
cisplatin	3	B-Chemical
.	9	O

Oncopaz	_	O
Cooperative	2	O
Group	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Although	9	O
the	5	O
prevalence	5	O
of	5	O
nonsmall	3	B-Disease
cell	3	I-Disease
lung	9	I-Disease
carcinoma	3	I-Disease
(	9	O
NSCLC	3	B-Disease
)	9	O
is	5	O
high	9	O
among	5	O
elderly	5	O
patients	5	O
,	9	O
few	5	O
data	5	O
are	5	O
available	5	O
regarding	5	O
the	5	O
efficacy	9	O
and	5	O
toxicity	9	B-Disease
of	5	O
chemotherapy	5	O
in	5	O
this	5	O
group	9	O
of	5	O
patients	5	O
.	9	O

Recent	9	O
reports	9	O
indicate	9	O
that	5	O
single	9	O
agent	9	O
therapy	5	O
with	5	O
vinorelbine	0	B-Chemical
(	9	O
VNB	4	B-Chemical
)	9	O
or	5	O
gemcitabine	3	B-Chemical
(	9	O
GEM	9	B-Chemical
)	9	O
may	5	O
obtain	5	O
a	5	O
response	9	O
rate	9	O
of	5	O
20	9	O
-	7	O
30	9	O
%	9	O
in	5	O
elderly	5	O
patients	5	O
,	9	O
with	5	O
acceptable	5	O
toxicity	9	B-Disease
and	5	O
improvement	5	O
in	5	O
symptoms	5	O
and	5	O
quality	5	O
of	5	O
life	5	O
.	9	O

In	9	O
the	5	O
current	5	O
study	9	O
the	5	O
efficacy	9	O
and	5	O
toxicity	9	B-Disease
of	5	O
the	5	O
combination	9	O
of	5	O
GEM	9	B-Chemical
and	5	O
VNB	4	B-Chemical
in	5	O
elderly	5	O
patients	5	O
with	5	O
advanced	5	O
NSCLC	3	B-Disease
or	5	O
those	5	O
with	5	O
some	5	O
contraindication	5	O
to	5	O
receiving	9	O
cisplatin	3	B-Chemical
were	9	O
assessed	9	O
.	9	O

METHODS	2	O
:	9	O
Forty	9	O
-	7	O
nine	9	O
patients	5	O
with	5	O
advanced	5	O
NSCLC	3	B-Disease
were	9	O
included	5	O
,	9	O
38	7	O
of	5	O
whom	5	O
were	9	O
age	5	O
>	0	O
/	9	O
=	7	O
70	9	O
years	5	O
and	5	O
11	7	O
were	9	O
age	5	O
<	0	O
70	9	O
years	5	O
but	9	O
who	5	O
had	9	O
some	5	O
contraindication	5	O
to	5	O
receiving	9	O
cisplatin	3	B-Chemical
.	9	O

All	9	O
patients	5	O
were	9	O
evaluable	9	O
for	5	O
response	9	O
and	5	O
toxicity	9	B-Disease
.	9	O

Treatment	9	O
was	9	O
comprised	9	O
of	5	O
VNB	4	B-Chemical
,	9	O
25	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
,	9	O
plus	9	O
GEM	9	B-Chemical
,	9	O
1000	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
,	9	O
both	9	O
on	5	O
Days	9	O
1	9	O
,	9	O
8	9	O
,	9	O
and	5	O
15	9	O
every	5	O
28	7	O
days	9	O
.	9	O

Patients	5	O
received	9	O
a	5	O
minimum	5	O
of	5	O
three	9	O
courses	5	O
unless	9	O
progressive	5	O
disease	5	O
was	9	O
detected	9	O
.	9	O

RESULTS	9	O
:	9	O
One	5	O
hundred	5	O
sixty	5	O
-	7	O
five	9	O
courses	5	O
were	9	O
administered	9	O
,	9	O
with	5	O
a	5	O
median	9	O
of	5	O
3	9	O
.	9	O

6	9	O
courses	5	O
per	9	O
patient	5	O
.	9	O

The	5	O
overall	5	O
response	9	O
rate	9	O
was	9	O
26	7	O
%	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
,	9	O
15	9	O
-	7	O
41	7	O
%	9	O
)	9	O
.	9	O

Two	9	O
patients	5	O
attained	9	O
a	5	O
complete	9	O
response	9	O
(	9	O
4	9	O
%	9	O
)	9	O
and	5	O
11	7	O
patients	5	O
(	9	O
22	7	O
%	9	O
)	9	O
achieved	5	O
a	5	O
partial	9	O
response	9	O
.	9	O

Eastern	4	O
Cooperative	2	O
Oncology	2	O
Group	9	O
performance	5	O
status	9	O
improved	5	O
in	5	O
35	9	O
%	9	O
of	5	O
those	5	O
patients	5	O
with	5	O
an	5	O
initial	9	O
value	9	O
>	0	O
0	7	O
,	9	O
whereas	9	O
relief	5	O
of	5	O
at	9	O
least	9	O
1	9	O
symptom	5	O
without	9	O
worsening	5	O
of	5	O
other	5	O
symptoms	5	O
was	9	O
noted	9	O
in	5	O
27	7	O
patients	5	O
(	9	O
55	7	O
%	9	O
)	9	O
.	9	O

The	5	O
median	9	O
time	5	O
to	5	O
progression	9	O
was	9	O
16	9	O
weeks	9	O
and	5	O
the	5	O
1	9	O
-	7	O
year	5	O
survival	9	O
rate	9	O
was	9	O
33	7	O
%	9	O
.	9	O

Toxicity	9	B-Disease
was	9	O
mild	9	O
.	9	O

Six	9	O
patients	5	O
(	9	O
12	9	O
%	9	O
)	9	O
had	9	O
World	5	O
Health	2	O
Organization	2	O
Grade	9	O
3	9	O
-	7	O
4	9	O
neutropenia	5	B-Disease
,	9	O
2	9	O
patients	5	O
(	9	O
4	9	O
%	9	O
)	9	O
had	9	O
Grade	9	O
3	9	O
-	7	O
4	9	O
thrombocytopenia	9	B-Disease
,	9	O
and	5	O
2	9	O
patients	5	O
(	9	O
4	9	O
%	9	O
)	9	O
had	9	O
Grade	9	O
3	9	O
neurotoxicity	9	B-Disease
.	9	O

Three	9	O
patients	5	O
with	5	O
severe	5	O
neutropenia	5	B-Disease
(	9	O
6	9	O
%	9	O
)	9	O
died	9	O
of	5	O
sepsis	9	B-Disease
.	9	O

The	5	O
median	9	O
age	5	O
of	5	O
those	5	O
patients	5	O
developing	5	O
Grade	9	O
3	9	O
-	7	O
4	9	O
neutropenia	5	B-Disease
was	9	O
significantly	9	O
higher	9	O
than	5	O
that	5	O
of	5	O
the	5	O
remaining	9	O
patients	5	O
(	9	O
75	9	O
years	5	O
vs	7	O
.	9	O
72	9	O
years	5	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
047	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
combination	9	O
of	5	O
GEM	9	B-Chemical
and	5	O
VNB	4	B-Chemical
is	5	O
moderately	9	O
active	9	O
and	5	O
well	9	O
tolerated	9	O
except	9	O
in	5	O
patients	5	O
age	5	O
>	0	O
/	9	O
=	7	O
75	9	O
years	5	O
.	9	O

This	5	O
age	5	O
group	9	O
had	9	O
an	5	O
increased	9	O
risk	5	O
of	5	O
myelosuppression	5	B-Disease
.	9	O

Therefore	9	O
the	5	O
prophylactic	5	O
use	5	O
of	5	O
granulocyte	3	O
-	7	O
colony	9	O
stimulating	9	O
factor	9	O
should	5	O
be	5	O
considered	5	O
with	5	O
this	5	O
treatment	9	O
.	9	O

New	2	O
chemotherapy	5	O
combinations	9	O
with	5	O
higher	9	O
activity	9	O
and	5	O
lower	9	O
toxicity	9	B-Disease
are	5	O
needed	5	O
for	5	O
elderly	5	O
patients	5	O
with	5	O
advanced	5	O
NSCLC	3	B-Disease
.	9	O

A	9	O
selective	9	O
dopamine	5	B-Chemical
D4	9	O
receptor	3	O
antagonist	3	O
,	9	O
NRA0160	_	B-Chemical
:	9	O
a	5	O
preclinical	9	O
neuropharmacological	5	O
profile	9	O
.	9	O

NRA0160	_	B-Chemical
,	9	O
5	9	B-Chemical
-	7	I-Chemical
[	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
fluorobenzylidene	_	I-Chemical
)	9	I-Chemical
piperidin	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
yl	0	I-Chemical
)	9	I-Chemical
ethyl	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
fluorophenyl	0	I-Chemical
)	9	I-Chemical
thiazole	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
carboxamide	0	I-Chemical
,	9	O
has	9	O
a	5	O
high	9	O
affinity	0	O
for	5	O
human	3	O
cloned	1	O
dopamine	5	B-Chemical
D4	9	O
.	9	O
2	9	O
,	9	O
D4	9	O
.	9	O
4	9	O
and	5	O
D4	9	O
.	9	O
7	9	O
receptors	3	O
,	9	O
with	5	O
Ki	0	O
values	5	O
of	5	O
0	7	O
.	9	O
5	9	O
,	9	O
0	7	O
.	9	O
9	7	O
and	5	O
2	9	O
.	9	O
7	9	O
nM	0	O
,	9	O
respectively	9	O
.	9	O

NRA0160	_	B-Chemical
is	5	O
over	5	O
20	9	O
,	9	O
000fold	_	O
more	5	O
potent	3	O
at	9	O
the	5	O
dopamine	5	B-Chemical
D4	9	O
.	9	O
2	9	O
receptor	3	O
compared	9	O
with	5	O
the	5	O
human	3	O
cloned	1	O
dopamine	5	B-Chemical
D2L	3	O
receptor	3	O
.	9	O

NRA0160	_	B-Chemical
has	9	O
negligible	9	O
affinity	0	O
for	5	O
the	5	O
human	3	O
cloned	1	O
dopamine	5	B-Chemical
D3	9	O
receptor	3	O
(	9	O
Ki	0	O
=	7	O
39	7	O
nM	0	O
)	9	O
,	9	O
rat	3	O
serotonin	9	B-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
)	9	O
2A	9	O
receptors	3	O
(	9	O
Ki	0	O
=	7	O
180	9	O
nM	0	O
)	9	O
and	5	O
rat	3	O
alpha1	9	O
adrenoceptor	5	O
(	9	O
Ki	0	O
=	7	O
237	7	O
nM	0	O
)	9	O
.	9	O

NRA0160	_	B-Chemical
and	5	O
clozapine	5	B-Chemical
antagonized	3	O
locomotor	5	O
hyperactivity	5	B-Disease
induced	3	O
by	9	O
methamphetamine	5	B-Chemical
(	9	O
MAP	9	B-Chemical
)	9	O
in	5	O
mice	3	O
.	9	O

NRA0160	_	B-Chemical
and	5	O
clozapine	5	B-Chemical
antagonized	3	O
MAP	9	B-Chemical
-	7	O
induced	3	O
stereotyped	5	O
behavior	5	O
in	5	O
mice	3	O
,	9	O
although	9	O
their	5	O
effects	9	O
did	9	O
not	5	O
exceed	5	O
50	0	O
%	9	O
inhibition	3	O
,	9	O
even	5	O
at	9	O
the	5	O
highest	9	O
dose	9	O
given	5	O
.	9	O

NRA0160	_	B-Chemical
and	5	O
clozapine	5	B-Chemical
significantly	9	O
induced	3	O
catalepsy	5	B-Disease
in	5	O
rats	9	O
,	9	O
although	9	O
their	5	O
effects	9	O
did	9	O
not	5	O
exceed	5	O
50	0	O
%	9	O
induction	3	O
even	5	O
at	9	O
the	5	O
highest	9	O
dose	9	O
given	5	O
.	9	O

NRA0160	_	B-Chemical
and	5	O
clozapine	5	B-Chemical
significantly	9	O
reversed	9	O
the	5	O
disruption	9	O
of	5	O
prepulse	5	O
inhibition	3	O
(	9	O
PPI	5	O
)	9	O
in	5	O
rats	9	O
produced	9	O
by	9	O
apomorphine	0	B-Chemical
.	9	O

NRA0160	_	B-Chemical
and	5	O
clozapine	5	B-Chemical
significantly	9	O
shortened	9	O
the	5	O
phencyclidine	0	B-Chemical
(	9	O
PCP	9	B-Chemical
)	9	O
-	7	O
induced	3	O
prolonged	9	O
swimming	5	O
latency	5	O
in	5	O
rats	9	O
in	5	O
a	5	O
water	0	O
maze	5	O
task	5	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
NRA0160	_	B-Chemical
may	5	O
have	5	O
unique	9	O
antipsychotic	5	O
activities	9	O
without	9	O
the	5	O
liability	5	O
of	5	O
motor	5	O
side	5	O
effects	9	O
typical	9	O
of	5	O
classical	9	O
antipsychotics	5	O
.	9	O

Warfarin	5	B-Chemical
-	7	O
induced	3	O
artery	5	B-Disease
calcification	5	I-Disease
is	5	O
accelerated	9	O
by	9	O
growth	3	O
and	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
.	9	O

The	5	O
present	9	O
studies	9	O
demonstrate	9	O
that	5	O
growth	3	O
and	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
treatment	9	O
enhance	9	O
the	5	O
extent	9	O
of	5	O
artery	5	B-Disease
calcification	5	I-Disease
in	5	O
rats	9	O
given	5	O
sufficient	9	O
doses	0	O
of	5	O
Warfarin	5	B-Chemical
to	5	O
inhibit	3	O
gamma	9	O
-	7	O
carboxylation	0	O
of	5	O
matrix	5	O
Gla	1	O
protein	1	O
,	9	O
a	5	O
calcification	5	B-Disease
inhibitor	3	O
known	9	O
to	5	O
be	5	O
expressed	3	O
by	9	O
smooth	5	O
muscle	9	O
cells	3	O
and	5	O
macrophages	3	O
in	5	O
the	5	O
artery	5	O
wall	5	O
.	9	O

The	5	O
first	9	O
series	5	O
of	5	O
experiments	9	O
examined	9	O
the	5	O
influence	5	O
of	5	O
age	5	O
and	5	O
growth	3	O
status	9	O
on	5	O
artery	5	B-Disease
calcification	5	I-Disease
in	5	O
Warfarin	5	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Treatment	9	O
for	5	O
2	9	O
weeks	9	O
with	5	O
Warfarin	5	B-Chemical
caused	9	O
massive	9	O
focal	5	O
calcification	5	B-Disease
of	5	I-Disease
the	5	I-Disease
artery	5	I-Disease
media	9	O
in	5	O
20	9	O
-	7	O
day	9	O
-	7	O
old	5	O
rats	9	O
and	5	O
less	5	O
extensive	5	O
focal	5	O
calcification	5	B-Disease
in	5	O
42	7	O
-	7	O
day	9	O
-	7	O
old	5	O
rats	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
no	9	O
artery	5	B-Disease
calcification	5	I-Disease
could	9	O
be	5	O
detected	9	O
in	5	O
10	9	O
-	7	O
month	5	O
-	7	O
old	5	O
adult	9	O
rats	9	O
even	5	O
after	9	O
4	9	O
weeks	9	O
of	5	O
Warfarin	5	B-Chemical
treatment	9	O
.	9	O

To	9	O
directly	9	O
examine	9	O
the	5	O
importance	5	O
of	5	O
growth	3	O
to	5	O
Warfarin	5	B-Chemical
-	7	O
induced	3	O
artery	5	B-Disease
calcification	5	I-Disease
in	5	O
animals	9	O
of	5	O
the	5	O
same	9	O
age	5	O
,	9	O
20	9	O
-	7	O
day	9	O
-	7	O
old	5	O
rats	9	O
were	9	O
fed	9	O
for	5	O
2	9	O
weeks	9	O
either	9	O
an	5	O
ad	9	O
libitum	9	O
diet	9	O
or	5	O
a	5	O
6	9	O
-	7	O
g	0	O
/	9	O
d	9	O
restricted	9	O
diet	9	O
that	5	O
maintains	9	O
weight	9	O
but	9	O
prevents	9	O
growth	3	O
.	9	O

Concurrent	9	O
treatment	9	O
of	5	O
both	9	O
dietary	5	O
groups	9	O
with	5	O
Warfarin	5	B-Chemical
produced	9	O
massive	9	O
focal	5	O
calcification	5	B-Disease
of	5	I-Disease
the	5	I-Disease
artery	5	I-Disease
media	9	O
in	5	O
the	5	O
ad	9	O
libitum	9	O
-	7	O
fed	9	O
rats	9	O
but	9	O
no	9	O
detectable	9	O
artery	5	B-Disease
calcification	5	I-Disease
in	5	O
the	5	O
restricted	9	O
-	7	O
diet	9	O
,	9	O
growth	3	O
-	7	O
inhibited	3	O
group	9	O
.	9	O

Although	9	O
the	5	O
explanation	5	O
for	5	O
the	5	O
association	9	O
between	5	O
artery	5	B-Disease
calcification	5	I-Disease
and	5	O
growth	3	O
status	9	O
cannot	5	O
be	5	O
determined	9	O
from	9	O
the	5	O
present	9	O
study	9	O
,	9	O
there	5	O
was	9	O
a	5	O
relationship	5	O
between	5	O
higher	9	O
serum	9	O
phosphate	0	B-Chemical
and	5	O
susceptibility	9	O
to	5	O
artery	5	B-Disease
calcification	5	I-Disease
,	9	O
with	5	O
30	9	O
%	9	O
higher	9	O
levels	3	O
of	5	O
serum	9	O
phosphate	0	B-Chemical
in	5	O
young	5	O
,	9	O
ad	9	O
libitum	9	O
-	7	O
fed	9	O
rats	9	O
compared	9	O
with	5	O
either	9	O
of	5	O
the	5	O
groups	9	O
that	5	O
was	9	O
resistant	9	O
to	5	O
Warfarin	5	B-Chemical
-	7	O
induced	3	O
artery	5	B-Disease
calcification	5	I-Disease
,	9	O
ie	5	O
,	9	O
the	5	O
10	9	O
-	7	O
month	5	O
-	7	O
old	5	O
rats	9	O
and	5	O
the	5	O
restricted	9	O
-	7	O
diet	9	O
,	9	O
growth	3	O
-	7	O
inhibited	3	O
young	5	O
rats	9	O
.	9	O

This	5	O
observation	9	O
suggests	9	O
that	5	O
increased	9	O
susceptibility	9	O
to	5	O
Warfarin	5	B-Chemical
-	7	O
induced	3	O
artery	5	B-Disease
calcification	5	I-Disease
could	9	O
be	5	O
related	9	O
to	5	O
higher	9	O
serum	9	O
phosphate	0	B-Chemical
levels	3	O
.	9	O

The	5	O
second	9	O
set	5	O
of	5	O
experiments	9	O
examined	9	O
the	5	O
possible	5	O
synergy	9	O
between	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
and	5	O
Warfarin	5	B-Chemical
in	5	O
artery	5	B-Disease
calcification	5	I-Disease
.	9	O

High	9	O
doses	0	O
of	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
are	5	O
known	9	O
to	5	O
cause	5	O
calcification	5	B-Disease
of	5	I-Disease
the	5	I-Disease
artery	5	I-Disease
media	9	O
in	5	O
as	5	O
little	9	O
as	5	O
3	9	O
to	5	O
4	9	O
days	9	O
.	9	O

High	9	O
doses	0	O
of	5	O
the	5	O
vitamin	0	B-Chemical
K	9	I-Chemical
antagonist	3	O
Warfarin	5	B-Chemical
are	5	O
also	9	O
known	9	O
to	5	O
cause	5	O
calcification	5	B-Disease
of	5	I-Disease
the	5	I-Disease
artery	5	I-Disease
media	9	O
,	9	O
but	9	O
at	9	O
treatment	9	O
times	5	O
of	5	O
2	9	O
weeks	9	O
or	5	O
longer	5	O
yet	9	O
not	5	O
at	9	O
1	9	O
week	9	O
.	9	O

In	9	O
the	5	O
current	5	O
study	9	O
,	9	O
we	5	O
investigated	9	O
the	5	O
synergy	9	O
between	5	O
these	5	O
2	9	O
treatments	9	O
and	5	O
found	9	O
that	5	O
concurrent	5	O
Warfarin	5	B-Chemical
administration	9	O
dramatically	9	O
increased	9	O
the	5	O
extent	9	O
of	5	O
calcification	5	B-Disease
in	5	O
the	5	O
media	9	O
of	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
-	7	O
treated	3	O
rats	9	O
at	9	O
3	9	O
and	5	O
4	9	O
days	9	O
.	9	O

There	5	O
was	9	O
a	5	O
close	5	O
parallel	5	O
between	5	O
the	5	O
effect	9	O
of	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
dose	9	O
on	5	O
artery	5	B-Disease
calcification	5	I-Disease
and	5	O
the	5	O
effect	9	O
of	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
dose	9	O
on	5	O
the	5	O
elevation	9	O
of	5	O
serum	9	O
calcium	0	B-Chemical
,	9	O
which	5	O
suggests	9	O
that	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
may	5	O
induce	3	O
artery	5	B-Disease
calcification	5	I-Disease
through	9	O
its	9	O
effect	9	O
on	5	O
serum	9	O
calcium	0	B-Chemical
.	9	O

Because	9	O
Warfarin	5	B-Chemical
treatment	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
the	5	O
elevation	9	O
in	5	O
serum	9	O
calcium	0	B-Chemical
produced	9	O
by	9	O
vitamin	0	B-Chemical
D	9	I-Chemical
,	9	O
the	5	O
synergy	9	O
between	5	O
Warfarin	5	B-Chemical
and	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
is	5	O
probably	9	O
best	5	O
explained	5	O
by	9	O
the	5	O
hypothesis	9	O
that	5	O
Warfarin	5	B-Chemical
inhibits	3	O
the	5	O
activity	9	O
of	5	O
matrix	5	O
Gla	1	O
protein	1	O
as	5	O
a	5	O
calcification	5	B-Disease
inhibitor	3	O
.	9	O

High	9	O
levels	3	O
of	5	O
matrix	5	O
Gla	1	O
protein	1	O
are	5	O
found	9	O
at	9	O
sites	9	O
of	5	O
artery	5	B-Disease
calcification	5	I-Disease
in	5	O
rats	9	O
treated	3	O
with	5	O
vitamin	0	B-Chemical
D	9	I-Chemical
plus	9	O
Warfarin	5	B-Chemical
,	9	O
and	5	O
chemical	0	O
analysis	9	O
showed	9	O
that	5	O
the	5	O
protein	1	O
that	5	O
accumulated	9	O
was	9	O
indeed	9	O
not	5	O
gamma	9	B-Chemical
-	7	I-Chemical
carboxylated	0	I-Chemical
.	9	O

These	5	O
observations	9	O
indicate	9	O
that	5	O
although	9	O
the	5	O
gamma	9	B-Chemical
-	7	I-Chemical
carboxyglutamate	7	I-Chemical
residues	1	O
of	5	O
matrix	5	O
Gla	1	O
protein	1	O
are	5	O
apparently	9	O
required	9	O
for	5	O
its	9	O
function	9	O
as	5	O
a	5	O
calcification	5	B-Disease
inhibitor	3	O
,	9	O
they	5	O
are	5	O
not	5	O
required	9	O
for	5	O
its	9	O
accumulation	9	O
at	9	O
calcification	5	B-Disease
sites	9	O
.	9	O

Test	5	O
conditions	9	O
influence	5	O
the	5	O
response	9	O
to	5	O
a	5	O
drug	5	O
challenge	9	O
in	5	O
rodents	9	O
.	9	O

These	5	O
studies	9	O
were	9	O
conducted	9	O
to	5	O
examine	9	O
the	5	O
differential	9	O
response	9	O
to	5	O
a	5	O
drug	5	O
challenge	9	O
under	9	O
varied	9	O
experimental	5	O
test	5	O
conditions	9	O
routinely	9	O
employed	5	O
to	5	O
study	9	O
drug	5	O
-	7	O
induced	3	O
behavioral	5	O
and	5	O
neurophysiological	5	O
responses	5	O
in	5	O
rodents	9	O
.	9	O

Apomorphine	0	B-Chemical
,	9	O
a	5	O
nonselective	0	O
dopamine	5	B-Chemical
agonist	3	I-Chemical
,	9	O
was	9	O
selected	9	O
due	5	O
to	5	O
its	9	O
biphasic	9	O
behavioral	5	O
effects	9	O
,	9	O
its	9	O
ability	9	O
to	5	O
induce	3	O
hypothermia	5	B-Disease
,	9	O
and	5	O
to	5	O
produce	9	O
distinct	9	O
changes	9	O
to	5	O
dopamine	5	B-Chemical
turnover	9	O
in	5	O
the	5	O
rodent	9	O
brain	5	O
.	9	O

From	5	O
such	5	O
experiments	9	O
there	5	O
is	5	O
evidence	9	O
that	5	O
characterization	9	O
and	5	O
detection	9	O
of	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
activity	9	O
in	5	O
rodents	9	O
critically	9	O
depends	5	O
upon	9	O
the	5	O
test	5	O
conditions	9	O
employed	5	O
.	9	O

In	9	O
rats	9	O
,	9	O
detection	9	O
of	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
was	9	O
facilitated	5	O
by	9	O
a	5	O
period	5	O
of	5	O
acclimatization	5	O
to	5	O
the	5	O
test	5	O
conditions	9	O
.	9	O

Moreover	9	O
,	9	O
test	5	O
conditions	9	O
can	5	O
impact	5	O
upon	9	O
other	5	O
physiological	9	O
responses	5	O
to	5	O
apomorphine	0	B-Chemical
such	5	O
as	5	O
drug	5	O
-	7	O
induced	3	O
hypothermia	5	B-Disease
.	9	O

In	9	O
mice	3	O
,	9	O
apomorphine	0	B-Chemical
produced	9	O
qualitatively	9	O
different	9	O
responses	5	O
under	9	O
novel	9	O
conditions	9	O
when	5	O
compared	9	O
to	5	O
those	5	O
behaviors	5	O
elicited	9	O
in	5	O
the	5	O
home	5	O
test	5	O
cage	5	O
.	9	O

Drug	5	O
-	7	O
induced	3	O
gross	5	O
activity	9	O
counts	9	O
were	9	O
increased	9	O
in	5	O
the	5	O
novel	9	O
exploratory	5	O
box	9	O
only	9	O
,	9	O
while	9	O
measures	5	O
of	5	O
stereotypic	5	O
behavior	5	O
were	9	O
similar	9	O
in	5	O
both	9	O
.	9	O

By	5	O
contrast	9	O
,	9	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
locomotion	5	O
was	9	O
more	5	O
prominent	9	O
in	5	O
the	5	O
novel	9	O
exploratory	5	O
box	9	O
.	9	O

Dopamine	0	B-Chemical
turnover	9	O
ratios	9	O
(	9	O
DOPAC	0	B-Chemical
:	9	O
DA	9	B-Chemical
and	5	O
HVA	0	B-Chemical
:	9	O
DA	9	B-Chemical
)	9	O
were	9	O
found	9	O
to	5	O
be	5	O
lower	9	O
in	5	O
those	5	O
animals	9	O
exposed	9	O
to	5	O
the	5	O
exploratory	5	O
box	9	O
when	5	O
compared	9	O
to	5	O
their	5	O
home	5	O
cage	5	O
counterparts	9	O
.	9	O

However	9	O
,	9	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
reductions	9	O
in	5	O
striatal	3	O
dopamine	5	B-Chemical
turnover	9	O
were	9	O
detected	9	O
in	5	O
both	9	O
novel	9	O
and	5	O
home	5	O
cage	5	O
environments	5	O
.	9	O

The	5	O
implications	5	O
of	5	O
these	5	O
findings	9	O
are	5	O
discussed	5	O
with	5	O
particular	5	O
emphasis	5	O
upon	9	O
conducting	5	O
psychopharmacological	5	O
challenge	9	O
tests	5	O
in	5	O
rodents	9	O
.	9	O

Hemolysis	0	B-Disease
of	5	O
human	3	O
erythrocytes	9	O
induced	3	O
by	9	O
tamoxifen	9	B-Chemical
is	5	O
related	9	O
to	5	O
disruption	9	O
of	5	O
membrane	9	O
structure	9	O
.	9	O

Tamoxifen	0	B-Chemical
(	9	O
TAM	3	B-Chemical
)	9	O
,	9	O
the	5	O
antiestrogenic	0	O
drug	5	O
most	9	O
widely	5	O
prescribed	5	O
in	5	O
the	5	O
chemotherapy	5	O
of	5	O
breast	3	B-Disease
cancer	3	I-Disease
,	9	O
induces	3	O
changes	9	O
in	5	O
normal	9	O
discoid	5	O
shape	5	O
of	5	O
erythrocytes	9	O
and	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

This	5	O
work	5	O
evaluates	5	O
the	5	O
effects	9	O
of	5	O
TAM	3	B-Chemical
on	5	O
isolated	9	O
human	3	O
erythrocytes	9	O
,	9	O
attempting	5	O
to	5	O
identify	9	O
the	5	O
underlying	5	O
mechanisms	9	O
on	5	O
TAM	3	B-Chemical
-	7	O
induced	3	O
hemolytic	0	B-Disease
anemia	9	I-Disease
and	5	O
the	5	O
involvement	9	O
of	5	O
biomembranes	0	O
in	5	O
its	9	O
cytostatic	3	O
action	5	O
mechanisms	9	O
.	9	O

TAM	3	B-Chemical
induces	3	O
hemolysis	9	B-Disease
of	5	O
erythrocytes	9	O
as	5	O
a	5	O
function	9	O
of	5	O
concentration	0	O
.	9	O

The	5	O
extension	9	O
of	5	O
hemolysis	9	B-Disease
is	5	O
variable	5	O
with	5	O
erythrocyte	9	O
samples	9	O
,	9	O
but	9	O
12	9	O
.	9	O
5	9	O
microM	0	O
TAM	3	B-Chemical
induces	3	O
total	9	O
hemolysis	9	B-Disease
of	5	O
all	5	O
tested	9	O
suspensions	0	O
.	9	O

Despite	5	O
inducing	3	O
extensive	5	O
erythrocyte	9	O
lysis	3	O
,	9	O
TAM	3	B-Chemical
does	9	O
not	5	O
shift	9	O
the	5	O
osmotic	0	O
fragility	5	O
curves	5	O
of	5	O
erythrocytes	9	O
.	9	O

The	5	O
hemolytic	0	B-Disease
effect	9	O
of	5	O
TAM	3	B-Chemical
is	5	O
prevented	9	O
by	9	O
low	9	O
concentrations	0	O
of	5	O
alpha	9	B-Chemical
-	7	I-Chemical
tocopherol	0	I-Chemical
(	9	O
alpha	9	B-Chemical
-	7	I-Chemical
T	3	I-Chemical
)	9	O
and	5	O
alpha	9	B-Chemical
-	7	I-Chemical
tocopherol	0	I-Chemical
acetate	0	I-Chemical
(	9	O
alpha	9	B-Chemical
-	7	I-Chemical
TAc	7	I-Chemical
)	9	O
(	9	O
inactivated	9	O
functional	9	O
hydroxyl	0	B-Chemical
)	9	O
indicating	9	O
that	5	O
TAM	3	B-Chemical
-	7	O
induced	3	O
hemolysis	9	B-Disease
is	5	O
not	5	O
related	9	O
to	5	O
oxidative	9	O
membrane	9	O
damage	9	O
.	9	O

This	5	O
was	9	O
further	9	O
evidenced	9	O
by	9	O
absence	3	O
of	5	O
oxygen	0	B-Chemical
consumption	5	O
and	5	O
hemoglobin	0	O
oxidation	0	O
both	9	O
determined	9	O
in	5	O
parallel	5	O
with	5	O
TAM	3	B-Chemical
-	7	O
induced	3	O
hemolysis	9	B-Disease
.	9	O

Furthermore	9	O
,	9	O
it	5	O
was	9	O
observed	9	O
that	5	O
TAM	3	B-Chemical
inhibits	3	O
the	5	O
peroxidation	0	O
of	5	O
human	3	O
erythrocytes	9	O
induced	3	O
by	9	O
AAPH	0	B-Chemical
,	9	O
thus	9	O
ruling	9	O
out	9	O
TAM	3	B-Chemical
-	7	O
induced	3	O
cell	3	O
oxidative	9	O
stress	9	O
.	9	O

Hemolysis	0	B-Disease
caused	9	O
by	9	O
TAM	3	B-Chemical
was	9	O
not	5	O
preceded	9	O
by	9	O
the	5	O
leakage	9	O
of	5	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
from	9	O
the	5	O
cells	3	O
,	9	O
also	9	O
excluding	9	O
a	5	O
colloid	0	O
-	7	O
osmotic	0	O
type	9	O
mechanism	9	O
of	5	O
hemolysis	9	B-Disease
,	9	O
according	9	O
to	5	O
the	5	O
effects	9	O
on	5	O
osmotic	0	O
fragility	5	O
curves	5	O
.	9	O

However	9	O
,	9	O
TAM	3	B-Chemical
induces	3	O
release	9	O
of	5	O
peripheral	9	O
proteins	1	O
of	5	O
membrane	9	O
-	7	O
cytoskeleton	3	O
and	5	O
cytosol	3	O
proteins	1	O
essentially	9	O
bound	9	O
to	5	O
band	9	O
3	9	O
.	9	O

Either	9	O
alpha	9	B-Chemical
-	7	I-Chemical
T	3	I-Chemical
or	5	O
alpha	9	B-Chemical
-	7	I-Chemical
TAc	7	I-Chemical
increases	9	O
membrane	9	O
packing	5	O
and	5	O
prevents	9	O
TAM	3	B-Chemical
partition	5	O
into	9	O
model	5	O
membranes	0	O
.	9	O

These	5	O
effects	9	O
suggest	9	O
that	5	O
the	5	O
protection	9	O
from	9	O
hemolysis	9	B-Disease
by	9	O
tocopherols	0	B-Chemical
is	5	O
related	9	O
to	5	O
a	5	O
decreased	9	O
TAM	3	B-Chemical
incorporation	0	O
in	5	O
condensed	9	O
membranes	0	O
and	5	O
the	5	O
structural	9	O
damage	9	O
of	5	O
the	5	O
erythrocyte	9	O
membrane	9	O
is	5	O
consequently	9	O
avoided	5	O
.	9	O

Therefore	9	O
,	9	O
TAM	3	B-Chemical
-	7	O
induced	3	O
hemolysis	9	B-Disease
results	9	O
from	9	O
a	5	O
structural	9	O
perturbation	5	O
of	5	O
red	9	O
cell	3	O
membrane	9	O
,	9	O
leading	9	O
to	5	O
changes	9	O
in	5	O
the	5	O
framework	5	O
of	5	O
the	5	O
erythrocyte	9	O
membrane	9	O
and	5	O
its	9	O
cytoskeleton	3	O
caused	9	O
by	9	O
its	9	O
high	9	O
partition	5	O
in	5	O
the	5	O
membrane	9	O
.	9	O

These	5	O
defects	9	O
explain	9	O
the	5	O
abnormal	9	O
erythrocyte	9	O
shape	5	O
and	5	O
decreased	9	O
mechanical	5	O
stability	9	O
promoted	3	O
by	9	O
TAM	3	B-Chemical
,	9	O
resulting	9	O
in	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

Additionally	9	O
,	9	O
since	9	O
membrane	9	O
leakage	9	O
is	5	O
a	5	O
final	9	O
stage	9	O
of	5	O
cytotoxicity	3	O
,	9	O
the	5	O
disruption	9	O
of	5	O
the	5	O
structural	9	O
characteristics	5	O
of	5	O
biomembranes	0	O
by	9	O
TAM	3	B-Chemical
may	5	O
contribute	9	O
to	5	O
the	5	O
multiple	5	O
mechanisms	9	O
of	5	O
its	9	O
anticancer	0	O
action	5	O
.	9	O

Changes	9	O
of	5	O
sodium	0	B-Chemical
and	5	O
ATP	0	B-Chemical
affinities	9	O
of	5	O
the	5	O
cardiac	5	O
(	9	O
Na	0	B-Chemical
,	9	O
K	9	B-Chemical
)	9	O
-	7	O
ATPase	1	O
during	5	O
and	5	O
after	9	O
nitric	0	B-Chemical
oxide	0	I-Chemical
deficient	3	O
hypertension	5	B-Disease
.	9	O

In	9	O
the	5	O
cardiovascular	5	O
system	5	O
,	9	O
NO	9	B-Chemical
is	5	O
involved	9	O
in	5	O
the	5	O
regulation	9	O
of	5	O
a	5	O
variety	5	O
of	5	O
functions	9	O
.	9	O

Inhibition	3	O
of	5	O
NO	9	B-Chemical
synthesis	9	O
induces	3	O
sustained	5	O
hypertension	5	B-Disease
.	9	O

In	9	O
several	9	O
models	5	O
of	5	O
hypertension	5	B-Disease
,	9	O
elevation	9	O
of	5	O
intracellular	3	O
sodium	0	B-Chemical
level	9	O
was	9	O
documented	9	O
in	5	O
cardiac	5	O
tissue	9	O
.	9	O

To	9	O
assess	5	O
the	5	O
molecular	9	O
basis	5	O
of	5	O
disturbances	5	O
in	5	O
transmembraneous	3	O
transport	9	O
of	5	O
Na	0	B-Chemical
+	9	O
,	9	O
we	5	O
studied	9	O
the	5	O
response	9	O
of	5	O
cardiac	5	O
(	9	O
Na	0	B-Chemical
,	9	O
K	9	B-Chemical
)	9	O
-	7	O
ATPase	1	O
to	5	O
NO	9	B-Chemical
-	7	O
deficient	3	O
hypertension	5	B-Disease
induced	3	O
in	5	O
rats	9	O
by	9	O
NO	9	B-Chemical
-	7	O
synthase	1	O
inhibition	3	O
with	5	O
40	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
N	9	B-Chemical
(	9	I-Chemical
G	9	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
nitro	0	I-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
methyl	0	I-Chemical
ester	0	I-Chemical
(	9	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
)	9	O
for	5	O
4	9	O
four	9	O
weeks	9	O
.	9	O

After	9	O
4	9	O
-	7	O
week	9	O
administration	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
,	9	O
the	5	O
systolic	5	O
blood	9	O
pressure	5	O
(	9	O
SBP	9	O
)	9	O
increased	9	O
by	9	O
36	9	O
%	9	O
.	9	O

Two	9	O
weeks	9	O
after	9	O
terminating	9	O
the	5	O
treatment	9	O
,	9	O
the	5	O
SBP	9	O
recovered	9	O
to	5	O
control	9	O
value	9	O
.	9	O

When	9	O
activating	3	O
the	5	O
(	9	O
Na	0	B-Chemical
,	9	O
K	9	B-Chemical
)	9	O
-	7	O
ATPase	1	O
with	5	O
its	9	O
substrate	0	O
ATP	0	B-Chemical
,	9	O
no	9	O
changes	9	O
in	5	O
Km	0	O
and	5	O
Vmax	0	O
values	5	O
were	9	O
observed	9	O
in	5	O
NO	9	B-Chemical
-	7	O
deficient	3	O
rats	9	O
.	9	O

During	5	O
activation	3	O
with	5	O
Na	0	B-Chemical
+	9	O
,	9	O
the	5	O
Vmax	0	O
remained	9	O
unchanged	9	O
,	9	O
however	9	O
the	5	O
K	9	B-Chemical
(	9	O
Na	0	B-Chemical
)	9	O
increased	9	O
by	9	O
50	0	O
%	9	O
,	9	O
indicating	9	O
a	5	O
profound	9	O
decrease	9	O
in	5	O
the	5	O
affinity	0	O
of	5	O
the	5	O
Na	0	B-Chemical
+	9	O
-	7	O
binding	1	O
site	9	O
in	5	O
NO	9	B-Chemical
-	7	O
deficient	3	O
rats	9	O
.	9	O

After	9	O
recovery	9	O
from	9	O
hypertension	5	B-Disease
,	9	O
the	5	O
activity	9	O
of	5	O
(	9	O
Na	0	B-Chemical
,	9	O
K	9	B-Chemical
)	9	O
-	7	O
ATPase	1	O
increased	9	O
,	9	O
due	5	O
to	5	O
higher	9	O
affinity	0	O
of	5	O
the	5	O
ATP	0	B-Chemical
-	7	O
binding	1	O
site	9	O
,	9	O
as	5	O
revealed	9	O
from	9	O
the	5	O
lowered	9	O
Km	0	O
value	9	O
for	5	O
ATP	0	B-Chemical
.	9	O

The	5	O
K	9	B-Chemical
(	9	O
Na	0	B-Chemical
)	9	O
value	9	O
for	5	O
Na	0	B-Chemical
+	9	O
returned	5	O
to	5	O
control	9	O
value	9	O
.	9	O

Inhibition	3	O
of	5	O
NO	9	B-Chemical
-	7	O
synthase	1	O
induced	3	O
a	5	O
reversible	9	O
hypertension	5	B-Disease
accompanied	9	O
by	9	O
depressed	5	B-Disease
Na	0	B-Chemical
+	9	O
-	7	O
extrusion	9	O
from	9	O
cardiac	5	O
cells	3	O
as	5	O
a	5	O
consequence	5	O
of	5	O
deteriorated	5	O
Na	0	B-Chemical
+	9	O
-	7	O
binding	1	O
properties	9	O
of	5	O
the	5	O
(	9	O
Na	0	B-Chemical
,	9	O
K	9	B-Chemical
)	9	O
-	7	O
ATPase	1	O
.	9	O

After	9	O
recovery	9	O
of	5	O
blood	9	O
pressure	5	O
to	5	O
control	9	O
values	5	O
,	9	O
the	5	O
extrusion	9	O
of	5	O
Na	0	B-Chemical
+	9	O
from	9	O
cardiac	5	O
cells	3	O
was	9	O
normalized	9	O
,	9	O
as	5	O
revealed	9	O
by	9	O
restoration	5	O
of	5	O
the	5	O
(	9	O
Na	0	B-Chemical
,	9	O
K	9	B-Chemical
)	9	O
-	7	O
ATPase	1	O
activity	9	O
.	9	O

Effects	9	O
of	5	O
long	5	O
-	7	O
term	5	O
pretreatment	0	O
with	5	O
isoproterenol	0	B-Chemical
on	5	O
bromocriptine	0	B-Chemical
-	7	O
induced	3	O
tachycardia	5	B-Disease
in	5	O
conscious	5	O
rats	9	O
.	9	O

It	5	O
has	9	O
been	9	O
shown	9	O
that	5	O
bromocriptine	0	B-Chemical
-	7	O
induced	3	O
tachycardia	5	B-Disease
,	9	O
which	5	O
persisted	9	O
after	9	O
adrenalectomy	5	O
,	9	O
is	5	O
(	9	O
i	9	O
)	9	O
mediated	3	O
by	9	O
central	5	O
dopamine	5	B-Chemical
D2	9	O
receptor	3	O
activation	3	O
and	5	O
(	9	O
ii	9	O
)	9	O
reduced	9	O
by	9	O
5	9	O
-	7	O
day	9	O
isoproterenol	0	B-Chemical
pretreatment	0	O
,	9	O
supporting	9	O
therefore	5	O
the	5	O
hypothesis	9	O
that	5	O
this	5	O
effect	9	O
is	5	O
dependent	9	O
on	5	O
sympathetic	5	O
outflow	5	O
to	5	O
the	5	O
heart	5	O
.	9	O

This	5	O
study	9	O
was	9	O
conducted	9	O
to	5	O
examine	9	O
whether	9	O
prolonged	9	O
pretreatment	0	O
with	5	O
isoproterenol	0	B-Chemical
could	9	O
abolish	9	O
bromocriptine	0	B-Chemical
-	7	O
induced	3	O
tachycardia	5	B-Disease
in	5	O
conscious	5	O
rats	9	O
.	9	O

Isoproterenol	0	B-Chemical
pretreatment	0	O
for	5	O
15	9	O
days	9	O
caused	9	O
cardiac	5	B-Disease
hypertrophy	9	I-Disease
without	9	O
affecting	9	O
baseline	5	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
.	9	O

In	9	O
control	9	O
rats	9	O
,	9	O
intravenous	0	O
bromocriptine	0	B-Chemical
(	9	O
150	0	O
microg	0	O
/	9	O
kg	0	O
)	9	O
induced	3	O
significant	9	O
hypotension	5	B-Disease
and	5	O
tachycardia	5	B-Disease
.	9	O

Bromocriptine	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
was	9	O
unaffected	9	O
by	9	O
isoproterenol	0	B-Chemical
pretreatment	0	O
,	9	O
while	9	O
tachycardia	5	B-Disease
was	9	O
reversed	9	O
to	5	O
significant	9	O
bradycardia	5	B-Disease
,	9	O
an	5	O
effect	9	O
that	5	O
was	9	O
partly	9	O
reduced	9	O
by	9	O
i	9	O
.	9	O
v	0	O
.	9	O
domperidone	0	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

Neither	9	O
cardiac	5	O
vagal	5	O
nor	9	O
sympathetic	5	O
tone	5	O
was	9	O
altered	9	O
by	9	O
isoproterenol	0	B-Chemical
pretreatment	0	O
.	9	O

In	9	O
isolated	9	O
perfused	0	O
heart	5	O
preparations	9	O
from	9	O
isoproterenol	0	B-Chemical
-	7	O
pretreated	3	O
rats	9	O
,	9	O
the	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
maximal	9	O
increase	9	O
in	5	O
left	5	O
ventricular	5	O
systolic	5	O
pressure	5	O
was	9	O
significantly	9	O
reduced	9	O
,	9	O
compared	9	O
with	5	O
saline	0	O
-	7	O
pretreated	3	O
rats	9	O
(	9	O
the	5	O
EC50	0	O
of	5	O
the	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
increase	9	O
in	5	O
left	5	O
ventricular	5	O
systolic	5	O
pressure	5	O
was	9	O
enhanced	3	O
approximately	9	O
22	7	O
-	7	O
fold	9	O
)	9	O
.	9	O

These	5	O
results	9	O
show	9	O
that	5	O
15	9	O
-	7	O
day	9	O
isoproterenol	0	B-Chemical
pretreatment	0	O
not	5	O
only	9	O
abolished	3	O
but	9	O
reversed	9	O
bromocriptine	0	B-Chemical
-	7	O
induced	3	O
tachycardia	5	B-Disease
to	5	O
bradycardia	5	B-Disease
,	9	O
an	5	O
effect	9	O
that	5	O
is	5	O
mainly	9	O
related	9	O
to	5	O
further	9	O
cardiac	5	O
beta	9	O
-	7	O
adrenoceptor	5	O
desensitization	3	O
rather	5	O
than	5	O
to	5	O
impairment	5	O
of	5	O
autonomic	5	O
regulation	9	O
of	5	O
the	5	O
heart	5	O
.	9	O

They	5	O
suggest	9	O
that	5	O
,	9	O
in	5	O
normal	9	O
conscious	5	O
rats	9	O
,	9	O
the	5	O
central	5	O
tachycardia	5	B-Disease
of	5	O
bromocriptine	0	B-Chemical
appears	9	O
to	5	O
predominate	9	O
and	5	O
to	5	O
mask	5	O
the	5	O
bradycardia	5	B-Disease
of	5	O
this	5	O
agonist	3	O
at	9	O
peripheral	9	O
dopamine	5	B-Chemical
D2	9	O
receptors	3	O
.	9	O

A	9	O
developmental	9	O
analysis	9	O
of	5	O
clonidine	0	B-Chemical
'	9	O
s	9	O
effects	9	O
on	5	O
cardiac	5	O
rate	9	O
and	5	O
ultrasound	5	O
production	9	O
in	5	O
infant	5	O
rats	9	O
.	9	O

Under	9	O
controlled	5	O
conditions	9	O
,	9	O
infant	5	O
rats	9	O
emit	5	O
ultrasonic	5	O
vocalizations	5	O
during	5	O
extreme	5	O
cold	9	O
exposure	9	O
and	5	O
after	9	O
administration	9	O
of	5	O
the	5	O
alpha	9	O
(	9	O
2	9	O
)	9	O
adrenoceptor	5	O
agonist	3	O
,	9	O
clonidine	0	B-Chemical
.	9	O

Previous	9	O
investigations	9	O
have	5	O
determined	9	O
that	5	O
,	9	O
in	5	O
response	9	O
to	5	O
clonidine	0	B-Chemical
,	9	O
ultrasound	5	O
production	9	O
increases	9	O
through	9	O
the	5	O
2nd	9	O
-	7	O
week	9	O
postpartum	5	O
and	5	O
decreases	9	O
thereafter	9	O
.	9	O

Given	9	O
that	5	O
sympathetic	5	O
neural	5	O
dominance	5	O
exhibits	9	O
a	5	O
similar	9	O
developmental	9	O
pattern	9	O
,	9	O
and	5	O
given	5	O
that	5	O
clonidine	0	B-Chemical
induces	3	O
sympathetic	5	O
withdrawal	5	O
and	5	O
bradycardia	5	B-Disease
,	9	O
we	5	O
hypothesized	9	O
that	5	O
clonidine	0	B-Chemical
'	9	O
s	9	O
developmental	9	O
effects	9	O
on	5	O
cardiac	5	O
rate	9	O
and	5	O
ultrasound	5	O
production	9	O
would	5	O
mirror	5	O
each	5	O
other	5	O
.	9	O

Therefore	9	O
,	9	O
in	5	O
the	5	O
present	9	O
experiment	9	O
,	9	O
the	5	O
effects	9	O
of	5	O
clonidine	0	B-Chemical
administration	9	O
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
on	5	O
cardiac	5	O
rate	9	O
and	5	O
ultrasound	5	O
production	9	O
were	9	O
examined	9	O
in	5	O
2	9	O
-	7	O
,	9	O
8	9	O
-	7	O
,	9	O
15	9	O
-	7	O
,	9	O
and	5	O
20	9	O
-	7	O
day	9	O
-	7	O
old	5	O
rats	9	O
.	9	O

Age	7	O
-	7	O
related	9	O
changes	9	O
in	5	O
ultrasound	5	O
production	9	O
corresponded	9	O
with	5	O
changes	9	O
in	5	O
cardiovascular	5	O
variables	5	O
,	9	O
including	9	O
baseline	5	O
cardiac	5	O
rate	9	O
and	5	O
clonidine	0	B-Chemical
-	7	O
induced	3	O
bradycardia	5	B-Disease
.	9	O

This	5	O
experiment	9	O
is	5	O
discussed	5	O
with	5	O
regard	5	O
to	5	O
the	5	O
hypothesis	9	O
that	5	O
ultrasound	5	O
production	9	O
is	5	O
the	5	O
acoustic	5	O
by	9	O
-	7	O
product	9	O
of	5	O
a	5	O
physiological	9	O
maneuver	5	O
that	5	O
compensates	9	O
for	5	O
clonidine	0	B-Chemical
'	9	O
s	9	O
detrimental	9	O
effects	9	O
on	5	O
cardiovascular	5	O
function	9	O
.	9	O

Recurrent	5	O
use	5	O
of	5	O
newer	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
and	5	O
the	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
.	9	O

The	5	O
epidemiological	5	O
studies	9	O
that	5	O
assessed	9	O
the	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
(	9	O
VTE	5	B-Disease
)	9	O
associated	9	O
with	5	O
newer	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
(	9	O
OC	9	B-Chemical
)	9	O
did	9	O
not	5	O
distinguish	9	O
between	5	O
patterns	5	O
of	5	O
OC	9	B-Chemical
use	5	O
,	9	O
namely	9	O
first	9	O
-	7	O
time	5	O
users	5	O
,	9	O
repeaters	5	O
and	5	O
switchers	5	O
.	9	O

Data	5	O
from	9	O
a	5	O
Transnational	2	O
case	5	O
-	7	O
control	9	O
study	9	O
were	9	O
used	5	O
to	5	O
assess	5	O
the	5	O
risk	5	O
of	5	O
VTE	5	B-Disease
for	5	O
the	5	O
latter	9	O
patterns	5	O
of	5	O
use	5	O
,	9	O
while	9	O
accounting	5	O
for	5	O
duration	5	O
of	5	O
use	5	O
.	9	O

Over	5	O
the	5	O
period	5	O
1993	2	O
-	7	O
1996	2	O
,	9	O
551	7	O
cases	5	O
of	5	O
VTE	5	B-Disease
were	9	O
identified	9	O
in	5	O
Germany	2	O
and	5	O
the	5	O
UK	2	O
along	9	O
with	5	O
2066	7	O
controls	9	O
.	9	O

Totals	7	O
of	5	O
128	9	O
cases	5	O
and	5	O
650	9	O
controls	9	O
were	9	O
analysed	9	O
for	5	O
repeat	9	O
use	5	O
and	5	O
135	7	O
cases	5	O
and	5	O
622	7	O
controls	9	O
for	5	O
switching	5	O
patterns	5	O
.	9	O

The	5	O
adjusted	9	O
rate	9	O
ratio	9	O
of	5	O
VTE	5	B-Disease
for	5	O
repeat	9	O
users	5	O
of	5	O
third	9	O
generation	9	O
OC	9	B-Chemical
was	9	O
0	7	O
.	9	O
6	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
0	7	O
.	9	O
3	9	O
-	7	O
1	9	O
.	9	O
2	9	O
)	9	O
relative	9	O
to	5	O
repeat	9	O
users	5	O
of	5	O
second	9	O
generation	9	O
pills	5	O
,	9	O
whereas	9	O
it	5	O
was	9	O
1	9	O
.	9	O
3	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
:	9	O
0	7	O
.	9	O
7	9	O
-	7	O
2	9	O
.	9	O
4	9	O
)	9	O
for	5	O
switchers	5	O
from	9	O
second	9	O
to	5	O
third	9	O
generation	9	O
pills	5	O
relative	9	O
to	5	O
switchers	5	O
from	9	O
third	9	O
to	5	O
second	9	O
generation	9	O
pills	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
second	9	O
and	5	O
third	9	O
generation	9	O
agents	5	O
are	5	O
associated	9	O
with	5	O
equivalent	9	O
risks	5	O
of	5	O
VTE	5	B-Disease
when	5	O
the	5	O
same	9	O
agent	9	O
is	5	O
used	5	O
repeatedly	5	O
after	9	O
interruption	5	O
periods	5	O
or	5	O
when	5	O
users	5	O
are	5	O
switched	9	O
between	5	O
the	5	O
two	5	O
generations	5	O
of	5	O
pills	5	O
.	9	O

These	5	O
analyses	9	O
suggest	9	O
that	5	O
the	5	O
higher	9	O
risk	5	O
observed	9	O
for	5	O
the	5	O
newer	5	O
OC	9	B-Chemical
in	5	O
other	5	O
studies	9	O
may	5	O
be	5	O
the	5	O
result	9	O
of	5	O
inadequate	5	O
comparisons	5	O
of	5	O
pill	5	O
users	5	O
with	5	O
different	9	O
patterns	5	O
of	5	O
pill	5	O
use	5	O
.	9	O

Differential	9	O
effects	9	O
of	5	O
systemically	9	O
administered	9	O
ketamine	0	B-Chemical
and	5	O
lidocaine	0	B-Chemical
on	5	O
dynamic	5	O
and	5	O
static	5	O
hyperalgesia	3	B-Disease
induced	3	O
by	9	O
intradermal	9	O
capsaicin	0	B-Chemical
in	5	O
humans	9	O
.	9	O

We	9	O
have	5	O
examined	9	O
the	5	O
effect	9	O
of	5	O
systemic	9	O
administration	9	O
of	5	O
ketamine	0	B-Chemical
and	5	O
lidocaine	0	B-Chemical
on	5	O
brush	9	O
-	7	O
evoked	5	O
(	9	O
dynamic	5	O
)	9	O
pain	5	B-Disease
and	5	O
punctate	4	O
-	7	O
evoked	5	O
(	9	O
static	5	O
)	9	O
hyperalgesia	3	B-Disease
induced	3	O
by	9	O
capsaicin	0	B-Chemical
.	9	O

In	9	O
a	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
crossover	5	O
study	9	O
,	9	O
we	5	O
studied	9	O
12	9	O
volunteers	5	O
in	5	O
three	9	O
experiments	9	O
.	9	O

Capsaicin	0	B-Chemical
100	0	O
micrograms	0	O
was	9	O
injected	3	O
intradermally	3	O
on	5	O
the	5	O
volar	5	O
forearm	5	O
followed	9	O
by	9	O
an	5	O
i	9	O
.	9	O
v	0	O
.	9	O
infusion	0	O
of	5	O
ketamine	0	B-Chemical
(	9	O
bolus	0	O
0	7	O
.	9	O
1	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
over	5	O
10	9	O
min	0	O
followed	9	O
by	9	O
infusion	0	O
of	5	O
7	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
min	0	O
-	7	O
1	9	O
)	9	O
,	9	O
lidocaine	0	B-Chemical
5	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
or	5	O
saline	0	O
for	5	O
50	0	O
min	0	O
.	9	O

Infusion	0	O
started	5	O
15	9	O
min	0	O
after	9	O
injection	9	O
of	5	O
capsaicin	0	B-Chemical
.	9	O

The	5	O
following	9	O
were	9	O
measured	9	O
:	9	O
spontaneous	5	O
pain	5	B-Disease
,	9	O
pain	5	B-Disease
evoked	5	O
by	9	O
punctate	4	O
and	5	O
brush	9	O
stimuli	5	O
(	9	O
VAS	5	O
)	9	O
,	9	O
and	5	O
areas	5	O
of	5	O
brush	9	O
-	7	O
evoked	5	O
and	5	O
punctate	4	O
-	7	O
evoked	5	O
hyperalgesia	3	B-Disease
.	9	O

Ketamine	0	B-Chemical
reduced	9	O
both	9	O
the	5	O
area	5	O
of	5	O
brush	9	O
-	7	O
evoked	5	O
and	5	O
punctate	4	O
-	7	O
evoked	5	O
hyperalgesia	3	B-Disease
significantly	9	O
and	5	O
it	5	O
tended	5	O
to	5	O
reduce	5	O
brush	9	O
-	7	O
evoked	5	O
pain	5	B-Disease
.	9	O

Lidocaine	0	B-Chemical
reduced	9	O
the	5	O
area	5	O
of	5	O
punctate	4	O
-	7	O
evoked	5	O
hyperalgesia	3	B-Disease
significantly	9	O
.	9	O

It	5	O
tended	5	O
to	5	O
reduce	5	O
VAS	5	O
scores	5	O
of	5	O
spontaneous	5	O
pain	5	B-Disease
but	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
evoked	5	O
pain	5	B-Disease
.	9	O

The	5	O
differential	9	O
effects	9	O
of	5	O
ketamine	0	B-Chemical
and	5	O
lidocaine	0	B-Chemical
on	5	O
static	5	O
and	5	O
dynamic	5	O
hyperalgesia	3	B-Disease
suggest	9	O
that	5	O
the	5	O
two	5	O
types	9	O
of	5	O
hyperalgesia	3	B-Disease
are	5	O
mediated	3	O
by	9	O
separate	9	O
mechanisms	9	O
and	5	O
have	5	O
a	5	O
distinct	9	O
pharmacology	5	O
.	9	O

Development	2	O
of	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
aggressive	5	B-Disease
behavior	5	I-Disease
:	9	O
comparison	9	O
of	5	O
adult	9	O
male	9	O
and	5	O
female	9	O
Wistar	9	O
rats	9	O
.	9	O

The	5	O
development	9	O
of	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
(	9	O
1	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
once	5	O
daily	5	O
)	9	O
aggressive	5	B-Disease
behavior	5	I-Disease
of	5	O
adult	9	O
male	9	O
and	5	O
female	9	O
Wistar	9	O
rats	9	O
obtained	9	O
from	9	O
the	5	O
same	9	O
breeder	5	O
was	9	O
studied	9	O
in	5	O
two	5	O
consecutive	5	O
sets	5	O
.	9	O

In	9	O
male	9	O
animals	9	O
,	9	O
repeated	5	O
apomorphine	0	B-Chemical
treatment	9	O
induced	3	O
a	5	O
gradual	9	O
development	9	O
of	5	O
aggressive	5	B-Disease
behavior	5	I-Disease
as	5	O
evidenced	9	O
by	9	O
the	5	O
increased	9	O
intensity	5	O
of	5	O
aggressiveness	5	B-Disease
and	5	O
shortened	9	O
latency	5	O
before	9	O
the	5	O
first	9	O
attack	5	O
toward	5	O
the	5	O
opponent	5	O
.	9	O

In	9	O
female	9	O
rats	9	O
,	9	O
only	9	O
a	5	O
weak	9	O
tendency	5	O
toward	5	O
aggressiveness	5	B-Disease
was	9	O
found	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
the	5	O
present	9	O
study	9	O
demonstrates	9	O
gender	5	O
differences	9	O
in	5	O
the	5	O
development	9	O
of	5	O
the	5	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
aggressive	5	B-Disease
behavior	5	I-Disease
and	5	O
indicates	9	O
that	5	O
the	5	O
female	9	O
rats	9	O
do	5	O
not	5	O
fill	5	O
the	5	O
validation	5	O
criteria	5	O
for	5	O
use	5	O
in	5	O
this	5	O
method	5	O
.	9	O

Intracranial	5	B-Disease
aneurysms	5	I-Disease
and	5	O
cocaine	5	B-Disease
abuse	5	I-Disease
:	9	O
analysis	9	O
of	5	O
prognostic	5	O
indicators	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
outcome	5	O
of	5	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
associated	9	O
with	5	O
cocaine	5	B-Disease
abuse	5	I-Disease
is	5	O
reportedly	9	O
poor	5	O
.	9	O

However	9	O
,	9	O
no	9	O
study	9	O
in	5	O
the	5	O
literature	5	O
has	9	O
reported	9	O
the	5	O
use	5	O
of	5	O
a	5	O
statistical	5	O
model	5	O
to	5	O
analyze	9	O
the	5	O
variables	5	O
that	5	O
influence	5	O
outcome	5	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
review	5	O
of	5	O
admissions	5	O
during	5	O
a	5	O
6	9	O
-	7	O
year	5	O
period	5	O
revealed	9	O
14	7	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
related	9	O
aneurysms	5	B-Disease
.	9	O

This	5	O
group	9	O
was	9	O
compared	9	O
with	5	O
a	5	O
control	9	O
group	9	O
of	5	O
135	7	O
patients	5	O
with	5	O
ruptured	5	B-Disease
aneurysms	5	I-Disease
and	5	O
no	9	O
history	5	O
of	5	O
cocaine	5	B-Disease
abuse	5	I-Disease
.	9	O

Age	7	O
at	9	O
presentation	5	O
,	9	O
time	5	O
of	5	O
ictus	5	O
after	9	O
intoxication	9	O
,	9	O
Hunt	6	O
and	5	O
Hess	6	O
grade	9	O
of	5	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
,	9	O
size	9	O
of	5	O
the	5	O
aneurysm	5	B-Disease
,	9	O
location	5	O
of	5	O
the	5	O
aneurysm	5	B-Disease
,	9	O
and	5	O
the	5	O
Glasgow	5	O
Outcome	5	O
Scale	5	O
score	5	O
were	9	O
assessed	9	O
and	5	O
compared	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
patients	5	O
in	5	O
the	5	O
study	9	O
group	9	O
were	9	O
significantly	9	O
younger	5	O
than	5	O
the	5	O
patients	5	O
in	5	O
the	5	O
control	9	O
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

In	9	O
patients	5	O
in	5	O
the	5	O
study	9	O
group	9	O
,	9	O
all	5	O
aneurysms	5	B-Disease
were	9	O
located	9	O
in	5	O
the	5	O
anterior	5	O
circulation	9	O
.	9	O

The	5	O
majority	9	O
of	5	O
these	5	O
aneurysms	5	B-Disease
were	9	O
smaller	5	O
than	5	O
those	5	O
of	5	O
the	5	O
control	9	O
group	9	O
(	9	O
8	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
08	7	O
mm	9	O
versus	9	O
11	7	O
+	9	O
/	9	O
-	7	O
5	9	O
.	9	O
4	9	O
mm	9	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
differences	9	O
in	5	O
mortality	5	O
and	5	O
morbidity	5	O
between	5	O
the	5	O
two	5	O
groups	9	O
were	9	O
not	5	O
significant	9	O
.	9	O

Hunt	6	O
and	5	O
Hess	6	O
grade	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
005	7	O
)	9	O
and	5	O
age	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
007	2	O
)	9	O
were	9	O
significant	9	O
predictors	5	O
of	5	O
outcome	5	O
for	5	O
the	5	O
patients	5	O
with	5	O
cocaine	5	B-Chemical
-	7	O
related	9	O
aneurysms	5	B-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Cocaine	5	B-Chemical
use	5	O
predisposed	5	O
aneurysmal	5	B-Disease
rupture	5	I-Disease
at	9	O
a	5	O
significantly	9	O
earlier	9	O
age	5	O
and	5	O
in	5	O
much	5	O
smaller	5	O
aneurysms	5	B-Disease
.	9	O

Contrary	9	O
to	5	O
the	5	O
published	9	O
literature	5	O
,	9	O
this	5	O
group	9	O
did	9	O
reasonably	5	O
well	9	O
with	5	O
aggressive	5	O
management	5	O
.	9	O

Effect	0	O
of	5	O
intravenous	0	O
nimodipine	0	B-Chemical
on	5	O
blood	9	O
pressure	5	O
and	5	O
outcome	5	O
after	9	O
acute	9	B-Disease
stroke	5	I-Disease
.	9	O

BACKGROUND	2	O
AND	2	O
PURPOSE	2	O
:	9	O
The	5	O
Intravenous	0	O
Nimodipine	0	B-Chemical
West	4	O
European	5	O
Stroke	5	B-Disease
Trial	5	O
(	9	O
INWEST	9	O
)	9	O
found	9	O
a	5	O
correlation	9	O
between	5	O
nimodipine	0	B-Chemical
-	7	O
induced	3	O
reduction	9	B-Disease
in	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
(	9	O
BP	9	O
)	9	O
and	5	O
an	5	O
unfavorable	5	O
outcome	5	O
in	5	O
acute	9	B-Disease
stroke	5	I-Disease
.	9	O

We	9	O
sought	9	O
to	5	O
confirm	9	O
this	5	O
correlation	9	O
with	5	O
and	5	O
without	9	O
adjustment	5	O
for	5	O
prognostic	5	O
variables	5	O
and	5	O
to	5	O
investigate	9	O
outcome	5	O
in	5	O
subgroups	9	O
with	5	O
increasing	9	O
levels	3	O
of	5	O
BP	9	B-Disease
reduction	9	I-Disease
.	9	O

METHODS	2	O
:	9	O
Patients	5	O
with	5	O
a	5	O
clinical	5	O
diagnosis	5	O
of	5	O
ischemic	9	B-Disease
stroke	5	I-Disease
(	9	O
within	9	O
24	9	O
hours	9	O
)	9	O
were	9	O
consecutively	5	O
allocated	5	O
to	5	O
receive	5	O
placebo	9	O
(	9	O
n	9	O
=	7	O
100	0	O
)	9	O
,	9	O
1	9	O
mg	0	O
/	9	O
h	0	O
(	9	O
low	9	O
-	7	O
dose	9	O
)	9	O
nimodipine	0	B-Chemical
(	9	O
n	9	O
=	7	O
101	7	O
)	9	O
,	9	O
or	5	O
2	9	O
mg	0	O
/	9	O
h	0	O
(	9	O
high	9	O
-	7	O
dose	9	O
)	9	O
nimodipine	0	B-Chemical
(	9	O
n	9	O
=	7	O
94	7	O
)	9	O
.	9	O

The	5	O
correlation	9	O
between	5	O
average	5	O
BP	9	O
change	9	O
during	5	O
the	5	O
first	9	O
2	9	O
days	9	O
and	5	O
the	5	O
outcome	5	O
at	9	O
day	9	O
21	7	O
was	9	O
analyzed	9	O
.	9	O

RESULTS	9	O
:	9	O
Two	9	O
hundred	5	O
sixty	5	O
-	7	O
five	9	O
patients	5	O
were	9	O
included	5	O
in	5	O
this	5	O
analysis	9	O
(	9	O
n	9	O
=	7	O
92	7	O
,	9	O
93	7	O
,	9	O
and	5	O
80	9	O
for	5	O
placebo	9	O
,	9	O
low	9	O
dose	9	O
,	9	O
and	5	O
high	9	O
dose	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Nimodipine	0	B-Chemical
treatment	9	O
resulted	9	O
in	5	O
a	5	O
statistically	9	O
significant	9	O
reduction	9	B-Disease
in	5	I-Disease
systolic	5	I-Disease
BP	9	I-Disease
(	9	O
SBP	9	O
)	9	O
and	5	O
diastolic	5	O
BP	9	O
(	9	O
DBP	9	O
)	9	O
from	9	O
baseline	5	O
compared	9	O
with	5	O
placebo	9	O
during	5	O
the	5	O
first	9	O
few	5	O
days	9	O
.	9	O

In	9	O
multivariate	5	O
analysis	9	O
,	9	O
a	5	O
significant	9	O
correlation	9	O
between	5	O
DBP	9	B-Disease
reduction	9	I-Disease
and	5	O
worsening	5	O
of	5	O
the	5	O
neurological	5	O
score	5	O
was	9	O
found	9	O
for	5	O
the	5	O
high	9	O
-	7	O
dose	9	O
group	9	O
(	9	O
beta	9	O
=	7	O
0	7	O
.	9	O
49	7	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
048	7	O
)	9	O
.	9	O

Patients	5	O
with	5	O
a	5	O
DBP	9	B-Disease
reduction	9	I-Disease
of	5	O
>	0	O
or	5	O
=	7	O
20	9	O
%	9	O
in	5	O
the	5	O
high	9	O
-	7	O
dose	9	O
group	9	O
had	9	O
a	5	O
significantly	9	O
increased	9	O
adjusted	9	O
OR	9	O
for	5	O
the	5	O
compound	0	O
outcome	5	O
variable	5	O
death	9	B-Disease
or	5	O
dependency	5	O
(	9	O
Barthel	5	O
Index	5	O
<	0	O
60	9	O
)	9	O
(	9	O
n	9	O
/	9	O
N	9	O
=	7	O
25	9	O
/	9	O
26	7	O
,	9	O
OR	9	O
10	9	O
.	9	O
16	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
02	7	O
to	5	O
101	7	O
.	9	O
74	7	O
)	9	O
and	5	O
death	9	B-Disease
alone	9	O
(	9	O
n	9	O
/	9	O
N	9	O
=	7	O
9	7	O
/	9	O
26	7	O
,	9	O
OR	9	O
4	9	O
.	9	O
336	7	O
,	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
131	7	O
16	9	O
.	9	O
619	7	O
)	9	O
compared	9	O
with	5	O
all	5	O
placebo	9	O
patients	5	O
(	9	O
n	9	O
/	9	O
N	9	O
=	7	O
62	7	O
/	9	O
92	7	O
and	5	O
14	7	O
/	9	O
92	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

There	5	O
was	9	O
no	9	O
correlation	9	O
between	5	O
SBP	9	O
change	9	O
and	5	O
outcome	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
DBP	9	O
,	9	O
but	9	O
not	5	O
SBP	9	O
,	9	O
reduction	9	O
was	9	O
associated	9	O
with	5	O
neurological	5	O
worsening	5	O
after	9	O
the	5	O
intravenous	0	O
administration	9	O
of	5	O
high	9	O
-	7	O
dose	9	O
nimodipine	0	B-Chemical
after	9	O
acute	9	B-Disease
stroke	5	I-Disease
.	9	O

For	9	O
low	9	O
-	7	O
dose	9	O
nimodipine	0	B-Chemical
,	9	O
the	5	O
results	9	O
were	9	O
not	5	O
conclusive	9	O
.	9	O

These	5	O
results	9	O
do	5	O
not	5	O
confirm	9	O
or	5	O
exclude	9	O
a	5	O
neuroprotective	9	O
property	5	O
of	5	O
nimodipine	0	B-Chemical
.	9	O

Neonatal	9	O
pyridoxine	0	B-Chemical
responsive	9	O
convulsions	5	B-Disease
due	5	O
to	5	O
isoniazid	0	B-Chemical
therapy	5	O
.	9	O

A	9	O
17	7	O
-	7	O
day	9	O
-	7	O
old	5	O
infant	5	O
on	5	O
isoniazid	0	B-Chemical
therapy	5	O
13	7	O
mg	0	O
/	9	O
kg	0	O
daily	5	O
from	9	O
birth	5	O
because	5	O
of	5	O
maternal	9	O
tuberculosis	9	B-Disease
was	9	O
admitted	5	O
after	9	O
4	9	O
days	9	O
of	5	O
clonic	5	B-Disease
fits	5	I-Disease
.	9	O

No	9	O
underlying	5	O
infective	9	O
or	5	O
biochemical	9	O
cause	5	O
could	9	O
be	5	O
found	9	O
.	9	O

The	5	O
fits	5	B-Disease
ceased	5	O
within	9	O
4	9	O
hours	9	O
of	5	O
administering	9	O
intramuscular	9	O
pyridoxine	0	B-Chemical
,	9	O
suggesting	9	O
an	5	O
aetiology	5	O
of	5	O
pyridoxine	0	B-Chemical
deficiency	9	O
secondary	9	O
to	5	O
isoniazid	0	B-Chemical
medication	5	O
.	9	O

Ketamine	0	B-Chemical
sedation	5	O
for	5	O
the	5	O
reduction	9	O
of	5	O
children	5	O
'	9	O
s	9	O
fractures	5	B-Disease
in	5	O
the	5	O
emergency	5	O
department	5	O
.	9	O

BACKGROUND	2	O
:	9	O
There	5	O
recently	9	O
has	9	O
been	9	O
a	5	O
resurgence	5	O
in	5	O
the	5	O
utilization	9	O
of	5	O
ketamine	0	B-Chemical
,	9	O
a	5	O
unique	9	O
anesthetic	5	O
,	9	O
for	5	O
emergency	5	O
-	7	O
department	5	O
procedures	5	O
requiring	5	O
sedation	5	O
.	9	O

The	5	O
purpose	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
examine	9	O
the	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
ketamine	0	B-Chemical
for	5	O
sedation	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
children	5	O
'	9	O
s	9	O
fractures	5	B-Disease
in	5	O
the	5	O
emergency	5	O
department	5	O
.	9	O

METHODS	2	O
:	9	O
One	5	O
hundred	5	O
and	5	O
fourteen	9	O
children	5	O
(	9	O
average	5	O
age	5	O
,	9	O
5	9	O
.	9	O
3	9	O
years	5	O
;	9	O
range	9	O
,	9	O
twelve	9	O
months	5	O
to	5	O
ten	9	O
years	5	O
and	5	O
ten	9	O
months	5	O
)	9	O
who	5	O
underwent	5	O
closed	5	O
reduction	9	O
of	5	O
an	5	O
isolated	9	O
fracture	5	B-Disease
or	5	O
dislocation	5	B-Disease
in	5	O
the	5	O
emergency	5	O
department	5	O
at	9	O
a	5	O
level	9	O
-	7	O
I	9	O
trauma	5	B-Disease
center	5	O
were	9	O
prospectively	5	O
evaluated	9	O
.	9	O

Ketamine	0	B-Chemical
hydrochloride	0	I-Chemical
was	9	O
administered	9	O
intravenously	0	O
(	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
two	5	O
milligrams	0	O
per	9	O
kilogram	0	O
of	5	O
body	5	O
weight	9	O
)	9	O
in	5	O
ninety	5	O
-	7	O
nine	9	O
of	5	O
the	5	O
patients	5	O
and	5	O
intramuscularly	0	O
(	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
four	9	O
milligrams	0	O
per	9	O
kilogram	0	O
of	5	O
body	5	O
weight	9	O
)	9	O
in	5	O
the	5	O
other	5	O
fifteen	9	O
.	9	O

A	9	O
board	5	O
-	7	O
certified	5	O
emergency	5	O
physician	5	O
skilled	5	O
in	5	O
airway	5	O
management	5	O
supervised	5	O
administration	9	O
of	5	O
the	5	O
anesthetic	5	O
,	9	O
and	5	O
the	5	O
patients	5	O
were	9	O
monitored	9	O
by	9	O
a	5	O
registered	5	O
nurse	5	O
.	9	O

Any	5	O
pain	5	B-Disease
during	5	O
the	5	O
reduction	9	O
was	9	O
rated	5	O
by	9	O
the	5	O
orthopaedic	5	O
surgeon	5	O
treating	5	O
the	5	O
patient	5	O
according	9	O
to	5	O
the	5	O
Children	5	O
'	9	O
s	9	O
Hospital	2	O
of	5	O
Eastern	4	O
Ontario	2	O
Pain	5	B-Disease
Scale	5	O
(	9	O
CHEOPS	5	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
average	5	O
time	5	O
from	9	O
intravenous	0	O
administration	9	O
of	5	O
ketamine	0	B-Chemical
to	5	O
manipulation	5	O
of	5	O
the	5	O
fracture	5	B-Disease
or	5	O
dislocation	5	B-Disease
was	9	O
one	5	O
minute	5	O
and	5	O
thirty	5	O
-	7	O
six	9	O
seconds	5	O
(	9	O
range	9	O
,	9	O
twenty	5	O
seconds	5	O
to	5	O
five	9	O
minutes	0	O
)	9	O
,	9	O
and	5	O
the	5	O
average	5	O
time	5	O
from	9	O
intramuscular	9	O
administration	9	O
to	5	O
manipulation	5	O
was	9	O
four	9	O
minutes	0	O
and	5	O
forty	5	O
-	7	O
two	5	O
seconds	5	O
(	9	O
range	9	O
,	9	O
sixty	5	O
seconds	5	O
to	5	O
fifteen	9	O
minutes	0	O
)	9	O
.	9	O

The	5	O
average	5	O
score	5	O
according	9	O
to	5	O
the	5	O
Children	5	O
'	9	O
s	9	O
Hospital	2	O
of	5	O
Eastern	4	O
Ontario	2	O
Pain	5	B-Disease
Scale	5	O
was	9	O
6	9	O
.	9	O
4	9	O
points	5	O
(	9	O
range	9	O
,	9	O
5	9	O
to	5	O
10	9	O
points	5	O
)	9	O
,	9	O
reflecting	5	O
minimal	9	O
or	5	O
no	9	O
pain	5	B-Disease
during	5	O
fracture	5	B-Disease
reduction	9	O
.	9	O

Adequate	5	O
fracture	5	B-Disease
reduction	9	O
was	9	O
obtained	9	O
in	5	O
111	7	O
of	5	O
the	5	O
children	5	O
.	9	O

Ninety	5	O
-	7	O
nine	9	O
percent	5	O
(	9	O
sixty	5	O
-	7	O
eight	9	O
)	9	O
of	5	O
the	5	O
sixty	5	O
-	7	O
nine	9	O
parents	5	O
present	9	O
during	5	O
the	5	O
reduction	9	O
were	9	O
pleased	5	O
with	5	O
the	5	O
sedation	5	O
and	5	O
would	5	O
allow	5	O
it	5	O
to	5	O
be	5	O
used	5	O
again	9	O
in	5	O
a	5	O
similar	9	O
situation	5	O
.	9	O

Patency	5	O
of	5	O
the	5	O
airway	5	O
and	5	O
independent	9	O
respiration	9	O
were	9	O
maintained	9	O
in	5	O
all	5	O
of	5	O
the	5	O
patients	5	O
.	9	O

Blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
remained	9	O
stable	9	O
.	9	O

Minor	9	O
side	5	O
effects	9	O
included	5	O
nausea	5	B-Disease
(	9	O
thirteen	9	O
patients	5	O
)	9	O
,	9	O
emesis	5	B-Disease
(	9	O
eight	9	O
of	5	O
the	5	O
thirteen	9	O
patients	5	O
with	5	O
nausea	5	B-Disease
)	9	O
,	9	O
clumsiness	5	B-Disease
(	9	O
evident	9	O
as	5	O
ataxic	5	B-Disease
movements	5	I-Disease
in	5	O
ten	9	O
patients	5	O
)	9	O
,	9	O
and	5	O
dysphoric	5	B-Disease
reaction	9	I-Disease
(	9	O
one	5	O
patient	5	O
)	9	O
.	9	O

No	9	O
long	5	O
-	7	O
term	5	O
sequelae	5	O
were	9	O
noted	9	O
,	9	O
and	5	O
no	9	O
patients	5	O
had	9	O
hallucinations	5	B-Disease
or	5	O
nightmares	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Ketamine	0	B-Chemical
reliably	5	O
,	9	O
safely	5	O
,	9	O
and	5	O
quickly	5	O
provided	9	O
adequate	5	O
sedation	5	O
to	5	O
effectively	5	O
facilitate	5	O
the	5	O
reduction	9	O
of	5	O
children	5	O
'	9	O
s	9	O
fractures	5	B-Disease
in	5	O
the	5	O
emergency	5	O
department	5	O
at	9	O
our	5	O
institution	5	O
.	9	O

Ketamine	0	B-Chemical
should	5	O
only	9	O
be	5	O
used	5	O
in	5	O
an	5	O
environment	5	O
such	5	O
as	5	O
the	5	O
emergency	5	O
department	5	O
,	9	O
where	5	O
proper	5	O
one	5	O
-	7	O
on	5	O
-	7	O
one	5	O
monitoring	5	O
is	5	O
used	5	O
and	5	O
board	5	O
-	7	O
certified	5	O
physicians	5	O
skilled	5	O
in	5	O
airway	5	O
management	5	O
are	5	O
directly	9	O
involved	9	O
in	5	O
the	5	O
care	5	O
of	5	O
the	5	O
patient	5	O
.	9	O

Cyclosporine	0	B-Chemical
and	5	O
tacrolimus	0	B-Chemical
-	7	O
associated	9	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
.	9	O

The	5	O
development	9	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
(	9	O
TMA	9	B-Disease
)	9	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
cyclosporine	0	B-Chemical
has	9	O
been	9	O
well	9	O
documented	9	O
.	9	O

Treatments	9	O
have	5	O
included	5	O
discontinuation	5	O
or	5	O
reduction	9	O
of	5	O
cyclosporine	0	B-Chemical
dose	9	O
with	5	O
or	5	O
without	9	O
concurrent	5	O
plasma	9	O
exchange	9	O
,	9	O
plasma	9	O
infusion	0	O
,	9	O
anticoagulation	5	O
,	9	O
and	5	O
intravenous	0	O
immunoglobulin	3	O
G	9	O
infusion	0	O
.	9	O

However	9	O
,	9	O
for	5	O
recipients	9	O
of	5	O
organ	5	O
transplantation	9	O
,	9	O
removing	5	O
the	5	O
inciting	5	O
agent	9	O
is	5	O
not	5	O
without	9	O
the	5	O
attendant	5	O
risk	5	O
of	5	O
precipitating	9	O
acute	9	O
rejection	5	O
and	5	O
graft	5	O
loss	9	O
.	9	O

The	5	O
last	5	O
decade	5	O
has	9	O
seen	9	O
the	5	O
emergence	9	O
of	5	O
tacrolimus	0	B-Chemical
as	5	O
a	5	O
potent	3	O
immunosuppressive	9	O
agent	9	O
with	5	O
mechanisms	9	O
of	5	O
action	5	O
virtually	9	O
identical	9	O
to	5	O
those	5	O
of	5	O
cyclosporine	0	B-Chemical
.	9	O

As	9	O
a	5	O
result	9	O
,	9	O
switching	5	O
to	5	O
tacrolimus	0	B-Chemical
has	9	O
been	9	O
reported	9	O
to	5	O
be	5	O
a	5	O
viable	9	O
therapeutic	5	O
option	5	O
in	5	O
the	5	O
setting	5	O
of	5	O
cyclosporine	0	B-Chemical
-	7	O
induced	3	O
TMA	9	B-Disease
.	9	O

With	5	O
the	5	O
more	5	O
widespread	5	O
application	5	O
of	5	O
tacrolimus	0	B-Chemical
in	5	O
organ	5	O
transplantation	9	O
,	9	O
tacrolimus	0	B-Chemical
-	7	O
associated	9	O
TMA	9	B-Disease
has	9	O
also	9	O
been	9	O
recognized	9	O
.	9	O

However	9	O
,	9	O
literature	5	O
regarding	5	O
the	5	O
incidence	5	O
of	5	O
the	5	O
recurrence	5	O
of	5	O
TMA	9	B-Disease
in	5	O
patients	5	O
exposed	9	O
sequentially	9	O
to	5	O
cyclosporine	0	B-Chemical
and	5	O
tacrolimus	0	B-Chemical
is	5	O
limited	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
a	5	O
living	5	O
donor	9	O
renal	9	O
transplant	9	O
recipient	9	O
who	5	O
developed	5	O
cyclosporine	0	B-Chemical
-	7	O
induced	3	O
TMA	9	B-Disease
that	5	O
responded	9	O
to	5	O
the	5	O
withdrawal	5	O
of	5	O
cyclosporine	0	B-Chemical
in	5	O
conjunction	9	O
with	5	O
plasmapheresis	5	O
and	5	O
fresh	9	O
frozen	9	O
plasma	9	O
replacement	9	O
therapy	5	O
.	9	O

Introduction	5	O
of	5	O
tacrolimus	0	B-Chemical
as	5	O
an	5	O
alternative	5	O
immunosuppressive	9	O
agent	9	O
resulted	9	O
in	5	O
the	5	O
recurrence	5	O
of	5	O
TMA	9	B-Disease
and	5	O
the	5	O
subsequent	9	O
loss	9	O
of	5	O
the	5	O
renal	9	O
allograft	5	O
.	9	O

Patients	5	O
who	5	O
are	5	O
switched	9	O
from	9	O
cyclosporine	0	B-Chemical
to	5	O
tacrolimus	0	B-Chemical
or	5	O
vice	9	O
versa	9	O
should	5	O
be	5	O
closely	9	O
monitored	9	O
for	5	O
the	5	O
signs	5	O
and	5	O
symptoms	5	O
of	5	O
recurrent	5	O
TMA	9	B-Disease
.	9	O

Analgesic	0	O
effect	9	O
of	5	O
intravenous	0	O
ketamine	0	B-Chemical
in	5	O
cancer	3	B-Disease
patients	5	O
on	5	O
morphine	0	B-Chemical
therapy	5	O
:	9	O
a	5	O
randomized	5	O
,	9	O
controlled	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
crossover	5	O
,	9	O
double	9	O
-	7	O
dose	9	O
study	9	O
.	9	O

Pain	5	B-Disease
not	5	O
responsive	9	O
to	5	O
morphine	0	B-Chemical
is	5	O
often	5	O
problematic	5	O
.	9	O

Animal	2	O
and	5	O
clinical	5	O
studies	9	O
have	5	O
suggested	9	O
that	5	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
antagonists	3	O
,	9	O
such	5	O
as	5	O
ketamine	0	B-Chemical
,	9	O
may	5	O
be	5	O
effective	5	O
in	5	O
improving	5	O
opioid	5	O
analgesia	5	O
in	5	O
difficult	5	O
pain	5	B-Disease
syndromes	5	O
,	9	O
such	5	O
as	5	O
neuropathic	5	B-Disease
pain	5	I-Disease
.	9	O

A	9	O
slow	5	O
bolus	0	O
of	5	O
subhypnotic	5	O
doses	0	O
of	5	O
ketamine	0	B-Chemical
(	9	O
0	7	O
.	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
or	5	O
0	7	O
.	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
given	5	O
to	5	O
10	9	O
cancer	3	B-Disease
patients	5	O
whose	9	O
pain	5	B-Disease
was	9	O
unrelieved	5	O
by	9	O
morphine	0	B-Chemical
in	5	O
a	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
crossover	5	O
,	9	O
double	9	O
-	7	O
dose	9	O
study	9	O
.	9	O

Pain	5	B-Disease
intensity	5	O
on	5	O
a	5	O
0	7	O
to	5	O
10	9	O
numerical	5	O
scale	5	O
;	9	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
,	9	O
drowsiness	5	O
,	9	O
confusion	5	B-Disease
,	9	O
and	5	O
dry	0	B-Disease
mouth	5	I-Disease
,	9	O
using	9	O
a	5	O
scale	5	O
from	9	O
0	7	O
to	5	O
3	9	O
(	9	O
not	5	O
at	9	O
all	5	O
,	9	O
slight	9	O
,	9	O
a	5	O
lot	5	O
,	9	O
awful	5	O
)	9	O
;	9	O
Mini	0	O
-	7	O
Mental	5	O
State	2	O
Examination	9	O
(	9	O
MMSE	5	O
)	9	O
(	9	O
0	7	O
-	7	O
30	9	O
)	9	O
;	9	O
and	5	O
arterial	5	O
pressure	5	O
were	9	O
recorded	5	O
before	9	O
administration	9	O
of	5	O
drugs	5	O
(	9	O
T0	9	O
)	9	O
and	5	O
after	9	O
30	9	O
minutes	0	O
(	9	O
T30	9	O
)	9	O
,	9	O
60	9	O
minutes	0	O
(	9	O
T60	0	O
)	9	O
,	9	O
120	9	O
minutes	0	O
(	9	O
T120	1	O
)	9	O
,	9	O
and	5	O
180	9	O
minutes	0	O
(	9	O
T180	3	O
)	9	O
.	9	O

Ketamine	0	B-Chemical
,	9	O
but	9	O
not	5	O
saline	0	O
solution	0	O
,	9	O
significantly	9	O
reduced	9	O
the	5	O
pain	5	B-Disease
intensity	5	O
in	5	O
almost	9	O
all	5	O
the	5	O
patients	5	O
at	9	O
both	9	O
doses	0	O
.	9	O

This	5	O
effect	9	O
was	9	O
more	5	O
relevant	5	O
in	5	O
patients	5	O
treated	3	O
with	5	O
higher	9	O
doses	0	O
.	9	O

Hallucinations	5	B-Disease
occurred	9	O
in	5	O
4	9	O
patients	5	O
,	9	O
and	5	O
an	5	O
unpleasant	5	O
sensation	5	O
(	9	O
"	5	O
empty	3	O
head	5	O
"	5	O
)	9	O
was	9	O
also	9	O
reported	9	O
by	9	O
2	9	O
patients	5	O
.	9	O

These	5	O
episodes	5	O
reversed	9	O
after	9	O
the	5	O
administration	9	O
of	5	O
diazepam	0	B-Chemical
1	9	O
mg	0	O
intravenously	0	O
.	9	O

Significant	9	O
increases	9	O
in	5	O
drowsiness	5	O
were	9	O
reported	9	O
in	5	O
patients	5	O
treated	3	O
with	5	O
ketamine	0	B-Chemical
in	5	O
both	9	O
groups	9	O
and	5	O
were	9	O
more	5	O
marked	9	O
with	5	O
ketamine	0	B-Chemical
0	7	O
.	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
.	9	O

A	9	O
significant	9	O
difference	9	O
in	5	O
MMSE	5	O
was	9	O
observed	9	O
at	9	O
T30	9	O
in	5	O
patients	5	O
who	5	O
received	9	O
0	7	O
.	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
of	5	O
ketamine	0	B-Chemical
.	9	O

Ketamine	0	B-Chemical
can	5	O
improve	5	O
morphine	0	B-Chemical
analgesia	5	O
in	5	O
difficult	5	O
pain	5	B-Disease
syndromes	5	O
,	9	O
such	5	O
as	5	O
neuropathic	5	B-Disease
pain	5	I-Disease
.	9	O

However	9	O
,	9	O
the	5	O
occurrence	5	O
of	5	O
central	5	O
adverse	5	O
effects	9	O
should	5	O
be	5	O
taken	5	O
into	9	O
account	5	O
,	9	O
especially	5	O
when	5	O
using	9	O
higher	9	O
doses	0	O
.	9	O

This	5	O
observation	9	O
should	5	O
be	5	O
tested	9	O
in	5	O
studies	9	O
of	5	O
prolonged	9	O
ketamine	0	B-Chemical
administration	9	O
.	9	O

Paclitaxel	0	B-Chemical
,	9	O
cisplatin	3	B-Chemical
,	9	O
and	5	O
gemcitabine	3	B-Chemical
combination	9	O
chemotherapy	5	O
within	9	O
a	5	O
multidisciplinary	5	O
therapeutic	5	O
approach	5	O
in	5	O
metastatic	3	O
nonsmall	3	B-Disease
cell	3	I-Disease
lung	9	I-Disease
carcinoma	3	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Cisplatin	0	B-Chemical
-	7	O
based	5	O
chemotherapy	5	O
combinations	9	O
improve	5	O
quality	5	O
of	5	O
life	5	O
and	5	O
survival	9	O
in	5	O
advanced	5	O
nonsmall	3	B-Disease
cell	3	I-Disease
lung	9	I-Disease
carcinoma	3	I-Disease
(	9	O
NSCLC	3	B-Disease
)	9	O
.	9	O

The	5	O
emergence	9	O
of	5	O
new	5	O
active	9	O
drugs	5	O
might	9	O
translate	5	O
into	9	O
more	5	O
effective	5	O
regimens	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
this	5	O
disease	5	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
feasibility	5	O
,	9	O
response	9	O
rate	9	O
,	9	O
and	5	O
toxicity	9	B-Disease
of	5	O
a	5	O
paclitaxel	0	B-Chemical
,	9	O
cisplatin	3	B-Chemical
,	9	O
and	5	O
gemcitabine	3	B-Chemical
combination	9	O
to	5	O
treat	5	O
metastatic	3	O
NSCLC	3	B-Disease
.	9	O

Thirty	9	O
-	7	O
five	9	O
consecutive	5	O
chemotherapy	5	O
-	7	O
naive	3	O
patients	5	O
with	5	O
Stage	9	O
IV	9	O
NSCLC	3	B-Disease
and	5	O
an	5	O
Eastern	4	O
Cooperative	2	O
Oncology	2	O
Group	9	O
performance	5	O
status	9	O
of	5	O
0	7	O
-	7	O
2	9	O
were	9	O
treated	3	O
with	5	O
a	5	O
combination	9	O
of	5	O
paclitaxel	0	B-Chemical
(	9	O
135	7	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
given	5	O
intravenously	0	O
in	5	O
3	9	O
hours	9	O
)	9	O
on	5	O
Day	9	O
1	9	O
,	9	O
cisplatin	3	B-Chemical
(	9	O
120	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
given	5	O
intravenously	0	O
in	5	O
6	9	O
hours	9	O
)	9	O
on	5	O
Day	9	O
1	9	O
,	9	O
and	5	O
gemcitabine	3	B-Chemical
(	9	O
800	0	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
given	5	O
intravenously	0	O
in	5	O
30	9	O
minutes	0	O
)	9	O
on	5	O
Days	9	O
1	9	O
and	5	O
8	9	O
,	9	O
every	5	O
4	9	O
weeks	9	O
.	9	O

Although	9	O
responding	5	O
patients	5	O
were	9	O
scheduled	5	O
to	5	O
receive	5	O
consolidation	5	O
radiotherapy	5	O
and	5	O
24	9	O
patients	5	O
received	9	O
preplanned	5	O
second	9	O
-	7	O
line	9	O
chemotherapy	5	O
after	9	O
disease	5	O
progression	9	O
,	9	O
the	5	O
response	9	O
and	5	O
toxicity	9	B-Disease
rates	5	O
reported	9	O
refer	5	O
only	9	O
to	5	O
the	5	O
chemotherapy	5	O
regimen	5	O
given	5	O
.	9	O

RESULTS	9	O
:	9	O
All	9	O
the	5	O
patients	5	O
were	9	O
examined	9	O
for	5	O
toxicity	9	B-Disease
;	9	O
34	7	O
were	9	O
examinable	5	O
for	5	O
response	9	O
.	9	O

An	5	O
objective	5	O
response	9	O
was	9	O
observed	9	O
in	5	O
73	7	O
.	9	O
5	9	O
%	9	O
of	5	O
the	5	O
patients	5	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
[	9	O
CI	7	O
]	9	O
,	9	O
55	7	O
.	9	O
6	9	O
-	7	O
87	7	O
.	9	O
1	9	O
%	9	O
)	9	O
,	9	O
including	9	O
4	9	O
complete	9	O
responses	5	O
(	9	O
11	7	O
.	9	O
7	9	O
%	9	O
)	9	O
.	9	O

According	5	O
to	5	O
intention	5	O
-	7	O
to	5	O
-	7	O
treat	5	O
,	9	O
the	5	O
overall	5	O
response	9	O
rate	9	O
was	9	O
71	7	O
.	9	O
4	9	O
%	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
53	7	O
.	9	O
7	9	O
-	7	O
85	9	O
.	9	O
4	9	O
%	9	O
)	9	O
.	9	O

After	9	O
154	7	O
courses	5	O
of	5	O
therapy	5	O
,	9	O
the	5	O
median	9	O
dose	9	O
intensity	5	O
was	9	O
131	7	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
for	5	O
paclitaxel	0	B-Chemical
(	9	O
97	7	O
.	9	O
3	9	O
%	9	O
)	9	O
,	9	O
117	7	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
for	5	O
cisplatin	3	B-Chemical
(	9	O
97	7	O
.	9	O
3	9	O
%	9	O
)	9	O
,	9	O
and	5	O
1378	7	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
for	5	O
gemcitabine	3	B-Chemical
(	9	O
86	7	O
.	9	O
2	9	O
%	9	O
)	9	O
.	9	O

World	5	O
Health	2	O
Organization	2	O
Grade	9	O
3	9	O
-	7	O
4	9	O
neutropenia	5	B-Disease
and	5	O
thrombocytopenia	9	B-Disease
occurred	9	O
in	5	O
39	7	O
.	9	O
9	7	O
%	9	O
and	5	O
11	7	O
.	9	O
4	9	O
%	9	O
of	5	O
patients	5	O
,	9	O
respectively	9	O
.	9	O

There	5	O
was	9	O
one	5	O
treatment	9	O
-	7	O
related	9	O
death	9	B-Disease
.	9	O

Nonhematologic	7	O
toxicities	5	B-Disease
were	9	O
mild	9	O
.	9	O

After	9	O
a	5	O
median	9	O
follow	5	O
-	7	O
up	5	O
of	5	O
22	7	O
months	5	O
,	9	O
the	5	O
median	9	O
progression	9	O
free	9	O
survival	9	O
rate	9	O
was	9	O
7	9	O
months	5	O
,	9	O
and	5	O
the	5	O
median	9	O
survival	9	O
time	5	O
was	9	O
16	9	O
months	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
combination	9	O
of	5	O
paclitaxel	0	B-Chemical
,	9	O
cisplatin	3	B-Chemical
,	9	O
and	5	O
gemcitabine	3	B-Chemical
is	5	O
well	9	O
tolerated	9	O
and	5	O
shows	9	O
high	9	O
activity	9	O
in	5	O
metastatic	3	O
NSCLC	3	B-Disease
.	9	O

This	5	O
treatment	9	O
merits	5	O
further	9	O
comparison	9	O
with	5	O
other	5	O
cisplatin	3	B-Chemical
-	7	O
based	5	O
regimens	5	O
.	9	O

Serotonergic	5	B-Chemical
antidepressants	5	I-Chemical
and	5	O
urinary	9	B-Disease
incontinence	5	I-Disease
.	9	O

Many	5	O
new	5	O
serotonergic	5	B-Chemical
antidepressants	5	I-Chemical
have	5	O
been	9	O
introduced	9	O
over	5	O
the	5	O
past	5	O
decade	5	O
.	9	O

Although	9	O
urinary	9	B-Disease
incontinence	5	I-Disease
is	5	O
listed	9	O
as	5	O
one	5	O
side	5	O
effect	9	O
of	5	O
these	5	O
drugs	5	O
in	5	O
their	5	O
package	5	O
inserts	9	O
there	5	O
is	5	O
only	9	O
one	5	O
report	5	O
in	5	O
the	5	O
literature	5	O
.	9	O

This	5	O
concerns	5	O
2	9	O
male	9	O
patients	5	O
who	5	O
experienced	5	O
incontinence	5	B-Disease
while	9	O
taking	5	O
venlafaxine	5	B-Chemical
.	9	O

In	9	O
the	5	O
present	9	O
paper	5	O
the	5	O
authors	5	O
describe	5	O
2	9	O
female	9	O
patients	5	O
who	5	O
developed	5	O
incontinence	5	B-Disease
secondary	9	O
to	5	O
the	5	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	O
inhibitors	3	O
paroxetine	0	B-Chemical
and	5	O
sertraline	5	B-Chemical
,	9	O
as	5	O
well	9	O
as	5	O
a	5	O
third	9	O
who	5	O
developed	5	O
this	5	O
side	5	O
effect	9	O
on	5	O
venlafaxine	5	B-Chemical
.	9	O

In	9	O
2	9	O
of	5	O
the	5	O
3	9	O
cases	5	O
the	5	O
patients	5	O
were	9	O
also	9	O
taking	5	O
lithium	0	B-Chemical
carbonate	0	I-Chemical
and	5	O
beta	9	O
-	7	O
blockers	9	O
,	9	O
both	9	O
of	5	O
which	5	O
could	9	O
have	5	O
contributed	9	O
to	5	O
the	5	O
incontinence	5	B-Disease
.	9	O

Animal	2	O
studies	9	O
suggest	9	O
that	5	O
incontinence	5	B-Disease
secondary	9	O
to	5	O
serotonergic	5	B-Chemical
antidepressants	5	I-Chemical
could	9	O
be	5	O
mediated	3	O
by	9	O
the	5	O
5HT4	3	O
receptors	3	O
found	9	O
on	5	O
the	5	O
bladder	9	O
.	9	O

Further	9	O
research	5	O
is	5	O
needed	5	O
to	5	O
delineate	9	O
the	5	O
frequency	5	O
of	5	O
this	5	O
troubling	5	O
side	5	O
effect	9	O
and	5	O
how	5	O
best	5	O
to	5	O
treat	5	O
it	5	O
.	9	O

Acute	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
:	9	O
differential	9	O
sensitivity	9	O
of	5	O
six	9	O
inbred	9	O
mouse	3	O
strains	1	O
.	9	O

Mature	9	O
male	9	O
and	5	O
female	9	O
mice	3	O
from	9	O
six	9	O
inbred	9	O
stains	9	O
were	9	O
tested	9	O
for	5	O
susceptibility	9	O
to	5	O
behavioral	5	O
seizures	5	B-Disease
induced	3	O
by	9	O
a	5	O
single	9	O
injection	9	O
of	5	O
cocaine	5	B-Chemical
.	9	O

Cocaine	5	B-Chemical
was	9	O
injected	3	O
ip	0	O
over	5	O
a	5	O
range	9	O
of	5	O
doses	0	O
(	9	O
50	0	O
-	7	O
100	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
behavior	5	O
was	9	O
monitored	9	O
for	5	O
20	9	O
minutes	0	O
.	9	O

Seizure	5	B-Disease
end	9	O
points	5	O
included	5	O
latency	5	O
to	5	O
forelimb	5	O
or	5	O
hindlimb	9	O
clonus	5	O
,	9	O
latency	5	O
to	5	O
clonic	5	O
running	5	O
seizure	5	B-Disease
and	5	O
latency	5	O
to	5	O
jumping	5	O
bouncing	5	O
seizure	5	B-Disease
.	9	O

A	9	O
range	9	O
of	5	O
strain	1	O
specific	9	O
sensitivities	9	O
was	9	O
documented	9	O
with	5	O
A	9	O
/	9	O
J	9	O
and	5	O
SJL	3	O
mice	3	O
being	5	O
most	9	O
sensitive	9	O
and	5	O
C57BL	3	O
/	9	O
6J	3	O
most	9	O
resistant	9	O
.	9	O

DBA	3	O
/	9	O
2J	3	O
,	9	O
BALB	3	O
/	9	O
cByJ	3	O
and	5	O
NZW	3	O
/	9	O
LacJ	3	O
strains	1	O
exhibited	9	O
intermediate	9	O
sensitivity	9	O
.	9	O

EEG	5	O
recordings	5	O
were	9	O
made	5	O
in	5	O
SJL	3	O
,	9	O
A	9	O
/	9	O
J	9	O
and	5	O
C57BL	3	O
/	9	O
6J	3	O
mice	3	O
revealing	9	O
a	5	O
close	5	O
correspondence	5	O
between	5	O
electrical	5	O
activity	9	O
and	5	O
behavior	5	O
.	9	O

Additionally	9	O
,	9	O
levels	3	O
of	5	O
cocaine	5	B-Chemical
determined	9	O
in	5	O
hippocampus	9	O
and	5	O
cortex	5	O
were	9	O
not	5	O
different	9	O
between	5	O
sensitive	9	O
and	5	O
resistant	9	O
strains	1	O
.	9	O

Additional	9	O
studies	9	O
of	5	O
these	5	O
murine	3	O
strains	1	O
may	5	O
be	5	O
useful	5	O
for	5	O
investigating	5	O
genetic	5	O
influences	5	O
on	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

Hypotension	7	B-Disease
following	9	O
the	5	O
initiation	9	O
of	5	O
tizanidine	0	B-Chemical
in	5	O
a	5	O
patient	5	O
treated	3	O
with	5	O
an	5	O
angiotensin	9	B-Chemical
converting	9	O
enzyme	0	O
inhibitor	3	O
for	5	O
chronic	5	O
hypertension	5	B-Disease
.	9	O

Centrally	5	O
acting	9	O
alpha	9	O
-	7	O
2	9	O
adrenergic	9	O
agonists	3	O
are	5	O
one	5	O
of	5	O
several	9	O
pharmacologic	9	O
agents	5	O
used	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
spasticity	5	B-Disease
related	9	O
to	5	O
disorders	5	B-Disease
of	5	I-Disease
the	5	I-Disease
central	5	I-Disease
nervous	5	I-Disease
system	5	I-Disease
.	9	O

In	9	O
addition	9	O
to	5	O
their	5	O
effects	9	O
on	5	O
spasticity	5	B-Disease
,	9	O
certain	5	O
adverse	5	O
cardiorespiratory	5	O
effects	9	O
have	5	O
been	9	O
reported	9	O
.	9	O

Adults	9	O
chronically	9	O
treated	3	O
with	5	O
angiotensin	9	B-Chemical
converting	9	O
enzyme	0	O
inhibitors	3	O
may	5	O
have	5	O
a	5	O
limited	5	O
ability	9	O
to	5	O
respond	5	O
to	5	O
hypotension	5	B-Disease
when	5	O
the	5	O
sympathetic	5	O
response	9	O
is	5	O
simultaneously	5	O
blocked	3	O
.	9	O

The	5	O
authors	5	O
present	9	O
a	5	O
10	9	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
chronically	9	O
treated	3	O
with	5	O
lisinopril	0	B-Chemical
,	9	O
an	5	O
angiotensin	9	B-Chemical
converting	9	O
enzyme	0	O
inhibitor	3	O
,	9	O
to	5	O
control	9	O
hypertension	5	B-Disease
who	5	O
developed	5	O
hypotension	5	B-Disease
following	9	O
the	5	O
addition	9	O
of	5	O
tizanidine	0	B-Chemical
,	9	O
an	5	O
alpha	9	O
-	7	O
2	9	O
agonist	3	O
,	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
spasticity	5	B-Disease
.	9	O

The	5	O
possible	5	O
interaction	9	O
of	5	O
tizanidine	0	B-Chemical
and	5	O
other	5	O
antihypertensive	5	O
agents	5	O
should	5	O
be	5	O
kept	9	O
in	5	O
mind	5	O
when	5	O
prescribing	5	O
therapy	5	O
to	5	O
treat	5	O
either	9	O
hypertension	5	B-Disease
or	5	O
spasticity	5	B-Disease
in	5	O
such	5	O
patients	5	O
.	9	O

Two	9	O
mouse	3	O
lines	3	O
selected	9	O
for	5	O
differential	9	O
sensitivities	9	O
to	5	O
beta	9	B-Chemical
-	7	I-Chemical
carboline	0	I-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
are	5	O
also	9	O
differentially	9	O
sensitive	9	O
to	5	O
various	9	O
pharmacological	9	O
effects	9	O
of	5	O
other	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
receptor	3	O
ligands	3	O
.	9	O

Two	9	O
mouse	3	O
lines	3	O
were	9	O
selectively	3	O
bred	9	O
according	9	O
to	5	O
their	5	O
sensitivity	9	O
(	9	O
BS	9	O
line	9	O
)	9	O
or	5	O
resistance	9	O
(	9	O
BR	9	O
line	9	O
)	9	O
to	5	O
seizures	5	B-Disease
induced	3	O
by	9	O
a	5	O
single	9	O
i	9	O
.	9	O
p	7	O
.	9	O
injection	9	O
of	5	O
methyl	0	B-Chemical
beta	9	I-Chemical
-	7	I-Chemical
carboline	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
carboxylate	0	I-Chemical
(	9	O
beta	9	B-Chemical
-	7	I-Chemical
CCM	9	I-Chemical
)	9	O
,	9	O
an	5	O
inverse	5	O
agonist	3	O
of	5	O
the	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
receptor	3	O
benzodiazepine	5	B-Chemical
site	9	O
.	9	O

Our	9	O
aim	5	O
was	9	O
to	5	O
characterize	9	O
both	9	O
lines	3	O
'	9	O
sensitivities	9	O
to	5	O
various	9	O
physiological	9	O
effects	9	O
of	5	O
other	5	O
ligands	3	O
of	5	O
the	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
receptor	3	O
.	9	O

We	9	O
measured	9	O
diazepam	0	B-Chemical
-	7	O
induced	3	O
anxiolysis	5	O
with	5	O
the	5	O
elevated	9	O
plus	9	O
-	7	O
maze	5	O
test	5	O
,	9	O
diazepam	0	B-Chemical
-	7	O
induced	3	O
sedation	5	O
by	9	O
recording	5	O
the	5	O
vigilance	5	O
states	5	O
,	9	O
and	5	O
picrotoxin	0	B-Chemical
-	7	O
and	5	O
pentylenetetrazol	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
after	9	O
i	9	O
.	9	O
p	7	O
.	9	O
injections	9	O
.	9	O

Results	9	O
presented	5	O
here	5	O
show	9	O
that	5	O
the	5	O
differential	9	O
sensitivities	9	O
of	5	O
BS	9	O
and	5	O
BR	9	O
lines	3	O
to	5	O
beta	9	B-Chemical
-	7	I-Chemical
CCM	9	I-Chemical
can	5	O
be	5	O
extended	5	O
to	5	O
diazepam	0	B-Chemical
,	9	O
picrotoxin	0	B-Chemical
,	9	O
and	5	O
pentylenetetrazol	0	B-Chemical
,	9	O
suggesting	9	O
a	5	O
genetic	5	O
selection	5	O
of	5	O
a	5	O
general	5	O
sensitivity	9	O
and	5	O
resistance	9	O
to	5	O
several	9	O
ligands	3	O
of	5	O
the	5	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
receptor	3	O
.	9	O

Propylthiouracil	0	B-Chemical
-	7	O
induced	3	O
perinuclear	3	O
-	7	O
staining	3	O
antineutrophil	3	O
cytoplasmic	3	O
autoantibody	3	O
-	7	O
positive	9	O
vasculitis	5	B-Disease
in	5	O
conjunction	9	O
with	5	O
pericarditis	5	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
describe	5	O
a	5	O
case	5	O
of	5	O
propylthiouracil	0	B-Chemical
-	7	O
induced	3	O
vasculitis	5	B-Disease
manifesting	5	O
with	5	O
pericarditis	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
We	9	O
present	9	O
the	5	O
first	9	O
case	5	O
report	5	O
of	5	O
a	5	O
woman	5	O
with	5	O
hyperthyroidism	5	B-Disease
treated	3	O
with	5	O
propylthiouracil	0	B-Chemical
in	5	O
whom	5	O
a	5	O
syndrome	5	O
of	5	O
pericarditis	5	B-Disease
,	9	O
fever	5	B-Disease
,	9	O
and	5	O
glomerulonephritis	3	B-Disease
developed	5	O
.	9	O

Serologic	9	O
testing	5	O
and	5	O
immunologic	9	O
studies	9	O
were	9	O
done	9	O
,	9	O
and	5	O
a	5	O
pericardial	5	O
biopsy	5	O
was	9	O
performed	9	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
25	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
Graves	5	B-Disease
'	9	I-Disease
disease	5	I-Disease
had	9	O
a	5	O
febrile	5	B-Disease
illness	5	I-Disease
and	5	O
evidence	9	O
of	5	O
pericarditis	5	B-Disease
,	9	O
which	5	O
was	9	O
confirmed	9	O
by	9	O
biopsy	5	O
.	9	O

Serologic	9	O
evaluation	5	O
revealed	9	O
the	5	O
presence	9	O
of	5	O
perinuclear	3	O
-	7	O
staining	3	O
antineutrophil	3	O
cytoplasmic	3	O
autoantibodies	3	O
(	9	O
pANCA	3	O
)	9	O
against	9	O
myeloperoxidase	0	O
(	9	O
MPO	0	O
)	9	O
.	9	O

Propylthiouracil	0	B-Chemical
therapy	5	O
was	9	O
withdrawn	9	O
,	9	O
and	5	O
she	5	O
was	9	O
treated	3	O
with	5	O
a	5	O
1	9	O
-	7	O
month	5	O
course	5	O
of	5	O
prednisone	0	B-Chemical
,	9	O
which	5	O
alleviated	9	O
her	5	O
symptoms	5	O
.	9	O

A	9	O
literature	5	O
review	5	O
revealed	9	O
no	9	O
prior	9	O
reports	9	O
of	5	O
pericarditis	5	B-Disease
in	5	O
anti	3	O
-	7	O
MPO	0	O
pANCA	3	O
-	7	O
positive	9	O
vasculitis	5	B-Disease
associated	9	O
with	5	O
propylthio	0	B-Chemical
-	7	I-Chemical
uracil	0	I-Chemical
therapy	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Pericarditis	7	B-Disease
may	5	O
be	5	O
the	5	O
initial	9	O
manifestation	5	O
of	5	O
drug	5	O
-	7	O
induced	3	O
vasculitis	5	B-Disease
attributable	9	O
to	5	O
propylthio	0	B-Chemical
-	7	I-Chemical
uracil	0	I-Chemical
therapy	5	O
.	9	O

Repeated	5	O
transient	9	O
anuria	5	B-Disease
following	9	O
losartan	0	B-Chemical
administration	9	O
in	5	O
a	5	O
patient	5	O
with	5	O
a	5	O
solitary	5	O
kidney	9	O
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
70	9	O
-	7	O
year	5	O
-	7	O
old	5	O
hypertensive	5	B-Disease
man	5	O
with	5	O
a	5	O
solitary	5	O
kidney	9	O
and	5	O
chronic	5	B-Disease
renal	9	I-Disease
insufficiency	9	I-Disease
who	5	O
developed	5	O
two	5	O
episodes	5	O
of	5	O
transient	9	O
anuria	5	B-Disease
after	9	O
losartan	0	B-Chemical
administration	9	O
.	9	O

He	5	O
was	9	O
hospitalized	5	O
for	5	O
a	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
with	5	O
pulmonary	5	B-Disease
edema	5	I-Disease
,	9	O
treated	3	O
with	5	O
high	9	O
-	7	O
dose	9	O
diuretics	5	O
.	9	O

Due	5	O
to	5	O
severe	5	O
systolic	5	B-Disease
dysfunction	9	I-Disease
losartan	0	B-Chemical
was	9	O
prescribed	5	O
.	9	O

Surprisingly	9	O
,	9	O
the	5	O
first	9	O
dose	9	O
of	5	O
50	0	O
mg	0	O
of	5	O
losartan	0	B-Chemical
resulted	9	O
in	5	O
a	5	O
sudden	5	O
anuria	5	B-Disease
,	9	O
which	5	O
lasted	5	O
eight	9	O
hours	9	O
despite	9	O
high	9	O
-	7	O
dose	9	O
furosemide	0	B-Chemical
and	5	O
amine	0	B-Chemical
infusion	0	O
.	9	O

One	5	O
week	9	O
later	9	O
,	9	O
by	9	O
mistake	5	O
,	9	O
losartan	0	B-Chemical
was	9	O
prescribed	5	O
again	9	O
and	5	O
after	9	O
the	5	O
second	9	O
dose	9	O
of	5	O
50	0	O
mg	0	O
,	9	O
the	5	O
patient	5	O
developed	5	O
a	5	O
second	9	O
episode	5	O
of	5	O
transient	9	O
anuria	5	B-Disease
lasting	5	O
10	9	O
hours	9	O
.	9	O

During	5	O
these	5	O
two	5	O
episodes	5	O
,	9	O
his	5	O
blood	9	O
pressure	5	O
diminished	9	O
but	9	O
no	9	O
severe	5	O
hypotension	5	B-Disease
was	9	O
noted	9	O
.	9	O

Ultimately	5	O
,	9	O
an	5	O
arteriography	5	O
showed	9	O
a	5	O
70	9	O
-	7	O
80	9	O
%	9	O
renal	9	B-Disease
artery	5	I-Disease
stenosis	5	I-Disease
.	9	O

In	9	O
this	5	O
patient	5	O
,	9	O
renal	9	B-Disease
artery	5	I-Disease
stenosis	5	I-Disease
combined	9	O
with	5	O
heart	5	B-Disease
failure	5	I-Disease
and	5	O
diuretic	5	O
therapy	5	O
certainly	5	O
resulted	9	O
in	5	O
a	5	O
strong	9	O
activation	3	O
of	5	O
the	5	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
(	9	O
RAS	9	O
)	9	O
.	9	O

Under	9	O
such	5	O
conditions	9	O
,	9	O
angiotensin	9	B-Chemical
II	9	I-Chemical
receptor	3	O
blockade	3	O
by	9	O
losartan	0	B-Chemical
probably	9	O
induced	3	O
a	5	O
critical	9	O
fall	5	O
in	5	O
glomerular	5	O
filtration	0	O
pressure	5	O
.	9	O

This	5	O
case	5	O
report	5	O
highlights	5	O
the	5	O
fact	9	O
that	5	O
the	5	O
angiotensin	9	B-Chemical
II	9	I-Chemical
receptor	3	O
antagonist	3	O
losartan	0	B-Chemical
can	5	O
cause	5	O
serious	5	O
unexpected	9	O
complications	5	O
in	5	O
patients	5	O
with	5	O
renovascular	5	B-Disease
disease	5	I-Disease
and	5	O
should	5	O
be	5	O
used	5	O
with	5	O
extreme	5	O
caution	5	O
in	5	O
this	5	O
setting	5	O
.	9	O

Calcineurin	3	O
-	7	O
inhibitor	3	O
induced	3	O
pain	5	B-Disease
syndrome	5	O
(	9	O
CIPS	5	B-Disease
)	9	O
:	9	O
a	5	O
severe	5	O
disabling	5	O
complication	5	O
after	9	O
organ	5	O
transplantation	9	O
.	9	O

Bone	9	O
pain	5	B-Disease
after	9	O
transplantation	9	O
is	5	O
a	5	O
frequent	5	O
complication	5	O
that	5	O
can	5	O
be	5	O
caused	9	O
by	9	O
several	9	O
diseases	5	O
.	9	O

Treatment	9	O
strategies	5	O
depend	5	O
on	5	O
the	5	O
correct	5	O
diagnosis	5	O
of	5	O
the	5	O
pain	5	B-Disease
.	9	O

Nine	9	O
patients	5	O
with	5	O
severe	5	O
pain	5	B-Disease
in	5	O
their	5	O
feet	5	O
,	9	O
which	5	O
was	9	O
registered	5	O
after	9	O
transplantation	9	O
,	9	O
were	9	O
investigated	9	O
.	9	O

Bone	9	O
scans	5	O
showed	9	O
an	5	O
increased	9	O
tracer	0	O
uptake	0	O
of	5	O
the	5	O
foot	5	O
bones	5	O
.	9	O

Magnetic	5	O
resonance	5	O
imaging	5	O
demonstrated	9	O
bone	5	B-Disease
marrow	3	I-Disease
oedema	5	I-Disease
in	5	O
the	5	O
painful	5	O
bones	5	O
.	9	O

Pain	5	B-Disease
was	9	O
not	5	O
explained	5	O
by	9	O
other	5	O
diseases	5	O
causing	9	O
foot	5	O
pain	5	B-Disease
,	9	O
like	9	O
reflex	5	B-Disease
sympathetic	5	I-Disease
dystrophy	9	I-Disease
,	9	O
polyneuropathy	5	B-Disease
,	9	O
Morton	6	B-Disease
'	9	I-Disease
s	9	I-Disease
neuralgia	5	I-Disease
,	9	O
gout	9	B-Disease
,	9	O
osteoporosis	5	B-Disease
,	9	O
avascular	5	B-Disease
necrosis	9	I-Disease
,	9	O
intermittent	5	B-Disease
claudication	5	I-Disease
,	9	O
orthopaedic	5	O
foot	5	B-Disease
deformities	5	I-Disease
,	9	O
stress	9	B-Disease
fractures	5	I-Disease
,	9	O
and	5	O
hyperparathyroidism	5	B-Disease
.	9	O

The	5	O
reduction	9	O
of	5	O
cyclosporine	0	B-Chemical
-	7	O
or	5	O
tacrolimus	0	B-Chemical
trough	9	O
levels	3	O
and	5	O
the	5	O
administration	9	O
of	5	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
led	9	O
to	5	O
relief	5	O
of	5	O
pain	5	B-Disease
.	9	O

The	5	O
Calcineurin	3	O
-	7	O
inhibitor	3	O
Induced	9	O
Pain	5	B-Disease
Syndrome	5	O
(	9	O
CIPS	5	B-Disease
)	9	O
is	5	O
a	5	O
rare	5	O
but	9	O
severe	5	O
side	5	O
effect	9	O
of	5	O
cyclosporine	0	B-Chemical
or	5	O
tacrolimus	0	B-Chemical
and	5	O
is	5	O
accurately	5	O
diagnosed	5	O
by	9	O
its	9	O
typical	9	O
presentation	5	O
,	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
and	5	O
bone	5	O
scans	5	O
.	9	O

Incorrect	5	O
diagnosis	5	O
of	5	O
the	5	O
syndrome	5	O
will	5	O
lead	5	O
to	5	O
a	5	O
significant	9	O
reduction	9	O
of	5	O
life	5	O
quality	5	O
in	5	O
patients	5	O
suffering	5	O
from	9	O
CIPS	5	B-Disease
.	9	O

Brain	9	O
natriuretic	9	O
peptide	9	O
is	5	O
a	5	O
predictor	5	O
of	5	O
anthracycline	9	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

Anthracyclines	0	B-Chemical
are	5	O
effective	5	O
antineoplastic	9	O
drugs	5	O
,	9	O
but	9	O
they	5	O
frequently	5	O
cause	5	O
dose	9	O
-	7	O
related	9	O
cardiotoxicity	9	B-Disease
.	9	O

The	5	O
cardiotoxicity	9	B-Disease
of	5	O
conventional	5	O
anthracycline	9	B-Chemical
therapy	5	O
highlights	5	O
a	5	O
need	5	O
to	5	O
search	5	O
for	5	O
methods	5	O
that	5	O
are	5	O
highly	9	O
sensitive	9	O
and	5	O
capable	9	O
of	5	O
predicting	5	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
.	9	O

We	9	O
measured	9	O
the	5	O
plasma	9	O
level	9	O
of	5	O
brain	5	O
natriuretic	9	O
peptide	9	O
(	9	O
BNP	9	O
)	9	O
to	5	O
determine	9	O
whether	9	O
BNP	9	O
might	9	O
serve	5	O
as	5	O
a	5	O
simple	5	O
diagnostic	5	O
indicator	9	O
of	5	O
anthracycline	9	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
leukemia	3	I-Disease
treated	3	O
with	5	O
a	5	O
daunorubicin	0	B-Chemical
(	9	O
DNR	5	B-Chemical
)	9	O
-	7	O
containing	0	O
regimen	5	O
.	9	O

Thirteen	9	O
patients	5	O
with	5	O
acute	9	B-Disease
leukemia	3	I-Disease
were	9	O
treated	3	O
with	5	O
a	5	O
DNR	5	B-Chemical
-	7	O
containing	0	O
regimen	5	O
.	9	O

Cardiac	9	O
functions	9	O
were	9	O
evaluated	9	O
with	5	O
radionuclide	5	O
angiography	5	O
before	9	O
chemotherapies	5	O
.	9	O

The	5	O
plasma	9	O
levels	3	O
of	5	O
atrial	5	O
natriuretic	9	O
peptide	9	O
(	9	O
ANP	9	O
)	9	O
and	5	O
BNP	9	O
were	9	O
measured	9	O
at	9	O
the	5	O
time	5	O
of	5	O
radionuclide	5	O
angiography	5	O
.	9	O

Three	9	O
patients	5	O
developed	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
after	9	O
the	5	O
completion	5	O
of	5	O
chemotherapy	5	O
.	9	O

Five	9	O
patients	5	O
were	9	O
diagnosed	5	O
as	5	O
having	5	O
subclinical	5	O
heart	5	B-Disease
failure	5	I-Disease
after	9	O
the	5	O
completion	5	O
of	5	O
chemotherapy	5	O
.	9	O

The	5	O
plasma	9	O
levels	3	O
of	5	O
BNP	9	O
in	5	O
all	5	O
the	5	O
patients	5	O
with	5	O
clinical	5	O
and	5	O
subclinical	5	O
heart	5	B-Disease
failure	5	I-Disease
increased	9	O
above	9	O
the	5	O
normal	9	O
limit	5	O
(	9	O
40	9	O
pg	7	O
/	9	O
ml	0	O
)	9	O
before	9	O
the	5	O
detection	9	O
of	5	O
clinical	5	O
or	5	O
subclinical	5	O
heart	5	B-Disease
failure	5	I-Disease
by	9	O
radionuclide	5	O
angiography	5	O
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
BNP	9	O
did	9	O
not	5	O
increase	9	O
in	5	O
the	5	O
patients	5	O
without	9	O
heart	5	B-Disease
failure	5	I-Disease
given	5	O
DNR	5	B-Chemical
,	9	O
even	5	O
at	9	O
more	5	O
than	5	O
700	9	O
mg	0	O
/	9	O
m	9	O
(	9	O
2	9	O
)	9	O
.	9	O

The	5	O
plasma	9	O
level	9	O
of	5	O
ANP	9	O
did	9	O
not	5	O
always	5	O
increase	9	O
in	5	O
all	5	O
the	5	O
patients	5	O
with	5	O
clinical	5	O
and	5	O
subclinical	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

These	5	O
preliminary	9	O
results	9	O
suggest	9	O
that	5	O
BNP	9	O
may	5	O
be	5	O
useful	5	O
as	5	O
an	5	O
early	9	O
and	5	O
sensitive	9	O
indicator	9	O
of	5	O
anthracycline	9	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
.	9	O

Nephrotoxicity	0	B-Disease
of	5	O
combined	9	O
cephalothin	0	B-Chemical
-	7	O
gentamicin	0	B-Chemical
regimen	5	O
.	9	O

Two	9	O
patients	5	O
developed	5	O
acute	9	B-Disease
tubular	9	I-Disease
necrosis	9	I-Disease
,	9	O
characterized	9	O
clinically	5	O
by	9	O
acute	9	O
oliguric	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
,	9	O
while	9	O
they	5	O
were	9	O
receiving	9	O
a	5	O
combination	9	O
of	5	O
cephalothin	0	B-Chemical
sodium	0	I-Chemical
and	5	O
gentamicin	0	B-Chemical
sulfate	0	I-Chemical
therapy	5	O
.	9	O

Patients	5	O
who	5	O
are	5	O
given	5	O
this	5	O
drug	5	O
regimen	5	O
should	5	O
be	5	O
observed	9	O
very	5	O
carefully	5	O
for	5	O
early	9	O
signs	5	O
of	5	O
nephrotoxicity	9	B-Disease
.	9	O

High	9	O
doses	0	O
of	5	O
this	5	O
antibiotic	5	O
combination	9	O
should	5	O
be	5	O
avoided	5	O
especially	5	O
in	5	O
elderly	5	O
patients	5	O
.	9	O

Patients	5	O
with	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
should	5	O
not	5	O
be	5	O
given	5	O
this	5	O
regimen	5	O
.	9	O

In	9	O
vivo	3	O
protection	9	O
of	5	O
dna	1	O
damage	9	O
associated	9	O
apoptotic	3	O
and	5	O
necrotic	3	B-Disease
cell	3	O
deaths	5	O
during	5	O
acetaminophen	0	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
,	9	O
amiodarone	0	B-Chemical
-	7	O
induced	3	O
lung	9	B-Disease
toxicity	9	I-Disease
and	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
by	9	O
a	5	O
novel	9	O
IH636	9	B-Chemical
grape	4	I-Chemical
seed	4	I-Chemical
proanthocyanidin	0	I-Chemical
extract	0	I-Chemical
.	9	O

Grape	4	B-Chemical
seed	4	I-Chemical
extract	0	I-Chemical
,	9	O
primarily	9	O
a	5	O
mixture	0	O
of	5	O
proanthocyanidins	0	B-Chemical
,	9	O
has	9	O
been	9	O
shown	9	O
to	5	O
modulate	9	O
a	5	O
wide	5	O
-	7	O
range	9	O
of	5	O
biological	5	O
,	9	O
pharmacological	9	O
and	5	O
toxicological	5	O
effects	9	O
which	5	O
are	5	O
mainly	9	O
cytoprotective	3	O
.	9	O

This	5	O
study	9	O
assessed	9	O
the	5	O
ability	9	O
of	5	O
IH636	9	B-Chemical
grape	4	I-Chemical
seed	4	I-Chemical
proanthocyanidin	0	I-Chemical
extract	0	I-Chemical
(	9	O
GSPE	0	B-Chemical
)	9	O
to	5	O
prevent	5	O
acetaminophen	0	B-Chemical
(	9	O
AAP	9	B-Chemical
)	9	O
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
,	9	O
amiodarone	0	B-Chemical
(	9	O
AMI	9	B-Chemical
)	9	O
-	7	O
induced	3	O
lung	9	B-Disease
toxicity	9	I-Disease
,	9	O
and	5	O
doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
-	7	O
induced	3	O
cardiotoxicity	9	B-Disease
in	5	O
mice	3	O
.	9	O

Experimental	9	O
design	5	O
consisted	5	O
of	5	O
four	9	O
groups	9	O
:	9	O
control	9	O
(	9	O
vehicle	3	O
alone	9	O
)	9	O
,	9	O
GSPE	0	B-Chemical
alone	9	O
,	9	O
drug	5	O
alone	9	O
and	5	O
GSPE	0	B-Chemical
+	9	O
drug	5	O
.	9	O

For	9	O
the	5	O
cytoprotection	3	O
study	9	O
,	9	O
animals	9	O
were	9	O
orally	0	O
gavaged	0	O
100	0	O
mg	0	O
/	9	O
Kg	0	O
GSPE	0	B-Chemical
for	5	O
7	9	O
-	7	O
10	9	O
days	9	O
followed	9	O
by	9	O
i	9	O
.	9	O
p	7	O
.	9	O
injections	9	O
of	5	O
organ	5	O
specific	9	O
three	9	O
drugs	5	O
(	9	O
AAP	9	B-Chemical
:	9	O
500	0	O
mg	0	O
/	9	O
Kg	0	O
for	5	O
24	9	O
h	0	O
;	9	O
AMI	9	B-Chemical
:	9	O
50	0	O
mg	0	O
/	9	O
Kg	0	O
/	9	O
day	9	O
for	5	O
four	9	O
days	9	O
;	9	O
DOX	0	B-Chemical
:	9	O
20	9	O
mg	0	O
/	9	O
Kg	0	O
for	5	O
48	9	O
h	0	O
)	9	O
.	9	O

Parameters	9	O
of	5	O
study	9	O
included	5	O
analysis	9	O
of	5	O
serum	9	O
chemistry	0	O
(	9	O
ALT	9	O
,	9	O
BUN	0	O
and	5	O
CPK	9	O
)	9	O
,	9	O
and	5	O
orderly	5	O
fragmentation	9	O
of	5	O
genomic	9	O
DNA	9	O
(	9	O
both	9	O
endonuclease	1	O
-	7	O
dependent	9	O
and	5	O
independent	9	O
)	9	O
in	5	O
addition	9	O
to	5	O
microscopic	9	O
evaluation	5	O
of	5	O
damage	9	O
and	5	O
/	9	O
or	5	O
protection	9	O
in	5	O
corresponding	9	O
PAS	9	O
stained	3	O
tissues	9	O
.	9	O

Results	9	O
indicate	9	O
that	5	O
GSPE	0	B-Chemical
preexposure	5	O
prior	9	O
to	5	O
AAP	9	B-Chemical
,	9	O
AMI	9	B-Chemical
and	5	O
DOX	0	B-Chemical
,	9	O
provided	9	O
near	9	O
complete	9	O
protection	9	O
in	5	O
terms	5	O
of	5	O
serum	9	O
chemistry	0	O
changes	9	O
(	9	O
ALT	9	O
,	9	O
BUN	0	O
and	5	O
CPK	9	O
)	9	O
,	9	O
and	5	O
significantly	9	O
reduced	9	O
DNA	9	O
fragmentation	9	O
.	9	O

Histopathological	9	O
examination	5	O
of	5	O
kidney	9	O
,	9	O
heart	5	O
and	5	O
lung	9	O
sections	9	O
revealed	9	O
moderate	9	O
to	5	O
massive	9	O
tissue	9	B-Disease
damage	9	I-Disease
with	5	O
a	5	O
variety	5	O
of	5	O
morphological	9	O
aberrations	5	O
by	9	O
all	5	O
the	5	O
three	9	O
drugs	5	O
in	5	O
the	5	O
absence	3	O
of	5	O
GSPE	0	B-Chemical
preexposure	5	O
than	5	O
in	5	O
its	9	O
presence	9	O
.	9	O

GSPE	0	B-Chemical
+	9	O
drug	5	O
exposed	9	O
tissues	9	O
exhibited	9	O
minor	9	O
residual	9	O
damage	9	O
or	5	O
near	9	O
total	9	O
recovery	9	O
.	9	O

Additionally	9	O
,	9	O
histopathological	9	O
alterations	9	O
mirrored	9	O
both	9	O
serum	9	O
chemistry	0	O
changes	9	O
and	5	O
the	5	O
pattern	9	O
of	5	O
DNA	9	O
fragmentation	9	O
.	9	O

Interestingly	9	O
,	9	O
all	5	O
the	5	O
drugs	5	O
,	9	O
such	5	O
as	5	O
,	9	O
AAP	9	B-Chemical
,	9	O
AMI	9	B-Chemical
and	5	O
DOX	0	B-Chemical
induced	3	O
apoptotic	3	O
death	9	O
in	5	O
addition	9	O
to	5	O
necrosis	9	B-Disease
in	5	O
the	5	O
respective	9	O
organs	9	O
which	5	O
was	9	O
very	5	O
effectively	5	O
blocked	3	O
by	9	O
GSPE	0	B-Chemical
.	9	O

Since	9	O
AAP	9	B-Chemical
,	9	O
AMI	9	B-Chemical
and	5	O
DOX	0	B-Chemical
undergo	9	O
biotransformation	0	O
and	5	O
are	5	O
known	9	O
to	5	O
produce	9	O
damaging	9	O
radicals	0	O
in	5	O
vivo	3	O
,	9	O
the	5	O
protection	9	O
by	9	O
GSPE	0	B-Chemical
may	5	O
be	5	O
linked	9	O
to	5	O
both	9	O
inhibition	3	O
of	5	O
metabolism	9	O
and	5	O
/	9	O
or	5	O
detoxification	9	O
of	5	O
cytotoxic	3	O
radicals	0	O
.	9	O

In	9	O
addition	9	O
,	9	O
its	9	O
'	9	O
presumed	9	O
contribution	9	O
to	5	O
DNA	9	O
repair	9	O
may	5	O
be	5	O
another	9	O
important	9	O
attribute	5	O
,	9	O
which	5	O
played	9	O
a	5	O
role	9	O
in	5	O
the	5	O
chemoprevention	5	O
process	5	O
.	9	O

Additionally	9	O
,	9	O
this	5	O
may	5	O
have	5	O
been	9	O
the	5	O
first	9	O
report	5	O
on	5	O
AMI	9	B-Chemical
-	7	O
induced	3	O
apoptotic	3	O
death	9	O
in	5	O
the	5	O
lung	9	O
tissue	9	O
.	9	O

Taken	9	O
together	9	O
,	9	O
these	5	O
events	5	O
undoubtedly	5	O
establish	5	O
GSPE	0	B-Chemical
'	9	O
s	9	O
abundant	9	O
bioavailability	0	O
,	9	O
and	5	O
the	5	O
power	5	O
to	5	O
defend	5	O
multiple	5	O
target	9	O
organs	9	O
from	9	O
toxic	0	O
assaults	5	O
induced	3	O
by	9	O
structurally	9	O
diverse	9	O
and	5	O
functionally	9	O
different	9	O
entities	5	O
in	5	O
vivo	3	O
.	9	O

Antidepressant	5	B-Chemical
-	7	O
induced	3	O
mania	5	B-Disease
in	5	O
bipolar	5	B-Disease
patients	5	O
:	9	O
identification	9	O
of	5	O
risk	5	O
factors	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Concerns	5	O
about	5	O
possible	5	O
risks	5	O
of	5	O
switching	5	O
to	5	O
mania	5	B-Disease
associated	9	O
with	5	O
antidepressants	5	B-Chemical
continue	5	O
to	5	O
interfere	9	O
with	5	O
the	5	O
establishment	9	O
of	5	O
an	5	O
optimal	5	O
treatment	9	O
paradigm	5	O
for	5	O
bipolar	5	B-Disease
depression	5	I-Disease
.	9	O

METHOD	2	O
:	9	O
The	5	O
response	9	O
of	5	O
44	7	O
patients	5	O
meeting	5	O
DSM	4	O
-	7	O
IV	9	O
criteria	5	O
for	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
to	5	O
naturalistic	5	O
treatment	9	O
was	9	O
assessed	9	O
for	5	O
at	9	O
least	9	O
6	9	O
weeks	9	O
using	9	O
the	5	O
Montgomery	6	O
-	7	O
Asberg	6	O
Depression	5	O
Rating	5	O
Scale	5	O
and	5	O
the	5	O
Bech	6	O
-	7	O
Rafaelson	2	O
Mania	5	O
Rating	5	O
Scale	5	O
.	9	O

Patients	5	O
who	5	O
experienced	5	O
a	5	O
manic	5	B-Disease
or	5	O
hypomanic	5	B-Disease
switch	9	O
were	9	O
compared	9	O
with	5	O
those	5	O
who	5	O
did	9	O
not	5	O
on	5	O
several	9	O
variables	5	O
including	9	O
age	5	O
,	9	O
sex	5	O
,	9	O
diagnosis	5	O
(	9	O
DSM	4	B-Disease
-	7	I-Disease
IV	9	I-Disease
bipolar	5	I-Disease
I	9	I-Disease
vs	7	O
.	9	O
bipolar	5	B-Disease
II	9	I-Disease
)	9	O
,	9	O
number	9	O
of	5	O
previous	9	O
manic	5	B-Disease
episodes	5	O
,	9	O
type	9	O
of	5	O
antidepressant	5	B-Chemical
therapy	5	O
used	5	O
(	9	O
electroconvulsive	5	O
therapy	5	O
vs	7	O
.	9	O
antidepressant	5	B-Chemical
drugs	5	O
and	5	O
,	9	O
more	5	O
particularly	5	O
,	9	O
selective	9	O
serotonin	9	B-Chemical
reuptake	0	I-Chemical
inhibitors	3	I-Chemical
[	9	O
SSRIs	5	B-Chemical
]	9	O
)	9	O
,	9	O
use	5	O
and	5	O
type	9	O
of	5	O
mood	5	O
stabilizers	0	O
(	9	O
lithium	0	B-Chemical
vs	7	O
.	9	O
anticonvulsants	5	O
)	9	O
,	9	O
and	5	O
temperament	5	O
of	5	O
the	5	O
patient	5	O
,	9	O
assessed	9	O
during	5	O
a	5	O
normothymic	9	O
period	5	O
using	9	O
the	5	O
hyperthymia	5	O
component	9	O
of	5	O
the	5	O
Semi	5	O
-	7	O
structured	5	O
Affective	5	O
Temperament	5	O
Interview	5	O
.	9	O

RESULTS	9	O
:	9	O
Switches	5	O
to	5	O
hypomania	5	B-Disease
or	5	O
mania	5	B-Disease
occurred	9	O
in	5	O
27	7	O
%	9	O
of	5	O
all	5	O
patients	5	O
(	9	O
N	9	O
=	7	O
12	9	O
)	9	O
(	9	O
and	5	O
in	5	O
24	9	O
%	9	O
of	5	O
the	5	O
subgroup	9	O
of	5	O
patients	5	O
treated	3	O
with	5	O
SSRIs	5	B-Chemical
[	9	O
8	9	O
/	9	O
33	7	O
]	9	O
)	9	O
;	9	O
16	9	O
%	9	O
(	9	O
N	9	O
=	7	O
7	9	O
)	9	O
experienced	5	O
manic	5	B-Disease
episodes	5	O
,	9	O
and	5	O
11	7	O
%	9	O
(	9	O
N	9	O
=	7	O
5	9	O
)	9	O
experienced	5	O
hypomanic	5	B-Disease
episodes	5	O
.	9	O

Sex	7	O
,	9	O
age	5	O
,	9	O
diagnosis	5	O
(	9	O
bipolar	5	B-Disease
I	9	I-Disease
vs	7	O
.	9	O
bipolar	5	B-Disease
II	9	I-Disease
)	9	O
,	9	O
and	5	O
additional	9	O
treatment	9	O
did	9	O
not	5	O
affect	9	O
the	5	O
risk	5	O
of	5	O
switching	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
mood	5	O
switches	5	O
seemed	9	O
not	5	O
to	5	O
differ	9	O
between	5	O
patients	5	O
receiving	9	O
an	5	O
anticonvulsant	5	O
and	5	O
those	5	O
receiving	9	O
no	9	O
mood	5	O
stabilizer	0	O
.	9	O

In	9	O
contrast	9	O
,	9	O
mood	5	O
switches	5	O
were	9	O
less	5	O
frequent	5	O
in	5	O
patients	5	O
receiving	9	O
lithium	0	B-Chemical
(	9	O
15	9	O
%	9	O
,	9	O
4	9	O
/	9	O
26	7	O
)	9	O
than	5	O
in	5	O
patients	5	O
not	5	O
treated	3	O
with	5	O
lithium	0	B-Chemical
(	9	O
44	7	O
%	9	O
,	9	O
8	9	O
/	9	O
18	7	O
;	9	O
p	7	O
=	7	O
.	9	O
04	7	O
)	9	O
.	9	O

The	5	O
number	9	O
of	5	O
previous	9	O
manic	5	B-Disease
episodes	5	O
did	9	O
not	5	O
affect	9	O
the	5	O
probability	5	O
of	5	O
switching	5	O
,	9	O
whereas	9	O
a	5	O
high	9	O
score	5	O
on	5	O
the	5	O
hyperthymia	5	O
component	9	O
of	5	O
the	5	O
Semistructured	5	O
Affective	5	O
Temperament	5	O
Interview	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
greater	5	O
risk	5	O
of	5	O
switching	5	O
(	9	O
p	7	O
=	7	O
.	9	O
008	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
frequency	5	O
of	5	O
mood	5	O
switching	5	O
associated	9	O
with	5	O
acute	9	O
antidepressant	5	B-Chemical
therapy	5	O
may	5	O
be	5	O
reduced	9	O
by	9	O
lithium	0	B-Chemical
treatment	9	O
.	9	O

Particular	5	O
attention	5	O
should	5	O
be	5	O
paid	5	O
to	5	O
patients	5	O
with	5	O
a	5	O
hyperthymic	5	O
temperament	5	O
,	9	O
who	5	O
have	5	O
a	5	O
greater	5	O
risk	5	O
of	5	O
mood	5	O
switches	5	O
.	9	O

Peritubular	0	O
capillary	0	O
basement	3	O
membrane	9	O
reduplication	5	O
in	5	O
allografts	5	O
and	5	O
native	9	O
kidney	9	B-Disease
disease	5	I-Disease
:	9	O
a	5	O
clinicopathologic	9	O
study	9	O
of	5	O
278	7	O
consecutive	5	O
renal	9	O
specimens	9	O
.	9	O

BACKGROUND	2	O
:	9	O
An	5	O
association	9	O
has	9	O
been	9	O
found	9	O
between	5	O
transplant	9	B-Disease
glomerulopathy	5	I-Disease
(	9	O
TG	9	B-Disease
)	9	O
and	5	O
reduplication	5	O
of	5	O
peritubular	3	O
capillary	0	O
basement	3	O
membranes	0	O
(	9	O
PTCR	1	O
)	9	O
.	9	O

Although	9	O
such	5	O
an	5	O
association	9	O
is	5	O
of	5	O
practical	5	O
and	5	O
theoretical	5	O
importance	5	O
,	9	O
only	9	O
one	5	O
prospective	5	O
study	9	O
has	9	O
tried	5	O
to	5	O
confirm	9	O
it	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
examined	9	O
278	7	O
consecutive	5	O
renal	9	O
specimens	9	O
(	9	O
from	9	O
135	7	O
transplants	9	O
and	5	O
143	7	O
native	9	O
kidneys	9	O
)	9	O
for	5	O
ultrastructural	9	O
evidence	9	O
of	5	O
PTCR	1	O
.	9	O

In	9	O
addition	9	O
to	5	O
renal	9	O
allografts	5	O
with	5	O
TG	9	B-Disease
,	9	O
we	5	O
also	9	O
examined	9	O
grafts	5	O
with	5	O
acute	9	O
rejection	5	O
,	9	O
recurrent	5	O
glomerulonephritis	3	B-Disease
,	9	O
chronic	5	B-Disease
allograft	5	I-Disease
nephropathy	9	I-Disease
and	5	O
stable	9	O
grafts	5	O
(	9	O
"	5	O
protocol	9	O
biopsies	9	O
"	5	O
)	9	O
.	9	O

Native	9	O
kidney	9	O
specimens	9	O
included	5	O
a	5	O
wide	5	O
range	9	O
of	5	O
glomerulopathies	5	B-Disease
as	5	O
well	9	O
as	5	O
cases	5	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
,	9	O
malignant	3	B-Disease
hypertension	5	I-Disease
,	9	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
,	9	O
and	5	O
acute	9	B-Disease
tubular	9	I-Disease
necrosis	9	I-Disease
.	9	O

RESULTS	9	O
:	9	O
We	9	O
found	9	O
PTCR	1	O
in	5	O
14	7	O
of	5	O
15	9	O
cases	5	O
of	5	O
TG	9	B-Disease
,	9	O
in	5	O
7	9	O
transplant	9	O
biopsy	5	O
specimens	9	O
without	9	O
TG	9	B-Disease
,	9	O
and	5	O
in	5	O
13	7	O
of	5	O
143	7	O
native	9	O
kidney	9	O
biopsy	5	O
specimens	9	O
.	9	O

These	5	O
13	7	O
included	5	O
cases	5	O
of	5	O
malignant	3	B-Disease
hypertension	5	I-Disease
,	9	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
,	9	O
lupus	9	B-Disease
nephritis	9	I-Disease
,	9	O
Henoch	2	B-Disease
-	7	I-Disease
Schonlein	2	I-Disease
nephritis	9	I-Disease
,	9	O
crescentic	5	O
glomerulonephritis	3	B-Disease
,	9	O
and	5	O
cocaine	5	B-Chemical
-	7	O
related	9	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

Mild	9	O
PTCR	1	O
in	5	O
allografts	5	O
without	9	O
TG	9	B-Disease
did	9	O
not	5	O
predict	5	O
renal	9	B-Disease
failure	5	I-Disease
or	5	O
significant	9	O
proteinuria	9	B-Disease
after	9	O
follow	5	O
-	7	O
up	5	O
periods	5	O
of	5	O
between	5	O
3	9	O
months	5	O
and	5	O
1	9	O
year	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
We	9	O
conclude	9	O
that	5	O
in	5	O
transplants	9	O
,	9	O
there	5	O
is	5	O
a	5	O
strong	9	O
association	9	O
between	5	O
well	9	O
-	7	O
developed	5	O
PTCR	1	O
and	5	O
TG	9	B-Disease
,	9	O
while	9	O
the	5	O
significance	9	O
of	5	O
mild	9	O
PTCR	1	O
and	5	O
its	9	O
predictive	5	O
value	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
TG	9	B-Disease
is	5	O
unclear	9	O
.	9	O

PTCR	1	O
also	9	O
occurs	9	O
in	5	O
certain	5	O
native	9	O
kidney	9	B-Disease
diseases	5	I-Disease
,	9	O
though	9	O
the	5	O
association	9	O
is	5	O
not	5	O
as	5	O
strong	9	O
as	5	O
that	5	O
for	5	O
TG	9	B-Disease
.	9	O

We	9	O
suggest	9	O
that	5	O
repeated	5	O
endothelial	3	B-Disease
injury	9	I-Disease
,	9	O
including	9	O
immunologic	9	B-Disease
injury	9	I-Disease
,	9	O
may	5	O
be	5	O
the	5	O
cause	5	O
of	5	O
this	5	O
lesion	5	O
both	9	O
in	5	O
allografts	5	O
and	5	O
native	9	O
kidneys	9	O
.	9	O

Caffeine	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
arrhythmia	5	I-Disease
:	9	O
an	5	O
unrecognised	5	O
danger	5	O
of	5	O
healthfood	_	O
products	9	O
.	9	O

We	9	O
describe	5	O
a	5	O
25	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
pre	9	O
-	7	O
existing	5	O
mitral	5	B-Disease
valve	5	I-Disease
prolapse	5	I-Disease
who	5	O
developed	5	O
intractable	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
after	9	O
consuming	5	O
a	5	O
"	5	O
natural	5	O
energy	5	O
"	5	O
guarana	0	O
health	5	O
drink	5	O
containing	0	O
a	5	O
high	9	O
concentration	0	O
of	5	O
caffeine	0	B-Chemical
.	9	O

This	5	O
case	5	O
highlights	5	O
the	5	O
need	5	O
for	5	O
adequate	5	O
labelling	9	O
and	5	O
regulation	9	O
of	5	O
such	5	O
products	9	O
.	9	O

Conformationally	0	O
restricted	9	O
analogs	0	O
of	5	O
BD1008	_	B-Chemical
and	5	O
an	5	O
antisense	3	O
oligodeoxynucleotide	3	B-Chemical
targeting	3	O
sigma1	3	O
receptors	3	O
produce	9	O
anti	3	O
-	7	O
cocaine	5	B-Chemical
effects	9	O
in	5	O
mice	3	O
.	9	O

Cocaine	5	B-Chemical
'	9	O
s	9	O
ability	9	O
to	5	O
interact	9	O
with	5	O
sigma	9	O
receptors	3	O
suggests	9	O
that	5	O
these	5	O
proteins	1	O
mediate	3	O
some	5	O
of	5	O
its	9	O
behavioral	5	O
effects	9	O
.	9	O

Therefore	9	O
,	9	O
three	9	O
novel	9	O
sigma	9	O
receptor	3	O
ligands	3	O
with	5	O
antagonist	3	O
activity	9	O
were	9	O
evaluated	9	O
in	5	O
Swiss	2	O
Webster	6	O
mice	3	O
:	9	O
BD1018	_	B-Chemical
(	9	O
3S	0	B-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dichlorophenyl	0	I-Chemical
)	9	I-Chemical
ethyl	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
diazabicyclo	0	I-Chemical
[	9	I-Chemical
4	9	I-Chemical
.	9	I-Chemical
3	9	I-Chemical
.	9	I-Chemical
0	7	I-Chemical
]	9	I-Chemical
nonane	0	I-Chemical
)	9	O
,	9	O
BD1063	0	B-Chemical
(	9	O
1	9	B-Chemical
-	7	I-Chemical
[	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dichlorophenyl	0	I-Chemical
)	9	I-Chemical
ethyl	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methylpiperazine	0	I-Chemical
)	9	O
,	9	O
and	5	O
LR132	_	B-Chemical
(	9	O
1R	9	O
,	9	O
2S	0	O
-	7	O
(	9	O
+	9	O
)	9	O
-	7	O
cis	9	O
-	7	O
N	9	O
-	7	O
[	9	O
2	9	O
-	7	O
(	9	O
3	9	O
,	9	O
4	9	O
-	7	O
dichlorophenyl	0	O
)	9	O
ethyl	0	O
]	9	O
-	7	O
2	9	O
-	7	O
(	9	O
1	9	O
-	7	O
pyrrolidinyl	0	O
)	9	O
cyclohexylamine	0	O
)	9	O
.	9	O

Competition	9	O
binding	1	O
assays	3	O
demonstrated	9	O
that	5	O
all	5	O
three	9	O
compounds	0	O
have	5	O
high	9	O
affinities	9	O
for	5	O
sigma1	3	O
receptors	3	O
.	9	O

The	5	O
three	9	O
compounds	0	O
vary	5	O
in	5	O
their	5	O
affinities	9	O
for	5	O
sigma2	9	O
receptors	3	O
and	5	O
exhibit	9	O
negligible	9	O
affinities	9	O
for	5	O
dopamine	5	B-Chemical
,	9	O
opioid	5	O
,	9	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
and	5	O
NMDA	3	B-Chemical
receptors	3	O
.	9	O

In	9	O
behavioral	5	O
studies	9	O
,	9	O
pre	9	O
-	7	O
treatment	9	O
of	5	O
mice	3	O
with	5	O
BD1018	_	B-Chemical
,	9	O
BD1063	0	B-Chemical
,	9	O
or	5	O
LR132	_	B-Chemical
significantly	9	O
attenuated	3	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
and	5	O
lethality	3	O
.	9	O

Moreover	9	O
,	9	O
post	9	O
-	7	O
treatment	9	O
with	5	O
LR132	_	B-Chemical
prevented	9	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
lethality	3	O
in	5	O
a	5	O
significant	9	O
proportion	9	O
of	5	O
animals	9	O
.	9	O

In	9	O
contrast	9	O
to	5	O
the	5	O
protection	9	O
provided	9	O
by	9	O
the	5	O
putative	1	O
antagonists	3	O
,	9	O
the	5	O
well	9	O
-	7	O
characterized	9	O
sigma	9	O
receptor	3	O
agonist	3	O
di	2	B-Chemical
-	7	I-Chemical
o	9	I-Chemical
-	7	I-Chemical
tolylguanidine	_	I-Chemical
(	9	O
DTG	0	B-Chemical
)	9	O
and	5	O
the	5	O
novel	9	O
sigma	9	O
receptor	3	O
agonist	3	O
BD1031	_	B-Chemical
(	9	O
3R	1	B-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
3	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dichlorophenyl	0	I-Chemical
)	9	I-Chemical
ethyl	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
diazabicyclo	0	I-Chemical
[	9	I-Chemical
4	9	I-Chemical
.	9	I-Chemical
3	9	I-Chemical
.	9	I-Chemical
0	7	I-Chemical
]	9	I-Chemical
nonane	0	I-Chemical
)	9	O
each	5	O
worsened	5	O
the	5	O
behavioral	5	O
toxicity	9	B-Disease
of	5	O
cocaine	5	B-Chemical
.	9	O

At	9	O
doses	0	O
where	5	O
alone	9	O
,	9	O
they	5	O
produced	9	O
no	9	O
significant	9	O
effects	9	O
on	5	O
locomotion	5	O
,	9	O
BD1018	_	B-Chemical
,	9	O
BD1063	0	B-Chemical
and	5	O
LR132	_	B-Chemical
significantly	9	O
attenuated	3	O
the	5	O
locomotor	5	O
stimulatory	3	O
effects	9	O
of	5	O
cocaine	5	B-Chemical
.	9	O

To	9	O
further	9	O
validate	9	O
the	5	O
hypothesis	9	O
that	5	O
the	5	O
anti	3	O
-	7	O
cocaine	5	B-Chemical
effects	9	O
of	5	O
the	5	O
novel	9	O
ligands	3	O
involved	9	O
antagonism	9	O
of	5	O
sigma	9	O
receptors	3	O
,	9	O
an	5	O
antisense	3	O
oligodeoxynucleotide	3	B-Chemical
against	9	O
sigma1	3	O
receptors	3	O
was	9	O
also	9	O
shown	9	O
to	5	O
significantly	9	O
attenuate	9	O
the	5	O
convulsive	5	B-Disease
and	5	O
locomotor	5	O
stimulatory	3	O
effects	9	O
of	5	O
cocaine	5	B-Chemical
.	9	O

Together	9	O
,	9	O
the	5	O
data	5	O
suggests	9	O
that	5	O
functional	9	O
antagonism	9	O
of	5	O
sigma	9	O
receptors	3	O
is	5	O
capable	9	O
of	5	O
attenuating	9	O
a	5	O
number	9	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
behaviors	5	O
.	9	O

Ranitidine	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
in	5	O
a	5	O
cadaveric	5	O
renal	9	O
allograft	5	O
.	9	O

Ranitidine	0	B-Chemical
frequently	5	O
is	5	O
used	5	O
for	5	O
preventing	9	O
peptic	5	O
ulceration	5	O
after	9	O
renal	9	O
transplantation	9	O
.	9	O

This	5	O
drug	5	O
occasionally	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
in	5	O
native	9	O
kidneys	9	O
.	9	O

There	5	O
are	5	O
no	9	O
similar	9	O
reports	9	O
with	5	O
renal	9	O
transplantation	9	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
ranitidine	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
in	5	O
a	5	O
recipient	9	O
of	5	O
a	5	O
cadaveric	5	O
renal	9	O
allograft	5	O
presenting	5	O
with	5	O
acute	9	O
allograft	5	O
dysfunction	9	O
within	9	O
48	9	O
hours	9	O
of	5	O
exposure	9	O
to	5	O
the	5	O
drug	5	O
.	9	O

The	5	O
biopsy	5	O
specimen	9	O
showed	9	O
pathognomonic	5	O
features	5	O
,	9	O
including	9	O
eosinophilic	5	O
infiltration	3	O
of	5	O
the	5	O
interstitial	9	O
compartment	9	O
.	9	O

Allograft	7	O
function	9	O
improved	5	O
rapidly	9	O
and	5	O
returned	5	O
to	5	O
baseline	5	O
after	9	O
stopping	5	O
the	5	O
drug	5	O
.	9	O

Liver	9	B-Disease
disease	5	I-Disease
caused	9	O
by	9	O
propylthiouracil	0	B-Chemical
.	9	O

This	5	O
report	5	O
presents	5	O
the	5	O
clinical	5	O
,	9	O
laboratory	9	O
,	9	O
and	5	O
light	9	O
and	5	O
electron	0	O
microscopic	9	O
observations	9	O
on	5	O
a	5	O
patient	5	O
with	5	O
chronic	5	B-Disease
active	9	I-Disease
(	9	I-Disease
aggressive	5	I-Disease
)	9	I-Disease
hepatitis	9	I-Disease
caused	9	O
by	9	O
the	5	O
administration	9	O
of	5	O
propylthiouracil	0	B-Chemical
.	9	O

This	5	O
is	5	O
an	5	O
addition	9	O
to	5	O
the	5	O
list	5	O
of	5	O
drugs	5	O
that	5	O
must	5	O
be	5	O
considered	5	O
in	5	O
the	5	O
evaluation	5	O
of	5	O
chronic	5	O
liver	9	B-Disease
disease	5	I-Disease
.	9	O

Withdrawal	5	B-Disease
-	7	I-Disease
emergent	5	I-Disease
rabbit	3	I-Disease
syndrome	5	I-Disease
during	5	O
dose	9	O
reduction	9	O
of	5	O
risperidone	5	B-Chemical
.	9	O

Rabbit	3	B-Disease
syndrome	5	I-Disease
(	9	O
RS	9	B-Disease
)	9	O
is	5	O
a	5	O
rare	5	O
extrapyramidal	5	O
side	5	O
effect	9	O
caused	9	O
by	9	O
prolonged	9	O
neuroleptic	5	O
medication	5	O
.	9	O

Here	9	O
we	5	O
present	9	O
a	5	O
case	5	O
of	5	O
withdrawal	5	B-Disease
-	7	I-Disease
emergent	5	I-Disease
RS	9	I-Disease
,	9	O
which	5	O
is	5	O
the	5	O
first	9	O
of	5	O
its	9	O
kind	5	O
to	5	O
be	5	O
reported	9	O
.	9	O

The	5	O
patient	5	O
developed	5	O
RS	9	B-Disease
during	5	O
dose	9	O
reduction	9	O
of	5	O
risperidone	5	B-Chemical
.	9	O

The	5	O
symptom	5	O
was	9	O
treated	3	O
successfully	5	O
with	5	O
trihexyphenidyl	0	B-Chemical
anticholinergic	5	O
therapy	5	O
.	9	O

The	5	O
underlying	5	O
mechanism	9	O
of	5	O
withdrawal	5	B-Disease
-	7	I-Disease
emergent	5	I-Disease
RS	9	I-Disease
in	5	O
the	5	O
present	9	O
case	5	O
may	5	O
have	5	O
been	9	O
related	9	O
to	5	O
the	5	O
pharmacological	9	O
profile	9	O
of	5	O
risperidone	5	B-Chemical
,	9	O
a	5	O
serotonin	9	B-Chemical
-	7	O
dopamine	5	B-Chemical
antagonist	3	O
,	9	O
suggesting	9	O
the	5	O
pathophysiologic	5	O
influence	5	O
of	5	O
the	5	O
serotonin	9	B-Chemical
system	5	O
in	5	O
the	5	O
development	9	O
of	5	O
RS	9	B-Disease
.	9	O

Pharmacokinetic	0	O
/	9	O
pharmacodynamic	5	O
assessment	5	O
of	5	O
the	5	O
effects	9	O
of	5	O
E4031	3	B-Chemical
,	9	O
cisapride	0	B-Chemical
,	9	O
terfenadine	0	B-Chemical
and	5	O
terodiline	0	B-Chemical
on	5	O
monophasic	5	O
action	5	O
potential	9	O
duration	5	O
in	5	O
dog	5	O
.	9	O

1	9	O
.	9	O

Torsades	2	B-Disease
de	2	I-Disease
pointes	5	I-Disease
(	9	O
TDP	0	B-Disease
)	9	O
is	5	O
a	5	O
potentially	5	O
fatal	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
associated	9	O
with	5	O
increases	9	O
in	5	O
QT	5	O
interval	5	O
and	5	O
monophasic	5	O
action	5	O
potential	9	O
duration	5	O
(	9	O
MAPD	5	O
)	9	O
.	9	O

TDP	0	B-Disease
is	5	O
a	5	O
side	5	O
-	7	O
effect	9	O
that	5	O
has	9	O
led	9	O
to	5	O
withdrawal	5	O
of	5	O
several	9	O
drugs	5	O
from	9	O
the	5	O
market	5	O
(	9	O
e	9	O
.	9	O
g	0	O
.	9	O
terfenadine	0	B-Chemical
and	5	O
terodiline	0	B-Chemical
)	9	O
.	9	O

2	9	O
.	9	O

The	5	O
potential	9	O
of	5	O
compounds	0	O
to	5	O
cause	5	O
TDP	0	B-Disease
was	9	O
evaluated	9	O
by	9	O
monitoring	5	O
their	5	O
effects	9	O
on	5	O
MAPD	5	O
in	5	O
dog	5	O
.	9	O

Four	9	O
compounds	0	O
known	9	O
to	5	O
increase	9	O
QT	5	O
interval	5	O
and	5	O
cause	5	O
TDP	0	B-Disease
were	9	O
investigated	9	O
:	9	O
terfenadine	0	B-Chemical
,	9	O
terodiline	0	B-Chemical
,	9	O
cisapride	0	B-Chemical
and	5	O
E4031	3	B-Chemical
.	9	O

On	5	O
the	5	O
basis	5	O
that	5	O
only	9	O
free	9	O
drug	5	O
in	5	O
the	5	O
systemic	9	O
circulation	9	O
will	5	O
elicit	9	O
a	5	O
pharmacological	9	O
response	9	O
target	9	O
,	9	O
free	9	O
concentrations	0	O
in	5	O
plasma	9	O
were	9	O
selected	9	O
to	5	O
mimic	9	O
the	5	O
free	9	O
drug	5	O
exposures	5	O
in	5	O
man	5	O
.	9	O

Infusion	0	O
regimens	5	O
were	9	O
designed	9	O
that	5	O
rapidly	9	O
achieved	5	O
and	5	O
maintained	9	O
target	9	O
-	7	O
free	9	O
concentrations	0	O
of	5	O
these	5	O
drugs	5	O
in	5	O
plasma	9	O
and	5	O
data	5	O
on	5	O
the	5	O
relationship	5	O
between	5	O
free	9	O
concentration	0	O
and	5	O
changes	9	O
in	5	O
MAPD	5	O
were	9	O
obtained	9	O
for	5	O
these	5	O
compounds	0	O
.	9	O

3	9	O
.	9	O

These	5	O
data	5	O
indicate	9	O
that	5	O
the	5	O
free	9	O
ED50	0	O
in	5	O
plasma	9	O
for	5	O
terfenadine	0	B-Chemical
(	9	O
1	9	O
.	9	O
9	7	O
nM	0	O
)	9	O
,	9	O
terodiline	0	B-Chemical
(	9	O
76	7	O
nM	0	O
)	9	O
,	9	O
cisapride	0	B-Chemical
(	9	O
11	7	O
nM	0	O
)	9	O
and	5	O
E4031	3	B-Chemical
(	9	O
1	9	O
.	9	O
9	7	O
nM	0	O
)	9	O
closely	9	O
correlate	9	O
with	5	O
the	5	O
free	9	O
concentration	0	O
in	5	O
man	5	O
causing	9	O
QT	5	O
effects	9	O
.	9	O

For	9	O
compounds	0	O
that	5	O
have	5	O
shown	9	O
TDP	0	B-Disease
in	5	O
the	5	O
clinic	5	O
(	9	O
terfenadine	0	B-Chemical
,	9	O
terodiline	0	B-Chemical
,	9	O
cisapride	0	B-Chemical
)	9	O
there	5	O
is	5	O
little	9	O
differentiation	3	O
between	5	O
the	5	O
dog	5	O
ED50	0	O
and	5	O
the	5	O
efficacious	5	O
free	9	O
plasma	9	O
concentrations	0	O
in	5	O
man	5	O
(	9	O
<	0	O
10	9	O
-	7	O
fold	9	O
)	9	O
reflecting	5	O
their	5	O
limited	5	O
safety	5	O
margins	5	O
.	9	O

These	5	O
data	5	O
underline	9	O
the	5	O
need	5	O
to	5	O
maximize	5	O
the	5	O
therapeutic	5	O
ratio	9	O
with	5	O
respect	9	O
to	5	O
TDP	0	B-Disease
in	5	O
potential	9	O
development	9	O
candidates	9	O
and	5	O
the	5	O
importance	5	O
of	5	O
using	9	O
free	9	O
drug	5	O
concentrations	0	O
in	5	O
pharmacokinetic	5	O
/	9	O
pharmacodynamic	5	O
studies	9	O
.	9	O

Bladder	9	O
retention	9	B-Disease
of	5	I-Disease
urine	9	I-Disease
as	5	O
a	5	O
result	9	O
of	5	O
continuous	5	O
intravenous	0	O
infusion	0	O
of	5	O
fentanyl	0	B-Chemical
:	9	O
2	9	O
case	5	O
reports	9	O
.	9	O

Sedation	5	O
has	9	O
been	9	O
commonly	5	O
used	5	O
in	5	O
the	5	O
neonate	9	O
to	5	O
decrease	9	O
the	5	O
stress	9	O
and	5	O
pain	5	B-Disease
from	9	O
the	5	O
noxious	5	O
stimuli	5	O
and	5	O
invasive	5	O
procedures	5	O
in	5	O
the	5	O
neonatal	9	O
intensive	5	O
care	5	O
unit	5	O
,	9	O
as	5	O
well	9	O
as	5	O
to	5	O
facilitate	5	O
synchrony	5	O
between	5	O
ventilator	5	O
and	5	O
spontaneous	5	O
breaths	5	O
.	9	O

Fentanyl	0	B-Chemical
,	9	O
an	5	O
opioid	5	O
analgesic	5	O
,	9	O
is	5	O
frequently	5	O
used	5	O
in	5	O
the	5	O
neonatal	9	O
intensive	5	O
care	5	O
unit	5	O
setting	5	O
for	5	O
these	5	O
very	5	O
purposes	5	O
.	9	O

Various	9	O
reported	9	O
side	5	O
effects	9	O
of	5	O
fentanyl	0	B-Chemical
administration	9	O
include	5	O
chest	5	B-Disease
wall	5	I-Disease
rigidity	5	I-Disease
,	9	O
hypotension	5	B-Disease
,	9	O
respiratory	5	B-Disease
depression	5	I-Disease
,	9	O
and	5	O
bradycardia	5	B-Disease
.	9	O

Here	9	O
,	9	O
2	9	O
cases	5	O
of	5	O
urinary	9	B-Disease
bladder	9	I-Disease
retention	9	I-Disease
leading	9	O
to	5	O
renal	9	O
pelvocalyceal	5	O
dilatation	5	O
mimicking	9	O
hydronephrosis	5	B-Disease
as	5	O
a	5	O
result	9	O
of	5	O
continuous	5	O
infusion	0	O
of	5	O
fentanyl	0	B-Chemical
are	5	O
reported	9	O
.	9	O

Fatal	5	O
myeloencephalopathy	9	B-Disease
due	5	O
to	5	O
accidental	5	O
intrathecal	3	O
vincristin	0	B-Chemical
administration	9	O
:	9	O
a	5	O
report	5	O
of	5	O
two	5	O
cases	5	O
.	9	O

We	9	O
report	5	O
on	5	O
two	5	O
fatal	5	O
cases	5	O
of	5	O
accidental	5	O
intrathecal	3	O
vincristine	0	B-Chemical
instillation	0	O
in	5	O
a	5	O
5	9	O
-	7	O
year	5	O
old	5	O
girl	5	O
with	5	O
recurrent	5	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leucemia	2	I-Disease
and	5	O
a	5	O
57	7	O
-	7	O
year	5	O
old	5	O
man	5	O
with	5	O
lymphoblastic	3	B-Disease
lymphoma	9	I-Disease
.	9	O

The	5	O
girl	5	O
died	9	O
seven	9	O
days	9	O
,	9	O
the	5	O
man	5	O
four	9	O
weeks	9	O
after	9	O
intrathecal	3	O
injection	9	O
of	5	O
vincristine	0	B-Chemical
.	9	O

Clinically	5	O
,	9	O
the	5	O
onset	5	O
was	9	O
characterized	9	O
by	9	O
the	5	O
signs	5	O
of	5	O
opistothonus	_	B-Disease
,	9	I-Disease
sensory	5	I-Disease
and	5	I-Disease
motor	5	I-Disease
dysfunction	9	I-Disease
and	5	O
ascending	5	O
paralysis	5	B-Disease
.	9	O

Histological	9	O
and	5	O
immunohistochemical	3	O
investigations	9	O
(	9	O
HE	9	O
-	7	O
LFB	3	O
,	9	O
CD	9	O
-	7	O
68	7	O
,	9	O
Neurofilament	3	O
)	9	O
revealed	9	O
degeneration	9	B-Disease
of	5	I-Disease
myelin	3	I-Disease
and	5	I-Disease
axons	5	I-Disease
as	5	O
well	9	O
as	5	O
pseudocystic	5	B-Disease
transformation	9	I-Disease
in	5	O
areas	5	O
exposed	9	O
to	5	O
vincristine	0	B-Chemical
,	9	O
accompanied	9	O
by	9	O
secondary	9	O
changes	9	O
with	5	O
numerous	9	O
prominent	9	O
macrophages	3	O
.	9	O

The	5	O
clinical	5	O
course	5	O
and	5	O
histopathological	9	O
results	9	O
of	5	O
the	5	O
two	5	O
cases	5	O
are	5	O
presented	5	O
.	9	O

A	9	O
review	5	O
of	5	O
all	5	O
reported	9	O
cases	5	O
in	5	O
the	5	O
literature	5	O
is	5	O
given	5	O
.	9	O

A	9	O
better	5	O
controlled	5	O
regimen	5	O
for	5	O
administering	9	O
vincristine	0	B-Chemical
and	5	O
intrathecal	3	O
chemotherapy	5	O
is	5	O
recommended	5	O
.	9	O

Palpebral	7	B-Disease
twitching	5	I-Disease
in	5	O
a	5	O
depressed	5	B-Disease
adolescent	5	O
on	5	O
citalopram	0	B-Chemical
.	9	O

Current	9	O
estimates	5	O
suggest	9	O
that	5	O
between	5	O
0	7	O
.	9	O
4	9	O
%	9	O
and	5	O
8	9	O
.	9	O
3	9	O
%	9	O
of	5	O
children	5	O
and	5	O
adolescents	5	O
are	5	O
affected	9	O
by	9	O
major	9	B-Disease
depression	5	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
favorable	5	O
response	9	O
to	5	O
treatment	9	O
with	5	O
citalopram	0	B-Chemical
by	9	O
a	5	O
15	9	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
with	5	O
major	9	B-Disease
depression	5	I-Disease
who	5	O
exhibited	9	O
palpebral	5	B-Disease
twitching	5	I-Disease
during	5	O
his	5	O
first	9	O
2	9	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

This	5	O
may	5	O
have	5	O
been	9	O
a	5	O
side	5	O
effect	9	O
of	5	O
citalopram	0	B-Chemical
as	5	O
it	5	O
remitted	5	O
with	5	O
redistribution	9	O
of	5	O
doses	0	O
.	9	O

The	5	O
3	9	O
-	7	O
week	9	O
sulphasalazine	0	B-Chemical
syndrome	5	O
strikes	5	O
again	9	O
.	9	O

A	9	O
34	7	O
-	7	O
year	5	O
-	7	O
old	5	O
lady	5	O
developed	5	O
a	5	O
constellation	5	O
of	5	O
dermatitis	5	B-Disease
,	9	O
fever	5	B-Disease
,	9	O
lymphadenopathy	5	B-Disease
and	5	O
hepatitis	9	B-Disease
,	9	O
beginning	5	O
on	5	O
the	5	O
17th	5	O
day	9	O
of	5	O
a	5	O
course	5	O
of	5	O
oral	9	O
sulphasalazine	0	B-Chemical
for	5	O
sero	5	O
-	7	O
negative	9	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
.	9	O

Cervical	5	O
and	5	O
inguinal	5	O
lymph	9	O
node	5	O
biopsies	9	O
showed	9	O
the	5	O
features	5	O
of	5	O
severe	5	O
necrotising	5	O
lymphadenitis	5	B-Disease
,	9	O
associated	9	O
with	5	O
erythrophagocytosis	3	O
and	5	O
prominent	9	O
eosinophilic	5	O
infiltrates	9	O
,	9	O
without	9	O
viral	9	O
inclusion	5	O
bodies	9	O
,	9	O
suggestive	9	O
of	5	O
an	5	O
adverse	5	B-Disease
drug	5	I-Disease
reaction	9	I-Disease
.	9	O
A	9	O
week	9	O
later	9	O
,	9	O
fulminant	5	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
hepatitis	9	I-Disease
,	9	O
associated	9	O
with	5	O
the	5	O
presence	9	O
of	5	O
anti	3	O
-	7	O
nuclear	3	O
autoantibodies	3	O
(	9	O
but	9	O
not	5	O
with	5	O
other	5	O
markers	3	O
of	5	O
autoimmunity	3	B-Disease
)	9	O
,	9	O
and	5	O
accompanied	9	O
by	9	O
multi	9	B-Disease
-	7	I-Disease
organ	5	I-Disease
failure	5	I-Disease
and	5	O
sepsis	9	B-Disease
,	9	O
supervened	5	O
.	9	O

She	5	O
subsequently	9	O
died	9	O
some	5	O
5	9	O
weeks	9	O
after	9	O
the	5	O
commencement	5	O
of	5	O
her	5	O
drug	5	O
therapy	5	O
.	9	O
Post	9	O
-	7	O
mortem	5	O
examination	5	O
showed	9	O
evidence	9	O
of	5	O
massive	9	B-Disease
hepatocellular	9	I-Disease
necrosis	9	I-Disease
,	9	O
acute	9	O
hypersensitivity	9	O
myocarditis	9	B-Disease
,	9	O
focal	5	O
acute	9	O
tubulo	2	O
-	7	O
interstitial	9	O
nephritis	9	B-Disease
and	5	O
extensive	5	O
bone	5	B-Disease
marrow	3	I-Disease
necrosis	9	I-Disease
,	9	O
with	5	O
no	9	O
evidence	9	O
of	5	O
malignancy	5	B-Disease
.	9	O

It	5	O
is	5	O
thought	5	O
that	5	O
the	5	O
clinico	2	O
-	7	O
pathological	5	O
features	5	O
and	5	O
chronology	5	O
of	5	O
this	5	O
case	5	O
bore	5	O
the	5	O
hallmarks	9	O
of	5	O
the	5	O
so	5	O
-	7	O
called	5	O
"	5	O
3	9	O
-	7	O
week	9	O
sulphasalazine	0	B-Chemical
syndrome	5	O
"	5	O
,	9	O
a	5	O
rare	5	O
,	9	O
but	9	O
often	5	O
fatal	5	O
,	9	O
immunoallergic	5	O
reaction	9	O
to	5	O
sulphasalazine	0	B-Chemical
.	9	O

Intravenous	0	O
administration	9	O
of	5	O
prochlorperazine	0	B-Chemical
by	9	O
15	9	O
-	7	O
minute	5	O
infusion	0	O
versus	9	O
2	9	O
-	7	O
minute	5	O
bolus	0	O
does	9	O
not	5	O
affect	9	O
the	5	O
incidence	5	O
of	5	O
akathisia	5	B-Disease
:	9	O
a	5	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
controlled	5	O
trial	5	O
.	9	O

STUDY	2	O
OBJECTIVE	2	O
:	9	O
We	9	O
sought	9	O
to	5	O
compare	9	O
the	5	O
rate	9	O
of	5	O
akathisia	5	B-Disease
after	9	O
administration	9	O
of	5	O
intravenous	0	O
prochlorperazine	0	B-Chemical
as	5	O
a	5	O
2	9	O
-	7	O
minute	5	O
bolus	0	O
or	5	O
15	9	O
-	7	O
minute	5	O
infusion	0	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
conducted	9	O
a	5	O
prospective	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
study	9	O
in	5	O
the	5	O
emergency	5	O
department	5	O
of	5	O
a	5	O
central	5	O
-	7	O
city	5	O
teaching	5	O
hospital	5	O
.	9	O

Patients	5	O
aged	9	O
18	7	O
years	5	O
or	5	O
older	5	O
treated	3	O
with	5	O
prochlorperazine	0	B-Chemical
for	5	O
headache	5	B-Disease
,	9	O
nausea	5	B-Disease
,	9	O
or	5	O
vomiting	5	B-Disease
were	9	O
eligible	5	O
for	5	O
inclusion	5	O
.	9	O

Study	5	O
participants	5	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
10	9	O
mg	0	O
of	5	O
prochlorperazine	0	B-Chemical
administered	9	O
intravenously	0	O
by	9	O
means	5	O
of	5	O
2	9	O
-	7	O
minute	5	O
push	5	O
(	9	O
bolus	0	O
group	9	O
)	9	O
or	5	O
10	9	O
mg	0	O
diluted	0	O
in	5	O
50	0	O
mL	0	O
of	5	O
normal	9	O
saline	0	O
solution	0	O
administered	9	O
by	9	O
means	5	O
of	5	O
intravenous	0	O
infusion	0	O
during	5	O
a	5	O
15	9	O
-	7	O
minute	5	O
period	5	O
(	9	O
infusion	0	O
group	9	O
)	9	O
.	9	O

The	5	O
main	5	O
outcome	5	O
was	9	O
the	5	O
number	9	O
of	5	O
study	9	O
participants	5	O
experiencing	5	O
akathisia	5	B-Disease
within	9	O
60	9	O
minutes	0	O
of	5	O
administration	9	O
.	9	O

Akathisia	5	O
was	9	O
defined	5	O
as	5	O
either	9	O
a	5	O
spontaneous	5	O
report	5	O
of	5	O
restlessness	5	O
or	5	O
agitation	5	B-Disease
or	5	O
a	5	O
change	9	O
of	5	O
2	9	O
or	5	O
more	5	O
in	5	O
the	5	O
patient	5	O
-	7	O
reported	9	O
akathisia	5	B-Disease
rating	5	O
scale	5	O
and	5	O
a	5	O
change	9	O
of	5	O
at	9	O
least	9	O
1	9	O
in	5	O
the	5	O
investigator	5	O
-	7	O
observed	9	O
akathisia	5	B-Disease
rating	5	O
scale	5	O
.	9	O

The	5	O
intensity	5	O
of	5	O
headache	5	B-Disease
and	5	O
nausea	5	B-Disease
was	9	O
measured	9	O
with	5	O
a	5	O
100	0	O
-	7	O
mm	9	O
visual	5	O
analog	0	O
scale	5	O
.	9	O

RESULTS	9	O
:	9	O
One	5	O
hundred	5	O
patients	5	O
were	9	O
enrolled	5	O
.	9	O

One	5	O
study	9	O
participant	5	O
was	9	O
excluded	9	O
after	9	O
protocol	9	O
violation	5	O
.	9	O

Seventy	5	O
-	7	O
three	9	O
percent	5	O
(	9	O
73	7	O
/	9	O
99	7	O
)	9	O
of	5	O
the	5	O
study	9	O
participants	5	O
were	9	O
treated	3	O
for	5	O
headache	5	B-Disease
and	5	O
70	9	O
%	9	O
(	9	O
70	9	O
/	9	O
99	7	O
)	9	O
for	5	O
nausea	5	B-Disease
.	9	O

In	9	O
the	5	O
bolus	0	O
group	9	O
,	9	O
26	7	O
.	9	O
0	7	O
%	9	O
(	9	O
13	7	O
/	9	O
50	0	O
)	9	O
had	9	O
akathisia	5	B-Disease
compared	9	O
with	5	O
32	7	O
.	9	O
7	9	O
%	9	O
(	9	O
16	9	O
/	9	O
49	7	O
)	9	O
in	5	O
the	5	O
infusion	0	O
group	9	O
(	9	O
Delta	9	O
=	7	O
-	7	O
6	9	O
.	9	O
7	9	O
%	9	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
[	9	O
CI	7	O
]	9	O
-	7	O
24	9	O
.	9	O
6	9	O
%	9	O
to	5	O
11	7	O
.	9	O
2	9	O
%	9	O
)	9	O
.	9	O

The	5	O
difference	9	O
between	5	O
the	5	O
bolus	0	O
and	5	O
infusion	0	O
groups	9	O
in	5	O
the	5	O
percentage	9	O
of	5	O
participants	5	O
who	5	O
saw	5	O
a	5	O
50	0	O
%	9	O
reduction	9	O
in	5	O
their	5	O
headache	5	B-Disease
intensity	5	O
within	9	O
30	9	O
minutes	0	O
was	9	O
11	7	O
.	9	O
8	9	O
%	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
-	7	O
9	7	O
.	9	O
6	9	O
%	9	O
to	5	O
33	7	O
.	9	O
3	9	O
%	9	O
)	9	O
.	9	O

The	5	O
difference	9	O
in	5	O
the	5	O
percentage	9	O
of	5	O
patients	5	O
with	5	O
a	5	O
50	0	O
%	9	O
reduction	9	O
in	5	O
their	5	O
nausea	5	B-Disease
was	9	O
12	9	O
.	9	O
6	9	O
%	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
-	7	O
4	9	O
.	9	O
6	9	O
%	9	O
to	5	O
29	7	O
.	9	O
8	9	O
%	9	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
A	9	O
50	0	O
%	9	O
reduction	9	O
in	5	O
the	5	O
incidence	5	O
of	5	O
akathisia	5	B-Disease
when	5	O
prochlorperazine	0	B-Chemical
was	9	O
administered	9	O
by	9	O
means	5	O
of	5	O
15	9	O
-	7	O
minute	5	O
intravenous	0	O
infusion	0	O
versus	9	O
a	5	O
2	9	O
-	7	O
minute	5	O
intravenous	0	O
push	5	O
was	9	O
not	5	O
detected	9	O
.	9	O

The	5	O
efficacy	9	O
of	5	O
prochlorperazine	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
headache	5	B-Disease
and	5	O
nausea	5	B-Disease
likewise	9	O
did	9	O
not	5	O
appear	9	O
to	5	O
be	5	O
affected	9	O
by	9	O
the	5	O
rate	9	O
of	5	O
administration	9	O
,	9	O
although	9	O
no	9	O
formal	5	O
statistical	5	O
comparisons	5	O
were	9	O
made	5	O
.	9	O

Combined	9	O
antiretroviral	5	O
therapy	5	O
causes	9	O
cardiomyopathy	5	B-Disease
and	5	O
elevates	9	O
plasma	9	O
lactate	0	B-Chemical
in	5	O
transgenic	3	O
AIDS	5	B-Disease
mice	3	O
.	9	O

Highly	9	O
active	9	O
antiretroviral	5	O
therapy	5	O
(	9	O
HAART	5	O
)	9	O
is	5	O
implicated	9	O
in	5	O
cardiomyopathy	5	B-Disease
(	9	O
CM	9	B-Disease
)	9	O
and	5	O
in	5	O
elevated	9	O
plasma	9	O
lactate	0	B-Chemical
(	9	O
LA	9	B-Chemical
)	9	O
in	5	O
AIDS	5	B-Disease
through	9	O
mechanisms	9	O
of	5	O
mitochondrial	9	B-Disease
dysfunction	9	I-Disease
.	9	O

To	9	O
determine	9	O
mitochondrial	9	O
events	5	O
from	9	O
HAART	5	O
in	5	O
vivo	3	O
,	9	O
8	9	O
-	7	O
week	9	O
-	7	O
old	5	O
hemizygous	1	O
transgenic	3	O
AIDS	5	B-Disease
mice	3	O
(	9	O
NL4	1	O
-	7	O
3Delta	_	O
gag	1	O
/	9	O
pol	1	O
;	9	O
TG	9	O
)	9	O
and	5	O
wild	1	O
-	7	O
type	9	O
FVB	3	O
/	9	O
n	9	O
littermates	3	O
were	9	O
treated	3	O
with	5	O
the	5	O
HAART	5	O
combination	9	O
of	5	O
zidovudine	5	B-Chemical
,	9	O
lamivudine	5	B-Chemical
,	9	O
and	5	O
indinavir	0	B-Chemical
or	5	O
vehicle	3	O
control	9	O
for	5	O
10	9	O
days	9	O
or	5	O
35	9	O
days	9	O
.	9	O

At	9	O
termination	9	O
of	5	O
the	5	O
experiments	9	O
,	9	O
mice	3	O
underwent	5	O
echocardiography	5	O
,	9	O
quantitation	9	O
of	5	O
abundance	9	O
of	5	O
molecular	9	O
markers	3	O
of	5	O
CM	9	B-Disease
(	9	O
ventricular	5	O
mRNA	3	O
encoding	1	O
atrial	5	O
natriuretic	9	O
factor	9	O
[	9	O
ANF	3	O
]	9	O
and	5	O
sarcoplasmic	0	O
calcium	0	B-Chemical
ATPase	1	O
[	9	O
SERCA2	3	O
]	9	O
)	9	O
,	9	O
and	5	O
determination	9	O
of	5	O
plasma	9	O
LA	9	B-Chemical
.	9	O

Myocardial	9	O
histologic	9	O
features	5	O
were	9	O
analyzed	9	O
semiquantitatively	9	O
and	5	O
results	9	O
were	9	O
confirmed	9	O
by	9	O
transmission	5	O
electron	0	O
microscopy	9	O
.	9	O

After	9	O
35	9	O
days	9	O
in	5	O
the	5	O
TG	9	O
+	9	O
HAART	5	O
cohort	9	O
,	9	O
left	5	O
ventricular	5	O
mass	9	O
increased	9	O
160	9	O
%	9	O
by	9	O
echocardiography	5	O
.	9	O

Molecularly	9	O
,	9	O
ANF	3	O
mRNA	3	O
increased	9	O
250	0	O
%	9	O
and	5	O
SERCA2	3	O
mRNA	3	O
decreased	9	O
57	7	O
%	9	O
.	9	O

Biochemically	9	O
,	9	O
LA	9	B-Chemical
was	9	O
elevated	9	O
(	9	O
8	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
0	7	O
mM	0	O
)	9	O
.	9	O

Pathologically	5	O
,	9	O
granular	9	O
cytoplasmic	3	O
changes	9	O
were	9	O
found	9	O
in	5	O
cardiac	5	O
myocytes	3	O
,	9	O
indicating	9	O
enlarged	9	O
,	9	O
damaged	9	O
mitochondria	3	O
.	9	O

Findings	5	O
were	9	O
confirmed	9	O
ultrastructurally	3	O
.	9	O

No	9	O
changes	9	O
were	9	O
found	9	O
in	5	O
other	5	O
cohorts	9	O
.	9	O

After	9	O
10	9	O
days	9	O
,	9	O
only	9	O
ANF	3	O
was	9	O
elevated	9	O
,	9	O
and	5	O
only	9	O
in	5	O
the	5	O
TG	9	O
+	9	O
HAART	5	O
cohort	9	O
.	9	O

Results	9	O
show	9	O
that	5	O
cumulative	5	O
HAART	5	O
caused	9	O
mitochondrial	9	O
CM	9	B-Disease
with	5	O
elevated	9	O
LA	9	B-Chemical
in	5	O
AIDS	5	B-Disease
transgenic	3	O
mice	3	O
.	9	O

A	9	O
Phase	9	O
II	9	O
trial	5	O
of	5	O
cisplatin	3	B-Chemical
plus	9	O
WR	9	B-Chemical
-	7	I-Chemical
2721	7	I-Chemical
(	9	O
amifostine	0	B-Chemical
)	9	O
for	5	O
metastatic	3	O
breast	3	B-Disease
carcinoma	3	I-Disease
:	9	O
an	5	O
Eastern	4	O
Cooperative	2	O
Oncology	2	O
Group	9	O
Study	5	O
(	9	O
E8188	_	O
)	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Cisplatin	0	B-Chemical
has	9	O
minimal	9	O
antitumor	3	O
activity	9	O
when	5	O
used	5	O
as	5	O
second	9	O
-	7	O
or	5	O
third	9	O
-	7	O
line	9	O
treatment	9	O
of	5	O
metastatic	3	O
breast	3	B-Disease
carcinoma	3	I-Disease
.	9	O

Older	5	O
reports	9	O
suggest	9	O
an	5	O
objective	5	O
response	9	O
rate	9	O
of	5	O
8	9	O
%	9	O
when	5	O
60	9	O
-	7	O
120	9	O
mg	0	O
/	9	O
m2	7	O
of	5	O
cisplatin	3	B-Chemical
is	5	O
administered	9	O
every	5	O
3	9	O
-	7	O
4	9	O
weeks	9	O
.	9	O

Although	9	O
a	5	O
dose	9	O
-	7	O
response	9	O
effect	9	O
has	9	O
been	9	O
observed	9	O
with	5	O
cisplatin	3	B-Chemical
,	9	O
the	5	O
dose	9	O
-	7	O
limiting	9	O
toxicities	5	B-Disease
associated	9	O
with	5	O
cisplatin	3	B-Chemical
(	9	O
e	9	O
.	9	O
g	0	O
.	9	O
,	9	O
nephrotoxicity	9	B-Disease
,	9	O
ototoxicity	5	B-Disease
,	9	O
and	5	O
neurotoxicity	9	B-Disease
)	9	O
have	5	O
limited	5	O
its	9	O
use	5	O
as	5	O
a	5	O
treatment	9	O
for	5	O
breast	3	B-Disease
carcinoma	3	I-Disease
.	9	O

WR	9	B-Chemical
-	7	I-Chemical
2721	7	I-Chemical
or	5	O
amifostine	0	B-Chemical
initially	9	O
was	9	O
developed	5	O
to	5	O
protect	9	O
military	5	O
personnel	5	O
in	5	O
the	5	O
event	5	O
of	5	O
nuclear	3	O
war	5	O
.	9	O

Amifostine	0	B-Chemical
subsequently	9	O
was	9	O
shown	9	O
to	5	O
protect	9	O
normal	9	O
tissues	9	O
from	9	O
the	5	O
toxic	0	O
effects	9	O
of	5	O
alkylating	0	B-Chemical
agents	5	I-Chemical
and	5	O
cisplatin	3	B-Chemical
without	9	O
decreasing	9	O
the	5	O
antitumor	3	O
effect	9	O
of	5	O
the	5	O
chemotherapy	5	O
.	9	O

Early	9	O
trials	5	O
of	5	O
cisplatin	3	B-Chemical
and	5	O
amifostine	0	B-Chemical
also	9	O
suggested	9	O
that	5	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
cisplatin	3	B-Chemical
-	7	O
induced	3	O
nephrotoxicity	9	B-Disease
,	9	O
ototoxicity	5	B-Disease
,	9	O
and	5	O
neuropathy	5	B-Disease
were	9	O
reduced	9	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
Phase	9	O
II	9	O
study	9	O
of	5	O
the	5	O
combination	9	O
of	5	O
cisplatin	3	B-Chemical
plus	9	O
amifostine	0	B-Chemical
was	9	O
conducted	9	O
in	5	O
patients	5	O
with	5	O
progressive	5	O
metastatic	3	O
breast	3	B-Disease
carcinoma	3	I-Disease
who	5	O
had	9	O
received	9	O
one	5	O
,	9	O
but	9	O
not	5	O
more	5	O
than	5	O
one	5	O
,	9	O
chemotherapy	5	O
regimen	5	O
for	5	O
metastatic	3	O
disease	5	O
.	9	O

Patients	5	O
received	9	O
amifostine	0	B-Chemical
,	9	O
910	7	O
mg	0	O
/	9	O
m2	7	O
intravenously	0	O
over	5	O
15	9	O
minutes	0	O
.	9	O

After	9	O
completion	5	O
of	5	O
the	5	O
amifostine	0	B-Chemical
infusion	0	O
,	9	O
cisplatin	3	B-Chemical
120	9	O
mg	0	O
/	9	O
m2	7	O
was	9	O
administered	9	O
over	5	O
30	9	O
minutes	0	O
.	9	O

Intravenous	0	O
hydration	0	O
and	5	O
mannitol	0	B-Chemical
was	9	O
administered	9	O
before	9	O
and	5	O
after	9	O
cisplatin	3	B-Chemical
.	9	O

Treatment	9	O
was	9	O
administered	9	O
every	5	O
3	9	O
weeks	9	O
until	5	O
disease	5	O
progression	9	O
.	9	O

RESULTS	9	O
:	9	O
Forty	9	O
-	7	O
four	9	O
patients	5	O
were	9	O
enrolled	5	O
in	5	O
the	5	O
study	9	O
of	5	O
which	5	O
7	9	O
(	9	O
16	9	O
%	9	O
)	9	O
were	9	O
ineligible	5	O
.	9	O

A	9	O
median	9	O
of	5	O
2	9	O
cycles	9	O
of	5	O
therapy	5	O
was	9	O
administered	9	O
to	5	O
the	5	O
37	9	O
eligible	5	O
patients	5	O
.	9	O

Six	9	O
partial	9	O
responses	5	O
were	9	O
observed	9	O
for	5	O
an	5	O
overall	5	O
response	9	O
rate	9	O
of	5	O
16	9	O
%	9	O
.	9	O

Most	5	O
patients	5	O
(	9	O
57	7	O
%	9	O
)	9	O
stopped	9	O
treatment	9	O
because	5	O
of	5	O
disease	5	O
progression	9	O
.	9	O

Neurologic	5	B-Disease
toxicity	9	I-Disease
was	9	O
reported	9	O
in	5	O
52	7	O
%	9	O
of	5	O
patients	5	O
.	9	O

Seven	9	O
different	9	O
life	5	O
-	7	O
threatening	5	O
toxicities	5	B-Disease
were	9	O
observed	9	O
in	5	O
patients	5	O
while	9	O
receiving	9	O
treatment	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
combination	9	O
of	5	O
cisplatin	3	B-Chemical
and	5	O
amifostine	0	B-Chemical
in	5	O
this	5	O
study	9	O
resulted	9	O
in	5	O
an	5	O
overall	5	O
response	9	O
rate	9	O
of	5	O
16	9	O
%	9	O
.	9	O

Neither	9	O
a	5	O
tumor	3	B-Disease
-	7	O
protective	9	O
effect	9	O
nor	9	O
reduced	9	O
toxicity	9	B-Disease
to	5	O
normal	9	O
tissues	9	O
was	9	O
observed	9	O
with	5	O
the	5	O
addition	9	O
of	5	O
amifostine	0	B-Chemical
to	5	O
cisplatin	3	B-Chemical
in	5	O
this	5	O
trial	5	O
.	9	O

Oral	9	B-Chemical
contraceptives	5	I-Chemical
and	5	O
the	5	O
risk	5	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
An	5	O
association	9	O
between	5	O
the	5	O
use	5	O
of	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
and	5	O
the	5	O
risk	5	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
has	9	O
been	9	O
found	9	O
in	5	O
some	5	O
,	9	O
but	9	O
not	5	O
all	5	O
,	9	O
studies	9	O
.	9	O

We	9	O
investigated	9	O
this	5	O
association	9	O
,	9	O
according	9	O
to	5	O
the	5	O
type	9	O
of	5	O
progestagen	0	B-Chemical
included	5	O
in	5	O
third	9	O
-	7	O
generation	9	O
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
desogestrel	0	B-Chemical
or	5	O
gestodene	0	B-Chemical
)	9	O
and	5	O
second	9	O
-	7	O
generation	9	O
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
levonorgestrel	0	B-Chemical
)	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
,	9	O
the	5	O
dose	9	O
of	5	O
estrogen	3	B-Chemical
,	9	O
and	5	O
the	5	O
presence	9	O
or	5	O
absence	3	O
of	5	O
prothrombotic	5	O
mutations	1	O
METHODS	2	O
:	9	O
In	9	O
a	5	O
nationwide	5	O
,	9	O
population	5	O
-	7	O
based	5	O
,	9	O
case	5	O
-	7	O
control	9	O
study	9	O
,	9	O
we	5	O
identified	9	O
and	5	O
enrolled	5	O
248	7	O
women	5	O
18	7	O
through	9	O
49	7	O
years	5	O
of	5	O
age	5	O
who	5	O
had	9	O
had	9	O
a	5	O
first	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
between	5	O
1990	2	O
and	5	O
1995	2	O
and	5	O
925	7	O
control	9	O
women	5	O
who	5	O
had	9	O
not	5	O
had	9	O
a	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
and	5	O
who	5	O
were	9	O
matched	9	O
for	5	O
age	5	O
,	9	O
calendar	5	O
year	5	O
of	5	O
the	5	O
index	5	O
event	5	O
,	9	O
and	5	O
area	5	O
of	5	O
residence	5	O
.	9	O

Subjects	5	O
supplied	9	O
information	5	O
on	5	O
oral	9	B-Chemical
-	7	I-Chemical
contraceptive	5	I-Chemical
use	5	O
and	5	O
major	9	O
cardiovascular	5	O
risk	5	O
factors	9	O
.	9	O

An	5	O
analysis	9	O
for	5	O
factor	9	O
V	9	O
Leiden	2	O
and	5	O
the	5	O
G20210A	5	O
mutation	1	O
in	5	O
the	5	O
prothrombin	9	O
gene	1	O
was	9	O
conducted	9	O
in	5	O
217	7	O
patients	5	O
and	5	O
763	7	O
controls	9	O
RESULTS	9	O
:	9	O
The	5	O
odds	5	O
ratio	9	O
for	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
among	5	O
women	5	O
who	5	O
used	5	O
any	5	O
type	9	O
of	5	O
combined	9	O
oral	9	B-Chemical
contraceptive	5	I-Chemical
,	9	O
as	5	O
compared	9	O
with	5	O
nonusers	5	O
,	9	O
was	9	O
2	9	O
.	9	O
0	7	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
1	9	O
.	9	O
5	9	O
to	5	O
2	9	O
.	9	O
8	9	O
)	9	O
.	9	O

The	5	O
adjusted	9	O
odds	5	O
ratio	9	O
was	9	O
2	9	O
.	9	O
5	9	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
1	9	O
.	9	O
5	9	O
to	5	O
4	9	O
.	9	O
1	9	O
)	9	O
among	5	O
women	5	O
who	5	O
used	5	O
second	9	O
-	7	O
generation	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
and	5	O
1	9	O
.	9	O
3	9	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
0	7	O
.	9	O
7	9	O
to	5	O
2	9	O
.	9	O
5	9	O
)	9	O
among	5	O
those	5	O
who	5	O
used	5	O
third	9	O
-	7	O
generation	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
.	9	O

Among	9	O
women	5	O
who	5	O
used	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
,	9	O
the	5	O
odds	5	O
ratio	9	O
was	9	O
2	9	O
.	9	O
1	9	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
1	9	O
.	9	O
5	9	O
to	5	O
3	9	O
.	9	O
0	7	O
)	9	O
for	5	O
those	5	O
without	9	O
a	5	O
prothrombotic	5	O
mutation	1	O
and	5	O
1	9	O
.	9	O
9	7	O
(	9	O
95	7	O
percent	5	O
confidence	5	O
interval	5	O
,	9	O
0	7	O
.	9	O
6	9	O
to	5	O
5	9	O
.	9	O
5	9	O
)	9	O
for	5	O
those	5	O
with	5	O
a	5	O
mutation	1	O
CONCLUSIONS	5	O
:	9	O
The	5	O
risk	5	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
was	9	O
increased	9	O
among	5	O
women	5	O
who	5	O
used	5	O
second	9	O
-	7	O
generation	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
.	9	O

The	5	O
results	9	O
with	5	O
respect	9	O
to	5	O
the	5	O
use	5	O
of	5	O
third	9	O
-	7	O
generation	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
were	9	O
inconclusive	9	O
but	9	O
suggested	9	O
that	5	O
the	5	O
risk	5	O
was	9	O
lower	9	O
than	5	O
the	5	O
risk	5	O
associated	9	O
with	5	O
second	9	O
-	7	O
generation	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
.	9	O

The	5	O
risk	5	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
was	9	O
similar	9	O
among	5	O
women	5	O
who	5	O
used	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
whether	9	O
or	5	O
not	5	O
they	5	O
had	9	O
a	5	O
prothrombotic	5	O
mutation	1	O
.	9	O

End	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
(	9	O
ESRD	5	B-Disease
)	9	O
after	9	O
orthotopic	3	O
liver	9	O
transplantation	9	O
(	9	O
OLTX	2	O
)	9	O
using	9	O
calcineurin	3	O
-	7	O
based	5	O
immunotherapy	5	O
:	9	O
risk	5	O
of	5	O
development	9	O
and	5	O
treatment	9	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
calcineurin	3	O
inhibitors	3	O
cyclosporine	0	B-Chemical
and	5	O
tacrolimus	0	B-Chemical
are	5	O
both	9	O
known	9	O
to	5	O
be	5	O
nephrotoxic	5	B-Disease
.	9	O

Their	5	O
use	5	O
in	5	O
orthotopic	3	O
liver	9	O
transplantation	9	O
(	9	O
OLTX	2	O
)	9	O
has	9	O
dramatically	9	O
improved	5	O
success	5	O
rates	5	O
.	9	O

Recently	9	O
,	9	O
however	9	O
,	9	O
we	5	O
have	5	O
had	9	O
an	5	O
increase	9	O
of	5	O
patients	5	O
who	5	O
are	5	O
presenting	5	O
after	9	O
OLTX	2	O
with	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
(	9	O
ESRD	5	B-Disease
)	9	O
.	9	O

This	5	O
retrospective	5	O
study	9	O
examines	5	O
the	5	O
incidence	5	O
and	5	O
treatment	9	O
of	5	O
ESRD	5	B-Disease
and	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
(	9	O
CRF	9	B-Disease
)	9	O
in	5	O
OLTX	2	O
patients	5	O
.	9	O

METHODS	2	O
:	9	O
Patients	5	O
receiving	9	O
an	5	O
OLTX	2	O
only	9	O
from	9	O
June	2	O
1985	2	O
through	9	O
December	2	O
of	5	O
1994	2	O
who	5	O
survived	9	O
6	9	O
months	5	O
postoperatively	5	O
were	9	O
studied	9	O
(	9	O
n	9	O
=	7	O
834	7	O
)	9	O
.	9	O

Our	9	O
prospectively	5	O
collected	9	O
database	5	O
was	9	O
the	5	O
source	5	O
of	5	O
information	5	O
.	9	O

Patients	5	O
were	9	O
divided	5	O
into	9	O
three	9	O
groups	9	O
:	9	O
Controls	9	O
,	9	O
no	9	O
CRF	9	B-Disease
or	5	O
ESRD	5	B-Disease
,	9	O
n	9	O
=	7	O
748	7	O
;	9	O
CRF	9	B-Disease
,	9	O
sustained	5	O
serum	9	O
creatinine	0	B-Chemical
>	0	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
dl	7	O
,	9	O
n	9	O
=	7	O
41	7	O
;	9	O
and	5	O
ESRD	5	B-Disease
,	9	O
n	9	O
=	7	O
45	9	O
.	9	O

Groups	9	O
were	9	O
compared	9	O
for	5	O
preoperative	5	O
laboratory	9	O
variables	5	O
,	9	O
diagnosis	5	O
,	9	O
postoperative	5	O
variables	5	O
,	9	O
survival	9	O
,	9	O
type	9	O
of	5	O
ESRD	5	B-Disease
therapy	5	O
,	9	O
and	5	O
survival	9	O
from	9	O
onset	5	O
of	5	O
ESRD	5	B-Disease
.	9	O

RESULTS	9	O
:	9	O
At	9	O
13	7	O
years	5	O
after	9	O
OLTX	2	O
,	9	O
the	5	O
incidence	5	O
of	5	O
severe	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
was	9	O
18	7	O
.	9	O
1	9	O
%	9	O
(	9	O
CRF	9	B-Disease
8	9	O
.	9	O
6	9	O
%	9	O
and	5	O
ESRD	5	B-Disease
9	7	O
.	9	O
5	9	O
%	9	O
)	9	O
.	9	O

Compared	9	O
with	5	O
control	9	O
patients	5	O
,	9	O
CRF	9	B-Disease
and	5	O
ESRD	5	B-Disease
patients	5	O
had	9	O
higher	9	O
preoperative	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
,	9	O
a	5	O
greater	5	O
percentage	9	O
of	5	O
patients	5	O
with	5	O
hepatorenal	5	B-Disease
syndrome	5	I-Disease
,	9	O
higher	9	O
percentage	9	O
requirement	9	O
for	5	O
dialysis	5	O
in	5	O
the	5	O
first	9	O
3	9	O
months	5	O
postoperatively	5	O
,	9	O
and	5	O
a	5	O
higher	9	O
1	9	O
-	7	O
year	5	O
serum	9	O
creatinine	0	B-Chemical
.	9	O

Multivariate	5	O
stepwise	5	O
logistic	5	O
regression	5	O
analysis	9	O
using	9	O
preoperative	5	O
and	5	O
postoperative	5	O
variables	5	O
identified	9	O
that	5	O
an	5	O
increase	9	O
of	5	O
serum	9	O
creatinine	0	B-Chemical
compared	9	O
with	5	O
average	5	O
at	9	O
1	9	O
year	5	O
,	9	O
3	9	O
months	5	O
,	9	O
and	5	O
4	9	O
weeks	9	O
postoperatively	5	O
were	9	O
independent	9	O
risk	5	O
factors	9	O
for	5	O
the	5	O
development	9	O
of	5	O
CRF	9	B-Disease
or	5	O
ESRD	5	B-Disease
with	5	O
odds	5	O
ratios	9	O
of	5	O
2	9	O
.	9	O
6	9	O
,	9	O
2	9	O
.	9	O
2	9	O
,	9	O
and	5	O
1	9	O
.	9	O
6	9	O
,	9	O
respectively	9	O
.	9	O

Overall	9	O
survival	9	O
from	9	O
the	5	O
time	5	O
of	5	O
OLTX	2	O
was	9	O
not	5	O
significantly	9	O
different	9	O
among	5	O
groups	9	O
,	9	O
but	9	O
by	9	O
year	5	O
13	7	O
,	9	O
the	5	O
survival	9	O
of	5	O
the	5	O
patients	5	O
who	5	O
had	9	O
ESRD	5	B-Disease
was	9	O
only	9	O
28	7	O
.	9	O
2	9	O
%	9	O
compared	9	O
with	5	O
54	7	O
.	9	O
6	9	O
%	9	O
in	5	O
the	5	O
control	9	O
group	9	O
.	9	O

Patients	5	O
developing	5	O
ESRD	5	B-Disease
had	9	O
a	5	O
6	9	O
-	7	O
year	5	O
survival	9	O
after	9	O
onset	5	O
of	5	O
ESRD	5	B-Disease
of	5	O
27	7	O
%	9	O
for	5	O
the	5	O
patients	5	O
receiving	9	O
hemodialysis	5	O
versus	9	O
71	7	O
.	9	O
4	9	O
%	9	O
for	5	O
the	5	O
patients	5	O
developing	5	O
ESRD	5	B-Disease
who	5	O
subsequently	9	O
received	9	O
kidney	9	O
transplants	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Patients	5	O
who	5	O
are	5	O
more	5	O
than	5	O
10	9	O
years	5	O
post	9	O
-	7	O
OLTX	2	O
have	5	O
CRF	9	B-Disease
and	5	O
ESRD	5	B-Disease
at	9	O
a	5	O
high	9	O
rate	9	O
.	9	O

The	5	O
development	9	O
of	5	O
ESRD	5	B-Disease
decreases	9	O
survival	9	O
,	9	O
particularly	5	O
in	5	O
those	5	O
patients	5	O
treated	3	O
with	5	O
dialysis	5	O
only	9	O
.	9	O

Patients	5	O
who	5	O
develop	5	O
ESRD	5	B-Disease
have	5	O
a	5	O
higher	9	O
preoperative	5	O
and	5	O
1	9	O
-	7	O
year	5	O
serum	9	O
creatinine	0	B-Chemical
and	5	O
are	5	O
more	5	O
likely	5	O
to	5	O
have	5	O
hepatorenal	5	B-Disease
syndrome	5	I-Disease
.	9	O

However	9	O
,	9	O
an	5	O
increase	9	O
of	5	O
serum	9	O
creatinine	0	B-Chemical
at	9	O
various	9	O
times	5	O
postoperatively	5	O
is	5	O
more	5	O
predictive	5	O
of	5	O
the	5	O
development	9	O
of	5	O
CRF	9	B-Disease
or	5	O
ESRD	5	B-Disease
.	9	O

New	2	O
strategies	5	O
for	5	O
long	5	O
-	7	O
term	5	O
immunosuppression	5	O
may	5	O
be	5	O
needed	5	O
to	5	O
decrease	9	O
this	5	O
complication	5	O
.	9	O

Epileptic	5	B-Disease
seizures	5	I-Disease
following	9	O
cortical	5	O
application	5	O
of	5	O
fibrin	0	O
sealants	5	O
containing	0	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
in	5	O
rats	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Fibrin	0	O
sealants	5	O
(	9	O
FS	9	O
)	9	O
derived	9	O
from	9	O
human	3	O
plasma	9	O
are	5	O
frequently	5	O
used	5	O
in	5	O
neurosurgery	5	O
.	9	O

In	9	O
order	5	O
to	5	O
increase	9	O
clot	5	O
stability	9	O
,	9	O
FS	9	O
typically	5	O
contain	9	O
aprotinin	0	O
,	9	O
a	5	O
natural	5	O
fibrinolysis	5	O
inhibitor	3	O
.	9	O

Recently	9	O
,	9	O
synthetic	0	O
fibrinolysis	5	O
inhibitors	3	O
such	5	O
as	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
(	9	O
tAMCA	_	B-Chemical
)	9	O
have	5	O
been	9	O
considered	5	O
as	5	O
substitutes	5	O
for	5	O
aprotinin	0	O
.	9	O

However	9	O
,	9	O
tAMCA	_	B-Chemical
has	9	O
been	9	O
shown	9	O
to	5	O
cause	5	O
epileptic	5	B-Disease
seizures	5	I-Disease
.	9	O

We	9	O
wanted	5	O
to	5	O
study	9	O
whether	9	O
tAMCA	_	B-Chemical
retains	9	O
its	9	O
convulsive	5	B-Disease
action	5	O
if	5	O
incorporated	9	O
into	9	O
a	5	O
FS	9	O
.	9	O

METHOD	2	O
:	9	O
FS	9	O
containing	0	O
aprotinin	0	O
or	5	O
different	9	O
concentrations	0	O
of	5	O
tAMCA	_	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
-	7	O
47	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
ml	0	O
)	9	O
were	9	O
applied	5	O
to	5	O
the	5	O
pial	5	O
surface	9	O
of	5	O
the	5	O
cortex	5	O
of	5	O
anaesthetized	0	O
rats	9	O
.	9	O

The	5	O
response	9	O
of	5	O
the	5	O
animals	9	O
was	9	O
evaluated	9	O
using	9	O
electroencephalography	5	O
and	5	O
by	9	O
monitoring	5	O
the	5	O
clinical	5	O
behaviour	5	O
during	5	O
and	5	O
after	9	O
recovery	9	O
from	9	O
anaesthesia	5	O
.	9	O

FINDINGS	2	O
:	9	O
FS	9	O
containing	0	O
tAMCA	_	B-Chemical
caused	9	O
paroxysmal	5	O
brain	5	O
activity	9	O
which	5	O
was	9	O
associated	9	O
with	5	O
distinct	9	O
convulsive	5	B-Disease
behaviours	5	O
.	9	O

The	5	O
degree	5	O
of	5	O
these	5	O
seizures	5	B-Disease
increased	9	O
with	5	O
increasing	9	O
concentration	0	O
of	5	O
tAMCA	_	B-Chemical
.	9	O

Thus	9	O
,	9	O
FS	9	O
containing	0	O
47	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
ml	0	O
tAMCA	_	B-Chemical
evoked	5	O
generalized	5	B-Disease
seizures	5	I-Disease
in	5	O
all	5	O
tested	9	O
rats	9	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
while	9	O
the	5	O
lowest	9	O
concentration	0	O
of	5	O
tAMCA	_	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
ml	0	O
)	9	O
only	9	O
evoked	5	O
brief	5	O
episodes	5	O
of	5	O
jerk	5	O
-	7	O
correlated	9	O
convulsive	5	B-Disease
potentials	5	O
in	5	O
1	9	O
of	5	O
6	9	O
rats	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
FS	9	O
containing	0	O
aprotinin	0	O
did	9	O
not	5	O
evoke	5	O
any	5	O
paroxysmal	5	O
activity	9	O
.	9	O

INTERPRETATION	2	O
:	9	O
Tranexamic	0	B-Chemical
acid	0	I-Chemical
retains	9	O
its	9	O
convulsive	5	B-Disease
action	5	O
within	9	O
FS	9	O
.	9	O

Thus	9	O
,	9	O
use	5	O
of	5	O
FS	9	O
containing	0	O
tAMCA	_	B-Chemical
for	5	O
surgery	5	O
within	9	O
or	5	O
close	5	O
to	5	O
the	5	O
CNS	9	O
may	5	O
pose	5	O
a	5	O
substantial	9	O
risk	5	O
to	5	O
the	5	O
patient	5	O
.	9	O

Sequential	5	O
observations	9	O
of	5	O
exencephaly	3	B-Disease
and	5	O
subsequent	9	O
morphological	9	O
changes	9	O
by	9	O
mouse	3	O
exo	1	O
utero	9	O
development	9	O
system	5	O
:	9	O
analysis	9	O
of	5	O
the	5	O
mechanism	9	O
of	5	O
transformation	9	O
from	9	O
exencephaly	3	B-Disease
to	5	O
anencephaly	5	B-Disease
.	9	O

Anencephaly	7	B-Disease
has	9	O
been	9	O
suggested	9	O
to	5	O
develop	5	O
from	9	O
exencephaly	3	B-Disease
;	9	O
however	9	O
,	9	O
there	5	O
is	5	O
little	9	O
direct	9	O
experimental	5	O
evidence	9	O
to	5	O
support	5	O
this	5	O
,	9	O
and	5	O
the	5	O
mechanism	9	O
of	5	O
transformation	9	O
remains	9	O
unclear	9	O
.	9	O

We	9	O
examined	9	O
this	5	O
theory	5	O
using	9	O
the	5	O
exo	1	O
utero	9	O
development	9	O
system	5	O
that	5	O
allows	5	O
direct	9	O
and	5	O
sequential	5	O
observations	9	O
of	5	O
mid	9	O
-	7	O
to	5	O
late	9	O
-	7	O
gestation	9	O
mouse	3	O
embryos	3	O
.	9	O

We	9	O
observed	9	O
the	5	O
exencephaly	3	B-Disease
induced	3	O
by	9	O
5	9	B-Chemical
-	7	I-Chemical
azacytidine	3	I-Chemical
at	9	O
embryonic	3	O
day	9	O
13	7	O
.	9	O
5	9	O
(	9	O
E13	3	O
.	9	O
5	9	O
)	9	O
,	9	O
let	5	O
the	5	O
embryos	3	O
develop	5	O
exo	1	O
utero	9	O
until	5	O
E18	3	O
.	9	O
5	9	O
,	9	O
and	5	O
re	5	O
-	7	O
observed	9	O
the	5	O
same	9	O
embryos	3	O
at	9	O
E18	3	O
.	9	O
5	9	O
.	9	O

We	9	O
confirmed	9	O
several	9	O
cases	5	O
of	5	O
transformation	9	O
from	9	O
exencephaly	3	B-Disease
to	5	O
anencephaly	5	B-Disease
.	9	O

However	9	O
,	9	O
in	5	O
many	5	O
cases	5	O
,	9	O
the	5	O
exencephalic	3	B-Disease
brain	5	O
tissue	9	O
was	9	O
preserved	9	O
with	5	O
more	5	O
or	5	O
less	5	O
reduction	9	O
during	5	O
this	5	O
period	5	O
.	9	O

To	9	O
analyze	9	O
the	5	O
transformation	9	O
patterns	5	O
,	9	O
we	5	O
classified	5	O
the	5	O
exencephaly	3	B-Disease
by	9	O
size	9	O
and	5	O
shape	5	O
of	5	O
the	5	O
exencephalic	3	B-Disease
tissue	9	O
into	9	O
several	9	O
types	9	O
at	9	O
E13	3	O
.	9	O
5	9	O
and	5	O
E18	3	O
.	9	O
5	9	O
.	9	O

It	5	O
was	9	O
found	9	O
that	5	O
the	5	O
transformation	9	O
of	5	O
exencephalic	3	B-Disease
tissue	9	O
was	9	O
not	5	O
simply	5	O
size	9	O
-	7	O
dependent	9	O
,	9	O
and	5	O
all	5	O
cases	5	O
of	5	O
anencephaly	5	B-Disease
at	9	O
E18	3	O
.	9	O
5	9	O
resulted	9	O
from	9	O
embryos	3	O
with	5	O
a	5	O
large	5	O
amount	9	O
of	5	O
exencephalic	3	B-Disease
tissue	9	O
at	9	O
E13	3	O
.	9	O
5	9	O
.	9	O

Microscopic	9	O
observation	9	O
showed	9	O
the	5	O
configuration	5	O
of	5	O
exencephaly	3	B-Disease
at	9	O
E13	3	O
.	9	O
5	9	O
,	9	O
frequent	5	O
hemorrhaging	5	B-Disease
and	5	O
detachment	9	O
of	5	O
the	5	O
neural	5	O
plate	0	O
from	9	O
surface	9	O
ectoderm	3	O
in	5	O
the	5	O
exencephalic	3	B-Disease
head	5	O
at	9	O
E15	3	O
.	9	O
5	9	O
,	9	O
and	5	O
multiple	5	O
modes	5	O
of	5	O
reduction	9	O
in	5	O
the	5	O
exencephalic	3	B-Disease
tissue	9	O
at	9	O
E18	3	O
.	9	O
5	9	O
.	9	O

From	5	O
observations	9	O
of	5	O
the	5	O
vasculature	5	O
,	9	O
altered	9	O
distribution	9	O
patterns	5	O
of	5	O
vessels	5	O
were	9	O
identified	9	O
in	5	O
the	5	O
exencephalic	3	B-Disease
head	5	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
overgrowth	9	O
of	5	O
the	5	O
exencephalic	3	B-Disease
neural	5	O
tissue	9	O
causes	9	O
the	5	O
altered	9	O
distribution	9	O
patterns	5	O
of	5	O
vessels	5	O
,	9	O
subsequent	9	O
peripheral	9	O
circulatory	5	B-Disease
failure	5	I-Disease
and	5	O
/	9	O
or	5	O
hemorrhaging	5	B-Disease
in	5	O
various	9	O
parts	5	O
of	5	O
the	5	O
exencephalic	3	B-Disease
head	5	O
,	9	O
leading	9	O
to	5	O
the	5	O
multiple	5	O
modes	5	O
of	5	O
tissue	9	O
reduction	9	O
during	5	O
transformation	9	O
from	9	O
exencephaly	3	B-Disease
to	5	O
anencephaly	5	B-Disease
.	9	O

99mTc	0	B-Chemical
-	7	I-Chemical
glucarate	0	I-Chemical
for	5	O
detection	9	O
of	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

Infarct	5	B-Disease
-	7	O
avid	9	O
radiopharmaceuticals	5	O
are	5	O
necessary	5	O
for	5	O
rapid	5	O
and	5	O
timely	5	O
diagnosis	5	O
of	5	O
acute	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

The	5	O
animal	5	O
model	5	O
used	5	O
to	5	O
produce	9	O
infarction	5	B-Disease
implies	5	O
artery	5	O
ligation	9	O
but	9	O
chemical	0	O
induction	3	O
can	5	O
be	5	O
easily	5	O
obtained	9	O
with	5	O
isoproterenol	0	B-Chemical
.	9	O

A	9	O
new	5	O
infarct	9	B-Disease
-	7	O
avid	9	O
radiopharmaceutical	5	O
based	5	O
on	5	O
glucaric	0	B-Chemical
acid	0	I-Chemical
was	9	O
prepared	0	O
in	5	O
the	5	O
hospital	5	O
radiopharmacy	5	O
of	5	O
the	5	O
INCMNSZ	2	O
.	9	O

99mTc	0	B-Chemical
-	7	I-Chemical
glucarate	0	I-Chemical
was	9	O
easy	5	O
to	5	O
prepare	9	O
,	9	O
stable	9	O
for	5	O
96	9	O
h	0	O
and	5	O
was	9	O
used	5	O
to	5	O
study	9	O
its	9	O
biodistribution	0	O
in	5	O
rats	9	O
with	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Histological	9	O
studies	9	O
demonstrated	9	O
that	5	O
the	5	O
rats	9	O
developed	5	O
an	5	O
infarct	9	B-Disease
18	7	O
h	0	O
after	9	O
isoproterenol	0	B-Chemical
administration	9	O
.	9	O

The	5	O
rat	3	O
biodistribution	0	O
studies	9	O
showed	9	O
a	5	O
rapid	5	O
blood	9	O
clearance	9	O
via	9	O
the	5	O
kidneys	9	O
.	9	O

Thirty	9	O
minutes	0	O
after	9	O
99mTc	0	B-Chemical
-	7	I-Chemical
glucarate	0	I-Chemical
administration	9	O
the	5	O
standardised	5	O
heart	5	O
uptake	0	O
value	9	O
S	9	O
(	9	O
h	0	O
)	9	O
UV	0	O
was	9	O
4	9	O
.	9	O
7	9	O
in	5	O
infarcted	3	O
rat	3	O
heart	5	O
which	5	O
is	5	O
six	9	O
times	5	O
more	5	O
than	5	O
in	5	O
normal	9	O
rats	9	O
.	9	O

ROIs	5	O
drawn	5	O
over	5	O
the	5	O
gamma	9	O
camera	5	O
images	5	O
showed	9	O
a	5	O
ratio	9	O
of	5	O
4	9	O
.	9	O
4	9	O
.	9	O

The	5	O
high	9	O
image	5	O
quality	5	O
suggests	9	O
that	5	O
high	9	O
contrast	9	O
images	5	O
can	5	O
be	5	O
obtained	9	O
in	5	O
humans	9	O
and	5	O
the	5	O
96	9	O
h	0	O
stability	9	O
makes	5	O
it	5	O
an	5	O
ideal	5	O
agent	9	O
to	5	O
detect	9	O
,	9	O
in	5	O
patients	5	O
,	9	O
early	9	O
cardiac	5	B-Disease
infarction	5	I-Disease
.	9	O

Bupropion	0	B-Chemical
(	9	O
Zyban	7	B-Chemical
)	9	O
toxicity	9	B-Disease
.	9	O

Bupropion	0	B-Chemical
is	5	O
a	5	O
monocyclic	0	O
antidepressant	5	B-Chemical
structurally	9	O
related	9	O
to	5	O
amphetamine	5	B-Chemical
.	9	O

Zyban	7	B-Chemical
,	9	O
a	5	O
sustained	5	O
-	7	O
release	9	O
formulation	5	O
of	5	O
bupropion	5	B-Chemical
hydrochloride	0	I-Chemical
,	9	O
was	9	O
recently	9	O
released	9	O
in	5	O
Ireland	2	O
,	9	O
as	5	O
a	5	O
smoking	5	O
cessation	5	O
aid	5	O
.	9	O

In	9	O
the	5	O
initial	9	O
6	9	O
months	5	O
since	9	O
it	5	O
'	9	O
s	9	O
introduction	9	O
,	9	O
12	9	O
overdose	0	B-Disease
cases	5	O
have	5	O
been	9	O
reported	9	O
to	5	O
The	5	O
National	2	O
Poisons	2	O
Information	5	O
Centre	2	O
.	9	O

8	9	O
patients	5	O
developed	5	O
symptoms	5	O
of	5	O
toxicity	9	B-Disease
.	9	O

Common	9	O
features	5	O
included	5	O
tachycardia	5	B-Disease
,	9	O
drowsiness	5	O
,	9	O
hallucinations	5	B-Disease
and	5	O
convulsions	5	B-Disease
.	9	O

Two	9	O
patients	5	O
developed	5	O
severe	5	O
cardiac	5	B-Disease
arrhythmias	5	I-Disease
,	9	O
including	9	O
one	5	O
patient	5	O
who	5	O
was	9	O
resuscitated	5	O
following	9	O
a	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
.	9	O

All	9	O
patients	5	O
recovered	9	O
without	9	O
sequelae	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
a	5	O
31	7	O
year	5	O
old	5	O
female	9	O
who	5	O
required	9	O
admission	5	O
to	5	O
the	5	O
Intensive	2	O
Care	2	O
Unit	2	O
for	5	O
ventilation	5	O
and	5	O
full	5	O
supportive	5	O
therapy	5	O
,	9	O
following	9	O
ingestion	9	O
of	5	O
13	7	O
.	9	O
5g	0	O
bupropion	5	B-Chemical
.	9	O

Recurrent	5	O
seizures	5	B-Disease
were	9	O
treated	3	O
with	5	O
diazepam	0	B-Chemical
and	5	O
broad	5	O
complex	9	O
tachycardia	5	B-Disease
was	9	O
successfully	5	O
treated	3	O
with	5	O
adenosine	0	B-Chemical
.	9	O

Zyban	7	B-Chemical
caused	9	O
significant	9	O
neurological	5	B-Disease
and	5	I-Disease
cardiovascular	5	I-Disease
toxicity	9	I-Disease
in	5	O
overdose	0	B-Disease
.	9	O

The	5	O
potential	9	O
toxic	0	O
effects	9	O
should	5	O
be	5	O
considered	5	O
when	5	O
prescribing	5	O
it	5	O
as	5	O
a	5	O
smoking	5	O
cessation	5	O
aid	5	O
.	9	O

GLEPP1	3	O
receptor	3	O
tyrosine	3	B-Chemical
phosphatase	0	O
(	9	O
Ptpro	1	O
)	9	O
in	5	O
rat	3	O
PAN	0	B-Chemical
nephrosis	0	B-Disease
.	9	O

A	9	O
marker	3	O
of	5	O
acute	9	O
podocyte	3	O
injury	9	O
.	9	O

Glomerular	9	O
epithelial	3	O
protein	1	O
1	9	O
(	9	O
GLEPP1	3	O
)	9	O
is	5	O
a	5	O
podocyte	3	O
receptor	3	O
membrane	9	O
protein	1	O
tyrosine	3	B-Chemical
phosphatase	0	O
located	9	O
on	5	O
the	5	O
apical	9	O
cell	3	O
membrane	9	O
of	5	O
visceral	9	O
glomerular	5	O
epithelial	3	O
cell	3	O
and	5	O
foot	5	O
processes	5	O
.	9	O

This	5	O
receptor	3	O
plays	9	O
a	5	O
role	9	O
in	5	O
regulating	9	O
the	5	O
structure	9	O
and	5	O
function	9	O
of	5	O
podocyte	3	O
foot	5	O
process	5	O
.	9	O

To	9	O
better	5	O
understand	5	O
the	5	O
utility	5	O
of	5	O
GLEPP1	3	O
as	5	O
a	5	O
marker	3	O
of	5	O
glomerular	5	B-Disease
injury	9	I-Disease
,	9	O
the	5	O
amount	9	O
and	5	O
distribution	9	O
of	5	O
GLEPP1	3	O
protein	1	O
and	5	O
mRNA	3	O
were	9	O
examined	9	O
by	9	O
immunohistochemistry	3	O
,	9	O
Western	3	O
blot	3	O
and	5	O
RNase	0	O
protection	9	O
assay	3	O
in	5	O
a	5	O
model	5	O
of	5	O
podocyte	3	O
injury	9	O
in	5	O
the	5	O
rat	3	O
.	9	O

Puromycin	0	B-Chemical
aminonucleoside	0	I-Chemical
nephrosis	0	B-Disease
was	9	O
induced	3	O
by	9	O
single	9	O
intraperitoneal	0	O
injection	9	O
of	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
,	9	O
20	9	O
mg	0	O
/	9	O
100g	0	O
BW	9	O
)	9	O
.	9	O

Tissues	9	O
were	9	O
analyzed	9	O
at	9	O
0	7	O
,	9	O
5	9	O
,	9	O
7	9	O
,	9	O
11	7	O
,	9	O
21	7	O
,	9	O
45	9	O
,	9	O
80	9	O
and	5	O
126	7	O
days	9	O
after	9	O
PAN	0	B-Chemical
injection	9	O
so	5	O
as	5	O
to	5	O
include	5	O
both	9	O
the	5	O
acute	9	O
phase	5	O
of	5	O
proteinuria	9	B-Disease
associated	9	O
with	5	O
foot	5	O
process	5	O
effacement	5	O
(	9	O
days	9	O
5	9	O
-	7	O
11	7	O
)	9	O
and	5	O
the	5	O
chronic	5	O
phase	5	O
of	5	O
proteinuria	9	B-Disease
associated	9	O
with	5	O
glomerulosclerosis	3	B-Disease
(	9	O
days	9	O
45	9	O
-	7	O
126	7	O
)	9	O
.	9	O

At	9	O
day	9	O
5	9	O
,	9	O
GLEPP1	3	O
protein	1	O
and	5	O
mRNA	3	O
were	9	O
reduced	9	O
from	9	O
the	5	O
normal	9	O
range	9	O
(	9	O
265	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
79	7	O
.	9	O
6	9	O
x	9	O
10	9	O
(	9	O
6	9	O
)	9	O
moles	0	O
/	9	O
glomerulus	9	O
and	5	O
100	0	O
%	9	O
)	9	O
to	5	O
15	9	O
%	9	O
of	5	O
normal	9	O
(	9	O
41	7	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
4	9	O
.	9	O
8	9	O
x	9	O
10	9	O
(	9	O
6	9	O
)	9	O
moles	0	O
/	9	O
glomerulus	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
005	7	O
)	9	O
.	9	O

This	5	O
occurred	9	O
in	5	O
association	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
urinary	9	O
protein	1	O
content	9	O
from	9	O
1	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
1	9	O
to	5	O
99	7	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
61	7	O
mg	0	O
/	9	O
day	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
podocalyxin	3	O
did	9	O
not	5	O
change	9	O
significantly	9	O
at	9	O
this	5	O
time	5	O
.	9	O

By	5	O
day	9	O
11	7	O
,	9	O
GLEPP1	3	O
protein	1	O
and	5	O
mRNA	3	O
had	9	O
begun	5	O
to	5	O
return	5	O
towards	5	O
baseline	5	O
.	9	O

By	5	O
day	9	O
45	9	O
-	7	O
126	7	O
,	9	O
at	9	O
a	5	O
time	5	O
when	5	O
glomerular	5	O
scarring	5	O
was	9	O
present	9	O
,	9	O
GLEPP1	3	O
was	9	O
absent	9	O
from	9	O
glomerulosclerotic	3	O
areas	5	O
although	9	O
the	5	O
total	9	O
glomerular	5	O
content	9	O
of	5	O
GLEPP1	3	O
was	9	O
not	5	O
different	9	O
from	9	O
normal	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
GLEPP1	3	O
expression	3	O
,	9	O
unlike	9	O
podocalyxin	3	O
,	9	O
reflects	5	O
podocyte	3	O
injury	9	O
induced	3	O
by	9	O
PAN	0	B-Chemical
.	9	O

GLEPP1	3	O
expression	3	O
may	5	O
be	5	O
a	5	O
useful	5	O
marker	3	O
of	5	O
podocyte	3	O
injury	9	O
.	9	O

Antithymocyte	7	B-Chemical
globulin	9	I-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
-	7	O
induced	3	O
aplastic	5	B-Disease
anemia	9	I-Disease
.	9	O

A	9	O
patient	5	O
who	5	O
received	9	O
antithymocyte	3	B-Chemical
globulin	9	I-Chemical
therapy	5	O
for	5	O
aplastic	5	B-Disease
anemia	9	I-Disease
due	5	O
to	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
therapy	5	O
is	5	O
described	9	O
.	9	O

Bone	9	O
marrow	3	O
recovery	9	O
and	5	O
peripheral	9	O
blood	9	O
recovery	9	O
were	9	O
complete	9	O
1	9	O
month	5	O
and	5	O
3	9	O
months	5	O
,	9	O
respectively	9	O
,	9	O
after	9	O
treatment	9	O
,	9	O
and	5	O
blood	9	O
transfusion	5	O
or	5	O
other	5	O
therapies	5	O
were	9	O
not	5	O
necessary	5	O
in	5	O
a	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
of	5	O
more	5	O
than	5	O
2	9	O
years	5	O
.	9	O

Use	5	O
of	5	O
antithymocyte	3	B-Chemical
globulin	9	I-Chemical
may	5	O
be	5	O
the	5	O
optimal	5	O
treatment	9	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
-	7	O
induced	3	O
aplastic	5	B-Disease
anemia	9	I-Disease
.	9	O

Metamizol	0	B-Chemical
potentiates	3	O
morphine	0	B-Chemical
antinociception	3	O
but	9	O
not	5	O
constipation	5	B-Disease
after	9	O
chronic	5	O
treatment	9	O
.	9	O

This	5	O
work	5	O
evaluates	5	O
the	5	O
antinociceptive	0	O
and	5	O
constipating	5	B-Disease
effects	9	O
of	5	O
the	5	O
combination	9	O
of	5	O
3	9	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
morphine	0	B-Chemical
with	5	O
177	7	O
.	9	O
8	9	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
metamizol	0	B-Chemical
in	5	O
acutely	9	O
and	5	O
chronically	9	O
treated	3	O
(	9	O
once	5	O
a	5	O
day	9	O
for	5	O
12	9	O
days	9	O
)	9	O
rats	9	O
.	9	O

On	5	O
the	5	O
13th	9	O
day	9	O
,	9	O
antinociceptive	0	O
effects	9	O
were	9	O
assessed	9	O
using	9	O
a	5	O
model	5	O
of	5	O
inflammatory	3	O
nociception	5	O
,	9	O
pain	5	B-Disease
-	7	O
induced	3	O
functional	9	O
impairment	5	O
model	5	O
,	9	O
and	5	O
the	5	O
charcoal	0	B-Chemical
meal	5	O
test	5	O
was	9	O
used	5	O
to	5	O
evaluate	9	O
the	5	O
intestinal	9	O
transit	9	O
.	9	O

Simultaneous	9	O
administration	9	O
of	5	O
morphine	0	B-Chemical
with	5	O
metamizol	0	B-Chemical
resulted	9	O
in	5	O
a	5	O
markedly	9	O
antinociceptive	0	O
potentiation	3	O
and	5	O
an	5	O
increasing	9	O
of	5	O
the	5	O
duration	5	O
of	5	O
action	5	O
after	9	O
a	5	O
single	9	O
(	9	O
298	7	O
+	9	O
/	9	O
-	7	O
7	9	O
vs	7	O
.	9	O
139	7	O
+	9	O
/	9	O
-	7	O
36	9	O
units	9	O
area	5	O
(	9	O
ua	5	O
)	9	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
and	5	O
repeated	5	O
administration	9	O
(	9	O
280	9	O
+	9	O
/	9	O
-	7	O
17	7	O
vs	7	O
.	9	O
131	7	O
+	9	O
/	9	O
-	7	O
22	7	O
ua	5	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Antinociceptive	0	O
effect	9	O
of	5	O
morphine	0	B-Chemical
was	9	O
reduced	9	O
in	5	O
chronically	9	O
treated	3	O
rats	9	O
(	9	O
39	7	O
+	9	O
/	9	O
-	7	O
10	9	O
vs	7	O
.	9	O
18	7	O
+	9	O
/	9	O
-	7	O
5	9	O
au	2	O
)	9	O
while	9	O
the	5	O
combination	9	O
-	7	O
induced	3	O
antinociception	3	O
was	9	O
remained	9	O
similar	9	O
as	5	O
an	5	O
acute	9	O
treatment	9	O
(	9	O
298	7	O
+	9	O
/	9	O
-	7	O
7	9	O
vs	7	O
.	9	O
280	9	O
+	9	O
/	9	O
-	7	O
17	7	O
au	2	O
)	9	O
.	9	O

Acute	5	O
antinociceptive	0	O
effects	9	O
of	5	O
the	5	O
combination	9	O
were	9	O
partially	9	O
prevented	9	O
by	9	O
3	9	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
naloxone	0	B-Chemical
s	9	O
.	9	O
c	9	O
.	9	O

(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
suggesting	9	O
the	5	O
partial	9	O
involvement	9	O
of	5	O
the	5	O
opioidergic	5	O
system	5	O
in	5	O
the	5	O
synergism	9	O
observed	9	O
.	9	O

In	9	O
independent	9	O
groups	9	O
,	9	O
morphine	0	B-Chemical
inhibited	3	O
the	5	O
intestinal	9	O
transit	9	O
in	5	O
48	9	O
+	9	O
/	9	O
-	7	O
4	9	O
%	9	O
and	5	O
38	7	O
+	9	O
/	9	O
-	7	O
4	9	O
%	9	O
after	9	O
acute	9	O
and	5	O
chronic	5	O
treatment	9	O
,	9	O
respectively	9	O
,	9	O
suggesting	9	O
that	5	O
tolerance	9	O
did	9	O
not	5	O
develop	5	O
to	5	O
the	5	O
constipating	5	B-Disease
effects	9	O
.	9	O

The	5	O
combination	9	O
inhibited	3	O
intestinal	9	O
transit	9	O
similar	9	O
to	5	O
that	5	O
produced	9	O
by	9	O
morphine	0	B-Chemical
regardless	9	O
of	5	O
the	5	O
time	5	O
of	5	O
treatment	9	O
,	9	O
suggesting	9	O
that	5	O
metamizol	0	B-Chemical
did	9	O
not	5	O
potentiate	3	O
morphine	0	B-Chemical
-	7	O
induced	3	O
constipation	5	B-Disease
.	9	O

These	5	O
findings	9	O
show	9	O
a	5	O
significant	9	O
interaction	9	O
between	5	O
morphine	0	B-Chemical
and	5	O
metamizol	0	B-Chemical
in	5	O
chronically	9	O
treated	3	O
rats	9	O
,	9	O
suggesting	9	O
that	5	O
this	5	O
combination	9	O
could	9	O
be	5	O
useful	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
chronic	5	B-Disease
pain	5	I-Disease
.	9	O

Ifosfamide	0	B-Chemical
encephalopathy	5	B-Disease
presenting	5	O
with	5	O
asterixis	5	B-Disease
.	9	O

CNS	9	O
toxic	0	O
effects	9	O
of	5	O
the	5	O
antineoplastic	9	O
agent	9	O
ifosfamide	0	B-Chemical
(	9	O
IFX	9	B-Chemical
)	9	O
are	5	O
frequent	5	O
and	5	O
include	5	O
a	5	O
variety	5	O
of	5	O
neurological	5	O
symptoms	5	O
that	5	O
can	5	O
limit	5	O
drug	5	O
use	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
a	5	O
51	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
developed	5	O
severe	5	O
,	9	O
disabling	5	O
negative	9	O
myoclonus	5	B-Disease
of	5	O
the	5	O
upper	9	O
and	5	O
lower	9	O
extremities	5	O
after	9	O
the	5	O
infusion	0	O
of	5	O
ifosfamide	0	B-Chemical
for	5	O
plasmacytoma	3	B-Disease
.	9	O

He	5	O
was	9	O
awake	5	O
,	9	O
revealed	9	O
no	9	O
changes	9	O
of	5	O
mental	5	O
status	9	O
and	5	O
at	9	O
rest	5	O
there	5	O
were	9	O
no	9	O
further	9	O
motor	5	O
symptoms	5	O
.	9	O

Cranial	5	O
magnetic	0	O
resonance	5	O
imaging	5	O
and	5	O
extensive	5	O
laboratory	9	O
studies	9	O
failed	9	O
to	5	O
reveal	9	O
structural	9	B-Disease
lesions	5	I-Disease
of	5	I-Disease
the	5	I-Disease
brain	5	I-Disease
and	5	O
metabolic	9	B-Disease
abnormalities	9	I-Disease
.	9	O

An	5	O
electroencephalogram	5	O
showed	9	O
continuous	5	O
,	9	O
generalized	5	O
irregular	5	O
slowing	5	O
with	5	O
admixed	9	O
periodic	5	O
triphasic	5	O
waves	5	O
indicating	9	O
symptomatic	5	O
encephalopathy	5	B-Disease
.	9	O

The	5	O
administration	9	O
of	5	O
ifosfamide	0	B-Chemical
was	9	O
discontinued	5	O
and	5	O
within	9	O
12	9	O
h	0	O
the	5	O
asterixis	5	B-Disease
resolved	9	O
completely	9	O
.	9	O

In	9	O
the	5	O
patient	5	O
described	9	O
,	9	O
the	5	O
presence	9	O
of	5	O
asterixis	5	B-Disease
during	5	O
infusion	0	O
of	5	O
ifosfamide	0	B-Chemical
,	9	O
normal	9	O
laboratory	9	O
findings	9	O
and	5	O
imaging	5	O
studies	9	O
and	5	O
the	5	O
resolution	5	O
of	5	O
symptoms	5	O
following	9	O
the	5	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
suggest	9	O
that	5	O
negative	9	O
myoclonus	5	B-Disease
is	5	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
IFX	9	B-Chemical
.	9	O

Antagonism	3	O
between	5	O
interleukin	3	O
3	9	O
and	5	O
erythropoietin	9	O
in	5	O
mice	3	O
with	5	O
azidothymidine	0	B-Chemical
-	7	O
induced	3	O
anemia	9	B-Disease
and	5	O
in	5	O
bone	5	O
marrow	3	O
endothelial	3	O
cells	3	O
.	9	O

Azidothymidine	0	B-Chemical
(	9	O
AZT	0	B-Chemical
)	9	O
-	7	O
induced	3	O
anemia	9	B-Disease
in	5	O
mice	3	O
can	5	O
be	5	O
reversed	9	O
by	9	O
the	5	O
administration	9	O
of	5	O
IGF	3	O
-	7	O
IL	0	O
-	7	O
3	9	O
(	9	O
fusion	1	O
protein	1	O
of	5	O
insulin	3	O
-	7	O
like	9	O
growth	3	O
factor	9	O
II	9	O
(	9	O
IGF	3	O
II	9	O
)	9	O
and	5	O
interleukin	3	O
3	9	O
)	9	O
.	9	O

Although	9	O
interleukin	3	O
3	9	O
(	9	O
IL	0	O
-	7	O
3	9	O
)	9	O
and	5	O
erythropoietin	9	O
(	9	O
EPO	3	O
)	9	O
are	5	O
known	9	O
to	5	O
act	9	O
synergistically	9	O
on	5	O
hematopoietic	3	O
cell	3	O
proliferation	3	O
in	5	O
vitro	3	O
,	9	O
injection	9	O
of	5	O
IGF	3	O
-	7	O
IL	0	O
-	7	O
3	9	O
and	5	O
EPO	3	O
in	5	O
AZT	0	B-Chemical
-	7	O
treated	3	O
mice	3	O
resulted	9	O
in	5	O
a	5	O
reduction	9	O
of	5	O
red	9	O
cells	3	O
and	5	O
an	5	O
increase	9	O
of	5	O
plasma	9	O
EPO	3	O
levels	3	O
as	5	O
compared	9	O
to	5	O
animals	9	O
treated	3	O
with	5	O
IGF	3	O
-	7	O
IL	0	O
-	7	O
3	9	O
or	5	O
EPO	3	O
alone	9	O
.	9	O

We	9	O
tested	9	O
the	5	O
hypothesis	9	O
that	5	O
the	5	O
antagonistic	9	O
effect	9	O
of	5	O
IL	0	O
-	7	O
3	9	O
and	5	O
EPO	3	O
on	5	O
erythroid	3	O
cells	3	O
may	5	O
be	5	O
mediated	3	O
by	9	O
endothelial	3	O
cells	3	O
.	9	O

Bovine	2	O
liver	9	O
erythroid	3	O
cells	3	O
were	9	O
cultured	3	O
on	5	O
monolayers	3	O
of	5	O
human	3	O
bone	5	O
marrow	3	O
endothelial	3	O
cells	3	O
previously	9	O
treated	3	O
with	5	O
EPO	3	O
and	5	O
IGF	3	O
-	7	O
IL	0	O
-	7	O
3	9	O
.	9	O

There	5	O
was	9	O
a	5	O
significant	9	O
reduction	9	O
of	5	O
thymidine	0	B-Chemical
incorporation	0	O
into	9	O
both	9	O
erythroid	3	O
and	5	O
endothelial	3	O
cells	3	O
in	5	O
cultures	3	O
pre	9	O
-	7	O
treated	3	O
with	5	O
IGF	3	O
-	7	O
IL	0	O
-	7	O
3	9	O
and	5	O
EPO	3	O
.	9	O

Endothelial	3	O
cell	3	O
culture	9	O
supernatants	3	O
separated	9	O
by	9	O
ultrafiltration	0	O
and	5	O
ultracentrifugation	0	O
from	9	O
cells	3	O
treated	3	O
with	5	O
EPO	3	O
and	5	O
IL	0	O
-	7	O
3	9	O
significantly	9	O
reduced	9	O
thymidine	0	B-Chemical
incorporation	0	O
into	9	O
erythroid	3	O
cells	3	O
as	5	O
compared	9	O
to	5	O
identical	9	O
fractions	0	O
obtained	9	O
from	9	O
the	5	O
media	9	O
of	5	O
cells	3	O
cultured	3	O
with	5	O
EPO	3	O
alone	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
endothelial	3	O
cells	3	O
treated	3	O
simultaneously	5	O
with	5	O
EPO	3	O
and	5	O
IL	0	O
-	7	O
3	9	O
have	5	O
a	5	O
negative	9	O
effect	9	O
on	5	O
erythroid	3	O
cell	3	O
production	9	O
.	9	O

The	5	O
relationship	5	O
between	5	O
hippocampal	3	O
acetylcholine	0	B-Chemical
release	9	O
and	5	O
cholinergic	3	O
convulsant	0	O
sensitivity	9	O
in	5	O
withdrawal	5	O
seizure	5	B-Disease
-	7	O
prone	5	O
and	5	O
withdrawal	5	O
seizure	5	B-Disease
-	7	O
resistant	9	O
selected	9	O
mouse	3	O
lines	3	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
septo	2	O
-	7	O
hippocampal	3	O
cholinergic	3	O
pathway	3	O
has	9	O
been	9	O
implicated	9	O
in	5	O
epileptogenesis	5	O
,	9	O
and	5	O
genetic	5	O
factors	9	O
influence	5	O
the	5	O
response	9	O
to	5	O
cholinergic	3	O
agents	5	O
,	9	O
but	9	O
limited	5	O
data	5	O
are	5	O
available	5	O
on	5	O
cholinergic	3	O
involvement	9	O
in	5	O
alcohol	5	B-Chemical
withdrawal	5	O
severity	5	O
.	9	O

Thus	9	O
,	9	O
the	5	O
relationship	5	O
between	5	O
cholinergic	3	O
activity	9	O
and	5	O
responsiveness	9	O
and	5	O
alcohol	5	B-Chemical
withdrawal	5	O
was	9	O
investigated	9	O
in	5	O
a	5	O
genetic	5	O
animal	5	O
model	5	O
of	5	O
ethanol	0	B-Chemical
withdrawal	5	O
severity	5	O
.	9	O

METHODS	2	O
:	9	O
Cholinergic	3	O
convulsant	0	O
sensitivity	9	O
was	9	O
examined	9	O
in	5	O
alcohol	5	B-Chemical
-	7	O
na	7	O
ve	9	O
Withdrawal	5	O
Seizure	5	B-Disease
-	7	O
Prone	5	O
(	9	O
WSP	4	O
)	9	O
and	5	O
-	7	O
Resistant	9	O
(	9	O
WSR	5	O
)	9	O
mice	3	O
.	9	O

Animals	9	O
were	9	O
administered	9	O
nicotine	0	B-Chemical
,	9	O
carbachol	0	B-Chemical
,	9	O
or	5	O
neostigmine	0	B-Chemical
via	9	O
timed	5	O
tail	9	O
vein	5	O
infusion	0	O
,	9	O
and	5	O
the	5	O
latencies	5	O
to	5	O
onset	5	O
of	5	O
tremor	5	B-Disease
and	5	O
clonus	5	O
were	9	O
recorded	5	O
and	5	O
converted	9	O
to	5	O
threshold	5	O
dose	9	O
.	9	O

We	9	O
also	9	O
used	5	O
microdialysis	5	O
to	5	O
measure	5	O
basal	3	O
and	5	O
potassium	0	B-Chemical
-	7	O
stimulated	3	O
acetylcholine	0	B-Chemical
(	9	O
ACh	0	B-Chemical
)	9	O
release	9	O
in	5	O
the	5	O
CA1	3	O
region	9	O
of	5	O
the	5	O
hippocampus	9	O
.	9	O

Potassium	0	B-Chemical
was	9	O
applied	5	O
by	9	O
reverse	9	O
dialysis	5	O
twice	9	O
,	9	O
separated	9	O
by	9	O
75	9	O
min	0	O
.	9	O

Hippocampal	3	O
ACh	0	B-Chemical
also	9	O
was	9	O
measured	9	O
during	5	O
testing	5	O
for	5	O
handling	5	O
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

RESULTS	9	O
:	9	O
Sensitivity	9	O
to	5	O
several	9	O
convulsion	5	B-Disease
endpoints	5	O
induced	3	O
by	9	O
nicotine	0	B-Chemical
,	9	O
carbachol	0	B-Chemical
,	9	O
and	5	O
neostigmine	0	B-Chemical
were	9	O
significantly	9	O
greater	5	O
in	5	O
WSR	5	O
versus	9	O
WSP	4	O
mice	3	O
.	9	O

In	9	O
microdialysis	5	O
experiments	9	O
,	9	O
the	5	O
lines	3	O
did	9	O
not	5	O
differ	9	O
in	5	O
basal	3	O
release	9	O
of	5	O
ACh	0	B-Chemical
,	9	O
and	5	O
50	0	O
mM	0	O
KCl	0	B-Chemical
increased	9	O
ACh	0	B-Chemical
output	5	O
in	5	O
both	9	O
lines	3	O
of	5	O
mice	3	O
.	9	O

However	9	O
,	9	O
the	5	O
increase	9	O
in	5	O
release	9	O
of	5	O
ACh	0	B-Chemical
produced	9	O
by	9	O
the	5	O
first	9	O
application	5	O
of	5	O
KCl	0	B-Chemical
was	9	O
2	9	O
-	7	O
fold	9	O
higher	9	O
in	5	O
WSP	4	O
versus	9	O
WSR	5	O
mice	3	O
.	9	O

When	9	O
hippocampal	3	O
ACh	0	B-Chemical
was	9	O
measured	9	O
during	5	O
testing	5	O
for	5	O
handling	5	O
-	7	O
induced	3	O
convulsions	5	B-Disease
,	9	O
extracellular	9	O
ACh	0	B-Chemical
was	9	O
significantly	9	O
elevated	9	O
(	9	O
192	9	O
%	9	O
)	9	O
in	5	O
WSP	4	O
mice	3	O
,	9	O
but	9	O
was	9	O
nonsignificantly	5	O
elevated	9	O
(	9	O
59	7	O
%	9	O
)	9	O
in	5	O
WSR	5	O
mice	3	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
results	9	O
suggest	9	O
that	5	O
differences	9	O
in	5	O
cholinergic	3	O
activity	9	O
and	5	O
postsynaptic	3	O
sensitivity	9	O
to	5	O
cholinergic	3	O
convulsants	0	B-Disease
may	5	O
be	5	O
associated	9	O
with	5	O
ethanol	0	B-Chemical
withdrawal	5	O
severity	5	O
and	5	O
implicate	9	O
cholinergic	3	O
mechanisms	9	O
in	5	O
alcohol	5	B-Chemical
withdrawal	5	O
.	9	O

Specifically	9	O
,	9	O
WSP	4	O
mice	3	O
may	5	O
have	5	O
lower	9	O
sensitivity	9	O
to	5	O
cholinergic	3	O
convulsants	0	B-Disease
compared	9	O
with	5	O
WSR	5	O
because	5	O
of	5	O
postsynaptic	3	O
receptor	3	O
desensitization	3	O
brought	5	O
on	5	O
by	9	O
higher	9	O
activity	9	O
of	5	O
cholinergic	3	O
neurons	3	O
.	9	O

Capsaicin	0	B-Chemical
-	7	O
induced	3	O
muscle	9	B-Disease
pain	5	I-Disease
alters	9	O
the	5	O
excitability	5	O
of	5	O
the	5	O
human	3	O
jaw	5	O
-	7	O
stretch	9	O
reflex	5	O
.	9	O

The	5	O
pathophysiology	9	O
of	5	O
painful	5	O
temporomandibular	5	B-Disease
disorders	5	I-Disease
is	5	O
not	5	O
fully	9	O
understood	5	O
,	9	O
but	9	O
evidence	9	O
suggests	9	O
that	5	O
muscle	9	B-Disease
pain	5	I-Disease
modulates	9	O
motor	5	O
function	9	O
in	5	O
characteristic	9	O
ways	5	O
.	9	O

This	5	O
study	9	O
tested	9	O
the	5	O
hypothesis	9	O
that	5	O
activation	3	O
of	5	O
nociceptive	5	B-Disease
muscle	9	I-Disease
afferent	5	O
fibers	9	O
would	5	O
be	5	O
linked	9	O
to	5	O
an	5	O
increased	9	O
excitability	5	O
of	5	O
the	5	O
human	3	O
jaw	5	O
-	7	O
stretch	9	O
reflex	5	O
and	5	O
whether	9	O
this	5	O
process	5	O
would	5	O
be	5	O
sensitive	9	O
to	5	O
length	9	O
and	5	O
velocity	5	O
of	5	O
the	5	O
stretch	9	O
.	9	O

Capsaicin	0	B-Chemical
(	9	O
10	9	O
micro	0	O
g	0	O
)	9	O
was	9	O
injected	3	O
into	9	O
the	5	O
masseter	5	O
muscle	9	O
to	5	O
induce	3	O
pain	5	B-Disease
in	5	O
11	7	O
healthy	5	O
volunteers	5	O
.	9	O

Short	5	O
-	7	O
latency	5	O
reflex	5	O
responses	5	O
were	9	O
evoked	5	O
in	5	O
the	5	O
masseter	5	O
and	5	O
temporalis	5	O
muscles	5	O
by	9	O
a	5	O
stretch	9	O
device	5	O
with	5	O
different	9	O
velocities	5	O
and	5	O
displacements	5	O
before	9	O
,	9	O
during	5	O
,	9	O
and	5	O
after	9	O
the	5	O
pain	5	B-Disease
.	9	O

The	5	O
normalized	9	O
reflex	5	O
amplitude	5	O
increased	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
velocity	5	O
at	9	O
a	5	O
given	5	O
displacement	5	O
,	9	O
but	9	O
remained	9	O
constant	9	O
with	5	O
different	9	O
displacements	5	O
at	9	O
a	5	O
given	5	O
velocity	5	O
.	9	O

The	5	O
normalized	9	O
reflex	5	O
amplitude	5	O
was	9	O
significantly	9	O
higher	9	O
during	5	O
pain	5	B-Disease
,	9	O
but	9	O
only	9	O
at	9	O
faster	5	O
stretches	5	O
in	5	O
the	5	O
painful	5	B-Disease
muscle	9	I-Disease
.	9	O

Increased	9	O
sensitivity	9	O
of	5	O
the	5	O
fusimotor	5	O
system	5	O
during	5	O
acute	9	O
muscle	9	B-Disease
pain	5	I-Disease
could	9	O
be	5	O
one	5	O
likely	5	O
mechanism	9	O
to	5	O
explain	9	O
the	5	O
findings	9	O
.	9	O

Effects	9	O
of	5	O
5	9	O
-	7	O
HT1B	3	O
receptor	3	O
ligands	3	O
microinjected	3	O
into	9	O
the	5	O
accumbal	5	O
shell	9	O
or	5	O
core	9	O
on	5	O
the	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
locomotor	5	B-Disease
hyperactivity	5	I-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
examine	9	O
the	5	O
effect	9	O
of	5	O
5	9	O
-	7	O
HT1B	3	O
receptor	3	O
ligands	3	O
microinjected	3	O
into	9	O
the	5	O
subregions	5	O
of	5	O
the	5	O
nucleus	9	O
accumbens	5	O
(	9	O
the	5	O
shell	9	O
and	5	O
the	5	O
core	9	O
)	9	O
on	5	O
the	5	O
locomotor	5	B-Disease
hyperactivity	5	I-Disease
induced	3	O
by	9	O
cocaine	5	B-Chemical
in	5	O
rats	9	O
.	9	O

Male	7	O
Wistar	9	O
rats	9	O
were	9	O
implanted	9	O
bilaterally	5	O
with	5	O
cannulae	5	O
into	9	O
the	5	O
accumbens	5	O
shell	9	O
or	5	O
core	9	O
,	9	O
and	5	O
then	9	O
were	9	O
locally	5	O
injected	3	O
with	5	O
GR	9	B-Chemical
55562	9	I-Chemical
(	9	O
an	5	O
antagonist	3	O
of	5	O
5	9	O
-	7	O
HT1B	3	O
receptors	3	O
)	9	O
or	5	O
CP	9	B-Chemical
93129	9	I-Chemical
(	9	O
an	5	O
agonist	3	O
of	5	O
5	9	O
-	7	O
HT1B	3	O
receptors	3	O
)	9	O
.	9	O

Given	9	O
alone	9	O
to	5	O
any	5	O
accumbal	5	O
subregion	9	O
,	9	O
GR	9	B-Chemical
55562	9	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
-	7	O
10	9	O
microg	0	O
/	9	O
side	5	O
)	9	O
or	5	O
CP	9	B-Chemical
93129	9	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
-	7	O
10	9	O
microg	0	O
/	9	O
side	5	O
)	9	O
did	9	O
not	5	O
change	9	O
basal	3	O
locomotor	5	O
activity	9	O
.	9	O

Systemic	9	O
cocaine	5	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
significantly	9	O
increased	9	O
the	5	O
locomotor	5	O
activity	9	O
of	5	O
rats	9	O
.	9	O

GR	9	B-Chemical
55562	9	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
-	7	O
10	9	O
microg	0	O
/	9	O
side	5	O
)	9	O
,	9	O
administered	9	O
intra	5	O
-	7	O
accumbens	5	O
shell	9	O
prior	9	O
to	5	O
cocaine	5	B-Chemical
,	9	O
dose	9	O
-	7	O
dependently	3	O
attenuated	3	O
the	5	O
psychostimulant	5	O
-	7	O
induced	3	O
locomotor	5	B-Disease
hyperactivity	5	I-Disease
.	9	O

Such	5	O
attenuation	9	O
was	9	O
not	5	O
found	9	O
in	5	O
animals	9	O
which	5	O
had	9	O
been	9	O
injected	3	O
with	5	O
GR	9	B-Chemical
55562	9	I-Chemical
into	9	O
the	5	O
accumbens	5	O
core	9	O
.	9	O

When	9	O
injected	3	O
into	9	O
the	5	O
accumbens	5	O
shell	9	O
(	9	O
but	9	O
not	5	O
the	5	O
core	9	O
)	9	O
before	9	O
cocaine	5	B-Chemical
,	9	O
CP	9	B-Chemical
93129	9	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
-	7	O
10	9	O
microg	0	O
/	9	O
side	5	O
)	9	O
enhanced	3	O
the	5	O
locomotor	5	O
response	9	O
to	5	O
cocaine	5	B-Chemical
;	9	O
the	5	O
maximum	5	O
effect	9	O
being	5	O
observed	9	O
after	9	O
10	9	O
microg	0	O
/	9	O
side	5	O
of	5	O
the	5	O
agonist	3	O
.	9	O

The	5	O
later	9	O
enhancement	9	O
was	9	O
attenuated	3	O
after	9	O
intra	5	O
-	7	O
accumbens	5	O
shell	9	O
treatment	9	O
with	5	O
GR	9	B-Chemical
55562	9	I-Chemical
(	9	O
1	9	O
microg	0	O
/	9	O
side	5	O
)	9	O
.	9	O

Our	9	O
findings	9	O
indicate	9	O
that	5	O
cocaine	5	B-Chemical
induced	3	O
hyperlocomotion	3	B-Disease
is	5	O
modified	9	O
by	9	O
5	9	O
-	7	O
HT1B	3	O
receptor	3	O
ligands	3	O
microinjected	3	O
into	9	O
the	5	O
accumbens	5	O
shell	9	O
,	9	O
but	9	O
not	5	O
core	9	O
,	9	O
this	5	O
modification	9	O
consisting	9	O
in	5	O
inhibitory	3	O
and	5	O
facilitatory	5	O
effects	9	O
of	5	O
the	5	O
5	9	O
-	7	O
HT1B	3	O
receptor	3	O
antagonist	3	O
(	9	O
GR	9	B-Chemical
55562	9	I-Chemical
)	9	O
and	5	O
agonist	3	O
(	9	O
CP	9	B-Chemical
93129	9	I-Chemical
)	9	O
,	9	O
respectively	9	O
.	9	O

In	9	O
other	5	O
words	5	O
,	9	O
the	5	O
present	9	O
results	9	O
suggest	9	O
that	5	O
the	5	O
accumbal	5	O
shell	9	O
5	9	O
-	7	O
HT1B	3	O
receptors	3	O
play	9	O
a	5	O
permissive	9	O
role	9	O
in	5	O
the	5	O
behavioural	5	O
response	9	O
to	5	O
the	5	O
psychostimulant	5	O
.	9	O

Cocaine	5	B-Chemical
related	9	O
chest	5	B-Disease
pain	5	I-Disease
:	9	O
are	5	O
we	5	O
seeing	5	O
the	5	O
tip	5	O
of	5	O
an	5	O
iceberg	5	O
?	5	O

The	5	O
recreational	5	O
use	5	O
of	5	O
cocaine	5	B-Chemical
is	5	O
on	5	O
the	5	O
increase	9	O
.	9	O

The	5	O
emergency	5	O
nurse	5	O
ought	5	O
to	5	O
be	5	O
familiar	5	O
with	5	O
some	5	O
of	5	O
the	5	O
cardiovascular	5	O
consequences	5	O
of	5	O
cocaine	5	B-Chemical
use	5	O
.	9	O

In	9	O
particular	5	O
,	9	O
the	5	O
tendency	5	O
of	5	O
cocaine	5	B-Chemical
to	5	O
produce	9	O
chest	5	B-Disease
pain	5	I-Disease
ought	5	O
to	5	O
be	5	O
in	5	O
the	5	O
mind	5	O
of	5	O
the	5	O
emergency	5	O
nurse	5	O
when	5	O
faced	5	O
with	5	O
a	5	O
young	5	O
victim	5	O
of	5	O
chest	5	B-Disease
pain	5	I-Disease
who	5	O
is	5	O
otherwise	9	O
at	9	O
low	9	O
risk	5	O
.	9	O

The	5	O
mechanism	9	O
of	5	O
chest	5	B-Disease
pain	5	I-Disease
related	9	O
to	5	O
cocaine	5	B-Chemical
use	5	O
is	5	O
discussed	5	O
and	5	O
treatment	9	O
dilemmas	5	O
are	5	O
discussed	5	O
.	9	O

Finally	9	O
,	9	O
moral	5	O
issues	5	O
relating	5	O
to	5	O
the	5	O
testing	5	O
of	5	O
potential	9	O
cocaine	5	B-Chemical
users	5	O
will	5	O
be	5	O
addressed	5	O
.	9	O

Crossover	5	O
comparison	9	O
of	5	O
efficacy	9	O
and	5	O
preference	5	O
for	5	O
rizatriptan	5	B-Chemical
10	9	O
mg	0	O
versus	9	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
in	5	O
migraine	5	B-Disease
.	9	O

Rizatriptan	0	B-Chemical
is	5	O
a	5	O
selective	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
(	9	O
1B	9	O
/	9	O
1D	9	O
)	9	O
receptor	3	O
agonist	3	O
with	5	O
rapid	5	O
oral	9	O
absorption	0	O
and	5	O
early	9	O
onset	5	O
of	5	O
action	5	O
in	5	O
the	5	O
acute	9	O
treatment	9	O
of	5	O
migraine	5	B-Disease
.	9	O

This	5	O
randomized	5	O
double	9	O
-	7	O
blind	5	O
crossover	5	O
outpatient	5	O
study	9	O
assessed	9	O
the	5	O
preference	5	O
for	5	O
1	9	O
rizatriptan	5	B-Chemical
10	9	O
mg	0	O
tablet	0	O
to	5	O
2	9	O
ergotamine	0	B-Chemical
1	9	O
mg	0	O
/	9	O
caffeine	0	B-Chemical
100	0	O
mg	0	O
tablets	0	O
in	5	O
439	7	O
patients	5	O
treating	5	O
a	5	O
single	9	O
migraine	5	B-Disease
attack	5	O
with	5	O
each	5	O
therapy	5	O
.	9	O

Of	9	O
patients	5	O
expressing	3	O
a	5	O
preference	5	O
(	9	O
89	7	O
.	9	O
1	9	O
%	9	O
)	9	O
,	9	O
more	5	O
than	5	O
twice	9	O
as	5	O
many	5	O
preferred	5	O
rizatriptan	5	B-Chemical
to	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
(	9	O
69	7	O
.	9	O
9	7	O
vs	7	O
.	9	O
30	9	O
.	9	O
1	9	O
%	9	O
,	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Faster	5	O
relief	5	O
of	5	O
headache	5	B-Disease
was	9	O
the	5	O
most	9	O
important	9	O
reason	5	O
for	5	O
preference	5	O
,	9	O
cited	5	O
by	9	O
67	7	O
.	9	O
3	9	O
%	9	O
of	5	O
patients	5	O
preferring	5	O
rizatriptan	5	B-Chemical
and	5	O
54	7	O
.	9	O
2	9	O
%	9	O
of	5	O
patients	5	O
who	5	O
preferred	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
.	9	O

The	5	O
co	9	O
-	7	O
primary	9	O
endpoint	5	O
of	5	O
being	5	O
pain	5	B-Disease
free	9	O
at	9	O
2	9	O
h	0	O
was	9	O
also	9	O
in	5	O
favor	9	O
of	5	O
rizatriptan	5	B-Chemical
.	9	O

Forty	9	O
-	7	O
nine	9	O
percent	5	O
of	5	O
patients	5	O
were	9	O
pain	5	B-Disease
free	9	O
2	9	O
h	0	O
after	9	O
rizatriptan	5	B-Chemical
,	9	O
compared	9	O
with	5	O
24	9	O
.	9	O
3	9	O
%	9	O
treated	3	O
with	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
(	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
rizatriptan	5	B-Chemical
being	5	O
superior	5	O
within	9	O
1	9	O
h	0	O
of	5	O
treatment	9	O
.	9	O

Headache	7	B-Disease
relief	5	O
at	9	O
2	9	O
h	0	O
was	9	O
75	9	O
.	9	O
9	7	O
%	9	O
for	5	O
rizatriptan	5	B-Chemical
and	5	O
47	7	O
.	9	O
3	9	O
%	9	O
for	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
(	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
with	5	O
rizatriptan	5	B-Chemical
being	5	O
superior	5	O
to	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
within	9	O
30	9	O
min	0	O
of	5	O
dosing	9	O
.	9	O

Almost	5	O
36	9	O
%	9	O
of	5	O
patients	5	O
taking	5	O
rizatriptan	5	B-Chemical
were	9	O
pain	5	B-Disease
free	9	O
at	9	O
2	9	O
h	0	O
and	5	O
had	9	O
no	9	O
recurrence	5	O
or	5	O
need	5	O
for	5	O
additional	9	O
medication	5	O
within	9	O
24	9	O
h	0	O
,	9	O
compared	9	O
to	5	O
20	9	O
%	9	O
of	5	O
patients	5	O
on	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
(	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Rizatriptan	0	B-Chemical
was	9	O
also	9	O
superior	5	O
to	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
in	5	O
the	5	O
proportions	9	O
of	5	O
patients	5	O
with	5	O
no	9	O
nausea	5	B-Disease
,	9	O
vomiting	5	B-Disease
,	9	O
phonophobia	5	B-Disease
or	5	O
photophobia	5	B-Disease
and	5	O
for	5	O
patients	5	O
with	5	O
normal	9	O
function	9	O
2	9	O
h	0	O
after	9	O
drug	5	O
intake	5	O
(	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

More	5	O
patients	5	O
were	9	O
(	9	O
completely	9	O
,	9	O
very	5	O
or	5	O
somewhat	5	O
)	9	O
satisfied	5	O
2	9	O
h	0	O
after	9	O
treatment	9	O
with	5	O
rizatriptan	5	B-Chemical
(	9	O
69	7	O
.	9	O
8	9	O
%	9	O
)	9	O
than	5	O
at	9	O
2	9	O
h	0	O
after	9	O
treatment	9	O
with	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
(	9	O
38	7	O
.	9	O
6	9	O
%	9	O
,	9	O
p	7	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Recurrence	5	O
rates	5	O
were	9	O
31	7	O
.	9	O
4	9	O
%	9	O
with	5	O
rizatriptan	5	B-Chemical
and	5	O
15	9	O
.	9	O
3	9	O
%	9	O
with	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
.	9	O

Both	9	O
active	9	O
treatments	9	O
were	9	O
well	9	O
tolerated	9	O
.	9	O

The	5	O
most	9	O
common	5	O
adverse	5	O
events	5	O
(	9	O
incidence	5	O
>	0	O
or	5	O
=	7	O
5	9	O
%	9	O
in	5	O
one	5	O
group	9	O
)	9	O
after	9	O
rizatriptan	5	B-Chemical
and	5	O
ergotamine	0	B-Chemical
/	9	O
caffeine	0	B-Chemical
,	9	O
respectively	9	O
,	9	O
were	9	O
dizziness	5	B-Disease
(	9	O
6	9	O
.	9	O
7	9	O
and	5	O
5	9	O
.	9	O
3	9	O
%	9	O
)	9	O
,	9	O
nausea	5	B-Disease
(	9	O
4	9	O
.	9	O
2	9	O
and	5	O
8	9	O
.	9	O
5	9	O
%	9	O
)	9	O
and	5	O
somnolence	5	B-Disease
(	9	O
5	9	O
.	9	O
5	9	O
and	5	O
2	9	O
.	9	O
3	9	O
%	9	O
)	9	O
.	9	O

Severe	9	O
ocular	5	B-Disease
and	5	I-Disease
orbital	5	I-Disease
toxicity	9	I-Disease
after	9	O
intracarotid	0	O
injection	9	O
of	5	O
carboplatin	0	B-Chemical
for	5	O
recurrent	5	O
glioblastomas	3	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Glioblastoma	3	B-Disease
is	5	O
a	5	O
malignant	3	B-Disease
tumor	3	I-Disease
that	5	O
occurs	9	O
in	5	O
the	5	O
cerebrum	9	O
during	5	O
adulthood	5	O
.	9	O

With	5	O
current	5	O
treatment	9	O
regimens	5	O
including	9	O
combined	9	O
surgery	5	O
,	9	O
radiation	9	O
and	5	O
chemotherapy	5	O
,	9	O
the	5	O
average	5	O
life	5	O
expectancy	5	O
of	5	O
the	5	O
patients	5	O
is	5	O
limited	5	O
to	5	O
approximately	9	O
1	9	O
year	5	O
.	9	O

Therefore	9	O
,	9	O
patients	5	O
with	5	O
glioblastoma	3	B-Disease
sometimes	5	O
have	5	O
intracarotid	0	O
injection	9	O
of	5	O
carcinostatics	9	O
added	0	O
to	5	O
the	5	O
treatment	9	O
regimen	5	O
.	9	O

Generally	5	O
,	9	O
carboplatin	0	B-Chemical
is	5	O
said	5	O
to	5	O
have	5	O
milder	9	O
side	5	O
effects	9	O
than	5	O
cisplatin	3	B-Chemical
,	9	O
whose	9	O
ocular	5	B-Disease
and	5	I-Disease
orbital	5	I-Disease
toxicity	9	I-Disease
are	5	O
well	9	O
known	9	O
.	9	O

However	9	O
,	9	O
we	5	O
experienced	5	O
a	5	O
case	5	O
of	5	O
severe	5	O
ocular	5	B-Disease
and	5	I-Disease
orbital	5	I-Disease
toxicity	9	I-Disease
after	9	O
intracarotid	0	O
injection	9	O
of	5	O
carboplatin	0	B-Chemical
,	9	O
which	5	O
is	5	O
infrequently	5	O
reported	9	O
.	9	O

CASE	2	O
:	9	O
A	9	O
58	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
received	9	O
an	5	O
intracarotid	0	O
injection	9	O
of	5	O
carboplatin	0	B-Chemical
for	5	O
recurrent	5	O
glioblastomas	3	B-Disease
in	5	O
his	5	O
left	5	O
temporal	5	O
lobe	5	O
.	9	O

He	5	O
complained	5	O
of	5	O
pain	5	B-Disease
and	5	I-Disease
visual	5	I-Disease
disturbance	5	I-Disease
in	5	I-Disease
the	5	I-Disease
ipsilateral	5	I-Disease
eye	5	I-Disease
30	9	O
h	0	O
after	9	O
the	5	O
injection	9	O
.	9	O

Various	9	O
ocular	5	O
symptoms	5	O
and	5	O
findings	9	O
caused	9	O
by	9	O
carboplatin	0	B-Chemical
toxicity	9	B-Disease
were	9	O
seen	9	O
.	9	O

RESULTS	9	O
:	9	O
He	5	O
was	9	O
treated	3	O
with	5	O
intravenous	0	O
administration	9	O
of	5	O
corticosteroids	5	O
and	5	O
glycerin	0	B-Chemical
for	5	O
6	9	O
days	9	O
after	9	O
the	5	O
injection	9	O
.	9	O

Although	9	O
the	5	O
intraocular	5	O
pressure	5	O
elevation	9	O
caused	9	O
by	9	O
secondary	9	O
acute	9	O
angle	5	O
-	7	O
closure	5	O
glaucoma	5	B-Disease
decreased	9	O
and	5	O
ocular	5	B-Disease
pain	5	I-Disease
diminished	9	O
,	9	O
inexorable	5	O
papilledema	5	B-Disease
and	5	O
exudative	5	O
retinal	5	B-Disease
detachment	9	I-Disease
continued	9	O
for	5	O
3	9	O
weeks	9	O
.	9	O

Finally	9	O
,	9	O
6	9	O
weeks	9	O
later	9	O
,	9	O
diffuse	5	O
chorioretinal	5	B-Disease
atrophy	5	I-Disease
with	5	O
optic	5	B-Disease
atrophy	5	I-Disease
occurred	9	O
and	5	O
the	5	O
vision	5	O
in	5	O
his	5	O
left	5	O
eye	5	O
was	9	O
lost	9	O
.	9	O

CONCLUSION	5	O
:	9	O
When	9	O
performing	5	O
intracarotid	0	O
injection	9	O
of	5	O
carboplatin	0	B-Chemical
,	9	O
we	5	O
must	5	O
be	5	O
aware	5	O
of	5	O
its	9	O
potentially	5	O
blinding	5	O
ocular	5	B-Disease
toxicity	9	I-Disease
.	9	O

It	5	O
is	5	O
recommended	5	O
that	5	O
further	9	O
studies	9	O
and	5	O
investigations	9	O
are	5	O
undertaken	5	O
in	5	O
the	5	O
effort	5	O
to	5	O
minimize	5	O
such	5	O
severe	5	O
side	5	O
effects	9	O
.	9	O

Visual	5	B-Disease
hallucinations	5	I-Disease
associated	9	O
with	5	O
zonisamide	0	B-Chemical
.	9	O

Zonisamide	0	B-Chemical
is	5	O
a	5	O
broad	5	O
-	7	O
spectrum	9	O
antiepileptic	5	O
drug	5	O
used	5	O
to	5	O
treat	5	O
various	9	O
types	9	O
of	5	O
seizures	5	B-Disease
.	9	O

Although	9	O
visual	5	B-Disease
hallucinations	5	I-Disease
have	5	O
not	5	O
been	9	O
reported	9	O
as	5	O
an	5	O
adverse	5	O
effect	9	O
of	5	O
this	5	O
agent	9	O
,	9	O
we	5	O
describe	5	O
three	9	O
patients	5	O
who	5	O
experienced	5	O
complex	9	O
visual	5	B-Disease
hallucinations	5	I-Disease
and	5	O
altered	9	O
mental	5	O
status	9	O
after	9	O
zonisamide	0	B-Chemical
treatment	9	O
was	9	O
begun	5	O
or	5	O
its	9	O
dosage	9	O
increased	9	O
.	9	O

All	9	O
three	9	O
had	9	O
been	9	O
diagnosed	5	O
earlier	9	O
with	5	O
epilepsy	5	B-Disease
,	9	O
and	5	O
their	5	O
electroencephalogram	5	O
(	9	O
EEG	5	O
)	9	O
findings	9	O
were	9	O
abnormal	9	O
.	9	O

During	5	O
monitoring	5	O
,	9	O
visual	5	B-Disease
hallucinations	5	I-Disease
did	9	O
not	5	O
correlate	9	O
with	5	O
EEG	5	O
readings	5	O
,	9	O
nor	9	O
did	9	O
video	5	O
recording	5	O
capture	5	O
any	5	O
of	5	O
the	5	O
described	9	O
events	5	O
.	9	O

None	9	O
of	5	O
the	5	O
patients	5	O
had	9	O
experienced	5	O
visual	5	B-Disease
hallucinations	5	I-Disease
before	9	O
this	5	O
event	5	O
.	9	O

The	5	O
only	9	O
recent	5	O
change	9	O
in	5	O
their	5	O
treatment	9	O
was	9	O
the	5	O
introduction	9	O
or	5	O
increased	9	O
dosage	9	O
of	5	O
zonisamide	0	B-Chemical
.	9	O

With	5	O
either	9	O
discontinuation	5	O
or	5	O
decreased	9	O
dosage	9	O
of	5	O
the	5	O
drug	5	O
the	5	O
symptoms	5	O
disappeared	9	O
and	5	O
did	9	O
not	5	O
recur	5	O
.	9	O

Further	9	O
observations	9	O
and	5	O
reports	9	O
will	5	O
help	5	O
clarify	9	O
this	5	O
adverse	5	O
effect	9	O
.	9	O

Until	5	O
then	9	O
,	9	O
clinicians	5	O
need	5	O
to	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
possible	5	O
complication	5	O
associated	9	O
with	5	O
zonisamide	0	B-Chemical
.	9	O

Anti	3	O
-	7	O
epileptic	5	B-Disease
drugs	5	O
-	7	O
induced	3	O
de	2	O
novo	9	O
absence	3	B-Disease
seizures	5	I-Disease
.	9	O

The	5	O
authors	5	O
present	9	O
three	9	O
patients	5	O
with	5	O
de	2	O
novo	9	O
absence	3	B-Disease
epilepsy	5	I-Disease
after	9	O
administration	9	O
of	5	O
carbamazepine	0	B-Chemical
and	5	O
vigabatrin	0	B-Chemical
.	9	O

Despite	5	O
the	5	O
underlying	5	O
diseases	5	O
,	9	O
the	5	O
prognosis	5	O
for	5	O
drug	5	O
-	7	O
induced	3	O
de	2	O
novo	9	O
absence	3	B-Disease
seizure	5	I-Disease
is	5	O
good	5	O
because	5	O
it	5	O
subsides	5	O
rapidly	9	O
after	9	O
discontinuing	5	O
the	5	O
use	5	O
of	5	O
the	5	O
offending	5	O
drugs	5	O
.	9	O

The	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
-	7	O
transmitted	5	O
thalamocortical	5	O
circuitry	5	O
accounts	5	O
for	5	O
a	5	O
major	9	O
part	9	O
of	5	O
the	5	O
underlying	5	O
neurophysiology	5	O
of	5	O
the	5	O
absence	3	B-Disease
epilepsy	5	I-Disease
.	9	O

Because	9	O
drug	5	O
-	7	O
induced	3	O
de	2	O
novo	9	O
absence	3	B-Disease
seizure	5	I-Disease
is	5	O
rare	5	O
,	9	O
pro	9	O
-	7	O
absence	3	O
drugs	5	O
can	5	O
only	9	O
be	5	O
considered	5	O
a	5	O
promoting	9	O
factor	9	O
.	9	O

The	5	O
underlying	5	O
epileptogenecity	5	O
of	5	O
the	5	O
patients	5	O
or	5	O
the	5	O
synergistic	9	O
effects	9	O
of	5	O
the	5	O
accompanying	5	O
drugs	5	O
is	5	O
required	9	O
to	5	O
trigger	9	O
the	5	O
de	2	O
novo	9	O
absence	3	B-Disease
seizure	5	I-Disease
.	9	O

The	5	O
possibility	9	O
of	5	O
drug	5	O
-	7	O
induced	3	O
aggravation	5	O
should	5	O
be	5	O
considered	5	O
whenever	5	O
an	5	O
unexpected	9	O
increase	9	O
in	5	O
seizure	5	B-Disease
frequency	5	O
and	5	O
/	9	O
or	5	O
new	5	O
seizure	5	B-Disease
types	9	O
appear	9	O
following	9	O
a	5	O
change	9	O
in	5	O
drug	5	O
treatment	9	O
.	9	O

By	5	O
understanding	5	O
the	5	O
underlying	5	O
mechanism	9	O
of	5	O
absence	3	B-Disease
epilepsy	5	I-Disease
,	9	O
we	5	O
can	5	O
avoid	5	O
the	5	O
inappropriate	5	O
use	5	O
of	5	O
anticonvulsants	5	O
in	5	O
children	5	O
with	5	O
epilepsy	5	B-Disease
and	5	O
prevent	5	O
drug	5	O
-	7	O
induced	3	O
absence	3	B-Disease
seizures	5	I-Disease
.	9	O

Prenatal	5	O
dexamethasone	0	B-Chemical
programs	5	O
hypertension	5	B-Disease
and	5	O
renal	9	B-Disease
injury	9	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Dexamethasone	0	O
is	5	O
frequently	5	O
administered	9	O
to	5	O
the	5	O
developing	5	O
fetus	5	O
to	5	O
accelerate	9	O
pulmonary	5	O
development	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
determine	9	O
if	5	O
prenatal	5	O
dexamethasone	0	B-Chemical
programmed	5	O
a	5	O
progressive	5	O
increase	9	B-Disease
in	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
and	5	O
renal	9	B-Disease
injury	9	I-Disease
in	5	O
rats	9	O
.	9	O

Pregnant	5	O
rats	9	O
were	9	O
given	5	O
either	9	O
vehicle	3	O
or	5	O
2	9	O
daily	5	O
intraperitoneal	0	O
injections	9	O
of	5	O
dexamethasone	0	B-Chemical
(	9	O
0	7	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
body	5	O
weight	9	O
)	9	O
on	5	O
gestational	5	O
days	9	O
11	7	O
and	5	O
12	9	O
,	9	O
13	7	O
and	5	O
14	7	O
,	9	O
15	9	O
and	5	O
16	9	O
,	9	O
17	7	O
and	5	O
18	7	O
,	9	O
or	5	O
19	7	O
and	5	O
20	9	O
.	9	O

Offspring	9	O
of	5	O
rats	9	O
administered	9	O
dexamethasone	0	B-Chemical
on	5	O
days	9	O
15	9	O
and	5	O
16	9	O
gestation	9	O
had	9	O
a	5	O
20	9	O
%	9	O
reduction	9	B-Disease
in	5	I-Disease
glomerular	5	I-Disease
number	9	I-Disease
compared	9	O
with	5	O
control	9	O
at	9	O
6	9	O
to	5	O
9	7	O
months	5	O
of	5	O
age	5	O
(	9	O
22	7	O
527	7	O
+	9	O
/	9	O
-	7	O
509	7	O
versus	9	O
28	7	O
050	2	O
+	9	O
/	9	O
-	7	O
561	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
which	5	O
was	9	O
comparable	9	O
to	5	O
the	5	O
percent	5	O
reduction	9	O
in	5	O
glomeruli	9	O
measured	9	O
at	9	O
3	9	O
weeks	9	O
of	5	O
age	5	O
.	9	O

Six	9	O
-	7	O
to	5	O
9	7	O
-	7	O
month	5	O
old	5	O
rats	9	O
receiving	9	O
prenatal	5	O
dexamethasone	0	B-Chemical
on	5	O
days	9	O
17	7	O
and	5	O
18	7	O
of	5	O
gestation	9	O
had	9	O
a	5	O
17	7	O
%	9	O
reduction	9	O
in	5	O
glomeruli	9	O
(	9	O
23	7	O
380	9	O
+	9	O
/	9	O
-	7	O
587	7	O
)	9	O
compared	9	O
with	5	O
control	9	O
rats	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Male	7	O
rats	9	O
that	5	O
received	9	O
prenatal	5	O
dexamethasone	0	B-Chemical
on	5	O
days	9	O
15	9	O
and	5	O
16	9	O
,	9	O
17	7	O
and	5	O
18	7	O
,	9	O
and	5	O
13	7	O
and	5	O
14	7	O
of	5	O
gestation	9	O
had	9	O
elevated	9	B-Disease
blood	9	I-Disease
pressures	5	I-Disease
at	9	O
6	9	O
months	5	O
of	5	O
age	5	O
;	9	O
the	5	O
latter	9	O
group	9	O
did	9	O
not	5	O
have	5	O
a	5	O
reduction	9	B-Disease
in	5	I-Disease
glomerular	5	I-Disease
number	9	I-Disease
.	9	O

Adult	9	O
rats	9	O
given	5	O
dexamethasone	0	B-Chemical
on	5	O
days	9	O
15	9	O
and	5	O
16	9	O
of	5	O
gestation	9	O
had	9	O
more	5	O
glomeruli	9	O
with	5	O
glomerulosclerosis	3	B-Disease
than	5	O
control	9	O
rats	9	O
.	9	O

This	5	O
study	9	O
shows	9	O
that	5	O
prenatal	5	O
dexamethasone	0	B-Chemical
in	5	O
rats	9	O
results	9	O
in	5	O
a	5	O
reduction	9	B-Disease
in	5	I-Disease
glomerular	5	I-Disease
number	9	I-Disease
,	9	O
glomerulosclerosis	3	B-Disease
,	9	O
and	5	O
hypertension	5	B-Disease
when	5	O
administered	9	O
at	9	O
specific	9	O
points	5	O
during	5	O
gestation	9	O
.	9	O

Hypertension	7	B-Disease
was	9	O
observed	9	O
in	5	O
animals	9	O
that	5	O
had	9	O
a	5	O
reduction	9	O
in	5	O
glomeruli	9	O
as	5	O
well	9	O
as	5	O
in	5	O
a	5	O
group	9	O
that	5	O
did	9	O
not	5	O
have	5	O
a	5	O
reduction	9	B-Disease
in	5	I-Disease
glomerular	5	I-Disease
number	9	I-Disease
,	9	O
suggesting	9	O
that	5	O
a	5	O
reduction	9	B-Disease
in	5	I-Disease
glomerular	5	I-Disease
number	9	I-Disease
is	5	O
not	5	O
the	5	O
sole	9	O
cause	5	O
for	5	O
the	5	O
development	9	O
of	5	O
hypertension	5	B-Disease
.	9	O

Kidney	9	O
function	9	O
and	5	O
morphology	9	O
after	9	O
short	5	O
-	7	O
term	5	O
combination	9	O
therapy	5	O
with	5	O
cyclosporine	0	B-Chemical
A	9	I-Chemical
,	9	O
tacrolimus	0	B-Chemical
and	5	O
sirolimus	0	B-Chemical
in	5	O
the	5	O
rat	3	O
.	9	O

BACKGROUND	2	O
:	9	O
Sirolimus	0	B-Chemical
(	9	O
SRL	0	B-Chemical
)	9	O
may	5	O
supplement	9	O
calcineurin	3	O
inhibitors	3	O
in	5	O
clinical	5	O
organ	5	O
transplantation	9	O
.	9	O

These	5	O
are	5	O
nephrotoxic	5	B-Disease
,	9	O
but	9	O
SRL	0	B-Chemical
seems	5	O
to	5	O
act	9	O
differently	9	O
displaying	9	O
only	9	O
minor	9	O
nephrotoxic	5	B-Disease
effects	9	O
,	9	O
although	9	O
this	5	O
question	5	O
is	5	O
still	5	O
open	5	O
.	9	O

In	9	O
a	5	O
number	9	O
of	5	O
treatment	9	O
protocols	5	O
where	5	O
SRL	0	B-Chemical
was	9	O
combined	9	O
with	5	O
a	5	O
calcineurin	3	O
inhibitor	3	O
indications	5	O
of	5	O
a	5	O
synergistic	9	O
nephrotoxic	5	B-Disease
effect	9	O
were	9	O
described	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
examine	9	O
further	9	O
the	5	O
renal	9	O
function	9	O
,	9	O
including	9	O
morphological	9	O
analysis	9	O
of	5	O
the	5	O
kidneys	9	O
of	5	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
treated	3	O
with	5	O
either	9	O
cyclosporine	0	B-Chemical
A	9	I-Chemical
(	9	O
CsA	0	B-Chemical
)	9	O
,	9	O
tacrolimus	0	B-Chemical
(	9	O
FK506	3	B-Chemical
)	9	O
or	5	O
SRL	0	B-Chemical
as	5	O
monotherapies	5	O
or	5	O
in	5	O
different	9	O
combinations	9	O
.	9	O

METHODS	2	O
:	9	O
For	9	O
a	5	O
period	5	O
of	5	O
2	9	O
weeks	9	O
,	9	O
CsA	0	B-Chemical
15	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
(	9	O
given	5	O
orally	0	O
)	9	O
,	9	O
FK506	3	B-Chemical
3	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
(	9	O
given	5	O
orally	0	O
)	9	O
or	5	O
SRL	0	B-Chemical
0	7	O
.	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
(	9	O
given	5	O
intraperitoneally	0	O
)	9	O
was	9	O
administered	9	O
once	5	O
a	5	O
day	9	O
as	5	O
these	5	O
doses	0	O
have	5	O
earlier	9	O
been	9	O
found	9	O
to	5	O
achieve	5	O
a	5	O
significant	9	O
immunosuppressive	9	O
effect	9	O
in	5	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
.	9	O

In	9	O
the	5	O
'	9	O
conscious	5	O
catheterized	5	O
rat	3	O
'	9	O
model	5	O
,	9	O
the	5	O
glomerular	5	O
filtration	0	O
rate	9	O
(	9	O
GFR	5	O
)	9	O
was	9	O
measured	9	O
as	5	O
the	5	O
clearance	9	O
of	5	O
Cr	0	O
(	9	O
EDTA	0	O
)	9	O
.	9	O

The	5	O
morphological	9	O
analysis	9	O
of	5	O
the	5	O
kidneys	9	O
included	5	O
a	5	O
semi	5	O
-	7	O
quantitative	9	O
scoring	5	O
system	5	O
analysing	5	O
the	5	O
degree	5	O
of	5	O
striped	4	O
fibrosis	9	B-Disease
,	9	O
subcapsular	5	O
fibrosis	9	B-Disease
and	5	O
the	5	O
number	9	O
of	5	O
basophilic	3	O
tubules	9	O
,	9	O
plus	9	O
an	5	O
additional	9	O
stereological	5	O
analysis	9	O
of	5	O
the	5	O
total	9	O
grade	9	O
of	5	O
fibrosis	9	B-Disease
in	5	O
the	5	O
cortex	5	O
stained	3	O
with	5	O
Sirius	0	O
Red	9	O
.	9	O

RESULTS	9	O
:	9	O
CsA	0	B-Chemical
,	9	O
FK506	3	B-Chemical
and	5	O
SRL	0	B-Chemical
all	5	O
significantly	9	O
decreased	9	O
the	5	O
GFR	5	O
.	9	O

A	9	O
further	9	O
deterioration	5	O
was	9	O
seen	9	O
when	5	O
CsA	0	B-Chemical
was	9	O
combined	9	O
with	5	O
either	9	O
FK506	3	B-Chemical
or	5	O
SRL	0	B-Chemical
,	9	O
whereas	9	O
the	5	O
GFR	5	O
remained	9	O
unchanged	9	O
in	5	O
the	5	O
group	9	O
treated	3	O
with	5	O
FK506	3	B-Chemical
plus	9	O
SRL	0	B-Chemical
when	5	O
compared	9	O
with	5	O
treatment	9	O
with	5	O
any	5	O
of	5	O
the	5	O
single	9	O
substances	0	O
.	9	O

The	5	O
morphological	9	O
changes	9	O
presented	5	O
a	5	O
similar	9	O
pattern	9	O
.	9	O

The	5	O
semi	5	O
-	7	O
quantitative	9	O
scoring	5	O
was	9	O
significantly	9	O
worst	5	O
in	5	O
the	5	O
group	9	O
treated	3	O
with	5	O
CsA	0	B-Chemical
plus	9	O
SRL	0	B-Chemical
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
compared	9	O
with	5	O
controls	9	O
)	9	O
and	5	O
the	5	O
analysis	9	O
of	5	O
the	5	O
total	9	O
grade	9	O
of	5	O
fibrosis	9	B-Disease
also	9	O
showed	9	O
the	5	O
highest	9	O
proportion	9	O
in	5	O
the	5	O
same	9	O
group	9	O
and	5	O
was	9	O
significantly	9	O
different	9	O
from	9	O
controls	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

The	5	O
FK506	3	B-Chemical
plus	9	O
SRL	0	B-Chemical
combination	9	O
showed	9	O
only	9	O
a	5	O
marginally	9	O
higher	9	O
degree	5	O
of	5	O
fibrosis	9	B-Disease
as	5	O
compared	9	O
with	5	O
controls	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
rat	3	O
study	9	O
demonstrated	9	O
a	5	O
synergistic	9	O
nephrotoxic	5	B-Disease
effect	9	O
of	5	O
CsA	0	B-Chemical
plus	9	O
SRL	0	B-Chemical
,	9	O
whereas	9	O
FK506	3	B-Chemical
plus	9	O
SRL	0	B-Chemical
was	9	O
better	5	O
tolerated	9	O
.	9	O

Evaluation	5	O
of	5	O
cardiac	5	O
troponin	9	O
I	9	O
and	5	O
T	3	O
levels	3	O
as	5	O
markers	3	O
of	5	O
myocardial	9	B-Disease
damage	9	I-Disease
in	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
rats	9	O
,	9	O
and	5	O
their	5	O
relationship	5	O
with	5	O
echocardiographic	5	O
and	5	O
histological	9	O
findings	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Cardiac	9	O
troponins	5	O
I	9	O
(	9	O
cTnI	9	O
)	9	O
and	5	O
T	3	O
(	9	O
cTnT	3	O
)	9	O
have	5	O
been	9	O
shown	9	O
to	5	O
be	5	O
highly	9	O
sensitive	9	O
and	5	O
specific	9	O
markers	3	O
of	5	O
myocardial	9	B-Disease
cell	3	I-Disease
injury	9	I-Disease
.	9	O

We	9	O
investigated	9	O
the	5	O
diagnostic	5	O
value	9	O
of	5	O
cTnI	9	O
and	5	O
cTnT	3	O
for	5	O
the	5	O
diagnosis	5	O
of	5	O
myocardial	9	B-Disease
damage	9	I-Disease
in	5	O
a	5	O
rat	3	O
model	5	O
of	5	O
doxorubicin	0	B-Chemical
(	9	O
DOX	0	B-Chemical
)	9	O
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
,	9	O
and	5	O
we	5	O
examined	9	O
the	5	O
relationship	5	O
between	5	O
serial	9	O
cTnI	9	O
and	5	O
cTnT	3	O
with	5	O
the	5	O
development	9	O
of	5	O
cardiac	5	B-Disease
disorders	5	I-Disease
monitored	9	O
by	9	O
echocardiography	5	O
and	5	O
histological	9	O
examinations	5	O
in	5	O
this	5	O
model	5	O
.	9	O

METHODS	2	O
:	9	O
Thirty	9	O
-	7	O
five	9	O
Wistar	9	O
rats	9	O
were	9	O
given	5	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
DOX	0	B-Chemical
,	9	O
i	9	O
.	9	O
v	0	O
.	9	O
,	9	O
weekly	5	O
for	5	O
up	5	O
to	5	O
8	9	O
weeks	9	O
for	5	O
a	5	O
total	9	O
cumulative	5	O
dose	9	O
of	5	O
12	9	O
mg	0	O
/	9	O
kg	0	O
BW	9	O
.	9	O

Ten	9	O
rats	9	O
received	9	O
saline	0	O
as	5	O
a	5	O
control	9	O
group	9	O
.	9	O

cTnI	9	O
was	9	O
measured	9	O
with	5	O
Access	5	O
(	9	O
R	9	O
)	9	O
(	9	O
ng	0	O
/	9	O
ml	0	O
)	9	O
and	5	O
a	5	O
research	5	O
immunoassay	0	O
(	9	O
pg	7	O
/	9	O
ml	0	O
)	9	O
,	9	O
and	5	O
compared	9	O
with	5	O
cTnT	3	O
,	9	O
CK	9	O
-	7	O
MB	0	O
mass	9	O
and	5	O
CK	9	O
.	9	O

By	5	O
using	9	O
transthoracic	5	O
echocardiography	5	O
,	9	O
anterior	5	O
and	5	O
posterior	5	O
wall	5	O
thickness	5	O
,	9	O
LV	9	O
diameters	5	O
and	5	O
LV	9	O
fractional	5	O
shortening	9	O
(	9	O
FS	9	O
)	9	O
were	9	O
measured	9	O
in	5	O
all	5	O
rats	9	O
before	9	O
DOX	0	B-Chemical
or	5	O
saline	0	O
,	9	O
and	5	O
at	9	O
weeks	9	O
6	9	O
and	5	O
9	7	O
after	9	O
treatment	9	O
in	5	O
all	5	O
surviving	9	O
rats	9	O
.	9	O

Histology	9	O
was	9	O
performed	9	O
in	5	O
DOX	0	B-Chemical
-	7	O
rats	9	O
at	9	O
6	9	O
and	5	O
9	7	O
weeks	9	O
after	9	O
the	5	O
last	5	O
DOX	0	B-Chemical
dose	9	O
and	5	O
in	5	O
all	5	O
controls	9	O
.	9	O

RESULTS	9	O
:	9	O
Eighteen	9	O
of	5	O
the	5	O
DOX	0	B-Chemical
rats	9	O
died	9	O
prematurely	5	O
of	5	O
general	5	O
toxicity	9	B-Disease
during	5	O
the	5	O
9	7	O
-	7	O
week	9	O
period	5	O
.	9	O

End	9	O
-	7	O
diastolic	5	O
(	9	O
ED	5	O
)	9	O
and	5	O
end	9	O
-	7	O
systolic	5	O
(	9	O
ES	3	O
)	9	O
LV	9	O
diameters	5	O
/	9	O
BW	9	O
significantly	9	O
increased	9	O
,	9	O
whereas	9	O
LV	9	O
FS	9	O
was	9	O
decreased	9	O
after	9	O
9	7	O
weeks	9	O
in	5	O
the	5	O
DOX	0	B-Chemical
group	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

These	5	O
parameters	5	O
remained	9	O
unchanged	9	O
in	5	O
controls	9	O
.	9	O

Histological	9	O
evaluation	5	O
of	5	O
hearts	3	O
from	9	O
all	5	O
rats	9	O
given	5	O
DOX	0	B-Chemical
revealed	9	O
significant	9	O
slight	9	O
degrees	5	O
of	5	O
perivascular	3	O
and	5	O
interstitial	9	O
fibrosis	9	B-Disease
.	9	O

In	9	O
7	9	O
of	5	O
the	5	O
18	7	O
rats	9	O
,	9	O
degeneration	9	O
and	5	O
myocyte	3	O
vacuolisation	3	O
were	9	O
found	9	O
.	9	O

Only	9	O
five	9	O
of	5	O
the	5	O
controls	9	O
exhibited	9	O
evidence	9	O
of	5	O
very	5	O
slight	9	O
perivascular	3	O
fibrosis	9	B-Disease
.	9	O

A	9	O
significant	9	O
rise	9	O
in	5	O
cTnT	3	O
was	9	O
found	9	O
in	5	O
DOX	0	B-Chemical
rats	9	O
after	9	O
cumulative	5	O
doses	0	O
of	5	O
7	9	O
.	9	O
5	9	O
and	5	O
12	9	O
mg	0	O
/	9	O
kg	0	O
in	5	O
comparison	9	O
with	5	O
baseline	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

cTnT	3	O
found	9	O
in	5	O
rats	9	O
after	9	O
12	9	O
mg	0	O
/	9	O
kg	0	O
were	9	O
significantly	9	O
greater	5	O
than	5	O
that	5	O
found	9	O
after	9	O
7	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
DOX	0	B-Chemical
.	9	O

Maximal	9	O
cTnI	9	O
(	9	O
pg	7	O
/	9	O
ml	0	O
)	9	O
and	5	O
cTnT	3	O
levels	3	O
were	9	O
significantly	9	O
increased	9	O
in	5	O
DOX	0	B-Chemical
rats	9	O
compared	9	O
with	5	O
controls	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
006	7	O
,	9	O
0	7	O
.	9	O
007	2	O
)	9	O
.	9	O

cTnI	9	O
(	9	O
ng	0	O
/	9	O
ml	0	O
)	9	O
,	9	O
CK	9	O
-	7	O
MB	0	O
mass	9	O
and	5	O
CK	9	O
remained	9	O
unchanged	9	O
in	5	O
DOX	0	B-Chemical
rats	9	O
compared	9	O
with	5	O
controls	9	O
.	9	O

All	9	O
markers	3	O
remained	9	O
stable	9	O
in	5	O
controls	9	O
.	9	O

Analysis	9	O
of	5	O
data	5	O
revealed	9	O
a	5	O
significant	9	O
correlation	9	O
between	5	O
maximal	9	O
cTnT	3	O
and	5	O
ED	5	O
and	5	O
ES	3	O
LV	9	O
diameters	5	O
/	9	O
BW	9	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
81	7	O
and	5	O
0	7	O
.	9	O
65	7	O
;	9	O
p	7	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

A	9	O
significant	9	O
relationship	5	O
was	9	O
observed	9	O
between	5	O
maximal	9	O
cTnT	3	O
and	5	O
the	5	O
extent	9	O
of	5	O
myocardial	9	O
morphological	9	O
changes	9	O
,	9	O
and	5	O
between	5	O
LV	9	O
diameters	5	O
/	9	O
BW	9	O
and	5	O
histological	9	O
findings	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Among	9	O
markers	3	O
of	5	O
ischemic	9	B-Disease
injury	9	I-Disease
after	9	O
DOX	0	B-Chemical
in	5	O
rats	9	O
,	9	O
cTnT	3	O
showed	9	O
the	5	O
greatest	9	O
ability	9	O
to	5	O
detect	9	O
myocardial	9	B-Disease
damage	9	I-Disease
assessed	9	O
by	9	O
echocardiographic	5	O
detection	9	O
and	5	O
histological	9	O
changes	9	O
.	9	O

Although	9	O
there	5	O
was	9	O
a	5	O
discrepancy	5	O
between	5	O
the	5	O
amount	9	O
of	5	O
cTnI	9	O
and	5	O
cTnT	3	O
after	9	O
DOX	0	B-Chemical
,	9	O
probably	9	O
due	5	O
to	5	O
heterogeneity	9	O
in	5	O
cross	5	O
-	7	O
reactivities	9	O
of	5	O
mAbs	3	O
to	5	O
various	9	O
cTnI	9	O
and	5	O
cTnT	3	O
forms	9	O
,	9	O
it	5	O
is	5	O
likely	5	O
that	5	O
cTnT	3	O
in	5	O
rats	9	O
after	9	O
DOX	0	B-Chemical
indicates	9	O
cell	3	O
damage	9	O
determined	9	O
by	9	O
the	5	O
magnitude	5	O
of	5	O
injury	9	O
induced	3	O
and	5	O
that	5	O
cTnT	3	O
should	5	O
be	5	O
a	5	O
useful	5	O
marker	3	O
for	5	O
the	5	O
prediction	5	O
of	5	O
experimentally	9	O
induced	3	O
cardiotoxicity	9	B-Disease
and	5	O
possibly	9	O
for	5	O
cardioprotective	9	O
experiments	9	O
.	9	O

Octreotide	0	B-Chemical
-	7	O
induced	3	O
hypoxemia	5	B-Disease
and	5	O
pulmonary	5	B-Disease
hypertension	5	I-Disease
in	5	O
premature	9	O
neonates	9	O
.	9	O

The	5	O
authors	5	O
report	5	O
2	9	O
cases	5	O
of	5	O
premature	9	O
neonates	9	O
who	5	O
had	9	O
enterocutaneous	5	O
fistula	5	B-Disease
complicating	5	O
necrotizing	5	B-Disease
enterocolitis	5	I-Disease
.	9	O

Pulmonary	9	B-Disease
hypertension	5	I-Disease
developed	5	O
after	9	O
administration	9	O
of	5	O
a	5	O
somatostatin	3	O
analogue	0	O
,	9	O
octreotide	0	B-Chemical
,	9	O
to	5	O
enhance	9	O
resolution	5	O
of	5	O
the	5	O
fistula	5	B-Disease
.	9	O

The	5	O
authors	5	O
discuss	5	O
the	5	O
mechanism	9	O
of	5	O
the	5	O
occurrence	5	O
of	5	O
this	5	O
complication	5	O
and	5	O
recommend	5	O
caution	5	O
of	5	O
its	9	O
use	5	O
in	5	O
high	9	O
-	7	O
risk	5	O
premature	9	O
neonates	9	O
.	9	O

The	5	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
in	5	O
women	5	O
prescribed	5	O
cyproterone	0	B-Chemical
acetate	0	I-Chemical
in	5	O
combination	9	O
with	5	O
ethinyl	0	B-Chemical
estradiol	0	I-Chemical
:	9	O
a	5	O
nested	9	O
cohort	9	O
analysis	9	O
and	5	O
case	5	O
-	7	O
control	9	O
study	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Cyproterone	0	B-Chemical
acetate	0	I-Chemical
combined	9	O
with	5	O
ethinyl	0	B-Chemical
estradiol	0	I-Chemical
(	9	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
)	9	O
is	5	O
licensed	5	O
in	5	O
the	5	O
UK	2	O
for	5	O
the	5	O
treatment	9	O
of	5	O
women	5	O
with	5	O
acne	5	B-Disease
and	5	O
hirsutism	5	B-Disease
and	5	O
is	5	O
also	9	O
a	5	O
treatment	9	O
option	5	O
for	5	O
polycystic	5	B-Disease
ovary	9	I-Disease
syndrome	5	I-Disease
(	9	O
PCOS	9	B-Disease
)	9	O
.	9	O

Previous	9	O
studies	9	O
have	5	O
demonstrated	9	O
an	5	O
increased	9	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
(	9	O
VTE	5	B-Disease
)	9	O
associated	9	O
with	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
compared	9	O
with	5	O
conventional	5	O
combined	9	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
(	9	O
COCs	9	O
)	9	O
.	9	O

We	9	O
believe	5	O
the	5	O
results	9	O
of	5	O
those	5	O
studies	9	O
may	5	O
have	5	O
been	9	O
affected	9	O
by	9	O
residual	9	O
confounding	5	O
.	9	O

METHODS	2	O
:	9	O
Using	9	O
the	5	O
General	2	O
Practice	5	O
Research	2	O
Database	2	O
we	5	O
conducted	9	O
a	5	O
cohort	9	O
analysis	9	O
and	5	O
case	5	O
-	7	O
control	9	O
study	9	O
nested	9	O
within	9	O
a	5	O
population	5	O
of	5	O
women	5	O
aged	9	O
between	5	O
15	9	O
and	5	O
39	7	O
years	5	O
with	5	O
acne	5	B-Disease
,	9	O
hirsutism	5	B-Disease
or	5	O
PCOS	9	B-Disease
to	5	O
estimate	5	O
the	5	O
risk	5	O
of	5	O
VTE	5	B-Disease
associated	9	O
with	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
The	5	O
age	5	O
-	7	O
adjusted	9	O
incidence	5	O
rate	9	O
ratio	9	O
for	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
versus	9	O
conventional	5	O
COCs	9	O
was	9	O
2	9	O
.	9	O
20	9	O
[	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
(	9	O
CI	7	O
)	9	O
1	9	O
.	9	O
35	9	O
-	7	O
3	9	O
.	9	O
58	7	O
]	9	O
.	9	O

Using	9	O
as	5	O
the	5	O
reference	9	O
group	9	O
women	5	O
who	5	O
were	9	O
not	5	O
using	9	O
oral	9	O
contraception	5	O
,	9	O
had	9	O
no	9	O
recent	5	O
pregnancy	5	O
or	5	O
menopausal	5	O
symptoms	5	O
,	9	O
the	5	O
case	5	O
-	7	O
control	9	O
analysis	9	O
gave	9	O
an	5	O
adjusted	9	O
odds	5	O
ratio	9	O
(	9	O
OR	9	O
(	9	O
adj	5	O
)	9	O
)	9	O
of	5	O
7	9	O
.	9	O
44	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
3	9	O
.	9	O
67	7	O
-	7	O
15	9	O
.	9	O
08	7	O
)	9	O
for	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
use	5	O
compared	9	O
with	5	O
an	5	O
OR	9	O
(	9	O
adj	5	O
)	9	O
of	5	O
2	9	O
.	9	O
58	7	O
(	9	O
95	7	O
%	9	O
CI	7	O
1	9	O
.	9	O
60	9	O
-	7	O
4	9	O
.	9	O
18	7	O
)	9	O
for	5	O
use	5	O
of	5	O
conventional	5	O
COCs	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
We	9	O
have	5	O
demonstrated	9	O
an	5	O
increased	9	O
risk	5	O
of	5	O
VTE	5	B-Disease
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
CPA	9	B-Chemical
/	9	O
EE	9	B-Chemical
in	5	O
women	5	O
with	5	O
acne	5	B-Disease
,	9	O
hirsutism	5	B-Disease
or	5	O
PCOS	9	B-Disease
although	9	O
residual	9	O
confounding	5	O
by	9	O
indication	5	O
cannot	5	O
be	5	O
excluded	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
treatment	9	O
with	5	O
gum	0	B-Chemical
Arabic	5	I-Chemical
on	5	O
gentamicin	0	B-Chemical
nephrotoxicity	9	B-Disease
in	5	O
rats	9	O
:	9	O
a	5	O
preliminary	9	O
study	9	O
.	9	O

In	9	O
the	5	O
present	9	O
work	5	O
we	5	O
assessed	9	O
the	5	O
effect	9	O
of	5	O
treatment	9	O
of	5	O
rats	9	O
with	5	O
gum	0	B-Chemical
Arabic	5	I-Chemical
on	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
induced	3	O
by	9	O
gentamicin	0	B-Chemical
(	9	O
GM	9	B-Chemical
)	9	O
nephrotoxicity	9	B-Disease
.	9	O

Rats	9	O
were	9	O
treated	3	O
with	5	O
the	5	O
vehicle	3	O
(	9	O
2	9	O
mL	0	O
/	9	O
kg	0	O
of	5	O
distilled	0	O
water	0	O
and	5	O
5	9	O
%	9	O
w	0	O
/	9	O
v	0	O
cellulose	0	O
,	9	O
10	9	O
days	9	O
)	9	O
,	9	O
gum	0	B-Chemical
Arabic	5	I-Chemical
(	9	O
2	9	O
mL	0	O
/	9	O
kg	0	O
of	5	O
a	5	O
10	9	O
%	9	O
w	0	O
/	9	O
v	0	O
aqueous	0	O
suspension	0	O
of	5	O
gum	0	B-Chemical
Arabic	5	I-Chemical
powder	0	O
,	9	O
orally	0	O
for	5	O
10	9	O
days	9	O
)	9	O
,	9	O
or	5	O
gum	0	B-Chemical
Arabic	5	I-Chemical
concomitantly	9	O
with	5	O
GM	9	B-Chemical
(	9	O
80mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
intramuscularly	0	O
,	9	O
during	5	O
the	5	O
last	5	O
six	9	O
days	9	O
of	5	O
the	5	O
treatment	9	O
period	5	O
)	9	O
.	9	O

Nephrotoxicity	0	B-Disease
was	9	O
assessed	9	O
by	9	O
measuring	9	O
the	5	O
concentrations	0	O
of	5	O
creatinine	0	B-Chemical
and	5	O
urea	0	B-Chemical
in	5	O
the	5	O
plasma	9	O
and	5	O
reduced	9	O
glutathione	0	B-Chemical
(	9	O
GSH	0	B-Chemical
)	9	O
in	5	O
the	5	O
kidney	9	O
cortex	5	O
,	9	O
and	5	O
by	9	O
light	9	O
microscopic	9	O
examination	5	O
of	5	O
kidney	9	O
sections	9	O
.	9	O

The	5	O
results	9	O
indicated	9	O
that	5	O
concomitant	9	O
treatment	9	O
with	5	O
gum	0	B-Chemical
Arabic	5	I-Chemical
and	5	O
GM	9	B-Chemical
significantly	9	O
increased	9	O
creatinine	0	B-Chemical
and	5	O
urea	0	B-Chemical
by	9	O
about	5	O
183	7	O
and	5	O
239	7	O
%	9	O
,	9	O
respectively	9	O
(	9	O
compared	9	O
to	5	O
432	7	O
and	5	O
346	7	O
%	9	O
,	9	O
respectively	9	O
,	9	O
in	5	O
rats	9	O
treated	3	O
with	5	O
cellulose	0	O
and	5	O
GM	9	B-Chemical
)	9	O
,	9	O
and	5	O
decreased	9	O
that	5	O
of	5	O
cortical	5	O
GSH	0	B-Chemical
by	9	O
21	7	O
%	9	O
(	9	O
compared	9	O
to	5	O
27	7	O
%	9	O
in	5	O
the	5	O
cellulose	0	O
plus	9	O
GM	9	B-Chemical
group	9	O
)	9	O
The	5	O
GM	9	B-Chemical
-	7	O
induced	3	O
proximal	9	O
tubular	9	B-Disease
necrosis	9	I-Disease
appeared	9	O
to	5	O
be	5	O
slightly	9	O
less	5	O
severe	5	O
in	5	O
rats	9	O
given	5	O
GM	9	B-Chemical
together	9	O
with	5	O
gum	0	B-Chemical
Arabic	5	I-Chemical
than	5	O
in	5	O
those	5	O
given	5	O
GM	9	B-Chemical
and	5	O
cellulose	0	O
.	9	O

It	5	O
could	9	O
be	5	O
inferred	5	O
that	5	O
gum	0	B-Chemical
Arabic	5	I-Chemical
treatment	9	O
has	9	O
induced	3	O
a	5	O
modest	9	O
amelioration	9	O
of	5	O
some	5	O
of	5	O
the	5	O
histological	9	O
and	5	O
biochemical	9	O
indices	5	O
of	5	O
GM	9	B-Chemical
nephrotoxicity	9	B-Disease
.	9	O

Further	9	O
work	5	O
is	5	O
warranted	9	O
on	5	O
the	5	O
effect	9	O
of	5	O
the	5	O
treatments	9	O
on	5	O
renal	9	O
functional	9	O
aspects	5	O
in	5	O
models	5	O
of	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
,	9	O
and	5	O
on	5	O
the	5	O
mechanism	9	O
(	9	O
s	9	O
)	9	O
involved	9	O
.	9	O

Increased	9	O
frequency	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
with	5	O
the	5	O
combination	9	O
of	5	O
docetaxel	0	B-Chemical
and	5	O
thalidomide	0	B-Chemical
in	5	O
patients	5	O
with	5	O
metastatic	3	O
androgen	3	O
-	7	O
independent	9	O
prostate	3	B-Disease
cancer	3	I-Disease
.	9	O

STUDY	2	O
OBJECTIVE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
frequency	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
(	9	O
VTE	5	B-Disease
)	9	O
in	5	O
patients	5	O
with	5	O
advanced	5	O
androgen	3	O
-	7	O
independent	9	O
prostate	3	B-Disease
cancer	3	I-Disease
who	5	O
were	9	O
treated	3	O
with	5	O
docetaxel	0	B-Chemical
alone	9	O
or	5	O
in	5	O
combination	9	O
with	5	O
thalidomide	0	B-Chemical
.	9	O

DESIGN	2	O
:	9	O
Retrospective	9	O
analysis	9	O
of	5	O
a	5	O
randomized	5	O
phase	5	O
II	9	O
trial	5	O
.	9	O

SETTING	2	O
:	9	O
National	2	O
Institutes	2	O
of	5	O
Health	2	O
clinical	5	O
research	5	O
center	5	O
.	9	O

PATIENTS	2	O
:	9	O
Seventy	5	O
men	5	O
,	9	O
aged	9	O
50	0	O
-	7	O
80	9	O
years	5	O
,	9	O
with	5	O
advanced	5	O
androgen	3	O
-	7	O
independent	9	O
prostate	3	B-Disease
cancer	3	I-Disease
.	9	O

INTERVENTION	2	O
:	9	O
Each	5	O
patient	5	O
received	9	O
either	9	O
intravenous	0	O
docetaxel	0	B-Chemical
30	9	O
mg	0	O
/	9	O
m2	7	O
/	9	O
week	9	O
for	5	O
3	9	O
consecutive	5	O
weeks	9	O
,	9	O
followed	9	O
by	9	O
1	9	O
week	9	O
off	5	O
,	9	O
or	5	O
the	5	O
combination	9	O
of	5	O
continuous	5	O
oral	9	O
thalidomide	0	B-Chemical
200	0	O
mg	0	O
every	5	O
evening	5	O
plus	9	O
the	5	O
same	9	O
docetaxel	0	B-Chemical
regimen	5	O
.	9	O

This	5	O
4	9	O
-	7	O
week	9	O
cycle	9	O
was	9	O
repeated	5	O
until	5	O
there	5	O
was	9	O
evidence	9	O
of	5	O
excessive	5	O
toxicity	9	B-Disease
or	5	O
disease	5	O
progression	9	O
.	9	O

MEASUREMENTS	2	O
AND	2	O
MAIN	2	O
RESULTS	9	O
:	9	O
None	9	O
of	5	O
23	7	O
patients	5	O
who	5	O
received	9	O
docetaxel	0	B-Chemical
alone	9	O
developed	5	O
VTE	5	B-Disease
,	9	O
whereas	9	O
9	7	O
of	5	O
47	7	O
patients	5	O
(	9	O
19	7	O
%	9	O
)	9	O
who	5	O
received	9	O
docetaxel	0	B-Chemical
plus	9	O
thalidomide	0	B-Chemical
developed	5	O
VTE	5	B-Disease
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
025	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
addition	9	O
of	5	O
thalidomide	0	B-Chemical
to	5	O
docetaxel	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
prostate	3	B-Disease
cancer	3	I-Disease
significantly	9	O
increases	9	O
the	5	O
frequency	5	O
of	5	O
VTE	5	B-Disease
.	9	O

Clinicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
potential	9	O
complication	5	O
when	5	O
adding	0	O
thalidomide	0	B-Chemical
to	5	O
chemotherapeutic	3	O
regimens	5	O
.	9	O

Ticlopidine	0	B-Chemical
-	7	O
induced	3	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
2	9	O
cases	5	O
of	5	O
ticlopidine	0	B-Chemical
-	7	O
induced	3	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
,	9	O
investigate	9	O
its	9	O
mechanism	9	O
,	9	O
and	5	O
compare	9	O
the	5	O
observed	9	O
main	5	O
characteristics	5	O
with	5	O
those	5	O
of	5	O
the	5	O
published	9	O
cases	5	O
.	9	O

CASE	2	O
SUMMARIES	2	O
:	9	O
Two	9	O
patients	5	O
developed	5	O
prolonged	9	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
after	9	O
receiving	9	O
ticlopidine	0	B-Chemical
following	9	O
percutaneous	5	O
coronary	5	O
angioplasty	5	O
,	9	O
with	5	O
complete	9	O
remission	5	O
during	5	O
the	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
.	9	O

T	3	O
-	7	O
cell	3	O
stimulation	3	O
by	9	O
therapeutic	5	O
concentration	0	O
of	5	O
ticlopidine	0	B-Chemical
was	9	O
demonstrated	9	O
in	5	O
vitro	3	O
in	5	O
the	5	O
patients	5	O
,	9	O
but	9	O
not	5	O
in	5	O
healthy	5	O
controls	9	O
.	9	O

DISCUSSION	9	O
:	9	O
Cholestatic	7	B-Disease
hepatitis	9	I-Disease
is	5	O
a	5	O
rare	5	O
complication	5	O
of	5	O
the	5	O
antiplatelet	5	O
agent	9	O
ticlopidine	0	B-Chemical
;	9	O
several	9	O
cases	5	O
have	5	O
been	9	O
reported	9	O
but	9	O
few	5	O
in	5	O
the	5	O
English	5	O
literature	5	O
.	9	O

Our	9	O
patients	5	O
developed	5	O
jaundice	5	B-Disease
following	9	O
treatment	9	O
with	5	O
ticlopidine	0	B-Chemical
and	5	O
showed	9	O
the	5	O
clinical	5	O
and	5	O
laboratory	9	O
characteristics	5	O
of	5	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
,	9	O
which	5	O
resolved	9	O
after	9	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
.	9	O

Hepatitis	9	B-Disease
may	5	O
develop	5	O
weeks	9	O
after	9	O
discontinuation	5	O
of	5	O
the	5	O
drug	5	O
and	5	O
may	5	O
run	5	O
a	5	O
prolonged	9	O
course	5	O
,	9	O
but	9	O
complete	9	O
remission	5	O
was	9	O
observed	9	O
in	5	O
all	5	O
reported	9	O
cases	5	O
.	9	O

An	5	O
objective	5	O
causality	5	O
assessment	5	O
revealed	9	O
that	5	O
the	5	O
adverse	5	O
drug	5	O
event	5	O
was	9	O
probably	9	O
related	9	O
to	5	O
the	5	O
use	5	O
of	5	O
ticlopidine	0	B-Chemical
.	9	O

The	5	O
mechanisms	9	O
of	5	O
this	5	O
ticlopidine	0	B-Chemical
-	7	O
induced	3	O
cholestasis	5	B-Disease
are	5	O
unclear	9	O
.	9	O

Immune	9	O
mechanisms	9	O
may	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
drug	5	O
'	9	O
s	9	O
hepatotoxicity	9	B-Disease
,	9	O
as	5	O
suggested	9	O
by	9	O
the	5	O
T	3	O
-	7	O
cell	3	O
stimulation	3	O
study	9	O
reported	9	O
here	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Cholestatic	7	B-Disease
hepatitis	9	I-Disease
is	5	O
a	5	O
rare	5	O
adverse	5	O
effect	9	O
of	5	O
ticlopidine	0	B-Chemical
that	5	O
may	5	O
be	5	O
immune	3	O
mediated	3	O
.	9	O

Patients	5	O
receiving	9	O
the	5	O
drug	5	O
should	5	O
be	5	O
monitored	9	O
with	5	O
liver	9	O
function	9	O
tests	5	O
along	9	O
with	5	O
complete	9	O
blood	9	O
cell	3	O
counts	9	O
.	9	O

This	5	O
complication	5	O
will	5	O
be	5	O
observed	9	O
even	5	O
less	5	O
often	5	O
in	5	O
the	5	O
future	5	O
as	5	O
ticlopidine	0	B-Chemical
is	5	O
being	5	O
replaced	9	O
by	9	O
the	5	O
newer	5	O
antiplatelet	5	O
agent	9	O
clopidogrel	0	B-Chemical
.	9	O

Epithelial	3	O
sodium	0	B-Chemical
channel	9	O
(	9	O
ENaC	3	O
)	9	O
subunit	1	O
mRNA	3	O
and	5	O
protein	1	O
expression	3	O
in	5	O
rats	9	O
with	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

In	9	O
experimental	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
,	9	O
urinary	9	O
sodium	0	B-Chemical
excretion	0	O
is	5	O
decreased	9	O
during	5	O
the	5	O
early	9	O
phase	5	O
of	5	O
the	5	O
disease	5	O
.	9	O

The	5	O
molecular	9	O
mechanism	9	O
(	9	O
s	9	O
)	9	O
leading	9	O
to	5	O
salt	0	O
retention	9	O
has	9	O
not	5	O
been	9	O
completely	9	O
elucidated	9	O
.	9	O

The	5	O
rate	9	O
-	7	O
limiting	9	O
constituent	9	O
of	5	O
collecting	5	O
duct	5	O
sodium	0	B-Chemical
transport	9	O
is	5	O
the	5	O
epithelial	3	O
sodium	0	B-Chemical
channel	9	O
(	9	O
ENaC	3	O
)	9	O
.	9	O

We	9	O
examined	9	O
the	5	O
abundance	9	O
of	5	O
ENaC	3	O
subunit	1	O
mRNAs	3	O
and	5	O
proteins	1	O
in	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
)	9	O
-	7	O
induced	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

The	5	O
time	5	O
courses	5	O
of	5	O
urinary	9	O
sodium	0	B-Chemical
excretion	0	O
,	9	O
plasma	9	O
aldosterone	9	B-Chemical
concentration	0	O
and	5	O
proteinuria	9	B-Disease
were	9	O
studied	9	O
in	5	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
treated	3	O
with	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
either	9	O
PAN	0	B-Chemical
or	5	O
vehicle	3	O
.	9	O

The	5	O
relative	9	O
amounts	9	O
of	5	O
alphaENaC	_	O
,	9	O
betaENaC	_	O
and	5	O
gammaENaC	_	O
mRNAs	3	O
were	9	O
determined	9	O
in	5	O
kidneys	9	O
from	9	O
these	5	O
rats	9	O
by	9	O
real	5	O
-	7	O
time	5	O
quantitative	9	O
TaqMan	9	O
PCR	9	O
,	9	O
and	5	O
the	5	O
amounts	9	O
of	5	O
proteins	1	O
by	9	O
Western	3	O
blot	3	O
.	9	O

The	5	O
kinetics	9	O
of	5	O
urinary	9	O
sodium	0	B-Chemical
excretion	0	O
and	5	O
the	5	O
appearance	9	O
of	5	O
proteinuria	9	B-Disease
were	9	O
comparable	9	O
with	5	O
those	5	O
reported	9	O
previously	9	O
.	9	O

Sodium	0	B-Chemical
retention	9	O
occurred	9	O
on	5	O
days	9	O
2	9	O
,	9	O
3	9	O
and	5	O
6	9	O
after	9	O
PAN	0	B-Chemical
injection	9	O
.	9	O

A	9	O
significant	9	O
up	5	O
-	7	O
regulation	9	O
of	5	O
alphaENaC	_	O
and	5	O
betaENaC	_	O
mRNA	3	O
abundance	9	O
on	5	O
days	9	O
1	9	O
and	5	O
2	9	O
preceded	9	O
sodium	0	B-Chemical
retention	9	O
on	5	O
days	9	O
2	9	O
and	5	O
3	9	O
.	9	O

Conversely	9	O
,	9	O
down	9	O
-	7	O
regulation	9	O
of	5	O
alphaENaC	_	O
,	9	O
betaENaC	_	O
and	5	O
gammaENaC	_	O
mRNA	3	O
expression	3	O
on	5	O
day	9	O
3	9	O
occurred	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
high	9	O
aldosterone	9	B-Chemical
concentrations	0	O
,	9	O
and	5	O
was	9	O
followed	9	O
by	9	O
a	5	O
return	5	O
of	5	O
sodium	0	B-Chemical
excretion	0	O
to	5	O
control	9	O
values	5	O
.	9	O

The	5	O
amounts	9	O
of	5	O
alphaENaC	_	O
,	9	O
betaENaC	_	O
and	5	O
gammaENaC	_	O
proteins	1	O
were	9	O
not	5	O
increased	9	O
during	5	O
PAN	0	B-Chemical
-	7	O
induced	3	O
sodium	0	B-Chemical
retention	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
ENaC	3	O
mRNA	3	O
expression	3	O
,	9	O
especially	5	O
alphaENaC	_	O
,	9	O
is	5	O
increased	9	O
in	5	O
the	5	O
very	5	O
early	9	O
phase	5	O
of	5	O
the	5	O
experimental	5	O
model	5	O
of	5	O
PAN	0	B-Chemical
-	7	O
induced	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
in	5	O
rats	9	O
,	9	O
but	9	O
appears	9	O
to	5	O
escape	5	O
from	9	O
the	5	O
regulation	9	O
by	9	O
aldosterone	9	B-Chemical
after	9	O
day	9	O
3	9	O
.	9	O

Sub	9	O
-	7	O
chronic	5	O
low	9	O
dose	9	O
gamma	9	B-Chemical
-	7	I-Chemical
vinyl	0	I-Chemical
GABA	0	I-Chemical
(	9	O
vigabatrin	0	B-Chemical
)	9	O
inhibits	3	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
increases	9	O
in	5	O
nucleus	9	O
accumbens	5	O
dopamine	5	B-Chemical
.	9	O

RATIONALE	2	O
:	9	O
gamma	9	B-Chemical
-	7	I-Chemical
Vinyl	0	I-Chemical
GABA	0	I-Chemical
(	9	O
GVG	0	B-Chemical
)	9	O
irreversibly	9	O
inhibits	3	O
GABA	0	B-Chemical
-	7	O
transaminase	0	O
.	9	O

This	5	O
non	9	O
-	7	O
receptor	3	O
mediated	3	O
inhibition	3	O
requires	5	O
de	2	O
novo	9	O
synthesis	9	O
for	5	O
restoration	5	O
of	5	O
functional	9	O
GABA	0	B-Chemical
catabolism	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
Given	9	O
its	9	O
preclinical	9	O
success	5	O
for	5	O
treating	5	O
substance	5	B-Disease
abuse	5	I-Disease
and	5	O
the	5	O
increased	9	O
risk	5	O
of	5	O
visual	5	B-Disease
field	5	I-Disease
defects	9	I-Disease
(	9	O
VFD	5	B-Disease
)	9	O
associated	9	O
with	5	O
cumulative	5	O
lifetime	5	O
exposure	9	O
,	9	O
we	5	O
explored	9	O
the	5	O
effects	9	O
of	5	O
sub	9	O
-	7	O
chronic	5	O
low	9	O
dose	9	O
GVG	0	B-Chemical
on	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
increases	9	O
in	5	O
nucleus	9	O
accumbens	5	O
(	9	O
NAcc	5	O
)	9	O
dopamine	5	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
.	9	O

METHODS	2	O
:	9	O
Using	9	O
in	5	O
vivo	3	O
microdialysis	5	O
,	9	O
we	5	O
compared	9	O
acute	9	O
exposure	9	O
(	9	O
450	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
to	5	O
an	5	O
identical	9	O
sub	9	O
-	7	O
chronic	5	O
exposure	9	O
(	9	O
150	0	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
for	5	O
3	9	O
days	9	O
)	9	O
,	9	O
followed	9	O
by	9	O
1	9	O
-	7	O
or	5	O
3	9	O
-	7	O
day	9	O
washout	0	O
.	9	O

Finally	9	O
,	9	O
we	5	O
examined	9	O
the	5	O
low	9	O
dose	9	O
of	5	O
150	0	O
mg	0	O
/	9	O
kg	0	O
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
)	9	O
using	9	O
a	5	O
similar	9	O
washout	0	O
period	5	O
.	9	O

RESULTS	9	O
:	9	O
Sub	9	O
-	7	O
chronic	5	O
GVG	0	B-Chemical
exposure	9	O
inhibited	3	O
the	5	O
effect	9	O
of	5	O
cocaine	5	B-Chemical
for	5	O
3	9	O
days	9	O
,	9	O
which	5	O
exceeded	9	O
in	5	O
magnitude	5	O
and	5	O
duration	5	O
the	5	O
identical	9	O
acute	9	O
dose	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Sub	9	O
-	7	O
chronic	5	O
low	9	O
dose	9	O
GVG	0	B-Chemical
potentiates	3	O
and	5	O
extends	9	O
the	5	O
inhibition	3	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
increases	9	O
in	5	O
dopamine	5	B-Chemical
,	9	O
effectively	5	O
reducing	9	O
cumulative	5	O
exposures	5	O
and	5	O
the	5	O
risk	5	O
for	5	O
VFDS	_	O
.	9	O

MR	9	O
imaging	5	O
with	5	O
quantitative	9	O
diffusion	5	O
mapping	5	O
of	5	O
tacrolimus	0	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
in	5	O
organ	5	O
transplant	9	O
patients	5	O
.	9	O

Our	9	O
objective	5	O
was	9	O
to	5	O
investigate	9	O
brain	5	O
MR	9	O
imaging	5	O
findings	9	O
and	5	O
the	5	O
utility	5	O
of	5	O
diffusion	5	O
-	7	O
weighted	5	O
(	9	O
DW	0	O
)	9	O
imaging	5	O
in	5	O
organ	5	O
transplant	9	O
patients	5	O
who	5	O
developed	5	O
neurologic	5	O
symptoms	5	O
during	5	O
tacrolimus	0	B-Chemical
therapy	5	O
.	9	O

Brain	9	O
MR	9	O
studies	9	O
,	9	O
including	9	O
DW	0	O
imaging	5	O
,	9	O
were	9	O
prospectively	5	O
performed	9	O
in	5	O
14	7	O
organ	5	O
transplant	9	O
patients	5	O
receiving	9	O
tacrolimus	0	B-Chemical
who	5	O
developed	5	O
neurologic	5	B-Disease
complications	5	I-Disease
.	9	O

In	9	O
each	5	O
patient	5	O
who	5	O
had	9	O
abnormalities	9	O
on	5	O
the	5	O
initial	9	O
MR	9	O
study	9	O
,	9	O
a	5	O
follow	5	O
-	7	O
up	5	O
MR	9	O
study	9	O
was	9	O
performed	9	O
1	9	O
month	5	O
later	9	O
.	9	O

Apparent	9	O
diffusion	5	O
coefficient	5	O
(	9	O
ADC	5	O
)	9	O
values	5	O
on	5	O
the	5	O
initial	9	O
MR	9	O
study	9	O
were	9	O
correlated	9	O
with	5	O
reversibility	9	O
of	5	O
the	5	O
lesions	5	O
.	9	O

Of	9	O
the	5	O
14	7	O
patients	5	O
,	9	O
5	9	O
(	9	O
35	9	O
.	9	O
7	9	O
%	9	O
)	9	O
had	9	O
white	9	B-Disease
matter	5	I-Disease
abnormalities	9	I-Disease
,	9	O
1	9	O
(	9	O
7	9	O
.	9	O
1	9	O
%	9	O
)	9	O
had	9	O
putaminal	5	B-Disease
hemorrhage	5	I-Disease
,	9	O
and	5	O
8	9	O
(	9	O
57	7	O
.	9	O
1	9	O
%	9	O
)	9	O
had	9	O
normal	9	O
findings	9	O
on	5	O
initial	9	O
MR	9	O
images	5	O
.	9	O

Among	9	O
the	5	O
5	9	O
patients	5	O
with	5	O
white	9	B-Disease
matter	5	I-Disease
abnormalities	9	I-Disease
,	9	O
4	9	O
patients	5	O
(	9	O
80	9	O
.	9	O
0	7	O
%	9	O
)	9	O
showed	9	O
higher	9	O
than	5	O
normal	9	O
ADC	5	O
values	5	O
on	5	O
initial	9	O
MR	9	O
images	5	O
,	9	O
and	5	O
all	5	O
showed	9	O
complete	9	O
resolution	5	O
on	5	O
follow	5	O
-	7	O
up	5	O
images	5	O
.	9	O

The	5	O
remaining	9	O
1	9	O
patient	5	O
(	9	O
20	9	O
.	9	O
0	7	O
%	9	O
)	9	O
showed	9	O
lower	9	O
than	5	O
normal	9	O
ADC	5	O
value	9	O
and	5	O
showed	9	O
incomplete	9	O
resolution	5	O
with	5	O
cortical	5	B-Disease
laminar	5	I-Disease
necrosis	9	I-Disease
.	9	O

Diffusion	5	O
-	7	O
weighted	5	O
imaging	5	O
may	5	O
be	5	O
useful	5	O
in	5	O
predicting	5	O
the	5	O
outcomes	5	O
of	5	O
the	5	O
lesions	5	O
of	5	O
tacrolimus	0	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
.	9	O

L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
transport	9	O
in	5	O
humans	9	O
with	5	O
cortisol	5	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
.	9	O

A	9	O
deficient	3	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
-	7	O
nitric	0	B-Chemical
oxide	0	I-Chemical
system	5	O
is	5	O
implicated	9	O
in	5	O
cortisol	5	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
.	9	O

We	9	O
investigate	9	O
whether	9	O
abnormalities	9	O
in	5	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
uptake	0	O
contribute	9	O
to	5	O
this	5	O
deficiency	9	O
.	9	O

Eight	9	O
healthy	5	O
men	5	O
were	9	O
recruited	9	O
.	9	O

Hydrocortisone	0	B-Chemical
acetate	0	I-Chemical
(	9	O
50	0	O
mg	0	O
)	9	O
was	9	O
given	5	O
orally	0	O
every	5	O
6	9	O
hours	9	O
for	5	O
24	9	O
hours	9	O
after	9	O
a	5	O
5	9	O
-	7	O
day	9	O
fixed	9	O
-	7	O
salt	0	O
diet	9	O
(	9	O
150	0	O
mmol	0	O
/	9	O
d	9	O
)	9	O
.	9	O

Crossover	5	O
studies	9	O
were	9	O
performed	9	O
2	9	O
weeks	9	O
apart	9	O
.	9	O

Thirty	9	O
milliliters	0	O
of	5	O
blood	9	O
was	9	O
obtained	9	O
for	5	O
isolation	9	O
of	5	O
peripheral	9	O
blood	9	O
mononuclear	3	O
cells	3	O
after	9	O
each	5	O
treatment	9	O
period	5	O
.	9	O

L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
uptake	0	O
was	9	O
assessed	9	O
in	5	O
mononuclear	3	O
cells	3	O
incubated	0	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
(	9	O
1	9	O
to	5	O
300	0	O
micromol	0	O
/	9	O
L	0	O
)	9	O
,	9	O
incorporating	5	O
100	0	O
nmol	0	O
/	9	O
L	0	O
[	9	B-Chemical
3H	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
for	5	O
a	5	O
period	5	O
of	5	O
5	9	O
minutes	0	O
at	9	O
37	9	O
degrees	5	O
C	9	O
.	9	O

Forearm	7	O
[	9	B-Chemical
3H	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
extraction	9	O
was	9	O
calculated	5	O
after	9	O
infusion	0	O
of	5	O
[	9	B-Chemical
3H	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
into	9	O
the	5	O
brachial	5	O
artery	5	O
at	9	O
a	5	O
rate	9	O
of	5	O
100	0	O
nCi	0	O
/	9	O
min	0	O
for	5	O
80	9	O
minutes	0	O
.	9	O

Deep	9	O
forearm	5	O
venous	5	O
samples	9	O
were	9	O
collected	9	O
for	5	O
determination	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
extraction	9	O
.	9	O

Plasma	0	O
cortisol	5	B-Chemical
concentrations	0	O
were	9	O
significantly	9	O
raised	9	O
during	5	O
the	5	O
active	9	O
phase	5	O
(	9	O
323	7	O
+	9	O
/	9	O
-	7	O
43	7	O
to	5	O
1082	7	O
+	9	O
/	9	O
-	7	O
245	7	O
mmol	0	O
/	9	O
L	0	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Systolic	7	O
blood	9	O
pressure	5	O
was	9	O
elevated	9	O
by	9	O
an	5	O
average	5	O
of	5	O
7	9	O
mm	9	O
Hg	0	O
.	9	O

Neither	9	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
transport	9	O
into	9	O
mononuclear	3	O
cells	3	O
(	9	O
placebo	9	O
vs	7	O
active	9	O
,	9	O
26	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
6	9	O
vs	7	O
29	7	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
1	9	O
pmol	0	O
/	9	O
10	9	O
000	9	O
cells	3	O
per	9	O
5	9	O
minutes	0	O
,	9	O
respectively	9	O
,	9	O
at	9	O
an	5	O
l	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
concentration	0	O
of	5	O
300	0	O
micromol	0	O
/	9	O
L	0	O
)	9	O
nor	9	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
extraction	9	O
in	5	O
the	5	O
forearm	5	O
(	9	O
at	9	O
80	9	O
minutes	0	O
,	9	O
placebo	9	O
vs	7	O
active	9	O
,	9	O
1	9	O
868	7	O
904	7	O
+	9	O
/	9	O
-	7	O
434	7	O
962	7	O
vs	7	O
2	9	O
013	7	O
910	7	O
+	9	O
/	9	O
-	7	O
770	9	O
619	7	O
disintegrations	0	O
per	9	O
minute	5	O
)	9	O
was	9	O
affected	9	O
by	9	O
cortisol	5	B-Chemical
treatment	9	O
;	9	O
ie	5	O
,	9	O
that	5	O
L	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
uptake	0	O
is	5	O
not	5	O
affected	9	O
by	9	O
short	5	O
-	7	O
term	5	O
cortisol	5	B-Chemical
treatment	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
cortisol	5	B-Chemical
-	7	O
induced	3	O
increases	9	B-Disease
in	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
are	5	O
not	5	O
associated	9	O
with	5	O
abnormalities	9	O
in	5	O
the	5	O
l	0	B-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
transport	9	O
system	5	O
.	9	O

Amount	9	O
of	5	O
bleeding	5	B-Disease
and	5	O
hematoma	5	B-Disease
size	9	O
in	5	O
the	5	O
collagenase	0	O
-	7	O
induced	3	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
rat	3	O
model	5	O
.	9	O

The	5	O
aggravated	9	O
risk	5	O
on	5	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
(	9	O
ICH	5	B-Disease
)	9	O
with	5	O
drugs	5	O
used	5	O
for	5	O
stroke	5	B-Disease
patients	5	O
should	5	O
be	5	O
estimated	5	O
carefully	5	O
.	9	O

We	9	O
therefore	5	O
established	9	O
sensitive	9	O
quantification	9	O
methods	5	O
and	5	O
provided	9	O
a	5	O
rat	3	O
ICH	5	B-Disease
model	5	O
for	5	O
detection	9	O
of	5	O
ICH	5	B-Disease
deterioration	5	O
.	9	O

In	9	O
ICH	5	B-Disease
intrastriatally	3	O
induced	3	O
by	9	O
0	7	O
.	9	O
014	2	O
-	7	O
unit	5	O
,	9	O
0	7	O
.	9	O
070	7	O
-	7	O
unit	5	O
,	9	O
and	5	O
0	7	O
.	9	O
350	9	O
-	7	O
unit	5	O
collagenase	0	O
,	9	O
the	5	O
amount	9	O
of	5	O
bleeding	5	B-Disease
was	9	O
measured	9	O
using	9	O
a	5	O
hemoglobin	0	O
assay	3	O
developed	5	O
in	5	O
the	5	O
present	9	O
study	9	O
and	5	O
was	9	O
compared	9	O
with	5	O
the	5	O
morphologically	4	O
determined	9	O
hematoma	5	B-Disease
volume	9	O
.	9	O

The	5	O
blood	9	O
amounts	9	O
and	5	O
hematoma	5	B-Disease
volumes	5	O
were	9	O
significantly	9	O
correlated	9	O
,	9	O
and	5	O
the	5	O
hematoma	5	B-Disease
induced	3	O
by	9	O
0	7	O
.	9	O
014	2	O
-	7	O
unit	5	O
collagenase	0	O
was	9	O
adequate	5	O
to	5	O
detect	9	O
ICH	5	B-Disease
deterioration	5	O
.	9	O

In	9	O
ICH	5	B-Disease
induction	3	O
using	9	O
0	7	O
.	9	O
014	2	O
-	7	O
unit	5	O
collagenase	0	O
,	9	O
heparin	0	B-Chemical
enhanced	3	O
the	5	O
hematoma	5	B-Disease
volume	9	O
3	9	O
.	9	O
4	9	O
-	7	O
fold	9	O
over	5	O
that	5	O
seen	9	O
in	5	O
control	9	O
ICH	5	B-Disease
animals	9	O
and	5	O
the	5	O
bleeding	5	B-Disease
7	9	O
.	9	O
6	9	O
-	7	O
fold	9	O
.	9	O

Data	5	O
suggest	9	O
that	5	O
this	5	O
sensitive	9	O
hemoglobin	0	O
assay	3	O
is	5	O
useful	5	O
for	5	O
ICH	5	B-Disease
detection	9	O
,	9	O
and	5	O
that	5	O
a	5	O
model	5	O
with	5	O
a	5	O
small	9	O
ICH	5	B-Disease
induced	3	O
with	5	O
a	5	O
low	9	O
-	7	O
dose	9	O
collagenase	0	O
should	5	O
be	5	O
used	5	O
for	5	O
evaluation	5	O
of	5	O
drugs	5	O
that	5	O
may	5	O
affect	9	O
ICH	5	B-Disease
.	9	O

Estradiol	0	B-Chemical
reduces	9	O
seizure	5	B-Disease
-	7	O
induced	3	O
hippocampal	3	B-Disease
injury	9	I-Disease
in	5	O
ovariectomized	3	O
female	9	O
but	9	O
not	5	O
in	5	O
male	9	O
rats	9	O
.	9	O

Estrogens	5	O
protect	9	O
ovariectomized	3	O
rats	9	O
from	9	O
hippocampal	3	B-Disease
injury	9	I-Disease
induced	3	O
by	9	O
kainic	0	B-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
(	9	O
SE	9	B-Disease
)	9	O
.	9	O

We	9	O
compared	9	O
the	5	O
effects	9	O
of	5	O
17beta	9	B-Chemical
-	7	I-Chemical
estradiol	0	I-Chemical
in	5	O
adult	9	O
male	9	O
and	5	O
ovariectomized	3	O
female	9	O
rats	9	O
subjected	9	O
to	5	O
lithium	0	B-Chemical
-	7	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
SE	9	B-Disease
.	9	O

Rats	9	O
received	9	O
subcutaneous	9	O
injections	9	O
of	5	O
17beta	9	B-Chemical
-	7	I-Chemical
estradiol	0	I-Chemical
(	9	O
2	9	O
microg	0	O
/	9	O
rat	3	O
)	9	O
or	5	O
oil	0	O
once	5	O
daily	5	O
for	5	O
four	9	O
consecutive	5	O
days	9	O
.	9	O

SE	9	B-Disease
was	9	O
induced	3	O
20	9	O
h	0	O
following	9	O
the	5	O
second	9	O
injection	9	O
and	5	O
terminated	9	O
3	9	O
h	0	O
later	9	O
.	9	O

The	5	O
extent	9	O
of	5	O
silver	0	B-Chemical
-	7	O
stained	3	O
CA3	3	O
and	5	O
CA1	3	O
hippocampal	3	O
neurons	3	O
was	9	O
evaluated	9	O
2	9	O
days	9	O
after	9	O
SE	9	B-Disease
.	9	O

17beta	9	B-Chemical
-	7	I-Chemical
Estradiol	0	I-Chemical
did	9	O
not	5	O
alter	9	O
the	5	O
onset	5	O
of	5	O
first	9	O
clonus	5	O
in	5	O
ovariectomized	3	O
rats	9	O
but	9	O
accelerated	9	O
it	5	O
in	5	O
males	9	O
.	9	O

17beta	9	B-Chemical
-	7	I-Chemical
Estradiol	0	I-Chemical
reduced	9	O
the	5	O
argyrophilic	5	O
neurons	3	O
in	5	O
the	5	O
CA1	3	O
and	5	O
CA3	3	O
-	7	O
C	9	O
sectors	5	O
of	5	O
ovariectomized	3	O
rats	9	O
.	9	O

In	9	O
males	9	O
,	9	O
estradiol	0	B-Chemical
increased	9	O
the	5	O
total	9	O
damage	9	O
score	5	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
the	5	O
effects	9	O
of	5	O
estradiol	0	B-Chemical
on	5	O
seizure	5	B-Disease
threshold	5	O
and	5	O
damage	9	O
may	5	O
be	5	O
altered	9	O
by	9	O
sex	5	O
-	7	O
related	9	O
differences	9	O
in	5	O
the	5	O
hormonal	9	O
environment	5	O
.	9	O

Pseudoacromegaly	_	B-Disease
induced	3	O
by	9	O
the	5	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
minoxidil	0	B-Chemical
.	9	O

Acromegaly	5	B-Disease
is	5	O
an	5	O
endocrine	9	B-Disease
disorder	5	I-Disease
caused	9	O
by	9	O
chronic	5	O
excessive	5	O
growth	3	O
hormone	9	O
secretion	3	O
from	9	O
the	5	O
anterior	5	O
pituitary	3	O
gland	9	O
.	9	O

Significant	9	O
disfiguring	5	O
changes	9	O
occur	5	O
as	5	O
a	5	O
result	9	O
of	5	O
bone	5	O
,	9	O
cartilage	5	O
,	9	O
and	5	O
soft	5	O
tissue	9	O
hypertrophy	9	B-Disease
,	9	O
including	9	O
the	5	O
thickening	5	O
of	5	O
the	5	O
skin	5	O
,	9	O
coarsening	5	O
of	5	O
facial	5	O
features	5	O
,	9	O
and	5	O
cutis	5	B-Disease
verticis	4	I-Disease
gyrata	4	I-Disease
.	9	O

Pseudoacromegaly	_	B-Disease
,	9	O
on	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
is	5	O
the	5	O
presence	9	O
of	5	O
similar	9	O
acromegaloid	5	O
features	5	O
in	5	O
the	5	O
absence	3	O
of	5	O
elevated	9	O
growth	3	O
hormone	9	O
or	5	O
insulin	3	O
-	7	O
like	9	O
growth	3	O
factor	9	O
levels	3	O
.	9	O

We	9	O
present	9	O
a	5	O
patient	5	O
with	5	O
pseudoacromegaly	5	B-Disease
that	5	O
resulted	9	O
from	9	O
the	5	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
minoxidil	0	B-Chemical
at	9	O
an	5	O
unusually	9	O
high	9	O
dose	9	O
.	9	O

This	5	O
is	5	O
the	5	O
first	9	O
case	5	O
report	5	O
of	5	O
pseudoacromegaly	5	B-Disease
as	5	O
a	5	O
side	5	O
effect	9	O
of	5	O
minoxidil	0	B-Chemical
use	5	O
.	9	O

Combined	9	O
androgen	3	O
blockade	3	O
-	7	O
induced	3	O
anemia	9	B-Disease
in	5	O
prostate	3	B-Disease
cancer	3	I-Disease
patients	5	O
without	9	O
bone	5	O
involvement	9	O
.	9	O

BACKGROUND	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
onset	5	O
and	5	O
extent	9	O
of	5	O
combined	9	O
androgen	3	O
blockade	3	O
(	9	O
CAB	9	O
)	9	O
-	7	O
induced	3	O
anemia	9	B-Disease
in	5	O
prostate	3	B-Disease
cancer	3	I-Disease
patients	5	O
without	9	O
bone	5	O
involvement	9	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
Forty	9	O
-	7	O
two	5	O
patients	5	O
with	5	O
biopsy	5	O
-	7	O
proven	5	O
prostatic	9	B-Disease
adenocarcinoma	3	I-Disease
[	9	O
26	7	O
with	5	O
stage	9	O
C	9	O
(	9	O
T3N0M0	7	O
)	9	O
and	5	O
16	9	O
with	5	O
stage	9	O
D1	3	O
(	9	O
T3N1M0	7	O
)	9	O
]	9	O
were	9	O
included	5	O
in	5	O
this	5	O
study	9	O
.	9	O

All	9	O
patients	5	O
received	9	O
CAB	9	O
[	9	O
leuprolide	0	B-Chemical
acetate	0	I-Chemical
(	9	O
LHRH	0	B-Chemical
-	7	I-Chemical
A	9	I-Chemical
)	9	O
3	9	O
.	9	O
75	9	O
mg	0	O
,	9	O
intramuscularly	0	O
,	9	O
every	5	O
28	7	O
days	9	O
plus	9	O
250	0	O
mg	0	O
flutamide	0	B-Chemical
,	9	O
tid	0	O
,	9	O
per	9	O
Os	0	O
]	9	O
and	5	O
were	9	O
evaluated	9	O
for	5	O
anemia	9	B-Disease
by	9	O
physical	5	O
examination	5	O
and	5	O
laboratory	9	O
tests	5	O
at	9	O
baseline	5	O
and	5	O
4	9	O
subsequent	9	O
intervals	5	O
(	9	O
1	9	O
,	9	O
2	9	O
,	9	O
3	9	O
and	5	O
6	9	O
months	5	O
post	9	O
-	7	O
CAB	9	O
)	9	O
.	9	O

Hb	9	O
,	9	O
PSA	9	O
and	5	O
Testosterone	0	B-Chemical
measurements	5	O
were	9	O
recorded	5	O
.	9	O

Patients	5	O
with	5	O
stage	9	O
D2	9	O
-	7	O
3	9	O
disease	5	O
,	9	O
abnormal	9	O
hemoglobin	0	O
level	9	O
or	5	O
renal	9	O
and	5	O
liver	9	O
function	9	O
tests	5	O
that	5	O
were	9	O
higher	9	O
than	5	O
the	5	O
upper	9	O
limits	5	O
were	9	O
excluded	9	O
from	9	O
the	5	O
study	9	O
.	9	O

The	5	O
duration	5	O
of	5	O
the	5	O
study	9	O
was	9	O
six	9	O
months	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
mean	5	O
hemoglobin	0	O
(	9	O
Hb	9	O
)	9	O
levels	3	O
were	9	O
significantly	9	O
declined	9	O
in	5	O
all	5	O
patients	5	O
from	9	O
baseline	5	O
of	5	O
14	7	O
.	9	O
2	9	O
g	0	O
/	9	O
dl	7	O
to	5	O
14	7	O
.	9	O
0	7	O
g	0	O
/	9	O
dl	7	O
,	9	O
13	7	O
.	9	O
5	9	O
g	0	O
/	9	O
dl	7	O
,	9	O
13	7	O
.	9	O
2	9	O
g	0	O
/	9	O
dl	7	O
and	5	O
12	9	O
.	9	O
7	9	O
g	0	O
/	9	O
dl	7	O
at	9	O
1	9	O
,	9	O
2	9	O
,	9	O
3	9	O
and	5	O
6	9	O
months	5	O
post	9	O
-	7	O
CAB	9	O
,	9	O
respectively	9	O
.	9	O

Severe	9	O
and	5	O
clinically	5	O
evident	9	O
anemia	9	B-Disease
of	5	O
Hb	9	O
<	0	O
11	7	O
g	0	O
/	9	O
dl	7	O
with	5	O
clinical	5	O
symptoms	5	O
was	9	O
detected	9	O
in	5	O
6	9	O
patients	5	O
(	9	O
14	7	O
.	9	O
3	9	O
%	9	O
)	9	O
.	9	O

This	5	O
CAB	9	O
-	7	O
induced	3	O
anemia	9	B-Disease
was	9	O
normochromic	5	O
and	5	O
normocytic	5	O
.	9	O

At	9	O
six	9	O
months	5	O
post	9	O
-	7	O
CAB	9	O
,	9	O
patients	5	O
with	5	O
severe	5	O
anemia	9	B-Disease
had	9	O
a	5	O
Hb	9	O
mean	5	O
value	9	O
of	5	O
10	9	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
g	0	O
/	9	O
dl	7	O
(	9	O
X	9	O
+	9	O
/	9	O
-	7	O
SE	9	O
)	9	O
,	9	O
whereas	9	O
the	5	O
other	5	O
patients	5	O
had	9	O
mild	9	O
anemia	9	B-Disease
with	5	O
Hb	9	O
mean	5	O
value	9	O
of	5	O
13	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
17	7	O
(	9	O
X	9	O
+	9	O
/	9	O
-	7	O
SE	9	O
)	9	O
.	9	O

The	5	O
development	9	O
of	5	O
severe	5	O
anemia	9	B-Disease
at	9	O
6	9	O
months	5	O
post	9	O
-	7	O
CAB	9	O
was	9	O
predictable	5	O
by	9	O
the	5	O
reduction	9	O
of	5	O
Hb	9	O
baseline	5	O
value	9	O
of	5	O
more	5	O
than	5	O
2	9	O
.	9	O
5	9	O
g	0	O
/	9	O
dl	7	O
after	9	O
3	9	O
months	5	O
of	5	O
CAB	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

The	5	O
development	9	O
of	5	O
severe	5	O
CAB	9	O
-	7	O
induced	3	O
anemia	9	B-Disease
in	5	O
prostate	3	B-Disease
cancer	3	I-Disease
patients	5	O
did	9	O
not	5	O
correlate	9	O
with	5	O
T	3	O
baseline	5	O
values	5	O
(	9	O
T	3	O
<	0	O
3	9	O
ng	0	O
/	9	O
ml	0	O
versus	9	O
T	3	O
>	0	O
or	5	O
=	7	O
3	9	O
ng	0	O
/	9	O
ml	0	O
)	9	O
,	9	O
with	5	O
age	5	O
(	9	O
<	0	O
76	7	O
yrs	7	O
versus	9	O
>	0	O
or	5	O
=	7	O
76	7	O
yrs	7	O
)	9	O
,	9	O
and	5	O
clinical	5	O
stage	9	O
(	9	O
stage	9	O
C	9	O
versus	9	O
stage	9	O
D1	3	O
)	9	O
.	9	O

Severe	9	O
and	5	O
clinically	5	O
evident	9	O
anemia	9	B-Disease
was	9	O
easily	5	O
corrected	5	O
by	9	O
subcutaneous	9	O
injections	9	O
(	9	O
3	9	O
times	5	O
/	9	O
week	9	O
for	5	O
1	9	O
month	5	O
)	9	O
of	5	O
recombinant	3	O
erythropoietin	9	O
(	9	O
rHuEPO	0	O
-	7	O
beta	9	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Our	9	O
data	5	O
suggest	9	O
that	5	O
rHuEPO	0	O
-	7	O
beta	9	O
correctable	5	O
CAB	9	O
-	7	O
induced	3	O
anemia	9	B-Disease
occurs	9	O
in	5	O
14	7	O
.	9	O
3	9	O
%	9	O
of	5	O
prostate	3	B-Disease
cancer	3	I-Disease
patients	5	O
after	9	O
6	9	O
months	5	O
of	5	O
therapy	5	O
.	9	O

Delirium	5	B-Disease
during	5	O
clozapine	5	B-Chemical
treatment	9	O
:	9	O
incidence	5	O
and	5	O
associated	9	O
risk	5	O
factors	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Incidence	9	O
and	5	O
risk	5	O
factors	9	O
for	5	O
delirium	5	B-Disease
during	5	O
clozapine	5	B-Chemical
treatment	9	O
require	5	O
further	9	O
clarification	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
used	5	O
computerized	5	O
pharmacy	5	O
records	5	O
to	5	O
identify	9	O
all	5	O
adult	9	O
psychiatric	5	B-Disease
inpatients	5	O
treated	3	O
with	5	O
clozapine	5	B-Chemical
(	9	O
1995	2	O
-	7	O
96	9	O
)	9	O
,	9	O
reviewed	9	O
their	5	O
medical	5	O
records	5	O
to	5	O
score	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
delirium	5	B-Disease
,	9	O
and	5	O
tested	9	O
associations	5	O
with	5	O
potential	9	O
risk	5	O
factors	9	O
.	9	O

RESULTS	9	O
:	9	O
Subjects	5	O
(	9	O
n	9	O
=	7	O
139	7	O
)	9	O
were	9	O
72	9	O
women	5	O
and	5	O
67	7	O
men	5	O
,	9	O
aged	9	O
40	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
12	9	O
.	9	O
1	9	O
years	5	O
,	9	O
hospitalized	5	O
for	5	O
24	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
23	7	O
.	9	O
3	9	O
days	9	O
,	9	O
and	5	O
given	5	O
clozapine	5	B-Chemical
,	9	O
gradually	9	O
increased	9	O
to	5	O
an	5	O
average	5	O
daily	5	O
dose	9	O
of	5	O
282	7	O
+	9	O
/	9	O
-	7	O
203	7	O
mg	0	O
(	9	O
3	9	O
.	9	O
45	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
45	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
for	5	O
18	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
16	9	O
.	9	O
4	9	O
days	9	O
.	9	O

Delirium	5	B-Disease
was	9	O
diagnosed	5	O
in	5	O
14	7	O
(	9	O
10	9	O
.	9	O
1	9	O
%	9	O
incidence	5	O
,	9	O
or	5	O
1	9	O
.	9	O
48	9	O
cases	5	O
/	9	O
person	5	O
-	7	O
years	5	O
of	5	O
exposure	9	O
)	9	O
;	9	O
71	7	O
.	9	O
4	9	O
%	9	O
of	5	O
cases	5	O
were	9	O
moderate	9	O
or	5	O
severe	5	O
.	9	O

Associated	9	O
factors	9	O
were	9	O
co	9	O
-	7	O
treatment	9	O
with	5	O
other	5	O
centrally	5	O
antimuscarinic	5	O
agents	5	O
,	9	O
poor	5	O
clinical	5	O
outcome	5	O
,	9	O
older	5	O
age	5	O
,	9	O
and	5	O
longer	5	O
hospitalization	5	O
(	9	O
by	9	O
17	7	O
.	9	O
5	9	O
days	9	O
,	9	O
increasing	9	O
cost	5	O
)	9	O
;	9	O
sex	5	O
,	9	O
diagnosis	5	O
or	5	O
medical	5	O
co	9	O
-	7	O
morbidity	5	O
,	9	O
and	5	O
daily	5	O
clozapine	5	B-Chemical
dose	9	O
,	9	O
which	5	O
fell	5	O
with	5	O
age	5	O
,	9	O
were	9	O
unrelated	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Delirium	5	B-Disease
was	9	O
found	9	O
in	5	O
10	9	O
%	9	O
of	5	O
clozapine	5	B-Chemical
-	7	O
treated	3	O
inpatients	5	O
,	9	O
particularly	5	O
in	5	O
older	5	O
patients	5	O
exposed	9	O
to	5	O
other	5	O
central	5	O
anticholinergics	5	O
.	9	O

Delirium	5	B-Disease
was	9	O
inconsistently	5	O
recognized	9	O
clinically	5	O
in	5	O
milder	9	O
cases	5	O
and	5	O
was	9	O
associated	9	O
with	5	O
increased	9	O
length	9	O
-	7	O
of	5	O
-	7	O
stay	5	O
and	5	O
higher	9	O
costs	5	O
,	9	O
and	5	O
inferior	5	O
clinical	5	O
outcome	5	O
.	9	O

Neuroprotective	0	O
action	5	O
of	5	O
MPEP	0	B-Chemical
,	9	O
a	5	O
selective	9	O
mGluR5	3	O
antagonist	3	O
,	9	O
in	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
dopaminergic	5	O
neurotoxicity	9	B-Disease
is	5	O
associated	9	O
with	5	O
a	5	O
decrease	9	O
in	5	O
dopamine	5	B-Chemical
outflow	5	O
and	5	O
inhibition	3	O
of	5	O
hyperthermia	5	B-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
examine	9	O
the	5	O
role	9	O
of	5	O
metabotropic	3	O
glutamate	0	B-Chemical
receptor	3	O
5	9	O
(	9	O
mGluR5	3	O
)	9	O
in	5	O
the	5	O
toxic	0	O
action	5	O
of	5	O
methamphetamine	5	B-Chemical
on	5	O
dopaminergic	5	O
neurones	3	O
in	5	O
rats	9	O
.	9	O

Methamphetamine	7	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
sc	9	O
)	9	O
,	9	O
administered	9	O
five	9	O
times	5	O
,	9	O
reduced	9	O
the	5	O
levels	3	O
of	5	O
dopamine	5	B-Chemical
and	5	O
its	9	O
metabolites	0	O
in	5	O
striatal	3	O
tissue	9	O
when	5	O
measured	9	O
72	9	O
h	0	O
after	9	O
the	5	O
last	5	O
injection	9	O
.	9	O

A	9	O
selective	9	O
antagonist	3	O
of	5	O
mGluR5	3	O
,	9	O
2	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
6	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
phenylethynyl	0	I-Chemical
)	9	I-Chemical
pyridine	0	I-Chemical
(	9	O
MPEP	0	B-Chemical
;	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
,	9	O
when	5	O
administered	9	O
five	9	O
times	5	O
immediately	9	O
before	9	O
each	5	O
methamphetamine	5	B-Chemical
injection	9	O
reversed	9	O
the	5	O
above	9	O
-	7	O
mentioned	5	O
methamphetamine	5	B-Chemical
effects	9	O
.	9	O

A	9	O
single	9	O
MPEP	0	B-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
injection	9	O
reduced	9	O
the	5	O
basal	3	O
extracellular	9	O
dopamine	5	B-Chemical
level	9	O
in	5	O
the	5	O
striatum	9	O
,	9	O
as	5	O
well	9	O
as	5	O
dopamine	5	B-Chemical
release	9	O
stimulated	3	O
either	9	O
by	9	O
methamphetamine	5	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
sc	9	O
)	9	O
or	5	O
by	9	O
intrastriatally	3	O
administered	9	O
veratridine	0	B-Chemical
(	9	O
100	0	O
microM	0	O
)	9	O
.	9	O

Moreover	9	O
,	9	O
it	5	O
transiently	3	O
diminished	9	O
the	5	O
methamphetamine	5	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
sc	9	O
)	9	O
-	7	O
induced	3	O
hyperthermia	5	B-Disease
and	5	O
reduced	9	O
basal	3	O
body	5	O
temperature	0	O
.	9	O

MPEP	0	B-Chemical
administered	9	O
into	9	O
the	5	O
striatum	9	O
at	9	O
high	9	O
concentrations	0	O
(	9	O
500	0	O
microM	0	O
)	9	O
increased	9	O
extracellular	9	O
dopamine	5	B-Chemical
levels	3	O
,	9	O
while	9	O
lower	9	O
concentrations	0	O
(	9	O
50	0	O
-	7	O
100	0	O
microM	0	O
)	9	O
were	9	O
devoid	9	O
of	5	O
any	5	O
effect	9	O
.	9	O

The	5	O
results	9	O
of	5	O
this	5	O
study	9	O
suggest	9	O
that	5	O
the	5	O
blockade	3	O
of	5	O
mGluR5	3	O
by	9	O
MPEP	0	B-Chemical
may	5	O
protect	9	O
dopaminergic	5	O
neurones	3	O
against	9	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
toxicity	9	B-Disease
.	9	O

Neuroprotection	3	O
rendered	9	O
by	9	O
MPEP	0	B-Chemical
may	5	O
be	5	O
associated	9	O
with	5	O
the	5	O
reduction	9	O
of	5	O
the	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
dopamine	5	B-Chemical
efflux	0	O
in	5	O
the	5	O
striatum	9	O
due	5	O
to	5	O
the	5	O
blockade	3	O
of	5	O
extrastriatal	5	O
mGluR5	3	O
,	9	O
and	5	O
with	5	O
a	5	O
decrease	9	O
in	5	O
hyperthermia	5	B-Disease
.	9	O

Protective	9	O
efficacy	9	O
of	5	O
neuroactive	5	O
steroids	9	B-Chemical
against	9	O
cocaine	5	B-Chemical
kindled	5	O
-	7	O
seizures	5	B-Disease
in	5	O
mice	3	O
.	9	O

Neuroactive	7	O
steroids	9	B-Chemical
demonstrate	9	O
pharmacological	9	O
actions	5	O
that	5	O
have	5	O
relevance	9	O
for	5	O
a	5	O
host	9	O
of	5	O
neurological	5	B-Disease
and	5	I-Disease
psychiatric	5	I-Disease
disorders	5	I-Disease
.	9	O

They	5	O
offer	5	O
protection	9	O
against	9	O
seizures	5	B-Disease
in	5	O
a	5	O
range	9	O
of	5	O
models	5	O
and	5	O
seem	5	O
to	5	O
inhibit	3	O
certain	5	O
stages	9	O
of	5	O
drug	5	B-Disease
dependence	5	I-Disease
in	5	O
preclinical	9	O
assessments	5	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
evaluate	9	O
two	5	O
endogenous	3	O
and	5	O
one	5	O
synthetic	0	O
neuroactive	5	O
steroid	9	B-Chemical
that	5	O
positively	9	O
modulate	9	O
the	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acid	0	I-Chemical
(	9	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
)	9	O
receptor	3	O
against	9	O
the	5	O
increase	9	O
in	5	O
sensitivity	9	O
to	5	O
the	5	O
convulsant	0	O
effects	9	O
of	5	O
cocaine	5	B-Chemical
engendered	5	O
by	9	O
repeated	5	O
cocaine	5	B-Chemical
administration	9	O
(	9	O
seizure	5	B-Disease
kindling	5	O
)	9	O
.	9	O

Allopregnanolone	0	B-Chemical
(	9	O
3alpha	1	B-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
-	7	I-Chemical
5alpha	7	I-Chemical
-	7	I-Chemical
pregnan	7	I-Chemical
-	7	I-Chemical
20	9	I-Chemical
-	7	I-Chemical
one	5	I-Chemical
)	9	O
,	9	O
pregnanolone	0	B-Chemical
(	9	O
3alpha	1	B-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
-	7	I-Chemical
5beta	7	I-Chemical
-	7	I-Chemical
pregnan	7	I-Chemical
-	7	I-Chemical
20	9	I-Chemical
-	7	I-Chemical
one	5	I-Chemical
)	9	O
and	5	O
ganaxolone	0	B-Chemical
(	9	O
a	5	O
synthetic	0	O
derivative	0	O
of	5	O
allopregnanolone	0	B-Chemical
3alpha	1	B-Chemical
-	7	I-Chemical
hydroxy	0	I-Chemical
-	7	I-Chemical
3beta	1	I-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
5alpha	7	I-Chemical
-	7	I-Chemical
pregnan	7	I-Chemical
-	7	I-Chemical
20	9	I-Chemical
-	7	I-Chemical
one	5	I-Chemical
)	9	O
were	9	O
tested	9	O
for	5	O
their	5	O
ability	9	O
to	5	O
suppress	3	O
the	5	O
expression	3	O
(	9	O
anticonvulsant	5	O
effect	9	O
)	9	O
and	5	O
development	9	O
(	9	O
antiepileptogenic	5	O
effect	9	O
)	9	O
of	5	O
cocaine	5	B-Chemical
-	7	O
kindled	5	O
seizures	5	B-Disease
in	5	O
male	9	O
,	9	O
Swiss	2	O
-	7	O
Webster	6	O
mice	3	O
.	9	O

Kindled	7	O
seizures	5	B-Disease
were	9	O
induced	3	O
by	9	O
daily	5	O
administration	9	O
of	5	O
60	9	O
mg	0	O
/	9	O
kg	0	O
cocaine	5	B-Chemical
for	5	O
5	9	O
days	9	O
.	9	O

All	9	O
of	5	O
these	5	O
positive	9	O
GABA	0	B-Chemical
(	9	O
A	9	O
)	9	O
modulators	9	O
suppressed	3	O
the	5	O
expression	3	O
of	5	O
kindled	5	O
seizures	5	B-Disease
,	9	O
whereas	9	O
only	9	O
allopregnanolone	0	B-Chemical
and	5	O
ganaxolone	0	B-Chemical
inhibited	3	O
the	5	O
development	9	O
of	5	O
kindling	5	O
.	9	O

Allopregnanolone	0	B-Chemical
and	5	O
pregnanolone	0	B-Chemical
,	9	O
but	9	O
not	5	O
ganaxolone	0	B-Chemical
,	9	O
also	9	O
reduced	9	O
cumulative	5	O
lethality	3	O
associated	9	O
with	5	O
kindling	5	O
.	9	O

These	5	O
findings	9	O
demonstrate	9	O
that	5	O
some	5	O
neuroactive	5	O
steroids	9	B-Chemical
attenuate	9	O
convulsant	0	O
and	5	O
sensitizing	3	O
properties	9	O
of	5	O
cocaine	5	B-Chemical
and	5	O
add	5	O
to	5	O
a	5	O
growing	9	O
literature	5	O
on	5	O
their	5	O
potential	9	O
use	5	O
in	5	O
the	5	O
modulation	9	O
of	5	O
effects	9	O
of	5	O
drugs	5	O
of	5	O
abuse	5	O
.	9	O

Effect	0	O
of	5	O
humoral	3	O
modulators	9	O
of	5	O
morphine	0	B-Chemical
-	7	O
induced	3	O
increase	9	B-Disease
in	5	I-Disease
locomotor	5	I-Disease
activity	9	I-Disease
of	5	O
mice	3	O
.	9	O

The	5	O
effect	9	O
of	5	O
humoral	3	O
modulators	9	O
on	5	O
the	5	O
morphine	0	B-Chemical
-	7	O
induced	3	O
increase	9	B-Disease
in	5	I-Disease
locomotor	5	I-Disease
activity	9	I-Disease
of	5	O
mice	3	O
was	9	O
studied	9	O
.	9	O

The	5	O
subcutaneous	9	O
administration	9	O
of	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
of	5	O
morphine	0	B-Chemical
-	7	O
HC1	0	O
produced	9	O
a	5	O
marked	9	O
increase	9	B-Disease
in	5	I-Disease
locomotor	5	I-Disease
activity	9	I-Disease
in	5	O
mice	3	O
.	9	O

The	5	O
morphine	0	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
was	9	O
potentiated	3	O
by	9	O
scopolamine	0	B-Chemical
and	5	O
attenuated	3	O
by	9	O
physostigmine	0	B-Chemical
.	9	O

In	9	O
contrast	9	O
,	9	O
both	9	O
methscopolamine	9	B-Chemical
and	5	O
neostigmine	0	B-Chemical
,	9	O
which	5	O
do	5	O
not	5	O
penetrate	9	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
,	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
the	5	O
hyperactivity	5	B-Disease
produced	9	O
by	9	O
morphine	0	B-Chemical
.	9	O

Pretreatment	3	O
of	5	O
mice	3	O
with	5	O
alpha	9	B-Chemical
-	7	I-Chemical
methyltyrosine	9	I-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
one	5	O
hour	0	O
)	9	O
,	9	O
an	5	O
inhibitor	3	O
of	5	O
tyrosine	3	B-Chemical
hydroxylase	1	O
,	9	O
significantly	9	O
decreased	9	O
the	5	O
activity	9	O
-	7	O
increasing	9	O
effects	9	O
of	5	O
morphine	0	B-Chemical
.	9	O

On	5	O
the	5	O
other	5	O
hand	5	O
,	9	O
pretreatment	0	O
with	5	O
p	7	B-Chemical
-	7	I-Chemical
chlorophenylalamine	_	I-Chemical
(	9	O
3	9	O
X	9	O
320	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
24	9	O
hr	0	O
)	9	O
,	9	O
a	5	O
serotonin	9	B-Chemical
depletor	0	O
,	9	O
caused	9	O
no	9	O
significant	9	O
change	9	O
in	5	O
the	5	O
hyperactivity	5	B-Disease
.	9	O

The	5	O
study	9	O
suggests	9	O
that	5	O
the	5	O
activity	9	O
-	7	O
increasing	9	O
effects	9	O
of	5	O
morphine	0	B-Chemical
are	5	O
mediated	3	O
by	9	O
the	5	O
release	9	O
of	5	O
catecholamines	9	B-Chemical
from	9	O
adrenergic	9	O
neurons	3	O
in	5	O
the	5	O
brain	5	O
.	9	O

And	5	O
the	5	O
results	9	O
are	5	O
consistent	9	O
with	5	O
the	5	O
hypothesis	9	O
that	5	O
morphine	0	B-Chemical
acts	9	O
by	9	O
retarding	9	O
the	5	O
release	9	O
of	5	O
acetylcholine	0	B-Chemical
at	9	O
some	5	O
central	5	O
cholinergic	3	O
synapses	5	O
.	9	O

It	5	O
is	5	O
also	9	O
suggested	9	O
from	9	O
collected	9	O
evidence	9	O
that	5	O
the	5	O
activity	9	O
-	7	O
increasing	9	O
effects	9	O
of	5	O
morphine	0	B-Chemical
in	5	O
mice	3	O
are	5	O
mediated	3	O
by	9	O
mechanisms	9	O
different	9	O
from	9	O
those	5	O
which	5	O
mediate	3	O
the	5	O
activity	9	O
-	7	O
increasing	9	O
effects	9	O
of	5	O
morphine	0	B-Chemical
in	5	O
rats	9	O
.	9	O

Effects	9	O
of	5	O
uninephrectomy	3	O
and	5	O
high	9	O
protein	1	O
feeding	5	O
on	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
in	5	O
rats	9	O
.	9	O

Rats	9	O
with	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
were	9	O
subjected	9	O
to	5	O
high	9	O
protein	1	O
(	9	O
HP	9	O
)	9	O
feeding	5	O
,	9	O
uninephrectomy	3	O
(	9	O
NX	9	O
)	9	O
or	5	O
a	5	O
combination	9	O
of	5	O
these	5	O
,	9	O
in	5	O
an	5	O
attempt	5	O
to	5	O
induce	3	O
glomerular	5	O
hyperfiltration	5	O
and	5	O
further	9	O
progression	9	O
of	5	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

Newborn	9	O
female	9	O
Wistar	9	O
rats	9	O
were	9	O
fed	9	O
a	5	O
lithium	0	B-Chemical
-	7	O
containing	0	O
diet	9	O
(	9	O
50	0	O
mmol	0	O
/	9	O
kg	0	O
)	9	O
for	5	O
8	9	O
weeks	9	O
and	5	O
then	9	O
randomized	5	O
to	5	O
normal	9	O
diet	9	O
,	9	O
HP	9	O
diet	9	O
(	9	O
40	9	O
vs	7	O
.	9	O
19	7	O
%	9	O
)	9	O
,	9	O
NX	9	O
or	5	O
HP	9	O
+	9	O
NX	9	O
for	5	O
another	9	O
8	9	O
weeks	9	O
.	9	O

Corresponding	9	O
non	9	O
-	7	O
lithium	0	B-Chemical
pretreated	3	O
groups	9	O
were	9	O
generated	9	O
.	9	O

When	9	O
comparing	9	O
all	5	O
lithium	0	B-Chemical
treated	3	O
versus	9	O
non	9	O
-	7	O
lithium	0	B-Chemical
-	7	O
treated	3	O
groups	9	O
,	9	O
lithium	0	B-Chemical
caused	9	O
a	5	O
reduction	9	O
in	5	O
glomerular	5	O
filtration	0	O
rate	9	O
(	9	O
GFR	5	O
)	9	O
without	9	O
significant	9	O
changes	9	O
in	5	O
effective	5	O
renal	9	O
plasma	9	O
flow	5	O
(	9	O
as	5	O
determined	9	O
by	9	O
a	5	O
marker	3	O
secreted	3	O
into	9	O
the	5	O
proximal	9	O
tubules	9	O
)	9	O
or	5	O
lithium	0	B-Chemical
clearance	9	O
.	9	O

Consequently	9	O
,	9	O
lithium	0	B-Chemical
pretreatment	0	O
caused	9	O
a	5	O
fall	5	O
in	5	O
filtration	0	O
fraction	9	O
and	5	O
an	5	O
increase	9	O
in	5	O
fractional	5	O
Li	6	B-Chemical
excretion	0	O
.	9	O

Lithium	0	B-Chemical
also	9	O
caused	9	O
proteinuria	9	B-Disease
and	5	O
systolic	5	O
hypertension	5	B-Disease
in	5	O
absence	3	O
of	5	O
glomerulosclerosis	3	B-Disease
.	9	O

HP	9	O
failed	9	O
to	5	O
accentuante	_	O
progression	9	O
of	5	O
renal	9	B-Disease
failure	5	I-Disease
and	5	O
in	5	O
fact	9	O
tended	5	O
to	5	O
increase	9	O
GFR	5	O
and	5	O
decrease	9	O
plasma	9	O
creatinine	0	B-Chemical
levels	3	O
in	5	O
lithium	0	B-Chemical
pretreated	3	O
rats	9	O
.	9	O

NX	9	O
caused	9	O
an	5	O
additive	9	O
deterioration	5	O
in	5	O
GFR	5	O
which	5	O
,	9	O
however	9	O
,	9	O
was	9	O
ameliorated	9	O
by	9	O
HP	9	O
.	9	O

NX	9	O
+	9	O
HP	9	O
caused	9	O
a	5	O
further	9	O
rise	9	O
in	5	O
blood	9	O
pressure	5	O
in	5	O
Li	6	B-Chemical
-	7	O
pretreated	3	O
rats	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
Li	6	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
,	9	O
even	5	O
when	5	O
the	5	O
GFR	5	O
is	5	O
only	9	O
modestly	9	O
reduced	9	O
,	9	O
is	5	O
associated	9	O
with	5	O
proteinuria	9	B-Disease
and	5	O
arterial	5	O
systolic	5	O
hypertension	5	B-Disease
.	9	O

In	9	O
this	5	O
model	5	O
of	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
the	5	O
decline	9	O
in	5	O
GFR	5	O
is	5	O
not	5	O
accompanied	9	O
by	9	O
a	5	O
corresponding	9	O
fall	5	O
in	5	O
effective	5	O
renal	9	O
plasma	9	O
flow	5	O
,	9	O
which	5	O
may	5	O
be	5	O
the	5	O
functional	9	O
expression	3	O
of	5	O
the	5	O
formation	9	O
of	5	O
nonfiltrating	_	O
atubular	5	O
glomeruli	9	O
.	9	O

The	5	O
fractional	5	O
reabsorption	0	O
of	5	O
tubular	9	O
fluid	5	O
by	9	O
the	5	O
proximal	9	O
tubules	9	O
is	5	O
reduced	9	O
,	9	O
leaving	5	O
the	5	O
distal	9	O
delivery	5	O
unchanged	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Treatment	9	O
of	5	O
Crohn	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
with	5	O
fusidic	0	B-Chemical
acid	0	I-Chemical
:	9	O
an	5	O
antibiotic	5	O
with	5	O
immunosuppressive	9	O
properties	9	O
similar	9	O
to	5	O
cyclosporin	0	B-Chemical
.	9	O

Fusidic	0	O
acid	0	O
is	5	O
an	5	O
antibiotic	5	O
with	5	O
T	3	O
-	7	O
cell	3	O
specific	9	O
immunosuppressive	9	O
effects	9	O
similar	9	O
to	5	O
those	5	O
of	5	O
cyclosporin	0	B-Chemical
.	9	O

Because	9	O
of	5	O
the	5	O
need	5	O
for	5	O
the	5	O
development	9	O
of	5	O
new	5	O
treatments	9	O
for	5	O
Crohn	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
,	9	O
a	5	O
pilot	5	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
estimate	5	O
the	5	O
pharmacodynamics	5	O
and	5	O
tolerability	5	O
of	5	O
fusidic	0	B-Chemical
acid	0	I-Chemical
treatment	9	O
in	5	O
chronic	5	O
active	9	O
,	9	O
therapy	5	O
-	7	O
resistant	9	O
patients	5	O
.	9	O

Eight	9	O
Crohn	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
patients	5	O
were	9	O
included	5	O
.	9	O

Fusidic	0	B-Chemical
acid	0	I-Chemical
was	9	O
administered	9	O
orally	0	O
in	5	O
a	5	O
dose	9	O
of	5	O
500	0	O
mg	0	O
t	5	O
.	9	O
d	9	O
.	9	O
s	9	O
.	9	O
and	5	O
the	5	O
treatment	9	O
was	9	O
planned	5	O
to	5	O
last	5	O
8	9	O
weeks	9	O
.	9	O

The	5	O
disease	5	O
activity	9	O
was	9	O
primarily	9	O
measured	9	O
by	9	O
a	5	O
modified	9	O
individual	5	O
grading	5	O
score	5	O
.	9	O

Five	9	O
of	5	O
8	9	O
patients	5	O
(	9	O
63	7	O
%	9	O
)	9	O
improved	5	O
during	5	O
fusidic	0	B-Chemical
acid	0	I-Chemical
treatment	9	O
:	9	O
3	9	O
at	9	O
two	5	O
weeks	9	O
and	5	O
2	9	O
after	9	O
four	9	O
weeks	9	O
.	9	O

There	5	O
were	9	O
no	9	O
serious	5	O
clinical	5	O
side	5	O
effects	9	O
,	9	O
but	9	O
dose	9	O
reduction	9	O
was	9	O
required	9	O
in	5	O
two	5	O
patients	5	O
because	5	O
of	5	O
nausea	5	B-Disease
.	9	O

Biochemically	9	O
,	9	O
an	5	O
increase	9	O
in	5	O
alkaline	0	O
phosphatases	1	O
was	9	O
noted	9	O
in	5	O
5	9	O
of	5	O
8	9	O
cases	5	O
(	9	O
63	7	O
%	9	O
)	9	O
,	9	O
and	5	O
the	5	O
greatest	9	O
increases	9	O
were	9	O
seen	9	O
in	5	O
those	5	O
who	5	O
had	9	O
elevated	9	O
levels	3	O
prior	9	O
to	5	O
treatment	9	O
.	9	O

All	9	O
reversed	9	O
to	5	O
pre	9	O
-	7	O
treatment	9	O
levels	3	O
after	9	O
cessation	5	O
of	5	O
treatment	9	O
.	9	O

The	5	O
results	9	O
of	5	O
this	5	O
pilot	5	O
study	9	O
suggest	9	O
that	5	O
fusidic	0	B-Chemical
acid	0	I-Chemical
may	5	O
be	5	O
of	5	O
benefit	5	O
in	5	O
selected	9	O
chronic	5	O
active	9	O
Crohn	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
patients	5	O
in	5	O
whom	5	O
conventional	5	O
treatment	9	O
is	5	O
ineffective	9	O
.	9	O

Because	9	O
there	5	O
seems	5	O
to	5	O
exist	9	O
a	5	O
scientific	5	O
rationale	5	O
for	5	O
the	5	O
use	5	O
of	5	O
fusidic	0	B-Chemical
acid	0	I-Chemical
at	9	O
the	5	O
cytokine	3	O
level	9	O
in	5	O
inflammatory	3	B-Disease
bowel	5	I-Disease
disease	5	I-Disease
,	9	O
we	5	O
suggest	9	O
that	5	O
the	5	O
role	9	O
of	5	O
this	5	O
treatment	9	O
should	5	O
be	5	O
further	9	O
investigated	9	O
.	9	O

Changes	9	O
in	5	O
depressive	5	B-Disease
status	9	O
associated	9	O
with	5	O
topical	0	O
beta	9	O
-	7	O
blockers	9	O
.	9	O

Depression	5	B-Disease
and	5	O
sexual	5	B-Disease
dysfunction	9	I-Disease
have	5	O
been	9	O
related	9	O
to	5	O
side	5	O
effects	9	O
of	5	O
topical	0	O
beta	9	O
-	7	O
blockers	9	O
.	9	O

We	9	O
performed	9	O
a	5	O
preliminary	9	O
study	9	O
in	5	O
order	5	O
to	5	O
determine	9	O
any	5	O
difference	9	O
between	5	O
a	5	O
non	9	O
selective	9	O
beta	9	O
-	7	O
blocker	0	O
(	9	O
timolol	0	B-Chemical
)	9	O
and	5	O
a	5	O
selective	9	O
beta	9	O
-	7	O
blocker	0	O
(	9	O
betaxolol	0	B-Chemical
)	9	O
regarding	5	O
CNS	9	O
side	5	O
effects	9	O
.	9	O

Eight	9	O
glaucomatous	5	B-Disease
patients	5	O
chronically	9	O
treated	3	O
with	5	O
timolol	0	B-Chemical
0	7	O
.	9	O
5	9	O
%	9	O
/	9	O
12h	0	O
,	9	O
suffering	5	O
from	9	O
depression	5	B-Disease
diagnosed	5	O
through	9	O
DMS	9	O
-	7	O
III	9	O
-	7	O
R	9	O
criteria	5	O
,	9	O
were	9	O
included	5	O
in	5	O
the	5	O
study	9	O
.	9	O

During	5	O
the	5	O
six	9	O
-	7	O
month	5	O
follow	5	O
up	5	O
,	9	O
depression	5	B-Disease
was	9	O
quantified	9	O
through	9	O
the	5	O
Beck	6	O
and	5	O
Zung	5	O
-	7	O
Conde	6	O
scales	5	O
every	5	O
two	5	O
months	5	O
.	9	O

In	9	O
a	5	O
double	9	O
blind	5	O
cross	5	O
-	7	O
over	5	O
study	9	O
with	5	O
control	9	O
group	9	O
,	9	O
the	5	O
patients	5	O
under	9	O
timolol	0	B-Chemical
treatment	9	O
presented	5	O
higher	9	O
depression	5	B-Disease
values	5	O
measured	9	O
through	9	O
the	5	O
Beck	6	O
and	5	O
the	5	O
Zung	5	O
-	7	O
Conde	6	O
scales	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
vs	7	O
control	9	O
)	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
betaxolol	0	B-Chemical
could	9	O
be	5	O
less	5	O
of	5	O
a	5	O
depression	5	B-Disease
-	7	O
inducer	3	O
than	5	O
timolol	0	B-Chemical
in	5	O
predisposed	5	O
patients	5	O
.	9	O

Protection	2	O
against	9	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
toward	5	O
striatal	3	O
dopamine	5	B-Chemical
neurons	3	O
in	5	O
rodents	9	O
by	9	O
LY274614	_	B-Chemical
,	9	O
an	5	O
excitatory	5	O
amino	1	B-Chemical
acid	0	I-Chemical
antagonist	3	O
.	9	O

LY274614	_	B-Chemical
,	9	O
3SR	2	B-Chemical
,	9	I-Chemical
4aRS	_	I-Chemical
,	9	I-Chemical
6SR	2	I-Chemical
,	9	I-Chemical
8aRS	_	I-Chemical
-	7	I-Chemical
6	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
phosphonomethyl	0	I-Chemical
]	9	I-Chemical
decahydr	_	I-Chemical
oisoquinoline	_	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
carboxylic	0	I-Chemical
acid	0	I-Chemical
,	9	O
has	9	O
been	9	O
described	9	O
as	5	O
a	5	O
potent	3	O
antagonist	3	O
of	5	O
the	5	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
subtype	9	O
of	5	O
glutamate	0	B-Chemical
receptor	3	O
.	9	O

Here	9	O
its	9	O
ability	9	O
to	5	O
antagonize	3	O
the	5	O
prolonged	9	O
depletion	3	O
of	5	O
dopamine	5	B-Chemical
in	5	O
the	5	O
striatum	9	O
by	9	O
amphetamine	5	B-Chemical
in	5	O
iprindole	9	B-Chemical
-	7	O
treated	3	O
rats	9	O
is	5	O
reported	9	O
.	9	O

A	9	O
single	9	O
18	7	O
.	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
dose	9	O
of	5	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
amphetamine	5	B-Chemical
hemisulfate	0	O
,	9	O
given	5	O
to	5	O
rats	9	O
pretreated	3	O
with	5	O
iprindole	9	B-Chemical
,	9	O
resulted	9	O
in	5	O
persistent	5	O
depletion	3	O
of	5	O
dopamine	5	B-Chemical
in	5	O
the	5	O
striatum	9	O
1	9	O
week	9	O
later	9	O
.	9	O

This	5	O
prolonged	9	O
depletion	3	O
of	5	O
dopamine	5	B-Chemical
in	5	O
the	5	O
striatum	9	O
was	9	O
antagonized	3	O
by	9	O
dizocilpine	0	B-Chemical
(	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
,	9	O
a	5	O
non	9	O
-	7	O
competitive	9	O
antagonist	3	O
of	5	O
NMDA	3	B-Chemical
receptors	3	O
)	9	O
or	5	O
by	9	O
LY274614	_	B-Chemical
(	9	O
a	5	O
competitive	9	O
antagonist	3	O
of	5	O
NMDA	3	B-Chemical
receptors	3	O
)	9	O
.	9	O

The	5	O
protective	9	O
effect	9	O
of	5	O
LY274614	_	B-Chemical
was	9	O
dose	9	O
-	7	O
dependent	9	O
,	9	O
being	5	O
maximum	5	O
at	9	O
10	9	O
-	7	O
40	9	O
mgkg	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

A	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
dose	9	O
of	5	O
LY274614	_	B-Chemical
was	9	O
effective	5	O
in	5	O
antagonizing	3	O
the	5	O
depletion	3	O
of	5	O
dopamine	5	B-Chemical
in	5	O
the	5	O
striatum	9	O
,	9	O
when	5	O
given	5	O
as	5	O
long	5	O
as	5	O
8	9	O
hr	0	O
prior	9	O
to	5	O
amphetamine	5	B-Chemical
but	9	O
not	5	O
when	5	O
given	5	O
24	9	O
hr	0	O
prior	9	O
to	5	O
amphetamine	5	B-Chemical
.	9	O

Depletion	3	O
of	5	O
dopamine	5	B-Chemical
in	5	O
the	5	O
striatum	9	O
was	9	O
also	9	O
antagonized	3	O
when	5	O
LY274614	_	B-Chemical
was	9	O
given	5	O
after	9	O
the	5	O
injection	9	O
of	5	O
amphetamine	5	B-Chemical
;	9	O
LY274614	_	B-Chemical
protected	9	O
when	5	O
given	5	O
up	5	O
to	5	O
4	9	O
hr	0	O
after	9	O
but	9	O
not	5	O
when	5	O
given	5	O
8	9	O
or	5	O
24	9	O
hr	0	O
after	9	O
amphetamine	5	B-Chemical
.	9	O

The	5	O
prolonged	9	O
depletion	3	O
of	5	O
dopamine	5	B-Chemical
in	5	O
the	5	O
striatum	9	O
in	5	O
mice	3	O
,	9	O
given	5	O
multiple	5	O
injections	9	O
of	5	O
methamphetamine	5	B-Chemical
,	9	O
was	9	O
also	9	O
antagonized	3	O
dose	9	O
-	7	O
dependently	3	O
and	5	O
completely	9	O
by	9	O
LY274614	_	B-Chemical
.	9	O

The	5	O
data	5	O
strengthen	5	O
the	5	O
evidence	9	O
that	5	O
the	5	O
neurotoxic	9	B-Disease
effect	9	O
of	5	O
amphetamine	5	B-Chemical
and	5	O
related	9	O
compounds	0	O
toward	5	O
nigrostriatal	3	O
dopamine	5	B-Chemical
neurons	3	O
involves	5	O
NMDA	3	B-Chemical
receptors	3	O
and	5	O
that	5	O
LY274614	_	B-Chemical
is	5	O
an	5	O
NMDA	3	B-Chemical
receptor	3	O
antagonist	3	O
with	5	O
long	5	O
-	7	O
lasting	5	O
in	5	O
vivo	3	O
effects	9	O
in	5	O
rats	9	O
.	9	O

Ketoconazole	0	B-Chemical
-	7	O
induced	3	O
neurologic	5	B-Disease
sequelae	5	I-Disease
.	9	O

A	9	O
77	7	O
-	7	O
y	9	O
-	7	O
old	5	O
patient	5	O
developed	5	O
weakness	5	B-Disease
of	5	I-Disease
extremities	5	I-Disease
,	9	O
legs	5	B-Disease
paralysis	5	I-Disease
,	9	O
dysarthria	5	B-Disease
and	5	O
tremor	5	B-Disease
1	9	O
h	0	O
after	9	O
ingestion	9	O
of	5	O
200	0	O
mg	0	O
ketoconazole	0	B-Chemical
for	5	O
the	5	O
first	9	O
time	5	O
in	5	O
his	5	O
life	5	O
.	9	O

All	9	O
complaints	5	O
faded	5	O
away	5	O
within	9	O
24	9	O
h	0	O
.	9	O

Few	9	O
days	9	O
later	9	O
,	9	O
the	5	O
patient	5	O
used	5	O
another	9	O
200	0	O
mg	0	O
ketoconazole	0	B-Chemical
tablet	0	O
,	9	O
and	5	O
within	9	O
an	5	O
hour	0	O
experienced	5	O
a	5	O
similar	9	O
clinical	5	O
picture	5	O
,	9	O
which	5	O
resolved	9	O
again	9	O
spontaneously	5	O
within	9	O
hours	9	O
.	9	O

Laboratory	2	O
evaluations	5	O
,	9	O
including	9	O
head	5	O
CT	9	O
scan	5	O
,	9	O
were	9	O
normal	9	O
.	9	O

This	5	O
case	5	O
illustrates	5	O
the	5	O
need	5	O
for	5	O
close	5	O
vigilance	5	O
in	5	O
adverse	5	B-Disease
drug	5	I-Disease
reactions	9	I-Disease
,	9	O
particularly	5	O
in	5	O
the	5	O
elderly	5	O
.	9	O

Development	2	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
in	5	O
parkinsonian	5	B-Disease
monkeys	5	O
may	5	O
depend	5	O
upon	9	O
rate	9	O
of	5	O
symptom	5	O
onset	5	O
and	5	O
/	9	O
or	5	O
duration	5	O
of	5	O
symptoms	5	O
.	9	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
(	9	O
LIDs	5	B-Disease
)	9	O
present	9	O
a	5	O
major	9	O
problem	5	O
for	5	O
the	5	O
long	5	O
-	7	O
term	5	O
management	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
patients	5	O
.	9	O

Due	5	O
to	5	O
the	5	O
interdependence	5	O
of	5	O
risk	5	O
factors	9	O
in	5	O
clinical	5	O
populations	9	O
,	9	O
it	5	O
is	5	O
difficult	5	O
to	5	O
independently	9	O
examine	9	O
factors	9	O
that	5	O
may	5	O
influence	5	O
the	5	O
development	9	O
of	5	O
LIDs	5	B-Disease
.	9	O

Using	9	O
macaque	9	O
monkeys	5	O
with	5	O
different	9	O
types	9	O
of	5	O
MPTP	3	B-Chemical
-	7	O
induced	3	O
parkinsonism	5	B-Disease
,	9	O
the	5	O
current	5	O
study	9	O
evaluated	9	O
the	5	O
degree	5	O
to	5	O
which	5	O
rate	9	O
of	5	O
symptom	5	O
progression	9	O
,	9	O
symptom	5	O
severity	5	O
,	9	O
and	5	O
response	9	O
to	5	O
and	5	O
duration	5	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
may	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
development	9	O
of	5	O
LIDs	5	B-Disease
.	9	O

Monkeys	5	O
with	5	O
acute	9	O
(	9	O
short	5	O
-	7	O
term	5	O
)	9	O
MPTP	3	B-Chemical
exposure	9	O
,	9	O
rapid	5	O
symptom	5	O
onset	5	O
and	5	O
short	5	O
symptom	5	O
duration	5	O
prior	9	O
to	5	O
initiation	9	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
developed	5	O
dyskinesia	5	B-Disease
between	5	O
11	7	O
and	5	O
24	9	O
days	9	O
of	5	O
daily	5	O
levodopa	5	B-Chemical
administration	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
monkeys	5	O
with	5	O
long	5	O
-	7	O
term	5	O
MPTP	3	B-Chemical
exposure	9	O
,	9	O
slow	5	O
symptom	5	O
progression	9	O
and	5	O
/	9	O
or	5	O
long	5	O
symptom	5	O
duration	5	O
prior	9	O
to	5	O
initiation	9	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
were	9	O
more	5	O
resistant	9	O
to	5	O
developing	5	O
LIDs	5	B-Disease
(	9	O
e	9	O
.	9	O
g	0	O
.	9	O
,	9	O
dyskinesia	5	B-Disease
developed	5	O
no	9	O
sooner	5	O
than	5	O
146	7	O
days	9	O
of	5	O
chronic	5	O
levodopa	5	B-Chemical
administration	9	O
)	9	O
.	9	O

All	9	O
animals	9	O
were	9	O
similarly	9	O
symptomatic	5	O
at	9	O
the	5	O
start	9	O
of	5	O
levodopa	5	B-Chemical
treatment	9	O
and	5	O
had	9	O
similar	9	O
therapeutic	5	O
responses	5	O
to	5	O
the	5	O
drug	5	O
.	9	O

These	5	O
data	5	O
suggest	9	O
distinct	9	O
differences	9	O
in	5	O
the	5	O
propensity	5	O
to	5	O
develop	5	O
LIDs	5	B-Disease
in	5	O
monkeys	5	O
with	5	O
different	9	O
rates	5	O
of	5	O
symptom	5	O
progression	9	O
or	5	O
symptom	5	O
durations	5	O
prior	9	O
to	5	O
levodopa	5	B-Chemical
and	5	O
demonstrate	9	O
the	5	O
value	9	O
of	5	O
these	5	O
models	5	O
for	5	O
further	9	O
studying	5	O
the	5	O
pathophysiology	9	O
of	5	O
LIDs	5	B-Disease
.	9	O

A	9	O
diet	9	O
promoting	9	O
sugar	0	B-Disease
dependency	5	I-Disease
causes	9	O
behavioral	5	B-Disease
cross	5	I-Disease
-	7	I-Disease
sensitization	9	I-Disease
to	5	O
a	5	O
low	9	O
dose	9	O
of	5	O
amphetamine	5	B-Chemical
.	9	O

Previous	9	O
research	5	O
in	5	O
this	5	O
laboratory	9	O
has	9	O
shown	9	O
that	5	O
a	5	O
diet	9	O
of	5	O
intermittent	5	O
excessive	5	O
sugar	0	O
consumption	5	O
produces	9	O
a	5	O
state	5	O
with	5	O
neurochemical	5	O
and	5	O
behavioral	5	O
similarities	9	O
to	5	O
drug	5	B-Disease
dependency	5	I-Disease
.	9	O

The	5	O
present	9	O
study	9	O
examined	9	O
whether	9	O
female	9	O
rats	9	O
on	5	O
various	9	O
regimens	5	O
of	5	O
sugar	0	O
access	5	O
would	5	O
show	9	O
behavioral	5	B-Disease
cross	5	I-Disease
-	7	I-Disease
sensitization	9	I-Disease
to	5	O
a	5	O
low	9	O
dose	9	O
of	5	O
amphetamine	5	B-Chemical
.	9	O

After	9	O
a	5	O
30	9	O
-	7	O
min	0	O
baseline	5	O
measure	5	O
of	5	O
locomotor	5	O
activity	9	O
(	9	O
day	9	O
0	7	O
)	9	O
,	9	O
animals	9	O
were	9	O
maintained	9	O
on	5	O
a	5	O
cyclic	0	O
diet	9	O
of	5	O
12	9	O
-	7	O
h	0	O
deprivation	9	O
followed	9	O
by	9	O
12	9	O
-	7	O
h	0	O
access	5	O
to	5	O
10	9	O
%	9	O
sucrose	0	B-Chemical
solution	0	O
and	5	O
chow	0	O
pellets	0	O
(	9	O
12	9	O
h	0	O
access	5	O
starting	9	O
4	9	O
h	0	O
after	9	O
onset	5	O
of	5	O
the	5	O
dark	9	O
period	5	O
)	9	O
for	5	O
21	7	O
days	9	O
.	9	O

Locomotor	5	O
activity	9	O
was	9	O
measured	9	O
again	9	O
for	5	O
30	9	O
min	0	O
at	9	O
the	5	O
beginning	5	O
of	5	O
days	9	O
1	9	O
and	5	O
21	7	O
of	5	O
sugar	0	O
access	5	O
.	9	O

Beginning	5	O
on	5	O
day	9	O
22	7	O
,	9	O
all	5	O
rats	9	O
were	9	O
maintained	9	O
on	5	O
ad	9	O
libitum	9	O
chow	0	O
.	9	O

Nine	9	O
days	9	O
later	9	O
locomotor	5	O
activity	9	O
was	9	O
measured	9	O
in	5	O
response	9	O
to	5	O
a	5	O
single	9	O
low	9	O
dose	9	O
of	5	O
amphetamine	5	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

The	5	O
animals	9	O
that	5	O
had	9	O
experienced	5	O
cyclic	0	O
sucrose	0	B-Chemical
and	5	O
chow	0	O
were	9	O
hyperactive	9	B-Disease
in	5	O
response	9	O
to	5	O
amphetamine	5	B-Chemical
compared	9	O
with	5	O
four	9	O
control	9	O
groups	9	O
(	9	O
ad	9	O
libitum	9	O
10	9	O
%	9	O
sucrose	0	B-Chemical
and	5	O
chow	0	O
followed	9	O
by	9	O
amphetamine	5	B-Chemical
injection	9	O
,	9	O
cyclic	0	O
chow	0	O
followed	9	O
by	9	O
amphetamine	5	B-Chemical
injection	9	O
,	9	O
ad	9	O
libitum	9	O
chow	0	O
with	5	O
amphetamine	5	B-Chemical
,	9	O
or	5	O
cyclic	0	O
10	9	O
%	9	O
sucrose	0	B-Chemical
and	5	O
chow	0	O
with	5	O
a	5	O
saline	0	O
injection	9	O
)	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
a	5	O
diet	9	O
comprised	9	O
of	5	O
alternating	5	O
deprivation	9	O
and	5	O
access	5	O
to	5	O
a	5	O
sugar	0	O
solution	0	O
and	5	O
chow	0	O
produces	9	O
bingeing	5	O
on	5	O
sugar	0	O
that	5	O
leads	9	O
to	5	O
a	5	O
long	5	O
lasting	5	O
state	5	O
of	5	O
increased	9	O
sensitivity	9	O
to	5	O
amphetamine	5	B-Chemical
,	9	O
possibly	9	O
due	5	O
to	5	O
a	5	O
lasting	5	O
alteration	9	O
in	5	O
the	5	O
dopamine	5	B-Chemical
system	5	O
.	9	O

Reversible	0	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
related	9	O
to	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
therapy	5	O
.	9	O

We	9	O
describe	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
and	5	O
clinical	5	O
congestive	5	O
heart	5	B-Disease
failure	5	I-Disease
after	9	O
2	9	O
months	5	O
of	5	O
therapy	5	O
with	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
(	9	O
AmB	0	B-Chemical
)	9	O
for	5	O
disseminated	5	O
coccidioidomycosis	5	B-Disease
.	9	O

His	9	O
echocardiographic	5	O
abnormalities	9	O
and	5	O
heart	5	B-Disease
failure	5	I-Disease
resolved	9	O
after	9	O
posaconazole	0	B-Chemical
was	9	O
substituted	0	O
for	5	O
AmB	0	B-Chemical
.	9	O

It	5	O
is	5	O
important	9	O
to	5	O
recognize	9	O
the	5	O
rare	5	O
and	5	O
potentially	5	O
reversible	9	O
toxicity	9	B-Disease
of	5	O
AmB	0	B-Chemical
.	9	O

NO	9	B-Chemical
-	7	O
induced	3	O
migraine	5	B-Disease
attack	5	O
:	9	O
strong	9	O
increase	9	O
in	5	O
plasma	9	O
calcitonin	3	B-Chemical
gene	1	I-Chemical
-	7	I-Chemical
related	9	I-Chemical
peptide	9	I-Chemical
(	9	O
CGRP	3	B-Chemical
)	9	O
concentration	0	O
and	5	O
negative	9	O
correlation	9	O
with	5	O
platelet	9	O
serotonin	9	B-Chemical
release	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
investigate	9	O
changes	9	O
in	5	O
the	5	O
plasma	9	O
calcitonin	3	B-Chemical
gene	1	I-Chemical
-	7	I-Chemical
related	9	I-Chemical
peptide	9	I-Chemical
(	9	O
CGRP	3	B-Chemical
)	9	O
concentration	0	O
and	5	O
platelet	9	O
serotonin	9	B-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytriptamine	_	I-Chemical
,	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
)	9	O
content	9	O
during	5	O
the	5	O
immediate	5	O
headache	5	B-Disease
and	5	O
the	5	O
delayed	9	O
genuine	5	O
migraine	5	B-Disease
attack	5	O
provoked	9	O
by	9	O
nitroglycerin	5	B-Chemical
.	9	O

Fifteen	9	O
female	9	O
migraineurs	5	B-Disease
(	9	I-Disease
without	9	I-Disease
aura	5	I-Disease
)	9	I-Disease
and	5	O
eight	9	O
controls	9	O
participated	5	O
in	5	O
the	5	O
study	9	O
.	9	O

Sublingual	5	O
nitroglycerin	5	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
)	9	O
was	9	O
administered	9	O
.	9	O

Blood	9	O
was	9	O
collected	9	O
from	9	O
the	5	O
antecubital	5	O
vein	5	O
four	9	O
times	5	O
:	9	O
60	9	O
min	0	O
before	9	O
and	5	O
after	9	O
the	5	O
nitroglycerin	5	B-Chemical
application	5	O
,	9	O
and	5	O
60	9	O
and	5	O
120	9	O
min	0	O
after	9	O
the	5	O
beginning	5	O
of	5	O
the	5	O
migraine	5	B-Disease
attack	5	O
(	9	O
mean	5	O
344	7	O
and	5	O
404	7	O
min	0	O
;	9	O
12	9	O
subjects	5	O
)	9	O
.	9	O

In	9	O
those	5	O
subjects	5	O
who	5	O
had	9	O
no	9	O
migraine	5	B-Disease
attack	5	O
(	9	O
11	7	O
subjects	5	O
)	9	O
a	5	O
similar	9	O
time	5	O
schedule	5	O
was	9	O
used	5	O
.	9	O

Plasma	0	O
CGRP	3	B-Chemical
concentration	0	O
increased	9	O
significantly	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
during	5	O
the	5	O
migraine	5	B-Disease
attack	5	O
and	5	O
returned	5	O
to	5	O
baseline	5	O
after	9	O
the	5	O
cessation	5	O
of	5	O
the	5	O
migraine	5	B-Disease
.	9	O

In	9	O
addition	9	O
,	9	O
both	9	O
change	9	O
and	5	O
peak	9	O
,	9	O
showed	9	O
significant	9	O
positive	9	O
correlations	5	O
with	5	O
migraine	5	B-Disease
headache	5	B-Disease
intensity	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

However	9	O
,	9	O
plasma	9	O
CGRP	3	B-Chemical
concentrations	0	O
failed	9	O
to	5	O
change	9	O
during	5	O
immediate	5	O
headache	5	B-Disease
and	5	O
in	5	O
the	5	O
subjects	5	O
with	5	O
no	9	O
migraine	5	B-Disease
attack	5	O
.	9	O

Basal	9	O
CGRP	3	B-Chemical
concentration	0	O
was	9	O
significantly	9	O
higher	9	O
and	5	O
platelet	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
content	9	O
tended	5	O
to	5	O
be	5	O
lower	9	O
in	5	O
subjects	5	O
who	5	O
experienced	5	O
a	5	O
migraine	5	B-Disease
attack	5	O
.	9	O

Platelet	9	O
serotonin	9	B-Chemical
content	9	O
decreased	9	O
significantly	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
after	9	O
nitroglycerin	5	B-Chemical
in	5	O
subjects	5	O
with	5	O
no	9	O
migraine	5	B-Disease
attack	5	O
but	9	O
no	9	O
consistent	9	O
change	9	O
was	9	O
observed	9	O
in	5	O
patients	5	O
with	5	O
migraine	5	B-Disease
attack	5	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
the	5	O
fact	9	O
that	5	O
plasma	9	O
CGRP	3	B-Chemical
concentration	0	O
correlates	9	O
with	5	O
the	5	O
timing	5	O
and	5	O
severity	5	O
of	5	O
a	5	O
migraine	5	B-Disease
headache	5	B-Disease
suggests	9	O
a	5	O
direct	9	O
relationship	5	O
between	5	O
CGRP	3	B-Chemical
and	5	O
migraine	5	B-Disease
.	9	O

In	9	O
contrast	9	O
,	9	O
serotonin	9	B-Chemical
release	9	O
from	9	O
platelets	3	O
does	9	O
not	5	O
provoke	9	O
migraine	5	B-Disease
,	9	O
it	5	O
may	5	O
even	5	O
counteract	9	O
the	5	O
headache	5	B-Disease
and	5	O
the	5	O
concomitant	9	O
CGRP	3	B-Chemical
release	9	O
in	5	O
this	5	O
model	5	O
.	9	O

Hyperbaric	2	O
oxygen	0	B-Chemical
therapy	5	O
for	5	O
control	9	O
of	5	O
intractable	5	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
intractable	5	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
due	5	O
to	5	O
cyclophosphamide	0	B-Chemical
therapy	5	O
for	5	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
.	9	O

Conservative	5	O
treatment	9	O
,	9	O
including	9	O
bladder	9	O
irrigation	5	O
with	5	O
physiological	9	O
saline	0	O
and	5	O
instillation	0	O
of	5	O
prostaglandin	0	B-Chemical
F2	9	I-Chemical
alpha	9	I-Chemical
,	9	O
failed	9	O
to	5	O
totally	9	O
control	9	O
hemorrhage	5	B-Disease
.	9	O

We	9	O
then	9	O
used	5	O
hyperbaric	5	O
oxygen	0	B-Chemical
at	9	O
an	5	O
absolute	5	O
pressure	5	O
of	5	O
2	9	O
atm	0	O
,	9	O
5	9	O
days	9	O
a	5	O
week	9	O
for	5	O
8	9	O
consecutive	5	O
weeks	9	O
.	9	O

The	5	O
bleeding	5	B-Disease
ceased	5	O
completely	9	O
by	9	O
the	5	O
end	9	O
of	5	O
treatment	9	O
and	5	O
the	5	O
patient	5	O
remained	9	O
free	9	O
of	5	O
hematuria	5	B-Disease
thereafter	9	O
.	9	O

No	9	O
side	5	O
effect	9	O
was	9	O
noted	9	O
during	5	O
the	5	O
course	5	O
of	5	O
therapy	5	O
.	9	O

In	9	O
future	5	O
,	9	O
this	5	O
form	9	O
of	5	O
therapy	5	O
can	5	O
offer	5	O
a	5	O
safe	5	O
alternative	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

Acute	5	B-Disease
psychosis	5	I-Disease
due	5	O
to	5	O
treatment	9	O
with	5	O
phenytoin	0	B-Chemical
in	5	O
a	5	O
nonepileptic	5	O
patient	5	O
.	9	O

The	5	O
development	9	O
of	5	O
psychosis	5	B-Disease
related	9	O
to	5	O
antiepileptic	5	O
drug	5	O
treatment	9	O
is	5	O
usually	5	O
attributed	9	O
to	5	O
the	5	O
interaction	9	O
between	5	O
the	5	O
epileptic	5	B-Disease
brain	5	O
substratum	9	O
and	5	O
the	5	O
antiepileptic	5	O
drugs	5	O
.	9	O

The	5	O
case	5	O
of	5	O
a	5	O
nonepileptic	5	O
patient	5	O
who	5	O
developed	5	O
psychosis	5	B-Disease
following	9	O
phenytoin	0	B-Chemical
treatment	9	O
for	5	O
trigeminal	5	B-Disease
neuralgia	5	I-Disease
is	5	O
described	9	O
.	9	O

This	5	O
case	5	O
suggests	9	O
that	5	O
the	5	O
psychotic	5	B-Disease
symptoms	5	I-Disease
that	5	O
occur	5	O
following	9	O
phenytoin	0	B-Chemical
treatment	9	O
in	5	O
some	5	O
epileptic	5	B-Disease
patients	5	O
may	5	O
be	5	O
the	5	O
direct	9	O
result	9	O
of	5	O
medication	5	O
,	9	O
unrelated	9	O
to	5	O
seizures	5	B-Disease
.	9	O

Risks	5	O
of	5	O
the	5	O
consumption	5	O
of	5	O
beverages	5	O
containing	0	O
quinine	0	B-Chemical
.	9	O

Although	9	O
the	5	O
United	9	O
States	9	O
Food	5	O
and	5	O
Drug	5	O
Administration	2	O
banned	5	O
its	9	O
use	5	O
for	5	O
nocturnal	5	B-Disease
leg	5	I-Disease
cramps	5	I-Disease
due	5	O
to	5	O
lack	9	O
of	5	O
safety	5	O
and	5	O
efficacy	9	O
,	9	O
quinine	0	B-Chemical
is	5	O
widely	5	O
available	5	O
in	5	O
beverages	5	O
including	9	O
tonic	5	O
water	0	O
and	5	O
bitter	5	O
lemon	4	O
.	9	O

Numerous	9	O
anecdotal	5	O
reports	9	O
suggest	9	O
that	5	O
products	9	O
containing	0	O
quinine	0	B-Chemical
may	5	O
produce	9	O
neurological	5	B-Disease
complications	5	I-Disease
,	9	O
including	9	O
confusion	5	B-Disease
,	9	O
altered	9	O
mental	5	O
status	9	O
,	9	O
seizures	5	B-Disease
,	9	O
and	5	O
coma	5	B-Disease
,	9	O
particularly	5	O
in	5	O
older	5	O
women	5	O
.	9	O

Psychologists	5	O
need	5	O
to	5	O
inquire	5	O
about	5	O
consumption	5	O
of	5	O
quinine	0	B-Chemical
-	7	O
containing	0	O
beverages	5	O
as	5	O
part	9	O
of	5	O
an	5	O
evaluation	5	O
process	5	O
.	9	O

Transient	9	O
platypnea	5	B-Disease
-	7	I-Disease
orthodeoxia	5	I-Disease
-	7	I-Disease
like	9	I-Disease
syndrome	5	I-Disease
induced	3	O
by	9	O
propafenone	0	B-Chemical
overdose	0	B-Disease
in	5	O
a	5	O
young	5	O
woman	5	O
with	5	O
Ebstein	5	B-Disease
'	9	I-Disease
s	9	I-Disease
anomaly	5	I-Disease
.	9	O

In	9	O
this	5	O
report	5	O
we	5	O
describe	5	O
the	5	O
case	5	O
of	5	O
a	5	O
37	9	O
-	7	O
year	5	O
-	7	O
old	5	O
white	9	O
woman	5	O
with	5	O
Ebstein	5	B-Disease
'	9	I-Disease
s	9	I-Disease
anomaly	5	I-Disease
,	9	O
who	5	O
developed	5	O
a	5	O
rare	5	O
syndrome	5	O
called	5	O
platypnea	5	B-Disease
-	7	I-Disease
orthodeoxia	5	I-Disease
,	9	O
characterized	9	O
by	9	O
massive	9	O
right	5	O
-	7	O
to	5	O
-	7	O
left	5	O
interatrial	5	O
shunting	5	O
with	5	O
transient	9	O
profound	9	O
hypoxia	3	B-Disease
and	5	O
cyanosis	5	B-Disease
.	9	O

This	5	O
shunt	5	O
of	5	O
blood	9	O
via	9	O
a	5	O
patent	5	B-Disease
foramen	5	I-Disease
ovale	4	I-Disease
occurred	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
a	5	O
normal	9	O
pulmonary	5	O
artery	5	O
pressure	5	O
,	9	O
and	5	O
was	9	O
probably	9	O
precipitated	0	O
by	9	O
a	5	O
propafenone	0	B-Chemical
overdose	0	B-Disease
.	9	O

This	5	O
drug	5	O
caused	9	O
biventricular	5	B-Disease
dysfunction	9	I-Disease
,	9	O
due	5	O
to	5	O
its	9	O
negative	9	O
inotropic	5	O
effect	9	O
,	9	O
and	5	O
hypotension	5	B-Disease
,	9	O
due	5	O
to	5	O
its	9	O
peripheral	9	O
vasodilatory	5	O
effect	9	O
.	9	O

These	5	O
effects	9	O
gave	9	O
rise	9	O
to	5	O
an	5	O
increase	9	O
in	5	O
the	5	O
right	5	O
atrial	5	O
pressure	5	O
and	5	O
a	5	O
decrease	9	O
in	5	O
the	5	O
left	5	O
one	5	O
with	5	O
a	5	O
consequent	9	O
stretching	5	O
of	5	O
the	5	O
foramen	5	O
ovale	4	O
and	5	O
the	5	O
creation	5	O
of	5	O
massive	9	O
right	5	O
-	7	O
to	5	O
-	7	O
left	5	O
shunting	5	O
.	9	O

In	9	O
our	5	O
case	5	O
this	5	O
interatrial	5	O
shunt	5	O
was	9	O
very	5	O
accurately	5	O
detected	9	O
at	9	O
bubble	5	O
contrast	9	O
echocardiography	5	O
.	9	O

Noxious	5	O
chemical	0	O
stimulation	3	O
of	5	O
rat	3	O
facial	5	O
mucosa	9	O
increases	9	O
intracranial	5	O
blood	9	O
flow	5	O
through	9	O
a	5	O
trigemino	9	O
-	7	O
parasympathetic	5	O
reflex	5	O
-	7	O
-	7	O
an	5	O
experimental	5	O
model	5	O
for	5	O
vascular	5	B-Disease
dysfunctions	5	I-Disease
in	5	O
cluster	9	B-Disease
headache	5	I-Disease
.	9	O

Cluster	9	B-Disease
headache	5	I-Disease
is	5	O
characterized	9	O
by	9	O
typical	9	O
autonomic	5	O
dysfunctions	5	O
including	9	O
facial	5	O
and	5	O
intracranial	5	B-Disease
vascular	5	I-Disease
disturbances	5	I-Disease
.	9	O

Both	9	O
the	5	O
trigeminal	5	O
and	5	O
the	5	O
cranial	5	O
parasympathetic	5	O
systems	5	O
may	5	O
be	5	O
involved	9	O
in	5	O
mediating	9	O
these	5	O
dysfunctions	5	O
.	9	O

An	5	O
experimental	5	O
model	5	O
was	9	O
developed	5	O
in	5	O
the	5	O
rat	3	O
to	5	O
measure	5	O
changes	9	O
in	5	O
lacrimation	5	O
and	5	O
intracranial	5	O
blood	9	O
flow	5	O
following	9	O
noxious	5	O
chemical	0	O
stimulation	3	O
of	5	O
facial	5	O
mucosa	9	O
.	9	O

Blood	9	O
flow	5	O
was	9	O
monitored	9	O
in	5	O
arteries	5	O
of	5	O
the	5	O
exposed	9	O
cranial	5	O
dura	5	O
mater	5	O
and	5	O
the	5	O
parietal	5	O
cortex	5	O
using	9	O
laser	5	O
Doppler	5	O
flowmetry	5	O
.	9	O

Capsaicin	0	B-Chemical
(	9	O
0	7	O
.	9	O
01	7	O
-	7	O
1	9	O
mm	9	O
)	9	O
applied	5	O
to	5	O
oral	9	O
or	5	O
nasal	5	O
mucosa	9	O
induced	3	O
increases	9	B-Disease
in	5	I-Disease
dural	5	I-Disease
and	5	I-Disease
cortical	5	I-Disease
blood	9	I-Disease
flow	5	I-Disease
and	5	O
provoked	9	O
lacrimation	5	O
.	9	O

These	5	O
responses	5	O
were	9	O
blocked	3	O
by	9	O
systemic	9	O
pre	9	O
-	7	O
administration	9	O
of	5	O
hexamethonium	0	B-Chemical
chloride	0	I-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

The	5	O
evoked	5	O
increases	9	B-Disease
in	5	I-Disease
dural	5	I-Disease
blood	9	I-Disease
flow	5	I-Disease
were	9	O
also	9	O
abolished	3	O
by	9	O
topical	0	O
pre	9	O
-	7	O
administration	9	O
of	5	O
atropine	0	B-Chemical
(	9	O
1	9	O
mm	9	O
)	9	O
and	5	O
[	9	O
Lys1	1	O
,	9	O
Pro2	1	O
,	9	O
5	9	O
,	9	O
Arg3	1	O
,	9	O
4	9	O
,	9	O
Tyr6	1	O
]	9	O
-	7	O
VIP	9	O
(	9	O
0	7	O
.	9	O
1	9	O
mm	9	O
)	9	O
,	9	O
a	5	O
vasoactive	5	O
intestinal	9	O
polypeptide	1	O
(	9	O
VIP	9	O
)	9	O
antagonist	3	O
,	9	O
onto	0	O
the	5	O
exposed	9	O
dura	5	O
mater	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
noxious	5	O
stimulation	3	O
of	5	O
facial	5	O
mucosa	9	O
increases	9	O
intracranial	5	O
blood	9	O
flow	5	O
and	5	O
lacrimation	5	O
via	9	O
a	5	O
trigemino	9	O
-	7	O
parasympathetic	5	O
reflex	5	O
.	9	O

The	5	O
blood	9	O
flow	5	O
responses	5	O
seem	5	O
to	5	O
be	5	O
mediated	3	O
by	9	O
the	5	O
release	9	O
of	5	O
acetylcholine	0	B-Chemical
and	5	O
VIP	9	O
within	9	O
the	5	O
meninges	5	O
.	9	O

Similar	9	O
mechanisms	9	O
may	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
cluster	9	B-Disease
headache	5	I-Disease
.	9	O

Organophosphate	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
and	5	O
prevention	5	O
of	5	O
neuropathological	5	B-Disease
damages	9	I-Disease
.	9	O

Such	5	O
organophosphorus	0	B-Chemical
(	9	O
OP	9	B-Chemical
)	9	O
compounds	0	O
as	5	O
diisopropylfluorophosphate	0	B-Chemical
(	9	O
DFP	0	B-Chemical
)	9	O
,	9	O
sarin	0	B-Chemical
and	5	O
soman	0	B-Chemical
are	5	O
potent	3	O
inhibitors	3	O
of	5	O
acetylcholinesterases	0	O
(	9	O
AChEs	4	O
)	9	O
and	5	O
butyrylcholinesterases	9	O
(	9	O
BChEs	9	O
)	9	O
.	9	O

The	5	O
acute	9	O
toxicity	9	B-Disease
of	5	O
OPs	5	B-Chemical
is	5	O
the	5	O
result	9	O
of	5	O
their	5	O
irreversible	9	O
binding	1	O
with	5	O
AChEs	4	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
(	9	O
CNS	9	O
)	9	O
,	9	O
which	5	O
elevates	9	O
acetylcholine	0	B-Chemical
(	9	O
ACh	0	B-Chemical
)	9	O
levels	3	O
.	9	O

The	5	O
protective	9	O
action	5	O
of	5	O
subcutaneously	3	O
(	9	O
SC	9	O
)	9	O
administered	9	O
antidotes	5	O
or	5	O
their	5	O
combinations	9	O
in	5	O
DFP	0	B-Chemical
(	9	O
2	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
BW	9	O
)	9	O
intoxication	9	O
was	9	O
studied	9	O
in	5	O
9	7	O
-	7	O
10	9	O
-	7	O
weeks	9	O
-	7	O
old	5	O
Han	6	O
-	7	O
Wistar	9	O
male	9	O
rats	9	O
.	9	O

The	5	O
rats	9	O
received	9	O
AChE	0	O
reactivator	0	O
pralidoxime	0	B-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
chloride	0	I-Chemical
(	9	O
2PAM	0	B-Chemical
)	9	O
(	9	O
30	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
BW	9	O
)	9	O
,	9	O
anticonvulsant	5	O
diazepam	0	B-Chemical
(	9	O
2	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
BW	9	O
)	9	O
,	9	O
A	9	O
(	9	O
1	9	O
)	9	O
-	7	O
adenosine	0	B-Chemical
receptor	3	O
agonist	3	O
N	9	B-Chemical
(	9	I-Chemical
6	9	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
cyclopentyl	0	I-Chemical
adenosine	0	I-Chemical
(	9	O
CPA	9	B-Chemical
)	9	O
(	9	O
2	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
BW	9	O
)	9	O
,	9	O
NMDA	3	B-Chemical
-	7	O
receptor	3	O
antagonist	3	O
dizocilpine	0	B-Chemical
maleate	0	I-Chemical
(	9	O
+	9	O
-	7	O
MK801	3	O
hydrogen	0	O
maleate	0	O
)	9	O
(	9	O
2	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
BW	9	O
)	9	O
or	5	O
their	5	O
combinations	9	O
with	5	O
cholinolytic	0	O
drug	5	O
atropine	0	B-Chemical
sulfate	0	I-Chemical
(	9	O
50	0	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
BW	9	O
)	9	O
immediately	9	O
or	5	O
30	9	O
min	0	O
after	9	O
the	5	O
single	9	O
SC	9	O
injection	9	O
of	5	O
DFP	0	B-Chemical
.	9	O

The	5	O
control	9	O
rats	9	O
received	9	O
atropine	0	B-Chemical
sulfate	0	I-Chemical
,	9	O
but	9	O
also	9	O
saline	0	O
and	5	O
olive	4	O
oil	0	O
instead	5	O
of	5	O
other	5	O
antidotes	5	O
and	5	O
DFP	0	B-Chemical
,	9	O
respectively	9	O
.	9	O

All	9	O
rats	9	O
were	9	O
terminated	9	O
either	9	O
24	9	O
h	0	O
or	5	O
3	9	O
weeks	9	O
after	9	O
the	5	O
DFP	0	B-Chemical
injection	9	O
.	9	O

The	5	O
rats	9	O
treated	3	O
with	5	O
DFP	0	B-Chemical
-	7	O
atropine	0	B-Chemical
showed	9	O
severe	5	O
typical	9	O
OP	9	B-Chemical
-	7	O
induced	3	O
toxicity	9	B-Disease
signs	5	O
.	9	O

When	9	O
CPA	9	B-Chemical
,	9	O
diazepam	0	B-Chemical
or	5	O
2PAM	0	B-Chemical
was	9	O
given	5	O
immediately	9	O
after	9	O
DFP	0	B-Chemical
-	7	O
atropine	0	B-Chemical
,	9	O
these	5	O
treatments	9	O
prevented	9	O
,	9	O
delayed	9	O
or	5	O
shortened	9	O
the	5	O
occurrence	5	O
of	5	O
serious	5	O
signs	5	O
of	5	O
poisoning	5	B-Disease
.	9	O

Atropine	0	B-Chemical
-	7	O
MK801	3	B-Chemical
did	9	O
not	5	O
offer	5	O
any	5	O
additional	9	O
protection	9	O
against	9	O
DFP	0	B-Chemical
toxicity	9	B-Disease
.	9	O

In	9	O
conclusion	9	O
,	9	O
CPA	9	B-Chemical
,	9	O
diazepam	0	B-Chemical
and	5	O
2PAM	0	B-Chemical
in	5	O
combination	9	O
with	5	O
atropine	0	B-Chemical
prevented	9	O
the	5	O
occurrence	5	O
of	5	O
serious	5	O
signs	5	O
of	5	O
poisoning	5	B-Disease
and	5	O
thus	9	O
reduced	9	O
the	5	O
toxicity	9	B-Disease
of	5	O
DFP	0	B-Chemical
in	5	O
rat	3	O
.	9	O

A	9	O
pyridoxine	0	B-Chemical
-	7	O
dependent	9	O
behavioral	5	B-Disease
disorder	5	I-Disease
unmasked	5	O
by	9	O
isoniazid	0	B-Chemical
.	9	O

A	9	O
3	9	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
had	9	O
behavioral	5	B-Disease
deterioration	5	I-Disease
,	9	O
with	5	O
hyperkinesis	5	B-Disease
,	9	O
irritability	5	B-Disease
,	9	O
and	5	O
sleeping	5	B-Disease
difficulties	5	I-Disease
after	9	O
the	5	O
therapeutic	5	O
administration	9	O
of	5	O
isoniazid	0	B-Chemical
.	9	O

The	5	O
administration	9	O
of	5	O
pharmacologic	9	O
doses	0	O
of	5	O
pyridoxine	0	B-Chemical
hydrochloride	0	I-Chemical
led	9	O
to	5	O
a	5	O
disappearance	9	O
of	5	O
symptoms	5	O
.	9	O

After	9	O
discontinuing	5	O
isoniazid	0	B-Chemical
therapy	5	O
a	5	O
similar	9	O
pattern	9	O
of	5	O
behavior	5	O
was	9	O
noted	9	O
that	5	O
was	9	O
controlled	5	O
by	9	O
pyridoxine	0	B-Chemical
.	9	O

A	9	O
placebo	9	O
had	9	O
no	9	O
effect	9	O
,	9	O
but	9	O
niacinamide	0	B-Chemical
was	9	O
as	5	O
effective	5	O
as	5	O
pyridoxine	0	B-Chemical
.	9	O

Periodic	5	O
withdrawal	5	O
of	5	O
pyridoxine	0	B-Chemical
was	9	O
associated	9	O
with	5	O
return	5	O
of	5	O
the	5	O
hyperkinesis	5	B-Disease
.	9	O

The	5	O
level	9	O
of	5	O
pyridoxal	0	B-Chemical
in	5	O
the	5	O
blood	9	O
was	9	O
normal	9	O
during	5	O
the	5	O
periods	5	O
of	5	O
relapse	5	O
.	9	O

Metabolic	9	O
studies	9	O
suggested	9	O
a	5	O
block	9	O
in	5	O
the	5	O
kynurenine	0	B-Chemical
pathway	3	O
of	5	O
tryptophan	0	B-Chemical
metabolism	9	O
.	9	O

The	5	O
patient	5	O
has	9	O
been	9	O
followed	9	O
for	5	O
six	9	O
years	5	O
and	5	O
has	9	O
required	9	O
pharmacologic	9	O
doses	0	O
of	5	O
pyridoxine	0	B-Chemical
to	5	O
control	9	O
her	5	O
behavior	5	O
.	9	O

Recurrent	5	O
excitation	0	O
in	5	O
the	5	O
dentate	3	O
gyrus	5	O
of	5	O
a	5	O
murine	3	O
model	5	O
of	5	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
.	9	O

Similar	9	O
to	5	O
rats	9	O
,	9	O
systemic	9	O
pilocarpine	0	B-Chemical
injection	9	O
causes	9	O
status	9	B-Disease
epilepticus	5	I-Disease
(	9	O
SE	9	B-Disease
)	9	O
and	5	O
the	5	O
eventual	5	O
development	9	O
of	5	O
spontaneous	5	O
seizures	5	B-Disease
and	5	O
mossy	5	O
fiber	5	O
sprouting	3	O
in	5	O
C57BL	3	O
/	9	O
6	9	O
and	5	O
CD1	3	O
mice	3	O
,	9	O
but	9	O
the	5	O
physiological	9	O
correlates	9	O
of	5	O
these	5	O
events	5	O
have	5	O
not	5	O
been	9	O
identified	9	O
in	5	O
mice	3	O
.	9	O

Population	5	O
responses	5	O
in	5	O
granule	3	O
cells	3	O
of	5	O
the	5	O
dentate	3	O
gyrus	5	O
were	9	O
examined	9	O
in	5	O
transverse	5	O
slices	9	O
of	5	O
the	5	O
ventral	5	O
hippocampus	9	O
from	9	O
pilocarpine	0	B-Chemical
-	7	O
treated	3	O
and	5	O
untreated	3	O
mice	3	O
.	9	O

In	9	O
Mg	0	B-Chemical
(	9	O
2	9	O
+	9	O
)	9	O
-	7	O
free	9	O
bathing	5	O
medium	0	O
containing	0	O
bicuculline	0	B-Chemical
,	9	O
conditions	9	O
designed	9	O
to	5	O
increase	9	O
excitability	5	O
in	5	O
the	5	O
slices	9	O
,	9	O
electrical	5	O
stimulation	3	O
of	5	O
the	5	O
hilus	3	O
resulted	9	O
in	5	O
a	5	O
single	9	O
population	5	O
spike	5	O
in	5	O
granule	3	O
cells	3	O
from	9	O
control	9	O
mice	3	O
and	5	O
pilocarpine	0	B-Chemical
-	7	O
treated	3	O
mice	3	O
that	5	O
did	9	O
not	5	O
experience	5	O
SE	9	B-Disease
.	9	O

In	9	O
SE	9	B-Disease
survivors	5	O
,	9	O
similar	9	O
stimulation	3	O
resulted	9	O
in	5	O
a	5	O
population	5	O
spike	5	O
followed	9	O
,	9	O
at	9	O
a	5	O
variable	5	O
latency	5	O
,	9	O
by	9	O
negative	9	O
DC	3	O
shifts	5	O
and	5	O
repetitive	5	O
afterdischarges	5	O
of	5	O
3	9	O
-	7	O
60	9	O
s	9	O
duration	5	O
,	9	O
which	5	O
were	9	O
blocked	3	O
by	9	O
ionotropic	3	O
glutamate	0	B-Chemical
receptor	3	O
antagonists	3	O
.	9	O

Focal	9	O
glutamate	0	B-Chemical
photostimulation	5	O
of	5	O
the	5	O
granule	3	O
cell	3	O
layer	9	O
at	9	O
sites	9	O
distant	5	O
from	9	O
the	5	O
recording	5	O
pipette	0	O
resulted	9	O
in	5	O
population	5	O
responses	5	O
of	5	O
1	9	O
-	7	O
30	9	O
s	9	O
duration	5	O
in	5	O
slices	9	O
from	9	O
SE	9	B-Disease
survivors	5	O
but	9	O
not	5	O
other	5	O
groups	9	O
.	9	O

These	5	O
data	5	O
support	5	O
the	5	O
hypothesis	9	O
that	5	O
SE	9	B-Disease
-	7	O
induced	3	O
mossy	5	O
fiber	5	O
sprouting	3	O
and	5	O
synaptic	5	O
reorganization	9	O
are	5	O
relevant	5	O
characteristics	5	O
of	5	O
seizure	5	B-Disease
development	9	O
in	5	O
these	5	O
murine	3	O
strains	1	O
,	9	O
resembling	9	O
rat	3	O
models	5	O
of	5	O
human	3	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
.	9	O

Urinary	9	B-Disease
bladder	9	I-Disease
cancer	3	I-Disease
in	5	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
:	9	O
risks	5	O
and	5	O
relation	5	O
to	5	O
cyclophosphamide	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
assess	5	O
and	5	O
characterise	9	O
the	5	O
risk	5	O
of	5	O
bladder	9	B-Disease
cancer	3	I-Disease
,	9	O
and	5	O
its	9	O
relation	5	O
to	5	O
cyclophosphamide	0	B-Chemical
,	9	O
in	5	O
patients	5	O
with	5	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
In	9	O
the	5	O
population	5	O
based	5	O
,	9	O
nationwide	5	O
Swedish	5	O
Inpatient	5	O
Register	5	O
a	5	O
cohort	9	O
of	5	O
1065	7	O
patients	5	O
with	5	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
,	9	O
1969	2	O
-	7	O
95	7	O
,	9	O
was	9	O
identified	9	O
.	9	O

Through	5	O
linkage	9	O
with	5	O
the	5	O
Swedish	5	O
Cancer	2	B-Disease
Register	5	O
,	9	O
all	5	O
subjects	5	O
in	5	O
this	5	O
cohort	9	O
diagnosed	5	O
with	5	O
bladder	9	B-Disease
cancer	3	I-Disease
were	9	O
identified	9	O
.	9	O

Nested	9	O
within	9	O
the	5	O
cohort	9	O
,	9	O
a	5	O
matched	9	O
case	5	O
-	7	O
control	9	O
study	9	O
was	9	O
performed	9	O
to	5	O
estimate	5	O
the	5	O
association	9	O
between	5	O
cyclophosphamide	0	B-Chemical
and	5	O
bladder	9	B-Disease
cancer	3	I-Disease
using	9	O
odds	5	O
ratios	9	O
(	9	O
ORs	9	O
)	9	O
as	5	O
relative	9	O
risk	5	O
.	9	O

In	9	O
the	5	O
cohort	9	O
the	5	O
cumulative	5	O
risk	5	O
of	5	O
bladder	9	B-Disease
cancer	3	I-Disease
after	9	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
,	9	O
and	5	O
the	5	O
relative	9	O
prevalence	5	O
of	5	O
a	5	O
history	5	O
of	5	O
bladder	9	B-Disease
cancer	3	I-Disease
at	9	O
the	5	O
time	5	O
of	5	O
diagnosis	5	O
of	5	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
,	9	O
were	9	O
also	9	O
estimated	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
median	9	O
cumulative	5	O
doses	0	O
of	5	O
cyclophosphamide	0	B-Chemical
among	5	O
cases	5	O
(	9	O
n	9	O
=	7	O
11	7	O
)	9	O
and	5	O
controls	9	O
(	9	O
n	9	O
=	7	O
25	9	O
)	9	O
were	9	O
113	7	O
g	0	O
and	5	O
25	9	O
g	0	O
,	9	O
respectively	9	O
.	9	O

The	5	O
risk	5	O
of	5	O
bladder	9	B-Disease
cancer	3	I-Disease
doubled	9	O
for	5	O
every	5	O
10	9	O
g	0	O
increment	9	O
in	5	O
cyclophosphamide	0	B-Chemical
(	9	O
OR	9	O
=	7	O
2	9	O
.	9	O
0	7	O
,	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
(	9	O
CI	7	O
)	9	O
0	7	O
.	9	O
8	9	O
to	5	O
4	9	O
.	9	O
9	7	O
)	9	O
.	9	O

Treatment	9	O
duration	5	O
longer	5	O
than	5	O
1	9	O
year	5	O
was	9	O
associated	9	O
with	5	O
an	5	O
eightfold	9	O
increased	9	O
risk	5	O
(	9	O
OR	9	O
=	7	O
7	9	O
.	9	O
7	9	O
,	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
9	7	O
to	5	O
69	7	O
)	9	O
.	9	O

The	5	O
absolute	5	O
risk	5	O
for	5	O
bladder	9	B-Disease
cancer	3	I-Disease
in	5	O
the	5	O
cohort	9	O
reached	9	O
10	9	O
%	9	O
16	9	O
years	5	O
after	9	O
diagnosis	5	O
of	5	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
,	9	O
and	5	O
a	5	O
history	5	O
of	5	O
bladder	9	B-Disease
cancer	3	I-Disease
was	9	O
(	9	O
non	9	O
-	7	O
significantly	9	O
)	9	O
twice	9	O
as	5	O
common	5	O
as	5	O
expected	9	O
at	9	O
the	5	O
time	5	O
of	5	O
diagnosis	5	O
of	5	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
results	9	O
indicate	9	O
a	5	O
dose	9	O
-	7	O
response	9	O
relationship	5	O
between	5	O
cyclophosphamide	0	B-Chemical
and	5	O
the	5	O
risk	5	O
of	5	O
bladder	9	B-Disease
cancer	3	I-Disease
,	9	O
high	9	O
cumulative	5	O
risks	5	O
in	5	O
the	5	O
entire	9	O
cohort	9	O
,	9	O
and	5	O
also	9	O
the	5	O
possibility	9	O
of	5	O
risk	5	O
factors	9	O
operating	5	O
even	5	O
before	9	O
Wegener	2	B-Disease
'	9	I-Disease
s	9	I-Disease
granulomatosis	5	I-Disease
.	9	O

Differential	9	O
modulation	9	O
by	9	O
estrogen	3	B-Chemical
of	5	O
alpha2	9	O
-	7	O
adrenergic	9	O
and	5	O
I1	9	O
-	7	O
imidazoline	0	B-Chemical
receptor	3	O
-	7	O
mediated	3	O
hypotension	5	B-Disease
in	5	O
female	9	O
rats	9	O
.	9	O

We	9	O
have	5	O
recently	9	O
shown	9	O
that	5	O
estrogen	3	B-Chemical
negatively	9	O
modulates	9	O
the	5	O
hypotensive	5	B-Disease
effect	9	O
of	5	O
clonidine	0	B-Chemical
(	9	O
mixed	9	O
alpha2	9	O
-	7	O
/	9	O
I1	9	O
-	7	O
receptor	3	O
agonist	3	O
)	9	O
in	5	O
female	9	O
rats	9	O
and	5	O
implicates	9	O
the	5	O
cardiovascular	5	O
autonomic	5	O
control	9	O
in	5	O
this	5	O
interaction	9	O
.	9	O

The	5	O
present	9	O
study	9	O
investigated	9	O
whether	9	O
this	5	O
effect	9	O
of	5	O
estrogen	3	B-Chemical
involves	5	O
interaction	9	O
with	5	O
alpha2	9	O
-	7	O
and	5	O
/	9	O
or	5	O
I1	9	O
-	7	O
receptors	3	O
.	9	O

Changes	9	O
evoked	5	O
by	9	O
a	5	O
single	9	O
intraperitoneal	0	O
injection	9	O
of	5	O
rilmenidine	0	B-Chemical
(	9	O
600	0	O
microg	0	O
/	9	O
kg	0	O
)	9	O
or	5	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
selective	9	O
I1	9	O
-	7	O
and	5	O
alpha2	9	O
-	7	O
receptor	3	O
agonists	3	O
,	9	O
respectively	9	O
,	9	O
in	5	O
blood	9	O
pressure	5	O
,	9	O
hemodynamic	5	O
variability	5	O
,	9	O
and	5	O
locomotor	5	O
activity	9	O
were	9	O
assessed	9	O
in	5	O
radiotelemetered	_	O
sham	9	O
-	7	O
operated	5	O
and	5	O
ovariectomized	3	O
(	9	O
Ovx	0	O
)	9	O
Sprague	9	O
-	7	O
Dawley	0	O
female	9	O
rats	9	O
with	5	O
or	5	O
without	9	O
12	9	O
-	7	O
wk	9	O
estrogen	3	B-Chemical
replacement	9	O
.	9	O

Three	9	O
time	5	O
domain	1	O
indexes	5	O
of	5	O
hemodynamic	5	O
variability	5	O
were	9	O
employed	5	O
:	9	O
the	5	O
standard	5	O
deviation	5	O
of	5	O
mean	5	O
arterial	5	O
pressure	5	O
as	5	O
a	5	O
measure	5	O
of	5	O
blood	9	O
pressure	5	O
variability	5	O
and	5	O
the	5	O
standard	5	O
deviation	5	O
of	5	O
beat	5	O
-	7	O
to	5	O
-	7	O
beat	5	O
intervals	5	O
(	9	O
SDRR	5	O
)	9	O
and	5	O
the	5	O
root	5	O
mean	5	O
square	5	O
of	5	O
successive	5	O
differences	9	O
in	5	O
R	9	O
-	7	O
wave	5	O
-	7	O
to	5	O
-	7	O
R	9	O
-	7	O
wave	5	O
intervals	5	O
as	5	O
measures	5	O
of	5	O
heart	5	O
rate	9	O
variability	5	O
.	9	O

In	9	O
sham	9	O
-	7	O
operated	5	O
rats	9	O
,	9	O
rilmenidine	0	B-Chemical
or	5	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
elicited	9	O
similar	9	O
hypotension	5	B-Disease
that	5	O
lasted	5	O
at	9	O
least	9	O
5	9	O
h	0	O
and	5	O
was	9	O
associated	9	O
with	5	O
reductions	9	O
in	5	O
standard	5	O
deviation	5	O
of	5	O
mean	5	O
arterial	5	O
pressure	5	O
.	9	O

SDRR	5	O
was	9	O
reduced	9	O
only	9	O
by	9	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
.	9	O

Ovx	0	O
significantly	9	O
enhanced	3	O
the	5	O
hypotensive	5	B-Disease
response	9	O
to	5	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
,	9	O
in	5	O
contrast	9	O
to	5	O
no	9	O
effect	9	O
on	5	O
rilmenidine	0	B-Chemical
hypotension	5	B-Disease
.	9	O

The	5	O
enhanced	3	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
hypotension	5	B-Disease
in	5	O
Ovx	0	O
rats	9	O
was	9	O
paralleled	9	O
with	5	O
further	9	O
reduction	9	O
in	5	O
SDRR	5	O
and	5	O
a	5	B-Disease
reduced	9	I-Disease
locomotor	5	I-Disease
activity	9	I-Disease
.	9	O

Estrogen	9	O
replacement	9	O
(	9	O
17beta	9	B-Chemical
-	7	I-Chemical
estradiol	0	I-Chemical
subcutaneous	9	O
pellet	0	O
,	9	O
14	7	O
.	9	O
2	9	O
microg	0	O
/	9	O
day	9	O
,	9	O
12	9	O
wk	9	O
)	9	O
of	5	O
Ovx	0	O
rats	9	O
restored	3	O
the	5	O
hemodynamic	5	O
and	5	O
locomotor	5	O
effects	9	O
of	5	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
to	5	O
sham	9	O
-	7	O
operated	5	O
levels	3	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
estrogen	3	B-Chemical
downregulates	3	O
alpha2	9	O
-	7	O
but	9	O
not	5	O
I1	9	O
-	7	O
receptor	3	O
-	7	O
mediated	3	O
hypotension	5	B-Disease
and	5	O
highlight	5	O
a	5	O
role	9	O
for	5	O
the	5	O
cardiac	5	O
autonomic	5	O
control	9	O
in	5	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
-	7	O
estrogen	3	B-Chemical
interaction	9	O
.	9	O

Severe	9	O
reversible	9	O
left	5	B-Disease
ventricular	5	I-Disease
systolic	5	I-Disease
and	5	I-Disease
diastolic	5	I-Disease
dysfunction	9	I-Disease
due	5	O
to	5	O
accidental	5	O
iatrogenic	5	O
epinephrine	0	B-Chemical
overdose	0	B-Disease
.	9	O

Catecholamine	0	B-Chemical
-	7	O
induced	3	O
cardiomyopathy	5	B-Disease
due	5	O
to	5	O
chronic	5	O
excess	9	O
of	5	O
endogenous	3	O
catecholamines	9	B-Chemical
has	9	O
been	9	O
recognized	9	O
for	5	O
decades	5	O
as	5	O
a	5	O
clinical	5	O
phenomenon	5	O
.	9	O

In	9	O
contrast	9	O
,	9	O
reports	9	O
of	5	O
myocardial	9	B-Disease
dysfunction	9	I-Disease
due	5	O
to	5	O
acute	9	O
iatrogenic	5	O
overdose	0	B-Disease
are	5	O
rare	5	O
.	9	O

A	9	O
35	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
whose	9	O
cervix	5	O
uteri	9	O
was	9	O
inadvertently	5	O
injected	3	O
with	5	O
8	9	O
mg	0	O
of	5	O
epinephrine	0	B-Chemical
developed	5	O
myocardial	9	B-Disease
stunning	5	I-Disease
that	5	O
was	9	O
characterized	9	O
by	9	O
severe	5	O
hemodynamic	5	O
compromise	5	O
,	9	O
profound	9	O
,	9	O
albeit	9	O
transient	9	O
,	9	O
left	5	B-Disease
ventricular	5	I-Disease
systolic	5	I-Disease
and	5	I-Disease
diastolic	5	I-Disease
dysfunction	9	I-Disease
,	9	O
and	5	O
only	9	O
modestly	9	O
elevated	9	O
biochemical	9	O
markers	3	O
of	5	O
myocardial	9	B-Disease
necrosis	9	I-Disease
.	9	O

Our	9	O
case	5	O
illustrates	5	O
the	5	O
serious	5	O
consequences	5	O
of	5	O
medical	5	O
errors	5	O
that	5	O
can	5	O
be	5	O
avoided	5	O
through	9	O
improved	5	O
medication	5	O
labeling	3	O
and	5	O
staff	5	O
supervision	5	O
.	9	O

Cardioprotective	0	O
effect	9	O
of	5	O
tincture	0	B-Chemical
of	5	I-Chemical
Crataegus	4	I-Chemical
on	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

Tincture	4	B-Chemical
of	5	I-Chemical
Crataegus	4	I-Chemical
(	9	O
TCR	3	B-Chemical
)	9	O
,	9	O
an	5	O
alcoholic	5	B-Chemical
extract	0	I-Chemical
of	5	I-Chemical
the	5	I-Chemical
berries	4	I-Chemical
of	5	I-Chemical
hawthorn	4	I-Chemical
(	9	O
Crataegus	4	B-Chemical
oxycantha	4	I-Chemical
)	9	O
,	9	O
is	5	O
used	5	O
in	5	O
herbal	5	O
and	5	O
homeopathic	5	O
medicine	5	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
done	9	O
to	5	O
investigate	9	O
the	5	O
protective	9	O
effect	9	O
of	5	O
TCR	3	B-Chemical
on	5	O
experimentally	9	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

Pretreatment	3	O
of	5	O
TCR	3	B-Chemical
,	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
0	7	O
.	9	O
5	9	O
mL	0	O
/	9	O
100	0	O
g	0	O
bodyweight	5	O
per	9	O
day	9	O
,	9	O
orally	0	O
for	5	O
30	9	O
days	9	O
,	9	O
prevented	9	O
the	5	O
increase	9	O
in	5	O
lipid	0	O
peroxidation	0	O
and	5	O
activity	9	O
of	5	O
marker	3	O
enzymes	1	O
observed	9	O
in	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
rats	9	O
(	9	O
85	9	O
mg	0	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
s	9	O
.	9	O
c	9	O
.	9	O
for	5	O
2	9	O
days	9	O
at	9	O
an	5	O
interval	5	O
of	5	O
24	9	O
h	0	O
)	9	O
.	9	O

TCR	3	B-Chemical
prevented	9	O
the	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
decrease	9	O
in	5	O
antioxidant	0	O
enzymes	1	O
in	5	O
the	5	O
heart	5	O
and	5	O
increased	9	O
the	5	O
rate	9	O
of	5	O
ADP	0	B-Chemical
-	7	O
stimulated	3	O
oxygen	0	B-Chemical
uptake	0	O
and	5	O
respiratory	5	O
coupling	9	O
ratio	9	O
.	9	O

TCR	3	B-Chemical
protected	9	O
against	9	O
pathological	5	O
changes	9	O
induced	3	O
by	9	O
isoproterenol	0	B-Chemical
in	5	O
rat	3	O
heart	5	O
.	9	O

The	5	O
results	9	O
show	9	O
that	5	O
pretreatment	0	O
with	5	O
TCR	3	B-Chemical
may	5	O
be	5	O
useful	5	O
in	5	O
preventing	9	O
the	5	O
damage	9	O
induced	3	O
by	9	O
isoproterenol	0	B-Chemical
in	5	O
rat	3	O
heart	5	O
.	9	O

Treatment	9	O
of	5	O
tinnitus	5	B-Disease
by	9	O
intratympanic	5	O
instillation	0	O
of	5	O
lignocaine	0	B-Chemical
(	9	O
lidocaine	0	B-Chemical
)	9	O
2	9	O
per	9	O
cent	5	O
through	9	O
ventilation	5	O
tubes	0	O
.	9	O

Idiopathic	5	B-Disease
subjective	5	I-Disease
tinnitus	5	I-Disease
(	9	O
IST	5	B-Disease
)	9	O
is	5	O
one	5	O
of	5	O
the	5	O
most	9	O
obscure	5	O
otological	5	O
pathologies	5	O
.	9	O

This	5	O
paper	5	O
presents	5	O
the	5	O
results	9	O
of	5	O
treating	5	O
IST	5	B-Disease
by	9	O
intratympanic	5	O
instillation	0	O
of	5	O
lignocaine	0	B-Chemical
(	9	O
lidocaine	0	B-Chemical
)	9	O
2	9	O
per	9	O
cent	5	O
through	9	O
a	5	O
grommet	5	O
,	9	O
for	5	O
five	9	O
weekly	5	O
courses	5	O
.	9	O

Fifty	9	O
-	7	O
two	5	O
patients	5	O
suffering	5	O
from	9	O
intractable	5	O
tinnitus	5	B-Disease
entered	5	O
this	5	O
therapeutic	5	O
trial	5	O
,	9	O
but	9	O
only	9	O
nine	9	O
finished	5	O
all	5	O
five	9	O
courses	5	O
.	9	O

In	9	O
one	5	O
patient	5	O
,	9	O
the	5	O
tinnitus	5	B-Disease
was	9	O
almost	9	O
completely	9	O
abolished	3	O
,	9	O
but	9	O
in	5	O
all	5	O
the	5	O
nine	9	O
patients	5	O
the	5	O
decompensated	5	O
tinnitus	5	B-Disease
changed	9	O
to	5	O
a	5	O
compensated	5	O
one	5	O
.	9	O

We	9	O
suggest	9	O
this	5	O
mode	5	O
of	5	O
treatment	9	O
for	5	O
patients	5	O
that	5	O
were	9	O
previously	9	O
treated	3	O
by	9	O
drugs	5	O
,	9	O
acupuncture	5	O
and	5	O
biofeedback	5	O
,	9	O
with	5	O
disappointing	5	O
results	9	O
.	9	O

Patients	5	O
should	5	O
be	5	O
warned	5	O
about	5	O
the	5	O
side	5	O
effects	9	O
of	5	O
vertigo	5	B-Disease
and	5	O
vomiting	5	B-Disease
,	9	O
which	5	O
subsides	5	O
gradually	9	O
with	5	O
every	5	O
new	5	O
instillation	0	O
,	9	O
and	5	O
that	5	O
the	5	O
tinnitus	5	B-Disease
may	5	O
not	5	O
disappear	5	O
but	9	O
will	5	O
be	5	O
alleviated	9	O
,	9	O
enabling	5	O
them	5	O
to	5	O
cope	5	O
more	5	O
easily	5	O
with	5	O
the	5	O
disease	5	O
and	5	O
lead	5	O
a	5	O
more	5	O
normal	9	O
life	5	O
.	9	O

The	5	O
alpha3	3	O
and	5	O
beta4	1	O
nicotinic	0	O
acetylcholine	0	B-Chemical
receptor	3	O
subunits	1	O
are	5	O
necessary	5	O
for	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
hypolocomotion	3	B-Disease
in	5	O
mice	3	O
.	9	O

Binding	9	O
of	5	O
nicotine	0	B-Chemical
to	5	O
nicotinic	0	O
acetylcholine	0	B-Chemical
receptors	3	O
(	9	O
nAChRs	3	O
)	9	O
elicits	9	O
a	5	O
series	5	O
of	5	O
dose	9	O
-	7	O
dependent	9	O
behaviors	5	O
that	5	O
go	5	O
from	9	O
altered	9	O
exploration	5	O
,	9	O
sedation	5	O
,	9	O
and	5	O
tremors	5	B-Disease
,	9	O
to	5	O
seizures	5	B-Disease
and	5	O
death	9	B-Disease
.	9	O

nAChRs	3	O
are	5	O
pentameric	1	O
ion	0	O
channels	9	O
usually	5	O
composed	9	O
of	5	O
alpha	9	O
and	5	O
beta	9	O
subunits	1	O
.	9	O

A	9	O
gene	1	O
cluster	9	O
comprises	9	O
the	5	O
alpha3	3	O
,	9	O
alpha5	3	O
and	5	O
beta4	1	O
subunits	1	O
,	9	O
which	5	O
coassemble	1	O
to	5	O
form	9	O
functional	9	O
receptors	3	O
.	9	O

We	9	O
examined	9	O
the	5	O
role	9	O
of	5	O
the	5	O
beta4	1	O
subunits	1	O
in	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
hypolocomotion	3	B-Disease
in	5	O
beta4	1	O
homozygous	1	O
null	1	O
(	9	O
beta4	1	O
-	7	O
/	9	O
-	7	O
)	9	O
and	5	O
alpha3	3	O
heterozygous	1	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
mice	3	O
.	9	O

beta4	1	O
-	7	O
/	9	O
-	7	O
mice	3	O
were	9	O
less	5	O
sensitive	9	O
to	5	O
the	5	O
effects	9	O
of	5	O
nicotine	0	B-Chemical
both	9	O
at	9	O
low	9	O
doses	0	O
,	9	O
measured	9	O
as	5	O
decreased	9	O
exploration	5	O
in	5	O
an	5	O
open	5	O
field	5	O
,	9	O
and	5	O
at	9	O
high	9	O
doses	0	O
,	9	O
measured	9	O
as	5	O
sensitivity	9	O
to	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

Using	9	O
in	5	O
situ	9	O
hybridization	9	O
probes	9	O
for	5	O
the	5	O
alpha3	3	O
and	5	O
alpha5	3	O
subunits	1	O
,	9	O
we	5	O
showed	9	O
that	5	O
alpha5	3	O
mRNA	3	O
levels	3	O
are	5	O
unchanged	9	O
,	9	O
whereas	9	O
alpha3	3	O
mRNA	3	O
levels	3	O
are	5	O
selectively	3	O
decreased	9	O
in	5	O
the	5	O
mitral	5	O
cell	3	O
layer	9	O
of	5	O
the	5	O
olfactory	5	O
bulb	9	O
,	9	O
and	5	O
the	5	O
inferior	5	O
and	5	O
the	5	O
superior	5	O
colliculus	5	O
of	5	O
beta4	1	O
-	7	O
/	9	O
-	7	O
brains	9	O
.	9	O

alpha3	3	O
+	9	O
/	9	O
-	7	O
mice	3	O
were	9	O
partially	9	O
resistant	9	O
to	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
when	5	O
compared	9	O
to	5	O
wild	1	O
-	7	O
type	9	O
littermates	3	O
.	9	O

mRNA	3	O
levels	3	O
for	5	O
the	5	O
alpha5	3	O
and	5	O
the	5	O
beta4	1	O
subunits	1	O
were	9	O
unchanged	9	O
in	5	O
alpha3	3	O
+	9	O
/	9	O
-	7	O
brains	9	O
.	9	O

Together	9	O
,	9	O
these	5	O
results	9	O
suggest	9	O
that	5	O
the	5	O
beta4	1	O
and	5	O
the	5	O
alpha3	3	O
subunits	1	O
are	5	O
mediators	9	O
of	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
hypolocomotion	3	B-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
sevoflurane	0	B-Chemical
on	5	O
lidocaine	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
.	9	O

The	5	O
influence	5	O
of	5	O
sevoflurane	0	B-Chemical
on	5	O
lidocaine	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
was	9	O
studied	9	O
in	5	O
cats	9	O
.	9	O

The	5	O
convulsive	5	B-Disease
threshold	5	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
was	9	O
41	7	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
5	9	O
mg	0	O
.	9	O

l	0	O
(	9	O
-	7	O
1	9	O
)	9	O
with	5	O
lidocaine	0	B-Chemical
infusion	0	O
(	9	O
6	9	O
mg	0	O
.	9	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
.	9	O
min	0	O
(	9	O
-	7	O
1	9	O
)	9	O
)	9	O
,	9	O
increasing	9	O
significantly	9	O
to	5	O
66	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
10	9	O
.	9	O
9	7	O
mg	0	O
.	9	O

l	0	O
(	9	O
-	7	O
1	9	O
)	9	O
when	5	O
the	5	O
end	9	O
-	7	O
tidal	5	O
concentration	0	O
of	5	O
sevoflurane	0	B-Chemical
was	9	O
0	7	O
.	9	O
8	9	O
%	9	O
.	9	O

However	9	O
,	9	O
the	5	O
threshold	5	O
(	9	O
61	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
8	9	O
.	9	O
7	9	O
mg	0	O
.	9	O
l	0	O
(	9	O
-	7	O
1	9	O
)	9	O
)	9	O
during	5	O
1	9	O
.	9	O
6	9	O
%	9	O
sevoflurane	0	B-Chemical
was	9	O
not	5	O
significant	9	O
from	9	O
that	5	O
during	5	O
0	7	O
.	9	O
8	9	O
%	9	O
sevoflurane	0	B-Chemical
,	9	O
indicating	9	O
a	5	O
celling	9	O
effect	9	O
.	9	O

There	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
in	5	O
the	5	O
convulsive	5	B-Disease
threshold	5	O
between	5	O
sevoflurane	0	B-Chemical
and	5	O
enflurane	0	B-Chemical
.	9	O

The	5	O
rise	9	O
in	5	O
blood	9	O
pressure	5	O
became	9	O
less	5	O
marked	9	O
when	5	O
higher	9	O
concentrations	0	O
of	5	O
sevoflurane	0	B-Chemical
or	5	O
enflurane	0	B-Chemical
were	9	O
administered	9	O
and	5	O
the	5	O
blood	9	O
pressure	5	O
at	9	O
convulsions	5	B-Disease
decreased	9	O
significantly	9	O
in	5	O
1	9	O
.	9	O
6	9	O
%	9	O
sevoflurane	0	B-Chemical
,	9	O
and	5	O
in	5	O
0	7	O
.	9	O
8	9	O
%	9	O
and	5	O
1	9	O
.	9	O
6	9	O
%	9	O
enflurane	0	B-Chemical
.	9	O

However	9	O
,	9	O
there	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
in	5	O
the	5	O
lidocaine	0	B-Chemical
concentrations	0	O
measured	9	O
when	5	O
the	5	O
systolic	5	O
blood	9	O
pressure	5	O
became	9	O
70	9	O
mmHg	7	O
.	9	O

Apamin	0	B-Chemical
,	9	O
a	5	O
selective	9	O
blocker	0	O
of	5	O
calcium	0	B-Chemical
-	7	O
dependent	9	O
potassium	0	B-Chemical
channels	9	O
,	9	O
was	9	O
administered	9	O
intracerebroventricularly	3	O
in	5	O
rats	9	O
anesthetized	0	O
with	5	O
0	7	O
.	9	O
8	9	O
%	9	O
sevoflurane	0	B-Chemical
to	5	O
investigate	9	O
the	5	O
mechanism	9	O
of	5	O
the	5	O
anticonvulsive	5	O
effects	9	O
.	9	O

Apamin	0	B-Chemical
(	9	O
10	9	O
ng	0	O
)	9	O
had	9	O
a	5	O
tendency	5	O
to	5	O
decrease	9	O
the	5	O
convulsive	5	B-Disease
threshold	5	O
(	9	O
21	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
2	9	O
to	5	O
19	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
5	9	O
mg	0	O
.	9	O
l	0	O
(	9	O
-	7	O
1	9	O
)	9	O
)	9	O
but	9	O
this	5	O
was	9	O
not	5	O
statistically	9	O
significant	9	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
sevoflurane	0	B-Chemical
reduces	9	O
the	5	O
convulsive	5	B-Disease
effect	9	O
of	5	O
lidocaine	0	B-Chemical
toxicity	9	B-Disease
but	9	O
carries	9	O
some	5	O
risk	5	O
due	5	O
to	5	O
circulatory	5	O
depression	5	B-Disease
.	9	O

Cardiac	9	B-Disease
toxicity	9	I-Disease
observed	9	O
in	5	O
association	9	O
with	5	O
high	9	O
-	7	O
dose	9	O
cyclophosphamide	0	B-Chemical
-	7	O
based	5	O
chemotherapy	5	O
for	5	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

INTRODUCTION	5	O
:	9	O
Cyclophosphamide	0	B-Chemical
is	5	O
an	5	O
alkylating	0	O
agent	9	O
given	5	O
frequently	5	O
as	5	O
a	5	O
component	9	O
of	5	O
many	5	O
conditioning	5	O
regimens	5	O
.	9	O

In	9	O
high	9	O
doses	0	O
,	9	O
its	9	O
nonhematological	5	O
dose	9	O
-	7	O
limiting	9	O
toxicity	9	B-Disease
is	5	O
cardiomyopathy	5	B-Disease
.	9	O

STUDY	2	O
DESIGN	2	O
:	9	O
We	9	O
combined	9	O
paclitaxel	0	B-Chemical
,	9	O
melphalan	0	B-Chemical
and	5	O
high	9	O
-	7	O
dose	9	O
cyclophosphamide	0	B-Chemical
,	9	O
thiotepa	0	B-Chemical
,	9	O
and	5	O
carboplatin	0	B-Chemical
in	5	O
a	5	O
triple	9	O
sequential	5	O
high	9	O
-	7	O
dose	9	O
regimen	5	O
for	5	O
patients	5	O
with	5	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
.	9	O

Analysis	9	O
was	9	O
performed	9	O
on	5	O
61	7	O
women	5	O
with	5	O
chemotherapy	5	O
-	7	O
responsive	9	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
receiving	9	O
96	9	O
-	7	O
h	0	O
infusional	5	O
cyclophosphamide	0	B-Chemical
as	5	O
part	9	O
of	5	O
a	5	O
triple	9	O
sequential	5	O
high	9	O
-	7	O
dose	9	O
regimen	5	O
to	5	O
assess	5	O
association	9	O
between	5	O
presence	9	O
of	5	O
peritransplant	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
(	9	O
CHF	9	B-Disease
)	9	O
and	5	O
the	5	O
following	9	O
pretreatment	0	O
characteristics	5	O
:	9	O
presence	9	O
of	5	O
electrocardiogram	5	O
(	9	O
EKG	5	O
)	9	O
abnormalities	9	O
,	9	O
age	5	O
,	9	O
hypertension	5	B-Disease
,	9	O
prior	9	O
cardiac	5	O
history	5	O
,	9	O
smoking	5	O
,	9	O
diabetes	5	B-Disease
mellitus	9	I-Disease
,	9	O
prior	9	O
use	5	O
of	5	O
anthracyclines	0	B-Chemical
,	9	O
and	5	O
left	5	O
-	7	O
sided	5	O
chest	5	O
irradiation	9	O
.	9	O

RESULTS	9	O
:	9	O
Six	9	O
of	5	O
61	7	O
women	5	O
(	9	O
10	9	O
%	9	O
)	9	O
developed	5	O
clinically	5	O
reversible	9	O
grade	9	O
3	9	O
CHF	9	B-Disease
following	9	O
infusional	5	O
cyclophosphamide	0	B-Chemical
with	5	O
a	5	O
median	9	O
percent	5	O
decline	9	O
in	5	O
ejection	5	O
fraction	9	O
of	5	O
31	7	O
%	9	O
.	9	O

Incidence	9	O
of	5	O
transient	9	O
cyclophosphamide	0	B-Chemical
-	7	O
related	9	O
cardiac	5	B-Disease
toxicity	9	I-Disease
(	9	O
10	9	O
%	9	O
)	9	O
is	5	O
comparable	9	O
to	5	O
previous	9	O
recorded	5	O
literature	5	O
.	9	O

Older	5	O
age	5	O
was	9	O
significantly	9	O
correlated	9	O
with	5	O
the	5	O
CHF	9	B-Disease
development	9	O
;	9	O
with	5	O
median	9	O
ages	5	O
for	5	O
the	5	O
entire	9	O
group	9	O
and	5	O
for	5	O
patients	5	O
developing	5	O
CHF	9	B-Disease
of	5	O
45	9	O
and	5	O
59	7	O
,	9	O
respectively	9	O
.	9	O

No	9	O
association	9	O
was	9	O
found	9	O
with	5	O
other	5	O
pretreatment	0	O
characteristics	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
As	9	O
a	5	O
result	9	O
of	5	O
these	5	O
findings	9	O
,	9	O
oncologists	5	O
should	5	O
carefully	5	O
monitor	5	O
fluid	5	O
balance	5	O
in	5	O
older	5	O
patients	5	O
.	9	O

Routine	5	O
EKG	5	O
monitoring	5	O
during	5	O
infusional	5	O
cyclophosphamide	0	B-Chemical
did	9	O
not	5	O
predict	5	O
CHF	9	B-Disease
development	9	O
.	9	O

Tremor	5	B-Disease
side	5	O
effects	9	O
of	5	O
salbutamol	0	B-Chemical
,	9	O
quantified	9	O
by	9	O
a	5	O
laser	5	O
pointer	5	O
technique	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
study	9	O
tremor	5	B-Disease
side	5	O
effects	9	O
of	5	O
salbutamol	0	B-Chemical
an	5	O
easily	5	O
applicable	5	O
,	9	O
quick	5	O
and	5	O
low	9	O
-	7	O
priced	5	O
method	5	O
is	5	O
needed	5	O
.	9	O

A	9	O
new	5	O
method	5	O
using	9	O
a	5	O
commercially	0	O
available	5	O
,	9	O
pen	5	O
-	7	O
shaped	5	O
laser	5	O
pointer	5	O
was	9	O
developed	5	O
.	9	O

Aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
sensitivity	9	O
,	9	O
reproducibility	5	O
,	9	O
reference	9	O
values	5	O
and	5	O
the	5	O
agreement	9	O
with	5	O
a	5	O
questionnaire	5	O
.	9	O

METHODS	2	O
:	9	O
Tremor	5	B-Disease
was	9	O
measured	9	O
using	9	O
a	5	O
laser	5	O
pointer	5	O
technique	5	O
.	9	O

To	9	O
determine	9	O
sensitivity	9	O
we	5	O
assessed	9	O
tremor	5	B-Disease
in	5	O
44	7	O
patients	5	O
with	5	O
obstructive	5	B-Disease
lung	9	I-Disease
disease	5	I-Disease
after	9	O
administration	9	O
of	5	O
cumulative	5	O
doses	0	O
of	5	O
salbutamol	0	B-Chemical
.	9	O

Subjects	5	O
were	9	O
asked	5	O
to	5	O
aim	5	O
at	9	O
the	5	O
centre	5	O
of	5	O
a	5	O
target	9	O
,	9	O
subdivided	9	O
in	5	O
concentric	5	O
circles	9	O
,	9	O
from	9	O
5	9	O
m	9	O
distance	5	O
.	9	O

The	5	O
circle	9	O
in	5	O
which	5	O
the	5	O
participant	5	O
succeeded	5	O
to	5	O
aim	5	O
was	9	O
recorded	5	O
in	5	O
millimetres	5	O
radius	5	O
.	9	O

In	9	O
another	9	O
series	5	O
of	5	O
measurements	5	O
,	9	O
reproducibility	5	O
and	5	O
reference	9	O
values	5	O
of	5	O
the	5	O
tremor	5	B-Disease
was	9	O
assessed	9	O
in	5	O
65	7	O
healthy	5	O
subjects	5	O
in	5	O
three	9	O
sessions	5	O
,	9	O
at	9	O
9	7	O
a	5	O
.	9	O
m	9	O
.	9	O
,	9	O
4	9	O
p	7	O
.	9	O
m	9	O
.	9	O
and	5	O
9	7	O
a	5	O
.	9	O
m	9	O
.	9	O
,	9	O
respectively	9	O
,	9	O
1	9	O
week	9	O
later	9	O
.	9	O

Postural	5	O
tremor	5	B-Disease
was	9	O
measured	9	O
with	5	O
the	5	O
arm	5	O
horizontally	5	O
outstretched	5	O
rest	5	O
tremor	5	B-Disease
with	5	O
the	5	O
arm	5	O
supported	9	O
by	9	O
an	5	O
armrest	5	O
and	5	O
finally	9	O
tremor	5	B-Disease
was	9	O
measured	9	O
after	9	O
holding	5	O
a	5	O
2	9	O
-	7	O
kg	0	O
weight	9	O
until	5	O
exhaustion	9	O
.	9	O

Inter	5	O
-	7	O
observer	5	O
variability	5	O
was	9	O
measured	9	O
in	5	O
a	5	O
series	5	O
of	5	O
10	9	O
healthy	5	O
subjects	5	O
.	9	O

Tremor	5	B-Disease
was	9	O
measured	9	O
simultaneously	5	O
by	9	O
two	5	O
independent	9	O
observers	5	O
.	9	O

RESULTS	9	O
:	9	O
Salbutamol	0	B-Chemical
significantly	9	O
increased	9	O
tremor	5	B-Disease
severity	5	O
in	5	O
patients	5	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
way	5	O
.	9	O

Within	9	O
healthy	5	O
adults	5	O
no	9	O
age	5	O
-	7	O
dependency	5	O
could	9	O
be	5	O
found	9	O
(	9	O
b	9	O
=	7	O
0	7	O
.	9	O
262	7	O
mm	9	O
/	9	O
year	5	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
72	9	O
)	9	O
.	9	O

There	5	O
was	9	O
no	9	O
agreement	9	O
between	5	O
the	5	O
questionnaire	5	O
and	5	O
tremor	5	B-Disease
severity	5	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
093	7	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
53	7	O
)	9	O
.	9	O

Postural	5	O
tremor	5	B-Disease
showed	9	O
no	9	O
significant	9	O
difference	9	O
between	5	O
the	5	O
first	9	O
and	5	O
third	9	O
session	5	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
07	7	O
)	9	O
.	9	O

Support	5	O
of	5	O
the	5	O
arm	5	O
decreased	9	O
tremor	5	B-Disease
severity	5	O
,	9	O
exhaustion	9	O
increased	9	O
tremor	5	B-Disease
severity	5	O
significantly	9	O
.	9	O

A	9	O
good	5	O
agreement	9	O
was	9	O
found	9	O
between	5	O
two	5	O
independent	9	O
observers	5	O
(	9	O
interclass	5	O
correlation	9	O
coefficient	5	O
0	7	O
.	9	O
72	9	O
)	9	O
.	9	O

DISCUSSION	9	O
:	9	O
Quantifying	5	O
tremor	5	B-Disease
by	9	O
using	9	O
an	5	O
inexpensive	5	O
laser	5	O
pointer	5	O
is	5	O
,	9	O
with	5	O
the	5	O
exception	9	O
of	5	O
children	5	O
(	9	O
<	0	O
12	9	O
years	5	O
)	9	O
a	5	O
sensitive	9	O
and	5	O
reproducible	5	O
method	5	O
.	9	O

Safety	5	O
and	5	O
adverse	5	O
effects	9	O
associated	9	O
with	5	O
raloxifene	0	B-Chemical
:	9	O
multiple	5	O
outcomes	5	O
of	5	O
raloxifene	0	B-Chemical
evaluation	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
examine	9	O
the	5	O
effect	9	O
of	5	O
raloxifene	0	B-Chemical
on	5	O
major	9	O
adverse	5	O
events	5	O
that	5	O
occur	5	O
with	5	O
postmenopausal	5	O
estrogen	3	B-Chemical
therapy	5	O
or	5	O
tamoxifen	9	B-Chemical
.	9	O

METHODS	2	O
:	9	O
The	5	O
Multiple	5	O
Outcomes	5	O
of	5	O
Raloxifene	0	B-Chemical
Evaluation	5	O
,	9	O
a	5	O
multicenter	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
trial	5	O
,	9	O
enrolled	5	O
7	9	O
,	9	O
705	7	O
postmenopausal	5	O
women	5	O
with	5	O
osteoporosis	5	B-Disease
.	9	O

Women	5	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
raloxifene	0	B-Chemical
60	9	O
mg	0	O
/	9	O
d	9	O
or	5	O
120	9	O
mg	0	O
/	9	O
d	9	O
or	5	O
placebo	9	O
.	9	O

Outcomes	5	O
included	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
,	9	O
cataracts	5	B-Disease
,	9	O
gallbladder	5	B-Disease
disease	5	I-Disease
,	9	O
and	5	O
endometrial	9	B-Disease
hyperplasia	9	I-Disease
or	5	I-Disease
cancer	3	I-Disease
.	9	O

RESULTS	9	O
:	9	O
During	5	O
a	5	O
mean	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
3	9	O
.	9	O
3	9	O
years	5	O
,	9	O
raloxifene	0	B-Chemical
was	9	O
associated	9	O
with	5	O
an	5	O
increased	9	O
risk	5	O
for	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
(	9	O
relative	9	O
risk	5	O
[	9	O
RR	9	O
]	9	O
2	9	O
.	9	O
1	9	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
[	9	O
CI	7	O
]	9	O
1	9	O
.	9	O
2	9	O
-	7	O
3	9	O
.	9	O
8	9	O
)	9	O
.	9	O

The	5	O
excess	9	O
event	5	O
rate	9	O
was	9	O
1	9	O
.	9	O
8	9	O
per	9	O
1	9	O
,	9	O
000	9	O
woman	5	O
-	7	O
years	5	O
(	9	O
95	7	O
%	9	O
CI	7	O
-	7	O
0	7	O
.	9	O
5	9	O
-	7	O
4	9	O
.	9	O
1	9	O
)	9	O
,	9	O
and	5	O
the	5	O
number	9	O
needed	5	O
to	5	O
treat	5	O
to	5	O
cause	5	O
1	9	O
event	5	O
was	9	O
170	9	O
(	9	O
95	7	O
%	9	O
CI	7	O
100	0	O
-	7	O
582	7	O
)	9	O
over	5	O
3	9	O
.	9	O
3	9	O
years	5	O
.	9	O

Risk	5	O
in	5	O
the	5	O
raloxifene	0	B-Chemical
group	9	O
was	9	O
higher	9	O
than	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
for	5	O
the	5	O
first	9	O
2	9	O
years	5	O
,	9	O
but	9	O
decreased	9	O
to	5	O
about	5	O
the	5	O
same	9	O
rate	9	O
as	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
thereafter	9	O
.	9	O

Raloxifene	0	B-Chemical
did	9	O
not	5	O
increase	9	O
risk	5	O
for	5	O
cataracts	5	B-Disease
(	9	O
RR	9	O
0	7	O
.	9	O
9	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
8	9	O
-	7	O
1	9	O
.	9	O
1	9	O
)	9	O
,	9	O
gallbladder	5	B-Disease
disease	5	I-Disease
(	9	O
RR	9	O
1	9	O
.	9	O
0	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
7	9	O
-	7	O
1	9	O
.	9	O
3	9	O
)	9	O
,	9	O
endometrial	9	B-Disease
hyperplasia	9	I-Disease
(	9	O
RR	9	O
1	9	O
.	9	O
3	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
4	9	O
-	7	O
5	9	O
.	9	O
1	9	O
)	9	O
,	9	O
or	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
(	9	O
RR	9	O
0	7	O
.	9	O
9	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
0	7	O
.	9	O
3	9	O
-	7	O
2	9	O
.	9	O
7	9	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Raloxifene	0	B-Chemical
was	9	O
associated	9	O
with	5	O
an	5	O
increased	9	O
risk	5	O
for	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
,	9	O
but	9	O
there	5	O
was	9	O
no	9	O
increased	9	O
risk	5	O
for	5	O
cataracts	5	B-Disease
,	9	O
gallbladder	5	B-Disease
disease	5	I-Disease
,	9	O
endometrial	9	B-Disease
hyperplasia	9	I-Disease
,	9	O
or	5	O
endometrial	9	B-Disease
cancer	3	I-Disease
.	9	O

LEVEL	2	O
OF	2	O
EVIDENCE	2	O
:	9	O
I	9	O

Optimization	5	O
of	5	O
levodopa	5	B-Chemical
therapy	5	O
.	9	O

While	9	O
there	5	O
is	5	O
no	9	O
single	9	O
correct	5	O
starting	9	O
dose	9	O
for	5	O
levodopa	5	B-Chemical
therapy	5	O
,	9	O
many	5	O
individuals	5	O
can	5	O
be	5	O
started	5	O
on	5	O
either	9	O
the	5	O
25	9	O
/	9	O
100	0	O
or	5	O
controlled	5	O
-	7	O
release	9	O
formula	9	O
,	9	O
following	9	O
the	5	O
general	5	O
rule	5	O
not	5	O
to	5	O
attempt	5	O
to	5	O
titrate	9	O
carbidopa	0	B-Chemical
-	7	O
levodopa	5	B-Chemical
to	5	O
the	5	O
point	5	O
of	5	O
"	5	O
normality	5	O
,	9	O
"	5	O
which	5	O
can	5	O
lead	5	O
to	5	O
toxicity	9	B-Disease
.	9	O

The	5	O
physician	5	O
should	5	O
also	9	O
determine	9	O
the	5	O
proper	5	O
use	5	O
of	5	O
any	5	O
adjunctive	5	O
medications	5	O
;	9	O
such	5	O
combined	9	O
therapy	5	O
has	9	O
become	5	O
the	5	O
standard	5	O
approach	5	O
to	5	O
treatment	9	O
.	9	O

Following	9	O
the	5	O
initial	9	O
period	5	O
of	5	O
therapy	5	O
,	9	O
emerging	5	O
difficulties	5	O
require	5	O
a	5	O
reassessment	5	O
of	5	O
therapeutic	5	O
approaches	5	O
,	9	O
such	5	O
as	5	O
dosage	9	O
adjustment	5	O
or	5	O
introduction	9	O
of	5	O
a	5	O
dopamine	5	B-Chemical
agonist	3	O
.	9	O

Other	9	O
possible	5	O
adverse	5	O
effects	9	O
-	7	O
-	7	O
such	5	O
as	5	O
gastrointestinal	9	B-Disease
disorders	5	I-Disease
,	9	O
orthostatic	5	B-Disease
hypotension	5	I-Disease
,	9	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
psychosis	5	B-Disease
,	9	O
sleep	5	B-Disease
disturbances	5	I-Disease
or	5	O
parasomnias	5	B-Disease
,	9	O
or	5	O
drug	5	O
interactions	9	O
-	7	O
-	7	O
also	9	O
require	5	O
carefully	5	O
monitored	9	O
individual	5	O
treatment	9	O
.	9	O

Nonpharmacologic	5	O
concerns	5	O
can	5	O
help	5	O
the	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
patient	5	O
achieve	5	O
and	5	O
maintain	5	O
optimal	5	O
functioning	5	O
,	9	O
including	9	O
daily	5	O
exercise	5	O
,	9	O
physical	5	O
therapy	5	O
,	9	O
and	5	O
involvement	9	O
with	5	O
support	5	O
groups	9	O
.	9	O

Long	9	O
term	5	O
audiological	5	O
evaluation	5	O
of	5	O
beta	9	B-Disease
-	7	I-Disease
thalassemic	5	I-Disease
patients	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
identify	9	O
the	5	O
incidence	5	O
and	5	O
to	5	O
monitor	5	O
the	5	O
progression	9	O
of	5	O
hearing	5	B-Disease
loss	9	I-Disease
in	5	O
children	5	O
and	5	O
young	5	O
adults	5	O
with	5	O
beta	9	B-Disease
-	7	I-Disease
thalassemia	9	I-Disease
major	9	O
.	9	O

METHODS	2	O
:	9	O
One	5	O
hundred	5	O
and	5	O
four	9	O
(	9	O
104	9	O
)	9	O
patients	5	O
aged	9	O
6	9	O
-	7	O
35	9	O
years	5	O
(	9	O
mean	5	O
17	7	O
,	9	O
2	9	O
years	5	O
)	9	O
participated	5	O
in	5	O
the	5	O
study	9	O
.	9	O

All	9	O
patients	5	O
were	9	O
on	5	O
a	5	O
regular	5	O
transfusion	5	O
-	7	O
chelation	0	O
program	5	O
maintaining	9	O
a	5	O
mean	5	O
hemoglobin	0	O
level	9	O
of	5	O
9	7	O
.	9	O
5	9	O
gr	9	O
/	9	O
dl	7	O
.	9	O

Subjects	5	O
were	9	O
receiving	9	O
desferrioxamine	0	B-Chemical
(	9	O
DFO	0	B-Chemical
)	9	O
chelation	0	O
treatment	9	O
with	5	O
a	5	O
mean	5	O
daily	5	O
dose	9	O
of	5	O
50	0	O
-	7	O
60	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
5	9	O
-	7	O
6	9	O
days	9	O
a	5	O
week	9	O
during	5	O
the	5	O
first	9	O
six	9	O
years	5	O
of	5	O
the	5	O
study	9	O
,	9	O
which	5	O
was	9	O
then	9	O
reduced	9	O
to	5	O
40	9	O
-	7	O
50	0	O
mg	0	O
/	9	O
kg	0	O
for	5	O
the	5	O
following	9	O
eight	9	O
years	5	O
.	9	O

Patients	5	O
were	9	O
followed	9	O
for	5	O
8	9	O
-	7	O
14	7	O
years	5	O
.	9	O

RESULTS	9	O
:	9	O
Overall	9	O
,	9	O
21	7	O
out	9	O
of	5	O
104	9	O
patients	5	O
(	9	O
20	9	O
.	9	O
2	9	O
%	9	O
)	9	O
presented	5	O
with	5	O
high	9	O
frequency	5	O
sensorineural	5	B-Disease
hearing	5	I-Disease
loss	9	I-Disease
(	9	O
SNHL	5	B-Disease
)	9	O
,	9	O
either	9	O
unilateral	5	O
or	5	O
bilateral	5	O
.	9	O

No	9	O
ototoxic	5	B-Disease
factor	9	O
,	9	O
other	5	O
than	5	O
DFO	0	B-Chemical
,	9	O
was	9	O
present	9	O
in	5	O
any	5	O
of	5	O
the	5	O
patients	5	O
.	9	O

Patients	5	O
with	5	O
SNHL	5	B-Disease
presented	5	O
with	5	O
relatively	5	O
lower	9	O
serum	9	O
ferritin	9	O
levels	3	O
than	5	O
those	5	O
with	5	O
normal	9	O
hearing	5	O
,	9	O
however	9	O
,	9	O
no	9	O
statistically	9	O
significant	9	O
difference	9	O
was	9	O
observed	9	O
.	9	O

Subjects	5	O
with	5	O
SNHL	5	B-Disease
were	9	O
submitted	9	O
to	5	O
DFO	0	B-Chemical
reduction	9	O
or	5	O
temporary	5	O
withdrawal	5	O
.	9	O

Following	9	O
intervention	5	O
,	9	O
7	9	O
out	9	O
of	5	O
21	7	O
affected	9	O
patients	5	O
recovered	9	O
,	9	O
10	9	O
remained	9	O
stable	9	O
and	5	O
4	9	O
demonstrated	9	O
aggravation	5	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
findings	9	O
are	5	O
indicative	9	O
of	5	O
DFO	0	B-Chemical
'	9	O
s	9	O
contributing	9	O
role	9	O
in	5	O
the	5	O
development	9	O
of	5	O
hearing	5	B-Disease
impairment	5	I-Disease
.	9	O

Regular	5	O
audiologic	5	O
evaluation	5	O
is	5	O
imperative	5	O
in	5	O
all	5	O
thalassemic	5	B-Disease
patients	5	O
so	5	O
that	5	O
early	9	O
changes	9	O
may	5	O
be	5	O
recognized	9	O
and	5	O
treatment	9	O
may	5	O
be	5	O
judiciously	5	O
adjusted	9	O
in	5	O
order	5	O
to	5	O
prevent	5	O
or	5	O
reverse	9	O
hearing	5	B-Disease
impairment	5	I-Disease
.	9	O

Individual	9	O
differences	9	O
in	5	O
renal	9	O
ACE	9	O
activity	9	O
in	5	O
healthy	5	O
rats	9	O
predict	5	O
susceptibility	9	O
to	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
damage	9	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
In	9	O
man	5	O
,	9	O
differences	9	O
in	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
(	9	O
ACE	9	O
)	9	O
levels	3	O
,	9	O
related	9	O
to	5	O
ACE	9	O
(	9	O
I	9	O
/	9	O
D	9	O
)	9	O
genotype	9	O
,	9	O
are	5	O
associated	9	O
with	5	O
renal	9	O
prognosis	5	O
.	9	O

This	5	O
raises	9	O
the	5	O
hypothesis	9	O
that	5	O
individual	5	O
differences	9	O
in	5	O
renal	9	O
ACE	9	O
activity	9	O
are	5	O
involved	9	O
in	5	O
renal	9	O
susceptibility	9	O
to	5	O
inflicted	5	O
damage	9	O
.	9	O

Therefore	9	O
,	9	O
we	5	O
studied	9	O
the	5	O
predictive	5	O
effect	9	O
of	5	O
renal	9	O
ACE	9	O
activity	9	O
for	5	O
the	5	O
severity	5	O
of	5	O
renal	9	B-Disease
damage	9	I-Disease
induced	3	O
by	9	O
a	5	O
single	9	O
injection	9	O
of	5	O
adriamycin	3	B-Chemical
in	5	O
rats	9	O
.	9	O

METHODS	2	O
:	9	O
Renal	9	O
ACE	9	O
activity	9	O
(	9	O
Hip	7	B-Chemical
-	7	I-Chemical
His	9	I-Chemical
-	7	I-Chemical
Leu	1	I-Chemical
cleavage	1	O
by	9	O
cortical	5	O
homogenates	9	O
)	9	O
was	9	O
determined	9	O
by	9	O
renal	9	O
biopsy	5	O
in	5	O
27	7	O
adult	9	O
male	9	O
Wistar	9	O
rats	9	O
.	9	O

After	9	O
1	9	O
week	9	O
of	5	O
recovery	9	O
,	9	O
proteinuria	9	B-Disease
was	9	O
induced	3	O
by	9	O
adriamycin	3	B-Chemical
[	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
intravenously	0	O
(	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
n	9	O
=	7	O
18	7	O
;	9	O
controls	9	O
,	9	O
saline	0	O
i	9	O
.	9	O
v	0	O
.	9	O
n	9	O
=	7	O
9	7	O
]	9	O
.	9	O

Proteinuria	7	B-Disease
was	9	O
measured	9	O
every	5	O
2	9	O
weeks	9	O
.	9	O

After	9	O
12	9	O
weeks	9	O
,	9	O
rats	9	O
were	9	O
sacrificed	3	O
and	5	O
their	5	O
kidneys	9	O
harvested	3	O
.	9	O

RESULTS	9	O
:	9	O
As	9	O
anticipated	5	O
,	9	O
adriamycin	3	B-Chemical
elicited	9	O
nephrotic	5	B-Disease
range	9	O
proteinuria	9	B-Disease
,	9	O
renal	9	B-Disease
interstitial	9	I-Disease
damage	9	I-Disease
and	5	O
mild	9	O
focal	5	B-Disease
glomerulosclerosis	3	I-Disease
.	9	O

Baseline	9	O
renal	9	O
ACE	9	O
positively	9	O
correlated	9	O
with	5	O
the	5	O
relative	9	O
rise	9	O
in	5	O
proteinuria	9	B-Disease
after	9	O
adriamycin	3	B-Chemical
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
62	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
renal	9	O
interstitial	9	O
alpha	9	O
-	7	O
smooth	5	O
muscle	9	O
actin	3	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
49	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
interstitial	9	O
macrophage	3	O
influx	9	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
56	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
interstitial	9	O
collagen	3	O
III	9	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
53	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
glomerular	5	O
alpha	9	O
-	7	O
smooth	5	O
muscle	9	O
actin	3	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
74	7	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
and	5	O
glomerular	5	O
desmin	3	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
48	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Baseline	9	O
renal	9	O
ACE	9	O
did	9	O
not	5	O
correlate	9	O
with	5	O
focal	5	B-Disease
glomerulosclerosis	3	I-Disease
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
22	7	O
,	9	O
NS	7	O
)	9	O
.	9	O

In	9	O
controls	9	O
,	9	O
no	9	O
predictive	5	O
values	5	O
for	5	O
renal	9	O
parameters	5	O
were	9	O
observed	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Individual	9	O
differences	9	O
in	5	O
renal	9	O
ACE	9	O
activity	9	O
predict	5	O
the	5	O
severity	5	O
of	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
damage	9	I-Disease
in	5	O
this	5	O
outbred	9	O
rat	3	O
strain	1	O
.	9	O

This	5	O
supports	9	O
the	5	O
assumption	5	O
that	5	O
differences	9	O
in	5	O
renal	9	O
ACE	9	O
activity	9	O
predispose	5	O
to	5	O
a	5	O
less	5	O
favourable	5	O
course	5	O
of	5	O
renal	9	B-Disease
damage	9	I-Disease
.	9	O

Recurrent	5	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
induced	3	O
by	9	O
azithromycin	9	B-Chemical
.	9	O

A	9	O
14	7	O
-	7	O
year	5	O
-	7	O
old	5	O
girl	5	O
is	5	O
reported	9	O
with	5	O
recurrent	5	O
,	9	O
azithromycin	9	B-Chemical
-	7	O
induced	3	O
,	9	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
.	9	O

The	5	O
second	9	O
episode	5	O
was	9	O
more	5	O
severe	5	O
than	5	O
the	5	O
first	9	O
;	9	O
and	5	O
although	9	O
both	9	O
were	9	O
treated	3	O
with	5	O
intensive	5	O
corticosteroid	5	O
therapy	5	O
,	9	O
renal	9	O
function	9	O
remained	9	O
impaired	9	O
.	9	O

Although	9	O
most	9	O
cases	5	O
of	5	O
antibiotic	5	O
induced	3	O
acute	9	O
interstitial	9	B-Disease
nephritis	9	I-Disease
are	5	O
benign	5	O
and	5	O
self	5	O
-	7	O
limited	5	O
,	9	O
some	5	O
patients	5	O
are	5	O
at	9	O
risk	5	O
for	5	O
permanent	5	O
renal	9	B-Disease
injury	9	I-Disease
.	9	O

Spironolactone	7	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
insufficiency	9	I-Disease
and	5	O
hyperkalemia	5	B-Disease
in	5	O
patients	5	O
with	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
A	9	O
previous	9	O
randomized	5	O
controlled	5	O
trial	5	O
evaluating	5	O
the	5	O
use	5	O
of	5	O
spironolactone	0	B-Chemical
in	5	O
heart	5	B-Disease
failure	5	I-Disease
patients	5	O
reported	9	O
a	5	O
low	9	O
risk	5	O
of	5	O
hyperkalemia	5	B-Disease
(	9	O
2	9	O
%	9	O
)	9	O
and	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
(	9	O
0	7	O
%	9	O
)	9	O
.	9	O

Because	9	O
treatments	9	O
for	5	O
heart	5	B-Disease
failure	5	I-Disease
have	5	O
changed	9	O
since	9	O
the	5	O
benefits	5	O
of	5	O
spironolactone	0	B-Chemical
were	9	O
reported	9	O
,	9	O
the	5	O
prevalence	5	O
of	5	O
these	5	O
complications	5	O
may	5	O
differ	9	O
in	5	O
current	5	O
clinical	5	O
practice	5	O
.	9	O

We	9	O
therefore	5	O
sought	9	O
to	5	O
determine	9	O
the	5	O
prevalence	5	O
and	5	O
clinical	5	O
associations	5	O
of	5	O
hyperkalemia	5	B-Disease
and	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
in	5	O
heart	5	B-Disease
failure	5	I-Disease
patients	5	O
treated	3	O
with	5	O
spironolactone	0	B-Chemical
.	9	O

METHODS	2	O
:	9	O
We	9	O
performed	9	O
a	5	O
case	5	O
control	9	O
study	9	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
patients	5	O
treated	3	O
with	5	O
spironolactone	0	B-Chemical
in	5	O
our	5	O
clinical	5	O
practice	5	O
.	9	O

Cases	9	O
were	9	O
patients	5	O
who	5	O
developed	5	O
hyperkalemia	5	B-Disease
(	9	O
K	9	B-Chemical
(	9	O
+	9	O
)	9	O
>	0	O
5	9	O
.	9	O
0	7	O
mEq	0	O
/	9	O
L	0	O
)	9	O
or	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
(	9	O
Cr	0	B-Chemical
>	0	O
or	5	O
=	7	O
2	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
dL	7	O
)	9	O
,	9	O
and	5	O
they	5	O
were	9	O
compared	9	O
to	5	O
2	9	O
randomly	5	O
selected	9	O
controls	9	O
per	9	O
case	5	O
.	9	O

Clinical	5	O
characteristics	5	O
,	9	O
medications	5	O
,	9	O
and	5	O
serum	9	O
chemistries	5	O
at	9	O
baseline	5	O
and	5	O
follow	5	O
-	7	O
up	5	O
time	5	O
periods	5	O
were	9	O
compared	9	O
.	9	O

RESULTS	9	O
:	9	O
Sixty	5	O
-	7	O
seven	9	O
of	5	O
926	7	O
patients	5	O
(	9	O
7	9	O
.	9	O
2	9	O
%	9	O
)	9	O
required	9	O
discontinuation	5	O
of	5	O
spironolactone	0	B-Chemical
due	5	O
to	5	O
hyperkalemia	5	B-Disease
(	9	O
n	9	O
=	7	O
33	7	O
)	9	O
or	5	O
renal	9	B-Disease
failure	5	I-Disease
(	9	O
n	9	O
=	7	O
34	7	O
)	9	O
.	9	O

Patients	5	O
who	5	O
developed	5	O
hyperkalemia	5	B-Disease
were	9	O
older	5	O
and	5	O
more	5	O
likely	5	O
to	5	O
have	5	O
diabetes	5	B-Disease
,	9	O
had	9	O
higher	9	O
baseline	5	O
serum	9	O
potassium	0	B-Chemical
levels	3	O
and	5	O
lower	9	O
baseline	5	O
potassium	0	B-Chemical
supplement	9	O
doses	0	O
,	9	O
and	5	O
were	9	O
more	5	O
likely	5	O
to	5	O
be	5	O
treated	3	O
with	5	O
beta	9	O
-	7	O
blockers	9	O
than	5	O
controls	9	O
(	9	O
n	9	O
=	7	O
134	7	O
)	9	O
.	9	O

Patients	5	O
who	5	O
developed	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
had	9	O
lower	9	O
baseline	5	O
body	5	O
weight	9	O
and	5	O
higher	9	O
baseline	5	O
serum	9	O
creatinine	0	B-Chemical
,	9	O
required	9	O
higher	9	O
doses	0	O
of	5	O
loop	9	O
diuretics	5	O
,	9	O
and	5	O
were	9	O
more	5	O
likely	5	O
to	5	O
be	5	O
treated	3	O
with	5	O
thiazide	5	B-Chemical
diuretics	5	O
than	5	O
controls	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Spironolactone	7	B-Chemical
-	7	O
induced	3	O
hyperkalemia	5	B-Disease
and	5	O
renal	9	B-Disease
insufficiency	9	I-Disease
are	5	O
more	5	O
common	5	O
in	5	O
our	5	O
clinical	5	O
experience	5	O
than	5	O
reported	9	O
previously	9	O
.	9	O

This	5	O
difference	9	O
is	5	O
explained	5	O
by	9	O
patient	5	O
comorbidities	5	O
and	5	O
more	5	O
frequent	5	O
use	5	O
of	5	O
beta	9	O
-	7	O
blockers	9	O
.	9	O

Acute	5	O
reserpine	0	B-Chemical
and	5	O
subchronic	0	O
haloperidol	5	B-Chemical
treatments	9	O
change	9	O
synaptosomal	3	O
brain	5	O
glutamate	0	B-Chemical
uptake	0	O
and	5	O
elicit	9	O
orofacial	5	B-Disease
dyskinesia	5	I-Disease
in	5	O
rats	9	O
.	9	O

Reserpine	0	B-Chemical
-	7	O
and	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
orofacial	5	B-Disease
dyskinesia	5	I-Disease
are	5	O
putative	1	O
animal	5	O
models	5	O
of	5	O
tardive	5	B-Disease
dyskinesia	5	I-Disease
(	9	O
TD	9	B-Disease
)	9	O
whose	9	O
pathophysiology	9	O
has	9	O
been	9	O
related	9	O
to	5	O
free	9	O
radical	0	O
generation	9	O
and	5	O
oxidative	9	O
stress	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
the	5	O
authors	5	O
induced	3	O
orofacial	5	B-Disease
dyskinesia	5	I-Disease
by	9	O
acute	9	O
reserpine	0	B-Chemical
and	5	O
subchronic	0	O
haloperidol	5	B-Chemical
administration	9	O
to	5	O
rats	9	O
.	9	O

Reserpine	0	B-Chemical
injection	9	O
(	9	O
one	5	O
dose	9	O
of	5	O
1	9	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
every	5	O
other	5	O
day	9	O
for	5	O
3	9	O
days	9	O
caused	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
vacuous	5	O
chewing	5	O
,	9	O
tongue	5	O
protrusion	5	O
and	5	O
duration	5	O
of	5	O
facial	5	O
twitching	5	O
,	9	O
compared	9	O
to	5	O
the	5	O
control	9	O
.	9	O

Haloperidol	7	B-Chemical
administration	9	O
(	9	O
one	5	O
dose	9	O
of	5	O
12	9	O
mg	0	O
/	9	O
kg	0	O
once	5	O
a	5	O
week	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
for	5	O
4	9	O
weeks	9	O
caused	9	O
an	5	O
increase	9	O
in	5	O
vacuous	5	O
chewing	5	O
,	9	O
tongue	5	O
protrusion	5	O
and	5	O
duration	5	O
of	5	O
facial	5	O
twitching	5	O
observed	9	O
in	5	O
four	9	O
weekly	5	O
evaluations	5	O
.	9	O

After	9	O
the	5	O
treatments	9	O
and	5	O
behavioral	5	O
observation	9	O
,	9	O
glutamate	0	B-Chemical
uptake	0	O
by	9	O
segments	9	O
of	5	O
the	5	O
brain	5	O
was	9	O
analyzed	9	O
.	9	O

A	9	O
decreased	9	O
glutamate	0	B-Chemical
uptake	0	O
was	9	O
observed	9	O
in	5	O
the	5	O
subcortical	5	O
parts	5	O
of	5	O
animals	9	O
treated	3	O
with	5	O
reserpine	0	B-Chemical
and	5	O
haloperidol	5	B-Chemical
,	9	O
compared	9	O
to	5	O
the	5	O
control	9	O
.	9	O

Importantly	9	O
,	9	O
a	5	O
decrease	9	O
in	5	O
glutamate	0	B-Chemical
uptake	0	O
correlates	9	O
negatively	9	O
with	5	O
an	5	O
increase	9	O
in	5	O
the	5	O
incidence	5	O
of	5	O
orofacial	5	B-Disease
diskinesia	5	I-Disease
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
early	9	O
changes	9	O
in	5	O
glutamate	0	B-Chemical
transport	9	O
may	5	O
be	5	O
related	9	O
to	5	O
the	5	O
development	9	O
of	5	O
vacuous	5	O
chewing	5	O
movements	5	O
in	5	O
rats	9	O
.	9	O

Ceftriaxone	7	B-Chemical
-	7	O
associated	9	O
biliary	5	B-Disease
pseudolithiasis	5	I-Disease
in	5	O
paediatric	5	O
surgical	5	O
patients	5	O
.	9	O

It	5	O
is	5	O
well	9	O
known	9	O
that	5	O
ceftriaxone	0	B-Chemical
leads	9	O
to	5	O
pseudolithiasis	5	B-Disease
in	5	O
some	5	O
patients	5	O
.	9	O

Clinical	5	O
and	5	O
experimental	5	O
studies	9	O
also	9	O
suggest	9	O
that	5	O
situations	5	O
causing	9	O
gallbladder	5	B-Disease
dysfunction	9	I-Disease
,	9	O
such	5	O
as	5	O
fasting	9	O
,	9	O
may	5	O
have	5	O
a	5	O
role	9	O
for	5	O
the	5	O
development	9	O
of	5	O
pseudolithiasis	5	B-Disease
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
prospectively	5	O
evaluated	9	O
the	5	O
incidence	5	O
and	5	O
clinical	5	O
importance	5	O
of	5	O
pseudolithiasis	5	B-Disease
in	5	O
paediatric	5	O
surgical	5	O
patients	5	O
receiving	9	O
ceftriaxone	0	B-Chemical
treatment	9	O
,	9	O
who	5	O
often	5	O
had	9	O
to	5	O
fast	5	O
in	5	O
the	5	O
post	9	O
-	7	O
operative	5	O
period	5	O
.	9	O

Fifty	9	O
children	5	O
who	5	O
were	9	O
given	5	O
ceftriaxone	0	B-Chemical
were	9	O
evaluated	9	O
by	9	O
serial	9	O
abdominal	5	O
sonograms	5	O
.	9	O

Of	9	O
those	5	O
,	9	O
13	7	O
(	9	O
26	7	O
%	9	O
)	9	O
developed	5	O
biliary	5	O
pathology	5	O
.	9	O

Comparison	9	O
of	5	O
the	5	O
patients	5	O
with	5	O
or	5	O
without	9	O
pseudolithiasis	5	B-Disease
revealed	9	O
no	9	O
significant	9	O
difference	9	O
with	5	O
respect	9	O
to	5	O
age	5	O
,	9	O
sex	5	O
,	9	O
duration	5	O
of	5	O
the	5	O
treatment	9	O
and	5	O
starvation	9	O
variables	5	O
.	9	O

After	9	O
cessation	5	O
of	5	O
the	5	O
treatment	9	O
,	9	O
pseudolithiasis	5	B-Disease
resolved	9	O
spontaneously	5	O
within	9	O
a	5	O
short	5	O
period	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
pseudolithiasis	5	B-Disease
is	5	O
not	5	O
affected	9	O
by	9	O
fasting	9	O
.	9	O

Coronary	5	B-Disease
aneurysm	5	I-Disease
after	9	O
implantation	5	O
of	5	O
a	5	O
paclitaxel	0	B-Chemical
-	7	O
eluting	0	O
stent	5	O
.	9	O

Formation	9	O
of	5	O
coronary	5	B-Disease
aneurysm	5	I-Disease
is	5	O
a	5	O
rare	5	O
complication	5	O
of	5	O
stenting	5	O
with	5	O
bare	5	O
metal	0	O
stents	5	O
,	9	O
but	9	O
based	5	O
on	5	O
experimental	5	O
studies	9	O
drug	5	O
-	7	O
eluting	0	O
stents	5	O
may	5	O
induce	3	O
toxic	0	O
effects	9	O
on	5	O
the	5	O
vessel	5	O
wall	5	O
with	5	O
incomplete	9	O
stent	5	O
apposition	5	O
,	9	O
aneurysm	5	B-Disease
formation	9	O
and	5	O
with	5	O
the	5	O
potential	9	O
of	5	O
stent	5	O
thrombosis	5	B-Disease
or	5	O
vessel	5	B-Disease
rupture	5	I-Disease
.	9	O

We	9	O
present	9	O
a	5	O
43	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
developed	5	O
a	5	O
coronary	5	B-Disease
aneurysm	5	I-Disease
in	5	O
the	5	O
right	5	O
coronary	5	O
artery	5	O
6	9	O
months	5	O
after	9	O
receiving	9	O
a	5	O
paclitaxel	0	B-Chemical
-	7	O
eluting	0	O
stent	5	O
.	9	O

The	5	O
patient	5	O
was	9	O
asymptomatic	5	O
and	5	O
the	5	O
aneurysm	5	B-Disease
was	9	O
detected	9	O
in	5	O
a	5	O
routine	5	O
control	9	O
.	9	O

Angiography	5	O
and	5	O
intracoronary	5	O
ultrasound	5	O
demonstrated	9	O
lack	9	O
of	5	O
contact	5	O
between	5	O
stent	5	O
and	5	O
vessel	5	O
wall	5	O
in	5	O
a	5	O
15	9	O
-	7	O
mm	9	O
long	5	O
segment	9	O
with	5	O
maximal	9	O
aneurysm	5	B-Disease
diameter	9	O
of	5	O
6	9	O
.	9	O
0	7	O
mm	9	O
.	9	O

The	5	O
patient	5	O
was	9	O
successfully	5	O
treated	3	O
with	5	O
a	5	O
graft	5	O
stent	5	O
.	9	O

Causes	5	O
of	5	O
acute	9	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
in	5	O
patients	5	O
receiving	9	O
kidney	9	O
transplantation	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
Thrombotic	5	B-Disease
microangiopathy	5	I-Disease
is	5	O
a	5	O
well	9	O
-	7	O
known	9	O
problem	5	O
in	5	O
patients	5	O
following	9	O
renal	9	O
transplantation	9	O
.	9	O

In	9	O
postrenal	5	O
transplantation	9	O
,	9	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
is	5	O
often	5	O
a	5	O
reflection	5	O
of	5	O
hemolytic	0	B-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
.	9	O

We	9	O
aimed	5	O
to	5	O
determine	9	O
the	5	O
causes	9	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
in	5	O
a	5	O
population	5	O
of	5	O
renal	9	O
transplantation	9	O
recipients	9	O
and	5	O
discuss	5	O
the	5	O
literature	5	O
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
We	9	O
investigated	9	O
the	5	O
causes	9	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
during	5	O
a	5	O
1	9	O
-	7	O
year	5	O
period	5	O
,	9	O
from	9	O
June	2	O
2003	2	O
to	5	O
June	2	O
2004	2	O
,	9	O
at	9	O
the	5	O
King	6	O
Fahad	2	O
National	2	O
Guard	2	O
Hospital	2	O
in	5	O
Riyadh	2	O
,	9	O
Saudi	4	O
Arabia	4	O
,	9	O
by	9	O
reviewing	5	O
the	5	O
slides	9	O
of	5	O
all	5	O
transplant	9	O
biopsies	9	O
(	9	O
n	9	O
=	7	O
25	9	O
)	9	O
performed	9	O
during	5	O
this	5	O
interval	5	O
.	9	O

Pre	9	O
-	7	O
and	5	O
posttransplant	5	O
crossmatching	5	O
was	9	O
done	9	O
when	5	O
possible	5	O
.	9	O

RESULTS	9	O
:	9	O
Five	9	O
cases	5	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
were	9	O
found	9	O
.	9	O

Three	9	O
of	5	O
these	5	O
cases	5	O
were	9	O
from	9	O
the	5	O
25	9	O
transplantations	5	O
performed	9	O
at	9	O
King	6	O
Fahad	2	O
National	2	O
Guard	2	O
Hospital	2	O
,	9	O
while	9	O
the	5	O
other	5	O
2	9	O
transplantations	5	O
had	9	O
been	9	O
performed	9	O
abroad	5	O
and	5	O
were	9	O
referred	5	O
to	5	O
us	5	O
for	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

Three	9	O
cases	5	O
were	9	O
related	9	O
to	5	O
cyclosporine	0	B-Chemical
,	9	O
and	5	O
1	9	O
case	5	O
was	9	O
secondary	9	O
to	5	O
both	9	O
cyclosporine	0	B-Chemical
and	5	O
tacrolimus	0	B-Chemical
.	9	O

The	5	O
fifth	9	O
case	5	O
had	9	O
features	5	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
related	9	O
to	5	O
an	5	O
antiphospholipid	5	B-Disease
syndrome	5	I-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
systemic	9	B-Disease
lupus	9	I-Disease
erythematosus	9	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
In	9	O
the	5	O
literature	5	O
,	9	O
the	5	O
most	9	O
-	7	O
frequent	5	O
cause	5	O
of	5	O
hemolytic	0	B-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
in	5	O
patients	5	O
following	9	O
renal	9	O
transplantation	9	O
is	5	O
recurrence	5	O
of	5	O
the	5	O
hemolytic	0	B-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
.	9	O

Other	9	O
causes	9	O
include	5	O
drug	5	O
-	7	O
related	9	O
(	9	O
cyclosporine	0	B-Chemical
,	9	O
tacrolimus	0	B-Chemical
)	9	O
toxicity	9	B-Disease
,	9	O
procoagulant	9	O
status	9	O
,	9	O
and	5	O
antibody	3	O
-	7	O
mediated	3	O
rejection	5	O
.	9	O

We	9	O
found	9	O
that	5	O
the	5	O
most	9	O
-	7	O
frequent	5	O
cause	5	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
was	9	O
drug	5	O
related	9	O
,	9	O
secondary	9	O
mainly	9	O
to	5	O
cyclosporine	0	B-Chemical
.	9	O

In	9	O
the	5	O
current	5	O
study	9	O
,	9	O
the	5	O
frequency	5	O
of	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
was	9	O
similar	9	O
to	5	O
the	5	O
percentage	9	O
reported	9	O
in	5	O
the	5	O
literature	5	O
(	9	O
20	9	O
%	9	O
)	9	O
.	9	O

Comparison	9	O
of	5	O
developmental	9	O
toxicity	9	B-Disease
of	5	O
selective	9	O
and	5	O
non	9	O
-	7	O
selective	9	O
cyclooxygenase	0	O
-	7	O
2	9	O
inhibitors	3	O
in	5	O
CRL	9	O
:	9	O
(	9	O
WI	9	O
)	9	O
WUBR	_	O
Wistar	9	O
rats	9	O
-	7	O
-	7	O
DFU	5	B-Chemical
and	5	O
piroxicam	0	B-Chemical
study	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Cyclooxygenase	0	O
(	9	O
COX	9	O
)	9	O
inhibitors	3	O
are	5	O
one	5	O
of	5	O
the	5	O
most	9	O
often	5	O
ingested	0	O
drugs	5	O
during	5	O
pregnancy	5	O
.	9	O

Unlike	9	O
general	5	O
toxicity	9	B-Disease
data	5	O
,	9	O
their	5	O
prenatal	5	O
toxic	0	O
effects	9	O
were	9	O
not	5	O
extensively	9	O
studied	9	O
before	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
experiment	9	O
was	9	O
to	5	O
evaluate	9	O
the	5	O
developmental	9	O
toxicity	9	B-Disease
of	5	O
the	5	O
non	9	O
-	7	O
selective	9	O
(	9	O
piroxicam	0	B-Chemical
)	9	O
and	5	O
selective	9	O
(	9	O
DFU	5	B-Chemical
;	9	O
5	9	B-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
dimethyl	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
fluorophenyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methylsulphonyl	0	I-Chemical
)	9	I-Chemical
phenyl	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
(	9	I-Chemical
5H	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
furanon	_	I-Chemical
)	9	O
COX	9	O
-	7	O
2	9	O
inhibitors	3	O
.	9	O

METHODS	2	O
:	9	O
Drugs	0	O
were	9	O
separately	9	O
,	9	O
orally	0	O
once	5	O
daily	5	O
dosed	0	O
to	5	O
pregnant	5	O
rats	9	O
from	9	O
day	9	O
8	9	O
to	5	O
21	7	O
(	9	O
GD1	1	O
=	7	O
plug	5	O
day	9	O
)	9	O
.	9	O

Doses	0	O
were	9	O
set	5	O
at	9	O
0	7	O
.	9	O
3	9	O
,	9	O
3	9	O
.	9	O
0	7	O
and	5	O
30	9	O
.	9	O
0mg	7	O
/	9	O
kg	0	O
for	5	O
piroxicam	0	B-Chemical
and	5	O
0	7	O
.	9	O
2	9	O
,	9	O
2	9	O
.	9	O
0	7	O
and	5	O
20	9	O
.	9	O
0mg	7	O
/	9	O
kg	0	O
for	5	O
DFU	5	B-Chemical
.	9	O

Fetuses	5	O
were	9	O
delivered	5	O
on	5	O
GD	9	O
21	7	O
and	5	O
routinely	9	O
examined	9	O
.	9	O

Comprehensive	2	O
clinical	5	O
and	5	O
developmental	9	O
measurements	5	O
were	9	O
done	9	O
.	9	O

The	5	O
pooled	9	O
statistical	5	O
analysis	9	O
for	5	O
ventricular	5	B-Disease
septal	5	I-Disease
(	9	I-Disease
VSD	5	I-Disease
)	9	I-Disease
and	5	I-Disease
midline	5	I-Disease
(	9	I-Disease
MD	9	I-Disease
)	9	I-Disease
defects	9	I-Disease
was	9	O
performed	9	O
for	5	O
rat	3	O
fetuses	9	O
exposed	9	O
to	5	O
piroxicam	0	B-Chemical
,	9	O
selective	9	O
and	5	O
non	9	O
-	7	O
selective	9	O
COX	9	O
-	7	O
2	9	O
inhibitor	3	O
based	5	O
on	5	O
present	9	O
and	5	O
historic	5	O
data	5	O
.	9	O

RESULTS	9	O
:	9	O
Maternal	9	O
toxicity	9	B-Disease
,	9	O
intrauterine	5	B-Disease
growth	3	I-Disease
retardation	9	I-Disease
,	9	O
and	5	O
increase	9	B-Disease
of	5	I-Disease
external	5	I-Disease
and	5	I-Disease
skeletal	9	I-Disease
variations	5	I-Disease
were	9	O
found	9	O
in	5	O
rats	9	O
treated	3	O
with	5	O
the	5	O
highest	9	O
dose	9	O
of	5	O
piroxicam	0	B-Chemical
.	9	O

Decrease	9	O
of	5	O
fetal	9	O
length	9	O
was	9	O
the	5	O
only	9	O
signs	5	O
of	5	O
the	5	O
DFU	5	B-Chemical
developmental	9	O
toxicity	9	B-Disease
observed	9	O
in	5	O
pups	9	O
exposed	9	O
to	5	O
the	5	O
highest	9	O
compound	0	O
dose	9	O
.	9	O

Lack	9	O
of	5	O
teratogenicity	5	O
was	9	O
found	9	O
in	5	O
piroxicam	0	B-Chemical
and	5	O
DFU	5	B-Chemical
-	7	O
exposed	9	O
groups	9	O
.	9	O

Prenatal	5	O
exposure	9	O
to	5	O
non	9	O
-	7	O
selective	9	O
COX	9	O
inhibitors	3	O
increases	9	O
the	5	O
risk	5	O
of	5	O
VSD	5	O
and	5	O
MD	9	O
when	5	O
compared	9	O
to	5	O
historic	5	O
control	9	O
but	9	O
not	5	O
with	5	O
selective	9	O
COX	9	O
-	7	O
2	9	O
inhibitors	3	O
.	9	O

CONCLUSION	5	O
:	9	O
Both	9	O
selective	9	O
and	5	O
non	9	O
-	7	O
selective	9	O
COX	9	O
-	7	O
2	9	O
inhibitors	3	O
were	9	O
toxic	0	O
for	5	O
rats	9	O
fetuses	9	O
when	5	O
administered	9	O
in	5	O
the	5	O
highest	9	O
dose	9	O
.	9	O

Unlike	9	O
DFU	5	B-Chemical
,	9	O
piroxicam	0	B-Chemical
was	9	O
also	9	O
highly	9	O
toxic	0	O
to	5	O
the	5	O
dams	9	O
.	9	O

Prenatal	5	O
exposure	9	O
to	5	O
selective	9	O
COX	9	O
-	7	O
2	9	O
inhibitors	3	O
does	9	O
not	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
ventricular	5	B-Disease
septal	5	I-Disease
and	5	I-Disease
midline	5	I-Disease
defects	9	I-Disease
in	5	O
rat	3	O
when	5	O
compared	9	O
to	5	O
non	9	O
-	7	O
selective	9	O
drugs	5	O
and	5	O
historic	5	O
control	9	O
.	9	O

Lone	6	O
atrial	5	B-Disease
fibrillation	5	I-Disease
associated	9	O
with	5	O
creatine	0	B-Chemical
monohydrate	0	O
supplementation	0	O
.	9	O

Atrial	7	B-Disease
fibrillation	5	I-Disease
in	5	O
young	5	O
patients	5	O
without	9	O
structural	9	O
heart	5	B-Disease
disease	5	I-Disease
is	5	O
rare	5	O
.	9	O

Therefore	9	O
,	9	O
when	5	O
the	5	O
arrhythmia	5	B-Disease
is	5	O
present	9	O
in	5	O
this	5	O
population	5	O
,	9	O
reversible	9	O
causes	9	O
must	5	O
be	5	O
identified	9	O
and	5	O
resolved	9	O
.	9	O

Thyroid	9	B-Disease
disorders	5	I-Disease
,	9	O
illicit	5	O
drug	5	O
or	5	O
stimulant	5	O
use	5	O
,	9	O
and	5	O
acute	9	B-Disease
alcohol	5	I-Disease
intoxication	9	I-Disease
are	5	O
among	5	O
these	5	O
causes	9	O
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
30	9	O
-	7	O
year	5	O
-	7	O
old	5	O
Caucasian	9	O
man	5	O
who	5	O
came	5	O
to	5	O
the	5	O
emergency	5	O
department	5	O
in	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
with	5	O
rapid	5	O
ventricular	5	O
response	9	O
.	9	O

His	9	O
medical	5	O
history	5	O
was	9	O
unremarkable	5	O
,	9	O
except	9	O
for	5	O
minor	9	O
fractures	5	B-Disease
of	5	O
the	5	O
fingers	5	O
and	5	O
foot	5	O
.	9	O

Thyroid	9	O
-	7	O
stimulating	9	O
hormone	9	O
,	9	O
magnesium	0	B-Chemical
,	9	O
and	5	O
potassium	0	B-Chemical
levels	3	O
were	9	O
within	9	O
normal	9	O
limits	5	O
,	9	O
urine	9	O
drug	5	O
screen	5	O
was	9	O
negative	9	O
,	9	O
and	5	O
alcohol	5	B-Chemical
use	5	O
was	9	O
denied	5	O
.	9	O

However	9	O
,	9	O
when	5	O
the	5	O
patient	5	O
was	9	O
questioned	5	O
about	5	O
use	5	O
of	5	O
herbal	5	O
products	9	O
and	5	O
supplements	9	O
,	9	O
the	5	O
use	5	O
of	5	O
creatine	0	B-Chemical
monohydrate	0	O
was	9	O
revealed	9	O
.	9	O

The	5	O
patient	5	O
was	9	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
,	9	O
anticoagulated	5	O
with	5	O
unfractionated	9	O
heparin	0	B-Chemical
,	9	O
and	5	O
given	5	O
intravenous	0	O
diltiazem	0	B-Chemical
for	5	O
rate	9	O
control	9	O
and	5	O
intravenous	0	O
amiodarone	0	B-Chemical
for	5	O
rate	9	O
and	5	O
rhythm	5	O
control	9	O
.	9	O

When	9	O
discharged	5	O
less	5	O
than	5	O
24	9	O
hours	9	O
later	9	O
,	9	O
he	5	O
was	9	O
receiving	9	O
metoprolol	0	B-Chemical
and	5	O
aspirin	9	B-Chemical
,	9	O
with	5	O
follow	5	O
-	7	O
up	5	O
plans	5	O
for	5	O
echocardiography	5	O
and	5	O
nuclear	3	O
imaging	5	O
to	5	O
assess	5	O
perfusion	5	O
.	9	O

Exogenous	3	O
creatine	0	B-Chemical
is	5	O
used	5	O
by	9	O
athletes	5	O
to	5	O
theoretically	5	O
improve	5	O
exercise	5	O
performance	5	O
.	9	O

Vegetarians	7	O
may	5	O
also	9	O
take	5	O
creatine	0	B-Chemical
to	5	O
replace	5	O
what	5	O
they	5	O
are	5	O
not	5	O
consuming	5	O
from	9	O
meat	5	O
,	9	O
fish	4	O
,	9	O
and	5	O
other	5	O
animal	5	O
products	9	O
.	9	O

Previous	9	O
anecdotal	5	O
reports	9	O
have	5	O
linked	9	O
creatine	0	B-Chemical
to	5	O
the	5	O
development	9	O
of	5	O
arrhythmia	5	B-Disease
.	9	O

Clinicians	5	O
must	5	O
be	5	O
diligent	2	O
when	5	O
interviewing	5	O
patients	5	O
about	5	O
their	5	O
drug	5	O
therapy	5	O
histories	5	O
and	5	O
include	5	O
questions	5	O
about	5	O
their	5	O
use	5	O
of	5	O
herbal	5	O
products	9	O
and	5	O
dietary	5	O
supplements	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
it	5	O
is	5	O
important	9	O
to	5	O
report	5	O
adverse	5	O
effects	9	O
associated	9	O
with	5	O
frequently	5	O
consumed	5	O
supplements	9	O
and	5	O
herbal	5	O
products	9	O
to	5	O
the	5	O
Food	5	O
and	5	O
Drug	5	O
Administration	2	O
and	5	O
in	5	O
the	5	O
literature	5	O
.	9	O

Seizures	5	B-Disease
induced	3	O
by	9	O
the	5	O
cocaine	5	B-Chemical
metabolite	0	O
benzoylecgonine	0	B-Chemical
in	5	O
rats	9	O
.	9	O

The	5	O
half	5	O
-	7	O
life	5	O
(	9	O
t1	9	O
/	9	O
2	9	O
)	9	O
of	5	O
cocaine	5	B-Chemical
is	5	O
relatively	5	O
short	5	O
,	9	O
but	9	O
some	5	O
of	5	O
the	5	O
consequences	5	O
of	5	O
its	9	O
use	5	O
,	9	O
such	5	O
as	5	O
seizures	5	B-Disease
and	5	O
strokes	5	B-Disease
,	9	O
can	5	O
occur	5	O
hours	9	O
after	9	O
exposure	9	O
.	9	O

This	5	O
led	9	O
us	5	O
to	5	O
hypothesize	9	O
that	5	O
a	5	O
metabolite	0	O
of	5	O
cocaine	5	B-Chemical
may	5	O
be	5	O
responsible	9	O
for	5	O
some	5	O
of	5	O
those	5	O
delayed	9	O
sequelae	5	O
.	9	O

We	9	O
evaluated	9	O
the	5	O
potential	9	O
of	5	O
the	5	O
major	9	O
metabolite	0	O
of	5	O
cocaine	5	B-Chemical
,	9	O
benzoylecgonine	0	B-Chemical
(	9	O
BE	9	B-Chemical
)	9	O
,	9	O
to	5	O
cause	5	O
seizures	5	B-Disease
.	9	O

Two	9	O
separate	9	O
equimolar	0	O
doses	0	O
(	9	O
0	7	O
.	9	O
2	9	O
and	5	O
0	7	O
.	9	O
4	9	O
mumol	7	O
)	9	O
of	5	O
either	9	O
cocaine	5	B-Chemical
or	5	O
BE	9	B-Chemical
were	9	O
injected	3	O
ventricularly	3	O
in	5	O
unanesthetized	5	O
juvenile	4	O
rats	9	O
.	9	O

Treated	9	O
rats	9	O
were	9	O
then	9	O
evaluated	9	O
for	5	O
incidence	5	O
,	9	O
latency	5	O
,	9	O
and	5	O
seizure	5	B-Disease
pattern	9	O
or	5	O
for	5	O
locomotor	5	O
activity	9	O
in	5	O
animals	9	O
without	9	O
seizures	5	B-Disease
.	9	O

BE	9	B-Chemical
-	7	O
Induced	9	O
seizures	5	B-Disease
occurred	9	O
more	5	O
frequently	5	O
and	5	O
had	9	O
significantly	9	O
longer	5	O
latencies	5	O
than	5	O
those	5	O
induced	3	O
by	9	O
equimolar	0	O
amounts	9	O
of	5	O
cocaine	5	B-Chemical
.	9	O

Whereas	9	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
were	9	O
best	5	O
characterized	9	O
as	5	O
brief	5	O
,	9	O
generalized	5	O
,	9	O
and	5	O
tonic	5	O
and	5	O
resulted	9	O
in	5	O
death	9	B-Disease
,	9	O
those	5	O
induced	3	O
by	9	O
BE	9	B-Chemical
were	9	O
prolonged	9	O
,	9	O
often	5	O
multiple	5	O
and	5	O
mixed	9	O
in	5	O
type	9	O
,	9	O
and	5	O
rarely	5	O
resulted	9	O
in	5	O
death	9	B-Disease
.	9	O

Electrical	5	O
recordings	5	O
from	9	O
the	5	O
hippocampus	9	O
showed	9	O
a	5	O
rhythmic	5	O
progression	9	O
in	5	O
EEG	5	O
frequency	5	O
and	5	O
voltage	5	O
with	5	O
clinical	5	O
seizure	5	B-Disease
expression	3	O
.	9	O

BE	9	B-Chemical
-	7	O
Injected	9	O
rats	9	O
that	5	O
did	9	O
not	5	O
have	5	O
seizures	5	B-Disease
had	9	O
significantly	9	O
more	5	O
locomotor	5	O
activity	9	O
than	5	O
cocaine	5	B-Chemical
-	7	O
injected	3	O
animals	9	O
without	9	O
seizures	5	B-Disease
.	9	O

The	5	O
finding	9	O
that	5	O
cocaine	5	B-Chemical
-	7	O
and	5	O
BE	9	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
differ	9	O
in	5	O
several	9	O
respects	5	O
suggests	9	O
more	5	O
than	5	O
one	5	O
mechanism	9	O
for	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
emphasizes	5	O
the	5	O
importance	5	O
of	5	O
a	5	O
cocaine	5	B-Chemical
metabolite	0	O
,	9	O
BE	9	B-Chemical
.	9	O

The	5	O
selective	9	O
5	9	O
-	7	O
HT6	1	O
receptor	3	O
antagonist	3	O
Ro4368554	_	B-Chemical
restores	3	O
memory	5	O
performance	5	O
in	5	O
cholinergic	3	O
and	5	O
serotonergic	5	O
models	5	O
of	5	O
memory	5	B-Disease
deficiency	9	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Antagonists	3	O
at	9	O
serotonin	9	B-Chemical
type	9	O
6	9	O
(	9	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
(	9	O
6	9	O
)	9	O
)	9	O
receptors	3	O
show	9	O
activity	9	O
in	5	O
models	5	O
of	5	O
learning	5	O
and	5	O
memory	5	O
.	9	O

Although	9	O
the	5	O
underlying	5	O
mechanism	9	O
(	9	O
s	9	O
)	9	O
are	5	O
not	5	O
well	9	O
understood	5	O
,	9	O
these	5	O
effects	9	O
may	5	O
involve	5	O
an	5	O
increase	9	O
in	5	O
acetylcholine	0	B-Chemical
(	9	O
ACh	0	B-Chemical
)	9	O
levels	3	O
.	9	O

The	5	O
present	9	O
study	9	O
sought	9	O
to	5	O
characterize	9	O
the	5	O
cognitive	5	O
-	7	O
enhancing	9	O
effects	9	O
of	5	O
the	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
(	9	O
6	9	O
)	9	O
antagonist	3	O
Ro4368554	_	B-Chemical
(	9	O
3	9	B-Chemical
-	7	I-Chemical
benzenesulfonyl	0	I-Chemical
-	7	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
piperazin	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
yl	0	I-Chemical
)	9	I-Chemical
1H	0	I-Chemical
-	7	I-Chemical
indole	0	I-Chemical
)	9	O
in	5	O
a	5	O
rat	3	O
object	5	O
recognition	5	O
task	5	O
employing	9	O
a	5	O
cholinergic	3	O
(	9	O
scopolamine	0	B-Chemical
pretreatment	0	O
)	9	O
and	5	O
a	5	O
serotonergic	5	O
-	7	O
(	9	O
tryptophan	0	B-Chemical
(	9	O
TRP	9	B-Chemical
)	9	O
depletion	3	O
)	9	O
deficient	3	O
model	5	O
,	9	O
and	5	O
compared	9	O
its	9	O
pattern	9	O
of	5	O
action	5	O
with	5	O
that	5	O
of	5	O
the	5	O
acetylcholinesterase	0	O
inhibitor	3	O
metrifonate	0	B-Chemical
.	9	O

Initial	9	O
testing	5	O
in	5	O
a	5	O
time	5	O
-	7	O
dependent	9	O
forgetting	5	O
task	5	O
employing	9	O
a	5	O
24	9	O
-	7	O
h	0	O
delay	5	O
between	5	O
training	5	O
and	5	O
testing	5	O
showed	9	O
that	5	O
metrifonate	0	B-Chemical
improved	5	O
object	5	O
recognition	5	O
(	9	O
at	9	O
10	9	O
and	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
,	9	O
whereas	9	O
Ro4368554	_	B-Chemical
was	9	O
inactive	9	O
.	9	O

Both	9	O
,	9	O
Ro4368554	_	B-Chemical
(	9	O
3	9	O
and	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
intraperitoneally	0	O
(	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
)	9	O
and	5	O
metrifonate	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
,	9	O
respectively	9	O
)	9	O
reversed	9	O
memory	5	B-Disease
deficits	5	I-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
and	5	O
TRP	9	B-Chemical
depletion	3	O
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
and	5	O
3	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
although	9	O
Ro4368554	_	B-Chemical
did	9	O
not	5	O
improve	5	O
a	5	O
time	5	O
-	7	O
related	9	O
retention	9	O
deficit	5	O
,	9	O
it	5	O
reversed	9	O
a	5	O
cholinergic	3	O
and	5	O
a	5	O
serotonergic	5	O
memory	5	B-Disease
deficit	5	I-Disease
,	9	O
suggesting	9	O
that	5	O
both	9	O
mechanisms	9	O
may	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
facilitation	5	O
of	5	O
object	5	O
memory	5	O
by	9	O
Ro4368554	_	B-Chemical
and	5	O
,	9	O
possibly	9	O
,	9	O
other	5	O
5	9	B-Chemical
-	7	I-Chemical
HT	9	I-Chemical
(	9	O
6	9	O
)	9	O
receptor	3	O
antagonists	3	O
.	9	O

Evaluation	5	O
of	5	O
the	5	O
anticocaine	_	O
monoclonal	3	O
antibody	3	O
GNC92H2	_	B-Chemical
as	5	O
an	5	O
immunotherapy	5	O
for	5	O
cocaine	5	B-Disease
overdose	0	I-Disease
.	9	O

The	5	O
illicit	5	O
use	5	O
of	5	O
cocaine	5	B-Chemical
continues	5	O
in	5	O
epidemic	5	O
proportions	9	O
and	5	O
treatment	9	O
for	5	O
cocaine	5	B-Disease
overdose	0	I-Disease
remains	9	O
elusive	9	O
.	9	O

Current	9	O
protein	1	O
-	7	O
based	5	O
technology	5	O
offers	5	O
a	5	O
new	5	O
therapeutic	5	O
venue	5	O
by	9	O
which	5	O
antibodies	3	O
bind	1	O
the	5	O
drug	5	O
in	5	O
the	5	O
blood	9	O
stream	5	O
,	9	O
inactivating	9	O
its	9	O
toxic	0	O
effects	9	O
.	9	O

The	5	O
therapeutic	5	O
potential	9	O
of	5	O
the	5	O
anticocaine	_	O
antibody	3	O
GNC92H2	_	B-Chemical
was	9	O
examined	9	O
using	9	O
a	5	O
model	5	O
of	5	O
cocaine	5	B-Disease
overdose	0	I-Disease
.	9	O

Swiss	2	O
albino	3	O
mice	3	O
prepared	0	O
with	5	O
intrajugular	0	O
catheters	5	O
were	9	O
tested	9	O
in	5	O
photocell	5	O
cages	5	O
after	9	O
administration	9	O
of	5	O
93	7	O
mg	0	O
/	9	O
kg	0	O
(	9	O
LD50	0	O
)	9	O
of	5	O
cocaine	5	B-Chemical
and	5	O
GNC92H2	_	B-Chemical
infusions	9	O
ranging	9	O
from	9	O
30	9	O
to	5	O
190	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

GNC92H2	_	B-Chemical
was	9	O
delivered	5	O
30	9	O
min	0	O
before	9	O
,	9	O
concomitantly	9	O
or	5	O
3	9	O
min	0	O
after	9	O
cocaine	5	B-Chemical
treatment	9	O
.	9	O

Significant	9	O
blockade	3	O
of	5	O
cocaine	5	B-Chemical
toxicity	9	B-Disease
was	9	O
observed	9	O
with	5	O
the	5	O
higher	9	O
dose	9	O
of	5	O
GNC92H2	_	B-Chemical
(	9	O
190	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
where	5	O
premorbid	5	O
behaviors	5	O
were	9	O
reduced	9	O
up	5	O
to	5	O
40	9	O
%	9	O
,	9	O
seizures	5	B-Disease
up	5	O
to	5	O
77	7	O
%	9	O
and	5	O
death	9	B-Disease
by	9	O
72	9	O
%	9	O
.	9	O

Importantly	9	O
,	9	O
GNC92H2	_	B-Chemical
prevented	9	O
death	9	B-Disease
even	5	O
post	9	O
-	7	O
cocaine	5	B-Chemical
injection	9	O
.	9	O

The	5	O
results	9	O
support	5	O
the	5	O
important	9	O
potential	9	O
of	5	O
GNC92H2	_	B-Chemical
as	5	O
a	5	O
therapeutic	5	O
tool	5	O
against	9	O
cocaine	5	B-Disease
overdose	0	I-Disease
.	9	O

Electrocardiographic	5	O
evidence	9	O
of	5	O
myocardial	9	B-Disease
injury	9	I-Disease
in	5	O
psychiatrically	5	O
hospitalized	5	O
cocaine	5	B-Chemical
abusers	5	O
.	9	O

The	5	O
electrocardiograms	5	O
(	9	O
ECG	5	O
)	9	O
of	5	O
99	7	O
cocaine	5	B-Chemical
-	7	O
abusing	5	O
patients	5	O
were	9	O
compared	9	O
with	5	O
the	5	O
ECGs	5	O
of	5	O
50	0	O
schizophrenic	5	B-Disease
controls	9	O
.	9	O

Eleven	9	O
of	5	O
the	5	O
cocaine	5	B-Chemical
abusers	5	O
and	5	O
none	9	O
of	5	O
the	5	O
controls	9	O
had	9	O
ECG	5	O
evidence	9	O
of	5	O
significant	9	O
myocardial	9	B-Disease
injury	9	I-Disease
defined	5	O
as	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
,	9	O
ischemia	9	B-Disease
,	9	O
and	5	O
bundle	5	B-Disease
branch	5	I-Disease
block	9	I-Disease
.	9	O

Behavioral	5	O
effects	9	O
of	5	O
urotensin	3	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
centrally	5	O
administered	9	O
in	5	O
mice	3	O
.	9	O

Urotensin	3	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
(	9	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
)	9	O
receptors	3	O
are	5	O
widely	5	O
distributed	5	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
.	9	O

Intracerebroventricular	3	O
(	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
injection	9	O
of	5	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
causes	9	O
hypertension	5	B-Disease
and	5	O
bradycardia	5	B-Disease
and	5	O
stimulates	3	O
prolactin	3	O
and	5	O
thyrotropin	9	O
secretion	3	O
.	9	O

However	9	O
,	9	O
the	5	O
behavioral	5	O
effects	9	O
of	5	O
centrally	5	O
administered	9	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
have	5	O
received	9	O
little	9	O
attention	5	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
we	5	O
tested	9	O
the	5	O
effects	9	O
of	5	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
injections	9	O
of	5	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
on	5	O
behavioral	5	O
,	9	O
metabolic	9	O
,	9	O
and	5	O
endocrine	9	O
responses	5	O
in	5	O
mice	3	O
.	9	O

Administration	2	O
of	5	O
graded	5	O
doses	0	O
of	5	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
(	9	O
1	9	O
-	7	O
10	9	O
,	9	O
000	9	O
ng	0	O
/	9	O
mouse	3	O
)	9	O
provoked	9	O
:	9	O
(	9	O
1	9	O
)	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
reduction	9	O
in	5	O
the	5	O
number	9	O
of	5	O
head	5	O
dips	5	O
in	5	O
the	5	O
hole	5	O
-	7	O
board	5	O
test	5	O
;	9	O
(	9	O
2	9	O
)	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
reduction	9	O
in	5	O
the	5	O
number	9	O
of	5	O
entries	5	O
in	5	O
the	5	O
white	9	O
chamber	9	O
in	5	O
the	5	O
black	9	O
-	7	O
and	5	O
-	7	O
white	9	O
compartment	9	O
test	5	O
,	9	O
and	5	O
in	5	O
the	5	O
number	9	O
of	5	O
entries	5	O
in	5	O
the	5	O
central	5	O
platform	5	O
and	5	O
open	5	O
arms	5	O
in	5	O
the	5	O
plus	9	O
-	7	O
maze	5	O
test	5	O
;	9	O
and	5	O
(	9	O
3	9	O
)	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
increase	9	O
in	5	O
the	5	O
duration	5	O
of	5	O
immobility	5	O
in	5	O
the	5	O
forced	5	O
-	7	O
swimming	5	O
test	5	O
and	5	O
tail	9	O
suspension	0	O
test	5	O
.	9	O

Intracerebroventricular	3	O
injection	9	O
of	5	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
also	9	O
caused	9	O
an	5	O
increase	9	O
in	5	O
:	9	O
food	5	O
intake	5	O
at	9	O
doses	0	O
of	5	O
100	0	O
and	5	O
1	9	O
,	9	O
000	9	O
ng	0	O
/	9	O
mouse	3	O
,	9	O
water	0	O
intake	5	O
at	9	O
doses	0	O
of	5	O
100	0	O
-	7	O
10	9	O
,	9	O
000	9	O
ng	0	O
/	9	O
mouse	3	O
,	9	O
and	5	O
horizontal	5	O
locomotion	5	O
activity	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
10	9	O
,	9	O
000	9	O
ng	0	O
/	9	O
mouse	3	O
.	9	O

Whatever	5	O
was	9	O
the	5	O
dose	9	O
,	9	O
the	5	O
central	5	O
administration	9	O
of	5	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
had	9	O
no	9	O
effect	9	O
on	5	O
body	5	O
temperature	0	O
,	9	O
nociception	5	O
,	9	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
penile	5	B-Disease
erection	5	I-Disease
and	5	O
climbing	5	O
behavior	5	O
,	9	O
and	5	O
stress	9	O
-	7	O
induced	3	O
plasma	9	O
corticosterone	3	B-Chemical
level	9	O
.	9	O

Taken	9	O
together	9	O
,	9	O
the	5	O
present	9	O
study	9	O
demonstrates	9	O
that	5	O
the	5	O
central	5	O
injection	9	O
of	5	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
at	9	O
doses	0	O
of	5	O
1	9	O
-	7	O
10	9	O
,	9	O
000	9	O
ng	0	O
/	9	O
mouse	3	O
induces	3	O
anxiogenic	5	O
-	7	O
and	5	O
depressant	5	O
-	7	O
like	9	O
effects	9	O
in	5	O
mouse	3	O
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
U	9	B-Chemical
-	7	I-Chemical
II	9	I-Chemical
may	5	O
be	5	O
involved	9	O
in	5	O
some	5	O
aspects	5	O
of	5	O
psychiatric	5	B-Disease
disorders	5	I-Disease
.	9	O

Learning	5	O
of	5	O
rats	9	O
under	9	O
amnesia	5	B-Disease
caused	9	O
by	9	O
pentobarbital	0	B-Chemical
.	9	O

Dissociated	3	O
learning	5	O
of	5	O
rats	9	O
in	5	O
the	5	O
normal	9	O
state	5	O
and	5	O
the	5	O
state	5	O
of	5	O
amnesia	5	B-Disease
produced	9	O
by	9	O
pentobarbital	0	B-Chemical
(	9	O
15	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
ip	0	O
)	9	O
was	9	O
carried	9	O
out	9	O
.	9	O

Rats	9	O
were	9	O
trained	5	O
to	5	O
approach	5	O
a	5	O
shelf	5	O
where	5	O
they	5	O
received	9	O
food	5	O
reinforcement	5	O
.	9	O

In	9	O
Group	9	O
1	9	O
the	5	O
rats	9	O
were	9	O
trained	5	O
under	9	O
the	5	O
influence	5	O
of	5	O
pentobarbital	0	B-Chemical
to	5	O
run	5	O
to	5	O
the	5	O
same	9	O
shelf	5	O
as	5	O
in	5	O
the	5	O
normal	9	O
state	5	O
.	9	O

In	9	O
Group	9	O
2	9	O
the	5	O
rats	9	O
were	9	O
trained	5	O
to	5	O
approach	5	O
different	9	O
shelves	5	O
in	5	O
different	9	O
drug	5	O
states	5	O
.	9	O

It	5	O
was	9	O
shown	9	O
that	5	O
memory	5	B-Disease
dissociation	9	I-Disease
occurred	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

Differences	9	O
in	5	O
the	5	O
parameters	5	O
of	5	O
training	5	O
under	9	O
the	5	O
influence	5	O
of	5	O
pentobarbital	0	B-Chemical
between	5	O
Groups	9	O
1	9	O
and	5	O
2	9	O
were	9	O
revealed	9	O
.	9	O

These	5	O
findings	9	O
show	9	O
that	5	O
the	5	O
brain	5	O
-	7	O
dissociated	3	O
state	5	O
induced	3	O
by	9	O
pentobarbital	0	B-Chemical
is	5	O
formed	9	O
with	5	O
the	5	O
participation	5	O
of	5	O
the	5	O
mechanisms	9	O
of	5	O
information	5	O
perception	5	O
.	9	O

The	5	O
effects	9	O
of	5	O
short	5	O
-	7	O
term	5	O
raloxifene	0	B-Chemical
therapy	5	O
on	5	O
fibrinolysis	5	O
markers	3	O
:	9	O
TAFI	9	O
,	9	O
tPA	9	O
,	9	O
and	5	O
PAI	9	O
-	7	O
1	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Markers	9	O
of	5	O
fibrinolysis	5	O
,	9	O
thrombin	0	O
-	7	O
activatable	0	O
fibrinolysis	5	O
inhibitor	3	O
(	9	O
TAFI	9	O
)	9	O
,	9	O
tissue	9	O
-	7	O
type	9	O
plasminogen	3	O
activator	3	O
(	9	O
tPA	9	O
)	9	O
,	9	O
and	5	O
plasminogen	3	O
activator	3	O
inhibitor	3	O
-	7	O
1	9	O
(	9	O
PAI	9	O
-	7	O
1	9	O
)	9	O
levels	3	O
were	9	O
studied	9	O
for	5	O
the	5	O
evaluation	5	O
of	5	O
short	5	O
-	7	O
term	5	O
effects	9	O
of	5	O
raloxifene	0	B-Chemical
administration	9	O
in	5	O
postmenopausal	5	O
women	5	O
.	9	O

METHODS	2	O
:	9	O
Thirty	9	O
-	7	O
nine	9	O
postmenopausal	5	O
women	5	O
with	5	O
osteopenia	5	B-Disease
or	5	O
osteoporosis	5	B-Disease
were	9	O
included	5	O
in	5	O
this	5	O
prospective	5	O
,	9	O
controlled	5	O
clinical	5	O
study	9	O
.	9	O

Twenty	9	O
-	7	O
five	9	O
women	5	O
were	9	O
given	5	O
raloxifene	0	B-Chemical
hydrochloride	0	I-Chemical
(	9	O
60	9	O
mg	0	O
/	9	O
day	9	O
)	9	O
plus	9	O
calcium	0	B-Chemical
(	9	O
500	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
.	9	O

Age	7	O
-	7	O
matched	9	O
controls	9	O
(	9	O
n	9	O
=	7	O
14	7	O
)	9	O
were	9	O
given	5	O
only	9	O
calcium	0	B-Chemical
.	9	O

Plasma	0	O
TAFI	9	O
,	9	O
tPA	9	O
,	9	O
and	5	O
PAI	9	O
-	7	O
1	9	O
antigen	3	O
levels	3	O
were	9	O
measured	9	O
at	9	O
baseline	5	O
and	5	O
after	9	O
3	9	O
months	5	O
of	5	O
treatment	9	O
by	9	O
commercially	0	O
available	5	O
ELISA	3	O
kits	9	O
.	9	O

Variations	9	O
of	5	O
individuals	5	O
were	9	O
assessed	9	O
by	9	O
Wilcoxon	5	O
'	9	O
s	9	O
test	5	O
.	9	O

Relationship	9	O
between	5	O
those	5	O
markers	3	O
and	5	O
demographic	5	O
characteristics	5	O
were	9	O
investigated	9	O
.	9	O

RESULTS	9	O
:	9	O
Three	9	O
months	5	O
of	5	O
raloxifene	0	B-Chemical
treatment	9	O
was	9	O
associated	9	O
with	5	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
the	5	O
plasma	9	O
TAFI	9	O
antigen	3	O
concentrations	0	O
(	9	O
16	9	O
%	9	O
change	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
and	5	O
a	5	O
significant	9	O
increase	9	O
in	5	O
tPA	9	O
antigen	3	O
concentrations	0	O
(	9	O
25	9	O
%	9	O
change	9	O
,	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

A	9	O
significant	9	O
correlation	9	O
was	9	O
found	9	O
between	5	O
baseline	5	O
TAFI	9	O
antigen	3	O
concentrations	0	O
and	5	O
the	5	O
duration	5	O
of	5	O
amenorrhea	5	B-Disease
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
;	9	O
r	9	O
=	7	O
0	7	O
.	9	O
33	7	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
We	9	O
suggest	9	O
that	5	O
the	5	O
increased	9	O
risk	5	O
of	5	O
venous	5	B-Disease
thromboembolism	5	I-Disease
due	5	O
to	5	O
raloxifene	0	B-Chemical
treatment	9	O
may	5	O
be	5	O
related	9	O
to	5	O
increased	9	O
tPA	9	O
levels	3	O
,	9	O
but	9	O
not	5	O
TAFI	9	O
levels	3	O
.	9	O

Valproate	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
.	9	O

Valproate	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
is	5	O
a	5	O
rare	5	O
syndrome	5	O
that	5	O
may	5	O
manifest	5	O
in	5	O
otherwise	9	O
normal	9	O
epileptic	5	B-Disease
individuals	5	O
.	9	O

It	5	O
may	5	O
even	5	O
present	9	O
in	5	O
patients	5	O
who	5	O
have	5	O
tolerated	9	O
this	5	O
medicine	5	O
well	9	O
in	5	O
the	5	O
past	5	O
.	9	O

It	5	O
is	5	O
usually	5	O
but	9	O
not	5	O
necessarily	5	O
associated	9	O
with	5	O
hyperammonemia	5	B-Disease
.	9	O

The	5	O
EEG	5	O
shows	9	O
characteristic	9	O
triphasic	5	O
waves	5	O
in	5	O
most	9	O
patients	5	O
with	5	O
this	5	O
complication	5	O
.	9	O

A	9	O
case	5	O
of	5	O
valproate	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
is	5	O
presented	5	O
.	9	O

The	5	O
problems	5	O
in	5	O
diagnosing	5	O
this	5	O
condition	5	O
are	5	O
subsequently	9	O
discussed	5	O
.	9	O

Recurrent	5	O
dysphonia	5	B-Disease
and	5	O
acitretin	0	B-Chemical
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
woman	5	O
complaining	5	O
of	5	O
dysphonia	5	B-Disease
while	9	O
she	5	O
was	9	O
treated	3	O
by	9	O
acitretin	0	B-Chemical
.	9	O

Her	5	O
symptoms	5	O
totally	9	O
regressed	5	O
after	9	O
drug	5	O
withdrawal	5	O
and	5	O
reappeared	9	O
when	5	O
acitretin	0	B-Chemical
was	9	O
reintroduced	9	O
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
case	5	O
of	5	O
acitretin	0	B-Chemical
-	7	O
induced	3	O
dysphonia	5	B-Disease
.	9	O

This	5	O
effect	9	O
may	5	O
be	5	O
related	9	O
to	5	O
the	5	O
pharmacological	9	O
effect	9	O
of	5	O
this	5	O
drug	5	O
on	5	O
mucous	5	O
membranes	0	O
.	9	O

Nitro	0	B-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
methyl	0	I-Chemical
ester	0	I-Chemical
:	9	O
a	5	O
potential	9	O
protector	5	O
against	9	O
gentamicin	0	B-Chemical
ototoxicity	5	B-Disease
.	9	O

The	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
inhibitor	3	O
nitro	0	B-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
arginine	0	I-Chemical
methyl	0	I-Chemical
ester	0	I-Chemical
(	9	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
)	9	O
may	5	O
act	9	O
as	5	O
an	5	O
otoprotectant	9	O
against	9	O
high	9	B-Disease
-	7	I-Disease
frequency	5	I-Disease
hearing	5	I-Disease
loss	9	I-Disease
caused	9	O
by	9	O
gentamicin	0	B-Chemical
,	9	O
but	9	O
further	9	O
studies	9	O
are	5	O
needed	5	O
to	5	O
confirm	9	O
this	5	O
.	9	O
Aminoglycoside	0	B-Chemical
antibiotics	5	O
are	5	O
still	5	O
widely	5	O
used	5	O
by	9	O
virtue	5	O
of	5	O
their	5	O
efficacy	9	O
and	5	O
low	9	O
cost	5	O
.	9	O

Their	5	O
ototoxicity	5	B-Disease
is	5	O
a	5	O
serious	5	O
health	5	O
problem	5	O
and	5	O
,	9	O
as	5	O
their	5	O
ototoxic	5	B-Disease
mechanism	9	O
involves	5	O
the	5	O
production	9	O
of	5	O
NO	9	B-Chemical
,	9	O
we	5	O
need	5	O
to	5	O
assess	5	O
the	5	O
use	5	O
of	5	O
NO	9	B-Chemical
inhibitors	3	O
for	5	O
the	5	O
prevention	5	O
of	5	O
aminoglycoside	9	B-Chemical
-	7	O
induced	3	O
sensorineural	5	B-Disease
hearing	5	I-Disease
loss	9	I-Disease
.	9	O

In	9	O
this	5	O
experimental	5	O
study	9	O
we	5	O
used	5	O
30	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
,	9	O
27	7	O
of	5	O
which	5	O
had	9	O
gentamicin	0	B-Chemical
instilled	9	O
into	9	O
the	5	O
middle	9	O
ear	5	O
.	9	O

The	5	O
otoprotectant	9	O
L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
was	9	O
administered	9	O
topically	0	O
to	5	O
12	9	O
/	9	O
27	7	O
animals	9	O
.	9	O

Its	5	O
effect	9	O
was	9	O
determined	9	O
in	5	O
terms	5	O
of	5	O
attenuation	9	O
of	5	O
hearing	5	B-Disease
loss	9	I-Disease
,	9	O
measured	9	O
by	9	O
shifts	5	O
in	5	O
the	5	O
auditory	5	O
brainstem	5	O
response	9	O
threshold	5	O
.	9	O

L	0	B-Chemical
-	7	I-Chemical
NAME	0	I-Chemical
reduced	9	O
gentamicin	0	B-Chemical
-	7	O
induced	3	O
hearing	5	B-Disease
loss	9	I-Disease
in	5	O
the	5	O
high	9	O
-	7	O
frequency	5	O
range	9	O
,	9	O
but	9	O
gave	9	O
no	9	O
protection	9	O
in	5	O
the	5	O
middle	9	O
or	5	O
low	9	O
frequencies	9	O
.	9	O

Safety	5	O
profile	9	O
of	5	O
a	5	O
nicotine	0	B-Chemical
lozenge	0	O
compared	9	O
with	5	O
that	5	O
of	5	O
nicotine	0	B-Chemical
gum	0	O
in	5	O
adult	9	O
smokers	5	O
with	5	O
underlying	5	O
medical	5	O
conditions	9	O
:	9	O
a	5	O
12	9	O
-	7	O
week	9	O
,	9	O
randomized	5	O
,	9	O
open	5	O
-	7	O
label	9	O
study	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Nicotine	0	B-Chemical
polacrilex	5	O
lozenges	0	O
deliver	5	O
25	9	O
%	9	O
to	5	O
27	7	O
%	9	O
more	5	O
nicotine	0	B-Chemical
compared	9	O
with	5	O
equivalent	9	O
doses	0	O
of	5	O
nicotine	0	B-Chemical
polacrilex	5	O
gum	0	O
.	9	O

The	5	O
increased	9	O
nicotine	0	B-Chemical
exposure	9	O
from	9	O
the	5	O
lozenge	0	O
has	9	O
raised	9	O
questions	5	O
about	5	O
the	5	O
relative	9	O
safety	5	O
of	5	O
the	5	O
lozenge	0	O
and	5	O
gum	0	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
compare	9	O
the	5	O
safety	5	O
profiles	9	O
of	5	O
the	5	O
4	9	O
-	7	O
mg	0	O
nicotine	0	B-Chemical
lozenge	0	O
and	5	O
4	9	O
-	7	O
mg	0	O
nicotine	0	B-Chemical
gum	0	O
in	5	O
smokers	5	O
with	5	O
selected	9	O
label	9	O
-	7	O
restricted	9	O
diseases	5	O
.	9	O

METHODS	2	O
:	9	O
This	5	O
was	9	O
a	5	O
multicenter	5	O
,	9	O
randomized	5	O
,	9	O
open	5	O
-	7	O
label	9	O
study	9	O
in	5	O
adult	9	O
smokers	5	O
with	5	O
heart	5	B-Disease
disease	5	I-Disease
,	9	O
hypertension	5	B-Disease
not	5	O
controlled	5	O
by	9	O
medication	5	O
,	9	O
and	5	O
/	9	O
or	5	O
diabetes	5	B-Disease
mellitus	9	I-Disease
.	9	O

Patients	5	O
were	9	O
randomized	5	O
in	5	O
a	5	O
1	9	O
:	9	O
1	9	O
ratio	9	O
to	5	O
receive	5	O
the	5	O
4	9	O
-	7	O
mg	0	O
nicotine	0	B-Chemical
lozenge	0	O
or	5	O
4	9	O
-	7	O
mg	0	O
nicotine	0	B-Chemical
gum	0	O
.	9	O

Safety	5	O
assessments	5	O
were	9	O
made	5	O
at	9	O
baseline	5	O
and	5	O
at	9	O
2	9	O
,	9	O
4	9	O
,	9	O
6	9	O
,	9	O
and	5	O
12	9	O
weeks	9	O
after	9	O
the	5	O
start	9	O
of	5	O
product	9	O
use	5	O
.	9	O

RESULTS	9	O
:	9	O
Nine	9	O
hundred	5	O
one	5	O
patients	5	O
were	9	O
randomized	5	O
to	5	O
treatment	9	O
,	9	O
447	7	O
who	5	O
received	9	O
the	5	O
lozenge	0	O
and	5	O
454	9	O
who	5	O
received	9	O
the	5	O
gum	0	O
(	9	O
safety	5	O
population	5	O
)	9	O
.	9	O

The	5	O
majority	9	O
were	9	O
women	5	O
(	9	O
52	7	O
.	9	O
7	9	O
%	9	O
)	9	O
.	9	O

Patients	5	O
'	9	O
mean	5	O
age	5	O
was	9	O
53	7	O
.	9	O
9	7	O
years	5	O
,	9	O
their	5	O
mean	5	O
weight	9	O
was	9	O
193	7	O
.	9	O
9	7	O
pounds	5	O
,	9	O
and	5	O
they	5	O
smoked	5	O
a	5	O
mean	5	O
of	5	O
25	9	O
.	9	O
2	9	O
cigarettes	5	O
per	9	O
day	9	O
at	9	O
baseline	5	O
.	9	O

Five	9	O
hundred	5	O
fifty	5	O
-	7	O
three	9	O
patients	5	O
,	9	O
264	7	O
taking	5	O
the	5	O
lozenge	0	O
and	5	O
289	7	O
taking	5	O
the	5	O
gum	0	O
,	9	O
used	5	O
the	5	O
study	9	O
product	9	O
for	5	O
>	0	O
or	5	O
=	7	O
4	9	O
days	9	O
per	9	O
week	9	O
during	5	O
the	5	O
first	9	O
2	9	O
weeks	9	O
(	9	O
evaluable	9	O
population	5	O
)	9	O
.	9	O

The	5	O
nicotine	0	B-Chemical
lozenge	0	O
and	5	O
nicotine	0	B-Chemical
gum	0	O
were	9	O
equally	9	O
well	9	O
tolerated	9	O
,	9	O
despite	9	O
increased	9	O
nicotine	0	B-Chemical
exposure	9	O
from	9	O
the	5	O
lozenge	0	O
.	9	O

The	5	O
incidence	5	O
of	5	O
adverse	5	O
events	5	O
in	5	O
the	5	O
2	9	O
groups	9	O
was	9	O
similar	9	O
during	5	O
the	5	O
first	9	O
2	9	O
weeks	9	O
of	5	O
product	9	O
use	5	O
(	9	O
evaluation	5	O
population	5	O
:	9	O
55	7	O
.	9	O
3	9	O
%	9	O
lozenge	0	O
,	9	O
54	7	O
.	9	O
7	9	O
%	9	O
gum	0	O
)	9	O
,	9	O
as	5	O
well	9	O
as	5	O
during	5	O
the	5	O
entire	9	O
study	9	O
(	9	O
safety	5	O
population	5	O
:	9	O
63	7	O
.	9	O
8	9	O
%	9	O
and	5	O
58	7	O
.	9	O
6	9	O
%	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Stratification	5	O
of	5	O
patients	5	O
by	9	O
sex	5	O
,	9	O
age	5	O
,	9	O
extent	9	O
of	5	O
concurrent	5	O
smoking	5	O
,	9	O
extent	9	O
of	5	O
product	9	O
use	5	O
,	9	O
and	5	O
severity	5	O
of	5	O
adverse	5	O
events	5	O
revealed	9	O
no	9	O
clinically	5	O
significant	9	O
differences	9	O
between	5	O
the	5	O
lozenge	0	O
and	5	O
gum	0	O
.	9	O

The	5	O
most	9	O
common	5	O
adverse	5	O
events	5	O
were	9	O
nausea	5	B-Disease
(	9	O
17	7	O
.	9	O
2	9	O
%	9	O
and	5	O
16	9	O
.	9	O
1	9	O
%	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
-	7	O
3	9	O
.	9	O
7	9	O
to	5	O
6	9	O
.	9	O
0	7	O
)	9	O
,	9	O
hiccups	5	B-Disease
(	9	O
10	9	O
.	9	O
7	9	O
%	9	O
and	5	O
6	9	O
.	9	O
6	9	O
%	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
0	7	O
.	9	O
5	9	O
to	5	O
7	9	O
.	9	O
8	9	O
)	9	O
,	9	O
and	5	O
headache	5	B-Disease
(	9	O
8	9	O
.	9	O
7	9	O
%	9	O
and	5	O
9	7	O
.	9	O
9	7	O
%	9	O
;	9	O
95	7	O
%	9	O
Cl	0	O
,	9	O
-	7	O
5	9	O
.	9	O
0	7	O
to	5	O
2	9	O
.	9	O
6	9	O
)	9	O
.	9	O

Serious	5	O
adverse	5	O
events	5	O
were	9	O
reported	9	O
in	5	O
11	7	O
and	5	O
13	7	O
patients	5	O
in	5	O
the	5	O
respective	9	O
groups	9	O
.	9	O

Fewer	5	O
than	5	O
6	9	O
%	9	O
of	5	O
patients	5	O
in	5	O
either	9	O
group	9	O
were	9	O
considered	5	O
by	9	O
the	5	O
investigator	5	O
to	5	O
have	5	O
a	5	O
worsening	5	O
of	5	O
their	5	O
overall	5	O
disease	5	O
condition	5	O
during	5	O
the	5	O
study	9	O
.	9	O

The	5	O
majority	9	O
of	5	O
patients	5	O
(	9	O
>	0	O
60	9	O
%	9	O
)	9	O
experienced	5	O
no	9	O
change	9	O
in	5	O
their	5	O
disease	5	O
status	9	O
from	9	O
baseline	5	O
.	9	O

CONCLUSION	5	O
:	9	O
The	5	O
4	9	O
-	7	O
mg	0	O
nicotine	0	B-Chemical
lozenge	0	O
and	5	O
4	9	O
-	7	O
mg	0	O
nicotine	0	B-Chemical
gum	0	O
had	9	O
comparable	9	O
safety	5	O
profiles	9	O
in	5	O
these	5	O
patients	5	O
with	5	O
label	9	O
-	7	O
restricted	9	O
medical	5	O
conditions	9	O
.	9	O

Pharmacological	9	O
modulation	9	O
of	5	O
pain	5	B-Disease
-	7	O
related	9	O
brain	5	O
activity	9	O
during	5	O
normal	9	O
and	5	O
central	5	O
sensitization	9	O
states	5	O
in	5	O
humans	9	O
.	9	O

Abnormal	9	O
processing	5	O
of	5	O
somatosensory	5	O
inputs	5	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
(	9	O
central	5	O
sensitization	9	O
)	9	O
is	5	O
the	5	O
mechanism	9	O
accounting	5	O
for	5	O
the	5	O
enhanced	3	O
pain	5	B-Disease
sensitivity	9	O
in	5	O
the	5	O
skin	5	O
surrounding	9	O
tissue	9	B-Disease
injury	9	I-Disease
(	9	O
secondary	9	B-Disease
hyperalgesia	3	I-Disease
)	9	O
.	9	O

Secondary	9	B-Disease
hyperalgesia	3	I-Disease
shares	9	O
clinical	5	O
characteristics	5	O
with	5	O
neurogenic	5	B-Disease
hyperalgesia	3	I-Disease
in	5	O
patients	5	O
with	5	O
neuropathic	5	B-Disease
pain	5	I-Disease
.	9	O

Abnormal	9	O
brain	5	O
responses	5	O
to	5	O
somatosensory	5	O
stimuli	5	O
have	5	O
been	9	O
found	9	O
in	5	O
patients	5	O
with	5	O
hyperalgesia	3	B-Disease
as	5	O
well	9	O
as	5	O
in	5	O
normal	9	O
subjects	5	O
during	5	O
experimental	5	O
central	5	O
sensitization	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
assess	5	O
the	5	O
effects	9	O
of	5	O
gabapentin	5	B-Chemical
,	9	O
a	5	O
drug	5	O
effective	5	O
in	5	O
neuropathic	5	B-Disease
pain	5	I-Disease
patients	5	O
,	9	O
on	5	O
brain	5	O
processing	5	O
of	5	O
nociceptive	5	O
information	5	O
in	5	O
normal	9	O
and	5	O
central	5	O
sensitization	9	O
states	5	O
.	9	O

Using	9	O
functional	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
(	9	O
fMRI	5	O
)	9	O
in	5	O
normal	9	O
volunteers	5	O
,	9	O
we	5	O
studied	9	O
the	5	O
gabapentin	5	B-Chemical
-	7	O
induced	3	O
modulation	9	O
of	5	O
brain	5	O
activity	9	O
in	5	O
response	9	O
to	5	O
nociceptive	5	O
mechanical	5	O
stimulation	3	O
of	5	O
normal	9	O
skin	5	O
and	5	O
capsaicin	0	B-Chemical
-	7	O
induced	3	O
secondary	9	B-Disease
hyperalgesia	3	I-Disease
.	9	O

The	5	O
dose	9	O
of	5	O
gabapentin	5	B-Chemical
was	9	O
1	9	O
,	9	O
800	0	O
mg	0	O
per	9	O
os	9	O
,	9	O
in	5	O
a	5	O
single	9	O
administration	9	O
.	9	O

We	9	O
found	9	O
that	5	O
(	9	O
i	9	O
)	9	O
gabapentin	5	B-Chemical
reduced	9	O
the	5	O
activations	5	O
in	5	O
the	5	O
bilateral	5	O
operculoinsular	5	O
cortex	5	O
,	9	O
independently	9	O
of	5	O
the	5	O
presence	9	O
of	5	O
central	5	O
sensitization	9	O
;	9	O
(	9	O
ii	9	O
)	9	O
gabapentin	5	B-Chemical
reduced	9	O
the	5	O
activation	3	O
in	5	O
the	5	O
brainstem	5	O
,	9	O
only	9	O
during	5	O
central	5	O
sensitization	9	O
;	9	O
(	9	O
iii	9	O
)	9	O
gabapentin	5	B-Chemical
suppressed	3	O
stimulus	5	O
-	7	O
induced	3	O
deactivations	5	O
,	9	O
only	9	O
during	5	O
central	5	O
sensitization	9	O
;	9	O
this	5	O
effect	9	O
was	9	O
more	5	O
robust	5	O
than	5	O
the	5	O
effect	9	O
on	5	O
brain	5	O
activation	3	O
.	9	O

The	5	O
observed	9	O
drug	5	O
-	7	O
induced	3	O
effects	9	O
were	9	O
not	5	O
due	5	O
to	5	O
changes	9	O
in	5	O
the	5	O
baseline	5	O
fMRI	5	O
signal	9	O
.	9	O

These	5	O
findings	9	O
indicate	9	O
that	5	O
gabapentin	5	B-Chemical
has	9	O
a	5	O
measurable	9	O
antinociceptive	0	O
effect	9	O
and	5	O
a	5	O
stronger	9	O
antihyperalgesic	0	O
effect	9	O
most	9	O
evident	9	O
in	5	O
the	5	O
brain	5	O
areas	5	O
undergoing	9	O
deactivation	9	O
,	9	O
thus	9	O
supporting	9	O
the	5	O
concept	5	O
that	5	O
gabapentin	5	B-Chemical
is	5	O
more	5	O
effective	5	O
in	5	O
modulating	9	O
nociceptive	5	O
transmission	5	O
when	5	O
central	5	O
sensitization	9	O
is	5	O
present	9	O
.	9	O

Investigation	9	O
of	5	O
mitochondrial	9	O
involvement	9	O
in	5	O
the	5	O
experimental	5	O
model	5	O
of	5	O
epilepsy	5	B-Disease
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
.	9	O

Mitochondrial	9	B-Disease
abnormalities	9	I-Disease
have	5	O
been	9	O
associated	9	O
with	5	O
several	9	O
aspects	5	O
of	5	O
epileptogenesis	5	O
,	9	O
such	5	O
as	5	O
energy	5	O
generation	9	O
,	9	O
control	9	O
of	5	O
cell	3	O
death	9	B-Disease
,	9	O
neurotransmitter	9	O
synthesis	9	O
,	9	O
and	5	O
free	9	O
radical	0	O
(	9	O
FR	9	O
)	9	O
production	9	O
.	9	O

Increased	9	O
production	9	O
of	5	O
FRs	5	O
may	5	O
cause	5	O
mtDNA	9	O
damage	9	O
leading	9	O
to	5	O
decreased	9	O
activities	9	O
of	5	O
oxidative	9	O
phosphorylation	3	O
complexes	9	O
containing	0	O
mtDNA	9	O
-	7	O
encoded	1	O
subunits	1	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
investigated	9	O
whether	9	O
increased	9	O
generation	9	O
of	5	O
FR	9	O
during	5	O
status	9	B-Disease
epilepticus	5	I-Disease
would	5	O
be	5	O
sufficient	9	O
to	5	O
provoke	9	O
abnormalities	9	O
in	5	O
mtDNA	9	O
and	5	O
in	5	O
the	5	O
expression	3	O
and	5	O
activity	9	O
of	5	O
cytochrome	0	O
c	9	O
oxidase	0	O
(	9	O
CCO	5	O
)	9	O
,	9	O
complex	9	O
IV	9	O
of	5	O
the	5	O
respiratory	5	O
chain	9	O
,	9	O
in	5	O
the	5	O
chronic	5	O
phase	5	O
of	5	O
the	5	O
pilocarpine	0	B-Chemical
model	5	O
of	5	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
.	9	O

DNA	9	O
analysis	9	O
revealed	9	O
low	9	O
amounts	9	O
of	5	O
a	5	O
4	9	O
.	9	O
8	9	O
kb	1	O
mtDNA	9	O
deletion	1	O
but	9	O
with	5	O
no	9	O
differences	9	O
in	5	O
frequency	5	O
or	5	O
quantity	9	O
in	5	O
the	5	O
control	9	O
and	5	O
experimental	5	O
groups	9	O
.	9	O

We	9	O
did	9	O
not	5	O
find	5	O
abnormalities	9	O
in	5	O
the	5	O
expression	3	O
and	5	O
distribution	9	O
of	5	O
an	5	O
mtDNA	9	O
-	7	O
encoded	1	O
subunit	1	O
of	5	O
CCO	5	O
(	9	O
CCO	5	O
-	7	O
I	9	O
)	9	O
or	5	O
a	5	O
relative	9	O
decrease	9	O
in	5	O
CCO	5	O
-	7	O
I	9	O
when	5	O
compared	9	O
with	5	O
nuclear	3	O
-	7	O
encoded	1	O
subunits	1	O
(	9	O
CCO	5	O
-	7	O
IV	9	O
and	5	O
SDH	9	O
-	7	O
fp	5	O
)	9	O
.	9	O

No	9	O
abnormality	9	O
in	5	O
CCO	5	O
activity	9	O
was	9	O
observed	9	O
through	9	O
histochemistry	9	O
.	9	O

Although	9	O
evidences	9	O
of	5	O
mitochondrial	9	B-Disease
abnormalities	9	I-Disease
were	9	O
found	9	O
in	5	O
previously	9	O
published	9	O
studies	9	O
,	9	O
our	5	O
results	9	O
do	5	O
not	5	O
suggest	9	O
that	5	O
the	5	O
FRs	5	O
,	9	O
generated	9	O
during	5	O
the	5	O
acute	9	O
phase	5	O
,	9	O
determined	9	O
important	9	O
abnormalities	9	O
in	5	O
mtDNA	9	O
,	9	O
in	5	O
expression	3	O
of	5	O
CCO	5	O
-	7	O
I	9	O
,	9	O
and	5	O
in	5	O
CCO	5	O
activity	9	O
.	9	O

Adverse	5	O
effect	9	O
of	5	O
the	5	O
calcium	0	B-Chemical
channel	9	O
blocker	0	O
nitrendipine	0	B-Chemical
on	5	O
nephrosclerosis	5	B-Disease
in	5	O
rats	9	O
with	5	O
renovascular	5	B-Disease
hypertension	5	I-Disease
.	9	O

The	5	O
effect	9	O
of	5	O
a	5	O
6	9	O
-	7	O
week	9	O
treatment	9	O
with	5	O
the	5	O
calcium	0	B-Chemical
channel	9	O
blocker	0	O
nitrendipine	0	B-Chemical
or	5	O
the	5	O
angiotensin	9	B-Chemical
converting	9	O
enzyme	0	O
inhibitor	3	O
enalapril	0	B-Chemical
on	5	O
blood	9	O
pressure	5	O
,	9	O
albuminuria	9	B-Disease
,	9	O
renal	9	O
hemodynamics	5	O
,	9	O
and	5	O
morphology	9	O
of	5	O
the	5	O
nonclipped	9	O
kidney	9	O
was	9	O
studied	9	O
in	5	O
rats	9	O
with	5	O
two	5	O
-	7	O
kidney	9	O
,	9	O
one	5	O
clip	5	O
renovascular	5	B-Disease
hypertension	5	I-Disease
.	9	O

Six	9	O
weeks	9	O
after	9	O
clipping	5	O
of	5	O
one	5	O
renal	9	O
artery	5	O
,	9	O
hypertensive	5	B-Disease
rats	9	O
(	9	O
178	7	O
+	9	O
/	9	O
-	7	O
4	9	O
mm	9	O
Hg	0	O
)	9	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
three	9	O
groups	9	O
:	9	O
untreated	3	O
hypertensive	5	B-Disease
controls	9	O
(	9	O
n	9	O
=	7	O
8	9	O
)	9	O
,	9	O
enalapril	0	B-Chemical
-	7	O
treated	3	O
(	9	O
n	9	O
=	7	O
8	9	O
)	9	O
,	9	O
or	5	O
nitrendipine	0	B-Chemical
-	7	O
treated	3	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
.	9	O

Sham	9	O
-	7	O
operated	5	O
rats	9	O
served	9	O
as	5	O
normotensive	9	O
controls	9	O
(	9	O
128	9	O
+	9	O
/	9	O
-	7	O
3	9	O
mm	9	O
Hg	0	O
,	9	O
n	9	O
=	7	O
8	9	O
)	9	O
.	9	O

After	9	O
6	9	O
weeks	9	O
of	5	O
treatment	9	O
,	9	O
renal	9	O
hemodynamics	5	O
(	9	O
glomerular	5	O
filtration	0	O
rate	9	O
and	5	O
renal	9	O
plasma	9	O
flow	5	O
)	9	O
were	9	O
measured	9	O
in	5	O
the	5	O
anesthetized	0	O
rats	9	O
.	9	O

Renal	9	O
tissue	9	O
was	9	O
obtained	9	O
for	5	O
determination	9	O
of	5	O
glomerular	5	O
size	9	O
and	5	O
sclerosis	5	O
.	9	O

Enalapril	0	B-Chemical
but	9	O
not	5	O
nitrendipine	0	B-Chemical
reduced	9	O
blood	9	O
pressure	5	O
significantly	9	O
.	9	O

After	9	O
6	9	O
weeks	9	O
of	5	O
therapy	5	O
,	9	O
glomerular	5	O
filtration	0	O
rate	9	O
was	9	O
not	5	O
different	9	O
among	5	O
the	5	O
studied	9	O
groups	9	O
.	9	O

Renal	9	O
plasma	9	O
flow	5	O
increased	9	O
,	9	O
but	9	O
albumin	0	O
excretion	0	O
and	5	O
glomerulosclerosis	3	B-Disease
did	9	O
not	5	O
change	9	O
after	9	O
enalapril	0	B-Chemical
treatment	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
in	5	O
the	5	O
nitrendipine	0	B-Chemical
-	7	O
treated	3	O
group	9	O
albuminuria	9	B-Disease
increased	9	O
from	9	O
12	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
2	9	O
progressively	9	O
to	5	O
163	7	O
+	9	O
/	9	O
-	7	O
55	7	O
compared	9	O
with	5	O
19	7	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
9	7	O
mg	0	O
/	9	O
24	9	O
hr	0	O
in	5	O
the	5	O
hypertensive	5	B-Disease
controls	9	O
.	9	O

Furthermore	9	O
,	9	O
glomerulosclerosis	3	B-Disease
index	5	O
was	9	O
significantly	9	O
increased	9	O
in	5	O
the	5	O
nitrendipine	0	B-Chemical
-	7	O
treated	3	O
group	9	O
compared	9	O
with	5	O
the	5	O
hypertensive	5	B-Disease
controls	9	O
(	9	O
0	7	O
.	9	O
38	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
versus	9	O
0	7	O
.	9	O
13	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
04	7	O
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
glomerular	5	O
size	9	O
was	9	O
higher	9	O
in	5	O
the	5	O
nitrendipine	0	B-Chemical
-	7	O
treated	3	O
group	9	O
(	9	O
14	7	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
17	7	O
10	9	O
(	9	O
-	7	O
3	9	O
)	9	O
mm2	9	O
)	9	O
but	9	O
lower	9	O
in	5	O
the	5	O
enalapril	0	B-Chemical
-	7	O
treated	3	O
group	9	O
(	9	O
11	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
15	9	O
10	9	O
(	9	O
-	7	O
3	9	O
)	9	O
mm2	9	O
)	9	O
compared	9	O
with	5	O
the	5	O
hypertensive	5	B-Disease
controls	9	O
(	9	O
12	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
17	7	O
10	9	O
(	9	O
-	7	O
3	9	O
)	9	O
mm2	9	O
)	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Ketoconazole	0	B-Chemical
induced	3	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
without	9	O
concomitant	9	O
use	5	O
of	5	O
QT	5	O
interval	5	O
-	7	O
prolonging	5	O
drug	5	O
.	9	O

Ketoconazole	0	B-Chemical
is	5	O
not	5	O
known	9	O
to	5	O
be	5	O
proarrhythmic	5	O
without	9	O
concomitant	9	O
use	5	O
of	5	O
QT	5	O
interval	5	O
-	7	O
prolonging	5	O
drugs	5	O
.	9	O

We	9	O
report	5	O
a	5	O
woman	5	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
who	5	O
developed	5	O
a	5	O
markedly	9	O
prolonged	9	B-Disease
QT	5	I-Disease
interval	5	I-Disease
and	5	O
torsades	5	B-Disease
de	2	I-Disease
pointes	5	I-Disease
(	9	O
TdP	5	B-Disease
)	9	O
after	9	O
taking	5	O
ketoconazole	0	B-Chemical
for	5	O
treatment	9	O
of	5	O
fungal	4	B-Disease
infection	9	I-Disease
.	9	O

Her	5	O
QT	5	O
interval	5	O
returned	5	O
to	5	O
normal	9	O
upon	9	O
withdrawal	5	O
of	5	O
ketoconazole	0	B-Chemical
.	9	O

Genetic	9	O
study	9	O
did	9	O
not	5	O
find	5	O
any	5	O
mutation	1	O
in	5	O
her	5	O
genes	1	O
that	5	O
encode	1	O
cardiac	5	O
IKr	5	O
channel	9	O
proteins	1	O
.	9	O

We	9	O
postulate	9	O
that	5	O
by	9	O
virtue	5	O
of	5	O
its	9	O
direct	9	O
blocking	3	O
action	5	O
on	5	O
IKr	5	O
,	9	O
ketoconazole	0	B-Chemical
alone	9	O
may	5	O
prolong	9	O
QT	5	O
interval	5	O
and	5	O
induce	3	O
TdP	5	B-Disease
.	9	O

This	5	O
calls	5	O
for	5	O
attention	5	O
when	5	O
ketoconazole	0	B-Chemical
is	5	O
administered	9	O
to	5	O
patients	5	O
with	5	O
risk	5	O
factors	9	O
for	5	O
acquired	5	O
long	5	B-Disease
QT	5	I-Disease
syndrome	5	I-Disease
.	9	O

Cerebral	5	B-Disease
vasculitis	5	I-Disease
following	9	O
oral	9	O
methylphenidate	5	B-Chemical
intake	5	O
in	5	O
an	5	O
adult	9	O
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

Methylphenidate	5	B-Chemical
is	5	O
structurally	9	O
and	5	O
functionally	9	O
similar	9	O
to	5	O
amphetamine	5	B-Chemical
.	9	O

Cerebral	5	B-Disease
vasculitis	5	I-Disease
associated	9	O
with	5	O
amphetamine	5	B-Disease
abuse	5	I-Disease
is	5	O
well	9	O
documented	9	O
,	9	O
and	5	O
in	5	O
rare	5	O
cases	5	O
ischaemic	5	B-Disease
stroke	5	I-Disease
has	9	O
been	9	O
reported	9	O
after	9	O
methylphenidate	5	B-Chemical
intake	5	O
in	5	O
children	5	O
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
63	7	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
who	5	O
was	9	O
treated	3	O
with	5	O
methylphenidate	5	B-Chemical
due	5	O
to	5	O
hyperactivity	5	B-Disease
and	5	O
suffered	5	O
from	9	O
multiple	5	O
ischaemic	5	B-Disease
strokes	5	I-Disease
.	9	O

We	9	O
consider	5	O
drug	5	O
-	7	O
induced	3	O
cerebral	5	B-Disease
vasculitis	5	I-Disease
as	5	O
the	5	O
most	9	O
likely	5	O
cause	5	O
of	5	O
recurrent	5	O
ischaemic	5	B-Disease
strokes	5	I-Disease
in	5	O
the	5	O
absence	3	O
of	5	O
any	5	O
pathological	5	O
findings	9	O
during	5	O
the	5	O
diagnostic	5	O
work	5	O
-	7	O
up	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
methylphenidate	5	B-Chemical
mediated	3	O
vasculitis	5	B-Disease
should	5	O
be	5	O
considered	5	O
in	5	O
patients	5	O
with	5	O
neurological	5	O
symptoms	5	O
and	5	O
a	5	O
history	5	O
of	5	O
methylphenidate	5	B-Chemical
therapy	5	O
.	9	O

This	5	O
potential	9	O
side	5	O
-	7	O
effect	9	O
,	9	O
though	9	O
very	5	O
rare	5	O
,	9	O
represents	9	O
one	5	O
more	5	O
reason	5	O
to	5	O
be	5	O
very	5	O
restrictive	5	O
in	5	O
the	5	O
use	5	O
of	5	O
methylphenidate	5	B-Chemical
.	9	O

MDMA	5	B-Chemical
polydrug	5	O
users	5	O
show	9	O
process	5	O
-	7	O
specific	9	O
central	5	O
executive	5	O
impairments	5	O
coupled	9	O
with	5	O
impaired	9	B-Disease
social	5	I-Disease
and	5	I-Disease
emotional	5	I-Disease
judgement	5	I-Disease
processes	5	I-Disease
.	9	O

In	9	O
recent	5	O
years	5	O
working	5	O
memory	5	B-Disease
deficits	5	I-Disease
have	5	O
been	9	O
reported	9	O
in	5	O
users	5	O
of	5	O
MDMA	5	B-Chemical
(	9	O
3	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methylenedioxymethamphetamine	0	I-Chemical
,	9	O
ecstasy	5	B-Chemical
)	9	O
.	9	O

The	5	O
current	5	O
study	9	O
aimed	5	O
to	5	O
assess	5	O
the	5	O
impact	5	O
of	5	O
MDMA	5	B-Chemical
use	5	O
on	5	O
three	9	O
separate	9	O
central	5	O
executive	5	O
processes	5	O
(	9	O
set	5	O
shifting	5	O
,	9	O
inhibition	3	O
and	5	O
memory	5	O
updating	5	O
)	9	O
and	5	O
also	9	O
on	5	O
"	5	O
prefrontal	5	O
"	5	O
mediated	3	O
social	5	O
and	5	O
emotional	5	O
judgement	5	O
processes	5	O
.	9	O

Fifteen	9	O
polydrug	5	O
ecstasy	5	B-Chemical
users	5	O
and	5	O
15	9	O
polydrug	5	O
non	9	O
-	7	O
ecstasy	5	B-Chemical
user	5	O
controls	9	O
completed	5	O
a	5	O
general	5	O
drug	5	O
use	5	O
questionnaire	5	O
,	9	O
the	5	O
Brixton	5	O
Spatial	5	O
Anticipation	5	O
task	5	O
(	9	O
set	5	O
shifting	5	O
)	9	O
,	9	O
Backward	5	O
Digit	5	O
Span	5	O
procedure	5	O
(	9	O
memory	5	O
updating	5	O
)	9	O
,	9	O
Inhibition	3	O
of	5	O
Return	5	O
(	9	O
inhibition	3	O
)	9	O
,	9	O
an	5	O
emotional	5	O
intelligence	5	O
scale	5	O
,	9	O
the	5	O
Tromso	2	O
Social	5	O
Intelligence	5	O
Scale	5	O
and	5	O
the	5	O
Dysexecutive	5	O
Questionnaire	5	O
(	9	O
DEX	0	O
)	9	O
.	9	O

Compared	9	O
with	5	O
MDMA	5	B-Chemical
-	7	O
free	9	O
polydrug	5	O
controls	9	O
,	9	O
MDMA	5	B-Chemical
polydrug	5	O
users	5	O
showed	9	O
impairments	5	O
in	5	O
set	5	O
shifting	5	O
and	5	O
memory	5	O
updating	5	O
,	9	O
and	5	O
also	9	O
in	5	O
social	5	O
and	5	O
emotional	5	O
judgement	5	O
processes	5	O
.	9	O

The	5	O
latter	9	O
two	5	O
deficits	5	O
remained	9	O
significant	9	O
after	9	O
controlling	9	O
for	5	O
other	5	O
drug	5	O
use	5	O
.	9	O

These	5	O
data	5	O
lend	5	O
further	9	O
support	5	O
to	5	O
the	5	O
proposal	5	O
that	5	O
cognitive	5	O
processes	5	O
mediated	3	O
by	9	O
the	5	O
prefrontal	5	O
cortex	5	O
may	5	O
be	5	O
impaired	9	O
by	9	O
recreational	5	O
ecstasy	5	B-Chemical
use	5	O
.	9	O

Phase	9	O
II	9	O
study	9	O
of	5	O
the	5	O
amsacrine	0	B-Chemical
analogue	0	O
CI	7	B-Chemical
-	7	I-Chemical
921	7	I-Chemical
(	9	O
NSC	3	B-Chemical
343499	_	I-Chemical
)	9	O
in	5	O
non	9	B-Disease
-	7	I-Disease
small	9	I-Disease
cell	3	I-Disease
lung	9	I-Disease
cancer	3	I-Disease
.	9	O

CI	7	B-Chemical
-	7	I-Chemical
921	7	I-Chemical
(	9	O
NSC	3	B-Chemical
343499	_	I-Chemical
;	9	O
9	7	B-Chemical
-	7	I-Chemical
[	9	I-Chemical
[	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
methoxy	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
(	9	I-Chemical
methylsulphonyl	0	I-Chemical
)	9	I-Chemical
amino	1	I-Chemical
]	9	I-Chemical
phenyl	0	I-Chemical
]	9	I-Chemical
amino	1	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
,	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
dimethyl	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
acridinecarboxamide	_	I-Chemical
)	9	O
is	5	O
a	5	O
topoisomerase	1	O
II	9	O
poison	9	O
with	5	O
high	9	O
experimental	5	O
antitumour	3	O
activity	9	O
.	9	O

It	5	O
was	9	O
administered	9	O
by	9	O
15	9	O
min	0	O
infusion	0	O
to	5	O
16	9	O
evaluable	9	O
patients	5	O
with	5	O
non	9	B-Disease
-	7	I-Disease
small	9	I-Disease
cell	3	I-Disease
lung	9	I-Disease
cancer	3	I-Disease
(	9	O
NSCLC	3	B-Disease
)	9	O
(	9	O
7	9	O
with	5	O
no	9	O
prior	9	O
treatment	9	O
,	9	O
9	7	O
patients	5	O
in	5	O
relapse	5	O
following	9	O
surgery	5	O
/	9	O
radiotherapy	5	O
)	9	O
at	9	O
a	5	O
dose	9	O
(	9	O
648	7	O
mg	0	O
/	9	O
m2	7	O
divided	5	O
over	5	O
3	9	O
days	9	O
,	9	O
repeated	5	O
every	5	O
3	9	O
weeks	9	O
)	9	O
determined	9	O
by	9	O
phase	5	O
I	9	O
trial	5	O
.	9	O

Patients	5	O
had	9	O
a	5	O
median	9	O
performance	5	O
status	9	O
of	5	O
1	9	O
(	9	O
WHO	5	O
)	9	O
,	9	O
and	5	O
median	9	O
age	5	O
of	5	O
61	7	O
years	5	O
.	9	O

The	5	O
histology	9	O
comprised	9	O
squamous	5	B-Disease
carcinoma	3	I-Disease
(	9	O
11	7	O
)	9	O
,	9	O
adenocarcinoma	3	B-Disease
(	9	O
1	9	O
)	9	O
,	9	O
mixed	9	O
histology	9	O
(	9	O
2	9	O
)	9	O
,	9	O
bronchio	9	B-Disease
-	7	I-Disease
alveolar	3	I-Disease
carcinoma	3	I-Disease
(	9	O
1	9	O
)	9	O
and	5	O
large	5	O
cell	3	O
undifferentiated	3	B-Disease
carcinoma	3	I-Disease
(	9	O
1	9	O
)	9	O
.	9	O

Neutropenia	7	B-Disease
grade	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
3	9	O
was	9	O
seen	9	O
in	5	O
15	9	O
patients	5	O
,	9	O
infections	5	B-Disease
with	5	O
recovery	9	O
in	5	O
3	9	O
,	9	O
and	5	O
grand	5	O
mal	2	O
seizures	5	B-Disease
in	5	O
1	9	O
patient	5	O
.	9	O

Grade	9	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
2	9	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
occurred	9	O
in	5	O
66	7	O
%	9	O
courses	5	O
and	5	O
phlebitis	5	B-Disease
in	5	O
the	5	O
infusion	0	O
arm	5	O
in	5	O
37	9	O
%	9	O
.	9	O

1	9	O
patient	5	O
with	5	O
squamous	5	B-Disease
cell	3	I-Disease
carcinoma	3	I-Disease
achieved	5	O
a	5	O
partial	9	O
response	9	O
lasting	5	O
5	9	O
months	5	O
.	9	O

Further	9	O
testing	5	O
in	5	O
this	5	O
and	5	O
other	5	O
tumour	3	B-Disease
types	9	O
using	9	O
multiple	5	O
daily	5	O
schedules	5	O
is	5	O
warranted	9	O
.	9	O

Pharmacokinetics	0	O
of	5	O
desipramine	0	B-Chemical
HCl	0	I-Chemical
when	5	O
administered	9	O
with	5	O
cinacalcet	0	B-Chemical
HCl	0	I-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
In	9	O
vitro	3	O
work	5	O
has	9	O
demonstrated	9	O
that	5	O
cinacalcet	0	B-Chemical
is	5	O
a	5	O
strong	9	O
inhibitor	3	O
of	5	O
cytochrome	0	O
P450	1	O
isoenzyme	9	O
(	9	O
CYP	0	O
)	9	O
2D6	0	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
evaluate	9	O
the	5	O
effect	9	O
of	5	O
cinacalcet	0	B-Chemical
on	5	O
CYP2D6	9	O
activity	9	O
,	9	O
using	9	O
desipramine	0	B-Chemical
as	5	O
a	5	O
probe	9	O
substrate	0	O
,	9	O
in	5	O
healthy	5	O
subjects	5	O
.	9	O

METHODS	2	O
:	9	O
Seventeen	9	O
subjects	5	O
who	5	O
were	9	O
genotyped	9	O
as	5	O
CYP2D6	9	O
extensive	5	O
metabolizers	5	O
were	9	O
enrolled	5	O
in	5	O
this	5	O
randomized	5	O
,	9	O
open	5	O
-	7	O
label	9	O
,	9	O
crossover	5	O
study	9	O
to	5	O
receive	5	O
a	5	O
single	9	O
oral	9	O
dose	9	O
of	5	O
desipramine	0	B-Chemical
(	9	O
50	0	O
mg	0	O
)	9	O
on	5	O
two	5	O
separate	9	O
occasions	5	O
,	9	O
once	5	O
alone	9	O
and	5	O
once	5	O
after	9	O
multiple	5	O
doses	0	O
of	5	O
cinacalcet	0	B-Chemical
(	9	O
90	9	O
mg	0	O
for	5	O
7	9	O
days	9	O
)	9	O
.	9	O

Blood	9	O
samples	9	O
were	9	O
obtained	9	O
predose	0	O
and	5	O
up	5	O
to	5	O
72	9	O
h	0	O
postdose	5	O
.	9	O

RESULTS	9	O
:	9	O
Fourteen	9	O
subjects	5	O
completed	5	O
both	9	O
treatment	9	O
arms	5	O
.	9	O

Relative	9	O
to	5	O
desipramine	0	B-Chemical
alone	9	O
,	9	O
mean	5	O
AUC	9	O
and	5	O
C	9	O
(	9	O
max	9	O
)	9	O
of	5	O
desipramine	0	B-Chemical
increased	9	O
3	9	O
.	9	O
6	9	O
-	7	O
and	5	O
1	9	O
.	9	O
8	9	O
-	7	O
fold	9	O
when	5	O
coadministered	0	O
with	5	O
cinacalcet	0	B-Chemical
.	9	O

The	5	O
t	5	O
(	9	O
1	9	O
/	9	O
2	9	O
,	9	O
z	9	O
)	9	O
of	5	O
desipramine	0	B-Chemical
was	9	O
longer	5	O
when	5	O
desipramine	0	B-Chemical
was	9	O
coadministered	0	O
with	5	O
cinacalcet	0	B-Chemical
(	9	O
21	7	O
.	9	O
0	7	O
versus	9	O
43	7	O
.	9	O
3	9	O
hs	9	O
)	9	O
.	9	O

The	5	O
t	5	O
(	9	O
max	9	O
)	9	O
was	9	O
similar	9	O
between	5	O
the	5	O
regimens	5	O
.	9	O

Fewer	5	O
subjects	5	O
reported	9	O
adverse	5	O
events	5	O
following	9	O
treatment	9	O
with	5	O
desipramine	0	B-Chemical
alone	9	O
than	5	O
when	5	O
receiving	9	O
desipramine	0	B-Chemical
with	5	O
cinacalcet	0	B-Chemical
(	9	O
33	7	O
versus	9	O
86	7	O
%	9	O
)	9	O
,	9	O
the	5	O
most	9	O
frequent	5	O
of	5	O
which	5	O
(	9	O
nausea	5	B-Disease
and	5	O
headache	5	B-Disease
)	9	O
have	5	O
been	9	O
reported	9	O
for	5	O
patients	5	O
treated	3	O
with	5	O
either	9	O
desipramine	0	B-Chemical
or	5	O
cinacalcet	0	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
study	9	O
demonstrates	9	O
that	5	O
cinacalcet	0	B-Chemical
is	5	O
a	5	O
strong	9	O
inhibitor	3	O
of	5	O
CYP2D6	9	O
.	9	O

These	5	O
data	5	O
suggest	9	O
that	5	O
during	5	O
concomitant	9	O
treatment	9	O
with	5	O
cinacalcet	0	B-Chemical
,	9	O
dose	9	O
adjustment	5	O
may	5	O
be	5	O
necessary	5	O
for	5	O
drugs	5	O
that	5	O
demonstrate	9	O
a	5	O
narrow	5	O
therapeutic	5	O
index	5	O
and	5	O
are	5	O
metabolized	0	O
by	9	O
CYP2D6	9	O
.	9	O

Case	5	O
report	5	O
:	9	O
acute	9	O
unintentional	5	O
carbachol	0	B-Chemical
intoxication	9	O
.	9	O

INTRODUCTION	5	O
:	9	O
Intoxications	2	O
with	5	O
carbachol	0	B-Chemical
,	9	O
a	5	O
muscarinic	3	O
cholinergic	3	O
receptor	3	O
agonist	3	O
are	5	O
rare	5	O
.	9	O

We	9	O
report	5	O
an	5	O
interesting	9	O
case	5	O
investigating	5	O
a	5	O
(	9	O
near	9	O
)	9	O
fatal	5	O
poisoning	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
The	5	O
son	5	O
of	5	O
an	5	O
84	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
discovered	9	O
a	5	O
newspaper	5	O
report	5	O
stating	5	O
clinical	5	O
success	5	O
with	5	O
plant	4	O
extracts	0	O
in	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

The	5	O
mode	5	O
of	5	O
action	5	O
was	9	O
said	5	O
to	5	O
be	5	O
comparable	9	O
to	5	O
that	5	O
of	5	O
the	5	O
synthetic	0	O
compound	0	O
'	9	O
carbamylcholin	_	B-Chemical
'	9	O
;	9	O
that	5	O
is	5	O
,	9	O
carbachol	0	B-Chemical
.	9	O

He	5	O
bought	5	O
25	9	O
g	0	O
of	5	O
carbachol	0	B-Chemical
as	5	O
pure	9	O
substance	5	O
in	5	O
a	5	O
pharmacy	5	O
,	9	O
and	5	O
the	5	O
father	5	O
was	9	O
administered	9	O
400	0	O
to	5	O
500	0	O
mg	0	O
.	9	O

Carbachol	0	B-Chemical
concentrations	0	O
in	5	O
serum	9	O
and	5	O
urine	9	O
on	5	O
day	9	O
1	9	O
and	5	O
2	9	O
of	5	O
hospital	5	O
admission	5	O
were	9	O
analysed	9	O
by	9	O
HPLC	0	O
-	7	O
mass	9	O
spectrometry	0	O
.	9	O

RESULTS	9	O
:	9	O
Minutes	5	O
after	9	O
oral	9	O
administration	9	O
,	9	O
the	5	O
patient	5	O
developed	5	O
nausea	5	B-Disease
,	9	O
sweating	5	O
and	5	O
hypotension	5	B-Disease
,	9	O
and	5	O
finally	9	O
collapsed	5	O
.	9	O

Bradycardia	7	B-Disease
,	9	O
cholinergic	3	O
symptoms	5	O
and	5	O
asystole	5	B-Disease
occurred	9	O
.	9	O

Initial	9	O
cardiopulmonary	5	O
resuscitation	5	O
and	5	O
immediate	5	O
treatment	9	O
with	5	O
adrenaline	0	B-Chemical
(	9	O
epinephrine	0	B-Chemical
)	9	O
,	9	O
atropine	0	B-Chemical
and	5	O
furosemide	0	B-Chemical
was	9	O
successful	5	O
.	9	O

On	5	O
hospital	5	O
admission	5	O
,	9	O
blood	9	O
pressure	5	O
of	5	O
the	5	O
intubated	5	O
,	9	O
bradyarrhythmic	9	O
patient	5	O
was	9	O
100	0	O
/	9	O
65	7	O
mmHg	7	O
.	9	O

Further	9	O
signs	5	O
were	9	O
hyperhidrosis	5	B-Disease
,	9	O
hypersalivation	5	B-Disease
,	9	O
bronchorrhoea	5	B-Disease
,	9	O
and	5	O
severe	5	O
miosis	5	B-Disease
;	9	O
the	5	O
electrocardiographic	5	O
finding	9	O
was	9	O
atrio	5	B-Disease
-	7	I-Disease
ventricular	5	I-Disease
dissociation	9	I-Disease
.	9	O

High	9	O
doses	0	O
of	5	O
atropine	0	B-Chemical
(	9	O
up	5	O
to	5	O
50	0	O
mg	0	O
per	9	O
24	9	O
hours	9	O
)	9	O
,	9	O
adrenaline	0	B-Chemical
and	5	O
dopamine	5	B-Chemical
were	9	O
necessary	5	O
.	9	O

The	5	O
patient	5	O
was	9	O
extubated	5	O
1	9	O
week	9	O
later	9	O
.	9	O

However	9	O
,	9	O
increased	9	O
dyspnoea	5	B-Disease
and	5	O
bronchospasm	5	B-Disease
necessitated	5	O
reintubation	5	O
.	9	O

Respiratory	9	B-Disease
insufficiency	9	I-Disease
was	9	O
further	9	O
worsened	5	O
by	9	O
Proteus	4	B-Disease
mirabilis	4	I-Disease
infection	9	I-Disease
and	5	O
severe	5	O
bronchoconstriction	5	O
.	9	O

One	5	O
week	9	O
later	9	O
,	9	O
the	5	O
patient	5	O
was	9	O
again	9	O
extubated	5	O
and	5	O
3	9	O
days	9	O
later	9	O
was	9	O
transferred	9	O
to	5	O
a	5	O
peripheral	9	O
ward	5	O
.	9	O

On	5	O
the	5	O
next	9	O
day	9	O
he	5	O
died	9	O
,	9	O
probably	9	O
as	5	O
a	5	O
result	9	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

Serum	9	O
samples	9	O
from	9	O
the	5	O
first	9	O
and	5	O
second	9	O
days	9	O
contained	9	O
3	9	O
.	9	O
6	9	O
and	5	O
1	9	O
.	9	O
9	7	O
mg	0	O
/	9	O
l	0	O
carbachol	0	B-Chemical
,	9	O
respectively	9	O
.	9	O

The	5	O
corresponding	9	O
urine	9	O
concentrations	0	O
amounted	9	O
to	5	O
374	7	O
and	5	O
554	7	O
mg	0	O
/	9	O
l	0	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
case	5	O
started	5	O
with	5	O
a	5	O
media	9	O
report	5	O
in	5	O
a	5	O
popular	5	O
newspaper	5	O
,	9	O
initiated	9	O
by	9	O
published	9	O
,	9	O
peer	5	O
-	7	O
reviewed	9	O
research	5	O
on	5	O
herbals	5	O
,	9	O
and	5	O
involved	9	O
human	3	O
failure	5	O
in	5	O
a	5	O
case	5	O
history	5	O
,	9	O
medical	5	O
examination	5	O
and	5	O
clinical	5	O
treatment	9	O
.	9	O

For	9	O
the	5	O
first	9	O
time	5	O
,	9	O
an	5	O
analytical	5	O
method	5	O
for	5	O
the	5	O
determination	9	O
of	5	O
carbachol	0	B-Chemical
in	5	O
plasma	9	O
and	5	O
urine	9	O
has	9	O
been	9	O
developed	5	O
.	9	O

The	5	O
analysed	9	O
carbachol	0	B-Chemical
concentration	0	O
exceeded	9	O
the	5	O
supposed	5	O
serum	9	O
level	9	O
resulting	9	O
from	9	O
a	5	O
therapeutic	5	O
dose	9	O
by	9	O
a	5	O
factor	9	O
of	5	O
130	9	O
to	5	O
260	9	O
.	9	O

Especially	9	O
in	5	O
old	5	O
patients	5	O
,	9	O
intensivists	5	O
should	5	O
consider	5	O
intoxications	5	O
(	9	O
with	5	O
cholinergics	0	O
)	9	O
as	5	O
a	5	O
cause	5	O
of	5	O
acute	9	B-Disease
cardiovascular	5	I-Disease
failure	5	I-Disease
.	9	O

Pharmacological	9	O
evidence	9	O
for	5	O
the	5	O
potential	9	O
of	5	O
Daucus	4	O
carota	4	O
in	5	O
the	5	O
management	5	O
of	5	O
cognitive	5	B-Disease
dysfunctions	5	I-Disease
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
aimed	5	O
at	9	O
investigating	5	O
the	5	O
effects	9	O
of	5	O
Daucus	4	O
carota	4	O
seeds	4	O
on	5	O
cognitive	5	O
functions	9	O
,	9	O
total	9	O
serum	9	O
cholesterol	0	B-Chemical
levels	3	O
and	5	O
brain	5	O
cholinesterase	0	O
activity	9	O
in	5	O
mice	3	O
.	9	O

The	5	O
ethanolic	0	O
extract	0	B-Chemical
of	5	I-Chemical
Daucus	4	I-Chemical
carota	4	I-Chemical
seeds	4	I-Chemical
(	9	O
DCE	5	B-Chemical
)	9	O
was	9	O
administered	9	O
orally	0	O
in	5	O
three	9	O
doses	0	O
(	9	O
100	0	O
,	9	O
200	0	O
,	9	O
400	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
for	5	O
seven	9	O
successive	5	O
days	9	O
to	5	O
different	9	O
groups	9	O
of	5	O
young	5	O
and	5	O
aged	9	O
mice	3	O
.	9	O

Elevated	9	O
plus	9	O
maze	5	O
and	5	O
passive	5	O
avoidance	5	O
apparatus	9	O
served	9	O
as	5	O
the	5	O
exteroceptive	5	O
behavioral	5	O
models	5	O
for	5	O
testing	5	O
memory	5	O
.	9	O

Diazepam	0	B-Chemical
-	7	O
,	9	O
scopolamine	0	B-Chemical
-	7	O
and	5	O
ageing	5	O
-	7	O
induced	3	O
amnesia	5	B-Disease
served	9	O
as	5	O
the	5	O
interoceptive	5	O
behavioral	5	O
models	5	O
.	9	O

DCE	5	B-Chemical
(	9	O
200	0	O
,	9	O
400	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
showed	9	O
significant	9	O
improvement	5	O
in	5	O
memory	5	O
scores	5	O
of	5	O
young	5	O
and	5	O
aged	9	O
mice	3	O
.	9	O

The	5	O
extent	9	O
of	5	O
memory	5	O
improvement	5	O
evoked	5	O
by	9	O
DCE	5	B-Chemical
was	9	O
23	7	O
%	9	O
at	9	O
the	5	O
dose	9	O
of	5	O
200	0	O
mg	0	O
/	9	O
kg	0	O
and	5	O
35	9	O
%	9	O
at	9	O
the	5	O
dose	9	O
of	5	O
400	0	O
mg	0	O
/	9	O
kg	0	O
in	5	O
young	5	O
mice	3	O
using	9	O
elevated	9	O
plus	9	O
maze	5	O
.	9	O

Similarly	9	O
,	9	O
significant	9	O
improvements	5	O
in	5	O
memory	5	O
scores	5	O
were	9	O
observed	9	O
using	9	O
passive	5	O
avoidance	5	O
apparatus	9	O
and	5	O
aged	9	O
mice	3	O
.	9	O

Furthermore	9	O
,	9	O
DCE	5	B-Chemical
reversed	9	O
the	5	O
amnesia	5	B-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
(	9	O
0	7	O
.	9	O
4	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
and	5	O
diazepam	0	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

Daucus	4	B-Chemical
carota	4	I-Chemical
extract	0	I-Chemical
(	9	O
200	0	O
,	9	O
400	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
reduced	9	O
significantly	9	O
the	5	O
brain	5	O
acetylcholinesterase	0	O
activity	9	O
and	5	O
cholesterol	0	B-Chemical
levels	3	O
in	5	O
young	5	O
and	5	O
aged	9	O
mice	3	O
.	9	O

The	5	O
extent	9	O
of	5	O
inhibition	3	O
of	5	O
brain	5	O
cholinesterase	0	O
activity	9	O
evoked	5	O
by	9	O
DCE	5	B-Chemical
at	9	O
the	5	O
dose	9	O
of	5	O
400	0	O
mg	0	O
/	9	O
kg	0	O
was	9	O
22	7	O
%	9	O
in	5	O
young	5	O
and	5	O
19	7	O
%	9	O
in	5	O
aged	9	O
mice	3	O
.	9	O

There	5	O
was	9	O
a	5	O
remarkable	9	O
reduction	9	O
in	5	O
total	9	O
cholesterol	0	B-Chemical
level	9	O
as	5	O
well	9	O
,	9	O
to	5	O
the	5	O
extent	9	O
of	5	O
23	7	O
%	9	O
in	5	O
young	5	O
and	5	O
21	7	O
%	9	O
in	5	O
aged	9	O
animals	9	O
with	5	O
this	5	O
dose	9	O
of	5	O
DCE	5	B-Chemical
.	9	O

Therefore	9	O
,	9	O
DCE	5	B-Chemical
may	5	O
prove	5	O
to	5	O
be	5	O
a	5	O
useful	5	O
remedy	5	O
for	5	O
the	5	O
management	5	O
of	5	O
cognitive	5	B-Disease
dysfunctions	5	I-Disease
on	5	O
account	5	O
of	5	O
its	9	O
multifarious	5	O
beneficial	9	O
effects	9	O
such	5	O
as	5	O
,	9	O
memory	5	O
improving	5	O
property	5	O
,	9	O
cholesterol	0	B-Chemical
lowering	9	O
property	5	O
and	5	O
anticholinesterase	0	O
activity	9	O
.	9	O

Valproic	0	B-Chemical
acid	0	I-Chemical
induced	3	O
encephalopathy	5	B-Disease
-	7	O
-	7	O
19	7	O
new	5	O
cases	5	O
in	5	O
Germany	2	O
from	9	O
1994	2	O
to	5	O
2003	2	O
-	7	O
-	7	O
a	5	O
side	5	O
effect	9	O
associated	9	O
to	5	O
VPA	9	B-Chemical
-	7	O
therapy	5	O
not	5	O
only	9	O
in	5	O
young	5	O
children	5	O
.	9	O

Valproic	0	B-Chemical
acid	0	I-Chemical
(	9	O
VPA	9	B-Chemical
)	9	O
is	5	O
a	5	O
broad	5	O
-	7	O
spectrum	9	O
antiepileptic	5	O
drug	5	O
and	5	O
is	5	O
usually	5	O
well	9	O
-	7	O
tolerated	9	O
.	9	O

Rare	9	O
serious	5	O
complications	5	O
may	5	O
occur	5	O
in	5	O
some	5	O
patients	5	O
,	9	O
including	9	O
haemorrhagic	5	O
pancreatitis	9	B-Disease
,	9	O
bone	5	B-Disease
marrow	3	I-Disease
suppression	9	I-Disease
,	9	O
VPA	9	B-Chemical
-	7	O
induced	3	O
hepatotoxicity	9	B-Disease
and	5	O
VPA	9	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
.	9	O

The	5	O
typical	9	O
signs	5	O
of	5	O
VPA	9	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
are	5	O
impaired	9	B-Disease
consciousness	5	I-Disease
,	9	O
sometimes	5	O
marked	9	O
EEG	5	O
background	9	O
slowing	5	O
,	9	O
increased	9	O
seizure	5	B-Disease
frequency	5	O
,	9	O
with	5	O
or	5	O
without	9	O
hyperammonemia	5	B-Disease
.	9	O

There	5	O
is	5	O
still	5	O
no	9	O
proof	5	O
of	5	O
causative	9	O
effect	9	O
of	5	O
VPA	9	B-Chemical
in	5	O
patients	5	O
with	5	O
encephalopathy	5	B-Disease
,	9	O
but	9	O
only	9	O
of	5	O
an	5	O
association	9	O
with	5	O
an	5	O
assumed	5	O
causal	5	O
relation	5	O
.	9	O

We	9	O
report	5	O
19	7	O
patients	5	O
with	5	O
VPA	9	B-Chemical
-	7	O
associated	9	O
encephalopathy	5	B-Disease
in	5	O
Germany	2	O
from	9	O
the	5	O
years	5	O
1994	2	O
to	5	O
2003	2	O
,	9	O
none	9	O
of	5	O
whom	5	O
had	9	O
been	9	O
published	9	O
previously	9	O
.	9	O

Cerebral	5	B-Disease
haemorrhage	5	I-Disease
induced	3	O
by	9	O
warfarin	5	B-Chemical
-	7	O
the	5	O
influence	5	O
of	5	O
drug	5	O
-	7	O
drug	5	O
interactions	9	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
frequency	5	O
,	9	O
severity	5	O
and	5	O
preventability	5	O
of	5	O
warfarin	5	B-Chemical
-	7	O
induced	3	O
cerebral	5	B-Disease
haemorrhages	5	I-Disease
due	5	O
to	5	O
warfarin	5	B-Chemical
and	5	O
warfarin	5	B-Chemical
-	7	O
drug	5	O
interactions	9	O
in	5	O
patients	5	O
living	5	O
in	5	O
the	5	O
county	5	O
of	5	O
Osterg	_	O
tland	9	O
,	9	O
Sweden	2	O
.	9	O

METHODS	2	O
:	9	O
All	9	O
patients	5	O
with	5	O
a	5	O
diagnosed	5	O
cerebral	5	B-Disease
haemorrhage	5	I-Disease
at	9	O
three	9	O
hospitals	5	O
during	5	O
the	5	O
period	5	O
2000	9	O
-	7	O
2002	2	O
were	9	O
identified	9	O
.	9	O

Medical	2	O
records	5	O
were	9	O
studied	9	O
retrospectively	5	O
to	5	O
evaluate	9	O
whether	9	O
warfarin	5	B-Chemical
and	5	O
warfarin	5	B-Chemical
-	7	O
drug	5	O
interactions	9	O
could	9	O
have	5	O
caused	9	O
the	5	O
cerebral	5	B-Disease
haemorrhage	5	I-Disease
.	9	O

The	5	O
proportion	9	O
of	5	O
possibly	9	O
avoidable	5	O
cases	5	O
due	5	O
to	5	O
drug	5	O
interactions	9	O
was	9	O
estimated	5	O
.	9	O

RESULTS	9	O
:	9	O
Among	9	O
593	9	O
patients	5	O
with	5	O
cerebral	5	B-Disease
haemorrhage	5	I-Disease
,	9	O
59	7	O
(	9	O
10	9	O
%	9	O
)	9	O
were	9	O
assessed	9	O
as	5	O
related	9	O
to	5	O
warfarin	5	B-Chemical
treatment	9	O
.	9	O

This	5	O
imply	9	O
an	5	O
incidence	5	O
of	5	O
1	9	O
.	9	O
7	9	O
/	9	O
100	0	O
,	9	O
000	9	O
treatment	9	O
years	5	O
.	9	O

Of	9	O
the	5	O
59	7	O
cases	5	O
,	9	O
26	7	O
(	9	O
44	7	O
%	9	O
)	9	O
had	9	O
a	5	O
fatal	5	O
outcome	5	O
,	9	O
compared	9	O
to	5	O
136	7	O
(	9	O
25	9	O
%	9	O
)	9	O
among	5	O
the	5	O
non	9	O
-	7	O
warfarin	5	B-Chemical
patients	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

A	9	O
warfarin	5	B-Chemical
-	7	O
drug	5	O
interaction	9	O
could	9	O
have	5	O
contributed	9	O
to	5	O
the	5	O
haemorrhage	5	B-Disease
in	5	O
24	9	O
(	9	O
41	7	O
%	9	O
)	9	O
of	5	O
the	5	O
warfarin	5	B-Chemical
patients	5	O
and	5	O
in	5	O
7	9	O
of	5	O
these	5	O
(	9	O
12	9	O
%	9	O
)	9	O
the	5	O
bleeding	5	B-Disease
complication	5	O
was	9	O
considered	5	O
being	5	O
possible	5	O
to	5	O
avoid	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Warfarin	5	B-Chemical
-	7	O
induced	3	O
cerebral	5	B-Disease
haemorrhages	5	I-Disease
are	5	O
a	5	O
major	9	O
clinical	5	O
problem	5	O
with	5	O
a	5	O
high	9	O
fatality	5	O
rate	9	O
.	9	O

Almost	5	O
half	5	O
of	5	O
the	5	O
cases	5	O
was	9	O
related	9	O
to	5	O
a	5	O
warfarin	5	B-Chemical
-	7	O
drug	5	O
interaction	9	O
.	9	O

A	9	O
significant	9	O
proportion	9	O
of	5	O
warfarin	5	B-Chemical
-	7	O
related	9	O
cerebral	5	B-Disease
haemorrhages	5	I-Disease
might	9	O
have	5	O
been	9	O
prevented	9	O
if	5	O
greater	5	O
caution	5	O
had	9	O
been	9	O
taken	5	O
when	5	O
prescribing	5	O
drugs	5	O
known	9	O
to	5	O
interact	9	O
with	5	O
warfarin	5	B-Chemical
.	9	O

Antipsychotic	5	O
-	7	O
like	9	O
profile	9	O
of	5	O
thioperamide	3	B-Chemical
,	9	O
a	5	O
selective	9	O
H3	1	O
-	7	O
receptor	3	O
antagonist	3	O
in	5	O
mice	3	O
.	9	O

Experimental	9	O
and	5	O
clinical	5	O
evidence	9	O
points	5	O
to	5	O
a	5	O
role	9	O
of	5	O
central	5	O
histaminergic	5	O
system	5	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
study	9	O
the	5	O
effect	9	O
of	5	O
histamine	0	B-Chemical
H	9	O
(	9	O
3	9	O
)	9	O
-	7	O
receptor	3	O
ligands	3	O
on	5	O
neuroleptic	5	O
-	7	O
induced	3	O
catalepsy	5	B-Disease
,	9	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
climbing	5	O
behavior	5	O
and	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
activities	9	O
in	5	O
mice	3	O
.	9	O

Catalepsy	0	B-Disease
was	9	O
induced	3	O
by	9	O
haloperidol	5	B-Chemical
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
,	9	O
while	9	O
apomorphine	0	B-Chemical
(	9	O
1	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
and	5	O
amphetamine	5	B-Chemical
(	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
were	9	O
used	5	O
for	5	O
studying	5	O
climbing	5	O
behavior	5	O
and	5	O
locomotor	5	O
activities	9	O
,	9	O
respectively	9	O
.	9	O

(	9	B-Chemical
R	9	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
methylhistamine	0	I-Chemical
(	9	O
RAMH	3	B-Chemical
)	9	O
(	9	O
5	9	O
microg	0	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
and	5	O
thioperamide	3	B-Chemical
(	9	O
THP	0	B-Chemical
)	9	O
(	9	O
15	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
,	9	O
per	9	O
se	9	O
did	9	O
not	5	O
cause	5	O
catalepsy	5	B-Disease
.	9	O

Administration	2	O
of	5	O
THP	0	B-Chemical
(	9	O
3	9	O
.	9	O
75	9	O
,	9	O
7	9	O
.	9	O
5	9	O
and	5	O
15	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
1	9	O
h	0	O
prior	9	O
to	5	O
haloperidol	5	B-Chemical
resulted	9	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
increase	9	O
in	5	O
the	5	O
catalepsy	5	B-Disease
times	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

However	9	O
,	9	O
pretreatment	0	O
with	5	O
RAMH	3	B-Chemical
significantly	9	O
reversed	9	O
such	5	O
an	5	O
effect	9	O
of	5	O
THP	0	B-Chemical
(	9	O
15	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

RAMH	3	B-Chemical
per	9	O
se	9	O
showed	9	O
significant	9	O
reduction	9	O
in	5	O
locomotor	5	O
time	5	O
,	9	O
distance	5	O
traveled	5	O
and	5	O
average	5	O
speed	5	O
but	9	O
THP	0	B-Chemical
(	9	O
15	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
per	9	O
se	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
these	5	O
parameters	5	O
.	9	O

On	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
,	9	O
THP	0	B-Chemical
(	9	O
3	9	O
.	9	O
75	9	O
and	5	O
7	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
reduced	9	O
locomotor	5	O
time	5	O
,	9	O
distance	5	O
traveled	5	O
and	5	O
average	5	O
speed	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Pretreatment	3	O
with	5	O
RAMH	3	B-Chemical
(	9	O
5	9	O
microg	0	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
could	9	O
partially	9	O
reverse	9	O
such	5	O
effects	9	O
of	5	O
THP	0	B-Chemical
(	9	O
3	9	O
.	9	O
75	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
.	9	O

Climbing	5	O
behavior	5	O
induced	3	O
by	9	O
apomorphine	0	B-Chemical
was	9	O
reduced	9	O
in	5	O
animals	9	O
treated	3	O
with	5	O
THP	0	B-Chemical
.	9	O

Such	5	O
an	5	O
effect	9	O
was	9	O
,	9	O
however	9	O
,	9	O
reversed	9	O
in	5	O
presence	9	O
of	5	O
RAMH	3	B-Chemical
.	9	O

THP	0	B-Chemical
exhibited	9	O
an	5	O
antipsychotic	5	O
-	7	O
like	9	O
profile	9	O
by	9	O
potentiating	3	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
,	9	O
reducing	9	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
and	5	O
reducing	9	O
apomorphine	0	B-Chemical
-	7	O
induced	3	O
climbing	5	O
in	5	O
mice	3	O
.	9	O

Such	5	O
effects	9	O
of	5	O
THP	0	B-Chemical
were	9	O
reversed	9	O
by	9	O
RAMH	3	B-Chemical
indicating	9	O
the	5	O
involvement	9	O
of	5	O
histamine	0	B-Chemical
H	9	O
(	9	O
3	9	O
)	9	O
-	7	O
receptors	3	O
.	9	O

Findings	5	O
suggest	9	O
a	5	O
potential	9	O
for	5	O
H	9	O
(	9	O
3	9	O
)	9	O
-	7	O
receptor	3	O
antagonists	3	O
in	5	O
improving	5	O
the	5	O
refractory	9	O
cases	5	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

Cauda	7	B-Disease
equina	4	I-Disease
syndrome	5	I-Disease
after	9	O
epidural	5	O
steroid	9	B-Chemical
injection	9	O
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
Conventional	5	O
treatment	9	O
methods	5	O
of	5	O
lumbusacral	_	O
radiculopathy	5	B-Disease
are	5	O
physical	5	O
therapy	5	O
,	9	O
epidural	5	O
steroid	9	B-Chemical
injections	9	O
,	9	O
oral	9	O
medications	5	O
,	9	O
and	5	O
spinal	5	O
manipulative	5	O
therapy	5	O
.	9	O

Cauda	7	B-Disease
equina	4	I-Disease
syndrome	5	I-Disease
is	5	O
a	5	O
rare	5	O
complication	5	O
of	5	O
epidural	5	O
anesthesia	5	O
.	9	O

The	5	O
following	9	O
case	5	O
is	5	O
a	5	O
report	5	O
of	5	O
cauda	9	B-Disease
equina	4	I-Disease
syndrome	5	I-Disease
possibly	9	O
caused	9	O
by	9	O
epidural	5	O
injection	9	O
of	5	O
triamcinolone	0	B-Chemical
and	5	O
bupivacaine	0	B-Chemical
.	9	O

CLINICAL	2	O
FEATURES	2	O
:	9	O
A	9	O
50	0	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
low	9	B-Disease
back	5	I-Disease
and	5	I-Disease
right	5	I-Disease
leg	5	I-Disease
pain	5	I-Disease
was	9	O
scheduled	5	O
for	5	O
epidural	5	O
steroid	9	B-Chemical
injection	9	O
.	9	O

INTERVENTION	2	O
AND	2	O
OUTCOME	2	O
:	9	O
An	5	O
18	7	O
-	7	O
gauge	5	O
Touhy	5	O
needle	5	O
was	9	O
inserted	9	O
until	5	O
loss	9	O
of	5	O
resistance	9	O
occurred	9	O
at	9	O
the	5	O
L4	9	O
-	7	O
5	9	O
level	9	O
.	9	O

Spread	5	O
of	5	O
the	5	O
contrast	9	O
medium	0	O
within	9	O
the	5	O
epidural	5	O
space	5	O
was	9	O
determined	9	O
by	9	O
radiographic	5	O
imaging	5	O
.	9	O

After	9	O
verifying	9	O
the	5	O
epidural	5	O
space	5	O
,	9	O
bupivacaine	0	B-Chemical
and	5	O
triamcinolone	0	B-Chemical
diacetate	0	I-Chemical
were	9	O
injected	3	O
.	9	O

After	9	O
the	5	O
injection	9	O
,	9	O
there	5	O
was	9	O
a	5	O
reduction	9	O
in	5	O
radicular	5	O
symptoms	5	O
.	9	O

Three	9	O
hours	9	O
later	9	O
,	9	O
she	5	O
complained	5	O
of	5	O
perineal	5	O
numbness	5	B-Disease
and	5	O
lower	9	B-Disease
extremity	5	I-Disease
weakness	5	I-Disease
.	9	O

The	5	O
neurologic	5	O
evaluation	5	O
revealed	9	O
loss	9	B-Disease
of	5	I-Disease
sensation	5	I-Disease
in	5	O
the	5	O
saddle	5	O
area	5	O
and	5	O
medial	5	O
aspect	5	O
of	5	O
her	5	O
right	5	O
leg	5	O
.	9	O

There	5	O
was	9	O
a	5	O
decrease	9	O
in	5	O
the	5	O
perception	5	O
of	5	O
pinprick	5	O
test	5	O
.	9	O

Deep	9	O
-	7	O
tendon	5	O
reflexes	5	O
were	9	O
decreased	9	O
especially	5	O
in	5	O
the	5	O
right	5	O
leg	5	O
.	9	O

She	5	O
was	9	O
unable	9	O
to	5	O
urinate	5	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
symptoms	5	O
improved	5	O
slightly	9	O
over	5	O
the	5	O
next	9	O
few	5	O
hours	9	O
.	9	O

She	5	O
had	9	O
a	5	O
gradual	9	O
return	5	O
of	5	O
motor	5	O
function	9	O
and	5	O
ability	9	O
of	5	O
feeling	5	O
Foley	6	O
catheter	5	O
.	9	O

All	9	O
of	5	O
the	5	O
symptoms	5	O
were	9	O
completely	9	O
resolved	9	O
over	5	O
the	5	O
next	9	O
8	9	O
hours	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Complications	5	O
associated	9	O
with	5	O
epidural	5	O
steroid	9	B-Chemical
injections	9	O
are	5	O
rare	5	O
.	9	O

Clinical	5	O
examination	5	O
and	5	O
continued	9	O
vigilance	5	O
for	5	O
neurologic	5	B-Disease
deterioration	5	I-Disease
after	9	O
epidural	5	O
steroid	9	B-Chemical
injections	9	O
is	5	O
important	9	O
.	9	O

High	9	O
-	7	O
dose	9	O
testosterone	9	B-Chemical
is	5	O
associated	9	O
with	5	O
atherosclerosis	9	B-Disease
in	5	O
postmenopausal	5	O
women	5	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
study	9	O
the	5	O
long	5	O
-	7	O
term	5	O
effects	9	O
of	5	O
androgen	3	O
treatment	9	O
on	5	O
atherosclerosis	9	B-Disease
in	5	O
postmenopausal	5	O
women	5	O
.	9	O

METHODS	2	O
:	9	O
In	9	O
a	5	O
population	5	O
-	7	O
based	5	O
study	9	O
in	5	O
513	7	O
naturally	9	O
postmenopausal	5	O
women	5	O
aged	9	O
54	7	O
-	7	O
67	7	O
years	5	O
,	9	O
we	5	O
studied	9	O
the	5	O
association	9	O
between	5	O
self	5	O
-	7	O
reported	9	O
intramuscularly	0	O
administered	9	O
high	9	O
-	7	O
dose	9	O
estrogen	3	B-Chemical
-	7	O
testosterone	9	B-Chemical
therapy	5	O
(	9	O
estradiol	0	B-Chemical
-	7	I-Chemical
and	5	I-Chemical
testosterone	9	I-Chemical
esters	0	I-Chemical
)	9	O
and	5	O
aortic	9	O
atherosclerosis	9	B-Disease
.	9	O

Aortic	9	O
atherosclerosis	9	B-Disease
was	9	O
diagnosed	5	O
by	9	O
radiographic	5	O
detection	9	O
of	5	O
calcified	5	O
deposits	9	O
in	5	O
the	5	O
abdominal	5	O
aorta	9	O
,	9	O
which	5	O
have	5	O
been	9	O
shown	9	O
to	5	O
reflect	5	O
intima	5	O
atherosclerosis	9	B-Disease
.	9	O

Hormone	9	O
therapy	5	O
users	5	O
were	9	O
compared	9	O
with	5	O
never	5	O
users	5	O
.	9	O

RESULTS	9	O
:	9	O
Intramuscular	0	O
hormone	9	O
therapy	5	O
use	5	O
for	5	O
1	9	O
year	5	O
or	5	O
longer	5	O
was	9	O
reported	9	O
by	9	O
25	9	O
women	5	O
.	9	O

In	9	O
almost	9	O
half	5	O
of	5	O
these	5	O
women	5	O
severe	5	O
atherosclerosis	9	B-Disease
of	5	O
the	5	O
aorta	9	O
was	9	O
present	9	O
(	9	O
n	9	O
=	7	O
11	7	O
)	9	O
,	9	O
while	9	O
in	5	O
women	5	O
without	9	O
hormone	9	O
use	5	O
severe	5	O
atherosclerosis	9	B-Disease
of	5	O
the	5	O
aorta	9	O
was	9	O
present	9	O
in	5	O
less	5	O
than	5	O
20	9	O
%	9	O
(	9	O
OR	9	O
3	9	O
.	9	O
1	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
1	9	O
-	7	O
8	9	O
.	9	O
5	9	O
,	9	O
adjusted	9	O
for	5	O
age	5	O
,	9	O
years	5	O
since	9	O
menopause	5	O
,	9	O
smoking	5	O
,	9	O
and	5	O
body	5	O
mass	9	O
index	5	O
)	9	O
.	9	O

The	5	O
association	9	O
remained	9	O
after	9	O
additional	9	O
adjustment	5	O
for	5	O
diabetes	5	B-Disease
,	9	O
cholesterol	0	B-Chemical
level	9	O
,	9	O
systolic	5	O
blood	9	O
pressure	5	O
,	9	O
or	5	O
alcohol	5	B-Chemical
use	5	O
.	9	O

No	9	O
association	9	O
was	9	O
found	9	O
for	5	O
hormone	9	O
use	5	O
less	5	O
than	5	O
1	9	O
year	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Our	9	O
results	9	O
suggest	9	O
that	5	O
high	9	O
-	7	O
dose	9	O
testosterone	9	B-Chemical
therapy	5	O
may	5	O
adversely	5	O
affect	9	O
atherosclerosis	9	B-Disease
in	5	O
postmenopausal	5	O
women	5	O
and	5	O
indicate	9	O
that	5	O
androgen	3	O
replacement	9	O
in	5	O
these	5	O
women	5	O
may	5	O
not	5	O
be	5	O
harmless	5	O
.	9	O

Optimising	5	O
stroke	5	B-Disease
prevention	5	O
in	5	O
non	9	O
-	7	O
valvular	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
.	9	O

Atrial	7	B-Disease
fibrillation	5	I-Disease
is	5	O
associated	9	O
with	5	O
substantial	9	O
morbidity	5	O
and	5	O
mortality	5	O
.	9	O

Pooled	9	O
data	5	O
from	9	O
trials	5	O
comparing	9	O
antithrombotic	5	O
treatment	9	O
with	5	O
placebo	9	O
have	5	O
shown	9	O
that	5	O
warfarin	5	B-Chemical
reduces	9	O
the	5	O
risk	5	O
of	5	O
stroke	5	B-Disease
by	9	O
62	7	O
%	9	O
,	9	O
and	5	O
that	5	O
aspirin	9	B-Chemical
alone	9	O
reduces	9	O
the	5	O
risk	5	O
by	9	O
22	7	O
%	9	O
.	9	O

Overall	9	O
,	9	O
in	5	O
high	9	O
-	7	O
risk	5	O
patients	5	O
,	9	O
warfarin	5	B-Chemical
is	5	O
superior	5	O
to	5	O
aspirin	9	B-Chemical
in	5	O
preventing	9	O
strokes	5	B-Disease
,	9	O
with	5	O
a	5	O
relative	9	O
risk	5	O
reduction	9	O
of	5	O
36	9	O
%	9	O
.	9	O

Ximelagatran	7	B-Chemical
,	9	O
an	5	O
oral	9	O
direct	9	O
thrombin	0	O
inhibitor	3	O
,	9	O
was	9	O
found	9	O
to	5	O
be	5	O
as	5	O
efficient	5	O
as	5	O
vitamin	0	B-Chemical
K	9	I-Chemical
antagonist	3	O
drugs	5	O
in	5	O
the	5	O
prevention	5	O
of	5	O
embolic	5	B-Disease
events	5	I-Disease
,	9	O
but	9	O
has	9	O
been	9	O
recently	9	O
withdrawn	9	O
because	5	O
of	5	O
abnormal	9	B-Disease
liver	9	I-Disease
function	9	I-Disease
tests	5	O
.	9	O

The	5	O
ACTIVE	2	O
-	7	O
W	9	O
(	9	O
Atrial	7	B-Disease
Fibrillation	5	I-Disease
Clopidogrel	0	B-Chemical
Trial	5	O
with	5	O
Irbesartan	0	B-Chemical
for	5	O
Prevention	2	O
of	5	O
Vascular	9	O
Events	5	O
)	9	O
study	9	O
has	9	O
demonstrated	9	O
that	5	O
warfarin	5	B-Chemical
is	5	O
superior	5	O
to	5	O
platelet	9	O
therapy	5	O
(	9	O
clopidogrel	0	B-Chemical
plus	9	O
aspirin	9	B-Chemical
)	9	O
in	5	O
the	5	O
prevention	5	O
af	2	O
embolic	5	B-Disease
events	5	I-Disease
.	9	O

Idraparinux	0	B-Chemical
,	9	O
a	5	O
Factor	9	O
Xa	9	O
inhibitor	3	O
,	9	O
is	5	O
being	5	O
evaluated	9	O
in	5	O
patients	5	O
with	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
.	9	O

Angiotensin	0	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
inhibitors	3	O
and	5	O
angiotensin	9	B-Chemical
II	9	I-Chemical
receptor	3	O
-	7	O
blocking	3	O
drugs	5	O
hold	5	O
promise	5	O
in	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
through	9	O
cardiac	5	B-Disease
remodelling	9	I-Disease
.	9	O

Preliminary	9	O
studies	9	O
suggest	9	O
that	5	O
statins	5	B-Chemical
could	9	O
interfere	9	O
with	5	O
the	5	O
risk	5	O
of	5	O
recurrence	5	O
after	9	O
electrical	5	O
cardioversion	5	O
.	9	O

Finally	9	O
,	9	O
percutaneous	5	O
methods	5	O
for	5	O
the	5	O
exclusion	5	O
of	5	O
left	5	O
atrial	5	O
appendage	9	O
are	5	O
under	9	O
investigation	9	O
in	5	O
high	9	O
-	7	O
risk	5	O
patients	5	O
.	9	O

Anti	3	O
-	7	O
oxidant	0	O
effects	9	O
of	5	O
atorvastatin	0	B-Chemical
in	5	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

1	9	O
.	9	O

Dexamethasone	0	B-Chemical
(	9	O
Dex	3	B-Chemical
)	9	O
-	7	O
induced	3	O
hypertension	5	B-Disease
is	5	O
characterized	9	O
by	9	O
endothelial	3	O
dysfunction	9	O
associated	9	O
with	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
(	9	O
NO	9	B-Chemical
)	9	O
deficiency	9	O
and	5	O
increased	9	O
superoxide	0	B-Chemical
(	9	O
O2	0	B-Chemical
-	7	I-Chemical
)	9	O
production	9	O
.	9	O

Atorvastatin	0	B-Chemical
(	9	O
Ato	2	B-Chemical
)	9	O
possesses	9	O
pleiotropic	9	O
properties	9	O
that	5	O
have	5	O
been	9	O
reported	9	O
to	5	O
improve	5	O
endothelial	3	O
function	9	O
through	9	O
increased	9	O
availability	5	O
of	5	O
NO	9	B-Chemical
and	5	O
reduced	9	O
O2	0	B-Chemical
-	7	I-Chemical
production	9	O
in	5	O
various	9	O
forms	9	O
of	5	O
hypertension	5	B-Disease
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
we	5	O
investigated	9	O
whether	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
,	9	O
Ato	2	B-Chemical
could	9	O
prevent	5	O
endothelial	3	O
NO	9	B-Chemical
synthase	1	O
(	9	O
eNOS	3	O
)	9	O
downregulation	3	O
and	5	O
the	5	O
increase	9	O
in	5	O
O2	0	B-Chemical
-	7	I-Chemical
in	5	O
Sprague	9	O
-	7	O
Dawley	0	O
(	9	O
SD	7	O
)	9	O
rats	9	O
,	9	O
thereby	9	O
reducing	9	O
blood	9	O
pressure	5	O
.	9	O

2	9	O
.	9	O

Male	7	O
SD	7	O
rats	9	O
(	9	O
n	9	O
=	7	O
30	9	O
)	9	O
were	9	O
treated	3	O
with	5	O
Ato	2	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
in	5	O
drinking	5	O
water	0	O
)	9	O
or	5	O
tap	5	O
water	0	O
for	5	O
15	9	O
days	9	O
.	9	O

Dexamethasone	0	B-Chemical
(	9	O
10	9	O
microg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
or	5	O
saline	0	O
was	9	O
started	5	O
after	9	O
4	9	O
days	9	O
in	5	O
Ato	2	B-Chemical
-	7	O
treated	3	O
and	5	O
non	9	O
-	7	O
treated	3	O
rats	9	O
and	5	O
continued	9	O
for	5	O
11	7	O
-	7	O
13	7	O
days	9	O
.	9	O

Systolic	7	O
blood	9	O
pressure	5	O
(	9	O
SBP	9	O
)	9	O
was	9	O
measured	9	O
on	5	O
alternate	9	O
days	9	O
using	9	O
the	5	O
tail	9	O
-	7	O
cuff	5	O
method	5	O
.	9	O

Endothelial	3	O
function	9	O
was	9	O
assessed	9	O
by	9	O
acetylcholine	0	B-Chemical
-	7	O
induced	3	O
vasorelaxation	0	O
and	5	O
phenylephrine	0	B-Chemical
-	7	O
induced	3	O
vasoconstriction	9	O
in	5	O
aortic	9	O
segments	9	O
.	9	O

Vascular	9	O
eNOS	3	O
mRNA	3	O
was	9	O
assessed	9	O
by	9	O
semi	5	O
-	7	O
quantitative	9	O
reverse	9	O
transcription	1	O
-	7	O
polymerase	1	O
chain	9	O
reaction	9	O
.	9	O

3	9	O
.	9	O

In	9	O
rats	9	O
treated	3	O
with	5	O
Dex	3	B-Chemical
alone	9	O
,	9	O
SBP	9	O
was	9	O
increased	9	O
from	9	O
109	7	O
+	9	O
/	9	O
-	7	O
2	9	O
to	5	O
133	7	O
+	9	O
/	9	O
-	7	O
2	9	O
mmHg	7	O
on	5	O
Days	9	O
4	9	O
and	5	O
Day	9	O
14	7	O
,	9	O
respectively	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

In	9	O
the	5	O
Ato	2	B-Chemical
+	9	O
Dex	3	B-Chemical
group	9	O
,	9	O
SBP	9	O
was	9	O
increased	9	O
from	9	O
113	7	O
+	9	O
/	9	O
-	7	O
2	9	O
to	5	O
119	7	O
+	9	O
/	9	O
-	7	O
2	9	O
mmHg	7	O
on	5	O
Days	9	O
4	9	O
to	5	O
14	7	O
,	9	O
respectively	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
but	9	O
was	9	O
significantly	9	O
lower	9	O
than	5	O
SBP	9	O
in	5	O
the	5	O
group	9	O
treated	3	O
with	5	O
Dex	3	B-Chemical
alone	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Endothelial	3	O
-	7	O
dependent	9	O
relaxation	5	O
and	5	O
eNOS	3	O
mRNA	3	O
expression	3	O
were	9	O
greater	5	O
in	5	O
the	5	O
Dex	3	B-Chemical
+	9	O
Ato	2	B-Chemical
group	9	O
than	5	O
in	5	O
the	5	O
Dex	3	B-Chemical
only	9	O
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
and	5	O
P	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Aortic	9	O
superoxide	0	B-Chemical
production	9	O
was	9	O
lower	9	O
in	5	O
the	5	O
Dex	3	B-Chemical
+	9	O
Ato	2	B-Chemical
group	9	O
compared	9	O
with	5	O
the	5	O
group	9	O
treated	3	O
with	5	O
Dex	3	B-Chemical
alone	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

4	9	O
.	9	O

Treatment	9	O
with	5	O
Ato	2	B-Chemical
improved	5	O
endothelial	3	O
function	9	O
,	9	O
reduced	9	O
superoxide	0	B-Chemical
production	9	O
and	5	O
reduced	9	O
SBP	9	O
in	5	O
Dex	3	B-Chemical
-	7	O
treated	3	O
SD	7	O
rats	9	O
.	9	O

Severe	9	O
citrate	0	B-Chemical
toxicity	9	B-Disease
complicating	5	O
volunteer	5	O
apheresis	5	O
platelet	9	O
donation	9	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
severe	5	O
citrate	0	B-Chemical
toxicity	9	B-Disease
during	5	O
volunteer	5	O
donor	9	O
apheresis	5	O
platelet	9	O
collection	5	O
.	9	O

The	5	O
donor	9	O
was	9	O
a	5	O
40	9	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
,	9	O
first	9	O
-	7	O
time	5	O
apheresis	5	O
platelet	9	O
donor	9	O
.	9	O

Past	5	O
medical	5	O
history	5	O
was	9	O
remarkable	9	O
for	5	O
hypertension	5	B-Disease
,	9	O
hyperlipidemia	9	B-Disease
,	9	O
and	5	O
depression	5	B-Disease
.	9	O

Reported	5	O
medications	5	O
included	5	O
bumetanide	0	B-Chemical
,	9	O
pravastatin	0	B-Chemical
,	9	O
and	5	O
paroxetine	0	B-Chemical
.	9	O

Thirty	9	O
minutes	0	O
from	9	O
the	5	O
start	9	O
of	5	O
the	5	O
procedure	5	O
,	9	O
the	5	O
donor	9	O
noted	9	O
tingling	5	O
around	5	O
the	5	O
mouth	5	O
,	9	O
hands	5	O
,	9	O
and	5	O
feet	5	O
.	9	O

She	5	O
then	9	O
very	5	O
rapidly	9	O
developed	5	O
acute	9	O
onset	5	O
of	5	O
severe	5	O
facial	5	O
and	5	O
extremity	5	O
tetany	5	B-Disease
.	9	O

Empirical	5	O
treatment	9	O
with	5	O
intravenous	0	O
calcium	0	B-Chemical
gluconate	0	I-Chemical
was	9	O
initiated	9	O
,	9	O
and	5	O
muscle	9	B-Disease
contractions	5	I-Disease
slowly	5	O
subsided	5	O
over	5	O
approximately	9	O
10	9	O
to	5	O
15	9	O
minutes	0	O
.	9	O

The	5	O
events	5	O
are	5	O
consistent	9	O
with	5	O
a	5	O
severe	5	O
reaction	9	O
to	5	O
calcium	0	B-Chemical
chelation	0	O
by	9	O
sodium	0	B-Chemical
citrate	0	I-Chemical
anticoagulant	9	O
resulting	9	O
in	5	O
symptomatic	5	O
systemic	9	O
hypocalcemia	5	B-Disease
.	9	O

Upon	9	O
additional	9	O
retrospective	5	O
analysis	9	O
,	9	O
it	5	O
was	9	O
noted	9	O
that	5	O
bumetanide	0	B-Chemical
is	5	O
a	5	O
loop	9	B-Chemical
diuretic	5	I-Chemical
that	5	O
may	5	O
cause	5	O
significant	9	O
hypocalcemia	5	B-Disease
.	9	O

We	9	O
conclude	9	O
that	5	O
careful	5	O
screening	5	O
for	5	O
medications	5	O
and	5	O
underlying	5	O
conditions	9	O
predisposing	5	O
to	5	O
hypocalcemia	5	B-Disease
is	5	O
recommended	5	O
to	5	O
help	5	O
prevent	5	O
severe	5	O
reactions	9	O
due	5	O
to	5	O
citrate	0	B-Chemical
toxicity	9	B-Disease
.	9	O

Laboratory	2	O
measurement	5	O
of	5	O
pre	9	O
-	7	O
procedure	5	O
serum	9	O
calcium	0	B-Chemical
levels	3	O
in	5	O
selected	9	O
donors	9	O
may	5	O
identify	9	O
cases	5	O
requiring	5	O
heightened	5	O
vigilance	5	O
.	9	O

The	5	O
case	5	O
also	9	O
illustrates	5	O
the	5	O
importance	5	O
of	5	O
maintaining	9	O
preparedness	5	O
for	5	O
managing	5	O
rare	5	O
but	9	O
serious	5	O
reactions	9	O
in	5	O
volunteer	5	O
apheresis	5	O
blood	9	O
donors	9	O
.	9	O

Sirolimus	0	B-Chemical
-	7	O
associated	9	O
proteinuria	9	B-Disease
and	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
.	9	O

Sirolimus	0	B-Chemical
is	5	O
a	5	O
novel	9	O
immunosuppressant	9	O
with	5	O
potent	3	O
antiproliferative	3	O
actions	5	O
through	9	O
its	9	O
ability	9	O
to	5	O
inhibit	3	O
the	5	O
raptor	3	O
-	7	O
containing	0	O
mammalian	9	O
target	9	O
of	5	O
rapamycin	3	B-Chemical
protein	1	O
kinase	3	O
.	9	O

Sirolimus	0	B-Chemical
represents	9	O
a	5	O
major	9	O
therapeutic	5	O
advance	5	O
in	5	O
the	5	O
prevention	5	O
of	5	O
acute	9	O
renal	9	O
allograft	5	O
rejection	5	O
and	5	O
chronic	5	O
allograft	5	O
nephropathy	9	B-Disease
.	9	O

Its	5	O
role	9	O
in	5	O
the	5	O
therapy	5	O
of	5	O
glomerulonephritis	3	B-Disease
,	9	O
autoimmunity	3	B-Disease
,	9	O
cystic	5	B-Disease
renal	9	I-Disease
diseases	5	I-Disease
and	5	O
renal	9	B-Disease
cancer	3	I-Disease
is	5	O
under	9	O
investigation	9	O
.	9	O

Because	9	O
sirolimus	0	B-Chemical
does	9	O
not	5	O
share	5	O
the	5	O
vasomotor	5	O
renal	9	O
adverse	5	O
effects	9	O
exhibited	9	O
by	9	O
calcineurin	3	O
inhibitors	3	O
,	9	O
it	5	O
has	9	O
been	9	O
designated	9	O
a	5	O
'	9	O
non	9	O
-	7	O
nephrotoxic	5	B-Disease
drug	5	O
'	9	O
.	9	O

However	9	O
,	9	O
clinical	5	O
reports	9	O
suggest	9	O
that	5	O
,	9	O
under	9	O
some	5	O
circumstances	5	O
,	9	O
sirolimus	0	B-Chemical
is	5	O
associated	9	O
with	5	O
proteinuria	9	B-Disease
and	5	O
acute	9	B-Disease
renal	9	I-Disease
dysfunction	9	I-Disease
.	9	O

A	9	O
common	5	O
risk	5	O
factor	9	O
appears	9	O
to	5	O
be	5	O
presence	9	O
of	5	O
pre	9	O
-	7	O
existing	5	O
chronic	5	B-Disease
renal	9	I-Disease
damage	9	I-Disease
.	9	O

The	5	O
mechanisms	9	O
of	5	O
sirolimus	0	B-Chemical
-	7	O
associated	9	O
proteinuria	9	B-Disease
are	5	O
multifactorial	5	O
and	5	O
may	5	O
be	5	O
due	5	O
to	5	O
an	5	O
increase	9	O
in	5	O
glomerular	5	O
capillary	0	O
pressure	5	O
following	9	O
calcineurin	3	O
inhibitor	3	O
withdrawal	5	O
.	9	O

It	5	O
has	9	O
also	9	O
been	9	O
suggested	9	O
that	5	O
sirolimus	0	B-Chemical
directly	9	O
causes	9	O
increased	9	O
glomerular	5	O
permeability	0	O
/	9	O
injury	9	O
,	9	O
but	9	O
evidence	9	O
for	5	O
this	5	O
mechanism	9	O
is	5	O
currently	5	O
inconclusive	9	O
.	9	O

The	5	O
acute	9	B-Disease
renal	9	I-Disease
dysfunction	9	I-Disease
associated	9	O
with	5	O
sirolimus	0	B-Chemical
(	9	O
such	5	O
as	5	O
in	5	O
delayed	9	O
graft	5	O
function	9	O
)	9	O
may	5	O
be	5	O
due	5	O
to	5	O
suppression	9	O
of	5	O
compensatory	5	O
renal	9	O
cell	3	O
proliferation	3	O
and	5	O
survival	9	O
/	9	O
repair	9	O
processes	5	O
.	9	O

Although	9	O
these	5	O
adverse	5	O
effects	9	O
occur	5	O
in	5	O
some	5	O
patients	5	O
,	9	O
their	5	O
occurrence	5	O
could	9	O
be	5	O
minimised	5	O
by	9	O
knowledge	5	O
of	5	O
the	5	O
molecular	9	O
effects	9	O
of	5	O
sirolimus	0	B-Chemical
on	5	O
the	5	O
kidney	9	O
,	9	O
the	5	O
use	5	O
of	5	O
sirolimus	0	B-Chemical
in	5	O
appropriate	5	O
patient	5	O
populations	9	O
,	9	O
close	5	O
monitoring	5	O
of	5	O
proteinuria	9	B-Disease
and	5	O
renal	9	O
function	9	O
,	9	O
use	5	O
of	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
inhibitors	3	O
or	5	O
angiotensin	9	B-Chemical
II	9	I-Chemical
receptor	3	O
blockers	9	O
if	5	O
proteinuria	9	B-Disease
occurs	9	O
and	5	O
withdrawal	5	O
if	5	O
needed	5	O
.	9	O

Further	9	O
long	5	O
-	7	O
term	5	O
analysis	9	O
of	5	O
renal	9	O
allograft	5	O
studies	9	O
using	9	O
sirolimus	0	B-Chemical
as	5	O
de	2	O
novo	9	O
immunosuppression	5	O
along	9	O
with	5	O
clinical	5	O
and	5	O
laboratory	9	O
studies	9	O
will	5	O
refine	5	O
these	5	O
issues	5	O
in	5	O
the	5	O
future	5	O
.	9	O

Proteinuria	7	B-Disease
after	9	O
conversion	9	O
to	5	O
sirolimus	0	B-Chemical
in	5	O
renal	9	O
transplant	9	O
recipients	9	O
.	9	O

Sirolimus	0	B-Chemical
(	9	O
SRL	0	B-Chemical
)	9	O
is	5	O
a	5	O
new	5	O
,	9	O
potent	3	O
immunosuppressive	9	O
agent	9	O
.	9	O

More	5	O
recently	9	O
,	9	O
proteinuria	9	B-Disease
has	9	O
been	9	O
reported	9	O
as	5	O
a	5	O
consequence	5	O
of	5	O
sirolimus	0	B-Chemical
therapy	5	O
,	9	O
although	9	O
the	5	O
mechanism	9	O
has	9	O
remained	9	O
unclear	9	O
.	9	O

We	9	O
retrospectively	5	O
examined	9	O
the	5	O
records	5	O
of	5	O
25	9	O
renal	9	O
transplant	9	O
patients	5	O
,	9	O
who	5	O
developed	5	O
or	5	O
displayed	9	O
increased	9	O
proteinuria	9	B-Disease
after	9	O
SRL	0	B-Chemical
conversion	9	O
.	9	O

The	5	O
patient	5	O
cohort	9	O
(	9	O
14	7	O
men	5	O
,	9	O
11	7	O
women	5	O
)	9	O
was	9	O
treated	3	O
with	5	O
SRL	0	B-Chemical
as	5	O
conversion	9	O
therapy	5	O
,	9	O
due	5	O
to	5	O
chronic	5	B-Disease
allograft	5	I-Disease
nephropathy	9	I-Disease
(	9	O
CAN	9	B-Disease
)	9	O
(	9	O
n	9	O
=	7	O
15	9	O
)	9	O
neoplasia	5	B-Disease
(	9	O
n	9	O
=	7	O
8	9	O
)	9	O
;	9	O
Kaposi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
sarcoma	9	I-Disease
,	9	O
Four	9	O
skin	5	B-Disease
cancers	9	I-Disease
,	9	O
One	5	O
intestinal	9	B-Disease
tumors	3	I-Disease
,	9	O
One	5	O
renal	9	B-Disease
cell	3	I-Disease
carsinom	_	I-Disease
)	9	O
or	5	O
BK	9	O
virus	9	O
nephropathy	9	B-Disease
(	9	O
n	9	O
=	7	O
2	9	O
)	9	O
.	9	O

SRL	0	B-Chemical
was	9	O
started	5	O
at	9	O
a	5	O
mean	5	O
of	5	O
78	7	O
+	9	O
/	9	O
-	7	O
42	7	O
(	9	O
15	9	O
to	5	O
163	7	O
)	9	O
months	5	O
after	9	O
transplantation	9	O
.	9	O

Mean	9	O
follow	5	O
-	7	O
up	5	O
on	5	O
SRL	0	B-Chemical
therapy	5	O
was	9	O
20	9	O
+	9	O
/	9	O
-	7	O
12	9	O
(	9	O
6	9	O
to	5	O
43	7	O
)	9	O
months	5	O
.	9	O

Proteinuria	7	B-Disease
increased	9	O
from	9	O
0	7	O
.	9	O
445	7	O
(	9	O
0	7	O
to	5	O
1	9	O
.	9	O
5	9	O
)	9	O
g	0	O
/	9	O
d	9	O
before	9	O
conversion	9	O
to	5	O
3	9	O
.	9	O
2	9	O
g	0	O
/	9	O
dL	7	O
(	9	O
0	7	O
.	9	O
2	9	O
to	5	O
12	9	O
)	9	O
after	9	O
conversion	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

Before	9	O
conversion	9	O
8	9	O
(	9	O
32	7	O
%	9	O
)	9	O
patients	5	O
had	9	O
no	9	O
proteinuria	9	B-Disease
,	9	O
whereas	9	O
afterwards	5	O
all	5	O
patients	5	O
had	9	O
proteinuria	9	B-Disease
.	9	O

In	9	O
28	7	O
%	9	O
of	5	O
patients	5	O
proteinuria	9	B-Disease
remained	9	O
unchanged	9	O
,	9	O
whereas	9	O
it	5	O
increased	9	O
in	5	O
68	7	O
%	9	O
of	5	O
patients	5	O
.	9	O

In	9	O
40	9	O
%	9	O
it	5	O
increased	9	O
by	9	O
more	5	O
than	5	O
100	0	O
%	9	O
.	9	O

Twenty	9	O
-	7	O
eight	9	O
percent	5	O
of	5	O
patients	5	O
showed	9	O
increased	9	O
proteinuria	9	B-Disease
to	5	O
the	5	O
nephrotic	5	B-Disease
range	9	O
.	9	O

Biopsies	9	O
performed	9	O
in	5	O
five	9	O
patients	5	O
revealed	9	O
new	5	O
pathological	5	O
changes	9	O
:	9	O
One	5	O
membranoproliferative	5	B-Disease
glomerulopathy	5	I-Disease
and	5	O
interstitial	9	B-Disease
nephritis	9	I-Disease
.	9	O

These	5	O
patients	5	O
showed	9	O
persistently	9	O
good	5	O
graft	5	O
function	9	O
.	9	O

Serum	9	O
creatinine	0	B-Chemical
values	5	O
did	9	O
not	5	O
change	9	O
significantly	9	O
:	9	O
1	9	O
.	9	O
98	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
8	9	O
mg	0	O
/	9	O
dL	7	O
before	9	O
SRL	0	B-Chemical
therapy	5	O
and	5	O
2	9	O
.	9	O
53	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
9	7	O
mg	0	O
/	9	O
dL	7	O
at	9	O
last	5	O
follow	5	O
-	7	O
up	5	O
(	9	O
P	9	O
=	7	O
.	9	O
14	7	O
)	9	O
.	9	O

Five	9	O
grafts	5	O
were	9	O
lost	9	O
and	5	O
the	5	O
patients	5	O
returned	5	O
to	5	O
dialysis	5	O
.	9	O

Five	9	O
patients	5	O
displayed	9	O
CAN	9	B-Disease
and	5	O
Kaposi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
sarcoma	9	I-Disease
.	9	O

Mean	9	O
urinary	9	O
protein	1	O
of	5	O
patients	5	O
who	5	O
returned	5	O
to	5	O
dialysis	5	O
was	9	O
1	9	O
.	9	O
26	7	O
(	9	O
0	7	O
.	9	O
5	9	O
to	5	O
3	9	O
.	9	O
5	9	O
)	9	O
g	0	O
/	9	O
d	9	O
before	9	O
and	5	O
4	9	O
.	9	O
7	9	O
(	9	O
3	9	O
to	5	O
12	9	O
)	9	O
g	0	O
/	9	O
d	9	O
after	9	O
conversion	9	O
(	9	O
P	9	O
=	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Mean	9	O
serum	9	O
creatinine	0	B-Chemical
level	9	O
before	9	O
conversion	9	O
was	9	O
2	9	O
.	9	O
21	7	O
mg	0	O
/	9	O
dL	7	O
and	5	O
thereafter	9	O
,	9	O
4	9	O
.	9	O
93	7	O
mg	0	O
/	9	O
dL	7	O
(	9	O
P	9	O
=	7	O
.	9	O
02	7	O
)	9	O
.	9	O

Heavy	9	O
proteinuria	9	B-Disease
was	9	O
common	5	O
after	9	O
the	5	O
use	5	O
of	5	O
SRL	0	B-Chemical
as	5	O
rescue	3	O
therapy	5	O
for	5	O
renal	9	O
transplantation	9	O
.	9	O

Therefore	9	O
,	9	O
conversion	9	O
should	5	O
be	5	O
considered	5	O
for	5	O
patients	5	O
who	5	O
have	5	O
not	5	O
developed	5	O
advanced	5	O
CAN	9	B-Disease
and	5	O
proteinuria	9	B-Disease
.	9	O

The	5	O
possibility	9	O
of	5	O
de	2	O
novo	9	O
glomerular	5	O
pathology	5	O
under	9	O
SRL	0	B-Chemical
treatment	9	O
requires	5	O
further	9	O
investigation	9	O
by	9	O
renal	9	O
biopsy	5	O
.	9	O

Long	9	O
-	7	O
term	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
ifosfamide	0	B-Chemical
renal	9	B-Disease
toxicity	9	I-Disease
in	5	O
children	5	O
treated	3	O
for	5	O
malignant	3	B-Disease
mesenchymal	3	I-Disease
tumors	3	I-Disease
:	9	O
an	5	O
International	2	O
Society	2	O
of	5	O
Pediatric	2	O
Oncology	2	O
report	5	O
.	9	O

The	5	O
renal	9	O
function	9	O
of	5	O
74	7	O
children	5	O
with	5	O
malignant	3	B-Disease
mesenchymal	3	I-Disease
tumors	3	I-Disease
in	5	O
complete	9	O
remission	5	O
and	5	O
who	5	O
have	5	O
received	9	O
the	5	O
same	9	O
ifosfamide	0	B-Chemical
chemotherapy	5	O
protocol	9	O
(	9	O
International	2	O
Society	2	O
of	5	O
Pediatric	2	O
Oncology	2	O
Malignant	7	B-Disease
Mesenchymal	3	I-Disease
Tumor	9	I-Disease
Study	5	O
84	7	O
[	9	O
SIOP	5	O
MMT	5	O
84	7	O
]	9	O
)	9	O
were	9	O
studied	9	O
1	9	O
year	5	O
after	9	O
the	5	O
completion	5	O
of	5	O
treatment	9	O
.	9	O

Total	7	O
cumulative	5	O
doses	0	O
were	9	O
36	9	O
or	5	O
60	9	O
g	0	O
/	9	O
m2	7	O
of	5	O
ifosfamide	0	B-Chemical
(	9	O
six	9	O
or	5	O
10	9	O
cycles	9	O
of	5	O
ifosfamide	0	B-Chemical
,	9	I-Chemical
vincristine	0	I-Chemical
,	9	I-Chemical
and	5	I-Chemical
dactinomycin	0	I-Chemical
[	9	O
IVA	9	B-Chemical
]	9	O
)	9	O
.	9	O

None	9	O
of	5	O
them	5	O
had	9	O
received	9	O
cisplatin	3	B-Chemical
chemotherapy	5	O
.	9	O

Ages	5	O
ranged	9	O
from	9	O
4	9	O
months	5	O
to	5	O
17	7	O
years	5	O
;	9	O
58	7	O
patients	5	O
were	9	O
males	9	O
and	5	O
42	7	O
females	9	O
.	9	O

The	5	O
most	9	O
common	5	O
primary	9	O
tumor	3	B-Disease
site	9	O
was	9	O
the	5	O
head	5	O
and	5	O
neck	5	O
.	9	O

Renal	9	O
function	9	O
was	9	O
investigated	9	O
by	9	O
measuring	9	O
plasma	9	O
and	5	O
urinary	9	O
electrolytes	0	O
,	9	O
glucosuria	5	B-Disease
,	9	O
proteinuria	9	B-Disease
,	9	O
aminoaciduria	5	B-Disease
,	9	O
urinary	9	O
pH	0	O
,	9	O
osmolarity	0	O
,	9	O
creatinine	0	B-Chemical
clearance	9	O
,	9	O
phosphate	0	B-Chemical
tubular	9	O
reabsorption	0	O
,	9	O
beta	9	O
2	9	O
microglobulinuria	9	O
,	9	O
and	5	O
lysozymuria	_	O
.	9	O

Fifty	9	O
-	7	O
eight	9	O
patients	5	O
(	9	O
78	7	O
%	9	O
)	9	O
had	9	O
normal	9	O
renal	9	O
tests	5	O
,	9	O
whereas	9	O
16	9	O
patients	5	O
(	9	O
22	7	O
%	9	O
)	9	O
had	9	O
renal	9	B-Disease
abnormalities	9	I-Disease
.	9	O

Two	9	O
subsets	3	O
of	5	O
patients	5	O
were	9	O
identified	9	O
from	9	O
this	5	O
latter	9	O
group	9	O
:	9	O
the	5	O
first	9	O
included	5	O
four	9	O
patients	5	O
(	9	O
5	9	O
%	9	O
of	5	O
the	5	O
total	9	O
population	5	O
)	9	O
who	5	O
developed	5	O
major	9	O
toxicity	9	B-Disease
resulting	9	O
in	5	O
Fanconi	9	B-Disease
'	9	I-Disease
s	9	I-Disease
syndrome	5	I-Disease
(	9	O
TDFS	_	B-Disease
)	9	O
;	9	O
and	5	O
the	5	O
second	9	O
group	9	O
included	5	O
five	9	O
patients	5	O
with	5	O
elevated	9	O
beta	9	O
2	9	O
microglobulinuria	9	O
and	5	O
low	9	O
phosphate	0	B-Chemical
reabsorption	0	O
.	9	O

The	5	O
remaining	9	O
seven	9	O
patients	5	O
had	9	O
isolated	9	O
beta	9	O
2	9	O
microglobulinuria	9	O
.	9	O

Severe	9	O
toxicity	9	B-Disease
was	9	O
correlated	9	O
with	5	O
the	5	O
higher	9	O
cumulative	5	O
dose	9	O
of	5	O
60	9	O
g	0	O
/	9	O
m2	7	O
of	5	O
ifosfamide	0	B-Chemical
,	9	O
a	5	O
younger	5	O
age	5	O
(	9	O
less	5	O
than	5	O
2	9	O
1	9	O
/	9	O
2	9	O
years	5	O
old	5	O
)	9	O
,	9	O
and	5	O
a	5	O
predominance	9	O
of	5	O
vesicoprostatic	5	O
tumor	3	B-Disease
involvement	9	O
.	9	O

This	5	O
low	9	O
percentage	9	O
(	9	O
5	9	O
%	9	O
)	9	O
of	5	O
TDFS	_	O
must	5	O
be	5	O
evaluated	9	O
with	5	O
respect	9	O
to	5	O
the	5	O
efficacy	9	O
of	5	O
ifosfamide	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
mesenchymal	3	B-Disease
tumors	3	I-Disease
in	5	O
children	5	O
.	9	O

Progressive	5	O
myopathy	9	B-Disease
with	5	O
up	5	O
-	7	O
regulation	9	O
of	5	O
MHC	3	O
-	7	O
I	9	O
associated	9	O
with	5	O
statin	5	B-Chemical
therapy	5	O
.	9	O

Statins	7	B-Chemical
can	5	O
cause	5	O
a	5	O
necrotizing	5	O
myopathy	9	B-Disease
and	5	O
hyperCKaemia	9	B-Disease
which	5	O
is	5	O
reversible	9	O
on	5	O
cessation	5	O
of	5	O
the	5	O
drug	5	O
.	9	O

What	5	O
is	5	O
less	5	O
well	9	O
known	9	O
is	5	O
a	5	O
phenomenon	5	O
whereby	5	O
statins	5	B-Chemical
may	5	O
induce	3	O
a	5	O
myopathy	9	B-Disease
,	9	O
which	5	O
persists	9	O
or	5	O
may	5	O
progress	5	O
after	9	O
stopping	5	O
the	5	O
drug	5	O
.	9	O

We	9	O
investigated	9	O
the	5	O
muscle	9	O
pathology	5	O
in	5	O
8	9	O
such	5	O
cases	5	O
.	9	O

All	9	O
had	9	O
myofibre	3	O
necrosis	9	B-Disease
but	9	O
only	9	O
3	9	O
had	9	O
an	5	O
inflammatory	3	O
infiltrate	9	O
.	9	O

In	9	O
all	5	O
cases	5	O
there	5	O
was	9	O
diffuse	5	O
or	5	O
multifocal	5	O
up	5	O
-	7	O
regulation	9	O
of	5	O
MHC	3	O
-	7	O
I	9	O
expression	3	O
even	5	O
in	5	O
non	9	O
-	7	O
necrotic	3	B-Disease
fibres	9	O
.	9	O

Progressive	5	O
improvement	5	O
occurred	9	O
in	5	O
7	9	O
cases	5	O
after	9	O
commencement	5	O
of	5	O
prednisolone	0	B-Chemical
and	5	O
methotrexate	9	B-Chemical
,	9	O
and	5	O
in	5	O
one	5	O
case	5	O
spontaneously	5	O
.	9	O

These	5	O
observations	9	O
suggest	9	O
that	5	O
statins	5	B-Chemical
may	5	O
initiate	9	O
an	5	O
immune	3	O
-	7	O
mediated	3	O
myopathy	9	B-Disease
that	5	O
persists	9	O
after	9	O
withdrawal	5	O
of	5	O
the	5	O
drug	5	O
and	5	O
responds	9	O
to	5	O
immunosuppressive	9	O
therapy	5	O
.	9	O

The	5	O
mechanism	9	O
of	5	O
this	5	O
myopathy	9	B-Disease
is	5	O
uncertain	5	O
but	9	O
may	5	O
involve	5	O
the	5	O
induction	3	O
by	9	O
statins	5	B-Chemical
of	5	O
an	5	O
endoplasmic	3	O
reticulum	9	O
stress	9	O
response	9	O
with	5	O
associated	9	O
up	5	O
-	7	O
regulation	9	O
of	5	O
MHC	3	O
-	7	O
I	9	O
expression	3	O
and	5	O
antigen	3	O
presentation	5	O
by	9	O
muscle	9	O
fibres	9	O
.	9	O

Use	5	O
of	5	O
chromosome	1	O
substitution	9	O
strains	1	O
to	5	O
identify	9	O
seizure	5	B-Disease
susceptibility	9	O
loci	9	O
in	5	O
mice	3	O
.	9	O

Seizure	5	B-Disease
susceptibility	9	O
varies	9	O
among	5	O
inbred	9	O
mouse	3	O
strains	1	O
.	9	O

Chromosome	9	O
substitution	9	O
strains	1	O
(	9	O
CSS	5	O
)	9	O
,	9	O
in	5	O
which	5	O
a	5	O
single	9	O
chromosome	1	O
from	9	O
one	5	O
inbred	9	O
strain	1	O
(	9	O
donor	9	O
)	9	O
has	9	O
been	9	O
transferred	9	O
onto	0	O
a	5	O
second	9	O
strain	1	O
(	9	O
host	9	O
)	9	O
by	9	O
repeated	5	O
backcrossing	9	O
,	9	O
may	5	O
be	5	O
used	5	O
to	5	O
identify	9	O
quantitative	9	O
trait	5	O
loci	9	O
(	9	O
QTLs	9	O
)	9	O
that	5	O
contribute	9	O
to	5	O
seizure	5	B-Disease
susceptibility	9	O
.	9	O

QTLs	9	O
for	5	O
susceptibility	9	O
to	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
,	9	O
a	5	O
model	5	O
of	5	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
,	9	O
have	5	O
not	5	O
been	9	O
reported	9	O
,	9	O
and	5	O
CSS	5	O
have	5	O
not	5	O
previously	9	O
been	9	O
used	5	O
to	5	O
localize	9	O
seizure	5	B-Disease
susceptibility	9	O
genes	1	O
.	9	O

We	9	O
report	5	O
QTLs	9	O
identified	9	O
using	9	O
a	5	O
B6	3	O
(	9	O
host	9	O
)	9	O
x	9	O
A	9	O
/	9	O
J	9	O
(	9	O
donor	9	O
)	9	O
CSS	5	O
panel	3	O
to	5	O
localize	9	O
genes	1	O
involved	9	O
in	5	O
susceptibility	9	O
to	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

Three	9	O
hundred	5	O
fifty	5	O
-	7	O
five	9	O
adult	9	O
male	9	O
CSS	5	O
mice	3	O
,	9	O
58	7	O
B6	3	O
,	9	O
and	5	O
39	7	O
A	9	O
/	9	O
J	9	O
were	9	O
tested	9	O
for	5	O
susceptibility	9	O
to	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

Highest	7	O
stage	9	O
reached	9	O
and	5	O
latency	5	O
to	5	O
each	5	O
stage	9	O
were	9	O
recorded	5	O
for	5	O
all	5	O
mice	3	O
.	9	O

B6	3	O
mice	3	O
were	9	O
resistant	9	O
to	5	O
seizures	5	B-Disease
and	5	O
slower	9	O
to	5	O
reach	5	O
stages	9	O
compared	9	O
to	5	O
A	9	O
/	9	O
J	9	O
mice	3	O
.	9	O

The	5	O
CSS	5	O
for	5	O
Chromosomes	9	O
10	9	O
and	5	O
18	7	O
progressed	9	O
to	5	O
the	5	O
most	9	O
severe	5	O
stages	9	O
,	9	O
diverging	5	O
dramatically	9	O
from	9	O
the	5	O
B6	3	O
phenotype	3	O
.	9	O

Latencies	5	O
to	5	O
stages	9	O
were	9	O
also	9	O
significantly	9	O
shorter	9	O
for	5	O
CSS10	_	O
and	5	O
CSS18	3	O
mice	3	O
.	9	O

CSS	5	O
mapping	5	O
suggests	9	O
seizure	5	B-Disease
susceptibility	9	O
loci	9	O
on	5	O
mouse	3	O
Chromosomes	9	O
10	9	O
and	5	O
18	7	O
.	9	O

This	5	O
approach	5	O
provides	5	O
a	5	O
framework	5	O
for	5	O
identifying	5	O
potentially	5	O
novel	9	O
homologous	1	O
candidate	9	O
genes	1	O
for	5	O
human	3	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
.	9	O

In	9	O
vitro	3	O
characterization	9	O
of	5	O
parasympathetic	5	O
and	5	O
sympathetic	5	O
responses	5	O
in	5	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

In	9	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
in	5	O
the	5	O
rat	3	O
,	9	O
detrusor	5	O
function	9	O
is	5	O
impaired	9	O
and	5	O
the	5	O
expression	3	O
and	5	O
effects	9	O
of	5	O
muscarinic	3	O
receptors	3	O
altered	9	O
.	9	O

Whether	9	O
or	5	O
not	5	O
the	5	O
neuronal	3	O
transmission	5	O
may	5	O
be	5	O
affected	9	O
by	9	O
cystitis	9	B-Disease
was	9	O
presently	9	O
investigated	9	O
.	9	O

Responses	5	O
of	5	O
urinary	9	O
strip	5	O
preparations	9	O
from	9	O
control	9	O
and	5	O
cyclophosphamide	0	B-Chemical
-	7	O
pretreated	3	O
rats	9	O
to	5	O
electrical	5	O
field	5	O
stimulation	3	O
and	5	O
to	5	O
agonists	3	O
were	9	O
assessed	9	O
in	5	O
the	5	O
absence	3	O
and	5	O
presence	9	O
of	5	O
muscarinic	3	O
,	9	O
adrenergic	9	O
and	5	O
purinergic	3	O
receptor	3	O
antagonists	3	O
.	9	O

Generally	5	O
,	9	O
atropine	0	B-Chemical
reduced	9	O
contractions	5	O
,	9	O
but	9	O
in	5	O
contrast	9	O
to	5	O
controls	9	O
,	9	O
it	5	O
also	9	O
reduced	9	O
responses	5	O
to	5	O
low	9	O
electrical	5	O
field	5	O
stimulation	3	O
intensity	5	O
(	9	O
1	9	O
-	7	O
5	9	O
Hz	5	O
)	9	O
in	5	O
inflamed	3	O
preparations	9	O
.	9	O

In	9	O
both	9	O
types	9	O
,	9	O
purinoceptor	3	O
desensitization	3	O
with	5	O
alpha	9	B-Chemical
,	9	I-Chemical
beta	9	I-Chemical
-	7	I-Chemical
methylene	0	I-Chemical
adenosine	0	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
triphosphate	0	I-Chemical
(	9	O
alpha	9	B-Chemical
,	9	I-Chemical
beta	9	I-Chemical
-	7	I-Chemical
meATP	0	I-Chemical
)	9	O
caused	9	O
further	9	O
reductions	9	O
at	9	O
low	9	O
frequencies	9	O
(	9	O
<	0	O
10	9	O
Hz	5	O
)	9	O
.	9	O

The	5	O
muscarinic	3	O
receptor	3	O
antagonists	3	O
atropine	0	B-Chemical
,	9	O
4	9	B-Chemical
-	7	I-Chemical
diphenylacetoxy	_	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
methylpiperidine	0	I-Chemical
(	9	O
4	9	B-Chemical
-	7	I-Chemical
DAMP	3	I-Chemical
)	9	O
(	9	O
'	9	O
M	9	O
(	9	O
1	9	O
)	9	O
/	9	O
M	9	O
(	9	O
3	9	O
)	9	O
/	9	O
M	9	O
(	9	O
5	9	O
)	9	O
-	7	O
selective	9	O
'	9	O
)	9	O
,	9	O
methoctramine	0	B-Chemical
(	9	O
'	9	O
M	9	O
(	9	O
2	9	O
)	9	O
-	7	O
selective	9	O
'	9	O
)	9	O
and	5	O
pirenzepine	0	B-Chemical
(	9	O
'	9	O
M	9	O
(	9	O
1	9	O
)	9	O
-	7	O
selective	9	O
'	9	O
)	9	O
antagonized	3	O
the	5	O
tonic	5	O
component	9	O
of	5	O
the	5	O
electrical	5	O
field	5	O
stimulation	3	O
-	7	O
evoked	5	O
contractile	9	O
response	9	O
more	5	O
potently	3	O
than	5	O
the	5	O
phasic	5	O
component	9	O
.	9	O

4	9	B-Chemical
-	7	I-Chemical
DAMP	3	I-Chemical
inhibited	3	O
the	5	O
tonic	5	O
contractions	5	O
in	5	O
controls	9	O
more	5	O
potently	3	O
than	5	O
methoctramine	0	B-Chemical
and	5	O
pirenzepine	0	B-Chemical
.	9	O

In	9	O
inflamed	3	O
preparations	9	O
,	9	O
the	5	O
muscarinic	3	O
receptor	3	O
antagonism	9	O
on	5	O
the	5	O
phasic	5	O
component	9	O
of	5	O
the	5	O
electrical	5	O
field	5	O
stimulation	3	O
-	7	O
evoked	5	O
contraction	9	O
was	9	O
decreased	9	O
and	5	O
the	5	O
pirenzepine	0	B-Chemical
and	5	O
4	9	B-Chemical
-	7	I-Chemical
DAMP	3	I-Chemical
antagonism	9	O
on	5	O
the	5	O
tonic	5	O
component	9	O
was	9	O
much	5	O
less	5	O
efficient	5	O
than	5	O
in	5	O
controls	9	O
.	9	O

In	9	O
contrast	9	O
to	5	O
controls	9	O
,	9	O
methoctramine	0	B-Chemical
increased	9	O
-	7	O
-	7	O
instead	5	O
of	5	O
decreased	9	O
-	7	O
-	7	O
the	5	O
tonic	5	O
responses	5	O
at	9	O
high	9	O
frequencies	9	O
.	9	O

While	9	O
contractions	5	O
to	5	O
carbachol	0	B-Chemical
and	5	O
ATP	0	B-Chemical
were	9	O
the	5	O
same	9	O
in	5	O
inflamed	3	O
and	5	O
in	5	O
control	9	O
strips	0	O
when	5	O
related	9	O
to	5	O
a	5	O
reference	9	O
potassium	0	B-Chemical
response	9	O
,	9	O
isoprenaline	0	B-Chemical
-	7	O
induced	3	O
relaxations	0	O
were	9	O
smaller	5	O
in	5	O
inflamed	3	O
strips	0	O
.	9	O

Thus	9	O
,	9	O
in	5	O
cystitis	9	B-Disease
substantial	9	O
changes	9	O
of	5	O
the	5	O
efferent	5	O
functional	9	O
responses	5	O
occur	5	O
.	9	O

While	9	O
postjunctional	5	O
beta	9	O
-	7	O
adrenoceptor	5	O
-	7	O
mediated	3	O
relaxations	0	O
are	5	O
reduced	9	O
,	9	O
effects	9	O
by	9	O
prejunctional	0	O
inhibitory	3	O
muscarinic	3	O
receptors	3	O
may	5	O
be	5	O
increased	9	O
.	9	O

Direct	9	O
inhibition	3	O
of	5	O
cardiac	5	O
hyperpolarization	3	O
-	7	O
activated	3	O
cyclic	0	B-Chemical
nucleotide	1	I-Chemical
-	7	O
gated	3	O
pacemaker	5	O
channels	9	O
by	9	O
clonidine	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Inhibition	3	O
of	5	O
cardiac	5	O
sympathetic	5	O
tone	5	O
represents	9	O
an	5	O
important	9	O
strategy	5	O
for	5	O
treatment	9	O
of	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
,	9	O
including	9	O
arrhythmia	5	B-Disease
,	9	O
coronary	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
,	9	O
and	5	O
chronic	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

Activation	3	O
of	5	O
presynaptic	3	O
alpha2	9	O
-	7	O
adrenoceptors	3	O
is	5	O
the	5	O
most	9	O
widely	5	O
accepted	5	O
mechanism	9	O
of	5	O
action	5	O
of	5	O
the	5	O
antisympathetic	5	O
drug	5	O
clonidine	0	B-Chemical
;	9	O
however	9	O
,	9	O
other	5	O
target	9	O
proteins	1	O
have	5	O
been	9	O
postulated	9	O
to	5	O
contribute	9	O
to	5	O
the	5	O
in	5	O
vivo	3	O
actions	5	O
of	5	O
clonidine	0	B-Chemical
.	9	O

METHODS	2	O
AND	2	O
RESULTS	9	O
:	9	O
To	9	O
test	5	O
whether	9	O
clonidine	0	B-Chemical
elicits	9	O
pharmacological	9	O
effects	9	O
independent	9	O
of	5	O
alpha2	9	O
-	7	O
adrenoceptors	3	O
,	9	O
we	5	O
have	5	O
generated	9	O
mice	3	O
with	5	O
a	5	O
targeted	9	O
deletion	1	O
of	5	O
all	5	O
3	9	O
alpha2	9	O
-	7	O
adrenoceptor	5	O
subtypes	9	O
(	9	O
alpha2ABC	_	O
-	7	O
/	9	O
-	7	O
)	9	O
.	9	O

Alpha2ABC	_	O
-	7	O
/	9	O
-	7	O
mice	3	O
were	9	O
completely	9	O
unresponsive	9	O
to	5	O
the	5	O
analgesic	5	O
and	5	O
hypnotic	5	O
effects	9	O
of	5	O
clonidine	0	B-Chemical
;	9	O
however	9	O
,	9	O
clonidine	0	B-Chemical
significantly	9	O
lowered	9	O
heart	5	O
rate	9	O
in	5	O
alpha2ABC	_	O
-	7	O
/	9	O
-	7	O
mice	3	O
by	9	O
up	5	O
to	5	O
150	0	O
bpm	5	O
.	9	O

Clonidine	0	B-Chemical
-	7	O
induced	3	O
bradycardia	5	B-Disease
in	5	O
conscious	5	O
alpha2ABC	_	O
-	7	O
/	9	O
-	7	O
mice	3	O
was	9	O
32	7	O
.	9	O
3	9	O
%	9	O
(	9	O
10	9	O
microg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
26	7	O
.	9	O
6	9	O
%	9	O
(	9	O
100	0	O
microg	0	O
/	9	O
kg	0	O
)	9	O
of	5	O
the	5	O
effect	9	O
in	5	O
wild	1	O
-	7	O
type	9	O
mice	3	O
.	9	O

A	9	O
similar	9	O
bradycardic	5	O
effect	9	O
of	5	O
clonidine	0	B-Chemical
was	9	O
observed	9	O
in	5	O
isolated	9	O
spontaneously	5	O
beating	5	O
right	5	O
atria	9	O
from	9	O
alpha2ABC	_	O
-	7	O
knockout	3	O
and	5	O
wild	1	O
-	7	O
type	9	O
mice	3	O
.	9	O

Clonidine	0	B-Chemical
inhibited	3	O
the	5	O
native	9	O
pacemaker	5	O
current	5	O
(	9	O
I	9	O
(	9	O
f	9	O
)	9	O
)	9	O
in	5	O
isolated	9	O
sinoatrial	5	O
node	5	O
pacemaker	5	O
cells	3	O
and	5	O
the	5	O
I	9	O
(	9	O
f	9	O
)	9	O
-	7	O
generating	9	O
hyperpolarization	3	O
-	7	O
activated	3	O
cyclic	0	B-Chemical
nucleotide	1	I-Chemical
-	7	O
gated	3	O
(	9	O
HCN	0	O
)	9	O
2	9	O
and	5	O
HCN4	3	O
channels	9	O
in	5	O
transfected	3	O
HEK293	3	O
cells	3	O
.	9	O

As	9	O
a	5	O
consequence	5	O
of	5	O
blocking	3	O
I	9	O
(	9	O
f	9	O
)	9	O
,	9	O
clonidine	0	B-Chemical
reduced	9	O
the	5	O
slope	5	O
of	5	O
the	5	O
diastolic	5	O
depolarization	9	O
and	5	O
the	5	O
frequency	5	O
of	5	O
pacemaker	5	O
potentials	5	O
in	5	O
sinoatrial	5	O
node	5	O
cells	3	O
from	9	O
wild	1	O
-	7	O
type	9	O
and	5	O
alpha2ABC	_	O
-	7	O
knockout	3	O
mice	3	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Direct	9	O
inhibition	3	O
of	5	O
cardiac	5	O
HCN	0	O
pacemaker	5	O
channels	9	O
contributes	9	O
to	5	O
the	5	O
bradycardic	5	O
effects	9	O
of	5	O
clonidine	0	B-Chemical
gene	1	O
-	7	O
targeted	9	O
mice	3	O
in	5	O
vivo	3	O
,	9	O
and	5	O
thus	9	O
,	9	O
clonidine	0	B-Chemical
-	7	O
like	9	O
drugs	5	O
represent	9	O
novel	9	O
structures	9	O
for	5	O
future	5	O
HCN	0	O
channel	9	O
inhibitors	3	O
.	9	O

Granulomatous	5	B-Disease
hepatitis	9	I-Disease
due	5	O
to	5	O
combination	9	B-Chemical
of	5	I-Chemical
amoxicillin	0	I-Chemical
and	5	I-Chemical
clavulanic	0	I-Chemical
acid	0	I-Chemical
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
patient	5	O
with	5	O
amoxicillin	0	B-Chemical
-	7	I-Chemical
clavulanic	0	I-Chemical
acid	0	I-Chemical
-	7	O
induced	3	O
hepatitis	9	B-Disease
with	5	O
histologic	9	O
multiple	5	O
granulomas	9	B-Disease
.	9	O

This	5	O
type	9	O
of	5	O
lesion	5	O
broadens	5	O
the	5	O
spectrum	9	O
of	5	O
liver	9	B-Disease
injury	9	I-Disease
due	5	O
to	5	O
this	5	O
drug	5	O
combination	9	O
,	9	O
mainly	9	O
represented	9	O
by	9	O
a	5	O
benign	5	O
cholestatic	5	B-Disease
syndrome	5	I-Disease
.	9	O

The	5	O
association	9	O
of	5	O
granulomas	9	B-Disease
and	5	O
eosinophilia	3	B-Disease
favor	9	O
an	5	O
immunoallergic	5	O
mechanism	9	O
.	9	O

As	9	O
penicillin	0	B-Chemical
derivatives	0	O
and	5	O
amoxicillin	0	B-Chemical
alone	9	O
are	5	O
known	9	O
to	5	O
induce	3	O
such	5	O
types	9	O
of	5	O
lesions	5	O
,	9	O
the	5	O
amoxicillin	0	B-Chemical
component	9	O
,	9	O
with	5	O
or	5	O
without	9	O
a	5	O
potentiating	3	O
effect	9	O
of	5	O
clavulanic	0	B-Chemical
acid	0	I-Chemical
,	9	O
might	9	O
have	5	O
a	5	O
major	9	O
role	9	O
.	9	O

Dobutamine	0	B-Chemical
stress	9	O
echocardiography	5	O
:	9	O
a	5	O
sensitive	9	O
indicator	9	O
of	5	O
diminished	9	O
myocardial	9	O
function	9	O
in	5	O
asymptomatic	5	O
doxorubicin	0	B-Chemical
-	7	O
treated	3	O
long	5	O
-	7	O
term	5	O
survivors	5	O
of	5	O
childhood	5	O
cancer	3	B-Disease
.	9	O

Doxorubicin	0	B-Chemical
is	5	O
an	5	O
effective	5	O
anticancer	0	O
chemotherapeutic	3	O
agent	9	O
known	9	O
to	5	O
cause	5	O
acute	9	O
and	5	O
chronic	5	O
cardiomyopathy	5	B-Disease
.	9	O

To	9	O
develop	5	O
a	5	O
more	5	O
sensitive	9	O
echocardiographic	5	O
screening	5	O
test	5	O
for	5	O
cardiac	5	B-Disease
damage	9	I-Disease
due	5	O
to	5	O
doxorubicin	0	B-Chemical
,	9	O
a	5	O
cohort	9	O
study	9	O
was	9	O
performed	9	O
using	9	O
dobutamine	5	B-Chemical
infusion	0	O
to	5	O
differentiate	9	O
asymptomatic	5	O
long	5	O
-	7	O
term	5	O
survivors	5	O
of	5	O
childhood	5	O
cancer	3	B-Disease
treated	3	O
with	5	O
doxorubicin	0	B-Chemical
from	9	O
healthy	5	O
control	9	O
subjects	5	O
.	9	O

Echocardiographic	5	O
data	5	O
from	9	O
the	5	O
experimental	5	O
group	9	O
of	5	O
21	7	O
patients	5	O
(	9	O
mean	5	O
age	5	O
16	9	O
+	9	O
/	9	O
-	7	O
5	9	O
years	5	O
)	9	O
treated	3	O
from	9	O
1	9	O
.	9	O
6	9	O
to	5	O
14	7	O
.	9	O
3	9	O
years	5	O
(	9	O
median	9	O
5	9	O
.	9	O
3	9	O
)	9	O
before	9	O
this	5	O
study	9	O
with	5	O
27	7	O
to	5	O
532	9	O
mg	0	O
/	9	O
m2	7	O
of	5	O
doxorubicin	0	B-Chemical
(	9	O
mean	5	O
196	7	O
)	9	O
were	9	O
compared	9	O
with	5	O
echocardiographic	5	O
data	5	O
from	9	O
12	9	O
normal	9	O
age	5	O
-	7	O
matched	9	O
control	9	O
subjects	5	O
.	9	O

Graded	5	O
dobutamine	5	B-Chemical
infusions	9	O
of	5	O
0	7	O
.	9	O
5	9	O
,	9	O
2	9	O
.	9	O
5	9	O
,	9	O
5	9	O
and	5	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
per	9	O
min	0	O
were	9	O
administered	9	O
.	9	O

Echocardiographic	5	O
Doppler	5	O
studies	9	O
were	9	O
performed	9	O
before	9	O
infusion	0	O
and	5	O
after	9	O
15	9	O
min	0	O
of	5	O
infusion	0	O
at	9	O
each	5	O
rate	9	O
.	9	O

Dobutamine	0	B-Chemical
infusion	0	O
at	9	O
10	9	O
micrograms	0	O
/	9	O
kg	0	O
per	9	O
min	0	O
was	9	O
discontinued	5	O
after	9	O
six	9	O
studies	9	O
secondary	9	O
to	5	O
a	5	O
50	0	O
%	9	O
incidence	5	O
rate	9	O
of	5	O
adverse	5	O
symptoms	5	O
.	9	O

The	5	O
most	9	O
important	9	O
findings	9	O
were	9	O
that	5	O
compared	9	O
with	5	O
values	5	O
in	5	O
control	9	O
subjects	5	O
,	9	O
end	9	O
-	7	O
systolic	5	O
left	5	O
ventricular	5	O
posterior	5	O
wall	5	O
dimension	5	O
and	5	O
percent	5	O
of	5	O
left	5	O
ventricular	5	O
posterior	5	O
wall	5	O
thickening	5	O
in	5	O
doxorubicin	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
were	9	O
decreased	9	O
at	9	O
baseline	5	O
study	9	O
and	5	O
these	5	O
findings	9	O
were	9	O
more	5	O
clearly	9	O
delineated	5	O
with	5	O
dobutamine	5	B-Chemical
stimulation	3	O
.	9	O

End	9	O
-	7	O
systolic	5	O
left	5	O
ventricular	5	O
posterior	5	O
wall	5	O
dimension	5	O
at	9	O
baseline	5	O
for	5	O
the	5	O
doxorubicin	0	B-Chemical
-	7	O
treated	3	O
group	9	O
was	9	O
11	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
9	7	O
mm	9	O
versus	9	O
13	7	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
5	9	O
mm	9	O
for	5	O
control	9	O
subjects	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

End	9	O
-	7	O
systolic	5	O
left	5	O
ventricular	5	O
posterior	5	O
wall	5	O
dimension	5	O
at	9	O
the	5	O
5	9	O
-	7	O
micrograms	0	O
/	9	O
kg	0	O
per	9	O
min	0	O
dobutamine	5	B-Chemical
infusion	0	O
for	5	O
the	5	O
doxorubicin	0	B-Chemical
-	7	O
treated	3	O
group	9	O
was	9	O
14	7	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
4	9	O
mm	9	O
versus	9	O
19	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
6	9	O
mm	9	O
for	5	O
control	9	O
subjects	5	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Influence	9	O
of	5	O
smoking	5	B-Chemical
on	5	O
developing	5	O
cochlea	5	O
.	9	O

Does	5	O
smoking	5	B-Chemical
during	5	O
pregnancy	5	O
affect	9	O
the	5	O
amplitudes	5	O
of	5	O
transient	9	O
evoked	5	O
otoacoustic	5	O
emissions	5	O
in	5	O
newborns	5	O
?	5	O

OBJECTIVE	2	O
:	9	O
Maternal	9	O
tobacco	5	O
smoking	5	B-Chemical
has	9	O
negative	9	O
effects	9	O
on	5	O
fetal	9	O
growth	3	O
.	9	O

The	5	O
influence	5	O
of	5	O
smoking	5	B-Chemical
during	5	O
pregnancy	5	O
on	5	O
the	5	O
developing	5	O
cochlea	5	O
has	9	O
not	5	O
been	9	O
estimated	5	O
,	9	O
although	9	O
smoking	5	B-Chemical
has	9	O
been	9	O
positively	9	O
associated	9	O
with	5	O
hearing	5	B-Disease
loss	9	I-Disease
in	5	O
adults	5	O
.	9	O

The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
effects	9	O
of	5	O
maternal	9	O
smoking	5	B-Chemical
on	5	O
transient	9	O
evoked	5	O
otoacoustic	5	O
emissions	5	O
(	9	O
TEOAEs	5	O
)	9	O
of	5	O
healthy	5	O
neonates	9	O
.	9	O

METHODS	2	O
:	9	O
This	5	O
study	9	O
was	9	O
undertaken	5	O
as	5	O
part	9	O
of	5	O
neonatal	9	O
screening	5	O
for	5	O
hearing	5	B-Disease
impairment	5	I-Disease
and	5	O
involved	9	O
both	9	O
ears	5	O
of	5	O
200	0	O
newborns	5	O
.	9	O

Newborns	5	O
whose	9	O
mothers	5	O
reported	9	O
smoking	5	B-Chemical
during	5	O
pregnancy	5	O
(	9	O
n	9	O
=	7	O
200	0	O
ears	5	O
)	9	O
were	9	O
compared	9	O
to	5	O
a	5	O
control	9	O
group	9	O
of	5	O
newborns	5	O
(	9	O
n	9	O
=	7	O
200	0	O
ears	5	O
)	9	O
,	9	O
whose	9	O
mothers	5	O
were	9	O
non	9	O
-	7	O
smokers	5	O
.	9	O

Exposure	9	O
to	5	O
tobacco	5	O
was	9	O
characterized	9	O
as	5	O
low	9	O
(	9	O
<	0	O
5	9	O
cigarettes	5	O
per	9	O
day	9	O
,	9	O
n	9	O
=	7	O
88	7	O
ears	5	O
)	9	O
,	9	O
moderate	9	O
(	9	O
5	9	O
<	0	O
or	5	O
=	7	O
cigarettes	5	O
per	9	O
day	9	O
<	0	O
10	9	O
,	9	O
n	9	O
=	7	O
76	7	O
)	9	O
or	5	O
high	9	O
(	9	O
>	0	O
or	5	O
=	7	O
10	9	O
cigarettes	5	O
per	9	O
day	9	O
,	9	O
n	9	O
=	7	O
36	9	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
In	9	O
exposed	9	O
neonates	9	O
,	9	O
TEOAEs	5	O
mean	5	O
response	9	O
(	9	O
across	5	O
frequency	5	O
)	9	O
and	5	O
mean	5	O
amplitude	5	O
at	9	O
4000Hz	9	O
was	9	O
significantly	9	O
lower	9	O
than	5	O
in	5	O
non	9	O
-	7	O
exposed	9	O
neonates	9	O
.	9	O

Comparisons	9	O
between	5	O
exposed	9	O
newborns	5	O
'	9	O
subgroups	9	O
revealed	9	O
no	9	O
significant	9	O
differences	9	O
.	9	O

However	9	O
,	9	O
by	9	O
comparing	9	O
each	5	O
subgroup	9	O
to	5	O
control	9	O
group	9	O
,	9	O
we	5	O
found	9	O
statistically	9	O
significant	9	O
decreases	9	B-Disease
of	5	I-Disease
TEOAEs	5	I-Disease
amplitudes	5	I-Disease
at	9	O
4000Hz	9	O
for	5	O
all	5	O
three	9	O
groups	9	O
.	9	O

Mean	9	O
TEOAEs	5	O
responses	5	O
of	5	O
highly	9	O
exposed	9	O
newborns	5	O
were	9	O
also	9	O
significantly	9	O
lower	9	O
in	5	O
comparison	9	O
to	5	O
our	5	O
control	9	O
group	9	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
utero	9	O
,	9	O
exposure	9	O
to	5	O
tobacco	5	O
smoking	5	B-Chemical
seems	5	O
to	5	O
have	5	O
a	5	O
small	9	O
impact	5	O
on	5	O
outer	9	O
hair	5	O
cells	3	O
.	9	O

These	5	O
effects	9	O
seem	5	O
to	5	O
be	5	O
equally	9	O
true	5	O
for	5	O
all	5	O
exposed	9	O
newborns	5	O
,	9	O
regardless	9	O
of	5	O
the	5	O
degree	5	O
of	5	O
exposure	9	O
.	9	O

Further	9	O
studies	9	O
are	5	O
needed	5	O
in	5	O
order	5	O
to	5	O
establish	5	O
a	5	O
potential	9	O
negative	9	O
effect	9	O
of	5	O
maternal	9	O
smoking	5	B-Chemical
on	5	O
the	5	O
neonate	9	O
'	9	O
s	9	O
hearing	5	O
acuity	5	O
.	9	O

Simvastatin	0	B-Chemical
-	7	O
induced	3	O
bilateral	5	O
leg	5	O
compartment	9	B-Disease
syndrome	5	I-Disease
and	5	O
myonecrosis	5	B-Disease
associated	9	O
with	5	O
hypothyroidism	5	B-Disease
.	9	O

A	9	O
54	7	O
-	7	O
year	5	O
-	7	O
old	5	O
hypothyroid	9	B-Disease
male	9	O
taking	5	O
thyroxine	0	B-Chemical
and	5	O
simvastatin	0	B-Chemical
presented	5	O
with	5	O
bilateral	5	O
leg	5	O
compartment	9	B-Disease
syndrome	5	I-Disease
and	5	O
myonecrosis	5	B-Disease
.	9	O

Urgent	5	O
fasciotomies	5	O
were	9	O
performed	9	O
and	5	O
the	5	O
patient	5	O
made	5	O
an	5	O
uneventful	5	O
recovery	9	O
with	5	O
the	5	O
withdrawal	5	O
of	5	O
simvastatin	0	B-Chemical
.	9	O

It	5	O
is	5	O
likely	5	O
that	5	O
this	5	O
complication	5	O
will	5	O
be	5	O
seen	9	O
more	5	O
often	5	O
with	5	O
the	5	O
increased	9	O
worldwide	5	O
use	5	O
of	5	O
this	5	O
drug	5	O
and	5	O
its	9	O
approval	5	O
for	5	O
all	5	O
arteriopathic	5	B-Disease
patients	5	O
.	9	O

Neuroinflammation	3	B-Disease
and	5	O
behavioral	5	B-Disease
abnormalities	9	I-Disease
after	9	O
neonatal	9	O
terbutaline	0	B-Chemical
treatment	9	O
in	5	O
rats	9	O
:	9	O
implications	5	O
for	5	O
autism	5	B-Disease
.	9	O

Autism	5	B-Disease
is	5	O
a	5	O
neurodevelopmental	5	B-Disease
disorder	5	I-Disease
presenting	5	O
before	9	O
3	9	O
years	5	O
of	5	O
age	5	O
with	5	O
deficits	5	B-Disease
in	5	I-Disease
communication	5	I-Disease
and	5	I-Disease
social	5	I-Disease
skills	5	I-Disease
and	5	O
repetitive	5	B-Disease
behaviors	5	I-Disease
.	9	O

In	9	O
addition	9	O
to	5	O
genetic	5	O
influences	5	O
,	9	O
recent	5	O
studies	9	O
suggest	9	O
that	5	O
prenatal	5	O
drug	5	O
or	5	O
chemical	0	O
exposures	5	O
are	5	O
risk	5	O
factors	9	O
for	5	O
autism	5	B-Disease
.	9	O

Terbutaline	7	B-Chemical
,	9	O
a	5	O
beta2	5	O
-	7	O
adrenoceptor	5	O
agonist	3	O
used	5	O
to	5	O
arrest	3	O
preterm	5	B-Disease
labor	5	I-Disease
,	9	O
has	9	O
been	9	O
associated	9	O
with	5	O
increased	9	O
concordance	9	O
for	5	O
autism	5	B-Disease
in	5	O
dizygotic	5	O
twins	5	O
.	9	O

We	9	O
studied	9	O
the	5	O
effects	9	O
of	5	O
terbutaline	0	B-Chemical
on	5	O
microglial	3	O
activation	3	O
in	5	O
different	9	O
brain	5	O
regions	9	O
and	5	O
behavioral	5	O
outcomes	5	O
in	5	O
developing	5	O
rats	9	O
.	9	O

Newborn	9	O
rats	9	O
were	9	O
given	5	O
terbutaline	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
daily	5	O
on	5	O
postnatal	9	O
days	9	O
(	9	O
PN	9	O
)	9	O
2	9	O
to	5	O
5	9	O
or	5	O
PN	9	O
11	7	O
to	5	O
14	7	O
and	5	O
examined	9	O
24	9	O
h	0	O
after	9	O
the	5	O
last	5	O
dose	9	O
and	5	O
at	9	O
PN	9	O
30	9	O
.	9	O

Immunohistochemical	3	O
studies	9	O
showed	9	O
that	5	O
administration	9	O
of	5	O
terbutaline	0	B-Chemical
on	5	O
PN	9	O
2	9	O
to	5	O
5	9	O
produced	9	O
a	5	O
robust	5	O
increase	9	O
in	5	O
microglial	3	O
activation	3	O
on	5	O
PN	9	O
30	9	O
in	5	O
the	5	O
cerebral	5	O
cortex	5	O
,	9	O
as	5	O
well	9	O
as	5	O
in	5	O
cerebellar	5	O
and	5	O
cerebrocortical	3	O
white	9	O
matter	5	O
.	9	O

None	9	O
of	5	O
these	5	O
effects	9	O
occurred	9	O
in	5	O
animals	9	O
given	5	O
terbutaline	0	B-Chemical
on	5	O
PN	9	O
11	7	O
to	5	O
14	7	O
.	9	O

In	9	O
behavioral	5	O
tests	5	O
,	9	O
animals	9	O
treated	3	O
with	5	O
terbutaline	0	B-Chemical
on	5	O
PN	9	O
2	9	O
to	5	O
5	9	O
showed	9	O
consistent	9	O
patterns	5	O
of	5	O
hyper	5	O
-	7	O
reactivity	9	O
to	5	O
novelty	5	O
and	5	O
aversive	5	O
stimuli	5	O
when	5	O
assessed	9	O
in	5	O
a	5	O
novel	9	O
open	5	O
field	5	O
,	9	O
as	5	O
well	9	O
as	5	O
in	5	O
the	5	O
acoustic	5	O
startle	5	O
response	9	O
test	5	O
.	9	O

Our	9	O
findings	9	O
indicate	9	O
that	5	O
beta2	5	O
-	7	O
adrenoceptor	5	O
overstimulation	5	O
during	5	O
an	5	O
early	9	O
critical	9	O
period	5	O
results	9	O
in	5	O
microglial	3	O
activation	3	O
associated	9	O
with	5	O
innate	5	O
neuroinflammatory	3	O
pathways	9	O
and	5	O
behavioral	5	B-Disease
abnormalities	9	I-Disease
,	9	O
similar	9	O
to	5	O
those	5	O
described	9	O
in	5	O
autism	5	B-Disease
.	9	O

This	5	O
study	9	O
provides	5	O
a	5	O
useful	5	O
animal	5	O
model	5	O
for	5	O
understanding	5	O
the	5	O
neuropathological	5	O
processes	5	O
underlying	5	O
autism	5	B-Disease
spectrum	9	I-Disease
disorders	5	I-Disease
.	9	O

Upregulation	3	O
of	5	O
brain	5	O
expression	3	O
of	5	O
P	9	O
-	7	O
glycoprotein	3	O
in	5	O
MRP2	3	O
-	7	O
deficient	3	O
TR	9	O
(	9	O
-	7	O
)	9	O
rats	9	O
resembles	9	O
seizure	5	B-Disease
-	7	O
induced	3	O
up	5	O
-	7	O
regulation	9	O
of	5	O
this	5	O
drug	5	O
efflux	0	O
transporter	1	O
in	5	O
normal	9	O
rats	9	O
.	9	O

PURPOSE	2	O
:	9	O
The	5	O
multidrug	9	O
resistance	9	O
protein	1	O
2	9	O
(	9	O
MRP2	3	O
)	9	O
is	5	O
a	5	O
drug	5	O
efflux	0	O
transporter	1	O
that	5	O
is	5	O
expressed	3	O
predominantly	9	O
at	9	O
the	5	O
apical	9	O
domain	1	O
of	5	O
hepatocytes	3	O
but	9	O
seems	5	O
also	9	O
to	5	O
be	5	O
expressed	3	O
at	9	O
the	5	O
apical	9	O
membrane	9	O
of	5	O
brain	5	O
capillary	0	O
endothelial	3	O
cells	3	O
that	5	O
form	9	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
(	9	O
BBB	9	O
)	9	O
.	9	O

MRP2	3	O
is	5	O
absent	9	O
in	5	O
the	5	O
transport	9	O
-	7	O
deficient	3	O
(	9	O
TR	9	O
(	9	O
-	7	O
)	9	O
)	9	O
Wistar	9	O
rat	3	O
mutant	1	O
,	9	O
so	5	O
that	5	O
this	5	O
rat	3	O
strain	1	O
was	9	O
very	5	O
helpful	6	O
in	5	O
defining	5	O
substrates	0	O
of	5	O
MRP2	3	O
by	9	O
comparing	9	O
tissue	9	O
concentrations	0	O
or	5	O
functional	9	O
activities	9	O
of	5	O
compounds	0	O
in	5	O
MRP2	3	O
-	7	O
deficient	3	O
rats	9	O
with	5	O
those	5	O
in	5	O
transport	9	O
-	7	O
competent	9	O
Wistar	9	O
rats	9	O
.	9	O

By	5	O
using	9	O
this	5	O
strategy	5	O
to	5	O
study	9	O
the	5	O
involvement	9	O
of	5	O
MRP2	3	O
in	5	O
brain	5	O
access	5	O
of	5	O
antiepileptic	5	O
drugs	5	O
(	9	O
AEDs	5	O
)	9	O
,	9	O
we	5	O
recently	9	O
reported	9	O
that	5	O
phenytoin	0	B-Chemical
is	5	O
a	5	O
substrate	0	O
for	5	O
MRP2	3	O
in	5	O
the	5	O
BBB	9	O
.	9	O

However	9	O
,	9	O
one	5	O
drawback	5	O
of	5	O
such	5	O
studies	9	O
in	5	O
genetically	9	O
deficient	3	O
rats	9	O
is	5	O
the	5	O
fact	9	O
that	5	O
compensatory	5	O
changes	9	O
with	5	O
upregulation	3	O
of	5	O
other	5	O
transporters	1	O
can	5	O
occur	5	O
.	9	O

This	5	O
prompted	9	O
us	5	O
to	5	O
study	9	O
the	5	O
brain	5	O
expression	3	O
of	5	O
P	9	O
-	7	O
glycoprotein	3	O
(	9	O
Pgp	3	O
)	9	O
,	9	O
a	5	O
major	9	O
drug	5	O
efflux	0	O
transporter	1	O
in	5	O
many	5	O
tissues	9	O
,	9	O
including	9	O
the	5	O
BBB	9	O
,	9	O
in	5	O
TR	9	O
(	9	O
-	7	O
)	9	O
rats	9	O
compared	9	O
with	5	O
nonmutant	1	O
(	9	O
wild	1	O
-	7	O
type	9	O
)	9	O
Wistar	9	O
rats	9	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
expression	3	O
of	5	O
MRP2	3	O
and	5	O
Pgp	3	O
in	5	O
brain	5	O
and	5	O
liver	9	O
sections	9	O
of	5	O
TR	9	O
(	9	O
-	7	O
)	9	O
rats	9	O
and	5	O
normal	9	O
Wistar	9	O
rats	9	O
was	9	O
determined	9	O
with	5	O
immunohistochemistry	3	O
,	9	O
by	9	O
using	9	O
a	5	O
novel	9	O
,	9	O
highly	9	O
selective	9	O
monoclonal	3	O
MRP2	3	O
antibody	3	O
and	5	O
the	5	O
monoclonal	3	O
Pgp	3	O
antibody	3	O
C219	8	O
,	9	O
respectively	9	O
.	9	O

RESULTS	9	O
:	9	O
Immunofluorescence	3	O
staining	3	O
with	5	O
the	5	O
MRP2	3	O
antibody	3	O
was	9	O
found	9	O
to	5	O
label	9	O
a	5	O
high	9	O
number	9	O
of	5	O
microvessels	3	O
throughout	9	O
the	5	O
brain	5	O
in	5	O
normal	9	O
Wistar	9	O
rats	9	O
,	9	O
whereas	9	O
such	5	O
labeling	3	O
was	9	O
absent	9	O
in	5	O
TR	9	O
(	9	O
-	7	O
)	9	O
rats	9	O
.	9	O

TR	9	O
(	9	O
-	7	O
)	9	O
rats	9	O
exhibited	9	O
a	5	O
significant	9	O
up	5	O
-	7	O
regulation	9	O
of	5	O
Pgp	3	O
in	5	O
brain	5	O
capillary	0	O
endothelial	3	O
cells	3	O
compared	9	O
with	5	O
wild	1	O
-	7	O
type	9	O
controls	9	O
.	9	O

No	9	O
such	5	O
obvious	9	O
upregulation	3	O
of	5	O
Pgp	3	O
was	9	O
observed	9	O
in	5	O
liver	9	O
sections	9	O
.	9	O

A	9	O
comparable	9	O
overexpression	3	O
of	5	O
Pgp	3	O
in	5	O
the	5	O
BBB	9	O
was	9	O
obtained	9	O
after	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
in	5	O
wild	1	O
-	7	O
type	9	O
Wistar	9	O
rats	9	O
.	9	O

Experiments	9	O
with	5	O
systemic	9	O
administration	9	O
of	5	O
the	5	O
Pgp	3	O
substrate	0	O
phenobarbital	0	B-Chemical
and	5	O
the	5	O
selective	9	O
Pgp	3	O
inhibitor	3	O
tariquidar	0	B-Chemical
in	5	O
TR	9	O
(	9	O
-	7	O
)	9	O
rats	9	O
substantiated	9	O
that	5	O
Pgp	3	O
is	5	O
functional	9	O
and	5	O
compensates	9	O
for	5	O
the	5	O
lack	9	O
of	5	O
MRP2	3	O
in	5	O
the	5	O
BBB	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
data	5	O
on	5	O
TR	9	O
(	9	O
-	7	O
)	9	O
rats	9	O
indicate	9	O
that	5	O
Pgp	3	O
plays	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
compensation	5	O
of	5	O
MRP2	3	O
deficiency	9	O
in	5	O
the	5	O
BBB	9	O
.	9	O

Because	9	O
such	5	O
a	5	O
compensatory	5	O
mechanism	9	O
most	9	O
likely	5	O
occurs	9	O
to	5	O
reduce	5	O
injury	9	B-Disease
to	5	I-Disease
the	5	I-Disease
brain	5	I-Disease
from	9	O
cytotoxic	3	O
compounds	0	O
,	9	O
the	5	O
present	9	O
data	5	O
substantiate	9	O
the	5	O
concept	5	O
that	5	O
MRP2	3	O
performs	5	O
a	5	O
protective	9	O
role	9	O
in	5	O
the	5	O
BBB	9	O
.	9	O

Furthermore	9	O
,	9	O
our	5	O
data	5	O
suggest	9	O
that	5	O
TR	9	O
(	9	O
-	7	O
)	9	O
rats	9	O
are	5	O
an	5	O
interesting	9	O
tool	5	O
to	5	O
study	9	O
consequences	5	O
of	5	O
overexpression	3	O
of	5	O
Pgp	3	O
in	5	O
the	5	O
BBB	9	O
on	5	O
access	5	O
of	5	O
drugs	5	O
in	5	O
the	5	O
brain	5	O
,	9	O
without	9	O
the	5	O
need	5	O
of	5	O
inducing	3	O
seizures	5	B-Disease
or	5	O
other	5	O
Pgp	3	O
-	7	O
enhancing	9	O
events	5	O
for	5	O
this	5	O
purpose	5	O
.	9	O

Role	9	O
of	5	O
xanthine	0	B-Chemical
oxidase	0	O
in	5	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
rats	9	O
.	9	O

1	9	O
.	9	O

Glucocorticoid	9	O
-	7	O
induced	3	O
hypertension	5	B-Disease
(	9	O
GC	9	O
-	7	O
HT	9	B-Disease
)	9	O
in	5	O
the	5	O
rat	3	O
is	5	O
associated	9	O
with	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
-	7	O
redox	0	O
imbalance	9	O
.	9	O

2	9	O
.	9	O

We	9	O
studied	9	O
the	5	O
role	9	O
of	5	O
xanthine	0	B-Chemical
oxidase	0	O
(	9	O
XO	0	O
)	9	O
,	9	O
which	5	O
is	5	O
implicated	9	O
in	5	O
the	5	O
production	9	O
of	5	O
reactive	9	O
oxygen	0	O
species	4	O
,	9	O
in	5	O
dexamethasone	0	B-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
(	9	O
dex	3	B-Chemical
-	7	O
HT	9	B-Disease
)	9	O
.	9	O

3	9	O
.	9	O

Thirty	9	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
divided	5	O
randomly	5	O
into	9	O
four	9	O
treatment	9	O
groups	9	O
:	9	O
saline	0	O
,	9	O
dexamethasone	0	B-Chemical
(	9	O
dex	3	B-Chemical
)	9	O
,	9	O
allopurinol	0	B-Chemical
plus	9	O
saline	0	O
,	9	O
and	5	O
allopurinol	0	B-Chemical
plus	9	O
dex	3	B-Chemical
.	9	O

4	9	O
.	9	O

Systolic	7	O
blood	9	O
pressures	5	O
(	9	O
SBP	9	O
)	9	O
and	5	O
bodyweights	5	O
were	9	O
recorded	5	O
each	5	O
alternate	9	O
day	9	O
.	9	O

Thymus	9	O
weight	9	O
was	9	O
used	5	O
as	5	O
a	5	O
marker	3	O
of	5	O
glucocorticoid	9	O
activity	9	O
,	9	O
and	5	O
serum	9	O
urate	0	B-Chemical
to	5	O
assess	5	O
XO	0	O
inhibition	3	O
.	9	O

5	9	O
.	9	O

Dex	3	B-Chemical
increased	9	B-Disease
SBP	9	I-Disease
(	9	O
110	9	O
+	9	O
/	9	O
-	7	O
2	9	O
-	7	O
126	7	O
+	9	O
/	9	O
-	7	O
3	9	O
mmHg	7	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
and	5	O
decreased	9	B-Disease
thymus	3	I-Disease
(	9	I-Disease
P	9	I-Disease
<	0	I-Disease
0	7	I-Disease
.	9	I-Disease
001	9	I-Disease
)	9	I-Disease
and	5	I-Disease
bodyweights	5	I-Disease
(	9	O
P	9	O
"	5	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Allopurinol	0	B-Chemical
decreased	9	O
serum	9	O
urate	0	B-Chemical
from	9	O
76	7	O
+	9	O
/	9	O
-	7	O
5	9	O
to	5	O
30	9	O
+	9	O
/	9	O
-	7	O
3	9	O
micromol	0	O
/	9	O
L	0	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
in	5	O
saline	0	O
and	5	O
from	9	O
84	7	O
+	9	O
/	9	O
-	7	O
13	7	O
to	5	O
28	7	O
+	9	O
/	9	O
-	7	O
2	9	O
micromol	0	O
/	9	O
L	0	O
in	5	O
dex	3	B-Chemical
-	7	O
treated	3	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
groups	9	O
.	9	O

6	9	O
.	9	O

Allopurinol	0	B-Chemical
did	9	O
not	5	O
prevent	5	O
dex	3	B-Chemical
-	7	O
HT	9	B-Disease
.	9	O

This	5	O
,	9	O
together	9	O
with	5	O
our	5	O
previous	9	O
findings	9	O
that	5	O
allopurinol	0	B-Chemical
failed	9	O
to	5	O
prevent	5	O
adrenocorticotrophic	0	O
hormone	9	O
induced	3	O
hypertension	5	B-Disease
,	9	O
suggests	9	O
that	5	O
XO	0	O
activity	9	O
is	5	O
not	5	O
a	5	O
major	9	O
determinant	9	O
of	5	O
GC	9	O
-	7	O
HT	9	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Side	5	O
effects	9	O
of	5	O
postoperative	5	O
administration	9	O
of	5	O
methylprednisolone	0	B-Chemical
and	5	O
gentamicin	0	B-Chemical
into	9	O
the	5	O
posterior	5	O
sub	9	O
-	7	O
Tenon	2	O
'	9	O
s	9	O
space	5	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
assess	5	O
the	5	O
incidence	5	O
of	5	O
postoperative	5	O
emetic	5	O
side	5	O
effects	9	O
after	9	O
the	5	O
administration	9	O
of	5	O
methylprednisolone	0	B-Chemical
and	5	O
gentamicin	0	B-Chemical
into	9	O
the	5	O
posterior	5	O
sub	9	O
-	7	O
Tenon	2	O
'	9	O
s	9	O
space	5	O
at	9	O
the	5	O
end	9	O
of	5	O
routine	5	O
cataract	5	B-Disease
surgery	5	O
.	9	O

SETTING	2	O
:	9	O
St	2	O
.	9	O

Luke	6	O
'	9	O
s	9	O
Hospital	2	O
,	9	O
Gwardamangia	_	O
,	9	O
Malta	2	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
double	9	O
-	7	O
blind	5	O
double	9	O
-	7	O
armed	5	O
prospective	5	O
study	9	O
comprised	9	O
40	9	O
patients	5	O
who	5	O
had	9	O
uneventful	5	O
sutureless	5	O
phacoemulsification	5	O
under	9	O
sub	9	O
-	7	O
Tenon	2	O
'	9	O
s	9	O
local	5	O
infiltration	3	O
of	5	O
3	9	O
mL	0	O
of	5	O
plain	5	O
lignocaine	0	B-Chemical
.	9	O

At	9	O
the	5	O
end	9	O
of	5	O
the	5	O
procedure	5	O
,	9	O
Group	9	O
A	9	O
(	9	O
n	9	O
=	7	O
20	9	O
)	9	O
had	9	O
20	9	O
mg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
mL	0	O
of	5	O
methylprednisolone	0	B-Chemical
and	5	O
10	9	O
mg	0	O
/	9	O
0	7	O
.	9	O
5	9	O
mL	0	O
of	5	O
gentamicin	0	B-Chemical
injected	3	O
into	9	O
the	5	O
posterior	5	O
sub	9	O
-	7	O
Tenon	2	O
'	9	O
s	9	O
space	5	O
and	5	O
Group	9	O
B	9	O
(	9	O
n	9	O
=	7	O
20	9	O
)	9	O
had	9	O
the	5	O
same	9	O
combination	9	O
injected	3	O
into	9	O
the	5	O
anterior	5	O
sub	9	O
-	7	O
Tenon	2	O
'	9	O
s	9	O
space	5	O
.	9	O

Postoperatively	5	O
,	9	O
all	5	O
patients	5	O
were	9	O
assessed	9	O
for	5	O
symptoms	5	O
of	5	O
nausea	5	B-Disease
,	9	I-Disease
vomiting	5	I-Disease
,	9	O
and	5	O
headache	5	B-Disease
.	9	O

A	9	O
chi	5	O
-	7	O
square	5	O
test	5	O
was	9	O
used	5	O
to	5	O
assess	5	O
the	5	O
statistical	5	O
significance	9	O
of	5	O
results	9	O
.	9	O

RESULTS	9	O
:	9	O
Sixty	5	O
percent	5	O
in	5	O
Group	9	O
A	9	O
developed	5	O
postoperative	5	B-Disease
emetic	5	I-Disease
symptoms	5	I-Disease
,	9	O
headache	5	B-Disease
,	9	O
or	5	O
both	9	O
;	9	O
1	9	O
patient	5	O
in	5	O
Group	9	O
B	9	O
developed	5	O
symptoms	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
administration	9	O
of	5	O
methylprednisolone	0	B-Chemical
and	5	O
gentamicin	0	B-Chemical
in	5	O
the	5	O
posterior	5	O
sub	9	O
-	7	O
Tenon	2	O
'	9	O
s	9	O
space	5	O
was	9	O
related	9	O
to	5	O
a	5	O
high	9	O
incidence	5	O
of	5	O
side	5	O
effects	9	O
including	9	O
nausea	5	B-Disease
,	9	I-Disease
vomiting	5	I-Disease
,	9	O
and	5	O
headache	5	B-Disease
.	9	O

All	9	O
adverse	5	O
effects	9	O
were	9	O
self	5	O
-	7	O
limiting	9	O
.	9	O

Assessment	5	O
of	5	O
a	5	O
new	5	O
non	9	O
-	7	O
invasive	5	O
index	5	O
of	5	O
cardiac	5	O
performance	5	O
for	5	O
detection	9	O
of	5	O
dobutamine	5	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Electrocardiography	5	O
has	9	O
a	5	O
very	5	O
low	9	O
sensitivity	9	O
in	5	O
detecting	9	O
dobutamine	5	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
assess	5	O
the	5	O
added	0	O
diagnostic	5	O
value	9	O
of	5	O
a	5	O
new	5	O
cardiac	5	O
performance	5	O
index	5	O
(	9	O
dP	5	O
/	9	O
dtejc	_	O
)	9	O
measurement	5	O
,	9	O
based	5	O
on	5	O
brachial	5	O
artery	5	O
flow	5	O
changes	9	O
,	9	O
as	5	O
compared	9	O
to	5	O
standard	5	O
12	9	O
-	7	O
lead	5	O
ECG	5	O
,	9	O
for	5	O
detecting	9	O
dobutamine	5	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
,	9	O
using	9	O
Tc99m	0	B-Chemical
-	7	I-Chemical
Sestamibi	0	I-Chemical
single	9	O
-	7	O
photon	5	O
emission	0	O
computed	5	O
tomography	5	O
as	5	O
the	5	O
gold	0	O
standard	5	O
of	5	O
comparison	9	O
to	5	O
assess	5	O
the	5	O
presence	9	O
or	5	O
absence	3	O
of	5	O
ischemia	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
The	5	O
study	9	O
group	9	O
comprised	9	O
40	9	O
patients	5	O
undergoing	9	O
Sestamibi	0	B-Chemical
-	7	O
SPECT	5	O
/	9	O
dobutamine	5	B-Chemical
stress	9	O
test	5	O
.	9	O

Simultaneous	9	O
measurements	5	O
of	5	O
ECG	5	O
and	5	O
brachial	5	O
artery	5	O
dP	5	O
/	9	O
dtejc	_	O
were	9	O
performed	9	O
at	9	O
each	5	O
dobutamine	5	B-Chemical
level	9	O
.	9	O

In	9	O
19	7	O
of	5	O
the	5	O
40	9	O
patients	5	O
perfusion	5	O
defects	9	O
compatible	5	O
with	5	O
ischemia	9	B-Disease
were	9	O
detected	9	O
on	5	O
SPECT	5	O
.	9	O

The	5	O
increase	9	O
in	5	O
dP	5	O
/	9	O
dtejc	_	O
during	5	O
infusion	0	O
of	5	O
dobutamine	5	B-Chemical
in	5	O
this	5	O
group	9	O
was	9	O
severely	9	O
impaired	9	O
as	5	O
compared	9	O
to	5	O
the	5	O
non	9	O
-	7	O
ischemic	9	O
group	9	O
.	9	O

dP	5	O
/	9	O
dtejc	_	O
outcome	5	O
was	9	O
combined	9	O
with	5	O
the	5	O
ECG	5	O
results	9	O
,	9	O
giving	5	O
an	5	O
ECG	5	O
-	7	O
enhanced	3	O
value	9	O
,	9	O
and	5	O
compared	9	O
to	5	O
ECG	5	O
alone	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
sensitivity	9	O
improved	5	O
dramatically	9	O
from	9	O
16	9	O
%	9	O
to	5	O
79	7	O
%	9	O
,	9	O
positive	9	O
predictive	5	O
value	9	O
increased	9	O
from	9	O
60	9	O
%	9	O
to	5	O
68	7	O
%	9	O
and	5	O
negative	9	O
predictive	5	O
value	9	O
from	9	O
54	7	O
%	9	O
to	5	O
78	7	O
%	9	O
,	9	O
and	5	O
specificity	9	O
decreased	9	O
from	9	O
90	9	O
%	9	O
to	5	O
67	7	O
%	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
If	5	O
ECG	5	O
alone	9	O
is	5	O
used	5	O
for	5	O
specificity	9	O
,	9	O
the	5	O
combination	9	O
with	5	O
dP	5	O
/	9	O
dtejc	_	O
improved	5	O
the	5	O
sensitivity	9	O
of	5	O
the	5	O
test	5	O
and	5	O
could	9	O
be	5	O
a	5	O
cost	5	O
-	7	O
savings	5	O
alternative	5	O
to	5	O
cardiac	5	O
imaging	5	O
or	5	O
perfusion	5	O
studies	9	O
to	5	O
detect	9	O
myocardial	9	B-Disease
ischemia	9	I-Disease
,	9	O
especially	5	O
in	5	O
patients	5	O
unable	9	O
to	5	O
exercise	5	O
.	9	O

Cocaine	5	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
:	9	O
clinical	5	O
observations	9	O
and	5	O
pathogenetic	5	O
considerations	5	O
.	9	O

Clinical	5	O
and	5	O
experimental	5	O
data	5	O
published	9	O
to	5	O
date	5	O
suggest	9	O
several	9	O
possible	5	O
mechanisms	9	O
by	9	O
which	5	O
cocaine	5	B-Chemical
may	5	O
result	9	O
in	5	O
acute	9	B-Disease
myocardial	9	I-Disease
infarction	5	I-Disease
.	9	O

In	9	O
individuals	5	O
with	5	O
preexisting	9	O
,	9	O
high	9	O
-	7	O
grade	9	O
coronary	5	O
arterial	5	O
narrowing	5	O
,	9	O
acute	9	B-Disease
myocardial	9	I-Disease
infarction	5	I-Disease
may	5	O
result	9	O
from	9	O
an	5	O
increase	9	O
in	5	O
myocardial	9	O
oxygen	0	B-Chemical
demand	5	O
associated	9	O
with	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
increase	9	O
in	5	O
rate	9	O
-	7	O
pressure	5	O
product	9	O
.	9	O

In	9	O
other	5	O
individuals	5	O
with	5	O
no	9	O
underlying	5	O
atherosclerotic	3	B-Disease
obstruction	5	I-Disease
,	9	O
coronary	5	B-Disease
occlusion	5	I-Disease
may	5	O
be	5	O
due	5	O
to	5	O
spasm	5	B-Disease
,	9	O
thrombus	5	B-Disease
,	9	O
or	5	O
both	9	O
.	9	O

With	5	O
regard	5	O
to	5	O
spasm	5	B-Disease
,	9	O
the	5	O
clinical	5	O
findings	9	O
are	5	O
largely	9	O
circumstantial	9	O
,	9	O
and	5	O
the	5	O
locus	1	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
vasoconstriction	9	O
remains	9	O
speculative	5	O
.	9	O

Although	9	O
certain	5	O
clinical	5	O
and	5	O
experimental	5	O
findings	9	O
support	5	O
the	5	O
hypothesis	9	O
that	5	O
spasm	5	B-Disease
involves	5	O
the	5	O
epicardial	5	O
,	9	O
medium	0	O
-	7	O
size	9	O
vessels	5	O
,	9	O
other	5	O
data	5	O
suggest	9	O
intramural	5	O
vasoconstriction	9	O
.	9	O

Diffuse	9	O
intramural	5	O
vasoconstriction	9	O
is	5	O
not	5	O
consistent	9	O
with	5	O
reports	9	O
of	5	O
segmental	5	O
,	9	O
discrete	5	O
infarction	5	B-Disease
.	9	O

Whereas	9	O
certain	5	O
in	5	O
vivo	3	O
data	5	O
suggest	9	O
that	5	O
these	5	O
effects	9	O
are	5	O
alpha	9	O
-	7	O
mediated	3	O
,	9	O
other	5	O
in	5	O
vitro	3	O
data	5	O
suggest	9	O
the	5	O
opposite	9	O
.	9	O

The	5	O
finding	9	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
vasoconstriction	9	O
in	5	O
segments	9	O
of	5	O
(	9	O
noninnervated	3	O
)	9	O
human	3	O
umbilical	3	O
artery	5	O
suggests	9	O
that	5	O
the	5	O
presence	9	O
or	5	O
absence	3	O
of	5	O
intact	9	O
innervation	5	O
is	5	O
not	5	O
sufficient	9	O
to	5	O
explain	9	O
the	5	O
discrepant	5	O
data	5	O
involving	5	O
the	5	O
possibility	9	O
of	5	O
alpha	9	O
-	7	O
mediated	3	O
effects	9	O
.	9	O

Finally	9	O
,	9	O
the	5	O
contribution	9	O
of	5	O
a	5	O
primary	9	O
,	9	O
thrombotic	5	B-Disease
effect	9	O
of	5	O
cocaine	5	B-Chemical
has	9	O
not	5	O
been	9	O
excluded	9	O
.	9	O

Proteomic	9	O
analysis	9	O
of	5	O
striatal	3	O
proteins	1	O
in	5	O
the	5	O
rat	3	O
model	5	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
.	9	O

L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
(	9	O
LID	5	B-Disease
)	9	O
is	5	O
among	5	O
the	5	O
motor	5	O
complications	5	O
that	5	O
arise	5	O
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
patients	5	O
after	9	O
a	5	O
prolonged	9	O
treatment	9	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
.	9	O

To	9	O
this	5	O
day	9	O
,	9	O
transcriptome	9	O
analysis	9	O
has	9	O
been	9	O
performed	9	O
in	5	O
a	5	O
rat	3	O
model	5	O
of	5	O
LID	5	B-Disease
[	9	O
Neurobiol	2	O
.	9	O
Dis	2	O
.	9	O
,	9	O
17	7	O
(	9	O
2004	2	O
)	9	O
,	9	O
219	7	O
]	9	O
but	9	O
information	5	O
regarding	5	O
the	5	O
proteome	9	O
is	5	O
still	5	O
lacking	1	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
we	5	O
investigated	9	O
the	5	O
changes	9	O
occurring	9	O
at	9	O
the	5	O
protein	1	O
level	9	O
in	5	O
striatal	3	O
samples	9	O
obtained	9	O
from	9	O
the	5	O
unilaterally	5	O
6	9	B-Chemical
-	7	I-Chemical
hydroxydopamine	0	I-Chemical
-	7	O
lesion	5	O
rat	3	O
model	5	O
of	5	O
PD	9	B-Disease
treated	3	O
with	5	O
saline	0	O
,	9	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
or	5	O
bromocriptine	0	B-Chemical
using	9	O
two	5	O
-	7	O
dimensional	5	O
difference	9	O
gel	0	O
electrophoresis	0	O
and	5	O
mass	9	O
spectrometry	0	O
(	9	O
MS	9	O
)	9	O
.	9	O

Rats	9	O
treated	3	O
with	5	O
L	0	B-Chemical
-	7	I-Chemical
DOPA	0	I-Chemical
were	9	O
allocated	5	O
to	5	O
two	5	O
groups	9	O
based	5	O
on	5	O
the	5	O
presence	9	O
or	5	O
absence	3	O
of	5	O
LID	5	B-Disease
.	9	O

Among	9	O
the	5	O
2000	9	O
spots	9	O
compared	9	O
for	5	O
statistical	5	O
difference	9	O
,	9	O
67	7	O
spots	9	O
were	9	O
significantly	9	O
changed	9	O
in	5	O
abundance	9	O
and	5	O
identified	9	O
using	9	O
matrix	5	O
-	7	O
assisted	5	O
laser	5	O
desorption	0	O
/	9	O
ionization	0	O
time	5	O
-	7	O
of	5	O
-	7	O
flight	5	O
MS	9	O
,	9	O
atmospheric	5	O
pressure	5	O
matrix	5	O
-	7	O
assisted	5	O
laser	5	O
desorption	0	O
/	9	O
ionization	0	O
and	5	O
HPLC	0	O
coupled	9	O
tandem	1	O
MS	9	O
(	9	O
LC	9	O
/	9	O
MS	9	O
/	9	O
MS	9	O
)	9	O
.	9	O

Out	9	O
of	5	O
these	5	O
67	7	O
proteins	1	O
,	9	O
LID	5	B-Disease
significantly	9	O
changed	9	O
the	5	O
expression	3	O
level	9	O
of	5	O
five	9	O
proteins	1	O
:	9	O
alphabeta	1	O
-	7	O
crystalin	9	O
,	9	O
gamma	9	O
-	7	O
enolase	1	O
,	9	O
guanidoacetate	0	O
methyltransferase	1	O
,	9	O
vinculin	3	O
,	9	O
and	5	O
proteasome	3	O
alpha	9	O
-	7	O
2	9	O
subunit	1	O
.	9	O

Complementary	5	O
techniques	5	O
such	5	O
as	5	O
western	3	O
immunoblotting	3	O
and	5	O
immunohistochemistry	3	O
were	9	O
performed	9	O
to	5	O
investigate	9	O
the	5	O
validity	5	O
of	5	O
the	5	O
data	5	O
obtained	9	O
using	9	O
the	5	O
proteomic	9	O
approach	5	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
this	5	O
study	9	O
provides	5	O
new	5	O
insights	5	O
into	9	O
the	5	O
protein	1	O
changes	9	O
occurring	9	O
in	5	O
LID	5	B-Disease
.	9	O

Cardiac	9	O
Angiography	5	O
in	5	O
Renally	9	O
Impaired	9	O
Patients	5	O
(	9	O
CARE	2	O
)	9	O
study	9	O
:	9	O
a	5	O
randomized	5	O
double	9	O
-	7	O
blind	5	O
trial	5	O
of	5	O
contrast	9	O
-	7	O
induced	3	O
nephropathy	9	B-Disease
in	5	O
patients	5	O
with	5	O
chronic	5	B-Disease
kidney	9	I-Disease
disease	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
No	9	O
direct	9	O
comparisons	5	O
exist	9	O
of	5	O
the	5	O
renal	9	O
tolerability	5	O
of	5	O
the	5	O
low	9	O
-	7	O
osmolality	0	O
contrast	9	B-Chemical
medium	0	I-Chemical
iopamidol	0	B-Chemical
with	5	O
that	5	O
of	5	O
the	5	O
iso	0	O
-	7	O
osmolality	0	O
contrast	9	B-Chemical
medium	0	I-Chemical
iodixanol	0	B-Chemical
in	5	O
high	9	O
-	7	O
risk	5	O
patients	5	O
.	9	O

METHODS	2	O
AND	2	O
RESULTS	9	O
:	9	O
The	5	O
present	9	O
study	9	O
is	5	O
a	5	O
multicenter	5	O
,	9	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
comparison	9	O
of	5	O
iopamidol	0	B-Chemical
and	5	O
iodixanol	0	B-Chemical
in	5	O
patients	5	O
with	5	O
chronic	5	B-Disease
kidney	9	I-Disease
disease	5	I-Disease
(	9	O
estimated	5	O
glomerular	5	O
filtration	0	O
rate	9	O
,	9	O
20	9	O
to	5	O
59	7	O
mL	0	O
/	9	O
min	0	O
)	9	O
who	5	O
underwent	5	O
cardiac	5	O
angiography	5	O
or	5	O
percutaneous	5	O
coronary	5	O
interventions	5	O
.	9	O

Serum	9	O
creatinine	0	B-Chemical
(	9	O
SCr	5	O
)	9	O
levels	3	O
and	5	O
estimated	5	O
glomerular	5	O
filtration	0	O
rate	9	O
were	9	O
assessed	9	O
at	9	O
baseline	5	O
and	5	O
2	9	O
to	5	O
5	9	O
days	9	O
after	9	O
receiving	9	O
medications	5	O
.	9	O

The	5	O
primary	9	O
outcome	5	O
was	9	O
a	5	O
postdose	5	O
SCr	5	O
increase	9	O
>	0	O
or	5	O
=	7	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
dL	7	O
(	9	O
44	7	O
.	9	O
2	9	O
micromol	0	O
/	9	O
L	0	O
)	9	O
over	5	O
baseline	5	O
.	9	O

Secondary	9	O
outcomes	5	O
were	9	O
a	5	O
postdose	5	O
SCr	5	O
increase	9	O
>	0	O
or	5	O
=	7	O
25	9	O
%	9	O
,	9	O
a	5	O
postdose	5	O
estimated	5	O
glomerular	5	O
filtration	0	O
rate	9	O
decrease	9	O
of	5	O
>	0	O
or	5	O
=	7	O
25	9	O
%	9	O
,	9	O
and	5	O
the	5	O
mean	5	O
peak	9	O
change	9	O
in	5	O
SCr	5	O
.	9	O

In	9	O
414	7	O
patients	5	O
,	9	O
contrast	9	O
volume	9	O
,	9	O
presence	9	O
of	5	O
diabetes	5	B-Disease
mellitus	9	I-Disease
,	9	O
use	5	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
acetylcysteine	0	I-Chemical
,	9	O
mean	5	O
baseline	5	O
SCr	5	O
,	9	O
and	5	O
estimated	5	O
glomerular	5	O
filtration	0	O
rate	9	O
were	9	O
comparable	9	O
in	5	O
the	5	O
2	9	O
groups	9	O
.	9	O

SCr	5	O
increases	9	O
>	0	O
or	5	O
=	7	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
dL	7	O
occurred	9	O
in	5	O
4	9	O
.	9	O
4	9	O
%	9	O
(	9	O
9	7	O
of	5	O
204	7	O
patients	5	O
)	9	O
after	9	O
iopamidol	0	B-Chemical
and	5	O
6	9	O
.	9	O
7	9	O
%	9	O
(	9	O
14	7	O
of	5	O
210	9	O
patients	5	O
)	9	O
after	9	O
iodixanol	0	B-Chemical
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
39	7	O
)	9	O
,	9	O
whereas	9	O
rates	5	O
of	5	O
SCr	5	O
increases	9	O
>	0	O
or	5	O
=	7	O
25	9	O
%	9	O
were	9	O
9	7	O
.	9	O
8	9	O
%	9	O
and	5	O
12	9	O
.	9	O
4	9	O
%	9	O
,	9	O
respectively	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
44	7	O
)	9	O
.	9	O

In	9	O
patients	5	O
with	5	O
diabetes	5	B-Disease
,	9	O
SCr	5	O
increases	9	O
>	0	O
or	5	O
=	7	O
0	7	O
.	9	O
5	9	O
mg	0	O
/	9	O
dL	7	O
were	9	O
5	9	O
.	9	O
1	9	O
%	9	O
(	9	O
4	9	O
of	5	O
78	7	O
patients	5	O
)	9	O
with	5	O
iopamidol	0	B-Chemical
and	5	O
13	7	O
.	9	O
0	7	O
%	9	O
(	9	O
12	9	O
of	5	O
92	7	O
patients	5	O
)	9	O
with	5	O
iodixanol	0	B-Chemical
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
11	7	O
)	9	O
,	9	O
whereas	9	O
SCr	5	O
increases	9	O
>	0	O
or	5	O
=	7	O
25	9	O
%	9	O
were	9	O
10	9	O
.	9	O
3	9	O
%	9	O
and	5	O
15	9	O
.	9	O
2	9	O
%	9	O
,	9	O
respectively	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
37	9	O
)	9	O
.	9	O

Mean	9	O
post	9	O
-	7	O
SCr	5	O
increases	9	O
were	9	O
significantly	9	O
less	5	O
with	5	O
iopamidol	0	B-Chemical
(	9	O
all	5	O
patients	5	O
:	9	O
0	7	O
.	9	O
07	7	O
versus	9	O
0	7	O
.	9	O
12	9	O
mg	0	O
/	9	O
dL	7	O
,	9	O
6	9	O
.	9	O
2	9	O
versus	9	O
10	9	O
.	9	O
6	9	O
micromol	0	O
/	9	O
L	0	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
03	7	O
;	9	O
patients	5	O
with	5	O
diabetes	5	B-Disease
:	9	O
0	7	O
.	9	O
07	7	O
versus	9	O
0	7	O
.	9	O
16	9	O
mg	0	O
/	9	O
dL	7	O
,	9	O
6	9	O
.	9	O
2	9	O
versus	9	O
14	7	O
.	9	O
1	9	O
micromol	0	O
/	9	O
L	0	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
rate	9	O
of	5	O
contrast	9	O
-	7	O
induced	3	O
nephropathy	9	B-Disease
,	9	O
defined	5	O
by	9	O
multiple	5	O
end	9	O
points	5	O
,	9	O
is	5	O
not	5	O
statistically	9	O
different	9	O
after	9	O
the	5	O
intraarterial	5	O
administration	9	O
of	5	O
iopamidol	0	B-Chemical
or	5	O
iodixanol	0	B-Chemical
to	5	O
high	9	O
-	7	O
risk	5	O
patients	5	O
,	9	O
with	5	O
or	5	O
without	9	O
diabetes	5	B-Disease
mellitus	9	I-Disease
.	9	O

Any	5	O
true	5	O
difference	9	O
between	5	O
the	5	O
agents	5	O
is	5	O
small	9	O
and	5	O
not	5	O
likely	5	O
to	5	O
be	5	O
clinically	5	O
significant	9	O
.	9	O

A	9	O
novel	9	O
compound	0	O
,	9	O
maltolyl	_	B-Chemical
p	7	I-Chemical
-	7	I-Chemical
coumarate	0	I-Chemical
,	9	O
attenuates	3	O
cognitive	5	B-Disease
deficits	5	I-Disease
and	5	O
shows	9	O
neuroprotective	9	O
effects	9	O
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
dementia	5	B-Disease
models	5	O
.	9	O

To	9	O
develop	5	O
a	5	O
novel	9	O
and	5	O
effective	5	O
drug	5	O
that	5	O
could	9	O
enhance	9	O
cognitive	5	O
function	9	O
and	5	O
neuroprotection	3	O
,	9	O
we	5	O
newly	9	O
synthesized	0	O
maltolyl	_	B-Chemical
p	7	I-Chemical
-	7	I-Chemical
coumarate	0	I-Chemical
by	9	O
the	5	O
esterification	0	O
of	5	O
maltol	0	B-Chemical
and	5	O
p	7	B-Chemical
-	7	I-Chemical
coumaric	0	I-Chemical
acid	0	I-Chemical
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
we	5	O
investigated	9	O
whether	9	O
maltolyl	_	B-Chemical
p	7	I-Chemical
-	7	I-Chemical
coumarate	0	I-Chemical
could	9	O
improve	5	O
cognitive	5	B-Disease
decline	9	I-Disease
in	5	O
scopolamine	0	B-Chemical
-	7	O
injected	3	O
rats	9	O
and	5	O
in	5	O
amyloid	3	B-Chemical
beta	9	I-Chemical
peptide	9	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
42	7	I-Chemical
)	9	I-Chemical
-	7	O
infused	9	O
rats	9	O
.	9	O

Maltolyl	_	B-Chemical
p	7	I-Chemical
-	7	I-Chemical
coumarate	0	I-Chemical
was	9	O
found	9	O
to	5	O
attenuate	9	O
cognitive	5	B-Disease
deficits	5	I-Disease
in	5	O
both	9	O
rat	3	O
models	5	O
using	9	O
passive	5	O
avoidance	5	O
test	5	O
and	5	O
to	5	O
reduce	5	O
apoptotic	3	O
cell	3	O
death	9	O
observed	9	O
in	5	O
the	5	O
hippocampus	9	O
of	5	O
the	5	O
amyloid	3	B-Chemical
beta	9	I-Chemical
peptide	9	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
42	7	I-Chemical
)	9	I-Chemical
-	7	O
infused	9	O
rats	9	O
.	9	O

We	9	O
also	9	O
examined	9	O
the	5	O
neuroprotective	9	O
effects	9	O
of	5	O
maltolyl	_	B-Chemical
p	7	I-Chemical
-	7	I-Chemical
coumarate	0	I-Chemical
in	5	O
vitro	3	O
using	9	O
SH	9	O
-	7	O
SY5Y	3	O
cells	3	O
.	9	O

Cells	3	O
were	9	O
pretreated	3	O
with	5	O
maltolyl	_	B-Chemical
p	7	I-Chemical
-	7	I-Chemical
coumarate	0	I-Chemical
,	9	O
before	9	O
exposed	9	O
to	5	O
amyloid	3	B-Chemical
beta	9	I-Chemical
peptide	9	I-Chemical
(	9	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
42	7	I-Chemical
)	9	I-Chemical
,	9	O
glutamate	0	B-Chemical
or	5	O
H2O2	0	B-Chemical
.	9	O

We	9	O
found	9	O
that	5	O
maltolyl	_	B-Chemical
p	7	I-Chemical
-	7	I-Chemical
coumarate	0	I-Chemical
significantly	9	O
decreased	9	O
apoptotic	3	O
cell	3	O
death	9	O
and	5	O
reduced	9	O
reactive	9	O
oxygen	0	O
species	4	O
,	9	O
cytochrome	0	O
c	9	O
release	9	O
,	9	O
and	5	O
caspase	3	O
3	9	O
activation	3	O
.	9	O

Taking	5	O
these	5	O
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
results	9	O
together	9	O
,	9	O
our	5	O
study	9	O
suggests	9	O
that	5	O
maltolyl	_	B-Chemical
p	7	I-Chemical
-	7	I-Chemical
coumarate	0	I-Chemical
is	5	O
a	5	O
potentially	5	O
effective	5	O
candidate	9	O
against	9	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
that	5	O
is	5	O
characterized	9	O
by	9	O
wide	5	O
spread	5	O
neuronal	3	B-Disease
death	9	I-Disease
and	5	O
progressive	5	O
decline	9	B-Disease
of	5	I-Disease
cognitive	5	I-Disease
function	9	I-Disease
.	9	O

Attenuation	9	O
of	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
nigrostriatal	3	O
dopaminergic	5	O
neurotoxicity	9	B-Disease
in	5	O
mice	3	O
by	9	O
lipopolysaccharide	3	B-Chemical
pretreatment	0	O
.	9	O

Immunological	9	O
activation	3	O
has	9	O
been	9	O
proposed	5	O
to	5	O
play	9	O
a	5	O
role	9	O
in	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
dopaminergic	5	B-Disease
terminal	9	I-Disease
damage	9	I-Disease
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
examined	9	O
the	5	O
roles	9	O
of	5	O
lipopolysaccharide	3	B-Chemical
,	9	O
a	5	O
pro	9	O
-	7	O
inflammatory	3	O
and	5	O
inflammatory	3	O
factor	9	O
,	9	O
treatment	9	O
in	5	O
modulating	9	O
the	5	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
nigrostriatal	3	O
dopamine	5	B-Chemical
neurotoxicity	9	B-Disease
.	9	O

Lipopolysaccharide	0	B-Chemical
pretreatment	0	O
did	9	O
not	5	O
affect	9	O
the	5	O
basal	3	O
body	5	O
temperature	0	O
or	5	O
methamphetamine	5	B-Chemical
-	7	O
elicited	9	O
hyperthermia	5	B-Disease
three	9	O
days	9	O
later	9	O
.	9	O

Such	5	O
systemic	9	O
lipopolysaccharide	3	B-Chemical
treatment	9	O
mitigated	9	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
striatal	3	O
dopamine	5	B-Chemical
and	5	O
3	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dihydroxyphenylacetic	0	I-Chemical
acid	0	I-Chemical
depletions	3	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

As	9	O
the	5	O
most	9	O
potent	3	O
dose	9	O
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
of	5	O
lipopolysaccharide	3	B-Chemical
was	9	O
administered	9	O
two	5	O
weeks	9	O
,	9	O
one	5	O
day	9	O
before	9	O
or	5	O
after	9	O
the	5	O
methamphetamine	5	B-Chemical
dosing	9	O
regimen	5	O
,	9	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
striatal	3	O
dopamine	5	B-Chemical
and	5	O
3	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dihydroxyphenylacetic	0	I-Chemical
acid	0	I-Chemical
depletions	3	O
remained	9	O
unaltered	9	O
.	9	O

Moreover	9	O
,	9	O
systemic	9	O
lipopolysaccharide	3	B-Chemical
pretreatment	0	O
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
attenuated	3	O
local	5	O
methamphetamine	5	B-Chemical
infusion	0	O
-	7	O
produced	9	O
dopamine	5	B-Chemical
and	5	O
3	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dihydroxyphenylacetic	0	I-Chemical
acid	0	I-Chemical
depletions	3	O
in	5	O
the	5	O
striatum	9	O
,	9	O
indicating	9	O
that	5	O
the	5	O
protective	9	O
effect	9	O
of	5	O
lipopolysaccharide	3	B-Chemical
is	5	O
less	5	O
likely	5	O
due	5	O
to	5	O
interrupted	5	O
peripheral	9	O
distribution	9	O
or	5	O
metabolism	9	O
of	5	O
methamphetamine	5	B-Chemical
.	9	O

We	9	O
concluded	9	O
a	5	O
critical	9	O
time	5	O
window	5	O
for	5	O
systemic	9	O
lipopolysaccharide	3	B-Chemical
pretreatment	0	O
in	5	O
exerting	9	O
effective	5	O
protection	9	O
against	9	O
methamphetamine	5	B-Chemical
-	7	O
induced	3	O
nigrostriatal	3	O
dopamine	5	B-Chemical
neurotoxicity	9	B-Disease
.	9	O

Acute	5	O
myocarditis	9	B-Disease
associated	9	O
with	5	O
clozapine	5	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
A	9	O
case	5	O
of	5	O
acute	9	O
myocarditis	9	B-Disease
associated	9	O
with	5	O
the	5	O
commencement	5	O
of	5	O
clozapine	5	B-Chemical
is	5	O
described	9	O
,	9	O
highlighting	9	O
the	5	O
onset	5	O
,	9	O
course	5	O
and	5	O
possible	5	O
contributing	9	O
factors	9	O
.	9	O

There	5	O
is	5	O
an	5	O
urgent	5	O
need	5	O
to	5	O
raise	9	O
awareness	5	O
about	5	O
this	5	O
potentially	5	O
fatal	5	O
complication	5	O
of	5	O
clozapine	5	B-Chemical
use	5	O
.	9	O

RESULTS	9	O
:	9	O
A	9	O
20	9	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
with	5	O
schizophrenia	5	B-Disease
developed	5	O
a	5	O
sudden	5	O
onset	5	O
of	5	O
myocarditis	9	B-Disease
after	9	O
commencement	5	O
of	5	O
clozapine	5	B-Chemical
.	9	O

The	5	O
patient	5	O
recovered	9	O
with	5	O
intensive	5	O
medical	5	O
support	5	O
.	9	O

The	5	O
symptoms	5	O
occurred	9	O
around	5	O
2	9	O
weeks	9	O
after	9	O
starting	9	O
clozapine	5	B-Chemical
in	5	O
an	5	O
inpatient	5	O
setting	5	O
.	9	O

Possible	9	O
contributing	9	O
factors	9	O
may	5	O
have	5	O
been	9	O
concomitant	9	O
antidepressant	5	B-Chemical
use	5	O
and	5	O
unaccustomed	5	O
physical	5	O
activity	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Myocarditis	7	B-Disease
is	5	O
an	5	O
increasingly	5	O
recognized	9	O
complication	5	O
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
clozapine	5	B-Chemical
.	9	O

It	5	O
can	5	O
be	5	O
fatal	5	O
if	5	O
not	5	O
recognized	9	O
and	5	O
treated	3	O
early	9	O
.	9	O

Considering	9	O
that	5	O
clozapine	5	B-Chemical
remains	9	O
the	5	O
gold	0	O
standard	5	O
in	5	O
treatment	9	O
of	5	O
resistant	9	O
psychosis	5	B-Disease
,	9	O
there	5	O
is	5	O
an	5	O
urgent	5	O
need	5	O
to	5	O
raise	9	O
awareness	5	O
among	5	O
medical	5	O
and	5	O
paramedical	5	O
staff	5	O
involved	9	O
in	5	O
the	5	O
care	5	O
of	5	O
these	5	O
patients	5	O
.	9	O

There	5	O
are	5	O
also	9	O
implications	5	O
for	5	O
recommendations	5	O
and	5	O
regulations	5	O
regarding	5	O
the	5	O
use	5	O
of	5	O
clozapine	5	B-Chemical
.	9	O

Severe	9	O
rhabdomyolysis	5	B-Disease
and	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
secondary	9	O
to	5	O
concomitant	9	O
use	5	O
of	5	O
simvastatin	0	B-Chemical
,	9	O
amiodarone	0	B-Chemical
,	9	O
and	5	O
atazanavir	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
a	5	O
severe	5	O
interaction	9	O
between	5	O
simvastatin	0	B-Chemical
,	9	O
amiodarone	0	B-Chemical
,	9	O
and	5	O
atazanavir	0	B-Chemical
resulting	9	O
in	5	O
rhabdomyolysis	5	B-Disease
and	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
A	9	O
72	9	O
-	7	O
year	5	O
-	7	O
old	5	O
white	9	O
man	5	O
with	5	O
underlying	5	O
human	3	B-Disease
immunodeficiency	9	I-Disease
virus	9	I-Disease
,	9	O
atrial	5	B-Disease
fibrillation	5	I-Disease
,	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
,	9	O
and	5	O
hyperlipidemia	9	B-Disease
presented	5	O
with	5	O
generalized	5	O
pain	5	B-Disease
,	9	O
fatigue	5	B-Disease
,	9	O
and	5	O
dark	9	O
orange	9	O
urine	9	O
for	5	O
3	9	O
days	9	O
.	9	O

The	5	O
patient	5	O
was	9	O
taking	5	O
80	9	O
mg	0	O
simvastatin	0	B-Chemical
at	9	O
bedtime	5	O
(	9	O
initiated	9	O
27	7	O
days	9	O
earlier	9	O
)	9	O
;	9	O
amiodarone	0	B-Chemical
at	9	O
a	5	O
dose	9	O
of	5	O
400	0	O
mg	0	O
daily	5	O
for	5	O
7	9	O
days	9	O
,	9	O
then	9	O
200	0	O
mg	0	O
daily	5	O
(	9	O
initiated	9	O
19	7	O
days	9	O
earlier	9	O
)	9	O
;	9	O
and	5	O
400	0	O
mg	0	O
atazanavir	0	B-Chemical
daily	5	O
(	9	O
initiated	9	O
at	9	O
least	9	O
2	9	O
years	5	O
previously	9	O
)	9	O
.	9	O

Laboratory	2	O
evaluation	5	O
revealed	9	O
66	7	O
,	9	O
680	9	O
U	9	O
/	9	O
L	0	O
creatine	0	B-Chemical
kinase	3	O
,	9	O
93	7	O
mg	0	O
/	9	O
dL	7	O
blood	9	B-Chemical
urea	0	I-Chemical
nitrogen	0	I-Chemical
,	9	O
4	9	O
.	9	O
6	9	O
mg	0	O
/	9	O
dL	7	O
creatinine	0	B-Chemical
,	9	O
1579	7	O
U	9	O
/	9	O
L	0	O
aspartate	1	B-Chemical
aminotransferase	7	O
,	9	O
and	5	O
738	7	O
U	9	O
/	9	O
L	0	O
alanine	1	B-Chemical
aminotransferase	7	O
.	9	O

Simvastatin	0	B-Chemical
,	9	O
amiodarone	0	B-Chemical
,	9	O
and	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
human	3	B-Disease
immunodeficiency	9	I-Disease
virus	9	I-Disease
medications	5	O
were	9	O
all	5	O
temporarily	5	O
discontinued	5	O
and	5	O
the	5	O
patient	5	O
was	9	O
given	5	O
forced	5	O
alkaline	0	O
diuresis	5	O
and	5	O
started	5	O
on	5	O
dialysis	5	O
.	9	O

Nine	9	O
days	9	O
later	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
creatine	0	B-Chemical
kinase	3	O
had	9	O
dropped	9	O
to	5	O
1695	7	O
U	9	O
/	9	O
L	0	O
and	5	O
creatinine	0	B-Chemical
was	9	O
3	9	O
.	9	O
3	9	O
mg	0	O
/	9	O
dL	7	O
.	9	O

The	5	O
patient	5	O
was	9	O
discharged	5	O
and	5	O
continued	9	O
outpatient	5	O
dialysis	5	O
for	5	O
1	9	O
month	5	O
until	5	O
his	5	O
renal	9	O
function	9	O
recovered	9	O
.	9	O

DISCUSSION	9	O
:	9	O
The	5	O
risk	5	O
of	5	O
rhabdomyolysis	5	B-Disease
is	5	O
increased	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
concomitant	9	O
drugs	5	O
that	5	O
inhibit	3	O
simvastatin	0	B-Chemical
metabolism	9	O
.	9	O

Simvastatin	0	B-Chemical
is	5	O
metabolized	0	O
by	9	O
CYP3A4	3	O
.	9	O

Amiodarone	7	B-Chemical
and	5	O
atazanavir	0	B-Chemical
are	5	O
recognized	9	O
CYP3A4	3	O
inhibitors	3	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Pharmacokinetic	0	O
differences	9	O
in	5	O
statins	5	B-Chemical
are	5	O
an	5	O
important	9	O
consideration	5	O
for	5	O
assessing	5	O
the	5	O
risk	5	O
of	5	O
potential	9	O
drug	5	O
interactions	9	O
.	9	O

In	9	O
patients	5	O
requiring	5	O
the	5	O
concurrent	5	O
use	5	O
of	5	O
statins	5	B-Chemical
and	5	O
CYP3A4	3	O
inhibitors	3	O
,	9	O
pravastatin	0	B-Chemical
,	9	O
fluvastatin	0	B-Chemical
,	9	O
and	5	O
rosuvastatin	0	B-Chemical
carry	9	O
the	5	O
lowest	9	O
risk	5	O
of	5	O
drug	5	O
interactions	9	O
;	9	O
atorvastatin	0	B-Chemical
carries	9	O
moderate	9	O
risk	5	O
,	9	O
whereas	9	O
simvastatin	0	B-Chemical
and	5	O
lovastatin	0	B-Chemical
have	5	O
the	5	O
highest	9	O
risk	5	O
and	5	O
should	5	O
be	5	O
avoided	5	O
in	5	O
patients	5	O
taking	5	O
concomitant	9	O
CYP3A4	3	O
inhibitors	3	O
.	9	O

Interaction	9	O
between	5	O
warfarin	5	B-Chemical
and	5	O
levofloxacin	0	B-Chemical
:	9	O
case	5	O
series	5	O
.	9	O

Warfarin	5	B-Chemical
is	5	O
the	5	O
most	9	O
widely	5	O
used	5	O
oral	9	O
anticoagulant	9	O
and	5	O
is	5	O
indicated	9	O
for	5	O
many	5	O
clinical	5	O
conditions	9	O
.	9	O

Levofloxacin	7	B-Chemical
,	9	O
a	5	O
fluoroquinolone	5	B-Chemical
,	9	O
is	5	O
one	5	O
of	5	O
the	5	O
most	9	O
commonly	5	O
prescribed	5	O
antibiotics	5	O
in	5	O
clinical	5	O
practice	5	O
and	5	O
is	5	O
effective	5	O
against	9	O
Gram	9	O
-	7	O
positive	9	O
,	9	O
Gram	9	O
-	7	O
negative	9	O
,	9	O
and	5	O
atypical	5	O
bacteria	9	O
.	9	O

While	9	O
small	9	O
prospective	5	O
studies	9	O
have	5	O
not	5	O
revealed	9	O
any	5	O
significant	9	O
drug	5	O
-	7	O
drug	5	O
interaction	9	O
between	5	O
warfarin	5	B-Chemical
and	5	O
levofloxacin	0	B-Chemical
,	9	O
several	9	O
case	5	O
reports	9	O
have	5	O
indicated	9	O
that	5	O
levofloxacin	0	B-Chemical
may	5	O
significantly	9	O
potentiate	3	O
the	5	O
anticoagulation	5	O
effect	9	O
of	5	O
warfarin	5	B-Chemical
.	9	O

We	9	O
report	5	O
3	9	O
cases	5	O
of	5	O
serious	5	O
bleeding	5	B-Disease
complications	5	O
that	5	O
appear	9	O
to	5	O
be	5	O
the	5	O
result	9	O
of	5	O
the	5	O
interaction	9	O
between	5	O
warfarin	5	B-Chemical
and	5	O
levofloxacin	0	B-Chemical
.	9	O

Physicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
potential	9	O
interaction	9	O
and	5	O
use	5	O
caution	5	O
when	5	O
prescribing	5	O
levofloxacin	0	B-Chemical
to	5	O
patients	5	O
taking	5	O
warfarin	5	B-Chemical
.	9	O

Mutations	1	O
associated	9	O
with	5	O
lamivudine	5	B-Chemical
-	7	O
resistance	9	O
in	5	O
therapy	5	O
-	7	O
na	7	B-Chemical
ve	9	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	I-Disease
(	9	I-Disease
HBV	9	I-Disease
)	9	I-Disease
infected	3	I-Disease
patients	5	O
with	5	O
and	5	O
without	9	O
HIV	5	B-Disease
co	9	I-Disease
-	7	I-Disease
infection	9	I-Disease
:	9	O
implications	5	O
for	5	O
antiretroviral	5	O
therapy	5	O
in	5	O
HBV	9	B-Disease
and	5	I-Disease
HIV	5	I-Disease
co	9	I-Disease
-	7	I-Disease
infected	3	I-Disease
South	4	O
African	5	O
patients	5	O
.	9	O

This	5	O
was	9	O
an	5	O
exploratory	5	O
study	9	O
to	5	O
investigate	9	O
lamivudine	5	B-Chemical
-	7	O
resistant	9	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
(	9	O
HBV	9	O
)	9	O
strains	1	O
in	5	O
selected	9	O
lamivudine	5	B-Chemical
-	7	O
na	7	B-Chemical
ve	9	O
HBV	9	O
carriers	9	O
with	5	O
and	5	O
without	9	O
human	3	B-Disease
immunodeficiency	9	I-Disease
virus	9	I-Disease
(	9	I-Disease
HIV	5	I-Disease
)	9	I-Disease
co	9	I-Disease
-	7	I-Disease
infection	9	I-Disease
in	5	O
South	4	O
African	5	O
patients	5	O
.	9	O

Thirty	9	O
-	7	O
five	9	O
lamivudine	5	B-Chemical
-	7	O
na	7	B-Chemical
ve	9	O
HBV	9	B-Disease
infected	3	I-Disease
patients	5	O
with	5	O
or	5	O
without	9	O
HIV	5	B-Disease
co	9	I-Disease
-	7	I-Disease
infection	9	I-Disease
were	9	O
studied	9	O
:	9	O
15	9	O
chronic	5	O
HBV	9	B-Disease
mono	0	I-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
and	5	O
20	9	O
HBV	9	B-Disease
-	7	I-Disease
HIV	5	I-Disease
co	9	I-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
.	9	O

The	5	O
latter	9	O
group	9	O
was	9	O
further	9	O
sub	9	O
-	7	O
divided	5	O
into	9	O
13	7	O
occult	5	O
HBV	9	O
(	9	O
HBsAg	9	B-Chemical
-	7	O
negative	9	O
)	9	O
and	5	O
7	9	O
overt	5	O
HBV	9	O
(	9	O
HBsAg	9	B-Chemical
-	7	O
positive	9	O
)	9	O
patients	5	O
.	9	O

HBsAg	9	B-Chemical
,	9	O
anti	3	O
-	7	O
HBs	3	O
,	9	O
anti	3	O
-	7	O
HBc	3	O
,	9	O
and	5	O
anti	3	O
-	7	O
HIV	5	O
1	9	O
/	9	O
2	9	O
were	9	O
determined	9	O
as	5	O
part	9	O
of	5	O
routine	5	O
diagnosis	5	O
using	9	O
Axsym	0	O
assays	3	O
(	9	O
Abbott	2	O
Laboratories	0	O
,	9	O
North	4	O
Chicago	2	O
,	9	O
IL	0	O
)	9	O
.	9	O

Serum	9	O
samples	9	O
were	9	O
PCR	9	O
amplified	1	O
with	5	O
HBV	9	O
reverse	9	O
transcriptase	9	O
(	9	O
RT	9	O
)	9	O
primers	1	O
,	9	O
followed	9	O
by	9	O
direct	9	O
sequencing	9	O
across	5	O
the	5	O
tyrosine	3	B-Chemical
-	7	O
methionine	0	B-Chemical
-	7	O
aspartate	1	B-Chemical
-	7	O
aspartate	1	B-Chemical
(	9	O
YMDD	1	O
)	9	O
motif	1	O
of	5	O
the	5	O
major	9	O
catalytic	1	O
region	9	O
in	5	O
the	5	O
C	9	O
domain	1	O
of	5	O
the	5	O
HBV	9	O
RT	9	O
enzyme	0	O
.	9	O

HBV	9	O
viral	9	O
load	5	O
was	9	O
performed	9	O
with	5	O
Amplicor	5	O
HBV	9	O
Monitor	5	O
test	5	O
v2	9	O
.	9	O
0	7	O
(	9	O
Roche	0	O
Diagnostics	2	O
,	9	O
Penzberg	0	O
,	9	O
Germany	2	O
)	9	O
.	9	O

HBV	9	O
lamivudine	5	B-Chemical
-	7	O
resistant	9	O
strains	1	O
were	9	O
detected	9	O
in	5	O
3	9	O
of	5	O
15	9	O
mono	0	O
-	7	O
infected	3	O
chronic	5	O
hepatitis	9	B-Disease
B	9	I-Disease
patients	5	O
and	5	O
10	9	O
of	5	O
20	9	O
HBV	9	B-Disease
-	7	I-Disease
HIV	5	I-Disease
co	9	I-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
.	9	O

To	9	O
the	5	O
best	5	O
of	5	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
constitutes	9	O
the	5	O
first	9	O
report	5	O
of	5	O
HBV	9	O
lamivudine	5	B-Chemical
-	7	O
resistant	9	O
strains	1	O
in	5	O
therapy	5	O
-	7	O
na	7	B-Chemical
ve	9	O
HBV	9	B-Disease
-	7	I-Disease
HIV	5	I-Disease
co	9	I-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
.	9	O

The	5	O
HBV	9	O
viral	9	O
loads	9	O
for	5	O
mono	0	O
-	7	O
infected	3	O
and	5	O
co	9	O
-	7	O
infected	3	O
patients	5	O
ranged	9	O
from	9	O
3	9	O
.	9	O
32	7	O
x	9	O
10	9	O
(	9	O
2	9	O
)	9	O
to	5	O
3	9	O
.	9	O
82	7	O
x	9	O
10	9	O
(	9	O
7	9	O
)	9	O
and	5	O
<	0	O
200	0	O
to	5	O
4	9	O
.	9	O
40	9	O
x	9	O
10	9	O
(	9	O
3	9	O
)	9	O
copies	9	O
/	9	O
ml	0	O
,	9	O
respectively	9	O
.	9	O

It	5	O
remains	9	O
to	5	O
be	5	O
seen	9	O
whether	9	O
such	5	O
pre	9	O
-	7	O
existing	5	O
antiviral	9	O
mutations	1	O
could	9	O
result	9	O
in	5	O
widespread	5	O
emergence	9	O
of	5	O
HBV	9	O
resistant	9	O
strains	1	O
when	5	O
lamivudine	5	B-Chemical
-	7	O
containing	0	O
highly	9	O
active	9	O
antiretroviral	5	O
(	9	O
ARV	5	O
)	9	O
treatment	9	O
(	9	O
HAART	5	O
)	9	O
regimens	5	O
become	5	O
widely	5	O
applied	5	O
in	5	O
South	4	O
Africa	5	O
,	9	O
as	5	O
this	5	O
is	5	O
likely	5	O
to	5	O
have	5	O
potential	9	O
implications	5	O
in	5	O
the	5	O
management	5	O
of	5	O
HBV	9	B-Disease
-	7	I-Disease
HIV	5	I-Disease
co	9	I-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
.	9	O

Rabbit	3	B-Disease
syndrome	5	I-Disease
,	9	O
antidepressant	5	B-Chemical
use	5	O
,	9	O
and	5	O
cerebral	5	O
perfusion	5	O
SPECT	5	O
scan	5	O
findings	9	O
.	9	O

The	5	O
rabbit	3	B-Disease
syndrome	5	I-Disease
is	5	O
an	5	O
extrapyramidal	5	O
side	5	O
effect	9	O
associated	9	O
with	5	O
chronic	5	O
neuroleptic	5	O
therapy	5	O
.	9	O

Its	5	O
occurrence	5	O
in	5	O
a	5	O
patient	5	O
being	5	O
treated	3	O
with	5	O
imipramine	0	B-Chemical
is	5	O
described	9	O
,	9	O
representing	9	O
the	5	O
first	9	O
reported	9	O
case	5	O
of	5	O
this	5	O
syndrome	5	O
in	5	O
conjunction	9	O
with	5	O
antidepressants	5	B-Chemical
.	9	O

Repeated	5	O
cerebral	5	O
perfusion	5	O
SPECT	5	O
scans	5	O
revealed	9	O
decreased	9	B-Disease
basal	3	I-Disease
ganglia	5	I-Disease
perfusion	5	I-Disease
while	9	O
the	5	O
movement	5	B-Disease
disorder	5	I-Disease
was	9	O
present	9	O
,	9	O
and	5	O
a	5	O
return	5	O
to	5	O
normal	9	O
perfusion	5	O
when	5	O
the	5	O
rabbit	3	B-Disease
syndrome	5	I-Disease
resolved	9	O
.	9	O

Estrogen	9	O
prevents	9	O
cholesteryl	0	B-Chemical
ester	0	I-Chemical
accumulation	9	O
in	5	O
macrophages	3	O
induced	3	O
by	9	O
the	5	O
HIV	5	O
protease	0	O
inhibitor	3	O
ritonavir	0	B-Chemical
.	9	O

Individuals	5	O
with	5	O
HIV	5	O
can	5	O
now	5	O
live	9	O
long	5	O
lives	5	O
with	5	O
drug	5	O
therapy	5	O
that	5	O
often	5	O
includes	5	O
protease	0	O
inhibitors	3	O
such	5	O
as	5	O
ritonavir	0	B-Chemical
.	9	O

Many	5	O
patients	5	O
,	9	O
however	9	O
,	9	O
develop	5	O
negative	9	O
long	5	O
-	7	O
term	5	O
side	5	O
effects	9	O
such	5	O
as	5	O
premature	9	B-Disease
atherosclerosis	9	I-Disease
.	9	O

We	9	O
have	5	O
previously	9	O
demonstrated	9	O
that	5	O
ritonavir	0	B-Chemical
treatment	9	O
increases	9	O
atherosclerotic	3	B-Disease
lesion	5	I-Disease
formation	9	O
in	5	O
male	9	O
mice	3	O
to	5	O
a	5	O
greater	5	O
extent	9	O
than	5	O
in	5	O
female	9	O
mice	3	O
.	9	O

Furthermore	9	O
,	9	O
peripheral	9	O
blood	9	O
monocytes	3	O
isolated	9	O
from	9	O
ritonavir	0	B-Chemical
-	7	O
treated	3	O
females	9	O
had	9	O
less	5	O
cholesteryl	0	B-Chemical
ester	0	I-Chemical
accumulation	9	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
we	5	O
have	5	O
investigated	9	O
the	5	O
molecular	9	O
mechanisms	9	O
by	9	O
which	5	O
female	9	O
hormones	9	O
influence	5	O
cholesterol	0	B-Chemical
metabolism	9	O
in	5	O
macrophages	3	O
in	5	O
response	9	O
to	5	O
the	5	O
HIV	5	O
protease	0	O
inhibitor	3	O
ritonavir	0	B-Chemical
.	9	O

We	9	O
have	5	O
utilized	9	O
the	5	O
human	3	O
monocyte	3	O
cell	3	O
line	9	O
,	9	O
THP	0	O
-	7	O
1	9	O
as	5	O
a	5	O
model	5	O
to	5	O
address	5	O
this	5	O
question	5	O
.	9	O

Briefly	9	O
,	9	O
cells	3	O
were	9	O
differentiated	3	O
for	5	O
72	9	O
h	0	O
with	5	O
100	0	O
nM	0	O
PMA	3	O
to	5	O
obtain	5	O
a	5	O
macrophage	3	O
-	7	O
like	9	O
phenotype	3	O
in	5	O
the	5	O
presence	9	O
or	5	O
absence	3	O
of	5	O
1	9	O
nM	0	O
17beta	9	B-Chemical
-	7	I-Chemical
estradiol	0	I-Chemical
(	9	O
E2	3	B-Chemical
)	9	O
,	9	O
100	0	O
nM	0	O
progesterone	3	B-Chemical
or	5	O
vehicle	3	O
(	9	O
0	7	O
.	9	O
01	7	O
%	9	O
ethanol	0	B-Chemical
)	9	O
.	9	O

Cells	3	O
were	9	O
then	9	O
treated	3	O
with	5	O
30	9	O
ng	0	O
/	9	O
ml	0	O
ritonavir	0	B-Chemical
or	5	O
vehicle	3	O
in	5	O
the	5	O
presence	9	O
of	5	O
aggregated	5	O
LDL	0	O
for	5	O
24	9	O
h	0	O
.	9	O

Cell	3	O
extracts	0	O
were	9	O
harvested	3	O
,	9	O
and	5	O
lipid	0	O
or	5	O
total	9	O
RNA	9	O
was	9	O
isolated	9	O
.	9	O

E2	3	B-Chemical
decreased	9	O
the	5	O
accumulation	9	O
of	5	O
cholesteryl	0	B-Chemical
esters	0	I-Chemical
in	5	O
macrophages	3	O
following	9	O
ritonavir	0	B-Chemical
treatment	9	O
.	9	O

Ritonavir	0	B-Chemical
increased	9	O
the	5	O
expression	3	O
of	5	O
the	5	O
scavenger	0	O
receptor	3	O
,	9	O
CD36	3	O
mRNA	3	O
,	9	O
responsible	9	O
for	5	O
the	5	O
uptake	0	O
of	5	O
LDL	0	O
.	9	O

Additionally	9	O
,	9	O
ritonavir	0	B-Chemical
treatment	9	O
selectively	3	O
increased	9	O
the	5	O
relative	9	O
levels	3	O
of	5	O
PPARgamma	3	O
mRNA	3	O
,	9	O
a	5	O
transcription	1	O
factor	9	O
responsible	9	O
for	5	O
the	5	O
regulation	9	O
of	5	O
CD36	3	O
mRNA	3	O
expression	3	O
.	9	O

Treatment	9	O
with	5	O
E2	3	B-Chemical
,	9	O
however	9	O
,	9	O
failed	9	O
to	5	O
prevent	5	O
these	5	O
increases	9	O
at	9	O
the	5	O
mRNA	3	O
level	9	O
.	9	O

E2	3	B-Chemical
did	9	O
,	9	O
however	9	O
,	9	O
significantly	9	O
suppress	3	O
CD36	3	O
protein	1	O
levels	3	O
as	5	O
measured	9	O
by	9	O
fluorescent	3	O
immunocytochemistry	3	O
.	9	O

This	5	O
data	5	O
suggests	9	O
that	5	O
E2	3	B-Chemical
modifies	9	O
the	5	O
expression	3	O
of	5	O
CD36	3	O
at	9	O
the	5	O
level	9	O
of	5	O
protein	1	O
expression	3	O
in	5	O
monocyte	3	O
-	7	O
derived	9	O
macrophages	3	O
resulting	9	O
in	5	O
reduced	9	O
cholesteryl	0	B-Chemical
ester	0	I-Chemical
accumulation	9	O
following	9	O
ritonavir	0	B-Chemical
treatment	9	O
.	9	O

Acute	5	O
hepatitis	9	B-Disease
attack	5	O
after	9	O
exposure	9	O
to	5	O
telithromycin	0	B-Chemical
.	9	O

INTRODUCTION	5	O
:	9	O
Antibiotic	9	O
-	7	O
associated	9	O
hepatotoxicity	9	B-Disease
is	5	O
rare	5	O
.	9	O

With	5	O
widespread	5	O
use	5	O
of	5	O
antimicrobial	9	O
agents	5	O
,	9	O
however	9	O
,	9	O
hepatic	9	B-Disease
injury	9	I-Disease
occurs	9	O
frequently	5	O
,	9	O
and	5	O
among	5	O
adverse	5	B-Disease
drug	5	I-Disease
reactions	9	I-Disease
,	9	O
idiosyncratic	5	O
reactions	9	O
are	5	O
the	5	O
most	9	O
serious	5	O
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
25	9	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
patient	5	O
,	9	O
with	5	O
a	5	O
height	5	O
of	5	O
175	7	O
cm	9	O
and	5	O
weight	9	O
of	5	O
72	9	O
kg	0	O
presented	5	O
to	5	O
Marmara	2	O
University	2	O
Hospital	2	O
Emergency	2	O
Department	2	O
,	9	O
Istanbul	2	O
,	9	O
Turkey	4	O
,	9	O
with	5	O
5	9	O
days	9	O
'	9	O
history	5	O
of	5	O
jaundice	5	B-Disease
,	9	O
malaise	4	O
,	9	O
nausea	5	B-Disease
,	9	O
and	5	O
vomiting	5	B-Disease
.	9	O

He	5	O
had	9	O
been	9	O
prescribed	5	O
telithromycin	0	B-Chemical
400	0	O
mg	0	O
/	9	O
d	9	O
PO	9	O
to	5	O
treat	5	O
an	5	O
upper	9	B-Disease
respiratory	5	I-Disease
tract	9	I-Disease
infection	9	I-Disease
7	9	O
days	9	O
prior	9	O
.	9	O

Admission	7	O
laboratory	9	O
tests	5	O
were	9	O
as	5	O
follows	9	O
:	9	O
alanine	1	B-Chemical
aminotransferase	7	O
,	9	O
67	7	O
U	9	O
/	9	O
L	0	O
(	9	O
reference	9	O
range	9	O
,	9	O
10	9	O
-	7	O
37	9	O
U	9	O
/	9	O
L	0	O
)	9	O
;	9	O
aspartate	1	B-Chemical
aminotransferase	7	O
,	9	O
98	7	O
U	9	O
/	9	O
L	0	O
(	9	O
10	9	O
-	7	O
40	9	O
U	9	O
/	9	O
L	0	O
)	9	O
;	9	O
alkaline	0	O
phosphatase	0	O
,	9	O
513	7	O
U	9	O
/	9	O
L	0	O
(	9	O
0	7	O
-	7	O
270	9	O
U	9	O
/	9	O
L	0	O
)	9	O
;	9	O
gamma	9	O
-	7	O
glutamyltransferase	7	O
,	9	O
32	7	O
U	9	O
/	9	O
L	0	O
(	9	O
7	9	O
-	7	O
49	7	O
U	9	O
/	9	O
L	0	O
)	9	O
;	9	O
amylase	9	O
,	9	O
46	7	O
U	9	O
/	9	O
L	0	O
(	9	O
0	7	O
-	7	O
220	9	O
U	9	O
/	9	O
L	0	O
)	9	O
;	9	O
total	9	O
bilirubin	0	B-Chemical
,	9	O
20	9	O
.	9	O
1	9	O
mg	0	O
/	9	O
dL	7	O
(	9	O
0	7	O
.	9	O
2	9	O
-	7	O
1	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
dL	7	O
)	9	O
;	9	O
direct	9	O
bilirubin	0	B-Chemical
,	9	O
14	7	O
.	9	O
8	9	O
mg	0	O
/	9	O
dL	7	O
(	9	O
0	7	O
-	7	O
0	7	O
.	9	O
3	9	O
mg	0	O
/	9	O
dL	7	O
)	9	O
;	9	O
and	5	O
albumin	0	O
,	9	O
4	9	O
.	9	O
7	9	O
mg	0	O
/	9	O
dL	7	O
(	9	O
3	9	O
.	9	O
5	9	O
-	7	O
5	9	O
.	9	O
4	9	O
mg	0	O
/	9	O
dL	7	O
)	9	O
.	9	O

No	9	O
toxin	1	O
,	9	O
alcohol	5	B-Chemical
,	9	O
or	5	O
other	5	O
drugs	5	O
were	9	O
reported	9	O
.	9	O

The	5	O
patient	5	O
had	9	O
suffered	5	O
a	5	O
previous	9	O
episode	5	O
of	5	O
"	5	O
acute	9	O
hepatitis	9	B-Disease
of	5	O
unknown	9	O
origin	9	O
,	9	O
"	5	O
that	5	O
occurred	9	O
after	9	O
telithromycin	0	B-Chemical
usage	9	O
.	9	O

Both	9	O
incidents	5	O
occurred	9	O
within	9	O
a	5	O
year	5	O
.	9	O

DISCUSSION	9	O
:	9	O
Telithromycin	7	B-Chemical
is	5	O
the	5	O
first	9	O
of	5	O
the	5	O
ketolide	5	O
antibacterials	5	O
to	5	O
receive	5	O
US	5	O
Food	5	O
and	5	O
Drug	5	O
Administration	2	O
approval	5	O
for	5	O
clinical	5	O
use	5	O
.	9	O

It	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
infrequent	5	O
and	5	O
usually	5	O
reversible	9	O
severe	5	O
hepatic	9	B-Disease
dysfunction	9	I-Disease
.	9	O

Based	9	O
on	5	O
a	5	O
score	5	O
of	5	O
8	9	O
on	5	O
the	5	O
Naranjo	6	O
adverse	5	B-Disease
drug	5	I-Disease
reaction	9	I-Disease
probability	5	O
scale	5	O
,	9	O
telithromycin	0	B-Chemical
was	9	O
the	5	O
probable	9	O
cause	5	O
of	5	O
acute	9	O
hepatitis	9	B-Disease
in	5	O
this	5	O
patient	5	O
,	9	O
and	5	O
pathological	5	O
findings	9	O
suggested	9	O
drug	5	O
-	7	O
induced	3	O
toxic	0	B-Disease
hepatitis	9	I-Disease
.	9	O

Recurrence	5	O
of	5	O
hepatitis	9	B-Disease
attack	5	O
might	9	O
have	5	O
been	9	O
avoided	5	O
if	5	O
the	5	O
initial	9	O
incident	5	O
had	9	O
been	9	O
communicated	5	O
to	5	O
the	5	O
attending	5	O
physician	5	O
who	5	O
prescribed	5	O
telithromycin	0	B-Chemical
the	5	O
second	9	O
time	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Here	9	O
we	5	O
report	5	O
a	5	O
case	5	O
of	5	O
acute	9	O
hepatitis	9	B-Disease
probably	9	O
associated	9	O
with	5	O
the	5	O
administration	9	O
of	5	O
telithromycin	0	B-Chemical
.	9	O

A	9	O
study	9	O
on	5	O
the	5	O
effect	9	O
of	5	O
the	5	O
duration	5	O
of	5	O
subcutaneous	9	O
heparin	0	B-Chemical
injection	9	O
on	5	O
bruising	5	B-Disease
and	5	O
pain	5	B-Disease
.	9	O

AIM	9	O
:	9	O
This	5	O
study	9	O
was	9	O
carried	9	O
out	9	O
to	5	O
determine	9	O
the	5	O
effect	9	O
of	5	O
injection	9	O
duration	5	O
on	5	O
bruising	5	B-Disease
and	5	O
pain	5	B-Disease
following	9	O
the	5	O
administration	9	O
of	5	O
the	5	O
subcutaneous	9	O
injection	9	O
of	5	O
heparin	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Although	9	O
different	9	O
methods	5	O
to	5	O
prevent	5	O
bruising	5	B-Disease
and	5	O
pain	5	B-Disease
following	9	O
the	5	O
subcutaneous	9	O
injection	9	O
of	5	O
heparin	0	B-Chemical
have	5	O
been	9	O
widely	5	O
studied	9	O
and	5	O
described	9	O
,	9	O
the	5	O
effect	9	O
of	5	O
injection	9	O
duration	5	O
on	5	O
the	5	O
occurrence	5	O
of	5	O
bruising	5	B-Disease
and	5	O
pain	5	B-Disease
is	5	O
little	9	O
documented	9	O
.	9	O

DESIGN	2	O
:	9	O
This	5	O
study	9	O
was	9	O
designed	9	O
as	5	O
within	9	O
-	7	O
subject	5	O
,	9	O
quasi	5	O
-	7	O
experimental	5	O
research	5	O
.	9	O

METHOD	2	O
:	9	O
The	5	O
sample	9	O
for	5	O
the	5	O
study	9	O
consisted	5	O
of	5	O
50	0	O
patients	5	O
to	5	O
whom	5	O
subcutaneous	9	O
heparin	0	B-Chemical
was	9	O
administered	9	O
.	9	O

Heparin	0	B-Chemical
was	9	O
injected	3	O
over	5	O
10	9	O
seconds	5	O
on	5	O
the	5	O
right	5	O
abdominal	5	O
site	9	O
and	5	O
30	9	O
seconds	5	O
on	5	O
the	5	O
left	5	O
abdominal	5	O
site	9	O
.	9	O

Injections	9	O
areas	5	O
were	9	O
assessed	9	O
for	5	O
the	5	O
presence	9	O
of	5	O
bruising	5	B-Disease
at	9	O
48	9	O
and	5	O
72	9	O
hours	9	O
after	9	O
each	5	O
injection	9	O
.	9	O

Dimensions	5	O
of	5	O
the	5	O
bruising	5	B-Disease
on	5	O
the	5	O
heparin	0	B-Chemical
applied	5	O
areas	5	O
were	9	O
measured	9	O
using	9	O
transparent	5	O
millimetric	5	O
measuring	9	O
paper	5	O
.	9	O

The	5	O
visual	5	O
analog	0	O
scale	5	O
(	9	O
VAS	5	O
)	9	O
was	9	O
used	5	O
to	5	O
measure	5	O
pain	5	B-Disease
intensity	5	O
and	5	O
a	5	O
stop	9	O
-	7	O
watch	5	O
was	9	O
used	5	O
to	5	O
time	5	O
the	5	O
pain	5	B-Disease
period	5	O
.	9	O

Data	5	O
were	9	O
analysed	9	O
using	9	O
chi	5	O
-	7	O
square	5	O
test	5	O
,	9	O
Mann	9	O
-	7	O
Whitney	9	O
U	9	O
,	9	O
Wilcoxon	5	O
signed	5	O
ranks	5	O
tests	5	O
and	5	O
correlation	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
percentage	9	O
of	5	O
bruising	5	B-Disease
occurrence	5	O
was	9	O
64	7	O
%	9	O
with	5	O
the	5	O
injection	9	O
of	5	O
10	9	O
seconds	5	O
duration	5	O
and	5	O
42	7	O
%	9	O
in	5	O
the	5	O
30	9	O
-	7	O
second	9	O
injection	9	O
.	9	O

It	5	O
was	9	O
determined	9	O
that	5	O
the	5	O
size	9	O
of	5	O
the	5	O
bruising	5	B-Disease
was	9	O
smaller	5	O
in	5	O
the	5	O
30	9	O
-	7	O
second	9	O
injection	9	O
.	9	O

Pain	5	B-Disease
intensity	5	O
and	5	O
pain	5	B-Disease
period	5	O
were	9	O
statistically	9	O
significantly	9	O
lower	9	O
for	5	O
the	5	O
30	9	O
-	7	O
second	9	O
injection	9	O
than	5	O
for	5	O
the	5	O
10	9	O
-	7	O
second	9	O
injection	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
It	5	O
was	9	O
determined	9	O
that	5	O
injection	9	O
duration	5	O
had	9	O
an	5	O
effect	9	O
on	5	O
bruising	5	B-Disease
and	5	O
pain	5	B-Disease
following	9	O
the	5	O
subcutaneous	9	O
administration	9	O
of	5	O
heparin	0	B-Chemical
.	9	O

This	5	O
study	9	O
should	5	O
be	5	O
repeated	5	O
on	5	O
a	5	O
larger	5	O
sample	9	O
.	9	O

RELEVANCE	2	O
TO	2	O
CLINICAL	2	O
PRACTICE	2	O
:	9	O
When	9	O
administering	9	O
subcutaneous	9	O
heparin	0	B-Chemical
injections	9	O
,	9	O
it	5	O
is	5	O
important	9	O
to	5	O
extend	9	O
the	5	O
duration	5	O
of	5	O
the	5	O
injection	9	O
.	9	O

Acute	5	B-Disease
liver	9	I-Disease
failure	5	I-Disease
in	5	O
two	5	O
patients	5	O
with	5	O
regular	5	O
alcohol	5	B-Chemical
consumption	5	O
ingesting	5	O
paracetamol	0	B-Chemical
at	9	O
therapeutic	5	O
dosage	9	O
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
possible	5	O
role	9	O
of	5	O
alcohol	5	B-Chemical
in	5	O
the	5	O
development	9	O
of	5	O
hepatotoxicity	9	B-Disease
associated	9	O
with	5	O
therapeutic	5	O
doses	0	O
of	5	O
paracetamol	0	B-Chemical
(	9	O
acetaminophen	0	B-Chemical
)	9	O
is	5	O
currently	5	O
debated	5	O
.	9	O

CASE	2	O
REPORT	5	O
:	9	O
We	9	O
describe	5	O
2	9	O
patients	5	O
who	5	O
were	9	O
regular	5	O
consumers	5	O
of	5	O
alcohol	5	B-Chemical
and	5	O
who	5	O
developed	5	O
liver	9	B-Disease
failure	5	I-Disease
within	9	O
3	9	O
-	7	O
5	9	O
days	9	O
after	9	O
hospitalization	5	O
and	5	O
stopping	5	O
alcohol	5	B-Chemical
consumption	5	O
while	9	O
being	5	O
treated	3	O
with	5	O
4	9	O
g	0	O
paracetamol	0	B-Chemical
/	9	O
day	9	O
.	9	O

A	9	O
paracetamol	0	B-Chemical
serum	9	O
level	9	O
obtained	9	O
in	5	O
one	5	O
of	5	O
these	5	O
patients	5	O
was	9	O
not	5	O
in	5	O
the	5	O
toxic	0	O
range	9	O
.	9	O

Possible	9	O
risk	5	O
factors	9	O
for	5	O
the	5	O
development	9	O
of	5	O
hepatotoxicity	9	B-Disease
in	5	O
patients	5	O
treated	3	O
with	5	O
therapeutic	5	O
doses	0	O
of	5	O
paracetamol	0	B-Chemical
are	5	O
discussed	5	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
patients	5	O
with	5	O
risk	5	O
factors	9	O
,	9	O
e	9	O
.	9	O
g	0	O
.	9	O
regular	5	O
consumption	5	O
of	5	O
alcohol	5	B-Chemical
,	9	O
liver	9	B-Disease
failure	5	I-Disease
is	5	O
possible	5	O
when	5	O
therapeutic	5	O
doses	0	O
are	5	O
ingested	0	O
.	9	O

We	9	O
propose	9	O
that	5	O
the	5	O
paracetamol	0	B-Chemical
dose	9	O
should	5	O
not	5	O
exceed	5	O
2	9	O
g	0	O
/	9	O
day	9	O
in	5	O
such	5	O
patients	5	O
and	5	O
that	5	O
their	5	O
liver	9	O
function	9	O
should	5	O
be	5	O
monitored	9	O
closely	9	O
while	9	O
being	5	O
treated	3	O
with	5	O
paracetamol	0	B-Chemical
.	9	O

Associations	5	O
between	5	O
use	5	O
of	5	O
benzodiazepines	5	B-Chemical
or	5	O
related	9	O
drugs	5	O
and	5	O
health	5	O
,	9	O
physical	5	O
abilities	5	O
and	5	O
cognitive	5	O
function	9	O
:	9	O
a	5	O
non	9	O
-	7	O
randomised	5	O
clinical	5	O
study	9	O
in	5	O
the	5	O
elderly	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
describe	5	O
associations	5	O
between	5	O
the	5	O
use	5	O
of	5	O
benzodiazepines	5	B-Chemical
or	5	O
related	9	O
drugs	5	O
(	9	O
BZDs	5	B-Chemical
/	9	O
RDs	5	O
)	9	O
and	5	O
health	5	O
,	9	O
functional	9	O
abilities	5	O
and	5	O
cognitive	5	O
function	9	O
in	5	O
the	5	O
elderly	5	O
.	9	O

METHODS	2	O
:	9	O
A	9	O
non	9	O
-	7	O
randomised	5	O
clinical	5	O
study	9	O
of	5	O
patients	5	O
aged	9	O
>	0	O
or	5	O
=	7	O
65	7	O
years	5	O
admitted	5	O
to	5	O
acute	9	O
hospital	5	O
wards	5	O
during	5	O
1	9	O
month	5	O
.	9	O

164	7	O
patients	5	O
(	9	O
mean	5	O
age	5	O
+	9	O
/	9	O
-	7	O
standard	5	O
deviation	5	O
[	9	O
SD	7	O
]	9	O
81	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
8	9	O
years	5	O
)	9	O
were	9	O
admitted	5	O
.	9	O

Of	9	O
these	5	O
,	9	O
nearly	9	O
half	5	O
(	9	O
n	9	O
=	7	O
78	7	O
)	9	O
had	9	O
used	5	O
BZDs	5	B-Chemical
/	9	O
RDs	5	O
before	9	O
admission	5	O
,	9	O
and	5	O
the	5	O
remainder	9	O
(	9	O
n	9	O
=	7	O
86	7	O
)	9	O
were	9	O
non	9	O
-	7	O
users	5	O
.	9	O

Cognitive	5	O
ability	9	O
was	9	O
assessed	9	O
by	9	O
the	5	O
Mini	0	O
-	7	O
Mental	5	O
State	2	O
Examination	9	O
(	9	O
MMSE	5	O
)	9	O
.	9	O

Patients	5	O
scoring	5	O
>	0	O
or	5	O
=	7	O
20	9	O
MMSE	5	O
sum	5	O
points	5	O
were	9	O
interviewed	5	O
(	9	O
n	9	O
=	7	O
79	7	O
)	9	O
and	5	O
questioned	5	O
regarding	5	O
symptoms	5	O
and	5	O
functional	9	O
abilities	5	O
during	5	O
the	5	O
week	9	O
prior	9	O
to	5	O
admission	5	O
.	9	O

Data	5	O
on	5	O
use	5	O
of	5	O
BZDs	5	B-Chemical
/	9	O
RDs	5	O
before	9	O
admission	5	O
,	9	O
current	5	O
medications	5	O
and	5	O
discharge	5	O
diagnoses	5	O
were	9	O
collected	9	O
from	9	O
medical	5	O
records	5	O
.	9	O

Health	2	O
,	9	O
physical	5	O
abilities	5	O
and	5	O
cognitive	5	O
function	9	O
were	9	O
compared	9	O
between	5	O
BZD	5	O
/	9	O
RD	9	O
users	5	O
and	5	O
non	9	O
-	7	O
users	5	O
,	9	O
and	5	O
adjustments	5	O
were	9	O
made	5	O
for	5	O
confounding	5	O
variables	5	O
.	9	O

The	5	O
residual	9	O
serum	9	O
concentrations	0	O
of	5	O
oxazepam	0	B-Chemical
,	9	O
temazepam	0	B-Chemical
and	5	O
zopiclone	5	B-Chemical
were	9	O
analysed	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
duration	5	O
of	5	O
BZD	5	O
/	9	O
RD	9	O
use	5	O
was	9	O
7	9	O
+	9	O
/	9	O
-	7	O
7	9	O
years	5	O
(	9	O
range	9	O
1	9	O
-	7	O
31	7	O
)	9	O
.	9	O

Two	9	O
or	5	O
three	9	O
BZDs	5	B-Chemical
/	9	O
RDs	5	O
were	9	O
concomitantly	9	O
taken	5	O
by	9	O
26	7	O
%	9	O
of	5	O
users	5	O
(	9	O
n	9	O
=	7	O
20	9	O
)	9	O
.	9	O

Long	9	O
-	7	O
term	5	O
use	5	O
of	5	O
these	5	O
drugs	5	O
was	9	O
associated	9	O
with	5	O
female	9	O
sex	5	O
and	5	O
use	5	O
of	5	O
a	5	O
higher	9	O
number	9	O
of	5	O
drugs	5	O
with	5	O
effects	9	O
on	5	O
the	5	O
CNS	9	O
,	9	O
which	5	O
tended	5	O
to	5	O
be	5	O
related	9	O
to	5	O
diagnosed	5	O
dementia	5	B-Disease
.	9	O

After	9	O
adjustment	5	O
for	5	O
these	5	O
variables	5	O
as	5	O
confounders	5	O
,	9	O
use	5	O
of	5	O
BZDs	5	B-Chemical
/	9	O
RDs	5	O
was	9	O
not	5	O
associated	9	O
with	5	O
cognitive	5	O
function	9	O
as	5	O
measured	9	O
by	9	O
the	5	O
MMSE	5	O
.	9	O

However	9	O
,	9	O
use	5	O
of	5	O
BZDs	5	B-Chemical
/	9	O
RDs	5	O
was	9	O
associated	9	O
with	5	O
dizziness	5	B-Disease
,	9	O
inability	9	B-Disease
to	5	I-Disease
sleep	5	I-Disease
after	9	O
awaking	5	O
at	9	O
night	5	O
and	5	O
tiredness	5	B-Disease
in	5	O
the	5	O
mornings	5	O
during	5	O
the	5	O
week	9	O
prior	9	O
to	5	O
admission	5	O
and	5	O
with	5	O
stronger	9	O
depressive	5	B-Disease
symptoms	5	I-Disease
measured	9	O
at	9	O
the	5	O
beginning	5	O
of	5	O
the	5	O
hospital	5	O
stay	5	O
.	9	O

Use	5	O
of	5	O
BZDs	5	B-Chemical
/	9	O
RDs	5	O
tended	5	O
to	5	O
be	5	O
associated	9	O
with	5	O
a	5	O
reduced	9	O
ability	9	O
to	5	O
walk	5	O
and	5	O
shorter	9	O
night	5	O
-	7	O
time	5	O
sleep	5	O
during	5	O
the	5	O
week	9	O
prior	9	O
to	5	O
admission	5	O
.	9	O

A	9	O
higher	9	O
residual	9	O
serum	9	O
concentration	0	O
of	5	O
temazepam	0	B-Chemical
correlated	9	O
with	5	O
a	5	O
lower	9	O
MMSE	5	O
sum	5	O
score	5	O
after	9	O
adjustment	5	O
for	5	O
confounding	5	O
variables	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Long	9	O
-	7	O
term	5	O
use	5	O
and	5	O
concomitant	9	O
use	5	O
of	5	O
more	5	O
than	5	O
one	5	O
BZD	5	O
/	9	O
RD	9	O
were	9	O
common	5	O
in	5	O
elderly	5	O
patients	5	O
hospitalised	5	O
because	5	O
of	5	O
acute	9	O
illnesses	5	O
.	9	O

Long	9	O
-	7	O
term	5	O
use	5	O
was	9	O
associated	9	O
with	5	O
daytime	5	O
and	5	O
night	5	O
-	7	O
time	5	O
symptoms	5	O
indicative	9	O
of	5	O
poorer	5	O
health	5	O
and	5	O
potentially	5	O
caused	9	O
by	9	O
the	5	O
adverse	5	O
effects	9	O
of	5	O
these	5	O
drugs	5	O
.	9	O

Acute	5	O
vocal	5	B-Disease
fold	9	I-Disease
palsy	5	I-Disease
after	9	O
acute	9	O
disulfiram	0	B-Chemical
intoxication	9	O
.	9	O

Acute	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
caused	9	O
by	9	O
a	5	O
disulfiram	0	B-Chemical
overdose	0	B-Disease
is	5	O
very	5	O
rare	5	O
and	5	O
there	5	O
is	5	O
no	9	O
report	5	O
of	5	O
it	5	O
leading	9	O
to	5	O
vocal	5	B-Disease
fold	9	I-Disease
palsy	5	I-Disease
.	9	O

A	9	O
49	7	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
was	9	O
transferred	9	O
to	5	O
our	5	O
department	5	O
because	5	O
of	5	O
quadriparesis	5	B-Disease
,	9	O
lancinating	5	O
pain	5	B-Disease
,	9	O
sensory	5	B-Disease
loss	9	I-Disease
,	9	O
and	5	O
paresthesia	5	B-Disease
of	5	O
the	5	O
distal	9	O
limbs	5	O
.	9	O

One	5	O
month	5	O
previously	9	O
,	9	O
she	5	O
had	9	O
taken	5	O
a	5	O
single	9	O
high	9	O
dose	9	O
of	5	O
disulfiram	0	B-Chemical
(	9	O
130	9	O
tablets	0	O
of	5	O
ALCOHOL	2	B-Chemical
STOP	1	O
TAB	2	O
,	9	O
Shin	6	O
-	7	O
Poong	2	O
Pharm	2	O
.	9	O
Co	0	O
.	9	O
,	9	O
Ansan	2	O
,	9	O
Korea	2	O
)	9	O
in	5	O
a	5	O
suicide	5	O
attempt	5	O
.	9	O

She	5	O
was	9	O
not	5	O
an	5	O
alcoholic	5	O
.	9	O

For	9	O
the	5	O
first	9	O
few	5	O
days	9	O
after	9	O
ingestion	9	O
,	9	O
she	5	O
was	9	O
in	5	O
a	5	O
confused	4	O
state	5	O
and	5	O
had	9	O
mild	9	O
to	5	O
moderate	9	O
ataxia	5	B-Disease
and	5	O
giddiness	5	B-Disease
.	9	O

She	5	O
noticed	9	O
hoarseness	5	B-Disease
and	5	O
distally	5	O
accentuated	5	O
motor	5	O
and	5	O
sensory	5	O
dysfunction	9	O
after	9	O
she	5	O
had	9	O
recovered	9	O
from	9	O
this	5	O
state	5	O
.	9	O

A	9	O
nerve	5	O
conduction	5	O
study	9	O
was	9	O
consistent	9	O
with	5	O
severe	5	O
sensorimotor	5	O
axonal	3	O
polyneuropathy	5	B-Disease
.	9	O

Laryngeal	5	O
electromyography	5	O
(	9	O
thyroarytenoid	5	O
muscle	9	O
)	9	O
showed	9	O
ample	5	O
denervation	5	O
potentials	5	O
.	9	O

Laryngoscopy	5	O
revealed	9	O
asymmetric	9	O
vocal	5	O
fold	9	O
movements	5	O
during	5	O
phonation	5	O
.	9	O

Her	5	O
vocal	5	O
change	9	O
and	5	O
weakness	5	O
began	5	O
to	5	O
improve	5	O
spontaneously	5	O
about	5	O
3	9	O
weeks	9	O
after	9	O
transfer	9	O
.	9	O

This	5	O
was	9	O
a	5	O
case	5	O
of	5	O
acute	9	O
palsy	5	B-Disease
of	5	O
the	5	O
recurrent	5	O
laryngeal	5	O
nerve	5	O
and	5	O
superimposed	5	O
severe	5	O
acute	9	O
sensorimotor	5	O
axonal	3	O
polyneuropathy	5	B-Disease
caused	9	O
by	9	O
high	9	O
-	7	O
dose	9	O
disulfiram	0	B-Chemical
intoxication	9	O
.	9	O

Encephalopathy	5	B-Disease
induced	3	O
by	9	O
levetiracetam	5	B-Chemical
added	0	O
to	5	O
valproate	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
We	9	O
report	5	O
on	5	O
the	5	O
manifestation	5	O
of	5	O
a	5	O
levetiracetam	5	B-Chemical
(	9	O
LEV	0	B-Chemical
)	9	O
-	7	O
induced	3	O
encephalopathy	5	B-Disease
.	9	O

FINDINGS	2	O
:	9	O
A	9	O
28	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
suffering	5	O
from	9	O
idiopathic	5	B-Disease
epilepsy	5	I-Disease
with	5	O
generalized	5	O
seizures	5	B-Disease
was	9	O
treated	3	O
with	5	O
LEV	0	B-Chemical
(	9	O
3000	0	O
mg	0	O
)	9	O
added	0	O
to	5	O
valproate	0	B-Chemical
(	9	O
VPA	9	B-Chemical
)	9	O
(	9	O
2000	9	O
mg	0	O
)	9	O
.	9	O

Frequency	5	O
of	5	O
generalized	5	O
tonic	5	B-Disease
-	7	I-Disease
clonic	5	I-Disease
seizures	5	I-Disease
increased	9	O
from	9	O
one	5	O
per	9	O
6	9	O
months	5	O
to	5	O
two	5	O
per	9	O
month	5	O
.	9	O

Neuropsychological	5	O
testing	5	O
showed	9	O
impaired	9	B-Disease
word	5	I-Disease
fluency	5	I-Disease
,	9	I-Disease
psychomotor	5	I-Disease
speed	5	I-Disease
and	5	I-Disease
working	5	I-Disease
memory	5	I-Disease
.	9	O

The	5	O
interictal	5	O
electroencephalogram	5	O
(	9	O
EEG	5	O
)	9	O
showed	9	O
a	5	O
generalized	5	O
slowing	5	O
to	5	O
5	9	O
per	9	O
second	9	O
theta	5	O
rhythms	5	O
with	5	O
bilateral	5	O
generalized	5	O
high	9	O
-	7	O
amplitude	5	O
discharges	5	O
.	9	O

OUTCOME	2	O
:	9	O
Following	9	O
discontinuation	5	O
of	5	O
LEV	0	B-Chemical
,	9	O
EEG	5	O
and	5	O
neuropsychological	5	O
findings	9	O
improved	5	O
and	5	O
seizure	5	B-Disease
frequency	5	O
decreased	9	O
.	9	O

Norepinephrine	0	B-Chemical
signaling	3	O
through	9	O
beta	9	O
-	7	O
adrenergic	9	O
receptors	3	O
is	5	O
critical	9	O
for	5	O
expression	3	O
of	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
anxiety	5	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Cocaine	5	B-Chemical
is	5	O
a	5	O
widely	5	O
abused	5	O
psychostimulant	5	O
that	5	O
has	9	O
both	9	O
rewarding	5	O
and	5	O
aversive	5	O
properties	9	O
.	9	O

While	9	O
the	5	O
mechanisms	9	O
underlying	5	O
cocaine	5	B-Chemical
'	9	O
s	9	O
rewarding	5	O
effects	9	O
have	5	O
been	9	O
studied	9	O
extensively	9	O
,	9	O
less	5	O
attention	5	O
has	9	O
been	9	O
paid	5	O
to	5	O
the	5	O
unpleasant	5	O
behavioral	5	O
states	5	O
induced	3	O
by	9	O
cocaine	5	B-Chemical
,	9	O
such	5	O
as	5	O
anxiety	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
evaluated	9	O
the	5	O
performance	5	O
of	5	O
dopamine	5	B-Chemical
beta	9	O
-	7	O
hydroxylase	1	O
knockout	3	O
(	9	O
Dbh	1	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
,	9	O
which	5	O
lack	9	O
norepinephrine	9	B-Chemical
(	9	O
NE	9	B-Chemical
)	9	O
,	9	O
in	5	O
the	5	O
elevated	9	O
plus	9	O
maze	5	O
(	9	O
EPM	9	O
)	9	O
to	5	O
examine	9	O
the	5	O
contribution	9	O
of	5	O
noradrenergic	5	O
signaling	3	O
to	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
anxiety	5	B-Disease
.	9	O

RESULTS	9	O
:	9	O
We	9	O
found	9	O
that	5	O
cocaine	5	B-Chemical
dose	9	O
-	7	O
dependently	3	O
increased	9	O
anxiety	5	B-Disease
-	7	O
like	9	O
behavior	5	O
in	5	O
control	9	O
(	9	O
Dbh	1	O
+	9	O
/	9	O
-	7	O
)	9	O
mice	3	O
,	9	O
as	5	O
measured	9	O
by	9	O
a	5	O
decrease	9	O
in	5	O
open	5	O
arm	5	O
exploration	5	O
.	9	O

The	5	O
Dbh	1	O
-	7	O
/	9	O
-	7	O
mice	3	O
had	9	O
normal	9	O
baseline	5	O
performance	5	O
in	5	O
the	5	O
EPM	9	O
but	9	O
were	9	O
completely	9	O
resistant	9	O
to	5	O
the	5	O
anxiogenic	5	O
effects	9	O
of	5	O
cocaine	5	B-Chemical
.	9	O

Cocaine	5	B-Chemical
-	7	O
induced	3	O
anxiety	5	B-Disease
was	9	O
also	9	O
attenuated	3	O
in	5	O
Dbh	1	O
+	9	O
/	9	O
-	7	O
mice	3	O
following	9	O
administration	9	O
of	5	O
disulfiram	0	B-Chemical
,	9	O
a	5	O
dopamine	5	B-Chemical
beta	9	O
-	7	O
hydroxylase	1	O
(	9	O
DBH	9	O
)	9	O
inhibitor	3	O
.	9	O

In	9	O
experiments	9	O
using	9	O
specific	9	O
adrenergic	9	O
antagonists	3	O
,	9	O
we	5	O
found	9	O
that	5	O
pretreatment	0	O
with	5	O
the	5	O
beta	9	O
-	7	O
adrenergic	9	O
receptor	3	O
antagonist	3	O
propranolol	0	B-Chemical
blocked	3	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
anxiety	5	B-Disease
-	7	O
like	9	O
behavior	5	O
in	5	O
Dbh	1	O
+	9	O
/	9	O
-	7	O
and	5	O
wild	1	O
-	7	O
type	9	O
C57BL6	3	O
/	9	O
J	9	O
mice	3	O
,	9	O
while	9	O
the	5	O
alpha	9	O
(	9	O
1	9	O
)	9	O
antagonist	3	O
prazosin	0	B-Chemical
and	5	O
the	5	O
alpha	9	O
(	9	O
2	9	O
)	9	O
antagonist	3	O
yohimbine	0	B-Chemical
had	9	O
no	9	O
effect	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
results	9	O
indicate	9	O
that	5	O
noradrenergic	5	O
signaling	3	O
via	9	O
beta	9	O
-	7	O
adrenergic	9	O
receptors	3	O
is	5	O
required	9	O
for	5	O
cocaine	5	B-Chemical
-	7	O
induced	3	O
anxiety	5	B-Disease
in	5	O
mice	3	O
.	9	O

Hypothalamic	3	O
prolactin	3	O
receptor	3	O
messenger	9	O
ribonucleic	0	B-Chemical
acid	0	I-Chemical
levels	3	O
,	9	O
prolactin	3	O
signaling	3	O
,	9	O
and	5	O
hyperprolactinemic	3	B-Disease
inhibition	3	O
of	5	O
pulsatile	5	O
luteinizing	0	O
hormone	9	O
secretion	3	O
are	5	O
dependent	9	O
on	5	O
estradiol	0	B-Chemical
.	9	O

Hyperprolactinemia	5	B-Disease
can	5	O
reduce	5	O
fertility	5	O
and	5	O
libido	5	O
.	9	O

Although	9	O
central	5	O
prolactin	3	O
actions	5	O
are	5	O
thought	5	O
to	5	O
contribute	9	O
to	5	O
this	5	O
,	9	O
the	5	O
mechanisms	9	O
are	5	O
poorly	9	O
understood	5	O
.	9	O

We	9	O
first	9	O
tested	9	O
whether	9	O
chronic	5	O
hyperprolactinemia	5	B-Disease
inhibited	3	O
two	5	O
neuroendocrine	5	O
parameters	5	O
necessary	5	O
for	5	O
female	9	O
fertility	5	O
:	9	O
pulsatile	5	O
LH	9	O
secretion	3	O
and	5	O
the	5	O
estrogen	3	B-Chemical
-	7	O
induced	3	O
LH	9	O
surge	5	O
.	9	O

Chronic	9	O
hyperprolactinemia	5	B-Disease
induced	3	O
by	9	O
the	5	O
dopamine	5	B-Chemical
antagonist	3	O
sulpiride	0	B-Chemical
caused	9	O
a	5	O
40	9	O
%	9	O
reduction	9	O
LH	9	O
pulse	5	O
frequency	5	O
in	5	O
ovariectomized	3	O
rats	9	O
,	9	O
but	9	O
only	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
chronic	5	O
low	9	O
levels	3	O
of	5	O
estradiol	0	B-Chemical
.	9	O

Sulpiride	7	B-Chemical
did	9	O
not	5	O
affect	9	O
the	5	O
magnitude	5	O
of	5	O
a	5	O
steroid	9	B-Chemical
-	7	O
induced	3	O
LH	9	O
surge	5	O
or	5	O
the	5	O
percentage	9	O
of	5	O
GnRH	3	O
neurons	3	O
activated	3	O
during	5	O
the	5	O
surge	5	O
.	9	O

Estradiol	0	B-Chemical
is	5	O
known	9	O
to	5	O
influence	5	O
expression	3	O
of	5	O
the	5	O
long	5	O
form	9	O
of	5	O
prolactin	3	O
receptors	3	O
(	9	O
PRL	3	O
-	7	O
R	9	O
)	9	O
and	5	O
components	5	O
of	5	O
prolactin	3	O
'	9	O
s	9	O
signaling	3	O
pathway	3	O
.	9	O

To	9	O
test	5	O
the	5	O
hypothesis	9	O
that	5	O
estrogen	3	B-Chemical
increases	9	O
PRL	3	O
-	7	O
R	9	O
expression	3	O
and	5	O
sensitivity	9	O
to	5	O
prolactin	3	O
,	9	O
we	5	O
next	9	O
demonstrated	9	O
that	5	O
estradiol	0	B-Chemical
greatly	9	O
augments	3	O
prolactin	3	O
-	7	O
induced	3	O
STAT5	3	O
activation	3	O
.	9	O

Lastly	9	O
,	9	O
we	5	O
measured	9	O
PRL	3	O
-	7	O
R	9	O
and	5	O
suppressor	3	O
of	5	O
cytokine	3	O
signaling	3	O
(	9	O
SOCS	1	O
-	7	O
1	9	O
and	5	O
-	7	O
3	9	O
and	5	O
CIS	9	O
,	9	O
which	5	O
reflect	5	O
the	5	O
level	9	O
of	5	O
prolactin	3	O
signaling	3	O
)	9	O
mRNAs	3	O
in	5	O
response	9	O
to	5	O
sulpiride	0	B-Chemical
and	5	O
estradiol	0	B-Chemical
.	9	O

Sulpiride	7	B-Chemical
induced	3	O
only	9	O
SOCS	1	O
-	7	O
1	9	O
in	5	O
the	5	O
medial	5	O
preoptic	5	O
area	5	O
,	9	O
where	5	O
GnRH	3	O
neurons	3	O
are	5	O
regulated	3	O
,	9	O
but	9	O
in	5	O
the	5	O
arcuate	5	O
nucleus	9	O
and	5	O
choroid	9	O
plexus	9	O
,	9	O
PRL	3	O
-	7	O
R	9	O
,	9	O
SOCS	1	O
-	7	O
3	9	O
,	9	O
and	5	O
CIS	9	O
mRNA	3	O
levels	3	O
were	9	O
also	9	O
induced	3	O
.	9	O

Estradiol	0	B-Chemical
enhanced	3	O
these	5	O
effects	9	O
on	5	O
SOCS	1	O
-	7	O
3	9	O
and	5	O
CIS	9	O
.	9	O

Interestingly	9	O
,	9	O
estradiol	0	B-Chemical
also	9	O
induced	3	O
PRL	3	O
-	7	O
R	9	O
,	9	O
SOCS	1	O
-	7	O
3	9	O
,	9	O
and	5	O
CIS	9	O
mRNA	3	O
levels	3	O
independently	9	O
.	9	O

These	5	O
data	5	O
show	9	O
that	5	O
GnRH	3	O
pulse	5	O
frequency	5	O
is	5	O
inhibited	3	O
by	9	O
chronic	5	O
hyperprolactinemia	5	B-Disease
in	5	O
a	5	O
steroid	9	B-Chemical
-	7	O
dependent	9	O
manner	9	O
.	9	O

They	5	O
also	9	O
provide	5	O
evidence	9	O
for	5	O
estradiol	0	B-Chemical
-	7	O
dependent	9	O
and	5	O
brain	5	O
region	9	O
-	7	O
specific	9	O
regulation	9	O
of	5	O
PRL	3	O
-	7	O
R	9	O
expression	3	O
and	5	O
signaling	3	O
responses	5	O
by	9	O
prolactin	3	O
.	9	O

Clonidine	0	B-Chemical
for	5	O
attention	5	B-Disease
-	7	I-Disease
deficit	5	I-Disease
/	9	I-Disease
hyperactivity	5	I-Disease
disorder	5	I-Disease
:	9	O
II	9	O
.	9	O

ECG	5	O
changes	9	O
and	5	O
adverse	5	O
events	5	O
analysis	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
examine	9	O
the	5	O
safety	5	O
and	5	O
tolerability	5	O
of	5	O
clonidine	0	B-Chemical
used	5	O
alone	9	O
or	5	O
with	5	O
methylphenidate	5	B-Chemical
in	5	O
children	5	O
with	5	O
attention	5	B-Disease
-	7	I-Disease
deficit	5	I-Disease
/	9	I-Disease
hyperactivity	5	I-Disease
disorder	5	I-Disease
(	9	O
ADHD	5	B-Disease
)	9	O
.	9	O

METHOD	2	O
:	9	O
In	9	O
a	5	O
16	9	O
-	7	O
week	9	O
multicenter	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
trial	5	O
,	9	O
122	7	O
children	5	O
with	5	O
ADHD	5	B-Disease
were	9	O
randomly	5	O
assigned	5	O
to	5	O
clonidine	0	B-Chemical
(	9	O
n	9	O
=	7	O
31	7	O
)	9	O
,	9	O
methylphenidate	5	B-Chemical
(	9	O
n	9	O
=	7	O
29	7	O
)	9	O
,	9	O
clonidine	0	B-Chemical
and	5	O
methylphenidate	5	B-Chemical
(	9	O
n	9	O
=	7	O
32	7	O
)	9	O
,	9	O
or	5	O
placebo	9	O
(	9	O
n	9	O
=	7	O
30	9	O
)	9	O
.	9	O

Doses	0	O
were	9	O
flexibly	5	O
titrated	0	O
up	5	O
to	5	O
0	7	O
.	9	O
6	9	O
mg	0	O
/	9	O
day	9	O
for	5	O
clonidine	0	B-Chemical
and	5	O
60	9	O
mg	0	O
/	9	O
day	9	O
for	5	O
methylphenidate	5	B-Chemical
(	9	O
both	9	O
with	5	O
divided	5	O
dosing	9	O
)	9	O
.	9	O

Groups	9	O
were	9	O
compared	9	O
regarding	5	O
adverse	5	O
events	5	O
and	5	O
changes	9	O
from	9	O
baseline	5	O
to	5	O
week	9	O
16	9	O
in	5	O
electrocardiograms	5	O
and	5	O
vital	5	O
signs	5	O
.	9	O

RESULTS	9	O
:	9	O
There	5	O
were	9	O
more	5	O
incidents	5	O
of	5	O
bradycardia	5	B-Disease
in	5	O
subjects	5	O
treated	3	O
with	5	O
clonidine	0	B-Chemical
compared	9	O
with	5	O
those	5	O
not	5	O
treated	3	O
with	5	O
clonidine	0	B-Chemical
(	9	O
17	7	O
.	9	O
5	9	O
%	9	O
versus	9	O
3	9	O
.	9	O
4	9	O
%	9	O
;	9	O
p	7	O
=	7	O
.	9	O
02	7	O
)	9	O
,	9	O
but	9	O
no	9	O
other	5	O
significant	9	O
group	9	O
differences	9	O
regarding	5	O
electrocardiogram	5	O
and	5	O
other	5	O
cardiovascular	5	O
outcomes	5	O
.	9	O

There	5	O
were	9	O
no	9	O
suggestions	6	O
of	5	O
interactions	9	O
between	5	O
clonidine	0	B-Chemical
and	5	O
methylphenidate	5	B-Chemical
regarding	5	O
cardiovascular	5	O
outcomes	5	O
.	9	O

Moderate	7	O
or	5	O
severe	5	O
adverse	5	O
events	5	O
were	9	O
more	5	O
common	5	O
in	5	O
subjects	5	O
on	5	O
clonidine	0	B-Chemical
(	9	O
79	7	O
.	9	O
4	9	O
%	9	O
versus	9	O
49	7	O
.	9	O
2	9	O
%	9	O
;	9	O
p	7	O
=	7	O
.	9	O
0006	7	O
)	9	O
but	9	O
not	5	O
associated	9	O
with	5	O
higher	9	O
rates	5	O
of	5	O
early	9	O
study	9	O
withdrawal	5	O
.	9	O

Drowsiness	7	B-Disease
was	9	O
common	5	O
on	5	O
clonidine	0	B-Chemical
,	9	O
but	9	O
generally	5	O
resolved	9	O
by	9	O
6	9	O
to	5	O
8	9	O
weeks	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Clonidine	0	B-Chemical
,	9	O
used	5	O
alone	9	O
or	5	O
with	5	O
methylphenidate	5	B-Chemical
,	9	O
appears	9	O
safe	5	O
and	5	O
well	9	O
tolerated	9	O
in	5	O
childhood	5	O
ADHD	5	B-Disease
.	9	O

Physicians	5	O
prescribing	5	O
clonidine	0	B-Chemical
should	5	O
monitor	5	O
for	5	O
bradycardia	5	B-Disease
and	5	O
advise	5	O
patients	5	O
about	5	O
the	5	O
high	9	O
likelihood	5	O
of	5	O
initial	9	O
drowsiness	5	B-Disease
.	9	O

Renal	9	B-Disease
Fanconi	9	I-Disease
syndrome	5	I-Disease
and	5	O
myopathy	9	B-Disease
after	9	O
liver	9	O
transplantation	9	O
:	9	O
drug	5	O
-	7	O
related	9	O
mitochondrial	9	B-Disease
cytopathy	9	I-Disease
?	5	O

Advances	5	O
in	5	O
the	5	O
field	5	O
of	5	O
transplantation	9	O
provide	5	O
a	5	O
better	5	O
quality	5	O
of	5	O
life	5	O
and	5	O
allow	5	O
more	5	O
favorable	5	O
conditions	9	O
for	5	O
growth	3	O
and	5	O
development	9	O
in	5	O
children	5	O
.	9	O

However	9	O
,	9	O
combinations	9	O
of	5	O
different	9	O
therapeutic	5	O
regimens	5	O
require	5	O
consideration	5	O
of	5	O
potential	9	O
adverse	5	O
reactions	9	O
.	9	O

We	9	O
describe	5	O
a	5	O
15	9	O
-	7	O
yr	7	O
-	7	O
old	5	O
girl	5	O
who	5	O
had	9	O
orthotopic	3	O
liver	9	O
transplantation	9	O
because	5	O
of	5	O
Wilson	6	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Tacrolimus	0	B-Chemical
,	9	O
MMF	9	B-Chemical
,	9	O
and	5	O
steroids	9	B-Chemical
were	9	O
given	5	O
as	5	O
immunosuppressant	9	O
.	9	O

Lamivudine	7	B-Chemical
was	9	O
added	0	O
because	5	O
of	5	O
de	2	O
nova	4	O
hepatitis	9	B-Disease
B	9	I-Disease
infection	9	I-Disease
during	5	O
her	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

Three	9	O
yr	7	O
after	9	O
transplantation	9	O
she	5	O
developed	5	O
renal	9	B-Disease
Fanconi	9	I-Disease
syndrome	5	I-Disease
with	5	O
severe	5	O
metabolic	9	B-Disease
acidosis	5	I-Disease
,	9	O
hypophosphatemia	5	B-Disease
,	9	O
glycosuria	5	B-Disease
,	9	O
and	5	O
aminoaciduria	5	B-Disease
.	9	O

Although	9	O
tacrolimus	0	B-Chemical
was	9	O
suspected	5	O
to	5	O
be	5	O
the	5	O
cause	5	O
of	5	O
late	9	O
post	9	O
-	7	O
transplant	9	O
renal	9	O
acidosis	5	B-Disease
and	5	O
was	9	O
replaced	9	O
by	9	O
sirolimus	0	B-Chemical
,	9	O
acidosis	5	B-Disease
,	9	O
and	5	O
electrolyte	0	O
imbalance	9	O
got	5	O
worse	5	O
.	9	O

Proximal	9	O
muscle	9	B-Disease
weakness	5	I-Disease
has	9	O
developed	5	O
during	5	O
her	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

Fanconi	9	B-Disease
syndrome	5	I-Disease
,	9	O
as	5	O
well	9	O
as	5	O
myopathy	9	B-Disease
,	9	O
is	5	O
well	9	O
recognized	9	O
in	5	O
patients	5	O
with	5	O
mitochondrial	9	B-Disease
disorders	5	I-Disease
and	5	O
caused	9	O
by	9	O
depletion	3	O
of	5	O
mtDNA	9	O
.	9	O

We	9	O
suggest	9	O
that	5	O
our	5	O
patient	5	O
'	9	O
s	9	O
tubular	9	B-Disease
dysfunction	9	I-Disease
and	5	O
myopathy	9	B-Disease
may	5	O
have	5	O
resulted	9	O
from	9	O
mitochondrial	9	B-Disease
dysfunction	9	I-Disease
which	5	O
is	5	O
triggered	9	O
by	9	O
tacrolimus	0	B-Chemical
and	5	O
augmented	9	O
by	9	O
lamivudine	5	B-Chemical
.	9	O

Higher	9	O
optical	5	O
density	9	O
of	5	O
an	5	O
antigen	3	O
assay	3	O
predicts	5	O
thrombosis	5	B-Disease
in	5	O
patients	5	O
with	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
correlate	9	O
optical	5	O
density	9	O
and	5	O
percent	5	O
inhibition	3	O
of	5	O
a	5	O
two	5	O
-	7	O
step	9	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
(	9	O
HIT	5	B-Disease
)	9	O
antigen	3	O
assay	3	O
with	5	O
thrombosis	5	B-Disease
;	9	O
the	5	O
assay	3	O
utilizes	9	O
reaction	9	O
inhibition	3	O
characteristics	5	O
of	5	O
a	5	O
high	9	O
heparin	0	B-Chemical
concentration	0	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
Patients	5	O
with	5	O
more	5	O
than	5	O
50	0	O
%	9	O
decrease	9	O
in	5	O
platelet	9	O
count	9	O
or	5	O
thrombocytopenia	9	B-Disease
(	9	O
<	0	O
150	0	O
x	9	O
10	9	O
(	9	O
9	7	O
)	9	O
/	9	O
L	0	O
)	9	O
after	9	O
exposure	9	O
to	5	O
heparin	0	B-Chemical
,	9	O
who	5	O
had	9	O
a	5	O
positive	9	O
two	5	O
-	7	O
step	9	O
antigen	3	O
assay	3	O
[	9	O
optical	5	O
density	9	O
(	9	O
OD	9	O
)	9	O
>	0	O
0	7	O
.	9	O
4	9	O
and	5	O
>	0	O
50	0	O
inhibition	3	O
with	5	O
high	9	O
concentration	0	O
of	5	O
heparin	0	B-Chemical
]	9	O
were	9	O
included	5	O
in	5	O
the	5	O
study	9	O
.	9	O

RESULTS	9	O
:	9	O
Forty	9	O
of	5	O
94	7	O
HIT	5	B-Disease
patients	5	O
had	9	O
thrombosis	5	B-Disease
at	9	O
diagnosis	5	O
;	9	O
54	7	O
/	9	O
94	7	O
had	9	O
isolated	9	O
-	7	O
HIT	5	B-Disease
without	9	O
thrombosis	5	B-Disease
.	9	O

Eight	9	O
of	5	O
the	5	O
isolated	9	O
-	7	O
HIT	5	B-Disease
patients	5	O
developed	5	O
thrombosis	5	B-Disease
within	9	O
the	5	O
next	9	O
30	9	O
d	9	O
;	9	O
thus	9	O
,	9	O
a	5	O
total	9	O
of	5	O
48	9	O
patients	5	O
had	9	O
thrombosis	5	B-Disease
at	9	O
day	9	O
30	9	O
.	9	O

At	9	O
diagnosis	5	O
there	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
in	5	O
OD	9	O
between	5	O
HIT	5	B-Disease
patients	5	O
with	5	O
thrombosis	5	B-Disease
and	5	O
those	5	O
with	5	O
isolated	9	O
-	7	O
HIT	5	B-Disease
.	9	O

However	9	O
,	9	O
OD	9	O
was	9	O
significantly	9	O
higher	9	O
in	5	O
all	5	O
patients	5	O
with	5	O
thrombosis	5	B-Disease
(	9	O
n	9	O
=	7	O
48	9	O
,	9	O
1	9	O
.	9	O
34	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
89	7	O
)	9	O
,	9	O
including	9	O
isolated	9	O
-	7	O
HIT	5	B-Disease
patients	5	O
who	5	O
later	9	O
developed	5	O
thrombosis	5	B-Disease
within	9	O
30	9	O
d	9	O
(	9	O
n	9	O
=	7	O
8	9	O
,	9	O
1	9	O
.	9	O
84	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
64	7	O
)	9	O
as	5	O
compared	9	O
to	5	O
isolated	9	O
-	7	O
HIT	5	B-Disease
patients	5	O
who	5	O
did	9	O
not	5	O
develop	5	O
thrombosis	5	B-Disease
(	9	O
0	7	O
.	9	O
96	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
75	9	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
011	2	O
and	5	O
P	9	O
=	7	O
0	7	O
.	9	O
008	7	O
)	9	O
.	9	O

The	5	O
Receiver	5	O
Operative	5	O
Characteristic	9	O
Curve	5	O
showed	9	O
that	5	O
OD	9	O
>	0	O
1	9	O
.	9	O
27	7	O
in	5	O
the	5	O
isolated	9	O
-	7	O
HIT	5	B-Disease
group	9	O
had	9	O
a	5	O
significantly	9	O
higher	9	O
chance	5	O
of	5	O
developing	5	O
thrombosis	5	B-Disease
by	9	O
day	9	O
30	9	O
.	9	O

None	9	O
of	5	O
these	5	O
groups	9	O
showed	9	O
significant	9	O
difference	9	O
in	5	O
percent	5	O
inhibition	3	O
.	9	O

Multivariate	5	O
analysis	9	O
showed	9	O
a	5	O
2	9	O
.	9	O
8	9	O
-	7	O
fold	9	O
increased	9	O
risk	5	O
of	5	O
thrombosis	5	B-Disease
in	5	O
females	9	O
.	9	O

Similarly	9	O
,	9	O
thrombotic	5	B-Disease
risk	5	O
increased	9	O
with	5	O
age	5	O
and	5	O
OD	9	O
values	5	O
.	9	O

CONCLUSION	5	O
:	9	O
Higher	9	O
OD	9	O
is	5	O
associated	9	O
with	5	O
significant	9	O
risk	5	O
of	5	O
subsequent	9	O
thrombosis	5	B-Disease
in	5	O
patients	5	O
with	5	O
isolated	9	O
-	7	O
HIT	5	B-Disease
;	9	O
percent	5	O
inhibition	3	O
,	9	O
however	9	O
,	9	O
was	9	O
not	5	O
predictive	5	O
.	9	O

Thalidomide	0	B-Chemical
has	9	O
limited	5	O
single	9	O
-	7	O
agent	9	O
activity	9	O
in	5	O
relapsed	5	O
or	5	O
refractory	9	O
indolent	5	O
non	9	B-Disease
-	7	I-Disease
Hodgkin	5	I-Disease
lymphomas	3	I-Disease
:	9	O
a	5	O
phase	5	O
II	9	O
trial	5	O
of	5	O
the	5	O
Cancer	2	B-Disease
and	5	O
Leukemia	2	B-Disease
Group	9	O
B	9	O
.	9	O

Thalidomide	0	B-Chemical
is	5	O
an	5	O
immunomodulatory	9	O
agent	9	O
with	5	O
demonstrated	9	O
activity	9	O
in	5	O
multiple	5	B-Disease
myeloma	3	I-Disease
,	9	O
mantle	5	B-Disease
cell	3	I-Disease
lymphoma	9	I-Disease
and	5	O
lymphoplasmacytic	5	B-Disease
lymphoma	9	I-Disease
.	9	O

Its	5	O
activity	9	O
is	5	O
believed	5	O
to	5	O
be	5	O
due	5	O
modulation	9	O
of	5	O
the	5	O
tumour	3	B-Disease
milieu	9	O
,	9	O
including	9	O
downregulation	3	O
of	5	O
angiogenesis	3	O
and	5	O
inflammatory	3	O
cytokines	3	O
.	9	O

Between	9	O
July	2	O
2001	2	O
and	5	O
April	2	O
2004	2	O
,	9	O
24	9	O
patients	5	O
with	5	O
relapsed	5	O
/	9	O
refractory	9	O
indolent	5	O
lymphomas	3	B-Disease
received	9	O
thalidomide	0	B-Chemical
200	0	O
mg	0	O
daily	5	O
with	5	O
escalation	5	O
by	9	O
100	0	O
mg	0	O
daily	5	O
every	5	O
1	9	O
-	7	O
2	9	O
weeks	9	O
as	5	O
tolerated	9	O
,	9	O
up	5	O
to	5	O
a	5	O
maximum	5	O
of	5	O
800	0	O
mg	0	O
daily	5	O
.	9	O

Patients	5	O
had	9	O
received	9	O
a	5	O
median	9	O
of	5	O
2	9	O
(	9	O
range	9	O
,	9	O
1	9	O
-	7	O
4	9	O
)	9	O
prior	9	O
regimens	5	O
.	9	O

Of	9	O
24	9	O
evaluable	9	O
patients	5	O
,	9	O
two	5	O
achieved	5	O
a	5	O
complete	9	O
remission	5	O
and	5	O
one	5	O
achieved	5	O
a	5	O
partial	9	O
remission	5	O
for	5	O
an	5	O
overall	5	O
response	9	O
rate	9	O
of	5	O
12	9	O
.	9	O
5	9	O
%	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
:	9	O
2	9	O
.	9	O
6	9	O
-	7	O
32	7	O
.	9	O
4	9	O
%	9	O
)	9	O
.	9	O

Eleven	9	O
patients	5	O
progressed	9	O
during	5	O
therapy	5	O
.	9	O

Grade	9	O
3	9	O
-	7	O
4	9	O
adverse	5	O
effects	9	O
included	5	O
myelosuppression	5	B-Disease
,	9	O
fatigue	5	B-Disease
,	9	O
somnolence	5	B-Disease
/	9	O
depressed	5	B-Disease
mood	5	I-Disease
,	9	O
neuropathy	5	B-Disease
and	5	O
dyspnea	5	B-Disease
.	9	O

Of	9	O
concern	5	O
was	9	O
the	5	O
occurrence	5	O
of	5	O
four	9	O
thromboembolic	5	B-Disease
events	5	O
.	9	O

Our	9	O
results	9	O
failed	9	O
to	5	O
demonstrate	9	O
an	5	O
important	9	O
response	9	O
rate	9	O
to	5	O
single	9	O
agent	9	O
thalidomide	0	B-Chemical
in	5	O
indolent	5	O
lymphomas	3	B-Disease
and	5	O
contrast	9	O
with	5	O
the	5	O
higher	9	O
activity	9	O
level	9	O
reported	9	O
with	5	O
the	5	O
second	9	O
generation	9	O
immunomodulatory	9	O
agent	9	O
,	9	O
lenalidomide	0	B-Chemical
.	9	O

Sex	7	O
differences	9	O
in	5	O
NMDA	3	B-Chemical
antagonist	3	O
enhancement	9	O
of	5	O
morphine	0	B-Chemical
antihyperalgesia	3	O
in	5	O
a	5	O
capsaicin	0	B-Chemical
model	5	O
of	5	O
persistent	5	O
pain	5	B-Disease
:	9	O
comparisons	5	O
to	5	O
two	5	O
models	5	O
of	5	O
acute	9	B-Disease
pain	5	I-Disease
.	9	O

In	9	O
acute	9	B-Disease
pain	5	I-Disease
models	5	O
,	9	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
antagonists	3	O
enhance	9	O
the	5	O
antinociceptive	0	O
effects	9	O
of	5	O
morphine	0	B-Chemical
to	5	O
a	5	O
greater	5	O
extent	9	O
in	5	O
males	9	O
than	5	O
females	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
investigation	9	O
was	9	O
to	5	O
extend	9	O
these	5	O
findings	9	O
to	5	O
a	5	O
persistent	5	O
pain	5	B-Disease
model	5	O
which	5	O
could	9	O
be	5	O
distinguished	9	O
from	9	O
acute	9	B-Disease
pain	5	I-Disease
models	5	O
on	5	O
the	5	O
basis	5	O
of	5	O
the	5	O
nociceptive	5	O
fibers	9	O
activated	3	O
,	9	O
neurochemical	5	O
substrates	0	O
,	9	O
and	5	O
duration	5	O
of	5	O
the	5	O
nociceptive	5	O
stimulus	5	O
.	9	O

To	9	O
this	5	O
end	9	O
,	9	O
persistent	5	O
hyperalgesia	3	B-Disease
was	9	O
induced	3	O
by	9	O
administration	9	O
of	5	O
capsaicin	0	B-Chemical
in	5	O
the	5	O
tail	9	O
of	5	O
gonadally	3	O
intact	9	O
F344	3	O
rats	9	O
,	9	O
following	9	O
which	5	O
the	5	O
tail	9	O
was	9	O
immersed	0	O
in	5	O
a	5	O
mildly	9	O
noxious	5	O
thermal	9	O
stimulus	5	O
,	9	O
and	5	O
tail	9	O
-	7	O
withdrawal	5	O
latencies	5	O
measured	9	O
.	9	O

For	9	O
comparison	9	O
,	9	O
tests	5	O
were	9	O
conducted	9	O
in	5	O
two	5	O
acute	9	B-Disease
pain	5	I-Disease
models	5	O
,	9	O
the	5	O
hotplate	0	O
and	5	O
warm	5	O
water	0	O
tail	9	O
-	7	O
withdrawal	5	O
procedures	5	O
.	9	O

In	9	O
males	9	O
,	9	O
the	5	O
non	9	O
-	7	O
competitive	9	O
NMDA	3	B-Chemical
antagonist	3	O
dextromethorphan	0	B-Chemical
enhanced	3	O
the	5	O
antihyperalgesic	0	O
effect	9	O
of	5	O
low	9	O
to	5	O
moderate	9	O
doses	0	O
of	5	O
morphine	0	B-Chemical
in	5	O
a	5	O
dose	9	O
-	7	O
and	5	O
time	5	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

Across	5	O
the	5	O
doses	0	O
and	5	O
pretreatment	0	O
times	5	O
examined	9	O
,	9	O
enhancement	9	O
was	9	O
not	5	O
observed	9	O
in	5	O
females	9	O
.	9	O

Enhancement	9	O
of	5	O
morphine	0	B-Chemical
antinociception	3	O
by	9	O
dextromethorphan	0	B-Chemical
was	9	O
seen	9	O
in	5	O
both	9	O
males	9	O
and	5	O
females	9	O
in	5	O
the	5	O
acute	9	B-Disease
pain	5	I-Disease
models	5	O
,	9	O
with	5	O
the	5	O
magnitude	5	O
of	5	O
this	5	O
effect	9	O
being	5	O
greater	5	O
in	5	O
males	9	O
.	9	O

These	5	O
findings	9	O
demonstrate	9	O
a	5	O
sexually	5	O
-	7	O
dimorphic	4	O
interaction	9	O
between	5	O
NMDA	3	B-Chemical
antagonists	3	O
and	5	O
morphine	0	B-Chemical
in	5	O
a	5	O
persistent	5	O
pain	5	B-Disease
model	5	O
that	5	O
can	5	O
be	5	O
distinguished	9	O
from	9	O
those	5	O
observed	9	O
in	5	O
acute	9	B-Disease
pain	5	I-Disease
models	5	O
.	9	O

Development	2	O
of	5	O
proteinuria	9	B-Disease
after	9	O
switch	9	O
to	5	O
sirolimus	0	B-Chemical
-	7	O
based	5	O
immunosuppression	5	O
in	5	O
long	5	O
-	7	O
term	5	O
cardiac	5	O
transplant	9	O
patients	5	O
.	9	O

Calcineurin	3	O
-	7	O
inhibitor	3	O
therapy	5	O
can	5	O
lead	5	O
to	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
in	5	O
heart	5	O
transplantation	9	O
patients	5	O
.	9	O

The	5	O
novel	9	O
immunosuppressive	9	O
(	9	O
IS	9	O
)	9	O
drug	5	O
sirolmus	_	B-Chemical
(	9	O
Srl	2	B-Chemical
)	9	O
lacks	1	O
nephrotoxic	5	B-Disease
effects	9	O
;	9	O
however	9	O
,	9	O
proteinuria	9	B-Disease
associated	9	O
with	5	O
Srl	2	B-Chemical
has	9	O
been	9	O
reported	9	O
following	9	O
renal	9	O
transplantation	9	O
.	9	O

In	9	O
cardiac	5	O
transplantation	9	O
,	9	O
the	5	O
incidence	5	O
of	5	O
proteinuria	9	B-Disease
associated	9	O
with	5	O
Srl	2	B-Chemical
is	5	O
unknown	9	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
long	5	O
-	7	O
term	5	O
cardiac	5	O
transplant	9	O
patients	5	O
were	9	O
switched	9	O
from	9	O
cyclosporine	0	B-Chemical
to	5	O
Srl	2	B-Chemical
-	7	O
based	5	O
IS	9	O
.	9	O

Concomitant	9	O
IS	9	O
consisted	5	O
of	5	O
mycophenolate	0	B-Chemical
mofetil	0	I-Chemical
+	9	O
/	9	O
-	7	O
steroids	9	B-Chemical
.	9	O

Proteinuria	7	O
increased	9	O
significantly	9	O
from	9	O
a	5	O
median	9	O
of	5	O
0	7	O
.	9	O
13	7	O
g	0	O
/	9	O
day	9	O
(	9	O
range	9	O
0	7	O
-	7	O
5	9	O
.	9	O
7	9	O
)	9	O
preswitch	5	O
to	5	O
0	7	O
.	9	O
23	7	O
g	0	O
/	9	O
day	9	O
(	9	O
0	7	O
-	7	O
9	7	O
.	9	O
88	7	O
)	9	O
at	9	O
24	9	O
months	5	O
postswitch	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0024	7	O
)	9	O
.	9	O

Before	9	O
the	5	O
switch	9	O
,	9	O
11	7	O
.	9	O
5	9	O
%	9	O
of	5	O
patients	5	O
had	9	O
high	9	O
-	7	O
grade	9	O
proteinuria	9	B-Disease
(	9	O
>	0	O
1	9	O
.	9	O
0	7	O
g	0	O
/	9	O
day	9	O
)	9	O
;	9	O
this	5	O
increased	9	O
to	5	O
22	7	O
.	9	O
9	7	O
%	9	O
postswitch	5	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
006	7	O
)	9	O
.	9	O

ACE	9	B-Chemical
inhibitor	3	I-Chemical
and	5	O
angiotensin	9	B-Chemical
-	7	I-Chemical
releasing	9	I-Chemical
blocker	0	I-Chemical
(	9	O
ARB	9	B-Chemical
)	9	O
therapy	5	O
reduced	9	O
proteinuria	9	B-Disease
development	9	O
.	9	O

Patients	5	O
without	9	O
proteinuria	9	B-Disease
had	9	O
increased	9	O
renal	9	O
function	9	O
(	9	O
median	9	O
42	7	O
.	9	O
5	9	O
vs	7	O
.	9	O
64	7	O
.	9	O
1	9	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
25	9	O
)	9	O
,	9	O
whereas	9	O
patients	5	O
who	5	O
developed	5	O
high	9	O
-	7	O
grade	9	O
proteinuria	9	B-Disease
showed	9	O
decreased	9	O
renal	9	O
function	9	O
at	9	O
the	5	O
end	9	O
of	5	O
follow	5	O
-	7	O
up	5	O
(	9	O
median	9	O
39	7	O
.	9	O
6	9	O
vs	7	O
.	9	O
29	7	O
.	9	O
2	9	O
,	9	O
p	7	O
=	7	O
0	7	O
.	9	O
125	9	O
)	9	O
.	9	O

Thus	9	O
,	9	O
proteinuria	9	B-Disease
may	5	O
develop	5	O
in	5	O
cardiac	5	O
transplant	9	O
patients	5	O
after	9	O
switch	9	O
to	5	O
Srl	2	B-Chemical
,	9	O
which	5	O
may	5	O
have	5	O
an	5	O
adverse	5	O
effect	9	O
on	5	O
renal	9	O
function	9	O
in	5	O
these	5	O
patients	5	O
.	9	O

Srl	2	B-Chemical
should	5	O
be	5	O
used	5	O
with	5	O
ACEi	5	B-Chemical
/	9	O
ARB	9	B-Chemical
therapy	5	O
and	5	O
patients	5	O
monitored	9	O
for	5	O
proteinuria	9	B-Disease
and	5	O
increased	9	O
renal	9	B-Disease
dysfunction	9	I-Disease
.	9	O

Ginsenoside	0	B-Chemical
Rg1	0	I-Chemical
restores	3	O
the	5	O
impairment	5	B-Disease
of	5	I-Disease
learning	5	I-Disease
induced	3	O
by	9	O
chronic	5	O
morphine	0	B-Chemical
administration	9	O
in	5	O
rats	9	O
.	9	O

Rg1	0	B-Chemical
,	9	O
as	5	O
a	5	O
ginsenoside	0	B-Chemical
extracted	9	O
from	9	O
Panax	4	O
ginseng	4	O
,	9	O
could	9	O
ameliorate	9	O
spatial	5	O
learning	5	B-Disease
impairment	5	I-Disease
.	9	O

Previous	9	O
studies	9	O
have	5	O
demonstrated	9	O
that	5	O
Rg1	0	B-Chemical
might	9	O
be	5	O
a	5	O
useful	5	O
agent	9	O
for	5	O
the	5	O
prevention	5	O
and	5	O
treatment	9	O
of	5	O
the	5	O
adverse	5	O
effects	9	O
of	5	O
morphine	0	B-Chemical
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
effect	9	O
of	5	O
Rg1	0	B-Chemical
on	5	O
learning	5	B-Disease
impairment	5	I-Disease
by	9	O
chronic	5	O
morphine	0	B-Chemical
administration	9	O
and	5	O
the	5	O
mechanism	9	O
responsible	9	O
for	5	O
this	5	O
effect	9	O
.	9	O

Male	7	O
rats	9	O
were	9	O
subcutaneously	3	O
injected	3	O
with	5	O
morphine	0	B-Chemical
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
twice	9	O
a	5	O
day	9	O
at	9	O
12	9	O
hour	0	O
intervals	5	O
for	5	O
10	9	O
days	9	O
,	9	O
and	5	O
Rg1	0	B-Chemical
(	9	O
30	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
was	9	O
intraperitoneally	0	O
injected	3	O
2	9	O
hours	9	O
after	9	O
the	5	O
second	9	O
injection	9	O
of	5	O
morphine	0	B-Chemical
once	5	O
a	5	O
day	9	O
for	5	O
10	9	O
days	9	O
.	9	O

Spatial	5	O
learning	5	O
capacity	9	O
was	9	O
assessed	9	O
in	5	O
the	5	O
Morris	6	O
water	0	O
maze	5	O
.	9	O

The	5	O
results	9	O
showed	9	O
that	5	O
rats	9	O
treated	3	O
with	5	O
Morphine	0	B-Chemical
/	9	O
Rg1	0	B-Chemical
decreased	9	O
escape	5	O
latency	5	O
and	5	O
increased	9	O
the	5	O
time	5	O
spent	5	O
in	5	O
platform	5	O
quadrant	5	O
and	5	O
entering	5	O
frequency	5	O
.	9	O

By	5	O
implantation	5	O
of	5	O
electrodes	5	O
and	5	O
electrophysiological	5	O
recording	5	O
in	5	O
vivo	3	O
,	9	O
the	5	O
results	9	O
showed	9	O
that	5	O
Rg1	0	B-Chemical
restored	3	O
the	5	O
long	5	O
-	7	O
term	5	O
potentiation	3	O
(	9	O
LTP	3	O
)	9	O
impaired	9	O
by	9	O
morphine	0	B-Chemical
in	5	O
both	9	O
freely	5	O
moving	5	O
and	5	O
anaesthetised	5	O
rats	9	O
.	9	O

The	5	O
electrophysiological	5	O
recording	5	O
in	5	O
vitro	3	O
showed	9	O
that	5	O
Rg1	0	B-Chemical
restored	3	O
the	5	O
LTP	3	O
in	5	O
slices	9	O
from	9	O
the	5	O
rats	9	O
treated	3	O
with	5	O
morphine	0	B-Chemical
,	9	O
but	9	O
not	5	O
changed	9	O
LTP	3	O
in	5	O
the	5	O
slices	9	O
from	9	O
normal	9	O
saline	0	O
-	7	O
or	5	O
morphine	0	B-Chemical
/	9	O
Rg1	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
;	9	O
this	5	O
restoration	5	O
could	9	O
be	5	O
inhibited	3	O
by	9	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
receptor	3	O
antagonist	3	O
MK801	3	B-Chemical
.	9	O

We	9	O
conclude	9	O
that	5	O
Rg1	0	B-Chemical
may	5	O
significantly	9	O
improve	5	O
the	5	O
spatial	5	O
learning	5	O
capacity	9	O
impaired	9	O
by	9	O
chonic	5	O
morphine	0	B-Chemical
administration	9	O
and	5	O
restore	9	O
the	5	O
morphine	0	B-Chemical
-	7	O
inhibited	3	O
LTP	3	O
.	9	O

This	5	O
effect	9	O
is	5	O
NMDA	3	B-Chemical
receptor	3	O
dependent	9	O
.	9	O

Synthesis	0	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
pyrimidinyl	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
phenoxyacetamides	_	I-Chemical
as	5	O
adenosine	0	B-Chemical
A2A	3	O
receptor	3	O
antagonists	3	O
.	9	O

A	9	O
series	5	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
pyrimidinyl	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
phenoxyacetamide	9	I-Chemical
adenosine	0	B-Chemical
A	9	O
(	9	O
2A	9	O
)	9	O
antagonists	3	O
is	5	O
described	9	O
.	9	O

SAR	9	O
studies	9	O
led	9	O
to	5	O
compound	0	O
14	7	O
with	5	O
excellent	5	O
potency	9	O
(	9	O
K	9	O
(	9	O
i	9	O
)	9	O
=	7	O
0	7	O
.	9	O
4	9	O
nM	0	O
)	9	O
,	9	O
selectivity	9	O
(	9	O
A	9	O
(	9	O
1	9	O
)	9	O
/	9	O
A	9	O
(	9	O
2A	9	O
)	9	O
>	0	O
100	0	O
)	9	O
,	9	O
and	5	O
efficacy	9	O
(	9	O
MED	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
in	5	O
the	5	O
rat	3	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
model	5	O
for	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Evidence	9	O
for	5	O
an	5	O
involvement	9	O
of	5	O
D1	3	O
and	5	O
D2	9	O
dopamine	5	B-Chemical
receptors	3	O
in	5	O
mediating	9	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
in	5	O
rats	9	O
.	9	O

Previous	9	O
studies	9	O
have	5	O
suggested	9	O
that	5	O
repeated	5	O
exposure	9	O
of	5	O
rats	9	O
to	5	O
the	5	O
drug	5	O
or	5	O
to	5	O
the	5	O
experimental	5	O
environment	5	O
is	5	O
necessary	5	O
to	5	O
observe	9	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
stimulation	3	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
the	5	O
role	9	O
of	5	O
habituation	5	O
to	5	O
the	5	O
experimental	5	O
environment	5	O
on	5	O
the	5	O
stimulant	5	O
effect	9	O
of	5	O
nicotine	0	B-Chemical
in	5	O
rats	9	O
was	9	O
examined	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
the	5	O
role	9	O
of	5	O
dopamine	5	B-Chemical
receptors	3	O
in	5	O
mediating	9	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
stimulation	3	O
was	9	O
investigated	9	O
by	9	O
examining	5	O
the	5	O
effects	9	O
of	5	O
selective	9	O
D1	3	O
and	5	O
D2	9	O
dopamine	5	B-Chemical
receptor	3	O
antagonists	3	O
on	5	O
activity	9	O
induced	3	O
by	9	O
nicotine	0	B-Chemical
.	9	O

Locomotor	5	O
activity	9	O
was	9	O
assessed	9	O
in	5	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
tested	9	O
in	5	O
photocell	5	O
cages	5	O
.	9	O

Nicotine	0	B-Chemical
(	9	O
1	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
caused	9	O
a	5	O
significant	9	O
increase	9	B-Disease
in	5	I-Disease
locomotor	5	I-Disease
activity	9	I-Disease
in	5	O
rats	9	O
that	5	O
were	9	O
habituated	5	O
to	5	O
the	5	O
test	5	O
environment	5	O
,	9	O
but	9	O
had	9	O
only	9	O
a	5	O
weak	9	O
and	5	O
delayed	9	O
stimulant	5	O
action	5	O
in	5	O
rats	9	O
that	5	O
were	9	O
unfamiliar	5	O
with	5	O
the	5	O
test	5	O
environment	5	O
.	9	O

The	5	O
stimulant	5	O
action	5	O
of	5	O
nicotine	0	B-Chemical
was	9	O
blocked	3	O
by	9	O
the	5	O
central	5	O
nicotinic	0	O
antagonist	3	O
mecamylamine	0	B-Chemical
but	9	O
not	5	O
by	9	O
the	5	O
peripheral	9	O
nicotinic	0	O
blocker	0	O
hexamethonium	0	B-Chemical
,	9	O
indicating	9	O
that	5	O
the	5	O
response	9	O
is	5	O
probably	9	O
mediated	3	O
by	9	O
central	5	O
nicotinic	0	O
receptors	3	O
.	9	O

Nicotine	0	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
was	9	O
blocked	3	O
by	9	O
the	5	O
selective	9	O
D1	3	O
antagonist	3	O
SCH	9	B-Chemical
23390	0	I-Chemical
,	9	O
the	5	O
selective	9	O
D2	9	O
antagonist	3	O
raclopride	0	B-Chemical
and	5	O
the	5	O
D1	3	O
/	9	O
D2	9	O
antagonist	3	O
fluphenazine	0	B-Chemical
.	9	O

Pretreatment	3	O
with	5	O
the	5	O
D2	9	O
agonist	3	O
PHNO	0	B-Chemical
enhanced	3	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
,	9	O
whereas	9	O
the	5	O
D1	3	O
agonist	3	O
SKF	3	B-Chemical
38393	3	I-Chemical
had	9	O
no	9	O
effect	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
acute	9	O
nicotine	0	B-Chemical
injection	9	O
induces	3	O
a	5	O
pronounced	9	O
hyperactivity	5	B-Disease
in	5	O
rats	9	O
habituated	5	O
to	5	O
the	5	O
test	5	O
environment	5	O
.	9	O

The	5	O
effect	9	O
appears	9	O
to	5	O
be	5	O
mediated	3	O
by	9	O
central	5	O
nicotine	0	B-Chemical
receptors	3	O
,	9	O
possibly	9	O
located	9	O
on	5	O
dopaminergic	5	O
neurons	3	O
,	9	O
and	5	O
also	9	O
requires	5	O
the	5	O
activation	3	O
of	5	O
both	9	O
D1	3	O
and	5	O
D2	9	O
dopamine	5	B-Chemical
receptors	3	O
.	9	O

Central	4	O
retinal	5	B-Disease
vein	5	I-Disease
occlusion	5	I-Disease
associated	9	O
with	5	O
clomiphene	5	B-Chemical
-	7	O
induced	3	O
ovulation	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
central	5	O
retinal	5	B-Disease
vein	5	I-Disease
occlusion	5	I-Disease
associated	9	O
with	5	O
clomiphene	5	B-Chemical
citrate	0	I-Chemical
(	9	O
CC	9	B-Chemical
)	9	O
.	9	O

DESIGN	2	O
:	9	O
Case	5	O
study	9	O
.	9	O

SETTING	2	O
:	9	O
Ophthalmology	2	O
clinic	5	O
of	5	O
an	5	O
academic	5	O
hospital	5	O
.	9	O

PATIENT	2	O
(	9	O
S	9	O
)	9	O
:	9	O
A	9	O
36	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
referred	5	O
from	9	O
the	5	O
infertility	5	B-Disease
clinic	5	O
for	5	O
blurred	5	B-Disease
vision	5	I-Disease
.	9	O

INTERVENTION	2	O
(	9	O
S	9	O
)	9	O
:	9	O
Ophthalmic	2	O
examination	5	O
after	9	O
CC	9	B-Chemical
therapy	5	O
.	9	O

MAIN	2	O
OUTCOME	2	O
MEASURE	2	O
(	9	O
S	9	O
)	9	O
:	9	O
Central	4	O
retinal	5	B-Disease
vein	5	I-Disease
occlusion	5	I-Disease
after	9	O
ovulation	5	O
induction	3	O
with	5	O
CC	9	B-Chemical
.	9	O

RESULT	2	O
(	9	O
S	9	O
)	9	O
:	9	O
A	9	O
36	9	O
-	7	O
year	5	O
-	7	O
old	5	O
Chinese	9	O
woman	5	O
developed	5	O
central	5	O
retinal	5	B-Disease
vein	5	I-Disease
occlusion	5	I-Disease
after	9	O
eight	9	O
courses	5	O
of	5	O
CC	9	B-Chemical
.	9	O

A	9	O
search	5	O
of	5	O
the	5	O
literature	5	O
on	5	O
the	5	O
thromboembolic	5	B-Disease
complications	5	O
of	5	O
CC	9	B-Chemical
does	9	O
not	5	O
include	5	O
this	5	O
severe	5	O
ophthalmic	5	O
complication	5	O
,	9	O
although	9	O
mild	9	O
visual	5	B-Disease
disturbance	5	I-Disease
after	9	O
CC	9	B-Chemical
intake	5	O
is	5	O
not	5	O
uncommon	5	O
.	9	O

CONCLUSION	5	O
(	9	O
S	9	O
)	9	O
:	9	O
This	5	O
is	5	O
the	5	O
first	9	O
reported	9	O
case	5	O
of	5	O
central	5	O
retinal	5	B-Disease
vein	5	I-Disease
occlusion	5	I-Disease
after	9	O
treatment	9	O
with	5	O
CC	9	B-Chemical
.	9	O

Extra	9	O
caution	5	O
is	5	O
warranted	9	O
in	5	O
treating	5	O
infertility	5	B-Disease
patients	5	O
with	5	O
CC	9	B-Chemical
,	9	O
and	5	O
patients	5	O
should	5	O
be	5	O
well	9	O
informed	5	O
of	5	O
this	5	O
side	5	O
effect	9	O
before	9	O
commencement	5	O
of	5	O
therapy	5	O
.	9	O

Acute	5	O
bronchodilating	5	O
effects	9	O
of	5	O
ipratropium	5	B-Chemical
bromide	0	I-Chemical
and	5	O
theophylline	0	B-Chemical
in	5	O
chronic	5	B-Disease
obstructive	5	I-Disease
pulmonary	5	I-Disease
disease	5	I-Disease
.	9	O

The	5	O
bronchodilator	5	O
effects	9	O
of	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
ipratropium	5	B-Chemical
bromide	0	I-Chemical
aerosol	5	O
(	9	O
36	9	O
micrograms	0	O
)	9	O
and	5	O
short	5	O
-	7	O
acting	9	O
theophylline	0	B-Chemical
tablets	0	O
(	9	O
dose	9	O
titrated	0	O
to	5	O
produce	9	O
serum	9	O
levels	3	O
of	5	O
10	9	O
-	7	O
20	9	O
micrograms	0	O
/	9	O
mL	0	O
)	9	O
were	9	O
compared	9	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
crossover	5	O
study	9	O
in	5	O
21	7	O
patients	5	O
with	5	O
stable	9	O
,	9	O
chronic	5	B-Disease
obstructive	5	I-Disease
pulmonary	5	I-Disease
disease	5	I-Disease
.	9	O

Mean	9	O
peak	9	O
forced	5	O
expiratory	5	O
volume	9	O
in	5	O
1	9	O
second	9	O
(	9	O
FEV1	5	O
)	9	O
increases	9	O
over	5	O
baseline	5	O
and	5	O
the	5	O
proportion	9	O
of	5	O
patients	5	O
attaining	5	O
at	9	O
least	9	O
a	5	O
15	9	O
%	9	O
increase	9	O
in	5	O
the	5	O
FEV1	5	O
(	9	O
responders	5	O
)	9	O
were	9	O
31	7	O
%	9	O
and	5	O
90	9	O
%	9	O
,	9	O
respectively	9	O
,	9	O
for	5	O
ipratropium	5	B-Chemical
and	5	O
17	7	O
%	9	O
and	5	O
50	0	O
%	9	O
,	9	O
respectively	9	O
,	9	O
for	5	O
theophylline	0	B-Chemical
.	9	O

The	5	O
average	5	O
FEV1	5	O
increases	9	O
during	5	O
the	5	O
6	9	O
-	7	O
hour	0	O
observation	9	O
period	5	O
were	9	O
18	7	O
%	9	O
for	5	O
ipratropium	5	B-Chemical
and	5	O
8	9	O
%	9	O
for	5	O
theophylline	0	B-Chemical
.	9	O

The	5	O
mean	5	O
duration	5	O
of	5	O
action	5	O
was	9	O
3	9	O
.	9	O
8	9	O
hours	9	O
with	5	O
ipratropium	5	B-Chemical
and	5	O
2	9	O
.	9	O
4	9	O
hours	9	O
with	5	O
theophylline	0	B-Chemical
.	9	O

While	9	O
side	5	O
effects	9	O
were	9	O
rare	5	O
,	9	O
those	5	O
experienced	5	O
after	9	O
theophylline	0	B-Chemical
use	5	O
did	9	O
involve	5	O
the	5	O
cardiovascular	5	B-Disease
and	5	I-Disease
gastrointestinal	9	I-Disease
systems	5	I-Disease
.	9	O

These	5	O
results	9	O
show	9	O
that	5	O
ipratropium	5	B-Chemical
is	5	O
a	5	O
more	5	O
potent	3	O
bronchodilator	5	O
than	5	O
oral	9	O
theophylline	0	B-Chemical
in	5	O
patients	5	O
with	5	O
chronic	5	B-Disease
airflow	5	I-Disease
obstruction	5	I-Disease
.	9	O

Methamphetamine	7	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
and	5	O
microglial	3	O
activation	3	O
are	5	O
not	5	O
mediated	3	O
by	9	O
fractalkine	3	O
receptor	3	O
signaling	3	O
.	9	O

Methamphetamine	7	B-Chemical
(	9	O
METH	9	B-Chemical
)	9	O
damages	9	O
dopamine	5	B-Chemical
(	9	O
DA	9	B-Chemical
)	9	O
nerve	5	O
endings	5	O
by	9	O
a	5	O
process	5	O
that	5	O
has	9	O
been	9	O
linked	9	O
to	5	O
microglial	3	O
activation	3	O
but	9	O
the	5	O
signaling	3	O
pathways	9	O
that	5	O
mediate	3	O
this	5	O
response	9	O
have	5	O
not	5	O
yet	9	O
been	9	O
delineated	5	O
.	9	O

Cardona	6	O
et	6	O
al	6	O
.	9	O

[	9	O
Nat	2	O
.	9	O
Neurosci	2	O
.	9	O
9	7	O
(	9	O
2006	2	O
)	9	O
,	9	O
917	7	O
]	9	O
recently	9	O
identified	9	O
the	5	O
microglial	3	O
-	7	O
specific	9	O
fractalkine	3	O
receptor	3	O
(	9	O
CX3CR1	3	O
)	9	O
as	5	O
an	5	O
important	9	O
mediator	9	O
of	5	O
MPTP	3	B-Chemical
-	7	O
induced	3	O
neurodegeneration	3	B-Disease
of	5	O
DA	9	B-Chemical
neurons	3	O
.	9	O

Because	9	O
the	5	O
CNS	9	B-Disease
damage	9	I-Disease
caused	9	O
by	9	O
METH	9	B-Chemical
and	5	O
MPTP	3	B-Chemical
is	5	O
highly	9	O
selective	9	O
for	5	O
the	5	O
DA	9	B-Chemical
neuronal	3	O
system	5	O
in	5	O
mouse	3	O
models	5	O
of	5	O
neurotoxicity	9	B-Disease
,	9	O
we	5	O
hypothesized	9	O
that	5	O
the	5	O
CX3CR1	3	O
plays	9	O
a	5	O
role	9	O
in	5	O
METH	9	B-Chemical
-	7	O
induced	3	O
neurotoxicity	9	B-Disease
and	5	O
microglial	3	O
activation	3	O
.	9	O

Mice	3	O
in	5	O
which	5	O
the	5	O
CX3CR1	3	O
gene	1	O
has	9	O
been	9	O
deleted	1	O
and	5	O
replaced	9	O
with	5	O
a	5	O
cDNA	1	O
encoding	1	O
enhanced	3	O
green	9	O
fluorescent	3	O
protein	1	O
(	9	O
eGFP	3	O
)	9	O
were	9	O
treated	3	O
with	5	O
METH	9	B-Chemical
and	5	O
examined	9	O
for	5	O
striatal	3	O
neurotoxicity	9	B-Disease
.	9	O

METH	9	B-Chemical
depleted	3	O
DA	9	B-Chemical
,	9	O
caused	9	O
microglial	3	O
activation	3	O
,	9	O
and	5	O
increased	9	O
body	5	O
temperature	0	O
in	5	O
CX3CR1	3	O
knockout	3	O
mice	3	O
to	5	O
the	5	O
same	9	O
extent	9	O
and	5	O
over	5	O
the	5	O
same	9	O
time	5	O
course	5	O
seen	9	O
in	5	O
wild	1	O
-	7	O
type	9	O
controls	9	O
.	9	O

The	5	O
effects	9	O
of	5	O
METH	9	B-Chemical
in	5	O
CX3CR1	3	O
knockout	3	O
mice	3	O
were	9	O
not	5	O
gender	5	O
-	7	O
dependent	9	O
and	5	O
did	9	O
not	5	O
extend	9	O
beyond	5	O
the	5	O
striatum	9	O
.	9	O

Striatal	3	O
microglia	3	O
expressing	3	O
eGFP	3	O
constitutively	3	O
show	9	O
morphological	9	O
changes	9	O
after	9	O
METH	9	B-Chemical
that	5	O
are	5	O
characteristic	9	O
of	5	O
activation	3	O
.	9	O

This	5	O
response	9	O
was	9	O
restricted	9	O
to	5	O
the	5	O
striatum	9	O
and	5	O
contrasted	5	O
sharply	9	O
with	5	O
unresponsive	9	O
eGFP	3	O
-	7	O
microglia	3	O
in	5	O
surrounding	9	O
brain	5	O
areas	5	O
that	5	O
are	5	O
not	5	O
damaged	9	O
by	9	O
METH	9	B-Chemical
.	9	O

We	9	O
conclude	9	O
from	9	O
these	5	O
studies	9	O
that	5	O
CX3CR1	3	O
signaling	3	O
does	9	O
not	5	O
modulate	9	O
METH	9	B-Chemical
neurotoxicity	9	B-Disease
or	5	O
microglial	3	O
activation	3	O
.	9	O

Furthermore	9	O
,	9	O
it	5	O
appears	9	O
that	5	O
striatal	3	O
-	7	O
resident	9	O
microglia	3	O
respond	5	O
to	5	O
METH	9	B-Chemical
with	5	O
an	5	O
activation	3	O
cascade	9	O
and	5	O
then	9	O
return	5	O
to	5	O
a	5	O
surveying	5	O
state	5	O
without	9	O
undergoing	9	O
apoptosis	3	O
or	5	O
migration	3	O
.	9	O

Nicotine	0	B-Chemical
-	7	O
induced	3	O
nystagmus	5	B-Disease
correlates	9	O
with	5	O
midpontine	5	O
activation	3	O
.	9	O

The	5	O
pathomechanism	5	O
of	5	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
nystagmus	5	B-Disease
(	9	O
NIN	1	B-Disease
)	9	O
is	5	O
unknown	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
delineate	9	O
brain	5	O
structures	9	O
that	5	O
are	5	O
involved	9	O
in	5	O
NIN	1	B-Disease
generation	9	O
.	9	O

Eight	9	O
healthy	5	O
volunteers	5	O
inhaled	5	O
nicotine	0	B-Chemical
in	5	O
darkness	9	O
during	5	O
a	5	O
functional	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
(	9	O
fMRI	5	O
)	9	O
experiment	9	O
;	9	O
eye	5	O
movements	5	O
were	9	O
registered	5	O
using	9	O
video	5	O
-	7	O
oculography	5	O
.	9	O

NIN	1	B-Disease
correlated	9	O
with	5	O
blood	9	O
oxygen	0	B-Chemical
level	9	O
-	7	O
dependent	9	O
(	9	O
BOLD	5	O
)	9	O
activity	9	O
levels	3	O
in	5	O
a	5	O
midpontine	5	O
site	9	O
in	5	O
the	5	O
posterior	5	O
basis	5	O
pontis	4	O
.	9	O

NIN	1	B-Disease
-	7	O
induced	3	O
midpontine	5	O
activation	3	O
may	5	O
correspond	9	O
to	5	O
activation	3	O
of	5	O
the	5	O
dorsomedial	5	O
pontine	5	O
nuclei	3	O
and	5	O
the	5	O
nucleus	9	O
reticularis	5	O
tegmenti	2	O
pontis	4	O
,	9	O
structures	9	O
known	9	O
to	5	O
participate	5	O
in	5	O
the	5	O
generation	9	O
of	5	O
multidirectional	5	O
saccades	5	O
and	5	O
smooth	5	O
pursuit	5	O
eye	5	O
movements	5	O
.	9	O

Acute	5	O
effects	9	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
propylpentanoyl	_	I-Chemical
)	9	I-Chemical
urea	0	I-Chemical
on	5	O
hippocampal	3	O
amino	1	B-Chemical
acid	0	I-Chemical
neurotransmitters	9	O
in	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizure	5	B-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
present	9	O
study	9	O
aimed	5	O
to	5	O
investigate	9	O
the	5	O
anticonvulsant	5	O
activity	9	O
as	5	O
well	9	O
as	5	O
the	5	O
effects	9	O
on	5	O
the	5	O
level	9	O
of	5	O
hippocampal	3	O
amino	1	B-Chemical
acid	0	I-Chemical
neurotransmitters	9	O
(	9	O
glutamate	0	B-Chemical
,	9	O
aspartate	1	B-Chemical
,	9	O
glycine	0	B-Chemical
and	5	O
GABA	0	B-Chemical
)	9	O
of	5	O
N	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
propylpentanoyl	_	I-Chemical
)	9	I-Chemical
urea	0	I-Chemical
(	9	O
VPU	1	B-Chemical
)	9	O
in	5	O
comparison	9	O
to	5	O
its	9	O
parent	9	O
compound	0	O
,	9	O
valproic	0	B-Chemical
acid	0	I-Chemical
(	9	O
VPA	9	B-Chemical
)	9	O
.	9	O

VPU	1	B-Chemical
was	9	O
more	5	O
potent	3	O
than	5	O
VPA	9	B-Chemical
,	9	O
exhibiting	9	O
the	5	O
median	9	O
effective	5	O
dose	9	O
(	9	O
ED	5	O
(	9	O
50	0	O
)	9	O
)	9	O
of	5	O
49	7	O
mg	0	O
/	9	O
kg	0	O
in	5	O
protecting	9	O
rats	9	O
against	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizure	5	B-Disease
whereas	9	O
the	5	O
corresponding	9	O
value	9	O
for	5	O
VPA	9	B-Chemical
was	9	O
322	7	O
mg	0	O
/	9	O
kg	0	O
.	9	O

In	9	O
vivo	3	O
microdialysis	5	O
demonstrated	9	O
that	5	O
an	5	O
intraperitoneal	0	O
administration	9	O
of	5	O
pilocarpine	0	B-Chemical
induced	3	O
a	5	O
pronounced	9	O
increment	9	O
of	5	O
hippocampal	3	O
glutamate	0	B-Chemical
and	5	O
aspartate	1	B-Chemical
whereas	9	O
no	9	O
significant	9	O
change	9	O
was	9	O
observed	9	O
on	5	O
the	5	O
level	9	O
of	5	O
glycine	0	B-Chemical
and	5	O
GABA	0	B-Chemical
.	9	O

Pretreatment	3	O
with	5	O
either	9	O
VPU	1	B-Chemical
(	9	O
50	0	O
and	5	O
100	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
or	5	O
VPA	9	B-Chemical
(	9	O
300	0	O
and	5	O
600	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
completely	9	O
abolished	3	O
pilocarpine	0	B-Chemical
-	7	O
evoked	5	O
increases	9	O
in	5	O
extracellular	9	O
glutamate	0	B-Chemical
and	5	O
aspartate	1	B-Chemical
.	9	O

In	9	O
addition	9	O
,	9	O
a	5	O
statistically	9	O
significant	9	O
reduction	9	O
was	9	O
also	9	O
observed	9	O
on	5	O
the	5	O
level	9	O
of	5	O
GABA	0	B-Chemical
and	5	O
glycine	0	B-Chemical
but	9	O
less	5	O
than	5	O
a	5	O
drastic	9	O
reduction	9	O
of	5	O
glutamate	0	B-Chemical
and	5	O
aspartate	1	B-Chemical
level	9	O
.	9	O

Based	9	O
on	5	O
the	5	O
finding	9	O
that	5	O
VPU	1	B-Chemical
and	5	O
VPA	9	B-Chemical
could	9	O
protect	9	O
the	5	O
animals	9	O
against	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizure	5	B-Disease
it	5	O
is	5	O
suggested	9	O
that	5	O
the	5	O
reduction	9	O
of	5	O
inhibitory	3	O
amino	1	B-Chemical
acid	0	I-Chemical
neurotransmitters	9	O
was	9	O
comparatively	9	O
minor	9	O
and	5	O
offset	5	O
by	9	O
a	5	O
pronounced	9	O
reduction	9	O
of	5	O
glutamate	0	B-Chemical
and	5	O
aspartate	1	B-Chemical
.	9	O

Therefore	9	O
,	9	O
like	9	O
VPA	9	B-Chemical
,	9	O
the	5	O
finding	9	O
that	5	O
VPU	1	B-Chemical
could	9	O
drastically	9	O
reduce	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
increases	9	O
in	5	O
glutamate	0	B-Chemical
and	5	O
aspartate	1	B-Chemical
should	5	O
account	5	O
,	9	O
at	9	O
least	9	O
partly	9	O
,	9	O
for	5	O
its	9	O
anticonvulsant	5	O
activity	9	O
observed	9	O
in	5	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
seizure	5	B-Disease
in	5	O
experimental	5	O
animals	9	O
.	9	O

Some	5	O
other	5	O
mechanism	9	O
than	5	O
those	5	O
being	5	O
reported	9	O
herein	9	O
should	5	O
be	5	O
further	9	O
investigated	9	O
.	9	O

Protective	9	O
effect	9	O
of	5	O
verapamil	0	B-Chemical
on	5	O
gastric	9	B-Disease
hemorrhagic	5	I-Disease
ulcers	5	B-Disease
in	5	O
severe	5	O
atherosclerotic	3	B-Disease
rats	9	O
.	9	O

Studies	9	O
concerning	5	O
with	5	O
pathogenesis	9	O
of	5	O
gastric	9	B-Disease
hemorrhage	5	I-Disease
and	5	O
mucosal	9	O
ulceration	5	O
produced	9	O
in	5	O
atherosclerotic	3	B-Disease
rats	9	O
are	5	O
lacking	1	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
is	5	O
to	5	O
examine	9	O
the	5	O
role	9	O
of	5	O
gastric	9	O
acid	0	O
back	5	O
-	7	O
diffusion	5	O
,	9	O
mast	3	O
cell	3	O
histamine	0	B-Chemical
release	9	O
,	9	O
lipid	0	O
peroxide	0	O
(	9	O
LPO	0	O
)	9	O
generation	9	O
and	5	O
mucosal	9	O
microvascular	5	O
permeability	0	O
in	5	O
modulating	9	O
gastric	9	B-Disease
hemorrhage	5	I-Disease
and	5	O
ulcer	5	B-Disease
in	5	O
rats	9	O
with	5	O
atherosclerosis	9	B-Disease
induced	3	O
by	9	O
coadministration	0	O
of	5	O
vitamin	0	B-Chemical
D2	9	I-Chemical
and	5	O
cholesterol	0	B-Chemical
.	9	O

Additionally	9	O
,	9	O
the	5	O
protective	9	O
effect	9	O
of	5	O
verapamil	0	B-Chemical
on	5	O
this	5	O
ulcer	5	B-Disease
model	5	O
was	9	O
evaluated	9	O
.	9	O

Male	7	O
Wistar	9	O
rats	9	O
were	9	O
challenged	3	O
intragastrically	0	O
once	5	O
daily	5	O
for	5	O
9	7	O
days	9	O
with	5	O
1	9	O
.	9	O
0	7	O
ml	0	O
/	9	O
kg	0	O
of	5	O
corn	4	O
oil	0	O
containing	0	O
vitamin	0	B-Chemical
D2	9	I-Chemical
and	5	O
cholesterol	0	B-Chemical
to	5	O
induce	3	O
atherosclerosis	9	B-Disease
.	9	O

Control	9	O
rats	9	O
received	9	O
corn	4	O
oil	0	O
only	9	O
.	9	O

After	9	O
gastric	9	O
surgery	5	O
,	9	O
rat	3	O
stomachs	9	O
were	9	O
irrigated	5	O
for	5	O
3	9	O
h	0	O
with	5	O
either	9	O
simulated	5	O
gastric	9	O
juice	0	O
or	5	O
normal	9	O
saline	0	O
.	9	O

Gastric	9	O
acid	0	O
back	5	O
-	7	O
diffusion	5	O
,	9	O
mucosal	9	O
LPO	0	O
generation	9	O
,	9	O
histamine	0	B-Chemical
concentration	0	O
,	9	O
microvascular	5	O
permeability	0	O
,	9	O
luminal	3	B-Chemical
hemoglobin	0	O
content	9	O
and	5	O
ulcer	5	B-Disease
areas	5	O
were	9	O
determined	9	O
.	9	O

Elevated	9	O
atherosclerotic	3	B-Disease
parameters	5	O
,	9	O
such	5	O
as	5	O
serum	9	O
calcium	0	B-Chemical
,	9	O
total	9	O
cholesterol	0	B-Chemical
and	5	O
low	9	O
-	7	O
density	9	O
lipoprotein	9	O
concentration	0	O
were	9	O
obtained	9	O
in	5	O
atherosclerotic	3	B-Disease
rats	9	O
.	9	O

Severe	9	O
gastric	9	O
ulcers	5	B-Disease
accompanied	9	O
with	5	O
increased	9	O
ulcerogenic	0	O
factors	9	O
,	9	O
including	9	O
gastric	9	O
acid	0	O
back	5	O
-	7	O
diffusion	5	O
,	9	O
histamine	0	B-Chemical
release	9	O
,	9	O
LPO	0	O
generation	9	O
and	5	O
luminal	3	B-Chemical
hemoglobin	0	O
content	9	O
were	9	O
also	9	O
observed	9	O
in	5	O
these	5	O
rats	9	O
.	9	O

Moreover	9	O
,	9	O
a	5	O
positive	9	O
correlation	9	O
of	5	O
histamine	0	B-Chemical
to	5	O
gastric	9	B-Disease
hemorrhage	5	I-Disease
and	5	O
to	5	O
ulcer	5	B-Disease
was	9	O
found	9	O
in	5	O
those	5	O
atherosclerotic	3	B-Disease
rats	9	O
.	9	O

This	5	O
hemorrhagic	5	B-Disease
ulcer	5	B-Disease
and	5	O
various	9	O
ulcerogenic	0	O
parameters	5	O
were	9	O
dose	9	O
-	7	O
dependently	3	O
ameliorated	9	O
by	9	O
daily	5	O
intragastric	0	O
verapamil	0	B-Chemical
.	9	O

Atherosclerosis	5	B-Disease
could	9	O
produce	9	O
gastric	9	B-Disease
hemorrhagic	5	I-Disease
ulcer	5	B-Disease
via	9	O
aggravation	5	O
of	5	O
gastric	9	O
acid	0	O
back	5	O
-	7	O
diffusion	5	O
,	9	O
LPO	0	O
generation	9	O
,	9	O
histamine	0	B-Chemical
release	9	O
and	5	O
microvascular	5	O
permeability	0	O
that	5	O
could	9	O
be	5	O
ameliorated	9	O
by	9	O
verapamil	0	B-Chemical
in	5	O
rats	9	O
.	9	O

Lamivudine	7	B-Chemical
for	5	O
the	5	O
prevention	5	O
of	5	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
reactivation	9	O
in	5	O
hepatitis	9	B-Chemical
-	7	I-Chemical
B	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
(	9	O
HBSAG	9	B-Chemical
)	9	O
seropositive	9	O
cancer	3	B-Disease
patients	5	O
undergoing	9	O
cytotoxic	3	O
chemotherapy	5	O
.	9	O

Hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
(	9	O
HBV	9	O
)	9	O
is	5	O
one	5	O
of	5	O
the	5	O
major	9	O
causes	9	O
of	5	O
chronic	5	O
liver	9	B-Disease
disease	5	I-Disease
worldwide	5	O
.	9	O

Cancer	2	B-Disease
patients	5	O
who	5	O
are	5	O
chronic	5	O
carriers	9	O
of	5	O
HBV	9	O
have	5	O
a	5	O
higher	9	O
hepatic	9	B-Disease
complication	5	I-Disease
rate	9	O
while	9	O
receiving	9	O
cytotoxic	3	O
chemotherapy	5	O
(	9	O
CT	9	O
)	9	O
and	5	O
this	5	O
has	9	O
mainly	9	O
been	9	O
attributed	9	O
to	5	O
HBV	9	O
reactivation	9	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
cancer	3	B-Disease
patients	5	O
who	5	O
have	5	O
solid	9	O
and	5	O
hematological	9	B-Disease
malignancies	5	I-Disease
with	5	O
chronic	5	O
HBV	9	B-Disease
infection	9	I-Disease
received	9	O
the	5	O
antiviral	9	O
agent	9	O
lamivudine	5	B-Chemical
prior	9	O
and	5	O
during	5	O
CT	9	O
compared	9	O
with	5	O
historical	5	O
control	9	O
group	9	O
who	5	O
did	9	O
not	5	O
receive	5	O
lamivudine	5	B-Chemical
.	9	O

The	5	O
objectives	5	O
were	9	O
to	5	O
assess	5	O
the	5	O
efficacy	9	O
of	5	O
lamivudine	5	B-Chemical
in	5	O
reducing	9	O
the	5	O
incidence	5	O
of	5	O
HBV	9	O
reactivation	9	O
,	9	O
and	5	O
diminishing	5	O
morbidity	5	O
and	5	O
mortality	5	O
during	5	O
CT	9	O
.	9	O

Two	9	O
groups	9	O
were	9	O
compared	9	O
in	5	O
this	5	O
study	9	O
.	9	O

The	5	O
prophylactic	5	O
lamivudin	9	B-Chemical
group	9	O
consisted	5	O
of	5	O
37	9	O
patients	5	O
who	5	O
received	9	O
prophylactic	5	O
lamivudine	5	B-Chemical
treatment	9	O
.	9	O

The	5	O
historical	5	O
controls	9	O
consisted	5	O
of	5	O
50	0	O
consecutive	5	O
patients	5	O
who	5	O
underwent	5	O
CT	9	O
without	9	O
prophylactic	5	O
lamivudine	5	B-Chemical
.	9	O

They	5	O
were	9	O
followed	9	O
up	5	O
during	5	O
and	5	O
for	5	O
8	9	O
weeks	9	O
after	9	O
CT	9	O
.	9	O

The	5	O
outcomes	5	O
were	9	O
compared	9	O
for	5	O
both	9	O
groups	9	O
.	9	O

Of	9	O
our	5	O
control	9	O
group	9	O
(	9	O
n	9	O
=	7	O
50	0	O
)	9	O
,	9	O
21	7	O
patients	5	O
(	9	O
42	7	O
%	9	O
)	9	O
were	9	O
established	9	O
hepatitis	9	B-Disease
.	9	O

Twelve	9	O
(	9	O
24	9	O
%	9	O
)	9	O
of	5	O
them	5	O
were	9	O
evaluated	9	O
as	5	O
severe	5	O
hepatitis	9	B-Disease
.	9	O

In	9	O
the	5	O
prophylactic	5	O
lamivudine	5	B-Chemical
group	9	O
severe	5	O
hepatitis	9	B-Disease
were	9	O
observed	9	O
only	9	O
in	5	O
1	9	O
patient	5	O
(	9	O
2	9	O
.	9	O
7	9	O
%	9	O
)	9	O
of	5	O
37	9	O
patients	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
006	7	O
)	9	O
.	9	O

Comparison	9	O
of	5	O
the	5	O
mean	5	O
ALT	9	O
values	5	O
revealed	9	O
significantly	9	O
higher	9	O
mean	5	O
alanine	1	B-Chemical
aminotransferase	7	O
(	9	O
ALT	9	O
)	9	O
values	5	O
in	5	O
the	5	O
control	9	O
group	9	O
than	5	O
the	5	O
prophylactic	5	O
lamivudine	5	B-Chemical
group	9	O
;	9	O
154	7	O
:	9	O
64	7	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
32	7	O
)	9	O
.	9	O

Our	9	O
study	9	O
suggests	9	O
that	5	O
prophylactic	5	O
lamivudine	5	B-Chemical
significantly	9	O
decreases	9	O
the	5	O
incidence	5	O
of	5	O
HBV	9	O
reactivation	9	O
and	5	O
overall	5	O
morbidity	5	O
in	5	O
cancer	3	B-Disease
patients	5	O
during	5	O
and	5	O
after	9	O
immunosuppressive	9	O
therapy	5	O
.	9	O

Further	9	O
studies	9	O
are	5	O
needed	5	O
to	5	O
determine	9	O
the	5	O
most	9	O
appropriate	5	O
nucleoside	0	B-Chemical
or	5	O
nucleotide	1	B-Chemical
analogue	0	O
for	5	O
antiviral	9	O
prophylaxis	5	O
during	5	O
CT	9	O
and	5	O
the	5	O
optimal	5	O
duration	5	O
of	5	O
administration	9	O
after	9	O
completion	5	O
of	5	O
CT	9	O
.	9	O

Recovery	9	O
of	5	O
tacrolimus	0	B-Chemical
-	7	O
associated	9	O
brachial	5	B-Disease
neuritis	5	I-Disease
after	9	O
conversion	9	O
to	5	O
everolimus	0	B-Chemical
in	5	O
a	5	O
pediatric	5	O
renal	9	O
transplant	9	O
recipient	9	O
-	7	O
-	7	O
case	5	O
report	5	O
and	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
.	9	O

TAC	9	B-Chemical
has	9	O
been	9	O
shown	9	O
to	5	O
be	5	O
a	5	O
potent	3	O
immunosuppressive	9	O
agent	9	O
for	5	O
solid	9	O
organ	5	O
transplantation	9	O
in	5	O
pediatrics	5	O
.	9	O

Neurotoxicity	0	B-Disease
is	5	O
a	5	O
potentially	5	O
serious	5	O
toxic	0	O
effect	9	O
.	9	O

It	5	O
is	5	O
characterized	9	O
by	9	O
encephalopathy	5	B-Disease
,	9	O
headaches	5	B-Disease
,	9	O
seizures	5	B-Disease
,	9	O
or	5	O
neurological	5	B-Disease
deficits	5	I-Disease
.	9	O

Here	9	O
,	9	O
we	5	O
describe	5	O
an	5	O
eight	9	O
-	7	O
and	5	O
-	7	O
a	5	O
-	7	O
half	5	O
-	7	O
yr	7	O
-	7	O
old	5	O
male	9	O
renal	9	O
transplant	9	O
recipient	9	O
with	5	O
right	5	O
BN	9	O
.	9	O

MRI	5	O
demonstrated	9	O
hyperintense	5	O
T2	9	O
signals	9	O
in	5	O
the	5	O
cervical	5	O
cord	9	O
and	5	O
right	5	O
brachial	5	O
plexus	9	O
roots	4	O
indicative	9	O
of	5	O
both	9	O
myelitis	5	B-Disease
and	5	O
right	5	O
brachial	5	B-Disease
plexitis	5	I-Disease
.	9	O

Symptoms	5	O
persisted	9	O
for	5	O
three	9	O
months	5	O
despite	9	O
TAC	9	B-Chemical
dose	9	O
reduction	9	O
,	9	O
administration	9	O
of	5	O
IVIG	9	O
and	5	O
four	9	O
doses	0	O
of	5	O
methylprednisolone	0	B-Chemical
pulse	5	O
therapy	5	O
.	9	O

Improvement	5	O
and	5	O
eventually	5	O
full	5	O
recovery	9	O
only	9	O
occurred	9	O
after	9	O
TAC	9	B-Chemical
was	9	O
completely	9	O
discontinued	5	O
and	5	O
successfully	5	O
replaced	9	O
by	9	O
everolimus	0	B-Chemical
.	9	O

Omitting	5	O
fentanyl	0	B-Chemical
reduces	9	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
,	9	O
without	9	O
increasing	9	O
pain	5	B-Disease
,	9	O
after	9	O
sevoflurane	0	B-Chemical
for	5	O
day	9	O
surgery	5	O
.	9	O

BACKGROUND	2	O
AND	2	O
OBJECTIVE	2	O
:	9	O
Despite	5	O
advantages	5	O
of	5	O
induction	3	O
and	5	O
maintenance	9	O
of	5	O
anaesthesia	5	O
with	5	O
sevoflurane	0	B-Chemical
,	9	O
postoperative	5	B-Disease
nausea	5	I-Disease
and	5	I-Disease
vomiting	5	I-Disease
occurs	9	O
frequently	5	O
.	9	O

Fentanyl	0	B-Chemical
is	5	O
a	5	O
commonly	5	O
used	5	O
supplement	9	O
that	5	O
may	5	O
contribute	9	O
to	5	O
this	5	O
,	9	O
although	9	O
it	5	O
may	5	O
also	9	O
improve	5	O
analgesia	5	O
.	9	O

METHODS	2	O
:	9	O
This	5	O
double	9	O
-	7	O
blind	5	O
study	9	O
examined	9	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
postoperative	5	B-Disease
nausea	5	I-Disease
and	5	I-Disease
vomiting	5	I-Disease
and	5	O
pain	5	B-Disease
in	5	O
the	5	O
first	9	O
24	9	O
h	0	O
after	9	O
sevoflurane	0	B-Chemical
anaesthesia	5	O
in	5	O
216	7	O
adult	9	O
day	9	O
surgery	5	O
patients	5	O
.	9	O

Patients	5	O
were	9	O
randomly	5	O
allocated	5	O
to	5	O
either	9	O
receive	5	O
or	5	O
not	5	O
receive	5	O
1	9	O
1	9	O
fentanyl	0	B-Chemical
,	9	O
while	9	O
a	5	O
third	9	O
group	9	O
received	9	O
dexamethasone	0	B-Chemical
in	5	O
addition	9	O
to	5	O
fentanyl	0	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
Omission	9	O
of	5	O
fentanyl	0	B-Chemical
did	9	O
not	5	O
reduce	5	O
the	5	O
overall	5	O
incidence	5	O
of	5	O
postoperative	5	B-Disease
nausea	5	I-Disease
and	5	I-Disease
vomiting	5	I-Disease
,	9	O
but	9	O
did	9	O
reduce	5	O
the	5	O
incidence	5	O
of	5	O
vomiting	5	B-Disease
and	5	O
/	9	O
or	5	O
moderate	9	O
to	5	O
severe	5	O
nausea	5	B-Disease
prior	9	O
to	5	O
discharge	5	O
from	9	O
20	9	O
%	9	O
and	5	O
17	7	O
%	9	O
with	5	O
fentanyl	0	B-Chemical
and	5	O
fentanyl	0	B-Chemical
-	7	O
dexamethasone	0	B-Chemical
,	9	O
respectively	9	O
,	9	O
to	5	O
5	9	O
%	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
013	7	O
)	9	O
.	9	O

Antiemetic	5	O
requirements	5	O
were	9	O
reduced	9	O
from	9	O
24	9	O
%	9	O
and	5	O
31	7	O
%	9	O
to	5	O
7	9	O
%	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
0012	7	O
)	9	O
.	9	O

Dexamethasone	0	B-Chemical
had	9	O
no	9	O
significant	9	O
effect	9	O
on	5	O
the	5	O
incidence	5	O
or	5	O
severity	5	O
of	5	O
postoperative	5	B-Disease
nausea	5	I-Disease
and	5	I-Disease
vomiting	5	I-Disease
.	9	O

Combining	5	O
the	5	O
two	5	O
fentanyl	0	B-Chemical
groups	9	O
revealed	9	O
further	9	O
significant	9	O
benefits	5	O
from	9	O
the	5	O
avoidance	5	O
of	5	O
opioids	5	O
,	9	O
reducing	9	O
postoperative	5	B-Disease
nausea	5	I-Disease
and	5	I-Disease
vomiting	5	I-Disease
and	5	O
nausea	5	B-Disease
prior	9	O
to	5	O
discharge	5	O
from	9	O
35	9	O
%	9	O
and	5	O
33	7	O
%	9	O
to	5	O
22	7	O
%	9	O
and	5	O
19	7	O
%	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
049	7	O
and	5	O
P	9	O
=	7	O
0	7	O
.	9	O
035	7	O
)	9	O
,	9	O
respectively	9	O
,	9	O
while	9	O
nausea	5	B-Disease
in	5	O
the	5	O
first	9	O
24	9	O
h	0	O
was	9	O
decreased	9	O
from	9	O
42	7	O
%	9	O
to	5	O
27	7	O
%	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
034	7	O
)	9	O
.	9	O

Pain	5	B-Disease
severity	5	O
and	5	O
analgesic	5	O
requirements	5	O
were	9	O
unaffected	9	O
by	9	O
the	5	O
omission	5	O
of	5	O
fentanyl	0	B-Chemical
.	9	O

Fentanyl	0	B-Chemical
did	9	O
reduce	5	O
minor	9	O
intraoperative	5	O
movement	5	O
but	9	O
had	9	O
no	9	O
sevoflurane	0	B-Chemical
-	7	O
sparing	5	O
effect	9	O
and	5	O
increased	9	O
respiratory	5	B-Disease
depression	5	I-Disease
,	9	O
hypotension	5	B-Disease
and	5	O
bradycardia	5	B-Disease
.	9	O

CONCLUSION	5	O
:	9	O
As	9	O
fentanyl	0	B-Chemical
exacerbated	9	O
postoperative	5	B-Disease
nausea	5	I-Disease
and	5	I-Disease
vomiting	5	I-Disease
without	9	O
an	5	O
improvement	5	O
in	5	O
postoperative	5	B-Disease
pain	5	I-Disease
and	5	O
also	9	O
had	9	O
adverse	5	O
cardiorespiratory	5	O
effects	9	O
,	9	O
it	5	O
appears	9	O
to	5	O
be	5	O
an	5	O
unnecessary	5	O
and	5	O
possibly	9	O
detrimental	9	O
supplement	9	O
to	5	O
sevoflurane	0	B-Chemical
in	5	O
day	9	O
surgery	5	O
.	9	O

Valvular	7	B-Disease
heart	5	I-Disease
disease	5	I-Disease
in	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
treated	3	O
with	5	O
pergolide	0	B-Chemical
.	9	O

Course	5	O
following	9	O
treatment	9	O
modifications	9	O
.	9	O

Valvular	7	B-Disease
heart	5	I-Disease
abnormalities	9	I-Disease
have	5	O
been	9	O
reported	9	O
in	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
treated	3	O
with	5	O
pergolide	0	B-Chemical
.	9	O

However	9	O
,	9	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
these	5	O
abnormalities	9	O
vary	5	O
from	9	O
study	9	O
to	5	O
study	9	O
and	5	O
their	5	O
course	5	O
after	9	O
drug	5	O
withdrawal	5	O
has	9	O
not	5	O
been	9	O
systematically	5	O
assessed	9	O
.	9	O

OBJECTIVES	2	O
:	9	O
To	9	O
estimate	5	O
the	5	O
frequency	5	O
and	5	O
severity	5	O
of	5	O
valvular	5	B-Disease
heart	5	I-Disease
abnormality	9	I-Disease
and	5	O
its	9	O
possible	5	O
reversibility	9	O
after	9	O
drug	5	O
withdrawal	5	O
in	5	O
a	5	O
case	5	O
-	7	O
control	9	O
study	9	O
.	9	O

METHODS	2	O
:	9	O
All	9	O
PD	9	B-Disease
patients	5	O
in	5	O
the	5	O
Amiens	2	O
area	5	O
treated	3	O
with	5	O
pergolide	0	B-Chemical
were	9	O
invited	5	O
to	5	O
attend	5	O
a	5	O
cardiologic	5	O
assessment	5	O
including	9	O
transthoracic	5	O
echocardiography	5	O
.	9	O

Thirty	9	O
PD	9	B-Disease
patients	5	O
participated	5	O
in	5	O
the	5	O
study	9	O
.	9	O

A	9	O
second	9	O
echocardiography	5	O
was	9	O
performed	9	O
(	9	O
median	9	O
interval	5	O
:	9	O
13	7	O
months	5	O
)	9	O
after	9	O
pergolide	0	B-Chemical
withdrawal	5	O
(	9	O
n	9	O
=	7	O
10	9	O
patients	5	O
)	9	O
.	9	O

Controls	9	O
were	9	O
age	5	O
-	7	O
and	5	O
sex	5	O
-	7	O
matched	9	O
non	9	O
-	7	O
PD	9	B-Disease
patients	5	O
referred	5	O
to	5	O
the	5	O
cardiology	5	O
department	5	O
.	9	O

RESULTS	9	O
:	9	O
Compared	9	O
to	5	O
controls	9	O
,	9	O
aortic	9	B-Disease
regurgitation	5	I-Disease
(	9	O
OR	9	O
:	9	O
3	9	O
.	9	O
1	9	O
;	9	O
95	7	O
%	9	O
IC	9	O
:	9	O
1	9	O
.	9	O
1	9	O
-	7	O
8	9	O
.	9	O
8	9	O
)	9	O
and	5	O
mitral	5	B-Disease
regurgitation	5	I-Disease
(	9	O
OR	9	O
:	9	O
10	9	O
.	9	O
7	9	O
;	9	O
95	7	O
%	9	O
IC	9	O
:	9	O
2	9	O
.	9	O
1	9	O
-	7	O
53	7	O
)	9	O
were	9	O
more	5	O
frequent	5	O
in	5	O
PD	9	B-Disease
patients	5	O
(	9	O
tricuspid	5	O
:	9	O
NS	7	O
)	9	O
.	9	O

The	5	O
number	9	O
of	5	O
affected	9	O
valves	5	O
(	9	O
n	9	O
=	7	O
2	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
)	9	O
and	5	O
the	5	O
sum	5	O
of	5	O
regurgitation	5	O
grades	5	O
(	9	O
n	9	O
=	7	O
2	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
09	7	O
)	9	O
were	9	O
higher	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
008	7	O
and	5	O
p	7	O
=	7	O
0	7	O
.	9	O
006	7	O
,	9	O
respectively	9	O
)	9	O
in	5	O
the	5	O
pergolide	0	B-Chemical
group	9	O
.	9	O

Severity	5	O
of	5	O
regurgitation	5	O
was	9	O
not	5	O
correlated	9	O
with	5	O
pergolide	0	B-Chemical
cumulative	5	O
dose	9	O
.	9	O

A	9	O
restrictive	5	O
pattern	9	O
of	5	O
valvular	5	B-Disease
regurgitation	5	I-Disease
,	9	O
suggestive	9	O
of	5	O
the	5	O
role	9	O
of	5	O
pergolide	0	B-Chemical
,	9	O
was	9	O
observed	9	O
in	5	O
12	9	O
/	9	O
30	9	O
(	9	O
40	9	O
%	9	O
)	9	O
patients	5	O
including	9	O
two	5	O
with	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

Pergolide	7	B-Chemical
was	9	O
discontinued	5	O
in	5	O
10	9	O
patients	5	O
with	5	O
valvular	5	B-Disease
heart	5	I-Disease
disease	5	I-Disease
,	9	O
resulting	9	O
in	5	O
a	5	O
lower	9	O
regurgitation	5	O
grade	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
at	9	O
the	5	O
second	9	O
transthoracic	5	O
echocardiography	5	O
and	5	O
the	5	O
two	5	O
patients	5	O
with	5	O
heart	5	B-Disease
failure	5	I-Disease
returned	5	O
to	5	O
nearly	9	O
normal	9	O
clinical	5	O
examination	5	O
.	9	O

This	5	O
study	9	O
supports	9	O
the	5	O
high	9	O
frequency	5	O
of	5	O
restrictive	5	O
valve	5	B-Disease
regurgitation	5	I-Disease
in	5	O
PD	9	B-Disease
patients	5	O
treated	3	O
with	5	O
pergolide	0	B-Chemical
and	5	O
reveals	9	O
that	5	O
a	5	O
significant	9	O
improvement	5	O
is	5	O
usual	5	O
when	5	O
the	5	O
treatment	9	O
is	5	O
converted	9	O
to	5	O
non	9	O
-	7	O
ergot	0	O
dopamine	5	B-Chemical
agonists	3	O
.	9	O

Adriamycin	0	B-Chemical
-	7	O
induced	3	O
autophagic	3	O
cardiomyocyte	3	O
death	9	B-Disease
plays	9	O
a	5	O
pathogenic	9	O
role	9	O
in	5	O
a	5	O
rat	3	O
model	5	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
mechanisms	9	O
underlying	5	O
heart	5	B-Disease
failure	5	I-Disease
induced	3	O
by	9	O
adriamycin	3	B-Chemical
are	5	O
very	5	O
complicated	5	O
and	5	O
still	5	O
unclear	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
whether	9	O
autophagy	3	O
was	9	O
involved	9	O
in	5	O
the	5	O
progression	9	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
induced	3	O
by	9	O
adriamycin	3	B-Chemical
,	9	O
so	5	O
that	5	O
we	5	O
can	5	O
develop	5	O
a	5	O
novel	9	O
treatment	9	O
strategy	5	O
for	5	O
heart	5	B-Disease
failure	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
3	9	B-Chemical
-	7	I-Chemical
methyladenine	0	I-Chemical
(	9	O
3MA	3	B-Chemical
)	9	O
,	9	O
a	5	O
specific	9	O
inhibitor	3	O
on	5	O
autophagy	3	O
was	9	O
used	5	O
in	5	O
a	5	O
heart	5	B-Disease
failure	5	I-Disease
model	5	O
of	5	O
rats	9	O
induced	3	O
by	9	O
adriamycin	3	B-Chemical
.	9	O

Neonatal	9	O
cardiomyocytes	3	O
were	9	O
isolated	9	O
from	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rat	3	O
hearts	3	O
and	5	O
randomly	5	O
divided	5	O
into	9	O
controls	9	O
,	9	O
an	5	O
adriamycin	3	B-Chemical
-	7	O
treated	3	O
group	9	O
,	9	O
and	5	O
a	5	O
3MA	3	B-Chemical
plus	9	O
adriamycin	3	B-Chemical
-	7	O
treated	3	O
group	9	O
.	9	O

We	9	O
then	9	O
examined	9	O
the	5	O
morphology	9	O
,	9	O
expression	3	O
of	5	O
beclin	3	O
1	9	O
gene	1	O
,	9	O
mitochondrial	9	O
permeability	0	O
transition	9	O
(	9	O
MPT	9	O
)	9	O
,	9	O
and	5	O
Na	0	O
+	9	O
-	7	O
K	9	B-Chemical
+	9	O
ATPase	1	O
activity	9	O
in	5	O
vivo	3	O
.	9	O

We	9	O
also	9	O
assessed	9	O
cell	3	O
viability	3	O
,	9	O
mitochondrial	9	O
membrane	9	O
potential	9	O
changes	9	O
and	5	O
counted	9	O
autophagic	3	O
vacuoles	9	O
in	5	O
cultured	3	O
cardiomyocytes	3	O
.	9	O

In	9	O
addition	9	O
,	9	O
we	5	O
analyzed	9	O
the	5	O
expression	3	O
of	5	O
autophagy	3	O
associated	9	O
gene	1	O
,	9	O
beclin	3	O
1	9	O
using	9	O
RT	9	O
-	7	O
PCR	9	O
and	5	O
Western	3	O
blotting	3	O
in	5	O
an	5	O
animal	5	O
model	5	O
.	9	O

RESULTS	9	O
:	9	O
3MA	3	B-Chemical
significantly	9	O
improved	5	O
cardiac	5	O
function	9	O
and	5	O
reduced	9	O
mitochondrial	9	O
injury	9	O
.	9	O

Furthermore	9	O
,	9	O
adriamycin	3	B-Chemical
induced	3	O
the	5	O
formation	9	O
of	5	O
autophagic	3	O
vacuoles	9	O
,	9	O
and	5	O
3MA	3	B-Chemical
strongly	9	O
downregulated	3	O
the	5	O
expression	3	O
of	5	O
beclin	3	O
1	9	O
in	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
failing	5	O
heart	5	O
and	5	O
inhibited	3	O
the	5	O
formation	9	O
of	5	O
autophagic	3	O
vacuoles	9	O
.	9	O

CONCLUSION	5	O
:	9	O
Autophagic	3	O
cardiomyocyte	3	O
death	9	B-Disease
plays	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
in	5	O
rats	9	O
induced	3	O
by	9	O
adriamycin	3	B-Chemical
.	9	O

Mitochondrial	9	O
injury	9	O
may	5	O
be	5	O
involved	9	O
in	5	O
the	5	O
progression	9	O
of	5	O
heart	5	B-Disease
failure	5	I-Disease
caused	9	O
by	9	O
adriamycin	3	B-Chemical
via	9	O
the	5	O
autophagy	3	O
pathway	3	O
.	9	O

mToR	3	O
inhibitors	3	O
-	7	O
induced	3	O
proteinuria	9	B-Disease
:	9	O
mechanisms	9	O
,	9	O
significance	9	O
,	9	O
and	5	O
management	5	O
.	9	O

Massive	5	O
urinary	9	O
protein	1	O
excretion	0	O
has	9	O
been	9	O
observed	9	O
after	9	O
conversion	9	O
from	9	O
calcineurin	3	O
inhibitors	3	O
to	5	O
mammalian	9	O
target	9	O
of	5	O
rapamycin	3	B-Chemical
(	9	O
mToR	3	O
)	9	O
inhibitors	3	O
,	9	O
especially	5	O
sirolimus	0	B-Chemical
,	9	O
in	5	O
renal	9	O
transplant	9	O
recipients	9	O
with	5	O
chronic	5	B-Disease
allograft	5	I-Disease
nephropathy	9	I-Disease
.	9	O

Because	9	O
proteinuria	9	B-Disease
is	5	O
a	5	O
major	9	O
predictive	5	O
factor	9	O
of	5	O
poor	5	O
transplantation	9	O
outcome	5	O
,	9	O
many	5	O
studies	9	O
focused	5	O
on	5	O
this	5	O
adverse	5	O
event	5	O
during	5	O
the	5	O
past	5	O
years	5	O
.	9	O

Whether	9	O
proteinuria	9	B-Disease
was	9	O
due	5	O
to	5	O
sirolimus	0	B-Chemical
or	5	O
only	9	O
a	5	O
consequence	5	O
of	5	O
calcineurin	3	O
inhibitors	3	O
withdrawal	5	O
remained	9	O
unsolved	9	O
until	5	O
high	9	O
range	9	O
proteinuria	9	B-Disease
has	9	O
been	9	O
observed	9	O
during	5	O
sirolimus	0	B-Chemical
therapy	5	O
in	5	O
islet	3	O
transplantation	9	O
and	5	O
in	5	O
patients	5	O
who	5	O
received	9	O
sirolimus	0	B-Chemical
de	2	O
novo	9	O
.	9	O

Podocyte	3	O
injury	9	O
and	5	O
focal	5	O
segmental	5	O
glomerulosclerosis	3	B-Disease
have	5	O
been	9	O
related	9	O
to	5	O
mToR	3	O
inhibition	3	O
in	5	O
some	5	O
patients	5	O
,	9	O
but	9	O
the	5	O
pathways	9	O
underlying	5	O
these	5	O
lesions	5	O
remain	9	O
hypothetic	5	O
.	9	O

We	9	O
discuss	5	O
herein	9	O
the	5	O
possible	5	O
mechanisms	9	O
and	5	O
the	5	O
significance	9	O
of	5	O
mToR	3	O
blockade	3	O
-	7	O
induced	3	O
proteinuria	9	B-Disease
.	9	O

Neuropsychiatric	5	O
side	5	O
effects	9	O
after	9	O
the	5	O
use	5	O
of	5	O
mefloquine	0	B-Chemical
.	9	O

This	5	O
study	9	O
describes	5	O
neuropsychiatric	5	O
side	5	O
effects	9	O
in	5	O
patients	5	O
after	9	O
treatment	9	O
with	5	O
mefloquine	0	B-Chemical
.	9	O

Reactions	0	O
consisted	5	O
mainly	9	O
of	5	O
seizures	5	B-Disease
,	9	O
acute	9	O
psychoses	5	B-Disease
,	9	O
anxiety	5	B-Disease
neurosis	5	I-Disease
,	9	O
and	5	O
major	9	O
disturbances	5	B-Disease
of	5	I-Disease
sleep	5	I-Disease
-	7	I-Disease
wake	5	I-Disease
rhythm	5	I-Disease
.	9	O

Side	5	O
effects	9	O
occurred	9	O
after	9	O
both	9	O
therapeutic	5	O
and	5	O
prophylactic	5	O
intake	5	O
and	5	O
were	9	O
graded	5	O
from	9	O
moderate	9	O
to	5	O
severe	5	O
.	9	O

In	9	O
a	5	O
risk	5	O
analysis	9	O
of	5	O
neuropsychiatric	5	O
side	5	O
effects	9	O
in	5	O
Germany	2	O
,	9	O
it	5	O
is	5	O
estimated	5	O
that	5	O
one	5	O
of	5	O
8	9	O
,	9	O
000	9	O
mefloquine	0	B-Chemical
users	5	O
suffers	5	O
from	9	O
such	5	O
reactions	9	O
.	9	O

The	5	O
incidence	5	O
calculation	5	O
revealed	9	O
that	5	O
one	5	O
of	5	O
215	7	O
therapeutic	5	O
users	5	O
had	9	O
reactions	9	O
,	9	O
compared	9	O
with	5	O
one	5	O
of	5	O
13	7	O
,	9	O
000	9	O
in	5	O
the	5	O
prophylaxis	5	O
group	9	O
,	9	O
making	5	O
the	5	O
risk	5	O
of	5	O
neuropsychiatric	5	O
reactions	9	O
after	9	O
mefloquine	0	B-Chemical
treatment	9	O
60	9	O
times	5	O
higher	9	O
than	5	O
after	9	O
prophylaxis	5	O
.	9	O

Therefore	9	O
,	9	O
certain	5	O
limitations	5	O
for	5	O
malaria	5	B-Disease
prophylaxis	5	O
and	5	O
treatment	9	O
with	5	O
mefloquine	0	B-Chemical
are	5	O
recommended	5	O
.	9	O

Prenatal	5	O
protein	1	O
deprivation	9	O
alters	9	O
dopamine	5	B-Chemical
-	7	O
mediated	3	O
behaviors	5	O
and	5	O
dopaminergic	5	O
and	5	O
glutamatergic	3	O
receptor	3	O
binding	1	O
.	9	O

Epidemiological	5	O
evidence	9	O
indicates	9	O
that	5	O
prenatal	5	O
nutritional	5	O
deprivation	9	O
may	5	O
increase	9	O
the	5	O
risk	5	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

The	5	O
goal	5	O
of	5	O
these	5	O
studies	9	O
was	9	O
to	5	O
use	5	O
an	5	O
animal	5	O
model	5	O
to	5	O
examine	9	O
the	5	O
effects	9	O
of	5	O
prenatal	5	O
protein	1	O
deprivation	9	O
on	5	O
behaviors	5	O
and	5	O
receptor	3	O
binding	1	O
with	5	O
relevance	9	O
to	5	O
schizophrenia	5	B-Disease
.	9	O

We	9	O
report	5	O
that	5	O
prenatally	5	O
protein	1	O
deprived	9	O
(	9	O
PD	9	O
)	9	O
female	9	O
rats	9	O
showed	9	O
an	5	O
increased	9	O
stereotypic	5	O
response	9	O
to	5	O
apomorphine	0	B-Chemical
and	5	O
an	5	O
increased	9	O
locomotor	5	O
response	9	O
to	5	O
amphetamine	5	B-Chemical
in	5	O
adulthood	5	O
.	9	O

These	5	O
differences	9	O
were	9	O
not	5	O
observed	9	O
during	5	O
puberty	5	O
.	9	O

No	9	O
changes	9	O
in	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
catalepsy	5	B-Disease
or	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
-	7	O
induced	3	O
locomotion	5	O
were	9	O
seen	9	O
following	9	O
PD	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
PD	9	O
female	9	O
rats	9	O
showed	9	O
increased	9	O
(	9	O
3	9	O
)	9	O
H	9	B-Chemical
-	7	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
binding	1	O
in	5	O
the	5	O
striatum	9	O
and	5	O
hippocampus	9	O
,	9	O
but	9	O
not	5	O
in	5	O
the	5	O
cortex	5	O
.	9	O

PD	9	O
female	9	O
rats	9	O
also	9	O
showed	9	O
increased	9	O
(	9	O
3	9	O
)	9	O
H	9	B-Chemical
-	7	O
haloperidol	5	B-Chemical
binding	1	O
and	5	O
decreased	9	O
dopamine	5	B-Chemical
transporter	1	O
binding	1	O
in	5	O
striatum	9	O
.	9	O

No	9	O
statistically	9	O
significant	9	O
changes	9	O
in	5	O
behavior	5	O
or	5	O
receptor	3	O
binding	1	O
were	9	O
found	9	O
in	5	O
PD	9	O
males	9	O
with	5	O
the	5	O
exception	9	O
of	5	O
increased	9	O
(	9	O
3	9	O
)	9	O
H	9	B-Chemical
-	7	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
binding	1	O
in	5	O
cortex	5	O
.	9	O

This	5	O
animal	5	O
model	5	O
may	5	O
be	5	O
useful	5	O
to	5	O
explore	5	O
the	5	O
mechanisms	9	O
by	9	O
which	5	O
prenatal	5	O
nutritional	5	B-Disease
deficiency	9	I-Disease
enhances	3	O
risk	5	O
for	5	O
schizophrenia	5	B-Disease
in	5	O
humans	9	O
and	5	O
may	5	O
also	9	O
have	5	O
implications	5	O
for	5	O
developmental	9	O
processes	5	O
leading	9	O
to	5	O
differential	9	O
sensitivity	9	O
to	5	O
drugs	5	O
of	5	O
abuse	5	O
.	9	O

Adverse	5	O
effects	9	O
of	5	O
topical	0	O
papaverine	0	B-Chemical
on	5	O
auditory	5	O
nerve	5	O
function	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Papaverine	0	B-Chemical
hydrochloride	0	I-Chemical
is	5	O
a	5	O
direct	9	O
-	7	O
acting	9	O
vasodilator	0	O
used	5	O
to	5	O
manage	5	O
vasospasm	5	B-Disease
during	5	O
various	9	O
neurosurgical	5	O
operations	5	O
.	9	O

Transient	9	O
cranial	5	B-Disease
nerve	5	I-Disease
dysfunction	9	I-Disease
has	9	O
been	9	O
described	9	O
in	5	O
a	5	O
few	5	O
cases	5	O
with	5	O
topical	0	O
papaverine	0	B-Chemical
.	9	O

This	5	O
study	9	O
supports	9	O
previous	9	O
reports	9	O
and	5	O
provides	5	O
neurophysiological	5	O
evidence	9	O
of	5	O
an	5	O
adverse	5	O
effect	9	O
on	5	O
the	5	O
auditory	5	O
nerve	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
conducted	9	O
a	5	O
retrospective	5	O
review	5	O
of	5	O
70	9	O
consecutive	5	O
microvascular	5	O
decompression	5	O
operations	5	O
and	5	O
studied	9	O
those	5	O
patients	5	O
who	5	O
received	9	O
topical	0	O
papaverine	0	B-Chemical
for	5	O
vasospasm	5	B-Disease
.	9	O

Topical	0	O
papaverine	0	B-Chemical
was	9	O
used	5	O
as	5	O
a	5	O
direct	9	O
therapeutic	5	O
action	5	O
to	5	O
manage	5	O
vasospasm	5	B-Disease
in	5	O
a	5	O
total	9	O
of	5	O
11	7	O
patients	5	O
.	9	O

The	5	O
timing	5	O
of	5	O
papaverine	0	B-Chemical
application	5	O
and	5	O
ongoing	5	O
operative	5	O
events	5	O
was	9	O
reviewed	9	O
relative	9	O
to	5	O
changes	9	O
in	5	O
neurophysiological	5	O
recordings	5	O
.	9	O

Brainstem	5	O
auditory	5	O
evoked	5	O
potentials	5	O
(	9	O
BAEPs	5	O
)	9	O
were	9	O
routinely	9	O
used	5	O
to	5	O
monitor	5	O
cochlear	5	O
nerve	5	O
function	9	O
during	5	O
these	5	O
operations	5	O
.	9	O

FINDINGS	2	O
:	9	O
A	9	O
temporal	5	O
relationship	5	O
was	9	O
found	9	O
between	5	O
topical	0	O
papaverine	0	B-Chemical
and	5	O
BAEP	5	O
changes	9	O
leading	9	O
to	5	O
complete	9	O
waveform	5	O
loss	9	O
.	9	O

The	5	O
average	5	O
temporal	5	O
delay	5	O
between	5	O
papaverine	0	B-Chemical
and	5	O
the	5	O
onset	5	O
of	5	O
an	5	O
adverse	5	O
BAEP	5	O
change	9	O
was	9	O
5	9	O
min	0	O
.	9	O

In	9	O
10	9	O
of	5	O
11	7	O
patients	5	O
,	9	O
BAEP	5	O
waves	5	O
II	9	O
/	9	O
III	9	O
-	7	O
V	9	O
completely	9	O
disappeared	9	O
within	9	O
2	9	O
to	5	O
25	9	O
min	0	O
after	9	O
papaverine	0	B-Chemical
.	9	O

Eight	9	O
of	5	O
these	5	O
10	9	O
patients	5	O
had	9	O
complete	9	O
loss	9	O
of	5	O
BAEP	5	O
waveforms	5	O
within	9	O
10	9	O
min	0	O
.	9	O

One	5	O
patient	5	O
showed	9	O
no	9	O
recovery	9	O
of	5	O
later	9	O
waves	5	O
and	5	O
a	5	O
delayed	9	O
profound	9	O
sensorineural	5	B-Disease
hearing	5	I-Disease
loss	9	I-Disease
.	9	O

The	5	O
average	5	O
recovery	9	O
time	5	O
of	5	O
BAEP	5	O
waveforms	5	O
to	5	O
pre	9	O
-	7	O
papaverine	0	B-Chemical
baseline	5	O
values	5	O
was	9	O
39	7	O
min	0	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Topical	0	O
papaverine	0	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
vasospasm	5	B-Disease
was	9	O
associated	9	O
with	5	O
the	5	O
onset	5	O
of	5	O
a	5	O
transient	9	O
disturbance	5	O
in	5	O
neurophysiological	5	O
function	9	O
of	5	O
the	5	O
ascending	5	O
auditory	5	O
brainstem	5	O
pathway	3	O
.	9	O

The	5	O
complete	9	O
disappearance	9	O
of	5	O
BAEP	5	O
waveforms	5	O
with	5	O
a	5	O
consistent	9	O
temporal	5	O
delay	5	O
suggests	9	O
a	5	O
possible	5	O
adverse	5	B-Disease
effect	9	I-Disease
on	5	I-Disease
the	5	I-Disease
proximal	9	I-Disease
eighth	5	I-Disease
nerve	5	I-Disease
.	9	O

Recommendations	5	O
to	5	O
avoid	5	O
potential	9	O
cranial	5	B-Disease
nerve	5	I-Disease
deficits	5	I-Disease
from	9	O
papaverine	0	B-Chemical
are	5	O
provided	9	O
.	9	O

Simvastatin	0	B-Chemical
-	7	I-Chemical
ezetimibe	0	I-Chemical
-	7	O
induced	3	O
hepatic	9	B-Disease
failure	5	I-Disease
necessitating	5	O
liver	9	O
transplantation	9	O
.	9	O

Abstract	2	O
Serum	9	O
aminotransferase	7	O
elevations	9	O
are	5	O
a	5	O
commonly	5	O
known	9	O
adverse	5	O
effect	9	O
of	5	O
3	9	O
-	7	O
hydroxy	0	O
-	7	O
3	9	O
-	7	O
methylglutaryl	1	O
coenzyme	0	O
A	9	O
reductase	0	O
inhibitor	3	O
(	9	O
statin	5	B-Chemical
)	9	O
therapy	5	O
.	9	O

However	9	O
,	9	O
hepatotoxic	0	B-Disease
events	5	O
have	5	O
not	5	O
been	9	O
widely	5	O
published	9	O
with	5	O
ezetimibe	0	B-Chemical
or	5	O
the	5	O
combination	9	O
agent	9	O
simvastatin	0	B-Chemical
-	7	I-Chemical
ezetimibe	0	I-Chemical
.	9	O

We	9	O
describe	5	O
a	5	O
70	9	O
-	7	O
year	5	O
-	7	O
old	5	O
Hispanic	7	O
woman	5	O
who	5	O
developed	5	O
fulminant	5	B-Disease
hepatic	9	I-Disease
failure	5	I-Disease
necessitating	5	O
liver	9	O
transplantation	9	O
10	9	O
weeks	9	O
after	9	O
conversion	9	O
from	9	O
simvastatin	0	B-Chemical
40	9	O
mg	0	O
/	9	O
day	9	O
to	5	O
simvastatin	0	B-Chemical
10	9	I-Chemical
mg	0	I-Chemical
-	7	I-Chemical
ezetimibe	0	I-Chemical
40	9	I-Chemical
mg	0	I-Chemical
/	9	O
day	9	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
lipid	0	O
panel	3	O
had	9	O
been	9	O
maintained	9	O
with	5	O
simvastatin	0	B-Chemical
for	5	O
18	7	O
months	5	O
before	9	O
the	5	O
conversion	9	O
without	9	O
evidence	9	O
of	5	O
hepatotoxicity	9	B-Disease
.	9	O

A	9	O
routine	5	O
laboratory	9	O
work	5	O
-	7	O
up	5	O
10	9	O
weeks	9	O
after	9	O
conversion	9	O
revealed	9	O
elevated	9	O
serum	9	O
aminotransferase	7	O
levels	3	O
.	9	O

Simvastatinezetimibe	_	B-Chemical
and	5	O
escitalopram	5	B-Chemical
(	9	O
which	5	O
she	5	O
was	9	O
taking	5	O
for	5	O
depression	5	B-Disease
)	9	O
were	9	O
discontinued	5	O
,	9	O
and	5	O
other	5	O
potential	9	O
causes	9	O
of	5	O
hepatotoxicity	9	B-Disease
were	9	O
excluded	9	O
.	9	O

A	9	O
repeat	9	O
work	5	O
-	7	O
up	5	O
revealed	9	O
further	9	O
elevations	9	O
in	5	O
aminotransferase	7	O
levels	3	O
,	9	O
and	5	O
liver	9	O
biopsy	5	O
revealed	9	O
evidence	9	O
of	5	O
moderate	9	O
-	7	O
to	5	O
-	7	O
severe	5	O
drug	5	B-Disease
toxicity	9	I-Disease
.	9	O

She	5	O
underwent	5	O
liver	9	O
transplantation	9	O
with	5	O
an	5	O
uneventful	5	O
postoperative	5	O
course	5	O
.	9	O

Her	5	O
aminotransferase	7	O
levels	3	O
returned	5	O
to	5	O
normal	9	O
by	9	O
postoperative	5	O
day	9	O
23	7	O
,	9	O
and	5	O
her	5	O
2	9	O
-	7	O
year	5	O
follow	5	O
-	7	O
up	5	O
showed	9	O
no	9	O
adverse	5	O
events	5	O
.	9	O

Ezetimibe	0	B-Chemical
undergoes	9	O
extensive	5	O
glucuronidation	0	O
by	9	O
uridine	0	B-Chemical
diphosphate	0	I-Chemical
glucoronosyltransferases	9	O
(	9	O
UGT	1	O
)	9	O
in	5	O
the	5	O
intestine	9	O
and	5	O
liver	9	O
and	5	O
may	5	O
have	5	O
inhibited	3	O
the	5	O
glucuronidation	0	O
of	5	O
simvastatin	0	B-Chemical
hydroxy	0	I-Chemical
acid	0	I-Chemical
,	9	O
resulting	9	O
in	5	O
increased	9	O
simvastatin	0	B-Chemical
exposure	9	O
and	5	O
subsequent	9	O
hepatotoxicity	9	B-Disease
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
case	5	O
report	5	O
of	5	O
simvastatin	0	B-Chemical
-	7	I-Chemical
ezetimibe	0	I-Chemical
-	7	O
induced	3	O
liver	9	B-Disease
failure	5	I-Disease
that	5	O
resulted	9	O
in	5	O
liver	9	O
transplantation	9	O
.	9	O

We	9	O
postulate	9	O
that	5	O
the	5	O
mechanism	9	O
of	5	O
the	5	O
simvastatinezetimibe	_	B-Chemical
-	7	O
induced	3	O
hepatotoxicity	9	B-Disease
is	5	O
the	5	O
increased	9	O
simvastatin	0	B-Chemical
exposure	9	O
by	9	O
ezetimibe	0	B-Chemical
inhibition	3	O
of	5	O
UGT	1	O
enzymes	1	O
.	9	O

Clinicians	5	O
should	5	O
be	5	O
aware	5	O
of	5	O
potential	9	O
hepatotoxicity	9	B-Disease
with	5	O
simvastatin	0	B-Chemical
-	7	I-Chemical
ezetimibe	0	I-Chemical
especially	5	O
in	5	O
elderly	5	O
patients	5	O
and	5	O
should	5	O
carefully	5	O
monitor	5	O
serum	9	O
aminotransferase	7	O
levels	3	O
when	5	O
starting	9	O
therapy	5	O
and	5	O
titrating	0	O
the	5	O
dosage	9	O
.	9	O

Massive	5	O
proteinuria	9	B-Disease
and	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
after	9	O
oral	9	O
bisphosphonate	5	B-Chemical
(	9	O
alendronate	0	B-Chemical
)	9	O
administration	9	O
in	5	O
a	5	O
patient	5	O
with	5	O
focal	5	B-Disease
segmental	5	I-Disease
glomerulosclerosis	3	I-Disease
.	9	O

A	9	O
61	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Japanese	9	O
man	5	O
with	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
due	5	O
to	5	O
focal	5	B-Disease
segmental	5	I-Disease
glomerulosclerosis	3	I-Disease
was	9	O
initially	9	O
responding	5	O
well	9	O
to	5	O
steroid	9	B-Chemical
therapy	5	O
.	9	O

The	5	O
amount	9	O
of	5	O
daily	5	O
urinary	9	O
protein	1	O
decreased	9	O
from	9	O
15	9	O
.	9	O
6	9	O
to	5	O
2	9	O
.	9	O
8	9	O
g	0	O
.	9	O

Within	9	O
14	7	O
days	9	O
of	5	O
the	5	O
oral	9	O
bisphosphonate	5	B-Chemical
(	9	O
alendronate	0	B-Chemical
sodium	0	I-Chemical
)	9	O
administration	9	O
,	9	O
the	5	O
amount	9	O
of	5	O
daily	5	O
urinary	9	O
protein	1	O
increased	9	O
rapidly	9	O
up	5	O
to	5	O
12	9	O
.	9	O
8	9	O
g	0	O
with	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

After	9	O
discontinuing	5	O
the	5	O
oral	9	O
alendronate	0	B-Chemical
,	9	O
the	5	O
patient	5	O
underwent	5	O
six	9	O
cycles	9	O
of	5	O
hemodialysis	5	O
and	5	O
four	9	O
cycles	9	O
of	5	O
LDL	0	O
apheresis	5	O
.	9	O

Urinary	9	O
volume	9	O
and	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
recovered	9	O
to	5	O
the	5	O
normal	9	O
range	9	O
,	9	O
with	5	O
urinary	9	O
protein	1	O
disappearing	5	O
completely	9	O
within	9	O
40	9	O
days	9	O
.	9	O

This	5	O
report	5	O
demonstrates	9	O
that	5	O
not	5	O
only	9	O
intravenous	0	O
,	9	O
but	9	O
also	9	O
oral	9	O
bisphosphonates	5	B-Chemical
can	5	O
aggravate	9	O
proteinuria	9	B-Disease
and	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

Serum	9	O
-	7	O
and	5	O
glucocorticoid	9	O
-	7	O
inducible	3	O
kinase	3	O
1	9	O
in	5	O
doxorubicin	0	B-Chemical
-	7	O
induced	3	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

Doxorubicin	0	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
leads	9	O
to	5	O
epithelial	3	O
sodium	0	B-Chemical
channel	9	O
(	9	O
ENaC	3	O
)	9	O
-	7	O
dependent	9	O
volume	9	B-Disease
retention	9	I-Disease
and	5	O
renal	9	O
fibrosis	9	B-Disease
.	9	O

The	5	O
aldosterone	9	B-Chemical
-	7	O
sensitive	9	O
serum	9	O
-	7	O
and	5	O
glucocorticoid	9	O
-	7	O
inducible	3	O
kinase	3	O
SGK1	3	O
has	9	O
been	9	O
shown	9	O
to	5	O
participate	5	O
in	5	O
the	5	O
stimulation	3	O
of	5	O
ENaC	3	O
and	5	O
to	5	O
mediate	3	O
renal	9	O
fibrosis	9	B-Disease
following	9	O
mineralocorticoid	5	O
and	5	O
salt	0	O
excess	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
performed	9	O
to	5	O
elucidate	9	O
the	5	O
role	9	O
of	5	O
SGK1	3	O
in	5	O
the	5	O
volume	9	B-Disease
retention	9	I-Disease
and	5	O
fibrosis	9	B-Disease
during	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

To	9	O
this	5	O
end	9	O
,	9	O
doxorubicin	0	B-Chemical
(	9	O
15	9	O
mug	5	O
/	9	O
g	0	O
body	5	O
wt	3	O
)	9	O
was	9	O
injected	3	O
intravenously	0	O
into	9	O
gene	1	O
-	7	O
targeted	9	O
mice	3	O
lacking	1	O
SGK1	3	O
(	9	O
sgk1	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
)	9	O
and	5	O
their	5	O
wild	1	O
-	7	O
type	9	O
littermates	3	O
(	9	O
sgk1	3	O
(	9	O
+	9	O
/	9	O
+	9	O
)	9	O
)	9	O
.	9	O

Doxorubicin	0	B-Chemical
treatment	9	O
resulted	9	O
in	5	O
heavy	9	O
proteinuria	9	B-Disease
(	9	O
>	0	O
100	0	O
mg	0	O
protein	1	O
/	9	O
mg	0	O
crea	0	O
)	9	O
in	5	O
15	9	O
/	9	O
44	7	O
of	5	O
sgk1	3	O
(	9	O
+	9	O
/	9	O
+	9	O
)	9	O
and	5	O
15	9	O
/	9	O
44	7	O
of	5	O
sgk1	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
leading	9	O
to	5	O
severe	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
with	5	O
ascites	3	B-Disease
,	9	O
lipidemia	5	B-Disease
,	9	O
and	5	O
hypoalbuminemia	5	B-Disease
in	5	O
both	9	O
genotypes	9	O
.	9	O

Plasma	0	O
aldosterone	9	B-Chemical
levels	3	O
increased	9	O
in	5	O
nephrotic	5	B-Disease
mice	3	O
of	5	O
both	9	O
genotypes	9	O
and	5	O
was	9	O
followed	9	O
by	9	O
increased	9	O
SGK1	3	O
protein	1	O
expression	3	O
in	5	O
sgk1	3	O
(	9	O
+	9	O
/	9	O
+	9	O
)	9	O
mice	3	O
.	9	O

Urinary	9	O
sodium	0	B-Chemical
excretion	0	O
reached	9	O
signficantly	3	O
lower	9	O
values	5	O
in	5	O
sgk1	3	O
(	9	O
+	9	O
/	9	O
+	9	O
)	9	O
mice	3	O
(	9	O
15	9	O
+	9	O
/	9	O
-	7	O
5	9	O
mumol	7	O
/	9	O
mg	0	O
crea	0	O
)	9	O
than	5	O
in	5	O
sgk1	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
(	9	O
35	9	O
+	9	O
/	9	O
-	7	O
5	9	O
mumol	7	O
/	9	O
mg	0	O
crea	0	O
)	9	O
and	5	O
was	9	O
associated	9	O
with	5	O
a	5	O
significantly	9	O
higher	9	O
body	5	O
weight	9	B-Disease
gain	5	I-Disease
in	5	O
sgk1	3	O
(	9	O
+	9	O
/	9	O
+	9	O
)	9	O
compared	9	O
with	5	O
sgk1	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
(	9	O
+	9	O
6	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
7	9	O
vs	7	O
.	9	O
+	9	O
4	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
8	9	O
g	0	O
)	9	O
.	9	O

During	5	O
the	5	O
course	5	O
of	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
,	9	O
serum	9	O
urea	0	B-Chemical
concentrations	0	O
increased	9	O
significantly	9	O
faster	5	O
in	5	O
sgk1	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
than	5	O
in	5	O
sgk1	3	O
(	9	O
+	9	O
/	9	O
+	9	O
)	9	O
mice	3	O
leading	9	O
to	5	O
uremia	5	B-Disease
and	5	O
a	5	O
reduced	9	O
median	9	O
survival	9	O
in	5	O
sgk1	3	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
(	9	O
29	7	O
vs	7	O
.	9	O
40	9	O
days	9	O
in	5	O
sgk1	3	O
(	9	O
+	9	O
/	9	O
+	9	O
)	9	O
mice	3	O
)	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
gene	1	O
-	7	O
targeted	9	O
mice	3	O
lacking	1	O
SGK1	3	O
showed	9	O
blunted	9	O
volume	9	B-Disease
retention	9	I-Disease
,	9	O
yet	9	O
were	9	O
not	5	O
protected	9	O
against	9	O
renal	9	O
fibrosis	9	B-Disease
during	5	O
experimental	5	O
nephrotic	5	B-Disease
syndrome	5	I-Disease
.	9	O

Severe	9	O
thrombocytopenia	9	B-Disease
and	5	O
haemolytic	9	B-Disease
anaemia	5	I-Disease
associated	9	O
with	5	O
ciprofloxacin	0	B-Chemical
:	9	O
a	5	O
case	5	O
report	5	O
with	5	O
fatal	5	O
outcome	5	O
.	9	O

Haematological	9	O
adverse	5	O
reactions	9	O
associated	9	O
with	5	O
fatal	5	O
outcome	5	O
are	5	O
rare	5	O
during	5	O
treatment	9	O
with	5	O
ciprofloxacin	0	B-Chemical
.	9	O

A	9	O
30	9	O
-	7	O
year	5	O
old	5	O
Caucasian	9	O
man	5	O
reported	9	O
with	5	O
abdominal	5	B-Disease
pain	5	I-Disease
and	5	O
jaundice	5	B-Disease
after	9	O
3	9	O
-	7	O
day	9	O
administration	9	O
of	5	O
oral	9	O
ciprofloxacin	0	B-Chemical
for	5	O
a	5	O
suspect	5	O
of	5	O
urinary	9	B-Disease
tract	9	I-Disease
infection	9	I-Disease
.	9	O

Clinical	5	O
evaluations	5	O
suggested	9	O
an	5	O
initial	9	O
diagnosis	5	O
of	5	O
severe	5	O
thrombocytopenia	9	B-Disease
and	5	O
haemolysis	9	B-Disease
.	9	O

The	5	O
patient	5	O
progressively	9	O
developed	5	O
petechiae	5	B-Disease
and	5	O
purpura	5	B-Disease
on	5	O
thorax	5	O
and	5	O
lower	9	O
limbs	5	O
.	9	O

Despite	5	O
pharmacological	9	O
and	5	O
supportive	5	O
interventions	5	O
,	9	O
laboratory	9	O
parameters	5	O
worsened	5	O
and	5	O
the	5	O
patient	5	O
died	9	O
17	7	O
hours	9	O
after	9	O
admission	5	O
.	9	O

An	5	O
accurate	5	O
autopsy	5	O
revealed	9	O
most	9	O
organs	9	O
with	5	O
diffuse	5	O
petechial	5	O
haemorrhages	5	B-Disease
.	9	O

No	9	O
signs	5	O
of	5	O
bone	5	B-Disease
marrow	3	I-Disease
depression	5	I-Disease
were	9	O
found	9	O
.	9	O

No	9	O
thrombi	5	B-Disease
or	5	O
signs	5	O
of	5	O
microangiopathies	5	B-Disease
were	9	O
observed	9	O
in	5	O
arterial	5	O
vessels	5	O
.	9	O

Blood	9	O
and	5	O
urine	9	O
cultures	3	O
did	9	O
not	5	O
show	9	O
any	5	O
bacterial	9	O
growth	3	O
.	9	O

This	5	O
case	5	O
report	5	O
shows	9	O
that	5	O
ciprofloxacin	0	B-Chemical
may	5	O
precipitate	0	O
life	5	O
-	7	O
threatening	5	O
thrombocytopenia	9	B-Disease
and	5	O
haemolytic	9	B-Disease
anaemia	5	I-Disease
,	9	O
even	5	O
in	5	O
the	5	O
early	9	O
phases	5	O
of	5	O
treatment	9	O
and	5	O
without	9	O
apparent	9	O
previous	9	O
exposures	5	O
.	9	O

Alpha	9	B-Chemical
-	7	I-Chemical
lipoic	0	I-Chemical
acid	0	I-Chemical
prevents	9	O
mitochondrial	9	B-Disease
damage	9	I-Disease
and	5	O
neurotoxicity	9	B-Disease
in	5	O
experimental	5	O
chemotherapy	5	O
neuropathy	5	B-Disease
.	9	O

The	5	O
study	9	O
investigates	5	O
if	5	O
alpha	9	B-Chemical
-	7	I-Chemical
lipoic	0	I-Chemical
acid	0	I-Chemical
is	5	O
neuroprotective	9	O
against	9	O
chemotherapy	5	O
induced	3	O
neurotoxicity	9	B-Disease
,	9	O
if	5	O
mitochondrial	9	B-Disease
damage	9	I-Disease
plays	9	O
a	5	O
critical	9	O
role	9	O
in	5	O
toxic	0	B-Disease
neurodegenerative	9	I-Disease
cascade	9	I-Disease
,	9	O
and	5	O
if	5	O
neuroprotective	9	O
effects	9	O
of	5	O
alpha	9	B-Chemical
-	7	I-Chemical
lipoic	0	I-Chemical
acid	0	I-Chemical
depend	5	O
on	5	O
mitochondria	3	O
protection	9	O
.	9	O

We	9	O
used	5	O
an	5	O
in	5	O
vitro	3	O
model	5	O
of	5	O
chemotherapy	5	O
induced	3	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
that	5	O
closely	9	O
mimic	9	O
the	5	O
in	5	O
vivo	3	O
condition	5	O
by	9	O
exposing	9	O
primary	9	O
cultures	3	O
of	5	O
dorsal	5	O
root	5	O
ganglion	5	O
(	9	O
DRG	3	O
)	9	O
sensory	5	O
neurons	3	O
to	5	O
paclitaxel	0	B-Chemical
and	5	O
cisplatin	3	B-Chemical
,	9	O
two	5	O
widely	5	O
used	5	O
and	5	O
highly	9	O
effective	5	O
chemotherapeutic	3	O
drugs	5	O
.	9	O

This	5	O
approach	5	O
allowed	9	O
investigating	5	O
the	5	O
efficacy	9	O
of	5	O
alpha	9	B-Chemical
-	7	I-Chemical
lipoic	0	I-Chemical
acid	0	I-Chemical
in	5	O
preventing	9	O
axonal	3	B-Disease
damage	9	I-Disease
and	5	O
apoptosis	3	O
and	5	O
the	5	O
function	9	O
and	5	O
ultrastructural	9	O
morphology	9	O
of	5	O
mitochondria	3	O
after	9	O
exposure	9	O
to	5	O
toxic	0	O
agents	5	O
and	5	O
alpha	9	B-Chemical
-	7	I-Chemical
lipoic	0	I-Chemical
acid	0	I-Chemical
.	9	O

Our	9	O
results	9	O
demonstrate	9	O
that	5	O
both	9	O
cisplatin	3	B-Chemical
and	5	O
paclitaxel	0	B-Chemical
cause	5	O
early	9	O
mitochondrial	9	B-Disease
impairment	5	I-Disease
with	5	O
loss	9	O
of	5	O
membrane	9	O
potential	9	O
and	5	O
induction	3	O
of	5	O
autophagic	3	O
vacuoles	9	O
in	5	O
neurons	3	O
.	9	O

Alpha	9	B-Chemical
-	7	I-Chemical
lipoic	0	I-Chemical
acid	0	I-Chemical
exerts	9	O
neuroprotective	9	O
effects	9	O
against	9	O
chemotherapy	5	O
induced	3	O
neurotoxicity	9	B-Disease
in	5	O
sensory	5	O
neurons	3	O
:	9	O
it	5	O
rescues	3	O
the	5	O
mitochondrial	9	B-Disease
toxicity	9	I-Disease
and	5	O
induces	3	O
the	5	O
expression	3	O
of	5	O
frataxin	1	O
,	9	O
an	5	O
essential	9	O
mitochondrial	9	O
protein	1	O
with	5	O
anti	3	O
-	7	O
oxidant	0	O
and	5	O
chaperone	1	O
properties	9	O
.	9	O

In	9	O
conclusion	9	O
mitochondrial	9	B-Disease
toxicity	9	I-Disease
is	5	O
an	5	O
early	9	O
common	5	O
event	5	O
both	9	O
in	5	O
paclitaxel	0	B-Chemical
and	5	O
cisplatin	3	B-Chemical
induced	3	O
neurotoxicity	9	B-Disease
.	9	O

Alpha	9	B-Chemical
-	7	I-Chemical
lipoic	0	I-Chemical
acid	0	I-Chemical
protects	3	O
sensory	5	O
neurons	3	O
through	9	O
its	9	O
anti	3	O
-	7	O
oxidant	0	O
and	5	O
mitochondrial	9	O
regulatory	1	O
functions	9	O
,	9	O
possibly	9	O
inducing	3	O
the	5	O
expression	3	O
of	5	O
frataxin	1	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
alpha	9	B-Chemical
-	7	I-Chemical
lipoic	0	I-Chemical
acid	0	I-Chemical
might	9	O
reduce	5	O
the	5	O
risk	5	O
of	5	O
developing	5	O
peripheral	9	B-Disease
nerve	5	I-Disease
toxicity	9	I-Disease
in	5	O
patients	5	O
undergoing	9	O
chemotherapy	5	O
and	5	O
encourage	5	O
further	9	O
confirmatory	5	O
clinical	5	O
trials	5	O
.	9	O

Toxicity	9	B-Disease
in	5	O
rhesus	9	O
monkeys	5	O
following	9	O
administration	9	O
of	5	O
the	5	O
8	9	B-Chemical
-	7	I-Chemical
aminoquinoline	0	I-Chemical
8	9	B-Chemical
-	7	I-Chemical
[	9	I-Chemical
(	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
amino	1	I-Chemical
-	7	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
methylbutyl	0	I-Chemical
)	9	I-Chemical
amino	1	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
l	0	I-Chemical
-	7	I-Chemical
hexyloxy	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
6	9	I-Chemical
-	7	I-Chemical
methoxy	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
methylquinoline	_	I-Chemical
(	9	O
WR242511	_	B-Chemical
)	9	O
.	9	O

INTRODUCTION	5	O
:	9	O
Many	5	O
substances	0	O
that	5	O
form	9	O
methemoglobin	0	O
(	9	O
MHb	3	O
)	9	O
effectively	5	O
counter	5	O
cyanide	0	O
(	9	O
CN	9	O
)	9	O
toxicity	9	B-Disease
.	9	O

Although	9	O
MHb	3	O
formers	0	O
are	5	O
generally	5	O
applied	5	O
as	5	O
treatments	9	O
for	5	O
CN	9	O
poisoning	5	B-Disease
,	9	O
it	5	O
has	9	O
been	9	O
proposed	5	O
that	5	O
a	5	O
stable	9	O
,	9	O
long	5	O
-	7	O
acting	9	O
MHb	3	O
former	5	O
could	9	O
serve	5	O
as	5	O
a	5	O
CN	9	O
pretreatment	0	O
.	9	O

Using	9	O
this	5	O
rationale	5	O
,	9	O
the	5	O
8	9	B-Chemical
-	7	I-Chemical
aminoquinoline	0	I-Chemical
WR242511	_	B-Chemical
,	9	O
a	5	O
potent	3	O
long	5	O
-	7	O
lasting	5	O
MHb	3	O
former	5	O
in	5	O
rodents	9	O
and	5	O
beagle	0	O
dogs	5	O
,	9	O
was	9	O
studied	9	O
in	5	O
the	5	O
rhesus	9	O
monkey	9	O
for	5	O
advanced	5	O
development	9	O
as	5	O
a	5	O
potential	9	O
CN	9	O
pretreatment	0	O
.	9	O

METHODS	2	O
:	9	O
In	9	O
this	5	O
study	9	O
,	9	O
WR242511	_	B-Chemical
was	9	O
administered	9	O
intravenously	0	O
(	9	O
IV	9	O
)	9	O
in	5	O
2	9	O
female	9	O
and	5	O
4	9	O
male	9	O
rhesus	9	O
monkeys	5	O
in	5	O
doses	0	O
of	5	O
3	9	O
.	9	O
5	9	O
and	5	O
/	9	O
or	5	O
7	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
;	9	O
a	5	O
single	9	O
male	9	O
also	9	O
received	9	O
WR242511	_	B-Chemical
orally	0	O
(	9	O
PO	9	O
)	9	O
at	9	O
7	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
.	9	O

Health	2	O
status	9	O
and	5	O
MHb	3	O
levels	3	O
were	9	O
monitored	9	O
following	9	O
exposure	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
selected	9	O
doses	0	O
of	5	O
WR242511	_	B-Chemical
,	9	O
which	5	O
produced	9	O
significant	9	O
methemoglobinemia	5	B-Disease
in	5	O
beagle	0	O
dogs	5	O
in	5	O
earlier	9	O
studies	9	O
conducted	9	O
elsewhere	9	O
,	9	O
produced	9	O
very	5	O
little	9	O
MHb	3	O
(	9	O
mean	5	O
<	0	O
2	9	O
.	9	O
0	7	O
%	9	O
)	9	O
in	5	O
the	5	O
rhesus	9	O
monkey	9	O
.	9	O

Furthermore	9	O
,	9	O
transient	9	O
hemoglobinuria	3	B-Disease
was	9	O
noted	9	O
approximately	9	O
60	9	O
minutes	0	O
postinjection	0	O
of	5	O
WR242511	_	B-Chemical
(	9	O
3	9	O
.	9	O
5	9	O
or	5	O
7	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
and	5	O
2	9	O
lethalities	3	O
occurred	9	O
(	9	O
one	5	O
IV	9	O
and	5	O
one	5	O
PO	9	O
)	9	O
following	9	O
the	5	O
7	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
dose	9	O
.	9	O

Myoglobinuria	7	B-Disease
was	9	O
also	9	O
observed	9	O
following	9	O
the	5	O
7	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
dose	9	O
.	9	O

Histopathology	9	O
analyses	9	O
in	5	O
the	5	O
2	9	O
animals	9	O
that	5	O
died	9	O
revealed	9	O
liver	9	B-Disease
and	5	I-Disease
kidney	9	I-Disease
toxicity	9	I-Disease
,	9	O
with	5	O
greater	5	O
severity	5	O
in	5	O
the	5	O
orally	0	O
-	7	O
treated	3	O
animal	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
These	5	O
data	5	O
demonstrate	9	O
direct	9	O
and	5	O
/	9	O
or	5	O
indirect	5	O
drug	5	O
-	7	O
induced	3	O
toxicity	9	B-Disease
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
WR242511	_	B-Chemical
should	5	O
not	5	O
be	5	O
pursued	5	O
as	5	O
a	5	O
pretreatment	0	O
for	5	O
CN	9	O
poisoning	5	B-Disease
unless	9	O
the	5	O
anti	3	O
-	7	O
CN	9	O
characteristics	5	O
of	5	O
this	5	O
compound	0	O
can	5	O
be	5	O
successfully	5	O
dissociated	3	O
from	9	O
those	5	O
producing	9	O
undesirable	5	O
toxicity	9	B-Disease
.	9	O

Repetitive	5	O
transcranial	5	O
magnetic	0	O
stimulation	3	O
for	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

In	9	O
a	5	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
single	9	O
-	7	O
blinded	5	O
,	9	O
crossover	5	O
study	9	O
,	9	O
we	5	O
assessed	9	O
the	5	O
effect	9	O
of	5	O
"	5	O
real	5	O
"	5	O
repetitive	5	O
transcranial	5	O
magnetic	0	O
stimulation	3	O
(	9	O
rTMS	5	O
)	9	O
versus	9	O
"	5	O
sham	9	O
"	5	O
rTMS	5	O
(	9	O
placebo	9	O
)	9	O
on	5	O
peak	9	O
dose	9	O
dyskinesias	5	B-Disease
in	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
.	9	O

Ten	9	O
patients	5	O
with	5	O
PD	9	B-Disease
and	5	O
prominent	9	O
dyskinesias	5	B-Disease
had	9	O
rTMS	5	O
(	9	O
1	9	O
,	9	O
800	0	O
pulses	5	O
;	9	O
1	9	O
Hz	5	O
rate	9	O
)	9	O
delivered	5	O
over	5	O
the	5	O
motor	5	O
cortex	5	O
for	5	O
4	9	O
consecutive	5	O
days	9	O
twice	9	O
,	9	O
once	5	O
real	5	O
stimuli	5	O
and	5	O
once	5	O
sham	9	O
stimulation	3	O
were	9	O
used	5	O
;	9	O
evaluations	5	O
were	9	O
done	9	O
at	9	O
the	5	O
baseline	5	O
and	5	O
1	9	O
day	9	O
after	9	O
the	5	O
end	9	O
of	5	O
each	5	O
of	5	O
the	5	O
treatment	9	O
series	5	O
.	9	O

Direct	9	O
comparison	9	O
between	5	O
sham	9	O
and	5	O
real	5	O
rTMS	5	O
effects	9	O
showed	9	O
no	9	O
significant	9	O
difference	9	O
in	5	O
clinician	5	O
-	7	O
assessed	9	O
dyskinesia	5	B-Disease
severity	5	O
.	9	O

However	9	O
,	9	O
comparison	9	O
with	5	O
the	5	O
baseline	5	O
showed	9	O
small	9	O
but	9	O
significant	9	O
reduction	9	O
in	5	O
dyskinesia	5	B-Disease
severity	5	O
following	9	O
real	5	O
rTMS	5	O
but	9	O
not	5	O
placebo	9	O
.	9	O

The	5	O
major	9	O
effect	9	O
was	9	O
on	5	O
dystonia	5	B-Disease
subscore	5	O
.	9	O

Similarly	9	O
,	9	O
in	5	O
patient	5	O
diaries	5	O
,	9	O
although	9	O
both	9	O
treatments	9	O
caused	9	O
reduction	9	O
in	5	O
subjective	5	O
dyskinesia	5	B-Disease
scores	5	O
during	5	O
the	5	O
days	9	O
of	5	O
intervention	5	O
,	9	O
the	5	O
effect	9	O
was	9	O
sustained	5	O
for	5	O
3	9	O
days	9	O
after	9	O
the	5	O
intervention	5	O
for	5	O
the	5	O
real	5	O
rTMS	5	O
only	9	O
.	9	O

Following	9	O
rTMS	5	O
,	9	O
no	9	O
side	5	O
effects	9	O
and	5	O
no	9	O
adverse	5	O
effects	9	O
on	5	O
motor	5	O
function	9	O
and	5	O
PD	9	B-Disease
symptoms	5	O
were	9	O
noted	9	O
.	9	O

The	5	O
results	9	O
suggest	9	O
the	5	O
existence	9	O
of	5	O
residual	9	O
beneficial	9	O
clinical	5	O
aftereffects	5	O
of	5	O
consecutive	5	O
daily	5	O
applications	5	O
of	5	O
low	9	O
-	7	O
frequency	5	O
rTMS	5	O
on	5	O
dyskinesias	5	B-Disease
in	5	O
PD	9	B-Disease
.	9	O

The	5	O
effects	9	O
may	5	O
be	5	O
further	9	O
exploited	5	O
for	5	O
potential	9	O
therapeutic	5	O
uses	5	O
.	9	O

Intracavernous	9	O
epinephrine	0	B-Chemical
:	9	O
a	5	O
minimally	5	O
invasive	5	O
treatment	9	O
for	5	O
priapism	5	B-Disease
in	5	O
the	5	O
emergency	5	O
department	5	O
.	9	O

Priapism	5	B-Disease
is	5	O
the	5	O
prolonged	9	O
erection	5	O
of	5	O
the	5	O
penis	5	O
in	5	O
the	5	O
absence	3	O
of	5	O
sexual	5	O
arousal	5	O
.	9	O

A	9	O
45	9	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
,	9	O
an	5	O
admitted	5	O
frequent	5	O
cocaine	5	B-Chemical
user	5	O
,	9	O
presented	5	O
to	5	O
the	5	O
Emergency	2	O
Department	2	O
(	9	O
ED	5	O
)	9	O
on	5	O
two	5	O
separate	9	O
occasions	5	O
with	5	O
a	5	O
history	5	O
of	5	O
priapism	5	B-Disease
after	9	O
cocaine	5	B-Chemical
use	5	O
.	9	O

The	5	O
management	5	O
options	5	O
in	5	O
the	5	O
ED	5	O
,	9	O
as	5	O
exemplified	9	O
by	9	O
four	9	O
individual	5	O
case	5	O
reports	9	O
,	9	O
in	5	O
particular	5	O
the	5	O
use	5	O
of	5	O
a	5	O
minimally	5	O
invasive	5	O
method	5	O
of	5	O
intracorporal	5	O
epinephrine	0	B-Chemical
instillation	0	O
,	9	O
are	5	O
discussed	5	O
.	9	O

Prophylactic	5	O
use	5	O
of	5	O
lamivudine	5	B-Chemical
with	5	O
chronic	5	O
immunosuppressive	9	O
therapy	5	O
for	5	O
rheumatologic	5	B-Disease
disorders	5	I-Disease
.	9	O

The	5	O
objective	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
report	5	O
our	5	O
experience	5	O
concerning	5	O
the	5	O
effectiveness	5	O
of	5	O
the	5	O
prophylactic	5	O
administration	9	O
of	5	O
lamivudine	5	B-Chemical
in	5	O
hepatitis	9	B-Chemical
B	9	I-Chemical
virus	9	I-Chemical
surface	9	I-Chemical
antigen	3	I-Chemical
(	9	O
HBs	3	B-Chemical
Ag	0	I-Chemical
)	9	O
positive	9	O
patients	5	O
with	5	O
rheumatologic	5	B-Disease
disease	5	I-Disease
.	9	O

From	5	O
June	2	O
2004	2	O
to	5	O
October	2	O
2006	2	O
,	9	O
11	7	O
HBs	3	B-Chemical
Ag	0	I-Chemical
positive	9	O
patients	5	O
with	5	O
rheumatologic	5	B-Disease
diseases	5	I-Disease
,	9	O
who	5	O
were	9	O
on	5	O
both	9	O
immunosuppressive	9	O
and	5	O
prophylactic	5	O
lamivudine	5	B-Chemical
therapies	5	O
,	9	O
were	9	O
retrospectively	5	O
assessed	9	O
.	9	O

Liver	9	O
function	9	O
tests	5	O
,	9	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
(	9	O
HBV	9	O
)	9	O
serologic	9	O
markers	3	O
,	9	O
and	5	O
HBV	9	O
DNA	9	O
levels	3	O
of	5	O
the	5	O
patients	5	O
during	5	O
follow	5	O
-	7	O
up	5	O
were	9	O
obtained	9	O
from	9	O
hospital	5	O
file	9	O
records	5	O
.	9	O

Eleven	9	O
patients	5	O
(	9	O
six	9	O
male	9	O
)	9	O
with	5	O
median	9	O
age	5	O
47	7	O
years	5	O
(	9	O
range	9	O
27	7	O
-	7	O
73	7	O
)	9	O
,	9	O
median	9	O
disease	5	O
duration	5	O
50	0	O
months	5	O
(	9	O
range	9	O
9	7	O
-	7	O
178	7	O
)	9	O
and	5	O
median	9	O
follow	5	O
-	7	O
up	5	O
period	5	O
of	5	O
patients	5	O
13	7	O
.	9	O
8	9	O
months	5	O
(	9	O
range	9	O
5	9	O
-	7	O
27	7	O
)	9	O
were	9	O
enrolled	5	O
in	5	O
this	5	O
study	9	O
.	9	O

Lamivudine	7	B-Chemical
therapy	5	O
was	9	O
started	5	O
3	9	O
-	7	O
7	9	O
days	9	O
prior	9	O
to	5	O
immunosuppressive	9	O
therapy	5	O
in	5	O
all	5	O
patients	5	O
.	9	O

Baseline	9	O
,	9	O
liver	9	O
function	9	O
tests	5	O
were	9	O
elevated	9	O
in	5	O
two	5	O
patients	5	O
(	9	O
fourth	9	O
patient	5	O
:	9	O
ALT	9	O
:	9	O
122	7	O
IU	0	O
/	9	O
l	0	O
,	9	O
AST	9	O
:	9	O
111	7	O
IU	0	O
/	9	O
l	0	O
,	9	O
tenth	5	O
patient	5	O
:	9	O
ALT	9	O
:	9	O
294	7	O
IU	0	O
/	9	O
l	0	O
,	9	O
AST	9	O
:	9	O
274	7	O
IU	0	O
/	9	O
l	0	O
,	9	O
with	5	O
minimal	9	O
changes	9	O
in	5	O
the	5	O
liver	9	O
biopsy	5	O
in	5	O
both	9	O
)	9	O
.	9	O

Shortly	9	O
after	9	O
treatment	9	O
their	5	O
tests	5	O
normalized	9	O
and	5	O
during	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
none	9	O
of	5	O
the	5	O
patients	5	O
had	9	O
abnormal	9	B-Disease
liver	9	I-Disease
function	9	I-Disease
tests	5	O
.	9	O

In	9	O
four	9	O
patients	5	O
HBV	9	O
DNA	9	O
levels	3	O
were	9	O
higher	9	O
than	5	O
normal	9	O
at	9	O
baseline	5	O
.	9	O

Two	9	O
of	5	O
these	5	O
normalized	9	O
and	5	O
the	5	O
others	5	O
increased	9	O
later	9	O
.	9	O

In	9	O
three	9	O
additional	9	O
patients	5	O
,	9	O
HBV	9	O
DNA	9	O
levels	3	O
were	9	O
increased	9	O
during	5	O
follow	5	O
-	7	O
up	5	O
.	9	O

None	9	O
of	5	O
the	5	O
patients	5	O
had	9	O
significant	9	O
clinical	5	O
sings	5	O
of	5	O
HBV	9	O
activation	3	O
.	9	O

Lamivudine	7	B-Chemical
was	9	O
well	9	O
tolerated	9	O
and	5	O
was	9	O
continued	9	O
in	5	O
all	5	O
patients	5	O
.	9	O

Prophylactic	5	O
administration	9	O
of	5	O
lamivudine	5	B-Chemical
in	5	O
patients	5	O
who	5	O
required	9	O
immunosuppressive	9	O
therapy	5	O
seems	5	O
to	5	O
be	5	O
safe	5	O
,	9	O
well	9	O
tolerated	9	O
and	5	O
effective	5	O
in	5	O
preventing	9	O
HBV	9	O
reactivation	9	O
.	9	O

Effect	0	O
of	5	O
green	9	B-Chemical
tea	0	I-Chemical
and	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
combination	9	O
in	5	O
isoproterenol	0	B-Chemical
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
aimed	5	O
to	5	O
investigate	9	O
the	5	O
combined	9	O
effects	9	O
of	5	O
green	9	B-Chemical
tea	0	I-Chemical
and	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
on	5	O
heart	5	O
weight	9	O
,	9	O
body	5	O
weight	9	O
,	9	O
serum	9	O
marker	3	O
enzymes	1	O
,	9	O
lipid	0	O
peroxidation	0	O
,	9	O
endogenous	3	O
antioxidants	0	O
and	5	O
membrane	9	O
bound	9	O
ATPases	1	O
in	5	O
isoproterenol	0	B-Chemical
(	9	O
ISO	0	B-Chemical
)	9	O
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

Adult	9	O
male	9	O
albino	3	O
rats	9	O
,	9	O
treated	3	O
with	5	O
ISO	0	B-Chemical
(	9	O
200	0	O
mg	0	O
/	9	O
kg	0	O
,	9	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
for	5	O
2	9	O
days	9	O
at	9	O
an	5	O
interval	5	O
of	5	O
24	9	O
h	0	O
caused	9	O
a	5	O
significant	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
elevation	9	O
of	5	O
heart	5	O
weight	9	O
,	9	O
serum	9	O
marker	3	O
enzymes	1	O
,	9	O
lipid	0	O
peroxidation	0	O
and	5	O
Ca	0	B-Chemical
+	9	O
2	9	O
ATPase	1	O
level	9	O
whereas	9	O
there	5	O
was	9	O
a	5	O
significant	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
decrease	9	O
in	5	O
body	5	O
weight	9	O
,	9	O
endogenous	3	O
antioxidants	0	O
,	9	O
Na	0	B-Chemical
+	9	O
/	9	O
K	9	B-Chemical
+	9	O
ATPase	1	O
and	5	O
Mg	0	B-Chemical
+	9	O
2	9	O
ATPase	1	O
levels	3	O
.	9	O

Administration	2	O
of	5	O
green	9	B-Chemical
tea	0	I-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
and	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
together	9	O
for	5	O
30	9	O
consecutive	5	O
days	9	O
and	5	O
challenged	3	O
with	5	O
ISO	0	B-Chemical
on	5	O
the	5	O
day	9	O
29th	2	O
and	5	O
30th	9	O
,	9	O
showed	9	O
a	5	O
significant	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
decrease	9	O
in	5	O
heart	5	O
weight	9	O
,	9	O
serum	9	O
marker	3	O
enzymes	1	O
,	9	O
lipid	0	O
peroxidation	0	O
,	9	O
Ca	0	B-Chemical
+	9	O
2	9	O
ATPase	1	O
and	5	O
a	5	O
significant	9	O
increase	9	O
in	5	O
the	5	O
body	5	O
weight	9	O
,	9	O
endogenous	3	O
antioxidants	0	O
,	9	O
Na	0	B-Chemical
+	9	O
/	9	O
K	9	B-Chemical
+	9	O
ATPase	1	O
and	5	O
Mg	0	B-Chemical
+	9	O
2	9	O
ATPase	1	O
when	5	O
compared	9	O
with	5	O
ISO	0	B-Chemical
treated	3	O
group	9	O
and	5	O
green	9	B-Chemical
tea	0	I-Chemical
or	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
alone	9	O
treated	3	O
groups	9	O
.	9	O

These	5	O
findings	9	O
indicate	9	O
the	5	O
synergistic	9	O
protective	9	O
effect	9	O
of	5	O
green	9	B-Chemical
tea	0	I-Chemical
and	5	O
vitamin	0	B-Chemical
E	9	I-Chemical
during	5	O
ISO	0	B-Chemical
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

Irreversible	9	O
damage	9	O
to	5	O
the	5	O
medullary	5	O
interstitium	9	O
in	5	O
experimental	5	O
analgesic	5	O
nephropathy	9	B-Disease
in	5	O
F344	3	O
rats	9	O
.	9	O

Renal	9	B-Disease
papillary	5	I-Disease
necrosis	9	I-Disease
(	9	O
RPN	5	B-Disease
)	9	O
and	5	O
a	5	O
decreased	9	O
urinary	9	O
concentrating	5	O
ability	9	O
developed	5	O
during	5	O
continuous	5	O
long	5	O
-	7	O
term	5	O
treatment	9	O
with	5	O
aspirin	9	B-Chemical
and	5	O
paracetamol	0	B-Chemical
in	5	O
female	9	O
Fischer	6	O
344	7	O
rats	9	O
.	9	O

Renal	9	O
structure	9	O
and	5	O
concentrating	5	O
ability	9	O
were	9	O
examined	9	O
after	9	O
a	5	O
recovery	9	O
period	5	O
of	5	O
up	5	O
to	5	O
18	7	O
weeks	9	O
,	9	O
when	5	O
no	9	O
analgesics	5	O
were	9	O
given	5	O
,	9	O
to	5	O
investigate	9	O
whether	9	O
the	5	O
analgesic	5	O
-	7	O
induced	3	O
changes	9	O
were	9	O
reversible	9	O
.	9	O

There	5	O
was	9	O
no	9	O
evidence	9	O
of	5	O
repair	9	O
to	5	O
the	5	O
damaged	9	O
medullary	5	O
interstitial	9	O
matrix	5	O
,	9	O
or	5	O
proliferation	3	O
of	5	O
remaining	9	O
undamaged	9	O
type	9	O
1	9	O
medullary	5	O
interstitial	9	O
cells	3	O
after	9	O
the	5	O
recovery	9	O
period	5	O
following	9	O
analgesic	5	O
treatment	9	O
.	9	O

The	5	O
recovery	9	O
of	5	O
urinary	9	O
concentrating	5	O
ability	9	O
was	9	O
related	9	O
to	5	O
the	5	O
length	9	O
of	5	O
analgesic	5	O
treatment	9	O
and	5	O
the	5	O
extent	9	O
of	5	O
the	5	O
resulting	9	O
inner	9	O
medullary	5	O
structural	9	O
damage	9	O
.	9	O

During	5	O
the	5	O
early	9	O
stages	9	O
of	5	O
analgesic	5	O
treatment	9	O
,	9	O
the	5	O
changes	9	O
in	5	O
urinary	9	O
concentrating	5	O
ability	9	O
were	9	O
reversible	9	O
,	9	O
but	9	O
after	9	O
prolonged	9	O
analgesic	5	O
treatment	9	O
,	9	O
maximum	5	O
urinary	9	O
concentrating	5	O
ability	9	O
failed	9	O
to	5	O
recover	9	O
.	9	O

This	5	O
study	9	O
shows	9	O
that	5	O
prolonged	9	O
analgesic	5	O
treatment	9	O
in	5	O
Fischer	6	O
344	7	O
rats	9	O
causes	9	O
progressive	5	O
and	5	O
irreversible	9	O
damage	9	O
to	5	O
the	5	O
interstitial	9	O
matrix	5	O
and	5	O
type	9	O
1	9	O
interstitial	9	O
cells	3	O
leading	9	O
to	5	O
RPN	5	B-Disease
.	9	O

The	5	O
associated	9	O
urinary	9	O
concentrating	5	O
defect	9	O
is	5	O
reversible	9	O
only	9	O
during	5	O
the	5	O
early	9	O
stages	9	O
of	5	O
structural	9	O
damage	9	O
to	5	O
the	5	O
inner	9	O
medulla	9	O
.	9	O

Testosterone	0	B-Chemical
-	7	O
dependent	9	O
hypertension	5	B-Disease
and	5	O
upregulation	3	O
of	5	O
intrarenal	5	O
angiotensinogen	3	O
in	5	O
Dahl	6	O
salt	0	B-Chemical
-	7	O
sensitive	9	O
rats	9	O
.	9	O

Blood	9	O
pressure	5	O
(	9	O
BP	9	O
)	9	O
is	5	O
more	5	O
salt	0	B-Chemical
sensitive	9	O
in	5	O
men	5	O
than	5	O
in	5	O
premenopausal	5	O
women	5	O
.	9	O

In	9	O
Dahl	6	O
salt	0	B-Chemical
-	7	O
sensitive	9	O
rats	9	O
(	9	O
DS	9	O
)	9	O
,	9	O
high	9	O
-	7	O
salt	0	B-Chemical
(	9	O
HS	9	O
)	9	O
diet	9	O
increases	9	O
BP	9	O
more	5	O
in	5	O
males	9	O
than	5	O
females	9	O
.	9	O

In	9	O
contrast	9	O
to	5	O
the	5	O
systemic	9	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
,	9	O
which	5	O
is	5	O
suppressed	3	O
in	5	O
response	9	O
to	5	O
HS	9	O
in	5	O
male	9	O
DS	9	O
,	9	O
intrarenal	5	O
angiotensinogen	3	O
expression	3	O
is	5	O
increased	9	O
,	9	O
and	5	O
intrarenal	5	O
levels	3	O
of	5	O
ANG	3	O
II	9	O
are	5	O
not	5	O
suppressed	3	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
the	5	O
hypothesis	9	O
was	9	O
tested	9	O
that	5	O
there	5	O
is	5	O
a	5	O
sexual	5	O
dimorphism	4	O
in	5	O
HS	9	O
-	7	O
induced	3	O
upregulation	3	O
of	5	O
intrarenal	5	O
angiotensinogen	3	O
mediated	3	O
by	9	O
testosterone	9	B-Chemical
that	5	O
also	9	O
causes	9	O
increases	9	O
in	5	O
BP	9	O
and	5	O
renal	9	B-Disease
injury	9	I-Disease
.	9	O

On	5	O
a	5	O
low	9	O
-	7	O
salt	0	B-Chemical
(	9	O
LS	9	O
)	9	O
diet	9	O
,	9	O
male	9	O
DS	9	O
had	9	O
higher	9	O
levels	3	O
of	5	O
intrarenal	5	O
angiotensinogen	3	O
mRNA	3	O
than	5	O
females	9	O
.	9	O

HS	9	O
diet	9	O
for	5	O
4	9	O
wk	9	O
increased	9	O
renal	9	O
cortical	5	O
angiotensinogen	3	O
mRNA	3	O
and	5	O
protein	1	O
only	9	O
in	5	O
male	9	O
DS	9	O
,	9	O
which	5	O
was	9	O
prevented	9	O
by	9	O
castration	3	O
.	9	O

Ovariectomy	3	O
of	5	O
female	9	O
DS	9	O
had	9	O
no	9	O
effect	9	O
on	5	O
intrarenal	5	O
angiotensinogen	3	O
expression	3	O
on	5	O
either	9	O
diet	9	O
.	9	O

Radiotelemetric	9	O
BP	9	O
was	9	O
similar	9	O
between	5	O
males	9	O
and	5	O
castrated	3	O
rats	9	O
on	5	O
LS	9	O
diet	9	O
.	9	O

HS	9	O
diet	9	O
for	5	O
4	9	O
wk	9	O
caused	9	O
a	5	O
progressive	5	O
increase	9	O
in	5	O
BP	9	O
,	9	O
protein	1	O
and	5	O
albumin	0	O
excretion	0	O
,	9	O
and	5	O
glomerular	5	B-Disease
sclerosis	5	I-Disease
in	5	O
male	9	O
DS	9	O
rats	9	O
,	9	O
which	5	O
were	9	O
attenuated	3	O
by	9	O
castration	3	O
.	9	O

Testosterone	0	B-Chemical
replacement	9	O
in	5	O
castrated	3	O
DS	9	O
rats	9	O
increased	9	O
BP	9	O
,	9	O
renal	9	B-Disease
injury	9	I-Disease
,	9	O
and	5	O
upregulation	3	O
of	5	O
renal	9	O
angiotensinogen	3	O
associated	9	O
with	5	O
HS	9	O
diet	9	O
.	9	O

Testosterone	0	B-Chemical
contributes	9	O
to	5	O
the	5	O
development	9	O
of	5	O
hypertension	5	B-Disease
and	5	O
renal	9	B-Disease
injury	9	I-Disease
in	5	O
male	9	O
DS	9	O
rats	9	O
on	5	O
HS	9	O
diet	9	O
possibly	9	O
through	9	O
upregulation	3	O
of	5	O
the	5	O
intrarenal	5	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
.	9	O

Explicit	5	O
episodic	5	O
memory	5	O
for	5	O
sensory	5	O
-	7	O
discriminative	5	O
components	5	O
of	5	O
capsaicin	0	B-Chemical
-	7	O
induced	3	O
pain	5	B-Disease
:	9	O
immediate	5	O
and	5	O
delayed	9	O
ratings	5	O
.	9	O

Pain	5	B-Disease
memory	5	O
is	5	O
thought	5	O
to	5	O
affect	9	O
future	5	O
pain	5	B-Disease
sensitivity	9	O
and	5	O
thus	9	O
contribute	9	O
to	5	O
clinical	5	O
pain	5	B-Disease
conditions	9	O
.	9	O

Systematic	5	O
investigations	9	O
of	5	O
the	5	O
human	3	O
capacity	9	O
to	5	O
remember	5	O
sensory	5	O
features	5	O
of	5	O
experimental	5	O
pain	5	B-Disease
are	5	O
sparse	5	O
.	9	O

In	9	O
order	5	O
to	5	O
address	5	O
long	5	O
-	7	O
term	5	O
pain	5	B-Disease
memory	5	O
,	9	O
nine	9	O
healthy	5	O
male	9	O
volunteers	5	O
received	9	O
intradermal	9	O
injections	9	O
of	5	O
three	9	O
doses	0	O
of	5	O
capsaicin	0	B-Chemical
(	9	O
0	7	O
.	9	O
05	7	O
,	9	O
1	9	O
and	5	O
20	9	O
microg	0	O
,	9	O
separated	9	O
by	9	O
15	9	O
min	0	O
breaks	5	O
)	9	O
,	9	O
each	5	O
given	5	O
three	9	O
times	5	O
in	5	O
a	5	O
balanced	5	O
design	5	O
across	5	O
three	9	O
sessions	5	O
at	9	O
one	5	O
week	9	O
intervals	5	O
.	9	O

Pain	5	B-Disease
rating	5	O
was	9	O
performed	9	O
using	9	O
a	5	O
computerized	5	O
visual	5	O
analogue	0	O
scale	5	O
(	9	O
0	7	O
-	7	O
100	0	O
)	9	O
digitized	5	O
at	9	O
1	9	O
/	9	O
s	9	O
,	9	O
either	9	O
immediately	9	O
online	5	O
or	5	O
one	5	O
hour	0	O
or	5	O
one	5	O
day	9	O
after	9	O
injection	9	O
.	9	O

Subjects	5	O
also	9	O
recalled	5	O
their	5	O
pains	5	B-Disease
one	5	O
week	9	O
later	9	O
.	9	O

Capsaicin	0	B-Chemical
injection	9	O
reliably	5	O
induced	3	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
flare	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
without	9	O
any	5	O
difference	9	O
within	9	O
or	5	O
across	5	O
sessions	5	O
.	9	O

The	5	O
strong	9	O
burning	5	O
pain	5	B-Disease
decayed	5	O
exponentially	9	O
within	9	O
a	5	O
few	5	O
minutes	0	O
.	9	O

Subjects	5	O
were	9	O
able	9	O
to	5	O
reliably	5	O
discriminate	5	O
pain	5	B-Disease
magnitude	5	O
and	5	O
duration	5	O
across	5	O
capsaicin	0	B-Chemical
doses	0	O
(	9	O
both	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
regardless	9	O
of	5	O
whether	9	O
first	9	O
-	7	O
time	5	O
ratings	5	O
were	9	O
requested	5	O
immediately	9	O
,	9	O
after	9	O
one	5	O
hour	0	O
or	5	O
after	9	O
one	5	O
day	9	O
.	9	O

Pain	5	B-Disease
recall	5	O
after	9	O
one	5	O
week	9	O
was	9	O
similarly	9	O
precise	5	O
(	9	O
magnitude	5	O
:	9	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
,	9	O
duration	5	O
:	9	O
p	7	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Correlation	9	O
with	5	O
rating	5	O
recall	5	O
after	9	O
one	5	O
week	9	O
was	9	O
best	5	O
when	5	O
first	9	O
-	7	O
time	5	O
ratings	5	O
were	9	O
requested	5	O
as	5	O
late	9	O
as	5	O
one	5	O
day	9	O
after	9	O
injection	9	O
(	9	O
R	9	O
(	9	O
2	9	O
)	9	O
=	7	O
0	7	O
.	9	O
79	7	O
)	9	O
indicating	9	O
that	5	O
both	9	O
rating	5	O
retrievals	5	O
utilized	9	O
similar	9	O
memory	5	O
traces	9	O
.	9	O

These	5	O
results	9	O
indicate	9	O
a	5	O
reliable	5	O
memory	5	O
for	5	O
magnitude	5	O
and	5	O
duration	5	O
of	5	O
experimentally	9	O
induced	3	O
pain	5	B-Disease
.	9	O

The	5	O
data	5	O
further	9	O
suggest	9	O
that	5	O
the	5	O
consolidation	5	O
of	5	O
this	5	O
memory	5	O
is	5	O
an	5	O
important	9	O
interim	5	O
stage	9	O
,	9	O
and	5	O
may	5	O
take	5	O
up	5	O
to	5	O
one	5	O
day	9	O
.	9	O

Severe	9	O
and	5	O
long	5	O
lasting	5	O
cholestasis	5	B-Disease
after	9	O
high	9	O
-	7	O
dose	9	O
co	9	B-Chemical
-	7	I-Chemical
trimoxazole	0	I-Chemical
treatment	9	O
for	5	O
Pneumocystis	9	B-Disease
pneumonia	5	I-Disease
in	5	O
HIV	5	B-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
-	7	O
-	7	O
a	5	O
report	5	O
of	5	O
two	5	O
cases	5	O
.	9	O

Pneumocystis	9	B-Disease
pneumonia	5	I-Disease
(	9	O
PCP	9	B-Disease
)	9	O
,	9	O
a	5	O
common	5	O
opportunistic	5	B-Disease
infection	9	I-Disease
in	5	O
HIV	5	B-Disease
-	7	I-Disease
infected	3	I-Disease
individuals	5	O
,	9	O
is	5	O
generally	5	O
treated	3	O
with	5	O
high	9	O
doses	0	O
of	5	O
co	9	B-Chemical
-	7	I-Chemical
trimoxazole	0	I-Chemical
.	9	O

However	9	O
,	9	O
treatment	9	O
is	5	O
often	5	O
limited	5	O
by	9	O
adverse	5	O
effects	9	O
.	9	O

Here	9	O
,	9	O
we	5	O
report	5	O
two	5	O
cases	5	O
of	5	O
severely	9	O
immunocompromised	5	O
HIV	5	B-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
who	5	O
developed	5	O
severe	5	O
intrahepatic	9	B-Disease
cholestasis	5	I-Disease
,	9	O
and	5	O
in	5	O
one	5	O
patient	5	O
lesions	5	O
mimicking	9	O
liver	9	B-Disease
abscess	5	I-Disease
formation	9	O
on	5	O
radiologic	5	O
exams	5	O
,	9	O
during	5	O
co	9	B-Chemical
-	7	I-Chemical
trimoxazole	0	I-Chemical
treatment	9	O
for	5	O
PCP	9	B-Disease
.	9	O

Whereas	9	O
patient	5	O
1	9	O
showed	9	O
lesions	5	O
of	5	O
up	5	O
to	5	O
1	9	O
cm	9	O
readily	9	O
detectable	9	O
on	5	O
magnetic	0	O
resonance	5	O
imaging	5	O
under	9	O
prolonged	9	O
co	9	B-Chemical
-	7	I-Chemical
trimoxazole	0	I-Chemical
treatment	9	O
,	9	O
therapy	5	O
of	5	O
patient	5	O
2	9	O
was	9	O
switched	9	O
early	9	O
.	9	O

Bradykinin	0	B-Chemical
receptors	3	O
antagonists	3	O
and	5	O
nitric	0	B-Chemical
oxide	0	I-Chemical
synthase	1	O
inhibitors	3	O
in	5	O
vincristine	0	B-Chemical
and	5	O
streptozotocin	0	B-Chemical
induced	3	O
hyperalgesia	3	B-Disease
in	5	O
chemotherapy	5	O
and	5	O
diabetic	9	B-Disease
neuropathy	5	I-Disease
rat	3	O
model	5	O
.	9	O

PURPOSE	2	O
:	9	O
The	5	O
influence	5	O
of	5	O
an	5	O
irreversible	9	O
inhibitor	3	O
of	5	O
constitutive	3	O
NO	9	B-Chemical
synthase	1	O
(	9	O
L	0	O
-	7	O
NOArg	_	O
;	9	O
1	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
,	9	O
a	5	O
relatively	5	O
selective	9	O
inhibitor	3	O
of	5	O
inducible	3	O
NO	9	B-Chemical
synthase	1	O
(	9	O
L	0	O
-	7	O
NIL	9	O
;	9	O
1	9	O
.	9	O
0	7	O
mg	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
and	5	O
a	5	O
relatively	5	O
specific	9	O
inhibitor	3	O
of	5	O
neuronal	3	O
NO	9	B-Chemical
synthase	1	O
(	9	O
7	9	O
-	7	O
NI	9	O
;	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
,	9	O
on	5	O
antihyperalgesic	0	O
action	5	O
of	5	O
selective	9	O
antagonists	3	O
of	5	O
B2	9	O
and	5	O
B1	9	O
receptors	3	O
:	9	O
D	9	O
-	7	O
Arg	1	O
-	7	O
[	9	O
Hyp3	1	O
,	9	O
Thi5	2	O
,	9	O
D	9	O
-	7	O
Tic7	_	O
,	9	O
Oic8	0	O
]	9	O
bradykinin	0	B-Chemical
(	9	O
HOE	0	B-Chemical
140	9	I-Chemical
;	9	O
70	9	O
nmol	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
or	5	O
des	2	B-Chemical
Arg10	1	I-Chemical
HOE	0	I-Chemical
140	9	I-Chemical
(	9	O
70	9	O
nmol	0	O
/	9	O
kg	0	O
ip	0	O
)	9	O
respectively	9	O
,	9	O
in	5	O
model	5	O
of	5	O
diabetic	9	B-Disease
(	9	I-Disease
streptozotocin	0	I-Disease
-	7	I-Disease
induced	3	I-Disease
)	9	I-Disease
and	5	I-Disease
toxic	0	I-Disease
(	9	I-Disease
vincristine	0	I-Disease
-	7	I-Disease
induced	3	I-Disease
)	9	I-Disease
neuropathy	5	I-Disease
was	9	O
investigated	9	O
.	9	O

METHODS	2	O
:	9	O
The	5	O
changes	9	O
in	5	O
pain	5	B-Disease
thresholds	5	O
were	9	O
determined	9	O
using	9	O
mechanical	5	O
stimuli	5	O
-	7	O
-	7	O
the	5	O
modification	9	O
of	5	O
the	5	O
classic	5	O
paw	5	O
withdrawal	5	O
test	5	O
described	9	O
by	9	O
Randall	6	O
-	7	O
Selitto	6	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
results	9	O
of	5	O
this	5	O
paper	5	O
confirm	9	O
that	5	O
inhibition	3	O
of	5	O
bradykinin	0	B-Chemical
receptors	3	O
and	5	O
inducible	3	O
NO	9	B-Chemical
synthase	1	O
but	9	O
not	5	O
neuronal	3	O
NO	9	B-Chemical
synthase	1	O
activity	9	O
reduces	9	O
diabetic	9	B-Disease
hyperalgesia	3	I-Disease
.	9	O

Pretreatment	3	O
with	5	O
L	0	O
-	7	O
NOArg	_	O
and	5	O
L	0	O
-	7	O
NIL	9	O
but	9	O
not	5	O
7	9	O
-	7	O
NI	9	O
,	9	O
significantly	9	O
increases	9	O
antihyperalgesic	0	O
activity	9	O
both	9	O
HOE	0	B-Chemical
140	9	I-Chemical
and	5	O
des	2	B-Chemical
Arg10	1	I-Chemical
HOE	0	I-Chemical
140	9	I-Chemical
.	9	O

It	5	O
was	9	O
also	9	O
shown	9	O
that	5	O
both	9	O
products	9	O
of	5	O
inducible	3	O
NO	9	B-Chemical
synthase	1	O
and	5	O
neuronal	3	O
NO	9	B-Chemical
synthase	1	O
activation	3	O
as	5	O
well	9	O
as	5	O
bradykinin	0	B-Chemical
are	5	O
involved	9	O
in	5	O
hyperalgesia	3	B-Disease
produced	9	O
by	9	O
vincristine	0	B-Chemical
.	9	O

Moreover	9	O
,	9	O
L	0	O
-	7	O
NOArg	_	O
and	5	O
7	9	O
-	7	O
NI	9	O
but	9	O
not	5	O
L	0	O
-	7	O
NIL	9	O
intensify	5	O
antihyperalgesic	0	O
activity	9	O
of	5	O
HOE	0	B-Chemical
140	9	I-Chemical
or	5	O
des	2	B-Chemical
-	7	I-Chemical
Arg10HOE	_	I-Chemical
140	9	I-Chemical
in	5	O
toxic	0	B-Disease
neuropathy	5	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Results	9	O
of	5	O
these	5	O
studies	9	O
suggest	9	O
that	5	O
B1	9	O
and	5	O
B2	9	O
receptors	3	O
are	5	O
engaged	5	O
in	5	O
transmission	5	O
of	5	O
nociceptive	5	O
stimuli	5	O
in	5	O
both	9	O
diabetic	9	B-Disease
and	5	I-Disease
toxic	0	I-Disease
neuropathy	5	I-Disease
.	9	O

In	9	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
hyperalgesia	3	B-Disease
,	9	O
inducible	3	O
NO	9	B-Chemical
synthase	1	O
participates	9	O
in	5	O
pronociceptive	3	O
activity	9	O
of	5	O
bradykinin	0	B-Chemical
,	9	O
whereas	9	O
in	5	O
vincristine	0	B-Chemical
-	7	O
induced	3	O
hyperalgesia	3	B-Disease
bradykinin	0	B-Chemical
seemed	9	O
to	5	O
activate	3	O
neuronal	3	O
NO	9	B-Chemical
synthase	1	O
pathway	3	O
.	9	O

Therefore	9	O
,	9	O
concomitant	9	O
administration	9	O
of	5	O
small	9	O
doses	0	O
of	5	O
bradykinin	0	B-Chemical
receptor	3	O
antagonists	3	O
and	5	O
NO	9	B-Chemical
synthase	1	O
inhibitors	3	O
can	5	O
be	5	O
effective	5	O
in	5	O
alleviation	5	O
of	5	O
neuropathic	5	B-Disease
pain	5	I-Disease
,	9	O
even	5	O
in	5	O
hospital	5	O
care	5	O
.	9	O

Confusion	5	B-Disease
,	9	O
a	5	O
rather	5	O
serious	5	O
adverse	5	O
drug	5	O
reaction	9	O
with	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
:	9	O
a	5	O
review	5	O
of	5	O
the	5	O
French	2	O
Pharmacovigilance	5	O
database	5	O
.	9	O

INTRODUCTION	5	O
:	9	O
Confusion	5	B-Disease
is	5	O
an	5	O
adverse	5	O
drug	5	O
reaction	9	O
frequently	5	O
observed	9	O
with	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
.	9	O

Some	5	O
case	5	O
reports	9	O
are	5	O
published	9	O
in	5	O
the	5	O
literature	5	O
but	9	O
no	9	O
systematic	5	O
study	9	O
from	9	O
a	5	O
sample	9	O
of	5	O
patients	5	O
has	9	O
been	9	O
published	9	O
.	9	O

We	9	O
performed	9	O
this	5	O
study	9	O
in	5	O
order	5	O
to	5	O
describe	5	O
the	5	O
main	5	O
characteristics	5	O
of	5	O
this	5	O
adverse	5	O
drug	5	O
reaction	9	O
.	9	O

METHODS	2	O
:	9	O
Using	9	O
the	5	O
French	2	O
Pharmacovigilance	5	O
database	5	O
,	9	O
we	5	O
selected	9	O
the	5	O
cases	5	O
of	5	O
confusion	5	B-Disease
reported	9	O
since	9	O
1985	2	O
with	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
.	9	O

RESULTS	9	O
:	9	O
272	7	O
cases	5	O
of	5	O
confusion	5	B-Disease
were	9	O
reported	9	O
with	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
:	9	O
153	7	O
women	5	O
and	5	O
119	7	O
men	5	O
.	9	O

Confusion	5	B-Disease
mostly	9	O
occurred	9	O
during	5	O
the	5	O
two	5	O
first	9	O
weeks	9	O
following	9	O
valproic	0	B-Chemical
acid	0	I-Chemical
exposure	9	O
(	9	O
39	7	O
.	9	O
7	9	O
%	9	O
)	9	O
.	9	O

It	5	O
was	9	O
"	5	O
serious	5	O
"	5	O
for	5	O
almost	9	O
2	9	O
/	9	O
3	9	O
of	5	O
the	5	O
patients	5	O
(	9	O
62	7	O
.	9	O
5	9	O
%	9	O
)	9	O
and	5	O
its	9	O
outcome	5	O
favourable	5	O
in	5	O
most	9	O
of	5	O
the	5	O
cases	5	O
(	9	O
82	7	O
%	9	O
)	9	O
.	9	O

The	5	O
occurrence	5	O
of	5	O
this	5	O
ADR	9	O
was	9	O
more	5	O
frequent	5	O
in	5	O
patients	5	O
aged	9	O
between	5	O
61	7	O
and	5	O
80	9	O
years	5	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
work	5	O
shows	9	O
that	5	O
confusion	5	B-Disease
with	5	O
valproic	0	B-Chemical
acid	0	I-Chemical
is	5	O
a	5	O
serious	5	O
,	9	O
rather	5	O
frequent	5	O
but	9	O
reversible	9	O
adverse	5	O
drug	5	O
reaction	9	O
.	9	O

It	5	O
occurs	9	O
especially	5	O
in	5	O
older	5	O
patients	5	O
and	5	O
during	5	O
the	5	O
first	9	O
two	5	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

Reversible	0	O
inferior	5	B-Disease
colliculus	5	I-Disease
lesion	5	I-Disease
in	5	O
metronidazole	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
:	9	O
magnetic	0	O
resonance	5	O
findings	9	O
on	5	O
diffusion	5	O
-	7	O
weighted	5	O
and	5	O
fluid	5	O
attenuated	3	O
inversion	5	O
recovery	9	O
imaging	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
This	5	O
is	5	O
to	5	O
present	9	O
reversible	9	O
inferior	5	B-Disease
colliculus	5	I-Disease
lesions	5	I-Disease
in	5	O
metronidazole	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
,	9	O
to	5	O
focus	5	O
on	5	O
the	5	O
diffusion	5	O
-	7	O
weighted	5	O
imaging	5	O
(	9	O
DWI	5	O
)	9	O
and	5	O
fluid	5	O
attenuated	3	O
inversion	5	O
recovery	9	O
(	9	O
FLAIR	5	O
)	9	O
imaging	5	O
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
From	5	O
November	2	O
2005	2	O
to	5	O
September	2	O
2007	2	O
,	9	O
8	9	O
patients	5	O
(	9	O
5	9	O
men	5	O
and	5	O
3	9	O
women	5	O
)	9	O
were	9	O
diagnosed	5	O
as	5	O
having	5	O
metronidazole	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
(	9	O
age	5	O
range	9	O
;	9	O
43	7	O
-	7	O
78	7	O
years	5	O
)	9	O
.	9	O

They	5	O
had	9	O
been	9	O
taking	5	O
metronidazole	0	B-Chemical
(	9	O
total	9	O
dosage	9	O
,	9	O
45	9	O
-	7	O
120	9	O
g	0	O
;	9	O
duration	5	O
,	9	O
30	9	O
days	9	O
to	5	O
2	9	O
months	5	O
)	9	O
to	5	O
treat	5	O
the	5	O
infection	9	B-Disease
in	5	O
various	9	O
organs	9	O
.	9	O

Initial	9	O
brain	5	O
magnetic	0	O
resonance	5	O
imaging	5	O
(	9	O
MRI	5	O
)	9	O
were	9	O
obtained	9	O
after	9	O
the	5	O
hospitalization	5	O
,	9	O
including	9	O
DWI	5	O
(	9	O
8	9	O
/	9	O
8	9	O
)	9	O
,	9	O
apparent	9	O
diffusion	5	O
coefficient	5	O
(	9	O
ADC	5	O
)	9	O
map	5	O
(	9	O
4	9	O
/	9	O
8	9	O
)	9	O
,	9	O
FLAIR	5	O
(	9	O
7	9	O
/	9	O
8	9	O
)	9	O
,	9	O
and	5	O
T2	9	O
-	7	O
weighted	5	O
image	5	O
(	9	O
8	9	O
/	9	O
8	9	O
)	9	O
.	9	O

Follow	5	O
-	7	O
up	5	O
MRIs	5	O
were	9	O
performed	9	O
on	5	O
5	9	O
patients	5	O
from	9	O
third	9	O
to	5	O
14th	9	O
days	9	O
after	9	O
discontinuation	5	O
of	5	O
metronidazole	0	B-Chemical
administration	9	O
.	9	O

Findings	5	O
of	5	O
initial	9	O
and	5	O
follow	5	O
-	7	O
up	5	O
MRIs	5	O
were	9	O
retrospectively	5	O
evaluated	9	O
by	9	O
2	9	O
neuroradiologists	5	O
by	9	O
consensus	9	O
,	9	O
to	5	O
analyze	9	O
the	5	O
presence	9	O
of	5	O
abnormal	9	O
signal	9	O
intensities	9	O
,	9	O
their	5	O
locations	5	O
,	9	O
and	5	O
signal	9	O
changes	9	O
on	5	O
follow	5	O
-	7	O
up	5	O
images	5	O
.	9	O

RESULTS	9	O
:	9	O
Initial	9	O
MRIs	5	O
showed	9	O
abnormal	9	O
high	9	O
signal	9	O
intensities	9	O
on	5	O
DWI	5	O
and	5	O
FLAIR	5	O
(	9	O
or	5	O
T2	9	O
-	7	O
weighted	5	O
image	5	O
)	9	O
at	9	O
the	5	O
dentate	3	O
nucleus	9	O
(	9	O
8	9	O
/	9	O
8	9	O
)	9	O
,	9	O
inferior	5	O
colliculus	5	O
(	9	O
6	9	O
/	9	O
8	9	O
)	9	O
,	9	O
corpus	5	O
callosum	5	O
(	9	O
2	9	O
/	9	O
8	9	O
)	9	O
,	9	O
pons	5	O
(	9	O
2	9	O
/	9	O
8	9	O
)	9	O
,	9	O
medulla	9	O
(	9	O
1	9	O
/	9	O
8	9	O
)	9	O
,	9	O
and	5	O
bilateral	5	O
cerebral	5	O
white	9	O
matter	5	O
(	9	O
1	9	O
/	9	O
8	9	O
)	9	O
.	9	O

High	9	O
-	7	O
signal	9	O
intensity	5	O
lesions	5	O
on	5	O
DWI	5	O
tended	5	O
to	5	O
show	9	O
low	9	O
signal	9	O
intensity	5	O
on	5	O
ADC	5	O
map	5	O
(	9	O
3	9	O
/	9	O
4	9	O
)	9	O
,	9	O
but	9	O
in	5	O
one	5	O
patient	5	O
,	9	O
high	9	O
signal	9	O
intensity	5	O
was	9	O
shown	9	O
at	9	O
bilateral	5	O
dentate	3	O
nuclei	3	O
on	5	O
not	5	O
only	9	O
DWI	5	O
but	9	O
also	9	O
ADC	5	O
map	5	O
.	9	O

All	9	O
the	5	O
lesions	5	O
in	5	O
dentate	3	O
,	9	O
inferior	5	O
colliculus	5	O
,	9	O
pons	5	O
,	9	O
and	5	O
medullas	3	O
had	9	O
been	9	O
resolved	9	O
completely	9	O
on	5	O
follow	5	O
-	7	O
up	5	O
MRIs	5	O
in	5	O
5	9	O
patients	5	O
,	9	O
but	9	O
in	5	O
1	9	O
patient	5	O
of	5	O
them	5	O
,	9	O
corpus	5	O
callosal	5	B-Disease
lesion	5	I-Disease
persisted	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Reversible	0	O
inferior	5	B-Disease
colliculus	5	I-Disease
lesions	5	I-Disease
could	9	O
be	5	O
considered	5	O
as	5	O
the	5	O
characteristic	9	O
for	5	O
metronidazole	0	B-Chemical
-	7	O
induced	3	O
encephalopathy	5	B-Disease
,	9	O
next	9	O
to	5	O
the	5	O
dentate	3	O
nucleus	9	O
involvement	9	O
.	9	O

Clinically	5	O
significant	9	O
proteinuria	9	B-Disease
following	9	O
the	5	O
administration	9	O
of	5	O
sirolimus	0	B-Chemical
to	5	O
renal	9	O
transplant	9	O
recipients	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Sirolimus	0	B-Chemical
is	5	O
the	5	O
latest	5	O
immunosuppressive	9	O
agent	9	O
used	5	O
to	5	O
prevent	5	O
rejection	5	O
,	9	O
and	5	O
may	5	O
have	5	O
less	5	O
nephrotoxicity	9	B-Disease
than	5	O
calcineurin	3	O
inhibitor	3	O
(	9	O
CNI	9	O
)	9	O
-	7	O
based	5	O
regimens	5	O
.	9	O

To	9	O
date	5	O
there	5	O
has	9	O
been	9	O
little	9	O
documentation	5	O
of	5	O
clinically	5	O
significant	9	O
proteinuria	9	B-Disease
linked	9	O
with	5	O
the	5	O
use	5	O
of	5	O
sirolimus	0	B-Chemical
.	9	O

We	9	O
have	5	O
encountered	5	O
several	9	O
patients	5	O
who	5	O
developed	5	O
substantial	9	O
proteinuria	9	B-Disease
associated	9	O
with	5	O
sirolimus	0	B-Chemical
use	5	O
.	9	O

In	9	O
each	5	O
patient	5	O
,	9	O
the	5	O
close	5	O
temporal	5	O
association	9	O
between	5	O
the	5	O
commencement	5	O
of	5	O
sirolimus	0	B-Chemical
therapy	5	O
and	5	O
proteinuria	9	B-Disease
implicated	9	O
sirolimus	0	B-Chemical
as	5	O
the	5	O
most	9	O
likely	5	O
etiology	9	O
of	5	O
the	5	O
proteinuria	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
We	9	O
analyzed	9	O
the	5	O
clinical	5	O
and	5	O
laboratory	9	O
information	5	O
available	5	O
for	5	O
all	5	O
119	7	O
patients	5	O
transplanted	3	O
at	9	O
the	5	O
Washington	2	O
Hospital	2	O
Center	2	O
between	5	O
1999	2	O
-	7	O
2003	2	O
for	5	O
whom	5	O
sirolimus	0	B-Chemical
was	9	O
a	5	O
component	9	O
of	5	O
their	5	O
immunosuppressant	9	O
regimen	5	O
.	9	O

In	9	O
these	5	O
patients	5	O
,	9	O
the	5	O
magnitude	5	O
of	5	O
proteinuria	9	B-Disease
was	9	O
assessed	9	O
on	5	O
morning	5	O
urine	9	O
samples	9	O
by	9	O
turbidometric	0	O
measurement	5	O
or	5	O
random	5	O
urine	9	O
protein	1	O
:	9	O
creatinine	0	B-Chemical
ratios	9	O
,	9	O
an	5	O
estimate	5	O
of	5	O
grams	0	O
of	5	O
proteinuria	9	B-Disease
/	9	O
day	9	O
.	9	O

Laboratory	2	O
results	9	O
were	9	O
compared	9	O
between	5	O
prior	9	O
,	9	O
during	5	O
and	5	O
following	9	O
sirolimus	0	B-Chemical
use	5	O
.	9	O

RESULTS	9	O
:	9	O
Twenty	9	O
-	7	O
eight	9	O
patients	5	O
(	9	O
24	9	O
%	9	O
)	9	O
developed	5	O
increased	9	O
proteinuria	9	B-Disease
from	9	O
baseline	5	O
during	5	O
their	5	O
post	9	O
-	7	O
transplantation	9	O
course	5	O
.	9	O

In	9	O
21	7	O
patients	5	O
an	5	O
alternative	5	O
cause	5	O
of	5	O
proteinuria	9	B-Disease
was	9	O
either	9	O
obvious	9	O
or	5	O
insufficient	5	O
data	5	O
was	9	O
available	5	O
to	5	O
be	5	O
conclusive	9	O
.	9	O

In	9	O
7	9	O
of	5	O
the	5	O
28	7	O
patients	5	O
there	5	O
was	9	O
a	5	O
striking	9	O
temporal	5	O
association	9	O
between	5	O
the	5	O
initiation	9	O
of	5	O
sirolimus	0	B-Chemical
and	5	O
the	5	O
development	9	O
of	5	O
nephrotic	5	B-Disease
-	7	O
range	9	O
proteinuria	9	B-Disease
.	9	O

Proteinuria	7	B-Disease
correlated	9	O
most	9	O
strongly	9	O
with	5	O
sirolimus	0	B-Chemical
therapy	5	O
when	5	O
compared	9	O
to	5	O
other	5	O
demographic	5	O
and	5	O
clinical	5	O
variables	5	O
.	9	O

In	9	O
most	9	O
patients	5	O
,	9	O
discontinuation	5	O
of	5	O
sirolimus	0	B-Chemical
resulted	9	O
in	5	O
a	5	O
decrease	9	O
,	9	O
but	9	O
not	5	O
resolution	5	O
,	9	O
of	5	O
proteinuria	9	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Sirolimus	0	B-Chemical
induces	3	O
or	5	O
aggravates	9	O
pre	9	O
-	7	O
existing	5	O
proteinuria	9	B-Disease
in	5	O
an	5	O
unpredictable	5	O
subset	9	O
of	5	O
renal	9	O
allograft	5	O
recipients	9	O
.	9	O

Proteinuria	7	B-Disease
may	5	O
improve	5	O
,	9	O
but	9	O
does	9	O
not	5	O
resolve	5	O
,	9	O
when	5	O
sirolimus	0	B-Chemical
is	5	O
withdrawn	9	O
.	9	O

Components	5	O
of	5	O
lemon	4	O
essential	9	O
oil	0	O
attenuate	9	O
dementia	5	B-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
.	9	O

The	5	O
anti	3	O
-	7	O
dementia	5	B-Disease
effects	9	O
of	5	O
s	9	B-Chemical
-	7	I-Chemical
limonene	0	I-Chemical
and	5	O
s	9	B-Chemical
-	7	I-Chemical
perillyl	0	I-Chemical
alcohol	5	I-Chemical
were	9	O
observed	9	O
using	9	O
the	5	O
passive	5	O
avoidance	5	O
test	5	O
(	9	O
PA	9	O
)	9	O
and	5	O
the	5	O
open	5	O
field	5	O
habituation	5	O
test	5	O
(	9	O
OFH	5	O
)	9	O
.	9	O

These	5	O
lemon	4	O
essential	9	O
oils	4	O
showed	9	O
strong	9	O
ability	9	O
to	5	O
improve	5	O
memory	5	B-Disease
impaired	9	I-Disease
by	9	O
scopolamine	0	B-Chemical
;	9	O
however	9	O
,	9	O
s	9	B-Chemical
-	7	I-Chemical
perillyl	0	I-Chemical
alcohol	5	I-Chemical
relieved	5	O
the	5	O
deficit	5	B-Disease
of	5	I-Disease
associative	5	I-Disease
memory	5	I-Disease
in	5	O
PA	9	O
only	9	O
,	9	O
and	5	O
did	9	O
not	5	O
improve	5	O
non	9	O
-	7	O
associative	5	O
memory	5	O
significantly	9	O
in	5	O
OFH	5	O
.	9	O

Analysis	9	O
of	5	O
neurotransmitter	9	O
concentration	0	O
in	5	O
some	5	O
brain	5	O
regions	9	O
on	5	O
the	5	O
test	5	O
day	9	O
showed	9	O
that	5	O
dopamine	5	B-Chemical
concentration	0	O
of	5	O
the	5	O
vehicle	3	O
/	9	O
scopolamine	0	B-Chemical
group	9	O
was	9	O
significantly	9	O
lower	9	O
than	5	O
that	5	O
of	5	O
the	5	O
vehicle	3	O
/	9	O
vehicle	3	O
group	9	O
,	9	O
but	9	O
this	5	O
phenomenon	5	O
was	9	O
reversed	9	O
when	5	O
s	9	B-Chemical
-	7	I-Chemical
limonene	0	I-Chemical
or	5	O
s	9	B-Chemical
-	7	I-Chemical
perillyl	0	I-Chemical
alcohol	5	I-Chemical
were	9	O
administered	9	O
before	9	O
the	5	O
injection	9	O
of	5	O
scopolamine	0	B-Chemical
.	9	O

Simultaneously	9	O
,	9	O
we	5	O
found	9	O
that	5	O
these	5	O
two	5	O
lemon	4	O
essential	9	O
oil	0	O
components	5	O
could	9	O
inhibit	3	O
acetylcholinesterase	0	O
activity	9	O
in	5	O
vitro	3	O
using	9	O
the	5	O
Ellman	0	O
method	5	O
.	9	O

Attentional	5	O
modulation	9	O
of	5	O
perceived	5	O
pain	5	B-Disease
intensity	5	O
in	5	O
capsaicin	0	B-Chemical
-	7	O
induced	3	O
secondary	9	O
hyperalgesia	3	B-Disease
.	9	O

Perceived	5	O
pain	5	B-Disease
intensity	5	O
is	5	O
modulated	9	O
by	9	O
attention	5	O
.	9	O

However	9	O
,	9	O
it	5	O
is	5	O
not	5	O
known	9	O
that	5	O
how	5	O
pain	5	B-Disease
intensity	5	O
ratings	5	O
are	5	O
affected	9	O
by	9	O
attention	5	O
in	5	O
capsaicin	0	B-Chemical
-	7	O
induced	3	O
secondary	9	O
hyperalgesia	3	B-Disease
.	9	O

Here	9	O
we	5	O
show	9	O
that	5	O
perceived	5	O
pain	5	B-Disease
intensity	5	O
in	5	O
secondary	9	O
hyperalgesia	3	B-Disease
is	5	O
decreased	9	O
when	5	O
attention	5	O
is	5	O
distracted	5	O
away	5	O
from	9	O
the	5	O
painful	5	O
pinprick	5	O
stimulus	5	O
with	5	O
a	5	O
visual	5	O
task	5	O
.	9	O

Furthermore	9	O
,	9	O
it	5	O
was	9	O
found	9	O
that	5	O
the	5	O
magnitude	5	O
of	5	O
attentional	5	O
modulation	9	O
in	5	O
secondary	9	O
hyperalgesia	3	B-Disease
is	5	O
very	5	O
similar	9	O
to	5	O
that	5	O
of	5	O
capsaicin	0	B-Chemical
-	7	O
untreated	3	O
,	9	O
control	9	O
condition	5	O
.	9	O

Our	9	O
findings	9	O
,	9	O
showing	9	O
no	9	O
interaction	9	O
between	5	O
capsaicin	0	B-Chemical
treatment	9	O
and	5	O
attentional	5	O
modulation	9	O
suggest	9	O
that	5	O
capsaicin	0	B-Chemical
-	7	O
induced	3	O
secondary	9	O
hyperalgesia	3	B-Disease
and	5	O
attention	5	O
might	9	O
affect	9	O
mechanical	5	O
pain	5	B-Disease
through	9	O
independent	9	O
mechanisms	9	O
.	9	O

Cardioprotective	0	O
effect	9	O
of	5	O
salvianolic	0	B-Chemical
acid	0	I-Chemical
A	9	I-Chemical
on	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
evaluate	9	O
the	5	O
cardioprotective	9	O
potential	9	O
of	5	O
salvianolic	0	B-Chemical
acid	0	I-Chemical
A	9	I-Chemical
on	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
rats	9	O
.	9	O

Hemodynamic	5	O
parameters	5	O
and	5	O
lead	5	O
II	9	O
electrocardiograph	5	O
were	9	O
monitored	9	O
and	5	O
recorded	5	O
continuously	5	O
.	9	O

Cardiac	9	O
marker	3	O
enzymes	1	O
and	5	O
antioxidative	0	O
parameters	5	O
in	5	O
serum	9	O
and	5	O
heart	5	O
tissues	9	O
were	9	O
measured	9	O
.	9	O

Assay	0	O
for	5	O
mitochondrial	9	O
respiratory	5	O
function	9	O
and	5	O
histopathological	9	O
examination	5	O
of	5	O
heart	5	O
tissues	9	O
were	9	O
performed	9	O
.	9	O

Isoproterenol	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
showed	9	O
significant	9	O
increases	9	O
in	5	O
the	5	O
levels	3	O
of	5	O
lactate	0	B-Chemical
dehydrogenase	1	O
,	9	O
aspartate	1	B-Chemical
transaminase	0	O
,	9	O
creatine	0	B-Chemical
kinase	3	O
and	5	O
malondialdehyde	0	B-Chemical
and	5	O
significant	9	O
decreases	9	O
in	5	O
the	5	O
activities	9	O
of	5	O
superoxide	0	B-Chemical
dismutase	0	O
,	9	O
catalase	0	O
and	5	O
glutathione	0	B-Chemical
peroxidase	0	O
in	5	O
serum	9	O
and	5	O
heart	5	O
.	9	O

These	5	O
rats	9	O
also	9	O
showed	9	O
declines	9	O
in	5	O
left	5	O
ventricular	5	O
systolic	5	O
pressure	5	O
,	9	O
maximum	5	O
and	5	O
minimum	5	O
rate	9	O
of	5	O
developed	5	O
left	5	O
ventricular	5	O
pressure	5	O
,	9	O
and	5	O
elevation	9	O
of	5	O
left	5	O
ventricular	5	O
end	9	O
-	7	O
diastolic	5	O
pressure	5	O
and	5	O
ST	9	O
-	7	O
segment	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
mitochondrial	9	O
respiratory	5	B-Disease
dysfunction	9	I-Disease
characterized	9	O
by	9	O
decreased	9	O
respiratory	5	O
control	9	O
ratio	9	O
and	5	O
ADP	0	B-Chemical
/	9	O
O	9	O
was	9	O
observed	9	O
in	5	O
isoproterenol	0	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

Administration	2	O
of	5	O
salvianolic	0	B-Chemical
acid	0	I-Chemical
A	9	I-Chemical
for	5	O
a	5	O
period	5	O
of	5	O
8	9	O
days	9	O
significantly	9	O
attenuated	3	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
dysfunction	9	I-Disease
and	5	O
myocardial	9	B-Disease
injury	9	I-Disease
and	5	O
improved	5	O
mitochondrial	9	O
respiratory	5	O
function	9	O
.	9	O

The	5	O
protective	9	O
role	9	O
of	5	O
salvianolic	0	B-Chemical
acid	0	I-Chemical
A	9	I-Chemical
against	9	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
damage	9	I-Disease
was	9	O
further	9	O
confirmed	9	O
by	9	O
histopathological	9	O
examination	5	O
.	9	O

The	5	O
results	9	O
of	5	O
our	5	O
study	9	O
suggest	9	O
that	5	O
salvianolic	0	B-Chemical
acid	0	I-Chemical
A	9	I-Chemical
possessing	9	O
antioxidant	0	O
activity	9	O
has	9	O
a	5	O
significant	9	O
protective	9	O
effect	9	O
against	9	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
glutamate	0	B-Chemical
supplementation	0	O
failed	9	O
to	5	O
protect	9	O
against	9	O
peripheral	9	B-Disease
neurotoxicity	9	I-Disease
of	5	O
paclitaxel	0	B-Chemical
.	9	O

Toxic	0	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
is	5	O
still	5	O
a	5	O
significant	9	O
limiting	9	O
factor	9	O
for	5	O
chemotherapy	5	O
with	5	O
paclitaxel	0	B-Chemical
(	9	O
PAC	9	B-Chemical
)	9	O
,	9	O
although	9	O
glutamate	0	B-Chemical
and	5	O
its	9	O
closely	9	O
related	9	O
amino	1	B-Chemical
acid	0	I-Chemical
glutamine	0	B-Chemical
were	9	O
claimed	5	O
to	5	O
ameliorate	9	O
PAC	9	B-Chemical
neurotoxicity	9	B-Disease
.	9	O

This	5	O
pilot	5	O
trial	5	O
aimed	5	O
to	5	O
evaluate	9	O
the	5	O
role	9	O
of	5	O
glutamate	0	B-Chemical
supplementation	0	O
for	5	O
preventing	9	O
PAC	9	B-Chemical
-	7	O
induced	3	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
in	5	O
a	5	O
randomized	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
,	9	O
double	9	O
-	7	O
blinded	5	O
clinical	5	O
and	5	O
electro	5	O
-	7	O
diagnostic	5	O
study	9	O
.	9	O

Forty	9	O
-	7	O
three	9	O
ovarian	9	B-Disease
cancer	3	I-Disease
patients	5	O
were	9	O
available	5	O
for	5	O
analysis	9	O
following	9	O
six	9	O
cycles	9	O
of	5	O
the	5	O
same	9	O
PAC	9	B-Chemical
-	7	O
containing	0	O
regimen	5	O
:	9	O
23	7	O
had	9	O
been	9	O
supplemented	0	O
by	9	O
glutamate	0	B-Chemical
all	5	O
along	9	O
the	5	O
treatment	9	O
period	5	O
,	9	O
at	9	O
a	5	O
daily	5	O
dose	9	O
of	5	O
three	9	O
times	5	O
500	0	O
mg	0	O
(	9	O
group	9	O
G	9	O
)	9	O
,	9	O
and	5	O
20	9	O
had	9	O
received	9	O
a	5	O
placebo	9	O
(	9	O
group	9	O
P	9	O
)	9	O
.	9	O

Patients	5	O
were	9	O
evaluated	9	O
by	9	O
neurological	5	O
examinations	5	O
,	9	O
questionnaires	5	O
and	5	O
sensory	5	O
-	7	O
motor	5	O
nerve	5	O
conduction	5	O
studies	9	O
.	9	O

There	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
in	5	O
the	5	O
frequency	5	O
of	5	O
signs	5	O
or	5	O
symptoms	5	O
between	5	O
the	5	O
two	5	O
groups	9	O
although	9	O
neurotoxicity	9	B-Disease
symptoms	5	O
presented	5	O
mostly	9	O
with	5	O
lower	9	O
scores	5	O
of	5	O
severity	5	O
in	5	O
group	9	O
G	9	O
.	9	O

However	9	O
,	9	O
this	5	O
difference	9	O
reached	9	O
statistical	5	O
significance	9	O
only	9	O
with	5	O
regard	5	O
to	5	O
reported	9	O
pain	5	B-Disease
sensation	5	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
011	2	O
)	9	O
.	9	O

Also	9	O
the	5	O
frequency	5	O
of	5	O
abnormal	9	O
electro	5	O
-	7	O
diagnostic	5	O
findings	9	O
showed	9	O
similarity	5	O
between	5	O
the	5	O
two	5	O
groups	9	O
(	9	O
G	9	O
:	9	O
7	9	O
/	9	O
23	7	O
=	7	O
30	9	O
.	9	O
4	9	O
%	9	O
;	9	O
P	9	O
:	9	O
6	9	O
/	9	O
20	9	O
=	7	O
30	9	O
%	9	O
)	9	O
.	9	O

This	5	O
pilot	5	O
study	9	O
leads	9	O
to	5	O
the	5	O
conclusion	9	O
that	5	O
glutamate	0	B-Chemical
supplementation	0	O
at	9	O
the	5	O
chosen	5	O
regimen	5	O
fails	9	O
to	5	O
protect	9	O
against	9	O
peripheral	9	B-Disease
neurotoxicity	9	I-Disease
of	5	O
PAC	9	B-Chemical
.	9	O

Development	2	O
of	5	O
ocular	5	B-Disease
myasthenia	9	I-Disease
during	5	O
pegylated	0	B-Chemical
interferon	3	I-Chemical
and	5	O
ribavirin	9	B-Chemical
treatment	9	O
for	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
.	9	O

A	9	O
63	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
experienced	5	O
sudden	5	O
diplopia	5	B-Disease
after	9	O
9	7	O
weeks	9	O
of	5	O
administration	9	O
of	5	O
pegylated	0	B-Chemical
interferon	3	I-Chemical
(	9	I-Chemical
IFN	3	I-Chemical
)	9	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
2b	9	I-Chemical
and	5	O
ribavirin	9	B-Chemical
for	5	O
chronic	5	B-Disease
hepatitis	9	I-Disease
C	9	I-Disease
(	9	O
CHC	9	B-Disease
)	9	O
.	9	O

Ophthalmologic	2	O
examinations	5	O
showed	9	O
ptosis	5	B-Disease
on	5	I-Disease
the	5	I-Disease
right	5	I-Disease
upper	9	I-Disease
lid	5	I-Disease
and	5	O
restricted	9	B-Disease
right	5	I-Disease
eye	5	I-Disease
movement	5	I-Disease
without	9	O
any	5	O
other	5	O
neurological	5	O
signs	5	O
.	9	O

A	9	O
brain	5	O
imaging	5	O
study	9	O
and	5	O
repetitive	5	O
nerve	5	O
stimulation	3	O
test	5	O
indicated	9	O
no	9	O
abnormality	9	O
.	9	O

The	5	O
acetylcholine	0	B-Chemical
receptor	3	O
antibody	3	O
titer	9	O
and	5	O
response	9	O
to	5	O
acetylcholinesterase	0	O
inhibitors	3	O
were	9	O
negative	9	O
,	9	O
and	5	O
the	5	O
results	9	O
of	5	O
thyroid	9	O
function	9	O
tests	5	O
were	9	O
normal	9	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
ophthalmological	5	O
symptoms	5	O
improved	5	O
rapidly	9	O
3	9	O
weeks	9	O
after	9	O
discontinuation	5	O
of	5	O
pegylated	0	B-Chemical
IFN	3	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
2b	9	I-Chemical
and	5	O
ribavirin	9	B-Chemical
.	9	O

The	5	O
ocular	5	B-Disease
myasthenia	9	I-Disease
associated	9	O
with	5	O
combination	9	O
therapy	5	O
of	5	O
pegylated	0	B-Chemical
IFN	3	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
2b	9	I-Chemical
and	5	O
ribavirin	9	B-Chemical
for	5	O
CHC	9	B-Disease
is	5	O
very	5	O
rarely	5	O
reported	9	O
;	9	O
therefore	5	O
,	9	O
we	5	O
present	9	O
this	5	O
case	5	O
with	5	O
a	5	O
review	5	O
of	5	O
the	5	O
various	9	O
eye	5	O
complications	5	O
of	5	O
IFN	3	B-Chemical
therapy	5	O
.	9	O

Learning	5	B-Disease
and	5	I-Disease
memory	5	I-Disease
deficits	5	I-Disease
in	5	O
ecstasy	5	B-Chemical
users	5	O
and	5	O
their	5	O
neural	5	O
correlates	9	O
during	5	O
a	5	O
face	5	O
-	7	O
learning	5	O
task	5	O
.	9	O

It	5	O
has	9	O
been	9	O
consistently	9	O
shown	9	O
that	5	O
ecstasy	5	B-Chemical
users	5	O
display	9	O
impairments	5	B-Disease
in	5	I-Disease
learning	5	I-Disease
and	5	I-Disease
memory	5	I-Disease
performance	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
working	5	O
memory	5	O
processing	5	O
in	5	O
ecstasy	5	B-Chemical
users	5	O
has	9	O
been	9	O
shown	9	O
to	5	O
be	5	O
associated	9	O
with	5	O
neural	5	O
alterations	9	O
in	5	O
hippocampal	3	O
and	5	O
/	9	O
or	5	O
cortical	5	O
regions	9	O
as	5	O
measured	9	O
by	9	O
functional	9	O
magnetic	0	O
resonance	5	O
imaging	5	O
(	9	O
fMRI	5	O
)	9	O
.	9	O

Using	9	O
functional	9	O
imaging	5	O
and	5	O
a	5	O
face	5	O
-	7	O
learning	5	O
task	5	O
,	9	O
we	5	O
investigated	9	O
neural	5	O
correlates	9	O
of	5	O
encoding	1	O
and	5	O
recalling	5	O
face	5	O
-	7	O
name	5	O
associations	5	O
in	5	O
20	9	O
recreational	5	O
drug	5	O
users	5	O
whose	9	O
predominant	9	O
drug	5	O
use	5	O
was	9	O
ecstasy	5	B-Chemical
and	5	O
20	9	O
controls	9	O
.	9	O

To	9	O
address	5	O
the	5	O
potential	9	O
confounding	5	O
effects	9	O
of	5	O
the	5	O
cannabis	5	B-Chemical
use	5	O
of	5	O
the	5	O
ecstasy	5	B-Chemical
using	9	O
group	9	O
,	9	O
a	5	O
second	9	O
analysis	9	O
included	5	O
14	7	O
previously	9	O
tested	9	O
cannabis	5	B-Chemical
users	5	O
(	9	O
Nestor	6	O
,	9	O
L	0	O
.	9	O
,	9	O
Roberts	6	O
,	9	O
G	9	O
.	9	O
,	9	O
Garavan	6	O
,	9	O
H	9	O
.	9	O
,	9	O
Hester	6	O
,	9	O
R	9	O
.	9	O
,	9	O
2008	2	O
.	9	O
Deficits	5	B-Disease
in	5	I-Disease
learning	5	I-Disease
and	5	I-Disease
memory	5	I-Disease
:	9	O
parahippocampal	5	O
hyperactivity	5	B-Disease
and	5	O
frontocortical	5	O
hypoactivity	5	O
in	5	O
cannabis	5	B-Chemical
users	5	O
.	9	O
Neuroimage	2	O
40	9	O
,	9	O
1328	7	O
-	7	O
1339	7	O
)	9	O
.	9	O

Ecstasy	7	B-Chemical
users	5	O
performed	9	O
significantly	9	O
worse	5	O
in	5	O
learning	5	O
and	5	O
memory	5	O
compared	9	O
to	5	O
controls	9	O
and	5	O
cannabis	5	B-Chemical
users	5	O
.	9	O

A	9	O
conjunction	9	O
analysis	9	O
of	5	O
the	5	O
encode	1	O
and	5	O
recall	5	O
phases	5	O
of	5	O
the	5	O
task	5	O
revealed	9	O
ecstasy	5	B-Chemical
-	7	O
specific	9	O
hyperactivity	5	B-Disease
in	5	O
bilateral	5	O
frontal	5	O
regions	9	O
,	9	O
left	5	O
temporal	5	O
,	9	O
right	5	O
parietal	5	O
,	9	O
bilateral	5	O
temporal	5	O
,	9	O
and	5	O
bilateral	5	O
occipital	5	O
brain	5	O
regions	9	O
.	9	O

Ecstasy	7	B-Chemical
-	7	O
specific	9	O
hypoactivity	5	O
was	9	O
evident	9	O
in	5	O
the	5	O
right	5	O
dorsal	5	O
anterior	5	O
cingulated	5	O
cortex	5	O
(	9	O
ACC	9	O
)	9	O
and	5	O
left	5	O
posterior	5	O
cingulated	5	O
cortex	5	O
.	9	O

In	9	O
both	9	O
ecstasy	5	B-Chemical
and	5	O
cannabis	5	B-Chemical
groups	9	O
brain	5	O
activation	3	O
was	9	O
decreased	9	O
in	5	O
the	5	O
right	5	O
medial	5	O
frontal	5	O
gyrus	5	O
,	9	O
left	5	O
parahippocampal	5	O
gyrus	5	O
,	9	O
left	5	O
dorsal	5	O
cingulate	5	O
gyrus	5	O
,	9	O
and	5	O
left	5	O
caudate	5	O
.	9	O

These	5	O
results	9	O
elucidated	9	O
ecstasy	5	B-Chemical
-	7	O
related	9	O
deficits	5	O
,	9	O
only	9	O
some	5	O
of	5	O
which	5	O
might	9	O
be	5	O
attributed	9	O
to	5	O
cannabis	5	B-Chemical
use	5	O
.	9	O

These	5	O
ecstasy	5	B-Chemical
-	7	O
specific	9	O
effects	9	O
may	5	O
be	5	O
related	9	O
to	5	O
the	5	O
vulnerability	5	O
of	5	O
isocortical	5	O
and	5	O
allocortical	5	O
regions	9	O
to	5	O
the	5	O
neurotoxic	9	B-Disease
effects	9	O
of	5	O
ecstasy	5	B-Chemical
.	9	O

Disulfiram	0	B-Chemical
-	7	O
like	9	O
syndrome	5	O
after	9	O
hydrogen	0	B-Chemical
cyanamide	0	I-Chemical
professional	5	O
skin	5	O
exposure	9	O
:	9	O
two	5	O
case	5	O
reports	9	O
in	5	O
France	2	O
.	9	O

Hydrogen	0	B-Chemical
cyanamide	0	I-Chemical
is	5	O
a	5	O
plant	4	O
growth	3	O
regulator	1	O
used	5	O
in	5	O
agriculture	5	O
to	5	O
induce	3	O
bud	9	O
break	5	O
in	5	O
fruit	4	O
trees	4	O
.	9	O

Contact	5	O
with	5	O
the	5	O
skin	5	O
can	5	O
result	9	O
in	5	O
percutaneous	5	O
absorption	0	O
of	5	O
the	5	O
substance	5	O
that	5	O
inhibits	3	O
aldehyde	0	B-Chemical
dehydrogenase	1	O
and	5	O
can	5	O
induce	3	O
acetaldehyde	0	B-Chemical
syndrome	5	O
in	5	O
case	5	O
of	5	O
alcohol	5	B-Chemical
use	5	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
report	5	O
is	5	O
to	5	O
describe	5	O
two	5	O
cases	5	O
of	5	O
a	5	O
disulfiram	0	B-Chemical
-	7	O
like	9	O
syndrome	5	O
following	9	O
occupational	5	O
exposure	9	O
to	5	O
hydrogen	0	B-Chemical
cyanamide	0	I-Chemical
.	9	O

The	5	O
first	9	O
case	5	O
involved	9	O
a	5	O
59	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
used	5	O
Dormex	_	B-Chemical
,	9	O
which	5	O
contains	9	O
hydrogen	0	B-Chemical
cyanamide	0	I-Chemical
,	9	O
without	9	O
protection	9	O
after	9	O
consuming	5	O
a	5	O
large	5	O
amount	9	O
of	5	O
alcohol	5	B-Chemical
during	5	O
a	5	O
meal	5	O
.	9	O

In	9	O
less	5	O
than	5	O
1	9	O
hour	0	O
after	9	O
the	5	O
ingestion	9	O
of	5	O
alcohol	5	B-Chemical
,	9	O
he	5	O
developed	5	O
malaise	4	O
with	5	O
flushing	5	B-Disease
of	5	I-Disease
the	5	I-Disease
face	5	I-Disease
,	9	O
tachycardia	5	B-Disease
,	9	O
and	5	O
dyspnea	5	B-Disease
.	9	O

Manifestations	5	O
regressed	5	O
spontaneously	5	O
under	9	O
surveillance	5	O
in	5	O
the	5	O
hospital	5	O
.	9	O

The	5	O
second	9	O
case	5	O
occurred	9	O
in	5	O
a	5	O
55	7	O
-	7	O
year	5	O
-	7	O
old	5	O
farmer	5	O
following	9	O
cutaneous	5	O
contact	5	O
with	5	O
Dormex	_	B-Chemical
.	9	O

Five	9	O
hours	9	O
after	9	O
exposure	9	O
,	9	O
he	5	O
developed	5	O
disulfiram	0	B-Chemical
-	7	O
like	9	O
syndrome	5	O
with	5	O
flushing	5	B-Disease
,	9	O
tachycardia	5	B-Disease
,	9	O
and	5	O
arterial	5	B-Disease
hypotension	5	I-Disease
after	9	O
consuming	5	O
three	9	O
glasses	5	O
of	5	O
wine	0	O
.	9	O

The	5	O
patient	5	O
recovered	9	O
spontaneously	5	O
in	5	O
3	9	O
hours	9	O
under	9	O
surveillance	5	O
in	5	O
the	5	O
hospital	5	O
.	9	O

These	5	O
cases	5	O
confirm	9	O
the	5	O
necessity	5	O
of	5	O
avoiding	5	O
alcohol	5	B-Chemical
consumption	5	O
as	5	O
recommended	5	O
in	5	O
the	5	O
instructions	5	O
for	5	O
use	5	O
of	5	O
Dormex	_	B-Chemical
and	5	O
of	5	O
preventing	9	O
cutaneous	5	O
contact	5	O
during	5	O
use	5	O
.	9	O

Sulpiride	7	B-Chemical
-	7	O
induced	3	O
tardive	5	B-Disease
dystonia	5	I-Disease
.	9	O

Sulpiride	7	B-Chemical
is	5	O
a	5	O
selective	9	O
D2	9	O
-	7	O
receptor	3	O
antagonist	3	O
with	5	O
antipsychotic	5	O
and	5	O
antidepressant	5	B-Chemical
properties	9	O
.	9	O

Although	9	O
initially	9	O
thought	5	O
to	5	O
be	5	O
free	9	O
of	5	O
extrapyramidal	5	O
side	5	O
effects	9	O
,	9	O
sulpiride	0	B-Chemical
-	7	O
induced	3	O
tardive	5	B-Disease
dyskinesia	5	I-Disease
and	5	O
parkinsonism	5	B-Disease
have	5	O
been	9	O
reported	9	O
occasionally	5	O
.	9	O

We	9	O
studied	9	O
a	5	O
37	9	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
developed	5	O
persistent	5	O
segmental	5	O
dystonia	5	B-Disease
within	9	O
2	9	O
months	5	O
after	9	O
starting	9	O
sulpiride	0	B-Chemical
therapy	5	O
.	9	O

We	9	O
could	9	O
not	5	O
find	5	O
any	5	O
previous	9	O
reports	9	O
of	5	O
sulpiride	0	B-Chemical
-	7	O
induced	3	O
tardive	5	B-Disease
dystonia	5	I-Disease
.	9	O

Comparative	9	O
cognitive	5	O
and	5	O
subjective	5	O
side	5	O
effects	9	O
of	5	O
immediate	5	O
-	7	O
release	9	O
oxycodone	0	B-Chemical
in	5	O
healthy	5	O
middle	9	O
-	7	O
aged	9	O
and	5	O
older	5	O
adults	5	O
.	9	O

This	5	O
study	9	O
measured	9	O
the	5	O
objective	5	O
and	5	O
subjective	5	O
neurocognitive	5	O
effects	9	O
of	5	O
a	5	O
single	9	O
10	9	O
-	7	O
mg	0	O
dose	9	O
of	5	O
immediate	5	O
-	7	O
release	9	O
oxycodone	0	B-Chemical
in	5	O
healthy	5	O
,	9	O
older	5	O
(	9	O
>	0	O
65	7	O
years	5	O
)	9	O
,	9	O
and	5	O
middle	9	O
-	7	O
aged	9	O
(	9	O
35	9	O
to	5	O
55	7	O
years	5	O
)	9	O
adults	5	O
who	5	O
were	9	O
not	5	O
suffering	5	O
from	9	O
chronic	5	O
or	5	O
significant	9	O
daily	5	O
pain	5	B-Disease
.	9	O

Seventy	5	O
-	7	O
one	5	O
participants	5	O
completed	5	O
2	9	O
separate	9	O
study	9	O
days	9	O
and	5	O
were	9	O
blind	5	O
to	5	O
medication	5	O
condition	5	O
(	9	O
placebo	9	O
,	9	O
10	9	O
-	7	O
mg	0	O
oxycodone	0	B-Chemical
)	9	O
.	9	O

Plasma	0	O
oxycodone	0	B-Chemical
concentration	0	O
peaked	9	O
between	5	O
60	9	O
and	5	O
90	9	O
minutes	0	O
postdose	5	O
(	9	O
P	9	O
<	0	O
.	9	O
01	7	O
)	9	O
and	5	O
pupil	5	O
size	9	O
,	9	O
an	5	O
indication	5	O
of	5	O
physiological	9	O
effects	9	O
of	5	O
the	5	O
medication	5	O
,	9	O
peaked	9	O
at	9	O
approximately	9	O
90	9	O
to	5	O
120	9	O
minutes	0	O
postdose	5	O
(	9	O
P	9	O
<	0	O
.	9	O
01	7	O
)	9	O
.	9	O

Significant	9	O
declines	9	B-Disease
in	5	I-Disease
simple	5	I-Disease
and	5	I-Disease
sustained	5	I-Disease
attention	5	I-Disease
,	9	I-Disease
working	5	I-Disease
memory	5	I-Disease
,	9	I-Disease
and	5	I-Disease
verbal	5	I-Disease
memory	5	I-Disease
were	9	O
observed	9	O
at	9	O
1	9	O
hour	0	O
postdose	5	O
compared	9	O
to	5	O
baseline	5	O
for	5	O
both	9	O
age	5	O
groups	9	O
with	5	O
a	5	O
trend	9	O
toward	5	O
return	5	O
to	5	O
baseline	5	O
by	9	O
5	9	O
hours	9	O
postdose	5	O
.	9	O

For	9	O
almost	9	O
all	5	O
cognitive	5	O
measures	5	O
,	9	O
there	5	O
were	9	O
no	9	O
medication	5	O
by	9	O
age	5	O
-	7	O
interaction	9	O
effects	9	O
,	9	O
which	5	O
indicates	9	O
that	5	O
the	5	O
2	9	O
age	5	O
groups	9	O
exhibited	9	O
similar	9	O
responses	5	O
to	5	O
the	5	O
medication	5	O
challenge	9	O
.	9	O

This	5	O
study	9	O
suggests	9	O
that	5	O
for	5	O
healthy	5	O
older	5	O
adults	5	O
who	5	O
are	5	O
not	5	O
suffering	5	O
from	9	O
chronic	5	B-Disease
pain	5	I-Disease
,	9	O
neurocognitive	5	O
and	5	O
pharmacodynamic	5	O
changes	9	O
in	5	O
response	9	O
to	5	O
a	5	O
10	9	O
-	7	O
mg	0	O
dose	9	O
of	5	O
immediate	5	O
-	7	O
release	9	O
oxycodone	0	B-Chemical
are	5	O
similar	9	O
to	5	O
those	5	O
observed	9	O
for	5	O
middle	9	O
-	7	O
aged	9	O
adults	5	O
.	9	O

PERSPECTIVE	2	O
:	9	O
Study	5	O
findings	9	O
indicate	9	O
that	5	O
the	5	O
metabolism	9	O
,	9	O
neurocognitive	5	O
effects	9	O
,	9	O
and	5	O
physical	5	O
side	5	O
effects	9	O
of	5	O
oral	9	O
oxycodone	0	B-Chemical
are	5	O
similar	9	O
for	5	O
healthy	5	O
middle	9	O
-	7	O
aged	9	O
and	5	O
older	5	O
adults	5	O
.	9	O

Therefore	9	O
,	9	O
clinicians	5	O
should	5	O
not	5	O
avoid	5	O
prescribing	5	O
oral	9	O
opioids	5	O
to	5	O
older	5	O
adults	5	O
based	5	O
on	5	O
the	5	O
belief	5	O
that	5	O
older	5	O
adults	5	O
are	5	O
at	9	O
higher	9	O
risk	5	O
for	5	O
side	5	O
effects	9	O
than	5	O
younger	5	O
adults	5	O
.	9	O

The	5	O
glycine	0	B-Chemical
transporter	1	O
-	7	O
1	9	O
inhibitor	3	O
SSR103800	9	B-Chemical
displays	9	O
a	5	O
selective	9	O
and	5	O
specific	9	O
antipsychotic	5	O
-	7	O
like	9	O
profile	9	O
in	5	O
normal	9	O
and	5	O
transgenic	3	O
mice	3	O
.	9	O

Schizophrenia	5	B-Disease
has	9	O
been	9	O
initially	9	O
associated	9	O
with	5	O
dysfunction	9	O
in	5	O
dopamine	5	B-Chemical
neurotransmission	5	O
.	9	O

However	9	O
,	9	O
the	5	O
observation	9	O
that	5	O
antagonists	3	O
of	5	O
the	5	O
glutamate	0	B-Chemical
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
D	9	I-Chemical
-	7	I-Chemical
aspartate	1	I-Chemical
(	9	O
NMDA	3	B-Chemical
)	9	O
receptor	3	O
produce	9	O
schizophrenic	5	B-Disease
-	7	O
like	9	O
symptoms	5	O
in	5	O
humans	9	O
has	9	O
led	9	O
to	5	O
the	5	O
idea	5	O
of	5	O
a	5	O
dysfunctioning	5	O
of	5	O
the	5	O
glutamatergic	3	O
system	5	O
via	9	O
its	9	O
NMDA	3	B-Chemical
receptor	3	O
.	9	O

As	9	O
a	5	O
result	9	O
,	9	O
there	5	O
is	5	O
a	5	O
growing	9	O
interest	5	O
in	5	O
the	5	O
development	9	O
of	5	O
pharmacological	9	O
agents	5	O
with	5	O
potential	9	O
antipsychotic	5	O
properties	9	O
that	5	O
enhance	9	O
the	5	O
activity	9	O
of	5	O
the	5	O
glutamatergic	3	O
system	5	O
via	9	O
a	5	O
modulation	9	O
of	5	O
the	5	O
NMDA	3	B-Chemical
receptor	3	O
.	9	O

Among	9	O
them	5	O
are	5	O
glycine	0	B-Chemical
transporter	1	O
-	7	O
1	9	O
(	9	O
GlyT1	3	O
)	9	O
inhibitors	3	O
such	5	O
as	5	O
SSR103800	9	B-Chemical
,	9	O
which	5	O
indirectly	9	O
enhance	9	O
NMDA	3	B-Chemical
receptor	3	O
function	9	O
by	9	O
increasing	9	O
the	5	O
glycine	0	B-Chemical
(	9	O
a	5	O
co	9	O
-	7	O
agonist	3	O
for	5	O
the	5	O
NMDA	3	B-Chemical
receptor	3	O
)	9	O
levels	3	O
in	5	O
the	5	O
synapse	5	O
.	9	O

This	5	O
study	9	O
aimed	5	O
at	9	O
investigating	5	O
the	5	O
potential	9	O
antipsychotic	5	O
-	7	O
like	9	O
properties	9	O
of	5	O
SSR103800	9	B-Chemical
,	9	O
with	5	O
a	5	O
particular	5	O
focus	5	O
on	5	O
models	5	O
of	5	O
hyperactivity	5	B-Disease
,	9	O
involving	5	O
either	9	O
drug	5	O
challenge	9	O
(	9	O
ie	5	O
,	9	O
amphetamine	5	B-Chemical
and	5	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
)	9	O
or	5	O
transgenic	3	O
mice	3	O
(	9	O
ie	5	O
,	9	O
NMDA	3	B-Chemical
Nr1	1	O
(	9	O
neo	1	O
-	7	O
/	9	O
-	7	O
)	9	O
and	5	O
DAT	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
)	9	O
.	9	O

Results	9	O
showed	9	O
that	5	O
SSR103800	9	B-Chemical
(	9	O
10	9	O
-	7	O
30	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
blocked	3	O
hyperactivity	5	B-Disease
induced	3	O
by	9	O
the	5	O
non	9	O
-	7	O
competitive	9	O
NMDA	3	B-Chemical
receptor	3	O
antagonist	3	O
,	9	O
MK	9	B-Chemical
-	7	I-Chemical
801	7	I-Chemical
and	5	O
partially	9	O
reversed	9	O
spontaneous	5	O
hyperactivity	5	B-Disease
of	5	O
NMDA	3	B-Chemical
Nr1	1	O
(	9	O
neo	1	O
-	7	O
/	9	O
-	7	O
)	9	O
mice	3	O
.	9	O

In	9	O
contrast	9	O
,	9	O
SSR103800	9	B-Chemical
failed	9	O
to	5	O
affect	9	O
hyperactivity	5	B-Disease
induced	3	O
by	9	O
amphetamine	5	B-Chemical
or	5	O
naturally	9	O
observed	9	O
in	5	O
dopamine	5	B-Chemical
transporter	1	O
(	9	O
DAT	9	O
(	9	O
-	7	O
/	9	O
-	7	O
)	9	O
)	9	O
knockout	3	O
mice	3	O
(	9	O
10	9	O
-	7	O
30	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O
)	9	O
.	9	O

Importantly	9	O
,	9	O
both	9	O
classical	9	O
(	9	O
haloperidol	5	B-Chemical
)	9	O
and	5	O
atypical	5	O
(	9	O
olanzapine	5	B-Chemical
,	9	O
clozapine	5	B-Chemical
and	5	O
aripiprazole	5	B-Chemical
)	9	O
antipsychotics	5	O
were	9	O
effective	5	O
in	5	O
all	5	O
these	5	O
models	5	O
of	5	O
hyperactivity	5	B-Disease
.	9	O

However	9	O
,	9	O
unlike	9	O
these	5	O
latter	9	O
,	9	O
SSR103800	9	B-Chemical
did	9	O
not	5	O
produce	9	O
catalepsy	5	B-Disease
(	9	O
retention	9	O
on	5	O
the	5	O
bar	9	O
test	5	O
)	9	O
up	5	O
to	5	O
30	9	O
mg	0	O
/	9	O
kg	0	O
p	7	O
.	9	O
o	9	O
.	9	O

Together	9	O
these	5	O
findings	9	O
show	9	O
that	5	O
the	5	O
GlyT1	3	O
inhibitor	3	O
,	9	O
SSR103800	9	B-Chemical
,	9	O
produces	9	O
antipsychotic	5	O
-	7	O
like	9	O
effects	9	O
,	9	O
which	5	O
differ	9	O
from	9	O
those	5	O
observed	9	O
with	5	O
compounds	0	O
primarily	9	O
targeting	3	O
the	5	O
dopaminergic	5	O
system	5	O
,	9	O
and	5	O
has	9	O
a	5	O
reduced	9	O
side	5	O
-	7	O
effect	9	O
potential	9	O
as	5	O
compared	9	O
with	5	O
these	5	O
latter	9	O
drugs	5	O
.	9	O

Pyrrolidine	0	B-Chemical
dithiocarbamate	0	I-Chemical
protects	3	O
the	5	O
piriform	5	O
cortex	5	O
in	5	O
the	5	O
pilocarpine	0	B-Chemical
status	9	B-Disease
epilepticus	5	I-Disease
model	5	O
.	9	O

Pyrrolidine	0	B-Chemical
dithiocarbamate	0	I-Chemical
(	9	O
PDTC	3	B-Chemical
)	9	O
has	9	O
a	5	O
dual	9	O
mechanism	9	O
of	5	O
action	5	O
as	5	O
an	5	O
antioxidant	0	O
and	5	O
an	5	O
inhibitor	3	O
of	5	O
the	5	O
transcription	1	O
factor	9	O
kappa	9	O
-	7	O
beta	9	O
.	9	O

Both	9	O
,	9	O
production	9	O
of	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
as	5	O
well	9	O
as	5	O
activation	3	O
of	5	O
NF	9	O
-	7	O
kappaB	3	O
have	5	O
been	9	O
implicated	9	O
in	5	O
severe	5	O
neuronal	3	B-Disease
damage	9	I-Disease
in	5	O
different	9	O
sub	9	O
-	7	O
regions	9	O
of	5	O
the	5	O
hippocampus	9	O
as	5	O
well	9	O
as	5	O
in	5	O
the	5	O
surrounding	9	O
cortices	5	O
.	9	O

The	5	O
effect	9	O
of	5	O
PDTC	3	B-Chemical
on	5	O
status	9	B-Disease
epilepticus	5	I-Disease
-	7	O
associated	9	O
cell	3	O
loss	9	O
in	5	O
the	5	O
hippocampus	9	O
and	5	O
piriform	5	O
cortex	5	O
was	9	O
evaluated	9	O
in	5	O
the	5	O
rat	3	O
fractionated	0	O
pilocarpine	0	B-Chemical
model	5	O
.	9	O

Treatment	9	O
with	5	O
150	0	O
mg	0	O
/	9	O
kg	0	O
PDTC	3	B-Chemical
before	9	O
and	5	O
following	9	O
status	9	B-Disease
epilepticus	5	I-Disease
significantly	9	O
increased	9	O
the	5	O
mortality	5	O
rate	9	O
to	5	O
100	0	O
%	9	O
.	9	O

Administration	2	O
of	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
PDTC	3	B-Chemical
(	9	O
low	9	O
-	7	O
dose	9	O
)	9	O
did	9	O
not	5	O
exert	9	O
major	9	O
effects	9	O
on	5	O
the	5	O
development	9	O
of	5	O
a	5	O
status	9	B-Disease
epilepticus	5	I-Disease
or	5	O
the	5	O
mortality	5	O
rate	9	O
.	9	O

In	9	O
vehicle	3	O
-	7	O
treated	3	O
rats	9	O
,	9	O
status	9	B-Disease
epilepticus	5	I-Disease
caused	9	O
pronounced	9	O
neuronal	3	B-Disease
damage	9	I-Disease
in	5	O
the	5	O
piriform	5	O
cortex	5	O
comprising	9	O
both	9	O
pyramidal	3	O
cells	3	O
and	5	O
interneurons	5	O
.	9	O

Low	9	O
-	7	O
dose	9	O
PDTC	3	B-Chemical
treatment	9	O
almost	9	O
completely	9	O
protected	9	O
from	9	O
lesions	5	O
in	5	O
the	5	O
piriform	5	O
cortex	5	O
.	9	O

A	9	O
significant	9	O
decrease	9	O
in	5	O
neuronal	3	O
density	9	O
of	5	O
the	5	O
hippocampal	3	O
hilar	5	O
formation	9	O
was	9	O
identified	9	O
in	5	O
vehicle	3	O
-	7	O
and	5	O
PDTC	3	B-Chemical
-	7	O
treated	3	O
rats	9	O
following	9	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

In	9	O
conclusion	9	O
,	9	O
the	5	O
NF	9	O
-	7	O
kappaB	3	O
inhibitor	3	O
and	5	O
antioxidant	0	O
PDTC	3	B-Chemical
protected	9	O
the	5	O
piriform	5	O
cortex	5	O
,	9	O
whereas	9	O
it	5	O
did	9	O
not	5	O
affect	9	O
hilar	5	O
neuronal	3	B-Disease
loss	9	I-Disease
.	9	O

These	5	O
data	5	O
might	9	O
indicate	9	O
that	5	O
the	5	O
generation	9	O
of	5	O
reactive	9	O
oxygen	0	B-Chemical
species	4	O
and	5	O
activation	3	O
of	5	O
NF	9	O
-	7	O
kappaB	3	O
plays	9	O
a	5	O
more	5	O
central	5	O
role	9	O
in	5	O
seizure	5	B-Disease
-	7	O
associated	9	O
neuronal	3	B-Disease
damage	9	I-Disease
in	5	O
the	5	O
temporal	5	O
cortex	5	O
as	5	O
compared	9	O
to	5	O
the	5	O
hippocampal	3	O
hilus	3	O
.	9	O

However	9	O
,	9	O
future	5	O
investigations	9	O
are	5	O
necessary	5	O
to	5	O
exactly	5	O
analyze	9	O
the	5	O
biochemical	9	O
mechanisms	9	O
by	9	O
which	5	O
PDTC	3	B-Chemical
exerted	9	O
its	9	O
beneficial	9	O
effects	9	O
in	5	O
the	5	O
piriform	5	O
cortex	5	O
.	9	O

Anaesthetists	2	O
'	9	O
nightmare	5	O
:	9	O
masseter	5	B-Disease
spasm	5	I-Disease
after	9	O
induction	3	O
in	5	O
an	5	O
undiagnosed	5	O
case	5	O
of	5	O
myotonia	5	B-Disease
congenita	5	I-Disease
.	9	O

We	9	O
report	5	O
an	5	O
undiagnosed	5	O
case	5	O
of	5	O
myotonia	5	B-Disease
congenita	5	I-Disease
in	5	O
a	5	O
24	9	O
-	7	O
year	5	O
-	7	O
old	5	O
previously	9	O
healthy	5	O
primigravida	5	O
,	9	O
who	5	O
developed	5	O
life	5	O
threatening	5	O
masseter	5	B-Disease
spasm	5	I-Disease
following	9	O
a	5	O
standard	5	O
dose	9	O
of	5	O
intravenous	0	O
suxamethonium	5	B-Chemical
for	5	O
induction	3	O
of	5	O
anaesthesia	5	O
.	9	O

Neither	9	O
the	5	O
patient	5	O
nor	9	O
the	5	O
anaesthetist	5	O
was	9	O
aware	5	O
of	5	O
the	5	O
diagnosis	5	O
before	9	O
this	5	O
potentially	5	O
lethal	9	O
complication	5	O
occurred	9	O
.	9	O

Twin	5	O
preterm	5	O
neonates	9	O
with	5	O
cardiac	5	B-Disease
toxicity	9	I-Disease
related	9	O
to	5	O
lopinavir	0	B-Chemical
/	9	I-Chemical
ritonavir	0	I-Chemical
therapy	5	O
.	9	O

We	9	O
report	5	O
twin	5	O
neonates	9	O
who	5	O
were	9	O
born	5	O
prematurely	5	O
at	9	O
32	7	O
weeks	9	O
of	5	O
gestation	9	O
to	5	O
a	5	O
mother	5	O
with	5	O
human	3	B-Disease
immunodeficiency	9	I-Disease
virus	9	I-Disease
infection	9	I-Disease
.	9	O

One	5	O
of	5	O
the	5	O
twins	5	O
developed	5	O
complete	9	O
heart	5	B-Disease
block	9	I-Disease
and	5	O
dilated	5	B-Disease
cardiomyopathy	5	I-Disease
related	9	O
to	5	O
lopinavir	0	B-Chemical
/	9	I-Chemical
ritonavir	0	I-Chemical
therapy	5	O
,	9	O
a	5	O
boosted	9	O
protease	0	O
-	7	O
inhibitor	3	O
agent	9	O
,	9	O
while	9	O
the	5	O
other	5	O
twin	5	O
developed	5	O
mild	9	O
bradycardia	5	B-Disease
.	9	O

We	9	O
recommend	5	O
caution	5	O
in	5	O
the	5	O
use	5	O
of	5	O
lopinavir	0	B-Chemical
/	9	I-Chemical
ritonavir	0	I-Chemical
in	5	O
the	5	O
immediate	5	O
neonatal	9	O
period	5	O
.	9	O

When	9	O
drugs	5	O
disappear	5	O
from	9	O
the	5	O
patient	5	O
:	9	O
elimination	9	O
of	5	O
intravenous	0	O
medication	5	O
by	9	O
hemodiafiltration	5	O
.	9	O

Twenty	9	O
-	7	O
three	9	O
hours	9	O
after	9	O
heart	5	O
transplantation	9	O
,	9	O
life	5	O
-	7	O
threatening	5	O
acute	9	O
right	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
was	9	O
diagnosed	5	O
in	5	O
a	5	O
patient	5	O
requiring	5	O
continuous	5	O
venovenous	5	O
hemodiafiltration	5	O
(	9	O
CVVHDF	5	O
)	9	O
.	9	O

Increasing	9	O
doses	0	O
of	5	O
catecholamines	9	B-Chemical
,	9	O
sedatives	5	O
,	9	O
and	5	O
muscle	9	O
relaxants	5	O
administered	9	O
through	9	O
a	5	O
central	5	O
venous	5	O
catheter	5	O
were	9	O
ineffective	9	O
.	9	O

However	9	O
,	9	O
a	5	O
bolus	0	O
of	5	O
epinephrine	0	B-Chemical
injected	3	O
through	9	O
an	5	O
alternative	5	O
catheter	5	O
provoked	9	O
a	5	O
hypertensive	5	B-Disease
crisis	5	O
.	9	O

Thus	9	O
,	9	O
interference	9	O
with	5	O
the	5	O
central	5	O
venous	5	O
infusion	0	O
by	9	O
the	5	O
dialysis	5	O
catheter	5	O
was	9	O
suspected	5	O
.	9	O

The	5	O
catheters	5	O
were	9	O
changed	9	O
,	9	O
and	5	O
hemodynamics	5	O
stabilized	9	O
at	9	O
lower	9	O
catecholamine	9	B-Chemical
doses	0	O
.	9	O

When	9	O
the	5	O
effects	9	O
of	5	O
IV	9	O
drugs	5	O
are	5	O
inadequate	5	O
in	5	O
patients	5	O
receiving	9	O
CVVHDF	5	O
,	9	O
interference	9	O
with	5	O
adjacent	9	O
catheters	5	O
resulting	9	O
in	5	O
elimination	9	O
of	5	O
the	5	O
drug	5	O
by	9	O
CVVHDF	5	O
should	5	O
be	5	O
suspected	5	O
.	9	O

Less	5	O
frequent	5	O
lithium	0	B-Chemical
administration	9	O
and	5	O
lower	9	O
urine	9	O
volume	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
determine	9	O
whether	9	O
patients	5	O
maintained	9	O
on	5	O
a	5	O
regimen	5	O
of	5	O
lithium	0	B-Chemical
on	5	O
a	5	O
once	5	O
-	7	O
per	9	O
-	7	O
day	9	O
schedule	5	O
have	5	O
lower	9	O
urine	9	O
volumes	5	O
than	5	O
do	5	O
patients	5	O
receiving	9	O
multiple	5	O
doses	0	O
per	9	O
day	9	O
.	9	O

METHOD	2	O
:	9	O
This	5	O
was	9	O
a	5	O
cross	5	O
-	7	O
sectional	5	O
study	9	O
of	5	O
85	9	O
patients	5	O
from	9	O
a	5	O
lithium	0	B-Chemical
clinic	5	O
who	5	O
received	9	O
different	9	O
dose	9	O
schedules	5	O
.	9	O

Patients	5	O
were	9	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
for	5	O
measurement	5	O
of	5	O
lithium	0	B-Chemical
level	9	O
,	9	O
creatinine	0	B-Chemical
clearance	9	O
,	9	O
urine	9	O
volume	9	O
,	9	O
and	5	O
maximum	5	O
osmolality	0	O
.	9	O

RESULTS	9	O
:	9	O
Multiple	5	O
daily	5	O
doses	0	O
of	5	O
lithium	0	B-Chemical
were	9	O
associated	9	O
with	5	O
higher	9	O
urine	9	O
volumes	5	O
.	9	O

The	5	O
dosing	9	O
schedule	5	O
,	9	O
duration	5	O
of	5	O
lithium	0	B-Chemical
treatment	9	O
,	9	O
and	5	O
daily	5	O
dose	9	O
of	5	O
lithium	0	B-Chemical
did	9	O
not	5	O
affect	9	O
maximum	5	O
osmolality	0	O
or	5	O
creatinine	0	B-Chemical
clearance	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Urine	9	O
volume	9	O
can	5	O
be	5	O
reduced	9	O
by	9	O
giving	5	O
lithium	0	B-Chemical
once	5	O
daily	5	O
and	5	O
/	9	O
or	5	O
by	9	O
lowering	9	O
the	5	O
total	9	O
daily	5	O
dose	9	O
.	9	O

Lithium	0	B-Chemical
-	7	O
induced	3	O
polyuria	5	B-Disease
seems	5	O
to	5	O
be	5	O
related	9	O
to	5	O
extrarenal	5	O
as	5	O
well	9	O
as	5	O
to	5	O
renal	9	O
effects	9	O
.	9	O

Antibacterial	0	O
medication	5	O
use	5	O
during	5	O
pregnancy	5	O
and	5	O
risk	5	O
of	5	O
birth	5	B-Disease
defects	9	I-Disease
:	9	O
National	2	O
Birth	7	B-Disease
Defects	9	I-Disease
Prevention	2	O
Study	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
estimate	5	O
the	5	O
association	9	O
between	5	O
antibacterial	0	O
medications	5	O
and	5	O
selected	9	O
birth	5	B-Disease
defects	9	I-Disease
.	9	O

DESIGN	2	O
,	9	O
SETTING	2	O
,	9	O
AND	2	O
PARTICIPANTS	2	O
:	9	O
Population	5	O
-	7	O
based	5	O
,	9	O
multisite	5	O
,	9	O
case	5	O
-	7	O
control	9	O
study	9	O
of	5	O
women	5	O
who	5	O
had	9	O
pregnancies	5	O
affected	9	O
by	9	O
1	9	O
of	5	O
more	5	O
than	5	O
30	9	O
eligible	5	O
major	9	O
birth	5	B-Disease
defects	9	I-Disease
identified	9	O
via	9	O
birth	5	B-Disease
defect	9	I-Disease
surveillance	5	O
programs	5	O
in	5	O
10	9	O
states	5	O
(	9	O
n	9	O
=	7	O
13	7	O
155	7	O
)	9	O
and	5	O
control	9	O
women	5	O
randomly	5	O
selected	9	O
from	9	O
the	5	O
same	9	O
geographical	5	O
regions	9	O
(	9	O
n	9	O
=	7	O
4941	7	O
)	9	O
.	9	O

MAIN	2	O
EXPOSURE	2	O
:	9	O
Reported	5	O
maternal	9	O
use	5	O
of	5	O
antibacterials	5	O
(	9	O
1	9	O
month	5	O
before	9	O
pregnancy	5	O
through	9	O
the	5	O
end	9	O
of	5	O
the	5	O
first	9	O
trimester	5	O
)	9	O
.	9	O

MAIN	2	O
OUTCOME	2	O
MEASURE	2	O
:	9	O
Odds	5	O
ratios	9	O
(	9	O
ORs	9	O
)	9	O
measuring	9	O
the	5	O
association	9	O
between	5	O
antibacterial	0	O
use	5	O
and	5	O
selected	9	O
birth	5	B-Disease
defects	9	I-Disease
adjusted	9	O
for	5	O
potential	9	O
confounders	5	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
reported	9	O
use	5	O
of	5	O
antibacterials	5	O
increased	9	O
during	5	O
pregnancy	5	O
,	9	O
peaking	9	O
during	5	O
the	5	O
third	9	O
month	5	O
.	9	O

Sulfonamides	0	B-Chemical
were	9	O
associated	9	O
with	5	O
anencephaly	5	B-Disease
(	9	O
adjusted	9	O
OR	9	O
[	9	O
AOR	5	O
]	9	O
=	7	O
3	9	O
.	9	O
4	9	O
;	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
[	9	O
CI	7	O
]	9	O
,	9	O
1	9	O
.	9	O
3	9	O
-	7	O
8	9	O
.	9	O
8	9	O
)	9	O
,	9	O
hypoplastic	5	B-Disease
left	5	I-Disease
heart	5	I-Disease
syndrome	5	I-Disease
(	9	O
AOR	5	O
=	7	O
3	9	O
.	9	O
2	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
3	9	O
-	7	O
7	9	O
.	9	O
6	9	O
)	9	O
,	9	O
coarctation	5	B-Disease
of	5	I-Disease
the	5	I-Disease
aorta	9	I-Disease
(	9	O
AOR	5	O
=	7	O
2	9	O
.	9	O
7	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
3	9	O
-	7	O
5	9	O
.	9	O
6	9	O
)	9	O
,	9	O
choanal	5	B-Disease
atresia	5	I-Disease
(	9	O
AOR	5	O
=	7	O
8	9	O
.	9	O
0	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
2	9	O
.	9	O
7	9	O
-	7	O
23	7	O
.	9	O
5	9	O
)	9	O
,	9	O
transverse	5	B-Disease
limb	5	I-Disease
deficiency	9	I-Disease
(	9	O
AOR	5	O
=	7	O
2	9	O
.	9	O
5	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
0	7	O
-	7	O
5	9	O
.	9	O
9	7	O
)	9	O
,	9	O
and	5	O
diaphragmatic	5	B-Disease
hernia	5	I-Disease
(	9	O
AOR	5	O
=	7	O
2	9	O
.	9	O
4	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
1	9	O
-	7	O
5	9	O
.	9	O
4	9	O
)	9	O
.	9	O

Nitrofurantoins	_	B-Chemical
were	9	O
associated	9	O
with	5	O
anophthalmia	5	B-Disease
or	5	O
microphthalmos	5	B-Disease
(	9	O
AOR	5	O
=	7	O
3	9	O
.	9	O
7	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
1	9	O
-	7	O
12	9	O
.	9	O
2	9	O
)	9	O
,	9	O
hypoplastic	5	B-Disease
left	5	I-Disease
heart	5	I-Disease
syndrome	5	I-Disease
(	9	O
AOR	5	O
=	7	O
4	9	O
.	9	O
2	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
9	7	O
-	7	O
9	7	O
.	9	O
1	9	O
)	9	O
,	9	O
atrial	5	B-Disease
septal	5	I-Disease
defects	9	I-Disease
(	9	O
AOR	5	O
=	7	O
1	9	O
.	9	O
9	7	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
1	9	O
-	7	O
3	9	O
.	9	O
4	9	O
)	9	O
,	9	O
and	5	O
cleft	5	B-Disease
lip	5	I-Disease
with	5	O
cleft	5	B-Disease
palate	5	I-Disease
(	9	O
AOR	5	O
=	7	O
2	9	O
.	9	O
1	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
1	9	O
.	9	O
2	9	O
-	7	O
3	9	O
.	9	O
9	7	O
)	9	O
.	9	O

Other	9	O
antibacterial	0	O
agents	5	O
that	5	O
showed	9	O
associations	5	O
included	5	O
erythromycins	9	B-Chemical
(	9	O
2	9	O
defects	9	O
)	9	O
,	9	O
penicillins	0	B-Chemical
(	9	O
1	9	O
defect	9	O
)	9	O
,	9	O
cephalosporins	5	B-Chemical
(	9	O
1	9	O
defect	9	O
)	9	O
,	9	O
and	5	O
quinolones	9	B-Chemical
(	9	O
1	9	O
defect	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Reassuringly	5	O
,	9	O
penicillins	0	B-Chemical
,	9	O
erythromycins	9	B-Chemical
,	9	O
and	5	O
cephalosporins	5	B-Chemical
,	9	O
although	9	O
used	5	O
commonly	5	O
by	9	O
pregnant	5	O
women	5	O
,	9	O
were	9	O
not	5	O
associated	9	O
with	5	O
many	5	O
birth	5	B-Disease
defects	9	I-Disease
.	9	O

Sulfonamides	0	B-Chemical
and	5	O
nitrofurantoins	9	B-Chemical
were	9	O
associated	9	O
with	5	O
several	9	O
birth	5	B-Disease
defects	9	I-Disease
,	9	O
indicating	9	O
a	5	O
need	5	O
for	5	O
additional	9	O
scrutiny	5	O
.	9	O

Differential	9	O
impact	5	O
of	5	O
immune	3	O
escape	5	O
mutations	1	O
G145R	1	O
and	5	O
P120T	9	O
on	5	O
the	5	O
replication	9	O
of	5	O
lamivudine	5	B-Chemical
-	7	O
resistant	9	O
hepatitis	9	B-Chemical
B	9	I-Chemical
virus	9	I-Chemical
e	9	I-Chemical
antigen	3	I-Chemical
-	7	O
positive	9	O
and	5	O
-	7	O
negative	9	O
strains	1	O
.	9	O

Immune	9	O
escape	5	O
variants	1	O
of	5	O
the	5	O
hepatitis	9	B-Disease
B	9	I-Disease
virus	9	O
(	9	O
HBV	9	O
)	9	O
represent	9	O
an	5	O
emerging	5	O
clinical	5	O
challenge	9	O
,	9	O
because	5	O
they	5	O
can	5	O
be	5	O
associated	9	O
with	5	O
vaccine	5	O
escape	5	O
,	9	O
HBV	9	O
reactivation	9	O
,	9	O
and	5	O
failure	5	O
of	5	O
diagnostic	5	O
tests	5	O
.	9	O

Recent	9	O
data	5	O
suggest	9	O
a	5	O
preferential	9	O
selection	5	O
of	5	O
immune	3	O
escape	5	O
mutants	1	O
in	5	O
distinct	9	O
peripheral	9	O
blood	9	O
leukocyte	3	O
compartments	9	O
of	5	O
infected	3	O
individuals	5	O
.	9	O

We	9	O
therefore	5	O
systematically	5	O
analyzed	9	O
the	5	O
functional	9	O
impact	5	O
of	5	O
the	5	O
most	9	O
prevalent	9	O
immune	3	O
escape	5	O
variants	1	O
,	9	O
the	5	O
sG145R	1	O
and	5	O
sP120T	9	O
mutants	1	O
,	9	O
on	5	O
the	5	O
viral	9	O
replication	9	O
efficacy	9	O
and	5	O
antiviral	9	O
drug	5	O
susceptibility	9	O
of	5	O
common	5	O
treatment	9	O
-	7	O
associated	9	O
mutants	1	O
with	5	O
resistance	9	O
to	5	O
lamivudine	5	B-Chemical
(	9	O
LAM	9	B-Chemical
)	9	O
and	5	O
/	9	O
or	5	O
HBeAg	9	B-Chemical
negativity	5	O
.	9	O

Replication	9	O
-	7	O
competent	9	O
HBV	9	O
strains	1	O
with	5	O
sG145R	1	O
or	5	O
sP120T	9	O
and	5	O
LAM	9	B-Chemical
resistance	9	O
(	9	O
rtM204I	1	O
or	5	O
rtL180M	7	O
/	9	O
rtM204V	1	O
)	9	O
were	9	O
generated	9	O
on	5	O
an	5	O
HBeAg	9	B-Chemical
-	7	O
positive	9	O
and	5	O
an	5	O
HBeAg	9	B-Chemical
-	7	O
negative	9	O
background	9	O
with	5	O
precore	1	O
(	9	O
PC	9	O
)	9	O
and	5	O
basal	3	O
core	9	O
promoter	1	O
(	9	O
BCP	9	O
)	9	O
mutants	1	O
.	9	O

The	5	O
sG145R	1	O
mutation	1	O
strongly	9	O
reduced	9	O
HBsAg	9	B-Chemical
levels	3	O
and	5	O
was	9	O
able	9	O
to	5	O
fully	9	O
restore	9	O
the	5	O
impaired	9	O
replication	9	O
of	5	O
LAM	9	B-Chemical
-	7	O
resistant	9	O
HBV	9	O
mutants	1	O
to	5	O
the	5	O
levels	3	O
of	5	O
wild	1	O
-	7	O
type	9	O
HBV	9	O
,	9	O
and	5	O
PC	9	O
or	5	O
BCP	9	O
mutations	1	O
further	9	O
enhanced	3	O
viral	9	O
replication	9	O
.	9	O

Although	9	O
the	5	O
sP120T	9	O
substitution	9	O
also	9	O
impaired	9	O
HBsAg	9	B-Chemical
secretion	3	O
,	9	O
it	5	O
did	9	O
not	5	O
enhance	9	O
the	5	O
replication	9	O
of	5	O
LAM	9	B-Chemical
-	7	O
resistant	9	O
clones	3	O
.	9	O

However	9	O
,	9	O
the	5	O
concomitant	9	O
occurrence	5	O
of	5	O
HBeAg	9	B-Chemical
negativity	5	O
(	9	O
PC	9	O
/	9	O
BCP	9	O
)	9	O
,	9	O
sP120T	9	O
,	9	O
and	5	O
LAM	9	B-Chemical
resistance	9	O
resulted	9	O
in	5	O
the	5	O
restoration	5	O
of	5	O
replication	9	O
to	5	O
levels	3	O
of	5	O
wild	1	O
-	7	O
type	9	O
HBV	9	O
.	9	O

In	9	O
all	5	O
clones	3	O
with	5	O
combined	9	O
immune	3	O
escape	5	O
and	5	O
LAM	9	B-Chemical
resistance	9	O
mutations	1	O
,	9	O
the	5	O
nucleotide	1	B-Chemical
analogues	0	O
adefovir	0	B-Chemical
and	5	O
tenofovir	0	B-Chemical
remained	9	O
effective	5	O
in	5	O
suppressing	3	O
viral	9	O
replication	9	O
in	5	O
vitro	3	O
.	9	O

These	5	O
findings	9	O
reveal	9	O
the	5	O
differential	9	O
impact	5	O
of	5	O
immune	3	O
escape	5	O
variants	1	O
on	5	O
the	5	O
replication	9	O
and	5	O
drug	5	O
susceptibility	9	O
of	5	O
complex	9	O
HBV	9	O
mutants	1	O
,	9	O
supporting	9	O
the	5	O
need	5	O
of	5	O
close	5	O
surveillance	5	O
and	5	O
treatment	9	O
adjustment	5	O
in	5	O
response	9	O
to	5	O
the	5	O
selection	5	O
of	5	O
distinct	9	O
mutational	9	O
patterns	5	O
.	9	O

Hemolytic	0	B-Disease
anemia	9	I-Disease
associated	9	O
with	5	O
the	5	O
use	5	O
of	5	O
omeprazole	0	B-Chemical
.	9	O

Omeprazole	0	B-Chemical
is	5	O
the	5	O
first	9	O
drug	5	O
designed	9	O
to	5	O
block	9	O
the	5	O
final	9	O
step	9	O
in	5	O
the	5	O
acid	0	O
secretory	3	O
process	5	O
within	9	O
the	5	O
parietal	5	O
cell	3	O
.	9	O

It	5	O
has	9	O
been	9	O
shown	9	O
to	5	O
be	5	O
extremely	5	O
effective	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
peptic	5	B-Disease
ulcer	5	I-Disease
disease	5	I-Disease
,	9	O
reflux	5	B-Disease
esophagitis	5	I-Disease
,	9	O
and	5	O
the	5	O
Zollinger	6	B-Disease
-	7	I-Disease
Ellison	6	I-Disease
syndrome	5	I-Disease
.	9	O

Although	9	O
clinical	5	O
experience	5	O
with	5	O
omeprazole	0	B-Chemical
is	5	O
still	5	O
limited	5	O
,	9	O
many	5	O
controlled	5	O
studies	9	O
have	5	O
established	9	O
the	5	O
short	5	O
-	7	O
term	5	O
safety	5	O
of	5	O
this	5	O
drug	5	O
.	9	O

We	9	O
report	5	O
the	5	O
first	9	O
case	5	O
of	5	O
a	5	O
serious	5	O
short	5	O
-	7	O
term	5	O
adverse	5	O
reaction	9	O
with	5	O
the	5	O
use	5	O
of	5	O
omeprazole	0	B-Chemical
:	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
.	9	O

The	5	O
patient	5	O
developed	5	O
weakness	5	O
,	9	O
lethargy	5	B-Disease
,	9	O
and	5	O
shortness	5	B-Disease
of	5	I-Disease
breath	5	I-Disease
2	9	O
days	9	O
after	9	O
starting	9	O
therapy	5	O
with	5	O
omeprazole	0	B-Chemical
.	9	O

Two	9	O
weeks	9	O
after	9	O
the	5	O
initiation	9	O
of	5	O
therapy	5	O
,	9	O
her	5	O
hematocrit	9	O
had	9	O
decreased	9	O
from	9	O
44	7	O
.	9	O
1	9	O
%	9	O
to	5	O
20	9	O
.	9	O
4	9	O
%	9	O
,	9	O
and	5	O
she	5	O
had	9	O
a	5	O
positive	9	O
direct	9	O
Coombs	6	O
antiglobulin	3	O
test	5	O
and	5	O
an	5	O
elevated	9	O
indirect	5	O
bilirubin	0	B-Chemical
.	9	O

After	9	O
she	5	O
discontinued	5	O
the	5	O
omeprazole	0	B-Chemical
,	9	O
her	5	O
hemoglobin	0	O
and	5	O
hematocrit	9	O
gradually	9	O
returned	5	O
to	5	O
normal	9	O
.	9	O

The	5	O
mechanism	9	O
by	9	O
which	5	O
omeprazole	0	B-Chemical
caused	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
is	5	O
uncertain	5	O
,	9	O
but	9	O
physicians	5	O
should	5	O
be	5	O
alerted	5	O
to	5	O
this	5	O
possible	5	O
adverse	5	O
effect	9	O
.	9	O

Phenylephrine	0	B-Chemical
but	9	O
not	5	O
ephedrine	0	B-Chemical
reduces	9	B-Disease
frontal	5	I-Disease
lobe	5	I-Disease
oxygenation	5	I-Disease
following	9	O
anesthesia	5	O
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Vasopressor	7	O
agents	5	O
are	5	O
used	5	O
to	5	O
correct	5	O
anesthesia	5	O
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

We	9	O
describe	5	O
the	5	O
effect	9	O
of	5	O
phenylephrine	0	B-Chemical
and	5	O
ephedrine	0	B-Chemical
on	5	O
frontal	5	O
lobe	5	O
oxygenation	5	O
(	9	O
S	9	O
(	9	O
c	9	O
)	9	O
O	9	O
(	9	O
2	9	O
)	9	O
)	9	O
following	9	O
anesthesia	5	O
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Following	9	O
induction	3	O
of	5	O
anesthesia	5	O
by	9	O
fentanyl	0	B-Chemical
(	9	O
0	7	O
.	9	O
15	9	O
mg	0	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
)	9	O
and	5	O
propofol	0	B-Chemical
(	9	O
2	9	O
.	9	O
0	7	O
mg	0	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
)	9	O
,	9	O
13	7	O
patients	5	O
received	9	O
phenylephrine	0	B-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
mg	0	O
iv	9	O
)	9	O
and	5	O
12	9	O
patients	5	O
received	9	O
ephedrine	0	B-Chemical
(	9	O
10	9	O
mg	0	O
iv	9	O
)	9	O
to	5	O
restore	9	O
mean	5	O
arterial	5	O
pressure	5	O
(	9	O
MAP	9	O
)	9	O
.	9	O

Heart	2	O
rate	9	O
(	9	O
HR	9	O
)	9	O
,	9	O
MAP	9	O
,	9	O
stroke	5	B-Disease
volume	9	O
(	9	O
SV	9	O
)	9	O
,	9	O
cardiac	5	O
output	5	O
(	9	O
CO	0	O
)	9	O
,	9	O
and	5	O
frontal	5	O
lobe	5	O
oxygenation	5	O
(	9	O
S	9	O
(	9	O
c	9	O
)	9	O
O	9	O
(	9	O
2	9	O
)	9	O
)	9	O
were	9	O
registered	5	O
.	9	O

RESULTS	9	O
:	9	O
Induction	3	O
of	5	O
anesthesia	5	O
was	9	O
followed	9	O
by	9	O
a	5	B-Disease
decrease	9	I-Disease
in	5	I-Disease
MAP	9	I-Disease
,	9	I-Disease
HR	9	I-Disease
,	9	I-Disease
SV	9	I-Disease
,	9	I-Disease
and	5	I-Disease
CO	0	I-Disease
concomitant	9	O
with	5	O
an	5	O
elevation	9	O
in	5	O
S	9	O
(	9	O
c	9	O
)	9	O
O	9	O
(	9	O
2	9	O
)	9	O
.	9	O

After	9	O
administration	9	O
of	5	O
phenylephrine	0	B-Chemical
,	9	O
MAP	9	O
increased	9	O
(	9	O
51	7	O
+	9	O
/	9	O
-	7	O
12	9	O
to	5	O
81	7	O
+	9	O
/	9	O
-	7	O
13	7	O
mmHg	7	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
;	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
.	9	O

However	9	O
,	9	O
a	5	O
14	7	O
%	9	O
(	9	O
from	9	O
70	9	O
+	9	O
/	9	O
-	7	O
8	9	O
%	9	O
to	5	O
60	9	O
+	9	O
/	9	O
-	7	O
7	9	O
%	9	O
)	9	O
reduction	9	O
in	5	O
S	9	O
(	9	O
c	9	O
)	9	O
O	9	O
(	9	O
2	9	O
)	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
followed	9	O
with	5	O
no	9	O
change	9	O
in	5	O
CO	0	O
(	9	O
3	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
1	9	O
to	5	O
3	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
9	7	O
l	0	O
min	0	O
(	9	O
-	7	O
1	9	O
)	9	O
)	9	O
.	9	O

The	5	O
administration	9	O
of	5	O
ephedrine	0	B-Chemical
led	9	O
to	5	O
a	5	O
similar	9	O
increase	9	O
in	5	O
MAP	9	O
(	9	O
53	7	O
+	9	O
/	9	O
-	7	O
9	7	O
to	5	O
79	7	O
+	9	O
/	9	O
-	7	O
8	9	O
mmHg	7	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
restored	3	O
CO	0	O
(	9	O
3	9	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
2	9	O
to	5	O
5	9	O
.	9	O
0	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
3	9	O
l	0	O
min	0	O
(	9	O
-	7	O
1	9	O
)	9	O
)	9	O
,	9	O
and	5	O
preserved	9	O
S	9	O
(	9	O
c	9	O
)	9	O
O	9	O
(	9	O
2	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
utilization	9	O
of	5	O
phenylephrine	0	B-Chemical
to	5	O
correct	5	O
hypotension	5	B-Disease
induced	3	O
by	9	O
anesthesia	5	O
has	9	O
a	5	O
negative	9	O
impact	5	O
on	5	O
S	9	O
(	9	O
c	9	O
)	9	O
O	9	O
(	9	O
2	9	O
)	9	O
while	9	O
ephedrine	0	B-Chemical
maintains	9	O
frontal	5	O
lobe	5	O
oxygenation	5	O
potentially	5	O
related	9	O
to	5	O
an	5	O
increase	9	O
in	5	O
CO	0	O
.	9	O

Prolonged	9	O
elevation	9	O
of	5	O
plasma	9	O
argatroban	5	B-Chemical
in	5	O
a	5	O
cardiac	5	O
transplant	9	O
patient	5	O
with	5	O
a	5	O
suspected	5	O
history	5	O
of	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
with	5	O
thrombosis	5	B-Disease
.	9	O

BACKGROUND	2	O
:	9	O
Direct	9	O
thrombin	0	O
inhibitors	3	O
(	9	O
DTIs	5	O
)	9	O
provide	5	O
an	5	O
alternative	5	O
method	5	O
of	5	O
anticoagulation	5	O
for	5	O
patients	5	O
with	5	O
a	5	O
history	5	O
of	5	O
heparin	0	B-Chemical
-	7	O
induced	3	O
thrombocytopenia	9	B-Disease
(	9	O
HIT	5	B-Disease
)	9	O
or	5	O
HIT	5	B-Disease
with	5	O
thrombosis	5	B-Disease
(	9	O
HITT	5	B-Disease
)	9	O
undergoing	9	O
cardiopulmonary	5	O
bypass	5	O
(	9	O
CPB	5	O
)	9	O
.	9	O

In	9	O
the	5	O
following	9	O
report	5	O
,	9	O
a	5	O
65	7	O
-	7	O
year	5	O
-	7	O
old	5	O
critically	9	B-Disease
ill	5	I-Disease
patient	5	O
with	5	O
a	5	O
suspected	5	O
history	5	O
of	5	O
HITT	5	B-Disease
was	9	O
administered	9	O
argatroban	5	B-Chemical
for	5	O
anticoagulation	5	O
on	5	O
bypass	5	O
during	5	O
heart	5	O
transplantation	9	O
.	9	O

The	5	O
patient	5	O
required	9	O
massive	9	O
transfusion	5	O
support	5	O
(	9	O
55	7	O
units	9	O
of	5	O
red	9	O
blood	9	O
cells	3	O
,	9	O
42	7	O
units	9	O
of	5	O
fresh	9	O
-	7	O
frozen	9	O
plasma	9	O
,	9	O
40	9	O
units	9	O
of	5	O
cryoprecipitate	5	O
,	9	O
40	9	O
units	9	O
of	5	O
platelets	3	O
,	9	O
and	5	O
three	9	O
doses	0	O
of	5	O
recombinant	3	O
Factor	9	O
VIIa	3	O
)	9	O
for	5	O
severe	5	O
intraoperative	5	B-Disease
and	5	I-Disease
postoperative	5	I-Disease
bleeding	5	I-Disease
.	9	O

STUDY	2	O
DESIGN	2	O
AND	2	O
METHODS	2	O
:	9	O
Plasma	0	O
samples	9	O
from	9	O
before	9	O
and	5	O
after	9	O
CPB	5	O
were	9	O
analyzed	9	O
postoperatively	5	O
for	5	O
argatroban	5	B-Chemical
concentration	0	O
using	9	O
a	5	O
modified	9	O
ecarin	0	O
clotting	5	O
time	5	O
(	9	O
ECT	5	O
)	9	O
assay	3	O
.	9	O

RESULTS	9	O
:	9	O
Unexpectedly	9	O
high	9	O
concentrations	0	O
of	5	O
argatroban	5	B-Chemical
were	9	O
measured	9	O
in	5	O
these	5	O
samples	9	O
(	9	O
range	9	O
,	9	O
0	7	O
-	7	O
32	7	O
microg	0	O
/	9	O
mL	0	O
)	9	O
,	9	O
and	5	O
a	5	O
prolonged	9	O
plasma	9	O
argatroban	5	B-Chemical
half	5	O
life	5	O
(	9	O
t	5	O
(	9	O
1	9	O
/	9	O
2	9	O
)	9	O
)	9	O
of	5	O
514	7	O
minutes	0	O
was	9	O
observed	9	O
(	9	O
published	9	O
elimination	9	O
t	5	O
(	9	O
1	9	O
/	9	O
2	9	O
)	9	O
is	5	O
39	7	O
-	7	O
51	7	O
minutes	0	O
[	9	O
<	0	O
or	5	O
=	7	O
181	7	O
minutes	0	O
with	5	O
hepatic	9	B-Disease
impairment	5	I-Disease
]	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Correlation	9	O
of	5	O
plasma	9	O
argatroban	5	B-Chemical
concentration	0	O
versus	9	O
the	5	O
patient	5	O
'	9	O
s	9	O
coagulation	5	O
variables	5	O
and	5	O
clinical	5	O
course	5	O
suggest	9	O
that	5	O
prolonged	9	O
elevated	9	O
levels	3	O
of	5	O
plasma	9	O
argatroban	5	B-Chemical
may	5	O
have	5	O
contributed	9	O
to	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
extended	5	O
coagulopathy	5	B-Disease
.	9	O

Because	9	O
DTIs	5	O
do	5	O
not	5	O
have	5	O
reversal	9	O
agents	5	O
,	9	O
surgical	5	O
teams	5	O
and	5	O
transfusion	5	O
services	5	O
should	5	O
remain	9	O
aware	5	O
of	5	O
the	5	O
possibility	9	O
of	5	O
massive	9	O
transfusion	5	O
events	5	O
during	5	O
anticoagulation	5	O
with	5	O
these	5	O
agents	5	O
.	9	O

This	5	O
is	5	O
the	5	O
first	9	O
report	5	O
to	5	O
measure	5	O
plasma	9	O
argatroban	5	B-Chemical
concentration	0	O
in	5	O
the	5	O
context	5	O
of	5	O
CPB	5	O
and	5	O
extended	5	O
coagulopathy	5	B-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
the	5	O
adjunctive	5	O
bupropion	5	B-Chemical
on	5	O
male	9	O
sexual	5	B-Disease
dysfunction	9	I-Disease
induced	3	O
by	9	O
a	5	O
selective	9	B-Chemical
serotonin	9	I-Chemical
reuptake	0	I-Chemical
inhibitor	3	I-Chemical
:	9	O
a	5	O
double	9	O
-	7	O
blind	5	O
placebo	9	O
-	7	O
controlled	5	O
and	5	O
randomized	5	O
study	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
determine	9	O
the	5	O
safety	5	O
and	5	O
efficacy	9	O
of	5	O
adjunctive	5	O
bupropion	5	B-Chemical
sustained	5	O
-	7	O
release	9	O
(	9	O
SR	9	O
)	9	O
on	5	O
male	9	O
sexual	5	B-Disease
dysfunction	9	I-Disease
(	9	O
SD	7	B-Disease
)	9	O
induced	3	O
by	9	O
a	5	O
selective	9	B-Chemical
serotonin	9	I-Chemical
reuptake	0	I-Chemical
inhibitor	3	I-Chemical
(	9	O
SSRI	5	B-Chemical
)	9	O
,	9	O
as	5	O
SD	7	B-Disease
is	5	O
a	5	O
common	5	O
side	5	O
-	7	O
effect	9	O
of	5	O
SSRIs	5	B-Chemical
and	5	O
the	5	O
most	9	O
effective	5	O
treatments	9	O
have	5	O
yet	9	O
to	5	O
be	5	O
determined	9	O
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
The	5	O
randomized	5	O
sample	9	O
consisted	5	O
of	5	O
234	7	O
euthymic	3	O
men	5	O
who	5	O
were	9	O
receiving	9	O
some	5	O
type	9	O
of	5	O
SSRI	5	B-Chemical
.	9	O

The	5	O
men	5	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
bupropion	5	B-Chemical
SR	9	O
(	9	O
150	0	O
mg	0	O
twice	9	O
daily	5	O
,	9	O
117	7	O
)	9	O
or	5	O
placebo	9	O
(	9	O
twice	9	O
daily	5	O
,	9	O
117	7	O
)	9	O
for	5	O
12	9	O
weeks	9	O
.	9	O

Efficacy	5	O
was	9	O
evaluated	9	O
using	9	O
the	5	O
Clinical	5	O
Global	5	O
Impression	5	O
-	7	O
Sexual	5	O
Function	9	O
(	9	O
CGI	5	O
-	7	O
SF	9	O
;	9	O
the	5	O
primary	9	O
outcome	5	O
measure	5	O
)	9	O
,	9	O
the	5	O
International	2	O
Index	5	O
of	5	O
Erectile	5	O
Function	9	O
(	9	O
IIEF	5	O
)	9	O
,	9	O
Arizona	4	O
Sexual	5	O
Experience	5	O
Scale	5	O
(	9	O
ASEX	5	O
)	9	O
,	9	O
and	5	O
Erectile	5	B-Disease
Dysfunction	5	I-Disease
Inventory	5	O
of	5	O
Treatment	9	O
Satisfaction	5	O
(	9	O
EDITS	5	O
)	9	O
(	9	O
secondary	9	O
outcome	5	O
measures	5	O
)	9	O
.	9	O

Participants	5	O
were	9	O
followed	9	O
biweekly	5	O
during	5	O
study	9	O
period	5	O
.	9	O

RESULTS	9	O
:	9	O
After	9	O
12	9	O
weeks	9	O
of	5	O
treatment	9	O
,	9	O
the	5	O
mean	5	O
(	9	O
sd	9	O
)	9	O
scores	5	O
for	5	O
CGI	5	O
-	7	O
SF	9	O
were	9	O
significantly	9	O
lower	9	O
,	9	O
i	9	O
.	9	O
e	9	O
.	9	O
better	5	O
,	9	O
in	5	O
patients	5	O
on	5	O
bupropion	5	B-Chemical
SR	9	O
,	9	O
at	9	O
2	9	O
.	9	O
4	9	O
(	9	O
1	9	O
.	9	O
2	9	O
)	9	O
,	9	O
than	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
,	9	O
at	9	O
3	9	O
.	9	O
9	7	O
(	9	O
1	9	O
.	9	O
1	9	O
)	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

Men	7	O
who	5	O
received	9	O
bupropion	5	B-Chemical
had	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
the	5	O
total	9	O
IIEF	5	O
score	5	O
(	9	O
54	7	O
.	9	O
4	9	O
%	9	O
vs	7	O
1	9	O
.	9	O
2	9	O
%	9	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
003	2	O
)	9	O
,	9	O
and	5	O
in	5	O
the	5	O
five	9	O
different	9	O
domains	1	O
of	5	O
the	5	O
IIEF	5	O
.	9	O

Total	7	O
ASEX	5	O
scores	5	O
were	9	O
significantly	9	O
lower	9	O
,	9	O
i	9	O
.	9	O
e	9	O
.	9	O
better	5	O
,	9	O
among	5	O
men	5	O
who	5	O
received	9	O
bupropion	5	B-Chemical
than	5	O
placebo	9	O
,	9	O
at	9	O
15	9	O
.	9	O
5	9	O
(	9	O
4	9	O
.	9	O
3	9	O
)	9	O
vs	7	O
21	7	O
.	9	O
5	9	O
(	9	O
4	9	O
.	9	O
7	9	O
)	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

The	5	O
EDITS	5	O
scores	5	O
were	9	O
67	7	O
.	9	O
4	9	O
(	9	O
10	9	O
.	9	O
2	9	O
)	9	O
for	5	O
the	5	O
bupropion	5	B-Chemical
and	5	O
36	9	O
.	9	O
3	9	O
(	9	O
11	7	O
.	9	O
7	9	O
)	9	O
for	5	O
the	5	O
placebo	9	O
group	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

The	5	O
ASEX	5	O
score	5	O
and	5	O
CGI	5	O
-	7	O
SF	9	O
score	5	O
were	9	O
correlated	9	O
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
003	2	O
)	9	O
.	9	O

In	9	O
linear	5	O
regression	5	O
analyses	9	O
the	5	O
CGI	5	O
-	7	O
SF	9	O
score	5	O
was	9	O
not	5	O
affected	9	O
significantly	9	O
by	9	O
the	5	O
duration	5	O
of	5	O
SD	7	B-Disease
,	9	O
type	9	O
of	5	O
SSRI	5	B-Chemical
used	5	O
and	5	O
age	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Bupropion	0	B-Chemical
is	5	O
an	5	O
effective	5	O
treatment	9	O
for	5	O
male	9	O
SD	7	B-Disease
induced	3	O
by	9	O
SSRIs	5	B-Chemical
.	9	O

These	5	O
results	9	O
provide	5	O
empirical	5	O
support	5	O
for	5	O
conducting	5	O
a	5	O
further	9	O
study	9	O
of	5	O
bupropion	5	B-Chemical
.	9	O

Prevention	2	O
of	5	O
seizures	5	B-Disease
and	5	O
reorganization	9	O
of	5	O
hippocampal	3	O
functions	9	O
by	9	O
transplantation	9	O
of	5	O
bone	5	O
marrow	3	O
cells	3	O
in	5	O
the	5	O
acute	9	O
phase	5	O
of	5	O
experimental	5	O
epilepsy	5	B-Disease
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
we	5	O
investigated	9	O
the	5	O
therapeutic	5	O
potential	9	O
of	5	O
bone	5	O
marrow	3	O
mononuclear	3	O
cells	3	O
(	9	O
BMCs	3	O
)	9	O
in	5	O
a	5	O
model	5	O
of	5	O
epilepsy	5	B-Disease
induced	3	O
by	9	O
pilocarpine	0	B-Chemical
in	5	O
rats	9	O
.	9	O

BMCs	3	O
obtained	9	O
from	9	O
green	9	O
fluorescent	3	O
protein	1	O
(	9	O
GFP	3	O
)	9	O
transgenic	3	O
mice	3	O
or	5	O
rats	9	O
were	9	O
transplanted	3	O
intravenously	0	O
after	9	O
induction	3	O
of	5	O
status	9	B-Disease
epilepticus	5	I-Disease
(	9	O
SE	9	B-Disease
)	9	O
.	9	O

Spontaneous	9	B-Disease
recurrent	5	I-Disease
seizures	5	I-Disease
(	9	O
SRS	5	B-Disease
)	9	O
were	9	O
monitored	9	O
using	9	O
Racine	6	O
'	9	O
s	9	O
seizure	5	B-Disease
severity	5	O
scale	5	O
.	9	O

All	9	O
of	5	O
the	5	O
rats	9	O
in	5	O
the	5	O
saline	0	O
-	7	O
treated	3	O
epileptic	5	B-Disease
control	9	O
group	9	O
developed	5	O
SRS	5	B-Disease
,	9	O
whereas	9	O
none	9	O
of	5	O
the	5	O
BMC	9	O
-	7	O
treated	3	O
epileptic	5	B-Disease
animals	9	O
had	9	O
seizures	5	B-Disease
in	5	O
the	5	O
short	5	O
term	5	O
(	9	O
15	9	O
days	9	O
after	9	O
transplantation	9	O
)	9	O
,	9	O
regardless	9	O
of	5	O
the	5	O
BMC	9	O
source	5	O
.	9	O

Over	5	O
the	5	O
long	5	O
-	7	O
term	5	O
chronic	5	O
phase	5	O
(	9	O
120	9	O
days	9	O
after	9	O
transplantation	9	O
)	9	O
,	9	O
only	9	O
25	9	O
%	9	O
of	5	O
BMC	9	O
-	7	O
treated	3	O
epileptic	5	B-Disease
animals	9	O
had	9	O
seizures	5	B-Disease
,	9	O
but	9	O
with	5	O
a	5	O
lower	9	O
frequency	5	O
and	5	O
duration	5	O
compared	9	O
to	5	O
the	5	O
epileptic	5	B-Disease
control	9	O
group	9	O
.	9	O

The	5	O
density	9	O
of	5	O
hippocampal	3	O
neurons	3	O
in	5	O
the	5	O
brains	9	O
of	5	O
animals	9	O
treated	3	O
with	5	O
BMCs	3	O
was	9	O
markedly	9	O
preserved	9	O
.	9	O

At	9	O
hippocampal	3	O
Schaeffer	6	O
collateral	5	O
-	7	O
CA1	3	O
synapses	5	O
,	9	O
long	5	O
-	7	O
term	5	O
potentiation	3	O
was	9	O
preserved	9	O
in	5	O
BMC	9	O
-	7	O
transplanted	3	O
rats	9	O
compared	9	O
to	5	O
epileptic	5	B-Disease
controls	9	O
.	9	O

The	5	O
donor	9	O
-	7	O
derived	9	O
GFP	3	O
(	9	O
+	9	O
)	9	O
cells	3	O
were	9	O
rarely	5	O
found	9	O
in	5	O
the	5	O
brains	9	O
of	5	O
transplanted	3	O
epileptic	5	B-Disease
rats	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
treatment	9	O
with	5	O
BMCs	3	O
can	5	O
prevent	5	O
the	5	O
development	9	O
of	5	O
chronic	5	O
seizures	5	B-Disease
,	9	O
reduce	5	O
neuronal	3	B-Disease
loss	9	I-Disease
,	9	O
and	5	O
influence	5	O
the	5	O
reorganization	9	O
of	5	O
the	5	O
hippocampal	3	O
neuronal	3	O
network	5	O
.	9	O

Normalizing	5	O
effects	9	O
of	5	O
modafinil	5	B-Chemical
on	5	O
sleep	5	O
in	5	O
chronic	5	O
cocaine	5	B-Chemical
users	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
purpose	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
effect	9	O
of	5	O
morning	5	O
-	7	O
dosed	0	O
modafinil	5	B-Chemical
on	5	O
sleep	5	O
and	5	O
daytime	5	B-Disease
sleepiness	5	I-Disease
in	5	O
chronic	5	O
cocaine	5	B-Chemical
users	5	O
.	9	O

METHOD	2	O
:	9	O
Twenty	9	O
cocaine	5	B-Chemical
-	7	O
dependent	9	O
participants	5	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
receive	5	O
modafinil	5	B-Chemical
,	9	O
400	0	O
mg	0	O
(	9	O
N	9	O
=	7	O
10	9	O
)	9	O
,	9	O
or	5	O
placebo	9	O
(	9	O
N	9	O
=	7	O
10	9	O
)	9	O
every	5	O
morning	5	O
at	9	O
7	9	O
:	9	O
30	9	O
a	5	O
.	9	O
m	9	O
.	9	O
for	5	O
16	9	O
days	9	O
in	5	O
an	5	O
inpatient	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
randomized	5	O
trial	5	O
.	9	O

Participants	5	O
underwent	5	O
polysomnographic	5	O
sleep	5	O
recordings	5	O
on	5	O
days	9	O
1	9	O
to	5	O
3	9	O
,	9	O
7	9	O
to	5	O
9	7	O
,	9	O
and	5	O
14	7	O
to	5	O
16	9	O
(	9	O
first	9	O
,	9	O
second	9	O
,	9	O
and	5	O
third	9	O
weeks	9	O
of	5	O
abstinence	5	O
)	9	O
.	9	O

The	5	O
Multiple	5	O
Sleep	5	O
Latency	5	O
Test	5	O
was	9	O
performed	9	O
at	9	O
11	7	O
:	9	O
30	9	O
a	5	O
.	9	O
m	9	O
.	9	O
,	9	O
2	9	O
:	9	O
00	7	O
p	7	O
.	9	O
m	9	O
.	9	O
,	9	O
and	5	O
4	9	O
:	9	O
30	9	O
p	7	O
.	9	O
m	9	O
.	9	O
on	5	O
days	9	O
2	9	O
,	9	O
8	9	O
,	9	O
and	5	O
15	9	O
.	9	O

For	9	O
comparison	9	O
of	5	O
sleep	5	O
architecture	5	O
variables	5	O
,	9	O
12	9	O
healthy	5	O
comparison	9	O
participants	5	O
underwent	5	O
a	5	O
single	9	O
night	5	O
of	5	O
experimental	5	O
polysomnography	5	O
that	5	O
followed	9	O
1	9	O
night	5	O
of	5	O
accommodation	5	O
polysomnography	5	O
.	9	O

RESULTS	9	O
:	9	O
Progressive	5	O
abstinence	5	O
from	9	O
cocaine	5	B-Chemical
was	9	O
associated	9	O
with	5	O
worsening	5	O
of	5	O
all	5	O
measured	9	O
polysomnographic	5	O
sleep	5	O
outcomes	5	O
.	9	O

Compared	9	O
with	5	O
placebo	9	O
,	9	O
modafinil	5	B-Chemical
decreased	9	O
nighttime	5	O
sleep	5	O
latency	5	O
and	5	O
increased	9	O
slow	5	O
-	7	O
wave	5	O
sleep	5	O
time	5	O
in	5	O
cocaine	5	B-Chemical
-	7	O
dependent	9	O
participants	5	O
.	9	O

The	5	O
effect	9	O
of	5	O
modafinil	5	B-Chemical
interacted	9	O
with	5	O
the	5	O
abstinence	5	O
week	9	O
and	5	O
was	9	O
associated	9	O
with	5	O
longer	5	O
total	9	O
sleep	5	O
time	5	O
and	5	O
shorter	9	O
REM	5	O
sleep	5	O
latency	5	O
in	5	O
the	5	O
third	9	O
week	9	O
of	5	O
abstinence	5	O
.	9	O

Comparison	9	O
of	5	O
slow	5	O
-	7	O
wave	5	O
sleep	5	O
time	5	O
,	9	O
total	9	O
sleep	5	O
time	5	O
,	9	O
and	5	O
sleep	5	O
latency	5	O
in	5	O
cocaine	5	B-Chemical
-	7	O
dependent	9	O
and	5	O
healthy	5	O
participants	5	O
revealed	9	O
a	5	O
normalizing	9	O
effect	9	O
of	5	O
modafinil	5	B-Chemical
in	5	O
cocaine	5	B-Chemical
-	7	O
dependent	9	O
participants	5	O
.	9	O

Modafinil	5	B-Chemical
was	9	O
associated	9	O
with	5	O
increased	9	O
daytime	5	O
sleep	5	O
latency	5	O
,	9	O
as	5	O
measured	9	O
by	9	O
the	5	O
Multiple	5	O
Sleep	5	O
Latency	5	O
Test	5	O
,	9	O
and	5	O
a	5	O
nearly	9	O
significant	9	O
decrease	9	O
in	5	O
subjective	5	O
daytime	5	B-Disease
sleepiness	5	I-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Morning	5	O
-	7	O
dosed	0	O
modafinil	5	B-Chemical
promotes	3	O
nocturnal	5	O
sleep	5	O
,	9	O
normalizes	9	O
sleep	5	O
architecture	5	O
,	9	O
and	5	O
decreases	9	O
daytime	5	B-Disease
sleepiness	5	I-Disease
in	5	O
abstinent	5	O
cocaine	5	B-Chemical
users	5	O
.	9	O

These	5	O
effects	9	O
may	5	O
be	5	O
relevant	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
cocaine	5	B-Chemical
dependence	5	O
.	9	O

Safety	5	O
of	5	O
transesophageal	5	O
echocardiography	5	O
in	5	O
adults	5	O
:	9	O
study	9	O
in	5	O
a	5	O
multidisciplinary	5	O
hospital	5	O
.	9	O

BACKGROUND	2	O
:	9	O
TEE	5	O
is	5	O
a	5	O
semi	5	O
-	7	O
invasive	5	O
tool	5	O
broadly	5	O
used	5	O
and	5	O
its	9	O
utilization	9	O
associated	9	O
to	5	O
sedatives	5	O
drugs	5	O
might	9	O
to	5	O
affect	9	O
the	5	O
procedure	5	O
safety	5	O
.	9	O

OBJECTIVE	2	O
:	9	O
to	5	O
analyze	9	O
aspects	5	O
of	5	O
TEE	5	O
safety	5	O
associated	9	O
to	5	O
the	5	O
use	5	O
of	5	O
Midazolan	9	B-Chemical
(	9	O
MZ	9	B-Chemical
)	9	O
and	5	O
Flumazenil	0	B-Chemical
(	9	O
FL	9	B-Chemical
)	9	O
and	5	O
the	5	O
influence	5	O
of	5	O
the	5	O
clinical	5	O
variables	5	O
on	5	O
the	5	O
event	5	O
rate	9	O
.	9	O

METHOD	2	O
:	9	O
prospective	5	O
study	9	O
with	5	O
137	7	O
patients	5	O
that	5	O
underwent	5	O
TEE	5	O
with	5	O
MZ	9	B-Chemical
associated	9	O
to	5	O
moderate	9	O
sedation	5	O
.	9	O

We	9	O
analyzed	9	O
the	5	O
following	9	O
events	5	O
:	9	O
complications	5	O
related	9	O
with	5	O
the	5	O
topical	0	O
anesthesia	5	O
,	9	O
with	5	O
MZ	9	B-Chemical
use	5	O
and	5	O
with	5	O
the	5	O
procedure	5	O
.	9	O

Uni	2	O
-	7	O
and	5	O
multivariate	5	O
analyses	9	O
were	9	O
used	5	O
to	5	O
test	5	O
the	5	O
influence	5	O
of	5	O
the	5	O
clinical	5	O
variables	5	O
:	9	O
age	5	O
,	9	O
sex	5	O
,	9	O
stroke	5	B-Disease
,	9	O
myocardiopathy	5	B-Disease
(	9	O
MP	9	B-Disease
)	9	O
,	9	O
duration	5	O
of	5	O
the	5	O
test	5	O
,	9	O
mitral	5	B-Disease
regurgitation	5	I-Disease
(	9	O
MR	9	B-Disease
)	9	O
and	5	O
the	5	O
MZ	9	B-Chemical
dose	9	O
.	9	O

RESULTS	9	O
:	9	O
All	9	O
patients	5	O
(	9	O
65	7	O
+	9	O
/	9	O
-	7	O
16	9	O
yrs	7	O
;	9	O
58	7	O
%	9	O
males	9	O
)	9	O
finished	5	O
the	5	O
examination	5	O
.	9	O

The	5	O
mean	5	O
doses	0	O
of	5	O
MZ	9	B-Chemical
and	5	O
FL	9	B-Chemical
were	9	O
4	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
9	7	O
mg	0	O
and	5	O
0	7	O
.	9	O
28	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
mg	0	O
,	9	O
respectively	9	O
.	9	O

The	5	O
duration	5	O
of	5	O
the	5	O
examination	5	O
and	5	O
the	5	O
mean	5	O
ejection	5	O
fraction	9	O
(	9	O
EF	9	O
)	9	O
were	9	O
16	9	O
.	9	O
4	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
1	9	O
minutes	0	O
and	5	O
60	9	O
+	9	O
/	9	O
-	7	O
9	7	O
%	9	O
,	9	O
respectively	9	O
.	9	O

Mild	9	O
hypoxia	3	B-Disease
(	9	O
SO2	0	O
<	0	O
90	9	O
%	9	O
)	9	O
was	9	O
the	5	O
most	9	O
common	5	O
event	5	O
(	9	O
11	7	O
patients	5	O
)	9	O
;	9	O
3	9	O
patients	5	O
(	9	O
2	9	O
%	9	O
)	9	O
presented	5	O
transient	9	O
hypoxia	3	B-Disease
due	5	O
to	5	O
upper	9	O
airway	5	B-Disease
obstruction	5	I-Disease
by	9	O
probe	9	O
introduction	9	O
and	5	O
8	9	O
(	9	O
5	9	O
.	9	O
8	9	O
%	9	O
)	9	O
due	5	O
to	5	O
hypoxia	3	B-Disease
caused	9	O
by	9	O
MZ	9	B-Chemical
use	5	O
.	9	O

Transient	9	O
hypotension	5	B-Disease
(	9	O
SAP	9	O
<	0	O
90mmHg	5	O
)	9	O
occurred	9	O
in	5	O
1	9	O
patient	5	O
(	9	O
0	7	O
.	9	O
7	9	O
%	9	O
)	9	O
.	9	O

The	5	O
multivariate	5	O
analysis	9	O
showed	9	O
that	5	O
severe	5	O
MR	9	B-Disease
,	9	O
MP	9	B-Disease
(	9	O
EF	9	O
<	0	O
45	9	O
%	9	O
)	9	O
and	5	O
high	9	O
doses	0	O
of	5	O
MZ	9	B-Chemical
(	9	O
>	0	O
5mg	0	O
)	9	O
were	9	O
associated	9	O
with	5	O
events	5	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

The	5	O
EF	9	O
was	9	O
40	9	O
%	9	O
,	9	O
in	5	O
the	5	O
group	9	O
with	5	O
MP	9	B-Disease
and	5	O
44	7	O
%	9	O
in	5	O
the	5	O
group	9	O
with	5	O
severe	5	O
MR	9	B-Disease
and	5	O
it	5	O
can	5	O
be	5	O
a	5	O
factor	9	O
associated	9	O
with	5	O
clinical	5	O
events	5	O
in	5	O
the	5	O
last	5	O
group	9	O
.	9	O

CONCLUSION	5	O
:	9	O
TEE	5	O
with	5	O
sedation	5	O
presents	5	O
a	5	O
low	9	O
rate	9	O
of	5	O
events	5	O
.	9	O

There	5	O
were	9	O
no	9	O
severe	5	O
events	5	O
and	5	O
there	5	O
was	9	O
no	9	O
need	5	O
to	5	O
interrupt	9	O
the	5	O
examinations	5	O
.	9	O

Effect	0	O
of	5	O
direct	9	O
intracoronary	5	O
administration	9	O
of	5	O
methylergonovine	0	B-Chemical
in	5	O
patients	5	O
with	5	O
and	5	O
without	9	O
variant	1	B-Disease
angina	5	I-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
intracoronary	5	O
administration	9	O
of	5	O
methylergonovine	0	B-Chemical
were	9	O
studied	9	O
in	5	O
21	7	O
patients	5	O
with	5	O
variant	1	B-Disease
angina	5	I-Disease
and	5	O
22	7	O
patients	5	O
with	5	O
atypical	5	O
chest	5	B-Disease
pain	5	I-Disease
and	5	O
in	5	O
others	5	O
without	9	O
angina	5	B-Disease
pectoris	5	I-Disease
(	9	O
control	9	O
group	9	O
)	9	O
.	9	O

Methylergonovine	9	B-Chemical
was	9	O
administered	9	O
continuously	5	O
at	9	O
a	5	O
rate	9	O
of	5	O
10	9	O
micrograms	0	O
/	9	O
min	0	O
up	5	O
to	5	O
50	0	O
micrograms	0	O
.	9	O

In	9	O
all	5	O
patients	5	O
with	5	O
variant	1	B-Disease
angina	5	I-Disease
,	9	O
coronary	5	B-Disease
spasm	5	I-Disease
was	9	O
provoked	9	O
at	9	O
a	5	O
mean	5	O
dose	9	O
of	5	O
28	7	O
+	9	O
/	9	O
-	7	O
13	7	O
micrograms	0	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
.	9	O

In	9	O
the	5	O
control	9	O
group	9	O
neither	9	O
ischemic	9	O
ST	9	O
change	9	O
nor	9	O
localized	9	O
spasm	5	B-Disease
occurred	9	O
.	9	O

The	5	O
basal	3	O
tone	5	O
of	5	O
the	5	O
right	5	O
coronary	5	O
artery	5	O
was	9	O
significantly	9	O
lower	9	O
than	5	O
that	5	O
of	5	O
the	5	O
left	5	O
coronary	5	O
artery	5	O
.	9	O

The	5	O
percentage	9	O
of	5	O
vasoconstriction	9	O
of	5	O
the	5	O
right	5	O
coronary	5	O
artery	5	O
was	9	O
significantly	9	O
higher	9	O
than	5	O
that	5	O
of	5	O
the	5	O
left	5	O
coronary	5	O
artery	5	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
spasm	5	B-Disease
provocation	5	O
tests	5	O
,	9	O
which	5	O
use	5	O
an	5	O
intracoronary	5	O
injection	9	O
of	5	O
a	5	O
relatively	5	O
low	9	O
dose	9	O
of	5	O
methylergonovine	0	B-Chemical
,	9	O
have	5	O
a	5	O
high	9	O
sensitivity	9	O
in	5	O
variant	1	B-Disease
angina	5	I-Disease
and	5	O
the	5	O
vasoreactivity	5	O
of	5	O
the	5	O
right	5	O
coronary	5	O
artery	5	O
may	5	O
be	5	O
greater	5	O
than	5	O
that	5	O
of	5	O
the	5	O
other	5	O
coronary	5	O
arteries	5	O
.	9	O

Oral	9	O
manifestations	5	O
of	5	O
"	5	O
meth	0	B-Disease
mouth	5	I-Disease
"	5	O
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

AIM	9	O
:	9	O
The	5	O
aim	5	O
of	5	O
the	5	O
documentation	5	O
of	5	O
this	5	O
clinical	5	O
case	5	O
is	5	O
to	5	O
make	5	O
clinicians	5	O
aware	5	O
of	5	O
"	5	O
meth	0	B-Disease
mouth	5	I-Disease
"	5	O
and	5	O
the	5	O
medical	5	O
risks	5	O
associated	9	O
with	5	O
this	5	O
serious	5	O
condition	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Methamphetamine	7	B-Chemical
is	5	O
a	5	O
very	5	O
addictive	5	O
,	9	O
powerful	5	O
stimulant	5	O
that	5	O
increases	9	O
wakefulness	5	O
and	5	O
physical	5	O
activity	9	O
and	5	O
can	5	O
produce	9	O
other	5	O
effects	9	O
such	5	O
as	5	O
cardiac	5	B-Disease
dysrhythmias	5	I-Disease
,	9	O
hypertension	5	B-Disease
,	9	O
hallucinations	5	B-Disease
,	9	O
and	5	O
violent	5	B-Disease
behavior	5	I-Disease
.	9	O

Dental	2	O
patients	5	O
abusing	5	O
methamphetamine	5	B-Chemical
can	5	O
present	9	O
with	5	O
poor	5	O
oral	9	O
hygiene	5	O
,	9	O
xerostomia	5	B-Disease
,	9	O
rampant	5	O
caries	5	B-Disease
(	9	O
"	5	O
meth	0	B-Disease
mouth	5	I-Disease
"	5	O
)	9	O
,	9	O
and	5	O
excessive	5	O
tooth	5	B-Disease
wear	5	I-Disease
.	9	O

Oral	9	O
rehabilitation	5	O
of	5	O
patients	5	O
using	9	O
methamphetamine	5	B-Chemical
can	5	O
be	5	O
challenging	5	O
.	9	O

CASE	2	O
DESCRIPTION	2	O
:	9	O
A	9	O
30	9	O
-	7	O
year	5	O
-	7	O
old	5	O
Caucasian	9	O
woman	5	O
presented	5	O
with	5	O
dental	5	O
pain	5	B-Disease
,	9	O
bad	5	B-Disease
breath	5	I-Disease
,	9	O
and	5	O
self	5	O
-	7	O
reported	9	O
poor	5	O
esthetics	5	O
.	9	O

A	9	O
comprehensive	5	O
examination	5	O
including	9	O
her	5	O
medical	5	O
history	5	O
,	9	O
panoramic	5	O
radiograph	5	O
,	9	O
and	5	O
intraoral	5	O
examination	5	O
revealed	9	O
19	7	O
carious	5	B-Disease
lesions	5	I-Disease
,	9	O
which	5	O
is	5	O
not	5	O
very	5	O
common	5	O
for	5	O
a	5	O
healthy	5	O
adult	9	O
.	9	O

She	5	O
reported	9	O
her	5	O
use	5	O
of	5	O
methamphetamine	5	B-Chemical
for	5	O
five	9	O
years	5	O
and	5	O
had	9	O
not	5	O
experienced	5	O
any	5	O
major	9	O
carious	5	B-Disease
episodes	5	I-Disease
before	9	O
she	5	O
started	5	O
using	9	O
the	5	O
drug	5	O
.	9	O

SUMMARY	9	O
:	9	O
The	5	O
patient	5	O
'	9	O
s	9	O
medical	5	O
and	5	O
dental	5	O
histories	5	O
along	9	O
with	5	O
radiographic	5	O
and	5	O
clinical	5	O
findings	9	O
lead	5	O
to	5	O
a	5	O
diagnosis	5	O
of	5	O
"	5	O
meth	0	B-Disease
mouth	5	I-Disease
.	9	O
"	5	O
Although	9	O
three	9	O
different	9	O
dental	5	O
treatment	9	O
modalities	5	O
(	9	O
either	9	O
conventional	5	O
or	5	O
implant	5	O
-	7	O
supported	9	O
)	9	O
have	5	O
been	9	O
offered	5	O
to	5	O
the	5	O
patient	5	O
since	9	O
August	2	O
2007	2	O
,	9	O
the	5	O
patient	5	O
has	9	O
yet	9	O
to	5	O
initiate	9	O
any	5	O
treatment	9	O
.	9	O

CLINICAL	2	O
SIGNIFICANCE	2	O
:	9	O
This	5	O
clinical	5	O
case	5	O
showing	9	O
oral	9	O
manifestations	5	O
of	5	O
meth	0	B-Disease
mouth	5	I-Disease
was	9	O
presented	5	O
to	5	O
help	5	O
dental	5	O
practitioners	5	O
recognize	9	O
and	5	O
manage	5	O
patients	5	O
who	5	O
may	5	O
be	5	O
abusing	5	O
methamphetamines	5	B-Chemical
.	9	O

Dental	2	O
practitioners	5	O
also	9	O
may	5	O
be	5	O
skeptical	5	O
about	5	O
the	5	O
reliability	5	O
of	5	O
appointment	5	O
keeping	5	O
by	9	O
these	5	O
patients	5	O
,	9	O
as	5	O
they	5	O
frequently	5	O
miss	5	O
their	5	O
appointments	5	O
without	9	O
reasonable	5	O
justification	5	O
.	9	O

Antituberculosis	2	B-Chemical
therapy	5	O
-	7	O
induced	3	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
:	9	O
magnitude	5	O
,	9	O
profile	9	O
,	9	O
prognosis	5	O
,	9	O
and	5	O
predictors	5	O
of	5	O
outcome	5	O
.	9	O

Antituberculosis	2	B-Chemical
therapy	5	O
(	9	O
ATT	9	O
)	9	O
-	7	O
associated	9	O
acute	9	B-Disease
liver	9	I-Disease
failure	5	I-Disease
(	9	O
ATT	9	O
-	7	O
ALF	9	B-Disease
)	9	O
is	5	O
the	5	O
commonest	5	O
drug	5	O
-	7	O
induced	3	O
ALF	9	B-Disease
in	5	O
South	4	O
Asia	4	O
.	9	O

Prospective	5	O
studies	9	O
on	5	O
ATT	9	O
-	7	O
ALF	9	B-Disease
are	5	O
lacking	1	O
.	9	O

The	5	O
current	5	O
study	9	O
prospectively	5	O
evaluated	9	O
the	5	O
magnitude	5	O
,	9	O
clinical	5	O
course	5	O
,	9	O
outcome	5	O
,	9	O
and	5	O
prognostic	5	O
factors	9	O
in	5	O
ATT	9	O
-	7	O
ALF	9	B-Disease
.	9	O

From	5	O
January	2	O
1986	2	O
to	5	O
January	2	O
2009	2	O
,	9	O
1223	7	O
consecutive	5	O
ALF	9	B-Disease
patients	5	O
were	9	O
evaluated	9	O
:	9	O
ATT	9	O
alone	9	O
was	9	O
the	5	O
cause	5	O
in	5	O
70	9	O
(	9	O
5	9	O
.	9	O
7	9	O
%	9	O
)	9	O
patients	5	O
.	9	O

Another	5	O
15	9	O
(	9	O
1	9	O
.	9	O
2	9	O
%	9	O
)	9	O
had	9	O
ATT	9	O
and	5	O
simultaneous	5	O
hepatitis	9	B-Disease
virus	9	I-Disease
infection	9	I-Disease
.	9	O

In	9	O
44	7	O
(	9	O
62	7	O
.	9	O
8	9	O
%	9	O
)	9	O
patients	5	O
,	9	O
ATT	9	O
was	9	O
prescribed	5	O
empirically	5	O
without	9	O
definitive	5	O
evidence	9	O
of	5	O
tuberculosis	9	B-Disease
.	9	O

ATT	9	O
-	7	O
ALF	9	B-Disease
patients	5	O
were	9	O
younger	5	O
(	9	O
32	7	O
.	9	O
87	7	O
[	9	O
+	9	O
/	9	O
-	7	O
15	9	O
.	9	O
8	9	O
]	9	O
years	5	O
)	9	O
,	9	O
and	5	O
49	7	O
(	9	O
70	9	O
%	9	O
)	9	O
of	5	O
them	5	O
were	9	O
women	5	O
.	9	O

Most	5	O
had	9	O
hyperacute	5	O
presentation	5	O
;	9	O
the	5	O
median	9	O
icterus	5	B-Disease
encephalopathy	5	B-Disease
interval	5	O
was	9	O
4	9	O
.	9	O
5	9	O
(	9	O
0	7	O
-	7	O
30	9	O
)	9	O
days	9	O
.	9	O

The	5	O
median	9	O
duration	5	O
of	5	O
ATT	9	O
before	9	O
ALF	9	B-Disease
was	9	O
30	9	O
(	9	O
7	9	O
-	7	O
350	9	O
)	9	O
days	9	O
.	9	O

At	9	O
presentation	5	O
,	9	O
advanced	5	O
encephalopathy	5	B-Disease
and	5	O
cerebral	5	B-Disease
edema	5	I-Disease
were	9	O
present	9	O
in	5	O
51	7	O
(	9	O
76	7	O
%	9	O
)	9	O
and	5	O
29	7	O
(	9	O
41	7	O
.	9	O
4	9	O
%	9	O
)	9	O
patients	5	O
,	9	O
respectively	9	O
.	9	O

Gastrointestinal	9	B-Disease
bleed	5	I-Disease
,	9	O
seizures	5	B-Disease
,	9	O
infection	9	B-Disease
,	9	O
and	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
were	9	O
documented	9	O
in	5	O
seven	9	O
(	9	O
10	9	O
%	9	O
)	9	O
,	9	O
five	9	O
(	9	O
7	9	O
.	9	O
1	9	O
%	9	O
)	9	O
,	9	O
26	7	O
(	9	O
37	9	O
.	9	O
1	9	O
%	9	O
)	9	O
,	9	O
and	5	O
seven	9	O
(	9	O
10	9	O
%	9	O
)	9	O
patients	5	O
,	9	O
respectively	9	O
.	9	O

Compared	9	O
with	5	O
hepatitis	9	B-Disease
E	9	I-Disease
virus	9	O
(	9	O
HEV	9	O
)	9	O
and	5	O
non	9	O
-	7	O
A	9	O
non	9	O
-	7	O
E	9	O
-	7	O
induced	3	O
ALF	9	B-Disease
,	9	O
ATT	9	O
-	7	O
ALF	9	B-Disease
patients	5	O
had	9	O
nearly	9	O
similar	9	O
presentations	5	O
except	9	O
for	5	O
older	5	O
age	5	O
and	5	O
less	5	O
elevation	9	O
of	5	O
liver	9	O
enzymes	1	O
.	9	O

The	5	O
mortality	5	O
rate	9	O
among	5	O
patients	5	O
with	5	O
ATT	9	O
-	7	O
ALF	9	B-Disease
was	9	O
high	9	O
(	9	O
67	7	O
.	9	O
1	9	O
%	9	O
,	9	O
n	9	O
=	7	O
47	7	O
)	9	O
,	9	O
and	5	O
only	9	O
23	7	O
(	9	O
32	7	O
.	9	O
9	7	O
%	9	O
)	9	O
patients	5	O
recovered	9	O
with	5	O
medical	5	O
treatment	9	O
.	9	O

In	9	O
multivariate	5	O
analysis	9	O
,	9	O
three	9	O
factors	9	O
independently	9	O
predicted	9	O
mortality	5	O
:	9	O
serum	9	O
bilirubin	0	B-Chemical
(	9	O
>	0	O
or	5	O
=	7	O
10	9	O
.	9	O
8	9	O
mg	0	O
/	9	O
dL	7	O
)	9	O
,	9	O
prothrombin	9	O
time	5	O
(	9	O
PT	9	O
)	9	O
prolongation	9	O
(	9	O
>	0	O
or	5	O
=	7	O
26	7	O
seconds	5	O
)	9	O
,	9	O
and	5	O
grade	9	O
III	9	O
/	9	O
IV	9	O
encephalopathy	5	B-Disease
at	9	O
presentation	5	O
.	9	O

CONCLUSION	5	O
:	9	O
ATT	9	O
-	7	O
ALF	9	B-Disease
constituted	9	O
5	9	O
.	9	O
7	9	O
%	9	O
of	5	O
ALF	9	B-Disease
at	9	O
our	5	O
center	5	O
and	5	O
had	9	O
a	5	O
high	9	O
mortality	5	O
rate	9	O
.	9	O

Because	9	O
the	5	O
mortality	5	O
rate	9	O
is	5	O
so	5	O
high	9	O
,	9	O
determining	9	O
which	5	O
factors	9	O
are	5	O
predictors	5	O
is	5	O
less	5	O
important	9	O
.	9	O

A	9	O
high	9	O
proportion	9	O
of	5	O
patients	5	O
had	9	O
consumed	5	O
ATT	9	O
empirically	5	O
,	9	O
which	5	O
could	9	O
have	5	O
been	9	O
prevented	9	O
.	9	O

Design	5	O
and	5	O
analysis	9	O
of	5	O
the	5	O
HYPREN	_	O
-	7	O
trial	5	O
:	9	O
safety	5	O
of	5	O
enalapril	0	B-Chemical
and	5	O
prazosin	0	B-Chemical
in	5	O
the	5	O
initial	9	O
treatment	9	O
phase	5	O
of	5	O
patients	5	O
with	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
.	9	O

Since	9	O
the	5	O
introduction	9	O
of	5	O
angiotensin	9	B-Chemical
converting	9	I-Chemical
enzyme	0	I-Chemical
(	9	I-Chemical
ACE	9	I-Chemical
)	9	I-Chemical
inhibitors	3	I-Chemical
into	9	O
the	5	O
adjunctive	5	O
treatment	9	O
of	5	O
patients	5	O
with	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
,	9	O
cases	5	O
of	5	O
severe	5	O
hypotension	5	B-Disease
,	9	O
especially	5	O
on	5	O
the	5	O
first	9	O
day	9	O
of	5	O
treatment	9	O
,	9	O
have	5	O
occasionally	5	O
been	9	O
reported	9	O
.	9	O

To	9	O
assess	5	O
the	5	O
safety	5	O
of	5	O
the	5	O
ACE	9	B-Chemical
inhibitor	3	I-Chemical
enalapril	0	B-Chemical
a	5	O
multicenter	5	O
,	9	O
randomized	5	O
,	9	O
prazosin	0	B-Chemical
-	7	O
controlled	5	O
trial	5	O
was	9	O
designed	9	O
that	5	O
compared	9	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
symptomatic	5	O
hypotension	5	B-Disease
on	5	O
the	5	O
first	9	O
day	9	O
of	5	O
treatment	9	O
.	9	O

Trial	5	O
medication	5	O
was	9	O
2	9	O
.	9	O
5	9	O
mg	0	O
enalapril	0	B-Chemical
or	5	O
0	7	O
.	9	O
5	9	O
prazosin	0	B-Chemical
.	9	O

Subjects	5	O
were	9	O
1210	7	O
inpatients	5	O
with	5	O
New	2	O
York	2	O
Heart	2	O
Association	2	O
(	9	O
NYHA	5	O
)	9	O
functional	9	O
class	9	O
II	9	O
and	5	O
III	9	O
.	9	O

Patients	5	O
who	5	O
received	9	O
enalapril	0	B-Chemical
experienced	5	O
clinically	5	O
and	5	O
statistically	9	O
significantly	9	O
less	5	O
symptomatic	5	O
hypotension	5	B-Disease
(	9	O
5	9	O
.	9	O
2	9	O
%	9	O
)	9	O
than	5	O
the	5	O
patients	5	O
who	5	O
received	9	O
prazosin	0	B-Chemical
(	9	O
12	9	O
.	9	O
9	7	O
%	9	O
)	9	O
.	9	O

All	9	O
patients	5	O
recovered	9	O
.	9	O

It	5	O
was	9	O
concluded	9	O
that	5	O
treatment	9	O
with	5	O
enalapril	0	B-Chemical
was	9	O
well	9	O
tolerated	9	O
and	5	O
it	5	O
is	5	O
,	9	O
therefore	5	O
,	9	O
unreasonable	5	O
to	5	O
restrict	5	O
the	5	O
initiation	9	O
of	5	O
treatment	9	O
with	5	O
enalapril	0	B-Chemical
to	5	O
inpatients	5	O
.	9	O

Central	4	B-Disease
nervous	5	I-Disease
system	5	I-Disease
complications	5	I-Disease
during	5	O
treatment	9	O
of	5	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
in	5	O
a	5	O
single	9	O
pediatric	5	O
institution	5	O
.	9	O

Central	4	B-Disease
nervous	5	I-Disease
system	5	I-Disease
(	9	I-Disease
CNS	9	I-Disease
)	9	I-Disease
complications	5	I-Disease
during	5	O
treatment	9	O
of	5	O
childhood	5	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
(	9	O
ALL	9	B-Disease
)	9	O
remain	9	O
a	5	O
challenging	5	O
clinical	5	O
problem	5	O
.	9	O

Outcome	5	O
improvement	5	O
with	5	O
more	5	O
intensive	5	O
chemotherapy	5	O
has	9	O
significantly	9	O
increased	9	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
adverse	5	O
events	5	O
.	9	O

This	5	O
study	9	O
analyzed	9	O
the	5	O
incidence	5	O
of	5	O
neurological	5	B-Disease
complications	5	I-Disease
during	5	O
ALL	9	B-Disease
treatment	9	O
in	5	O
a	5	O
single	9	O
pediatric	5	O
institution	5	O
,	9	O
focusing	5	O
on	5	O
clinical	5	O
,	9	O
radiological	5	O
,	9	O
and	5	O
electrophysiological	5	O
findings	9	O
.	9	O

Exclusion	5	O
criteria	5	O
included	5	O
CNS	9	O
leukemic	3	B-Disease
infiltration	3	I-Disease
at	9	O
diagnosis	5	O
,	9	O
therapy	5	O
-	7	O
related	9	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
,	9	O
late	9	O
-	7	O
onset	5	O
encephalopathy	5	B-Disease
,	9	O
or	5	O
long	5	O
-	7	O
term	5	O
neurocognitive	5	B-Disease
defects	9	I-Disease
.	9	O

During	5	O
a	5	O
9	7	O
-	7	O
year	5	O
period	5	O
,	9	O
we	5	O
retrospectively	5	O
collected	9	O
27	7	O
neurological	5	O
events	5	O
(	9	O
11	7	O
%	9	O
)	9	O
in	5	O
as	5	O
many	5	O
patients	5	O
,	9	O
from	9	O
253	7	O
children	5	O
enrolled	5	O
in	5	O
the	5	O
ALL	9	B-Disease
front	5	O
-	7	O
line	9	O
protocol	9	O
.	9	O

CNS	9	O
complications	5	O
included	5	O
posterior	5	O
reversible	9	O
leukoencephalopathy	5	B-Disease
syndrome	5	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
,	9	O
stroke	5	B-Disease
(	9	O
n	9	O
=	7	O
5	9	O
)	9	O
,	9	O
temporal	5	B-Disease
lobe	5	I-Disease
epilepsy	5	I-Disease
(	9	O
n	9	O
=	7	O
2	9	O
)	9	O
,	9	O
high	9	O
-	7	O
dose	9	O
methotrexate	9	B-Chemical
toxicity	9	B-Disease
(	9	O
n	9	O
=	7	O
2	9	O
)	9	O
,	9	O
syndrome	5	O
of	5	O
inappropriate	5	B-Disease
antidiuretic	5	I-Disease
hormone	9	I-Disease
secretion	3	I-Disease
(	9	O
n	9	O
=	7	O
1	9	O
)	9	O
,	9	O
and	5	O
other	5	O
unclassified	9	O
events	5	O
(	9	O
n	9	O
=	7	O
7	9	O
)	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
CNS	9	O
complications	5	O
are	5	O
frequent	5	O
events	5	O
during	5	O
ALL	9	B-Disease
therapy	5	O
,	9	O
and	5	O
require	5	O
rapid	5	O
detection	9	O
and	5	O
prompt	5	O
treatment	9	O
to	5	O
limit	5	O
permanent	5	O
damage	9	O
.	9	O

Cocaine	5	B-Chemical
causes	9	O
memory	5	B-Disease
and	5	I-Disease
learning	5	I-Disease
impairments	5	I-Disease
in	5	O
rats	9	O
:	9	O
involvement	9	O
of	5	O
nuclear	3	O
factor	9	O
kappa	9	O
B	9	O
and	5	O
oxidative	9	O
stress	9	O
,	9	O
and	5	O
prevention	5	O
by	9	O
topiramate	5	B-Chemical
.	9	O

Different	9	O
mechanisms	9	O
have	5	O
been	9	O
suggested	9	O
for	5	O
cocaine	5	B-Chemical
toxicity	9	B-Disease
including	9	O
an	5	O
increase	9	O
in	5	O
oxidative	9	O
stress	9	O
but	9	O
the	5	O
association	9	O
between	5	O
oxidative	9	O
status	9	O
in	5	O
the	5	O
brain	5	O
and	5	O
cocaine	5	B-Chemical
induced	3	O
-	7	O
behaviour	5	O
is	5	O
poorly	9	O
understood	5	O
.	9	O

Nuclear	9	O
factor	9	O
kappa	9	O
B	9	O
(	9	O
NFkappaB	3	O
)	9	O
is	5	O
a	5	O
sensor	5	O
of	5	O
oxidative	9	O
stress	9	O
and	5	O
participates	9	O
in	5	O
memory	5	O
formation	9	O
that	5	O
could	9	O
be	5	O
involved	9	O
in	5	O
drug	5	O
toxicity	9	B-Disease
and	5	O
addiction	5	O
mechanisms	9	O
.	9	O

Therefore	9	O
NFkappaB	3	O
activity	9	O
,	9	O
oxidative	9	O
stress	9	O
,	9	O
neuronal	3	O
nitric	0	B-Chemical
oxide	0	I-Chemical
synthase	1	O
(	9	O
nNOS	3	O
)	9	O
activity	9	O
,	9	O
spatial	5	O
learning	5	O
and	5	O
memory	5	O
as	5	O
well	9	O
as	5	O
the	5	O
effect	9	O
of	5	O
topiramate	5	B-Chemical
,	9	O
a	5	O
previously	9	O
proposed	5	O
therapy	5	O
for	5	O
cocaine	5	B-Disease
addiction	5	I-Disease
,	9	O
were	9	O
evaluated	9	O
in	5	O
an	5	O
experimental	5	O
model	5	O
of	5	O
cocaine	5	B-Chemical
administration	9	O
in	5	O
rats	9	O
.	9	O

NFkappaB	3	O
activity	9	O
was	9	O
decreased	9	O
in	5	O
the	5	O
frontal	5	O
cortex	5	O
of	5	O
cocaine	5	B-Chemical
treated	3	O
rats	9	O
,	9	O
as	5	O
well	9	O
as	5	O
GSH	0	B-Chemical
concentration	0	O
and	5	O
glutathione	0	B-Chemical
peroxidase	0	O
activity	9	O
in	5	O
the	5	O
hippocampus	9	O
,	9	O
whereas	9	O
nNOS	3	O
activity	9	O
in	5	O
the	5	O
hippocampus	9	O
was	9	O
increased	9	O
.	9	O

Memory	5	O
retrieval	5	O
of	5	O
experiences	5	O
acquired	5	O
prior	9	O
to	5	O
cocaine	5	B-Chemical
administration	9	O
was	9	O
impaired	9	O
and	5	O
negatively	9	O
correlated	9	O
with	5	O
NFkappaB	3	O
activity	9	O
in	5	O
the	5	O
frontal	5	O
cortex	5	O
.	9	O

In	9	O
contrast	9	O
,	9	O
learning	5	O
of	5	O
new	5	O
tasks	5	O
was	9	O
enhanced	3	O
and	5	O
correlated	9	O
with	5	O
the	5	O
increase	9	O
of	5	O
nNOS	3	O
activity	9	O
and	5	O
the	5	O
decrease	9	O
of	5	O
glutathione	0	B-Chemical
peroxidase	0	O
.	9	O

These	5	O
results	9	O
provide	5	O
evidence	9	O
for	5	O
a	5	O
possible	5	O
mechanistic	9	O
role	9	O
of	5	O
oxidative	9	O
and	5	O
nitrosative	3	O
stress	9	O
and	5	O
NFkappaB	3	O
in	5	O
the	5	O
alterations	9	O
induced	3	O
by	9	O
cocaine	5	B-Chemical
.	9	O

Topiramate	0	B-Chemical
prevented	9	O
all	5	O
the	5	O
alterations	9	O
observed	9	O
,	9	O
showing	9	O
novel	9	O
neuroprotective	9	O
properties	9	O
.	9	O

Efficacy	5	O
and	5	O
safety	5	O
of	5	O
asenapine	5	B-Chemical
in	5	O
a	5	O
placebo	9	O
-	7	O
and	5	O
haloperidol	5	B-Chemical
-	7	O
controlled	5	O
trial	5	O
in	5	O
patients	5	O
with	5	O
acute	9	O
exacerbation	5	O
of	5	O
schizophrenia	5	B-Disease
.	9	O

Asenapine	7	B-Chemical
is	5	O
approved	2	O
by	9	O
the	5	O
Food	5	O
and	5	O
Drugs	0	O
Administration	2	O
in	5	O
adults	5	O
for	5	O
acute	9	O
treatment	9	O
of	5	O
schizophrenia	5	B-Disease
or	5	O
of	5	O
manic	5	B-Disease
or	5	O
mixed	9	O
episodes	5	O
associated	9	O
with	5	O
bipolar	5	B-Disease
I	9	I-Disease
disorder	5	I-Disease
with	5	O
or	5	O
without	9	O
psychotic	5	B-Disease
features	5	O
.	9	O

In	9	O
a	5	O
double	9	O
-	7	O
blind	5	O
6	9	O
-	7	O
week	9	O
trial	5	O
,	9	O
458	7	O
patients	5	O
with	5	O
acute	9	O
schizophrenia	5	B-Disease
were	9	O
randomly	5	O
assigned	5	O
to	5	O
fixed	9	O
-	7	O
dose	9	O
treatment	9	O
with	5	O
asenapine	5	B-Chemical
at	9	O
5	9	O
mg	0	O
twice	9	O
daily	5	O
(	9	O
BID	9	O
)	9	O
,	9	O
asenapine	5	B-Chemical
at	9	O
10	9	O
mg	0	O
BID	9	O
,	9	O
placebo	9	O
,	9	O
or	5	O
haloperidol	5	B-Chemical
at	9	O
4	9	O
mg	0	O
BID	9	O
(	9	O
to	5	O
verify	9	O
assay	3	O
sensitivity	9	O
)	9	O
.	9	O

With	5	O
last	5	O
observations	9	O
carried	9	O
forward	9	O
(	9	O
LOCF	5	O
)	9	O
,	9	O
mean	5	O
Positive	7	O
and	5	O
Negative	7	O
Syndrome	5	O
Scale	5	O
total	9	O
score	5	O
reductions	9	O
from	9	O
baseline	5	O
to	5	O
endpoint	5	O
were	9	O
significantly	9	O
greater	5	O
with	5	O
asenapine	5	B-Chemical
at	9	O
5	9	O
mg	0	O
BID	9	O
(	9	O
-	7	O
16	9	O
.	9	O
2	9	O
)	9	O
and	5	O
haloperidol	5	B-Chemical
(	9	O
-	7	O
15	9	O
.	9	O
4	9	O
)	9	O
than	5	O
placebo	9	O
(	9	O
-	7	O
10	9	O
.	9	O
7	9	O
;	9	O
both	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
;	9	O
using	9	O
mixed	9	O
model	5	O
for	5	O
repeated	5	O
measures	5	O
(	9	O
MMRM	5	O
)	9	O
,	9	O
changes	9	O
at	9	O
day	9	O
42	7	O
were	9	O
significantly	9	O
greater	5	O
with	5	O
asenapine	5	B-Chemical
at	9	O
5	9	O
and	5	O
10	9	O
mg	0	O
BID	9	O
(	9	O
-	7	O
21	7	O
.	9	O
3	9	O
and	5	O
-	7	O
19	7	O
.	9	O
4	9	O
,	9	O
respectively	9	O
)	9	O
and	5	O
haloperidol	5	B-Chemical
(	9	O
-	7	O
20	9	O
.	9	O
0	7	O
)	9	O
than	5	O
placebo	9	O
(	9	O
-	7	O
14	7	O
.	9	O
6	9	O
;	9	O
all	5	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

On	5	O
the	5	O
Positive	7	O
and	5	O
Negative	7	O
Syndrome	5	O
Scale	5	O
positive	9	O
subscale	5	O
,	9	O
all	5	O
treatments	9	O
were	9	O
superior	5	O
to	5	O
placebo	9	O
with	5	O
LOCF	5	O
and	5	O
MMRM	5	O
;	9	O
asenapine	5	B-Chemical
at	9	O
5	9	O
mg	0	O
BID	9	O
was	9	O
superior	5	O
to	5	O
placebo	9	O
on	5	O
the	5	O
negative	9	O
subscale	5	O
with	5	O
MMRM	5	O
and	5	O
on	5	O
the	5	O
general	5	O
psychopathology	5	O
subscale	5	O
with	5	O
LOCF	5	O
and	5	O
MMRM	5	O
.	9	O

Treatment	9	O
-	7	O
related	9	O
adverse	5	O
events	5	O
(	9	O
AEs	5	O
)	9	O
occurred	9	O
in	5	O
44	7	O
%	9	O
and	5	O
52	7	O
%	9	O
,	9	O
57	7	O
%	9	O
,	9	O
and	5	O
41	7	O
%	9	O
of	5	O
the	5	O
asenapine	5	B-Chemical
at	9	O
5	9	O
and	5	O
10	9	O
mg	0	O
BID	9	O
,	9	O
haloperidol	5	B-Chemical
,	9	O
and	5	O
placebo	9	O
groups	9	O
,	9	O
respectively	9	O
.	9	O

Extrapyramidal	5	B-Disease
symptoms	5	I-Disease
reported	9	O
as	5	O
AEs	5	O
occurred	9	O
in	5	O
15	9	O
%	9	O
and	5	O
18	7	O
%	9	O
,	9	O
34	7	O
%	9	O
,	9	O
and	5	O
10	9	O
%	9	O
of	5	O
the	5	O
asenapine	5	B-Chemical
at	9	O
5	9	O
and	5	O
10	9	O
mg	0	O
BID	9	O
,	9	O
haloperidol	5	B-Chemical
,	9	O
and	5	O
placebo	9	O
groups	9	O
,	9	O
respectively	9	O
.	9	O

Across	5	O
all	5	O
groups	9	O
,	9	O
no	9	O
more	5	O
than	5	O
5	9	O
%	9	O
of	5	O
patients	5	O
had	9	O
clinically	5	O
significant	9	O
weight	9	O
change	9	O
.	9	O

Post	9	O
hoc	5	O
analyses	9	O
indicated	9	O
that	5	O
efficacy	9	O
was	9	O
similar	9	O
with	5	O
asenapine	5	B-Chemical
and	5	O
haloperidol	5	B-Chemical
;	9	O
greater	5	O
contrasts	5	O
were	9	O
seen	9	O
in	5	O
AEs	5	O
,	9	O
especially	5	O
extrapyramidal	5	B-Disease
symptoms	5	I-Disease
.	9	O

Salvage	5	O
therapy	5	O
with	5	O
nelarabine	5	B-Chemical
,	9	O
etoposide	3	B-Chemical
,	9	O
and	5	O
cyclophosphamide	0	B-Chemical
in	5	O
relapsed	5	O
/	9	O
refractory	9	O
paediatric	5	O
T	3	B-Disease
-	7	I-Disease
cell	3	I-Disease
lymphoblastic	3	I-Disease
leukaemia	3	I-Disease
and	5	I-Disease
lymphoma	9	I-Disease
.	9	O

A	9	O
combination	9	O
of	5	O
5	9	O
d	9	O
of	5	O
nelarabine	5	B-Chemical
(	9	O
AraG	1	B-Chemical
)	9	O
with	5	O
5	9	O
d	9	O
of	5	O
etoposide	3	B-Chemical
(	9	O
VP	9	B-Chemical
)	9	O
and	5	O
cyclophosphamide	0	B-Chemical
(	9	O
CPM	9	B-Chemical
)	9	O
and	5	O
prophylactic	5	O
intrathecal	3	O
chemotherapy	5	O
was	9	O
used	5	O
as	5	O
salvage	5	O
therapy	5	O
in	5	O
seven	9	O
children	5	O
with	5	O
refractory	9	O
or	5	O
relapsed	5	O
T	3	B-Disease
-	7	I-Disease
cell	3	I-Disease
leukaemia	3	I-Disease
or	5	I-Disease
lymphoma	9	I-Disease
.	9	O

The	5	O
most	9	O
common	5	O
side	5	O
effects	9	O
attributable	9	O
to	5	O
the	5	O
AraG	1	B-Chemical
included	5	O
Grade	9	O
2	9	O
and	5	O
3	9	O
sensory	5	O
and	5	O
motor	5	O
neuropathy	5	B-Disease
and	5	O
musculoskeletal	5	B-Disease
pain	5	I-Disease
.	9	O

Haematological	9	B-Disease
toxicity	9	I-Disease
was	9	O
greater	5	O
for	5	O
the	5	O
combination	9	O
than	5	O
AraG	1	B-Chemical
alone	9	O
,	9	O
although	9	O
median	9	O
time	5	O
to	5	O
neutrophil	3	O
and	5	O
platelet	9	O
recovery	9	O
was	9	O
consistent	9	O
with	5	O
other	5	O
salvage	5	O
therapies	5	O
.	9	O

All	9	O
patients	5	O
had	9	O
some	5	O
response	9	O
to	5	O
the	5	O
combined	9	O
therapy	5	O
and	5	O
five	9	O
of	5	O
the	5	O
seven	9	O
went	5	O
into	9	O
complete	9	O
remission	5	O
after	9	O
one	5	O
or	5	O
two	5	O
courses	5	O
of	5	O
AraG	1	B-Chemical
/	9	O
VP	9	B-Chemical
/	9	O
CPM	9	B-Chemical
.	9	O

Our	9	O
experience	5	O
supports	9	O
the	5	O
safety	5	O
of	5	O
giving	5	O
AraG	1	B-Chemical
as	5	O
salvage	5	O
therapy	5	O
in	5	O
synchrony	5	O
with	5	O
etoposide	3	B-Chemical
and	5	O
cyclophosphamide	0	B-Chemical
,	9	O
although	9	O
neurological	5	B-Disease
toxicity	9	I-Disease
must	5	O
be	5	O
closely	9	O
monitored	9	O
.	9	O

Effect	0	O
of	5	O
adriamycin	3	B-Chemical
combined	9	O
with	5	O
whole	9	O
body	5	O
hyperthermia	5	B-Disease
on	5	O
tumor	3	B-Disease
and	5	O
normal	9	O
tissues	9	O
.	9	O

Thermal	0	O
enhancement	9	O
of	5	O
Adriamycin	0	B-Chemical
-	7	O
mediated	3	O
antitumor	3	O
activity	9	O
and	5	O
normal	9	O
tissue	9	O
toxicities	5	B-Disease
by	9	O
whole	9	O
body	5	O
hyperthermia	5	B-Disease
were	9	O
compared	9	O
using	9	O
a	5	O
F344	3	O
rat	3	O
model	5	O
.	9	O

Antitumor	0	O
activity	9	O
was	9	O
studied	9	O
using	9	O
a	5	O
tumor	3	B-Disease
growth	3	O
delay	5	O
assay	3	O
.	9	O

Acute	5	O
normal	9	O
tissue	9	O
toxicities	5	B-Disease
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
leukopenia	9	B-Disease
and	5	O
thrombocytopenia	9	B-Disease
)	9	O
and	5	O
late	9	O
normal	9	O
tissue	9	O
toxicities	5	B-Disease
(	9	O
i	9	O
.	9	O
e	9	O
.	9	O
,	9	O
myocardial	9	B-Disease
and	5	I-Disease
kidney	9	I-Disease
injury	9	I-Disease
)	9	O
were	9	O
evaluated	9	O
by	9	O
functional	9	O
/	9	O
physiological	9	O
assays	3	O
and	5	O
by	9	O
morphological	9	O
techniques	5	O
.	9	O

Whole	9	O
body	5	O
hyperthermia	5	B-Disease
(	9	O
120	9	O
min	0	O
at	9	O
41	7	O
.	9	O
5	9	O
degrees	5	O
C	9	O
)	9	O
enhanced	3	O
both	9	O
Adriamycin	0	B-Chemical
-	7	O
mediated	3	O
antitumor	3	O
activity	9	O
and	5	O
toxic	0	O
side	5	O
effects	9	O
.	9	O

The	5	O
thermal	9	O
enhancement	9	O
ratio	9	O
calculated	5	O
for	5	O
antitumor	3	O
activity	9	O
was	9	O
1	9	O
.	9	O
6	9	O
.	9	O

Thermal	0	O
enhancement	9	O
ratios	9	O
estimated	5	O
for	5	O
"	5	O
acute	9	O
"	5	O
hematological	9	O
changes	9	O
were	9	O
1	9	O
.	9	O
3	9	O
,	9	O
whereas	9	O
those	5	O
estimated	5	O
for	5	O
"	5	O
late	9	O
"	5	O
damage	9	O
(	9	O
based	5	O
on	5	O
morphological	9	O
cardiac	5	B-Disease
and	5	I-Disease
renal	9	I-Disease
lesions	5	I-Disease
)	9	O
varied	9	O
between	5	O
2	9	O
.	9	O
4	9	O
and	5	O
4	9	O
.	9	O
3	9	O
.	9	O

Thus	9	O
,	9	O
while	9	O
whole	9	O
body	5	O
hyperthermia	5	B-Disease
enhances	3	O
Adriamycin	0	B-Chemical
-	7	O
mediated	3	O
antitumor	3	O
effect	9	O
,	9	O
normal	9	O
tissue	9	O
toxicity	9	B-Disease
is	5	O
also	9	O
increased	9	O
,	9	O
and	5	O
the	5	O
potential	9	O
therapeutic	5	O
gain	5	O
of	5	O
the	5	O
combined	9	O
modality	5	O
treatment	9	O
is	5	O
eroded	5	O
.	9	O

Permeability	0	O
,	9	O
ultrastructural	9	O
changes	9	O
,	9	O
and	5	O
distribution	9	O
of	5	O
novel	9	O
proteins	1	O
in	5	O
the	5	O
glomerular	5	O
barrier	5	O
in	5	O
early	9	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
nephrosis	0	B-Disease
.	9	O

BACKGROUND	2	O
/	9	O
AIMS	5	O
:	9	O
It	5	O
is	5	O
still	5	O
unclear	9	O
what	5	O
happens	5	O
in	5	O
the	5	O
glomerulus	9	O
when	5	O
proteinuria	9	B-Disease
starts	5	O
.	9	O

Using	9	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
nephrosis	0	B-Disease
(	9	O
PAN	0	O
)	9	O
rats	9	O
,	9	O
we	5	O
studied	9	O
early	9	O
ultrastructural	9	O
and	5	O
permeability	0	O
changes	9	O
in	5	O
relation	5	O
to	5	O
the	5	O
expression	3	O
of	5	O
the	5	O
podocyte	3	O
-	7	O
associated	9	O
molecules	3	O
nephrin	3	O
,	9	O
a	5	O
-	7	O
actinin	3	O
,	9	O
dendrin	3	O
,	9	O
and	5	O
plekhh2	_	O
,	9	O
the	5	O
last	5	O
two	5	O
of	5	O
which	5	O
were	9	O
only	9	O
recently	9	O
discovered	9	O
in	5	O
podocytes	3	O
.	9	O

METHODS	2	O
:	9	O
Using	9	O
immune	3	O
stainings	3	O
,	9	O
semiquantitative	9	O
measurement	5	O
was	9	O
performed	9	O
under	9	O
the	5	O
electron	0	O
microscope	0	O
.	9	O

Permeability	0	O
was	9	O
assessed	9	O
using	9	O
isolated	9	O
kidney	9	O
perfusion	5	O
with	5	O
tracers	0	O
.	9	O

Possible	9	O
effects	9	O
of	5	O
ACE	9	O
inhibition	3	O
were	9	O
tested	9	O
.	9	O

RESULTS	9	O
:	9	O
By	5	O
day	9	O
2	9	O
,	9	O
some	5	O
patchy	5	O
foot	5	O
process	5	O
effacement	5	O
,	9	O
but	9	O
no	9	O
proteinuria	9	B-Disease
,	9	O
appeared	9	O
.	9	O

The	5	O
amount	9	O
of	5	O
nephrin	3	O
was	9	O
reduced	9	O
in	5	O
both	9	O
diseased	5	O
and	5	O
normal	9	O
areas	5	O
.	9	O

The	5	O
other	5	O
proteins	1	O
showed	9	O
few	5	O
changes	9	O
,	9	O
which	5	O
were	9	O
limited	5	O
to	5	O
diseased	5	O
areas	5	O
.	9	O

By	5	O
day	9	O
4	9	O
,	9	O
foot	5	O
process	5	O
effacement	5	O
was	9	O
complete	9	O
and	5	O
proteinuria	9	B-Disease
appeared	9	O
in	5	O
parallel	5	O
with	5	O
signs	5	O
of	5	O
size	9	O
barrier	5	O
damage	9	O
.	9	O

Nephrin	3	O
decreased	9	O
further	9	O
,	9	O
while	9	O
dendrin	3	O
and	5	O
plekhh2	_	O
also	9	O
decreased	9	O
but	9	O
a	5	O
-	7	O
actinin	3	O
remained	9	O
unchanged	9	O
.	9	O

ACE	9	O
inhibition	3	O
had	9	O
no	9	O
significant	9	O
protective	9	O
effect	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
PAN	0	O
glomeruli	9	O
already	5	O
showed	9	O
significant	9	O
pathology	5	O
by	9	O
day	9	O
4	9	O
,	9	O
despite	9	O
relatively	5	O
mild	9	O
proteinuria	9	B-Disease
.	9	O

This	5	O
was	9	O
preceded	9	O
by	9	O
altered	9	O
nephrin	3	O
expression	3	O
,	9	O
supporting	9	O
its	9	O
pivotal	9	O
role	9	O
in	5	O
podocyte	3	O
morphology	9	O
.	9	O

The	5	O
novel	9	O
proteins	1	O
dendrin	3	O
and	5	O
plekhh2	_	O
were	9	O
both	9	O
reduced	9	O
,	9	O
suggesting	9	O
roles	9	O
in	5	O
PAN	0	O
,	9	O
whereas	9	O
a	5	O
-	7	O
actinin	3	O
was	9	O
unchanged	9	O
.	9	O

A	9	O
novel	9	O
,	9	O
multiple	5	O
symptom	5	O
model	5	O
of	5	O
obsessive	5	B-Disease
-	7	I-Disease
compulsive	5	I-Disease
-	7	I-Disease
like	9	I-Disease
behaviors	5	I-Disease
in	5	O
animals	9	O
.	9	O

BACKGROUND	2	O
:	9	O
Current	9	O
animal	5	O
models	5	O
of	5	O
obsessive	5	B-Disease
-	7	I-Disease
compulsive	5	I-Disease
disorder	5	I-Disease
(	9	O
OCD	5	B-Disease
)	9	O
typically	5	O
involve	5	O
acute	9	O
,	9	O
drug	5	O
-	7	O
induced	3	O
symptom	5	O
provocation	5	O
or	5	O
a	5	O
genetic	5	O
association	9	O
with	5	O
stereotypies	5	O
or	5	O
anxiety	5	B-Disease
.	9	O

None	9	O
of	5	O
these	5	O
current	5	O
models	5	O
demonstrate	9	O
multiple	5	O
OCD	5	B-Disease
-	7	O
like	9	O
behaviors	5	O
.	9	O

METHODS	2	O
:	9	O
Neonatal	9	O
rats	9	O
were	9	O
treated	3	O
with	5	O
the	5	O
tricyclic	0	O
antidepressant	5	B-Chemical
clomipramine	0	B-Chemical
or	5	O
vehicle	3	O
between	5	O
days	9	O
9	7	O
and	5	O
16	9	O
twice	9	O
daily	5	O
and	5	O
behaviorally	5	O
tested	9	O
in	5	O
adulthood	5	O
.	9	O

RESULTS	9	O
:	9	O
Clomipramine	7	B-Chemical
exposure	9	O
in	5	O
immature	3	O
rats	9	O
produced	9	O
significant	9	O
behavioral	5	O
and	5	O
biochemical	9	O
changes	9	O
that	5	O
include	5	O
enhanced	3	O
anxiety	5	B-Disease
(	9	O
elevated	9	O
plus	9	O
maze	5	O
and	5	O
marble	5	O
burying	5	O
)	9	O
,	9	O
behavioral	5	B-Disease
inflexibility	5	I-Disease
(	9	O
perseveration	5	O
in	5	O
the	5	O
spontaneous	5	O
alternation	5	O
task	5	O
and	5	O
impaired	9	O
reversal	9	O
learning	5	O
)	9	O
,	9	O
working	5	O
memory	5	B-Disease
impairment	5	I-Disease
(	9	O
e	9	O
.	9	O
g	0	O
.	9	O
,	9	O
win	5	O
-	7	O
shift	9	O
paradigm	5	O
)	9	O
,	9	O
hoarding	5	B-Disease
,	9	O
and	5	O
corticostriatal	5	B-Disease
dysfunction	9	I-Disease
.	9	O

Dopamine	0	B-Chemical
D2	9	O
receptors	3	O
were	9	O
elevated	9	O
in	5	O
the	5	O
striatum	9	O
,	9	O
whereas	9	O
serotonin	9	B-Chemical
2C	9	O
,	9	O
but	9	O
not	5	O
serotonin	9	B-Chemical
1A	9	O
,	9	O
receptors	3	O
were	9	O
elevated	9	O
in	5	O
the	5	O
orbital	5	O
frontal	5	O
cortex	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
This	5	O
is	5	O
the	5	O
first	9	O
demonstration	9	O
of	5	O
multiple	5	O
symptoms	5	O
consistent	9	O
with	5	O
an	5	O
OCD	5	B-Disease
-	7	O
like	9	O
profile	9	O
in	5	O
animals	9	O
.	9	O

Moreover	9	O
,	9	O
these	5	O
behaviors	5	O
are	5	O
accompanied	9	O
by	9	O
biochemical	9	O
changes	9	O
in	5	O
brain	5	O
regions	9	O
previously	9	O
identified	9	O
as	5	O
relevant	5	O
to	5	O
OCD	5	B-Disease
.	9	O

This	5	O
novel	9	O
model	5	O
of	5	O
OCD	5	B-Disease
demonstrates	9	O
that	5	O
drug	5	O
exposure	9	O
during	5	O
a	5	O
sensitive	9	O
period	5	O
can	5	O
program	5	O
disease	5	O
-	7	O
like	9	O
systems	5	O
permanently	5	O
,	9	O
which	5	O
could	9	O
have	5	O
implications	5	O
for	5	O
current	5	O
and	5	O
future	5	O
therapeutic	5	O
strategies	5	O
for	5	O
this	5	O
and	5	O
other	5	O
psychiatric	5	B-Disease
disorders	5	I-Disease
.	9	O

Elevation	9	O
of	5	O
ADAM10	3	O
,	9	O
ADAM17	3	O
,	9	O
MMP	3	O
-	7	O
2	9	O
and	5	O
MMP	3	O
-	7	O
9	7	O
expression	3	O
with	5	O
media	9	O
degeneration	9	O
features	5	O
CaCl2	0	B-Chemical
-	7	O
induced	3	O
thoracic	5	B-Disease
aortic	9	I-Disease
aneurysm	5	I-Disease
in	5	O
a	5	O
rat	3	O
model	5	O
.	9	O

PURPOSE	2	O
:	9	O
This	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
establish	5	O
a	5	O
rat	3	O
model	5	O
of	5	O
thoracic	5	B-Disease
aortic	9	I-Disease
aneurysm	5	I-Disease
(	9	O
TAA	9	B-Disease
)	9	O
by	9	O
calcium	0	B-Chemical
chloride	0	I-Chemical
(	9	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
)	9	O
-	7	O
induced	3	O
arterial	5	B-Disease
injury	9	I-Disease
and	5	O
to	5	O
explore	5	O
the	5	O
potential	9	O
role	9	O
of	5	O
a	5	O
disintegrin	1	O
and	5	O
metalloproteinase	3	O
(	9	O
ADAM	3	O
)	9	O
,	9	O
matrix	5	O
metalloproteinases	3	O
(	9	O
MMPs	3	O
)	9	O
and	5	O
their	5	O
endogenous	3	O
inhibitors	3	O
(	9	O
TIMPs	3	O
)	9	O
in	5	O
TAA	9	B-Disease
formation	9	O
.	9	O

METHODS	2	O
:	9	O
Thoracic	5	O
aorta	9	O
of	5	O
male	9	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
was	9	O
exposed	9	O
to	5	O
0	7	O
.	9	O
5M	0	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
or	5	O
normal	9	O
saline	0	O
(	9	O
NaCl	0	B-Chemical
)	9	O
.	9	O

After	9	O
12weeks	7	O
,	9	O
animals	9	O
were	9	O
euthanized	9	O
,	9	O
and	5	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
-	7	O
treated	3	O
,	9	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
-	7	O
untreated	3	O
(	9	O
n	9	O
=	7	O
12	9	O
)	9	O
and	5	O
NaCl	0	B-Chemical
-	7	O
treated	3	O
aortic	9	O
segments	9	O
(	9	O
n	9	O
=	7	O
12	9	O
)	9	O
were	9	O
collected	9	O
for	5	O
histological	9	O
and	5	O
molecular	9	O
assessments	5	O
.	9	O

MMP	3	O
-	7	O
TIMP	3	O
and	5	O
ADAM	3	O
mRNAs	3	O
were	9	O
semi	5	O
-	7	O
quantitatively	9	O
analyzed	9	O
and	5	O
protein	1	O
expressions	9	O
were	9	O
determined	9	O
by	9	O
immunohistochemistry	3	O
.	9	O

RESULTS	9	O
:	9	O
Despite	5	O
similar	9	O
external	5	O
diameters	5	O
among	5	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
-	7	O
treated	3	O
,	9	O
non	9	O
-	7	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
-	7	O
treated	3	O
and	5	O
NaCl	0	B-Chemical
-	7	O
treated	3	O
segments	9	O
,	9	O
aneurymal	9	O
alteration	9	O
(	9	O
n	9	O
=	7	O
6	9	O
,	9	O
50	0	O
%	9	O
)	9	O
,	9	O
media	9	O
degeneration	9	O
with	5	O
regional	5	O
disruption	9	O
,	9	O
fragmentation	9	O
of	5	O
elastic	5	O
fiber	5	O
,	9	O
and	5	O
increased	9	O
collagen	3	O
deposition	9	O
(	9	O
n	9	O
=	7	O
12	9	O
,	9	O
100	0	O
%	9	O
)	9	O
were	9	O
demonstrated	9	O
in	5	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
-	7	O
treated	3	O
segments	9	O
.	9	O

MMP	3	O
-	7	O
2	9	O
,	9	O
MMP	3	O
-	7	O
9	7	O
,	9	O
ADAM	3	O
-	7	O
10	9	O
and	5	O
ADAM	3	O
-	7	O
17	7	O
mRNA	3	O
levels	3	O
were	9	O
increased	9	O
in	5	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
-	7	O
treated	3	O
segments	9	O
(	9	O
all	5	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
with	5	O
trends	5	O
of	5	O
elevation	9	O
in	5	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
-	7	O
untreated	3	O
segments	9	O
,	9	O
as	5	O
compared	9	O
with	5	O
NaCl	0	B-Chemical
-	7	O
treated	3	O
segments	9	O
.	9	O

Immunohistochemistry	3	O
displayed	9	O
significantly	9	O
increased	9	O
expressions	9	O
of	5	O
MMP	3	O
-	7	O
2	9	O
,	9	O
MMP	3	O
-	7	O
9	7	O
,	9	O
ADAM	3	O
-	7	O
10	9	O
and	5	O
ADAM	3	O
-	7	O
17	7	O
(	9	O
all	5	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
in	5	O
intima	5	O
and	5	O
media	9	O
for	5	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
-	7	O
treated	3	O
segments	9	O
.	9	O

TIMP	3	O
mRNA	3	O
and	5	O
tissue	9	O
levels	3	O
did	9	O
not	5	O
differ	9	O
obviously	9	O
among	5	O
the	5	O
three	9	O
aortic	9	O
segments	9	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
study	9	O
establishes	9	O
a	5	O
TAA	9	B-Disease
model	5	O
by	9	O
periarterial	5	O
CaCl	0	B-Chemical
(	9	I-Chemical
2	9	I-Chemical
)	9	I-Chemical
exposure	9	O
in	5	O
rats	9	O
,	9	O
and	5	O
demonstrates	9	O
a	5	O
significant	9	O
elevation	9	O
of	5	O
expression	3	O
of	5	O
MMP	3	O
-	7	O
2	9	O
,	9	O
MMP	3	O
-	7	O
9	7	O
,	9	O
ADAM10	3	O
and	5	O
ADAM17	3	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
vascular	5	O
remodeling	9	O
.	9	O

Suxamethonium	0	B-Chemical
induced	3	O
prolonged	9	O
apnea	5	B-Disease
in	5	O
a	5	O
patient	5	O
receiving	9	O
electroconvulsive	5	O
therapy	5	O
.	9	O

Suxamethonium	0	B-Chemical
causes	9	O
prolonged	9	O
apnea	5	B-Disease
in	5	O
patients	5	O
in	5	O
whom	5	O
pseudocholinesterase	0	O
enzyme	0	O
gets	5	O
deactivated	5	O
by	9	O
organophosphorus	0	B-Chemical
(	9	I-Chemical
OP	9	I-Chemical
)	9	I-Chemical
poisons	5	I-Chemical
.	9	O

Here	9	O
,	9	O
we	5	O
present	9	O
a	5	O
similar	9	O
incident	5	O
in	5	O
a	5	O
severely	9	O
depressed	5	B-Disease
patient	5	O
who	5	O
received	9	O
electroconvulsive	5	O
therapy	5	O
(	9	O
ECT	5	O
)	9	O
.	9	O

Prolonged	9	O
apnea	5	B-Disease
in	5	O
our	5	O
case	5	O
ensued	5	O
because	5	O
the	5	O
information	5	O
about	5	O
suicidal	5	O
attempt	5	O
by	9	O
OP	9	B-Chemical
compound	0	I-Chemical
was	9	O
concealed	5	O
from	9	O
the	5	O
treating	5	O
team	5	O
.	9	O

Curcumin	0	B-Chemical
ameliorates	3	O
cognitive	5	B-Disease
dysfunction	9	I-Disease
and	5	O
oxidative	9	O
damage	9	O
in	5	O
phenobarbitone	0	B-Chemical
and	5	O
carbamazepine	0	B-Chemical
administered	9	O
rats	9	O
.	9	O

The	5	O
antiepileptic	5	O
drugs	5	O
,	9	O
phenobarbitone	0	B-Chemical
and	5	O
carbamazepine	0	B-Chemical
are	5	O
well	9	O
known	9	O
to	5	O
cause	5	O
cognitive	5	B-Disease
impairment	5	I-Disease
on	5	O
chronic	5	O
use	5	O
.	9	O

The	5	O
increase	9	O
in	5	O
free	9	O
radical	0	O
generation	9	O
has	9	O
been	9	O
implicated	9	O
as	5	O
one	5	O
of	5	O
the	5	O
important	9	O
mechanisms	9	O
of	5	O
cognitive	5	B-Disease
impairment	5	I-Disease
by	9	O
antiepileptic	5	O
drugs	5	O
.	9	O

Curcumin	0	B-Chemical
has	9	O
shown	9	O
antioxidant	0	O
,	9	O
anti	3	O
-	7	O
inflammatory	3	O
and	5	O
neuro	9	O
-	7	O
protective	9	O
properties	9	O
.	9	O

Therefore	9	O
,	9	O
the	5	O
present	9	O
study	9	O
was	9	O
carried	9	O
out	9	O
to	5	O
investigate	9	O
the	5	O
effect	9	O
of	5	O
chronic	5	O
curcumin	0	B-Chemical
administration	9	O
on	5	O
phenobarbitone	0	B-Chemical
-	7	O
and	5	O
carbamazepine	0	B-Chemical
-	7	O
induced	3	O
cognitive	5	B-Disease
impairment	5	I-Disease
and	5	O
oxidative	9	O
stress	9	O
in	5	O
rats	9	O
.	9	O

Pharmacokinetic	0	O
interactions	9	O
of	5	O
curcumin	0	B-Chemical
with	5	O
phenobarbitone	0	B-Chemical
and	5	O
carbamazepine	0	B-Chemical
were	9	O
also	9	O
studied	9	O
.	9	O

Vehicle	0	O
/	9	O
drugs	5	O
were	9	O
administered	9	O
daily	5	O
for	5	O
21days	0	O
to	5	O
male	9	O
Wistar	9	O
rats	9	O
.	9	O

Passive	5	O
avoidance	5	O
paradigm	5	O
and	5	O
elevated	9	O
plus	9	O
maze	5	O
test	5	O
were	9	O
used	5	O
to	5	O
assess	5	O
cognitive	5	O
function	9	O
.	9	O

At	9	O
the	5	O
end	9	O
of	5	O
study	9	O
period	5	O
,	9	O
serum	9	O
phenobarbitone	0	B-Chemical
and	5	O
carbamazepine	0	B-Chemical
,	9	O
whole	9	O
brain	5	O
malondialdehyde	0	B-Chemical
and	5	O
reduced	9	O
glutathione	0	B-Chemical
levels	3	O
were	9	O
estimated	5	O
.	9	O

The	5	O
administration	9	O
of	5	O
phenobarbitone	0	B-Chemical
and	5	O
carbamazepine	0	B-Chemical
for	5	O
21days	0	O
caused	9	O
a	5	O
significant	9	O
impairment	5	B-Disease
of	5	I-Disease
learning	5	I-Disease
and	5	I-Disease
memory	5	I-Disease
as	5	O
well	9	O
as	5	O
an	5	O
increased	9	O
oxidative	9	O
stress	9	O
.	9	O

Concomitant	9	O
curcumin	0	B-Chemical
administration	9	O
prevented	9	O
the	5	O
cognitive	5	B-Disease
impairment	5	I-Disease
and	5	O
decreased	9	O
the	5	O
increased	9	O
oxidative	9	O
stress	9	O
induced	3	O
by	9	O
these	5	O
antiepileptic	5	O
drugs	5	O
.	9	O

Curcumin	0	B-Chemical
co	9	O
-	7	O
administration	9	O
did	9	O
not	5	O
cause	5	O
any	5	O
significant	9	O
alteration	9	O
in	5	O
the	5	O
serum	9	O
concentrations	0	O
of	5	O
both	9	O
phenobarbitone	0	B-Chemical
as	5	O
well	9	O
as	5	O
carbamazepine	0	B-Chemical
.	9	O

These	5	O
results	9	O
show	9	O
that	5	O
curcumin	0	B-Chemical
has	9	O
beneficial	9	O
effect	9	O
in	5	O
mitigating	5	O
the	5	O
deterioration	5	B-Disease
of	5	I-Disease
cognitive	5	I-Disease
functions	9	I-Disease
and	5	O
oxidative	9	O
damage	9	O
in	5	O
rats	9	O
treated	3	O
with	5	O
phenobarbitone	0	B-Chemical
and	5	O
carbamazepine	0	B-Chemical
without	9	O
significantly	9	O
altering	9	O
their	5	O
serum	9	O
concentrations	0	O
.	9	O

The	5	O
findings	9	O
suggest	9	O
that	5	O
curcumin	0	B-Chemical
can	5	O
be	5	O
considered	5	O
as	5	O
a	5	O
potential	9	O
safe	5	O
and	5	O
effective	5	O
adjuvant	9	O
to	5	O
phenobarbitone	0	B-Chemical
and	5	O
carbamazepine	0	B-Chemical
therapy	5	O
in	5	O
preventing	9	O
cognitive	5	B-Disease
impairment	5	I-Disease
associated	9	O
with	5	O
these	5	O
drugs	5	O
.	9	O

Can	5	O
angiogenesis	3	O
be	5	O
a	5	O
target	9	O
of	5	O
treatment	9	O
for	5	O
ribavirin	9	B-Chemical
associated	9	O
hemolytic	0	B-Disease
anemia	9	I-Disease
?	5	O

BACKGROUND	2	O
/	9	O
AIMS	5	O
:	9	O
Recently	9	O
ribavirin	9	B-Chemical
has	9	O
been	9	O
found	9	O
to	5	O
inhibit	3	O
angiogenesis	3	O
and	5	O
a	5	O
number	9	O
of	5	O
angiogenesis	3	O
inhibitors	3	O
such	5	O
as	5	O
sunitinib	9	B-Chemical
and	5	O
sorafenib	3	B-Chemical
have	5	O
been	9	O
found	9	O
to	5	O
cause	5	O
acute	9	O
hemolysis	9	B-Disease
.	9	O

We	9	O
aimed	5	O
to	5	O
investigate	9	O
whether	9	O
there	5	O
is	5	O
a	5	O
relation	5	O
between	5	O
hemoglobin	0	O
,	9	O
haptoglobin	9	O
and	5	O
angiogenesis	3	O
soluble	0	O
markers	3	O
which	5	O
are	5	O
modifiable	5	O
and	5	O
can	5	O
help	5	O
in	5	O
developing	5	O
strategies	5	O
against	9	O
anemia	9	B-Disease
.	9	O

METHODS	2	O
:	9	O
Fourteen	9	O
patients	5	O
chronically	9	B-Disease
infected	3	I-Disease
with	5	I-Disease
hepatitis	9	I-Disease
C	9	I-Disease
virus	9	I-Disease
were	9	O
treated	3	O
by	9	O
pegylated	0	B-Chemical
interferon	3	I-Chemical
alpha	9	I-Chemical
2a	9	I-Chemical
and	5	O
ribavirin	9	B-Chemical
.	9	O

Serum	9	O
hemoglobin	0	O
,	9	O
haptoglobin	9	O
and	5	O
angiogenesis	3	O
markers	3	O
of	5	O
vascular	5	O
endothelial	3	O
growth	3	O
factor	9	O
and	5	O
angiopoetin	3	O
-	7	O
2	9	O
were	9	O
investigated	9	O
before	9	O
and	5	O
after	9	O
therapy	5	O
.	9	O

RESULTS	9	O
:	9	O
We	9	O
observed	9	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
haptoglobin	9	O
levels	3	O
at	9	O
the	5	O
end	9	O
of	5	O
the	5	O
treatment	9	O
period	5	O
.	9	O

Hemoglobin	7	O
levels	3	O
also	9	O
decreased	9	O
but	9	O
insignificantly	9	O
by	9	O
treatment	9	O
.	9	O

In	9	O
contrast	9	O
with	5	O
the	5	O
literature	5	O
,	9	O
serum	9	O
levels	3	O
of	5	O
angiogenesis	3	O
factors	9	O
did	9	O
not	5	O
change	9	O
significantly	9	O
by	9	O
pegylated	0	B-Chemical
interferon	3	I-Chemical
and	5	O
ribavirin	9	B-Chemical
therapy	5	O
.	9	O

We	9	O
found	9	O
no	9	O
correlation	9	O
of	5	O
angiogenesis	3	O
soluble	0	O
markers	3	O
with	5	O
either	9	O
hemoglobin	0	O
or	5	O
haptoglobin	9	O
.	9	O

CONCLUSION	5	O
:	9	O
This	5	O
is	5	O
the	5	O
first	9	O
study	9	O
in	5	O
the	5	O
literature	5	O
investigating	5	O
a	5	O
link	5	O
between	5	O
angiogenesis	3	O
soluble	0	O
markers	3	O
and	5	O
ribavirin	9	B-Chemical
induced	3	O
anemia	9	B-Disease
in	5	O
patients	5	O
with	5	O
hepatitis	9	B-Disease
C	9	I-Disease
and	5	O
we	5	O
could	9	O
not	5	O
find	5	O
any	5	O
relation	5	O
.	9	O

Future	5	O
research	5	O
with	5	O
larger	5	O
number	9	O
of	5	O
patients	5	O
is	5	O
needed	5	O
to	5	O
find	5	O
out	9	O
modifiable	5	O
factors	9	O
that	5	O
will	5	O
improve	5	O
the	5	O
safety	5	O
of	5	O
ribavirin	9	B-Chemical
therapy	5	O
.	9	O

Reduction	9	O
in	5	O
injection	9	O
pain	5	B-Disease
using	9	O
buffered	0	O
lidocaine	0	B-Chemical
as	5	O
a	5	O
local	5	O
anesthetic	5	O
before	9	O
cardiac	5	O
catheterization	5	O
.	9	O

Previous	9	O
reports	9	O
have	5	O
suggested	9	O
that	5	O
pain	5	B-Disease
associated	9	O
with	5	O
the	5	O
injection	9	O
of	5	O
lidocaine	0	B-Chemical
is	5	O
related	9	O
to	5	O
the	5	O
acidic	0	O
pH	0	O
of	5	O
the	5	O
solution	0	O
.	9	O

To	9	O
determine	9	O
if	5	O
the	5	O
addition	9	O
of	5	O
a	5	O
buffering	5	O
solution	0	O
to	5	O
adjust	5	O
the	5	O
pH	0	O
of	5	O
lidocaine	0	B-Chemical
into	9	O
the	5	O
physiologic	9	O
range	9	O
would	5	O
reduce	5	O
pain	5	B-Disease
during	5	O
injection	9	O
,	9	O
we	5	O
performed	9	O
a	5	O
blinded	5	O
randomized	5	O
study	9	O
in	5	O
patients	5	O
undergoing	9	O
cardiac	5	O
catheterization	5	O
.	9	O

Twenty	9	O
patients	5	O
were	9	O
asked	5	O
to	5	O
quantify	9	O
the	5	O
severity	5	O
of	5	O
pain	5	B-Disease
after	9	O
receiving	9	O
standard	5	O
lidocaine	0	B-Chemical
in	5	O
one	5	O
femoral	5	O
area	5	O
and	5	O
buffered	0	O
lidocaine	0	B-Chemical
in	5	O
the	5	O
opposite	9	O
femoral	5	O
area	5	O
.	9	O

The	5	O
mean	5	O
pain	5	B-Disease
score	5	O
for	5	O
buffered	0	O
lidocaine	0	B-Chemical
was	9	O
significantly	9	O
lower	9	O
than	5	O
the	5	O
mean	5	O
score	5	O
for	5	O
standard	5	O
lidocaine	0	B-Chemical
(	9	O
2	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
9	7	O
vs	7	O
.	9	O
3	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
2	9	O
,	9	O
P	9	O
=	7	O
0	7	O
.	9	O
03	7	O
)	9	O
.	9	O

The	5	O
pH	0	O
adjustment	5	O
of	5	O
standard	5	O
lidocaine	0	B-Chemical
can	5	O
be	5	O
accomplished	5	O
easily	5	O
in	5	O
the	5	O
catheterization	5	O
laboratory	9	O
before	9	O
injection	9	O
and	5	O
results	9	O
in	5	O
a	5	O
reduction	9	O
of	5	O
the	5	O
pain	5	B-Disease
occurring	9	O
during	5	O
the	5	O
infiltration	3	O
of	5	O
tissues	9	O
.	9	O

Effect	0	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
glyceryl	0	I-Chemical
-	7	I-Chemical
phosphorylcholine	0	I-Chemical
on	5	O
amnesia	5	B-Disease
caused	9	O
by	9	O
scopolamine	0	B-Chemical
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
carried	9	O
out	9	O
to	5	O
test	5	O
the	5	O
effects	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
glycerylphosphorylcholine	0	I-Chemical
(	9	O
L	0	B-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
GFC	5	I-Chemical
)	9	O
on	5	O
memory	5	B-Disease
impairment	5	I-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
in	5	O
man	5	O
.	9	O

Thirty	9	O
-	7	O
two	5	O
healthy	5	O
young	5	O
volunteers	5	O
were	9	O
randomly	5	O
allocated	5	O
to	5	O
four	9	O
different	9	O
groups	9	O
.	9	O

They	5	O
were	9	O
given	5	O
a	5	O
ten	9	O
day	9	O
pretreatment	0	O
with	5	O
either	9	O
L	0	B-Chemical
-	7	I-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
GFC	5	I-Chemical
or	5	O
placebo	9	O
,	9	O
p	7	O
.	9	O
o	9	O
.	9	O
,	9	O
and	5	O
on	5	O
the	5	O
eleventh	5	O
day	9	O
either	9	O
scopolamine	0	B-Chemical
or	5	O
placebo	9	O
,	9	O
i	9	O
.	9	O
m	9	O
.	9	O

Before	9	O
and	5	O
0	7	O
.	9	O
5	9	O
,	9	O
1	9	O
,	9	O
2	9	O
,	9	O
3	9	O
,	9	O
and	5	O
6	9	O
h	0	O
after	9	O
injection	9	O
the	5	O
subjects	5	O
were	9	O
given	5	O
attention	5	O
and	5	O
mnemonic	5	O
tests	5	O
.	9	O

The	5	O
findings	9	O
of	5	O
this	5	O
study	9	O
indicate	9	O
that	5	O
the	5	O
drug	5	O
is	5	O
able	9	O
to	5	O
antagonize	3	O
impairment	5	B-Disease
of	5	I-Disease
attention	5	I-Disease
and	5	I-Disease
memory	5	I-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
.	9	O

Safety	5	O
of	5	O
capecitabine	0	B-Chemical
:	9	O
a	5	O
review	5	O
.	9	O

IMPORTANCE	2	O
OF	2	O
THE	2	O
FIELD	2	O
:	9	O
Fluoropyrimidines	0	B-Chemical
,	9	O
in	5	O
particular	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
,	9	O
have	5	O
been	9	O
the	5	O
mainstay	5	O
of	5	O
treatment	9	O
for	5	O
several	9	O
solid	9	O
tumors	3	B-Disease
,	9	O
including	9	O
colorectal	9	B-Disease
,	9	I-Disease
breast	3	I-Disease
and	5	I-Disease
head	5	I-Disease
and	5	I-Disease
neck	5	I-Disease
cancers	9	I-Disease
,	9	O
for	5	O
>	0	O
40	9	O
years	5	O
.	9	O

AREAS	2	O
COVERED	2	O
IN	2	O
THIS	2	O
REVIEW	2	O
:	9	O
This	5	O
article	6	O
reviews	5	O
the	5	O
pharmacology	5	O
and	5	O
efficacy	9	O
of	5	O
capecitabine	0	B-Chemical
with	5	O
a	5	O
special	5	O
emphasis	5	O
on	5	O
its	9	O
safety	5	O
.	9	O

WHAT	2	O
THE	2	O
READER	2	O
WILL	2	O
GAIN	5	O
:	9	O
The	5	O
reader	5	O
will	5	O
gain	5	O
better	5	O
insight	5	O
into	9	O
the	5	O
safety	5	O
of	5	O
capecitabine	0	B-Chemical
in	5	O
special	5	O
populations	9	O
such	5	O
as	5	O
patients	5	O
with	5	O
advanced	5	O
age	5	O
,	9	O
renal	9	B-Disease
and	5	I-Disease
kidney	9	I-Disease
disease	5	I-Disease
.	9	O

We	9	O
also	9	O
explore	5	O
different	9	O
dosing	9	O
and	5	O
schedules	5	O
of	5	O
capecitabine	0	B-Chemical
administration	9	O
.	9	O

TAKE	2	O
HOME	5	O
MESSAGE	2	O
:	9	O
Capecitabine	0	B-Chemical
is	5	O
an	5	O
oral	9	O
prodrug	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
and	5	O
was	9	O
developed	5	O
to	5	O
fulfill	5	O
the	5	O
need	5	O
for	5	O
a	5	O
more	5	O
convenient	5	O
therapy	5	O
and	5	O
provide	5	O
an	5	O
improved	5	O
safety	5	O
/	9	O
efficacy	9	O
profile	9	O
.	9	O

It	5	O
has	9	O
shown	9	O
promising	5	O
results	9	O
alone	9	O
or	5	O
in	5	O
combination	9	O
with	5	O
other	5	O
chemotherapeutic	3	O
agents	5	O
in	5	O
colorectal	9	B-Disease
,	9	I-Disease
breast	3	I-Disease
,	9	I-Disease
pancreaticobiliary	5	I-Disease
,	9	I-Disease
gastric	9	I-Disease
,	9	I-Disease
renal	9	I-Disease
cell	3	I-Disease
and	5	I-Disease
head	5	I-Disease
and	5	I-Disease
neck	5	I-Disease
cancers	9	I-Disease
.	9	O

The	5	O
most	9	O
commonly	5	O
reported	9	O
toxic	0	O
effects	9	O
of	5	O
capecitabine	0	B-Chemical
are	5	O
diarrhea	5	B-Disease
,	9	O
nausea	5	B-Disease
,	9	O
vomiting	5	B-Disease
,	9	O
stomatitis	9	B-Disease
and	5	O
hand	5	B-Disease
-	7	I-Disease
foot	5	I-Disease
syndrome	5	I-Disease
.	9	O

Capecitabine	0	B-Chemical
has	9	O
a	5	O
well	9	O
-	7	O
established	9	O
safety	5	O
profile	9	O
and	5	O
can	5	O
be	5	O
given	5	O
safely	5	O
to	5	O
patients	5	O
with	5	O
advanced	5	O
age	5	O
,	9	O
hepatic	9	B-Disease
and	5	I-Disease
renal	9	I-Disease
dysfunctions	5	I-Disease
.	9	O

Levodopa	0	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
in	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
:	9	O
filling	5	O
the	5	O
bench	5	O
-	7	O
to	5	O
-	7	O
bedside	5	O
gap	5	O
.	9	O

Levodopa	0	B-Chemical
is	5	O
the	5	O
most	9	O
effective	5	O
drug	5	O
for	5	O
the	5	O
treatment	9	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

However	9	O
,	9	O
the	5	O
long	5	O
-	7	O
term	5	O
use	5	O
of	5	O
this	5	O
dopamine	5	B-Chemical
precursor	9	O
is	5	O
complicated	5	O
by	9	O
highly	9	O
disabling	5	O
fluctuations	5	O
and	5	O
dyskinesias	5	B-Disease
.	9	O

Although	9	O
preclinical	9	O
and	5	O
clinical	5	O
findings	9	O
suggest	9	O
pulsatile	5	O
stimulation	3	O
of	5	O
striatal	3	O
postsynaptic	3	O
receptors	3	O
as	5	O
a	5	O
key	9	O
mechanism	9	O
underlying	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
,	9	O
their	5	O
pathogenesis	9	O
is	5	O
still	5	O
unclear	9	O
.	9	O

In	9	O
recent	5	O
years	5	O
,	9	O
evidence	9	O
from	9	O
animal	5	O
models	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
has	9	O
provided	9	O
important	9	O
information	5	O
to	5	O
understand	5	O
the	5	O
effect	9	O
of	5	O
specific	9	O
receptor	3	O
and	5	O
post	9	O
-	7	O
receptor	3	O
molecular	9	O
mechanisms	9	O
underlying	5	O
the	5	O
development	9	O
of	5	O
dyskinetic	5	B-Disease
movements	5	I-Disease
.	9	O

Recent	9	O
preclinical	9	O
and	5	O
clinical	5	O
data	5	O
from	9	O
promising	5	O
lines	3	O
of	5	O
research	5	O
focus	5	O
on	5	O
the	5	O
differential	9	O
role	9	O
of	5	O
presynaptic	3	O
versus	9	O
postsynaptic	3	O
mechanisms	9	O
,	9	O
dopamine	5	B-Chemical
receptor	3	O
subtypes	9	O
,	9	O
ionotropic	3	O
and	5	O
metabotropic	3	O
glutamate	0	B-Chemical
receptors	3	O
,	9	O
and	5	O
non	9	O
-	7	O
dopaminergic	5	O
neurotransmitter	9	O
systems	5	O
in	5	O
the	5	O
pathophysiology	9	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesias	5	B-Disease
.	9	O

Effects	9	O
of	5	O
pallidal	5	O
neurotensin	3	B-Chemical
on	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
parkinsonian	5	B-Disease
catalepsy	5	I-Disease
:	9	O
behavioral	5	O
and	5	O
electrophysiological	5	O
studies	9	O
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
globus	5	O
pallidus	4	O
plays	9	O
a	5	O
critical	9	O
role	9	O
in	5	O
movement	5	O
regulation	9	O
.	9	O

Previous	9	O
studies	9	O
have	5	O
indicated	9	O
that	5	O
the	5	O
globus	5	O
pallidus	4	O
receives	5	O
neurotensinergic	3	O
innervation	5	O
from	9	O
the	5	O
striatum	9	O
,	9	O
and	5	O
systemic	9	O
administration	9	O
of	5	O
a	5	O
neurotensin	3	B-Chemical
analog	0	O
could	9	O
produce	9	O
antiparkinsonian	5	O
effects	9	O
.	9	O

The	5	O
present	9	O
study	9	O
aimed	5	O
to	5	O
investigate	9	O
the	5	O
effects	9	O
of	5	O
pallidal	5	O
neurotensin	3	B-Chemical
on	5	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
parkinsonian	5	B-Disease
symptoms	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
Behavioral	5	O
experiments	9	O
and	5	O
electrophysiological	5	O
recordings	5	O
were	9	O
performed	9	O
in	5	O
the	5	O
present	9	O
study	9	O
.	9	O

RESULTS	9	O
:	9	O
Bilateral	5	O
infusions	9	O
of	5	O
neurotensin	3	B-Chemical
into	9	O
the	5	O
globus	5	O
pallidus	4	O
reversed	9	O
haloperidol	5	B-Chemical
-	7	O
induced	3	O
parkinsonian	5	B-Disease
catalepsy	5	I-Disease
in	5	O
rats	9	O
.	9	O

Electrophysiological	5	O
recordings	5	O
showed	9	O
that	5	O
microinjection	3	O
of	5	O
neurotensin	3	B-Chemical
induced	3	O
excitation	0	O
of	5	O
pallidal	5	O
neurons	3	O
in	5	O
the	5	O
presence	9	O
of	5	O
systemic	9	O
haloperidol	5	B-Chemical
administration	9	O
.	9	O

The	5	O
neurotensin	3	B-Chemical
type	9	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
receptor	3	I-Chemical
antagonist	3	I-Chemical
SR48692	3	B-Chemical
blocked	3	O
both	9	O
the	5	O
behavioral	5	O
and	5	O
the	5	O
electrophysiological	5	O
effects	9	O
induced	3	O
by	9	O
neurotensin	3	B-Chemical
.	9	O

CONCLUSION	5	O
:	9	O
Activation	3	O
of	5	O
pallidal	5	O
neurotensin	3	B-Chemical
receptors	3	O
may	5	O
be	5	O
involved	9	O
in	5	O
neurotensin	3	B-Chemical
-	7	O
induced	3	O
antiparkinsonian	5	O
effects	9	O
.	9	O

Carmofur	9	B-Chemical
-	7	O
induced	3	O
organic	0	B-Disease
mental	5	I-Disease
disorders	5	I-Disease
.	9	O

Organic	0	B-Disease
mental	5	I-Disease
disorder	5	I-Disease
was	9	O
observed	9	O
in	5	O
a	5	O
29	7	O
-	7	O
year	5	O
-	7	O
old	5	O
female	9	O
in	5	O
the	5	O
prognostic	5	O
period	5	O
after	9	O
the	5	O
onset	5	O
of	5	O
carmofur	0	B-Chemical
-	7	O
induced	3	O
leukoencephalopathy	5	B-Disease
.	9	O

Symptoms	5	O
such	5	O
as	5	O
euphoria	5	O
,	9	O
emotional	5	O
lability	9	O
and	5	O
puerile	5	O
attitude	5	O
noted	9	O
in	5	O
the	5	O
patient	5	O
were	9	O
diagnosed	5	O
as	5	O
organic	0	B-Disease
personality	5	I-Disease
syndrome	5	I-Disease
according	9	O
to	5	O
the	5	O
criteria	5	O
defined	5	O
in	5	O
the	5	O
DSM	4	O
-	7	O
III	9	O
-	7	O
R	9	O
.	9	O

It	5	O
is	5	O
referred	5	O
to	5	O
as	5	O
a	5	O
frontal	5	B-Disease
lobe	5	I-Disease
syndrome	5	I-Disease
.	9	O

Brain	9	O
CT	9	O
revealed	9	O
a	5	O
periventricular	5	O
low	9	O
density	9	O
area	5	O
in	5	O
the	5	O
frontal	5	O
white	9	O
matter	5	O
and	5	O
moderate	9	O
dilatation	5	O
of	5	O
the	5	O
lateral	5	O
ventricles	5	O
especially	5	O
at	9	O
the	5	O
bilateral	5	O
anterior	5	O
horns	5	O
.	9	O

Consequently	9	O
,	9	O
carmofur	0	B-Chemical
-	7	O
induced	3	O
leukoencephalopathy	5	B-Disease
may	5	O
uncommonly	5	O
result	9	O
in	5	O
organic	0	B-Disease
personality	5	I-Disease
syndrome	5	I-Disease
in	5	O
the	5	O
residual	9	O
state	5	O
.	9	O

It	5	O
may	5	O
be	5	O
attributed	9	O
to	5	O
the	5	O
structural	9	B-Disease
damage	9	I-Disease
to	5	I-Disease
the	5	I-Disease
frontal	5	I-Disease
lobe	5	I-Disease
.	9	O

Butyrylcholinesterase	7	O
gene	1	O
mutations	1	O
in	5	O
patients	5	O
with	5	O
prolonged	9	O
apnea	5	B-Disease
after	9	O
succinylcholine	5	B-Chemical
for	5	O
electroconvulsive	5	O
therapy	5	O
.	9	O

BACKGROUND	2	O
:	9	O
patients	5	O
undergoing	9	O
electroconvulsive	5	O
therapy	5	O
(	9	O
ECT	5	O
)	9	O
often	5	O
receive	5	O
succinylcholine	5	B-Chemical
as	5	O
part	9	O
of	5	O
the	5	O
anesthetic	5	O
procedure	5	O
.	9	O

The	5	O
duration	5	O
of	5	O
action	5	O
may	5	O
be	5	O
prolonged	9	O
in	5	O
patients	5	O
with	5	O
genetic	5	O
variants	1	O
of	5	O
the	5	O
butyrylcholinesterase	0	O
enzyme	0	O
(	9	O
BChE	0	O
)	9	O
,	9	O
the	5	O
most	9	O
common	5	O
being	5	O
the	5	O
K	9	O
-	7	O
and	5	O
the	5	O
A	9	O
-	7	O
variants	1	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
assess	5	O
the	5	O
clinical	5	O
significance	9	O
of	5	O
genetic	5	O
variants	1	O
in	5	O
butyrylcholinesterase	0	O
gene	1	O
(	9	O
BCHE	7	O
)	9	O
in	5	O
patients	5	O
with	5	O
a	5	O
suspected	5	O
prolonged	9	O
duration	5	O
of	5	O
action	5	O
of	5	O
succinylcholine	5	B-Chemical
after	9	O
ECT	5	O
.	9	O

METHODS	2	O
:	9	O
a	5	O
total	9	O
of	5	O
13	7	O
patients	5	O
were	9	O
referred	5	O
to	5	O
the	5	O
Danish	5	O
Cholinesterase	0	O
Research	2	O
Unit	2	O
after	9	O
ECT	5	O
during	5	O
38	7	O
months	5	O
.	9	O

We	9	O
determined	9	O
the	5	O
BChE	0	O
activity	9	O
and	5	O
the	5	O
BCHE	7	O
genotype	9	O
using	9	O
molecular	9	O
genetic	5	O
methods	5	O
,	9	O
the	5	O
duration	5	O
of	5	O
apnea	5	B-Disease
,	9	O
time	5	O
to	5	O
sufficient	9	O
spontaneous	5	O
ventilation	5	O
and	5	O
whether	9	O
neuromuscular	5	O
monitoring	5	O
was	9	O
used	5	O
.	9	O

The	5	O
duration	5	O
of	5	O
apnea	5	B-Disease
was	9	O
compared	9	O
with	5	O
published	9	O
data	5	O
on	5	O
normal	9	O
subjects	5	O
.	9	O

RESULTS	9	O
:	9	O
in	5	O
11	7	O
patients	5	O
,	9	O
mutations	1	O
were	9	O
found	9	O
in	5	O
the	5	O
BCHE	7	O
gene	1	O
,	9	O
the	5	O
K	9	O
-	7	O
variant	1	O
being	5	O
the	5	O
most	9	O
frequent	5	O
.	9	O

The	5	O
duration	5	O
of	5	O
apnea	5	B-Disease
was	9	O
5	9	O
-	7	O
15	9	O
min	0	O
compared	9	O
with	5	O
3	9	O
-	7	O
5	9	O
.	9	O
3	9	O
min	0	O
from	9	O
the	5	O
literature	5	O
.	9	O

Severe	9	O
distress	5	O
was	9	O
noted	9	O
in	5	O
the	5	O
recovery	9	O
phase	5	O
in	5	O
two	5	O
patients	5	O
.	9	O

Neuromuscular	2	O
monitoring	5	O
was	9	O
used	5	O
in	5	O
two	5	O
patients	5	O
.	9	O

CONCLUSION	5	O
:	9	O
eleven	9	O
of	5	O
13	7	O
patients	5	O
with	5	O
a	5	O
prolonged	9	O
duration	5	O
of	5	O
action	5	O
of	5	O
succinylcholine	5	B-Chemical
had	9	O
mutations	1	O
in	5	O
BCHE	7	O
,	9	O
indicating	9	O
that	5	O
this	5	O
is	5	O
the	5	O
possible	5	O
reason	5	O
for	5	O
a	5	O
prolonged	9	O
period	5	O
of	5	O
apnea	5	B-Disease
.	9	O

We	9	O
recommend	5	O
objective	5	O
neuromuscular	5	O
monitoring	5	O
during	5	O
the	5	O
first	9	O
ECT	5	O
.	9	O

Perhexiline	0	B-Chemical
maleate	0	I-Chemical
and	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
.	9	O

Peripheral	9	B-Disease
neuropathy	5	I-Disease
has	9	O
been	9	O
noted	9	O
as	5	O
a	5	O
complication	5	O
of	5	O
therapy	5	O
with	5	O
perhexiline	0	B-Chemical
maleate	0	I-Chemical
,	9	O
a	5	O
drug	5	O
widely	5	O
used	5	O
in	5	O
France	2	O
(	9	O
and	5	O
in	5	O
clinical	5	O
trials	5	O
in	5	O
the	5	O
United	9	O
States	9	O
)	9	O
for	5	O
the	5	O
prophylactic	5	O
treatment	9	O
of	5	O
angina	5	B-Disease
pectoris	5	I-Disease
.	9	O

In	9	O
24	9	O
patients	5	O
with	5	O
this	5	O
complication	5	O
,	9	O
the	5	O
marked	9	O
slowing	5	O
of	5	O
motor	5	O
nerve	5	O
conduction	5	O
velocity	5	O
and	5	O
the	5	O
electromyographic	5	O
changes	9	O
imply	9	O
mainly	9	O
a	5	O
demyelinating	9	B-Disease
disorder	5	I-Disease
.	9	O

Improvement	5	O
was	9	O
noted	9	O
with	5	O
cessation	5	O
of	5	O
therapy	5	O
.	9	O

In	9	O
a	5	O
few	5	O
cases	5	O
the	5	O
presence	9	O
of	5	O
active	9	O
denervation	5	O
signified	5	O
a	5	O
poor	5	O
prognosis	5	O
,	9	O
with	5	O
only	9	O
slight	9	O
improvement	5	O
.	9	O

The	5	O
underlying	5	O
mechanism	9	O
causing	9	O
the	5	O
neuropathy	5	B-Disease
is	5	O
not	5	O
yet	9	O
fully	9	O
known	9	O
,	9	O
although	9	O
some	5	O
evidence	9	O
indicates	9	O
that	5	O
it	5	O
may	5	O
be	5	O
a	5	O
lipid	0	O
storage	9	O
process	5	O
.	9	O

A	9	O
phase	5	O
I	9	O
study	9	O
of	5	O
4	9	B-Chemical
'	9	I-Chemical
-	7	I-Chemical
0	7	I-Chemical
-	7	I-Chemical
tetrahydropyranyladriamycin	_	I-Chemical
.	9	O

Clinical	5	O
pharmacology	5	O
and	5	O
pharmacokinetics	9	O
.	9	O

A	9	O
Phase	9	O
I	9	O
study	9	O
of	5	O
intravenous	0	O
(	9	O
IV	9	O
)	9	O
bolus	0	O
4	9	B-Chemical
'	9	I-Chemical
-	7	I-Chemical
0	7	I-Chemical
-	7	I-Chemical
tetrahydropyranyladriamycin	_	I-Chemical
(	9	O
Pirarubicin	0	B-Chemical
)	9	O
was	9	O
done	9	O
in	5	O
55	7	O
patients	5	O
in	5	O
good	5	O
performance	5	O
status	9	O
with	5	O
refractory	9	O
tumors	3	B-Disease
.	9	O

Twenty	9	O
-	7	O
six	9	O
had	9	O
minimal	9	O
prior	9	O
therapy	5	O
(	9	O
good	5	O
risk	5	O
)	9	O
,	9	O
23	7	O
had	9	O
extensive	5	O
prior	9	O
therapy	5	O
(	9	O
poor	5	O
risk	5	O
)	9	O
,	9	O
and	5	O
six	9	O
had	9	O
renal	9	B-Disease
and	5	I-Disease
/	9	I-Disease
or	5	I-Disease
hepatic	9	I-Disease
dysfunction	9	I-Disease
.	9	O

A	9	O
total	9	O
of	5	O
167	7	O
courses	5	O
at	9	O
doses	0	O
of	5	O
15	9	O
to	5	O
70	9	O
mg	0	O
/	9	O
m2	7	O
were	9	O
evaluable	9	O
.	9	O

Maximum	9	O
tolerated	9	O
dose	9	O
in	5	O
good	5	O
-	7	O
risk	5	O
patients	5	O
was	9	O
70	9	O
mg	0	O
/	9	O
m2	7	O
,	9	O
and	5	O
in	5	O
poor	5	O
-	7	O
risk	5	O
patients	5	O
,	9	O
60	9	O
mg	0	O
/	9	O
m2	7	O
.	9	O

The	5	O
dose	9	O
-	7	O
limiting	9	O
toxic	0	O
effect	9	O
was	9	O
transient	9	O
noncumulative	5	O
granulocytopenia	5	B-Disease
.	9	O

Granulocyte	3	O
nadir	9	O
was	9	O
on	5	O
day	9	O
14	7	O
(	9	O
range	9	O
,	9	O
4	9	O
-	7	O
22	7	O
)	9	O
.	9	O

Less	5	O
frequent	5	O
toxic	0	O
effects	9	O
included	5	O
thrombocytopenia	9	B-Disease
,	9	O
anemia	9	B-Disease
,	9	O
nausea	5	B-Disease
,	9	O
mild	9	O
alopecia	5	B-Disease
,	9	O
phlebitis	5	B-Disease
,	9	O
and	5	O
mucositis	5	B-Disease
.	9	O

Myelosuppression	5	B-Disease
was	9	O
more	5	O
in	5	O
patients	5	O
with	5	O
hepatic	9	B-Disease
dysfunction	9	I-Disease
.	9	O

Pharmacokinetic	0	O
analyses	9	O
in	5	O
21	7	O
patients	5	O
revealed	9	O
Pirarubicin	0	B-Chemical
plasma	9	O
T	3	O
1	9	O
/	9	O
2	9	O
alpha	9	O
(	9	O
+	9	O
/	9	O
-	7	O
SE	9	O
)	9	O
of	5	O
2	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
85	9	O
minutes	0	O
,	9	O
T	3	O
beta	9	O
1	9	O
/	9	O
2	9	O
of	5	O
25	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
5	9	O
minutes	0	O
,	9	O
and	5	O
T	3	O
1	9	O
/	9	O
2	9	O
gamma	9	O
of	5	O
23	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
7	9	O
.	9	O
6	9	O
hours	9	O
.	9	O

The	5	O
area	5	O
under	9	O
the	5	O
curve	9	O
was	9	O
537	7	O
+	9	O
/	9	O
-	7	O
149	7	O
ng	0	O
/	9	O
ml	0	O
x	9	O
hours	9	O
,	9	O
volume	9	O
of	5	O
distribution	9	O
(	9	O
Vd	9	O
)	9	O
3504	7	O
+	9	O
/	9	O
-	7	O
644	7	O
l	0	O
/	9	O
m2	7	O
,	9	O
and	5	O
total	9	O
clearance	9	O
(	9	O
ClT	0	O
)	9	O
was	9	O
204	7	O
+	9	O
39	7	O
.	9	O
3	9	O
l	0	O
/	9	O
hour	0	O
/	9	O
m2	7	O
.	9	O

Adriamycinol	9	B-Chemical
,	9	O
doxorubicin	0	B-Chemical
,	9	O
adriamycinone	9	B-Chemical
,	9	O
and	5	O
tetrahydropyranyladriamycinol	_	B-Chemical
were	9	O
the	5	O
metabolites	0	O
detected	9	O
in	5	O
plasma	9	O
and	5	O
the	5	O
amount	9	O
of	5	O
doxorubicin	0	B-Chemical
was	9	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
10	9	O
%	9	O
of	5	O
the	5	O
total	9	O
metabolites	0	O
.	9	O

Urinary	9	O
excretion	0	O
of	5	O
Pirarubicin	0	B-Chemical
in	5	O
the	5	O
first	9	O
24	9	O
hours	9	O
was	9	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
10	9	O
%	9	O
.	9	O

Activity	9	O
was	9	O
noted	9	O
in	5	O
mesothelioma	5	B-Disease
,	9	O
leiomyosarcoma	5	B-Disease
,	9	O
and	5	O
basal	3	B-Disease
cell	3	I-Disease
carcinoma	3	I-Disease
.	9	O

The	5	O
recommended	5	O
starting	9	O
dose	9	O
for	5	O
Phase	9	O
II	9	O
trials	5	O
is	5	O
60	9	O
mg	0	O
/	9	O
m2	7	O
IV	9	O
bolus	0	O
every	5	O
3	9	O
weeks	9	O
.	9	O

Ocular	5	B-Disease
and	5	I-Disease
auditory	5	I-Disease
toxicity	9	I-Disease
in	5	O
hemodialyzed	5	O
patients	5	O
receiving	9	O
desferrioxamine	0	B-Chemical
.	9	O

During	5	O
an	5	O
18	7	O
-	7	O
month	5	O
period	5	O
of	5	O
study	9	O
41	7	O
hemodialyzed	5	O
patients	5	O
receiving	9	O
desferrioxamine	0	B-Chemical
(	9	O
10	9	O
-	7	O
40	9	O
mg	0	O
/	9	O
kg	0	O
BW	9	O
/	9	O
3	9	O
times	5	O
weekly	5	O
)	9	O
for	5	O
the	5	O
first	9	O
time	5	O
were	9	O
monitored	9	O
for	5	O
detection	9	O
of	5	O
audiovisual	5	B-Disease
toxicity	9	I-Disease
.	9	O

6	9	O
patients	5	O
presented	5	O
clinical	5	O
symptoms	5	O
of	5	O
visual	5	B-Disease
or	5	I-Disease
auditory	5	I-Disease
toxicity	9	I-Disease
.	9	O

Moreover	9	O
,	9	O
detailed	5	O
ophthalmologic	5	O
and	5	O
audiologic	5	O
studies	9	O
disclosed	9	O
abnormalities	9	O
in	5	O
7	9	O
more	5	O
asymptomatic	5	O
patients	5	O
.	9	O

Visual	5	B-Disease
toxicity	9	I-Disease
was	9	O
of	5	O
retinal	5	O
origin	9	O
and	5	O
was	9	O
characterized	9	O
by	9	O
a	5	O
tritan	5	O
-	7	O
type	9	O
dyschromatopsy	_	B-Disease
,	9	O
sometimes	5	O
associated	9	O
with	5	O
a	5	B-Disease
loss	9	I-Disease
of	5	I-Disease
visual	5	I-Disease
acuity	5	I-Disease
and	5	O
pigmentary	5	B-Disease
retinal	5	I-Disease
deposits	9	I-Disease
.	9	O

Auditory	5	B-Disease
toxicity	9	I-Disease
was	9	O
characterized	9	O
by	9	O
a	5	O
mid	9	O
-	7	O
to	5	O
high	9	O
-	7	O
frequency	5	O
neurosensorial	5	B-Disease
hearing	5	I-Disease
loss	9	I-Disease
and	5	O
the	5	O
lesion	5	O
was	9	O
of	5	O
the	5	O
cochlear	5	O
type	9	O
.	9	O

Desferrioxamine	0	B-Chemical
withdrawal	5	O
resulted	9	O
in	5	O
a	5	O
complete	9	O
recovery	9	O
of	5	O
visual	5	O
function	9	O
in	5	O
1	9	O
patient	5	O
and	5	O
partial	9	O
recovery	9	O
in	5	O
3	9	O
,	9	O
and	5	O
a	5	O
complete	9	O
reversal	9	O
of	5	O
hearing	5	B-Disease
loss	9	I-Disease
in	5	O
3	9	O
patients	5	O
and	5	O
partial	9	O
recovery	9	O
in	5	O
3	9	O
.	9	O

This	5	O
toxicity	9	B-Disease
appeared	9	O
in	5	O
patients	5	O
receiving	9	O
the	5	O
higher	9	O
doses	0	O
of	5	O
desferrioxamine	0	B-Chemical
or	5	O
coincided	9	O
with	5	O
the	5	O
normalization	5	O
of	5	O
ferritin	9	O
or	5	O
aluminium	0	B-Chemical
serum	9	O
levels	3	O
.	9	O

The	5	O
data	5	O
indicate	9	O
that	5	O
audiovisual	5	B-Disease
toxicity	9	I-Disease
is	5	O
not	5	O
an	5	O
infrequent	5	O
complication	5	O
in	5	O
hemodialyzed	5	O
patients	5	O
receiving	9	O
desferrioxamine	0	B-Chemical
.	9	O

Periodical	2	O
audiovisual	5	O
monitoring	5	O
should	5	O
be	5	O
performed	9	O
on	5	O
hemodialyzed	5	O
patients	5	O
receiving	9	O
the	5	O
drug	5	O
in	5	O
order	5	O
to	5	O
detect	9	O
adverse	5	O
effects	9	O
as	5	O
early	9	O
as	5	O
possible	5	O
.	9	O

Serial	9	O
epilepsy	5	B-Disease
caused	9	O
by	9	O
levodopa	5	B-Chemical
/	9	I-Chemical
carbidopa	0	I-Chemical
administration	9	O
in	5	O
two	5	O
patients	5	O
on	5	O
hemodialysis	5	O
.	9	O

Two	9	O
patients	5	O
with	5	O
similar	9	O
clinical	5	O
features	5	O
are	5	O
presented	5	O
:	9	O
both	9	O
patients	5	O
had	9	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
,	9	O
on	5	O
hemodialysis	5	O
for	5	O
many	5	O
years	5	O
but	9	O
recently	9	O
begun	5	O
on	5	O
a	5	O
high	9	O
-	7	O
flux	9	O
dialyzer	0	O
;	9	O
both	9	O
had	9	O
been	9	O
receiving	9	O
a	5	O
carbidopa	0	B-Chemical
/	9	I-Chemical
levodopa	5	I-Chemical
preparation	9	O
;	9	O
and	5	O
both	9	O
had	9	O
the	5	O
onset	5	O
of	5	O
hallucinosis	5	B-Disease
and	5	O
recurrent	5	O
seizures	5	B-Disease
,	9	O
which	5	O
were	9	O
refractory	9	O
to	5	O
anticonvulsants	5	O
.	9	O

The	5	O
first	9	O
patient	5	O
died	9	O
without	9	O
a	5	O
diagnosis	5	O
;	9	O
the	5	O
second	9	O
patient	5	O
had	9	O
a	5	O
dramatic	9	O
recovery	9	O
following	9	O
the	5	O
administration	9	O
of	5	O
vitamin	0	B-Chemical
B6	3	I-Chemical
.	9	O

Neither	9	O
patient	5	O
was	9	O
considered	5	O
to	5	O
have	5	O
a	5	O
renal	9	O
state	5	O
sufficiently	5	O
severe	5	O
enough	5	O
to	5	O
explain	9	O
their	5	O
presentation	5	O
.	9	O

Randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
trial	5	O
of	5	O
mazindol	0	B-Chemical
in	5	O
Duchenne	5	B-Disease
dystrophy	9	I-Disease
.	9	O

There	5	O
is	5	O
evidence	9	O
that	5	O
growth	3	O
hormone	9	O
may	5	O
be	5	O
related	9	O
to	5	O
the	5	O
progression	9	O
of	5	O
weakness	5	B-Disease
in	5	O
Duchenne	5	B-Disease
dystrophy	9	I-Disease
.	9	O

We	9	O
conducted	9	O
a	5	O
12	9	O
-	7	O
month	5	O
controlled	5	O
trial	5	O
of	5	O
mazindol	0	B-Chemical
,	9	O
a	5	O
putative	1	O
growth	3	O
hormone	9	O
secretion	3	O
inhibitor	3	O
,	9	O
in	5	O
83	7	O
boys	5	O
with	5	O
Duchenne	5	B-Disease
dystrophy	9	I-Disease
.	9	O

Muscle	9	O
strength	5	O
,	9	O
contractures	5	O
,	9	O
functional	9	O
ability	9	O
and	5	O
pulmonary	5	O
function	9	O
were	9	O
tested	9	O
at	9	O
baseline	5	O
,	9	O
and	5	O
6	9	O
and	5	O
12	9	O
months	5	O
after	9	O
treatment	9	O
with	5	O
mazindol	0	B-Chemical
(	9	O
3	9	O
mg	0	O
/	9	O
d	9	O
)	9	O
or	5	O
placebo	9	O
.	9	O

The	5	O
study	9	O
was	9	O
designed	9	O
to	5	O
have	5	O
a	5	O
power	5	O
of	5	O
greater	5	O
than	5	O
0	7	O
.	9	O
90	9	O
to	5	O
detect	9	O
a	5	O
slowing	5	O
to	5	O
25	9	O
%	9	O
of	5	O
the	5	O
expected	9	O
rate	9	O
of	5	O
progression	9	O
of	5	O
weakness	5	B-Disease
at	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
.	9	O

Mazindol	0	B-Chemical
did	9	O
not	5	O
benefit	5	O
strength	5	O
at	9	O
any	5	O
point	5	O
in	5	O
the	5	O
study	9	O
.	9	O

Side	5	O
effects	9	O
attributable	9	O
to	5	O
mazindol	0	B-Chemical
included	5	O
decreased	9	B-Disease
appetite	5	I-Disease
(	9	O
36	9	O
%	9	O
)	9	O
,	9	O
dry	0	B-Disease
mouth	5	I-Disease
(	9	O
10	9	O
%	9	O
)	9	O
,	9	O
behavioral	5	O
change	9	O
(	9	O
22	7	O
%	9	O
)	9	O
,	9	O
and	5	O
gastrointestinal	9	B-Disease
symptoms	5	I-Disease
(	9	O
18	7	O
%	9	O
)	9	O
;	9	O
mazindol	0	B-Chemical
dosage	9	O
was	9	O
reduced	9	O
in	5	O
43	7	O
%	9	O
of	5	O
patients	5	O
.	9	O

The	5	O
effect	9	O
of	5	O
mazindol	0	B-Chemical
on	5	O
GH	9	O
secretion	3	O
was	9	O
estimated	5	O
indirectly	9	O
by	9	O
comparing	9	O
the	5	O
postabsorptive	5	O
IGF	3	O
-	7	O
I	9	O
levels	3	O
obtained	9	O
following	9	O
3	9	O
,	9	O
6	9	O
,	9	O
9	7	O
,	9	O
and	5	O
12	9	O
months	5	O
in	5	O
the	5	O
mazindol	0	B-Chemical
treated	3	O
to	5	O
those	5	O
in	5	O
the	5	O
placebo	9	O
groups	9	O
.	9	O

Although	9	O
mazindol	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
gained	5	O
less	5	O
weight	9	O
and	5	O
height	5	O
than	5	O
placebo	9	O
-	7	O
treated	3	O
patients	5	O
,	9	O
no	9	O
significant	9	O
effect	9	O
on	5	O
IGF	3	O
-	7	O
I	9	O
levels	3	O
was	9	O
observed	9	O
.	9	O

Mazindol	0	B-Chemical
doses	0	O
not	5	O
slow	5	O
the	5	O
progression	9	O
of	5	O
weakness	5	B-Disease
in	5	O
Duchenne	5	B-Disease
dystrophy	9	I-Disease
.	9	O

Facilitation	5	O
of	5	O
memory	5	O
retrieval	5	O
by	9	O
pre	9	O
-	7	O
test	5	O
morphine	0	B-Chemical
and	5	O
its	9	O
state	5	O
dependency	5	O
in	5	O
the	5	O
step	9	O
-	7	O
through	9	O
type	9	O
passive	5	O
avoidance	5	O
learning	5	O
test	5	O
in	5	O
mice	3	O
.	9	O

Amnesia	5	B-Disease
produced	9	O
by	9	O
scopolamine	0	B-Chemical
and	5	O
cycloheximide	3	B-Chemical
were	9	O
reversed	9	O
by	9	O
morphine	0	B-Chemical
given	5	O
30	9	O
min	0	O
before	9	O
the	5	O
test	5	O
trial	5	O
(	9	O
pre	9	O
-	7	O
test	5	O
)	9	O
,	9	O
and	5	O
pre	9	O
-	7	O
test	5	O
morphine	0	B-Chemical
also	9	O
facilitated	5	O
the	5	O
memory	5	O
retrieval	5	O
in	5	O
the	5	O
animals	9	O
administered	9	O
naloxone	0	B-Chemical
during	5	O
the	5	O
training	5	O
trial	5	O
.	9	O

Similarly	9	O
,	9	O
pre	9	O
-	7	O
test	5	O
scopolamine	0	B-Chemical
partially	9	O
reversed	9	O
the	5	O
scopolamine	0	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
,	9	O
but	9	O
not	5	O
significantly	9	O
;	9	O
and	5	O
pre	9	O
-	7	O
test	5	O
cycloheximide	3	B-Chemical
failed	9	O
to	5	O
reverse	9	O
the	5	O
cycloheximide	3	B-Chemical
-	7	O
induced	3	O
amnesia	5	B-Disease
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
the	5	O
facilitation	5	O
of	5	O
memory	5	O
retrieval	5	O
by	9	O
pre	9	O
-	7	O
test	5	O
morphine	0	B-Chemical
might	9	O
be	5	O
the	5	O
direct	9	O
action	5	O
of	5	O
morphine	0	B-Chemical
rather	5	O
than	5	O
a	5	O
state	5	O
dependent	9	O
effect	9	O
.	9	O

Naloxone	0	B-Chemical
reverses	3	O
the	5	O
antihypertensive	5	O
effect	9	O
of	5	O
clonidine	0	B-Chemical
.	9	O

In	9	O
unanesthetized	5	O
,	9	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
the	5	O
decrease	9	O
in	5	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
produced	9	O
by	9	O
intravenous	0	O
clonidine	0	B-Chemical
,	9	O
5	9	O
to	5	O
20	9	O
micrograms	0	O
/	9	O
kg	0	O
,	9	O
was	9	O
inhibited	3	O
or	5	O
reversed	9	O
by	9	O
nalozone	_	B-Chemical
,	9	O
0	7	O
.	9	O
2	9	O
to	5	O
2	9	O
mg	0	O
/	9	O
kg	0	O
.	9	O

The	5	O
hypotensive	5	B-Disease
effect	9	O
of	5	O
100	0	O
mg	0	O
/	9	O
kg	0	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
was	9	O
also	9	O
partially	9	O
reversed	9	O
by	9	O
naloxone	0	B-Chemical
.	9	O

Naloxone	0	B-Chemical
alone	9	O
did	9	O
not	5	O
affect	9	O
either	9	O
blood	9	O
pressure	5	O
or	5	O
heart	5	O
rate	9	O
.	9	O

In	9	O
brain	5	O
membranes	0	O
from	9	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
clonidine	0	B-Chemical
,	9	O
10	9	O
(	9	O
-	7	O
8	9	O
)	9	O
to	5	O
10	9	O
(	9	O
-	7	O
5	9	O
)	9	O
M	9	O
,	9	O
did	9	O
not	5	O
influence	5	O
stereoselective	0	O
binding	1	O
of	5	O
[	9	B-Chemical
3H	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
naloxone	0	I-Chemical
(	9	O
8	9	O
nM	0	O
)	9	O
,	9	O
and	5	O
naloxone	0	B-Chemical
,	9	O
10	9	O
(	9	O
-	7	O
8	9	O
)	9	O
to	5	O
10	9	O
(	9	O
-	7	O
4	9	O
)	9	O
M	9	O
,	9	O
did	9	O
not	5	O
influence	5	O
clonidine	0	B-Chemical
-	7	O
suppressible	3	O
binding	1	O
of	5	O
[	9	B-Chemical
3H	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
dihydroergocryptine	9	I-Chemical
(	9	O
1	9	O
nM	0	O
)	9	O
.	9	O

These	5	O
findings	9	O
indicate	9	O
that	5	O
in	5	O
spontaneously	5	O
hypertensive	5	B-Disease
rats	9	O
the	5	O
effects	9	O
of	5	O
central	5	O
alpha	9	O
-	7	O
adrenoceptor	5	O
stimulation	3	O
involve	5	O
activation	3	O
of	5	O
opiate	5	O
receptors	3	O
.	9	O

As	9	O
naloxone	0	B-Chemical
and	5	O
clonidine	0	B-Chemical
do	5	O
not	5	O
appear	9	O
to	5	O
interact	9	O
with	5	O
the	5	O
same	9	O
receptor	3	O
site	9	O
,	9	O
the	5	O
observed	9	O
functional	9	O
antagonism	9	O
suggests	9	O
the	5	O
release	9	O
of	5	O
an	5	O
endogenous	3	O
opiate	5	O
by	9	O
clonidine	0	B-Chemical
or	5	O
alpha	9	B-Chemical
-	7	I-Chemical
methyldopa	0	I-Chemical
and	5	O
the	5	O
possible	5	O
role	9	O
of	5	O
the	5	O
opiate	5	O
in	5	O
the	5	O
central	5	O
control	9	O
of	5	O
sympathetic	5	O
tone	5	O
.	9	O

Neurotoxicity	0	B-Disease
of	5	O
halogenated	0	B-Chemical
hydroxyquinolines	_	I-Chemical
:	9	O
clinical	5	O
analysis	9	O
of	5	O
cases	5	O
reported	9	O
outside	5	O
Japan	2	O
.	9	O

An	5	O
analysis	9	O
is	5	O
presented	5	O
of	5	O
220	9	O
cases	5	O
of	5	O
possible	5	O
neurotoxic	9	B-Disease
reactions	9	O
to	5	O
halogenated	0	B-Chemical
hydroxyquinolines	_	I-Chemical
reported	9	O
from	9	O
outside	5	O
Japan	2	O
.	9	O

In	9	O
80	9	O
cases	5	O
insufficient	5	O
information	5	O
was	9	O
available	5	O
for	5	O
adequate	5	O
comment	5	O
and	5	O
in	5	O
29	7	O
a	5	O
relationship	5	O
to	5	O
the	5	O
administration	9	O
of	5	O
clioquinol	0	B-Chemical
could	9	O
be	5	O
excluded	9	O
.	9	O

Of	9	O
the	5	O
remainder	9	O
,	9	O
a	5	O
relationship	5	O
to	5	O
clioquinol	0	B-Chemical
was	9	O
considered	5	O
probable	9	O
in	5	O
42	7	O
and	5	O
possible	5	O
in	5	O
69	7	O
cases	5	O
.	9	O

In	9	O
six	9	O
of	5	O
the	5	O
probable	9	O
cases	5	O
the	5	O
neurological	5	B-Disease
disturbance	5	I-Disease
consisted	5	O
of	5	O
an	5	O
acute	9	O
reversible	9	O
encephalopathy	5	B-Disease
usually	5	O
related	9	O
to	5	O
the	5	O
ingestion	9	O
of	5	O
a	5	O
high	9	O
dose	9	O
of	5	O
clioquinol	0	B-Chemical
over	5	O
a	5	O
short	5	O
period	5	O
.	9	O

The	5	O
most	9	O
common	5	O
manifestation	5	O
,	9	O
observed	9	O
in	5	O
15	9	O
further	9	O
cases	5	O
,	9	O
was	9	O
isolated	9	O
optic	5	B-Disease
atrophy	5	I-Disease
.	9	O

This	5	O
was	9	O
most	9	O
frequently	5	O
found	9	O
in	5	O
children	5	O
,	9	O
many	5	O
of	5	O
whom	5	O
had	9	O
received	9	O
clioquinol	0	B-Chemical
as	5	O
treatment	9	O
for	5	O
acrodermatitis	4	B-Disease
enteropathica	4	I-Disease
.	9	O

In	9	O
the	5	O
remaining	9	O
cases	5	O
,	9	O
a	5	O
combination	9	O
of	5	O
myelopathy	5	B-Disease
,	9	O
visual	5	B-Disease
disturbance	5	I-Disease
,	9	O
and	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
was	9	O
the	5	O
most	9	O
common	5	O
manifestation	5	O
.	9	O

Isolated	9	O
myelopathy	5	B-Disease
or	5	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
,	9	O
or	5	O
these	5	O
manifestations	5	O
occurring	9	O
together	9	O
,	9	O
were	9	O
infrequent	5	O
.	9	O

The	5	O
onset	5	O
of	5	O
all	5	O
manifestations	5	O
(	9	O
except	9	O
toxic	0	O
encephalopathy	5	B-Disease
)	9	O
was	9	O
usually	5	O
subacute	5	O
,	9	O
with	5	O
subsequent	9	O
partial	9	O
recovery	9	O
.	9	O

Older	5	O
subjects	5	O
tended	5	O
to	5	O
display	9	O
more	5	O
side	5	O
effects	9	O
.	9	O

The	5	O
full	5	O
syndrome	5	O
of	5	O
subacute	5	O
myelo	3	B-Disease
-	7	I-Disease
optic	5	I-Disease
neuropathy	5	I-Disease
was	9	O
more	5	O
frequent	5	O
in	5	O
women	5	O
,	9	O
but	9	O
they	5	O
tended	5	O
to	5	O
have	5	O
taken	5	O
greater	5	O
quantities	9	O
of	5	O
the	5	O
drug	5	O
.	9	O

Prazosin	0	B-Chemical
-	7	O
induced	3	O
stress	9	B-Disease
incontinence	5	I-Disease
.	9	O

A	9	O
case	5	O
of	5	O
genuine	5	O
stress	9	B-Disease
incontinence	5	I-Disease
due	5	O
to	5	O
prazosin	0	B-Chemical
,	9	O
a	5	O
common	5	O
antihypertensive	5	O
drug	5	O
,	9	O
is	5	O
presented	5	O
.	9	O

Prazosin	0	B-Chemical
exerts	9	O
its	9	O
antihypertensive	5	O
effects	9	O
through	9	O
vasodilatation	5	O
caused	9	O
by	9	O
selective	9	O
blockade	3	O
of	5	O
postsynaptic	3	O
alpha	9	O
-	7	O
1	9	O
adrenergic	9	O
receptors	3	O
.	9	O

As	9	O
an	5	O
alpha	9	O
-	7	O
blocker	0	O
,	9	O
it	5	O
also	9	O
exerts	9	O
a	5	O
significant	9	O
relaxant	0	O
effect	9	O
on	5	O
the	5	O
bladder	9	O
neck	5	O
and	5	O
urethra	5	O
.	9	O

The	5	O
patient	5	O
'	9	O
s	9	O
clinical	5	O
course	5	O
is	5	O
described	9	O
and	5	O
correlated	9	O
with	5	O
initial	9	O
urodynamic	5	O
studies	9	O
while	9	O
on	5	O
prazosin	0	B-Chemical
and	5	O
subsequent	9	O
studies	9	O
while	9	O
taking	5	O
verapamil	0	B-Chemical
.	9	O

Her	5	O
incontinence	5	B-Disease
resolved	9	O
with	5	O
the	5	O
change	9	O
of	5	O
medication	5	O
.	9	O

The	5	O
restoration	5	O
of	5	O
continence	5	O
was	9	O
accompanied	9	O
by	9	O
a	5	O
substantial	9	O
rise	9	O
in	5	O
maximum	5	O
urethral	5	O
pressure	5	O
,	9	O
maximum	5	O
urethral	5	O
closure	5	O
pressure	5	O
,	9	O
and	5	O
functional	9	O
urethral	5	O
length	9	O
.	9	O

Patients	5	O
who	5	O
present	9	O
with	5	O
stress	9	B-Disease
incontinence	5	I-Disease
while	9	O
taking	5	O
prazosin	0	B-Chemical
should	5	O
change	9	O
their	5	O
antihypertensive	5	O
medication	5	O
before	9	O
considering	5	O
surgery	5	O
,	9	O
because	5	O
their	5	O
incontinence	5	B-Disease
may	5	O
resolve	5	O
spontaneously	5	O
with	5	O
a	5	O
change	9	O
in	5	O
drug	5	O
therapy	5	O
.	9	O

Myocardial	9	B-Disease
infarction	5	I-Disease
following	9	O
sublingual	5	O
administration	9	O
of	5	O
isosorbide	0	B-Chemical
dinitrate	0	I-Chemical
.	9	O

A	9	O
78	7	O
-	7	O
year	5	O
-	7	O
old	5	O
with	5	O
healed	5	O
septal	5	O
necrosis	9	B-Disease
suffered	5	O
a	5	O
recurrent	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
of	5	O
the	5	O
anterior	5	O
wall	5	O
following	9	O
the	5	O
administration	9	O
of	5	O
isosorbide	0	B-Chemical
dinitrate	0	I-Chemical
5	9	O
mg	0	O
sublingually	0	O
.	9	O

After	9	O
detailing	5	O
the	5	O
course	5	O
of	5	O
events	5	O
,	9	O
we	5	O
discuss	5	O
the	5	O
role	9	O
of	5	O
paradoxical	5	O
coronary	5	O
spasm	5	B-Disease
and	5	O
hypotension	5	B-Disease
-	7	O
mediated	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
occurring	9	O
downstream	1	O
to	5	O
significant	9	O
coronary	5	B-Disease
arterial	5	I-Disease
stenosis	5	I-Disease
in	5	O
the	5	O
pathophysiology	9	O
of	5	O
acute	9	B-Disease
coronary	5	I-Disease
insufficiency	9	I-Disease
.	9	O

Comparison	9	O
of	5	O
the	5	O
respiratory	5	O
effects	9	O
of	5	O
i	9	O
.	9	O
v	0	O
.	9	O
infusions	9	O
of	5	O
morphine	0	B-Chemical
and	5	O
regional	5	O
analgesia	5	O
by	9	O
extradural	5	O
block	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
postoperative	5	O
respiratory	5	O
apnoea	5	B-Disease
was	9	O
compared	9	O
between	5	O
five	9	O
patients	5	O
receiving	9	O
a	5	O
continuous	5	O
i	9	O
.	9	O
v	0	O
.	9	O
infusion	0	O
of	5	O
morphine	0	B-Chemical
(	9	O
mean	5	O
73	7	O
.	9	O
6	9	O
mg	0	O
)	9	O
and	5	O
five	9	O
patients	5	O
receiving	9	O
a	5	O
continuous	5	O
extradural	5	O
infusion	0	O
of	5	O
0	7	O
.	9	O
25	9	O
%	9	O
bupivacaine	0	B-Chemical
(	9	O
mean	5	O
192	9	O
mg	0	O
)	9	O
in	5	O
the	5	O
24	9	O
-	7	O
h	0	O
period	5	O
following	9	O
upper	9	O
abdominal	5	O
surgery	5	O
.	9	O

Monitoring	5	O
consisted	5	O
of	5	O
airflow	5	O
detection	9	O
by	9	O
a	5	O
carbon	0	B-Chemical
dioxide	0	I-Chemical
analyser	0	O
,	9	O
chest	5	O
wall	5	O
movement	5	O
detected	9	O
by	9	O
pneumatic	5	O
capsules	0	O
,	9	O
and	5	O
continuous	5	O
electrocardiograph	5	O
recorded	5	O
with	5	O
a	5	O
Holter	5	O
ambulatory	5	O
monitor	5	O
.	9	O

Both	9	O
obstructive	5	B-Disease
(	9	I-Disease
P	9	I-Disease
less	5	I-Disease
than	5	I-Disease
0	7	I-Disease
.	9	I-Disease
05	7	I-Disease
)	9	I-Disease
and	5	I-Disease
central	5	I-Disease
apnoea	5	I-Disease
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
occurred	9	O
more	5	O
frequently	5	O
in	5	O
patients	5	O
who	5	O
had	9	O
a	5	O
morphine	0	B-Chemical
infusion	0	O
.	9	O

There	5	O
was	9	O
also	9	O
a	5	O
higher	9	O
incidence	5	O
of	5	O
tachyarrhythmias	5	B-Disease
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
ventricular	5	B-Disease
ectopic	3	I-Disease
beats	5	I-Disease
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
in	5	O
the	5	O
morphine	0	B-Chemical
infusion	0	O
group	9	O
.	9	O

Effects	9	O
of	5	O
aminophylline	0	B-Chemical
on	5	O
the	5	O
threshold	5	O
for	5	O
initiating	9	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
during	5	O
respiratory	5	B-Disease
failure	5	I-Disease
.	9	O

Cardiac	9	B-Disease
arrhythmias	5	I-Disease
have	5	O
frequently	5	O
been	9	O
reported	9	O
in	5	O
association	9	O
with	5	O
respiratory	5	B-Disease
failure	5	I-Disease
.	9	O

The	5	O
possible	5	O
additive	9	O
role	9	O
of	5	O
pharmacologic	9	O
agents	5	O
in	5	O
precipitating	9	O
cardiac	5	B-Disease
disturbances	5	I-Disease
in	5	O
patients	5	O
with	5	O
respiratory	5	B-Disease
failure	5	I-Disease
has	9	O
only	9	O
recently	9	O
been	9	O
emphasized	5	O
.	9	O

The	5	O
effects	9	O
of	5	O
aminophylline	0	B-Chemical
on	5	O
the	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
threshold	5	O
during	5	O
normal	9	O
acid	0	O
-	7	O
base	5	O
conditions	9	O
and	5	O
during	5	O
respiratory	5	B-Disease
failure	5	I-Disease
were	9	O
studied	9	O
in	5	O
anesthetized	0	O
open	5	O
chest	5	O
dogs	5	O
.	9	O

The	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
threshold	5	O
was	9	O
measured	9	O
by	9	O
passing	5	O
a	5	O
gated	3	O
train	5	O
of	5	O
12	9	O
constant	9	O
current	5	O
pulses	5	O
through	9	O
the	5	O
ventricular	5	O
myocardium	9	O
during	5	O
the	5	O
vulnerable	5	O
period	5	O
of	5	O
the	5	O
cardiac	5	O
cycle	9	O
.	9	O

During	5	O
the	5	O
infusion	0	O
of	5	O
aminophylline	0	B-Chemical
,	9	O
the	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
threshold	5	O
was	9	O
reduced	9	O
by	9	O
30	9	O
to	5	O
40	9	O
percent	5	O
of	5	O
the	5	O
control	9	O
when	5	O
pH	0	O
and	5	O
partial	9	O
pressures	5	O
of	5	O
oxygen	0	B-Chemical
(	9	O
PO2	0	B-Chemical
)	9	O
and	5	O
carbon	0	B-Chemical
dioxide	0	I-Chemical
(	9	O
CO2	0	B-Chemical
)	9	O
were	9	O
kept	9	O
within	9	O
normal	9	O
limits	5	O
.	9	O

When	9	O
respiratory	5	B-Disease
failure	5	I-Disease
was	9	O
produced	9	O
by	9	O
hypoventilation	5	B-Disease
(	9	O
pH	0	O
7	9	O
.	9	O
05	7	O
to	5	O
7	9	O
.	9	O
25	9	O
;	9	O
PC02	0	O
70	9	O
to	5	O
100	0	O
mm	9	O
Hg	0	O
:	9	O
P02	9	O
20	9	O
to	5	O
40	9	O
mm	9	O
Hg	0	O
)	9	O
,	9	O
infusion	0	O
of	5	O
aminophylline	0	B-Chemical
resulted	9	O
in	5	O
an	5	O
even	5	O
greater	5	O
decrease	9	O
in	5	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
threshold	5	O
to	5	O
60	9	O
percent	5	O
of	5	O
the	5	O
control	9	O
level	9	O
.	9	O

These	5	O
experiments	9	O
suggest	9	O
that	5	O
although	9	O
many	5	O
factors	9	O
may	5	O
contribute	9	O
to	5	O
the	5	O
increased	9	O
incidence	5	O
of	5	O
ventricular	5	B-Disease
arrhythmias	5	I-Disease
in	5	O
respiratory	5	B-Disease
failure	5	I-Disease
,	9	O
pharmacologic	9	O
agents	5	O
,	9	O
particularly	5	O
aminophylline	0	B-Chemical
,	9	O
may	5	O
play	9	O
a	5	O
significant	9	O
role	9	O
.	9	O

Pentoxifylline	0	B-Chemical
(	9	O
Trental	0	B-Chemical
)	9	O
does	9	O
not	5	O
inhibit	3	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
coronary	5	O
hyperemia	5	B-Disease
:	9	O
implications	5	O
for	5	O
dipyridamole	0	B-Chemical
-	7	O
thallium	0	B-Chemical
-	7	O
201	7	O
myocardial	9	O
imaging	5	O
.	9	O

Dipyridamole	0	B-Chemical
-	7	O
thallium	0	B-Chemical
-	7	O
201	7	O
imaging	5	O
is	5	O
often	5	O
performed	9	O
in	5	O
patients	5	O
unable	9	O
to	5	O
exercise	5	O
because	5	O
of	5	O
peripheral	9	B-Disease
vascular	5	I-Disease
disease	5	I-Disease
.	9	O

Many	5	O
of	5	O
these	5	O
patients	5	O
are	5	O
taking	5	O
pentoxifylline	0	B-Chemical
(	9	O
Trental	0	B-Chemical
)	9	O
,	9	O
a	5	O
methylxanthine	0	B-Chemical
derivative	0	O
which	5	O
may	5	O
improve	5	O
intermittent	5	B-Disease
claudication	5	I-Disease
.	9	O

Whether	9	O
pentoxifylline	0	B-Chemical
inhibits	3	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
coronary	5	O
hyperemia	5	B-Disease
like	9	O
other	5	O
methylxanthines	0	B-Chemical
such	5	O
as	5	O
theophylline	0	B-Chemical
and	5	O
should	5	O
be	5	O
stopped	9	O
prior	9	O
to	5	O
dipyridamole	0	B-Chemical
-	7	O
thallium	0	B-Chemical
-	7	O
201	7	O
imaging	5	O
is	5	O
unknown	9	O
.	9	O

Therefore	9	O
,	9	O
we	5	O
studied	9	O
the	5	O
hyperemic	5	O
response	9	O
to	5	O
dipyridamole	0	B-Chemical
in	5	O
seven	9	O
open	5	O
-	7	O
chest	5	O
anesthetized	0	O
dogs	5	O
after	9	O
pretreatment	0	O
with	5	O
either	9	O
pentoxifylline	0	B-Chemical
(	9	O
0	7	O
,	9	O
7	9	O
.	9	O
5	9	O
,	9	O
or	5	O
15	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
or	5	O
theophylline	0	B-Chemical
(	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
.	9	O

Baseline	9	O
circumflex	5	O
coronary	5	O
blood	9	O
flows	5	O
did	9	O
not	5	O
differ	9	O
significantly	9	O
among	5	O
treatment	9	O
groups	9	O
.	9	O

Dipyridamole	0	B-Chemical
significantly	9	O
increased	9	O
coronary	5	O
blood	9	O
flow	5	O
before	9	O
and	5	O
after	9	O
7	9	O
.	9	O
5	9	O
or	5	O
15	9	O
mm	9	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
pentoxifylline	0	B-Chemical
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

Neither	9	O
dose	9	O
of	5	O
pentoxifylline	0	B-Chemical
significantly	9	O
decreased	9	O
the	5	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
hyperemia	5	B-Disease
,	9	O
while	9	O
peak	9	O
coronary	5	O
blood	9	O
flow	5	O
was	9	O
significantly	9	O
lower	9	O
after	9	O
theophylline	0	B-Chemical
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
pentoxyifylline	_	B-Chemical
does	9	O
not	5	O
inhibit	3	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
coronary	5	O
hyperemia	5	B-Disease
even	5	O
at	9	O
high	9	O
doses	0	O
.	9	O

Cause	5	O
of	5	O
death	9	B-Disease
among	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
:	9	O
a	5	O
rare	5	O
mortality	5	O
due	5	O
to	5	O
cerebral	5	B-Disease
haemorrhage	5	I-Disease
.	9	O

Causes	5	O
of	5	O
death	9	B-Disease
,	9	O
with	5	O
special	5	O
reference	9	O
to	5	O
cerebral	5	B-Disease
haemorrhage	5	I-Disease
,	9	O
among	5	O
240	9	O
patients	5	O
with	5	O
pathologically	5	O
verified	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
were	9	O
investigated	9	O
using	9	O
the	5	O
Annuals	2	O
of	5	O
the	5	O
Pathological	9	O
Autopsy	5	O
Cases	9	O
in	5	O
Japan	2	O
from	9	O
1981	2	O
to	5	O
1985	2	O
.	9	O

The	5	O
leading	9	O
causes	9	O
of	5	O
death	9	B-Disease
were	9	O
pneumonia	5	B-Disease
and	5	O
bronchitis	5	B-Disease
(	9	O
44	7	O
.	9	O
1	9	O
%	9	O
)	9	O
,	9	O
malignant	3	O
neoplasms	5	B-Disease
(	9	O
11	7	O
.	9	O
6	9	O
%	9	O
)	9	O
,	9	O
heart	5	B-Disease
diseases	5	I-Disease
(	9	O
4	9	O
.	9	O
1	9	O
%	9	O
)	9	O
,	9	O
cerebral	5	B-Disease
infarction	5	I-Disease
(	9	O
3	9	O
.	9	O
7	9	O
%	9	O
)	9	O
and	5	O
septicaemia	5	B-Disease
(	9	O
3	9	O
.	9	O
3	9	O
%	9	O
)	9	O
.	9	O

Cerebral	5	B-Disease
haemorrhage	5	I-Disease
was	9	O
the	5	O
11th	9	O
most	9	O
frequent	5	O
cause	5	O
of	5	O
death	9	B-Disease
,	9	O
accounting	5	O
for	5	O
only	9	O
0	7	O
.	9	O
8	9	O
%	9	O
of	5	O
deaths	5	B-Disease
among	5	O
the	5	O
patients	5	O
,	9	O
whereas	9	O
it	5	O
was	9	O
the	5	O
5th	9	O
most	9	O
common	5	O
cause	5	O
of	5	O
death	9	B-Disease
among	5	O
the	5	O
Japanese	9	O
general	5	O
population	5	O
in	5	O
1985	2	O
.	9	O

The	5	O
low	9	O
incidence	5	O
of	5	O
cerebral	5	B-Disease
haemorrhage	5	I-Disease
as	5	O
a	5	O
cause	5	O
of	5	O
death	9	B-Disease
in	5	O
patients	5	O
with	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
may	5	O
reflect	5	O
the	5	O
hypotensive	5	B-Disease
effect	9	O
of	5	O
levodopa	5	B-Chemical
and	5	O
a	5	O
hypotensive	5	B-Disease
mechanism	9	O
due	5	O
to	5	O
reduced	9	O
noradrenaline	0	B-Chemical
levels	3	O
in	5	O
the	5	O
parkinsonian	5	B-Disease
brain	5	O
.	9	O

Possible	9	O
intramuscular	9	O
midazolam	0	B-Chemical
-	7	O
associated	9	O
cardiorespiratory	5	B-Disease
arrest	3	I-Disease
and	5	O
death	9	B-Disease
.	9	O

Midazolam	0	B-Chemical
hydrochloride	0	I-Chemical
is	5	O
commonly	5	O
used	5	O
for	5	O
dental	5	O
or	5	O
endoscopic	5	O
procedures	5	O
.	9	O

Although	9	O
generally	5	O
consisted	5	O
safe	5	O
when	5	O
given	5	O
intramuscularly	0	O
,	9	O
intravenous	0	O
administration	9	O
is	5	O
known	9	O
to	5	O
cause	5	O
respiratory	5	B-Disease
and	5	I-Disease
cardiovascular	5	I-Disease
depression	5	I-Disease
.	9	O

This	5	O
report	5	O
describes	5	O
the	5	O
first	9	O
published	9	O
case	5	O
of	5	O
cardiorespiratory	5	B-Disease
arrest	3	I-Disease
and	5	O
death	9	B-Disease
associated	9	O
with	5	O
intramuscular	9	O
administration	9	O
of	5	O
midazolam	0	B-Chemical
.	9	O

Information	5	O
regarding	5	O
midazolam	0	B-Chemical
use	5	O
is	5	O
reviewed	9	O
to	5	O
provide	5	O
recommendation	5	O
for	5	O
safe	5	O
administration	9	O
.	9	O

Myasthenia	2	B-Disease
gravis	2	I-Disease
presenting	5	O
as	5	O
weakness	5	O
after	9	O
magnesium	0	B-Chemical
administration	9	O
.	9	O

We	9	O
studied	9	O
a	5	O
patient	5	O
with	5	O
no	9	O
prior	9	O
history	5	O
of	5	O
neuromuscular	5	B-Disease
disease	5	I-Disease
who	5	O
became	9	O
virtually	9	O
quadriplegic	5	B-Disease
after	9	O
parenteral	5	O
magnesium	0	B-Chemical
administration	9	O
for	5	O
preeclampsia	5	B-Disease
.	9	O

The	5	O
serum	9	O
magnesium	0	B-Chemical
concentration	0	O
was	9	O
3	9	O
.	9	O
0	7	O
mEq	0	O
/	9	O
L	0	O
,	9	O
which	5	O
is	5	O
usually	5	O
well	9	O
tolerated	9	O
.	9	O

The	5	O
magnesium	0	B-Chemical
was	9	O
stopped	9	O
and	5	O
she	5	O
recovered	9	O
over	5	O
a	5	O
few	5	O
days	9	O
.	9	O

While	9	O
she	5	O
was	9	O
weak	9	O
,	9	O
2	9	O
-	7	O
Hz	5	O
repetitive	5	O
stimulation	3	O
revealed	9	O
a	5	O
decrement	5	O
without	9	O
significant	9	O
facilitation	5	O
at	9	O
rapid	5	O
rates	5	O
or	5	O
after	9	O
exercise	5	O
,	9	O
suggesting	9	O
postsynaptic	3	B-Disease
neuromuscular	5	I-Disease
blockade	3	I-Disease
.	9	O

After	9	O
her	5	O
strength	5	O
returned	5	O
,	9	O
repetitive	5	O
stimulation	3	O
was	9	O
normal	9	O
,	9	O
but	9	O
single	9	O
fiber	5	O
EMG	5	O
revealed	9	O
increased	9	O
jitter	5	O
and	5	O
blocking	3	O
.	9	O

Her	5	O
acetylcholine	0	B-Chemical
receptor	3	O
antibody	3	O
level	9	O
was	9	O
markedly	9	O
elevated	9	O
.	9	O

Although	9	O
paralysis	5	B-Disease
after	9	O
magnesium	0	B-Chemical
administration	9	O
has	9	O
been	9	O
described	9	O
in	5	O
patients	5	O
with	5	O
known	9	O
myasthenia	9	B-Disease
gravis	2	I-Disease
,	9	O
it	5	O
has	9	O
not	5	O
previously	9	O
been	9	O
reported	9	O
to	5	O
be	5	O
the	5	O
initial	9	O
or	5	O
only	9	O
manifestation	5	O
of	5	O
the	5	O
disease	5	O
.	9	O

Patients	5	O
who	5	O
are	5	O
unusually	9	O
sensitive	9	O
to	5	O
the	5	O
neuromuscular	5	O
effects	9	O
of	5	O
magnesium	0	B-Chemical
should	5	O
be	5	O
suspected	5	O
of	5	O
having	5	O
an	5	O
underlying	5	O
disorder	5	B-Disease
of	5	I-Disease
neuromuscular	5	I-Disease
transmission	5	I-Disease
.	9	O

No	9	O
enhancement	9	O
by	9	O
phenobarbital	0	B-Chemical
of	5	O
the	5	O
hepatocarcinogenicity	0	O
of	5	O
a	5	O
choline	0	B-Chemical
-	7	O
devoid	9	O
diet	9	O
in	5	O
the	5	O
rat	3	O
.	9	O

An	5	O
experiment	9	O
was	9	O
performed	9	O
to	5	O
test	5	O
whether	9	O
inclusion	5	O
of	5	O
phenobarbital	0	B-Chemical
in	5	O
a	5	O
choline	0	B-Chemical
-	7	O
devoid	9	O
diet	9	O
would	5	O
increase	9	O
the	5	O
hepatocarcinogenicity	0	O
of	5	O
the	5	O
diet	9	O
.	9	O

Groups	9	O
of	5	O
5	9	O
-	7	O
week	9	O
old	5	O
male	9	O
Fischer	6	O
-	7	O
344	7	O
rats	9	O
were	9	O
fed	9	O
for	5	O
7	9	O
-	7	O
25	9	O
months	5	O
semipurified	0	O
choline	0	B-Chemical
-	7	O
devoid	9	O
or	5	O
choline	0	B-Chemical
-	7	O
supplemented	0	O
diets	9	O
,	9	O
containing	0	O
or	5	O
not	5	O
0	7	O
.	9	O
06	7	O
%	9	O
phenobarbital	0	B-Chemical
.	9	O

No	9	O
hepatic	9	O
preneoplastic	3	O
nodules	9	O
or	5	O
hepatocellular	9	B-Disease
carcinomas	3	I-Disease
developed	5	O
in	5	O
rats	9	O
fed	9	O
the	5	O
plain	5	O
choline	0	B-Chemical
-	7	O
supplemented	0	O
diet	9	O
,	9	O
while	9	O
one	5	O
preneoplastic	3	O
nodule	5	O
and	5	O
one	5	O
hepatocellular	9	B-Disease
carcinoma	3	I-Disease
developed	5	O
in	5	O
two	5	O
rats	9	O
fed	9	O
the	5	O
same	9	O
diet	9	O
containing	0	O
phenobarbital	0	B-Chemical
.	9	O

The	5	O
incidence	5	O
of	5	O
preneoplastic	3	O
nodules	9	O
and	5	O
of	5	O
hepatocellular	9	B-Disease
carcinomas	3	I-Disease
was	9	O
10	9	O
%	9	O
and	5	O
37	9	O
%	9	O
,	9	O
respectively	9	O
,	9	O
in	5	O
rats	9	O
fed	9	O
the	5	O
plain	5	O
choline	0	B-Chemical
-	7	O
devoid	9	O
diet	9	O
,	9	O
and	5	O
17	7	O
%	9	O
and	5	O
30	9	O
%	9	O
,	9	O
in	5	O
rats	9	O
fed	9	O
the	5	O
phenobarbital	0	B-Chemical
-	7	O
containing	0	O
choline	0	B-Chemical
-	7	O
devoid	9	O
diet	9	O
.	9	O

The	5	O
results	9	O
evinced	5	O
no	9	O
enhancement	9	O
of	5	O
the	5	O
hepatocarcinogenicity	0	O
of	5	O
the	5	O
choline	0	B-Chemical
-	7	O
devoid	9	O
diet	9	O
by	9	O
phenobarbital	0	B-Chemical
.	9	O

Sporadic	9	O
neoplastic	3	O
lesions	5	O
were	9	O
observed	9	O
in	5	O
organs	9	O
other	5	O
than	5	O
the	5	O
liver	9	O
of	5	O
some	5	O
of	5	O
the	5	O
animals	9	O
,	9	O
irrespective	9	O
of	5	O
the	5	O
diet	9	O
fed	9	O
.	9	O

On	5	O
two	5	O
paradoxical	5	O
side	5	O
-	7	O
effects	9	O
of	5	O
prednisolone	0	B-Chemical
in	5	O
rats	9	O
,	9	O
ribosomal	1	O
RNA	9	O
biosyntheses	0	O
,	9	O
and	5	O
a	5	O
mechanism	9	O
of	5	O
action	5	O
.	9	O

Liver	9	B-Disease
enlargement	5	I-Disease
and	5	O
muscle	9	B-Disease
wastage	5	I-Disease
occurred	9	O
in	5	O
Wistar	9	O
rats	9	O
following	9	O
the	5	O
subcutaneous	9	O
administration	9	O
of	5	O
prednisolone	0	B-Chemical
.	9	O

In	9	O
the	5	O
liver	9	O
both	9	O
the	5	O
content	9	O
of	5	O
RNA	9	O
and	5	O
the	5	O
biosynthesis	0	O
of	5	O
ribosomal	1	O
RNA	9	O
increased	9	O
while	9	O
both	9	O
the	5	O
RNA	9	O
content	9	O
and	5	O
ribosomal	1	O
RNA	9	O
biosynthesis	0	O
were	9	O
reduced	9	O
in	5	O
the	5	O
gastrocnemius	9	O
muscle	9	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
the	5	O
drug	5	O
acted	9	O
in	5	O
a	5	O
selective	9	O
and	5	O
tissue	9	O
-	7	O
specific	9	O
manner	9	O
to	5	O
enhance	9	O
ribosomal	1	O
RNA	9	O
synthesis	9	O
in	5	O
the	5	O
liver	9	O
and	5	O
depress	5	O
such	5	O
synthesis	9	O
in	5	O
the	5	O
muscle	9	O
.	9	O

This	5	O
view	5	O
supports	9	O
the	5	O
contention	9	O
that	5	O
the	5	O
liver	9	O
and	5	O
muscle	9	O
are	5	O
independent	9	O
sites	9	O
of	5	O
prednisolone	0	B-Chemical
action	5	O
.	9	O

Differential	9	O
effects	9	O
of	5	O
gamma	9	B-Chemical
-	7	I-Chemical
hexachlorocyclohexane	0	I-Chemical
(	9	O
lindane	0	B-Chemical
)	9	O
on	5	O
pharmacologically	9	O
-	7	O
induced	3	O
seizures	5	B-Disease
.	9	O

Gamma	9	B-Chemical
-	7	I-Chemical
hexachlorocyclohexane	0	I-Chemical
(	9	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
)	9	O
,	9	O
the	5	O
active	9	O
ingredient	0	O
of	5	O
the	5	O
insecticide	5	O
lindane	0	B-Chemical
,	9	O
has	9	O
been	9	O
shown	9	O
to	5	O
decrease	9	O
seizure	5	B-Disease
threshold	5	O
to	5	O
pentylenetrazol	_	O
(	9	O
PTZ	0	B-Chemical
)	9	O
3	9	O
h	0	O
after	9	O
exposure	9	O
to	5	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
and	5	O
conversely	9	O
increase	9	O
threshold	5	O
to	5	O
PTZ	0	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
24	9	O
h	0	O
after	9	O
exposure	9	O
to	5	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
(	9	O
Vohland	_	O
et	6	O
al	6	O
.	9	O
1981	2	O
)	9	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
the	5	O
severity	5	O
of	5	O
response	9	O
to	5	O
other	5	O
seizure	5	B-Disease
-	7	O
inducing	3	O
agents	5	O
was	9	O
tested	9	O
in	5	O
mice	3	O
1	9	O
and	5	O
24	9	O
h	0	O
after	9	O
intraperitoneal	0	O
administration	9	O
of	5	O
80	9	O
mg	0	O
/	9	O
kg	0	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
.	9	O

One	5	O
hour	0	O
after	9	O
the	5	O
administration	9	O
of	5	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
,	9	O
the	5	O
activity	9	O
of	5	O
seizure	5	B-Disease
-	7	O
inducing	3	O
agents	5	O
was	9	O
increased	9	O
,	9	O
regardless	9	O
of	5	O
their	5	O
mechanism	9	O
,	9	O
while	9	O
24	9	O
h	0	O
after	9	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
a	5	O
differential	9	O
response	9	O
was	9	O
observed	9	O
.	9	O

Seizure	5	B-Disease
activity	9	O
due	5	O
to	5	O
PTZ	0	B-Chemical
and	5	O
picrotoxin	0	B-Chemical
(	9	O
PTX	3	B-Chemical
)	9	O
was	9	O
significantly	9	O
decreased	9	O
;	9	O
however	9	O
,	9	O
seizure	5	B-Disease
activity	9	O
due	5	O
to	5	O
3	9	B-Chemical
-	7	I-Chemical
mercaptopropionic	0	I-Chemical
acid	0	I-Chemical
(	9	O
MPA	9	B-Chemical
)	9	O
,	9	O
bicuculline	0	B-Chemical
(	9	O
BCC	9	B-Chemical
)	9	O
,	9	O
methyl	0	B-Chemical
6	9	I-Chemical
,	9	I-Chemical
7	9	I-Chemical
-	7	I-Chemical
dimethoxy	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
ethyl	0	I-Chemical
-	7	I-Chemical
B	9	I-Chemical
-	7	I-Chemical
carboline	0	I-Chemical
-	7	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
carboxylate	0	I-Chemical
(	9	O
DMCM	0	B-Chemical
)	9	O
,	9	O
or	5	O
strychnine	0	B-Chemical
(	9	O
STR	9	B-Chemical
)	9	O
was	9	O
not	5	O
different	9	O
from	9	O
control	9	O
.	9	O

In	9	O
vitro	3	O
,	9	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
,	9	O
pentylenetetrazol	0	B-Chemical
and	5	O
picrotoxin	0	B-Chemical
were	9	O
shown	9	O
to	5	O
inhibit	3	O
3H	0	B-Chemical
-	7	I-Chemical
TBOB	_	I-Chemical
binding	1	O
in	5	O
mouse	3	O
whole	9	O
brain	5	O
,	9	O
with	5	O
IC50	0	O
values	5	O
of	5	O
4	9	O
.	9	O
6	9	O
,	9	O
404	7	O
and	5	O
9	7	O
.	9	O
4	9	O
microM	0	O
,	9	O
respectively	9	O
.	9	O

MPA	9	B-Chemical
,	9	O
BCC	9	B-Chemical
,	9	O
DMCM	0	B-Chemical
,	9	O
and	5	O
STR	9	B-Chemical
showed	9	O
no	9	O
inhibition	3	O
of	5	O
3H	0	B-Chemical
-	7	I-Chemical
TBOB	_	I-Chemical
(	9	O
t	5	B-Chemical
-	7	I-Chemical
butyl	0	I-Chemical
bicyclo	0	I-Chemical
-	7	I-Chemical
orthobenzoate	0	I-Chemical
)	9	O
binding	1	O
at	9	O
concentrations	0	O
of	5	O
100	0	O
micron	0	O
.	9	O

The	5	O
pharmacological	9	O
challenge	9	O
data	5	O
suggest	9	O
that	5	O
tolerance	9	O
may	5	O
occur	5	O
to	5	O
seizure	5	B-Disease
activity	9	O
induced	3	O
by	9	O
PTZ	0	B-Chemical
and	5	O
PTX	3	B-Chemical
24	9	O
h	0	O
after	9	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
,	9	O
since	9	O
the	5	O
response	9	O
to	5	O
only	9	O
these	5	O
two	5	O
seizure	5	B-Disease
-	7	O
inducing	3	O
agents	5	O
is	5	O
decreased	9	O
.	9	O

The	5	O
in	5	O
vitro	3	O
data	5	O
suggest	9	O
that	5	O
the	5	O
site	9	O
responsible	9	O
for	5	O
the	5	O
decrease	9	O
in	5	O
seizure	5	B-Disease
activity	9	O
24	9	O
h	0	O
after	9	O
gamma	9	B-Chemical
-	7	I-Chemical
HCH	0	I-Chemical
may	5	O
be	5	O
the	5	O
GABA	0	B-Chemical
-	7	O
A	9	O
receptor	3	O
-	7	O
linked	9	O
chloride	0	O
channel	9	O
.	9	O

Tolerance	9	O
and	5	O
antiviral	9	O
effect	9	O
of	5	O
ribavirin	9	B-Chemical
in	5	O
patients	5	O
with	5	O
Argentine	4	B-Disease
hemorrhagic	5	I-Disease
fever	5	I-Disease
.	9	O

Tolerance	9	O
and	5	O
antiviral	9	O
effect	9	O
of	5	O
ribavirin	9	B-Chemical
was	9	O
studied	9	O
in	5	O
6	9	O
patients	5	O
with	5	O
Argentine	4	B-Disease
hemorrhagic	5	I-Disease
fever	5	I-Disease
(	9	O
AHF	9	B-Disease
)	9	O
of	5	O
more	5	O
than	5	O
8	9	O
days	9	O
of	5	O
evolution	5	O
.	9	O

Administration	2	O
of	5	O
ribavirin	9	B-Chemical
resulted	9	O
in	5	O
a	5	O
neutralization	3	O
of	5	O
viremia	9	B-Disease
and	5	O
a	5	O
drop	9	O
of	5	O
endogenous	3	O
interferon	3	O
titers	9	O
.	9	O

The	5	O
average	5	O
time	5	O
of	5	O
death	9	B-Disease
was	9	O
delayed	9	O
.	9	O

A	9	O
reversible	9	O
anemia	9	B-Disease
was	9	O
the	5	O
only	9	O
adverse	5	O
effect	9	O
observed	9	O
.	9	O

From	5	O
these	5	O
results	9	O
,	9	O
we	5	O
conclude	9	O
that	5	O
ribavirin	9	B-Chemical
has	9	O
an	5	O
antiviral	9	O
effect	9	O
in	5	O
advanced	5	O
cases	5	O
of	5	O
AHF	9	B-Disease
,	9	O
and	5	O
that	5	O
anemia	9	B-Disease
,	9	O
the	5	O
only	9	O
secondary	9	O
reaction	9	O
observed	9	O
,	9	O
can	5	O
be	5	O
easily	5	O
managed	5	O
.	9	O

The	5	O
possible	5	O
beneficial	9	O
effect	9	O
of	5	O
ribavirin	9	B-Chemical
during	5	O
the	5	O
initial	9	O
days	9	O
of	5	O
AHF	9	B-Disease
is	5	O
discussed	5	O
.	9	O

Is	9	O
the	5	O
treatment	9	O
of	5	O
scabies	5	B-Disease
hazardous	5	O
?	5	O

Treatment	9	O
for	5	O
scabies	5	B-Disease
is	5	O
usually	5	O
initiated	9	O
by	9	O
general	5	O
practitioners	5	O
;	9	O
most	9	O
consider	5	O
lindane	0	B-Chemical
(	9	O
gamma	9	B-Chemical
benzene	0	I-Chemical
hexachloride	0	I-Chemical
)	9	O
the	5	O
treatment	9	O
of	5	O
choice	5	O
.	9	O

Lindane	0	B-Chemical
is	5	O
also	9	O
widely	5	O
used	5	O
as	5	O
an	5	O
agricultural	5	O
and	5	O
industrial	5	O
pesticide	5	O
,	9	O
and	5	O
as	5	O
a	5	O
result	9	O
the	5	O
toxic	0	O
profile	9	O
of	5	O
this	5	O
insecticide	5	O
is	5	O
well	9	O
understood	5	O
.	9	O

Evidence	9	O
is	5	O
accumulating	9	O
that	5	O
lindane	0	B-Chemical
can	5	O
be	5	O
toxic	0	B-Disease
to	5	I-Disease
the	5	I-Disease
central	5	I-Disease
nervous	5	I-Disease
system	5	I-Disease
and	5	O
may	5	O
be	5	O
associated	9	O
with	5	O
aplastic	5	B-Disease
anaemia	5	I-Disease
.	9	O

Preparations	0	O
containing	0	O
lindane	0	B-Chemical
continue	5	O
to	5	O
be	5	O
sold	5	O
over	5	O
the	5	O
counter	5	O
and	5	O
may	5	O
represent	9	O
a	5	O
hazard	5	O
to	5	O
poorly	9	O
informed	5	O
patients	5	O
.	9	O

This	5	O
literature	5	O
review	5	O
suggests	9	O
that	5	O
general	5	O
practitioners	5	O
should	5	O
prescribe	5	O
scabicides	9	O
with	5	O
increased	9	O
caution	5	O
for	5	O
certain	5	O
at	9	O
-	7	O
risk	5	O
groups	9	O
,	9	O
and	5	O
give	5	O
adequate	5	O
warnings	5	O
regarding	5	O
potential	9	O
toxicity	9	B-Disease
.	9	O

Mouse	3	O
strain	1	O
-	7	O
dependent	9	O
effect	9	O
of	5	O
amantadine	0	B-Chemical
on	5	O
motility	9	O
and	5	O
brain	5	O
biogenic	0	O
amines	0	B-Chemical
.	9	O

The	5	O
effect	9	O
of	5	O
amantadine	0	B-Chemical
hydrochloride	0	I-Chemical
,	9	O
injected	3	O
i	9	O
.	9	O
p	7	O
.	9	O
in	5	O
6	9	O
increments	9	O
of	5	O
100	0	O
mg	0	O
/	9	O
kg	0	O
each	5	O
over	5	O
30	9	O
hr	0	O
,	9	O
on	5	O
mouse	3	O
motility	9	O
and	5	O
whole	9	O
brain	5	O
content	9	O
of	5	O
selected	9	O
biogenic	0	O
amines	0	B-Chemical
and	5	O
major	9	O
metabolites	0	O
was	9	O
studied	9	O
in	5	O
4	9	O
strains	1	O
of	5	O
mice	3	O
.	9	O

These	5	O
were	9	O
the	5	O
albino	3	O
Sprague	9	O
-	7	O
Dawley	0	O
ICR	9	O
and	5	O
BALB	3	O
/	9	O
C	9	O
,	9	O
the	5	O
black	9	O
C57BL	3	O
/	9	O
6	9	O
and	5	O
the	5	O
brown	4	O
CDF	5	O
-	7	O
I	9	O
mouse	3	O
strains	1	O
.	9	O

Amantadine	0	B-Chemical
treatment	9	O
produced	9	O
a	5	O
biphasic	9	O
effect	9	O
on	5	O
mouse	3	O
motility	9	O
.	9	O

The	5	O
initial	9	O
dose	9	O
of	5	O
amantadine	0	B-Chemical
depressed	5	B-Disease
locomotor	5	O
activity	9	O
in	5	O
all	5	O
mouse	3	O
strains	1	O
studied	9	O
with	5	O
the	5	O
BALB	3	O
/	9	O
C	9	O
mice	3	O
being	5	O
the	5	O
most	9	O
sensitive	9	O
.	9	O

Subsequent	9	O
amantadine	0	B-Chemical
treatments	9	O
produced	9	O
enhancement	9	O
of	5	O
motility	9	O
from	9	O
corresponding	9	O
control	9	O
in	5	O
all	5	O
mouse	3	O
strains	1	O
with	5	O
the	5	O
BALB	3	O
/	9	O
C	9	O
mice	3	O
being	5	O
the	5	O
least	9	O
sensitive	9	O
.	9	O

The	5	O
locomotor	5	O
activity	9	O
was	9	O
decreased	9	O
from	9	O
corresponding	9	O
controls	9	O
in	5	O
all	5	O
strains	1	O
studied	9	O
,	9	O
except	9	O
for	5	O
the	5	O
ICR	9	O
mice	3	O
,	9	O
during	5	O
an	5	O
overnight	0	O
drug	5	O
-	7	O
free	9	O
period	5	O
following	9	O
the	5	O
fourth	9	O
amantadine	0	B-Chemical
treatment	9	O
.	9	O

Readministration	9	O
of	5	O
amantadine	0	B-Chemical
,	9	O
after	9	O
a	5	O
drug	5	O
-	7	O
free	9	O
overnight	0	O
period	5	O
,	9	O
increased	9	O
motility	9	O
from	9	O
respective	9	O
saline	0	O
control	9	O
in	5	O
all	5	O
strains	1	O
with	5	O
exception	9	O
of	5	O
the	5	O
BALB	3	O
/	9	O
C	9	O
mice	3	O
where	5	O
suppression	9	B-Disease
of	5	I-Disease
motility	9	I-Disease
occurred	9	O
.	9	O

Treatment	9	O
with	5	O
amantadine	0	B-Chemical
did	9	O
not	5	O
alter	9	O
whole	9	O
brain	5	O
dopamine	5	B-Chemical
levels	3	O
but	9	O
decreased	9	O
the	5	O
amounts	9	O
of	5	O
3	9	B-Chemical
,	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
dihydroxyphenylacetic	0	I-Chemical
acid	0	I-Chemical
in	5	O
the	5	O
BALB	3	O
/	9	O
C	9	O
mice	3	O
compared	9	O
to	5	O
saline	0	O
control	9	O
.	9	O

Conversely	9	O
,	9	O
brain	5	O
normetanephrine	0	B-Chemical
concentration	0	O
was	9	O
increased	9	O
from	9	O
saline	0	O
control	9	O
by	9	O
amantadine	0	B-Chemical
in	5	O
the	5	O
BALB	3	O
/	9	O
C	9	O
mice	3	O
.	9	O

The	5	O
results	9	O
suggest	9	O
a	5	O
strain	1	O
-	7	O
dependent	9	O
effect	9	O
of	5	O
amantadine	0	B-Chemical
on	5	O
motility	9	O
and	5	O
indicate	9	O
a	5	O
differential	9	O
response	9	O
to	5	O
the	5	O
acute	9	O
and	5	O
multiple	5	O
dose	9	O
regimens	5	O
used	5	O
.	9	O

The	5	O
BALB	3	O
/	9	O
C	9	O
mouse	3	O
was	9	O
the	5	O
most	9	O
sensitive	9	O
strain	1	O
and	5	O
could	9	O
serve	5	O
as	5	O
the	5	O
strain	1	O
of	5	O
choice	5	O
for	5	O
evaluating	5	O
the	5	O
side	5	O
effects	9	O
of	5	O
amantadine	0	B-Chemical
.	9	O

The	5	O
biochemical	9	O
results	9	O
of	5	O
brain	5	O
biogenic	0	O
amines	0	B-Chemical
of	5	O
BALB	3	O
/	9	O
C	9	O
mouse	3	O
strain	1	O
suggest	9	O
a	5	O
probable	9	O
decrease	9	O
of	5	O
catecholamine	9	B-Chemical
turnover	9	O
rate	9	O
and	5	O
/	9	O
or	5	O
metabolism	9	O
by	9	O
monoamine	0	O
oxidase	0	O
and	5	O
a	5	O
resulting	9	O
increase	9	O
in	5	O
O	9	O
-	7	O
methylation	9	O
of	5	O
norepinephrine	9	B-Chemical
which	5	O
may	5	O
account	5	O
for	5	O
a	5	O
behavioral	5	B-Disease
depression	5	I-Disease
caused	9	O
by	9	O
amantadine	0	B-Chemical
in	5	O
the	5	O
BALB	3	O
/	9	O
C	9	O
mice	3	O
.	9	O

Chloroacetaldehyde	7	B-Chemical
and	5	O
its	9	O
contribution	9	O
to	5	O
urotoxicity	5	O
during	5	O
treatment	9	O
with	5	O
cyclophosphamide	0	B-Chemical
or	5	O
ifosfamide	0	B-Chemical
.	9	O

An	5	O
experimental	5	O
study	9	O
/	9	O
short	5	O
communication	5	O
.	9	O

Based	9	O
on	5	O
clinical	5	O
data	5	O
,	9	O
indicating	9	O
that	5	O
chloroacetaldehyde	0	B-Chemical
(	9	O
CAA	9	B-Chemical
)	9	O
is	5	O
an	5	O
important	9	O
metabolite	0	O
of	5	O
oxazaphosphorine	0	O
cytostatics	0	O
,	9	O
an	5	O
experimental	5	O
study	9	O
was	9	O
carried	9	O
out	9	O
in	5	O
order	5	O
to	5	O
elucidate	9	O
the	5	O
role	9	O
of	5	O
CAA	9	B-Chemical
in	5	O
the	5	O
development	9	O
of	5	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

The	5	O
data	5	O
demonstrate	9	O
that	5	O
CAA	9	B-Chemical
after	9	O
i	9	O
.	9	O
v	0	O
.	9	O
administration	9	O
does	9	O
not	5	O
contribute	9	O
to	5	O
bladder	9	B-Disease
damage	9	I-Disease
.	9	O

When	9	O
instilled	9	O
directly	9	O
into	9	O
the	5	O
bladder	9	O
,	9	O
CAA	9	B-Chemical
exerts	9	O
urotoxic	0	O
effects	9	O
,	9	O
it	5	O
is	5	O
,	9	O
however	9	O
,	9	O
susceptible	9	O
to	5	O
detoxification	9	O
with	5	O
mesna	0	B-Chemical
.	9	O

Source	9	O
of	5	O
pain	5	B-Disease
and	5	O
primitive	5	O
dysfunction	9	O
in	5	O
migraine	5	B-Disease
:	9	O
an	5	O
identical	9	O
site	9	O
?	5	O

Twenty	9	O
common	5	O
migraine	5	B-Disease
patients	5	O
received	9	O
a	5	O
one	5	O
sided	5	O
frontotemporal	5	O
application	5	O
of	5	O
nitroglycerin	5	B-Chemical
(	9	O
10	9	O
patients	5	O
)	9	O
or	5	O
placebo	9	O
ointment	0	O
(	9	O
10	9	O
patients	5	O
)	9	O
in	5	O
a	5	O
double	9	O
blind	5	O
study	9	O
.	9	O

Early	9	O
onset	5	O
migraine	5	B-Disease
attacks	5	O
were	9	O
induced	3	O
by	9	O
nitroglycerin	5	B-Chemical
in	5	O
seven	9	O
out	9	O
of	5	O
10	9	O
patients	5	O
versus	9	O
no	9	O
patient	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
.	9	O

Subsequently	9	O
20	9	O
migraine	5	B-Disease
patients	5	O
,	9	O
who	5	O
developed	5	O
an	5	O
early	9	O
onset	5	O
attack	5	O
with	5	O
frontotemporal	5	O
nitroglycerin	5	B-Chemical
,	9	O
received	9	O
the	5	O
drug	5	O
in	5	O
a	5	O
second	9	O
induction	3	O
test	5	O
at	9	O
other	5	O
body	5	O
areas	5	O
.	9	O

No	9	O
early	9	O
onset	5	O
migraine	5	B-Disease
was	9	O
observed	9	O
.	9	O

Thus	9	O
the	5	O
migraine	5	B-Disease
-	7	O
inducing	3	O
effect	9	O
of	5	O
nitroglycerin	5	B-Chemical
seems	5	O
to	5	O
depend	5	O
on	5	O
direct	9	O
stimulation	3	O
of	5	O
the	5	O
habitual	5	O
site	9	O
of	5	O
pain	5	B-Disease
,	9	O
suggesting	9	O
that	5	O
the	5	O
frontotemporal	5	O
region	9	O
is	5	O
of	5	O
crucial	9	O
importance	5	O
in	5	O
the	5	O
development	9	O
of	5	O
a	5	O
migraine	5	B-Disease
crisis	5	O
.	9	O

This	5	O
is	5	O
not	5	O
consistent	9	O
with	5	O
a	5	O
CNS	9	O
origin	9	O
of	5	O
migraine	5	B-Disease
attack	5	O
.	9	O

Hypersensitivity	9	B-Disease
to	5	O
carbamazepine	0	B-Chemical
presenting	5	O
with	5	O
a	5	O
leukemoid	5	B-Disease
reaction	9	I-Disease
,	9	O
eosinophilia	3	B-Disease
,	9	O
erythroderma	5	B-Disease
,	9	O
and	5	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
patient	5	O
in	5	O
whom	5	O
hypersensitivity	9	B-Disease
to	5	O
carbamazepine	0	B-Chemical
presented	5	O
with	5	O
generalized	5	O
erythroderma	5	B-Disease
,	9	O
a	5	O
severe	5	O
leukemoid	5	B-Disease
reaction	9	I-Disease
,	9	O
eosinophilia	3	B-Disease
,	9	O
hyponatremia	5	B-Disease
,	9	O
and	5	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

This	5	O
is	5	O
the	5	O
first	9	O
report	5	O
of	5	O
such	5	O
an	5	O
unusual	9	O
reaction	9	O
to	5	O
carbamazepine	0	B-Chemical
.	9	O

Fluoxetine	0	B-Chemical
-	7	O
induced	3	O
akathisia	5	B-Disease
:	9	O
clinical	5	O
and	5	O
theoretical	5	O
implications	5	O
.	9	O

Five	9	O
patients	5	O
receiving	9	O
fluoxetine	0	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
obsessive	5	B-Disease
compulsive	5	I-Disease
disorder	5	I-Disease
or	5	O
major	9	B-Disease
depression	5	I-Disease
developed	5	O
akathisia	5	B-Disease
.	9	O

The	5	O
typical	9	O
fluoxetine	0	B-Chemical
-	7	O
induced	3	O
symptoms	5	O
of	5	O
restlessness	5	O
,	9	O
constant	9	O
pacing	5	O
,	9	O
purposeless	5	O
movements	5	O
of	5	O
the	5	O
feet	5	O
and	5	O
legs	5	O
,	9	O
and	5	O
marked	9	O
anxiety	5	B-Disease
were	9	O
indistinguishable	9	O
from	9	O
those	5	O
of	5	O
neuroleptic	5	O
-	7	O
induced	3	O
akathisia	5	B-Disease
.	9	O

Three	9	O
patients	5	O
who	5	O
had	9	O
experienced	5	O
neuroleptic	5	O
-	7	O
induced	3	O
akathisia	5	B-Disease
in	5	O
the	5	O
past	5	O
reported	9	O
that	5	O
the	5	O
symptoms	5	O
of	5	O
fluoxetine	0	B-Chemical
-	7	O
induced	3	O
akathisia	5	B-Disease
were	9	O
identical	9	O
,	9	O
although	9	O
somewhat	5	O
milder	9	O
.	9	O

Akathisia	5	B-Disease
appeared	9	O
to	5	O
be	5	O
a	5	O
common	5	O
side	5	O
effect	9	O
of	5	O
fluoxetine	0	B-Chemical
and	5	O
generally	5	O
responded	9	O
well	9	O
to	5	O
treatment	9	O
with	5	O
the	5	O
beta	9	O
-	7	O
adrenergic	9	O
antagonist	3	O
propranolol	0	B-Chemical
,	9	O
dose	9	O
reduction	9	O
,	9	O
or	5	O
both	9	O
.	9	O

The	5	O
authors	5	O
suggest	9	O
that	5	O
fluoxetine	0	B-Chemical
-	7	O
induced	3	O
akathisia	5	B-Disease
may	5	O
be	5	O
caused	9	O
by	9	O
serotonergically	9	O
mediated	3	O
inhibition	3	O
of	5	O
dopaminergic	5	O
neurotransmission	5	O
and	5	O
that	5	O
the	5	O
pathophysiology	9	O
of	5	O
fluoxetine	0	B-Chemical
-	7	O
induced	3	O
akathisia	5	B-Disease
and	5	O
tricyclic	0	O
antidepressant	5	B-Chemical
-	7	O
induced	3	O
"	5	O
jitteriness	5	O
"	5	O
may	5	O
be	5	O
identical	9	O
.	9	O

Effect	0	O
of	5	O
converting	9	O
enzyme	0	O
inhibition	3	O
on	5	O
the	5	O
course	5	O
of	5	O
adriamycin	3	B-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
.	9	O

The	5	O
effect	9	O
of	5	O
the	5	O
converting	9	O
enzyme	0	O
inhibitor	3	O
(	9	O
CEI	2	O
)	9	O
enalapril	0	B-Chemical
was	9	O
assessed	9	O
in	5	O
Munich	2	O
-	7	O
Wistar	9	O
rats	9	O
with	5	O
established	9	O
adriamycin	3	B-Chemical
nephrosis	0	B-Disease
.	9	O

Rats	9	O
were	9	O
given	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
adriamycin	3	B-Chemical
and	5	O
one	5	O
month	5	O
later	9	O
divided	5	O
into	9	O
four	9	O
groups	9	O
matched	9	O
for	5	O
albuminuria	9	B-Disease
,	9	O
blood	9	O
pressure	5	O
,	9	O
and	5	O
plasma	9	O
albumin	0	O
concentration	0	O
.	9	O

Groups	9	O
1	9	O
and	5	O
3	9	O
remained	9	O
untreated	3	O
while	9	O
groups	9	O
2	9	O
and	5	O
4	9	O
received	9	O
enalapril	0	B-Chemical
.	9	O

Groups	9	O
1	9	O
and	5	O
2	9	O
underwent	5	O
micropuncture	5	O
studies	9	O
after	9	O
10	9	O
days	9	O
.	9	O

These	5	O
short	5	O
-	7	O
term	5	O
studies	9	O
showed	9	O
that	5	O
enalapril	0	B-Chemical
reduced	9	O
arterial	5	O
blood	9	O
pressure	5	O
(	9	O
101	7	O
+	9	O
/	9	O
-	7	O
2	9	O
vs	7	O
.	9	O
124	7	O
+	9	O
/	9	O
-	7	O
3	9	O
mm	9	O
Hg	0	O
,	9	O
group	9	O
2	9	O
vs	7	O
.	9	O
1	9	O
,	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
glomerular	5	O
capillary	0	O
pressure	5	O
(	9	O
54	7	O
+	9	O
/	9	O
-	7	O
1	9	O
vs	7	O
.	9	O
61	7	O
+	9	O
/	9	O
-	7	O
2	9	O
mm	9	O
Hg	0	O
,	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
without	9	O
reducing	9	O
albuminuria	9	B-Disease
(	9	O
617	7	O
+	9	O
/	9	O
-	7	O
50	0	O
vs	7	O
.	9	O
570	9	O
+	9	O
/	9	O
-	7	O
47	7	O
mg	0	O
/	9	O
day	9	O
)	9	O
or	5	O
GFR	5	O
(	9	O
1	9	O
.	9	O
03	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
04	7	O
vs	7	O
.	9	O
1	9	O
.	9	O
04	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
11	7	O
ml	0	O
/	9	O
min	0	O
)	9	O
.	9	O

Groups	9	O
3	9	O
and	5	O
4	9	O
were	9	O
studied	9	O
at	9	O
four	9	O
and	5	O
at	9	O
six	9	O
months	5	O
to	5	O
assess	5	O
the	5	O
effect	9	O
of	5	O
enalapril	0	B-Chemical
on	5	O
progression	9	O
of	5	O
renal	9	B-Disease
injury	9	I-Disease
in	5	O
adriamycin	3	B-Chemical
nephrosis	0	B-Disease
.	9	O

Chronic	9	O
enalapril	0	B-Chemical
treatment	9	O
reduced	9	O
blood	9	O
pressure	5	O
without	9	O
reducing	9	O
albuminuria	9	B-Disease
in	5	O
group	9	O
4	9	O
.	9	O

Untreated	9	O
group	9	O
3	9	O
rats	9	O
exhibited	9	O
a	5	O
progressive	5	O
reduction	9	O
in	5	O
GFR	5	O
(	9	O
0	7	O
.	9	O
35	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
08	7	O
ml	0	O
/	9	O
min	0	O
at	9	O
4	9	O
months	5	O
,	9	O
0	7	O
.	9	O
27	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
07	7	O
ml	0	O
/	9	O
min	0	O
at	9	O
6	9	O
months	5	O
)	9	O
.	9	O

Enalapril	0	B-Chemical
treatment	9	O
blunted	9	O
but	9	O
did	9	O
not	5	O
prevent	5	O
reduction	9	O
in	5	O
GFR	5	O
in	5	O
group	9	O
4	9	O
(	9	O
0	7	O
.	9	O
86	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
15	9	O
ml	0	O
/	9	O
min	0	O
at	9	O
4	9	O
months	5	O
,	9	O
0	7	O
.	9	O
69	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
13	7	O
ml	0	O
/	9	O
min	0	O
at	9	O
6	9	O
months	5	O
,	9	O
both	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
vs	7	O
.	9	O
group	9	O
3	9	O
)	9	O
.	9	O

Reduction	9	O
in	5	O
GFR	5	O
was	9	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
glomerular	5	B-Disease
sclerosis	5	I-Disease
in	5	O
both	9	O
treated	3	O
and	5	O
untreated	3	O
rats	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Clotiazepam	_	B-Chemical
-	7	O
induced	3	O
acute	9	O
hepatitis	9	B-Disease
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
patient	5	O
who	5	O
developed	5	O
acute	9	O
hepatitis	9	B-Disease
with	5	O
extensive	5	B-Disease
hepatocellular	9	I-Disease
necrosis	9	I-Disease
,	9	O
7	9	O
months	5	O
after	9	O
the	5	O
onset	5	O
of	5	O
administration	9	O
of	5	O
clotiazepam	0	B-Chemical
,	9	O
a	5	O
thienodiazepine	9	B-Chemical
derivative	0	O
.	9	O

Clotiazepam	_	B-Chemical
withdrawal	5	O
was	9	O
followed	9	O
by	9	O
prompt	5	O
recovery	9	O
.	9	O

The	5	O
administration	9	O
of	5	O
several	9	O
benzodiazepines	5	B-Chemical
,	9	O
chemically	0	O
related	9	O
to	5	O
clotiazepam	0	B-Chemical
,	9	O
did	9	O
not	5	O
interfere	9	O
with	5	O
recovery	9	O
and	5	O
did	9	O
not	5	O
induce	3	O
any	5	O
relapse	5	O
of	5	O
hepatitis	9	B-Disease
.	9	O

This	5	O
observation	9	O
shows	9	O
that	5	O
clotiazepam	0	B-Chemical
can	5	O
induce	3	O
acute	9	O
hepatitis	9	B-Disease
and	5	O
suggests	9	O
that	5	O
there	5	O
is	5	O
no	9	O
cross	5	O
hepatotoxicity	9	B-Disease
between	5	O
clotiazepam	0	B-Chemical
and	5	O
several	9	O
benzodiazepines	5	B-Chemical
.	9	O

5	9	B-Chemical
-	7	I-Chemical
azacytidine	3	I-Chemical
potentiates	3	O
initiation	9	B-Disease
induced	3	I-Disease
by	9	I-Disease
carcinogens	0	I-Disease
in	5	O
rat	3	O
liver	9	O
.	9	O

To	9	O
test	5	O
the	5	O
validity	5	O
of	5	O
the	5	O
hypothesis	9	O
that	5	O
hypomethylation	9	O
of	5	O
DNA	9	O
plays	9	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
initiation	9	B-Disease
of	5	I-Disease
carcinogenic	0	I-Disease
process	5	I-Disease
,	9	O
5	9	B-Chemical
-	7	I-Chemical
azacytidine	3	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
AzC	1	I-Chemical
)	9	O
(	9	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
an	5	O
inhibitor	3	O
of	5	O
DNA	9	O
methylation	9	O
,	9	O
was	9	O
given	5	O
to	5	O
rats	9	O
during	5	O
the	5	O
phase	5	O
of	5	O
repair	9	O
synthesis	9	O
induced	3	O
by	9	O
the	5	O
three	9	O
carcinogens	0	O
,	9	O
benzo	0	B-Chemical
[	9	I-Chemical
a	5	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
pyrene	0	I-Chemical
(	9	O
200	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
N	9	B-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
nitrosourea	0	I-Chemical
(	9	O
60	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
1	9	B-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
dimethylhydrazine	0	I-Chemical
(	9	O
1	9	B-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
DMH	9	I-Chemical
)	9	O
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

The	5	O
initiated	9	O
hepatocytes	3	O
in	5	O
the	5	O
liver	9	O
were	9	O
assayed	3	O
as	5	O
the	5	O
gamma	9	O
-	7	O
glutamyltransferase	7	O
(	9	O
gamma	9	O
-	7	O
GT	9	O
)	9	O
positive	9	O
foci	9	O
formed	9	O
following	9	O
a	5	O
2	9	O
-	7	O
week	9	O
selection	5	O
regimen	5	O
consisting	9	O
of	5	O
dietary	5	O
0	7	O
.	9	O
02	7	O
%	9	O
2	9	B-Chemical
-	7	I-Chemical
acetylaminofluorene	0	I-Chemical
coupled	9	O
with	5	O
a	5	O
necrogenic	0	O
dose	9	O
of	5	O
CCl4	0	B-Chemical
.	9	O

The	5	O
results	9	O
obtained	9	O
indicate	9	O
that	5	O
with	5	O
all	5	O
three	9	O
carcinogens	0	O
,	9	O
administration	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
AzC	1	I-Chemical
during	5	O
repair	9	O
synthesis	9	O
increased	9	O
the	5	O
incidence	5	O
of	5	O
initiated	9	O
hepatocytes	3	O
,	9	O
for	5	O
example	5	O
10	9	O
-	7	O
20	9	O
foci	9	O
/	9	O
cm2	0	O
in	5	O
5	9	B-Chemical
-	7	I-Chemical
AzC	1	I-Chemical
and	5	O
carcinogen	0	O
-	7	O
treated	3	O
rats	9	O
compared	9	O
with	5	O
3	9	O
-	7	O
5	9	O
foci	9	O
/	9	O
cm2	0	O
in	5	O
rats	9	O
treated	3	O
with	5	O
carcinogen	0	O
only	9	O
.	9	O

Administration	2	O
of	5	O
[	9	B-Chemical
3H	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
azadeoxycytidine	9	I-Chemical
during	5	O
the	5	O
repair	9	O
synthesis	9	O
induced	3	O
by	9	O
1	9	B-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
DMH	9	I-Chemical
further	9	O
showed	9	O
that	5	O
0	7	O
.	9	O
019	7	O
mol	0	O
%	9	O
of	5	O
cytosine	1	B-Chemical
residues	1	O
in	5	O
DNA	9	O
were	9	O
substituted	0	O
by	9	O
the	5	O
analogue	0	O
,	9	O
indicating	9	O
that	5	O
incorporation	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
AzC	1	I-Chemical
occurs	9	O
during	5	O
repair	9	O
synthesis	9	O
.	9	O

In	9	O
the	5	O
absence	3	O
of	5	O
the	5	O
carcinogen	0	O
,	9	O
5	9	B-Chemical
-	7	I-Chemical
AzC	1	I-Chemical
given	5	O
after	9	O
a	5	O
two	5	O
thirds	5	O
partial	9	O
hepatectomy	5	O
,	9	O
when	5	O
its	9	O
incorporation	0	O
should	5	O
be	5	O
maximum	5	O
,	9	O
failed	9	O
to	5	O
induce	3	O
any	5	O
gamma	9	O
-	7	O
GT	9	O
positive	9	O
foci	9	O
.	9	O

The	5	O
results	9	O
suggest	9	O
that	5	O
hypomethylation	9	O
of	5	O
DNA	9	O
per	9	O
se	9	O
may	5	O
not	5	O
be	5	O
sufficient	9	O
for	5	O
initiation	9	O
.	9	O

Perhaps	5	O
two	5	O
events	5	O
might	9	O
be	5	O
necessary	5	O
for	5	O
initiation	9	O
,	9	O
the	5	O
first	9	O
caused	9	O
by	9	O
the	5	O
carcinogen	0	O
and	5	O
a	5	O
second	9	O
involving	5	O
hypomethylation	9	O
of	5	O
DNA	9	O
.	9	O

Antihypertensive	7	O
drugs	5	O
and	5	O
depression	5	B-Disease
:	9	O
a	5	O
reappraisal	5	O
.	9	O

Eighty	5	O
-	7	O
nine	9	O
new	5	O
referral	5	O
hypertensive	5	B-Disease
out	9	O
-	7	O
patients	5	O
and	5	O
46	7	O
new	5	O
referral	5	O
non	9	O
-	7	O
hypertensive	5	B-Disease
chronically	9	O
physically	5	O
ill	5	O
out	9	O
-	7	O
patients	5	O
completed	5	O
a	5	O
mood	5	O
rating	5	O
scale	5	O
at	9	O
regular	5	O
intervals	5	O
for	5	O
one	5	O
year	5	O
.	9	O

The	5	O
results	9	O
showed	9	O
a	5	O
high	9	O
prevalence	5	O
of	5	O
depression	5	B-Disease
in	5	O
both	9	O
groups	9	O
of	5	O
patients	5	O
,	9	O
with	5	O
no	9	O
preponderance	9	O
in	5	O
the	5	O
hypertensive	5	B-Disease
group	9	O
.	9	O

Hypertensive	7	B-Disease
patients	5	O
with	5	O
psychiatric	5	B-Disease
histories	5	O
had	9	O
a	5	O
higher	9	O
prevalence	5	O
of	5	O
depression	5	B-Disease
than	5	O
the	5	O
comparison	9	O
patients	5	O
.	9	O

This	5	O
was	9	O
accounted	5	O
for	5	O
by	9	O
a	5	O
significant	9	O
number	9	O
of	5	O
depressions	5	B-Disease
occurring	9	O
in	5	O
methyl	0	B-Chemical
dopa	0	I-Chemical
treated	3	O
patients	5	O
with	5	O
psychiatric	5	B-Disease
histories	5	O
.	9	O

Chronic	9	B-Disease
active	9	I-Disease
hepatitis	9	I-Disease
associated	9	O
with	5	O
diclofenac	0	B-Chemical
sodium	0	I-Chemical
therapy	5	O
.	9	O

Diclofenac	0	B-Chemical
sodium	0	I-Chemical
(	9	O
Voltarol	9	B-Chemical
,	9	O
Geigy	2	O
Pharmaceuticals	2	O
)	9	O
is	5	O
a	5	O
non	9	O
-	7	O
steroidal	0	O
anti	3	O
-	7	O
inflammatory	3	O
derivative	0	O
of	5	O
phenylacetic	0	B-Chemical
acid	0	I-Chemical
.	9	O

Although	9	O
generally	5	O
well	9	O
-	7	O
tolerated	9	O
,	9	O
asymptomatic	5	O
abnormalities	9	B-Disease
of	5	I-Disease
liver	9	I-Disease
function	9	I-Disease
have	5	O
been	9	O
recorded	5	O
and	5	O
,	9	O
less	5	O
commonly	5	O
,	9	O
severe	5	O
hepatitis	9	B-Disease
induced	3	O
by	9	O
diclofenac	0	B-Chemical
.	9	O

The	5	O
patient	5	O
described	9	O
developed	5	O
chronic	5	B-Disease
active	9	I-Disease
hepatitis	9	I-Disease
after	9	O
six	9	O
months	5	O
therapy	5	O
with	5	O
diclofenac	0	B-Chemical
sodium	0	I-Chemical
which	5	O
progressed	9	O
despite	9	O
the	5	O
withdrawal	5	O
of	5	O
the	5	O
drug	5	O
,	9	O
a	5	O
finding	9	O
not	5	O
previously	9	O
reported	9	O
.	9	O

Arterial	5	O
hypertension	5	B-Disease
as	5	O
a	5	O
complication	5	O
of	5	O
prolonged	9	O
ketoconazole	0	B-Chemical
treatment	9	O
.	9	O

Two	9	O
of	5	O
14	7	O
patients	5	O
with	5	O
Cushing	5	B-Disease
'	9	I-Disease
s	9	I-Disease
syndrome	5	I-Disease
treated	3	O
on	5	O
a	5	O
long	5	O
-	7	O
term	5	O
basis	5	O
with	5	O
ketoconazole	0	B-Chemical
developed	5	O
sustained	5	O
hypertension	5	B-Disease
.	9	O

In	9	O
both	9	O
cases	5	O
normal	9	O
plasma	9	O
and	5	O
urinary	9	O
free	9	O
cortisol	5	B-Chemical
levels	3	O
had	9	O
been	9	O
achieved	5	O
following	9	O
ketoconazole	0	B-Chemical
therapy	5	O
,	9	O
yet	9	O
continuous	5	O
blood	9	O
pressure	5	O
monitoring	5	O
demonstrated	9	O
hypertension	5	B-Disease
31	7	O
(	9	O
patient	5	O
1	9	O
)	9	O
and	5	O
52	7	O
weeks	9	O
(	9	O
patient	5	O
2	9	O
)	9	O
after	9	O
treatment	9	O
.	9	O

In	9	O
patient	5	O
1	9	O
,	9	O
plasma	9	O
levels	3	O
of	5	O
deoxycorticosterone	0	B-Chemical
and	5	O
11	7	B-Chemical
-	7	I-Chemical
deoxycortisol	0	I-Chemical
were	9	O
elevated	9	O
.	9	O

In	9	O
patient	5	O
2	9	O
,	9	O
in	5	O
addition	9	O
to	5	O
an	5	O
increase	9	O
in	5	O
both	9	O
deoxycorticosterone	0	B-Chemical
and	5	O
11	7	B-Chemical
-	7	I-Chemical
deoxycortisol	0	I-Chemical
levels	3	O
,	9	O
plasma	9	O
aldosterone	9	B-Chemical
values	5	O
were	9	O
raised	9	O
,	9	O
with	5	O
a	5	O
concomitant	9	O
suppression	9	O
of	5	O
renin	9	O
levels	3	O
.	9	O

Our	9	O
findings	9	O
show	9	O
that	5	O
long	5	O
-	7	O
term	5	O
treatment	9	O
with	5	O
high	9	O
doses	0	O
of	5	O
ketoconazole	0	B-Chemical
may	5	O
induce	3	O
enzyme	0	O
blockade	3	O
leading	9	O
to	5	O
mineralocorticoid	5	O
-	7	O
related	9	O
hypertension	5	B-Disease
.	9	O

Effects	9	O
of	5	O
an	5	O
inhibitor	3	O
of	5	O
angiotensin	9	B-Chemical
converting	9	O
enzyme	0	O
(	9	O
Captopril	0	B-Chemical
)	9	O
on	5	O
pulmonary	5	B-Disease
and	5	I-Disease
renal	9	I-Disease
insufficiency	9	I-Disease
due	5	O
to	5	O
intravascular	5	B-Disease
coagulation	5	I-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

Induction	3	O
of	5	O
intravascular	5	B-Disease
coagulation	5	I-Disease
and	5	O
inhibition	3	O
of	5	O
fibrinolysis	5	O
by	9	O
injection	9	O
of	5	O
thrombin	0	O
and	5	O
tranexamic	0	B-Chemical
acid	0	I-Chemical
(	9	O
AMCA	0	B-Chemical
)	9	O
in	5	O
the	5	O
rat	3	O
gives	5	O
rise	9	O
to	5	O
pulmonary	5	B-Disease
and	5	I-Disease
renal	9	I-Disease
insufficiency	9	I-Disease
resembling	9	O
that	5	O
occurring	9	O
after	9	O
trauma	5	B-Disease
or	5	O
sepsis	9	B-Disease
in	5	O
man	5	O
.	9	O

Injection	9	O
of	5	O
Captopril	0	B-Chemical
(	9	O
1	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
,	9	O
an	5	O
inhibitor	3	O
of	5	O
angiotensin	9	B-Chemical
converting	9	O
enzyme	0	O
(	9	O
ACE	9	O
)	9	O
,	9	O
reduced	9	O
both	9	O
pulmonary	5	B-Disease
and	5	I-Disease
renal	9	I-Disease
insufficiency	9	I-Disease
in	5	O
this	5	O
rat	3	O
model	5	O
.	9	O

The	5	O
lung	9	O
weights	5	O
were	9	O
lower	9	O
and	5	O
PaO2	5	O
was	9	O
improved	5	O
in	5	O
rats	9	O
given	5	O
this	5	O
enzyme	0	O
-	7	O
blocking	3	O
agent	9	O
.	9	O

The	5	O
contents	9	O
of	5	O
albumin	0	O
in	5	O
the	5	O
lungs	3	O
were	9	O
not	5	O
changed	9	O
,	9	O
indicating	9	O
that	5	O
Captopril	0	B-Chemical
did	9	O
not	5	O
influence	5	O
the	5	O
extravasation	3	O
of	5	O
protein	1	O
.	9	O

Renal	9	B-Disease
damage	9	I-Disease
as	5	O
reflected	5	O
by	9	O
an	5	O
increase	9	O
in	5	O
serum	9	O
urea	0	B-Chemical
and	5	O
in	5	O
kidney	9	O
weight	9	O
was	9	O
prevented	9	O
by	9	O
Captopril	0	B-Chemical
.	9	O

The	5	O
amount	9	O
of	5	O
fibrin	0	O
in	5	O
the	5	O
kidneys	9	O
was	9	O
also	9	O
considerably	9	O
lower	9	O
than	5	O
in	5	O
animals	9	O
which	5	O
received	9	O
thrombin	0	O
and	5	O
AMCA	0	B-Chemical
alone	9	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
the	5	O
effects	9	O
of	5	O
Captopril	0	B-Chemical
on	5	O
the	5	O
lungs	3	O
may	5	O
be	5	O
attributable	9	O
to	5	O
a	5	O
vasodilatory	5	O
effect	9	O
due	5	O
to	5	O
a	5	O
reduction	9	O
in	5	O
the	5	O
circulating	9	O
level	9	O
of	5	O
Angiotension	9	B-Chemical
II	9	I-Chemical
and	5	O
an	5	O
increase	9	O
in	5	O
prostacyclin	0	B-Chemical
(	9	O
secondary	9	O
to	5	O
an	5	O
increase	9	O
in	5	O
bradykinin	0	B-Chemical
)	9	O
.	9	O

Captopril	0	B-Chemical
may	5	O
,	9	O
by	9	O
the	5	O
same	9	O
mechanism	9	O
,	9	O
reduce	5	O
the	5	O
increase	9	O
in	5	O
glomerular	5	O
filtration	0	O
that	5	O
is	5	O
known	9	O
to	5	O
occur	5	O
after	9	O
an	5	O
injection	9	O
of	5	O
thrombin	0	O
,	9	O
thereby	9	O
diminishing	5	O
the	5	O
aggregation	9	O
of	5	O
fibrin	0	O
monomers	0	O
in	5	O
the	5	O
glomeruli	9	O
,	9	O
with	5	O
the	5	O
result	9	O
that	5	O
less	5	O
fibrin	0	O
will	5	O
be	5	O
deposited	9	O
and	5	O
thus	9	O
less	5	O
kidney	9	B-Disease
damage	9	I-Disease
will	5	O
be	5	O
produced	9	O
.	9	O

Stroke	5	B-Disease
associated	9	O
with	5	O
cocaine	5	B-Chemical
use	5	O
.	9	O

We	9	O
describe	5	O
eight	9	O
patients	5	O
in	5	O
whom	5	O
cocaine	5	B-Chemical
use	5	O
was	9	O
related	9	O
to	5	O
stroke	5	B-Disease
and	5	O
review	5	O
39	7	O
cases	5	O
from	9	O
the	5	O
literature	5	O
.	9	O

Among	9	O
these	5	O
47	7	O
patients	5	O
the	5	O
mean	5	O
(	9	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
age	5	O
was	9	O
32	7	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
12	9	O
.	9	O
1	9	O
years	5	O
;	9	O
76	7	O
%	9	O
(	9	O
34	7	O
/	9	O
45	9	O
)	9	O
were	9	O
men	5	O
.	9	O

Stroke	5	B-Disease
followed	9	O
cocaine	5	B-Chemical
use	5	O
by	9	O
inhalation	5	O
,	9	O
intranasal	9	O
,	9	O
intravenous	0	O
,	9	O
and	5	O
intramuscular	9	O
routes	5	O
.	9	O

Intracranial	5	B-Disease
aneurysms	5	I-Disease
or	5	O
arteriovenous	5	B-Disease
malformations	5	I-Disease
were	9	O
present	9	O
in	5	O
17	7	O
of	5	O
32	7	O
patients	5	O
studied	9	O
angiographically	5	O
or	5	O
at	9	O
autopsy	5	O
;	9	O
cerebral	5	B-Disease
vasculitis	5	I-Disease
was	9	O
present	9	O
in	5	O
two	5	O
patients	5	O
.	9	O

Cerebral	5	B-Disease
infarction	5	I-Disease
occurred	9	O
in	5	O
10	9	O
patients	5	O
(	9	O
22	7	O
%	9	O
)	9	O
,	9	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
in	5	O
22	7	O
(	9	O
49	7	O
%	9	O
)	9	O
,	9	O
and	5	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
in	5	O
13	7	O
(	9	O
29	7	O
%	9	O
)	9	O
.	9	O

These	5	O
data	5	O
indicate	9	O
that	5	O
(	9	O
1	9	O
)	9	O
the	5	O
apparent	9	O
incidence	5	O
of	5	O
stroke	5	B-Disease
related	9	O
to	5	O
cocaine	5	B-Chemical
use	5	O
is	5	O
increasing	9	O
;	9	O
(	9	O
2	9	O
)	9	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
stroke	5	B-Disease
occurs	9	O
primarily	9	O
in	5	O
young	5	O
adults	5	O
;	9	O
(	9	O
3	9	O
)	9	O
stroke	5	B-Disease
may	5	O
follow	5	O
any	5	O
route	5	O
of	5	O
cocaine	5	B-Chemical
administration	9	O
;	9	O
(	9	O
4	9	O
)	9	O
stroke	5	B-Disease
after	9	O
cocaine	5	B-Chemical
use	5	O
is	5	O
frequently	5	O
associated	9	O
with	5	O
intracranial	5	B-Disease
aneurysms	5	I-Disease
and	5	O
arteriovenous	5	B-Disease
malformations	5	I-Disease
;	9	O
and	5	O
(	9	O
5	9	O
)	9	O
in	5	O
cocaine	5	B-Chemical
-	7	O
associated	9	O
stroke	5	B-Disease
,	9	O
the	5	O
frequency	5	O
of	5	O
intracranial	5	B-Disease
hemorrhage	5	I-Disease
exceeds	5	O
that	5	O
of	5	O
cerebral	5	B-Disease
infarction	5	I-Disease
.	9	O

A	9	O
randomized	5	O
comparison	9	O
of	5	O
labetalol	0	B-Chemical
and	5	O
nitroprusside	0	B-Chemical
for	5	O
induced	3	O
hypotension	5	B-Disease
.	9	O

In	9	O
a	5	O
randomized	5	O
study	9	O
,	9	O
labetalol	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
and	5	O
nitroprusside	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
were	9	O
compared	9	O
in	5	O
20	9	O
patients	5	O
(	9	O
10	9	O
in	5	O
each	5	O
group	9	O
)	9	O
scheduled	5	O
for	5	O
major	9	O
orthopedic	5	O
procedures	5	O
.	9	O

Each	5	O
patient	5	O
was	9	O
subjected	9	O
to	5	O
an	5	O
identical	9	O
anesthetic	5	O
protocol	9	O
and	5	O
similar	9	O
drug	5	O
-	7	O
induced	3	O
reductions	9	B-Disease
in	5	I-Disease
mean	5	I-Disease
arterial	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
(	9	O
BP	9	O
)	9	O
(	9	O
50	0	O
to	5	O
55	7	O
mmHg	7	O
)	9	O
.	9	O

Nitroprusside	0	O
infusion	0	O
was	9	O
associated	9	O
with	5	O
a	5	O
significant	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
increase	9	B-Disease
in	5	I-Disease
heart	5	I-Disease
rate	9	I-Disease
and	5	I-Disease
cardiac	5	I-Disease
output	5	I-Disease
;	9	O
rebound	5	O
hypertension	5	B-Disease
was	9	O
observed	9	O
in	5	O
three	9	O
patients	5	O
after	9	O
discontinuation	5	O
of	5	O
nitroprusside	0	B-Chemical
.	9	O

Labetalol	0	B-Chemical
administration	9	O
was	9	O
not	5	O
associated	9	O
with	5	O
any	5	O
of	5	O
these	5	O
findings	9	O
.	9	O

Arterial	5	O
PO2	0	B-Chemical
decreased	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

It	5	O
was	9	O
concluded	9	O
that	5	O
labetalol	0	B-Chemical
offers	5	O
advantages	5	O
over	5	O
nitroprusside	0	B-Chemical
.	9	O

Sodium	0	B-Chemical
status	9	O
influences	5	O
chronic	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
nephrotoxicity	9	B-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
nephrotoxic	5	B-Disease
potential	9	O
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
intraperitoneally	0	O
for	5	O
3	9	O
weeks	9	O
)	9	O
has	9	O
been	9	O
investigated	9	O
in	5	O
salt	0	O
-	7	O
depleted	3	O
,	9	O
normal	9	O
-	7	O
salt	0	O
,	9	O
and	5	O
salt	0	O
-	7	O
loaded	0	O
rats	9	O
.	9	O

In	9	O
salt	0	O
-	7	O
depleted	3	O
rats	9	O
,	9	O
amphotericin	0	B-Chemical
B	9	I-Chemical
decreased	9	O
creatinine	0	B-Chemical
clearance	9	O
linearly	5	O
with	5	O
time	5	O
,	9	O
with	5	O
an	5	O
85	9	O
%	9	O
reduction	9	O
by	9	O
week	9	O
3	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
in	5	O
normal	9	O
-	7	O
salt	0	O
rats	9	O
creatinine	0	B-Chemical
clearance	9	O
was	9	O
decreased	9	O
but	9	O
to	5	O
a	5	O
lesser	9	O
extent	9	O
at	9	O
week	9	O
2	9	O
and	5	O
3	9	O
,	9	O
and	5	O
in	5	O
salt	0	O
-	7	O
loaded	0	O
rats	9	O
creatinine	0	B-Chemical
clearance	9	O
did	9	O
not	5	O
change	9	O
for	5	O
2	9	O
weeks	9	O
and	5	O
was	9	O
decreased	9	O
by	9	O
43	7	O
%	9	O
at	9	O
week	9	O
3	9	O
.	9	O

All	9	O
rats	9	O
in	5	O
the	5	O
sodium	0	B-Chemical
-	7	O
depleted	3	O
group	9	O
had	9	O
histopathological	9	O
evidence	9	O
of	5	O
patchy	5	O
tubular	9	O
cytoplasmic	3	O
degeneration	9	O
in	5	O
tubules	9	O
that	5	O
was	9	O
not	5	O
observed	9	O
in	5	O
any	5	O
normal	9	O
-	7	O
salt	0	O
or	5	O
salt	0	O
-	7	O
loaded	0	O
rat	3	O
.	9	O

Concentrations	0	O
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
in	5	O
plasma	9	O
were	9	O
not	5	O
significantly	9	O
different	9	O
among	5	O
the	5	O
three	9	O
groups	9	O
at	9	O
any	5	O
time	5	O
during	5	O
the	5	O
study	9	O
.	9	O

However	9	O
,	9	O
at	9	O
the	5	O
end	9	O
of	5	O
3	9	O
weeks	9	O
,	9	O
amphotericin	0	B-Chemical
B	9	I-Chemical
levels	3	O
in	5	O
the	5	O
kidneys	9	O
and	5	O
liver	9	O
were	9	O
significantly	9	O
higher	9	O
in	5	O
salt	0	O
-	7	O
depleted	3	O
and	5	O
normal	9	O
-	7	O
salt	0	O
rats	9	O
than	5	O
those	5	O
in	5	O
salt	0	O
-	7	O
loaded	0	O
rats	9	O
,	9	O
with	5	O
plasma	9	O
/	9	O
kidney	9	O
ratios	9	O
of	5	O
21	7	O
,	9	O
14	7	O
,	9	O
and	5	O
8	9	O
in	5	O
salt	0	O
-	7	O
depleted	3	O
,	9	O
normal	9	O
-	7	O
salt	0	O
,	9	O
and	5	O
salt	0	O
-	7	O
loaded	0	O
rats	9	O
,	9	O
respectively	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
reductions	9	O
in	5	O
creatinine	0	B-Chemical
clearance	9	O
and	5	O
renal	9	O
amphotericin	0	B-Chemical
B	9	I-Chemical
accumulation	9	O
after	9	O
chronic	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
administration	9	O
were	9	O
enhanced	3	O
by	9	O
salt	0	O
depletion	3	O
and	5	O
attenuated	3	O
by	9	O
sodium	0	B-Chemical
loading	9	O
in	5	O
rats	9	O
.	9	O

Flestolol	_	B-Chemical
:	9	O
an	5	O
ultra	0	O
-	7	O
short	5	O
-	7	O
acting	9	O
beta	9	O
-	7	O
adrenergic	9	O
blocking	3	O
agent	9	O
.	9	O

Flestolol	_	B-Chemical
(	9	O
ACC	9	B-Chemical
-	7	I-Chemical
9089	7	I-Chemical
)	9	O
is	5	O
a	5	O
nonselective	0	O
,	9	O
competitive	9	O
,	9	O
ultra	0	O
-	7	O
short	5	O
-	7	O
acting	9	O
beta	9	O
-	7	O
adrenergic	9	O
blocking	3	O
agent	9	O
,	9	O
without	9	O
any	5	O
intrinsic	9	O
sympathomimetic	5	O
activity	9	O
.	9	O

Flestolol	_	B-Chemical
is	5	O
metabolized	0	O
by	9	O
plasma	9	O
esterases	0	O
and	5	O
has	9	O
an	5	O
elimination	9	O
half	5	O
-	7	O
life	5	O
of	5	O
approximately	9	O
6	9	O
.	9	O
5	9	O
minutes	0	O
.	9	O

This	5	O
agent	9	O
was	9	O
well	9	O
tolerated	9	O
in	5	O
healthy	5	O
volunteers	5	O
at	9	O
doses	0	O
up	5	O
to	5	O
100	0	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
.	9	O

In	9	O
long	5	O
-	7	O
term	5	O
infusion	0	O
studies	9	O
,	9	O
flestolol	_	B-Chemical
was	9	O
well	9	O
tolerated	9	O
at	9	O
the	5	O
effective	5	O
beta	9	O
-	7	O
blocking	3	O
dose	9	O
(	9	O
5	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
)	9	O
for	5	O
up	5	O
to	5	O
seven	9	O
days	9	O
.	9	O

Flestolol	_	B-Chemical
blood	9	O
concentrations	0	O
increased	9	O
linearly	5	O
with	5	O
increasing	9	O
dose	9	O
and	5	O
good	5	O
correlation	9	O
exists	9	O
between	5	O
blood	9	O
concentrations	0	O
of	5	O
flestolol	_	B-Chemical
and	5	O
beta	9	O
-	7	O
adrenergic	9	O
blockade	3	O
.	9	O

Flestolol	_	B-Chemical
produced	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
attenuation	9	O
of	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
tachycardia	5	B-Disease
.	9	O

Electrophysiologic	5	O
and	5	O
hemodynamic	5	O
effects	9	O
of	5	O
flestolol	_	B-Chemical
are	5	O
similar	9	O
to	5	O
those	5	O
of	5	O
other	5	O
beta	9	O
blockers	9	O
.	9	O

In	9	O
contrast	9	O
with	5	O
other	5	O
beta	9	O
blockers	9	O
,	9	O
flestolol	_	B-Chemical
-	7	O
induced	3	O
effects	9	O
reverse	9	O
rapidly	9	O
(	9	O
within	9	O
30	9	O
minutes	0	O
)	9	O
following	9	O
discontinuation	5	O
because	5	O
of	5	O
its	9	O
short	5	O
half	5	O
-	7	O
life	5	O
.	9	O

Flestolol	_	B-Chemical
effectively	5	O
reduced	9	O
heart	5	O
rate	9	O
in	5	O
patients	5	O
with	5	O
supraventricular	5	B-Disease
tachyarrhythmia	5	I-Disease
.	9	O

In	9	O
patients	5	O
with	5	O
unstable	5	B-Disease
angina	5	I-Disease
,	9	O
flestolol	_	B-Chemical
infusion	0	O
was	9	O
found	9	O
to	5	O
be	5	O
safe	5	O
and	5	O
effective	5	O
in	5	O
controlling	9	O
chest	5	B-Disease
pain	5	I-Disease
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
flestolol	_	B-Chemical
is	5	O
a	5	O
potent	3	O
,	9	O
well	9	O
-	7	O
tolerated	9	O
,	9	O
ultra	0	O
-	7	O
short	5	O
-	7	O
acting	9	O
beta	9	O
-	7	O
adrenergic	9	O
blocking	3	O
agent	9	O
.	9	O

Use	5	O
of	5	O
flestolol	_	B-Chemical
in	5	O
the	5	O
critical	9	O
care	5	O
setting	5	O
is	5	O
currently	5	O
undergoing	9	O
investigation	9	O
.	9	O

Immunohistochemical	3	O
,	9	O
electron	0	O
microscopic	9	O
and	5	O
morphometric	5	O
studies	9	O
of	5	O
estrogen	3	B-Chemical
-	7	O
induced	3	O
rat	3	O
prolactinomas	5	B-Disease
after	9	O
bromocriptine	0	B-Chemical
treatment	9	O
.	9	O

To	9	O
clarify	9	O
the	5	O
effects	9	O
of	5	O
bromocriptine	0	B-Chemical
on	5	O
prolactinoma	5	B-Disease
cells	3	O
in	5	O
vivo	3	O
,	9	O
immunohistochemical	3	O
,	9	O
ultrastructural	9	O
and	5	O
morphometrical	5	O
analyses	9	O
were	9	O
applied	5	O
to	5	O
estrogen	3	B-Chemical
-	7	O
induced	3	O
rat	3	O
prolactinoma	5	B-Disease
cells	3	O
1	9	O
h	0	O
and	5	O
6	9	O
h	0	O
after	9	O
injection	9	O
of	5	O
bromocriptine	0	B-Chemical
(	9	O
3	9	O
mg	0	O
/	9	O
kg	0	O
of	5	O
body	5	O
weight	9	O
)	9	O
.	9	O

One	5	O
h	0	O
after	9	O
treatment	9	O
,	9	O
serum	9	O
prolactin	3	O
levels	3	O
decreased	9	O
markedly	9	O
.	9	O

Electron	0	O
microscopy	9	O
disclosed	9	O
many	5	O
secretory	3	O
granules	9	O
,	9	O
slightly	9	O
distorted	5	O
rough	5	O
endoplasmic	3	O
reticulum	9	O
,	9	O
and	5	O
partially	9	O
dilated	5	O
Golgi	9	O
cisternae	0	O
in	5	O
the	5	O
prolactinoma	5	B-Disease
cells	3	O
.	9	O

Morphometric	9	O
analysis	9	O
revealed	9	O
that	5	O
the	5	O
volume	9	O
density	9	O
of	5	O
secretory	3	O
granules	9	O
increased	9	O
,	9	O
while	9	O
the	5	O
volume	9	O
density	9	O
of	5	O
cytoplasmic	3	O
microtubules	9	O
decreased	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
lowered	9	O
serum	9	O
prolactin	3	O
levels	3	O
in	5	O
the	5	O
early	9	O
phase	5	O
of	5	O
bromocriptine	0	B-Chemical
treatment	9	O
may	5	O
result	9	O
from	9	O
an	5	O
impaired	9	O
secretion	3	O
of	5	O
prolactin	3	O
due	5	O
to	5	O
decreasing	9	O
numbers	9	O
of	5	O
cytoplasmic	3	O
microtubules	9	O
.	9	O

At	9	O
6	9	O
h	0	O
after	9	O
injection	9	O
,	9	O
serum	9	O
prolactin	3	O
levels	3	O
were	9	O
still	5	O
considerably	9	O
lower	9	O
than	5	O
in	5	O
controls	9	O
.	9	O

The	5	O
prolactinoma	5	B-Disease
cells	3	O
at	9	O
this	5	O
time	5	O
were	9	O
well	9	O
granulated	9	O
,	9	O
with	5	O
vesiculated	5	O
rough	5	O
endoplasmic	3	O
reticulum	9	O
and	5	O
markedly	9	O
dilated	5	O
Golgi	9	O
cisternae	0	O
.	9	O

Electron	0	O
microscopical	9	O
immunohistochemistry	3	O
revealed	9	O
positive	9	O
reaction	9	O
products	9	O
noted	9	O
on	5	O
the	5	O
secretory	3	O
granules	9	O
,	9	O
Golgi	9	O
cisternae	0	O
,	9	O
and	5	O
endoplasmic	3	O
reticulum	9	O
of	5	O
the	5	O
untreated	3	O
rat	3	O
prolactinoma	5	B-Disease
cells	3	O
.	9	O

However	9	O
,	9	O
only	9	O
secretory	3	O
granules	9	O
showed	9	O
the	5	O
positive	9	O
reaction	9	O
products	9	O
for	5	O
prolactin	3	O
6	9	O
h	0	O
after	9	O
bromocriptine	0	B-Chemical
treatment	9	O
of	5	O
the	5	O
adenoma	9	B-Disease
cells	3	O
.	9	O

An	5	O
increase	9	O
in	5	O
the	5	O
volume	9	O
density	9	O
of	5	O
secretory	3	O
granules	9	O
and	5	O
a	5	O
decrease	9	O
in	5	O
the	5	O
volume	9	O
densities	9	O
of	5	O
rough	5	O
endoplasmic	3	O
reticulum	9	O
and	5	O
microtubules	9	O
was	9	O
determined	9	O
by	9	O
morphometric	5	O
analysis	9	O
,	9	O
suggesting	9	O
that	5	O
bromocriptine	0	B-Chemical
inhibits	3	O
protein	1	O
synthesis	9	O
as	5	O
well	9	O
as	5	O
bringing	5	O
about	5	O
a	5	O
disturbance	5	O
of	5	O
the	5	O
prolactin	3	O
secretion	3	O
.	9	O

Sulfasalazine	7	B-Chemical
-	7	O
induced	3	O
lupus	9	B-Disease
erythematosus	9	I-Disease
.	9	O

Pneumonitis	7	B-Disease
,	9	O
bilateral	5	O
pleural	5	B-Disease
effusions	5	I-Disease
,	9	O
echocardiographic	5	O
evidence	9	O
of	5	O
cardiac	5	B-Disease
tamponade	5	I-Disease
,	9	O
and	5	O
positive	9	O
autoantibodies	3	O
developed	5	O
in	5	O
a	5	O
43	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
,	9	O
who	5	O
was	9	O
receiving	9	O
long	5	O
-	7	O
term	5	O
sulfasalazine	0	B-Chemical
therapy	5	O
for	5	O
chronic	5	O
ulcerative	5	B-Disease
colitis	3	I-Disease
.	9	O

After	9	O
cessation	5	O
of	5	O
the	5	O
sulfasalazine	0	B-Chemical
and	5	O
completion	5	O
of	5	O
a	5	O
six	9	O
-	7	O
week	9	O
course	5	O
of	5	O
corticosteroids	5	O
,	9	O
these	5	O
problems	5	O
resolved	9	O
over	5	O
a	5	O
period	5	O
of	5	O
four	9	O
to	5	O
six	9	O
months	5	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
the	5	O
patient	5	O
had	9	O
sulfasalazine	0	B-Chemical
-	7	O
induced	3	O
lupus	9	B-Disease
,	9	O
which	5	O
manifested	9	O
with	5	O
serositis	5	B-Disease
and	5	O
pulmonary	5	O
parenchymal	5	O
involvement	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
joint	5	O
symptoms	5	O
.	9	O

Physicians	5	O
who	5	O
use	5	O
sulfasalazine	0	B-Chemical
to	5	O
treat	5	O
patients	5	O
with	5	O
inflammatory	3	B-Disease
bowel	5	I-Disease
disease	5	I-Disease
should	5	O
be	5	O
aware	5	O
of	5	O
the	5	O
signs	5	O
of	5	O
sulfasalazine	0	B-Chemical
-	7	O
induced	3	O
lupus	9	B-Disease
syndrome	5	I-Disease
.	9	O

Chronic	9	O
carbamazepine	0	B-Chemical
treatment	9	O
in	5	O
the	5	O
rat	3	O
:	9	O
efficacy	9	O
,	9	O
toxicity	9	B-Disease
,	9	O
and	5	O
effect	9	O
on	5	O
plasma	9	O
and	5	O
tissue	9	O
folate	9	B-Chemical
concentrations	0	O
.	9	O

Folate	7	B-Chemical
depletion	3	O
has	9	O
often	5	O
been	9	O
a	5	O
problem	5	O
in	5	O
chronic	5	O
antiepileptic	5	O
drug	5	O
(	9	O
AED	5	O
)	9	O
therapy	5	O
.	9	O

Carbamazepine	0	B-Chemical
(	9	O
CBZ	0	B-Chemical
)	9	O
,	9	O
a	5	O
commonly	5	O
used	5	O
AED	5	O
,	9	O
has	9	O
been	9	O
implicated	9	O
in	5	O
some	5	O
clinical	5	O
studies	9	O
.	9	O

A	9	O
rat	3	O
model	5	O
was	9	O
developed	5	O
to	5	O
examine	9	O
the	5	O
effects	9	O
of	5	O
chronic	5	O
CBZ	0	B-Chemical
treatment	9	O
on	5	O
folate	9	B-Chemical
concentrations	0	O
in	5	O
the	5	O
rat	3	O
.	9	O

In	9	O
the	5	O
course	5	O
of	5	O
developing	5	O
this	5	O
model	5	O
,	9	O
a	5	O
common	5	O
vehicle	3	O
,	9	O
propylene	0	B-Chemical
glycol	0	I-Chemical
,	9	O
by	9	O
itself	9	O
in	5	O
high	9	O
doses	0	O
,	9	O
was	9	O
found	9	O
to	5	O
exhibit	9	O
protective	9	O
properties	9	O
against	9	O
induced	3	O
seizures	5	B-Disease
and	5	O
inhibited	3	O
weight	9	B-Disease
gain	5	I-Disease
.	9	O

Seizures	5	B-Disease
induced	3	O
by	9	O
hexafluorodiethyl	_	B-Chemical
ether	0	I-Chemical
(	9	O
HFDE	9	B-Chemical
)	9	O
were	9	O
also	9	O
found	9	O
to	5	O
be	5	O
a	5	O
more	5	O
sensitive	9	O
measure	5	O
of	5	O
protection	9	O
by	9	O
CBZ	0	B-Chemical
than	5	O
seizures	5	B-Disease
induced	3	O
by	9	O
maximal	9	O
electroshock	5	O
(	9	O
MES	0	O
)	9	O
.	9	O

Oral	9	O
administration	9	O
of	5	O
CBZ	0	B-Chemical
as	5	O
an	5	O
aqueous	0	O
suspension	0	O
every	5	O
8	9	O
h	0	O
at	9	O
a	5	O
dose	9	O
of	5	O
250	0	O
mg	0	O
/	9	O
kg	0	O
was	9	O
continuously	5	O
protective	9	O
against	9	O
HFDE	9	B-Chemical
-	7	O
induced	3	O
seizures	5	B-Disease
and	5	O
was	9	O
minimally	5	O
toxic	0	O
as	5	O
measured	9	O
by	9	O
weight	9	B-Disease
gain	5	I-Disease
over	5	O
8	9	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

The	5	O
CBZ	0	B-Chemical
levels	3	O
measured	9	O
in	5	O
plasma	9	O
and	5	O
brain	5	O
of	5	O
these	5	O
animals	9	O
,	9	O
however	9	O
,	9	O
were	9	O
below	9	O
those	5	O
normally	9	O
considered	5	O
protective	9	O
.	9	O

This	5	O
treatment	9	O
with	5	O
CBZ	0	B-Chemical
had	9	O
no	9	O
apparent	9	O
adverse	5	O
effect	9	O
on	5	O
folate	9	B-Chemical
concentrations	0	O
in	5	O
the	5	O
rat	3	O
,	9	O
and	5	O
,	9	O
indeed	9	O
,	9	O
the	5	O
folate	9	B-Chemical
concentration	0	O
increased	9	O
in	5	O
liver	9	O
after	9	O
6	9	O
weeks	9	O
of	5	O
treatment	9	O
and	5	O
in	5	O
plasma	9	O
at	9	O
8	9	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

Dipyridamole	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
.	9	O

Angina	7	B-Disease
and	5	O
ischemic	9	O
electrocardiographic	5	O
changes	9	O
occurred	9	O
after	9	O
administration	9	O
of	5	O
oral	9	O
dipyridamole	0	B-Chemical
in	5	O
four	9	O
patients	5	O
awaiting	5	O
urgent	5	O
myocardial	9	O
revascularization	5	O
procedures	5	O
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
has	9	O
not	5	O
previously	9	O
been	9	O
reported	9	O
as	5	O
a	5	O
side	5	O
effect	9	O
of	5	O
preoperative	5	O
dipyridamole	0	B-Chemical
therapy	5	O
,	9	O
although	9	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
ischemia	9	I-Disease
has	9	O
been	9	O
demonstrated	9	O
to	5	O
occur	5	O
in	5	O
animals	9	O
and	5	O
humans	9	O
with	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
.	9	O

Epicardial	5	O
coronary	5	O
collateral	5	O
vessels	5	O
were	9	O
demonstrated	9	O
in	5	O
all	5	O
four	9	O
patients	5	O
;	9	O
a	5	O
coronary	5	O
"	5	O
steal	5	O
"	5	O
phenomenon	5	O
may	5	O
be	5	O
the	5	O
mechanism	9	O
of	5	O
the	5	O
dipyridamole	0	B-Chemical
-	7	O
induced	3	O
ischemia	9	B-Disease
observed	9	O
.	9	O

Inhibition	3	O
of	5	O
sympathoadrenal	3	O
activity	9	O
by	9	O
atrial	5	O
natriuretic	9	O
factor	9	O
in	5	O
dogs	5	O
.	9	O

In	9	O
six	9	O
conscious	5	O
,	9	O
trained	5	O
dogs	5	O
,	9	O
maintained	9	O
on	5	O
a	5	O
normal	9	O
sodium	0	B-Chemical
intake	5	O
of	5	O
2	9	O
to	5	O
4	9	O
mEq	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
,	9	O
sympathetic	5	O
activity	9	O
was	9	O
assessed	9	O
as	5	O
the	5	O
release	9	O
rate	9	O
of	5	O
norepinephrine	9	B-Chemical
and	5	O
epinephrine	0	B-Chemical
during	5	O
15	9	O
-	7	O
minute	5	O
i	9	O
.	9	O
v	0	O
.	9	O
infusions	9	O
of	5	O
human	3	O
alpha	9	O
-	7	O
atrial	5	O
natriuretic	9	O
factor	9	O
.	9	O

Mean	9	O
arterial	5	O
pressure	5	O
(	9	O
as	5	O
a	5	O
percentage	9	O
of	5	O
control	9	O
+	9	O
/	9	O
-	7	O
SEM	9	O
)	9	O
during	5	O
randomized	5	O
infusions	9	O
of	5	O
0	7	O
.	9	O
03	7	O
,	9	O
0	7	O
.	9	O
1	9	O
,	9	O
0	7	O
.	9	O
3	9	O
,	9	O
or	5	O
1	9	O
.	9	O
0	7	O
microgram	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
was	9	O
99	7	O
+	9	O
/	9	O
-	7	O
1	9	O
,	9	O
95	7	O
+	9	O
/	9	O
-	7	O
1	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
93	7	O
+	9	O
/	9	O
-	7	O
1	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
or	5	O
79	7	O
+	9	O
/	9	O
-	7	O
6	9	O
%	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
respectively	9	O
,	9	O
but	9	O
no	9	O
tachycardia	5	B-Disease
and	5	O
no	9	O
augmentation	9	O
of	5	O
the	5	O
norepinephrine	9	B-Chemical
release	9	O
rate	9	O
(	9	O
up	5	O
to	5	O
0	7	O
.	9	O
3	9	O
microgram	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
)	9	O
were	9	O
observed	9	O
,	9	O
which	5	O
is	5	O
in	5	O
contrast	9	O
to	5	O
comparable	9	O
hypotension	5	B-Disease
induced	3	O
by	9	O
hydralazine	0	B-Chemical
or	5	O
nitroglycerin	5	B-Chemical
.	9	O

The	5	O
release	9	O
rate	9	O
of	5	O
epinephrine	0	B-Chemical
(	9	O
control	9	O
,	9	O
6	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
6	9	O
ng	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
)	9	O
declined	9	O
immediately	9	O
during	5	O
infusions	9	O
of	5	O
atrial	5	O
natriuretic	9	O
factor	9	O
to	5	O
a	5	O
minimum	5	O
of	5	O
49	7	O
+	9	O
/	9	O
-	7	O
5	9	O
%	9	O
of	5	O
control	9	O
(	9	O
p	7	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
during	5	O
0	7	O
.	9	O
1	9	O
microgram	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
and	5	O
to	5	O
63	7	O
+	9	O
/	9	O
-	7	O
5	9	O
%	9	O
(	9	O
0	7	O
.	9	O
1	9	O
greater	5	O
than	5	O
p	7	O
greater	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
or	5	O
95	7	O
+	9	O
/	9	O
-	7	O
13	7	O
%	9	O
(	9	O
not	5	O
significant	9	O
)	9	O
during	5	O
0	7	O
.	9	O
3	9	O
or	5	O
1	9	O
.	9	O
0	7	O
microgram	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
.	9	O

Steady	9	O
state	5	O
arterial	5	O
plasma	9	O
concentrations	0	O
of	5	O
atrial	5	O
natriuretic	9	O
factor	9	O
were	9	O
39	7	O
+	9	O
/	9	O
-	7	O
10	9	O
pg	7	O
/	9	O
ml	0	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
during	5	O
infusions	9	O
of	5	O
saline	0	O
and	5	O
284	7	O
+	9	O
/	9	O
-	7	O
24	9	O
pg	7	O
/	9	O
ml	0	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
and	5	O
1520	7	O
+	9	O
/	9	O
-	7	O
300	0	O
pg	7	O
/	9	O
ml	0	O
(	9	O
n	9	O
=	7	O
9	7	O
)	9	O
during	5	O
0	7	O
.	9	O
03	7	O
and	5	O
0	7	O
.	9	O
1	9	O
microgram	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
infusions	9	O
of	5	O
the	5	O
factor	9	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Inhibition	3	O
of	5	O
immunoreactive	3	O
corticotropin	9	O
-	7	O
releasing	9	O
factor	9	O
secretion	3	O
into	9	O
the	5	O
hypophysial	5	O
-	7	O
portal	5	O
circulation	9	O
by	9	O
delayed	9	O
glucocorticoid	9	O
feedback	5	O
.	9	O

Nitroprusside	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
evokes	5	O
ACTH	0	O
secretion	3	O
which	5	O
is	5	O
primarily	9	O
mediated	3	O
by	9	O
enhanced	3	O
secretion	3	O
of	5	O
immunoreactive	3	O
corticotropin	9	O
-	7	O
releasing	9	O
factor	9	O
(	9	O
irCRF	_	O
)	9	O
into	9	O
the	5	O
hypophysial	5	O
-	7	O
portal	5	O
circulation	9	O
.	9	O

Portal	2	O
plasma	9	O
concentrations	0	O
of	5	O
neither	9	O
arginine	0	B-Chemical
vasopressin	9	I-Chemical
nor	9	O
oxytocin	5	B-Chemical
are	5	O
significantly	9	O
altered	9	O
in	5	O
this	5	O
paradigm	5	O
.	9	O

Application	9	O
of	5	O
a	5	O
delayed	9	O
feedback	5	O
signal	9	O
,	9	O
in	5	O
the	5	O
form	9	O
of	5	O
a	5	O
2	9	O
-	7	O
h	0	O
systemic	9	O
corticosterone	3	B-Chemical
infusion	0	O
in	5	O
urethane	0	B-Chemical
-	7	O
anesthetized	0	O
rats	9	O
with	5	O
pharmacological	9	O
blockade	3	O
of	5	O
glucocorticoid	9	O
synthesis	9	O
,	9	O
is	5	O
without	9	O
effect	9	O
on	5	O
the	5	O
resting	5	O
secretion	3	O
of	5	O
arginine	0	B-Chemical
vasopressin	9	I-Chemical
and	5	O
oxytocin	5	B-Chemical
at	9	O
any	5	O
corticosterone	3	B-Chemical
feedback	5	O
dose	9	O
tested	9	O
.	9	O

Resting	9	O
irCRF	_	O
levels	3	O
are	5	O
suppressed	3	O
only	9	O
at	9	O
the	5	O
highest	9	O
corticosterone	3	B-Chemical
infusion	0	O
rate	9	O
,	9	O
which	5	O
resulted	9	O
in	5	O
systemic	9	O
corticosterone	3	B-Chemical
levels	3	O
of	5	O
40	9	O
micrograms	0	O
/	9	O
dl	7	O
.	9	O

Suppression	9	O
of	5	O
irCRF	_	O
secretion	3	O
in	5	O
response	9	O
to	5	O
nitroprusside	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
is	5	O
observed	9	O
and	5	O
occurs	9	O
at	9	O
a	5	O
plasma	9	O
corticosterone	3	B-Chemical
level	9	O
between	5	O
8	9	O
-	7	O
12	9	O
micrograms	0	O
/	9	O
dl	7	O
.	9	O

These	5	O
studies	9	O
provide	5	O
further	9	O
evidence	9	O
for	5	O
a	5	O
strong	9	O
central	5	O
component	9	O
of	5	O
the	5	O
delayed	9	O
feedback	5	O
process	5	O
which	5	O
is	5	O
mediated	3	O
by	9	O
modulation	9	O
of	5	O
irCRF	_	O
release	9	O
.	9	O

Noradrenergic	5	O
involvement	9	O
in	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
delta	9	B-Chemical
9	7	I-Chemical
-	7	I-Chemical
tetrahydrocannabinol	0	I-Chemical
.	9	O

In	9	O
order	5	O
to	5	O
elucidate	9	O
the	5	O
role	9	O
of	5	O
the	5	O
catecholaminergic	3	O
system	5	O
in	5	O
the	5	O
cataleptogenic	9	O
effect	9	O
of	5	O
delta	9	B-Chemical
9	7	I-Chemical
-	7	I-Chemical
tetrahydrocannabinol	0	I-Chemical
(	9	O
THC	9	B-Chemical
)	9	O
,	9	O
the	5	O
effect	9	O
of	5	O
pretreatment	0	O
with	5	O
6	9	B-Chemical
-	7	I-Chemical
hydroxydopamine	0	I-Chemical
(	9	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
)	9	O
or	5	O
with	5	O
desipramine	0	B-Chemical
and	5	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
and	5	O
lesions	5	O
of	5	O
the	5	O
locus	1	O
coeruleus	4	O
were	9	O
investigated	9	O
in	5	O
rats	9	O
.	9	O

The	5	O
cataleptogenic	9	O
effect	9	O
of	5	O
THC	9	B-Chemical
was	9	O
significantly	9	O
reduced	9	O
in	5	O
rats	9	O
treated	3	O
with	5	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
and	5	O
in	5	O
rats	9	O
with	5	O
lesions	5	O
of	5	O
the	5	O
locus	1	O
coeruleus	4	O
but	9	O
not	5	O
in	5	O
rats	9	O
treated	3	O
with	5	O
desipramine	0	B-Chemical
and	5	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
,	9	O
as	5	O
compared	9	O
with	5	O
control	9	O
rats	9	O
.	9	O

On	5	O
the	5	O
contrary	9	O
,	9	O
the	5	O
cataleptogenic	9	O
effect	9	O
of	5	O
haloperidol	5	B-Chemical
was	9	O
significantly	9	O
reduced	9	O
in	5	O
rats	9	O
treated	3	O
with	5	O
desipramine	0	B-Chemical
and	5	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
but	9	O
not	5	O
in	5	O
rats	9	O
treated	3	O
with	5	O
6	9	B-Chemical
-	7	I-Chemical
OHDA	0	I-Chemical
or	5	O
in	5	O
rats	9	O
with	5	O
lesions	5	O
of	5	O
the	5	O
locus	1	O
coeruleus	4	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
noradrenergic	5	O
neurons	3	O
have	5	O
an	5	O
important	9	O
role	9	O
in	5	O
the	5	O
manifestation	5	O
of	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
THC	9	B-Chemical
,	9	O
whereas	9	O
dopaminergic	5	O
neurons	3	O
are	5	O
important	9	O
in	5	O
catalepsy	5	B-Disease
induced	3	O
by	9	O
haloperidol	5	B-Chemical
.	9	O

Reversibility	0	O
of	5	O
captopril	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
insufficiency	9	I-Disease
after	9	O
prolonged	9	O
use	5	O
in	5	O
an	5	O
unusual	9	O
case	5	O
of	5	O
renovascular	5	B-Disease
hypertension	5	I-Disease
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
severe	5	O
hypertension	5	B-Disease
with	5	O
an	5	O
occluded	5	O
renal	9	O
artery	5	O
to	5	O
a	5	O
solitary	5	O
kidney	9	O
,	9	O
who	5	O
developed	5	O
sudden	5	B-Disease
deterioration	5	I-Disease
of	5	I-Disease
renal	9	I-Disease
function	9	I-Disease
following	9	O
treatment	9	O
with	5	O
captopril	0	B-Chemical
.	9	O

His	9	O
renal	9	O
function	9	O
remained	9	O
impaired	9	O
but	9	O
stable	9	O
during	5	O
2	9	O
years	5	O
'	9	O
treatment	9	O
with	5	O
captopril	0	B-Chemical
but	9	O
returned	5	O
to	5	O
pre	9	O
-	7	O
treatment	9	O
levels	3	O
soon	5	O
after	9	O
cessation	5	O
of	5	O
the	5	O
drug	5	O
.	9	O

This	5	O
indicates	9	O
reversibility	9	O
in	5	O
captopril	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
failure	5	I-Disease
even	5	O
after	9	O
its	9	O
prolonged	9	O
use	5	O
and	5	O
suggests	9	O
that	5	O
no	9	O
organic	0	O
damage	9	O
occurs	9	O
to	5	O
glomerular	5	O
arterioles	9	O
following	9	O
chronic	5	O
ACE	9	O
inhibition	3	O
.	9	O

HMG	1	O
CoA	0	O
reductase	0	O
inhibitors	3	O
.	9	O

Current	9	O
clinical	5	O
experience	5	O
.	9	O

Lovastatin	0	B-Chemical
and	5	O
simvastatin	0	B-Chemical
are	5	O
the	5	O
2	9	O
best	5	O
-	7	O
known	9	O
members	9	O
of	5	O
the	5	O
class	9	O
of	5	O
hypolipidaemic	0	O
agents	5	O
known	9	O
as	5	O
HMG	1	O
CoA	0	O
reductase	0	O
inhibitors	3	O
.	9	O

Clinical	5	O
experience	5	O
with	5	O
lovastatin	0	B-Chemical
includes	5	O
over	5	O
5000	0	O
patients	5	O
,	9	O
700	9	O
of	5	O
whom	5	O
have	5	O
been	9	O
treated	3	O
for	5	O
2	9	O
years	5	O
or	5	O
more	5	O
,	9	O
and	5	O
experience	5	O
with	5	O
simvastatin	0	B-Chemical
includes	5	O
over	5	O
3500	9	O
patients	5	O
,	9	O
of	5	O
whom	5	O
350	9	O
have	5	O
been	9	O
treated	3	O
for	5	O
18	7	O
months	5	O
or	5	O
more	5	O
.	9	O

Lovastatin	0	B-Chemical
has	9	O
been	9	O
marketed	5	O
in	5	O
the	5	O
United	9	O
States	9	O
for	5	O
over	5	O
6	9	O
months	5	O
.	9	O

Both	9	O
agents	5	O
show	9	O
substantial	9	O
clinical	5	O
efficacy	9	O
,	9	O
with	5	O
reductions	9	O
in	5	O
total	9	O
cholesterol	0	B-Chemical
of	5	O
over	5	O
30	9	O
%	9	O
and	5	O
in	5	O
LDL	0	O
-	7	O
cholesterol	0	B-Chemical
of	5	O
40	9	O
%	9	O
in	5	O
clinical	5	O
studies	9	O
.	9	O

Modest	9	O
increases	9	O
in	5	O
HDL	9	O
-	7	O
cholesterol	0	B-Chemical
levels	3	O
of	5	O
about	5	O
10	9	O
%	9	O
are	5	O
also	9	O
reported	9	O
.	9	O

Clinical	5	O
tolerability	5	O
of	5	O
both	9	O
agents	5	O
has	9	O
been	9	O
good	5	O
,	9	O
with	5	O
fewer	5	O
than	5	O
3	9	O
%	9	O
of	5	O
patients	5	O
withdrawn	9	O
from	9	O
treatment	9	O
because	5	O
of	5	O
clinical	5	O
adverse	5	O
experiences	5	O
.	9	O

Ophthalmological	2	O
examinations	5	O
in	5	O
over	5	O
1100	9	O
patients	5	O
treated	3	O
with	5	O
one	5	O
or	5	O
the	5	O
other	5	O
agent	9	O
have	5	O
revealed	9	O
no	9	O
evidence	9	O
of	5	O
significant	9	O
short	5	O
term	5	O
(	9	O
up	5	O
to	5	O
2	9	O
years	5	O
)	9	O
cataractogenic	3	O
potential	9	O
.	9	O

One	5	O
to	5	O
2	9	O
%	9	O
of	5	O
patients	5	O
have	5	O
elevations	9	O
of	5	O
serum	9	O
transaminases	9	O
to	5	O
greater	5	O
than	5	O
3	9	O
times	5	O
the	5	O
upper	9	O
limit	5	O
of	5	O
normal	9	O
.	9	O

These	5	O
episodes	5	O
are	5	O
asymptomatic	5	O
and	5	O
reversible	9	O
when	5	O
therapy	5	O
is	5	O
discontinued	5	O
.	9	O

Minor	9	O
elevations	9	O
of	5	O
creatine	0	B-Chemical
kinase	3	O
levels	3	O
are	5	O
reported	9	O
in	5	O
about	5	O
5	9	O
%	9	O
of	5	O
patients	5	O
.	9	O

Myopathy	7	B-Disease
,	9	O
associated	9	O
in	5	O
some	5	O
cases	5	O
with	5	O
myoglobinuria	5	B-Disease
,	9	O
and	5	O
in	5	O
2	9	O
cases	5	O
with	5	O
transient	9	O
renal	9	B-Disease
failure	5	I-Disease
,	9	O
has	9	O
been	9	O
rarely	5	O
reported	9	O
with	5	O
lovastatin	0	B-Chemical
,	9	O
especially	5	O
in	5	O
patients	5	O
concomitantly	9	O
treated	3	O
with	5	O
cyclosporin	0	B-Chemical
,	9	O
gemfibrozil	0	B-Chemical
or	5	O
niacin	0	B-Chemical
.	9	O

Lovastatin	0	B-Chemical
and	5	O
simvastatin	0	B-Chemical
are	5	O
both	9	O
effective	5	O
and	5	O
well	9	O
-	7	O
tolerated	9	O
agents	5	O
for	5	O
lowering	9	O
elevated	9	O
levels	3	O
of	5	O
serum	9	O
cholesterol	0	B-Chemical
.	9	O

As	9	O
wider	5	O
use	5	O
confirms	9	O
their	5	O
safety	5	O
profile	9	O
,	9	O
they	5	O
will	5	O
gain	5	O
increasing	9	O
importance	5	O
in	5	O
the	5	O
therapeutic	5	O
approach	5	O
to	5	O
hypercholesterolaemia	5	B-Disease
and	5	O
its	9	O
consequences	5	O
.	9	O

Hepatic	9	O
reactions	9	O
associated	9	O
with	5	O
ketoconazole	0	B-Chemical
in	5	O
the	5	O
United	9	O
Kingdom	2	O
.	9	O

Ketoconazole	0	B-Chemical
was	9	O
introduced	9	O
in	5	O
the	5	O
United	9	O
Kingdom	2	O
in	5	O
1981	2	O
.	9	O

By	5	O
November	2	O
1984	2	O
the	5	O
Committee	2	O
on	5	O
Safety	5	O
of	5	O
Medicines	5	O
had	9	O
received	9	O
82	7	O
reports	9	O
of	5	O
possible	5	O
hepatotoxicity	9	B-Disease
associated	9	O
with	5	O
the	5	O
drug	5	O
,	9	O
including	9	O
five	9	O
deaths	5	B-Disease
.	9	O

An	5	O
analysis	9	O
of	5	O
the	5	O
75	9	O
cases	5	O
that	5	O
had	9	O
been	9	O
adequately	5	O
followed	9	O
up	5	O
suggested	9	O
that	5	O
16	9	O
,	9	O
including	9	O
three	9	O
deaths	5	B-Disease
,	9	O
were	9	O
probably	9	O
related	9	O
to	5	O
treatment	9	O
with	5	O
the	5	O
drug	5	O
.	9	O

Of	9	O
the	5	O
remainder	9	O
,	9	O
48	9	O
were	9	O
possibly	9	O
related	9	O
to	5	O
treatment	9	O
,	9	O
five	9	O
were	9	O
unlikely	9	O
to	5	O
be	5	O
so	5	O
,	9	O
and	5	O
six	9	O
were	9	O
unclassifiable	5	O
.	9	O

The	5	O
mean	5	O
age	5	O
of	5	O
patients	5	O
in	5	O
the	5	O
16	9	O
probable	9	O
cases	5	O
was	9	O
57	7	O
.	9	O
9	7	O
,	9	O
with	5	O
hepatotoxicity	9	B-Disease
being	5	O
more	5	O
common	5	O
in	5	O
women	5	O
.	9	O

The	5	O
average	5	O
duration	5	O
of	5	O
treatment	9	O
before	9	O
the	5	O
onset	5	O
of	5	O
jaundice	5	B-Disease
was	9	O
61	7	O
days	9	O
.	9	O

None	9	O
of	5	O
these	5	O
well	9	O
validated	5	O
cases	5	O
occurred	9	O
within	9	O
the	5	O
first	9	O
10	9	O
days	9	O
after	9	O
treatment	9	O
.	9	O

The	5	O
results	9	O
of	5	O
serum	9	O
liver	9	O
function	9	O
tests	5	O
suggested	9	O
hepatocellular	9	B-Disease
injury	9	I-Disease
in	5	O
10	9	O
(	9	O
63	7	O
%	9	O
)	9	O
;	9	O
the	5	O
rest	5	O
showed	9	O
a	5	O
mixed	9	O
pattern	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
the	5	O
results	9	O
of	5	O
histological	9	O
examination	5	O
of	5	O
the	5	O
liver	9	O
often	5	O
showed	9	O
evidence	9	O
of	5	O
cholestasis	5	B-Disease
.	9	O

The	5	O
characteristics	5	O
of	5	O
the	5	O
48	9	O
patients	5	O
in	5	O
the	5	O
possible	5	O
cases	5	O
were	9	O
similar	9	O
.	9	O

Allergic	9	O
manifestations	5	O
such	5	O
as	5	O
rash	5	B-Disease
and	5	O
eosinophilia	3	B-Disease
were	9	O
rare	5	O
.	9	O

Hepatitis	9	B-Disease
was	9	O
usually	5	O
reversible	9	O
when	5	O
treatment	9	O
was	9	O
stopped	9	O
,	9	O
with	5	O
the	5	O
results	9	O
of	5	O
liver	9	O
function	9	O
tests	5	O
returning	5	O
to	5	O
normal	9	O
after	9	O
an	5	O
average	5	O
of	5	O
3	9	O
.	9	O
1	9	O
months	5	O
.	9	O

In	9	O
two	5	O
of	5	O
the	5	O
three	9	O
deaths	5	B-Disease
probably	9	O
associated	9	O
with	5	O
ketoconazole	0	B-Chemical
treatment	9	O
the	5	O
drug	5	O
had	9	O
been	9	O
continued	9	O
after	9	O
the	5	O
onset	5	O
of	5	O
jaundice	5	B-Disease
and	5	O
other	5	O
symptoms	5	O
of	5	O
hepatitis	9	B-Disease
.	9	O

Clinical	5	O
and	5	O
biochemical	9	O
monitoring	5	O
at	9	O
regular	5	O
intervals	5	O
for	5	O
evidence	9	O
of	5	O
hepatitis	9	B-Disease
is	5	O
advised	5	O
during	5	O
long	5	O
term	5	O
treatment	9	O
with	5	O
ketoconazole	0	B-Chemical
to	5	O
prevent	5	O
possible	5	O
serious	5	O
hepatic	9	B-Disease
injury	9	I-Disease
.	9	O

Glyburide	0	B-Chemical
-	7	O
induced	3	O
hepatitis	9	B-Disease
.	9	O

Drug	5	O
-	7	O
induced	3	O
hepatotoxicity	9	B-Disease
,	9	O
although	9	O
common	5	O
,	9	O
has	9	O
been	9	O
reported	9	O
only	9	O
infrequently	5	O
with	5	O
sulfonylureas	5	B-Chemical
.	9	O

For	9	O
glyburide	0	B-Chemical
,	9	O
a	5	O
second	9	O
-	7	O
generation	9	O
sulfonylurea	5	B-Chemical
,	9	O
only	9	O
two	5	O
brief	5	O
reports	9	O
of	5	O
hepatotoxicity	9	B-Disease
exist	9	O
.	9	O

Two	9	O
patients	5	O
with	5	O
type	9	B-Disease
II	9	I-Disease
diabetes	5	I-Disease
mellitus	9	I-Disease
developed	5	O
an	5	O
acute	9	B-Disease
hepatitis	9	I-Disease
-	7	I-Disease
like	9	I-Disease
syndrome	5	I-Disease
soon	5	O
after	9	O
initiation	9	O
of	5	O
glyburide	0	B-Chemical
therapy	5	O
.	9	O

There	5	O
was	9	O
no	9	O
serologic	9	O
evidence	9	O
of	5	O
viral	9	B-Disease
infection	9	I-Disease
,	9	O
and	5	O
a	5	O
liver	9	O
biopsy	5	O
sample	9	O
showed	9	O
a	5	O
histologic	9	O
pattern	9	O
consistent	9	O
with	5	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
hepatitis	9	I-Disease
.	9	O

Both	9	O
patients	5	O
recovered	9	O
quickly	5	O
after	9	O
stopping	5	O
glyburide	0	B-Chemical
therapy	5	O
and	5	O
have	5	O
remained	9	O
well	9	O
for	5	O
a	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
of	5	O
1	9	O
year	5	O
.	9	O

Glyburide	0	B-Chemical
can	5	O
produce	9	O
an	5	O
acute	9	B-Disease
hepatitis	9	I-Disease
-	7	I-Disease
like	9	I-Disease
illness	5	I-Disease
in	5	O
some	5	O
persons	5	O
.	9	O

Intracranial	5	O
pressure	5	O
increases	9	O
during	5	O
alfentanil	0	B-Chemical
-	7	O
induced	3	O
rigidity	5	B-Disease
.	9	O

Intracranial	5	O
pressure	5	O
(	9	O
ICP	5	O
)	9	O
was	9	O
measured	9	O
during	5	O
alfentanil	0	B-Chemical
-	7	O
induced	3	O
rigidity	5	B-Disease
in	5	O
rats	9	O
.	9	O

Ten	9	O
rats	9	O
had	9	O
arterial	5	O
,	9	O
central	5	O
venous	5	O
(	9	O
CVP	5	O
)	9	O
,	9	O
and	5	O
subdural	5	O
cannulae	5	O
inserted	9	O
under	9	O
halothane	0	B-Chemical
anesthesia	5	O
.	9	O

The	5	O
animals	9	O
were	9	O
mechanically	5	O
ventilated	5	O
to	5	O
achieve	5	O
normocarbia	5	O
(	9	O
PCO2	9	O
=	7	O
42	7	O
+	9	O
/	9	O
-	7	O
1	9	O
mmHg	7	O
,	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SE	9	O
)	9	O
.	9	O

Following	9	O
instrumentation	5	O
,	9	O
halothane	0	B-Chemical
was	9	O
discontinued	5	O
and	5	O
alfentanil	0	B-Chemical
(	9	O
125	9	O
mu	9	O
/	9	O
kg	0	O
)	9	O
administered	9	O
iv	9	O
during	5	O
emergence	9	O
from	9	O
halothane	0	B-Chemical
anesthesia	5	O
.	9	O

In	9	O
the	5	O
five	9	O
rats	9	O
that	5	O
developed	5	O
somatic	9	B-Disease
rigidity	5	I-Disease
,	9	O
ICP	5	O
and	5	O
CVP	5	O
increased	9	O
significantly	9	O
above	9	O
baseline	5	O
(	9	O
delta	9	O
ICP	5	O
7	9	O
.	9	O
5	9	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
0	7	O
mmHg	7	O
,	9	O
delta	9	O
CVP	5	O
5	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
1	9	O
.	9	O
3	9	O
mmHg	7	O
)	9	O
.	9	O

These	5	O
variables	5	O
returned	5	O
to	5	O
baseline	5	O
when	5	O
rigidity	5	B-Disease
was	9	O
abolished	3	O
with	5	O
metocurine	9	B-Chemical
.	9	O

In	9	O
five	9	O
rats	9	O
that	5	O
did	9	O
not	5	O
become	5	O
rigid	5	O
,	9	O
ICP	5	O
and	5	O
CVP	5	O
did	9	O
not	5	O
change	9	O
following	9	O
alfentanil	0	B-Chemical
.	9	O

These	5	O
observations	9	O
suggest	9	O
that	5	O
rigidity	5	B-Disease
should	5	O
be	5	O
prevented	9	O
when	5	O
alfentanil	0	B-Chemical
,	9	O
and	5	O
,	9	O
presumably	9	O
,	9	O
other	5	O
opiates	5	O
,	9	O
are	5	O
used	5	O
in	5	O
the	5	O
anesthetic	5	O
management	5	O
of	5	O
patients	5	O
with	5	O
ICP	5	O
problems	5	O
.	9	O

Verapamil	0	B-Chemical
withdrawal	5	O
as	5	O
a	5	O
possible	5	O
cause	5	O
of	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
a	5	O
hypertensive	5	B-Disease
woman	5	O
with	5	O
a	5	O
normal	9	O
coronary	5	O
angiogram	5	O
.	9	O

Verapamil	0	B-Chemical
is	5	O
an	5	O
effective	5	O
and	5	O
relatively	5	O
-	7	O
safe	5	O
antihypertensive	5	O
drug	5	O
.	9	O

Serious	5	O
adverse	5	O
effects	9	O
are	5	O
uncommon	5	O
and	5	O
mainly	9	O
have	5	O
been	9	O
related	9	O
to	5	O
the	5	O
depression	5	B-Disease
of	5	O
cardiac	5	O
contractility	9	O
and	5	O
conduction	5	O
,	9	O
especially	5	O
when	5	O
the	5	O
drug	5	O
is	5	O
combined	9	O
with	5	O
beta	9	O
-	7	O
blocking	3	O
agents	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
in	5	O
which	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
coincided	9	O
with	5	O
the	5	O
introduction	9	O
of	5	O
captopril	0	B-Chemical
and	5	O
the	5	O
withdrawal	5	O
of	5	O
verapamil	0	B-Chemical
in	5	O
a	5	O
previously	9	O
asymptomatic	5	O
woman	5	O
with	5	O
severe	5	O
hypertension	5	B-Disease
.	9	O

Possible	9	O
mechanisms	9	O
that	5	O
involve	5	O
a	5	O
verapamil	0	B-Chemical
-	7	O
related	9	O
increase	9	O
in	5	O
platelet	9	O
and	5	O
/	9	O
or	5	O
vascular	5	O
alpha	9	O
2	9	O
-	7	O
adrenoreceptor	0	O
affinity	0	O
for	5	O
catecholamines	9	B-Chemical
are	5	O
discussed	5	O
.	9	O

Haemolytic	0	B-Disease
-	7	I-Disease
uraemic	9	I-Disease
syndrome	5	I-Disease
after	9	O
treatment	9	O
with	5	O
metronidazole	0	B-Chemical
.	9	O

This	5	O
paper	5	O
describes	5	O
the	5	O
clinical	5	O
features	5	O
of	5	O
six	9	O
children	5	O
who	5	O
developed	5	O
the	5	O
haemolytic	9	B-Disease
-	7	I-Disease
uraemic	9	I-Disease
syndrome	5	I-Disease
after	9	O
treatment	9	O
with	5	O
metronidazole	0	B-Chemical
.	9	O

These	5	O
children	5	O
were	9	O
older	5	O
and	5	O
were	9	O
more	5	O
likely	5	O
to	5	O
have	5	O
undergone	5	O
recent	5	O
bowel	5	O
surgery	5	O
than	5	O
are	5	O
other	5	O
children	5	O
with	5	O
this	5	O
condition	5	O
.	9	O

While	9	O
the	5	O
involvement	9	O
of	5	O
metronidazole	0	B-Chemical
in	5	O
the	5	O
aetiology	5	O
of	5	O
the	5	O
haemolytic	9	B-Disease
-	7	I-Disease
uraemic	9	I-Disease
syndrome	5	I-Disease
is	5	O
not	5	O
established	9	O
firmly	5	O
,	9	O
the	5	O
action	5	O
of	5	O
this	5	O
drug	5	O
in	5	O
sensitizing	3	O
tissues	9	O
to	5	O
oxidation	0	O
injury	9	O
and	5	O
the	5	O
reported	9	O
evidence	9	O
of	5	O
oxidation	0	O
changes	9	O
in	5	O
the	5	O
haemolytic	9	B-Disease
-	7	I-Disease
uraemic	9	I-Disease
syndrome	5	I-Disease
suggest	9	O
a	5	O
possible	5	O
link	5	O
between	5	O
metronidazole	0	B-Chemical
treatment	9	O
and	5	O
some	5	O
cases	5	O
of	5	O
the	5	O
haemolytic	9	B-Disease
-	7	I-Disease
uraemic	9	I-Disease
syndrome	5	I-Disease
.	9	O

Adverse	5	O
cardiac	5	O
effects	9	O
during	5	O
induction	3	O
chemotherapy	5	O
treatment	9	O
with	5	O
cis	9	B-Chemical
-	7	I-Chemical
platin	0	I-Chemical
and	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
.	9	O

Survival	9	O
for	5	O
patients	5	O
with	5	O
advanced	5	O
head	5	B-Disease
and	5	I-Disease
neck	5	I-Disease
carcinoma	3	I-Disease
and	5	O
esophageal	5	B-Disease
carcinoma	3	I-Disease
is	5	O
poor	5	O
with	5	O
radiotherapy	5	O
and	5	O
/	9	O
or	5	O
surgery	5	O
.	9	O

Obviously	5	O
,	9	O
there	5	O
is	5	O
a	5	O
need	5	O
for	5	O
effective	5	O
chemotherapy	5	O
.	9	O

In	9	O
the	5	O
present	9	O
study	9	O
,	9	O
cis	9	B-Chemical
-	7	I-Chemical
platin	0	I-Chemical
(	9	O
80	9	O
-	7	O
120	9	O
mg	0	O
/	9	O
m2BSA	9	O
)	9	O
and	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
(	9	O
1000	9	O
mg	0	O
/	9	O
m2BSA	9	O
daily	5	O
as	5	O
a	5	O
continuous	5	O
infusion	0	O
during	5	O
5	9	O
days	9	O
)	9	O
were	9	O
given	5	O
to	5	O
76	7	O
patients	5	O
before	9	O
radiotherapy	5	O
and	5	O
surgery	5	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
study	9	O
was	9	O
to	5	O
clarify	9	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
adverse	5	O
cardiac	5	O
effects	9	O
to	5	O
this	5	O
treatment	9	O
.	9	O

Before	9	O
treatment	9	O
all	5	O
patients	5	O
had	9	O
a	5	O
cardiac	5	O
evaluation	5	O
and	5	O
during	5	O
treatment	9	O
serial	9	O
ECG	5	O
recordings	5	O
were	9	O
performed	9	O
.	9	O

In	9	O
the	5	O
pre	9	O
-	7	O
treatment	9	O
evaluation	5	O
,	9	O
signs	5	O
of	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
were	9	O
found	9	O
in	5	O
33	7	O
patients	5	O
(	9	O
43	7	O
%	9	O
)	9	O
.	9	O

During	5	O
treatment	9	O
,	9	O
adverse	5	O
cardiac	5	O
effects	9	O
were	9	O
observed	9	O
in	5	O
14	7	O
patients	5	O
(	9	O
18	7	O
%	9	O
)	9	O
.	9	O

The	5	O
mean	5	O
age	5	O
of	5	O
these	5	O
patients	5	O
was	9	O
the	5	O
same	9	O
as	5	O
for	5	O
the	5	O
entire	9	O
group	9	O
,	9	O
64	7	O
years	5	O
.	9	O

The	5	O
incidence	5	O
of	5	O
cardiotoxicity	9	B-Disease
was	9	O
not	5	O
higher	9	O
in	5	O
patients	5	O
with	5	O
signs	5	O
of	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
than	5	O
in	5	O
those	5	O
without	9	O
in	5	O
the	5	O
pre	9	O
-	7	O
treatment	9	O
evaluation	5	O
.	9	O

The	5	O
most	9	O
common	5	O
signs	5	O
of	5	O
cardiotoxicity	9	B-Disease
were	9	O
chest	5	B-Disease
pain	5	I-Disease
,	9	O
ST	9	O
-	7	O
T	3	O
wave	5	O
changes	9	O
and	5	O
atrial	5	B-Disease
fibrillation	5	I-Disease
.	9	O

This	5	O
was	9	O
followed	9	O
by	9	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
in	5	O
one	5	O
patient	5	O
and	5	O
sudden	5	B-Disease
death	9	I-Disease
in	5	O
another	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
patients	5	O
on	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
treatment	9	O
should	5	O
be	5	O
under	9	O
close	5	O
supervision	5	O
and	5	O
that	5	O
the	5	O
treatment	9	O
should	5	O
be	5	O
discontinued	5	O
if	5	O
chest	5	B-Disease
pain	5	I-Disease
or	5	O
tachyarrhythmia	5	B-Disease
is	5	O
observed	9	O
.	9	O

Death	9	B-Disease
from	9	O
chemotherapy	5	O
in	5	O
gestational	5	B-Disease
trophoblastic	3	I-Disease
disease	5	I-Disease
.	9	O

Multiple	5	O
cytotoxic	3	O
drug	5	O
administration	9	O
is	5	O
the	5	O
generally	5	O
accepted	5	O
treatment	9	O
of	5	O
patients	5	O
with	5	O
a	5	O
high	9	O
-	7	O
risk	5	O
stage	9	O
of	5	O
choriocarcinoma	3	B-Disease
.	9	O

Based	9	O
on	5	O
this	5	O
principle	5	O
a	5	O
27	7	O
-	7	O
year	5	O
old	5	O
woman	5	O
,	9	O
classified	5	O
as	5	O
being	5	O
in	5	O
the	5	O
high	9	O
-	7	O
risk	5	O
group	9	O
(	9	O
Goldstein	6	O
and	5	O
Berkowitz	6	O
score	5	O
:	9	O
11	7	O
)	9	O
,	9	O
was	9	O
treated	3	O
with	5	O
multiple	5	O
cytotoxic	3	O
drugs	5	O
.	9	O

The	5	O
multiple	5	O
drug	5	O
schema	5	O
consisted	5	O
of	5	O
:	9	O
Etoposide	3	B-Chemical
16	9	O
.	9	O
213	7	O
,	9	O
Methotrexate	0	B-Chemical
,	9	O
Cyclophosphamide	0	B-Chemical
,	9	O
Actomycin	_	B-Chemical
-	7	I-Chemical
D	9	I-Chemical
,	9	O
and	5	O
Cisplatin	0	B-Chemical
.	9	O

On	5	O
the	5	O
first	9	O
day	9	O
of	5	O
the	5	O
schedule	5	O
,	9	O
moderate	9	O
high	9	O
doses	0	O
of	5	O
Methotrexate	0	B-Chemical
,	9	O
Etoposide	3	B-Chemical
and	5	O
Cyclophosphamide	0	B-Chemical
were	9	O
administered	9	O
.	9	O

Within	9	O
8	9	O
hours	9	O
after	9	O
initiation	9	O
of	5	O
therapy	5	O
the	5	O
patient	5	O
died	9	O
with	5	O
a	5	O
clinical	5	O
picture	5	O
resembling	9	O
massive	9	O
pulmonary	5	B-Disease
obstruction	5	I-Disease
due	5	O
to	5	O
choriocarcinomic	_	O
tissue	9	O
plugs	9	O
,	9	O
probably	9	O
originating	9	O
from	9	O
the	5	O
uterus	9	O
.	9	O

Formation	9	O
of	5	O
these	5	O
plugs	9	O
was	9	O
probably	9	O
due	5	O
to	5	O
extensive	5	O
tumor	3	B-Disease
necrosis	9	B-Disease
at	9	O
the	5	O
level	9	O
of	5	O
the	5	O
walls	5	O
of	5	O
the	5	O
major	9	O
uterine	5	O
veins	5	O
,	9	O
which	5	O
resulted	9	O
in	5	O
an	5	O
open	5	O
exchange	9	O
of	5	O
tumor	3	B-Disease
plugs	9	O
to	5	O
the	5	O
vascular	5	O
spaces	5	O
;	9	O
decrease	9	O
in	5	O
tumor	3	B-Disease
tissue	9	O
coherence	5	O
secondary	9	O
to	5	O
chemotherapy	5	O
may	5	O
have	5	O
further	9	O
contributed	9	O
to	5	O
the	5	O
formation	9	O
of	5	O
tumor	3	B-Disease
emboli	5	O
.	9	O

In	9	O
view	5	O
of	5	O
the	5	O
close	5	O
time	5	O
association	9	O
between	5	O
the	5	O
start	9	O
of	5	O
chemotherapy	5	O
and	5	O
the	5	O
acute	9	O
onset	5	O
of	5	O
massive	9	O
embolism	5	B-Disease
other	5	O
explanations	5	O
,	9	O
such	5	O
as	5	O
spontaneous	5	O
necrosis	9	B-Disease
,	9	O
must	5	O
be	5	O
considered	5	O
less	5	O
likely	5	O
.	9	O

Patients	5	O
with	5	O
large	5	O
pelvic	5	B-Disease
tumor	3	I-Disease
loads	9	O
are	5	O
,	9	O
according	9	O
to	5	O
existing	5	O
classifications	5	O
,	9	O
at	9	O
high	9	O
risk	5	O
to	5	O
die	5	O
and	5	O
to	5	O
develop	5	O
drug	5	O
resistance	9	O
.	9	O

Notwithstanding	5	O
these	5	O
facts	5	O
our	5	O
findings	9	O
suggest	9	O
that	5	O
these	5	O
patients	5	O
might	9	O
benefit	5	O
from	9	O
relatively	5	O
mild	9	O
initial	9	O
treatment	9	O
,	9	O
especially	5	O
true	5	O
for	5	O
patients	5	O
not	5	O
previously	9	O
exposed	9	O
to	5	O
this	5	O
drug	5	O
.	9	O

Close	9	O
observation	9	O
of	5	O
the	5	O
response	9	O
status	9	O
both	9	O
clinically	5	O
and	5	O
with	5	O
beta	9	O
-	7	O
hCG	9	O
values	5	O
may	5	O
indicate	9	O
whether	9	O
and	5	O
when	5	O
more	5	O
agressive	5	O
combination	9	O
chemotherapy	5	O
should	5	O
be	5	O
started	5	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Pulmonary	9	O
shunt	5	O
and	5	O
cardiovascular	5	O
responses	5	O
to	5	O
CPAP	5	O
during	5	O
nitroprusside	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
continuous	5	O
positive	9	O
airway	5	O
pressure	5	O
(	9	O
CPAP	5	O
)	9	O
on	5	O
cardiovascular	5	O
dynamics	5	O
and	5	O
pulmonary	5	O
shunt	5	O
(	9	O
QS	9	O
/	9	O
QT	5	O
)	9	O
were	9	O
investigated	9	O
in	5	O
12	9	O
dogs	5	O
before	9	O
and	5	O
during	5	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
infusion	0	O
that	5	O
decreased	9	O
mean	5	O
arterial	5	O
blood	9	O
pressure	5	O
40	9	O
-	7	O
50	0	O
per	9	O
cent	5	O
.	9	O

Before	9	O
nitroprusside	0	B-Chemical
infusion	0	O
,	9	O
5	9	O
cm	9	O
H2O	0	B-Chemical
CPAP	5	O
significantly	9	O
,	9	O
P	9	O
less	5	O
than	5	O
.	9	O
05	7	O
,	9	O
decreased	9	O
arterial	5	O
blood	9	O
pressure	5	O
,	9	O
but	9	O
did	9	O
not	5	O
significantly	9	O
alter	9	O
heart	5	O
rate	9	O
,	9	O
cardiac	5	O
output	5	O
,	9	O
systemic	9	O
vascular	5	O
resistance	9	O
,	9	O
or	5	O
QS	9	O
/	9	O
QT	5	O
.	9	O

Ten	9	O
cm	9	O
H2O	0	B-Chemical
CPAP	5	O
before	9	O
nitroprusside	0	B-Chemical
infusion	0	O
produced	9	O
a	5	O
further	9	O
decrease	9	B-Disease
in	5	I-Disease
arterial	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
and	5	O
significantly	9	O
increased	9	O
heart	5	O
rate	9	O
and	5	O
decreased	9	B-Disease
cardiac	5	I-Disease
output	5	I-Disease
and	5	O
QS	9	O
/	9	O
QT	5	O
.	9	O

Nitroprusside	0	B-Chemical
caused	9	O
significant	9	O
decreases	9	B-Disease
in	5	I-Disease
arterial	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
and	5	O
systemic	9	O
vascular	5	O
resistance	9	O
and	5	O
increases	9	O
in	5	O
heart	5	O
rate	9	O
,	9	O
but	9	O
did	9	O
not	5	O
change	9	O
cardiac	5	O
output	5	O
or	5	O
QS	9	O
/	9	O
QT	5	O
.	9	O

Five	9	O
cm	9	O
H2O	0	B-Chemical
CPAP	5	O
during	5	O
nitroprusside	0	B-Chemical
did	9	O
not	5	O
further	9	O
alter	9	O
any	5	O
of	5	O
the	5	O
above	9	O
-	7	O
mentioned	5	O
variables	5	O
.	9	O

However	9	O
,	9	O
10	9	O
cm	9	O
H2O	0	B-Chemical
CPAP	5	O
decreased	9	O
arterial	5	O
blood	9	O
pressure	5	O
,	9	O
cardiac	5	O
output	5	O
,	9	O
and	5	O
QS	9	O
/	9	O
QT	5	O
.	9	O

These	5	O
data	5	O
indicate	9	O
that	5	O
nitroprusside	0	B-Chemical
infusion	0	O
rates	5	O
that	5	O
decrease	9	O
mean	5	O
arterial	5	O
blood	9	O
pressure	5	O
by	9	O
40	9	O
-	7	O
50	0	O
per	9	O
cent	5	O
do	5	O
not	5	O
change	9	O
cardiac	5	O
output	5	O
or	5	O
QS	9	O
/	9	O
QT	5	O
.	9	O

During	5	O
nitroprusside	0	B-Chemical
infusion	0	O
low	9	O
levels	3	O
of	5	O
CPAP	5	O
do	5	O
not	5	O
markedly	9	O
alter	9	O
cardiovascular	5	O
dynamics	5	O
,	9	O
but	9	O
high	9	O
levels	3	O
of	5	O
CPAP	5	O
(	9	O
10	9	O
cm	9	O
H2O	0	B-Chemical
)	9	O
,	9	O
while	9	O
decreasing	9	O
QS	9	O
/	9	O
QT	5	O
,	9	O
produce	9	O
marked	9	O
decreases	9	B-Disease
in	5	I-Disease
arterial	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
and	5	I-Disease
cardiac	5	I-Disease
output	5	I-Disease
.	9	O

Systolic	7	O
pressure	5	O
variation	5	O
is	5	O
greater	5	O
during	5	O
hemorrhage	5	B-Disease
than	5	O
during	5	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
in	5	O
ventilated	5	O
dogs	5	O
.	9	O

The	5	O
systolic	5	O
pressure	5	O
variation	5	O
(	9	O
SPV	5	O
)	9	O
,	9	O
which	5	O
is	5	O
the	5	O
difference	9	O
between	5	O
the	5	O
maximal	9	O
and	5	O
minimal	9	O
values	5	O
of	5	O
the	5	O
systolic	5	O
blood	9	O
pressure	5	O
(	9	O
SBP	9	O
)	9	O
after	9	O
one	5	O
positive	9	O
-	7	O
pressure	5	O
breath	5	O
,	9	O
was	9	O
studied	9	O
in	5	O
ventilated	5	O
dogs	5	O
subjected	9	O
to	5	O
hypotension	5	B-Disease
.	9	O

Mean	9	O
arterial	5	O
pressure	5	O
was	9	O
decreased	9	O
to	5	O
50	0	O
mm	9	O
Hg	0	O
for	5	O
30	9	O
minutes	0	O
either	9	O
by	9	O
hemorrhage	5	B-Disease
(	9	O
HEM	0	B-Disease
,	9	O
n	9	O
=	7	O
7	9	O
)	9	O
or	5	O
by	9	O
continuous	5	O
infusion	0	O
of	5	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
(	9	O
SNP	9	B-Chemical
,	9	O
n	9	O
=	7	O
7	9	O
)	9	O
.	9	O

During	5	O
HEM	0	B-Disease
-	7	O
induced	3	O
hypotension	5	B-Disease
the	5	O
cardiac	5	O
output	5	O
was	9	O
significantly	9	O
lower	9	O
and	5	O
systemic	9	O
vascular	5	O
resistance	9	O
higher	9	O
compared	9	O
with	5	O
that	5	O
in	5	O
the	5	O
SNP	9	B-Chemical
group	9	O
.	9	O

The	5	O
systemic	9	O
,	9	O
central	5	O
venous	5	O
,	9	O
pulmonary	5	O
capillary	0	O
wedge	5	O
pressures	5	O
,	9	O
and	5	O
heart	5	O
rates	5	O
,	9	O
were	9	O
similar	9	O
in	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

Analysis	9	O
of	5	O
the	5	O
respiratory	5	O
changes	9	O
in	5	O
the	5	O
arterial	5	O
pressure	5	O
waveform	5	O
enabled	5	O
differentiation	3	O
between	5	O
the	5	O
two	5	O
groups	9	O
.	9	O

The	5	O
SPV	5	O
during	5	O
hypotension	5	B-Disease
was	9	O
15	9	O
.	9	O
7	9	O
+	9	O
/	9	O
-	7	O
6	9	O
.	9	O
7	9	O
mm	9	O
Hg	0	O
in	5	O
the	5	O
HEM	0	B-Disease
group	9	O
,	9	O
compared	9	O
with	5	O
9	7	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
0	7	O
mm	9	O
Hg	0	O
in	5	O
the	5	O
SNP	9	B-Chemical
group	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

The	5	O
delta	9	O
down	9	O
,	9	O
which	5	O
is	5	O
the	5	O
measure	5	O
of	5	O
decrease	9	O
of	5	O
SBP	9	O
after	9	O
a	5	O
mechanical	5	O
breath	5	O
,	9	O
was	9	O
20	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
8	9	O
.	9	O
4	9	O
and	5	O
10	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
3	9	O
.	9	O
8	9	O
mm	9	O
Hg	0	O
in	5	O
the	5	O
HEM	0	B-Disease
and	5	O
SNP	9	B-Chemical
groups	9	O
,	9	O
respectively	9	O
,	9	O
during	5	O
hypotension	5	B-Disease
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
02	7	O
)	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
increases	9	O
in	5	O
the	5	O
SPV	5	O
and	5	O
the	5	O
delta	9	O
down	9	O
are	5	O
characteristic	9	O
of	5	O
a	5	O
hypotensive	5	B-Disease
state	5	O
due	5	O
to	5	O
a	5	O
predominant	9	O
decrease	9	O
in	5	O
preload	5	O
.	9	O

They	5	O
are	5	O
thus	9	O
more	5	O
important	9	O
during	5	O
absolute	5	O
hypovolemia	5	B-Disease
than	5	O
during	5	O
deliberate	5	O
hypotension	5	B-Disease
.	9	O

Ventricular	5	B-Disease
tachyarrhythmias	5	I-Disease
during	5	O
cesarean	5	O
section	5	O
after	9	O
ritodrine	0	B-Chemical
therapy	5	O
:	9	O
interaction	9	O
with	5	O
anesthetics	5	O
.	9	O

This	5	O
case	5	O
illustrates	5	O
that	5	O
patients	5	O
receiving	9	O
ritodrine	0	B-Chemical
for	5	O
preterm	5	B-Disease
labor	5	I-Disease
may	5	O
risk	5	O
interactions	9	O
between	5	O
the	5	O
residual	9	O
betamimetic	9	O
effects	9	O
of	5	O
ritodrine	0	B-Chemical
and	5	O
the	5	O
effects	9	O
of	5	O
anesthetics	5	O
during	5	O
cesarean	5	O
section	5	O
.	9	O

Such	5	O
interactions	9	O
may	5	O
result	9	O
in	5	O
serious	5	O
cardiovascular	5	B-Disease
complications	5	I-Disease
even	5	O
after	9	O
cessation	5	O
of	5	O
an	5	O
infusion	0	O
of	5	O
ritodrine	0	B-Chemical
.	9	O

Preoperative	5	O
assessment	5	O
should	5	O
focus	5	O
on	5	O
cardiovascular	5	O
status	9	O
and	5	O
serum	9	O
potassium	0	B-Chemical
level	9	O
.	9	O

Delaying	5	O
induction	3	O
of	5	O
anesthesia	5	O
should	5	O
be	5	O
considered	5	O
whenever	5	O
possible	5	O
.	9	O

Careful	5	O
fluid	5	O
administration	9	O
and	5	O
cautious	5	O
use	5	O
of	5	O
titrated	0	O
doses	0	O
of	5	O
ephedrine	0	B-Chemical
are	5	O
advised	5	O
.	9	O

After	9	O
delivery	5	O
of	5	O
the	5	O
infant	5	O
,	9	O
there	5	O
should	5	O
be	5	O
no	9	O
contraindication	5	O
to	5	O
the	5	O
use	5	O
of	5	O
an	5	O
alpha	9	O
-	7	O
adrenergic	9	O
vasopressor	5	O
such	5	O
as	5	O
phenylephrine	0	B-Chemical
to	5	O
treat	5	O
hypotensive	5	B-Disease
patients	5	O
with	5	O
tachycardia	5	B-Disease
.	9	O

Verapamil	0	B-Chemical
-	7	O
induced	3	O
carbamazepine	0	B-Chemical
neurotoxicity	9	B-Disease
.	9	O

A	9	O
report	5	O
of	5	O
two	5	O
cases	5	O
.	9	O

Two	9	O
patients	5	O
with	5	O
signs	5	O
of	5	O
carbamazepine	0	B-Chemical
neurotoxicity	9	B-Disease
after	9	O
combined	9	O
treatment	9	O
with	5	O
verapamil	0	B-Chemical
showed	9	O
complete	9	O
recovery	9	O
after	9	O
discontinuation	5	O
of	5	O
the	5	O
calcium	0	B-Chemical
entry	9	O
blocker	0	O
.	9	O

Use	5	O
of	5	O
verapamil	0	B-Chemical
in	5	O
combination	9	O
with	5	O
carbamazepine	0	B-Chemical
should	5	O
either	9	O
be	5	O
avoided	5	O
or	5	O
prescribed	5	O
only	9	O
with	5	O
appropriate	5	O
adjustment	5	O
of	5	O
the	5	O
carbamazepine	0	B-Chemical
dose	9	O
(	9	O
usually	5	O
reduction	9	O
of	5	O
the	5	O
carbamazepine	0	B-Chemical
dose	9	O
by	9	O
one	5	O
half	5	O
)	9	O
.	9	O

Paracetamol	0	B-Chemical
-	7	O
associated	9	O
coma	5	B-Disease
,	9	O
metabolic	9	B-Disease
acidosis	5	I-Disease
,	9	O
renal	9	B-Disease
and	5	I-Disease
hepatic	9	I-Disease
failure	5	I-Disease
.	9	O

A	9	O
case	5	O
of	5	O
metabolic	9	B-Disease
acidosis	5	I-Disease
,	9	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
and	5	I-Disease
hepatic	9	I-Disease
failure	5	I-Disease
following	9	O
paracetamol	0	B-Chemical
ingestion	9	O
is	5	O
presented	5	O
.	9	O

The	5	O
diagnostic	5	O
difficulty	5	O
at	9	O
presentation	5	O
is	5	O
highlighted	9	O
.	9	O

Continuous	5	O
arteriovenous	5	O
haemofiltration	5	O
proved	9	O
a	5	O
valuable	5	O
means	5	O
of	5	O
maintaining	9	O
fluid	5	O
and	5	O
electrolyte	0	O
balance	5	O
.	9	O

The	5	O
patient	5	O
recovered	9	O
.	9	O

Sexual	5	B-Disease
dysfunction	9	I-Disease
among	5	O
patients	5	O
with	5	O
arthritis	9	B-Disease
.	9	O

The	5	O
relationship	5	O
of	5	O
arthritis	9	B-Disease
and	5	O
sexual	5	B-Disease
dysfunction	9	I-Disease
was	9	O
investigated	9	O
among	5	O
169	7	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
,	9	O
osteoarthritis	5	B-Disease
and	5	O
spondyloarthropathy	5	B-Disease
,	9	O
130	9	O
of	5	O
whom	5	O
were	9	O
pair	9	O
-	7	O
matched	9	O
to	5	O
controls	9	O
.	9	O

Assessments	5	O
of	5	O
marital	5	O
happiness	5	O
and	5	O
depressed	5	B-Disease
mood	5	I-Disease
were	9	O
also	9	O
made	5	O
using	9	O
the	5	O
CES	5	O
-	7	O
D	9	O
and	5	O
the	5	O
Azrin	6	O
Marital	7	O
Happiness	5	O
Scale	5	O
(	9	O
AMHS	5	O
)	9	O
.	9	O

Sexual	5	B-Disease
dysfunctions	5	I-Disease
were	9	O
found	9	O
to	5	O
be	5	O
common	5	O
among	5	O
patients	5	O
and	5	O
controls	9	O
,	9	O
the	5	O
majority	9	O
in	5	O
both	9	O
groups	9	O
reporting	5	O
one	5	O
or	5	O
more	5	O
dysfunctions	5	O
.	9	O

Impotence	2	B-Disease
was	9	O
more	5	O
common	5	O
among	5	O
male	9	O
patients	5	O
than	5	O
controls	9	O
and	5	O
was	9	O
found	9	O
to	5	O
be	5	O
associated	9	O
with	5	O
co	9	O
-	7	O
morbidity	5	O
and	5	O
the	5	O
taking	5	O
of	5	O
methotrexate	9	B-Chemical
.	9	O

Depressed	5	B-Disease
mood	5	I-Disease
was	9	O
more	5	O
common	5	O
among	5	O
patients	5	O
and	5	O
was	9	O
associated	9	O
with	5	O
certain	5	O
sexual	5	O
difficulties	5	O
,	9	O
but	9	O
not	5	O
with	5	O
impotence	5	B-Disease
.	9	O

Marital	7	O
unhappiness	5	O
,	9	O
as	5	O
indicated	9	O
by	9	O
AMHS	5	O
scores	5	O
,	9	O
was	9	O
not	5	O
associated	9	O
with	5	O
arthritis	9	B-Disease
but	9	O
was	9	O
associated	9	O
with	5	O
sexual	5	B-Disease
dysfunction	9	I-Disease
,	9	O
sexual	5	O
dissatisfaction	5	O
and	5	O
being	5	O
female	9	O
.	9	O

Does	5	O
paracetamol	0	B-Chemical
cause	5	O
urothelial	3	B-Disease
cancer	3	I-Disease
or	5	O
renal	9	B-Disease
papillary	5	I-Disease
necrosis	9	I-Disease
?	5	O

The	5	O
risk	5	O
of	5	O
developing	5	O
renal	9	B-Disease
papillary	5	I-Disease
necrosis	9	I-Disease
or	5	O
cancer	3	B-Disease
of	5	I-Disease
the	5	I-Disease
renal	9	I-Disease
pelvis	5	I-Disease
,	9	I-Disease
ureter	5	I-Disease
or	5	I-Disease
bladder	9	I-Disease
associated	9	O
with	5	O
consumption	5	O
of	5	O
either	9	O
phenacetin	0	B-Chemical
or	5	O
paracetamol	0	B-Chemical
was	9	O
calculated	5	O
from	9	O
data	5	O
acquired	5	O
by	9	O
questionnaire	5	O
from	9	O
381	7	O
cases	5	O
and	5	O
808	7	O
controls	9	O
.	9	O

The	5	O
risk	5	O
of	5	O
renal	9	B-Disease
papillary	5	I-Disease
necrosis	9	I-Disease
was	9	O
increased	9	O
nearly	9	O
20	9	O
-	7	O
fold	9	O
by	9	O
consumption	5	O
of	5	O
phenacetin	0	B-Chemical
,	9	O
which	5	O
also	9	O
increased	9	O
the	5	O
risk	5	O
for	5	O
cancer	3	B-Disease
of	5	I-Disease
the	5	I-Disease
renal	9	I-Disease
pelvis	5	I-Disease
and	5	I-Disease
bladder	9	I-Disease
but	9	O
not	5	O
for	5	O
ureteric	5	B-Disease
cancer	3	I-Disease
.	9	O

By	5	O
contrast	9	O
,	9	O
we	5	O
were	9	O
unable	9	O
to	5	O
substantiate	9	O
an	5	O
increased	9	O
risk	5	O
from	9	O
paracetamol	0	B-Chemical
consumption	5	O
for	5	O
renal	9	B-Disease
papillary	5	I-Disease
necrosis	9	I-Disease
or	5	O
any	5	O
of	5	O
these	5	O
cancers	9	B-Disease
although	9	O
there	5	O
was	9	O
a	5	O
suggestion	9	O
of	5	O
an	5	O
association	9	O
with	5	O
cancer	3	B-Disease
of	5	I-Disease
the	5	I-Disease
ureter	5	I-Disease
.	9	O

Dapsone	0	B-Chemical
-	7	O
associated	9	O
Heinz	6	O
body	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
in	5	O
a	5	O
Cambodian	5	O
woman	5	O
with	5	O
hemoglobin	0	O
E	9	O
trait	5	O
.	9	O

A	9	O
Cambodian	5	O
woman	5	O
with	5	O
hemoglobin	0	O
E	9	O
trait	5	O
(	9	O
AE	9	O
)	9	O
and	5	O
leprosy	5	B-Disease
developed	5	O
a	5	O
Heinz	6	O
body	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
while	9	O
taking	5	O
a	5	O
dose	9	O
of	5	O
dapsone	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
day	9	O
)	9	O
not	5	O
usually	5	O
associated	9	O
with	5	O
clinical	5	O
hemolysis	9	B-Disease
.	9	O

Her	5	O
red	9	O
blood	9	O
cells	3	O
(	9	O
RBCs	9	O
)	9	O
had	9	O
increased	9	O
incubated	0	O
Heinz	6	O
body	5	O
formation	9	O
,	9	O
decreased	9	O
reduced	9	O
glutathione	0	B-Chemical
(	9	O
GSH	0	B-Chemical
)	9	O
,	9	O
and	5	O
decreased	9	O
GSH	0	B-Chemical
stability	9	O
.	9	O

The	5	O
pentose	0	B-Chemical
phosphate	0	I-Chemical
shunt	5	O
activity	9	O
of	5	O
the	5	O
dapsone	0	B-Chemical
-	7	O
exposed	9	O
AE	9	O
RBCs	9	O
was	9	O
increased	9	O
compared	9	O
to	5	O
normal	9	O
RBCs	9	O
.	9	O

Although	9	O
the	5	O
AE	9	O
RBCs	9	O
from	9	O
an	5	O
individual	5	O
not	5	O
taking	5	O
dapsone	0	B-Chemical
had	9	O
increased	9	O
incubated	0	O
Heinz	6	O
body	5	O
formation	9	O
,	9	O
the	5	O
GSH	0	B-Chemical
content	9	O
and	5	O
GSH	0	B-Chemical
stability	9	O
were	9	O
normal	9	O
.	9	O

The	5	O
pentose	0	B-Chemical
phosphate	0	I-Chemical
shunt	5	O
activity	9	O
of	5	O
the	5	O
non	9	O
-	7	O
dapsone	0	B-Chemical
-	7	O
exposed	9	O
AE	9	O
RBCs	9	O
was	9	O
decreased	9	O
compared	9	O
to	5	O
normal	9	O
RBCs	9	O
.	9	O

Thus	9	O
,	9	O
AE	9	O
RBCs	9	O
appear	9	O
to	5	O
have	5	O
an	5	O
increased	9	O
sensitivity	9	O
to	5	O
oxidant	0	O
stress	9	O
both	9	O
in	5	O
vitro	3	O
and	5	O
in	5	O
vivo	3	O
,	9	O
since	9	O
dapsone	0	B-Chemical
does	9	O
not	5	O
cause	5	O
hemolytic	0	B-Disease
anemia	9	I-Disease
at	9	O
this	5	O
dose	9	O
in	5	O
hematologically	5	O
normal	9	O
individuals	5	O
.	9	O

Given	9	O
the	5	O
influx	9	O
of	5	O
Southeast	4	O
Asians	5	O
into	9	O
the	5	O
United	9	O
States	9	O
,	9	O
oxidant	0	O
medications	5	O
should	5	O
be	5	O
used	5	O
with	5	O
caution	5	O
,	9	O
especially	5	O
if	5	O
an	5	O
infection	9	B-Disease
is	5	O
present	9	O
,	9	O
in	5	O
individuals	5	O
of	5	O
ethnic	5	O
backgrounds	9	O
that	5	O
have	5	O
an	5	O
increased	9	O
prevalence	5	O
of	5	O
hemoglobin	0	O
E	9	O
.	9	O

Severe	9	O
complications	5	O
of	5	O
antianginal	5	O
drug	5	O
therapy	5	O
in	5	O
a	5	O
patient	5	O
identified	9	O
as	5	O
a	5	O
poor	5	O
metabolizer	5	O
of	5	O
metoprolol	0	B-Chemical
,	9	O
propafenone	0	B-Chemical
,	9	O
diltiazem	0	B-Chemical
,	9	O
and	5	O
sparteine	0	B-Chemical
.	9	O

A	9	O
47	7	O
-	7	O
year	5	O
-	7	O
old	5	O
patient	5	O
suffering	5	O
from	9	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
was	9	O
admitted	5	O
to	5	O
the	5	O
CCU	5	O
in	5	O
shock	9	B-Disease
with	5	O
III	9	O
.	9	O

AV	9	B-Disease
block	9	I-Disease
,	9	O
severe	5	O
hypotension	5	B-Disease
,	9	O
and	5	O
impairment	5	B-Disease
of	5	I-Disease
ventricular	5	I-Disease
function	9	I-Disease
.	9	O

One	5	O
week	9	O
prior	9	O
to	5	O
admission	5	O
a	5	O
therapy	5	O
with	5	O
standard	5	O
doses	0	O
of	5	O
metoprolol	0	B-Chemical
(	9	O
100	0	O
mg	0	O
t	5	O
.	9	O
i	9	O
.	9	O
d	9	O
.	9	O
and	5	O
then	9	O
100	0	O
mg	0	O
b	9	O
.	9	O
i	9	O
.	9	O
d	9	O
.	9	O
)	9	O
had	9	O
been	9	O
initiated	9	O
.	9	O

Two	9	O
days	9	O
before	9	O
admission	5	O
diltiazem	0	B-Chemical
(	9	O
60	9	O
mg	0	O
b	9	O
.	9	O
i	9	O
.	9	O
d	9	O
.	9	O
)	9	O
was	9	O
prescribed	5	O
in	5	O
addition	9	O
.	9	O

Analyses	9	O
of	5	O
a	5	O
blood	9	O
sample	9	O
revealed	9	O
unusually	9	O
high	9	O
plasma	9	O
concentrations	0	O
of	5	O
metoprolol	0	B-Chemical
(	9	O
greater	5	O
than	5	O
3000	0	O
ng	0	O
/	9	O
ml	0	O
)	9	O
and	5	O
diltiazem	0	B-Chemical
(	9	O
526	7	O
ng	0	O
/	9	O
ml	0	O
)	9	O
.	9	O

The	5	O
patient	5	O
recovered	9	O
within	9	O
1	9	O
week	9	O
following	9	O
discontinuation	5	O
of	5	O
antianginal	5	O
therapy	5	O
.	9	O

Three	9	O
months	5	O
later	9	O
the	5	O
patient	5	O
was	9	O
exposed	9	O
to	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
metoprolol	0	B-Chemical
,	9	O
diltiazem	0	B-Chemical
,	9	O
propafenone	0	B-Chemical
(	9	O
since	9	O
he	5	O
had	9	O
received	9	O
this	5	O
drug	5	O
in	5	O
the	5	O
past	5	O
)	9	O
,	9	O
and	5	O
sparteine	0	B-Chemical
(	9	O
as	5	O
a	5	O
probe	9	O
for	5	O
the	5	O
debrisoquine	0	B-Chemical
/	9	O
sparteine	0	B-Chemical
type	9	O
polymorphism	9	O
of	5	O
oxidative	9	O
drug	5	O
metabolism	9	O
)	9	O
.	9	O

It	5	O
was	9	O
found	9	O
that	5	O
he	5	O
was	9	O
a	5	O
poor	5	O
metabolizer	5	O
of	5	O
all	5	O
four	9	O
drugs	5	O
,	9	O
indicating	9	O
that	5	O
their	5	O
metabolism	9	O
is	5	O
under	9	O
the	5	O
same	9	O
genetic	5	O
control	9	O
.	9	O

Therefore	9	O
,	9	O
patients	5	O
belonging	4	O
to	5	O
the	5	O
poor	5	O
-	7	O
metabolizer	5	O
phenotype	3	O
of	5	O
sparteine	0	B-Chemical
/	9	O
debrisoquine	0	B-Chemical
polymorphism	9	O
in	5	O
drug	5	O
metabolism	9	O
,	9	O
which	5	O
constitutes	9	O
6	9	O
.	9	O
4	9	O
%	9	O
of	5	O
the	5	O
German	5	O
population	5	O
,	9	O
may	5	O
experience	5	O
adverse	5	B-Disease
drug	5	I-Disease
reactions	9	I-Disease
when	5	O
treated	3	O
with	5	O
standard	5	O
doses	0	O
of	5	O
one	5	O
of	5	O
these	5	O
drugs	5	O
alone	9	O
.	9	O

Moreover	9	O
,	9	O
the	5	O
coadministration	0	O
of	5	O
these	5	O
frequently	5	O
used	5	O
drugs	5	O
is	5	O
expected	9	O
to	5	O
be	5	O
especially	5	O
harmful	5	O
in	5	O
this	5	O
subgroup	9	O
of	5	O
patients	5	O
.	9	O

Clinical	5	O
experiences	5	O
in	5	O
an	5	O
open	5	O
and	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
trial	5	O
.	9	O

A	9	O
total	9	O
of	5	O
sixty	5	O
patients	5	O
were	9	O
trated	0	O
with	5	O
bromperidol	7	B-Chemical
first	9	O
in	5	O
open	5	O
conditions	9	O
(	9	O
20	9	O
patients	5	O
)	9	O
,	9	O
then	9	O
on	5	O
a	5	O
double	9	O
blind	5	O
basis	5	O
(	9	O
40	9	O
patients	5	O
)	9	O
with	5	O
haloperidol	5	B-Chemical
as	5	O
the	5	O
reference	9	O
substance	5	O
.	9	O

The	5	O
open	5	O
study	9	O
lasted	5	O
for	5	O
four	9	O
weeks	9	O
;	9	O
the	5	O
drug	5	O
was	9	O
administrated	0	O
in	5	O
the	5	O
form	9	O
of	5	O
1	9	O
mg	0	O
tablets	0	O
.	9	O

The	5	O
daily	5	O
dose	9	O
(	9	O
initial	9	O
dose	9	O
:	9	O
1	9	O
mg	0	O
;	9	O
mean	5	O
dose	9	O
at	9	O
the	5	O
end	9	O
of	5	O
the	5	O
trial	5	O
:	9	O
4	9	O
.	9	O
47	7	O
mg	0	O
)	9	O
was	9	O
always	5	O
administered	9	O
in	5	O
one	5	O
single	9	O
dose	9	O
.	9	O

Nineteen	9	O
patients	5	O
finished	5	O
the	5	O
trial	5	O
,	9	O
and	5	O
in	5	O
18	7	O
cases	5	O
the	5	O
therapeutic	5	O
result	9	O
was	9	O
considered	5	O
very	5	O
good	5	O
to	5	O
good	5	O
.	9	O

These	5	O
results	9	O
were	9	O
confirmed	9	O
by	9	O
statistical	5	O
analysis	9	O
.	9	O

Nine	9	O
patients	5	O
exhibited	9	O
mild	9	O
to	5	O
moderate	9	O
extrapyramidal	5	B-Disease
concomitant	9	I-Disease
symptoms	5	I-Disease
;	9	O
no	9	O
other	5	O
side	5	O
effects	9	O
were	9	O
observed	9	O
.	9	O

The	5	O
results	9	O
of	5	O
detailed	5	O
laboratory	9	O
tests	5	O
and	5	O
evaluations	5	O
of	5	O
various	9	O
quantitative	9	O
and	5	O
qualitative	5	O
tolerability	5	O
parameters	5	O
were	9	O
not	5	O
indicative	9	O
of	5	O
toxic	0	O
effects	9	O
.	9	O

In	9	O
the	5	O
double	9	O
blind	5	O
study	9	O
with	5	O
haloperidol	5	B-Chemical
,	9	O
both	9	O
substances	0	O
were	9	O
found	9	O
to	5	O
be	5	O
highly	9	O
effective	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
psychotic	5	B-Disease
syndromes	5	I-Disease
belonging	4	I-Disease
predominantly	9	I-Disease
to	5	I-Disease
the	5	I-Disease
schizophrenia	5	I-Disease
group	9	I-Disease
.	9	O

Certain	9	O
clues	5	O
,	9	O
including	9	O
the	5	O
onset	5	O
of	5	O
action	5	O
,	9	O
seem	5	O
to	5	O
be	5	O
indicative	9	O
of	5	O
the	5	O
superiority	5	O
of	5	O
bromperidol	7	B-Chemical
.	9	O

No	9	O
differences	9	O
were	9	O
observed	9	O
with	5	O
respect	9	O
to	5	O
side	5	O
effects	9	O
and	5	O
general	5	O
tolerability	5	O
.	9	O

Prolonged	9	O
cholestasis	5	B-Disease
after	9	O
troleandomycin	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
hepatitis	9	B-Disease
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
patient	5	O
in	5	O
whom	5	O
troleandomycin	0	B-Chemical
-	7	O
induced	3	O
hepatitis	9	B-Disease
was	9	O
followed	9	O
by	9	O
prolonged	9	O
anicteric	5	O
cholestasis	5	B-Disease
.	9	O

Jaundice	7	B-Disease
occurred	9	O
after	9	O
administration	9	O
of	5	O
troleandomycin	0	B-Chemical
for	5	O
7	9	O
days	9	O
and	5	O
was	9	O
associated	9	O
with	5	O
hypereosinophilia	5	B-Disease
.	9	O

Jaundice	7	B-Disease
disappeared	9	O
within	9	O
3	9	O
months	5	O
but	9	O
was	9	O
followed	9	O
by	9	O
prolonged	9	O
anicteric	5	O
cholestasis	5	B-Disease
marked	9	O
by	9	O
pruritus	5	B-Disease
and	5	O
high	9	O
levels	3	O
of	5	O
alkaline	0	O
phosphatase	0	O
and	5	O
gammaglutamyltransferase	9	O
activities	9	O
.	9	O

Finally	9	O
,	9	O
pruritus	5	B-Disease
disappeared	9	O
within	9	O
19	7	O
months	5	O
,	9	O
and	5	O
liver	9	O
tests	5	O
returned	5	O
to	5	O
normal	9	O
27	7	O
months	5	O
after	9	O
the	5	O
onset	5	O
of	5	O
hepatitis	9	B-Disease
.	9	O

This	5	O
observation	9	O
demonstrates	9	O
that	5	O
prolonged	9	O
cholestasis	5	B-Disease
can	5	O
follow	5	O
troleandomycin	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
hepatitis	9	B-Disease
.	9	O

Serial	9	O
studies	9	O
of	5	O
auditory	5	B-Disease
neurotoxicity	9	I-Disease
in	5	O
patients	5	O
receiving	9	O
deferoxamine	0	B-Chemical
therapy	5	O
.	9	O

Visual	5	B-Disease
and	5	I-Disease
auditory	5	I-Disease
neurotoxicity	9	I-Disease
was	9	O
previously	9	O
documented	9	O
in	5	O
42	7	O
of	5	O
89	7	O
patients	5	O
with	5	O
transfusion	5	O
-	7	O
dependent	9	O
anemia	9	B-Disease
who	5	O
were	9	O
receiving	9	O
iron	0	B-Chemical
chelation	0	O
therapy	5	O
with	5	O
daily	5	O
subcutaneous	9	O
deferoxamine	0	B-Chemical
.	9	O

Twenty	9	O
-	7	O
two	5	O
patients	5	O
in	5	O
the	5	O
affected	9	O
group	9	O
had	9	O
abnormal	9	B-Disease
audiograms	5	I-Disease
with	5	I-Disease
deficits	5	I-Disease
mostly	9	I-Disease
in	5	I-Disease
the	5	I-Disease
high	9	I-Disease
frequency	5	I-Disease
range	9	I-Disease
of	5	I-Disease
4	9	I-Disease
,	9	I-Disease
000	9	I-Disease
to	5	I-Disease
8	9	I-Disease
,	9	I-Disease
000	9	I-Disease
Hz	5	I-Disease
and	5	O
in	5	O
the	5	O
hearing	5	O
threshold	5	O
levels	3	O
of	5	O
30	9	O
to	5	O
100	0	O
decibels	5	O
.	9	O

When	9	O
deferoxamine	0	B-Chemical
therapy	5	O
was	9	O
discontinued	5	O
and	5	O
serial	9	O
studies	9	O
were	9	O
performed	9	O
,	9	O
audiograms	5	O
in	5	O
seven	9	O
cases	5	O
reverted	9	O
to	5	O
normal	9	O
or	5	O
near	9	O
normal	9	O
within	9	O
two	5	O
to	5	O
three	9	O
weeks	9	O
,	9	O
and	5	O
nine	9	O
of	5	O
13	7	O
patients	5	O
with	5	O
symptoms	5	O
became	9	O
asymptomatic	5	O
.	9	O

Audiograms	5	O
from	9	O
15	9	O
patients	5	O
remained	9	O
abnormal	9	O
and	5	O
four	9	O
patients	5	O
required	9	O
hearing	5	O
aids	5	O
because	5	O
of	5	O
permanent	5	B-Disease
disability	5	I-Disease
.	9	O

Since	9	O
18	7	O
of	5	O
the	5	O
22	7	O
patients	5	O
were	9	O
initially	9	O
receiving	9	O
deferoxamine	0	B-Chemical
doses	0	O
in	5	O
excess	9	O
of	5	O
the	5	O
commonly	5	O
recommended	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
per	9	O
dose	9	O
,	9	O
therapy	5	O
was	9	O
restarted	5	O
with	5	O
lower	9	O
doses	0	O
,	9	O
usually	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
per	9	O
dose	9	O
or	5	O
less	5	O
depending	5	O
on	5	O
the	5	O
degree	5	O
of	5	O
auditory	5	B-Disease
abnormality	9	I-Disease
,	9	O
and	5	O
with	5	O
the	5	O
exception	9	O
of	5	O
two	5	O
cases	5	O
no	9	O
further	9	O
toxicity	9	B-Disease
was	9	O
demonstrated	9	O
.	9	O

Auditory	5	O
deterioration	5	O
and	5	O
improvement	5	O
,	9	O
demonstrated	9	O
serially	9	O
in	5	O
individual	5	O
patients	5	O
receiving	9	O
and	5	O
not	5	O
receiving	9	O
deferoxamine	0	B-Chemical
,	9	O
respectively	9	O
,	9	O
provided	9	O
convincing	9	O
evidence	9	O
for	5	O
a	5	O
cause	5	O
-	7	O
and	5	O
-	7	O
effect	9	O
relation	5	O
between	5	O
deferoxamine	0	B-Chemical
administration	9	O
and	5	O
ototoxicity	5	B-Disease
.	9	O

Based	9	O
on	5	O
these	5	O
data	5	O
,	9	O
a	5	O
plan	5	O
of	5	O
management	5	O
was	9	O
developed	5	O
that	5	O
allows	5	O
effective	5	O
yet	9	O
safe	5	O
administration	9	O
of	5	O
deferoxamine	0	B-Chemical
.	9	O

A	9	O
dose	9	O
of	5	O
50	0	O
mg	0	O
/	9	O
kg	0	O
is	5	O
recommended	5	O
in	5	O
those	5	O
without	9	O
audiogram	5	O
abnormalities	9	O
.	9	O

With	5	O
mild	9	O
toxicity	9	B-Disease
,	9	O
a	5	O
reduction	9	O
to	5	O
30	9	O
or	5	O
40	9	O
mg	0	O
/	9	O
kg	0	O
per	9	O
dose	9	O
should	5	O
result	9	O
in	5	O
a	5	O
reversal	9	O
of	5	O
the	5	O
abnormal	9	O
results	9	O
to	5	O
normal	9	O
within	9	O
four	9	O
weeks	9	O
.	9	O

Moderate	7	O
abnormalities	9	O
require	5	O
a	5	O
reduction	9	O
of	5	O
deferoxamine	0	B-Chemical
to	5	O
25	9	O
mg	0	O
/	9	O
kg	0	O
per	9	O
dose	9	O
with	5	O
careful	5	O
monitoring	5	O
.	9	O

In	9	O
those	5	O
with	5	O
symptoms	5	O
of	5	O
hearing	5	B-Disease
loss	9	I-Disease
,	9	O
the	5	O
drug	5	O
should	5	O
be	5	O
stopped	9	O
for	5	O
four	9	O
weeks	9	O
,	9	O
and	5	O
when	5	O
the	5	O
audiogram	5	O
is	5	O
stable	9	O
or	5	O
improved	5	O
,	9	O
therapy	5	O
should	5	O
be	5	O
restarted	5	O
at	9	O
10	9	O
to	5	O
25	9	O
mg	0	O
/	9	O
kg	0	O
per	9	O
dose	9	O
.	9	O

Serial	9	O
audiograms	5	O
should	5	O
be	5	O
performed	9	O
every	5	O
six	9	O
months	5	O
in	5	O
those	5	O
without	9	O
problems	5	O
and	5	O
more	5	O
frequently	5	O
in	5	O
young	5	O
patients	5	O
with	5	O
normal	9	O
serum	9	O
ferritin	9	O
values	5	O
and	5	O
in	5	O
those	5	O
with	5	O
auditory	5	B-Disease
dysfunction	9	I-Disease
.	9	O

Lidocaine	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
asystole	5	I-Disease
.	9	O

Intravenous	0	O
administration	9	O
of	5	O
a	5	O
single	9	O
50	0	O
-	7	O
mg	0	O
bolus	0	O
of	5	O
lidocaine	0	B-Chemical
in	5	O
a	5	O
67	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
resulted	9	O
in	5	O
profound	9	O
depression	5	B-Disease
of	5	O
the	5	O
activity	9	O
of	5	O
the	5	O
sinoatrial	5	O
and	5	O
atrioventricular	5	O
nodal	5	O
pacemakers	5	O
.	9	O

The	5	O
patient	5	O
had	9	O
no	9	O
apparent	9	O
associated	9	O
conditions	9	O
which	5	O
might	9	O
have	5	O
predisposed	5	O
him	5	O
to	5	O
the	5	O
development	9	O
of	5	O
bradyarrhythmias	5	B-Disease
;	9	O
and	5	O
,	9	O
thus	9	O
,	9	O
this	5	O
probably	9	O
represented	9	O
a	5	O
true	5	O
idiosyncrasy	5	O
to	5	O
lidocaine	0	B-Chemical
.	9	O

Flurbiprofen	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
juvenile	4	B-Disease
rheumatoid	9	I-Disease
arthritis	9	I-Disease
.	9	O

Thirty	9	O
-	7	O
four	9	O
patients	5	O
with	5	O
juvenile	4	B-Disease
rheumatoid	9	I-Disease
arthritis	9	I-Disease
,	9	O
who	5	O
were	9	O
treated	3	O
with	5	O
flurbiprofen	0	B-Chemical
at	9	O
a	5	O
maximum	5	O
dose	9	O
of	5	O
4	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
,	9	O
had	9	O
statistically	9	O
significant	9	O
decreases	9	O
from	9	O
baseline	5	O
in	5	O
6	9	O
arthritis	9	B-Disease
indices	5	O
after	9	O
12	9	O
weeks	9	O
of	5	O
treatment	9	O
.	9	O

Improvements	5	O
were	9	O
seen	9	O
in	5	O
the	5	O
number	9	O
of	5	O
tender	5	B-Disease
joints	5	I-Disease
,	9	O
the	5	O
severity	5	O
of	5	O
swelling	5	B-Disease
and	5	O
tenderness	5	B-Disease
,	9	O
the	5	O
time	5	O
of	5	O
walk	5	O
50	0	O
feet	5	O
,	9	O
the	5	O
duration	5	O
of	5	O
morning	5	B-Disease
stiffness	5	I-Disease
and	5	O
the	5	O
circumference	5	O
of	5	O
the	5	O
left	5	O
knee	5	O
.	9	O

The	5	O
most	9	O
frequently	5	O
observed	9	O
side	5	O
effect	9	O
was	9	O
fecal	9	B-Disease
occult	5	I-Disease
blood	9	I-Disease
(	9	O
25	9	O
%	9	O
of	5	O
patients	5	O
)	9	O
;	9	O
however	9	O
,	9	O
there	5	O
was	9	O
no	9	O
other	5	O
evidence	9	O
of	5	O
gastrointestinal	9	B-Disease
(	9	I-Disease
GI	9	I-Disease
)	9	I-Disease
bleeding	5	I-Disease
in	5	O
these	5	O
patients	5	O
.	9	O

One	5	O
patient	5	O
was	9	O
prematurely	5	O
discontinued	5	O
from	9	O
the	5	O
study	9	O
for	5	O
severe	5	O
headache	5	B-Disease
and	5	O
abdominal	5	B-Disease
pain	5	I-Disease
.	9	O

Most	5	O
side	5	O
effects	9	O
were	9	O
mild	9	O
and	5	O
related	9	O
to	5	O
the	5	O
GI	9	O
tract	9	O
.	9	O

Hyperkalemia	7	B-Disease
associated	9	O
with	5	O
sulindac	0	B-Chemical
therapy	5	O
.	9	O

Hyperkalemia	7	B-Disease
has	9	O
recently	9	O
been	9	O
recognized	9	O
as	5	O
a	5	O
complication	5	O
of	5	O
nonsteroidal	5	O
antiinflammatory	9	O
agents	5	O
(	9	O
NSAID	5	O
)	9	O
such	5	O
as	5	O
indomethacin	0	B-Chemical
.	9	O

Several	9	O
recent	5	O
studies	9	O
have	5	O
stressed	9	O
the	5	O
renal	9	O
sparing	5	O
features	5	O
of	5	O
sulindac	0	B-Chemical
,	9	O
owing	5	O
to	5	O
its	9	O
lack	9	O
of	5	O
interference	9	O
with	5	O
renal	9	O
prostacyclin	0	B-Chemical
synthesis	9	O
.	9	O

We	9	O
describe	5	O
4	9	O
patients	5	O
in	5	O
whom	5	O
hyperkalemia	5	B-Disease
ranging	9	O
from	9	O
6	9	O
.	9	O
1	9	O
to	5	O
6	9	O
.	9	O
9	7	O
mEq	0	O
/	9	O
l	0	O
developed	5	O
within	9	O
3	9	O
to	5	O
8	9	O
days	9	O
of	5	O
sulindac	0	B-Chemical
administration	9	O
.	9	O

In	9	O
all	5	O
of	5	O
them	5	O
normal	9	O
serum	9	O
potassium	0	B-Chemical
levels	3	O
reached	9	O
within	9	O
2	9	O
to	5	O
4	9	O
days	9	O
of	5	O
stopping	5	O
sulindac	0	B-Chemical
.	9	O

As	9	O
no	9	O
other	5	O
medications	5	O
known	9	O
to	5	O
effect	9	O
serum	9	O
potassium	0	B-Chemical
had	9	O
been	9	O
given	5	O
concomitantly	9	O
,	9	O
this	5	O
course	5	O
of	5	O
events	5	O
is	5	O
suggestive	9	O
of	5	O
a	5	O
cause	5	O
-	7	O
and	5	O
-	7	O
effect	9	O
relationship	5	O
between	5	O
sulindac	0	B-Chemical
and	5	O
hyperkalemia	5	B-Disease
.	9	O

These	5	O
observations	9	O
indicate	9	O
that	5	O
initial	9	O
hopes	5	O
that	5	O
sulindac	0	B-Chemical
may	5	O
not	5	O
be	5	O
associated	9	O
with	5	O
the	5	O
adverse	5	O
renal	9	O
effects	9	O
of	5	O
other	5	O
NSAID	5	O
are	5	O
probably	9	O
not	5	O
justified	5	O
.	9	O

Drug	5	O
-	7	O
induced	3	O
arterial	5	O
spasm	5	B-Disease
relieved	5	O
by	9	O
lidocaine	0	B-Chemical
.	9	O

Case	5	O
report	5	O
.	9	O

Following	9	O
major	9	O
intracranial	5	O
surgery	5	O
in	5	O
a	5	O
35	9	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
,	9	O
sodium	0	B-Chemical
pentothal	0	I-Chemical
was	9	O
intravenously	0	O
infused	9	O
to	5	O
minimize	5	O
cerebral	5	B-Disease
ischaemia	9	I-Disease
.	9	O

Intense	9	O
vasospasm	5	B-Disease
with	5	O
threatened	5	O
gangrene	5	B-Disease
arose	9	O
in	5	O
the	5	O
arm	5	O
used	5	O
for	5	O
the	5	O
infusion	0	O
.	9	O

Since	9	O
the	5	O
cranial	5	O
condition	5	O
precluded	5	O
use	5	O
of	5	O
more	5	O
usual	5	O
methods	5	O
,	9	O
lidocaine	0	B-Chemical
was	9	O
given	5	O
intra	5	O
-	7	O
arterially	0	O
,	9	O
with	5	O
careful	5	O
cardiovascular	5	O
monitoring	5	O
,	9	O
to	5	O
counteract	9	O
the	5	O
vasospasm	5	B-Disease
.	9	O

The	5	O
treatment	9	O
was	9	O
rapidly	9	O
successful	5	O
.	9	O

Regional	2	O
localization	3	O
of	5	O
the	5	O
antagonism	9	O
of	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
by	9	O
intracerebral	5	O
calcitonin	3	B-Chemical
injections	9	O
.	9	O

Calcitonin	0	B-Chemical
receptors	3	O
are	5	O
found	9	O
in	5	O
the	5	O
brain	5	O
,	9	O
and	5	O
intracerebral	5	O
infusions	9	O
of	5	O
calcitonin	3	B-Chemical
can	5	O
produce	9	O
behavioral	5	O
effects	9	O
.	9	O

Among	9	O
these	5	O
behavioral	5	O
effects	9	O
are	5	O
decreases	9	O
in	5	O
food	5	O
intake	5	O
and	5	O
decreases	9	O
in	5	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
activity	9	O
.	9	O

In	9	O
previous	9	O
experiments	9	O
we	5	O
found	9	O
that	5	O
decreases	9	O
in	5	O
food	5	O
intake	5	O
were	9	O
induced	3	O
by	9	O
local	5	O
administration	9	O
of	5	O
calcitonin	3	B-Chemical
into	9	O
several	9	O
hypothalamic	3	O
sites	9	O
and	5	O
into	9	O
the	5	O
nucleus	9	O
accumbens	5	O
.	9	O

In	9	O
the	5	O
present	9	O
experiment	9	O
calcitonin	3	B-Chemical
decreased	9	O
locomotor	5	O
activity	9	O
when	5	O
locally	5	O
injected	3	O
into	9	O
the	5	O
same	9	O
sites	9	O
where	5	O
it	5	O
decreases	9	O
food	5	O
intake	5	O
.	9	O

The	5	O
areas	5	O
where	5	O
calcitonin	3	B-Chemical
is	5	O
most	9	O
effective	5	O
in	5	O
decreasing	9	O
locomotor	5	O
activity	9	O
are	5	O
located	9	O
in	5	O
the	5	O
hypothalamus	9	O
and	5	O
nucleus	9	O
accumbens	5	O
,	9	O
suggesting	9	O
that	5	O
these	5	O
areas	5	O
are	5	O
the	5	O
major	9	O
sites	9	O
of	5	O
action	5	O
of	5	O
calcitonin	3	B-Chemical
in	5	O
inhibiting	3	O
amphetamine	5	B-Chemical
-	7	O
induced	3	O
locomotor	5	O
activity	9	O
.	9	O

The	5	O
hematologic	5	O
effects	9	O
of	5	O
cefonicid	9	B-Chemical
and	5	O
cefazedone	9	B-Chemical
in	5	O
the	5	O
dog	5	O
:	9	O
a	5	O
potential	9	O
model	5	O
of	5	O
cephalosporin	0	B-Chemical
hematotoxicity	5	B-Disease
in	5	O
man	5	O
.	9	O

Cephalosporin	7	B-Chemical
antibiotics	5	O
cause	5	O
a	5	O
variety	5	O
of	5	O
hematologic	5	B-Disease
disturbances	5	I-Disease
in	5	O
man	5	O
,	9	O
the	5	O
pathogeneses	5	O
and	5	O
hematopathology	5	O
of	5	O
which	5	O
remain	9	O
poorly	9	O
characterized	9	O
.	9	O

There	5	O
is	5	O
a	5	O
need	5	O
for	5	O
a	5	O
well	9	O
-	7	O
defined	5	O
animal	5	O
model	5	O
in	5	O
which	5	O
these	5	O
blood	9	B-Disease
dyscrasias	5	I-Disease
can	5	O
be	5	O
studied	9	O
.	9	O

In	9	O
four	9	O
subacute	5	O
toxicity	9	B-Disease
studies	9	O
,	9	O
the	5	O
intravenous	0	O
administration	9	O
of	5	O
cefonicid	9	B-Chemical
or	5	O
cefazedone	9	B-Chemical
to	5	O
beagle	0	O
dogs	5	O
caused	9	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
incidence	5	O
of	5	O
anemia	9	B-Disease
,	9	O
neutropenia	5	B-Disease
,	9	O
and	5	O
thrombocytopenia	9	B-Disease
after	9	O
1	9	O
-	7	O
3	9	O
months	5	O
of	5	O
treatment	9	O
.	9	O

A	9	O
nonregenerative	5	O
anemia	9	B-Disease
was	9	O
the	5	O
most	9	O
compromising	5	O
of	5	O
the	5	O
cytopenias	5	B-Disease
and	5	O
occurred	9	O
in	5	O
approximately	9	O
50	0	O
%	9	O
of	5	O
dogs	5	O
receiving	9	O
400	0	O
-	7	O
500	0	O
mg	0	O
/	9	O
kg	0	O
cefonicid	9	B-Chemical
or	5	O
540	9	O
-	7	O
840	9	O
mg	0	O
/	9	O
kg	0	O
cefazedone	9	B-Chemical
.	9	O

All	9	O
three	9	O
cytopenias	5	B-Disease
were	9	O
completely	9	O
reversible	9	O
following	9	O
cessation	5	O
of	5	O
treatment	9	O
;	9	O
the	5	O
time	5	O
required	9	O
for	5	O
recovery	9	O
of	5	O
the	5	O
erythron	3	O
(	9	O
approximately	9	O
1	9	O
month	5	O
)	9	O
was	9	O
considerably	9	O
longer	5	O
than	5	O
that	5	O
of	5	O
the	5	O
granulocytes	3	O
and	5	O
platelets	3	O
(	9	O
hours	9	O
to	5	O
a	5	O
few	5	O
days	9	O
)	9	O
.	9	O

Upon	9	O
rechallenge	3	O
with	5	O
either	9	O
cephalosporin	0	B-Chemical
,	9	O
the	5	O
hematologic	5	B-Disease
syndrome	5	I-Disease
was	9	O
reproduced	9	O
in	5	O
most	9	O
dogs	5	O
tested	9	O
;	9	O
cefonicid	9	B-Chemical
(	9	O
but	9	O
not	5	O
cefazedone	9	B-Chemical
)	9	O
-	7	O
treated	3	O
dogs	5	O
showed	9	O
a	5	O
substantially	9	O
reduced	9	O
induction	3	O
period	5	O
(	9	O
15	9	O
+	9	O
/	9	O
-	7	O
5	9	O
days	9	O
)	9	O
compared	9	O
to	5	O
that	5	O
of	5	O
the	5	O
first	9	O
exposure	9	O
to	5	O
the	5	O
drug	5	O
(	9	O
61	7	O
+	9	O
/	9	O
-	7	O
24	9	O
days	9	O
)	9	O
.	9	O

This	5	O
observation	9	O
,	9	O
along	9	O
with	5	O
the	5	O
rapid	5	O
rate	9	O
of	5	O
decline	9	O
in	5	O
red	9	O
cell	3	O
mass	9	O
parameters	5	O
of	5	O
affected	9	O
dogs	5	O
,	9	O
suggests	9	O
that	5	O
a	5	O
hemolytic	0	B-Disease
component	9	O
complicated	5	O
the	5	O
red	9	O
cell	3	O
production	9	O
problem	5	O
and	5	O
that	5	O
multiple	5	O
toxicologic	5	O
mechanisms	9	O
contributed	9	O
to	5	O
the	5	O
cytopenia	5	B-Disease
.	9	O

We	9	O
conclude	9	O
that	5	O
the	5	O
administration	9	O
of	5	O
high	9	O
doses	0	O
of	5	O
cefonicid	9	B-Chemical
or	5	O
cefazedone	9	B-Chemical
to	5	O
dogs	5	O
can	5	O
induce	3	O
hematotoxicity	5	B-Disease
similar	9	O
to	5	O
the	5	O
cephalosporin	0	B-Chemical
-	7	O
induced	3	O
blood	9	B-Disease
dyscrasias	5	I-Disease
described	9	O
in	5	O
man	5	O
and	5	O
thus	9	O
provides	5	O
a	5	O
useful	5	O
model	5	O
for	5	O
studying	5	O
the	5	O
mechanisms	9	O
of	5	O
these	5	O
disorders	5	O
.	9	O

Cerebral	5	O
blood	9	O
flow	5	O
and	5	O
metabolism	9	O
during	5	O
isoflurane	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
in	5	O
patients	5	O
subjected	9	O
to	5	O
surgery	5	O
for	5	O
cerebral	5	B-Disease
aneurysms	5	I-Disease
.	9	O

Cerebral	5	O
blood	9	O
flow	5	O
and	5	O
cerebral	5	O
metabolic	9	O
rate	9	O
for	5	O
oxygen	0	B-Chemical
were	9	O
measured	9	O
during	5	O
isoflurane	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
in	5	O
10	9	O
patients	5	O
subjected	9	O
to	5	O
craniotomy	5	O
for	5	O
clipping	5	O
of	5	O
a	5	O
cerebral	5	B-Disease
aneurysm	5	I-Disease
.	9	O

Flow	3	O
and	5	O
metabolism	9	O
were	9	O
measured	9	O
5	9	O
-	7	O
13	7	O
days	9	O
after	9	O
the	5	O
subarachnoid	5	B-Disease
haemorrhage	5	I-Disease
by	9	O
a	5	O
modification	9	O
of	5	O
the	5	O
classical	9	O
Kety	6	O
-	7	O
Schmidt	6	O
technique	5	O
using	9	O
xenon	0	B-Chemical
-	7	O
133	7	O
i	9	O
.	9	O
v	0	O
.	9	O
Anaesthesia	2	O
was	9	O
maintained	9	O
with	5	O
an	5	O
inspired	5	O
isoflurane	0	B-Chemical
concentration	0	O
of	5	O
0	7	O
.	9	O
75	9	O
%	9	O
(	9	O
plus	9	O
67	7	O
%	9	O
nitrous	0	B-Chemical
oxide	0	I-Chemical
in	5	O
oxygen	0	B-Chemical
)	9	O
,	9	O
during	5	O
which	5	O
CBF	9	O
and	5	O
CMRO2	5	O
were	9	O
34	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
1	9	O
ml	0	O
/	9	O
100	0	O
g	0	O
min	0	O
-	7	O
1	9	O
and	5	O
2	9	O
.	9	O
32	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
16	9	O
ml	0	O
/	9	O
100	0	O
g	0	O
min	0	O
-	7	O
1	9	O
at	9	O
PaCO2	5	O
4	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
1	9	O
kPa	0	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SEM	9	O
)	9	O
.	9	O

Controlled	5	O
hypotension	5	B-Disease
to	5	O
an	5	O
average	5	O
MAP	9	O
of	5	O
50	0	O
-	7	O
55	7	O
mm	9	O
Hg	0	B-Chemical
was	9	O
induced	3	O
by	9	O
increasing	9	O
the	5	O
dose	9	O
of	5	O
isoflurane	0	B-Chemical
,	9	O
and	5	O
maintained	9	O
at	9	O
an	5	O
inspired	5	O
concentration	0	O
of	5	O
2	9	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
2	9	O
%	9	O
.	9	O

This	5	O
resulted	9	O
in	5	O
a	5	O
significant	9	O
decrease	9	O
in	5	O
CMRO2	5	O
(	9	O
to	5	O
1	9	O
.	9	O
73	7	O
+	9	O
/	9	O
-	7	O
0	7	O
.	9	O
16	9	O
ml	0	O
/	9	O
100	0	O
g	0	O
min	0	O
-	7	O
1	9	O
)	9	O
,	9	O
while	9	O
CBF	9	O
was	9	O
unchanged	9	O
.	9	O

After	9	O
the	5	O
clipping	5	O
of	5	O
the	5	O
aneurysm	5	B-Disease
the	5	O
isoflurane	0	B-Chemical
concentration	0	O
was	9	O
reduced	9	O
to	5	O
0	7	O
.	9	O
75	9	O
%	9	O
.	9	O

There	5	O
was	9	O
a	5	O
significant	9	O
increase	9	O
in	5	O
CBF	9	O
,	9	O
although	9	O
CMRO2	5	O
was	9	O
unchanged	9	O
,	9	O
compared	9	O
with	5	O
pre	9	O
-	7	O
hypotensive	5	B-Disease
values	5	O
.	9	O

These	5	O
changes	9	O
might	9	O
offer	5	O
protection	9	O
to	5	O
brain	5	O
tissue	9	O
during	5	O
periods	5	O
of	5	O
induced	3	O
hypotension	5	B-Disease
.	9	O

Triazolam	7	B-Chemical
-	7	O
induced	3	O
brief	5	O
episodes	5	O
of	5	O
secondary	9	O
mania	5	B-Disease
in	5	O
a	5	O
depressed	5	B-Disease
patient	5	O
.	9	O

Large	9	O
doses	0	O
of	5	O
triazolam	0	B-Chemical
repeatedly	5	O
induced	3	O
brief	5	O
episodes	5	O
of	5	O
mania	5	B-Disease
in	5	O
a	5	O
depressed	5	B-Disease
elderly	5	O
woman	5	O
.	9	O

Features	5	O
of	5	O
organic	0	B-Disease
mental	5	I-Disease
disorder	5	I-Disease
(	9	O
delirium	5	B-Disease
)	9	O
were	9	O
not	5	O
present	9	O
.	9	O

Manic	2	B-Disease
excitement	5	O
was	9	O
coincident	9	O
with	5	O
the	5	O
duration	5	O
of	5	O
action	5	O
of	5	O
triazolam	0	B-Chemical
.	9	O

The	5	O
possible	5	O
contribution	9	O
of	5	O
the	5	O
triazolo	0	B-Chemical
group	9	O
to	5	O
changes	9	O
in	5	O
affective	5	O
status	9	O
is	5	O
discussed	5	O
.	9	O

The	5	O
correlation	9	O
between	5	O
neurotoxic	9	B-Disease
esterase	0	O
inhibition	3	O
and	5	O
mipafox	0	B-Chemical
-	7	O
induced	3	O
neuropathic	5	B-Disease
damage	9	I-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
correlation	9	O
between	5	O
neuropathic	5	B-Disease
damage	9	I-Disease
and	5	O
inhibition	3	O
of	5	O
neurotoxic	9	B-Disease
esterase	0	O
or	5	O
neuropathy	5	B-Disease
target	9	O
enzyme	0	O
(	9	O
NTE	0	O
)	9	O
was	9	O
examined	9	O
in	5	O
rats	9	O
acutely	9	O
exposed	9	O
to	5	O
Mipafox	9	B-Chemical
(	9	O
N	9	B-Chemical
,	9	I-Chemical
N	9	I-Chemical
'	9	I-Chemical
-	7	I-Chemical
diisopropylphosphorodiamidofluoridate	_	I-Chemical
)	9	O
,	9	O
a	5	O
neurotoxic	9	B-Disease
organophosphate	0	B-Chemical
.	9	O

Brain	9	O
and	5	O
spinal	5	O
cord	9	O
NTE	0	O
activities	9	O
were	9	O
measured	9	O
in	5	O
Long	9	O
-	7	O
Evans	6	O
male	9	O
rats	9	O
1	9	O
hr	0	O
post	9	O
-	7	O
exposure	9	O
to	5	O
various	9	O
dosages	9	O
of	5	O
Mipafox	9	B-Chemical
(	9	O
ip	0	O
,	9	O
1	9	O
-	7	O
15	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
.	9	O

These	5	O
data	5	O
were	9	O
correlated	9	O
with	5	O
histologically	9	O
scored	5	O
cervical	5	O
cord	9	B-Disease
damage	9	I-Disease
in	5	O
a	5	O
separate	9	O
group	9	O
of	5	O
similarly	9	O
dosed	0	O
rats	9	O
sampled	5	O
14	7	O
-	7	O
21	7	O
days	9	O
post	9	O
-	7	O
exposure	9	O
.	9	O

Those	5	O
dosages	9	O
(	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
that	5	O
inhibited	3	O
mean	5	O
NTE	0	O
activity	9	O
in	5	O
the	5	O
spinal	5	O
cord	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
73	7	O
%	9	O
and	5	O
brain	5	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
67	7	O
%	9	O
of	5	O
control	9	O
values	5	O
produced	9	O
severe	5	O
(	9	O
greater	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
3	9	O
)	9	O
cervical	5	O
cord	9	O
pathology	5	O
in	5	O
85	9	O
%	9	O
of	5	O
the	5	O
rats	9	O
.	9	O

In	9	O
contrast	9	O
,	9	O
dosages	9	O
of	5	O
Mipafox	9	B-Chemical
(	9	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
which	5	O
inhibited	3	O
mean	5	O
NTE	0	O
activity	9	O
in	5	O
spinal	5	O
cord	9	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
61	7	O
%	9	O
and	5	O
brain	5	O
less	5	O
than	5	O
or	5	O
equal	9	O
to	5	O
60	9	O
%	9	O
produced	9	O
this	5	O
degree	5	O
of	5	O
cord	9	B-Disease
damage	9	I-Disease
in	5	O
only	9	O
9	7	O
%	9	O
of	5	O
the	5	O
animals	9	O
.	9	O

These	5	O
data	5	O
indicate	9	O
that	5	O
a	5	O
critical	9	O
percentage	9	O
of	5	O
NTE	0	O
inhibition	3	O
in	5	O
brain	5	O
and	5	O
spinal	5	O
cord	9	O
sampled	5	O
shortly	9	O
after	9	O
Mipafox	9	B-Chemical
exposure	9	O
can	5	O
predict	5	O
neuropathic	5	B-Disease
damage	9	I-Disease
in	5	O
rats	9	O
several	9	O
weeks	9	O
later	9	O
.	9	O

Allergic	9	B-Disease
reaction	9	I-Disease
to	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
infusion	0	O
.	9	O

An	5	O
allergic	9	B-Disease
reaction	9	I-Disease
consisting	9	O
of	5	O
angioneurotic	2	B-Disease
edema	5	I-Disease
secondary	9	O
to	5	O
continuous	5	O
infusion	0	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
occurred	9	O
in	5	O
a	5	O
patient	5	O
with	5	O
recurrent	5	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
oral	9	I-Disease
cavity	5	I-Disease
,	9	O
cirrhosis	5	B-Disease
,	9	O
and	5	O
cisplatin	3	B-Chemical
-	7	O
induced	3	O
impaired	9	B-Disease
renal	9	I-Disease
function	9	I-Disease
.	9	O

This	5	O
reaction	9	O
occurred	9	O
during	5	O
the	5	O
sixth	9	O
and	5	O
seventh	9	O
courses	5	O
of	5	O
infusional	5	O
chemotherapy	5	O
.	9	O

Oral	9	O
diphenhydramine	0	B-Chemical
and	5	O
prednisone	0	B-Chemical
were	9	O
ineffective	9	O
in	5	O
preventing	9	O
the	5	O
recurrence	5	O
of	5	O
the	5	O
allergic	9	B-Disease
reaction	9	I-Disease
.	9	O

Discontinuance	5	O
of	5	O
effective	5	O
chemotherapy	5	O
in	5	O
this	5	O
patient	5	O
during	5	O
partial	9	O
remission	5	O
resulted	9	O
in	5	O
fatal	5	O
disease	5	O
progression	9	O
.	9	O

Myasthenia	2	B-Disease
gravis	2	I-Disease
caused	9	O
by	9	O
penicillamine	0	B-Chemical
and	5	O
chloroquine	0	B-Chemical
therapy	5	O
for	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
.	9	O

We	9	O
have	5	O
described	9	O
a	5	O
unique	9	O
patient	5	O
who	5	O
had	9	O
reversible	9	O
and	5	O
dose	9	O
-	7	O
related	9	O
myasthenia	9	B-Disease
gravis	2	I-Disease
after	9	O
penicillamine	0	B-Chemical
and	5	O
chloroquine	0	B-Chemical
therapy	5	O
for	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
.	9	O

Although	9	O
acetylcholine	0	B-Chemical
receptor	3	O
antibodies	3	O
were	9	O
not	5	O
detectable	9	O
,	9	O
the	5	O
time	5	O
course	5	O
was	9	O
consistent	9	O
with	5	O
an	5	O
autoimmune	3	O
process	5	O
.	9	O

On	5	O
the	5	O
mechanisms	9	O
of	5	O
the	5	O
development	9	O
of	5	O
tolerance	9	O
to	5	O
the	5	O
muscular	5	B-Disease
rigidity	5	I-Disease
produced	9	O
by	9	O
morphine	0	B-Chemical
in	5	O
rats	9	O
.	9	O

The	5	O
development	9	O
of	5	O
tolerance	9	O
to	5	O
the	5	O
muscular	5	B-Disease
rigidity	5	I-Disease
produced	9	O
by	9	O
morphine	0	B-Chemical
was	9	O
studied	9	O
in	5	O
rats	9	O
.	9	O

Saline	0	O
-	7	O
pretreated	3	O
controls	9	O
given	5	O
a	5	O
test	5	O
dose	9	O
of	5	O
morphine	0	B-Chemical
(	9	O
20	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
showed	9	O
a	5	O
pronounced	9	O
rigidity	5	B-Disease
recorded	5	O
as	5	O
tonic	5	O
activity	9	O
in	5	O
the	5	O
electromyogram	5	O
.	9	O

Rats	9	O
treated	3	O
for	5	O
11	7	O
days	9	O
with	5	O
morphine	0	B-Chemical
and	5	O
withdrawn	9	O
for	5	O
36	9	O
-	7	O
40	9	O
h	0	O
showed	9	O
differences	9	O
in	5	O
the	5	O
development	9	O
of	5	O
tolerance	9	O
:	9	O
about	5	O
half	5	O
of	5	O
the	5	O
animals	9	O
showed	9	O
a	5	O
rigidity	5	B-Disease
after	9	O
the	5	O
test	5	O
dose	9	O
of	5	O
morphine	0	B-Chemical
that	5	O
was	9	O
not	5	O
significantly	9	O
less	5	O
than	5	O
in	5	O
the	5	O
controls	9	O
and	5	O
were	9	O
akinetic	5	B-Disease
(	9	O
A	9	O
group	9	O
)	9	O
.	9	O

The	5	O
other	5	O
rats	9	O
showed	9	O
a	5	O
strong	9	O
decrease	9	O
in	5	O
the	5	O
rigidity	5	B-Disease
and	5	O
the	5	O
occurrence	5	O
of	5	O
stereotyped	5	O
(	9	O
S	9	O
)	9	O
licking	5	O
and	5	O
/	9	O
or	5	O
gnawing	5	O
in	5	O
presence	9	O
of	5	O
akinetic	5	B-Disease
or	5	O
hyperkinetic	5	B-Disease
(	9	O
K	9	O
)	9	O
behaviour	5	O
(	9	O
AS	9	O
/	9	O
KS	9	O
group	9	O
)	9	O
,	9	O
suggesting	9	O
signs	5	O
of	5	O
dopaminergic	5	O
activation	3	O
.	9	O

The	5	O
rigidity	5	B-Disease
was	9	O
considerably	9	O
decreased	9	O
in	5	O
both	9	O
groups	9	O
after	9	O
20	9	O
days	9	O
'	9	O
treatment	9	O
.	9	O

In	9	O
a	5	O
further	9	O
series	5	O
of	5	O
experiments	9	O
,	9	O
haloperidol	5	B-Chemical
(	9	O
0	7	O
.	9	O
2	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
was	9	O
used	5	O
in	5	O
order	5	O
to	5	O
block	9	O
the	5	O
dopaminergic	5	O
activation	3	O
and	5	O
to	5	O
estimate	5	O
the	5	O
real	5	O
degree	5	O
of	5	O
the	5	O
tolerance	9	O
to	5	O
the	5	O
rigidity	5	B-Disease
without	9	O
any	5	O
dopaminergic	5	O
interference	9	O
.	9	O

Haloperidol	7	B-Chemical
enhanced	3	O
the	5	O
rigidity	5	B-Disease
in	5	O
the	5	O
A	9	O
group	9	O
.	9	O

However	9	O
,	9	O
the	5	O
level	9	O
in	5	O
the	5	O
AS	9	O
/	9	O
KS	9	O
group	9	O
remained	9	O
considerably	9	O
lower	9	O
than	5	O
in	5	O
the	5	O
A	9	O
group	9	O
.	9	O

The	5	O
results	9	O
suggest	9	O
that	5	O
rigidity	5	B-Disease
,	9	O
which	5	O
is	5	O
assumed	5	O
to	5	O
be	5	O
due	5	O
to	5	O
an	5	O
action	5	O
of	5	O
morphine	0	B-Chemical
in	5	O
the	5	O
striatum	9	O
,	9	O
can	5	O
be	5	O
antagonized	3	O
by	9	O
another	9	O
process	5	O
leading	9	O
to	5	O
dopaminergic	5	O
activation	3	O
in	5	O
the	5	O
striatum	9	O
.	9	O

Nevertheless	9	O
,	9	O
there	5	O
occurs	9	O
some	5	O
real	5	O
tolerance	9	O
to	5	O
this	5	O
effect	9	O
.	9	O

The	5	O
rapid	5	O
alternations	5	O
of	5	O
rigidity	5	B-Disease
and	5	O
the	5	O
signs	5	O
of	5	O
dopaminergic	5	O
activation	3	O
observed	9	O
in	5	O
the	5	O
animals	9	O
of	5	O
the	5	O
AS	9	O
/	9	O
KS	9	O
group	9	O
might	9	O
be	5	O
due	5	O
to	5	O
rapid	5	O
shifts	5	O
in	5	O
the	5	O
predominance	9	O
of	5	O
various	9	O
DA	9	O
-	7	O
innervated	5	O
structures	9	O
.	9	O

A	9	O
case	5	O
of	5	O
massive	9	O
rhabdomyolysis	5	B-Disease
following	9	O
molindone	0	B-Chemical
administration	9	O
.	9	O

Rhabdomyolysis	5	B-Disease
is	5	O
a	5	O
potentially	5	O
lethal	9	O
syndrome	5	O
that	5	O
psychiatric	5	B-Disease
patients	5	O
seem	5	O
predisposed	5	O
to	5	O
develop	5	O
.	9	O

The	5	O
clinical	5	O
signs	5	O
and	5	O
symptoms	5	O
,	9	O
typical	9	O
laboratory	9	O
features	5	O
,	9	O
and	5	O
complications	5	O
of	5	O
rhabdomyolysis	5	B-Disease
are	5	O
presented	5	O
.	9	O

The	5	O
case	5	O
of	5	O
a	5	O
schizophrenic	5	B-Disease
patient	5	O
is	5	O
reported	9	O
to	5	O
illustrate	5	O
massive	9	O
rhabdomyolysis	5	B-Disease
and	5	O
subsequent	9	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
following	9	O
molindone	0	B-Chemical
administration	9	O
.	9	O

Physicians	5	O
who	5	O
prescribe	5	O
molindone	0	B-Chemical
should	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
reaction	9	O
.	9	O

Compression	5	B-Disease
neuropathy	5	I-Disease
of	5	I-Disease
the	5	I-Disease
radial	5	I-Disease
nerve	5	I-Disease
due	5	O
to	5	O
pentazocine	0	B-Chemical
-	7	O
induced	3	O
fibrous	5	B-Disease
myopathy	9	I-Disease
.	9	O

Fibrous	5	B-Disease
myopathy	9	I-Disease
is	5	O
a	5	O
common	5	O
,	9	O
well	9	O
-	7	O
known	9	O
side	5	O
effect	9	O
of	5	O
repeated	5	O
pentazocine	0	B-Chemical
injection	9	O
.	9	O

However	9	O
,	9	O
compression	5	B-Disease
neuropathy	5	I-Disease
due	5	O
to	5	O
fibrotic	5	O
muscle	9	O
affected	9	O
by	9	O
pentazocine	0	B-Chemical
-	7	O
induced	3	O
myopathy	9	B-Disease
has	9	O
not	5	O
previously	9	O
been	9	O
reported	9	O
.	9	O

In	9	O
a	5	O
37	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
documented	9	O
pentazocine	0	B-Chemical
-	7	O
induced	3	O
fibrous	5	B-Disease
myopathy	9	I-Disease
of	5	O
triceps	5	O
and	5	O
deltoid	5	O
muscles	5	O
bilaterally	5	O
and	5	O
a	5	O
three	9	O
-	7	O
week	9	O
history	5	O
of	5	O
right	5	O
wrist	5	O
drop	9	O
,	9	O
electrodiagnostic	5	O
examination	5	O
showed	9	O
a	5	O
severe	5	O
but	9	O
partial	9	O
lesion	5	O
of	5	O
the	5	O
right	5	O
radial	5	O
nerve	5	O
distal	9	O
to	5	O
the	5	O
branches	5	O
to	5	O
the	5	O
triceps	5	O
,	9	O
in	5	O
addition	9	O
to	5	O
the	5	O
fibrous	5	B-Disease
myopathy	9	I-Disease
.	9	O

Surgery	2	O
revealed	9	O
the	5	O
right	5	O
radial	5	O
nerve	5	O
to	5	O
be	5	O
severely	9	O
compressed	5	O
by	9	O
the	5	O
densely	5	O
fibrotic	5	O
lateral	5	O
head	5	O
of	5	O
the	5	O
triceps	5	O
.	9	O

Decompression	5	O
and	5	O
neurolysis	5	O
were	9	O
performed	9	O
with	5	O
good	5	O
subsequent	9	O
recovery	9	O
of	5	O
function	9	O
.	9	O

Recurrent	5	O
reversible	9	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
from	9	O
amphotericin	0	B-Chemical
.	9	O

A	9	O
patient	5	O
with	5	O
cryptogenic	5	O
cirrhosis	5	B-Disease
and	5	O
disseminated	5	O
sporotrichosis	4	B-Disease
developed	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
immediately	9	O
following	9	O
the	5	O
administration	9	O
of	5	O
amphotericin	0	B-Chemical
B	9	I-Chemical
on	5	O
four	9	O
separate	9	O
occasions	5	O
.	9	O

The	5	O
abruptness	5	O
of	5	O
the	5	O
renal	9	B-Disease
failure	5	I-Disease
and	5	O
its	9	O
reversibility	9	O
within	9	O
days	9	O
suggests	9	O
that	5	O
there	5	O
was	9	O
a	5	O
functional	9	O
component	9	O
to	5	O
the	5	O
renal	9	B-Disease
dysfunction	9	I-Disease
.	9	O

We	9	O
propose	9	O
that	5	O
amphotericin	0	B-Chemical
,	9	O
in	5	O
the	5	O
setting	5	O
of	5	O
reduced	9	O
effective	5	O
arterial	5	O
volume	9	O
,	9	O
may	5	O
activate	3	O
tubuloglomerular	5	O
feedback	5	O
,	9	O
thereby	9	O
contributing	9	O
to	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
.	9	O

Cerebral	5	B-Disease
infarction	5	I-Disease
with	5	O
a	5	O
single	9	O
oral	9	O
dose	9	O
of	5	O
phenylpropanolamine	0	B-Chemical
.	9	O

Phenylpropanolamine	7	B-Chemical
(	9	O
PPA	9	B-Chemical
)	9	O
,	9	O
a	5	O
synthetic	0	O
sympathomimetic	5	O
that	5	O
is	5	O
structurally	9	O
similar	9	O
to	5	O
amphetamine	5	B-Chemical
,	9	O
is	5	O
available	5	O
over	5	O
the	5	O
counter	5	O
in	5	O
anorectics	5	O
,	9	O
nasal	5	O
congestants	_	O
,	9	O
and	5	O
cold	9	O
preparations	9	O
.	9	O

Its	5	O
prolonged	9	O
use	5	O
or	5	O
overuse	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
seizures	5	B-Disease
,	9	O
intracerebral	5	B-Disease
hemorrhage	5	I-Disease
,	9	O
neuropsychiatric	5	B-Disease
symptoms	5	I-Disease
,	9	O
and	5	O
nonhemorrhagic	5	O
cerebral	5	B-Disease
infarction	5	I-Disease
.	9	O

We	9	O
report	5	O
the	5	O
case	5	O
of	5	O
a	5	O
young	5	O
woman	5	O
who	5	O
suffered	5	O
a	5	O
cerebral	5	B-Disease
infarction	5	I-Disease
after	9	O
taking	5	O
a	5	O
single	9	O
oral	9	O
dose	9	O
of	5	O
PPA	9	B-Chemical
.	9	O

Remission	5	O
induction	3	O
of	5	O
meningeal	5	B-Disease
leukemia	3	I-Disease
with	5	O
high	9	O
-	7	O
dose	9	O
intravenous	0	O
methotrexate	9	B-Chemical
.	9	O

Twenty	9	O
children	5	O
with	5	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
who	5	O
developed	5	O
meningeal	5	B-Disease
disease	5	I-Disease
were	9	O
treated	3	O
with	5	O
a	5	O
high	9	O
-	7	O
dose	9	O
intravenous	0	O
methotrexate	9	B-Chemical
regimen	5	O
that	5	O
was	9	O
designed	9	O
to	5	O
achieve	5	O
and	5	O
maintain	5	O
CSF	9	O
methotrexate	9	B-Chemical
concentrations	0	O
of	5	O
10	9	O
(	9	O
-	7	O
5	9	O
)	9	O
mol	0	O
/	9	O
L	0	O
without	9	O
the	5	O
need	5	O
for	5	O
concomitant	9	O
intrathecal	3	O
dosing	9	O
.	9	O

The	5	O
methotrexate	9	B-Chemical
was	9	O
administered	9	O
as	5	O
a	5	O
loading	9	O
dose	9	O
of	5	O
6	9	O
,	9	O
000	9	O
mg	0	O
/	9	O
m2	7	O
for	5	O
a	5	O
period	5	O
of	5	O
one	5	O
hour	0	O
followed	9	O
by	9	O
an	5	O
infusion	0	O
of	5	O
1	9	O
,	9	O
200	0	O
mg	0	O
/	9	O
m2	7	O
/	9	O
h	0	O
for	5	O
23	7	O
hours	9	O
.	9	O

Leucovorin	0	B-Chemical
rescue	3	O
was	9	O
initiated	9	O
12	9	O
hours	9	O
after	9	O
the	5	O
end	9	O
of	5	O
the	5	O
infusion	0	O
with	5	O
a	5	O
loading	9	O
dose	9	O
of	5	O
200	0	O
mg	0	O
/	9	O
m2	7	O
followed	9	O
by	9	O
12	9	O
mg	0	O
/	9	O
m2	7	O
every	5	O
three	9	O
hours	9	O
for	5	O
six	9	O
doses	0	O
and	5	O
then	9	O
every	5	O
six	9	O
hours	9	O
until	5	O
the	5	O
plasma	9	O
methotrexate	9	B-Chemical
level	9	O
decreased	9	O
to	5	O
less	5	O
than	5	O
1	9	O
X	9	O
10	9	O
(	9	O
-	7	O
7	9	O
)	9	O
mol	0	O
/	9	O
L	0	O
.	9	O

The	5	O
mean	5	O
steady	5	O
-	7	O
state	5	O
plasma	9	O
and	5	O
CSF	9	O
methotrexate	9	B-Chemical
concentrations	0	O
achieved	5	O
were	9	O
1	9	O
.	9	O
1	9	O
X	9	O
10	9	O
(	9	O
-	7	O
3	9	O
)	9	O
mol	0	O
/	9	O
L	0	O
and	5	O
3	9	O
.	9	O
6	9	O
X	9	O
10	9	O
(	9	O
-	7	O
5	9	O
)	9	O
mol	0	O
/	9	O
L	0	O
,	9	O
respectively	9	O
.	9	O

All	9	O
20	9	O
patients	5	O
responded	9	O
to	5	O
this	5	O
regimen	5	O
,	9	O
16	9	O
/	9	O
20	9	O
(	9	O
80	9	O
%	9	O
)	9	O
achieved	5	O
a	5	O
complete	9	O
remission	5	O
,	9	O
and	5	O
20	9	O
%	9	O
obtained	9	O
a	5	O
partial	9	O
remission	5	O
.	9	O

The	5	O
most	9	O
common	5	O
toxicities	5	B-Disease
encountered	5	O
were	9	O
transient	9	O
serum	9	O
transaminase	0	O
and	5	O
bilirubin	0	B-Chemical
elevations	9	O
,	9	O
neutropenia	5	B-Disease
,	9	O
and	5	O
mucositis	5	B-Disease
.	9	O

One	5	O
patient	5	O
had	9	O
focal	5	O
seizures	5	B-Disease
and	5	O
transient	9	B-Disease
hemiparesis	5	I-Disease
but	9	O
recovered	9	O
completely	9	O
.	9	O

High	9	O
-	7	O
dose	9	O
intravenous	0	O
methotrexate	9	B-Chemical
is	5	O
an	5	O
effective	5	O
treatment	9	O
for	5	O
the	5	O
induction	3	O
of	5	O
remission	5	O
after	9	O
meningeal	5	O
relapse	5	O
in	5	O
acute	9	B-Disease
lymphoblastic	3	I-Disease
leukemia	3	I-Disease
.	9	O

Interaction	9	O
of	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
with	5	O
antineoplastic	9	O
agents	5	O
.	9	O

A	9	O
synergistic	9	O
effect	9	O
of	5	O
etoposide	3	B-Chemical
and	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
was	9	O
observed	9	O
in	5	O
a	5	O
patient	5	O
with	5	O
acute	9	B-Disease
T	3	I-Disease
-	7	I-Disease
lymphocytic	3	I-Disease
leukemia	3	I-Disease
in	5	O
relapse	5	O
.	9	O

The	5	O
concomitant	9	O
administration	9	O
of	5	O
etoposide	3	B-Chemical
and	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
resulted	9	O
in	5	O
eradication	5	O
of	5	O
hitherto	9	O
refractory	9	O
leukemic	3	B-Disease
infiltration	3	I-Disease
of	5	O
bone	5	O
marrow	3	O
.	9	O

Severe	9	O
side	5	O
effects	9	O
in	5	O
terms	5	O
of	5	O
mental	5	O
confusion	5	B-Disease
and	5	O
progressive	5	O
hyperbilirubinemia	5	B-Disease
,	9	O
however	9	O
,	9	O
point	5	O
to	5	O
an	5	O
enhancement	9	O
not	5	O
only	9	O
of	5	O
antineoplastic	9	O
effects	9	O
but	9	O
also	9	O
of	5	O
toxicity	9	B-Disease
in	5	O
normal	9	O
tissues	9	O
.	9	O

This	5	O
report	5	O
demonstrates	9	O
for	5	O
the	5	O
first	9	O
time	5	O
that	5	O
the	5	O
pharmacodynamic	5	O
properties	9	O
of	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
may	5	O
not	5	O
be	5	O
confined	9	O
strictly	9	O
to	5	O
suppression	9	O
of	5	O
normal	9	O
T	3	O
-	7	O
cell	3	O
functions	9	O
.	9	O

Incidence	9	O
of	5	O
neoplasms	5	B-Disease
in	5	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
exposed	9	O
to	5	O
different	9	O
treatment	9	O
regimens	5	O
.	9	O

Immunosuppressive	9	O
drugs	5	O
have	5	O
been	9	O
used	5	O
during	5	O
the	5	O
last	5	O
30	9	O
years	5	O
in	5	O
treatment	9	O
of	5	O
patients	5	O
with	5	O
severe	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
.	9	O

The	5	O
drugs	5	O
commonly	5	O
used	5	O
are	5	O
cyclophosphamide	0	B-Chemical
and	5	O
chlorambucil	0	B-Chemical
(	9	O
alkylating	0	B-Chemical
agents	5	I-Chemical
)	9	O
,	9	O
azathioprine	5	B-Chemical
(	9	O
purine	0	B-Chemical
analogue	0	O
)	9	O
,	9	O
and	5	O
methotrexate	9	B-Chemical
(	9	O
folic	0	B-Chemical
acid	0	I-Chemical
analogue	0	O
)	9	O
.	9	O

There	5	O
is	5	O
evidence	9	O
that	5	O
all	5	O
four	9	O
immunosuppressive	9	O
drugs	5	O
can	5	O
reduce	5	O
synovitis	5	B-Disease
,	9	O
but	9	O
disease	5	O
activity	9	O
almost	9	O
always	5	O
recurs	5	O
after	9	O
therapy	5	O
is	5	O
stopped	9	O
.	9	O

Since	9	O
adverse	5	O
reactions	9	O
are	5	O
frequent	5	O
,	9	O
less	5	O
than	5	O
50	0	O
percent	5	O
of	5	O
patients	5	O
are	5	O
able	9	O
to	5	O
continue	5	O
a	5	O
particular	5	O
drug	5	O
for	5	O
more	5	O
than	5	O
one	5	O
year	5	O
.	9	O

Since	9	O
it	5	O
takes	5	O
three	9	O
to	5	O
12	9	O
months	5	O
to	5	O
achieve	5	O
maximal	9	O
effects	9	O
,	9	O
those	5	O
patients	5	O
who	5	O
are	5	O
unable	9	O
to	5	O
continue	5	O
the	5	O
drug	5	O
receive	5	O
little	9	O
benefit	5	O
from	9	O
it	5	O
.	9	O

Patients	5	O
treated	3	O
with	5	O
alkylating	0	B-Chemical
agents	5	I-Chemical
have	5	O
an	5	O
increased	9	O
risk	5	O
of	5	O
development	9	O
of	5	O
acute	9	B-Disease
nonlymphocytic	3	I-Disease
leukemia	3	I-Disease
,	9	O
and	5	O
both	9	O
alkylating	0	B-Chemical
agents	5	I-Chemical
and	5	O
azathioprine	5	B-Chemical
are	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
non	9	B-Disease
-	7	I-Disease
Hodgkin	5	I-Disease
'	9	I-Disease
s	9	I-Disease
lymphoma	9	I-Disease
.	9	O

Cyclophosphamide	0	B-Chemical
therapy	5	O
increases	9	O
the	5	O
risk	5	O
of	5	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
bladder	9	I-Disease
.	9	O

There	5	O
have	5	O
been	9	O
several	9	O
long	5	O
-	7	O
term	5	O
studies	9	O
of	5	O
patients	5	O
with	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
treated	3	O
with	5	O
azathioprine	5	B-Chemical
and	5	O
cyclophosphamide	0	B-Chemical
and	5	O
the	5	O
incidence	5	O
of	5	O
most	9	O
of	5	O
the	5	O
common	5	O
cancers	9	B-Disease
is	5	O
not	5	O
increased	9	O
.	9	O

Data	5	O
on	5	O
the	5	O
possible	5	O
increased	9	O
risk	5	O
of	5	O
malignancy	5	B-Disease
in	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
are	5	O
still	5	O
being	5	O
collected	9	O
,	9	O
and	5	O
until	5	O
further	9	O
information	5	O
is	5	O
available	5	O
,	9	O
the	5	O
use	5	O
of	5	O
immunosuppressive	9	O
drugs	5	O
,	9	O
particularly	5	O
alkylating	0	B-Chemical
agents	5	I-Chemical
,	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
rheumatoid	9	B-Disease
arthritis	9	I-Disease
should	5	O
be	5	O
reserved	5	O
for	5	O
patients	5	O
with	5	O
severe	5	O
progressive	5	O
disease	5	O
or	5	O
life	5	O
-	7	O
threatening	5	O
complications	5	O
.	9	O

Warfarin	5	B-Chemical
-	7	O
induced	3	O
iliopsoas	5	O
hemorrhage	5	B-Disease
with	5	O
subsequent	9	O
femoral	5	B-Disease
nerve	5	I-Disease
palsy	5	I-Disease
.	9	O

We	9	O
present	9	O
the	5	O
case	5	O
of	5	O
a	5	O
28	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
on	5	O
chronic	5	O
warfarin	5	B-Chemical
therapy	5	O
who	5	O
sustained	5	O
a	5	O
minor	9	O
muscle	9	B-Disease
tear	5	I-Disease
and	5	O
developed	5	O
increasing	9	O
pain	5	B-Disease
and	5	O
a	5	O
flexure	5	O
contracture	5	B-Disease
of	5	O
the	5	O
right	5	O
hip	5	O
.	9	O

Surgical	5	O
exploration	5	O
revealed	9	O
an	5	O
iliopsoas	5	O
hematoma	5	B-Disease
and	5	O
femoral	5	O
nerve	5	B-Disease
entrapment	5	I-Disease
,	9	O
resulting	9	O
in	5	O
a	5	O
femoral	5	B-Disease
nerve	5	I-Disease
palsy	5	I-Disease
and	5	O
partial	9	B-Disease
loss	9	I-Disease
of	5	I-Disease
quadriceps	5	I-Disease
functions	9	I-Disease
.	9	O

Anticoagulant	0	O
-	7	O
induced	3	O
femoral	5	B-Disease
nerve	5	I-Disease
palsy	5	I-Disease
represents	9	O
the	5	O
most	9	O
common	5	O
form	9	O
of	5	O
warfarin	5	B-Chemical
-	7	O
induced	3	O
peripheral	9	B-Disease
neuropathy	5	I-Disease
;	9	O
it	5	O
is	5	O
characterized	9	O
by	9	O
severe	5	O
pain	5	B-Disease
in	5	O
the	5	O
inguinal	5	O
region	9	O
,	9	O
varying	5	O
degrees	5	O
of	5	O
motor	5	B-Disease
and	5	I-Disease
sensory	5	I-Disease
impairment	5	I-Disease
,	9	O
and	5	O
flexure	5	O
contracture	5	B-Disease
of	5	O
the	5	O
involved	9	O
extremity	5	O
.	9	O

Pneumonitis	7	O
with	5	O
pleural	5	B-Disease
and	5	I-Disease
pericardial	5	I-Disease
effusion	5	I-Disease
and	5	O
neuropathy	5	B-Disease
during	5	O
amiodarone	0	B-Chemical
therapy	5	O
.	9	O

A	9	O
patient	5	O
with	5	O
sinuatrial	3	B-Disease
disease	5	I-Disease
and	5	O
implanted	9	O
pacemaker	5	O
was	9	O
treated	3	O
with	5	O
amiodarone	0	B-Chemical
(	9	O
maximum	5	O
dose	9	O
1000	9	O
mg	0	O
,	9	O
maintenance	9	O
dose	9	O
800	0	O
mg	0	O
daily	5	O
)	9	O
for	5	O
10	9	O
months	5	O
,	9	O
for	5	O
control	9	O
of	5	O
supraventricular	5	B-Disease
tachyarrhythmias	5	I-Disease
.	9	O

He	5	O
developed	5	O
pneumonitis	5	B-Disease
,	9	O
pleural	5	B-Disease
and	5	I-Disease
pericardial	5	I-Disease
effusions	5	I-Disease
,	9	O
and	5	O
a	5	O
predominantly	9	O
proximal	9	B-Disease
motor	5	I-Disease
neuropathy	5	I-Disease
.	9	O

Immediate	5	O
but	9	O
gradual	9	O
improvement	5	O
followed	9	O
withdrawal	5	O
of	5	O
amiodarone	0	B-Chemical
and	5	O
treatment	9	O
with	5	O
prednisolone	0	B-Chemical
.	9	O

Review	2	O
of	5	O
this	5	O
and	5	O
previously	9	O
reported	9	O
cases	5	O
indicates	9	O
the	5	O
need	5	O
for	5	O
early	9	O
diagnosis	5	O
of	5	O
amiodarone	0	B-Chemical
pneumonitis	5	B-Disease
,	9	O
immediate	5	O
withdrawal	5	O
of	5	O
amiodarone	0	B-Chemical
,	9	O
and	5	O
prompt	5	O
but	9	O
continued	9	O
steroid	9	B-Chemical
therapy	5	O
to	5	O
ensure	5	O
full	5	O
recovery	9	O
.	9	O

Amiodarone	7	B-Chemical
-	7	O
induced	3	O
sinoatrial	5	B-Disease
block	9	I-Disease
.	9	O

We	9	O
observed	9	O
sinoatrial	5	B-Disease
block	9	I-Disease
due	5	O
to	5	O
chronic	5	O
amiodarone	0	B-Chemical
administration	9	O
in	5	O
a	5	O
5	9	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
with	5	O
primary	9	B-Disease
cardiomyopathy	5	I-Disease
,	9	O
Wolff	6	B-Disease
-	7	I-Disease
Parkinson	5	I-Disease
-	7	I-Disease
White	9	I-Disease
syndrome	5	I-Disease
and	5	O
supraventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

Reduction	9	O
in	5	O
the	5	O
dosage	9	O
of	5	O
amiodarone	0	B-Chemical
resulted	9	O
in	5	O
the	5	O
disappearance	9	O
of	5	O
the	5	O
sinoatrial	5	B-Disease
block	9	I-Disease
and	5	O
the	5	O
persistence	9	O
of	5	O
asymptomatic	5	O
sinus	5	B-Disease
bradycardia	5	I-Disease
.	9	O

Desipramine	0	B-Chemical
-	7	O
induced	3	O
delirium	5	B-Disease
at	9	O
"	5	O
subtherapeutic	5	O
"	5	O
concentrations	0	O
:	9	O
a	5	O
case	5	O
report	5	O
.	9	O

An	5	O
elderly	5	O
patient	5	O
treated	3	O
with	5	O
low	9	O
dose	9	O
Desipramine	0	B-Chemical
developed	5	O
a	5	O
delirium	5	B-Disease
while	9	O
her	5	O
plasma	9	O
level	9	O
was	9	O
in	5	O
the	5	O
"	5	O
subtherapeutic	5	O
"	5	O
range	9	O
.	9	O

Delirium	5	B-Disease
,	9	O
which	5	O
may	5	O
be	5	O
induced	3	O
by	9	O
tricyclic	0	O
drug	5	O
therapy	5	O
in	5	O
the	5	O
elderly	5	O
,	9	O
can	5	O
be	5	O
caused	9	O
by	9	O
tricyclics	5	O
with	5	O
low	9	O
anticholinergic	5	O
potency	9	O
.	9	O

Therapeutic	5	O
ranges	5	O
for	5	O
antidepressants	5	B-Chemical
that	5	O
have	5	O
been	9	O
derived	9	O
from	9	O
general	5	O
adult	9	O
population	5	O
studies	9	O
may	5	O
not	5	O
be	5	O
appropriate	5	O
for	5	O
the	5	O
elderly	5	O
.	9	O

Further	9	O
studies	9	O
of	5	O
specifically	9	O
elderly	5	O
patients	5	O
are	5	O
now	5	O
required	9	O
to	5	O
establish	5	O
safer	5	O
and	5	O
more	5	O
appropriate	5	O
guidelines	5	O
for	5	O
drug	5	O
therapy	5	O
.	9	O

Indomethacin	0	B-Chemical
-	7	O
induced	3	O
renal	9	B-Disease
insufficiency	9	I-Disease
:	9	O
recurrence	5	O
on	5	O
rechallenge	3	O
.	9	O

We	9	O
have	5	O
reported	9	O
a	5	O
case	5	O
of	5	O
acute	9	O
oliguric	5	O
renal	9	B-Disease
failure	5	I-Disease
with	5	O
hyperkalemia	5	B-Disease
in	5	O
a	5	O
patient	5	O
with	5	O
cirrhosis	5	B-Disease
,	9	O
ascites	3	B-Disease
,	9	O
and	5	O
cor	5	B-Disease
pulmonale	5	I-Disease
after	9	O
indomethacin	0	B-Chemical
therapy	5	O
.	9	O

Prompt	5	O
restoration	5	O
of	5	O
renal	9	O
function	9	O
followed	9	O
drug	5	O
withdrawal	5	O
,	9	O
while	9	O
re	5	O
-	7	O
exposure	9	O
to	5	O
a	5	O
single	9	O
dose	9	O
of	5	O
indomethacin	0	B-Chemical
caused	9	O
recurrence	5	O
of	5	O
acute	9	O
reversible	9	O
oliguria	5	B-Disease
.	9	O

Our	9	O
case	5	O
supports	9	O
the	5	O
hypothesis	9	O
that	5	O
endogenous	3	O
renal	9	O
prostaglandins	0	B-Chemical
play	9	O
a	5	O
role	9	O
in	5	O
the	5	O
maintenance	9	O
of	5	O
renal	9	O
blood	9	O
flow	5	O
when	5	O
circulating	9	O
plasma	9	O
volume	9	O
is	5	O
diminished	9	O
.	9	O

Since	9	O
nonsteroidal	5	O
anti	3	O
-	7	O
inflammatory	3	O
agents	5	O
interfere	9	O
with	5	O
this	5	O
compensatory	5	O
mechanism	9	O
and	5	O
may	5	O
cause	5	O
acute	9	B-Disease
renal	9	I-Disease
failure	5	I-Disease
,	9	O
they	5	O
should	5	O
be	5	O
used	5	O
with	5	O
caution	5	O
in	5	O
such	5	O
patients	5	O
.	9	O

Patterns	5	O
of	5	O
hepatic	9	B-Disease
injury	9	I-Disease
induced	3	O
by	9	O
methyldopa	0	B-Chemical
.	9	O

Twelve	9	O
patients	5	O
with	5	O
liver	9	B-Disease
disease	5	I-Disease
related	9	O
to	5	O
methyldopa	0	B-Chemical
were	9	O
seen	9	O
between	5	O
1967	2	O
and	5	O
1977	2	O
.	9	O

Illness	5	O
occurred	9	O
within	9	O
1	9	O
-	7	O
-	7	O
9	7	O
weeks	9	O
of	5	O
commencement	5	O
of	5	O
therapy	5	O
in	5	O
9	7	O
patients	5	O
,	9	O
the	5	O
remaining	9	O
3	9	O
patients	5	O
having	5	O
received	9	O
the	5	O
drug	5	O
for	5	O
13	7	O
months	5	O
,	9	O
15	9	O
months	5	O
and	5	O
7	9	O
years	5	O
before	9	O
experiencing	5	O
symptoms	5	O
.	9	O

Jaundice	7	B-Disease
with	5	O
tender	5	O
hepatomegaly	5	B-Disease
,	9	O
usually	5	O
preceded	9	O
by	9	O
symptoms	5	O
of	5	O
malaise	4	O
,	9	O
anorexia	5	B-Disease
,	9	O
nausea	5	B-Disease
and	5	O
vomiting	5	B-Disease
,	9	O
and	5	O
associated	9	O
with	5	O
upper	9	O
abdominal	5	B-Disease
pain	5	I-Disease
,	9	O
was	9	O
an	5	O
invariable	9	O
finding	9	O
in	5	O
all	5	O
patients	5	O
.	9	O

Biochemical	9	O
liver	9	O
function	9	O
tests	5	O
indicated	9	O
hepatocellular	9	O
necrosis	9	B-Disease
and	5	O
correlated	9	O
with	5	O
histopathological	9	O
evidence	9	O
of	5	O
hepatic	9	B-Disease
injury	9	I-Disease
,	9	O
the	5	O
spectrum	9	O
of	5	O
which	5	O
ranged	9	O
from	9	O
fatty	0	B-Disease
change	9	I-Disease
and	5	O
focal	5	O
hepatocellular	9	O
necrosis	9	B-Disease
to	5	O
massive	9	B-Disease
hepatic	9	I-Disease
necrosis	9	I-Disease
.	9	O

Most	5	O
patients	5	O
showed	9	O
moderate	9	O
to	5	O
severe	5	O
acute	9	B-Disease
hepatitis	9	I-Disease
or	5	O
chronic	5	B-Disease
active	9	I-Disease
hepatitis	9	I-Disease
with	5	O
associated	9	O
cholestasis	5	B-Disease
.	9	O

The	5	O
drug	5	O
was	9	O
withdrawn	9	O
on	5	O
presentation	5	O
to	5	O
hospital	5	O
in	5	O
11	7	O
patients	5	O
,	9	O
with	5	O
rapid	5	O
clinical	5	O
improvement	5	O
in	5	O
9	7	O
.	9	O

One	5	O
patient	5	O
died	9	O
,	9	O
having	5	O
presented	5	O
in	5	O
hepatic	9	B-Disease
failure	5	I-Disease
,	9	O
and	5	O
another	9	O
,	9	O
who	5	O
had	9	O
been	9	O
taking	5	O
methyldopa	0	B-Chemical
for	5	O
7	9	O
years	5	O
,	9	O
showed	9	O
slower	9	O
clinical	5	O
and	5	O
biochemical	9	O
resolution	5	O
over	5	O
a	5	O
period	5	O
of	5	O
several	9	O
months	5	O
.	9	O

The	5	O
remaining	9	O
patient	5	O
in	5	O
the	5	O
series	5	O
developed	5	O
fulminant	5	B-Disease
hepatitis	9	I-Disease
when	5	O
the	5	O
drug	5	O
was	9	O
accidentally	5	O
recommenced	5	O
1	9	O
year	5	O
after	9	O
a	5	O
prior	9	O
episode	5	O
of	5	O
methyldopa	0	B-Chemical
-	7	O
induced	3	O
hepatitis	9	B-Disease
.	9	O

In	9	O
this	5	O
latter	9	O
patient	5	O
,	9	O
and	5	O
in	5	O
2	9	O
others	5	O
,	9	O
the	5	O
causal	5	O
relationship	5	O
between	5	O
methyldopa	0	B-Chemical
and	5	O
hepatic	9	B-Disease
dysfunction	9	I-Disease
was	9	O
proved	9	O
with	5	O
the	5	O
recurrence	5	O
of	5	O
hepatitis	9	B-Disease
within	9	O
2	9	O
weeks	9	O
of	5	O
re	5	O
-	7	O
exposure	9	O
to	5	O
the	5	O
drug	5	O
.	9	O

Suxamethonium	0	B-Chemical
infusion	0	O
rate	9	O
and	5	O
observed	9	O
fasciculations	5	B-Disease
.	9	O

A	9	O
dose	9	O
-	7	O
response	9	O
study	9	O
.	9	O

Suxamethonium	0	B-Chemical
chloride	0	I-Chemical
(	9	O
Sch	2	B-Chemical
)	9	O
was	9	O
administered	9	O
i	9	O
.	9	O
v	0	O
.	9	O
to	5	O
36	9	O
adult	9	O
males	9	O
at	9	O
six	9	O
rates	5	O
:	9	O
0	7	O
.	9	O
25	9	O
mg	0	O
s	9	O
-	7	O
1	9	O
to	5	O
20	9	O
mg	0	O
s	9	O
-	7	O
1	9	O
.	9	O

The	5	O
infusion	0	O
was	9	O
discontinued	5	O
either	9	O
when	5	O
there	5	O
was	9	O
no	9	O
muscular	5	O
response	9	O
to	5	O
tetanic	5	B-Disease
stimulation	3	O
of	5	O
the	5	O
ulnar	5	O
nerve	5	O
or	5	O
when	5	O
Sch	2	B-Chemical
120	9	O
mg	0	O
was	9	O
exceeded	9	O
.	9	O

Six	9	O
additional	9	O
patients	5	O
received	9	O
a	5	O
30	9	O
-	7	O
mg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
bolus	0	O
dose	9	O
.	9	O

Fasciculations	7	B-Disease
in	5	O
six	9	O
areas	5	O
of	5	O
the	5	O
body	5	O
were	9	O
scored	5	O
from	9	O
0	7	O
to	5	O
3	9	O
and	5	O
summated	5	O
as	5	O
a	5	O
total	9	O
fasciculation	5	B-Disease
score	5	O
.	9	O

The	5	O
times	5	O
to	5	O
first	9	O
fasciculation	5	B-Disease
,	9	O
twitch	5	B-Disease
suppression	9	O
and	5	O
tetanus	9	B-Disease
suppression	9	O
were	9	O
inversely	9	O
related	9	O
to	5	O
the	5	O
infusion	0	O
rates	5	O
.	9	O

Fasciculations	7	B-Disease
in	5	O
the	5	O
six	9	O
areas	5	O
and	5	O
the	5	O
total	9	O
fasciculation	5	B-Disease
score	5	O
were	9	O
related	9	O
directly	9	O
to	5	O
the	5	O
rate	9	O
of	5	O
infusion	0	O
.	9	O

Total	7	O
fasciculation	5	B-Disease
scores	5	O
in	5	O
the	5	O
30	9	O
-	7	O
mg	0	O
bolus	0	O
group	9	O
and	5	O
the	5	O
5	9	O
-	7	O
mg	0	O
s	9	O
-	7	O
1	9	O
and	5	O
20	9	O
-	7	O
mg	0	O
s	9	O
-	7	O
1	9	O
infusion	0	O
groups	9	O
were	9	O
not	5	O
significantly	9	O
different	9	O
.	9	O

Treatment	9	O
of	5	O
psoriasis	9	B-Disease
with	5	O
azathioprine	5	B-Chemical
.	9	O

Azathioprine	0	B-Chemical
treatment	9	O
benefited	5	O
19	7	O
(	9	O
66	7	O
%	9	O
)	9	O
out	9	O
of	5	O
29	7	O
patients	5	O
suffering	5	O
from	9	O
severe	5	O
psoriasis	9	B-Disease
.	9	O

Haematological	9	O
complications	5	O
were	9	O
not	5	O
troublesome	5	O
and	5	O
results	9	O
of	5	O
biochemical	9	O
liver	9	O
function	9	O
tests	5	O
remained	9	O
normal	9	O
.	9	O

Minimal	9	O
cholestasis	5	B-Disease
was	9	O
seen	9	O
in	5	O
two	5	O
cases	5	O
and	5	O
portal	5	O
fibrosis	9	B-Disease
of	5	O
a	5	O
reversible	9	O
degree	5	O
in	5	O
eight	9	O
.	9	O

Liver	9	O
biopsies	9	O
should	5	O
be	5	O
undertaken	5	O
at	9	O
regular	5	O
intervals	5	O
if	5	O
azathioprine	5	B-Chemical
therapy	5	O
is	5	O
continued	9	O
so	5	O
that	5	O
structural	9	O
liver	9	B-Disease
damage	9	I-Disease
may	5	O
be	5	O
detected	9	O
at	9	O
an	5	O
early	9	O
and	5	O
reversible	9	O
stage	9	O
.	9	O

Angiosarcoma	7	B-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
associated	9	O
with	5	O
diethylstilbestrol	0	B-Chemical
.	9	O

Angiosarcoma	7	B-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
occurred	9	O
in	5	O
a	5	O
76	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
who	5	O
had	9	O
been	9	O
treated	3	O
for	5	O
a	5	O
well	9	O
-	7	O
differentiated	3	O
adenocarcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
with	5	O
diethylstilbestrol	0	B-Chemical
for	5	O
13	7	O
years	5	O
.	9	O

Angiosarcoma	7	B-Disease
was	9	O
also	9	O
present	9	O
within	9	O
pulmonary	5	O
and	5	O
renal	9	O
arteries	5	O
.	9	O

The	5	O
possibility	9	O
that	5	O
the	5	O
intraarterial	5	B-Disease
lesions	5	I-Disease
might	9	O
represent	9	O
independent	9	O
primary	9	O
tumors	3	B-Disease
is	5	O
considered	5	O
.	9	O

Galanthamine	0	B-Chemical
hydrobromide	0	I-Chemical
,	9	O
a	5	O
longer	5	O
acting	9	O
anticholinesterase	0	O
drug	5	O
,	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
the	5	O
central	5	O
effects	9	O
of	5	O
scopolamine	0	B-Chemical
(	9	O
Hyoscine	0	B-Chemical
)	9	O
.	9	O

Galanthamine	0	B-Chemical
hydrobromide	0	I-Chemical
,	9	O
an	5	O
anticholinesterase	0	O
drug	5	O
capable	9	O
of	5	O
penetrating	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
,	9	O
was	9	O
used	5	O
in	5	O
a	5	O
patient	5	O
demonstrating	9	O
central	5	O
effects	9	O
of	5	O
scopolamine	0	B-Chemical
(	9	O
hyoscine	0	B-Chemical
)	9	O
overdosage	5	B-Disease
.	9	O

It	5	O
is	5	O
longer	5	O
acting	9	O
than	5	O
physostigmine	0	B-Chemical
and	5	O
is	5	O
used	5	O
in	5	O
anaesthesia	5	O
to	5	O
reverse	9	O
the	5	O
non	9	O
-	7	O
depolarizing	5	O
neuromuscular	5	O
block	9	O
.	9	O

However	9	O
,	9	O
studies	9	O
into	9	O
the	5	O
dose	9	O
necessary	5	O
to	5	O
combating	5	O
scopolamine	0	B-Chemical
intoxication	9	O
are	5	O
indicated	9	O
.	9	O

Comparison	9	O
of	5	O
the	5	O
subjective	5	O
effects	9	O
and	5	O
plasma	9	O
concentrations	0	O
following	9	O
oral	9	O
and	5	O
i	9	O
.	9	O
m	9	O
.	9	O
administration	9	O
of	5	O
flunitrazepam	0	B-Chemical
in	5	O
volunteers	5	O
.	9	O

Flunitrazepam	7	B-Chemical
0	7	O
.	9	O
5	9	O
,	9	O
1	9	O
.	9	O
0	7	O
or	5	O
2	9	O
.	9	O
0	7	O
mg	0	O
was	9	O
given	5	O
by	9	O
the	5	O
oral	9	O
or	5	O
i	9	O
.	9	O
m	9	O
.	9	O
routes	5	O
to	5	O
groups	9	O
of	5	O
volunteers	5	O
and	5	O
its	9	O
effects	9	O
compared	9	O
.	9	O

Plasma	0	O
concentrations	0	O
of	5	O
the	5	O
drug	5	O
were	9	O
estimated	5	O
by	9	O
gas	0	O
-	7	O
liquid	0	O
chromatography	0	O
,	9	O
in	5	O
a	5	O
smaller	5	O
number	9	O
of	5	O
the	5	O
subjects	5	O
.	9	O

The	5	O
most	9	O
striking	9	O
effect	9	O
was	9	O
sedation	5	O
which	5	O
increased	9	O
with	5	O
the	5	O
dose	9	O
,	9	O
2	9	O
mg	0	O
producing	9	O
deep	5	O
sleep	5	O
although	9	O
the	5	O
subjects	5	O
could	9	O
still	5	O
be	5	O
aroused	5	O
.	9	O

The	5	O
effects	9	O
of	5	O
i	9	O
.	9	O
m	9	O
.	9	O
administration	9	O
were	9	O
apparent	9	O
earlier	9	O
and	5	O
sometimes	5	O
lasted	5	O
longer	5	O
than	5	O
those	5	O
following	9	O
oral	9	O
administration	9	O
.	9	O

Dizziness	7	B-Disease
was	9	O
less	5	O
marked	9	O
than	5	O
sedation	5	O
,	9	O
but	9	O
increased	9	O
with	5	O
the	5	O
dose	9	O
.	9	O

There	5	O
was	9	O
pain	5	B-Disease
on	5	O
i	9	O
.	9	O
m	9	O
.	9	O
injection	9	O
of	5	O
flunitrazepam	0	B-Chemical
significantly	9	O
more	5	O
often	5	O
than	5	O
with	5	O
isotonic	0	O
saline	0	O
.	9	O

Plasma	0	O
concentrations	0	O
varied	9	O
with	5	O
dose	9	O
and	5	O
route	5	O
and	5	O
corresponded	9	O
qualitatively	9	O
with	5	O
the	5	O
subjective	5	O
effects	9	O
.	9	O

The	5	O
drug	5	O
was	9	O
still	5	O
present	9	O
in	5	O
measurable	9	O
quantities	9	O
after	9	O
24	9	O
h	0	O
even	5	O
with	5	O
the	5	O
smallest	5	O
dose	9	O
.	9	O

Possible	9	O
teratogenicity	5	O
of	5	O
sulphasalazine	0	B-Chemical
.	9	O

Three	9	O
infants	5	O
,	9	O
born	5	O
of	5	O
two	5	O
mothers	5	O
with	5	O
inflammatory	3	B-Disease
bowel	5	I-Disease
disease	5	I-Disease
who	5	O
received	9	O
treatment	9	O
with	5	O
sulphasalazine	0	B-Chemical
throughout	9	O
pregnancy	5	O
,	9	O
were	9	O
found	9	O
to	5	O
have	5	O
major	9	O
congenital	5	B-Disease
anomalies	5	I-Disease
.	9	O

In	9	O
the	5	O
singleton	5	O
pregnancy	5	O
,	9	O
the	5	O
mother	5	O
had	9	O
ulcerative	5	B-Disease
colitis	3	I-Disease
,	9	O
and	5	O
the	5	O
infant	5	O
,	9	O
a	5	O
male	9	O
,	9	O
had	9	O
coarctation	5	B-Disease
of	5	I-Disease
the	5	I-Disease
aorta	9	I-Disease
and	5	O
a	5	O
ventricular	5	B-Disease
septal	5	I-Disease
defect	9	I-Disease
.	9	O

In	9	O
the	5	O
twin	5	O
pregnancy	5	O
,	9	O
the	5	O
mother	5	O
had	9	O
Crohn	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

The	5	O
first	9	O
twin	5	O
,	9	O
a	5	O
female	9	O
,	9	O
had	9	O
a	5	O
left	5	O
Potter	6	B-Disease
-	7	I-Disease
type	9	I-Disease
IIa	9	I-Disease
polycystic	5	I-Disease
kidney	9	I-Disease
and	5	O
a	5	O
rudimentary	5	B-Disease
left	5	I-Disease
uterine	5	I-Disease
cornu	5	I-Disease
.	9	O

The	5	O
second	9	O
twin	5	O
,	9	O
a	5	O
male	9	O
,	9	O
had	9	O
some	5	O
features	5	O
of	5	O
Potter	6	B-Disease
'	9	I-Disease
s	9	I-Disease
facies	4	I-Disease
,	9	O
hypoplastic	5	B-Disease
lungs	3	I-Disease
,	9	O
absent	9	B-Disease
kidneys	9	I-Disease
and	5	I-Disease
ureters	5	I-Disease
,	9	O
and	5	O
talipes	5	B-Disease
equinovarus	5	I-Disease
.	9	O

Despite	5	O
reports	9	O
to	5	O
the	5	O
contrary	9	O
,	9	O
it	5	O
is	5	O
suggested	9	O
that	5	O
sulphasalazine	0	B-Chemical
may	5	O
be	5	O
teratogenic	5	O
.	9	O

Thrombotic	5	B-Disease
microangiopathy	5	I-Disease
and	5	O
renal	9	B-Disease
failure	5	I-Disease
associated	9	O
with	5	O
antineoplastic	9	O
chemotherapy	5	O
.	9	O

Five	9	O
patients	5	O
with	5	O
carcinoma	3	B-Disease
developed	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
(	9	O
characterized	9	O
by	9	O
renal	9	B-Disease
insufficiency	9	I-Disease
,	9	O
microangiopathic	5	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
,	9	O
and	5	O
usually	5	O
thrombocytopenia	9	B-Disease
)	9	O
after	9	O
treatment	9	O
with	5	O
cisplatin	3	B-Chemical
,	9	O
bleomycin	3	B-Chemical
,	9	O
and	5	O
a	5	O
vinca	0	B-Chemical
alkaloid	0	I-Chemical
.	9	O

One	5	O
patient	5	O
had	9	O
thrombotic	5	B-Disease
thrombocytopenic	5	I-Disease
purpura	5	I-Disease
,	9	O
three	9	O
the	5	O
hemolytic	0	B-Disease
-	7	I-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
,	9	O
and	5	O
one	5	O
an	5	O
apparent	9	O
forme	2	O
fruste	5	O
of	5	O
one	5	O
of	5	O
these	5	O
disorders	5	O
.	9	O

Histologic	9	O
examination	5	O
of	5	O
the	5	O
renal	9	O
tissue	9	O
showed	9	O
evidence	9	O
of	5	O
intravascular	5	B-Disease
coagulation	5	I-Disease
,	9	O
primarily	9	O
affecting	9	O
the	5	O
small	9	O
arteries	5	O
,	9	O
arterioles	9	O
,	9	O
and	5	O
glomeruli	9	O
.	9	O

Because	9	O
each	5	O
patient	5	O
was	9	O
tumor	3	B-Disease
-	7	O
free	9	O
or	5	O
had	9	O
only	9	O
a	5	O
small	9	O
tumor	3	B-Disease
at	9	O
the	5	O
onset	5	O
of	5	O
this	5	O
syndrome	5	O
,	9	O
the	5	O
thrombotic	5	B-Disease
microangiopathy	5	I-Disease
may	5	O
have	5	O
been	9	O
induced	3	O
by	9	O
chemotherapy	5	O
.	9	O

Diagnosis	9	O
of	5	O
this	5	O
potentially	5	O
fatal	5	O
complication	5	O
may	5	O
be	5	O
delayed	9	O
or	5	O
missed	5	O
if	5	O
renal	9	O
tissue	9	O
or	5	O
the	5	O
peripheral	9	O
blood	9	O
smear	5	O
is	5	O
not	5	O
examined	9	O
,	9	O
because	5	O
renal	9	B-Disease
failure	5	I-Disease
may	5	O
be	5	O
ascribed	9	O
to	5	O
cisplatin	3	B-Chemical
nephrotoxicity	9	B-Disease
and	5	O
the	5	O
anemia	9	B-Disease
and	5	O
thrombocytopenia	9	B-Disease
to	5	O
drug	5	O
-	7	O
induced	3	O
bone	5	B-Disease
marrow	3	I-Disease
suppression	9	I-Disease
.	9	O

International	2	O
mexiletine	0	B-Chemical
and	5	O
placebo	9	O
antiarrhythmic	5	O
coronary	5	O
trial	5	O
:	9	O
I	9	O
.	9	O

Report	5	O
on	5	O
arrhythmia	5	B-Disease
and	5	O
other	5	O
findings	9	O
.	9	O

Impact	5	O
Research	2	O
Group	9	O
.	9	O

The	5	O
antiarrhythmic	5	O
effects	9	O
of	5	O
the	5	O
sustained	5	O
release	9	O
form	9	O
of	5	O
mexiletine	0	B-Chemical
(	9	O
Mexitil	_	B-Chemical
-	7	I-Chemical
Perlongets	_	I-Chemical
)	9	O
were	9	O
evaluated	9	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
placebo	9	O
trial	5	O
in	5	O
630	9	O
patients	5	O
with	5	O
recent	5	O
documented	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

The	5	O
primary	9	O
response	9	O
variable	5	O
was	9	O
based	5	O
on	5	O
central	5	O
reading	5	O
of	5	O
24	9	O
hour	0	O
ambulatory	5	O
electrocardiographic	5	O
recordings	5	O
and	5	O
was	9	O
defined	5	O
as	5	O
the	5	O
occurrence	5	O
of	5	O
30	9	O
or	5	O
more	5	O
single	9	O
premature	9	O
ventricular	5	O
complexes	9	O
in	5	O
any	5	O
two	5	O
consecutive	5	O
30	9	O
minute	5	O
blocks	9	O
or	5	O
one	5	O
or	5	O
more	5	O
runs	5	O
of	5	O
two	5	O
or	5	O
more	5	O
premature	9	O
ventricular	5	O
complexes	9	O
in	5	O
the	5	O
entire	9	O
24	9	O
hour	0	O
electrocardiographic	5	O
recording	5	O
.	9	O

Large	9	O
differences	9	O
,	9	O
regarded	5	O
as	5	O
statistically	9	O
significant	9	O
,	9	O
between	5	O
the	5	O
mexiletine	0	B-Chemical
and	5	O
placebo	9	O
groups	9	O
were	9	O
noted	9	O
in	5	O
that	5	O
end	9	O
point	5	O
at	9	O
months	5	O
1	9	O
and	5	O
4	9	O
,	9	O
but	9	O
only	9	O
trends	5	O
were	9	O
observed	9	O
at	9	O
month	5	O
12	9	O
.	9	O

These	5	O
differences	9	O
were	9	O
observed	9	O
even	5	O
though	9	O
the	5	O
serum	9	O
mexiletine	0	B-Chemical
levels	3	O
obtained	9	O
in	5	O
this	5	O
study	9	O
were	9	O
generally	5	O
lower	9	O
than	5	O
those	5	O
observed	9	O
in	5	O
studies	9	O
that	5	O
have	5	O
used	5	O
the	5	O
regular	5	O
form	9	O
of	5	O
the	5	O
drug	5	O
.	9	O

There	5	O
were	9	O
more	5	O
deaths	5	B-Disease
in	5	O
the	5	O
mexiletine	0	B-Chemical
group	9	O
(	9	O
7	9	O
.	9	O
6	9	O
%	9	O
)	9	O
than	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
(	9	O
4	9	O
.	9	O
8	9	O
%	9	O
)	9	O
;	9	O
the	5	O
difference	9	O
was	9	O
not	5	O
statistically	9	O
significant	9	O
.	9	O

The	5	O
incidence	5	O
of	5	O
coronary	5	O
events	5	O
was	9	O
similar	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

Previously	9	O
recognized	9	O
side	5	O
effects	9	O
,	9	O
particularly	5	O
tremor	5	B-Disease
and	5	O
gastrointestinal	9	B-Disease
problems	5	I-Disease
,	9	O
were	9	O
more	5	O
frequent	5	O
in	5	O
the	5	O
mexiletine	0	B-Chemical
group	9	O
than	5	O
in	5	O
the	5	O
placebo	9	O
group	9	O
.	9	O

Changes	9	O
in	5	O
heart	5	O
size	9	O
during	5	O
long	5	O
-	7	O
term	5	O
timolol	0	B-Chemical
treatment	9	O
after	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

The	5	O
effect	9	O
of	5	O
long	5	O
-	7	O
term	5	O
timolol	0	B-Chemical
treatment	9	O
on	5	O
heart	5	O
size	9	O
after	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
was	9	O
evaluated	9	O
by	9	O
X	9	O
-	7	O
ray	5	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
study	9	O
including	9	O
241	7	O
patients	5	O
(	9	O
placebo	9	O
126	7	O
,	9	O
timolol	0	B-Chemical
115	7	O
)	9	O
.	9	O

The	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
was	9	O
12	9	O
months	5	O
.	9	O

The	5	O
timolol	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
showed	9	O
a	5	O
small	9	O
but	9	O
significant	9	O
increase	9	O
in	5	O
heart	5	O
size	9	O
from	9	O
baseline	5	O
in	5	O
contrast	9	O
to	5	O
a	5	O
decrease	9	O
in	5	O
the	5	O
placebo	9	O
group	9	O
.	9	O

These	5	O
differences	9	O
may	5	O
be	5	O
caused	9	O
by	9	O
timolol	0	B-Chemical
-	7	O
induced	3	O
bradycardia	5	B-Disease
and	5	O
a	5	O
compensatory	5	O
increase	9	O
in	5	O
end	9	O
-	7	O
diastolic	5	O
volume	9	O
.	9	O

The	5	O
timolol	0	B-Chemical
-	7	O
related	9	O
increase	9	O
in	5	O
heart	5	O
size	9	O
was	9	O
observed	9	O
only	9	O
in	5	O
patients	5	O
with	5	O
normal	9	O
and	5	O
borderline	9	O
heart	5	O
size	9	O
.	9	O

In	9	O
patients	5	O
with	5	O
cardiomegaly	5	B-Disease
,	9	O
the	5	O
increase	9	O
in	5	O
heart	5	O
size	9	O
was	9	O
similar	9	O
in	5	O
both	9	O
groups	9	O
.	9	O

After	9	O
re	5	O
-	7	O
infarction	5	B-Disease
,	9	O
heart	5	O
size	9	O
increased	9	O
in	5	O
the	5	O
placebo	9	O
group	9	O
and	5	O
remained	9	O
unchanged	9	O
in	5	O
the	5	O
timolol	0	B-Chemical
group	9	O
.	9	O

Vitamin	0	B-Chemical
D3	9	I-Chemical
toxicity	9	B-Disease
in	5	O
dairy	5	O
cows	5	O
.	9	O

Large	9	O
parenteral	5	O
doses	0	O
of	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
(	9	O
15	9	O
to	5	O
17	7	O
.	9	O
5	9	O
x	9	O
10	9	O
(	9	O
6	9	O
)	9	O
IU	0	O
vitamin	0	B-Chemical
D3	9	I-Chemical
)	9	O
were	9	O
associated	9	O
with	5	O
prolonged	9	O
hypercalcemia	5	B-Disease
,	9	O
hyperphosphatemia	5	B-Disease
,	9	O
and	5	O
large	5	O
increases	9	O
of	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
and	5	O
its	9	O
metabolites	0	O
in	5	O
the	5	O
blood	9	O
plasma	9	O
of	5	O
nonlactating	5	O
nonpregnant	5	O
and	5	O
pregnant	5	O
Jersey	2	O
cows	5	O
.	9	O

Calcium	0	B-Chemical
concentrations	0	O
1	9	O
day	9	O
postpartum	5	O
were	9	O
higher	9	O
in	5	O
cows	5	O
treated	3	O
with	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
about	5	O
32	7	O
days	9	O
prepartum	5	O
(	9	O
8	9	O
.	9	O
8	9	O
mg	0	O
/	9	O
100	0	O
ml	0	O
)	9	O
than	5	O
in	5	O
control	9	O
cows	5	O
(	9	O
5	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
100	0	O
ml	0	O
)	9	O
.	9	O

None	9	O
of	5	O
the	5	O
cows	5	O
treated	3	O
with	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
showed	9	O
signs	5	O
of	5	O
milk	9	B-Disease
fever	5	I-Disease
during	5	O
the	5	O
peripartal	5	O
period	5	O
;	9	O
however	9	O
,	9	O
22	7	O
%	9	O
of	5	O
the	5	O
control	9	O
cows	5	O
developed	5	O
clinical	5	O
signs	5	O
of	5	O
milk	9	B-Disease
fever	5	I-Disease
during	5	O
this	5	O
period	5	O
.	9	O

Signs	5	O
of	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
toxicity	9	B-Disease
were	9	O
not	5	O
observed	9	O
in	5	O
nonlactating	5	O
nonpregnant	5	O
cows	5	O
;	9	O
however	9	O
,	9	O
pregnant	5	O
cows	5	O
commonly	5	O
developed	5	O
severe	5	O
signs	5	O
of	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
toxicity	9	B-Disease
and	5	O
10	9	O
of	5	O
17	7	O
cows	5	O
died	9	O
.	9	O

There	5	O
was	9	O
widespread	5	O
metastatic	3	O
calcification	5	O
in	5	O
the	5	O
cows	5	O
that	5	O
died	9	O
.	9	O

Because	9	O
of	5	O
the	5	O
extreme	5	O
toxicity	9	B-Disease
of	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
in	5	O
pregnant	5	O
Jersey	2	O
cows	5	O
and	5	O
the	5	O
low	9	O
margin	5	O
of	5	O
safety	5	O
between	5	O
doses	0	O
of	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
that	5	O
prevent	5	O
milk	9	B-Disease
fever	5	I-Disease
and	5	O
doses	0	O
that	5	O
induce	3	O
milk	9	B-Disease
fever	5	I-Disease
,	9	O
we	5	O
concluded	9	O
that	5	O
vitamin	0	B-Chemical
D3	9	I-Chemical
cannot	5	O
be	5	O
used	5	O
practically	5	O
to	5	O
prevent	5	O
milk	9	B-Disease
fever	5	I-Disease
when	5	O
injected	3	O
several	9	O
weeks	9	O
prepartum	5	O
.	9	O

Diseases	2	B-Disease
of	5	I-Disease
peripheral	9	I-Disease
nerves	5	I-Disease
as	5	O
seen	9	O
in	5	O
the	5	O
Nigerian	5	O
African	5	O
.	9	O

The	5	O
anatomical	5	O
and	5	O
aetiological	5	O
diagnoses	5	O
of	5	O
peripheral	9	B-Disease
nerve	5	I-Disease
disease	5	I-Disease
excluding	9	O
its	9	O
primary	9	O
benign	5	O
and	5	O
malignant	3	O
disorders	5	O
,	9	O
as	5	O
seen	9	O
in	5	O
358	7	O
Nigerians	5	O
are	5	O
presented	5	O
.	9	O

There	5	O
is	5	O
a	5	O
male	9	O
preponderance	9	O
and	5	O
the	5	O
peak	9	O
incidence	5	O
is	5	O
in	5	O
the	5	O
fourth	9	O
decade	5	O
.	9	O

Sensori	5	B-Disease
-	7	I-Disease
motor	5	I-Disease
neuropathy	5	I-Disease
was	9	O
the	5	O
commonest	5	O
presentation	5	O
(	9	O
50	0	O
%	9	O
)	9	O
.	9	O

Guillain	5	B-Disease
-	7	I-Disease
Barr	6	I-Disease
syndrome	5	I-Disease
was	9	O
the	5	O
commonest	5	O
identifiable	5	O
cause	5	O
(	9	O
15	9	O
.	9	O
6	9	O
%	9	O
)	9	O
,	9	O
accounting	5	O
for	5	O
half	5	O
of	5	O
the	5	O
cases	5	O
with	5	O
motor	5	B-Disease
neuropathy	5	I-Disease
.	9	O

Peripheral	9	B-Disease
neuropathy	5	I-Disease
due	5	O
to	5	O
nutritional	5	B-Disease
deficiency	9	I-Disease
of	5	O
thiamine	0	B-Chemical
and	5	O
riboflavin	0	B-Chemical
was	9	O
common	5	O
(	9	O
10	9	O
.	9	O
1	9	O
%	9	O
)	9	O
and	5	O
presented	5	O
mainly	9	O
as	5	O
sensory	5	O
and	5	O
sensori	5	B-Disease
-	7	I-Disease
motor	5	I-Disease
neuropathy	5	I-Disease
.	9	O

Diabetes	7	B-Disease
mellitus	9	I-Disease
was	9	O
the	5	O
major	9	O
cause	5	O
of	5	O
autonomic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

Isoniazid	0	B-Chemical
was	9	O
the	5	O
most	9	O
frequent	5	O
agent	9	O
in	5	O
drug	5	O
-	7	O
induced	3	O
neuropathy	5	B-Disease
.	9	O

Migraine	5	B-Disease
(	9	O
20	9	O
%	9	O
)	9	O
was	9	O
not	5	O
an	5	O
uncommon	5	O
cause	5	O
of	5	O
cranial	5	B-Disease
neuropathy	5	I-Disease
although	9	O
malignancies	5	B-Disease
arising	5	O
from	9	O
the	5	O
reticuloendothelial	5	O
system	5	O
or	5	O
related	9	O
structures	9	O
of	5	O
the	5	O
head	5	O
and	5	O
neck	5	O
were	9	O
more	5	O
frequent	5	O
(	9	O
26	7	O
%	9	O
)	9	O
.	9	O

In	9	O
26	7	O
.	9	O
5	9	O
%	9	O
of	5	O
all	5	O
the	5	O
cases	5	O
,	9	O
the	5	O
aetiology	5	O
of	5	O
the	5	O
neuropathy	5	B-Disease
was	9	O
undetermined	9	O
.	9	O

Heredofamilial	7	O
and	5	O
connective	5	B-Disease
tissue	9	I-Disease
disorders	5	I-Disease
were	9	O
rare	5	O
.	9	O

Some	5	O
of	5	O
the	5	O
factors	9	O
related	9	O
to	5	O
the	5	O
clinical	5	O
presentation	5	O
and	5	O
pathogenesis	9	O
of	5	O
the	5	O
neuropathies	5	B-Disease
are	5	O
briefly	9	O
discussed	5	O
.	9	O

Reduction	9	O
in	5	O
caffeine	0	B-Chemical
toxicity	9	B-Disease
by	9	O
acetaminophen	0	B-Chemical
.	9	O

A	9	O
patient	5	O
who	5	O
allegedly	5	O
consumed	5	O
100	0	O
tablets	0	O
of	5	O
an	5	O
over	5	O
-	7	O
the	5	O
-	7	O
counter	5	O
analgesic	5	O
containing	0	O
sodium	0	B-Chemical
acetylsalicylate	0	I-Chemical
,	9	O
caffeine	0	B-Chemical
,	9	O
and	5	O
acetaminophen	0	B-Chemical
displayed	9	O
no	9	O
significant	9	O
CNS	9	O
stimulation	3	O
despite	9	O
the	5	O
presence	9	O
of	5	O
175	7	O
micrograms	0	O
of	5	O
caffeine	0	B-Chemical
per	9	O
mL	0	O
of	5	O
serum	9	O
.	9	O

Because	9	O
salicylates	0	O
have	5	O
been	9	O
reported	9	O
to	5	O
augment	9	O
the	5	O
stimulatory	3	O
effects	9	O
of	5	O
caffeine	0	B-Chemical
on	5	O
the	5	O
CNS	9	O
,	9	O
attention	5	O
was	9	O
focused	5	O
on	5	O
the	5	O
possibility	9	O
that	5	O
the	5	O
presence	9	O
of	5	O
acetaminophen	0	B-Chemical
(	9	O
52	7	O
micrograms	0	O
/	9	O
mL	0	O
)	9	O
reduced	9	O
the	5	O
CNS	9	O
toxicity	9	B-Disease
of	5	O
caffeine	0	B-Chemical
.	9	O

Studies	9	O
in	5	O
DBA	3	O
/	9	O
2J	3	O
mice	3	O
showed	9	O
that	5	O
:	9	O
1	9	O
)	9	O
pretreatment	0	O
with	5	O
acetaminophen	0	B-Chemical
(	9	O
100	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
increased	9	O
the	5	O
interval	5	O
between	5	O
the	5	O
administration	9	O
of	5	O
caffeine	0	B-Chemical
(	9	O
300	0	O
to	5	O
450	9	O
mg	0	O
/	9	O
kg	0	O
IP	9	O
)	9	O
and	5	O
the	5	O
onset	5	O
of	5	O
fatal	5	O
convulsions	5	B-Disease
by	9	O
a	5	O
factor	9	O
of	5	O
about	5	O
two	5	O
;	9	O
and	5	O
2	9	O
)	9	O
pretreatment	0	O
with	5	O
acetaminophen	0	B-Chemical
(	9	O
75	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
reduced	9	O
the	5	O
incidence	5	O
of	5	O
audiogenic	3	O
seizures	5	B-Disease
produced	9	O
in	5	O
the	5	O
presence	9	O
of	5	O
caffeine	0	B-Chemical
(	9	O
12	9	O
.	9	O
5	9	O
to	5	O
75	9	O
mg	0	O
/	9	O
kg	0	O
IP	9	O
)	9	O
.	9	O

The	5	O
frequency	5	O
of	5	O
sound	5	O
-	7	O
induced	3	O
seizures	5	B-Disease
after	9	O
12	9	O
.	9	O
5	9	O
or	5	O
25	9	O
mg	0	O
/	9	O
kg	0	O
caffeine	0	B-Chemical
was	9	O
reduced	9	O
from	9	O
50	0	O
to	5	O
5	9	O
%	9	O
by	9	O
acetaminophen	0	B-Chemical
.	9	O

In	9	O
the	5	O
absence	3	O
of	5	O
caffeine	0	B-Chemical
,	9	O
acetaminophen	0	B-Chemical
(	9	O
up	5	O
to	5	O
300	0	O
mg	0	O
/	9	O
kg	0	O
)	9	O
did	9	O
not	5	O
modify	9	O
the	5	O
seizures	5	B-Disease
induced	3	O
by	9	O
maximal	9	O
electroshock	5	O
and	5	O
did	9	O
not	5	O
alter	9	O
the	5	O
convulsant	0	O
dose	9	O
of	5	O
pentylenetetrezol	_	B-Chemical
in	5	O
mice	3	O
(	9	O
tests	5	O
performed	9	O
by	9	O
the	5	O
Anticonvulsant	0	O
Screening	9	O
Project	2	O
of	5	O
NINCDS	2	O
)	9	O
.	9	O

Acetaminophen	0	B-Chemical
(	9	O
up	5	O
to	5	O
150	0	O
micrograms	0	O
/	9	O
mL	0	O
)	9	O
did	9	O
not	5	O
retard	9	O
the	5	O
incorporation	0	O
of	5	O
radioactive	0	O
adenosine	0	B-Chemical
into	9	O
ATP	0	B-Chemical
in	5	O
slices	9	O
of	5	O
rat	3	O
cerebral	5	O
cortex	5	O
.	9	O

Thus	9	O
the	5	O
mechanism	9	O
by	9	O
which	5	O
acetaminophen	0	B-Chemical
antagonizes	3	O
the	5	O
actions	5	O
of	5	O
caffeine	0	B-Chemical
in	5	O
the	5	O
CNS	9	O
remains	9	O
unknown	9	O
.	9	O

A	9	O
double	9	O
-	7	O
blind	5	O
study	9	O
of	5	O
the	5	O
efficacy	9	O
and	5	O
safety	5	O
of	5	O
dothiepin	5	B-Chemical
hydrochloride	0	I-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
major	9	O
depressive	5	B-Disease
disorder	5	I-Disease
.	9	O

In	9	O
a	5	O
6	9	O
-	7	O
week	9	O
double	9	O
-	7	O
blind	5	O
parallel	5	O
treatment	9	O
study	9	O
,	9	O
dothiepin	5	B-Chemical
and	5	O
amitriptyline	0	B-Chemical
were	9	O
compared	9	O
to	5	O
placebo	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
33	7	O
depressed	5	B-Disease
outpatients	5	O
.	9	O

Dothiepin	0	B-Chemical
and	5	O
amitriptyline	0	B-Chemical
were	9	O
equally	9	O
effective	5	O
in	5	O
alleviating	5	O
the	5	O
symptoms	5	O
of	5	O
depressive	5	B-Disease
illness	5	I-Disease
,	9	O
and	5	O
both	9	O
were	9	O
significantly	9	O
superior	5	O
to	5	O
placebo	9	O
.	9	O

The	5	O
overall	5	O
incidence	5	O
of	5	O
side	5	O
effects	9	O
and	5	O
the	5	O
frequency	5	O
and	5	O
severity	5	O
of	5	O
blurred	5	B-Disease
vision	5	I-Disease
,	9	O
dry	0	B-Disease
mouth	5	I-Disease
,	9	O
and	5	O
drowsiness	5	O
were	9	O
significantly	9	O
less	5	O
with	5	O
dothiepin	5	B-Chemical
than	5	O
with	5	O
amitriptyline	0	B-Chemical
.	9	O

Dothiepin	0	B-Chemical
also	9	O
produced	9	O
fewer	5	O
CNS	9	O
and	5	O
cardiovascular	5	O
effects	9	O
.	9	O

There	5	O
were	9	O
no	9	O
clinically	5	O
important	9	O
changes	9	O
in	5	O
laboratory	9	O
parameters	5	O
.	9	O

Dothiepin	0	B-Chemical
thus	9	O
was	9	O
found	9	O
to	5	O
be	5	O
an	5	O
effective	5	O
antidepressant	5	B-Chemical
drug	5	O
associated	9	O
with	5	O
fewer	5	O
side	5	O
effects	9	O
than	5	O
amitriptyline	0	B-Chemical
in	5	O
the	5	O
treatment	9	O
of	5	O
depressed	5	B-Disease
outpatients	5	O
.	9	O

Behavioral	5	O
effects	9	O
of	5	O
diazepam	0	B-Chemical
and	5	O
propranolol	0	B-Chemical
in	5	O
patients	5	O
with	5	O
panic	5	B-Disease
disorder	5	I-Disease
and	5	O
agoraphobia	5	B-Disease
.	9	O

The	5	O
effects	9	O
of	5	O
oral	9	O
doses	0	O
of	5	O
diazepam	0	B-Chemical
(	9	O
single	9	O
dose	9	O
of	5	O
10	9	O
mg	0	O
and	5	O
a	5	O
median	9	O
dose	9	O
of	5	O
30	9	O
mg	0	O
/	9	O
day	9	O
for	5	O
2	9	O
weeks	9	O
)	9	O
and	5	O
propranolol	0	B-Chemical
(	9	O
single	9	O
dose	9	O
of	5	O
80	9	O
mg	0	O
and	5	O
a	5	O
median	9	O
dose	9	O
of	5	O
240	9	O
mg	0	O
/	9	O
day	9	O
for	5	O
2	9	O
weeks	9	O
)	9	O
on	5	O
psychological	5	O
performance	5	O
of	5	O
patients	5	O
with	5	O
panic	5	B-Disease
disorders	5	I-Disease
and	5	O
agoraphobia	5	B-Disease
were	9	O
investigated	9	O
in	5	O
a	5	O
double	9	O
-	7	O
blind	5	O
,	9	O
randomized	5	O
and	5	O
crossover	5	O
design	5	O
.	9	O

Both	9	O
drugs	5	O
impaired	9	B-Disease
immediate	5	I-Disease
free	9	I-Disease
recall	5	I-Disease
but	9	O
the	5	O
decrease	9	O
was	9	O
greater	5	O
for	5	O
diazepam	0	B-Chemical
than	5	O
propranolol	0	B-Chemical
.	9	O

Delayed	5	B-Disease
free	9	I-Disease
recall	5	I-Disease
was	9	I-Disease
also	9	I-Disease
impaired	9	I-Disease
but	9	O
the	5	O
two	5	O
drugs	5	O
did	9	O
not	5	O
differ	9	O
.	9	O

Patients	5	O
tapped	5	O
faster	5	O
after	9	O
propranolol	0	B-Chemical
than	5	O
diazepam	0	B-Chemical
and	5	O
they	5	O
were	9	O
more	5	O
sedated	5	O
after	9	O
diazepam	0	B-Chemical
than	5	O
propranolol	0	B-Chemical
.	9	O

After	9	O
2	9	O
weeks	9	O
of	5	O
treatment	9	O
,	9	O
patients	5	O
tested	9	O
5	9	O
-	7	O
8	9	O
h	0	O
after	9	O
the	5	O
last	5	O
dose	9	O
of	5	O
medication	5	O
did	9	O
not	5	O
show	9	O
any	5	O
decrement	5	O
of	5	O
performance	5	O
.	9	O

These	5	O
results	9	O
are	5	O
similar	9	O
to	5	O
those	5	O
previously	9	O
found	9	O
in	5	O
healthy	5	O
subjects	5	O
.	9	O

Accumulation	9	O
of	5	O
drugs	5	O
was	9	O
not	5	O
reflected	5	O
in	5	O
prolonged	9	O
behavioral	5	B-Disease
impairment	5	I-Disease
.	9	O

Comparison	9	O
of	5	O
i	9	O
.	9	O
v	0	O
.	9	O
glycopyrrolate	0	B-Chemical
and	5	O
atropine	0	B-Chemical
in	5	O
the	5	O
prevention	5	O
of	5	O
bradycardia	5	B-Disease
and	5	O
arrhythmias	5	B-Disease
following	9	O
repeated	5	O
doses	0	O
of	5	O
suxamethonium	5	B-Chemical
in	5	O
children	5	O
.	9	O

The	5	O
effectiveness	5	O
of	5	O
administration	9	O
of	5	O
glycopyrrolate	0	B-Chemical
5	9	O
and	5	O
10	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
and	5	O
atropine	0	B-Chemical
10	9	O
and	5	O
20	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
immediately	9	O
before	9	O
the	5	O
induction	3	O
of	5	O
anaesthesia	5	O
,	9	O
to	5	O
prevent	5	O
arrhythmia	5	B-Disease
and	5	O
bradycardia	5	B-Disease
following	9	O
repeated	5	O
doses	0	O
of	5	O
suxamethonium	5	B-Chemical
in	5	O
children	5	O
,	9	O
was	9	O
studied	9	O
.	9	O

A	9	O
control	9	O
group	9	O
was	9	O
included	5	O
for	5	O
comparison	9	O
with	5	O
the	5	O
lower	9	O
dose	9	O
range	9	O
of	5	O
glycopyrrolate	0	B-Chemical
and	5	O
atropine	0	B-Chemical
.	9	O

A	9	O
frequency	5	O
of	5	O
bradycardia	5	B-Disease
of	5	O
50	0	O
%	9	O
was	9	O
noted	9	O
in	5	O
the	5	O
control	9	O
group	9	O
,	9	O
but	9	O
this	5	O
was	9	O
not	5	O
significantly	9	O
different	9	O
from	9	O
the	5	O
frequency	5	O
with	5	O
the	5	O
active	9	O
drugs	5	O
.	9	O

Bradycardia	7	B-Disease
(	9	O
defined	5	O
as	5	O
a	5	O
decrease	9	O
in	5	O
heart	5	O
rate	9	O
to	5	O
less	5	O
than	5	O
50	0	O
beat	5	O
min	0	O
-	7	O
1	9	O
)	9	O
was	9	O
prevented	9	O
when	5	O
the	5	O
larger	5	O
dose	9	O
of	5	O
either	9	O
active	9	O
drug	5	O
was	9	O
used	5	O
.	9	O

It	5	O
is	5	O
recommended	5	O
that	5	O
either	9	O
glycopyrrolate	0	B-Chemical
10	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
or	5	O
atropine	0	B-Chemical
20	9	O
micrograms	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
should	5	O
immediately	9	O
precede	9	O
induction	3	O
of	5	O
anaesthesia	5	O
,	9	O
in	5	O
children	5	O
,	9	O
if	5	O
the	5	O
repeated	5	O
administration	9	O
of	5	O
suxamethonium	5	B-Chemical
is	5	O
anticipated	5	O
.	9	O

Veno	6	B-Disease
-	7	I-Disease
occlusive	5	I-Disease
liver	9	I-Disease
disease	5	I-Disease
after	9	O
dacarbazine	0	B-Chemical
therapy	5	O
(	9	O
DTIC	0	B-Chemical
)	9	O
for	5	O
melanoma	3	B-Disease
.	9	O

A	9	O
case	5	O
of	5	O
veno	5	B-Disease
-	7	I-Disease
occlusive	5	I-Disease
disease	5	I-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
with	5	O
fatal	5	O
outcome	5	O
after	9	O
dacarbazine	0	B-Chemical
(	9	O
DTIC	0	B-Chemical
)	9	O
therapy	5	O
for	5	O
melanoma	3	B-Disease
is	5	O
reported	9	O
.	9	O

There	5	O
was	9	O
a	5	O
fulminant	5	O
clinical	5	O
course	5	O
from	9	O
start	9	O
of	5	O
symptoms	5	O
until	5	O
death	9	B-Disease
.	9	O

At	9	O
autopsy	5	O
the	5	O
liver	9	O
was	9	O
enlarged	9	O
and	5	O
firm	5	O
with	5	O
signs	5	O
of	5	O
venous	5	B-Disease
congestion	5	I-Disease
.	9	O

Small	9	O
-	7	O
and	5	O
medium	0	O
-	7	O
sized	5	O
hepatic	9	O
veins	5	O
were	9	O
blocked	3	O
by	9	O
thrombosis	5	B-Disease
.	9	O

Eosinophilic	2	O
infiltrations	3	O
were	9	O
found	9	O
around	5	O
the	5	O
vessels	5	O
.	9	O

Published	9	O
cases	5	O
from	9	O
the	5	O
literature	5	O
are	5	O
reviewed	9	O
and	5	O
pertinent	5	O
features	5	O
discussed	5	O
.	9	O

Maternal	9	O
lithium	0	B-Chemical
and	5	O
neonatal	9	O
Ebstein	5	B-Disease
'	9	I-Disease
s	9	I-Disease
anomaly	5	I-Disease
:	9	O
evaluation	5	O
with	5	O
cross	5	O
-	7	O
sectional	5	O
echocardiography	5	O
.	9	O

Cross	2	O
-	7	O
sectional	5	O
echocardiography	5	O
was	9	O
used	5	O
to	5	O
evaluate	9	O
two	5	O
neonates	9	O
whose	9	O
mothers	5	O
ingested	0	O
lithium	0	B-Chemical
during	5	O
pregnancy	5	O
.	9	O

In	9	O
one	5	O
infant	5	O
,	9	O
Ebstein	5	B-Disease
'	9	I-Disease
s	9	I-Disease
anomaly	5	I-Disease
of	5	O
the	5	O
tricuspid	5	O
valve	5	O
was	9	O
identified	9	O
.	9	O

In	9	O
the	5	O
other	5	O
infant	5	O
cross	5	O
-	7	O
sectional	5	O
echocardiography	5	O
provided	9	O
reassurance	5	O
that	5	O
the	5	O
infant	5	O
did	9	O
not	5	O
have	5	O
Ebstein	5	B-Disease
'	9	I-Disease
s	9	I-Disease
anomaly	5	I-Disease
.	9	O

Cross	2	O
-	7	O
sectional	5	O
echocardiographic	5	O
screening	5	O
of	5	O
newborns	5	O
exposed	9	O
to	5	O
lithium	0	B-Chemical
during	5	O
gestation	9	O
can	5	O
provide	5	O
highly	9	O
accurate	5	O
,	9	O
noninvasive	5	O
assessment	5	O
of	5	O
the	5	O
presence	9	O
or	5	O
absence	3	O
of	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
malformations	5	I-Disease
.	9	O

Effects	9	O
of	5	O
training	5	O
on	5	O
the	5	O
extent	9	O
of	5	O
experimental	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
in	5	O
aging	5	O
rats	9	O
.	9	O

The	5	O
effects	9	O
of	5	O
exercise	5	O
on	5	O
the	5	O
severity	5	O
of	5	O
isoproterenol	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
infarction	5	I-Disease
were	9	O
studied	9	O
in	5	O
female	9	O
albino	3	O
rats	9	O
of	5	O
20	9	O
,	9	O
40	9	O
,	9	O
60	9	O
and	5	O
80	9	O
weeks	9	O
of	5	O
age	5	O
.	9	O

The	5	O
rats	9	O
were	9	O
trained	5	O
to	5	O
swim	5	O
for	5	O
a	5	O
specific	9	O
duration	5	O
and	5	O
for	5	O
a	5	O
particular	5	O
period	5	O
.	9	O

The	5	O
occurrence	5	O
of	5	O
infarcts	5	B-Disease
were	9	O
confirmed	9	O
by	9	O
histological	9	O
methods	5	O
.	9	O

Elevations	9	O
in	5	O
the	5	O
serum	9	O
GOT	0	O
and	5	O
GPT	0	O
were	9	O
maximum	5	O
in	5	O
the	5	O
sedentary	5	O
-	7	O
isoproterenols	_	B-Chemical
and	5	O
minimum	5	O
in	5	O
the	5	O
exercise	5	O
-	7	O
controls	9	O
.	9	O

These	5	O
changes	9	O
in	5	O
the	5	O
serum	9	O
transaminases	9	O
were	9	O
associated	9	O
with	5	O
corresponding	9	O
depletions	3	O
in	5	O
the	5	O
cardiac	5	O
GOT	0	O
and	5	O
GPT	0	O
.	9	O

However	9	O
,	9	O
age	5	O
was	9	O
seen	9	O
to	5	O
interfere	9	O
with	5	O
the	5	O
responses	5	O
exhibited	9	O
by	9	O
the	5	O
young	5	O
and	5	O
old	5	O
rats	9	O
.	9	O

Studies	9	O
dealing	5	O
with	5	O
myocardial	9	B-Disease
infarction	5	I-Disease
are	5	O
more	5	O
informative	5	O
when	5	O
dealt	5	O
with	5	O
age	5	O
.	9	O

Effect	0	O
of	5	O
polyethylene	0	B-Chemical
glycol	0	I-Chemical
400	0	I-Chemical
on	5	O
adriamycin	3	B-Chemical
toxicity	9	B-Disease
in	5	O
mice	3	O
.	9	O

The	5	O
effect	9	O
of	5	O
a	5	O
widely	5	O
used	5	O
organic	0	O
solvent	0	O
,	9	O
polyethylene	0	B-Chemical
glycol	0	I-Chemical
400	0	I-Chemical
(	9	O
PEG	0	B-Chemical
400	0	I-Chemical
)	9	O
,	9	O
on	5	O
the	5	O
toxic	0	O
action	5	O
of	5	O
an	5	O
acute	9	O
or	5	O
chronic	5	O
treatment	9	O
with	5	O
adriamycin	3	B-Chemical
(	9	O
ADR	9	B-Chemical
)	9	O
was	9	O
evaluated	9	O
in	5	O
mice	3	O
.	9	O

PEG	0	B-Chemical
400	0	I-Chemical
impressively	5	O
decreased	9	O
both	9	O
acute	9	O
high	9	O
-	7	O
dose	9	O
and	5	O
chronic	5	O
low	9	O
-	7	O
dose	9	O
-	7	O
ADR	9	B-Chemical
-	7	O
associated	9	O
lethality	3	O
.	9	O

Light	9	O
microscopic	9	O
analysis	9	O
showed	9	O
a	5	O
significant	9	O
protection	9	O
against	9	O
ADR	9	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
morphological	9	I-Disease
alterations	9	I-Disease
.	9	O

Such	5	O
treatment	9	O
did	9	O
not	5	O
diminish	9	O
the	5	O
ADR	9	B-Chemical
antitumor	3	O
activity	9	O
in	5	O
L1210	3	B-Disease
leukemia	3	I-Disease
and	5	O
in	5	O
Ehrlich	9	B-Disease
ascites	3	I-Disease
tumor	3	I-Disease
.	9	O

Sublingual	5	O
absorption	0	O
of	5	O
the	5	O
quaternary	0	B-Chemical
ammonium	0	I-Chemical
antiarrhythmic	5	O
agent	9	O
,	9	O
UM	9	B-Chemical
-	7	I-Chemical
272	7	I-Chemical
.	9	O

UM	9	B-Chemical
-	7	I-Chemical
272	7	I-Chemical
(	9	O
N	9	B-Chemical
,	9	I-Chemical
N	9	I-Chemical
-	7	I-Chemical
dimethylpropranolol	_	I-Chemical
)	9	O
,	9	O
a	5	O
quaternary	0	O
antiarrhythmic	5	O
agent	9	O
,	9	O
was	9	O
administered	9	O
sublingually	0	O
to	5	O
dogs	5	O
with	5	O
ouabain	0	B-Chemical
-	7	O
induced	3	O
ventricular	5	B-Disease
tachycardias	5	I-Disease
.	9	O

Both	9	O
anti	3	O
-	7	O
arrhythmic	5	O
efficacy	9	O
and	5	O
bioavailability	0	O
were	9	O
compared	9	O
to	5	O
oral	9	O
drug	5	O
.	9	O

Sublingual	5	O
UM	9	B-Chemical
-	7	I-Chemical
272	7	I-Chemical
converted	9	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
to	5	O
sinus	5	O
rhythm	5	O
in	5	O
all	5	O
5	9	O
dogs	5	O
.	9	O

The	5	O
area	5	O
under	9	O
the	5	O
plasma	9	O
concentration	0	O
time	5	O
curve	9	O
at	9	O
90	9	O
min	0	O
was	9	O
4	9	O
-	7	O
12	9	O
times	5	O
greater	5	O
than	5	O
for	5	O
oral	9	O
drug	5	O
,	9	O
suggesting	9	O
the	5	O
existence	9	O
of	5	O
an	5	O
absorption	0	O
-	7	O
limiting	9	O
process	5	O
in	5	O
the	5	O
intestine	9	O
,	9	O
and	5	O
providing	9	O
an	5	O
alternate	9	O
form	9	O
of	5	O
administration	9	O
for	5	O
quaternary	0	O
drugs	5	O
.	9	O

Early	9	O
adjuvant	9	O
adriamycin	3	B-Chemical
in	5	O
superficial	5	O
bladder	9	B-Disease
carcinoma	3	I-Disease
.	9	O

A	9	O
multicenter	5	O
study	9	O
was	9	O
performed	9	O
in	5	O
110	9	O
patients	5	O
with	5	O
superficial	5	O
transitional	9	O
cell	3	O
carcinoma	3	B-Disease
of	5	I-Disease
the	5	I-Disease
bladder	9	I-Disease
.	9	O

Adriamycin	0	B-Chemical
(	9	O
50	0	O
mg	0	O
/	9	O
50	0	O
ml	0	O
)	9	O
was	9	O
administered	9	O
intravesically	0	O
within	9	O
24	9	O
h	0	O
after	9	O
transurethral	5	O
resection	5	O
of	5	O
TA	9	O
-	7	O
T1	9	O
(	9	O
O	9	O
-	7	O
A	9	O
)	9	O
bladder	9	B-Disease
tumors	3	I-Disease
.	9	O

Instillation	0	O
was	9	O
repeated	5	O
twice	9	O
during	5	O
the	5	O
first	9	O
week	9	O
,	9	O
then	9	O
weekly	5	O
during	5	O
the	5	O
first	9	O
month	5	O
and	5	O
afterwards	5	O
monthly	5	O
for	5	O
1	9	O
year	5	O
.	9	O

The	5	O
tolerance	9	O
was	9	O
evaluated	9	O
in	5	O
these	5	O
110	9	O
patients	5	O
,	9	O
and	5	O
29	7	O
patients	5	O
presented	5	O
with	5	O
local	5	O
side	5	O
-	7	O
effects	9	O
.	9	O

In	9	O
24	9	O
of	5	O
these	5	O
patients	5	O
chemical	0	O
cystitis	9	B-Disease
was	9	O
severe	5	O
enough	5	O
for	5	O
them	5	O
to	5	O
drop	9	O
out	9	O
of	5	O
the	5	O
study	9	O
.	9	O

No	9	O
systemic	9	O
side	5	O
-	7	O
effects	9	O
were	9	O
observed	9	O
.	9	O

Recurrence	5	O
was	9	O
studied	9	O
in	5	O
82	7	O
evaluable	9	O
patients	5	O
after	9	O
1	9	O
year	5	O
of	5	O
follow	5	O
-	7	O
up	5	O
and	5	O
in	5	O
72	9	O
patients	5	O
followed	9	O
for	5	O
2	9	O
-	7	O
3	9	O
years	5	O
(	9	O
mean	5	O
32	7	O
months	5	O
)	9	O
.	9	O

Of	9	O
the	5	O
82	7	O
patients	5	O
studied	9	O
after	9	O
1	9	O
year	5	O
,	9	O
23	7	O
had	9	O
primary	9	O
and	5	O
59	7	O
recurrent	5	O
disease	5	O
.	9	O

Of	9	O
the	5	O
82	7	O
evaluable	9	O
patients	5	O
,	9	O
50	0	O
did	9	O
not	5	O
show	9	O
any	5	O
recurrence	5	O
after	9	O
1	9	O
year	5	O
(	9	O
61	7	O
%	9	O
)	9	O
,	9	O
while	9	O
32	7	O
presented	5	O
with	5	O
one	5	O
or	5	O
more	5	O
recurrences	5	O
(	9	O
39	7	O
%	9	O
)	9	O
.	9	O

Of	9	O
these	5	O
recurrences	5	O
,	9	O
27	7	O
were	9	O
T1	9	O
tumors	3	B-Disease
while	9	O
five	9	O
progressed	9	O
to	5	O
more	5	O
highly	9	O
invasive	5	O
lesions	5	O
.	9	O

In	9	O
patients	5	O
that	5	O
were	9	O
free	9	O
of	5	O
recurrence	5	O
during	5	O
the	5	O
first	9	O
year	5	O
,	9	O
80	9	O
%	9	O
remained	9	O
tumor	3	B-Disease
-	7	O
free	9	O
during	5	O
the	5	O
2	9	O
-	7	O
to	5	O
3	9	O
-	7	O
year	5	O
follow	5	O
-	7	O
up	5	O
period	5	O
.	9	O

Of	9	O
the	5	O
patients	5	O
developing	5	O
one	5	O
or	5	O
more	5	O
recurrences	5	O
during	5	O
the	5	O
first	9	O
year	5	O
,	9	O
only	9	O
50	0	O
%	9	O
presented	5	O
with	5	O
further	9	O
recurrence	5	O
once	5	O
the	5	O
instillations	0	O
were	9	O
stopped	9	O
.	9	O

The	5	O
beneficial	9	O
effect	9	O
of	5	O
Adriamycin	0	B-Chemical
appears	9	O
obvious	9	O
and	5	O
might	9	O
be	5	O
related	9	O
to	5	O
the	5	O
drug	5	O
itself	9	O
,	9	O
the	5	O
early	9	O
and	5	O
repeated	5	O
instillations	0	O
after	9	O
TUR	9	O
,	9	O
or	5	O
both	9	O
.	9	O

D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
-	7	O
induced	3	O
angiopathy	5	B-Disease
in	5	O
rats	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
high	9	O
dose	9	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
treatment	9	O
on	5	O
aortic	9	O
permeability	0	O
to	5	O
albumin	0	O
and	5	O
on	5	O
the	5	O
ultrastructure	9	O
of	5	O
the	5	O
vessel	5	O
.	9	O

Male	7	O
Sprague	9	O
-	7	O
Dawley	0	O
rats	9	O
were	9	O
treated	3	O
with	5	O
D	9	B-Chemical
-	7	I-Chemical
penicillamine	0	I-Chemical
(	9	O
D	9	B-Chemical
-	7	I-Chemical
pen	5	I-Chemical
)	9	O
500	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
for	5	O
10	9	O
or	5	O
42	7	O
days	9	O
.	9	O

Pair	5	O
fed	9	O
rats	9	O
served	9	O
as	5	O
controls	9	O
.	9	O

Changes	9	O
in	5	O
aortic	9	O
morphology	9	O
were	9	O
examined	9	O
by	9	O
light	9	O
-	7	O
and	5	O
transmission	5	O
-	7	O
electron	0	O
microscopy	9	O
(	9	O
TEM	9	O
)	9	O
.	9	O

In	9	O
addition	9	O
,	9	O
the	5	O
endothelial	3	O
permeability	0	O
and	5	O
the	5	O
penetration	5	O
through	9	O
the	5	O
aortic	9	O
wall	5	O
of	5	O
albumin	0	O
were	9	O
studied	9	O
10	9	O
minutes	0	O
,	9	O
24	9	O
and	5	O
48	9	O
hours	9	O
after	9	O
i	9	O
.	9	O
v	0	O
.	9	O
injection	9	O
of	5	O
human	3	O
serum	9	O
131I	0	O
-	7	O
albumin	0	O
(	9	O
131I	0	O
-	7	O
HSA	0	O
)	9	O
.	9	O

TEM	9	O
revealed	9	O
extensive	5	O
elastolysis	3	O
in	5	O
the	5	O
arterial	5	O
wall	5	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
pen	5	I-Chemical
-	7	O
treated	3	O
rats	9	O
,	9	O
consistent	9	O
with	5	O
an	5	O
inhibitory	3	O
effect	9	O
on	5	O
crosslink	0	O
formation	9	O
.	9	O

In	9	O
experimental	5	O
animals	9	O
excess	9	O
deposition	9	O
of	5	O
collagen	3	O
and	5	O
glycoaminoglycans	3	O
was	9	O
observed	9	O
in	5	O
the	5	O
subendothelial	3	O
and	5	O
medial	5	O
layer	9	O
of	5	O
the	5	O
aortic	9	O
wall	5	O
,	9	O
together	9	O
with	5	O
prominent	9	O
basal	3	O
membrane	9	O
substance	5	O
around	5	O
aortic	9	O
smooth	5	O
muscle	9	O
cells	3	O
.	9	O

The	5	O
aorta	9	O
/	9	O
serum	9	O
-	7	O
ratio	9	O
and	5	O
the	5	O
radioactive	0	O
build	5	O
-	7	O
up	5	O
24	9	O
and	5	O
48	9	O
hours	9	O
after	9	O
injection	9	O
of	5	O
131I	0	O
-	7	O
HSA	0	O
was	9	O
reduced	9	O
in	5	O
animals	9	O
treated	3	O
with	5	O
D	9	B-Chemical
-	7	I-Chemical
pen	5	I-Chemical
for	5	O
42	7	O
days	9	O
,	9	O
indicating	9	O
an	5	O
impeded	9	O
transmural	5	O
transport	9	O
of	5	O
tracer	0	O
which	5	O
may	5	O
be	5	O
caused	9	O
by	9	O
a	5	O
steric	0	O
exclusion	5	O
effect	9	O
of	5	O
abundant	9	O
hyaluronate	0	B-Chemical
.	9	O

The	5	O
endothelial	3	O
ultrastructure	9	O
was	9	O
unaffected	9	O
by	9	O
D	9	B-Chemical
-	7	I-Chemical
pen	5	I-Chemical
,	9	O
and	5	O
no	9	O
differences	9	O
in	5	O
aortic	9	O
131I	0	O
-	7	O
HSA	0	O
radioactivity	0	O
or	5	O
aorta	9	O
/	9	O
serum	9	O
-	7	O
ratio	9	O
were	9	O
recorded	5	O
between	5	O
experimental	5	O
and	5	O
control	9	O
groups	9	O
10	9	O
minutes	0	O
after	9	O
tracer	0	O
injection	9	O
,	9	O
indicating	9	O
that	5	O
the	5	O
permeability	0	O
of	5	O
the	5	O
endothelial	3	O
barrier	5	O
to	5	O
albumin	0	O
remained	9	O
unaffected	9	O
by	9	O
D	9	B-Chemical
-	7	I-Chemical
pen	5	I-Chemical
treatment	9	O
.	9	O

These	5	O
observations	9	O
support	5	O
the	5	O
hypothesis	9	O
that	5	O
treatment	9	O
with	5	O
high	9	O
doses	0	O
of	5	O
D	9	B-Chemical
-	7	I-Chemical
pen	5	I-Chemical
may	5	O
induce	3	O
a	5	O
fibroproliferative	5	O
response	9	O
in	5	O
rat	3	O
aorta	9	O
,	9	O
possibly	9	O
by	9	O
an	5	O
inhibitory	3	O
effect	9	O
on	5	O
the	5	O
cross	5	O
-	7	O
linking	9	O
of	5	O
collagen	3	O
and	5	O
elastin	9	O
.	9	O

Effect	0	O
of	5	O
aspirin	9	B-Chemical
on	5	O
N	9	B-Chemical
-	7	I-Chemical
[	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
nitro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
furyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
thiazolyl	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
formamide	0	I-Chemical
-	7	O
induced	3	O
epithelial	3	O
proliferation	3	O
in	5	O
the	5	O
urinary	9	O
bladder	9	O
and	5	O
forestomach	3	O
of	5	O
the	5	O
rat	3	O
.	9	O

The	5	O
co	9	O
-	7	O
administration	9	O
of	5	O
aspirin	9	B-Chemical
with	5	O
N	9	B-Chemical
-	7	I-Chemical
[	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
nitro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
furyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
thiazolyl	0	I-Chemical
]	9	I-Chemical
-	7	I-Chemical
formamide	0	I-Chemical
(	9	O
FANFT	0	B-Chemical
)	9	O
to	5	O
rats	9	O
resulted	9	O
in	5	O
a	5	O
reduced	9	O
incidence	5	O
of	5	O
FANFT	0	B-Chemical
-	7	O
induced	3	O
bladder	9	B-Disease
carcinomas	3	I-Disease
but	9	O
a	5	O
concomitant	9	O
induction	3	O
of	5	O
forestomach	3	B-Disease
tumors	3	I-Disease
.	9	O

An	5	O
autoradiographic	0	O
study	9	O
was	9	O
performed	9	O
on	5	O
male	9	O
F	7	O
-	7	O
344	7	O
rats	9	O
fed	9	O
diet	9	O
containing	0	O
FANFT	0	B-Chemical
at	9	O
a	5	O
level	9	O
of	5	O
0	7	O
.	9	O
2	9	O
%	9	O
and	5	O
/	9	O
or	5	O
aspirin	9	B-Chemical
at	9	O
a	5	O
level	9	O
of	5	O
0	7	O
.	9	O
5	9	O
%	9	O
to	5	O
evaluate	9	O
the	5	O
effect	9	O
of	5	O
aspirin	9	B-Chemical
on	5	O
the	5	O
increased	9	O
cell	3	O
proliferation	3	O
induced	3	O
by	9	O
FANFT	0	B-Chemical
in	5	O
the	5	O
forestomach	3	O
and	5	O
bladder	9	O
.	9	O

FANFT	0	B-Chemical
-	7	O
induced	3	O
cell	3	O
proliferation	3	O
in	5	O
the	5	O
bladder	9	O
was	9	O
significantly	9	O
suppressed	3	O
by	9	O
aspirin	9	B-Chemical
co	9	O
-	7	O
administration	9	O
after	9	O
4	9	O
weeks	9	O
but	9	O
not	5	O
after	9	O
12	9	O
weeks	9	O
.	9	O

In	9	O
the	5	O
forestomach	3	O
,	9	O
and	5	O
also	9	O
in	5	O
the	5	O
liver	9	O
,	9	O
aspirin	9	B-Chemical
did	9	O
not	5	O
affect	9	O
the	5	O
FANFT	0	B-Chemical
-	7	O
induced	3	O
increase	9	O
in	5	O
labeling	3	O
index	5	O
.	9	O

The	5	O
present	9	O
results	9	O
are	5	O
consistent	9	O
with	5	O
the	5	O
carcinogenicity	5	O
experiment	9	O
suggesting	9	O
that	5	O
different	9	O
mechanisms	9	O
are	5	O
involved	9	O
in	5	O
FANFT	0	B-Chemical
carcinogenesis	3	B-Disease
in	5	O
the	5	O
bladder	9	O
and	5	O
forestomach	3	O
,	9	O
and	5	O
that	5	O
aspirin	9	B-Chemical
'	9	O
s	9	O
effect	9	O
on	5	O
FANFT	0	B-Chemical
in	5	O
the	5	O
forestomach	3	O
is	5	O
not	5	O
due	5	O
to	5	O
an	5	O
irritant	0	O
effect	9	O
associated	9	O
with	5	O
increased	9	O
cell	3	O
proliferation	3	O
.	9	O

Also	9	O
,	9	O
there	5	O
appears	9	O
to	5	O
be	5	O
an	5	O
adaptation	5	O
by	9	O
the	5	O
rats	9	O
to	5	O
the	5	O
chronic	5	O
ingestion	9	O
of	5	O
aspirin	9	B-Chemical
.	9	O

A	9	O
case	5	O
of	5	O
tardive	5	B-Disease
dyskinesia	5	I-Disease
caused	9	O
by	9	O
metoclopramide	0	B-Chemical
.	9	O

Abnormal	9	B-Disease
involuntary	5	I-Disease
movements	5	I-Disease
appeared	9	O
in	5	O
the	5	O
mouth	5	O
,	9	O
tongue	5	O
,	9	O
neck	5	O
and	5	O
abdomen	5	O
of	5	O
a	5	O
64	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
patient	5	O
after	9	O
he	5	O
took	5	O
metoclopramide	0	B-Chemical
for	5	O
gastrointestinal	9	B-Disease
disorder	5	I-Disease
in	5	O
a	5	O
regimen	5	O
of	5	O
30	9	O
mg	0	O
per	9	O
day	9	O
for	5	O
a	5	O
total	9	O
of	5	O
about	5	O
260	9	O
days	9	O
.	9	O

The	5	O
symptoms	5	O
exacerbated	9	O
to	5	O
a	5	O
maximum	5	O
in	5	O
a	5	O
month	5	O
.	9	O

When	9	O
the	5	O
metoclopramide	0	B-Chemical
administration	9	O
was	9	O
discontinued	5	O
,	9	O
the	5	O
abnormal	9	B-Disease
movements	5	I-Disease
gradually	9	O
improved	5	O
to	5	O
a	5	O
considerable	5	O
extent	9	O
.	9	O

Attention	5	O
to	5	O
the	5	O
possible	5	O
induction	3	O
of	5	O
specific	9	O
tardive	5	B-Disease
dyskinesia	5	I-Disease
is	5	O
called	5	O
for	5	O
in	5	O
the	5	O
use	5	O
of	5	O
this	5	O
drug	5	O
.	9	O

Intra	5	O
-	7	O
arterial	5	O
BCNU	0	B-Chemical
chemotherapy	5	O
for	5	O
treatment	9	O
of	5	O
malignant	3	B-Disease
gliomas	3	I-Disease
of	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
.	9	O

Because	9	O
of	5	O
the	5	O
rapid	5	O
systemic	9	O
clearance	9	O
of	5	O
BCNU	0	B-Chemical
(	9	O
1	9	B-Chemical
,	9	I-Chemical
3	9	I-Chemical
-	7	I-Chemical
bis	0	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
chloroethyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
nitrosourea	0	I-Chemical
)	9	O
,	9	O
intra	5	O
-	7	O
arterial	5	O
administration	9	O
should	5	O
provide	5	O
a	5	O
substantial	9	O
advantage	5	O
over	5	O
intravenous	0	O
administration	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
malignant	3	B-Disease
gliomas	3	I-Disease
.	9	O

Thirty	9	O
-	7	O
six	9	O
patients	5	O
were	9	O
treated	3	O
with	5	O
BCNU	0	B-Chemical
every	5	O
6	9	O
to	5	O
8	9	O
weeks	9	O
,	9	O
either	9	O
by	9	O
transfemoral	5	O
catheterization	5	O
of	5	O
the	5	O
internal	5	O
carotid	5	O
or	5	O
vertebral	5	O
artery	5	O
or	5	O
through	9	O
a	5	O
fully	9	O
implantable	5	O
intracarotid	0	O
drug	5	O
delivery	5	O
system	5	O
,	9	O
beginning	5	O
with	5	O
a	5	O
dose	9	O
of	5	O
200	0	O
mg	0	O
/	9	O
sq	9	O
m	9	O
body	5	O
surface	9	O
area	5	O
.	9	O

Twelve	9	O
patients	5	O
with	5	O
Grade	9	O
III	9	O
or	5	O
IV	9	O
astrocytomas	3	B-Disease
were	9	O
treated	3	O
after	9	O
partial	9	O
resection	5	O
of	5	O
the	5	O
tumor	3	B-Disease
without	9	O
prior	9	O
radiation	9	O
therapy	5	O
.	9	O

After	9	O
two	5	O
to	5	O
seven	9	O
cycles	9	O
of	5	O
chemotherapy	5	O
,	9	O
nine	9	O
patients	5	O
showed	9	O
a	5	O
decrease	9	O
in	5	O
tumor	3	B-Disease
size	9	O
and	5	O
surrounding	9	O
edema	5	B-Disease
on	5	O
contrast	9	O
-	7	O
enhanced	3	O
computerized	5	O
tomography	5	O
scans	5	O
.	9	O

In	9	O
the	5	O
nine	9	O
responders	5	O
,	9	O
median	9	O
duration	5	O
of	5	O
chemotherapy	5	O
response	9	O
from	9	O
the	5	O
time	5	O
of	5	O
operation	5	O
was	9	O
25	9	O
weeks	9	O
(	9	O
range	9	O
12	9	O
to	5	O
more	5	O
than	5	O
91	7	O
weeks	9	O
)	9	O
.	9	O

The	5	O
median	9	O
duration	5	O
of	5	O
survival	9	O
in	5	O
the	5	O
12	9	O
patients	5	O
was	9	O
54	7	O
weeks	9	O
(	9	O
range	9	O
21	7	O
to	5	O
more	5	O
than	5	O
156	7	O
weeks	9	O
)	9	O
,	9	O
with	5	O
an	5	O
18	7	O
-	7	O
month	5	O
survival	9	O
rate	9	O
of	5	O
42	7	O
%	9	O
.	9	O

Twenty	9	O
-	7	O
four	9	O
patients	5	O
with	5	O
recurrent	5	O
Grade	9	O
I	9	O
to	5	O
IV	9	O
astrocytomas	3	B-Disease
,	9	O
whose	9	O
resection	5	O
and	5	O
irradiation	9	O
therapy	5	O
had	9	O
failed	9	O
,	9	O
received	9	O
two	5	O
to	5	O
eight	9	O
courses	5	O
of	5	O
intra	5	O
-	7	O
arterial	5	O
BCNU	0	B-Chemical
therapy	5	O
.	9	O

Seventeen	9	O
of	5	O
these	5	O
had	9	O
a	5	O
response	9	O
or	5	O
were	9	O
stable	9	O
for	5	O
a	5	O
median	9	O
of	5	O
20	9	O
weeks	9	O
(	9	O
range	9	O
6	9	O
to	5	O
more	5	O
than	5	O
66	7	O
weeks	9	O
)	9	O
.	9	O

The	5	O
catheterization	5	O
procedure	5	O
is	5	O
safe	5	O
,	9	O
with	5	O
no	9	O
immediate	5	O
complication	5	O
in	5	O
111	7	O
infusions	9	O
of	5	O
BCNU	0	B-Chemical
.	9	O

A	9	O
delayed	9	O
complication	5	O
in	5	O
nine	9	O
patients	5	O
has	9	O
been	9	O
unilateral	5	O
loss	9	B-Disease
of	5	I-Disease
vision	5	I-Disease
secondary	9	O
to	5	O
a	5	O
retinal	5	B-Disease
vasculitis	5	I-Disease
.	9	O

The	5	O
frequency	5	O
of	5	O
visual	5	B-Disease
loss	9	I-Disease
decreased	9	O
after	9	O
the	5	O
concentration	0	O
of	5	O
the	5	O
ethanol	0	B-Chemical
diluent	0	O
was	9	O
lowered	9	O
.	9	O

Provocation	5	O
of	5	O
postural	5	O
hypotension	5	B-Disease
by	9	O
nitroglycerin	5	B-Chemical
in	5	O
diabetic	9	B-Disease
autonomic	5	I-Disease
neuropathy	5	I-Disease
?	5	O

The	5	O
effect	9	O
of	5	O
nitroglycerin	5	B-Chemical
on	5	O
heart	5	O
rate	9	O
and	5	O
systolic	5	O
blood	9	O
pressure	5	O
was	9	O
compared	9	O
in	5	O
5	9	O
normal	9	O
subjects	5	O
,	9	O
12	9	O
diabetic	9	B-Disease
subjects	5	O
without	9	O
autonomic	5	B-Disease
neuropathy	5	I-Disease
,	9	O
and	5	O
5	9	O
diabetic	9	B-Disease
subjects	5	O
with	5	O
autonomic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

The	5	O
magnitude	5	O
and	5	O
time	5	O
course	5	O
of	5	O
the	5	O
increase	9	O
in	5	O
heart	5	O
rate	9	O
and	5	O
the	5	O
decrease	9	O
in	5	O
systolic	5	O
blood	9	O
pressure	5	O
after	9	O
nitroglycerin	5	B-Chemical
were	9	O
similar	9	O
in	5	O
the	5	O
normal	9	O
and	5	O
diabetic	9	B-Disease
subjects	5	O
without	9	O
autonomic	5	B-Disease
neuropathy	5	I-Disease
,	9	O
whereas	9	O
a	5	O
lesser	9	O
increase	9	O
in	5	O
heart	5	O
rate	9	O
and	5	O
a	5	O
greater	5	O
decrease	9	O
in	5	O
systolic	5	O
blood	9	O
pressure	5	O
occurred	9	O
in	5	O
the	5	O
diabetic	9	B-Disease
subjects	5	O
with	5	O
autonomic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

It	5	O
is	5	O
therefore	5	O
suggested	9	O
that	5	O
caution	5	O
should	5	O
be	5	O
exercised	5	O
when	5	O
prescribing	5	O
vasodilator	0	O
drugs	5	O
in	5	O
diabetic	9	B-Disease
patients	5	O
,	9	O
particularly	5	O
those	5	O
with	5	O
autonomic	5	B-Disease
neuropathy	5	I-Disease
.	9	O

Blood	9	O
pressure	5	O
response	9	O
to	5	O
chronic	5	O
low	9	O
-	7	O
dose	9	O
intrarenal	5	O
noradrenaline	0	B-Chemical
infusion	0	O
in	5	O
conscious	5	O
rats	9	O
.	9	O

Sodium	0	B-Chemical
chloride	0	I-Chemical
solution	0	O
(	9	O
0	7	O
.	9	O
9	7	O
%	9	O
)	9	O
or	5	O
noradrenaline	0	B-Chemical
in	5	O
doses	0	O
of	5	O
4	9	O
,	9	O
12	9	O
and	5	O
36	9	O
micrograms	0	O
h	0	O
-	7	O
1	9	O
kg	0	O
-	7	O
1	9	O
was	9	O
infused	9	O
for	5	O
five	9	O
consecutive	5	O
days	9	O
,	9	O
either	9	O
intrarenally	3	O
(	9	O
by	9	O
a	5	O
new	5	O
technique	5	O
)	9	O
or	5	O
intravenously	0	O
into	9	O
rats	9	O
with	5	O
one	5	O
kidney	9	O
removed	9	O
.	9	O

Intrarenal	3	O
infusion	0	O
of	5	O
noradrenaline	0	B-Chemical
caused	9	O
hypertension	5	B-Disease
at	9	O
doses	0	O
which	5	O
did	9	O
not	5	O
do	5	O
so	5	O
when	5	O
infused	9	O
intravenously	0	O
.	9	O

Intrarenal	3	O
compared	9	O
with	5	O
intravenous	0	O
infusion	0	O
of	5	O
noradrenaline	0	B-Chemical
caused	9	O
higher	9	O
plasma	9	O
noradrenaline	0	B-Chemical
concentrations	0	O
and	5	O
a	5	O
shift	9	O
of	5	O
the	5	O
plasma	9	O
noradrenaline	0	B-Chemical
concentration	0	O
-	7	O
blood	9	O
pressure	5	O
effect	9	O
curve	9	O
towards	5	O
lower	9	O
plasma	9	O
noradrenaline	0	B-Chemical
levels	3	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
hypertension	5	B-Disease
after	9	O
chronic	5	O
intrarenal	5	O
noradrenaline	0	B-Chemical
infusion	0	O
is	5	O
produced	9	O
by	9	O
relatively	5	O
higher	9	O
levels	3	O
of	5	O
circulating	9	O
noradrenaline	0	B-Chemical
and	5	O
by	9	O
triggering	9	O
of	5	O
an	5	O
additional	9	O
intrarenal	5	O
pressor	5	O
mechanism	9	O
.	9	O

Characterization	9	O
of	5	O
estrogen	3	B-Chemical
-	7	O
induced	3	O
adenohypophyseal	3	B-Disease
tumors	3	I-Disease
in	5	O
the	5	O
Fischer	6	O
344	7	O
rat	3	O
.	9	O

Pituitary	2	B-Disease
tumors	3	I-Disease
were	9	O
induced	3	O
in	5	O
F344	3	O
female	9	O
rats	9	O
by	9	O
chronic	5	O
treatment	9	O
with	5	O
diethylstilbestrol	0	B-Chemical
(	9	O
DES	9	B-Chemical
,	9	O
8	9	O
-	7	O
10	9	O
mg	0	O
)	9	O
implanted	9	O
subcutaneously	3	O
in	5	O
silastic	5	O
capsules	0	O
.	9	O

Over	5	O
a	5	O
range	9	O
of	5	O
1	9	O
-	7	O
150	0	O
days	9	O
of	5	O
DES	9	B-Chemical
treatment	9	O
,	9	O
pairs	9	O
of	5	O
control	9	O
and	5	O
DES	9	B-Chemical
-	7	O
treated	3	O
rats	9	O
were	9	O
sacrificed	3	O
,	9	O
and	5	O
their	5	O
pituitaries	3	O
dissociated	3	O
enzymatically	0	O
into	9	O
single	9	O
-	7	O
cell	3	O
preparations	9	O
.	9	O

The	5	O
cell	3	O
populations	9	O
were	9	O
examined	9	O
regarding	5	O
total	9	O
cell	3	O
recovery	9	O
correlated	9	O
with	5	O
gland	9	O
weight	9	O
,	9	O
intracellular	3	O
prolactin	3	O
(	9	O
PRL	3	O
)	9	O
content	9	O
and	5	O
subsequent	9	O
release	9	O
in	5	O
primary	9	O
culture	9	O
,	9	O
immunocytochemical	3	O
PRL	3	O
staining	3	O
,	9	O
density	9	O
and	5	O
/	9	O
or	5	O
size	9	O
alterations	9	O
via	9	O
separation	5	O
on	5	O
Ficoll	0	O
-	7	O
Hypaque	0	O
and	5	O
by	9	O
unit	5	O
gravity	5	O
sedimentation	0	O
,	9	O
and	5	O
cell	3	O
cycle	9	O
analysis	9	O
,	9	O
after	9	O
acriflavine	0	B-Chemical
DNA	9	O
staining	3	O
,	9	O
by	9	O
laser	5	O
flow	5	O
cytometry	3	O
.	9	O

Total	7	O
cell	3	O
yields	9	O
from	9	O
DES	9	B-Chemical
-	7	O
treated	3	O
pituitaries	3	O
increased	9	O
from	9	O
1	9	O
.	9	O
3	9	O
times	5	O
control	9	O
yields	9	O
at	9	O
8	9	O
days	9	O
of	5	O
treatment	9	O
to	5	O
58	7	O
.	9	O
9	7	O
times	5	O
control	9	O
values	5	O
by	9	O
day	9	O
150	0	O
.	9	O

Intracellular	3	O
PRL	3	O
content	9	O
ranged	9	O
from	9	O
1	9	O
.	9	O
9	7	O
to	5	O
9	7	O
.	9	O
4	9	O
times	5	O
control	9	O
levels	3	O
,	9	O
and	5	O
PRL	3	O
release	9	O
in	5	O
vitro	3	O
was	9	O
significantly	9	O
and	5	O
consistently	9	O
higher	9	O
than	5	O
controls	9	O
,	9	O
after	9	O
at	9	O
least	9	O
8	9	O
days	9	O
of	5	O
DES	9	B-Chemical
exposure	9	O
.	9	O

Beyond	5	O
8	9	O
days	9	O
of	5	O
DES	9	B-Chemical
exposure	9	O
,	9	O
the	5	O
immunochemically	3	O
PRL	3	O
-	7	O
positive	9	O
proportion	9	O
of	5	O
cells	3	O
increased	9	O
to	5	O
over	5	O
50	0	O
%	9	O
of	5	O
the	5	O
total	9	O
population	5	O
.	9	O

Increased	9	O
density	9	O
and	5	O
/	9	O
or	5	O
size	9	O
and	5	O
PRL	3	O
content	9	O
were	9	O
indicated	9	O
for	5	O
the	5	O
majority	9	O
of	5	O
the	5	O
PRL	3	O
cell	3	O
population	5	O
in	5	O
both	9	O
types	9	O
of	5	O
separation	5	O
protocols	5	O
.	9	O

All	9	O
these	5	O
effects	9	O
of	5	O
DES	9	B-Chemical
were	9	O
more	5	O
pronounced	9	O
among	5	O
previously	9	O
ovariectomized	3	O
animals	9	O
.	9	O

The	5	O
data	5	O
extend	9	O
the	5	O
findings	9	O
of	5	O
other	5	O
investigators	5	O
,	9	O
further	9	O
establishing	5	O
the	5	O
DES	9	B-Chemical
-	7	O
induced	3	O
tumor	3	B-Disease
as	5	O
a	5	O
model	5	O
for	5	O
study	9	O
of	5	O
PRL	3	O
cellular	3	O
control	9	O
mechanisms	9	O
.	9	O

Age	7	O
and	5	O
renal	9	O
clearance	9	O
of	5	O
cimetidine	0	B-Chemical
.	9	O

In	9	O
35	9	O
patients	5	O
(	9	O
ages	5	O
20	9	O
to	5	O
86	7	O
yr	7	O
)	9	O
receiving	9	O
cimetidine	0	B-Chemical
therapeutically	9	O
two	5	O
serum	9	O
samples	9	O
and	5	O
all	5	O
urine	9	O
formed	9	O
in	5	O
the	5	O
interim	5	O
were	9	O
collected	9	O
for	5	O
analysis	9	O
of	5	O
cimetidine	0	B-Chemical
by	9	O
high	9	O
-	7	O
pressure	5	O
liquid	0	O
chromatography	0	O
and	5	O
for	5	O
creatinine	0	B-Chemical
.	9	O

Cimetidine	0	B-Chemical
clearance	9	O
decreased	9	O
with	5	O
age	5	O
.	9	O

The	5	O
extrapolated	5	O
6	9	O
-	7	O
hr	0	O
serum	9	O
concentration	0	O
of	5	O
cimetidine	0	B-Chemical
per	9	O
unit	5	O
dose	9	O
,	9	O
after	9	O
intravenous	0	O
cimetidine	0	B-Chemical
,	9	O
increased	9	O
with	5	O
age	5	O
of	5	O
the	5	O
patients	5	O
.	9	O

The	5	O
ratio	9	O
of	5	O
cimetidine	0	B-Chemical
clearance	9	O
to	5	O
creatinine	0	B-Chemical
clearance	9	O
(	9	O
Rc	0	O
)	9	O
averaged	5	O
4	9	O
.	9	O
8	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
0	7	O
,	9	O
indicating	9	O
net	5	O
tubular	9	O
secretion	3	O
for	5	O
cimetidine	0	B-Chemical
.	9	O

Rc	0	O
seemed	9	O
to	5	O
be	5	O
independent	9	O
of	5	O
age	5	O
and	5	O
decreased	9	O
with	5	O
increasing	9	O
serum	9	O
concentration	0	O
of	5	O
cimetidine	0	B-Chemical
,	9	O
suggesting	9	O
that	5	O
secretion	3	O
of	5	O
cimetidine	0	B-Chemical
is	5	O
a	5	O
saturable	0	O
process	5	O
.	9	O

There	5	O
was	9	O
only	9	O
one	5	O
case	5	O
of	5	O
dementia	5	B-Disease
possibly	9	O
due	5	O
to	5	O
cimetidine	0	B-Chemical
(	9	O
with	5	O
a	5	O
drug	5	O
level	9	O
of	5	O
1	9	O
.	9	O
9	7	O
microgram	0	O
/	9	O
ml	0	O
6	9	O
hr	0	O
after	9	O
a	5	O
dose	9	O
)	9	O
in	5	O
a	5	O
group	9	O
of	5	O
13	7	O
patients	5	O
without	9	O
liver	9	B-Disease
or	5	I-Disease
kidney	9	I-Disease
disease	5	I-Disease
who	5	O
had	9	O
cimetidine	0	B-Chemical
levels	3	O
above	9	O
1	9	O
.	9	O
25	9	O
microgram	0	O
/	9	O
ml	0	O
.	9	O

Thus	9	O
,	9	O
high	9	O
cimetidine	0	B-Chemical
levels	3	O
alone	9	O
do	5	O
not	5	O
always	5	O
induce	3	O
dementia	5	B-Disease
.	9	O

Further	9	O
observations	9	O
on	5	O
the	5	O
electrophysiologic	5	O
effects	9	O
of	5	O
oral	9	O
amiodarone	0	B-Chemical
therapy	5	O
.	9	O

A	9	O
case	5	O
is	5	O
presented	5	O
of	5	O
a	5	O
reversible	9	O
intra	5	B-Disease
-	7	I-Disease
Hisian	5	I-Disease
block	9	I-Disease
occurring	9	O
under	9	O
amiodarone	0	B-Chemical
treatment	9	O
for	5	O
atrial	5	B-Disease
tachycardia	5	I-Disease
in	5	O
a	5	O
patient	5	O
without	9	O
clear	9	O
intraventricular	5	B-Disease
conduction	5	I-Disease
abnormalities	9	I-Disease
.	9	O

His	9	O
bundle	5	O
recordings	5	O
showed	9	O
an	5	O
atrial	5	B-Disease
tachycardia	5	I-Disease
with	5	O
intermittent	5	O
exit	9	O
block	9	O
and	5	O
greatly	9	O
prolonged	9	O
BH	9	O
and	5	O
HV	9	O
intervals	5	O
(	9	O
40	9	O
and	5	O
100	0	O
msec	5	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Thirty	9	O
days	9	O
after	9	O
amiodarone	0	B-Chemical
discontinuation	5	O
,	9	O
His	9	O
bundle	5	O
electrograms	5	O
showed	9	O
atrial	5	B-Disease
flutter	5	I-Disease
without	9	O
intra	5	O
-	7	O
Hisian	5	O
or	5	O
infra	9	O
-	7	O
Hisian	5	O
delay	5	O
.	9	O

Amiodarone	7	B-Chemical
should	5	O
be	5	O
used	5	O
with	5	O
caution	5	O
during	5	O
long	5	O
-	7	O
term	5	O
oral	9	O
therapy	5	O
in	5	O
patients	5	O
with	5	O
or	5	O
without	9	O
clear	9	O
intraventricular	5	O
conduction	5	O
defects	9	O
.	9	O

Development	2	O
of	5	O
clear	9	B-Disease
cell	3	I-Disease
adenocarcinoma	3	I-Disease
in	5	O
DES	9	B-Chemical
-	7	O
exposed	9	O
offspring	9	O
under	9	O
observation	9	O
.	9	O

Two	9	O
cases	5	O
of	5	O
clear	9	B-Disease
cell	3	I-Disease
adenocarcinoma	3	I-Disease
of	5	I-Disease
the	5	I-Disease
vagina	5	I-Disease
detected	9	O
at	9	O
follow	5	O
-	7	O
up	5	O
in	5	O
young	5	O
women	5	O
exposed	9	O
in	5	O
utero	9	O
to	5	O
diethylstilbestrol	0	B-Chemical
are	5	O
reported	9	O
.	9	O

One	5	O
patient	5	O
,	9	O
aged	9	O
23	7	O
,	9	O
had	9	O
been	9	O
followed	9	O
for	5	O
2	9	O
years	5	O
before	9	O
carcinoma	3	B-Disease
was	9	O
diagnosed	5	O
;	9	O
the	5	O
second	9	O
patient	5	O
,	9	O
aged	9	O
22	7	O
,	9	O
had	9	O
been	9	O
seen	9	O
on	5	O
a	5	O
regular	5	O
basis	5	O
for	5	O
5	9	O
years	5	O
,	9	O
8	9	O
months	5	O
.	9	O

In	9	O
both	9	O
instances	5	O
,	9	O
suspicion	5	O
of	5	O
the	5	O
presence	9	O
of	5	O
carcinoma	3	B-Disease
was	9	O
aroused	5	O
by	9	O
the	5	O
palpation	5	O
of	5	O
a	5	O
small	9	O
nodule	5	O
in	5	O
the	5	O
vaginal	9	O
fornix	5	O
.	9	O

Hysterosalpingography	5	O
was	9	O
performed	9	O
on	5	O
both	9	O
patients	5	O
and	5	O
,	9	O
in	5	O
1	9	O
instance	5	O
,	9	O
an	5	O
abnormal	9	O
x	9	O
-	7	O
ray	5	O
film	0	O
was	9	O
reflected	5	O
by	9	O
the	5	O
gross	5	O
appearance	9	O
of	5	O
the	5	O
uterine	5	O
cavity	5	O
found	9	O
in	5	O
the	5	O
surgical	5	O
specimen	9	O
.	9	O

Neurologic	5	O
effects	9	O
of	5	O
subarachnoid	5	O
administration	9	O
of	5	O
2	9	B-Chemical
-	7	I-Chemical
chloroprocaine	5	I-Chemical
-	7	I-Chemical
CE	9	I-Chemical
,	9	O
bupivacaine	0	B-Chemical
,	9	O
and	5	O
low	9	O
pH	0	O
normal	9	O
saline	0	O
in	5	O
dogs	5	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
evaluate	9	O
the	5	O
neurologic	5	O
consequences	5	O
of	5	O
deliberate	5	O
subarachnoid	5	O
injection	9	O
of	5	O
large	5	O
volumes	5	O
of	5	O
2	9	B-Chemical
-	7	I-Chemical
chloroprocaine	5	I-Chemical
-	7	I-Chemical
CE	9	I-Chemical
in	5	O
experimental	5	O
animals	9	O
.	9	O

The	5	O
possible	5	O
role	9	O
of	5	O
low	9	O
pH	0	O
as	5	O
well	9	O
as	5	O
total	9	O
volume	9	O
as	5	O
potential	9	O
factors	9	O
in	5	O
causing	9	O
neurotoxicity	9	B-Disease
was	9	O
evaluated	9	O
.	9	O

The	5	O
65	7	O
dogs	5	O
in	5	O
the	5	O
study	9	O
received	9	O
injections	9	O
in	5	O
the	5	O
subarachnoid	5	O
space	5	O
as	5	O
follows	9	O
:	9	O
6	9	O
to	5	O
8	9	O
ml	0	O
of	5	O
bupivacaine	0	B-Chemical
(	9	O
N	9	O
=	7	O
15	9	O
)	9	O
,	9	O
2	9	B-Chemical
-	7	I-Chemical
chloroprocaine	5	I-Chemical
-	7	I-Chemical
CE	9	I-Chemical
(	9	O
N	9	O
=	7	O
20	9	O
)	9	O
,	9	O
low	9	O
pH	0	O
normal	9	O
saline	0	O
(	9	O
pH	0	O
3	9	O
.	9	O
0	7	O
)	9	O
(	9	O
N	9	O
=	7	O
20	9	O
)	9	O
,	9	O
or	5	O
normal	9	O
saline	0	O
(	9	O
N	9	O
=	7	O
10	9	O
)	9	O
.	9	O

Of	9	O
the	5	O
20	9	O
animals	9	O
that	5	O
received	9	O
subarachnoid	5	O
injection	9	O
of	5	O
2	9	B-Chemical
-	7	I-Chemical
chloroprocaine	5	I-Chemical
-	7	I-Chemical
CE	9	I-Chemical
seven	9	O
(	9	O
35	9	O
%	9	O
)	9	O
developed	5	O
hind	4	O
-	7	O
limb	5	O
paralysis	5	B-Disease
.	9	O

None	9	O
of	5	O
the	5	O
animals	9	O
that	5	O
received	9	O
bupivacaine	0	B-Chemical
,	9	O
normal	9	O
saline	0	O
,	9	O
or	5	O
normal	9	O
saline	0	O
titrated	0	O
to	5	O
a	5	O
pH	0	O
3	9	O
.	9	O
0	7	O
developed	5	O
hind	4	O
-	7	O
limb	5	O
paralysis	5	B-Disease
.	9	O

Of	9	O
the	5	O
15	9	O
spinal	5	O
cords	3	O
of	5	O
the	5	O
animals	9	O
that	5	O
received	9	O
2	9	B-Chemical
-	7	I-Chemical
chloroprocaine	5	I-Chemical
-	7	I-Chemical
CE	9	I-Chemical
,	9	O
13	7	O
showed	9	O
subpial	5	B-Disease
necrosis	9	I-Disease
;	9	O
the	5	O
nerve	5	O
roots	4	O
and	5	O
subarachnoid	5	O
vessels	5	O
were	9	O
normal	9	O
.	9	O

The	5	O
spinal	5	O
cords	3	O
of	5	O
the	5	O
animals	9	O
that	5	O
received	9	O
bupivacaine	0	B-Chemical
,	9	O
low	9	O
pH	0	O
normal	9	O
saline	0	O
(	9	O
pH	0	O
3	9	O
.	9	O
0	7	O
)	9	O
,	9	O
or	5	O
normal	9	O
saline	0	O
did	9	O
not	5	O
show	9	O
abnormal	9	O
findings	9	O
.	9	O

Procainamide	0	B-Chemical
-	7	O
induced	3	O
polymorphous	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

Seven	9	O
cases	5	O
of	5	O
procainamide	0	B-Chemical
-	7	O
induced	3	O
polymorphous	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
are	5	O
presented	5	O
.	9	O

In	9	O
four	9	O
patients	5	O
,	9	O
polymorphous	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
appeared	9	O
after	9	O
intravenous	0	O
administration	9	O
of	5	O
200	0	O
to	5	O
400	0	O
mg	0	O
of	5	O
procainamide	0	B-Chemical
for	5	O
the	5	O
treatment	9	O
of	5	O
sustained	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

In	9	O
the	5	O
remaining	9	O
three	9	O
patients	5	O
,	9	O
procainamide	0	B-Chemical
was	9	O
administered	9	O
orally	0	O
for	5	O
treatment	9	O
of	5	O
chronic	5	O
premature	9	B-Disease
ventricular	5	I-Disease
contractions	5	I-Disease
or	5	O
atrial	5	B-Disease
flutter	5	I-Disease
.	9	O

These	5	O
patients	5	O
had	9	O
Q	9	B-Disease
-	7	I-Disease
T	3	I-Disease
prolongation	9	I-Disease
and	5	O
recurrent	5	O
syncope	5	B-Disease
due	5	O
to	5	O
polymorphous	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

In	9	O
four	9	O
patients	5	O
,	9	O
the	5	O
arrhythmia	5	B-Disease
was	9	O
rapidly	9	O
diagnosed	5	O
and	5	O
treated	3	O
with	5	O
disappearance	9	O
of	5	O
further	9	O
episodes	5	O
of	5	O
the	5	O
arrhythmia	5	B-Disease
.	9	O

In	9	O
two	5	O
patients	5	O
,	9	O
the	5	O
arrhythmia	5	B-Disease
degenerated	9	O
into	9	O
irreversible	9	O
ventricular	5	B-Disease
fibrillation	5	I-Disease
and	5	O
both	9	O
patients	5	O
died	9	O
.	9	O

In	9	O
the	5	O
seventh	9	O
patient	5	O
,	9	O
a	5	O
permanent	5	O
ventricular	5	O
pacemaker	5	O
was	9	O
inserted	9	O
and	5	O
,	9	O
despite	9	O
continuation	5	O
of	5	O
procainamide	0	B-Chemical
therapy	5	O
,	9	O
polymorphous	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
did	9	O
not	5	O
reoccur	5	O
.	9	O

These	5	O
seven	9	O
cases	5	O
demonstrate	9	O
that	5	O
procainamide	0	B-Chemical
can	5	O
produce	9	O
an	5	O
acquired	5	O
prolonged	9	B-Disease
Q	9	I-Disease
-	7	I-Disease
T	3	I-Disease
syndrome	5	I-Disease
with	5	O
polymorphous	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

Phenobarbitone	0	B-Chemical
-	7	O
induced	3	O
enlargement	5	B-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
in	5	O
the	5	O
rat	3	O
:	9	O
its	9	O
relationship	5	O
to	5	O
carbon	0	B-Chemical
tetrachloride	0	I-Chemical
-	7	O
induced	3	O
cirrhosis	5	B-Disease
.	9	O

The	5	O
yield	9	O
of	5	O
severe	5	O
cirrhosis	5	B-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
(	9	O
defined	5	O
as	5	O
a	5	O
shrunken	5	O
finely	4	O
nodular	5	O
liver	9	O
with	5	O
micronodular	5	O
histology	9	O
,	9	O
ascites	3	B-Disease
greater	5	O
than	5	O
30	9	O
ml	0	O
,	9	O
plasma	9	O
albumin	0	O
less	5	O
than	5	O
2	9	O
.	9	O
2	9	O
g	0	O
/	9	O
dl	7	O
,	9	O
splenomegaly	9	B-Disease
2	9	O
-	7	O
3	9	O
times	5	O
normal	9	O
,	9	O
and	5	O
testicular	9	O
atrophy	5	B-Disease
approximately	9	O
half	5	O
normal	9	O
weight	9	O
)	9	O
after	9	O
12	9	O
doses	0	O
of	5	O
carbon	0	B-Chemical
tetrachloride	0	I-Chemical
given	5	O
intragastrically	0	O
in	5	O
the	5	O
phenobarbitone	0	B-Chemical
-	7	O
primed	3	O
rat	3	O
was	9	O
increased	9	O
from	9	O
25	9	O
%	9	O
to	5	O
56	7	O
%	9	O
by	9	O
giving	5	O
the	5	O
initial	9	O
"	5	O
calibrating	5	O
"	5	O
dose	9	O
of	5	O
carbon	0	B-Chemical
tetrachloride	0	I-Chemical
at	9	O
the	5	O
peak	9	O
of	5	O
the	5	O
phenobarbitone	0	B-Chemical
-	7	O
induced	3	O
enlargement	5	B-Disease
of	5	I-Disease
the	5	I-Disease
liver	9	I-Disease
.	9	O

At	9	O
this	5	O
point	5	O
it	5	O
was	9	O
assumed	5	O
that	5	O
the	5	O
cytochrome	0	O
P450	1	O
/	9	O
CCl4	0	B-Chemical
toxic	0	O
state	5	O
was	9	O
both	9	O
maximal	9	O
and	5	O
stable	9	O
.	9	O

The	5	O
optimal	5	O
rat	3	O
size	9	O
to	5	O
begin	5	O
phenobarbitone	0	B-Chemical
was	9	O
determined	9	O
as	5	O
100	0	O
g	0	O
,	9	O
and	5	O
this	5	O
size	9	O
as	5	O
a	5	O
group	9	O
had	9	O
a	5	O
mean	5	O
maximum	5	O
relative	9	O
liver	9	O
weight	9	O
increase	9	O
47	7	O
%	9	O
greater	5	O
than	5	O
normal	9	O
rats	9	O
of	5	O
the	5	O
same	9	O
body	5	O
weight	9	O
.	9	O

The	5	O
optimal	5	O
time	5	O
for	5	O
the	5	O
initial	9	O
dose	9	O
of	5	O
carbon	0	B-Chemical
tetrachloride	0	I-Chemical
was	9	O
after	9	O
14	7	O
days	9	O
on	5	O
phenobarbitone	0	B-Chemical
.	9	O

Triamterene	7	B-Chemical
nephrolithiasis	5	B-Disease
complicating	5	O
dyazide	_	B-Chemical
therapy	5	O
.	9	O

A	9	O
case	5	O
of	5	O
triamterene	0	B-Chemical
nephrolithiasis	5	B-Disease
is	5	O
reported	9	O
in	5	O
a	5	O
man	5	O
after	9	O
4	9	O
years	5	O
of	5	O
hydrochlorothiazide	0	B-Chemical
-	7	I-Chemical
triamterene	0	I-Chemical
therapy	5	O
for	5	O
hypertension	5	B-Disease
.	9	O

The	5	O
stone	5	O
passed	5	O
spontaneously	5	O
and	5	O
was	9	O
found	9	O
to	5	O
contain	9	O
a	5	O
triamterene	0	B-Chemical
metabolite	0	O
admixed	9	O
with	5	O
uric	0	B-Chemical
acid	0	I-Chemical
salts	0	I-Chemical
.	9	O

Factors	5	O
affecting	9	O
triamterene	0	B-Chemical
nephrolithiasis	5	B-Disease
are	5	O
discussed	5	O
and	5	O
2	9	O
previously	9	O
reported	9	O
cases	5	O
are	5	O
reviewed	9	O
.	9	O

Busulfan	0	B-Chemical
-	7	O
induced	3	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
.	9	O

A	9	O
case	5	O
of	5	O
a	5	O
busulfan	0	B-Chemical
-	7	O
induced	3	O
hemorrhage	5	B-Disease
cystitis	9	I-Disease
is	5	O
reported	9	O
.	9	O

Spontaneous	9	O
resolution	5	O
occurred	9	O
following	9	O
cessation	5	O
of	5	O
the	5	O
drug	5	O
.	9	O

The	5	O
similarity	5	O
between	5	O
the	5	O
histologic	9	O
appearances	5	O
of	5	O
busulfan	0	B-Chemical
cystitis	9	B-Disease
and	5	O
both	9	O
radiation	9	O
and	5	O
cyclophosphamide	0	B-Chemical
-	7	O
induced	3	O
cystitis	9	B-Disease
is	5	O
discussed	5	O
and	5	O
the	5	O
world	5	O
literature	5	O
reviewed	9	O
.	9	O

In	9	O
view	5	O
of	5	O
the	5	O
known	9	O
tendency	5	O
of	5	O
busulfan	0	B-Chemical
to	5	O
induce	3	O
cellular	3	O
atypia	5	O
and	5	O
carcinoma	3	B-Disease
in	5	O
other	5	O
sites	9	O
,	9	O
periodic	5	O
urinary	9	O
cytology	5	O
is	5	O
suggested	9	O
in	5	O
patients	5	O
on	5	O
long	5	O
-	7	O
term	5	O
therapy	5	O
.	9	O

Variant	9	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
in	5	O
desipramine	0	B-Chemical
toxicity	9	B-Disease
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
variant	1	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
induced	3	O
by	9	O
desipramine	0	B-Chemical
toxicity	9	B-Disease
.	9	O

Unusual	9	O
features	5	O
of	5	O
the	5	O
arrhythmia	5	B-Disease
are	5	O
repetitive	5	O
group	9	O
beating	5	O
,	9	O
progressive	5	O
shortening	9	O
of	5	O
the	5	O
R	9	O
-	7	O
R	9	O
interval	5	O
,	9	O
progressive	5	O
widening	5	O
of	5	O
the	5	O
QRS	5	O
complex	9	O
with	5	O
eventual	5	O
failure	5	O
of	5	O
intraventricular	5	O
conduction	5	O
,	9	O
and	5	O
changes	9	O
in	5	O
direction	5	O
of	5	O
the	5	O
QRS	5	O
axis	5	O
.	9	O

Recognition	5	O
of	5	O
variant	1	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
is	5	O
important	9	O
because	5	O
therapy	5	O
differs	9	O
from	9	O
that	5	O
of	5	O
classic	5	O
ventricular	5	B-Disease
tachycardia	5	I-Disease
.	9	O

Rebound	5	O
hypertensive	5	B-Disease
after	9	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
prevented	9	O
by	9	O
saralasin	3	B-Chemical
in	5	O
rats	9	O
.	9	O

The	5	O
role	9	O
of	5	O
the	5	O
renin	9	O
-	7	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
in	5	O
the	5	O
maintenance	9	O
of	5	O
blood	9	O
pressure	5	O
during	5	O
halothane	0	B-Chemical
anesthesia	5	O
and	5	O
sodium	0	B-Chemical
nitroprusside	0	I-Chemical
(	9	O
SNP	9	B-Chemical
)	9	O
-	7	O
induced	3	O
hypotension	5	B-Disease
was	9	O
evaluated	9	O
.	9	O

Control	9	O
rats	9	O
received	9	O
halothane	0	B-Chemical
anesthesia	5	O
(	9	O
1	9	O
MAC	9	O
)	9	O
for	5	O
one	5	O
hour	0	O
,	9	O
followed	9	O
by	9	O
SNP	9	B-Chemical
infusion	0	O
,	9	O
40	9	O
microgram	0	O
/	9	O
kg	0	O
/	9	O
min	0	O
,	9	O
for	5	O
30	9	O
min	0	O
,	9	O
followed	9	O
by	9	O
a	5	O
30	9	O
-	7	O
min	0	O
recovery	9	O
period	5	O
.	9	O

A	9	O
second	9	O
group	9	O
of	5	O
rats	9	O
was	9	O
treated	3	O
identically	9	O
and	5	O
,	9	O
in	5	O
addition	9	O
,	9	O
received	9	O
an	5	O
infusion	0	O
of	5	O
saralasin	3	B-Chemical
(	9	O
a	5	O
competitive	9	O
inhibitor	3	O
of	5	O
angiotensin	9	B-Chemical
II	9	I-Chemical
)	9	O
throughout	9	O
the	5	O
experimental	5	O
period	5	O
.	9	O

In	9	O
each	5	O
group	9	O
,	9	O
SNP	9	B-Chemical
infusion	0	O
resulted	9	O
in	5	O
an	5	O
initial	9	O
decrease	9	O
in	5	O
blood	9	O
pressure	5	O
from	9	O
86	7	O
torr	0	O
and	5	O
83	7	O
torr	0	O
,	9	O
respectively	9	O
,	9	O
to	5	O
48	9	O
torr	0	O
.	9	O

During	5	O
the	5	O
SNP	9	B-Chemical
infusion	0	O
the	5	O
control	9	O
animals	9	O
demonstrated	9	O
a	5	O
progressive	5	O
increase	9	B-Disease
in	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
to	5	O
61	7	O
torr	0	O
,	9	O
whereas	9	O
the	5	O
saralasin	3	B-Chemical
-	7	O
treated	3	O
animals	9	O
showed	9	O
no	9	O
change	9	O
.	9	O

Following	9	O
discontinuation	5	O
of	5	O
SNP	9	B-Chemical
,	9	O
blood	9	O
pressure	5	O
in	5	O
the	5	O
control	9	O
animals	9	O
rebounded	9	O
to	5	O
94	7	O
torr	0	O
,	9	O
as	5	O
compared	9	O
with	5	O
78	7	O
torr	0	O
in	5	O
the	5	O
saralasin	3	B-Chemical
-	7	O
treated	3	O
rats	9	O
.	9	O

This	5	O
study	9	O
indicates	9	O
that	5	O
with	5	O
stable	9	O
halothane	0	B-Chemical
anesthesia	5	O
,	9	O
the	5	O
partial	9	O
recovery	9	O
of	5	O
blood	9	O
pressure	5	O
during	5	O
SNP	9	B-Chemical
infusion	0	O
and	5	O
the	5	O
post	9	O
-	7	O
SNP	9	B-Chemical
rebound	5	O
of	5	O
blood	9	O
pressure	5	O
can	5	O
be	5	O
completely	9	O
blocked	3	O
by	9	O
saralasin	3	B-Chemical
.	9	O

This	5	O
demonstrates	9	O
the	5	O
participation	5	O
of	5	O
the	5	O
renin	9	O
-	7	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
in	5	O
antagonizing	3	O
the	5	O
combined	9	O
hypotensive	5	B-Disease
effects	9	O
of	5	O
halothane	0	B-Chemical
and	5	O
SNP	9	B-Chemical
.	9	O

Clinical	5	O
nephrotoxicity	9	B-Disease
of	5	O
tobramycin	0	B-Chemical
and	5	O
gentamicin	0	B-Chemical
.	9	O

A	9	O
prospective	5	O
study	9	O
.	9	O

Nearly	9	O
3	9	O
.	9	O
2	9	O
million	5	O
people	5	O
in	5	O
this	5	O
country	5	O
receive	5	O
aminoglycoside	9	B-Chemical
antibiotics	5	O
annually	5	O
.	9	O

Gentamicin	0	B-Chemical
sulfate	0	I-Chemical
and	5	O
tobramycin	0	B-Chemical
sulfate	0	I-Chemical
continue	5	O
to	5	O
demonstrate	9	O
ototoxicity	5	B-Disease
and	5	O
nephrotoxicity	9	B-Disease
in	5	O
both	9	O
animal	5	O
and	5	O
clinical	5	O
studies	9	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
62	7	O
patients	5	O
with	5	O
confirmed	9	O
initial	9	O
normal	9	O
renal	9	O
function	9	O
and	5	O
treated	3	O
with	5	O
2	9	O
to	5	O
5	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
of	5	O
gentamicin	0	B-Chemical
sulfate	0	I-Chemical
or	5	O
tobramycin	0	B-Chemical
sulfate	0	I-Chemical
for	5	O
a	5	O
minimum	5	O
of	5	O
seven	9	O
days	9	O
were	9	O
followed	9	O
up	5	O
prospectively	5	O
for	5	O
the	5	O
development	9	O
of	5	O
aminoglycoside	9	B-Chemical
-	7	O
related	9	O
renal	9	B-Disease
failure	5	I-Disease
,	9	O
defined	5	O
as	5	O
at	9	O
least	9	O
a	5	O
one	5	O
-	7	O
third	9	O
reduction	9	O
in	5	O
renal	9	O
function	9	O
.	9	O

In	9	O
these	5	O
62	7	O
patients	5	O
,	9	O
no	9	O
other	5	O
causes	9	O
for	5	O
renal	9	B-Disease
failure	5	I-Disease
could	9	O
be	5	O
identified	9	O
.	9	O

Five	9	O
of	5	O
33	7	O
(	9	O
15	9	O
%	9	O
)	9	O
of	5	O
the	5	O
tobramycin	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
and	5	O
16	9	O
of	5	O
29	7	O
(	9	O
55	7	O
.	9	O
2	9	O
%	9	O
)	9	O
of	5	O
the	5	O
gentamicin	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
had	9	O
renal	9	B-Disease
failure	5	I-Disease
.	9	O

Thus	9	O
,	9	O
gentamicin	0	B-Chemical
was	9	O
associated	9	O
with	5	O
renal	9	B-Disease
failure	5	I-Disease
more	5	O
than	5	O
three	9	O
times	5	O
as	5	O
often	5	O
as	5	O
was	9	O
tobramycin	0	B-Chemical
.	9	O

Metabolic	9	O
involvement	9	O
in	5	O
adriamycin	3	B-Chemical
cardiotoxicity	9	B-Disease
.	9	O

The	5	O
cardiotoxic	5	B-Disease
effects	9	O
of	5	O
adriamycin	3	B-Chemical
were	9	O
studied	9	O
in	5	O
mammalian	9	O
myocardial	9	O
cells	3	O
in	5	O
culture	9	O
as	5	O
a	5	O
model	5	O
system	5	O
.	9	O

Adriamycin	0	B-Chemical
inhibited	3	O
cell	3	O
growth	3	O
and	5	O
the	5	O
rhythmic	5	O
contractions	5	O
characteristic	9	O
of	5	O
myocardial	9	O
cells	3	O
in	5	O
culture	9	O
.	9	O

A	9	O
possible	5	O
involvement	9	O
of	5	O
energy	5	O
metabolism	9	O
was	9	O
suggested	9	O
previously	9	O
,	9	O
and	5	O
in	5	O
this	5	O
study	9	O
the	5	O
adenylate	0	O
energy	5	O
charge	5	O
and	5	O
phosphorylcreatine	0	B-Chemical
mole	0	O
fraction	9	O
were	9	O
determined	9	O
in	5	O
the	5	O
adriamycin	3	B-Chemical
-	7	O
treated	3	O
cells	3	O
.	9	O

The	5	O
adenylate	0	O
energy	5	O
charge	5	O
was	9	O
found	9	O
to	5	O
be	5	O
significantly	9	O
decreased	9	O
,	9	O
while	9	O
the	5	O
phophorylcreatine	_	B-Chemical
mole	0	O
fraction	9	O
was	9	O
unchanged	9	O
.	9	O

Such	5	O
disparity	5	O
suggests	9	O
an	5	O
inhibition	3	O
of	5	O
creatine	0	B-Chemical
phosphokinase	0	O
.	9	O

The	5	O
addition	9	O
of	5	O
1	9	O
mM	0	O
adenosine	0	B-Chemical
to	5	O
the	5	O
myocardial	9	O
cell	3	O
cultures	3	O
markedly	9	O
increases	9	O
the	5	O
ATP	0	B-Chemical
concentration	0	O
through	9	O
a	5	O
pathway	3	O
reportedly	9	O
leading	9	O
to	5	O
a	5	O
compartmentalized	9	O
ATP	0	B-Chemical
pool	9	O
.	9	O

In	9	O
the	5	O
adriamycin	3	B-Chemical
-	7	O
treated	3	O
cells	3	O
,	9	O
the	5	O
addition	9	O
of	5	O
adenosine	0	B-Chemical
increased	9	O
the	5	O
adenylate	0	O
charge	5	O
and	5	O
,	9	O
concomitant	9	O
with	5	O
this	5	O
inrcease	_	O
,	9	O
the	5	O
cells	3	O
'	9	O
functional	9	O
integrity	9	O
,	9	O
in	5	O
terms	5	O
of	5	O
percentage	9	O
of	5	O
beating	5	O
cells	3	O
and	5	O
rate	9	O
of	5	O
contractions	5	O
,	9	O
was	9	O
maintained	9	O
.	9	O

Age	7	O
-	7	O
dependent	9	O
sensitivity	9	O
of	5	O
the	5	O
rat	3	O
to	5	O
neurotoxic	9	B-Disease
effects	9	O
of	5	O
streptomycin	0	B-Chemical
.	9	O

Streptomycin	0	B-Chemical
sulfate	0	O
(	9	O
300	0	O
mg	0	O
/	9	O
kg	0	O
s	9	O
.	9	O
c	9	O
.	9	O
)	9	O
was	9	O
injected	3	O
for	5	O
various	9	O
periods	5	O
into	9	O
preweanling	3	O
rats	9	O
and	5	O
for	5	O
3	9	O
weeks	9	O
into	9	O
weanling	3	O
rats	9	O
.	9	O

Beginning	5	O
at	9	O
8	9	O
days	9	O
of	5	O
age	5	O
,	9	O
body	5	O
movement	5	O
and	5	O
hearing	5	O
were	9	O
examined	9	O
for	5	O
6	9	O
and	5	O
up	5	O
to	5	O
17	7	O
weeks	9	O
,	9	O
respectively	9	O
.	9	O

Abnormal	9	B-Disease
movements	5	I-Disease
and	5	O
deafness	5	B-Disease
occurred	9	O
only	9	O
in	5	O
rats	9	O
treated	3	O
during	5	O
the	5	O
preweaning	5	O
period	5	O
;	9	O
within	9	O
this	5	O
period	5	O
the	5	O
greatest	9	O
sensitivities	9	O
for	5	O
these	5	O
abnormalities	9	O
occurred	9	O
from	9	O
2	9	O
to	5	O
11	7	O
-	7	O
17	7	O
and	5	O
5	9	O
to	5	O
11	7	O
days	9	O
of	5	O
age	5	O
,	9	O
respectively	9	O
,	9	O
indicating	9	O
that	5	O
the	5	O
cochlea	5	O
is	5	O
more	5	O
sensitive	9	O
to	5	O
streptomycin	0	B-Chemical
than	5	O
the	5	O
site	9	O
(	9	O
vestibular	5	O
or	5	O
central	5	O
)	9	O
responsible	9	O
for	5	O
the	5	O
dyskinesias	5	B-Disease
.	9	O

Late	9	O
,	9	O
late	9	O
doxorubicin	0	B-Chemical
cardiotoxicity	9	B-Disease
.	9	O

Cardiac	9	B-Disease
toxicity	9	I-Disease
is	5	O
a	5	O
major	9	O
complication	5	O
which	5	O
limits	5	O
the	5	O
use	5	O
of	5	O
adriamycin	3	B-Chemical
as	5	O
a	5	O
chemotherapeutic	3	O
agent	9	O
.	9	O

Cardiomyopathy	7	B-Disease
is	5	O
frequent	5	O
when	5	O
the	5	O
total	9	O
dose	9	O
exceeds	5	O
600	0	O
mg	0	O
/	9	O
m2	7	O
and	5	O
occurs	9	O
within	9	O
one	5	O
to	5	O
six	9	O
months	5	O
after	9	O
cessation	5	O
of	5	O
therapy	5	O
.	9	O

A	9	O
patient	5	O
is	5	O
reported	9	O
who	5	O
developed	5	O
progressive	5	O
cardiomyopathy	5	B-Disease
two	5	O
and	5	O
one	5	O
-	7	O
half	5	O
years	5	O
after	9	O
receiving	9	O
580	9	O
mg	0	O
/	9	O
m2	7	O
which	5	O
apparently	9	O
represents	9	O
late	9	O
,	9	O
late	9	O
cardiotoxicity	9	B-Disease
.	9	O

Attenuation	9	O
of	5	O
the	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
-	7	I-Disease
insipidus	5	I-Disease
-	7	I-Disease
like	9	I-Disease
syndrome	5	I-Disease
by	9	O
amiloride	0	B-Chemical
in	5	O
rats	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
amiloride	0	B-Chemical
on	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
polydipsia	5	B-Disease
and	5	O
polyuria	5	B-Disease
and	5	O
on	5	O
the	5	O
lithium	0	B-Chemical
concentration	0	O
in	5	O
the	5	O
plasma	9	O
,	9	O
brain	5	O
,	9	O
kidney	9	O
,	9	O
thyroid	9	O
and	5	O
red	9	O
blood	9	O
cells	3	O
was	9	O
investigated	9	O
in	5	O
rats	9	O
,	9	O
chronically	9	O
treated	3	O
with	5	O
LiCl	0	B-Chemical
.	9	O

Amiloride	0	B-Chemical
reduced	9	O
the	5	O
drinking	5	O
and	5	O
urine	9	O
volume	9	O
of	5	O
rats	9	O
in	5	O
an	5	O
acute	9	O
(	9	O
6	9	O
or	5	O
12	9	O
h	0	O
)	9	O
and	5	O
a	5	O
subacute	5	O
(	9	O
3	9	O
days	9	O
)	9	O
experiment	9	O
.	9	O

6	9	O
h	0	O
after	9	O
the	5	O
administration	9	O
of	5	O
amiloride	0	B-Chemical
,	9	O
a	5	O
reduction	9	O
was	9	O
observed	9	O
in	5	O
the	5	O
lithium	0	B-Chemical
content	9	O
of	5	O
the	5	O
renal	9	O
medulla	9	O
but	9	O
not	5	O
in	5	O
the	5	O
other	5	O
organs	9	O
studied	9	O
.	9	O

At	9	O
12	9	O
h	0	O
,	9	O
all	5	O
the	5	O
tissues	9	O
showed	9	O
a	5	O
slight	9	O
increase	9	O
in	5	O
lithium	0	B-Chemical
levels	3	O
.	9	O

After	9	O
3	9	O
days	9	O
of	5	O
combined	9	O
treatment	9	O
,	9	O
a	5	O
marked	9	O
elevation	9	O
in	5	O
plasma	9	O
and	5	O
tissue	9	O
lithium	0	B-Chemical
levels	3	O
accompanied	9	O
a	5	O
reduction	9	O
in	5	O
water	0	O
intake	5	O
.	9	O

In	9	O
all	5	O
the	5	O
experiments	9	O
,	9	O
the	5	O
attenuation	9	O
of	5	O
the	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
-	7	I-Disease
insipidus	5	I-Disease
-	7	I-Disease
like	9	I-Disease
syndrome	5	I-Disease
by	9	O
amiloride	0	B-Chemical
was	9	O
accompanied	9	O
by	9	O
a	5	O
reduction	9	O
of	5	O
the	5	O
ratio	9	O
between	5	O
the	5	O
lithium	0	B-Chemical
concentration	0	O
in	5	O
the	5	O
renal	9	O
medulla	9	O
and	5	O
its	9	O
levels	3	O
in	5	O
the	5	O
blood	9	O
and	5	O
an	5	O
elevation	9	O
in	5	O
the	5	O
plasma	9	O
potassium	0	B-Chemical
level	9	O
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
acute	9	O
amiloride	0	B-Chemical
administration	9	O
to	5	O
lithium	0	B-Chemical
-	7	O
treated	3	O
patients	5	O
suffering	5	O
from	9	O
polydipsia	5	B-Disease
and	5	O
polyuria	5	B-Disease
might	9	O
relieve	5	O
these	5	O
patients	5	O
but	9	O
prolonged	9	O
amiloride	0	B-Chemical
supplementation	0	O
would	5	O
result	9	O
in	5	O
elevated	9	O
lithium	0	B-Chemical
levels	3	O
and	5	O
might	9	O
be	5	O
hazardous	5	O
.	9	O

Cardiovascular	2	B-Disease
complications	5	I-Disease
associated	9	O
with	5	O
terbutaline	0	B-Chemical
treatment	9	O
for	5	O
preterm	5	B-Disease
labor	5	I-Disease
.	9	O

Severe	9	O
cardiovascular	5	B-Disease
complications	5	I-Disease
occurred	9	O
in	5	O
eight	9	O
of	5	O
160	9	O
patients	5	O
treated	3	O
with	5	O
terbutaline	0	B-Chemical
for	5	O
preterm	5	B-Disease
labor	5	I-Disease
.	9	O

Associated	9	O
corticosteroid	5	O
therapy	5	O
and	5	O
twin	5	O
gestations	5	O
appear	9	O
to	5	O
be	5	O
predisposing	5	O
factors	9	O
.	9	O

Potential	5	O
mechanisms	9	O
of	5	O
the	5	O
pathophysiology	9	O
are	5	O
briefly	9	O
discussed	5	O
.	9	O

Toxic	0	B-Disease
hepatitis	9	I-Disease
induced	3	O
by	9	O
antithyroid	0	O
drugs	5	O
:	9	O
four	9	O
cases	5	O
including	9	O
one	5	O
with	5	O
cross	5	O
-	7	O
reactivity	9	O
between	5	O
carbimazole	5	B-Chemical
and	5	O
benzylthiouracil	_	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
This	5	O
study	9	O
was	9	O
conducted	9	O
to	5	O
assess	5	O
the	5	O
occurrence	5	O
of	5	O
hepatic	9	B-Disease
adverse	5	I-Disease
effects	9	I-Disease
encountered	5	O
with	5	O
antithyroid	0	O
drugs	5	O
.	9	O

METHODS	2	O
:	9	O
Retrospective	9	O
review	5	O
of	5	O
medical	5	O
records	5	O
of	5	O
236	7	O
patients	5	O
with	5	O
hyperthyroidism	5	B-Disease
admitted	5	O
in	5	O
our	5	O
department	5	O
(	9	O
in	5	O
-	7	O
or	5	O
out	9	O
-	7	O
patients	5	O
)	9	O
from	9	O
1986	2	O
to	5	O
1992	2	O
.	9	O

RESULTS	9	O
:	9	O
Four	9	O
patients	5	O
(	9	O
1	9	O
.	9	O
7	9	O
%	9	O
)	9	O
were	9	O
identified	9	O
with	5	O
toxic	0	B-Disease
hepatitis	9	I-Disease
which	5	O
could	9	O
reasonably	5	O
be	5	O
attributed	9	O
to	5	O
the	5	O
use	5	O
of	5	O
antithyroid	0	O
agent	9	O
.	9	O

Two	9	O
patients	5	O
had	9	O
a	5	O
cholestatic	5	B-Disease
hepatitis	9	I-Disease
induced	3	O
by	9	O
carbimazole	5	B-Chemical
(	9	O
N	9	B-Chemical
omercazole	_	I-Chemical
)	9	O
.	9	O

Two	9	O
others	5	O
had	9	O
a	5	O
mixed	9	O
(	9	O
cholestatic	5	B-Disease
and	5	O
cytolytic	3	O
)	9	O
hepatitis	9	B-Disease
following	9	O
carbimazole	5	B-Chemical
.	9	O

One	5	O
of	5	O
the	5	O
latter	9	O
two	5	O
patients	5	O
further	9	O
experienced	5	O
a	5	O
cytolytic	3	O
hepatitis	9	B-Disease
which	5	O
appeared	9	O
after	9	O
Benzylthiouracil	_	B-Chemical
(	9	O
Basd	_	B-Chemical
ne	2	I-Chemical
)	9	O
had	9	O
replaced	9	O
carbimazole	5	B-Chemical
.	9	O

Biological	2	O
features	5	O
of	5	O
hepatitis	9	B-Disease
disappeared	9	O
in	5	O
all	5	O
cases	5	O
after	9	O
cessation	5	O
of	5	O
the	5	O
incriminated	5	O
drug	5	O
,	9	O
while	9	O
biliary	5	O
,	9	O
viral	9	O
and	5	O
immunological	9	O
searches	5	O
were	9	O
negative	9	O
.	9	O

Only	9	O
2	9	O
patients	5	O
of	5	O
our	5	O
retrospective	5	O
study	9	O
experienced	5	O
a	5	O
mild	9	O
or	5	O
severe	5	O
neutropenia	5	B-Disease
.	9	O

CONCLUSION	5	O
:	9	O
Toxic	0	B-Disease
hepatitis	9	I-Disease
is	5	O
a	5	O
potential	9	O
adverse	5	O
effect	9	O
of	5	O
antithyroid	0	O
drugs	5	O
which	5	O
warrants	9	O
,	9	O
as	5	O
for	5	O
haematological	5	O
disturbances	5	O
,	9	O
a	5	O
pre	9	O
-	7	O
therapeutic	5	O
determination	9	O
and	5	O
a	5	O
careful	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
relevant	5	O
biological	5	O
markers	3	O
.	9	O

Moreover	9	O
,	9	O
hepatotoxicity	9	B-Disease
may	5	O
not	5	O
be	5	O
restricted	9	O
to	5	O
one	5	O
class	9	O
of	5	O
antithyroid	0	O
agents	5	O
.	9	O

Interactive	5	O
effects	9	O
of	5	O
variations	5	O
in	5	O
[	9	O
Na	0	B-Chemical
]	9	O
o	9	O
and	5	O
[	9	O
Ca	0	B-Chemical
]	9	O
o	9	O
on	5	O
rat	3	O
atrial	5	O
spontaneous	5	O
frequency	5	O
.	9	O

The	5	O
effects	9	O
of	5	O
varying	5	O
the	5	O
extracellular	9	O
concentrations	0	O
of	5	O
Na	0	B-Chemical
and	5	O
Ca	0	B-Chemical
(	9	O
[	9	O
Na	0	B-Chemical
]	9	O
o	9	O
and	5	O
[	9	O
Ca	0	B-Chemical
]	9	O
o	9	O
)	9	O
on	5	O
both	9	O
,	9	O
the	5	O
spontaneous	5	O
beating	5	O
and	5	O
the	5	O
negative	9	O
chronotropic	5	O
action	5	O
of	5	O
verapamil	0	B-Chemical
,	9	O
were	9	O
studied	9	O
in	5	O
the	5	O
isolated	9	O
rat	3	O
atria	9	O
.	9	O

Basal	9	O
frequency	5	O
(	9	O
BF	9	O
)	9	O
evaluated	9	O
by	9	O
surface	9	O
electrogram	5	O
was	9	O
223	7	O
+	9	O
/	9	O
-	7	O
4	9	O
beats	5	O
/	9	O
min	0	O
.	9	O
in	5	O
control	9	O
Krebs	0	O
-	7	O
Ringer	0	O
containing	0	O
137	7	O
mM	0	O
Na	0	B-Chemical
and	5	O
1	9	O
.	9	O
35	9	O
mM	0	O
Ca	0	B-Chemical
(	9	O
N	9	O
)	9	O
.	9	O

It	5	O
decreased	9	O
by	9	O
16	9	O
+	9	O
/	9	O
-	7	O
3	9	O
%	9	O
by	9	O
lowering	9	O
[	9	O
Na	0	B-Chemical
]	9	O
o	9	O
to	5	O
78	7	O
mM	0	O
(	9	O
LNa	9	O
)	9	O
,	9	O
23	7	O
+	9	O
/	9	O
-	7	O
2	9	O
%	9	O
by	9	O
lowering	9	O
simultaneously	5	O
[	9	O
Na	0	B-Chemical
]	9	O
o	9	O
to	5	O
78	7	O
mM	0	O
and	5	O
[	9	O
Ca	0	B-Chemical
]	9	O
o	9	O
to	5	O
0	7	O
.	9	O
675	7	O
mM	0	O
(	9	O
LNa	9	O
+	9	O
LCa	3	O
)	9	O
and	5	O
31	7	O
+	9	O
/	9	O
-	7	O
5	9	O
%	9	O
by	9	O
lowering	9	O
[	9	O
Na	0	B-Chemical
]	9	O
o	9	O
to	5	O
78	7	O
mM	0	O
plus	9	O
increasing	9	O
[	9	O
Ca	0	B-Chemical
]	9	O
o	9	O
to	5	O
3	9	O
.	9	O
6	9	O
mM	0	O
(	9	O
LNa	9	O
+	9	O
HCa	7	O
)	9	O
.	9	O

At	9	O
normal	9	O
[	9	O
Na	0	B-Chemical
]	9	O
o	9	O
,	9	O
decrease	9	O
(	9	O
0	7	O
.	9	O
675	7	O
mM	0	O
)	9	O
or	5	O
increase	9	O
(	9	O
3	9	O
.	9	O
6	9	O
mM	0	O
)	9	O
of	5	O
[	9	O
Ca	0	B-Chemical
]	9	O
o	9	O
did	9	O
not	5	O
modify	9	O
BF	9	O
;	9	O
a	5	O
reduction	9	O
of	5	O
ten	9	O
times	5	O
(	9	O
0	7	O
.	9	O
135	7	O
mM	0	O
of	5	O
normal	9	O
[	9	O
Ca	0	B-Chemical
]	9	O
o	9	O
was	9	O
effective	5	O
to	5	O
reduce	5	O
BF	9	O
by	9	O
40	9	O
+	9	O
/	9	O
-	7	O
13	7	O
%	9	O
.	9	O

All	9	O
negative	9	O
chronotropic	5	O
effects	9	O
were	9	O
BF	9	O
-	7	O
dependent	9	O
.	9	O

Dose	0	O
-	7	O
dependent	9	O
bradycardia	5	B-Disease
induced	3	O
by	9	O
verapamil	0	B-Chemical
was	9	O
potentiated	3	O
by	9	O
LNa	9	O
,	9	O
LCa	3	O
,	9	O
and	5	O
HCa	7	O
.	9	O

Independent	9	O
but	9	O
not	5	O
additive	9	O
effects	9	O
of	5	O
Na	0	B-Chemical
and	5	O
Ca	0	B-Chemical
are	5	O
shown	9	O
by	9	O
decreases	9	O
in	5	O
the	5	O
values	5	O
of	5	O
[	9	O
verapamil	0	B-Chemical
]	9	O
o	9	O
needed	5	O
to	5	O
reduce	5	O
BF	9	O
by	9	O
30	9	O
%	9	O
(	9	O
IC30	0	O
)	9	O
with	5	O
the	5	O
following	9	O
order	5	O
of	5	O
inhibitory	3	O
potency	9	O
:	9	O
LNa	9	O
>	0	O
LCa	3	O
>	0	O
HCa	7	O
>	0	O
N	9	O
,	9	O
resulting	9	O
LNa	9	O
+	9	O
HCa	7	O
similar	9	O
to	5	O
LNa	9	O
.	9	O

The	5	O
[	9	O
verapamil	0	B-Chemical
]	9	O
o	9	O
that	5	O
arrested	3	O
atrial	5	O
beating	5	O
(	9	O
AC	9	O
)	9	O
was	9	O
also	9	O
potentiated	3	O
with	5	O
the	5	O
order	5	O
LNa	9	O
=	7	O
LNa	9	O
+	9	O
LCa	3	O
=	7	O
LNa	9	O
+	9	O
HCa	7	O
=	7	O
LCa	3	O
>	0	O
HCa	7	O
=	7	O
N	9	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
rat	3	O
atrial	5	O
spontaneous	5	O
beating	5	O
is	5	O
more	5	O
dependent	9	O
on	5	O
[	9	O
Na	0	B-Chemical
]	9	O
o	9	O
than	5	O
on	5	O
[	9	O
Ca	0	B-Chemical
]	9	O
o	9	O
in	5	O
a	5	O
range	9	O
of	5	O
+	9	O
/	9	O
-	7	O
50	0	O
%	9	O
of	5	O
their	5	O
normal	9	O
concentration	0	O
.	9	O

Also	9	O
the	5	O
enhancement	9	O
of	5	O
verapamil	0	B-Chemical
effects	9	O
on	5	O
atrial	5	O
beating	5	O
was	9	O
more	5	O
pronounced	9	O
at	9	O
LNa	9	O
than	5	O
at	9	O
LCa	3	O
.	9	O
(	9	O
ABSTRACT	2	O
TRUNCATED	2	O
AT	9	O
250	0	O
WORDS	3	O
)	9	O

Pseudo	7	O
-	7	O
allergic	9	B-Disease
reactions	9	I-Disease
to	5	O
corticosteroids	5	B-Chemical
:	9	O
diagnosis	5	O
and	5	O
alternatives	5	O
.	9	O

Two	9	O
patients	5	O
treated	3	O
with	5	O
parenteral	5	O
paramethasone	_	B-Chemical
(	9	O
Triniol	_	O
)	9	O
and	5	O
dexamethasone	0	B-Chemical
(	9	O
Sedionbel	_	O
)	9	O
are	5	O
described	9	O
.	9	O

A	9	O
few	5	O
minutes	0	O
after	9	O
administration	9	O
of	5	O
the	5	O
drugs	5	O
,	9	O
they	5	O
presented	5	O
urticaria	5	B-Disease
(	9	O
patients	5	O
1	9	O
and	5	O
2	9	O
)	9	O
and	5	O
conjunctivitis	5	B-Disease
(	9	O
patient	5	O
1	9	O
)	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
our	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
cause	5	O
of	5	O
the	5	O
patients	5	O
'	9	O
reactions	9	O
,	9	O
the	5	O
immunological	9	O
mechanisms	9	O
involved	9	O
and	5	O
whether	9	O
these	5	O
patients	5	O
would	5	O
be	5	O
able	9	O
to	5	O
tolerate	5	O
any	5	O
kind	5	O
of	5	O
corticoid	5	O
.	9	O

Clinical	5	O
examinations	5	O
and	5	O
skin	5	O
,	9	O
oral	9	O
and	5	O
parenteral	5	O
challenges	5	O
with	5	O
different	9	O
corticosteroids	5	B-Chemical
and	5	O
ELISA	3	O
tests	5	O
were	9	O
performed	9	O
.	9	O

In	9	O
the	5	O
two	5	O
patients	5	O
,	9	O
skin	5	O
and	5	O
ELISA	3	O
tests	5	O
with	5	O
paramethasone	_	B-Chemical
were	9	O
negative	9	O
,	9	O
as	5	O
was	9	O
the	5	O
prick	5	O
test	5	O
with	5	O
each	5	O
of	5	O
its	9	O
excipients	0	O
.	9	O

A	9	O
single	9	O
-	7	O
blind	5	O
parenteral	5	O
challenge	9	O
with	5	O
Triniol	_	O
was	9	O
positive	9	O
in	5	O
both	9	O
patients	5	O
after	9	O
the	5	O
administration	9	O
of	5	O
1	9	O
ml	0	O
of	5	O
the	5	O
drug	5	O
,	9	O
and	5	O
negative	9	O
with	5	O
its	9	O
excipients	0	O
.	9	O

We	9	O
also	9	O
carried	9	O
out	9	O
oral	9	O
and	5	O
parenteral	5	O
challenges	5	O
with	5	O
other	5	O
corticosteroids	5	B-Chemical
and	5	O
found	9	O
intolerance	5	O
to	5	O
some	5	O
of	5	O
them	5	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
paramethasone	_	B-Chemical
caused	9	O
pseudoallergic	5	O
reactions	9	O
in	5	O
our	5	O
patients	5	O
.	9	O

Corticosteroids	9	O
different	9	O
from	9	O
paramethasone	_	B-Chemical
also	9	O
produced	9	O
hypersensitivity	9	B-Disease
reactions	9	O
in	5	O
these	5	O
patients	5	O
;	9	O
however	9	O
,	9	O
a	5	O
few	5	O
of	5	O
them	5	O
were	9	O
tolerated	9	O
.	9	O

The	5	O
basic	5	O
mechanisms	9	O
of	5	O
those	5	O
reactions	9	O
are	5	O
not	5	O
yet	9	O
fully	9	O
understood	5	O
.	9	O

To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
report	5	O
of	5	O
a	5	O
pseudo	5	O
-	7	O
allergy	9	B-Disease
caused	9	O
by	9	O
paramethasone	_	B-Chemical
.	9	O

Study	5	O
of	5	O
the	5	O
role	9	O
of	5	O
vitamin	0	B-Chemical
B12	9	I-Chemical
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
supplementation	0	O
in	5	O
preventing	9	O
hematologic	5	O
toxicity	9	B-Disease
of	5	O
zidovudine	5	B-Chemical
.	9	O

A	9	O
prospective	5	O
,	9	O
randomized	5	O
study	9	O
was	9	O
conducted	9	O
to	5	O
evaluate	9	O
the	5	O
role	9	O
of	5	O
vitamin	0	B-Chemical
B12	9	I-Chemical
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
supplementation	0	O
in	5	O
preventing	9	O
zidovudine	5	B-Chemical
(	9	O
ZDV	5	B-Chemical
)	9	O
-	7	O
induced	3	O
bone	5	B-Disease
marrow	3	I-Disease
suppression	9	I-Disease
.	9	O

Seventy	5	O
-	7	O
five	9	O
human	3	B-Disease
immunodeficiency	9	I-Disease
virus	9	I-Disease
(	9	I-Disease
HIV	5	I-Disease
)	9	I-Disease
-	7	I-Disease
infected	3	I-Disease
patients	5	O
with	5	O
CD4	3	O
+	9	O
cell	3	O
counts	9	O
<	0	O
500	0	O
/	9	O
mm3	9	O
were	9	O
randomized	5	O
to	5	O
receive	5	O
either	9	O
ZDV	5	B-Chemical
(	9	O
500	0	O
mg	0	O
daily	5	O
)	9	O
alone	9	O
(	9	O
group	9	O
I	9	O
,	9	O
n	9	O
=	7	O
38	7	O
)	9	O
or	5	O
in	5	O
combination	9	O
with	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
(	9	O
15	9	O
mg	0	O
daily	5	O
)	9	O
and	5	O
intramascular	0	O
vitamin	0	B-Chemical
B12	9	I-Chemical
(	9	O
1000	9	O
micrograms	0	O
monthly	5	O
)	9	O
(	9	O
group	9	O
II	9	O
,	9	O
n	9	O
=	7	O
37	9	O
)	9	O
.	9	O

Finally	9	O
,	9	O
15	9	O
patients	5	O
were	9	O
excluded	9	O
from	9	O
the	5	O
study	9	O
(	9	O
noncompliance	5	O
14	7	O
,	9	O
death	9	B-Disease
1	9	O
)	9	O
;	9	O
thus	9	O
,	9	O
60	9	O
patients	5	O
(	9	O
31	7	O
in	5	O
group	9	O
I	9	O
and	5	O
29	7	O
in	5	O
group	9	O
II	9	O
)	9	O
were	9	O
eligible	5	O
for	5	O
analysis	9	O
.	9	O

No	9	O
significant	9	O
differences	9	O
between	5	O
groups	9	O
were	9	O
found	9	O
at	9	O
enrollment	5	O
.	9	O

During	5	O
the	5	O
study	9	O
,	9	O
vitamin	0	B-Chemical
B12	9	I-Chemical
and	5	O
folate	9	B-Chemical
levels	3	O
were	9	O
significantly	9	O
higher	9	O
in	5	O
group	9	O
II	9	O
patients	5	O
;	9	O
however	9	O
,	9	O
no	9	O
differences	9	O
in	5	O
hemoglobin	0	O
,	9	O
hematocrit	9	O
,	9	O
mean	5	O
corpuscular	0	O
volume	9	O
,	9	O
and	5	O
white	9	O
-	7	O
cell	3	O
,	9	O
neutrophil	3	O
and	5	O
platelet	9	O
counts	9	O
were	9	O
observed	9	O
between	5	O
groups	9	O
at	9	O
3	9	O
,	9	O
6	9	O
,	9	O
9	7	O
and	5	O
12	9	O
months	5	O
.	9	O

Severe	9	O
hematologic	5	O
toxicity	9	B-Disease
(	9	O
neutrophil	3	O
count	9	O
<	0	O
1000	9	O
/	9	O
mm3	9	O
and	5	O
/	9	O
or	5	O
hemoglobin	0	O
<	0	O
8	9	O
g	0	O
/	9	O
dl	7	O
)	9	O
occurred	9	O
in	5	O
4	9	O
patients	5	O
assigned	5	O
to	5	O
group	9	O
I	9	O
and	5	O
7	9	O
assigned	5	O
to	5	O
group	9	O
II	9	O
.	9	O

There	5	O
was	9	O
no	9	O
correlation	9	O
between	5	O
vitamin	0	B-Chemical
B12	9	I-Chemical
or	5	O
folate	9	B-Chemical
levels	3	O
and	5	O
development	9	O
of	5	O
myelosuppression	5	B-Disease
.	9	O

Vitamin	0	B-Chemical
B12	9	I-Chemical
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
supplementation	0	O
of	5	O
ZDV	5	B-Chemical
therapy	5	O
does	9	O
not	5	O
seem	5	O
useful	5	O
in	5	O
preventing	9	O
or	5	O
reducing	9	O
ZDV	5	B-Chemical
-	7	O
induced	3	O
myelotoxicity	5	B-Disease
in	5	O
the	5	O
overall	5	O
treated	3	O
population	5	O
,	9	O
although	9	O
a	5	O
beneficial	9	O
effect	9	O
in	5	O
certain	5	O
subgroups	9	O
of	5	O
patients	5	O
cannot	5	O
be	5	O
excluded	9	O
.	9	O

Safety	5	O
and	5	O
side	5	O
-	7	O
effects	9	O
of	5	O
alprazolam	0	B-Chemical
.	9	O

Controlled	5	O
study	9	O
in	5	O
agoraphobia	5	B-Disease
with	5	O
panic	5	B-Disease
disorder	5	I-Disease
.	9	O

BACKGROUND	2	O
:	9	O
The	5	O
widespread	5	O
use	5	O
of	5	O
benzodiazepines	5	B-Chemical
has	9	O
led	9	O
to	5	O
increasing	9	O
recognition	5	O
of	5	O
their	5	O
unwanted	5	O
effects	9	O
.	9	O

The	5	O
efficacy	9	O
of	5	O
alprazolam	0	B-Chemical
and	5	O
placebo	9	O
in	5	O
panic	5	B-Disease
disorder	5	I-Disease
with	5	O
agoraphobia	5	B-Disease
,	9	O
and	5	O
the	5	O
side	5	O
-	7	O
effect	9	O
and	5	O
adverse	5	O
effect	9	O
profiles	9	O
of	5	O
both	9	O
drug	5	O
groups	9	O
were	9	O
measured	9	O
.	9	O

METHOD	2	O
:	9	O
In	9	O
London	2	O
and	5	O
Toronto	2	O
154	7	O
patients	5	O
who	5	O
met	5	O
DSM	4	O
-	7	O
III	9	O
criteria	5	O
for	5	O
panic	5	B-Disease
disorder	5	I-Disease
with	5	O
agoraphobia	5	B-Disease
were	9	O
randomised	5	O
to	5	O
alprazolam	0	B-Chemical
or	5	O
placebo	9	O
.	9	O

Subjects	5	O
in	5	O
each	5	O
drug	5	O
group	9	O
also	9	O
received	9	O
either	9	O
exposure	9	O
or	5	O
relaxation	5	O
.	9	O

Treatment	9	O
was	9	O
from	9	O
weeks	9	O
0	7	O
to	5	O
8	9	O
and	5	O
was	9	O
then	9	O
tapered	5	O
from	9	O
weeks	9	O
8	9	O
to	5	O
16	9	O
.	9	O

RESULTS	9	O
:	9	O
Mean	9	O
alprazolam	0	B-Chemical
dose	9	O
was	9	O
5	9	O
mg	0	O
daily	5	O
.	9	O

Compared	9	O
with	5	O
placebo	9	O
subjects	5	O
,	9	O
alprazolam	0	B-Chemical
patients	5	O
developed	5	O
more	5	O
adverse	5	O
reactions	9	O
(	9	O
21	7	O
%	9	O
v	0	O
.	9	O
0	7	O
%	9	O
)	9	O
of	5	O
depression	5	B-Disease
,	9	O
enuresis	5	B-Disease
,	9	O
disinhibition	5	O
and	5	O
aggression	5	B-Disease
;	9	O
and	5	O
more	5	O
side	5	O
-	7	O
effects	9	O
,	9	O
particularly	5	O
sedation	5	O
,	9	O
irritability	5	B-Disease
,	9	O
impaired	9	B-Disease
memory	5	I-Disease
,	9	O
weight	9	B-Disease
loss	9	I-Disease
and	5	O
ataxia	5	B-Disease
.	9	O

Side	5	O
-	7	O
effects	9	O
tended	5	O
to	5	O
diminish	9	O
during	5	O
treatment	9	O
but	9	O
remained	9	O
significant	9	O
at	9	O
week	9	O
8	9	O
.	9	O

Despite	5	O
this	5	O
,	9	O
the	5	O
drop	9	O
-	7	O
out	9	O
rate	9	O
was	9	O
low	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Alprazolam	0	B-Chemical
caused	9	O
side	5	O
-	7	O
effects	9	O
and	5	O
adverse	5	O
effects	9	O
during	5	O
treatment	9	O
but	9	O
many	5	O
patients	5	O
were	9	O
willing	5	O
to	5	O
accept	5	O
these	5	O
.	9	O

Crescentic	7	O
fibrillary	3	O
glomerulonephritis	3	B-Disease
associated	9	O
with	5	O
intermittent	5	O
rifampin	0	B-Chemical
therapy	5	O
for	5	O
pulmonary	5	B-Disease
tuberculosis	9	I-Disease
.	9	O

This	5	O
case	5	O
study	9	O
reveals	9	O
an	5	O
unusual	9	O
finding	9	O
of	5	O
rapidly	9	O
proliferative	3	O
crescentic	5	O
glomerulonephritis	3	B-Disease
in	5	O
a	5	O
patient	5	O
treated	3	O
with	5	O
rifampin	0	B-Chemical
who	5	O
had	9	O
no	9	O
other	5	O
identifiable	5	O
causes	9	O
for	5	O
developing	5	O
this	5	O
disease	5	O
.	9	O

This	5	O
patient	5	O
underwent	5	O
a	5	O
10	9	O
-	7	O
month	5	O
regimen	5	O
of	5	O
rifampin	0	B-Chemical
and	5	O
isoniazid	0	B-Chemical
for	5	O
pulmonary	5	B-Disease
tuberculosis	9	I-Disease
and	5	O
was	9	O
discovered	9	O
to	5	O
have	5	O
developed	5	O
signs	5	O
of	5	O
severe	5	O
renal	9	B-Disease
failure	5	I-Disease
five	9	O
weeks	9	O
after	9	O
completion	5	O
of	5	O
therapy	5	O
.	9	O

Renal	9	O
biopsy	5	O
revealed	9	O
severe	5	O
glomerulonephritis	3	B-Disease
with	5	O
crescents	3	O
,	9	O
electron	0	O
dense	5	O
fibrillar	3	O
deposits	9	O
and	5	O
moderate	9	O
lymphocytic	3	O
interstitial	9	O
infiltrate	9	O
.	9	O

Other	9	O
possible	5	O
causes	9	O
of	5	O
rapidly	9	O
progressive	5	O
glomerulonephritis	3	B-Disease
were	9	O
investigated	9	O
and	5	O
ruled	9	O
out	9	O
.	9	O

This	5	O
report	5	O
documents	5	O
the	5	O
unusual	9	O
occurrence	5	O
of	5	O
rapidly	9	O
progressive	5	O
glomerulonephritis	3	B-Disease
with	5	O
crescents	3	O
and	5	O
fibrillar	3	O
glomerulonephritis	3	B-Disease
in	5	O
a	5	O
patient	5	O
treated	3	O
with	5	O
rifampin	0	B-Chemical
.	9	O

Acute	5	O
confusion	5	B-Disease
induced	3	O
by	9	O
a	5	O
high	9	O
-	7	O
dose	9	O
infusion	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
.	9	O

A	9	O
61	7	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
was	9	O
treated	3	O
with	5	O
combination	9	O
chemotherapy	5	O
incorporating	5	O
cisplatinum	0	B-Chemical
,	9	O
etoposide	3	B-Chemical
,	9	O
high	9	O
-	7	O
dose	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
2	9	O
,	9	O
250	0	O
mg	0	O
/	9	O
m2	7	O
/	9	O
24	9	O
hours	9	O
)	9	O
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
for	5	O
an	5	O
inoperable	5	O
gastric	9	B-Disease
adenocarcinoma	3	I-Disease
.	9	O

He	5	O
developed	5	O
acute	9	O
neurologic	5	O
symptoms	5	O
of	5	O
mental	5	O
confusion	5	B-Disease
,	9	O
disorientation	5	B-Disease
and	5	O
irritability	5	B-Disease
,	9	O
and	5	O
then	9	O
lapsed	5	O
into	9	O
a	5	O
deep	5	O
coma	5	B-Disease
,	9	O
lasting	5	O
for	5	O
approximately	9	O
40	9	O
hours	9	O
during	5	O
the	5	O
first	9	O
dose	9	O
(	9	O
day	9	O
2	9	O
)	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
infusion	0	O
.	9	O

This	5	O
complication	5	O
reappeared	9	O
on	5	O
day	9	O
25	9	O
during	5	O
the	5	O
second	9	O
dose	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
and	5	O
folinic	0	B-Chemical
acid	0	I-Chemical
,	9	O
which	5	O
were	9	O
then	9	O
the	5	O
only	9	O
drugs	5	O
given	5	O
.	9	O

Because	9	O
folinic	0	B-Chemical
acid	0	I-Chemical
was	9	O
unlikely	9	O
to	5	O
be	5	O
associated	9	O
with	5	O
this	5	O
condition	5	O
,	9	O
neurotoxicity	9	B-Disease
due	5	O
to	5	O
high	9	O
-	7	O
dose	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
was	9	O
highly	9	O
suspected	5	O
.	9	O

The	5	O
pathogenesis	9	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
neurotoxicity	9	B-Disease
may	5	O
be	5	O
due	5	O
to	5	O
a	5	O
Krebs	0	O
cycle	9	O
blockade	3	O
by	9	O
fluoroacetate	0	B-Chemical
and	5	O
fluorocitrate	3	B-Chemical
,	9	O
thiamine	0	B-Chemical
deficiency	9	O
,	9	O
or	5	O
dihydrouracil	0	B-Chemical
dehydrogenase	1	O
deficiency	9	O
.	9	O

High	9	O
-	7	O
dose	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
/	9	O
folinic	0	B-Chemical
acid	0	I-Chemical
infusion	0	O
therapy	5	O
has	9	O
recently	9	O
become	5	O
a	5	O
popular	5	O
regimen	5	O
for	5	O
various	9	O
cancers	9	B-Disease
.	9	O

It	5	O
is	5	O
necessary	5	O
that	5	O
both	9	O
oncologists	5	O
and	5	O
neurologists	5	O
be	5	O
fully	9	O
aware	5	O
of	5	O
this	5	O
unusual	9	O
complication	5	O
.	9	O

Effect	0	O
of	5	O
switching	5	O
carbamazepine	0	B-Chemical
to	5	O
oxcarbazepine	0	B-Chemical
on	5	O
the	5	O
plasma	9	O
levels	3	O
of	5	O
neuroleptics	5	O
.	9	O

A	9	O
case	5	O
report	5	O
.	9	O

Carbamazepine	0	B-Chemical
was	9	O
switched	9	O
to	5	O
its	9	O
10	9	O
-	7	O
keto	0	O
analogue	0	O
oxcarbazepine	0	B-Chemical
among	5	O
six	9	O
difficult	5	O
-	7	O
to	5	O
-	7	O
treat	5	O
schizophrenic	5	B-Disease
or	5	O
organic	0	B-Disease
psychotic	5	I-Disease
patients	5	O
using	9	O
concomitantly	9	O
haloperidol	5	B-Chemical
,	9	O
chlorpromazine	0	B-Chemical
or	5	O
clozapine	5	B-Chemical
.	9	O

This	5	O
change	9	O
resulted	9	O
within	9	O
2	9	O
-	7	O
4	9	O
weeks	9	O
in	5	O
the	5	O
50	0	O
-	7	O
200	0	O
%	9	O
increase	9	O
in	5	O
the	5	O
plasma	9	O
levels	3	O
of	5	O
these	5	O
neuroleptics	5	O
and	5	O
the	5	O
appearance	9	O
of	5	O
extrapyramidal	5	B-Disease
symptoms	5	I-Disease
.	9	O

None	9	O
of	5	O
the	5	O
patients	5	O
showed	9	O
any	5	O
clinical	5	O
deteriotation	9	O
during	5	O
the	5	O
following	9	O
3	9	O
-	7	O
6	9	O
months	5	O
.	9	O

The	5	O
results	9	O
of	5	O
this	5	O
case	5	O
report	5	O
support	5	O
the	5	O
idea	5	O
that	5	O
in	5	O
contrast	9	O
with	5	O
carbamazepine	0	B-Chemical
oxcarbazepine	0	B-Chemical
does	9	O
not	5	O
induce	3	O
the	5	O
hepatic	9	O
microsomal	0	O
enzyme	0	O
systems	5	O
regulating	9	O
the	5	O
inactivation	9	O
of	5	O
antipsychotic	5	O
drugs	5	O
.	9	O

Time	9	O
course	5	O
of	5	O
lipid	0	O
peroxidation	0	O
in	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
nephropathy	9	B-Disease
.	9	O

Reactive	0	O
oxygen	0	B-Chemical
species	4	O
have	5	O
been	9	O
implicated	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
acute	9	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
(	9	O
PAN	0	B-Chemical
)	9	O
-	7	O
induced	3	O
nephropathy	9	B-Disease
,	9	O
with	5	O
antioxidants	0	O
significantly	9	O
reducing	9	O
the	5	O
proteinuria	9	B-Disease
.	9	O

The	5	O
temporal	5	O
relationship	5	O
between	5	O
lipid	0	O
peroxidation	0	O
in	5	O
the	5	O
kidney	9	O
and	5	O
proteinuria	9	B-Disease
was	9	O
examined	9	O
in	5	O
this	5	O
study	9	O
.	9	O

Rats	9	O
were	9	O
treated	3	O
with	5	O
a	5	O
single	9	O
IV	9	O
injection	9	O
of	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
,	9	O
(	9	O
PAN	0	B-Chemical
,	9	O
7	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
)	9	O
and	5	O
24	9	O
hour	0	O
urine	9	O
samples	9	O
were	9	O
obtained	9	O
prior	9	O
to	5	O
sacrifice	9	O
on	5	O
days	9	O
3	9	O
,	9	O
5	9	O
,	9	O
7	9	O
,	9	O
10	9	O
,	9	O
17	7	O
,	9	O
27	7	O
,	9	O
41	7	O
(	9	O
N	9	O
=	7	O
5	9	O
-	7	O
10	9	O
per	9	O
group	9	O
)	9	O
.	9	O

The	5	O
kidneys	9	O
were	9	O
removed	9	O
,	9	O
flushed	9	O
with	5	O
ice	0	O
cold	9	O
TRIS	0	O
buffer	0	O
.	9	O

Kidney	9	O
cortices	5	O
from	9	O
each	5	O
animal	5	O
were	9	O
used	5	O
to	5	O
prepare	9	O
homogenates	9	O
.	9	O

Tissue	9	O
lipid	0	O
peroxidation	0	O
was	9	O
measured	9	O
in	5	O
whole	9	O
homogenates	9	O
as	5	O
well	9	O
as	5	O
in	5	O
lipid	0	O
extracts	0	O
from	9	O
homogenates	9	O
as	5	O
thiobarbituric	0	B-Chemical
acid	0	I-Chemical
reactive	9	O
substances	0	O
.	9	O

Proteinuria	7	B-Disease
was	9	O
evident	9	O
at	9	O
day	9	O
5	9	O
,	9	O
peaked	9	O
at	9	O
day	9	O
7	9	O
and	5	O
persisted	9	O
to	5	O
day	9	O
27	7	O
.	9	O

Lipid	0	O
peroxidation	0	O
in	5	O
homogenates	9	O
was	9	O
maximal	9	O
at	9	O
day	9	O
3	9	O
and	5	O
declined	9	O
rapidly	9	O
to	5	O
control	9	O
levels	3	O
by	9	O
day	9	O
17	7	O
.	9	O

This	5	O
study	9	O
supports	9	O
the	5	O
role	9	O
of	5	O
lipid	0	O
peroxidation	0	O
in	5	O
mediating	9	O
the	5	O
proteinuric	9	B-Disease
injury	9	I-Disease
in	5	O
PAN	0	B-Chemical
nephropathy	9	B-Disease
.	9	O

Composition	0	O
of	5	O
gall	4	B-Disease
bladder	9	I-Disease
stones	5	I-Disease
associated	9	O
with	5	O
octreotide	0	B-Chemical
:	9	O
response	9	O
to	5	O
oral	9	O
ursodeoxycholic	0	B-Chemical
acid	0	I-Chemical
.	9	O

Octreotide	0	B-Chemical
,	9	O
an	5	O
effective	5	O
treatment	9	O
for	5	O
acromegaly	5	B-Disease
,	9	O
induces	3	O
gall	4	B-Disease
bladder	9	I-Disease
stones	5	I-Disease
in	5	O
13	7	O
-	7	O
60	9	O
%	9	O
of	5	O
patients	5	O
.	9	O

Because	9	O
knowledge	5	O
of	5	O
stone	5	O
composition	9	O
is	5	O
essential	9	O
for	5	O
studies	9	O
of	5	O
their	5	O
pathogenesis	9	O
,	9	O
treatment	9	O
,	9	O
and	5	O
prevention	5	O
,	9	O
this	5	O
was	9	O
investigated	9	O
by	9	O
direct	9	O
and	5	O
indirect	5	O
methods	5	O
in	5	O
14	7	O
octreotide	0	B-Chemical
treated	3	O
acromegalic	5	B-Disease
patients	5	O
with	5	O
gall	4	B-Disease
stones	5	I-Disease
.	9	O

Chemical	0	O
analysis	9	O
of	5	O
gall	4	B-Disease
stones	5	I-Disease
retrieved	9	O
at	9	O
cholecystectomy	5	O
from	9	O
two	5	O
patients	5	O
,	9	O
showed	9	O
that	5	O
they	5	O
contained	9	O
71	7	O
%	9	O
and	5	O
87	7	O
%	9	O
cholesterol	0	B-Chemical
by	9	O
weight	9	O
.	9	O

In	9	O
the	5	O
remaining	9	O
12	9	O
patients	5	O
,	9	O
localised	9	O
computed	5	O
tomography	5	O
of	5	O
the	5	O
gall	4	O
bladder	9	O
showed	9	O
that	5	O
eight	9	O
had	9	O
stones	5	O
with	5	O
maximum	5	O
attenuation	9	O
scores	5	O
of	5	O
<	0	O
100	0	O
Hounsfield	5	O
units	9	O
(	9	O
values	5	O
of	5	O
<	0	O
100	0	O
HU	9	O
predict	5	O
cholesterol	0	B-Chemical
rich	9	O
,	9	O
dissolvable	0	O
stones	5	O
)	9	O
.	9	O

Gall	6	O
bladder	9	O
bile	0	O
was	9	O
obtained	9	O
by	9	O
ultrasound	5	O
guided	5	O
,	9	O
fine	5	O
needle	5	O
puncture	5	O
from	9	O
six	9	O
patients	5	O
.	9	O

All	9	O
six	9	O
patients	5	O
had	9	O
supersaturated	0	O
bile	0	O
(	9	O
mean	5	O
(	9	O
SEM	9	O
)	9	O
cholesterol	0	B-Chemical
saturation	9	O
index	5	O
of	5	O
1	9	O
.	9	O
19	7	O
(	9	O
0	7	O
.	9	O
08	7	O
)	9	O
(	9	O
range	9	O
1	9	O
.	9	O
01	7	O
-	7	O
1	9	O
.	9	O
53	7	O
)	9	O
)	9	O
and	5	O
all	5	O
had	9	O
abnormally	9	O
rapid	5	O
cholesterol	0	B-Chemical
microcrystal	0	O
nucleation	9	O
times	5	O
(	9	O
<	0	O
4	9	O
days	9	O
(	9	O
range	9	O
1	9	O
-	7	O
4	9	O
)	9	O
)	9	O
,	9	O
whilst	9	O
in	5	O
four	9	O
,	9	O
the	5	O
bile	0	O
contained	9	O
cholesterol	0	B-Chemical
microcrystals	0	O
immediately	9	O
after	9	O
sampling	5	O
.	9	O

Of	9	O
the	5	O
12	9	O
patients	5	O
considered	5	O
for	5	O
oral	9	O
ursodeoxycholic	0	B-Chemical
acid	0	I-Chemical
(	9	O
UDCA	0	B-Chemical
)	9	O
treatment	9	O
,	9	O
two	5	O
had	9	O
a	5	O
blocked	3	O
cystic	5	O
duct	5	O
and	5	O
were	9	O
not	5	O
started	5	O
on	5	O
UDCA	0	B-Chemical
while	9	O
one	5	O
was	9	O
lost	9	O
to	5	O
follow	5	O
up	5	O
.	9	O

After	9	O
one	5	O
year	5	O
of	5	O
treatment	9	O
,	9	O
five	9	O
of	5	O
the	5	O
remaining	9	O
nine	9	O
patients	5	O
showed	9	O
either	9	O
partial	9	O
(	9	O
n	9	O
=	7	O
3	9	O
)	9	O
or	5	O
complete	9	O
(	9	O
n	9	O
=	7	O
2	9	O
)	9	O
gall	4	B-Disease
stone	5	I-Disease
dissolution	0	O
,	9	O
suggesting	9	O
that	5	O
their	5	O
stones	5	O
were	9	O
cholesterol	0	B-Chemical
rich	9	O
.	9	O

This	5	O
corresponds	9	O
,	9	O
by	9	O
actuarial	5	O
(	9	O
life	5	O
table	5	O
)	9	O
analysis	9	O
,	9	O
to	5	O
a	5	O
combined	9	O
gall	4	B-Disease
stone	5	I-Disease
dissolution	0	O
rate	9	O
of	5	O
58	7	O
.	9	O
3	9	O
(	9	O
15	9	O
.	9	O
9	7	O
%	9	O
)	9	O
.	9	O

In	9	O
conclusion	9	O
,	9	O
octreotide	0	B-Chemical
induced	3	O
gall	4	B-Disease
stones	5	I-Disease
are	5	O
generally	5	O
small	9	O
,	9	O
multiple	5	O
,	9	O
and	5	O
cholesterol	0	B-Chemical
rich	9	O
although	9	O
,	9	O
in	5	O
common	5	O
with	5	O
spontaneous	5	O
gall	4	B-Disease
stone	5	I-Disease
disease	5	I-Disease
,	9	O
at	9	O
presentation	5	O
some	5	O
patients	5	O
will	5	O
have	5	O
a	5	O
blocked	3	O
cystic	5	O
duct	5	O
and	5	O
some	5	O
gall	4	B-Disease
stones	5	I-Disease
containing	0	O
calcium	0	B-Chemical
.	9	O

Erythema	2	B-Disease
multiforme	9	I-Disease
and	5	O
hypersensitivity	9	B-Disease
myocarditis	9	I-Disease
caused	9	O
by	9	O
ampicillin	0	B-Chemical
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
erythema	5	B-Disease
multiforme	9	I-Disease
and	5	O
hypersensitivity	9	B-Disease
myocarditis	9	I-Disease
caused	9	O
by	9	O
ampicillin	0	B-Chemical
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
13	7	O
-	7	O
year	5	O
-	7	O
old	5	O
boy	5	O
was	9	O
treated	3	O
with	5	O
ampicillin	0	B-Chemical
and	5	O
gentamicin	0	B-Chemical
because	5	O
of	5	O
suspected	5	O
septicemia	5	B-Disease
.	9	O

Medications	5	O
were	9	O
discontinued	5	O
when	5	O
erythema	5	B-Disease
multiforme	9	I-Disease
and	5	O
congestive	5	B-Disease
heart	5	I-Disease
failure	5	I-Disease
caused	9	O
by	9	O
myocarditis	9	B-Disease
occurred	9	O
.	9	O

The	5	O
patient	5	O
was	9	O
treated	3	O
with	5	O
methylprednisolone	0	B-Chemical
and	5	O
gradually	9	O
improved	5	O
.	9	O

Macrophage	3	O
-	7	O
migration	3	O
inhibition	3	O
(	9	O
MIF	3	O
)	9	O
test	5	O
with	5	O
ampicillin	0	B-Chemical
was	9	O
positive	9	O
.	9	O

DISCUSSION	9	O
:	9	O
After	9	O
most	9	O
infections	5	B-Disease
causing	9	O
erythema	5	B-Disease
multiforme	9	I-Disease
and	5	O
myocarditis	9	B-Disease
were	9	O
ruled	9	O
out	9	O
,	9	O
a	5	O
drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
allergic	9	I-Disease
reaction	9	I-Disease
was	9	O
suspected	5	O
.	9	O

Positive	7	O
MIF	3	O
test	5	O
for	5	O
ampicillin	0	B-Chemical
showed	9	O
sensitization	9	O
of	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
lymphocytes	3	O
to	5	O
ampicillin	0	B-Chemical
.	9	O

CONCLUSIONS	5	O
:	9	O
Hypersensitivity	9	B-Disease
myocarditis	9	I-Disease
is	5	O
a	5	O
rare	5	O
and	5	O
dangerous	5	O
manifestation	5	O
of	5	O
allergy	9	B-Disease
to	5	O
penicillins	0	B-Chemical
.	9	O

Clomipramine	7	B-Chemical
-	7	O
induced	3	O
sleep	5	B-Disease
disturbance	5	I-Disease
does	9	O
not	5	O
impair	9	O
its	9	O
prolactin	3	O
-	7	O
releasing	9	O
action	5	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
undertaken	5	O
to	5	O
examine	9	O
the	5	O
role	9	O
of	5	O
sleep	5	B-Disease
disturbance	5	I-Disease
,	9	O
induced	3	O
by	9	O
clomipramine	0	B-Chemical
administration	9	O
,	9	O
on	5	O
the	5	O
secretory	3	O
rate	9	O
of	5	O
prolactin	3	O
(	9	O
PRL	3	O
)	9	O
in	5	O
addition	9	O
to	5	O
the	5	O
direct	9	O
drug	5	O
effect	9	O
.	9	O

Two	9	O
groups	9	O
of	5	O
supine	5	O
subjects	5	O
were	9	O
studied	9	O
under	9	O
placebo	9	O
-	7	O
controlled	5	O
conditions	9	O
,	9	O
one	5	O
during	5	O
the	5	O
night	5	O
,	9	O
when	5	O
sleeping	5	O
(	9	O
n	9	O
=	7	O
7	9	O
)	9	O
and	5	O
the	5	O
other	5	O
at	9	O
daytime	5	O
,	9	O
when	5	O
awake	5	O
(	9	O
n	9	O
=	7	O
6	9	O
)	9	O
.	9	O

Each	5	O
subject	5	O
received	9	O
a	5	O
single	9	O
50	0	O
mg	0	O
dose	9	O
of	5	O
clomipramine	0	B-Chemical
given	5	O
orally	0	O
2	9	O
hours	9	O
before	9	O
blood	9	O
collection	5	O
.	9	O

Plasma	0	O
PRL	3	O
concentrations	0	O
were	9	O
analysed	9	O
at	9	O
10	9	O
min	0	O
intervals	5	O
and	5	O
underlying	5	O
secretory	3	O
rates	5	O
calculated	5	O
by	9	O
a	5	O
deconvolution	5	O
procedure	5	O
.	9	O

For	9	O
both	9	O
experiments	9	O
the	5	O
drug	5	O
intake	5	O
led	9	O
to	5	O
significant	9	O
increases	9	O
in	5	O
PRL	3	O
secretion	3	O
,	9	O
acting	9	O
preferentially	9	O
on	5	O
tonic	5	O
secretion	3	O
as	5	O
pulse	5	O
amplitude	5	O
and	5	O
frequency	5	O
did	9	O
not	5	O
differ	9	O
significantly	9	O
from	9	O
corresponding	9	O
control	9	O
values	5	O
.	9	O

During	5	O
the	5	O
night	5	O
clomipramine	0	B-Chemical
ingestion	9	O
altered	9	O
the	5	O
complete	9	O
sleep	5	O
architecture	5	O
in	5	O
that	5	O
it	5	O
suppressed	3	O
REM	5	O
sleep	5	O
and	5	O
the	5	O
sleep	5	O
cycles	9	O
and	5	O
induced	3	O
increased	9	O
wakefulness	5	O
.	9	O

As	9	O
the	5	O
relative	9	O
increase	9	O
in	5	O
PRL	3	O
secretion	3	O
expressed	3	O
as	5	O
a	5	O
percentage	9	O
of	5	O
the	5	O
mean	5	O
did	9	O
not	5	O
significantly	9	O
differ	9	O
between	5	O
the	5	O
night	5	O
and	5	O
day	9	O
time	5	O
studies	9	O
(	9	O
46	7	O
+	9	O
/	9	O
-	7	O
19	7	O
%	9	O
vs	7	O
34	7	O
+	9	O
/	9	O
-	7	O
10	9	O
%	9	O
)	9	O
,	9	O
it	5	O
can	5	O
be	5	O
concluded	9	O
that	5	O
the	5	O
observed	9	O
sleep	5	B-Disease
disturbance	5	I-Disease
did	9	O
not	5	O
interfere	9	O
with	5	O
the	5	O
drug	5	O
action	5	O
per	9	O
se	9	O
.	9	O

The	5	O
presence	9	O
of	5	O
REM	5	O
sleep	5	O
was	9	O
shown	9	O
not	5	O
to	5	O
be	5	O
a	5	O
determining	9	O
factor	9	O
either	9	O
for	5	O
secretory	3	O
pulse	5	O
amplitude	5	O
and	5	O
frequency	5	O
,	9	O
as	5	O
,	9	O
for	5	O
both	9	O
,	9	O
mean	5	O
nocturnal	5	O
values	5	O
were	9	O
similar	9	O
with	5	O
and	5	O
without	9	O
prior	9	O
clomipramine	0	B-Chemical
ingestion	9	O
.	9	O

Survey	5	O
of	5	O
complications	5	O
of	5	O
indocyanine	0	B-Chemical
green	9	I-Chemical
angiography	5	O
in	5	O
Japan	2	O
.	9	O

PURPOSE	2	O
:	9	O
We	9	O
evaluated	9	O
the	5	O
safety	5	O
of	5	O
indocyanine	0	B-Chemical
green	9	I-Chemical
for	5	O
use	5	O
in	5	O
fundus	5	O
angiography	5	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
sent	5	O
a	5	O
questionnaire	5	O
concerning	5	O
complications	5	O
of	5	O
indocyanine	0	B-Chemical
green	9	I-Chemical
to	5	O
32	7	O
institutions	5	O
in	5	O
Japan	2	O
,	9	O
which	5	O
were	9	O
selected	9	O
on	5	O
the	5	O
basis	5	O
of	5	O
the	5	O
client	5	O
list	5	O
from	9	O
the	5	O
Topcon	5	O
Company	2	O
,	9	O
which	5	O
manufactures	5	O
the	5	O
indocyanine	0	B-Chemical
green	9	I-Chemical
fundus	5	O
camera	5	O
.	9	O

RESULTS	9	O
:	9	O
Ophthalmologists	2	O
at	9	O
15	9	O
institutions	5	O
responded	9	O
,	9	O
reporting	5	O
a	5	O
total	9	O
of	5	O
3	9	O
,	9	O
774	7	O
indocyanine	0	B-Chemical
green	9	I-Chemical
angiograms	5	O
performed	9	O
on	5	O
2	9	O
,	9	O
820	7	O
patients	5	O
between	5	O
June	2	O
1984	2	O
and	5	O
September	2	O
1992	2	O
.	9	O

Before	9	O
angiography	5	O
,	9	O
intradermal	9	O
or	5	O
intravenous	0	O
indocyanine	0	B-Chemical
green	9	I-Chemical
testing	5	O
,	9	O
or	5	O
both	9	O
was	9	O
performed	9	O
at	9	O
13	7	O
of	5	O
15	9	O
institutions	5	O
.	9	O

For	9	O
three	9	O
patients	5	O
,	9	O
the	5	O
decision	5	O
was	9	O
made	5	O
not	5	O
to	5	O
proceed	9	O
with	5	O
angiography	5	O
after	9	O
positive	9	O
preangiographic	_	O
testing	5	O
.	9	O

The	5	O
dosage	9	O
of	5	O
indocyanine	0	B-Chemical
green	9	I-Chemical
used	5	O
for	5	O
angiography	5	O
varied	9	O
from	9	O
25	9	O
to	5	O
75	9	O
mg	0	O
,	9	O
depending	5	O
upon	9	O
the	5	O
institution	5	O
.	9	O

There	5	O
were	9	O
13	7	O
cases	5	O
of	5	O
adverse	5	O
reactions	9	O
(	9	O
0	7	O
.	9	O
34	7	O
%	9	O
)	9	O
,	9	O
ten	9	O
of	5	O
which	5	O
were	9	O
mild	9	O
reactions	9	O
such	5	O
as	5	O
nausea	5	B-Disease
,	9	O
exanthema	5	B-Disease
,	9	O
urtication	5	B-Disease
,	9	O
itchiness	5	B-Disease
,	9	O
and	5	O
urgency	5	O
to	5	O
defecate	5	O
,	9	O
and	5	O
did	9	O
not	5	O
require	5	O
treatment	9	O
.	9	O

Also	9	O
recorded	5	O
were	9	O
one	5	O
case	5	O
of	5	O
pain	5	B-Disease
of	5	O
the	5	O
vein	5	O
,	9	O
which	5	O
required	9	O
treatment	9	O
,	9	O
and	5	O
two	5	O
cases	5	O
of	5	O
hypotension	5	B-Disease
.	9	O

The	5	O
two	5	O
hypotensive	5	B-Disease
patients	5	O
required	9	O
treatment	9	O
for	5	O
shock	9	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
A	9	O
comparison	9	O
of	5	O
frequency	5	O
of	5	O
adverse	5	O
reactions	9	O
to	5	O
indocyanine	0	B-Chemical
green	9	I-Chemical
with	5	O
the	5	O
previously	9	O
reported	9	O
frequency	5	O
of	5	O
such	5	O
reactions	9	O
to	5	O
fluorescein	0	B-Chemical
sodium	0	I-Chemical
indicated	9	O
that	5	O
indocyanine	0	B-Chemical
green	9	I-Chemical
is	5	O
a	5	O
safe	5	O
as	5	O
fluorescein	0	B-Chemical
for	5	O
use	5	O
in	5	O
angiography	5	O
.	9	O

Angioedema	5	B-Disease
following	9	O
the	5	O
intravenous	0	O
administration	9	O
of	5	O
metoprolol	0	B-Chemical
.	9	O

A	9	O
72	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
was	9	O
admitted	5	O
to	5	O
the	5	O
hospital	5	O
with	5	O
"	5	O
flash	5	O
"	5	O
pulmonary	5	B-Disease
edema	5	I-Disease
,	9	O
preceded	9	O
by	9	O
chest	5	B-Disease
pain	5	I-Disease
,	9	O
requiring	5	O
intubation	5	O
.	9	O

Her	5	O
medical	5	O
history	5	O
included	5	O
coronary	5	B-Disease
artery	5	I-Disease
disease	5	I-Disease
with	5	O
previous	9	O
myocardial	9	B-Disease
infarctions	5	I-Disease
,	9	O
hypertension	5	B-Disease
,	9	O
and	5	O
diabetes	5	B-Disease
mellitus	9	I-Disease
.	9	O

A	9	O
history	5	O
of	5	O
angioedema	5	B-Disease
secondary	9	O
to	5	O
lisinopril	0	B-Chemical
therapy	5	O
was	9	O
elicited	9	O
.	9	O

Current	9	O
medications	5	O
did	9	O
not	5	O
include	5	O
angiotensin	9	B-Chemical
-	7	O
converting	9	O
enzyme	0	O
inhibitors	3	O
or	5	O
beta	9	O
-	7	O
blockers	9	O
.	9	O

She	5	O
had	9	O
no	9	O
previous	9	O
beta	9	O
-	7	O
blocking	3	O
drug	5	O
exposure	9	O
.	9	O

During	5	O
the	5	O
first	9	O
day	9	O
of	5	O
hospitalization	5	O
(	9	O
while	9	O
intubated	5	O
)	9	O
,	9	O
intravenous	0	O
metoprolol	0	B-Chemical
was	9	O
given	5	O
,	9	O
resulting	9	O
in	5	O
severe	5	O
angioedema	5	B-Disease
.	9	O

The	5	O
angioedema	5	B-Disease
resolved	9	O
after	9	O
therapy	5	O
with	5	O
intravenous	0	O
steroids	9	B-Chemical
and	5	O
diphenhydramine	0	B-Chemical
hydrochloride	0	O
.	9	O

Effect	0	O
of	5	O
coniine	5	B-Chemical
on	5	O
the	5	O
developing	5	O
chick	9	O
embryo	9	O
.	9	O

Coniine	_	B-Chemical
,	9	O
an	5	O
alkaloid	0	O
from	9	O
Conium	4	O
maculatum	4	O
(	9	O
poison	9	O
hemlock	4	O
)	9	O
,	9	O
has	9	O
been	9	O
shown	9	O
to	5	O
be	5	O
teratogenic	5	O
in	5	O
livestock	5	O
.	9	O

The	5	O
major	9	O
teratogenic	5	O
outcome	5	O
is	5	O
arthrogryposis	5	B-Disease
,	9	O
presumably	9	O
due	5	O
to	5	O
nicotinic	0	O
receptor	3	O
blockade	3	O
.	9	O

However	9	O
,	9	O
coniine	5	B-Chemical
has	9	O
failed	9	O
to	5	O
produce	9	O
arthrogryposis	5	B-Disease
in	5	O
rats	9	O
or	5	O
mice	3	O
and	5	O
is	5	O
only	9	O
weakly	9	O
teratogenic	5	O
in	5	O
rabbits	9	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
evaluate	9	O
and	5	O
compare	9	O
the	5	O
effects	9	O
of	5	O
coniine	5	B-Chemical
and	5	O
nicotine	0	B-Chemical
in	5	O
the	5	O
developing	5	O
chick	9	O
.	9	O

Concentrations	0	O
of	5	O
coniine	5	B-Chemical
and	5	O
nicotine	0	B-Chemical
sulfate	0	O
were	9	O
0	7	O
.	9	O
015	7	O
%	9	O
,	9	O
0	7	O
.	9	O
03	7	O
%	9	O
,	9	O
0	7	O
.	9	O
075	7	O
%	9	O
,	9	O
0	7	O
.	9	O
15	9	O
%	9	O
,	9	O
0	7	O
.	9	O
75	9	O
%	9	O
,	9	O
1	9	O
.	9	O
5	9	O
%	9	O
,	9	O
3	9	O
%	9	O
,	9	O
and	5	O
6	9	O
%	9	O
and	5	O
1	9	O
%	9	O
,	9	O
5	9	O
%	9	O
,	9	O
and	5	O
10	9	O
%	9	O
,	9	O
respectively	9	O
.	9	O

Both	9	O
compounds	0	O
caused	9	O
deformations	5	B-Disease
and	5	O
lethality	3	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

All	9	O
concentrations	0	O
of	5	O
nicotine	0	B-Chemical
sulfate	0	O
caused	9	O
some	5	O
lethality	3	O
but	9	O
a	5	O
no	9	O
effect	9	O
level	9	O
for	5	O
coniine	5	B-Chemical
lethality	3	O
was	9	O
0	7	O
.	9	O
75	9	O
%	9	O
.	9	O

The	5	O
deformations	5	B-Disease
caused	9	O
by	9	O
both	9	O
coniine	5	B-Chemical
and	5	O
nicotine	0	B-Chemical
sulfate	0	O
were	9	O
excessive	5	B-Disease
flexion	5	I-Disease
or	5	I-Disease
extension	9	I-Disease
of	5	I-Disease
one	5	I-Disease
or	5	I-Disease
more	5	I-Disease
toes	5	I-Disease
.	9	O

No	9	O
histopathological	9	O
alterations	9	O
or	5	O
differences	9	O
in	5	O
bone	5	O
formation	9	O
were	9	O
seen	9	O
in	5	O
the	5	O
limbs	5	O
or	5	O
toes	5	O
of	5	O
any	5	O
chicks	5	O
from	9	O
any	5	O
group	9	O
;	9	O
however	9	O
,	9	O
extensive	5	O
cranial	5	B-Disease
hemorrhage	5	I-Disease
occurred	9	O
in	5	O
all	5	O
nicotine	0	B-Chemical
sulfate	0	O
-	7	O
treated	3	O
chicks	5	O
.	9	O

There	5	O
was	9	O
a	5	O
statistically	9	O
significant	9	O
(	9	O
P	9	O
<	0	O
or	5	O
=	7	O
0	7	O
.	9	O
01	7	O
)	9	O
decrease	9	O
in	5	O
movement	5	O
in	5	O
coniine	5	B-Chemical
and	5	O
nicotine	0	B-Chemical
sulfate	0	O
treated	3	O
chicks	5	O
as	5	O
determined	9	O
by	9	O
ultrasound	5	O
.	9	O

Control	9	O
chicks	5	O
were	9	O
in	5	O
motion	5	O
an	5	O
average	5	O
of	5	O
33	7	O
.	9	O
67	7	O
%	9	O
of	5	O
the	5	O
time	5	O
,	9	O
while	9	O
coniine	5	B-Chemical
-	7	O
treated	3	O
chicks	5	O
were	9	O
only	9	O
moving	5	O
8	9	O
.	9	O
95	7	O
%	9	O
of	5	O
a	5	O
5	9	O
-	7	O
min	0	O
interval	5	O
,	9	O
and	5	O
no	9	O
movement	5	O
was	9	O
observed	9	O
for	5	O
nicotine	0	B-Chemical
sulfate	0	O
treated	3	O
chicks	5	O
.	9	O

In	9	O
summary	9	O
,	9	O
the	5	O
chick	9	O
embryo	9	O
provides	5	O
a	5	O
reliable	5	O
and	5	O
simple	5	O
experimental	5	O
animal	5	O
model	5	O
of	5	O
coniine	5	B-Chemical
-	7	O
induced	3	O
arthrogryposis	5	B-Disease
.	9	O

Data	5	O
from	9	O
this	5	O
model	5	O
support	5	O
a	5	O
mechanism	9	O
involving	5	O
nicotinic	0	O
receptor	3	O
blockade	3	O
with	5	O
subsequent	9	O
decreased	9	O
fetal	9	O
movement	5	O
.	9	O

Immediate	5	O
allergic	9	B-Disease
reactions	9	I-Disease
to	5	O
amoxicillin	0	B-Chemical
.	9	O

A	9	O
large	5	O
group	9	O
of	5	O
patients	5	O
with	5	O
suspected	5	O
allergic	9	B-Disease
reactions	9	I-Disease
to	5	O
beta	9	B-Chemical
-	7	I-Chemical
lactam	0	I-Chemical
antibiotics	5	O
was	9	O
evaluated	9	O
.	9	O

A	9	O
detailed	5	O
clinical	5	O
history	5	O
,	9	O
together	9	O
with	5	O
skin	5	O
tests	5	O
,	9	O
RAST	5	O
(	9	O
radioallergosorbent	0	O
test	5	O
)	9	O
,	9	O
and	5	O
controlled	5	O
challenge	9	O
tests	5	O
,	9	O
was	9	O
used	5	O
to	5	O
establish	5	O
whether	9	O
patients	5	O
allergic	9	B-Disease
to	5	O
beta	9	B-Chemical
-	7	I-Chemical
lactam	0	I-Chemical
antibiotics	5	O
had	9	O
selective	9	O
immediate	5	O
allergic	9	B-Disease
responses	5	O
to	5	O
amoxicillin	0	B-Chemical
(	9	O
AX	9	B-Chemical
)	9	O
or	5	O
were	9	O
cross	5	O
-	7	O
reacting	0	O
with	5	O
other	5	O
penicillin	0	B-Chemical
derivatives	0	O
.	9	O

Skin	9	O
tests	5	O
were	9	O
performed	9	O
with	5	O
benzylpenicilloyl	0	B-Chemical
-	7	I-Chemical
poly	0	I-Chemical
-	7	I-Chemical
L	0	I-Chemical
-	7	I-Chemical
lysine	0	I-Chemical
(	9	O
BPO	0	B-Chemical
-	7	I-Chemical
PLL	0	I-Chemical
)	9	O
,	9	O
benzylpenicilloate	_	B-Chemical
,	9	O
benzylpenicillin	0	B-Chemical
(	9	O
PG	9	B-Chemical
)	9	O
,	9	O
ampicillin	0	B-Chemical
(	9	O
AMP	0	B-Chemical
)	9	O
,	9	O
and	5	O
AX	9	B-Chemical
.	9	O

RAST	5	O
for	5	O
BPO	0	B-Chemical
-	7	I-Chemical
PLL	0	I-Chemical
and	5	O
AX	9	B-Chemical
-	7	O
PLL	0	O
was	9	O
done	9	O
.	9	O

When	9	O
both	9	O
skin	5	O
test	5	O
and	5	O
RAST	5	O
for	5	O
BPO	0	B-Chemical
were	9	O
negative	9	O
,	9	O
single	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
challenge	9	O
tests	5	O
were	9	O
done	9	O
to	5	O
ensure	5	O
tolerance	9	O
of	5	O
PG	9	B-Chemical
or	5	O
sensitivity	9	O
to	5	O
AX	9	B-Chemical
.	9	O

A	9	O
total	9	O
of	5	O
177	7	O
patients	5	O
were	9	O
diagnosed	5	O
as	5	O
allergic	9	B-Disease
to	5	O
beta	9	B-Chemical
-	7	I-Chemical
lactam	0	I-Chemical
antibiotics	5	O
.	9	O

We	9	O
selected	9	O
the	5	O
54	7	O
(	9	O
30	9	O
.	9	O
5	9	O
%	9	O
)	9	O
cases	5	O
of	5	O
immediate	5	O
AX	9	B-Chemical
allergy	9	B-Disease
with	5	O
good	5	O
tolerance	9	O
of	5	O
PG	9	B-Chemical
.	9	O

Anaphylaxis	5	B-Disease
was	9	O
seen	9	O
in	5	O
37	9	O
patients	5	O
(	9	O
69	7	O
%	9	O
)	9	O
,	9	O
the	5	O
other	5	O
17	7	O
(	9	O
31	7	O
%	9	O
)	9	O
having	5	O
urticaria	5	B-Disease
and	5	O
/	9	O
or	5	O
angioedema	5	B-Disease
.	9	O

All	9	O
the	5	O
patients	5	O
were	9	O
skin	5	O
test	5	O
negative	9	O
to	5	O
BPO	0	B-Chemical
;	9	O
49	7	O
of	5	O
51	7	O
(	9	O
96	9	O
%	9	O
)	9	O
were	9	O
also	9	O
negative	9	O
to	5	O
MDM	3	B-Disease
,	9	O
and	5	O
44	7	O
of	5	O
46	7	O
(	9	O
96	9	O
%	9	O
)	9	O
to	5	O
PG	9	B-Chemical
.	9	O

Skin	9	O
tests	5	O
with	5	O
AX	9	B-Chemical
were	9	O
positive	9	O
in	5	O
34	7	O
(	9	O
63	7	O
%	9	O
)	9	O
patients	5	O
.	9	O

RAST	5	O
was	9	O
positive	9	O
for	5	O
AX	9	B-Chemical
in	5	O
22	7	O
patients	5	O
(	9	O
41	7	O
%	9	O
)	9	O
and	5	O
to	5	O
BPO	0	B-Chemical
in	5	O
just	5	O
5	9	O
(	9	O
9	7	O
%	9	O
)	9	O
.	9	O

None	9	O
of	5	O
the	5	O
sera	3	O
with	5	O
negative	9	O
RAST	5	O
for	5	O
AX	9	B-Chemical
were	9	O
positive	9	O
to	5	O
BPO	0	B-Chemical
.	9	O

Challenge	9	O
tests	5	O
with	5	O
AX	9	B-Chemical
were	9	O
performed	9	O
in	5	O
23	7	O
subjects	5	O
(	9	O
43	7	O
%	9	O
)	9	O
to	5	O
establish	5	O
the	5	O
diagnosis	5	O
of	5	O
immediate	5	O
allergic	9	B-Disease
reaction	9	I-Disease
to	5	O
AX	9	B-Chemical
,	9	O
and	5	O
in	5	O
15	9	O
cases	5	O
(	9	O
28	7	O
%	9	O
)	9	O
both	9	O
skin	5	O
test	5	O
and	5	O
RAST	5	O
for	5	O
AX	9	B-Chemical
were	9	O
negative	9	O
.	9	O

PG	9	B-Chemical
was	9	O
well	9	O
tolerated	9	O
by	9	O
all	5	O
54	7	O
patients	5	O
.	9	O

We	9	O
describe	5	O
the	5	O
largest	5	O
group	9	O
of	5	O
AX	9	B-Chemical
-	7	O
allergic	9	B-Disease
patients	5	O
who	5	O
have	5	O
tolerated	9	O
PG	9	B-Chemical
reported	9	O
so	5	O
far	5	O
.	9	O

Diagnosis	9	O
of	5	O
these	5	O
patients	5	O
can	5	O
be	5	O
achieved	5	O
only	9	O
if	5	O
specific	9	O
AX	9	B-Chemical
-	7	O
related	9	O
reagents	0	O
are	5	O
employed	5	O
.	9	O

Further	9	O
studies	9	O
are	5	O
necessary	5	O
to	5	O
determine	9	O
the	5	O
exact	5	O
extent	9	O
of	5	O
this	5	O
problem	5	O
and	5	O
to	5	O
improve	5	O
the	5	O
efficacy	9	O
of	5	O
diagnostic	5	O
methods	5	O
.	9	O

Reversal	9	O
by	9	O
phenylephrine	0	B-Chemical
of	5	O
the	5	O
beneficial	9	O
effects	9	O
of	5	O
intravenous	0	O
nitroglycerin	5	B-Chemical
in	5	O
patients	5	O
with	5	O
acute	9	B-Disease
myocardial	9	I-Disease
infarction	5	I-Disease
.	9	O

Nitroglycerin	0	B-Chemical
has	9	O
been	9	O
shown	9	O
to	5	O
reduce	5	O
ST	9	O
-	7	O
segment	9	O
elevation	9	O
during	5	O
acute	9	B-Disease
myocardial	9	I-Disease
infarction	5	I-Disease
,	9	O
an	5	O
effect	9	O
potentiated	3	O
in	5	O
the	5	O
dog	5	O
by	9	O
agents	5	O
that	5	O
reverse	9	O
nitroglycerin	5	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

Our	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
determine	9	O
the	5	O
effects	9	O
of	5	O
combined	9	O
nitroglycerin	5	B-Chemical
and	5	O
phenylephrine	0	B-Chemical
therapy	5	O
.	9	O

Ten	9	O
patients	5	O
with	5	O
acute	9	O
transmural	5	O
myocardial	9	B-Disease
infarctions	5	I-Disease
received	9	O
intravenous	0	O
nitroglycerin	5	B-Chemical
,	9	O
sufficient	9	O
to	5	O
reduce	5	O
mean	5	O
arterial	5	O
pressure	5	O
from	9	O
107	9	O
+	9	O
/	9	O
-	7	O
6	9	O
to	5	O
85	9	O
+	9	O
/	9	O
-	7	O
6	9	O
mm	9	O
Hg	0	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
,	9	O
for	5	O
60	9	O
minutes	0	O
.	9	O

Left	9	O
ventricular	5	O
filling	5	O
pressure	5	O
decreased	9	O
from	9	O
19	7	O
+	9	O
/	9	O
-	7	O
2	9	O
to	5	O
11	7	O
+	9	O
/	9	O
-	7	O
2	9	O
mm	9	O
Hg	0	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

SigmaST	_	O
,	9	O
the	5	O
sum	5	O
of	5	O
ST	9	O
-	7	O
segment	9	O
elevations	9	O
in	5	O
16	9	O
precordial	5	O
leads	9	O
,	9	O
decreased	9	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
02	7	O
)	9	O
with	5	O
intravenous	0	O
nitroglycerin	5	B-Chemical
.	9	O

Subsequent	9	O
addition	9	O
of	5	O
phenylephrine	0	B-Chemical
infusion	0	O
,	9	O
sufficient	9	O
to	5	O
re	5	O
-	7	O
elevate	9	O
mean	5	O
arterial	5	O
pressure	5	O
to	5	O
106	9	O
+	9	O
/	9	O
-	7	O
4	9	O
mm	9	O
Hg	0	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
001	9	O
)	9	O
for	5	O
30	9	O
minutes	0	O
,	9	O
increased	9	O
left	5	O
ventricular	5	O
filling	5	O
pressure	5	O
to	5	O
17	7	O
+	9	O
/	9	O
-	7	O
2	9	O
mm	9	O
Hg	0	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
and	5	O
also	9	O
significantly	9	O
increased	9	O
sigmaST	_	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

Our	9	O
results	9	O
suggest	9	O
that	5	O
addition	9	O
of	5	O
phenylephrine	0	B-Chemical
to	5	O
nitroglycerin	5	B-Chemical
is	5	O
not	5	O
beneficial	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
patients	5	O
with	5	O
acute	9	B-Disease
myocardial	9	I-Disease
infarction	5	I-Disease
.	9	O

Acetazolamide	0	B-Chemical
-	7	O
induced	3	O
nephrolithiasis	5	B-Disease
:	9	O
implications	5	O
for	5	O
treatment	9	O
of	5	O
neuromuscular	5	B-Disease
disorders	5	I-Disease
.	9	O

Carbonic	7	O
anhydrase	0	O
inhibitors	3	O
can	5	O
cause	5	O
nephrolithiasis	5	B-Disease
.	9	O

We	9	O
studied	9	O
20	9	O
patients	5	O
receiving	9	O
long	5	O
-	7	O
term	5	O
carbonic	0	O
anhydrase	0	O
inhibitor	3	O
treatment	9	O
for	5	O
periodic	5	O
paralysis	5	B-Disease
and	5	O
myotonia	5	B-Disease
.	9	O

Three	9	O
patients	5	O
on	5	O
acetazolamide	0	B-Chemical
(	9	O
15	9	O
%	9	O
)	9	O
developed	5	O
renal	9	B-Disease
calculi	5	I-Disease
.	9	O

Extracorporeal	5	O
lithotripsy	5	O
successfully	5	O
removed	9	O
a	5	O
renal	9	B-Disease
calculus	5	I-Disease
in	5	O
one	5	O
patient	5	O
and	5	O
surgery	5	O
removed	9	O
a	5	O
staghorn	5	O
calculus	5	B-Disease
in	5	O
another	9	O
,	9	O
permitting	5	O
continued	9	O
treatment	9	O
.	9	O

Renal	9	O
function	9	O
remained	9	O
normal	9	O
in	5	O
all	5	O
patients	5	O
.	9	O

Nephrolithiasis	7	B-Disease
is	5	O
a	5	O
complication	5	O
of	5	O
acetazolamide	0	B-Chemical
but	9	O
does	9	O
not	5	O
preclude	5	O
its	9	O
use	5	O
.	9	O

Effects	9	O
of	5	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
on	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
toxicity	9	B-Disease
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
investigate	9	O
the	5	O
influence	5	O
of	5	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
on	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
toxicity	9	B-Disease
.	9	O

For	9	O
each	5	O
of	5	O
the	5	O
three	9	O
tested	9	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
(	9	O
diltiazem	0	B-Chemical
,	9	O
verapamil	0	B-Chemical
and	5	O
bepridil	0	B-Chemical
)	9	O
6	9	O
groups	9	O
of	5	O
mice	3	O
were	9	O
treated	3	O
by	9	O
two	5	O
different	9	O
doses	0	O
,	9	O
i	9	O
.	9	O
e	9	O
.	9	O
2	9	O
and	5	O
10	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
i	9	O
.	9	O
p	7	O
.	9	O
,	9	O
or	5	O
an	5	O
equal	9	O
volume	9	O
of	5	O
saline	0	O
for	5	O
the	5	O
control	9	O
group	9	O
(	9	O
n	9	O
=	7	O
20	9	O
)	9	O
;	9	O
15	9	O
minutes	0	O
later	9	O
,	9	O
all	5	O
the	5	O
animals	9	O
were	9	O
injected	3	O
with	5	O
a	5	O
single	9	O
50	0	O
mg	0	O
/	9	O
kg	0	O
/	9	O
i	9	O
.	9	O
p	7	O
.	9	O
dose	9	O
of	5	O
bupivacaine	0	B-Chemical
.	9	O

The	5	O
convulsant	0	O
activity	9	O
,	9	O
the	5	O
time	5	O
of	5	O
latency	5	O
to	5	O
convulse	5	O
and	5	O
the	5	O
mortality	5	O
rate	9	O
were	9	O
assessed	9	O
in	5	O
each	5	O
group	9	O
.	9	O

The	5	O
local	5	O
anesthetic	5	O
-	7	O
induced	3	O
mortality	5	O
was	9	O
significantly	9	O
increased	9	O
by	9	O
the	5	O
three	9	O
different	9	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
.	9	O

The	5	O
convulsant	0	O
activity	9	O
of	5	O
bupivacaine	0	B-Chemical
was	9	O
not	5	O
significantly	9	O
modified	9	O
but	9	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
decreased	9	O
the	5	O
time	5	O
of	5	O
latency	5	O
to	5	O
obtain	5	O
bupivacaine	0	B-Chemical
-	7	O
induced	3	O
convulsions	5	B-Disease
;	9	O
this	5	O
effect	9	O
was	9	O
less	5	O
pronounced	9	O
with	5	O
bepridil	0	B-Chemical
.	9	O

Epidural	5	O
blood	9	O
flow	5	O
during	5	O
prostaglandin	0	B-Chemical
E1	9	I-Chemical
or	5	O
trimethaphan	9	B-Chemical
induced	3	O
hypotension	5	B-Disease
.	9	O

To	9	O
evaluate	9	O
the	5	O
effect	9	O
of	5	O
prostaglandin	0	B-Chemical
E1	9	I-Chemical
(	9	O
PGE1	0	B-Chemical
)	9	O
or	5	O
trimethaphan	9	B-Chemical
(	9	O
TMP	0	B-Chemical
)	9	O
induced	3	O
hypotension	5	B-Disease
on	5	O
epidural	5	O
blood	9	O
flow	5	O
(	9	O
EBF	5	O
)	9	O
during	5	O
spinal	5	O
surgery	5	O
,	9	O
EBF	5	O
was	9	O
measured	9	O
using	9	O
the	5	O
heat	9	O
clearance	9	O
method	5	O
in	5	O
30	9	O
patients	5	O
who	5	O
underwent	5	O
postero	5	O
-	7	O
lateral	5	O
interbody	5	O
fusion	1	O
under	9	O
isoflurane	0	B-Chemical
anaesthesia	5	O
.	9	O

An	5	O
initial	9	O
dose	9	O
of	5	O
0	7	O
.	9	O
1	9	O
microgram	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
of	5	O
PGE1	0	B-Chemical
(	9	O
15	9	O
patients	5	O
)	9	O
,	9	O
or	5	O
10	9	O
micrograms	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
of	5	O
TMP	0	B-Chemical
(	9	O
15	9	O
patients	5	O
)	9	O
was	9	O
administered	9	O
intravenously	0	O
after	9	O
the	5	O
dural	5	O
opening	5	O
and	5	O
the	5	O
dose	9	O
was	9	O
adjusted	9	O
to	5	O
maintain	5	O
the	5	O
mean	5	O
arterial	5	O
blood	9	O
pressure	5	O
(	9	O
MAP	9	O
)	9	O
at	9	O
about	5	O
60	9	O
mmHg	7	O
.	9	O

The	5	O
hypotensive	5	B-Disease
drug	5	O
was	9	O
discontinued	5	O
at	9	O
the	5	O
completion	5	O
of	5	O
the	5	O
operative	5	O
procedure	5	O
.	9	O

After	9	O
starting	9	O
PGE1	0	B-Chemical
or	5	O
TMP	0	B-Chemical
,	9	O
MAP	9	O
and	5	O
rate	9	O
pressure	5	O
product	9	O
(	9	O
RPP	9	O
)	9	O
decreased	9	O
significantly	9	O
compared	9	O
with	5	O
preinfusion	0	O
values	5	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
01	7	O
)	9	O
,	9	O
and	5	O
the	5	O
degree	5	O
of	5	O
hypotension	5	B-Disease
due	5	O
to	5	O
PGE1	0	B-Chemical
remained	9	O
constant	9	O
until	5	O
60	9	O
min	0	O
after	9	O
its	9	O
discontinuation	5	O
.	9	O

Heart	2	O
rate	9	O
(	9	O
HR	9	O
)	9	O
did	9	O
not	5	O
change	9	O
in	5	O
either	9	O
group	9	O
.	9	O

EBFF	_	O
did	9	O
not	5	O
change	9	O
during	5	O
PGE1	0	B-Chemical
infusion	0	O
whereas	9	O
in	5	O
the	5	O
TMP	0	B-Chemical
group	9	O
,	9	O
EBF	5	O
decreased	9	O
significantly	9	O
at	9	O
30	9	O
and	5	O
60	9	O
min	0	O
after	9	O
the	5	O
start	9	O
of	5	O
TMP	0	B-Chemical
(	9	O
preinfusion	0	O
:	9	O
45	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
13	7	O
.	9	O
9	7	O
ml	0	O
/	9	O
100g	0	O
/	9	O
min	0	O
.	9	O
30	9	O
min	0	O
:	9	O
32	7	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
9	7	O
.	9	O
9	7	O
ml	0	O
/	9	O
100	0	O
g	0	O
/	9	O
min	0	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O
60	9	O
min	0	O
:	9	O
30	9	O
+	9	O
/	9	O
-	7	O
7	9	O
.	9	O
5	9	O
ml	0	O
/	9	O
100	0	O
g	0	O
/	9	O
min	0	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
)	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
PGE1	0	B-Chemical
may	5	O
be	5	O
preferable	5	O
to	5	O
TMP	0	B-Chemical
for	5	O
hypotensive	5	B-Disease
anaesthesia	5	O
in	5	O
spinal	5	O
surgery	5	O
because	5	O
TMP	0	B-Chemical
decreased	9	O
EBF	5	O
.	9	O

Dup	7	B-Chemical
753	7	I-Chemical
prevents	9	O
the	5	O
development	9	O
of	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
nephrosis	0	B-Disease
.	9	O

The	5	O
appearance	9	O
of	5	O
nephrotic	5	B-Disease
syndromes	5	I-Disease
such	5	O
as	5	O
proteinuria	9	B-Disease
,	9	O
hypoalbuminemia	5	B-Disease
,	9	O
hypercholesterolemia	9	B-Disease
and	5	O
increase	9	O
in	5	O
blood	9	B-Chemical
nitrogen	0	I-Chemical
urea	0	I-Chemical
,	9	O
induced	3	O
in	5	O
rats	9	O
by	9	O
injection	9	O
of	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
was	9	O
markedly	9	O
inhibited	3	O
by	9	O
oral	9	O
administration	9	O
of	5	O
Dup	7	B-Chemical
753	7	I-Chemical
(	9	O
losartan	0	B-Chemical
)	9	O
,	9	O
a	5	O
novel	9	O
angiotensin	9	B-Chemical
II	9	I-Chemical
receptor	3	O
antagonist	3	O
,	9	O
at	9	O
a	5	O
dose	9	O
of	5	O
1	9	O
or	5	O
2	9	O
mg	0	O
/	9	O
kg	0	O
per	9	O
day	9	O
.	9	O

The	5	O
results	9	O
suggest	9	O
a	5	O
possible	5	O
involvement	9	O
of	5	O
the	5	O
renin	9	O
-	7	O
angiotensin	9	B-Chemical
system	5	O
in	5	O
the	5	O
development	9	O
of	5	O
puromycin	3	B-Chemical
aminonucleoside	0	I-Chemical
-	7	O
induced	3	O
nephrosis	0	B-Disease
.	9	O

Neuroplasticity	5	O
of	5	O
the	5	O
adult	9	O
primate	9	O
auditory	5	O
cortex	5	O
following	9	O
cochlear	5	O
hearing	5	B-Disease
loss	9	I-Disease
.	9	O

Tonotopic	5	O
organization	5	O
is	5	O
an	5	O
essential	9	O
feature	5	O
of	5	O
the	5	O
primary	9	O
auditory	5	O
area	5	O
(	9	O
A1	9	O
)	9	O
of	5	O
primate	9	O
cortex	5	O
.	9	O

In	9	O
A1	9	O
of	5	O
macaque	9	O
monkeys	5	O
,	9	O
low	9	O
frequencies	9	O
are	5	O
represented	9	O
rostrolaterally	5	O
and	5	O
high	9	O
frequencies	9	O
are	5	O
represented	9	O
caudomedially	5	O
.	9	O

The	5	O
purpose	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
if	5	O
changes	9	O
occur	5	O
in	5	O
this	5	O
tonotopic	5	O
organization	5	O
following	9	O
cochlear	5	O
hearing	5	B-Disease
loss	9	I-Disease
.	9	O

Under	9	O
anesthesia	5	O
,	9	O
the	5	O
superior	5	O
temporal	5	O
gyrus	5	O
of	5	O
adult	9	O
macaque	9	O
monkeys	5	O
was	9	O
exposed	9	O
,	9	O
and	5	O
the	5	O
tonotopic	5	O
organization	5	O
of	5	O
A1	9	O
was	9	O
mapped	9	O
using	9	O
conventional	5	O
microelectrode	5	O
recording	5	O
techniques	5	O
.	9	O

Following	9	O
recovery	9	O
,	9	O
the	5	O
monkeys	5	O
were	9	O
selectively	3	O
deafened	5	O
for	5	O
high	9	O
frequencies	9	O
using	9	O
kanamycin	1	B-Chemical
and	5	O
furosemide	0	B-Chemical
.	9	O

The	5	O
actual	5	O
frequencies	9	O
deafened	5	O
were	9	O
determined	9	O
by	9	O
the	5	O
loss	9	O
of	5	O
tone	5	O
-	7	O
burst	5	O
elicited	9	O
auditory	5	O
brainstem	5	O
responses	5	O
.	9	O

Three	9	O
months	5	O
after	9	O
deafening	5	O
,	9	O
A1	9	O
was	9	O
remapped	5	O
.	9	O

Postmortem	5	O
cytoarchitectural	5	O
features	5	O
identifying	5	O
A1	9	O
were	9	O
correlated	9	O
with	5	O
the	5	O
electrophysiologic	5	O
data	5	O
.	9	O

The	5	O
results	9	O
indicate	9	O
that	5	O
the	5	O
deprived	9	O
area	5	O
of	5	O
A1	9	O
undergoes	9	O
extensive	5	O
reorganization	9	O
and	5	O
becomes	5	O
responsive	9	O
to	5	O
intact	9	O
cochlear	5	O
frequencies	9	O
.	9	O

The	5	O
region	9	O
of	5	O
cortex	5	O
that	5	O
represents	9	O
the	5	O
low	9	O
frequencies	9	O
was	9	O
not	5	O
obviously	9	O
affected	9	O
by	9	O
the	5	O
cochlear	5	O
hearing	5	B-Disease
loss	9	I-Disease
.	9	O

Sodium	0	B-Chemical
bicarbonate	0	I-Chemical
alleviates	9	O
penile	5	B-Disease
pain	5	I-Disease
induced	3	O
by	9	O
intracavernous	5	O
injections	9	O
for	5	O
erectile	5	B-Disease
dysfunction	9	I-Disease
.	9	O

In	9	O
an	5	O
attempt	5	O
to	5	O
determine	9	O
whether	9	O
penile	5	B-Disease
pain	5	I-Disease
associated	9	O
with	5	O
intracorporeal	5	O
injections	9	O
could	9	O
be	5	O
due	5	O
to	5	O
the	5	O
acidity	0	O
of	5	O
the	5	O
medication	5	O
,	9	O
we	5	O
performed	9	O
a	5	O
randomized	5	O
study	9	O
comparing	9	O
the	5	O
incidence	5	O
of	5	O
penile	5	B-Disease
pain	5	I-Disease
following	9	O
intracorporeal	5	O
injections	9	O
with	5	O
or	5	O
without	9	O
the	5	O
addition	9	O
of	5	O
sodium	0	B-Chemical
bicarbonate	0	I-Chemical
to	5	O
the	5	O
intracorporeal	5	O
medications	5	O
.	9	O

A	9	O
total	9	O
of	5	O
38	7	O
consecutive	5	O
patients	5	O
who	5	O
presented	5	O
to	5	O
our	5	O
clinic	5	O
with	5	O
impotence	5	B-Disease
received	9	O
0	7	O
.	9	O
2	9	O
ml	0	O
.	9	O
of	5	O
a	5	O
combination	9	O
of	5	O
3	9	O
drugs	5	O
:	9	O
6	9	O
mg	0	O
.	9	O
papaverine	0	B-Chemical
,	9	O
100	0	O
micrograms	0	O
.	9	O
phentolamine	0	B-Chemical
and	5	O
10	9	O
micrograms	0	O
.	9	O
prostaglandin	0	B-Chemical
E1	9	I-Chemical
with	5	O
(	9	O
pH	0	O
7	9	O
.	9	O
05	7	O
)	9	O
or	5	O
without	9	O
(	9	O
pH	0	O
4	9	O
.	9	O
17	7	O
)	9	O
the	5	O
addition	9	O
of	5	O
sodium	0	B-Chemical
bicarbonate	0	I-Chemical
(	9	O
0	7	O
.	9	O
03	7	O
mEq	0	O
.	9	O
)	9	O
.	9	O

Of	9	O
the	5	O
19	7	O
patients	5	O
without	9	O
sodium	0	B-Chemical
bicarbonate	0	I-Chemical
added	0	O
to	5	O
the	5	O
medication	5	O
11	7	O
(	9	O
58	7	O
%	9	O
)	9	O
complained	5	O
of	5	O
penile	5	B-Disease
pain	5	I-Disease
due	5	O
to	5	O
the	5	O
medication	5	O
,	9	O
while	9	O
only	9	O
1	9	O
of	5	O
the	5	O
19	7	O
men	5	O
(	9	O
5	9	O
%	9	O
)	9	O
who	5	O
received	9	O
sodium	0	B-Chemical
bicarbonate	0	I-Chemical
complained	5	O
of	5	O
penile	5	B-Disease
pain	5	I-Disease
.	9	O

From	5	O
these	5	O
data	5	O
we	5	O
conclude	9	O
that	5	O
the	5	O
penile	5	B-Disease
pain	5	I-Disease
following	9	O
intracorporeal	5	O
injections	9	O
is	5	O
most	9	O
likely	5	O
due	5	O
to	5	O
the	5	O
acidity	0	O
of	5	O
the	5	O
medication	5	O
,	9	O
which	5	O
can	5	O
be	5	O
overcome	5	O
by	9	O
elevating	9	O
the	5	O
pH	0	O
to	5	O
a	5	O
neutral	5	O
level	9	O
.	9	O

The	5	O
use	5	O
and	5	O
toxicity	9	B-Disease
of	5	O
didanosine	0	B-Chemical
(	9	O
ddI	0	B-Chemical
)	9	O
in	5	O
HIV	5	B-Disease
antibody	3	I-Disease
-	7	I-Disease
positive	9	I-Disease
individuals	5	O
intolerant	9	O
to	5	O
zidovudine	5	B-Chemical
(	9	O
AZT	0	B-Chemical
)	9	O

One	5	O
hundred	5	O
and	5	O
fifty	5	O
-	7	O
one	5	O
patients	5	O
intolerant	9	O
to	5	O
zidovudine	5	B-Chemical
(	9	O
AZT	0	B-Chemical
)	9	O
received	9	O
didanosine	0	B-Chemical
(	9	O
ddI	0	B-Chemical
)	9	O
to	5	O
a	5	O
maximum	5	O
dose	9	O
of	5	O
12	9	O
.	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
/	9	O
day	9	O
.	9	O

Patient	5	O
response	9	O
was	9	O
assessed	9	O
using	9	O
changes	9	O
in	5	O
CD4	3	O
+	9	O
lymphocyte	3	O
subset	9	O
count	9	O
,	9	O
HIV	5	O
p24	3	O
antigen	3	O
,	9	O
weight	9	O
,	9	O
and	5	O
quality	5	O
of	5	O
life	5	O
.	9	O

Seventy	5	O
patients	5	O
developed	5	O
major	9	O
opportunistic	5	B-Disease
infections	5	I-Disease
whilst	9	O
on	5	O
therapy	5	O
;	9	O
this	5	O
was	9	O
the	5	O
first	9	O
AIDS	5	B-Disease
diagnosis	5	O
in	5	O
17	7	O
.	9	O

Only	9	O
minor	9	O
changes	9	O
in	5	O
CD4	3	O
+	9	O
lymphocyte	3	O
subset	9	O
count	9	O
were	9	O
observed	9	O
in	5	O
AIDS	5	B-Disease
patients	5	O
,	9	O
although	9	O
a	5	O
more	5	O
significant	9	O
rise	9	O
occurred	9	O
in	5	O
those	5	O
with	5	O
earlier	9	O
stages	9	O
of	5	O
disease	5	O
.	9	O

Of	9	O
those	5	O
positive	9	O
for	5	O
p24	3	O
antigen	3	O
at	9	O
the	5	O
commencement	5	O
of	5	O
the	5	O
study	9	O
67	7	O
%	9	O
showed	9	O
a	5	O
positive	9	O
response	9	O
,	9	O
and	5	O
this	5	O
was	9	O
most	9	O
likely	5	O
in	5	O
those	5	O
with	5	O
CD4	3	O
+	9	O
lymphocyte	3	O
subset	9	O
counts	9	O
above	9	O
100	0	O
mm3	9	O
.	9	O

A	9	O
positive	9	O
weight	9	O
response	9	O
was	9	O
seen	9	O
in	5	O
16	9	O
%	9	O
of	5	O
patients	5	O
.	9	O

Most	5	O
patients	5	O
showed	9	O
improvement	5	O
in	5	O
individual	5	O
parameters	5	O
and	5	O
global	5	O
score	5	O
of	5	O
quality	5	O
of	5	O
life	5	O
.	9	O

Adverse	5	O
reactions	9	O
possibly	9	O
attributable	9	O
to	5	O
didanosine	0	B-Chemical
were	9	O
common	5	O
.	9	O

The	5	O
most	9	O
common	5	O
side	5	O
-	7	O
effect	9	O
was	9	O
diarrhoea	5	B-Disease
,	9	O
which	5	O
resulted	9	O
in	5	O
cessation	5	O
of	5	O
therapy	5	O
in	5	O
19	7	O
individuals	5	O
.	9	O

Peripheral	9	B-Disease
neuropathy	5	I-Disease
occurred	9	O
in	5	O
12	9	O
patients	5	O
and	5	O
pancreatitis	9	B-Disease
in	5	O
six	9	O
.	9	O

Thirteen	9	O
patients	5	O
developed	5	O
a	5	O
raised	9	O
serum	9	O
amylase	9	O
without	9	O
abdominal	5	B-Disease
pain	5	I-Disease
.	9	O

Seven	9	O
patients	5	O
developed	5	O
glucose	0	B-Disease
tolerance	9	I-Disease
curves	5	I-Disease
characteristic	9	O
of	5	O
diabetes	5	B-Disease
but	9	O
these	5	O
were	9	O
mild	9	O
,	9	O
did	9	O
not	5	O
require	5	O
treatment	9	O
and	5	O
returned	5	O
to	5	O
normal	9	O
on	5	O
ceasing	5	O
didanosine	0	B-Chemical
.	9	O

Immunohistochemical	3	O
studies	9	O
with	5	O
antibodies	3	O
to	5	O
neurofilament	3	O
proteins	1	O
on	5	O
axonal	3	B-Disease
damage	9	I-Disease
in	5	O
experimental	5	O
focal	5	O
lesions	5	O
in	5	O
rat	3	O
.	9	O

Immunohistochemistry	3	O
with	5	O
monoclonal	3	O
antibodies	3	O
against	9	O
neurofilament	3	O
(	9	O
NF	9	O
)	9	O
proteins	1	O
of	5	O
middle	9	O
and	5	O
high	9	O
molecular	9	O
weight	9	O
class	9	O
,	9	O
NF	9	O
-	7	O
M	9	O
and	5	O
NF	9	O
-	7	O
H	9	O
,	9	O
was	9	O
used	5	O
to	5	O
study	9	O
axonal	3	B-Disease
injury	9	I-Disease
in	5	O
the	5	O
borderzone	5	O
of	5	O
focal	5	O
lesions	5	O
in	5	O
rats	9	O
.	9	O

Focal	9	O
injury	9	B-Disease
in	5	I-Disease
the	5	I-Disease
cortex	5	I-Disease
was	9	O
produced	9	O
by	9	O
infusion	0	O
of	5	O
lactate	0	B-Chemical
at	9	O
acid	0	O
pH	0	O
or	5	O
by	9	O
stab	5	O
caused	9	O
by	9	O
needle	5	O
insertion	1	O
.	9	O

Infarcts	5	B-Disease
in	5	I-Disease
substantia	9	I-Disease
nigra	4	I-Disease
pars	4	I-Disease
reticulata	4	I-Disease
were	9	O
evoked	5	O
by	9	O
prolonged	9	O
pilocarpine	0	B-Chemical
-	7	O
induced	3	O
status	9	B-Disease
epilepticus	5	I-Disease
.	9	O

Immunohistochemical	3	O
staining	3	O
for	5	O
NFs	3	O
showed	9	O
characteristic	9	O
terminal	9	O
clubs	5	O
of	5	O
axons	5	O
in	5	O
the	5	O
borderzone	5	O
of	5	O
lesions	5	O
.	9	O

Differences	9	O
in	5	O
the	5	O
labelling	9	O
pattern	9	O
occurred	9	O
with	5	O
different	9	O
antibodies	3	O
which	5	O
apparently	9	O
depended	9	O
on	5	O
molecular	9	O
weight	9	O
class	9	O
of	5	O
NFs	3	O
and	5	O
phosphorylation	3	O
state	5	O
.	9	O

These	5	O
immunohistochemical	3	O
changes	9	O
of	5	O
NFs	3	O
can	5	O
serve	5	O
as	5	O
a	5	O
marker	3	O
for	5	O
axonal	3	B-Disease
damage	9	I-Disease
in	5	O
various	9	O
experimental	5	O
traumatic	5	B-Disease
or	5	O
ischemic	9	O
lesions	5	O
.	9	O

Pharmacokinetic	0	O
and	5	O
clinical	5	O
studies	9	O
in	5	O
patients	5	O
with	5	O
cimetidine	0	B-Chemical
-	7	O
associated	9	O
mental	5	O
confusion	5	B-Disease
.	9	O

15	9	O
cases	5	O
of	5	O
cimetidine	0	B-Chemical
-	7	O
associated	9	O
mental	5	O
confusion	5	B-Disease
have	5	O
been	9	O
reported	9	O
.	9	O

In	9	O
order	5	O
that	5	O
this	5	O
syndrome	5	O
might	9	O
be	5	O
investigated	9	O
changes	9	O
in	5	O
mental	5	O
status	9	O
(	9	O
M	9	O
.	9	O
S	9	O
.	9	O
)	9	O
were	9	O
correlated	9	O
with	5	O
serum	9	O
concentrations	0	O
and	5	O
renal	9	O
and	5	O
hepatic	9	O
function	9	O
in	5	O
36	9	O
patients	5	O
,	9	O
30	9	O
patients	5	O
had	9	O
no	9	O
M	9	O
.	9	O
S	9	O
.	9	O
change	9	O
on	5	O
cimetidine	0	B-Chemical
and	5	O
6	9	O
had	9	O
moderate	9	O
to	5	O
severe	5	O
changes	9	O
.	9	O

These	5	O
6	9	O
patients	5	O
had	9	O
both	9	O
renal	9	B-Disease
and	5	I-Disease
liver	9	I-Disease
dysfunction	9	I-Disease
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
,	9	O
as	5	O
well	9	O
as	5	O
cimetidine	0	B-Chemical
trough	9	O
-	7	O
concentrations	0	O
of	5	O
more	5	O
than	5	O
1	9	O
.	9	O
25	9	O
microgram	0	O
/	9	O
ml	0	O
(	9	O
P	9	O
less	5	O
than	5	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
severity	5	O
of	5	O
M	9	O
.	9	O
S	9	O
.	9	O
changes	9	O
increased	9	O
as	5	O
trough	9	O
-	7	O
concentrations	0	O
rose	9	O
,	9	O
5	9	O
patients	5	O
had	9	O
lumbar	5	O
puncture	5	O
.	9	O

The	5	O
cerebrospinal	9	O
fluid	5	O
:	9	O
serum	9	O
ratio	9	O
of	5	O
cimetidine	0	B-Chemical
concentrations	0	O
was	9	O
0	7	O
.	9	O
24	9	O
:	9	O
1	9	O
and	5	O
indicates	9	O
that	5	O
cimetidine	0	B-Chemical
passes	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
;	9	O
it	5	O
also	9	O
raises	9	O
the	5	O
possibility	9	O
that	5	O
M	9	O
.	9	O
S	9	O
.	9	O
changes	9	O
are	5	O
due	5	O
to	5	O
blockade	3	O
of	5	O
histamine	0	B-Chemical
H2	9	O
-	7	O
receptors	3	O
in	5	O
the	5	O
central	5	O
nervous	5	O
system	5	O
.	9	O

Patients	5	O
likely	5	O
to	5	O
have	5	O
both	9	O
raised	9	O
trough	9	O
-	7	O
concentrations	0	O
and	5	O
mental	5	O
confusion	5	B-Disease
are	5	O
those	5	O
with	5	O
both	9	O
severe	5	O
renal	9	B-Disease
and	5	I-Disease
hepatic	9	I-Disease
dysfunction	9	I-Disease
.	9	O

They	5	O
should	5	O
be	5	O
closely	9	O
observed	9	O
and	5	O
should	5	O
be	5	O
given	5	O
reduced	9	O
doses	0	O
of	5	O
cimetidine	0	B-Chemical
.	9	O

Prospective	5	O
study	9	O
of	5	O
the	5	O
long	5	O
-	7	O
term	5	O
effects	9	O
of	5	O
somatostatin	3	O
analog	0	O
(	9	O
octreotide	0	B-Chemical
)	9	O
on	5	O
gallbladder	5	O
function	9	O
and	5	O
gallstone	5	B-Disease
formation	9	O
in	5	O
Chinese	9	O
acromegalic	5	B-Disease
patients	5	O
.	9	O

This	5	O
article	6	O
reports	9	O
the	5	O
changes	9	O
in	5	O
gallbladder	5	O
function	9	O
examined	9	O
by	9	O
ultrasonography	5	O
in	5	O
20	9	O
Chinese	9	O
patients	5	O
with	5	O
active	9	O
acromegaly	5	B-Disease
treated	3	O
with	5	O
sc	9	O
injection	9	O
of	5	O
the	5	O
somatostatin	3	O
analog	0	O
octreotide	0	B-Chemical
in	5	O
dosages	9	O
of	5	O
300	0	O
-	7	O
1500	9	O
micrograms	0	O
/	9	O
day	9	O
for	5	O
a	5	O
mean	5	O
of	5	O
24	9	O
.	9	O
2	9	O
+	9	O
/	9	O
-	7	O
13	7	O
.	9	O
9	7	O
months	5	O
.	9	O

During	5	O
treatment	9	O
with	5	O
octreotide	0	B-Chemical
,	9	O
17	7	O
patients	5	O
developed	5	O
sludge	0	O
,	9	O
10	9	O
had	9	O
gallstones	5	B-Disease
,	9	O
and	5	O
1	9	O
developed	5	O
acute	9	B-Disease
cholecystitis	5	I-Disease
requiring	5	O
surgery	5	O
.	9	O

In	9	O
all	5	O
of	5	O
7	9	O
patients	5	O
examined	9	O
acutely	9	O
,	9	O
gallbladder	5	O
contractility	9	O
was	9	O
inhibited	3	O
after	9	O
a	5	O
single	9	O
100	0	O
-	7	O
micrograms	0	O
injection	9	O
.	9	O

In	9	O
8	9	O
patients	5	O
followed	9	O
for	5	O
24	9	O
weeks	9	O
,	9	O
gallbladder	5	O
contractility	9	O
remained	9	O
depressed	5	B-Disease
throughout	9	O
therapy	5	O
.	9	O

After	9	O
withdrawal	5	O
of	5	O
octreotide	0	B-Chemical
in	5	O
10	9	O
patients	5	O
without	9	O
gallstones	5	B-Disease
,	9	O
8	9	O
patients	5	O
assessed	9	O
had	9	O
return	5	O
of	5	O
normal	9	O
gallbladder	5	O
contractility	9	O
within	9	O
1	9	O
month	5	O
.	9	O

In	9	O
8	9	O
of	5	O
the	5	O
remaining	9	O
10	9	O
patients	5	O
who	5	O
developed	5	O
gallstones	5	B-Disease
during	5	O
treatment	9	O
,	9	O
gallbladder	5	O
contractility	9	O
normalized	9	O
in	5	O
5	9	O
patients	5	O
(	9	O
3	9	O
of	5	O
whom	5	O
has	9	O
disappearance	9	O
of	5	O
their	5	O
stones	5	O
within	9	O
3	9	O
weeks	9	O
)	9	O
,	9	O
and	5	O
remained	9	O
depressed	5	B-Disease
in	5	O
3	9	O
(	9	O
2	9	O
of	5	O
whom	5	O
had	9	O
stones	5	O
present	9	O
at	9	O
6	9	O
months	5	O
)	9	O
.	9	O

Our	9	O
results	9	O
suggest	9	O
that	5	O
the	5	O
suppression	9	O
of	5	O
gallbladder	5	O
contractility	9	O
is	5	O
the	5	O
cause	5	O
of	5	O
the	5	O
successive	5	O
formation	9	O
of	5	O
bile	0	O
sludge	0	O
,	9	O
gallstones	5	B-Disease
,	9	O
and	5	O
cholecystitis	5	B-Disease
during	5	O
octreotide	0	B-Chemical
therapy	5	O
in	5	O
Chinese	9	O
acromegalic	5	B-Disease
patients	5	O
.	9	O

It	5	O
is	5	O
therefore	5	O
very	5	O
important	9	O
to	5	O
follow	5	O
the	5	O
changes	9	O
of	5	O
gallbladder	5	O
function	9	O
during	5	O
long	5	O
-	7	O
term	5	O
octreotide	0	B-Chemical
therapy	5	O
of	5	O
acromegalic	5	B-Disease
patients	5	O
.	9	O

Increase	9	O
of	5	O
Parkinson	5	B-Disease
disability	5	I-Disease
after	9	O
fluoxetine	0	B-Chemical
medication	5	O
.	9	O

Depression	5	B-Disease
is	5	O
a	5	O
major	9	O
clinical	5	O
feature	5	O
of	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

We	9	O
report	5	O
the	5	O
increased	9	O
amount	9	O
of	5	O
motor	5	B-Disease
disability	5	I-Disease
in	5	O
four	9	O
patients	5	O
with	5	O
idiopathic	5	B-Disease
Parkinson	5	I-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
after	9	O
exposure	9	O
to	5	O
the	5	O
antidepressant	5	B-Chemical
fluoxetine	0	B-Chemical
.	9	O

The	5	O
possibility	9	O
of	5	O
a	5	O
clinically	5	O
relevant	5	O
dopamine	5	B-Chemical
-	7	O
antagonistic	9	O
capacity	9	O
of	5	O
fluoxetine	0	B-Chemical
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
patients	5	O
must	5	O
be	5	O
considered	5	O
.	9	O

Sinus	5	B-Disease
arrest	3	I-Disease
associated	9	O
with	5	O
continuous	5	O
-	7	O
infusion	0	O
cimetidine	0	B-Chemical
.	9	O

The	5	O
administration	9	O
of	5	O
intermittent	5	O
intravenous	0	O
infusions	9	O
of	5	O
cimetidine	0	B-Chemical
is	5	O
infrequently	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
bradyarrhythmias	5	B-Disease
.	9	O

A	9	O
40	9	O
-	7	O
year	5	O
-	7	O
old	5	O
man	5	O
with	5	O
leukemia	3	B-Disease
and	5	O
no	9	O
history	5	O
of	5	O
cardiac	5	B-Disease
disease	5	I-Disease
developed	5	O
recurrent	5	O
,	9	O
brief	5	O
episodes	5	O
of	5	O
apparent	9	O
sinus	5	B-Disease
arrest	3	I-Disease
while	9	O
receiving	9	O
continuous	5	O
-	7	O
infusion	0	O
cimetidine	0	B-Chemical
50	0	O
mg	0	O
/	9	O
hour	0	O
.	9	O

The	5	O
arrhythmias	5	B-Disease
were	9	O
temporally	5	O
related	9	O
to	5	O
cimetidine	0	B-Chemical
administration	9	O
,	9	O
disappeared	9	O
after	9	O
dechallenge	5	O
,	9	O
and	5	O
did	9	O
not	5	O
recur	5	O
during	5	O
ranitidine	0	B-Chemical
treatment	9	O
.	9	O

This	5	O
is	5	O
the	5	O
first	9	O
reported	9	O
case	5	O
of	5	O
sinus	5	B-Disease
arrest	3	I-Disease
associated	9	O
with	5	O
continuous	5	O
-	7	O
infusion	0	O
cimetidine	0	B-Chemical
.	9	O

Phase	9	O
II	9	O
trial	5	O
of	5	O
vinorelbine	0	B-Chemical
in	5	O
metastatic	3	O
squamous	5	B-Disease
cell	3	I-Disease
esophageal	5	I-Disease
carcinoma	3	I-Disease
.	9	O

European	5	O
Organization	2	O
for	5	O
Research	2	O
and	5	O
Treatment	9	O
of	5	O
Cancer	2	B-Disease
Gastrointestinal	9	O
Treat	9	O
Cancer	2	B-Disease
Cooperative	2	O
Group	9	O
.	9	O

PURPOSE	2	O
:	9	O
To	9	O
evaluate	9	O
the	5	O
response	9	O
rate	9	O
and	5	O
toxic	0	O
effects	9	O
of	5	O
vinorelbine	0	B-Chemical
(	9	O
VNB	4	B-Chemical
)	9	O
administered	9	O
as	5	O
a	5	O
single	9	O
agent	9	O
in	5	O
metastatic	3	O
squamous	5	B-Disease
cell	3	I-Disease
esophageal	5	I-Disease
carcinoma	3	I-Disease
.	9	O

PATIENTS	2	O
AND	2	O
METHODS	2	O
:	9	O
Forty	9	O
-	7	O
six	9	O
eligible	5	O
patients	5	O
with	5	O
measurable	9	O
lesions	5	O
were	9	O
included	5	O
and	5	O
were	9	O
stratified	5	O
according	9	O
to	5	O
previous	9	O
chemotherapy	5	O
.	9	O

Thirty	9	O
patients	5	O
without	9	O
prior	9	O
chemotherapy	5	O
and	5	O
16	9	O
pretreated	3	O
with	5	O
cisplatin	3	B-Chemical
-	7	O
based	5	O
chemotherapy	5	O
were	9	O
assessable	5	O
for	5	O
toxicity	9	B-Disease
and	5	O
response	9	O
.	9	O

VNB	4	B-Chemical
was	9	O
administered	9	O
weekly	5	O
as	5	O
a	5	O
25	9	O
-	7	O
mg	0	O
/	9	O
m2	7	O
short	5	O
intravenous	0	O
(	9	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
infusion	0	O
.	9	O

RESULTS	9	O
:	9	O
Six	9	O
of	5	O
30	9	O
patients	5	O
(	9	O
20	9	O
%	9	O
)	9	O
without	9	O
prior	9	O
chemotherapy	5	O
achieved	5	O
a	5	O
partial	9	O
response	9	O
(	9	O
PR	9	O
)	9	O
(	9	O
95	7	O
%	9	O
confidence	5	O
interval	5	O
[	9	O
CI	7	O
]	9	O
,	9	O
8	9	O
%	9	O
to	5	O
39	7	O
%	9	O
)	9	O
.	9	O

The	5	O
median	9	O
duration	5	O
of	5	O
response	9	O
was	9	O
21	7	O
weeks	9	O
(	9	O
range	9	O
,	9	O
17	7	O
to	5	O
28	7	O
)	9	O
.	9	O

One	5	O
of	5	O
16	9	O
patients	5	O
(	9	O
6	9	O
%	9	O
)	9	O
with	5	O
prior	9	O
chemotherapy	5	O
had	9	O
a	5	O
complete	9	O
response	9	O
(	9	O
CR	9	O
)	9	O
of	5	O
31	7	O
weeks	9	O
'	9	O
duration	5	O
(	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
0	7	O
%	9	O
to	5	O
30	9	O
%	9	O
)	9	O
.	9	O

The	5	O
overall	5	O
response	9	O
rate	9	O
(	9	O
World	5	O
Health	2	O
Organization	2	O
[	9	O
WHO	5	O
]	9	O
criteria	5	O
)	9	O
was	9	O
15	9	O
%	9	O
(	9	O
CR	9	O
,	9	O
2	9	O
%	9	O
;	9	O
PR	9	O
13	7	O
%	9	O
;	9	O
95	7	O
%	9	O
CI	7	O
,	9	O
6	9	O
%	9	O
to	5	O
29	7	O
%	9	O
)	9	O
.	9	O

The	5	O
median	9	O
dose	9	O
-	7	O
intensity	5	O
(	9	O
DI	9	O
)	9	O
was	9	O
20	9	O
mg	0	O
/	9	O
m2	7	O
/	9	O
wk	9	O
.	9	O

VNB	4	B-Chemical
was	9	O
well	9	O
tolerated	9	O
and	5	O
zero	5	O
instances	5	O
of	5	O
WHO	5	O
grade	9	O
4	9	O
nonhematologic	5	O
toxicity	9	B-Disease
occurred	9	O
.	9	O

At	9	O
least	9	O
one	5	O
episode	5	O
of	5	O
grade	9	O
3	9	O
or	5	O
4	9	O
granulocytopenia	5	B-Disease
was	9	O
seen	9	O
in	5	O
59	7	O
%	9	O
of	5	O
patients	5	O
.	9	O

A	9	O
grade	9	O
2	9	O
or	5	O
3	9	O
infection	9	B-Disease
occurred	9	O
in	5	O
16	9	O
%	9	O
of	5	O
patients	5	O
,	9	O
but	9	O
no	9	O
toxic	0	O
deaths	5	B-Disease
occurred	9	O
.	9	O

Other	9	O
side	5	O
effects	9	O
were	9	O
rare	5	O
,	9	O
and	5	O
peripheral	9	B-Disease
neurotoxicity	9	I-Disease
has	9	O
been	9	O
minor	9	O
(	9	O
26	7	O
%	9	O
grade	9	O
1	9	O
)	9	O
.	9	O

CONCLUSION	5	O
:	9	O
These	5	O
data	5	O
indicate	9	O
that	5	O
VNB	4	B-Chemical
is	5	O
an	5	O
active	9	O
agent	9	O
in	5	O
metastatic	3	O
esophageal	5	B-Disease
squamous	5	I-Disease
cell	3	I-Disease
carcinoma	3	I-Disease
.	9	O

Given	9	O
its	9	O
excellent	5	O
tolerance	9	O
profile	9	O
and	5	O
low	9	O
toxicity	9	B-Disease
,	9	O
further	9	O
evaluation	5	O
of	5	O
VNB	4	B-Chemical
in	5	O
combination	9	O
therapy	5	O
is	5	O
warranted	9	O
.	9	O

Evaluation	5	O
of	5	O
adverse	5	O
reactions	9	O
of	5	O
aponidine	_	B-Chemical
hydrochloride	0	I-Chemical
ophthalmic	5	O
solution	0	O
.	9	O

We	9	O
prospectively	5	O
evaluated	9	O
the	5	O
adverse	5	O
reactions	9	O
of	5	O
apraclonidine	0	B-Chemical
in	5	O
20	9	O
normal	9	O
volunteers	5	O
by	9	O
instilling	5	O
a	5	O
single	9	O
drop	9	O
of	5	O
1	9	O
%	9	O
apraclonidine	0	B-Chemical
in	5	O
their	5	O
right	5	O
eyes	5	O
.	9	O

Examinations	5	O
,	9	O
including	9	O
blood	9	O
pressure	5	O
,	9	O
pulse	5	O
rate	9	O
,	9	O
conjunctiva	5	O
and	5	O
cornea	5	O
,	9	O
intraocular	5	O
pressure	5	O
(	9	O
IOP	5	O
)	9	O
,	9	O
pupil	5	O
diameter	9	O
,	9	O
basal	3	O
tear	5	O
secretion	3	O
and	5	O
margin	5	O
reflex	5	O
distance	5	O
of	5	O
both	9	O
upper	9	O
and	5	O
lower	9	O
eyelids	5	O
,	9	O
were	9	O
performed	9	O
prior	9	O
to	5	O
entry	9	O
and	5	O
at	9	O
1	9	O
,	9	O
3	9	O
,	9	O
5	9	O
and	5	O
7	9	O
hours	9	O
after	9	O
instillation	0	O
.	9	O

The	5	O
ocular	5	B-Disease
hypotensive	5	I-Disease
effects	9	O
were	9	O
statistically	9	O
significant	9	O
for	5	O
apraclonidine	0	B-Chemical
-	7	O
treated	3	O
eyes	5	O
throughout	9	O
the	5	O
study	9	O
and	5	O
also	9	O
statistically	9	O
significant	9	O
for	5	O
contralateral	5	O
eyes	5	O
from	9	O
three	9	O
hours	9	O
after	9	O
topical	0	O
administration	9	O
of	5	O
1	9	O
%	9	O
apraclonidine	0	B-Chemical
.	9	O

Decreases	9	B-Disease
in	5	I-Disease
systolic	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
were	9	O
statistically	9	O
,	9	O
but	9	O
not	5	O
clinically	5	O
,	9	O
significant	9	O
.	9	O

No	9	O
significant	9	O
changes	9	O
in	5	O
diastolic	5	O
blood	9	O
pressure	5	O
,	9	O
pulse	5	O
rate	9	O
and	5	O
basal	3	O
tear	5	O
secretion	3	O
were	9	O
noted	9	O
.	9	O

Conjunctival	5	B-Disease
blanching	5	I-Disease
and	5	O
mydriasis	5	B-Disease
were	9	O
commonly	5	O
found	9	O
.	9	O

Upper	9	O
lid	5	O
retraction	5	O
was	9	O
frequently	5	O
noted	9	O
.	9	O

While	9	O
the	5	O
elevations	9	O
of	5	O
the	5	O
upper	9	O
lid	5	O
margin	5	O
in	5	O
most	9	O
subjects	5	O
were	9	O
not	5	O
more	5	O
than	5	O
2	9	O
mm	9	O
and	5	O
did	9	O
not	5	O
cause	5	O
noticeable	9	O
change	9	O
in	5	O
appearance	9	O
,	9	O
one	5	O
subject	5	O
suffered	5	O
from	9	O
mechanical	5	O
entropion	5	B-Disease
and	5	O
marked	9	O
corneal	5	B-Disease
abrasion	5	I-Disease
3	9	O
hours	9	O
after	9	O
instillation	0	O
of	5	O
the	5	O
medication	5	O
.	9	O

This	5	O
may	5	O
well	9	O
be	5	O
a	5	O
particularly	5	O
notable	9	O
finding	9	O
in	5	O
Asian	4	O
people	5	O
.	9	O

Thiopentone	0	B-Chemical
pretreatment	0	O
for	5	O
propofol	0	B-Chemical
injection	9	O
pain	5	B-Disease
in	5	O
ambulatory	5	O
patients	5	O
.	9	O

This	5	O
study	9	O
investigated	9	O
propofol	0	B-Chemical
injection	9	O
pain	5	B-Disease
in	5	O
patients	5	O
undergoing	9	O
ambulatory	5	O
anaesthesia	5	O
.	9	O

In	9	O
a	5	O
randomized	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
trial	5	O
,	9	O
90	9	O
women	5	O
were	9	O
allocated	5	O
to	5	O
receive	5	O
one	5	O
of	5	O
three	9	O
treatments	9	O
prior	9	O
to	5	O
induction	3	O
of	5	O
anaesthesia	5	O
with	5	O
propofol	0	B-Chemical
.	9	O

Patients	5	O
in	5	O
Group	9	O
C	9	O
received	9	O
2	9	O
ml	0	O
normal	9	O
saline	0	O
,	9	O
Group	9	O
L	0	O
,	9	O
2	9	O
ml	0	O
,	9	O
lidocaine	0	B-Chemical
2	9	O
%	9	O
(	9	O
40	9	O
mg	0	O
)	9	O
and	5	O
Group	9	O
T	3	O
,	9	O
2	9	O
ml	0	O
thiopentone	0	B-Chemical
2	9	O
.	9	O
5	9	O
%	9	O
(	9	O
50	0	O
mg	0	O
)	9	O
.	9	O

Venous	5	O
discomfort	5	O
was	9	O
assessed	9	O
with	5	O
a	5	O
visual	5	O
analogue	0	O
scale	5	O
(	9	O
VAS	5	O
)	9	O
5	9	O
-	7	O
15	9	O
sec	9	O
after	9	O
commencing	5	O
propofol	0	B-Chemical
administration	9	O
using	9	O
an	5	O
infusion	0	O
pump	0	O
(	9	O
rate	9	O
1000	9	O
micrograms	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
min	0	O
-	7	O
1	9	O
)	9	O
.	9	O

Loss	9	B-Disease
of	5	I-Disease
consciousness	5	I-Disease
occurred	9	O
in	5	O
60	9	O
-	7	O
90	9	O
sec	9	O
.	9	O

Visual	5	O
analogue	0	O
scores	5	O
(	9	O
mean	5	O
+	9	O
/	9	O
-	7	O
SD	7	O
)	9	O
during	5	O
induction	3	O
were	9	O
lower	9	O
in	5	O
Groups	9	O
L	0	O
(	9	O
3	9	O
.	9	O
3	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
5	9	O
)	9	O
and	5	O
T	3	O
(	9	O
4	9	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
7	9	O
)	9	O
than	5	O
in	5	O
Group	9	O
C	9	O
(	9	O
5	9	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
2	9	O
.	9	O
3	9	O
)	9	O
;	9	O
P	9	O
=	7	O
0	7	O
.	9	O
0031	7	O
.	9	O

The	5	O
incidence	5	O
of	5	O
venous	5	O
discomfort	5	O
was	9	O
lower	9	O
in	5	O
Group	9	O
L	0	O
(	9	O
76	7	O
.	9	O
6	9	O
%	9	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
than	5	O
in	5	O
Group	9	O
C	9	O
(	9	O
100	0	O
%	9	O
)	9	O
but	9	O
not	5	O
different	9	O
from	9	O
Group	9	O
T	3	O
(	9	O
90	9	O
%	9	O
)	9	O
.	9	O

The	5	O
VAS	5	O
scores	5	O
for	5	O
recall	5	O
of	5	O
pain	5	B-Disease
in	5	O
the	5	O
recovery	9	O
room	9	O
were	9	O
correlated	9	O
with	5	O
the	5	O
VAS	5	O
scores	5	O
during	5	O
induction	3	O
(	9	O
r	9	O
=	7	O
0	7	O
.	9	O
7045	7	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

Recovery	9	O
room	9	O
discharge	5	O
times	5	O
were	9	O
similar	9	O
:	9	O
C	9	O
(	9	O
75	9	O
.	9	O
9	7	O
+	9	O
/	9	O
-	7	O
19	7	O
.	9	O
4	9	O
min	0	O
)	9	O
;	9	O
L	0	O
73	7	O
.	9	O
6	9	O
+	9	O
/	9	O
-	7	O
21	7	O
.	9	O
6	9	O
min	0	O
)	9	O
;	9	O
T	3	O
(	9	O
77	7	O
.	9	O
1	9	O
+	9	O
/	9	O
-	7	O
18	7	O
.	9	O
9	7	O
min	0	O
)	9	O
.	9	O

Assessing	5	O
their	5	O
overall	5	O
satisfaction	5	O
,	9	O
89	7	O
.	9	O
7	9	O
%	9	O
would	5	O
choose	5	O
propofol	0	B-Chemical
anaesthesia	5	O
again	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
lidocaine	0	B-Chemical
reduces	9	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
propofol	0	B-Chemical
injection	9	O
pain	5	B-Disease
in	5	O
ambulatory	5	O
patients	5	O
whereas	9	O
thiopentone	0	B-Chemical
only	9	O
reduces	9	O
its	9	O
severity	5	O
.	9	O

Persistent	9	O
paralysis	5	B-Disease
after	9	O
prolonged	9	O
use	5	O
of	5	O
atracurium	0	B-Chemical
in	5	O
the	5	O
absence	3	O
of	5	O
corticosteroids	5	O
.	9	O

Neuromuscular	2	O
blocking	3	O
agents	5	O
(	9	O
NMBAs	5	O
)	9	O
are	5	O
often	5	O
used	5	O
for	5	O
patients	5	O
requiring	5	O
prolonged	9	O
mechanical	5	O
ventilation	5	O
.	9	O

Reports	5	O
of	5	O
persistent	5	O
paralysis	5	B-Disease
after	9	O
the	5	O
discontinuance	5	O
of	5	O
these	5	O
drugs	5	O
have	5	O
most	9	O
often	5	O
involved	9	O
aminosteroid	0	O
-	7	O
based	5	O
NMBAs	5	O
such	5	O
as	5	O
vecuronium	0	B-Chemical
bromide	0	I-Chemical
,	9	O
especially	5	O
when	5	O
used	5	O
in	5	O
conjunction	9	O
with	5	O
corticosteroids	5	O
.	9	O

Atracurium	0	B-Chemical
besylate	0	I-Chemical
,	9	O
a	5	O
short	5	O
-	7	O
acting	9	O
benzylisoquinolinium	5	B-Chemical
NMBA	0	O
that	5	O
is	5	O
eliminated	9	O
independently	9	O
of	5	O
renal	9	O
or	5	O
hepatic	9	O
function	9	O
,	9	O
has	9	O
also	9	O
been	9	O
associated	9	O
with	5	O
persistent	5	O
paralysis	5	B-Disease
,	9	O
but	9	O
only	9	O
when	5	O
used	5	O
with	5	O
corticosteroids	5	O
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
atracurium	0	B-Chemical
-	7	O
related	9	O
paralysis	5	B-Disease
persisting	9	O
for	5	O
approximately	9	O
50	0	O
hours	9	O
in	5	O
a	5	O
patient	5	O
who	5	O
was	9	O
not	5	O
treated	3	O
with	5	O
corticosteroids	5	O
.	9	O

A	9	O
phase	5	O
I	9	O
/	9	O
II	9	O
study	9	O
of	5	O
paclitaxel	0	B-Chemical
plus	9	O
cisplatin	3	B-Chemical
as	5	O
first	9	O
-	7	O
line	9	O
therapy	5	O
for	5	O
head	5	B-Disease
and	5	I-Disease
neck	5	I-Disease
cancers	9	I-Disease
:	9	O
preliminary	9	O
results	9	O
.	9	O

Improved	9	O
outcomes	5	O
among	5	O
patients	5	O
with	5	O
head	5	B-Disease
and	5	I-Disease
neck	5	I-Disease
carcinomas	3	I-Disease
require	5	O
investigations	9	O
of	5	O
new	5	O
drugs	5	O
for	5	O
induction	3	O
therapy	5	O
.	9	O

Preliminary	9	O
results	9	O
of	5	O
an	5	O
Eastern	4	O
Cooperative	2	O
Oncology	2	O
Group	9	O
study	9	O
of	5	O
single	9	O
-	7	O
agent	9	O
paclitaxel	0	B-Chemical
(	9	O
Taxol	0	B-Chemical
;	9	O
Bristol	2	O
-	7	O
Myers	6	O
Squibb	2	O
Company	2	O
,	9	O
Princeton	2	O
,	9	O
NJ	0	O
)	9	O
reported	9	O
a	5	O
37	9	O
%	9	O
response	9	O
rate	9	O
in	5	O
patients	5	O
with	5	O
head	5	B-Disease
and	5	I-Disease
neck	5	I-Disease
cancer	3	I-Disease
,	9	O
and	5	O
the	5	O
paclitaxel	0	B-Chemical
/	9	O
cisplatin	3	B-Chemical
combination	9	O
has	9	O
been	9	O
used	5	O
successfully	5	O
and	5	O
has	9	O
significantly	9	O
improved	5	O
median	9	O
response	9	O
duration	5	O
in	5	O
ovarian	9	B-Disease
cancer	3	I-Disease
patients	5	O
.	9	O

We	9	O
initiated	9	O
a	5	O
phase	5	O
I	9	O
/	9	O
II	9	O
trial	5	O
to	5	O
determine	9	O
the	5	O
response	9	O
and	5	O
toxicity	9	B-Disease
of	5	O
escalating	5	O
paclitaxel	0	B-Chemical
doses	0	O
combined	9	O
with	5	O
fixed	9	O
-	7	O
dose	9	O
cisplatin	3	B-Chemical
with	5	O
granulocyte	3	O
colony	9	O
-	7	O
stimulating	9	O
factor	9	O
support	5	O
in	5	O
patients	5	O
with	5	O
untreated	3	O
locally	5	O
advanced	5	O
inoperable	5	O
head	5	B-Disease
and	5	I-Disease
neck	5	I-Disease
carcinoma	3	I-Disease
.	9	O

To	9	O
date	5	O
,	9	O
23	7	O
men	5	O
with	5	O
a	5	O
median	9	O
age	5	O
of	5	O
50	0	O
years	5	O
and	5	O
good	5	O
performance	5	O
status	9	O
have	5	O
entered	5	O
the	5	O
trial	5	O
.	9	O

Primary	9	O
tumor	3	B-Disease
sites	9	O
were	9	O
oropharynx	5	O
,	9	O
10	9	O
patients	5	O
;	9	O
hypopharynx	5	O
,	9	O
four	9	O
;	9	O
larynx	5	O
,	9	O
two	5	O
;	9	O
oral	9	O
cavity	5	O
,	9	O
three	9	O
;	9	O
unknown	9	O
primary	9	O
,	9	O
two	5	O
;	9	O
and	5	O
nasal	5	O
cavity	5	O
and	5	O
parotid	5	O
gland	9	O
,	9	O
one	5	O
each	5	O
.	9	O

Of	9	O
20	9	O
patients	5	O
evaluable	9	O
for	5	O
toxicity	9	B-Disease
,	9	O
four	9	O
had	9	O
stage	9	O
III	9	O
and	5	O
16	9	O
had	9	O
stage	9	O
IV	9	O
disease	5	O
.	9	O

Treatment	9	O
,	9	O
given	5	O
every	5	O
21	7	O
days	9	O
for	5	O
a	5	O
maximum	5	O
of	5	O
three	9	O
cycles	9	O
,	9	O
consisted	5	O
of	5	O
paclitaxel	0	B-Chemical
by	9	O
3	9	O
-	7	O
hour	0	O
infusion	0	O
followed	9	O
the	5	O
next	9	O
day	9	O
by	9	O
a	5	O
fixed	9	O
dose	9	O
of	5	O
cisplatin	3	B-Chemical
(	9	O
75	9	O
mg	0	O
/	9	O
m2	7	O
)	9	O
.	9	O

The	5	O
dose	9	O
levels	3	O
incorporate	5	O
escalating	5	O
paclitaxel	0	B-Chemical
doses	0	O
,	9	O
and	5	O
intrapatient	5	O
escalations	5	O
within	9	O
a	5	O
given	5	O
dose	9	O
level	9	O
are	5	O
permitted	5	O
if	5	O
toxicity	9	B-Disease
permits	5	O
.	9	O

At	9	O
the	5	O
time	5	O
of	5	O
this	5	O
writing	5	O
,	9	O
dose	9	O
level	9	O
4	9	O
(	9	O
260	9	O
,	9	O
270	9	O
,	9	O
and	5	O
280	9	O
mg	0	O
/	9	O
m2	7	O
)	9	O
is	5	O
being	5	O
evaluated	9	O
;	9	O
three	9	O
patients	5	O
from	9	O
this	5	O
level	9	O
are	5	O
evaluable	9	O
.	9	O

With	5	O
paclitaxel	0	B-Chemical
doses	0	O
of	5	O
200	0	O
mg	0	O
/	9	O
m2	7	O
and	5	O
higher	9	O
,	9	O
granulocyte	3	O
colony	9	O
-	7	O
stimulating	9	O
factor	9	O
5	9	O
micrograms	0	O
/	9	O
kg	0	O
/	9	O
d	9	O
is	5	O
given	5	O
(	9	O
days	9	O
4	9	O
through	9	O
12	9	O
)	9	O
.	9	O

Of	9	O
18	7	O
patients	5	O
evaluable	9	O
for	5	O
response	9	O
,	9	O
seven	9	O
(	9	O
39	7	O
%	9	O
)	9	O
achieved	5	O
a	5	O
complete	9	O
response	9	O
and	5	O
six	9	O
(	9	O
33	7	O
%	9	O
)	9	O
achieved	5	O
a	5	O
partial	9	O
response	9	O
.	9	O

Three	9	O
patients	5	O
had	9	O
no	9	O
change	9	O
and	5	O
disease	5	O
progressed	9	O
in	5	O
two	5	O
.	9	O

The	5	O
overall	5	O
response	9	O
rate	9	O
is	5	O
72	9	O
%	9	O
.	9	O

Eleven	9	O
responding	5	O
patients	5	O
had	9	O
subsequent	9	O
surgery	5	O
/	9	O
radiotherapy	5	O
or	5	O
radical	0	O
radiotherapy	5	O
.	9	O

Two	9	O
pathologic	5	O
complete	9	O
responses	5	O
were	9	O
observed	9	O
in	5	O
patients	5	O
who	5	O
had	9	O
achieved	5	O
clinical	5	O
complete	9	O
responses	5	O
.	9	O

Alopecia	2	B-Disease
,	9	O
paresthesias	5	B-Disease
,	9	O
and	5	O
arthralgias	5	B-Disease
/	9	O
myalgias	5	B-Disease
have	5	O
occurred	9	O
frequently	5	O
,	9	O
but	9	O
with	5	O
one	5	O
exception	9	O
(	9	O
a	5	O
grade	9	O
3	9	O
myalgia	5	B-Disease
)	9	O
they	5	O
have	5	O
been	9	O
grade	9	O
1	9	O
or	5	O
2	9	O
.	9	O

No	9	O
dose	9	O
-	7	O
limiting	9	O
hematologic	5	O
toxicity	9	B-Disease
has	9	O
been	9	O
seen	9	O
.	9	O

Paclitaxel	0	B-Chemical
/	9	O
cisplatin	3	B-Chemical
is	5	O
an	5	O
effective	5	O
first	9	O
-	7	O
line	9	O
regimen	5	O
for	5	O
locoregionally	5	O
advanced	5	O
head	5	B-Disease
and	5	I-Disease
neck	5	I-Disease
cancer	3	I-Disease
and	5	O
continued	9	O
study	9	O
is	5	O
warranted	9	O
.	9	O

Results	9	O
thus	9	O
far	5	O
suggest	9	O
no	9	O
dose	9	O
-	7	O
response	9	O
effect	9	O
for	5	O
paclitaxel	0	B-Chemical
doses	0	O
above	9	O
200	0	O
mg	0	O
/	9	O
m2	7	O
.	9	O

Improvement	5	O
of	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
dyskinesia	5	B-Disease
by	9	O
propranolol	0	B-Chemical
in	5	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

Seven	9	O
patients	5	O
suffering	5	O
from	9	O
Parkinson	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
(	9	O
PD	9	B-Disease
)	9	O
with	5	O
severely	9	O
disabling	5	O
dyskinesia	5	B-Disease
received	9	O
low	9	O
-	7	O
dose	9	O
propranolol	0	B-Chemical
as	5	O
an	5	O
adjunct	5	O
to	5	O
the	5	O
currently	5	O
used	5	O
medical	5	O
treatment	9	O
.	9	O

There	5	O
was	9	O
a	5	O
significant	9	O
40	9	O
%	9	O
improvement	5	O
in	5	O
the	5	O
dyskinesia	5	B-Disease
score	5	O
without	9	O
increase	9	O
of	5	O
parkinsonian	5	B-Disease
motor	5	B-Disease
disability	5	I-Disease
.	9	O

Ballistic	5	O
and	5	O
choreic	5	O
dyskinesia	5	B-Disease
were	9	O
markedly	9	O
ameliorated	9	O
,	9	O
whereas	9	O
dystonia	5	B-Disease
was	9	O
not	5	O
.	9	O

This	5	O
study	9	O
suggests	9	O
that	5	O
administration	9	O
of	5	O
low	9	O
doses	0	O
of	5	O
beta	9	O
-	7	O
blockers	9	O
may	5	O
improve	5	O
levodopa	5	B-Chemical
-	7	O
induced	3	O
ballistic	5	O
and	5	O
choreic	5	O
dyskinesia	5	B-Disease
in	5	O
PD	9	B-Disease
.	9	O

Habitual	5	O
use	5	O
of	5	O
acetaminophen	0	B-Chemical
as	5	O
a	5	O
risk	5	O
factor	9	O
for	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
:	9	O
a	5	O
comparison	9	O
with	5	O
phenacetin	0	B-Chemical
.	9	O

Six	9	O
epidemiologic	5	O
studies	9	O
in	5	O
the	5	O
United	9	O
States	9	O
and	5	O
Europe	4	O
indicate	9	O
that	5	O
habitual	5	O
use	5	O
of	5	O
phenacetin	0	B-Chemical
is	5	O
associated	9	O
with	5	O
the	5	O
development	9	O
of	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
and	5	O
end	9	B-Disease
-	7	I-Disease
stage	9	I-Disease
renal	9	I-Disease
disease	5	I-Disease
(	9	O
ESRD	5	B-Disease
)	9	O
,	9	O
with	5	O
a	5	O
relative	9	O
risk	5	O
in	5	O
the	5	O
range	9	O
of	5	O
4	9	O
to	5	O
19	7	O
.	9	O

As	9	O
a	5	O
result	9	O
of	5	O
these	5	O
and	5	O
other	5	O
studies	9	O
,	9	O
phenacetin	0	B-Chemical
has	9	O
now	5	O
been	9	O
withdrawn	9	O
from	9	O
the	5	O
market	5	O
in	5	O
most	9	O
countries	5	O
.	9	O

However	9	O
,	9	O
three	9	O
case	5	O
control	9	O
studies	9	O
,	9	O
one	5	O
each	5	O
in	5	O
North	4	O
Carolina	2	O
,	9	O
northern	4	O
Maryland	2	O
,	9	O
and	5	O
West	4	O
Berlin	2	O
,	9	O
Germany	2	O
,	9	O
showed	9	O
that	5	O
habitual	5	O
use	5	O
of	5	O
acetaminophen	0	B-Chemical
is	5	O
also	9	O
associated	9	O
with	5	O
chronic	5	B-Disease
renal	9	I-Disease
failure	5	I-Disease
and	5	O
ESRD	5	B-Disease
,	9	O
with	5	O
a	5	O
relative	9	O
risk	5	O
in	5	O
the	5	O
range	9	O
of	5	O
2	9	O
to	5	O
4	9	O
.	9	O

These	5	O
studies	9	O
suggest	9	O
that	5	O
both	9	O
phenacetin	0	B-Chemical
and	5	O
acetaminophen	0	B-Chemical
may	5	O
contribute	9	O
to	5	O
the	5	O
burden	5	O
of	5	O
ESRD	5	B-Disease
,	9	O
with	5	O
the	5	O
risk	5	O
of	5	O
the	5	O
latter	9	O
being	5	O
somewhat	5	O
less	5	O
than	5	O
that	5	O
of	5	O
the	5	O
former	5	O
.	9	O

This	5	O
apparent	9	O
difference	9	O
in	5	O
risk	5	O
may	5	O
not	5	O
be	5	O
due	5	O
to	5	O
differences	9	O
in	5	O
nephrotoxic	5	B-Disease
potential	9	O
of	5	O
the	5	O
drugs	5	O
themselves	5	O
.	9	O

A	9	O
lower	9	O
relative	9	O
risk	5	O
would	5	O
be	5	O
expected	9	O
for	5	O
acetaminophen	0	B-Chemical
if	5	O
the	5	O
risk	5	O
of	5	O
both	9	O
drugs	5	O
in	5	O
combination	9	O
with	5	O
other	5	O
analgesics	5	O
was	9	O
higher	9	O
than	5	O
the	5	O
risk	5	O
of	5	O
either	9	O
agent	9	O
alone	9	O
.	9	O

Thus	9	O
,	9	O
acetaminophen	0	B-Chemical
has	9	O
been	9	O
used	5	O
both	9	O
as	5	O
a	5	O
single	9	O
agent	9	O
and	5	O
in	5	O
combination	9	O
with	5	O
other	5	O
analgesics	5	O
,	9	O
whereas	9	O
phenacetin	0	B-Chemical
was	9	O
available	5	O
only	9	O
in	5	O
combinations	9	O
.	9	O

The	5	O
possibility	9	O
that	5	O
habitual	5	O
use	5	O
of	5	O
acetaminophen	0	B-Chemical
alone	9	O
increases	9	O
the	5	O
risk	5	O
of	5	O
ESRD	5	B-Disease
has	9	O
not	5	O
been	9	O
clearly	9	O
demonstrated	9	O
,	9	O
but	9	O
cannot	5	O
be	5	O
dismissed	5	O
.	9	O

Acetaminophen	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
.	9	O

Through	5	O
30	9	O
years	5	O
of	5	O
widespread	5	O
use	5	O
,	9	O
acetaminophen	0	B-Chemical
has	9	O
been	9	O
shown	9	O
to	5	O
be	5	O
a	5	O
remarkably	9	O
safe	5	O
medication	5	O
in	5	O
therapeutic	5	O
dosages	9	O
.	9	O

The	5	O
potential	9	O
for	5	O
acetaminophen	0	B-Chemical
to	5	O
produce	9	O
cardiovascular	5	B-Disease
toxicities	5	I-Disease
is	5	O
very	5	O
low	9	O
.	9	O

However	9	O
,	9	O
acetaminophen	0	B-Chemical
has	9	O
been	9	O
demonstrated	9	O
to	5	O
produce	9	O
symptoms	5	O
of	5	O
anaphylaxis	9	B-Disease
,	9	O
including	9	O
hypotension	5	B-Disease
,	9	O
in	5	O
sensitive	9	O
individuals	5	O
.	9	O

This	5	O
article	6	O
describes	5	O
two	5	O
critically	9	B-Disease
ill	5	I-Disease
patients	5	O
in	5	O
whom	5	O
transient	9	O
episodes	5	O
of	5	O
hypotension	5	B-Disease
reproducibly	9	O
developed	5	O
after	9	O
administration	9	O
of	5	O
acetaminophen	0	B-Chemical
.	9	O

Other	9	O
symptoms	5	O
of	5	O
allergic	9	B-Disease
reactions	9	I-Disease
were	9	O
not	5	O
clinically	5	O
detectable	9	O
.	9	O

The	5	O
hypotensive	5	B-Disease
episodes	5	O
were	9	O
severe	5	O
enough	5	O
to	5	O
require	5	O
vasopressor	5	O
administration	9	O
.	9	O

The	5	O
reports	9	O
illustrate	5	O
the	5	O
need	5	O
for	5	O
clinicians	5	O
to	5	O
consider	5	O
acetaminophen	0	B-Chemical
in	5	O
patients	5	O
with	5	O
hypotension	5	B-Disease
of	5	O
unknown	9	O
origin	9	O
.	9	O

Reduction	9	O
of	5	O
heparan	3	B-Chemical
sulphate	0	I-Chemical
-	7	O
associated	9	O
anionic	0	O
sites	9	O
in	5	O
the	5	O
glomerular	5	O
basement	3	O
membrane	9	O
of	5	O
rats	9	O
with	5	O
streptozotocin	0	B-Chemical
-	7	O
induced	3	O
diabetic	9	B-Disease
nephropathy	9	I-Disease
.	9	O

Heparan	0	B-Chemical
sulphate	0	I-Chemical
-	7	O
associated	9	O
anionic	0	O
sites	9	O
in	5	O
the	5	O
glomerular	5	O
basement	3	O
membrane	9	O
were	9	O
studied	9	O
in	5	O
rats	9	O
8	9	O
months	5	O
after	9	O
induction	3	O
of	5	O
diabetes	5	B-Disease
by	9	O
streptozotocin	0	B-Chemical
and	5	O
in	5	O
age	5	O
-	7	O
adn	2	O
sex	5	O
-	7	O
matched	9	O
control	9	O
rats	9	O
,	9	O
employing	9	O
the	5	O
cationic	0	O
dye	0	O
cuprolinic	0	B-Chemical
blue	9	I-Chemical
.	9	O

Morphometric	9	O
analysis	9	O
at	9	O
the	5	O
ultrastructural	9	O
level	9	O
was	9	O
performed	9	O
using	9	O
a	5	O
computerized	5	O
image	5	O
processor	5	O
.	9	O

The	5	O
heparan	3	B-Chemical
sulphate	0	I-Chemical
specificity	9	O
of	5	O
the	5	O
cuprolinic	0	B-Chemical
blue	9	I-Chemical
staining	3	O
was	9	O
demonstrated	9	O
by	9	O
glycosaminoglycan	0	B-Chemical
-	7	O
degrading	9	O
enzymes	1	O
,	9	O
showing	9	O
that	5	O
pretreatment	0	O
of	5	O
the	5	O
sections	9	O
with	5	O
heparitinase	3	O
abolished	3	O
all	5	O
staining	3	O
,	9	O
whereas	9	O
chondroitinase	0	O
ABC	9	O
had	9	O
no	9	O
effect	9	O
.	9	O

The	5	O
majority	9	O
of	5	O
anionic	0	O
sites	9	O
(	9	O
74	7	O
%	9	O
in	5	O
diabetic	9	B-Disease
and	5	O
81	7	O
%	9	O
in	5	O
control	9	O
rats	9	O
)	9	O
were	9	O
found	9	O
within	9	O
the	5	O
lamina	9	O
rara	2	O
externa	4	O
of	5	O
the	5	O
glomerular	5	O
basement	3	O
membrane	9	O
.	9	O

A	9	O
minority	5	O
of	5	O
anionic	0	O
sites	9	O
were	9	O
scattered	5	O
throughout	9	O
the	5	O
lamina	9	O
densa	4	O
and	5	O
lamina	9	O
rara	2	O
interna	2	O
,	9	O
and	5	O
were	9	O
significantly	9	O
smaller	5	O
than	5	O
those	5	O
in	5	O
the	5	O
lamina	9	O
rara	2	O
externa	4	O
of	5	O
the	5	O
glomerular	5	O
basement	3	O
membrane	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
001	9	O
and	5	O
p	7	O
<	0	O
0	7	O
.	9	O
01	7	O
for	5	O
diabetic	9	B-Disease
and	5	O
control	9	O
rats	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Diabetic	9	B-Disease
rats	9	O
progressively	9	O
developed	5	O
albuminuria	9	B-Disease
reaching	5	O
40	9	O
.	9	O
3	9	O
(	9	O
32	7	O
.	9	O
2	9	O
-	7	O
62	7	O
.	9	O
0	7	O
)	9	O
mg	0	O
/	9	O
24	9	O
h	0	O
after	9	O
8	9	O
months	5	O
in	5	O
contrast	9	O
to	5	O
the	5	O
control	9	O
animals	9	O
(	9	O
0	7	O
.	9	O
8	9	O
(	9	O
0	7	O
.	9	O
2	9	O
-	7	O
0	7	O
.	9	O
9	7	O
)	9	O
mg	0	O
/	9	O
24	9	O
h	0	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
002	7	O
)	9	O
.	9	O

At	9	O
the	5	O
same	9	O
time	5	O
,	9	O
the	5	O
number	9	O
of	5	O
heparan	3	B-Chemical
sulphate	0	I-Chemical
anionic	0	O
sites	9	O
and	5	O
the	5	O
total	9	O
anionic	0	O
site	9	O
surface	9	O
(	9	O
number	9	O
of	5	O
anionic	0	O
sites	9	O
x	9	O
mean	5	O
anionic	0	O
site	9	O
surface	9	O
)	9	O
in	5	O
the	5	O
lamina	9	O
rara	2	O
externa	4	O
of	5	O
the	5	O
glomerular	5	O
basement	3	O
membrane	9	O
was	9	O
reduced	9	O
by	9	O
19	7	O
%	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
021	7	O
)	9	O
and	5	O
by	9	O
26	7	O
%	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
02	7	O
)	9	O
,	9	O
respectively	9	O
.	9	O

Number	9	O
and	5	O
total	9	O
anionic	0	O
site	9	O
surface	9	O
in	5	O
the	5	O
remaining	9	O
part	9	O
of	5	O
the	5	O
glomerular	5	O
basement	3	O
membrane	9	O
(	9	O
lamina	9	O
densa	4	O
and	5	O
lamina	9	O
rara	2	O
interna	2	O
)	9	O
were	9	O
not	5	O
significantly	9	O
changed	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
in	5	O
streptozotocin	0	B-Chemical
-	7	O
diabetic	9	B-Disease
rats	9	O
with	5	O
an	5	O
increased	9	O
urinary	9	O
albumin	0	O
excretion	0	O
,	9	O
a	5	O
reduced	9	O
heparan	3	B-Chemical
sulphate	0	I-Chemical
charge	5	O
barrier	5	O
/	9	O
density	9	O
is	5	O
found	9	O
at	9	O
the	5	O
lamina	9	O
rara	2	O
externa	4	O
of	5	O
the	5	O
glomerular	5	O
basement	3	O
membrane	9	O
.	9	O

Mediation	5	O
of	5	O
enhanced	3	O
reflex	5	O
vagal	5	O
bradycardia	5	B-Disease
by	9	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
via	9	O
central	5	O
dopamine	5	B-Chemical
formation	9	O
in	5	O
dogs	5	O
.	9	O

L	0	B-Chemical
-	7	I-Chemical
Dopa	0	I-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
decreased	9	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
after	9	O
extracerebral	5	O
decarboxylase	1	O
inhibition	3	O
with	5	O
MK	9	B-Chemical
-	7	I-Chemical
486	7	I-Chemical
(	9	O
25	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
in	5	O
anesthetize	5	O
MAO	0	B-Chemical
-	7	O
inhibited	3	O
dogs	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
reflex	5	O
bradycardia	5	B-Disease
caused	9	O
by	9	O
injected	3	O
norepinephrine	9	B-Chemical
was	9	O
significantly	9	O
enhanced	3	O
by	9	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
,	9	O
DL	9	B-Chemical
-	7	I-Chemical
Threo	1	I-Chemical
-	7	I-Chemical
dihydroxyphenylserine	_	I-Chemical
had	9	O
no	9	O
effect	9	O
on	5	O
blood	9	O
pressure	5	O
,	9	O
heart	5	O
rate	9	O
or	5	O
reflex	5	O
responses	5	O
to	5	O
norepinephrine	9	B-Chemical
.	9	O

FLA	9	B-Chemical
-	7	I-Chemical
63	7	I-Chemical
,	9	O
a	5	O
dopamine	5	B-Chemical
-	7	O
beta	9	O
-	7	O
oxidase	0	O
inhibitor	3	O
,	9	O
did	9	O
not	5	O
have	5	O
any	5	O
effect	9	O
on	5	O
the	5	O
hypotension	5	B-Disease
,	9	O
bradycardia	5	B-Disease
or	5	O
reflex	5	O
-	7	O
enhancing	9	O
effect	9	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
.	9	O

Pimozide	0	B-Chemical
did	9	O
not	5	O
affect	9	O
the	5	O
actions	5	O
of	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
on	5	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
but	9	O
completely	9	O
blocked	3	O
the	5	O
enhancement	9	O
of	5	O
reflexes	5	O
.	9	O

Removal	9	O
of	5	O
the	5	O
carotid	5	O
sinuses	5	O
caused	9	O
an	5	O
elevation	9	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
and	5	O
abolished	3	O
the	5	O
negative	9	O
chronotropic	5	O
effect	9	O
of	5	O
norepinephrine	9	B-Chemical
.	9	O

However	9	O
,	9	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
restored	3	O
the	5	O
bradycardia	5	B-Disease
caused	9	O
by	9	O
norepinephrine	9	B-Chemical
in	5	O
addition	9	O
to	5	O
decreasing	9	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
.	9	O

5	9	B-Chemical
-	7	I-Chemical
HTP	5	I-Chemical
(	9	O
5	9	O
mg	0	O
/	9	O
kg	0	O
i	9	O
.	9	O
v	0	O
.	9	O
)	9	O
decreased	9	O
blood	9	O
pressure	5	O
and	5	O
heart	5	O
rate	9	O
and	5	O
decreased	9	O
the	5	O
reflex	5	O
bradycardia	5	B-Disease
to	5	O
norepinephrine	9	B-Chemical
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
L	0	B-Chemical
-	7	I-Chemical
dopa	0	I-Chemical
enhances	3	O
reflex	5	O
bradycardia	5	B-Disease
through	9	O
central	5	O
alpha	9	O
-	7	O
receptor	3	O
stimulation	3	O
.	9	O

Furthermore	9	O
,	9	O
the	5	O
effects	9	O
are	5	O
mediated	3	O
through	9	O
dopamine	5	B-Chemical
rather	5	O
than	5	O
norepinephrine	9	B-Chemical
and	5	O
do	5	O
not	5	O
require	5	O
the	5	O
carotid	5	O
sinus	5	O
baroreceptors	5	O
.	9	O

Microangiopathic	2	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
complicating	5	O
FK506	3	B-Chemical
(	9	O
tacrolimus	0	B-Chemical
)	9	O
therapy	5	O
.	9	O

We	9	O
describe	5	O
3	9	O
episodes	5	O
of	5	O
microangiopathic	5	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
(	9	O
MAHA	0	B-Disease
)	9	O
in	5	O
2	9	O
solid	9	O
organ	5	O
recipients	9	O
under	9	O
FK506	3	B-Chemical
(	9	O
tacrolimus	0	B-Chemical
)	9	O
therapy	5	O
.	9	O

In	9	O
both	9	O
cases	5	O
,	9	O
discontinuation	5	O
of	5	O
FK506	3	B-Chemical
and	5	O
treatment	9	O
with	5	O
plasma	9	O
exchange	9	O
,	9	O
fresh	9	O
frozen	9	O
plasma	9	O
replacement	9	O
,	9	O
corticosteroids	5	B-Chemical
,	9	O
aspirin	9	B-Chemical
,	9	O
and	5	O
dipyridamole	0	B-Chemical
led	9	O
to	5	O
resolution	5	O
of	5	O
MAHA	0	B-Disease
.	9	O

In	9	O
one	5	O
patient	5	O
,	9	O
reintroduction	9	O
of	5	O
FK506	3	B-Chemical
led	9	O
to	5	O
rapid	5	O
recurrence	5	O
of	5	O
MAHA	0	B-Disease
.	9	O

FK506	3	B-Chemical
-	7	O
associated	9	O
MAHA	0	B-Disease
is	5	O
probably	9	O
rare	5	O
but	9	O
physicians	5	O
must	5	O
be	5	O
aware	5	O
of	5	O
this	5	O
severe	5	O
complication	5	O
.	9	O

In	9	O
our	5	O
experience	5	O
and	5	O
according	9	O
to	5	O
the	5	O
literature	5	O
,	9	O
FK506	3	B-Chemical
does	9	O
not	5	O
seem	5	O
to	5	O
cross	5	O
-	7	O
react	9	O
with	5	O
cyclosporin	0	B-Chemical
A	9	I-Chemical
(	9	O
CyA	0	B-Chemical
)	9	O
,	9	O
an	5	O
immuno	3	O
-	7	O
suppressive	3	O
drug	5	O
already	5	O
known	9	O
to	5	O
induce	3	O
MAHA	0	B-Disease
.	9	O

Effect	0	O
of	5	O
some	5	O
anticancer	0	O
drugs	5	O
and	5	O
combined	9	O
chemotherapy	5	O
on	5	O
renal	9	B-Disease
toxicity	9	I-Disease
.	9	O

The	5	O
nephrotoxic	5	B-Disease
action	5	O
of	5	O
anticancer	0	O
drugs	5	O
such	5	O
as	5	O
nitrogranulogen	_	B-Chemical
(	9	O
NG	9	B-Chemical
)	9	O
,	9	O
methotrexate	9	B-Chemical
(	9	O
MTX	0	B-Chemical
)	9	O
,	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
and	5	O
cyclophosphamide	0	B-Chemical
(	9	O
CY	9	B-Chemical
)	9	O
administered	9	O
alone	9	O
or	5	O
in	5	O
combination	9	O
[	9	O
MTX	0	B-Chemical
+	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
+	9	O
CY	9	B-Chemical
(	9	O
CMF	9	O
)	9	O
]	9	O
was	9	O
evaluated	9	O
in	5	O
experiments	9	O
on	5	O
Wistar	9	O
rats	9	O
.	9	O

After	9	O
drug	5	O
administration	9	O
,	9	O
creatinine	0	B-Chemical
concentrations	0	O
in	5	O
the	5	O
plasma	9	O
and	5	O
in	5	O
the	5	O
urine	9	O
of	5	O
the	5	O
rats	9	O
were	9	O
determined	9	O
,	9	O
as	5	O
well	9	O
as	5	O
creatinine	0	B-Chemical
clearance	9	O
.	9	O

Histopathologic	5	O
evaluation	5	O
of	5	O
the	5	O
kidneys	9	O
was	9	O
also	9	O
performed	9	O
.	9	O

After	9	O
MTX	0	B-Chemical
administration	9	O
a	5	O
significant	9	O
increase	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0228	7	O
)	9	O
in	5	O
the	5	O
plasma	9	O
creatinine	0	B-Chemical
concentration	0	O
and	5	O
a	5	O
significant	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0001	7	O
)	9	O
decrease	9	O
in	5	O
creatinine	0	B-Chemical
clearance	9	O
was	9	O
noted	9	O
compared	9	O
to	5	O
controls	9	O
.	9	O

After	9	O
the	5	O
administration	9	O
of	5	O
NG	9	B-Chemical
,	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
and	5	O
CY	9	B-Chemical
neither	9	O
a	5	O
statistically	9	O
significant	9	O
increase	9	O
in	5	O
creatinine	0	B-Chemical
concentration	0	O
nor	9	O
an	5	O
increase	9	O
in	5	O
creatinine	0	B-Chemical
clearance	9	O
was	9	O
observed	9	O
compared	9	O
to	5	O
the	5	O
group	9	O
receiving	9	O
no	9	O
cytostatics	0	O
.	9	O

Following	9	O
polytherapy	5	O
according	9	O
to	5	O
the	5	O
CMF	9	O
regimen	5	O
,	9	O
a	5	O
statistically	9	O
significant	9	O
decrease	9	O
(	9	O
p	7	O
=	7	O
0	7	O
.	9	O
0343	7	O
)	9	O
in	5	O
creatinine	0	B-Chemical
clearance	9	O
was	9	O
found	9	O
,	9	O
but	9	O
creatinine	0	B-Chemical
concentration	0	O
did	9	O
not	5	O
increase	9	O
significantly	9	O
compared	9	O
to	5	O
controls	9	O
.	9	O

CY	9	B-Chemical
caused	9	O
hemorrhagic	5	B-Disease
cystitis	9	I-Disease
in	5	O
40	9	O
%	9	O
of	5	O
rats	9	O
,	9	O
but	9	O
it	5	O
did	9	O
not	5	O
cause	5	O
this	5	O
complication	5	O
when	5	O
combined	9	O
with	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
and	5	O
MTX	0	B-Chemical
.	9	O

Histologic	9	O
changes	9	O
were	9	O
found	9	O
in	5	O
rat	3	O
kidneys	9	O
after	9	O
administration	9	O
of	5	O
MTX	0	B-Chemical
,	9	O
CY	9	B-Chemical
and	5	O
NG	9	B-Chemical
,	9	O
while	9	O
no	9	O
such	5	O
change	9	O
was	9	O
observed	9	O
after	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
and	5	O
joint	5	O
administration	9	O
of	5	O
MTX	0	B-Chemical
+	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
+	9	O
CY	9	B-Chemical
compared	9	O
to	5	O
controls	9	O
.	9	O

Our	9	O
studies	9	O
indicate	9	O
that	5	O
nephrotoxicity	9	B-Disease
of	5	O
MTX	0	B-Chemical
+	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
+	9	O
CY	9	B-Chemical
administered	9	O
jointly	5	O
is	5	O
lower	9	O
than	5	O
in	5	O
monotherapy	5	O
.	9	O

The	5	O
interpeduncular	5	O
nucleus	9	O
regulates	3	O
nicotine	0	B-Chemical
'	9	O
s	9	O
effects	9	O
on	5	O
free	9	O
-	7	O
field	5	O
activity	9	O
.	9	O

Partial	9	O
lesions	5	O
were	9	O
made	5	O
with	5	O
kainic	0	B-Chemical
acid	0	I-Chemical
in	5	O
the	5	O
interpeduncular	5	O
nucleus	9	O
of	5	O
the	5	O
ventral	5	O
midbrain	9	O
of	5	O
the	5	O
rat	3	O
.	9	O

Compared	9	O
with	5	O
sham	9	O
-	7	O
operated	5	O
controls	9	O
,	9	O
lesions	5	O
significantly	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
25	9	O
)	9	O
blunted	9	O
the	5	O
early	9	O
(	9	O
<	0	O
60	9	O
min	0	O
)	9	O
free	9	O
-	7	O
field	5	O
locomotor	5	B-Disease
hypoactivity	5	I-Disease
caused	9	O
by	9	O
nicotine	0	B-Chemical
(	9	O
0	7	O
.	9	O
5	9	O
mg	0	O
kg	0	O
(	9	O
-	7	O
1	9	O
)	9	O
,	9	O
i	9	O
.	9	O
m	9	O
.	9	O
)	9	O
,	9	O
enhanced	3	O
the	5	O
later	9	O
(	9	O
60	9	O
-	7	O
120	9	O
min	0	O
)	9	O
nicotine	0	B-Chemical
-	7	O
induced	3	O
hyperactivity	5	B-Disease
,	9	O
and	5	O
raised	9	O
spontaneous	5	O
nocturnal	5	O
activity	9	O
.	9	O

Lesions	5	O
reduced	9	O
the	5	O
extent	9	O
of	5	O
immunohistological	3	O
staining	3	O
for	5	O
choline	0	B-Chemical
acetyltransferase	1	O
in	5	O
the	5	O
interpeduncular	5	O
nucleus	9	O
(	9	O
p	7	O
<	0	O
0	7	O
.	9	O
025	7	O
)	9	O
,	9	O
but	9	O
not	5	O
for	5	O
tyrosine	3	B-Chemical
hydroxylase	1	O
in	5	O
the	5	O
surrounding	9	O
catecholaminergic	3	O
A10	9	O
region	9	O
.	9	O

We	9	O
conclude	9	O
that	5	O
the	5	O
interpeduncular	5	O
nucleus	9	O
mediates	3	O
nicotinic	0	O
depression	5	B-Disease
of	5	O
locomotor	5	O
activity	9	O
and	5	O
dampens	3	O
nicotinic	0	O
arousal	5	O
mechanisms	9	O
located	9	O
elsewhere	9	O
in	5	O
the	5	O
brain	5	O
.	9	O

Lithium	0	B-Chemical
-	7	O
associated	9	O
cognitive	5	B-Disease
and	5	I-Disease
functional	9	I-Disease
deficits	5	I-Disease
reduced	9	O
by	9	O
a	5	O
switch	9	O
to	5	O
divalproex	5	B-Chemical
sodium	0	I-Chemical
:	9	O
a	5	O
case	5	O
series	5	O
.	9	O

BACKGROUND	2	O
:	9	O
Lithium	0	B-Chemical
remains	9	O
a	5	O
first	9	O
-	7	O
line	9	O
treatment	9	O
for	5	O
the	5	O
acute	9	O
and	5	O
maintenance	9	O
treatment	9	O
of	5	O
bipolar	5	B-Disease
disorder	5	I-Disease
.	9	O

Although	9	O
much	5	O
has	9	O
been	9	O
written	5	O
about	5	O
the	5	O
management	5	O
of	5	O
the	5	O
more	5	O
common	5	O
adverse	5	O
effects	9	O
of	5	O
lithium	0	B-Chemical
,	9	O
such	5	O
as	5	O
polyuria	5	B-Disease
and	5	O
tremor	5	B-Disease
,	9	O
more	5	O
subtle	5	O
lithium	0	B-Chemical
side	5	O
effects	9	O
such	5	O
as	5	O
cognitive	5	B-Disease
deficits	5	I-Disease
,	9	O
loss	9	B-Disease
of	5	I-Disease
creativity	5	I-Disease
,	9	O
and	5	O
functional	9	B-Disease
impairments	5	I-Disease
remain	9	O
understudied	5	O
.	9	O

This	5	O
report	5	O
summarizes	5	O
our	5	O
experience	5	O
in	5	O
switching	5	O
bipolar	5	B-Disease
patients	5	O
from	9	O
lithium	0	B-Chemical
to	5	O
divalproex	5	B-Chemical
sodium	0	I-Chemical
to	5	O
alleviate	5	O
such	5	O
cognitive	5	B-Disease
and	5	I-Disease
functional	9	I-Disease
impairments	5	I-Disease
.	9	O

METHOD	2	O
:	9	O
Open	5	O
,	9	O
case	5	O
series	5	O
design	5	O
.	9	O

RESULTS	9	O
:	9	O
We	9	O
report	5	O
seven	9	O
cases	5	O
where	5	O
substitution	9	O
of	5	O
lithium	0	B-Chemical
,	9	O
either	9	O
fully	9	O
or	5	O
partially	9	O
,	9	O
with	5	O
divalproex	5	B-Chemical
sodium	0	I-Chemical
was	9	O
extremely	5	O
helpful	6	O
in	5	O
reducing	9	O
the	5	O
cognitive	5	B-Disease
,	9	I-Disease
motivational	5	I-Disease
,	9	I-Disease
or	5	I-Disease
creative	5	I-Disease
deficits	5	I-Disease
attributed	9	O
to	5	O
lithium	0	B-Chemical
in	5	O
our	5	O
bipolar	5	B-Disease
patients	5	O
.	9	O

CONCLUSION	5	O
:	9	O
In	9	O
this	5	O
preliminary	9	O
report	5	O
,	9	O
divalproex	5	B-Chemical
sodium	0	I-Chemical
was	9	O
a	5	O
superior	5	O
alternative	5	O
to	5	O
lithium	0	B-Chemical
in	5	O
bipolar	5	B-Disease
patients	5	O
experiencing	5	O
cognitive	5	B-Disease
deficits	5	I-Disease
,	9	O
loss	9	B-Disease
of	5	I-Disease
creativity	5	I-Disease
,	9	O
and	5	O
functional	9	B-Disease
impairments	5	I-Disease
.	9	O

Effect	0	O
of	5	O
nifedipine	0	B-Chemical
on	5	O
renal	9	O
function	9	O
in	5	O
liver	9	O
transplant	9	O
recipients	9	O
receiving	9	O
tacrolimus	0	B-Chemical
.	9	O

The	5	O
effect	9	O
of	5	O
nifedipine	0	B-Chemical
on	5	O
renal	9	O
function	9	O
in	5	O
liver	9	O
transplant	9	O
recipients	9	O
who	5	O
were	9	O
receiving	9	O
tacrolimus	0	B-Chemical
was	9	O
evaluated	9	O
between	5	O
January	2	O
1992	2	O
and	5	O
January	2	O
1996	2	O
.	9	O

Two	9	O
groups	9	O
of	5	O
patients	5	O
receiving	9	O
tacrolimus	0	B-Chemical
were	9	O
compared	9	O
over	5	O
a	5	O
period	5	O
of	5	O
1	9	O
year	5	O
,	9	O
one	5	O
group	9	O
comprising	9	O
hypertensive	5	B-Disease
patients	5	O
who	5	O
were	9	O
receiving	9	O
nifedipine	0	B-Chemical
,	9	O
and	5	O
the	5	O
other	5	O
comprising	9	O
nonhypertensive	5	O
patients	5	O
not	5	O
receiving	9	O
nifedipine	0	B-Chemical
.	9	O

The	5	O
time	5	O
from	9	O
transplant	9	O
to	5	O
baseline	5	O
was	9	O
similar	9	O
in	5	O
all	5	O
patients	5	O
.	9	O

Nifedipine	0	B-Chemical
significantly	9	O
improved	5	O
kidney	9	O
function	9	O
as	5	O
indicated	9	O
by	9	O
a	5	O
significant	9	O
lowering	9	O
of	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
at	9	O
6	9	O
and	5	O
12	9	O
months	5	O
.	9	O

The	5	O
observed	9	O
positive	9	O
impact	5	O
of	5	O
nifedipine	0	B-Chemical
on	5	O
reducing	9	O
the	5	O
nephrotoxicity	9	B-Disease
associated	9	O
with	5	O
tacrolimus	0	B-Chemical
in	5	O
liver	9	O
transplant	9	O
recipients	9	O
should	5	O
be	5	O
an	5	O
important	9	O
factor	9	O
in	5	O
selecting	5	O
an	5	O
agent	9	O
to	5	O
treat	5	O
hypertension	5	B-Disease
in	5	O
this	5	O
population	5	O
.	9	O

Alpha	9	O
and	5	O
beta	9	O
coma	5	B-Disease
in	5	O
drug	5	O
intoxication	9	O
uncomplicated	5	O
by	9	O
cerebral	5	B-Disease
hypoxia	3	I-Disease
.	9	O

Four	9	O
patients	5	O
who	5	O
were	9	O
rendered	9	O
comatose	5	B-Disease
or	5	O
stuporous	5	B-Disease
by	9	O
drug	5	O
intoxication	9	O
,	9	O
but	9	O
who	5	O
were	9	O
not	5	O
hypoxic	3	O
,	9	O
are	5	O
described	9	O
.	9	O

Three	9	O
patients	5	O
received	9	O
high	9	O
doses	0	O
of	5	O
chlormethiazole	0	B-Chemical
for	5	O
alcohol	5	B-Chemical
withdrawal	5	B-Disease
symptoms	5	I-Disease
,	9	O
and	5	O
one	5	O
took	5	O
a	5	O
suicidal	5	O
overdose	0	B-Disease
of	5	O
nitrazepam	0	B-Chemical
.	9	O

The	5	O
patient	5	O
with	5	O
nitrazepam	0	B-Chemical
overdose	0	B-Disease
and	5	O
two	5	O
of	5	O
those	5	O
with	5	O
chlormethiazole	0	B-Chemical
intoxication	9	O
conformed	9	O
to	5	O
the	5	O
criteria	5	O
of	5	O
'	9	O
alpha	9	O
coma	5	B-Disease
'	9	O
,	9	O
showing	9	O
non	9	O
-	7	O
reactive	9	O
generalized	5	O
or	5	O
frontally	5	O
predominant	9	O
alpha	9	O
activity	9	O
in	5	O
the	5	O
EEG	5	O
.	9	O

The	5	O
fourth	9	O
patient	5	O
who	5	O
was	9	O
unconscious	5	O
after	9	O
chlormethiazole	0	B-Chemical
administration	9	O
exhibite	9	O
generalized	5	O
non	9	O
-	7	O
reactive	9	O
activity	9	O
in	5	O
the	5	O
slow	5	O
beta	9	O
range	9	O
.	9	O

All	9	O
four	9	O
recovered	9	O
completely	9	O
without	9	O
neurological	5	B-Disease
sequelae	5	I-Disease
following	9	O
the	5	O
withdrawal	5	O
of	5	O
the	5	O
offending	5	O
agents	5	O
.	9	O

The	5	O
similarities	9	O
between	5	O
the	5	O
effects	9	O
of	5	O
structural	9	O
lesions	5	O
and	5	O
pharmacological	9	O
depression	5	B-Disease
of	5	O
the	5	O
brain	5	O
stem	3	O
reticular	5	O
formation	9	O
are	5	O
discussed	5	O
.	9	O

It	5	O
is	5	O
suggested	9	O
that	5	O
in	5	O
both	9	O
situations	5	O
disturbed	5	O
reticulo	3	O
-	7	O
thalamic	5	O
interactions	9	O
are	5	O
important	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
alpha	9	O
coma	5	B-Disease
.	9	O

It	5	O
is	5	O
concluded	9	O
that	5	O
when	5	O
this	5	O
electroencephalographic	5	O
and	5	O
behavioural	5	O
picture	5	O
is	5	O
seen	9	O
in	5	O
drug	5	O
intoxication	9	O
,	9	O
in	5	O
the	5	O
absence	3	O
of	5	O
significant	9	O
hypoxaemia	5	B-Disease
,	9	O
a	5	O
favourable	5	O
outcome	5	O
may	5	O
be	5	O
anticipated	5	O
.	9	O

Magnetic	5	O
resonance	5	O
volumetry	5	O
of	5	O
the	5	O
cerebellum	9	O
in	5	O
epileptic	5	B-Disease
patients	5	O
after	9	O
phenytoin	0	B-Chemical
overdosages	9	B-Disease
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
evaluate	9	O
the	5	O
relationship	5	O
between	5	O
phenytoin	0	B-Chemical
medication	5	O
and	5	O
cerebellar	5	B-Disease
atrophy	5	I-Disease
in	5	O
patients	5	O
who	5	O
had	9	O
experienced	5	O
clinical	5	O
intoxication	9	O
.	9	O

Five	9	O
females	9	O
and	5	O
6	9	O
males	9	O
,	9	O
21	7	O
-	7	O
59	7	O
years	5	O
of	5	O
age	5	O
,	9	O
were	9	O
examined	9	O
with	5	O
a	5	O
1	9	O
.	9	O
5	9	O
-	7	O
T	3	O
whole	9	O
-	7	O
body	5	O
system	5	O
using	9	O
a	5	O
circular	5	O
polarized	3	O
head	5	O
coil	5	O
.	9	O

Conventional	5	O
spin	0	O
echo	5	O
images	5	O
were	9	O
acquired	5	O
in	5	O
the	5	O
sagittal	5	O
and	5	O
transverse	5	O
orientation	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
we	5	O
performed	9	O
a	5	O
high	9	O
-	7	O
resolution	5	O
3D	5	O
gradient	9	O
echo	5	O
,	9	O
T1	9	O
-	7	O
weighted	5	O
sequences	1	O
at	9	O
a	5	O
1	9	O
-	7	O
mm	9	O
slice	5	O
thickness	5	O
.	9	O

The	5	O
images	5	O
were	9	O
subsequently	9	O
processed	9	O
to	5	O
obtain	5	O
volumetric	5	O
data	5	O
for	5	O
the	5	O
cerebellum	9	O
.	9	O

Cerebellar	9	O
volume	9	O
for	5	O
the	5	O
patient	5	O
group	9	O
ranged	9	O
between	5	O
67	7	O
.	9	O
66	7	O
and	5	O
131	7	O
.	9	O
08	7	O
ml	0	O
(	9	O
mean	5	O
108	9	O
.	9	O
9	7	O
ml	0	O
)	9	O
.	9	O

In	9	O
addition	9	O
3D	5	O
gradient	9	O
echo	5	O
data	5	O
sets	5	O
from	9	O
10	9	O
healthy	5	O
male	9	O
and	5	O
10	9	O
healthy	5	O
female	9	O
age	5	O
-	7	O
matched	9	O
volunteers	5	O
were	9	O
used	5	O
to	5	O
compare	9	O
cerebellar	5	O
volumes	5	O
.	9	O

Using	9	O
linear	5	O
regression	5	O
we	5	O
found	9	O
that	5	O
no	9	O
correlation	9	O
exists	9	O
between	5	O
seizure	5	B-Disease
duration	5	O
,	9	O
elevation	9	O
of	5	O
phenytoin	0	B-Chemical
serum	9	O
levels	3	O
and	5	O
cerebellar	5	O
volume	9	O
.	9	O

However	9	O
,	9	O
multiple	5	O
regression	5	O
for	5	O
the	5	O
daily	5	O
dosage	9	O
,	9	O
duration	5	O
of	5	O
phenytoin	0	B-Chemical
treatment	9	O
and	5	O
cerebellar	5	O
volume	9	O
revealed	9	O
a	5	O
correlation	9	O
of	5	O
these	5	O
parameters	5	O
.	9	O

We	9	O
conclude	9	O
that	5	O
phenytoin	0	B-Chemical
overdosage	5	B-Disease
does	9	O
not	5	O
necessarily	5	O
result	9	O
in	5	O
cerebellar	5	B-Disease
atrophy	5	I-Disease
and	5	O
it	5	O
is	5	O
unlikely	9	O
that	5	O
phenytoin	0	B-Chemical
medication	5	O
was	9	O
the	5	O
only	9	O
cause	5	O
of	5	O
cerebellar	5	B-Disease
atrophy	5	I-Disease
in	5	O
the	5	O
remaining	9	O
patients	5	O
.	9	O

Quantitative	9	O
morphometric	5	O
studies	9	O
of	5	O
the	5	O
cerebellum	9	O
provide	5	O
valuable	5	O
insights	5	O
into	9	O
the	5	O
pathogenesis	9	O
of	5	O
cerebellar	5	B-Disease
disorders	5	I-Disease
.	9	O

Late	9	O
recovery	9	O
of	5	O
renal	9	O
function	9	O
in	5	O
a	5	O
woman	5	O
with	5	O
the	5	O
hemolytic	0	B-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
.	9	O

A	9	O
case	5	O
is	5	O
reported	9	O
of	5	O
the	5	O
hemolytic	0	B-Disease
uremic	9	I-Disease
syndrome	5	I-Disease
(	9	O
HUS	9	B-Disease
)	9	O
in	5	O
a	5	O
woman	5	O
taking	5	O
oral	9	B-Chemical
contraceptives	5	I-Chemical
.	9	O

She	5	O
was	9	O
treated	3	O
with	5	O
heparin	0	B-Chemical
,	9	O
dipyridamole	0	B-Chemical
and	5	O
hemodialysis	5	O
;	9	O
and	5	O
after	9	O
more	5	O
than	5	O
three	9	O
months	5	O
,	9	O
her	5	O
urinary	9	O
output	5	O
rose	9	O
above	9	O
500	0	O
ml	0	O
;	9	O
and	5	O
six	9	O
months	5	O
after	9	O
the	5	O
onset	5	O
of	5	O
anuria	5	B-Disease
,	9	O
dialysis	5	O
treatment	9	O
was	9	O
stopped	9	O
.	9	O

This	5	O
case	5	O
emphasizes	5	O
the	5	O
possibility	9	O
that	5	O
HUS	9	B-Disease
in	5	O
adults	5	O
is	5	O
not	5	O
invariably	9	O
irreversible	9	O
and	5	O
that	5	O
,	9	O
despite	9	O
prolonged	9	O
oliguria	5	B-Disease
,	9	O
recovery	9	O
of	5	O
renal	9	O
function	9	O
can	5	O
be	5	O
obtained	9	O
.	9	O

Therefore	9	O
,	9	O
in	5	O
adult	9	O
patients	5	O
affected	9	O
by	9	O
HUS	9	B-Disease
,	9	O
dialysis	5	O
should	5	O
not	5	O
be	5	O
discontinued	5	O
prematurely	5	O
;	9	O
moreover	9	O
,	9	O
bilateral	5	O
nephrectomy	5	O
,	9	O
for	5	O
treatment	9	O
of	5	O
severe	5	O
hypertension	5	B-Disease
and	5	O
microangiopathic	5	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
,	9	O
should	5	O
be	5	O
performed	9	O
with	5	O
caution	5	O
.	9	O

Morphological	9	O
features	5	O
of	5	O
encephalopathy	5	B-Disease
after	9	O
chronic	5	O
administration	9	O
of	5	O
the	5	O
antiepileptic	5	O
drug	5	O
valproate	0	B-Chemical
to	5	O
rats	9	O
.	9	O

A	9	O
transmission	5	O
electron	0	O
microscopic	9	O
study	9	O
of	5	O
capillaries	5	O
in	5	O
the	5	O
cerebellar	5	O
cortex	5	O
.	9	O

Long	9	O
-	7	O
term	5	O
intragastric	0	O
application	5	O
of	5	O
the	5	O
antiepileptic	5	O
drug	5	O
sodium	0	B-Chemical
valproate	0	I-Chemical
(	9	O
Vupral	_	O
"	5	O
Polfa	0	O
"	5	O
)	9	O
at	9	O
the	5	O
effective	5	O
dose	9	O
of	5	O
200	0	O
mg	0	O
/	9	O
kg	0	O
b	9	O
.	9	O

w	0	O
.	9	O
once	5	O
daily	5	O
to	5	O
rats	9	O
for	5	O
1	9	O
,	9	O
3	9	O
,	9	O
6	9	O
,	9	O
9	7	O
and	5	O
12	9	O
months	5	O
revealed	9	O
neurological	5	B-Disease
disorders	5	I-Disease
indicating	9	O
cerebellum	9	B-Disease
damage	9	I-Disease
(	9	O
"	5	O
valproate	0	B-Chemical
encephalopathy	5	B-Disease
"	5	O
)	9	O
.	9	O

The	5	O
first	9	O
ultrastructural	9	O
changes	9	O
in	5	O
structural	9	O
elements	5	O
of	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
-	7	O
barrier	5	O
(	9	O
BBB	9	O
)	9	O
in	5	O
the	5	O
cerebellar	5	O
cortex	5	O
were	9	O
detectable	9	O
after	9	O
3	9	O
months	5	O
of	5	O
the	5	O
experiment	9	O
.	9	O

They	5	O
became	9	O
more	5	O
severe	5	O
in	5	O
the	5	O
later	9	O
months	5	O
of	5	O
the	5	O
experiment	9	O
,	9	O
and	5	O
were	9	O
most	9	O
severe	5	O
after	9	O
12	9	O
months	5	O
,	9	O
located	9	O
mainly	9	O
in	5	O
the	5	O
molecular	9	O
layer	9	O
of	5	O
the	5	O
cerebellar	5	O
cortex	5	O
.	9	O

Lesions	5	O
of	5	O
the	5	O
capillary	0	O
included	5	O
necrosis	9	B-Disease
of	5	O
endothelial	3	O
cells	3	O
.	9	O

Organelles	2	O
of	5	O
these	5	O
cells	3	O
,	9	O
in	5	O
particular	5	O
the	5	O
mitochondria	3	O
(	9	O
increased	9	O
number	9	O
and	5	O
size	9	O
,	9	O
distinct	9	O
degeneration	9	O
of	5	O
their	5	O
matrix	5	O
and	5	O
cristae	9	O
)	9	O
and	5	O
Golgi	9	O
apparatus	9	O
were	9	O
altered	9	O
.	9	O

Reduced	9	O
size	9	O
of	5	O
capillary	0	O
lumen	9	O
and	5	O
occlusion	5	O
were	9	O
caused	9	O
by	9	O
swollen	9	O
endothelial	3	O
cells	3	O
which	5	O
had	9	O
luminal	3	B-Chemical
protrusions	3	O
and	5	O
swollen	9	O
microvilli	3	O
.	9	O

Pressure	5	O
on	5	O
the	5	O
vessel	5	O
wall	5	O
was	9	O
produced	9	O
by	9	O
enlarged	9	O
perivascular	3	O
astrocytic	3	O
processes	5	O
.	9	O

Fragments	9	O
of	5	O
necrotic	3	B-Disease
endothelial	3	O
cells	3	O
were	9	O
in	5	O
the	5	O
vascular	5	O
lumens	5	O
and	5	O
in	5	O
these	5	O
there	5	O
was	9	O
loosening	5	O
and	5	O
breaking	5	O
of	5	O
tight	9	O
cellular	3	O
junctions	9	O
.	9	O

Damage	5	O
to	5	O
the	5	O
vascular	5	O
basement	3	O
lamina	9	O
was	9	O
also	9	O
observed	9	O
.	9	O

Damage	5	O
to	5	O
the	5	O
capillary	0	O
was	9	O
accompanied	9	O
by	9	O
marked	9	O
damage	9	O
to	5	O
neuroglial	3	O
cells	3	O
,	9	O
mainly	9	O
to	5	O
perivascular	3	O
processes	5	O
of	5	O
astrocytes	3	O
.	9	O

The	5	O
proliferation	3	O
of	5	O
astrocytes	3	O
(	9	O
Bergmann	6	O
'	9	O
s	9	O
in	5	O
particular	5	O
)	9	O
and	5	O
occasionally	5	O
of	5	O
oligodendrocytes	3	O
was	9	O
found	9	O
.	9	O

Alterations	9	O
in	5	O
the	5	O
structural	9	O
elements	5	O
of	5	O
the	5	O
BBB	9	O
coexisted	9	O
with	5	O
marked	9	O
lesions	5	O
of	5	O
neurons	3	O
of	5	O
the	5	O
cerebellum	9	O
(	9	O
Purkinje	3	O
cells	3	O
are	5	O
earliest	9	O
)	9	O
.	9	O

In	9	O
electron	0	O
micrographs	9	O
both	9	O
luminal	3	B-Chemical
and	5	O
antiluminal	9	O
sides	5	O
of	5	O
the	5	O
BBB	9	O
of	5	O
the	5	O
cerebellar	5	O
cortex	5	O
had	9	O
similar	9	O
lesions	5	O
.	9	O

The	5	O
possible	5	O
influence	5	O
of	5	O
the	5	O
hepatic	9	B-Disease
damage	9	I-Disease
,	9	O
mainly	9	O
hyperammonemia	5	B-Disease
,	9	O
upon	9	O
the	5	O
development	9	O
of	5	O
valproate	0	B-Chemical
encephalopathy	5	B-Disease
is	5	O
discussed	5	O
.	9	O

Fatal	5	O
intracranial	5	B-Disease
bleeding	5	I-Disease
associated	9	O
with	5	O
prehospital	5	O
use	5	O
of	5	O
epinephrine	0	B-Chemical
.	9	O

We	9	O
present	9	O
a	5	O
case	5	O
of	5	O
paramedic	5	O
misjudgment	5	O
in	5	O
the	5	O
execution	5	O
of	5	O
a	5	O
protocol	9	O
for	5	O
the	5	O
treatment	9	O
of	5	O
allergic	9	B-Disease
reaction	9	I-Disease
in	5	O
a	5	O
case	5	O
of	5	O
pulmonary	5	B-Disease
edema	5	I-Disease
with	5	O
wheezing	5	B-Disease
.	9	O

The	5	O
sudden	5	O
onset	5	O
of	5	O
respiratory	5	B-Disease
distress	5	I-Disease
,	9	O
rash	5	B-Disease
,	9	O
and	5	O
a	5	O
history	5	O
of	5	O
a	5	O
new	5	O
medicine	5	O
led	9	O
the	5	O
two	5	O
paramedics	5	O
on	5	O
the	5	O
scene	5	O
to	5	O
administer	5	O
subcutaneous	9	O
epinephrine	0	B-Chemical
.	9	O

Subsequently	9	O
,	9	O
acute	9	O
cardiac	5	B-Disease
arrest	3	I-Disease
and	5	O
fatal	5	O
subarachnoid	5	B-Disease
hemorrhage	5	I-Disease
occurred	9	O
.	9	O

Epinephrine	0	B-Chemical
has	9	O
a	5	O
proven	5	O
role	9	O
in	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
in	5	O
prehospital	5	O
care	5	O
;	9	O
however	9	O
,	9	O
use	5	O
by	9	O
paramedics	5	O
in	5	O
patients	5	O
with	5	O
suspected	5	O
allergic	9	B-Disease
reaction	9	I-Disease
and	5	O
severe	5	O
hypertension	5	B-Disease
should	5	O
be	5	O
viewed	5	O
with	5	O
caution	5	O
.	9	O

Role	9	O
of	5	O
activation	3	O
of	5	O
bradykinin	0	B-Chemical
B2	9	O
receptors	3	O
in	5	O
disruption	9	O
of	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
during	5	O
acute	9	O
hypertension	5	B-Disease
.	9	O

Cellular	9	O
mechanisms	9	O
which	5	O
account	5	O
for	5	O
disruption	9	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
during	5	O
acute	9	O
hypertension	5	B-Disease
are	5	O
not	5	O
clear	9	O
.	9	O

The	5	O
goal	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
determine	9	O
the	5	O
role	9	O
of	5	O
synthesis	9	O
/	9	O
release	9	O
of	5	O
bradykinin	0	B-Chemical
to	5	O
activate	3	O
B2	9	O
receptors	3	O
in	5	O
disruption	9	O
of	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
during	5	O
acute	9	O
hypertension	5	B-Disease
.	9	O

Permeability	0	O
of	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
was	9	O
quantitated	9	O
by	9	O
clearance	9	O
of	5	O
fluorescent	3	O
-	7	O
labeled	3	O
dextran	0	B-Chemical
before	9	O
and	5	O
during	5	O
phenylephrine	0	B-Chemical
-	7	O
induced	3	O
acute	9	O
hypertension	5	B-Disease
in	5	O
rats	9	O
treated	3	O
with	5	O
vehicle	3	O
and	5	O
Hoe	6	B-Chemical
-	7	I-Chemical
140	9	I-Chemical
(	9	O
0	7	O
.	9	O
1	9	O
microM	0	O
)	9	O
.	9	O

Phenylephrine	0	B-Chemical
infusion	0	O
increased	9	O
arterial	5	O
pressure	5	O
,	9	O
arteriolar	5	O
diameter	9	O
and	5	O
clearance	9	O
of	5	O
fluorescent	3	O
dextran	0	B-Chemical
by	9	O
a	5	O
similar	9	O
magnitude	5	O
in	5	O
both	9	O
groups	9	O
.	9	O

These	5	O
findings	9	O
suggest	9	O
that	5	O
disruption	9	O
of	5	O
the	5	O
blood	9	O
-	7	O
brain	5	O
barrier	5	O
during	5	O
acute	9	O
hypertension	5	B-Disease
is	5	O
not	5	O
related	9	O
to	5	O
the	5	O
synthesis	9	O
/	9	O
release	9	O
of	5	O
bradykinin	0	B-Chemical
to	5	O
activate	3	O
B2	9	O
receptors	3	O
.	9	O

Risk	5	O
factors	9	O
of	5	O
sensorineural	5	B-Disease
hearing	5	I-Disease
loss	9	I-Disease
in	5	O
preterm	5	O
infants	5	O
.	9	O

Among	9	O
547	7	O
preterm	5	O
infants	5	O
of	5	O
<	0	O
or	5	O
=	7	O
34	7	O
weeks	9	O
gestation	9	O
born	5	O
between	5	O
1987	2	O
and	5	O
1991	2	O
,	9	O
8	9	O
children	5	O
(	9	O
1	9	O
.	9	O
46	7	O
%	9	O
)	9	O
developed	5	O
severe	5	O
progressive	5	O
and	5	O
bilateral	5	O
sensorineural	5	B-Disease
hearing	5	I-Disease
loss	9	I-Disease
.	9	O

Perinatal	2	O
risk	5	O
factors	9	O
of	5	O
infants	5	O
with	5	O
hearing	5	B-Disease
loss	9	I-Disease
were	9	O
compared	9	O
with	5	O
those	5	O
of	5	O
two	5	O
control	9	O
groups	9	O
matched	9	O
for	5	O
gestation	9	O
and	5	O
birth	5	O
weight	9	O
and	5	O
for	5	O
perinatal	5	O
complications	5	O
.	9	O

Our	9	O
observations	9	O
demonstrated	9	O
an	5	O
association	9	O
of	5	O
hearing	5	B-Disease
loss	9	I-Disease
with	5	O
a	5	O
higher	9	O
incidence	5	O
of	5	O
perinatal	5	O
complications	5	O
.	9	O

Ototoxicity	7	B-Disease
appeared	9	O
closely	9	O
related	9	O
to	5	O
a	5	O
prolonged	9	O
administration	9	O
and	5	O
higher	9	O
total	9	O
dose	9	O
of	5	O
ototoxic	5	B-Disease
drugs	5	O
,	9	O
particularly	5	O
aminoglycosides	9	B-Chemical
and	5	O
furosemide	0	B-Chemical
.	9	O

Finally	9	O
,	9	O
we	5	O
strongly	9	O
recommend	5	O
to	5	O
prospectively	5	O
and	5	O
regularly	5	O
perform	5	O
audiologic	5	O
assessment	5	O
in	5	O
sick	5	O
preterm	5	O
children	5	O
as	5	O
hearing	5	B-Disease
loss	9	I-Disease
is	5	O
of	5	O
delayed	9	O
onset	5	O
and	5	O
in	5	O
most	9	O
cases	5	O
bilateral	5	O
and	5	O
severe	5	O
.	9	O

Seizure	5	B-Disease
resulting	9	O
from	9	O
a	5	O
venlafaxine	5	B-Chemical
overdose	0	B-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
To	9	O
report	5	O
a	5	O
case	5	O
of	5	O
venlafaxine	5	B-Chemical
overdose	0	B-Disease
.	9	O

CASE	2	O
SUMMARY	9	O
:	9	O
A	9	O
40	9	O
-	7	O
year	5	O
-	7	O
old	5	O
woman	5	O
with	5	O
major	9	B-Disease
depression	5	I-Disease
took	5	O
an	5	O
overdose	0	B-Disease
of	5	O
venlafaxine	5	B-Chemical
in	5	O
an	5	O
apparent	9	O
suicide	5	O
attempt	5	O
.	9	O

After	9	O
the	5	O
ingestion	9	O
of	5	O
26	7	O
venlafaxine	5	B-Chemical
50	0	O
-	7	O
mg	0	O
tablets	0	O
,	9	O
the	5	O
patient	5	O
experienced	5	O
a	5	O
witnessed	5	O
generalized	5	O
seizure	5	B-Disease
.	9	O

She	5	O
was	9	O
admitted	5	O
to	5	O
the	5	O
medical	5	O
intensive	5	O
care	5	O
unit	5	O
,	9	O
venlafaxine	5	B-Chemical
was	9	O
discontinued	5	O
,	9	O
and	5	O
no	9	O
further	9	O
sequelae	5	O
were	9	O
seen	9	O
.	9	O

DISCUSSION	9	O
:	9	O
To	9	O
our	5	O
knowledge	5	O
,	9	O
this	5	O
is	5	O
the	5	O
first	9	O
reported	9	O
case	5	O
of	5	O
venlafaxine	5	B-Chemical
overdose	0	B-Disease
that	5	O
resulted	9	O
in	5	O
a	5	O
generalized	5	O
seizure	5	B-Disease
.	9	O

Based	9	O
on	5	O
nonoverdose	_	O
pharmacokinetics	9	O
and	5	O
pharmacodynamics	5	O
of	5	O
venlafaxine	5	B-Chemical
and	5	O
the	5	O
potential	9	O
risks	5	O
of	5	O
available	5	O
interventions	5	O
,	9	O
no	9	O
emergent	5	O
therapy	5	O
was	9	O
instituted	5	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
venlafaxine	5	B-Chemical
overdose	0	B-Disease
in	5	O
our	5	O
patient	5	O
resulted	9	O
in	5	O
a	5	O
single	9	O
episode	5	O
of	5	O
generalized	5	O
seizure	5	B-Disease
but	9	O
elicited	9	O
no	9	O
further	9	O
sequelae	5	O
.	9	O

Combined	9	O
effects	9	O
of	5	O
prolonged	9	O
prostaglandin	0	B-Chemical
E1	9	I-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
and	5	O
haemodilution	5	B-Disease
on	5	O
human	3	O
hepatic	9	O
function	9	O
.	9	O

Combined	9	O
effects	9	O
of	5	O
prolonged	9	O
prostaglandin	0	B-Chemical
E1	9	I-Chemical
(	9	O
PGE1	0	B-Chemical
)	9	O
-	7	O
induced	3	O
hypotension	5	B-Disease
and	5	O
haemodilution	5	B-Disease
on	5	O
hepatic	9	O
function	9	O
were	9	O
studied	9	O
in	5	O
30	9	O
patients	5	O
undergoing	9	O
hip	5	O
surgery	5	O
.	9	O

The	5	O
patients	5	O
were	9	O
randomly	5	O
allocated	5	O
to	5	O
one	5	O
of	5	O
three	9	O
groups	9	O
;	9	O
those	5	O
in	5	O
group	9	O
A	9	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
were	9	O
subjected	9	O
to	5	O
controlled	5	O
hypotension	5	B-Disease
alone	9	O
,	9	O
those	5	O
in	5	O
group	9	O
B	9	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
to	5	O
haemodilution	5	B-Disease
alone	9	O
and	5	O
those	5	O
in	5	O
group	9	O
C	9	O
(	9	O
n	9	O
=	7	O
10	9	O
)	9	O
to	5	O
both	9	O
controlled	5	O
hypotension	5	B-Disease
and	5	O
haemodilution	5	B-Disease
.	9	O

Haemodilution	9	B-Disease
in	5	O
groups	9	O
B	9	O
and	5	O
C	9	O
was	9	O
produced	9	O
by	9	O
withdrawing	5	O
approximately	9	O
1000	9	O
mL	0	O
of	5	O
blood	9	O
and	5	O
replacing	9	O
it	5	O
with	5	O
the	5	O
same	9	O
amount	9	O
of	5	O
dextran	0	B-Chemical
solution	0	O
,	9	O
and	5	O
final	9	O
haematocrit	5	O
values	5	O
were	9	O
21	7	O
or	5	O
22	7	O
%	9	O
.	9	O

Controlled	5	O
hypotension	5	B-Disease
in	5	O
groups	9	O
A	9	O
and	5	O
C	9	O
was	9	O
induced	3	O
with	5	O
PGE1	0	B-Chemical
to	5	O
maintain	5	O
mean	5	O
arterial	5	O
blood	9	O
pressure	5	O
at	9	O
55	7	O
mmHg	7	O
for	5	O
180	9	O
min	0	O
.	9	O

Measurements	9	O
included	5	O
arterial	5	O
ketone	0	O
body	5	O
ratio	9	O
(	9	O
AKBR	5	O
,	9	O
aceto	0	B-Chemical
-	7	I-Chemical
acetate	0	I-Chemical
/	9	O
3	9	B-Chemical
-	7	I-Chemical
hydroxybutyrate	0	I-Chemical
)	9	O
and	5	O
clinical	5	O
hepatic	9	O
function	9	O
parameters	5	O
.	9	O

AKBR	5	O
and	5	O
biological	5	O
hepatic	9	O
function	9	O
tests	5	O
showed	9	O
no	9	O
change	9	O
throughout	9	O
the	5	O
time	5	O
course	5	O
in	5	O
groups	9	O
A	9	O
and	5	O
B	9	O
.	9	O

In	9	O
group	9	O
C	9	O
,	9	O
AKBR	5	O
showed	9	O
a	5	O
significant	9	O
decrease	9	O
at	9	O
120	9	O
min	0	O
(	9	O
-	7	O
40	9	O
%	9	O
)	9	O
and	5	O
at	9	O
180	9	O
min	0	O
(	9	O
-	7	O
49	7	O
%	9	O
)	9	O
after	9	O
the	5	O
start	9	O
of	5	O
hypotension	5	B-Disease
and	5	O
at	9	O
60	9	O
min	0	O
(	9	O
-	7	O
32	7	O
%	9	O
)	9	O
after	9	O
recovery	9	O
of	5	O
normotension	5	O
,	9	O
and	5	O
SGOT	0	O
,	9	O
SGPT	7	O
,	9	O
LDH	0	O
and	5	O
total	9	O
bilirubin	0	B-Chemical
showed	9	O
significant	9	O
increases	9	O
after	9	O
operation	5	O
.	9	O

The	5	O
results	9	O
suggest	9	O
that	5	O
a	5	O
prolonged	9	O
combination	9	O
of	5	O
more	5	O
than	5	O
120	9	O
min	0	O
of	5	O
PGE1	0	B-Chemical
-	7	O
induced	3	O
hypotension	5	B-Disease
and	5	O
moderate	9	O
haemodilution	5	B-Disease
would	5	O
cause	5	O
impairment	5	B-Disease
of	5	I-Disease
hepatic	9	I-Disease
function	9	I-Disease
.	9	O

Cardiovascular	2	B-Disease
alterations	9	I-Disease
in	5	O
rat	3	O
fetuses	9	O
exposed	9	O
to	5	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
.	9	O

Preclinical	9	O
toxicologic	5	O
investigation	9	O
suggested	9	O
that	5	O
a	5	O
new	5	O
calcium	0	B-Chemical
channel	9	O
blocker	0	O
,	9	O
Ro	0	B-Chemical
40	9	I-Chemical
-	7	I-Chemical
5967	7	I-Chemical
,	9	O
induced	3	O
cardiovascular	5	B-Disease
alterations	9	I-Disease
in	5	O
rat	3	O
fetuses	9	O
exposed	9	O
to	5	O
this	5	O
agent	9	O
during	5	O
organogenesis	9	O
.	9	O

The	5	O
present	9	O
study	9	O
was	9	O
designed	9	O
to	5	O
investigate	9	O
the	5	O
hypothesis	9	O
that	5	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
in	5	O
general	5	O
induce	3	O
cardiovascular	5	B-Disease
malformations	5	I-Disease
indicating	9	O
a	5	O
pharmacologic	9	O
class	9	O
effect	9	O
.	9	O

We	9	O
studied	9	O
three	9	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
of	5	O
different	9	O
structure	9	O
,	9	O
nifedipine	0	B-Chemical
,	9	O
diltiazem	0	B-Chemical
,	9	O
and	5	O
verapamil	0	B-Chemical
,	9	O
along	9	O
with	5	O
the	5	O
new	5	O
agent	9	O
.	9	O

Pregnant	5	O
rats	9	O
were	9	O
administered	9	O
one	5	O
of	5	O
these	5	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
during	5	O
the	5	O
period	5	O
of	5	O
cardiac	5	O
morphogenesis	9	O
and	5	O
the	5	O
offspring	9	O
examined	9	O
on	5	O
day	9	O
20	9	O
of	5	O
gestation	9	O
for	5	O
cardiovascular	5	B-Disease
malformations	5	I-Disease
.	9	O

A	9	O
low	9	O
incidence	5	O
of	5	O
cardiovascular	5	B-Disease
malformations	5	I-Disease
was	9	O
observed	9	O
after	9	O
exposure	9	O
to	5	O
each	5	O
of	5	O
the	5	O
four	9	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
,	9	O
but	9	O
this	5	O
incidence	5	O
was	9	O
statistically	9	O
significant	9	O
only	9	O
for	5	O
verapamil	0	B-Chemical
and	5	O
nifedipine	0	B-Chemical
.	9	O

All	9	O
four	9	O
agents	5	O
were	9	O
associated	9	O
with	5	O
aortic	9	O
arch	5	O
branching	9	O
variants	1	O
,	9	O
although	9	O
significantly	9	O
increased	9	O
only	9	O
for	5	O
Ro	0	B-Chemical
40	9	I-Chemical
-	7	I-Chemical
5967	7	I-Chemical
and	5	O
verapamil	0	B-Chemical
.	9	O

The	5	O
site	9	O
of	5	O
common	5	O
side	5	O
effects	9	O
of	5	O
sumatriptan	0	B-Chemical
.	9	O

Atypical	9	B-Disease
sensations	5	I-Disease
following	9	O
the	5	O
use	5	O
of	5	O
subcutaneous	9	O
sumatriptan	0	B-Chemical
are	5	O
common	5	O
,	9	O
but	9	O
of	5	O
uncertain	5	O
origin	9	O
.	9	O

They	5	O
are	5	O
almost	9	O
always	5	O
benign	5	O
,	9	O
but	9	O
can	5	O
be	5	O
mistaken	5	O
for	5	O
a	5	O
serious	5	O
adverse	5	O
event	5	O
by	9	O
the	5	O
patient	5	O
.	9	O

Two	9	O
patients	5	O
are	5	O
presented	5	O
with	5	O
tingling	5	B-Disease
or	5	I-Disease
burning	5	I-Disease
sensations	5	I-Disease
limited	5	O
to	5	O
areas	5	O
of	5	O
heat	9	O
exposure	9	O
or	5	O
sunburn	5	B-Disease
.	9	O

In	9	O
these	5	O
individuals	5	O
,	9	O
side	5	O
effects	9	O
are	5	O
most	9	O
likely	5	O
generated	9	O
superficially	4	O
in	5	O
the	5	O
skin	5	O
.	9	O

Macula	2	O
toxicity	9	B-Disease
after	9	O
intravitreal	0	O
amikacin	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Although	9	O
intravitreal	0	O
aminoglycosides	9	B-Chemical
have	5	O
substantially	9	O
improved	5	O
visual	5	O
prognosis	5	O
in	5	O
endophthalmitis	5	B-Disease
,	9	O
macular	5	O
infarction	5	B-Disease
may	5	O
impair	9	O
full	5	O
visual	5	O
recovery	9	O
.	9	O

METHODS	2	O
:	9	O
We	9	O
present	9	O
a	5	O
case	5	O
of	5	O
presumed	9	O
amikacin	0	B-Chemical
retinal	5	B-Disease
toxicity	9	I-Disease
following	9	O
treatment	9	O
with	5	O
amikacin	0	B-Chemical
and	5	O
vancomycin	9	B-Chemical
for	5	O
alpha	9	O
-	7	O
haemolytic	9	O
streptococcal	9	B-Disease
endophthalmitis	5	I-Disease
.	9	O

RESULTS	9	O
:	9	O
Endophthalmitis	5	B-Disease
resolved	9	O
with	5	O
improvement	5	O
in	5	O
visual	5	O
acuity	5	O
to	5	O
6	9	O
/	9	O
24	9	O
at	9	O
three	9	O
months	5	O
.	9	O

Fundus	0	O
fluorescein	0	B-Chemical
angiography	5	O
confirmed	9	O
macular	5	O
capillary	0	O
closure	5	O
and	5	O
telangiectasis	5	B-Disease
.	9	O

CONCLUSIONS	5	O
:	9	O
Currently	9	O
accepted	5	O
intravitreal	0	O
antibiotic	5	O
regimens	5	O
may	5	O
cause	5	O
retinal	5	B-Disease
toxicity	9	I-Disease
and	5	O
macular	5	O
ischaemia	9	B-Disease
.	9	O

Treatment	9	O
strategies	5	O
aimed	5	O
at	9	O
avoiding	5	O
retinal	5	B-Disease
toxicity	9	I-Disease
are	5	O
discussed	5	O
.	9	O

The	5	O
role	9	O
of	5	O
nicotine	0	B-Chemical
in	5	O
smoking	5	O
-	7	O
related	9	O
cardiovascular	5	B-Disease
disease	5	I-Disease
.	9	O

Nicotine	0	B-Chemical
activates	3	O
the	5	O
sympathetic	5	O
nervous	5	O
system	5	O
and	5	O
in	5	O
this	5	O
way	5	O
could	9	O
contribute	9	O
to	5	O
cardiovascular	5	B-Disease
disease	5	I-Disease
.	9	O

Animal	2	O
studies	9	O
and	5	O
mechanistic	9	O
studies	9	O
indicate	9	O
that	5	O
nicotine	0	B-Chemical
could	9	O
play	9	O
a	5	O
role	9	O
in	5	O
accelerating	9	O
atherosclerosis	9	B-Disease
,	9	O
but	9	O
evidence	9	O
among	5	O
humans	9	O
is	5	O
too	5	O
inadequate	5	O
to	5	O
be	5	O
definitive	5	O
about	5	O
such	5	O
an	5	O
effect	9	O
.	9	O

Almost	5	O
certainly	5	O
,	9	O
nicotine	0	B-Chemical
via	9	O
its	9	O
hemodynamic	5	O
effects	9	O
contributes	9	O
to	5	O
acute	9	O
cardiovascular	5	O
events	5	O
,	9	O
although	9	O
current	5	O
evidence	9	O
suggests	9	O
that	5	O
the	5	O
effects	9	O
of	5	O
nicotine	0	B-Chemical
are	5	O
much	5	O
less	5	O
important	9	O
than	5	O
are	5	O
the	5	O
prothrombotic	5	O
effects	9	O
of	5	O
cigarette	5	O
smoking	5	O
or	5	O
the	5	O
effects	9	O
of	5	O
carbon	0	B-Chemical
monoxide	0	I-Chemical
.	9	O

Nicotine	0	B-Chemical
does	9	O
not	5	O
appear	9	O
to	5	O
enhance	9	O
thrombosis	5	B-Disease
among	5	O
humans	9	O
.	9	O

Clinical	5	O
studies	9	O
of	5	O
pipe	5	O
smokers	5	O
and	5	O
people	5	O
using	9	O
transdermal	0	O
nicotine	0	B-Chemical
support	5	O
the	5	O
idea	5	O
that	5	O
toxins	9	O
other	5	O
than	5	O
nicotine	0	B-Chemical
are	5	O
the	5	O
most	9	O
important	9	O
causes	9	O
of	5	O
acute	9	O
cardiovascular	5	O
events	5	O
.	9	O

Finally	9	O
,	9	O
the	5	O
dose	9	O
response	9	O
for	5	O
cardiovascular	5	O
events	5	O
of	5	O
nicotine	0	B-Chemical
appears	9	O
to	5	O
be	5	O
flat	5	O
,	9	O
suggesting	9	O
that	5	O
if	5	O
nicotine	0	B-Chemical
is	5	O
involved	9	O
,	9	O
adverse	5	O
effects	9	O
might	9	O
be	5	O
seen	9	O
with	5	O
relatively	5	O
low	9	O
-	7	O
level	9	O
cigarette	5	O
exposures	5	O
.	9	O

Iatrogenically	5	O
induced	3	O
intractable	5	O
atrioventricular	5	B-Disease
reentrant	5	I-Disease
tachycardia	5	I-Disease
after	9	O
verapamil	0	B-Chemical
and	5	O
catheter	5	O
ablation	9	O
in	5	O
a	5	O
patient	5	O
with	5	O
Wolff	6	B-Disease
-	7	I-Disease
Parkinson	5	I-Disease
-	7	I-Disease
White	9	I-Disease
syndrome	5	I-Disease
and	5	O
idiopathic	5	B-Disease
dilated	5	I-Disease
cardiomyopathy	5	I-Disease
.	9	O

In	9	O
a	5	O
patient	5	O
with	5	O
WPW	5	B-Disease
syndrome	5	I-Disease
and	5	O
idiopathic	5	B-Disease
dilated	5	I-Disease
cardiomyopathy	5	I-Disease
,	9	O
intractable	5	O
atrioventricular	5	B-Disease
reentrant	5	I-Disease
tachycardia	5	I-Disease
(	9	O
AVRT	5	B-Disease
)	9	O
was	9	O
iatrogenically	5	O
induced	3	O
.	9	O

QRS	5	O
without	9	O
preexcitation	5	O
,	9	O
caused	9	O
by	9	O
junctional	9	O
escape	5	O
beats	5	O
after	9	O
verapamil	0	B-Chemical
or	5	O
unidirectional	5	O
antegrade	5	O
block	9	O
of	5	O
accessory	9	O
pathway	3	O
after	9	O
catheter	5	O
ablation	9	O
,	9	O
established	9	O
frequent	5	O
AVRT	5	B-Disease
attack	5	O
.	9	O

Epidemic	5	O
of	5	O
liver	9	B-Disease
disease	5	I-Disease
caused	9	O
by	9	O
hydrochlorofluorocarbons	0	B-Chemical
used	5	O
as	5	O
ozone	0	B-Chemical
-	7	O
sparing	5	O
substitutes	5	O
of	5	O
chlorofluorocarbons	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Hydrochlorofluorocarbons	9	B-Chemical
(	9	O
HCFCs	5	B-Chemical
)	9	O
are	5	O
used	5	O
increasingly	5	O
in	5	O
industry	5	O
as	5	O
substitutes	5	O
for	5	O
ozone	0	B-Chemical
-	7	O
depleting	3	O
chlorofluorocarbons	0	B-Chemical
(	9	O
CFCs	3	B-Chemical
)	9	O
.	9	O

Limited	9	O
studies	9	O
in	5	O
animals	9	O
indicate	9	O
potential	9	O
hepatotoxicity	9	B-Disease
of	5	O
some	5	O
of	5	O
these	5	O
compounds	0	O
.	9	O

We	9	O
investigated	9	O
an	5	O
epidemic	5	O
of	5	O
liver	9	B-Disease
disease	5	I-Disease
in	5	O
nine	9	O
industrial	5	O
workers	5	O
who	5	O
had	9	O
had	9	O
repeated	5	O
accidental	5	O
exposure	9	O
to	5	O
a	5	O
mixture	0	O
of	5	O
1	9	B-Chemical
,	9	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
dichloro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
trifluoroethane	9	I-Chemical
(	9	O
HCFC	0	B-Chemical
123	9	I-Chemical
)	9	O
and	5	O
1	9	B-Chemical
-	7	I-Chemical
chloro	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
tetrafluoroethane	0	I-Chemical
(	9	O
HCFC	0	B-Chemical
124	7	I-Chemical
)	9	O
.	9	O

All	9	O
nine	9	O
exposed	9	O
workers	5	O
were	9	O
affected	9	O
to	5	O
various	9	O
degrees	5	O
.	9	O

Both	9	O
compounds	0	O
are	5	O
metabolised	0	O
in	5	O
the	5	O
same	9	O
way	5	O
as	5	O
1	9	B-Chemical
-	7	I-Chemical
bromo	0	I-Chemical
-	7	I-Chemical
1	9	I-Chemical
-	7	I-Chemical
chloro	0	I-Chemical
-	7	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
,	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
trifluoroethane	9	I-Chemical
(	9	O
halothane	0	B-Chemical
)	9	O
to	5	O
form	9	O
reactive	9	O
trifluoroacetyl	0	B-Chemical
halide	0	O
intermediates	9	O
,	9	O
which	5	O
have	5	O
been	9	O
implicated	9	O
in	5	O
the	5	O
hepatotoxicity	9	B-Disease
of	5	O
halothane	0	B-Chemical
.	9	O

We	9	O
aimed	5	O
to	5	O
test	5	O
whether	9	O
HCFCs	5	B-Chemical
123	9	I-Chemical
and	5	I-Chemical
124	7	I-Chemical
can	5	O
result	9	O
in	5	O
serious	5	O
liver	9	B-Disease
disease	5	I-Disease
.	9	O

METHODS	2	O
:	9	O
For	9	O
one	5	O
severely	9	O
affected	9	O
worker	5	O
liver	9	O
biopsy	5	O
and	5	O
immunohistochemical	3	O
stainings	3	O
for	5	O
the	5	O
presence	9	O
of	5	O
trifluoroacetyl	0	B-Chemical
protein	1	O
adducts	0	O
were	9	O
done	9	O
.	9	O

The	5	O
serum	9	O
of	5	O
six	9	O
affected	9	O
workers	5	O
and	5	O
five	9	O
controls	9	O
was	9	O
tested	9	O
for	5	O
autoantibodies	3	O
that	5	O
react	9	O
with	5	O
human	3	O
liver	9	O
cytochrome	0	O
-	7	O
P450	1	O
2E1	0	O
(	9	O
P450	1	O
2E1	0	O
)	9	O
and	5	O
P58	1	O
protein	1	O
disulphide	1	O
isomerase	1	O
isoform	1	O
(	9	O
P58	1	O
)	9	O
.	9	O

FINDINGS	2	O
:	9	O
The	5	O
liver	9	O
biopsy	5	O
sample	9	O
showed	9	O
hepatocellular	9	O
necrosis	9	B-Disease
which	5	O
was	9	O
prominent	9	O
in	5	O
perivenular	3	O
zone	9	O
three	9	O
and	5	O
extended	5	O
focally	3	O
from	9	O
portal	5	O
tracts	5	O
to	5	O
portal	5	O
tracts	5	O
and	5	O
centrilobular	5	O
areas	5	O
(	9	O
bridging	5	O
necrosis	9	B-Disease
)	9	O
.	9	O

Trifluoroacetyl	0	B-Chemical
-	7	O
adducted	0	O
proteins	1	O
were	9	O
detected	9	O
in	5	O
surviving	9	O
hepatocytes	3	O
.	9	O

Autoantibodies	3	O
against	9	O
P450	1	O
2E1	0	O
or	5	O
P58	1	O
,	9	O
previously	9	O
associated	9	O
with	5	O
halothane	0	B-Disease
hepatitis	9	I-Disease
,	9	O
were	9	O
detected	9	O
in	5	O
the	5	O
serum	9	O
of	5	O
five	9	O
affected	9	O
workers	5	O
.	9	O

INTERPRETATION	2	O
:	9	O
Repeated	5	O
exposure	9	O
of	5	O
human	3	O
beings	5	O
to	5	O
HCFCs	5	B-Chemical
123	9	I-Chemical
and	5	I-Chemical
124	7	I-Chemical
can	5	O
result	9	O
in	5	O
serious	5	O
liver	9	B-Disease
injury	9	I-Disease
in	5	O
a	5	O
large	5	O
proportion	9	O
of	5	O
the	5	O
exposed	9	O
population	5	O
.	9	O

Although	9	O
the	5	O
exact	5	O
mechanism	9	O
of	5	O
hepatotoxicity	9	B-Disease
of	5	O
these	5	O
agents	5	O
is	5	O
not	5	O
known	9	O
,	9	O
the	5	O
results	9	O
suggest	9	O
that	5	O
trifluoroacetyl	0	B-Chemical
-	7	O
altered	9	O
liver	9	O
proteins	1	O
are	5	O
involved	9	O
.	9	O

In	9	O
view	5	O
of	5	O
the	5	O
potentially	5	O
widespread	5	O
use	5	O
of	5	O
these	5	O
compounds	0	O
,	9	O
there	5	O
is	5	O
an	5	O
urgent	5	O
need	5	O
to	5	O
develop	5	O
safer	5	O
alternatives	5	O
.	9	O

Bile	0	B-Disease
duct	5	I-Disease
hamartoma	5	I-Disease
occurring	9	O
in	5	O
association	9	O
with	5	O
long	5	O
-	7	O
term	5	O
treatment	9	O
with	5	O
danazol	0	B-Chemical
.	9	O

We	9	O
report	5	O
a	5	O
case	5	O
of	5	O
bile	0	B-Disease
duct	5	I-Disease
hamartoma	5	I-Disease
which	5	O
developed	5	O
in	5	O
a	5	O
patient	5	O
who	5	O
had	9	O
been	9	O
on	5	O
long	5	O
-	7	O
term	5	O
danazol	0	B-Chemical
treatment	9	O
.	9	O

Such	5	O
patients	5	O
should	5	O
be	5	O
under	9	O
close	5	O
follow	5	O
-	7	O
up	5	O
,	9	O
preferably	5	O
with	5	O
periodic	5	O
ultrasound	5	O
examination	5	O
of	5	O
the	5	O
liver	9	O
.	9	O

If	5	O
the	5	O
patient	5	O
develops	5	O
a	5	O
liver	9	B-Disease
mass	9	I-Disease
,	9	O
because	5	O
of	5	O
non	9	O
-	7	O
specific	9	O
clinical	5	O
features	5	O
and	5	O
imaging	5	O
appearances	5	O
,	9	O
biopsy	5	O
may	5	O
be	5	O
the	5	O
only	9	O
way	5	O
to	5	O
achieve	5	O
a	5	O
definitive	5	O
diagnosis	5	O
.	9	O

Endocrine	2	O
screening	5	O
in	5	O
1	9	O
,	9	O
022	7	O
men	5	O
with	5	O
erectile	5	B-Disease
dysfunction	9	I-Disease
:	9	O
clinical	5	O
significance	9	O
and	5	O
cost	5	O
-	7	O
effective	5	O
strategy	5	O
.	9	O

PURPOSE	2	O
:	9	O
We	9	O
reviewed	9	O
the	5	O
results	9	O
of	5	O
serum	9	O
testosterone	9	B-Chemical
and	5	O
prolactin	3	O
determination	9	O
in	5	O
1	9	O
,	9	O
022	7	O
patients	5	O
referred	5	O
because	5	O
of	5	O
erectile	5	B-Disease
dysfunction	9	I-Disease
and	5	O
compared	9	O
the	5	O
data	5	O
with	5	O
history	5	O
,	9	O
results	9	O
of	5	O
physical	5	O
examination	5	O
,	9	O
other	5	O
etiological	5	O
investigations	9	O
and	5	O
effects	9	O
of	5	O
endocrine	9	O
therapy	5	O
to	5	O
refine	5	O
the	5	O
rules	5	O
of	5	O
cost	5	O
-	7	O
effective	5	O
endocrine	9	O
screening	5	O
and	5	O
to	5	O
pinpoint	5	O
actual	5	O
responsibility	5	O
for	5	O
hormonal	9	O
abnormalities	9	O
.	9	O

MATERIALS	2	O
AND	2	O
METHODS	2	O
:	9	O
Testosterone	0	B-Chemical
and	5	O
prolactin	3	O
were	9	O
determined	9	O
by	9	O
radioimmunoassay	0	O
.	9	O

Every	5	O
patient	5	O
was	9	O
screened	9	O
for	5	O
testosterone	9	B-Chemical
and	5	O
451	7	O
were	9	O
screened	9	O
for	5	O
prolactin	3	O
on	5	O
the	5	O
basis	5	O
of	5	O
low	9	B-Disease
sexual	5	I-Disease
desire	5	I-Disease
,	9	O
gynecomastia	5	B-Disease
or	5	O
testosterone	9	B-Chemical
less	5	O
than	5	O
4	9	O
ng	0	O
.	9	O
/	9	O
ml	0	O
.	9	O

Determination	0	O
was	9	O
repeated	5	O
in	5	O
case	5	O
of	5	O
abnormal	9	O
first	9	O
results	9	O
.	9	O

Prolactin	9	O
results	9	O
were	9	O
compared	9	O
with	5	O
those	5	O
of	5	O
a	5	O
previous	9	O
personal	5	O
cohort	9	O
of	5	O
1	9	O
,	9	O
340	9	O
patients	5	O
with	5	O
erectile	5	B-Disease
dysfunction	9	I-Disease
and	5	O
systematic	5	O
prolactin	3	O
determination	9	O
.	9	O

Main	9	O
clinical	5	O
criteria	5	O
tested	9	O
regarding	5	O
efficiency	9	O
in	5	O
hormone	9	O
determination	9	O
were	9	O
low	9	B-Disease
sexual	5	I-Disease
desire	5	I-Disease
,	9	O
small	9	O
testes	9	O
and	5	O
gynecomastia	5	B-Disease
.	9	O

Endocrine	2	O
therapy	5	O
consisted	5	O
of	5	O
testosterone	9	B-Chemical
heptylate	9	I-Chemical
or	5	O
human	3	O
chorionic	9	O
gonadotropin	9	O
for	5	O
hypogonadism	5	B-Disease
and	5	O
bromocriptine	0	B-Chemical
for	5	O
hyperprolactinemia	5	B-Disease
.	9	O

RESULTS	9	O
:	9	O
Testosterone	0	B-Chemical
was	9	O
less	5	O
than	5	O
3	9	O
ng	0	O
.	9	O
/	9	O
ml	0	O
.	9	O
in	5	O
107	9	O
patients	5	O
but	9	O
normal	9	O
in	5	O
40	9	O
%	9	O
at	9	O
repeat	9	O
determination	9	O
.	9	O

The	5	O
prevalence	5	O
of	5	O
repeatedly	5	O
low	9	O
testosterone	9	B-Chemical
increased	9	O
with	5	O
age	5	O
(	9	O
4	9	O
%	9	O
before	9	O
age	5	O
50	0	O
years	5	O
and	5	O
9	7	O
%	9	O
50	0	O
years	5	O
or	5	O
older	5	O
)	9	O
.	9	O

Two	9	O
pituitary	3	B-Disease
tumors	3	I-Disease
were	9	O
discovered	9	O
after	9	O
testosterone	9	B-Chemical
determination	9	O
.	9	O

Most	5	O
of	5	O
the	5	O
other	5	O
low	9	O
testosterone	9	B-Chemical
levels	3	O
seemed	9	O
to	5	O
result	9	O
from	9	O
nonorganic	5	O
hypothalamic	3	B-Disease
dysfunction	9	I-Disease
because	5	O
of	5	O
normal	9	O
serum	9	O
luteinizing	0	O
hormone	9	O
and	5	O
prolactin	3	O
and	5	O
to	5	O
have	5	O
only	9	O
a	5	O
small	9	O
role	9	O
in	5	O
erectile	5	B-Disease
dysfunction	9	I-Disease
(	9	O
definite	5	O
improvement	5	O
in	5	O
only	9	O
16	9	O
of	5	O
44	7	O
[	9	O
36	9	O
%	9	O
]	9	O
after	9	O
androgen	3	O
therapy	5	O
,	9	O
normal	9	O
morning	5	O
or	5	O
nocturnal	5	O
erections	5	O
in	5	O
30	9	O
%	9	O
and	5	O
definite	5	O
vasculogenic	3	O
contributions	5	O
in	5	O
42	7	O
%	9	O
)	9	O
.	9	O

Determining	5	O
testosterone	9	B-Chemical
only	9	O
in	5	O
cases	5	O
of	5	O
low	9	B-Disease
sexual	5	I-Disease
desire	5	I-Disease
or	5	O
abnormal	9	O
physical	5	O
examination	5	O
would	5	O
have	5	O
missed	5	O
40	9	O
%	9	O
of	5	O
the	5	O
cases	5	O
with	5	O
low	9	O
testosterone	9	B-Chemical
,	9	O
including	9	O
37	9	O
%	9	O
of	5	O
those	5	O
subsequently	9	O
improved	5	O
by	9	O
androgen	3	O
therapy	5	O
.	9	O

Prolactin	9	O
exceeded	9	O
20	9	O
ng	0	O
.	9	O
/	9	O
ml	0	O
.	9	O
in	5	O
5	9	O
men	5	O
and	5	O
was	9	O
normal	9	O
in	5	O
2	9	O
at	9	O
repeat	9	O
determination	9	O
.	9	O

Only	9	O
1	9	O
prolactinoma	5	B-Disease
was	9	O
discovered	9	O
.	9	O

These	5	O
data	5	O
are	5	O
lower	9	O
than	5	O
those	5	O
we	5	O
found	9	O
during	5	O
the	5	O
last	5	O
2	9	O
decades	5	O
(	9	O
overall	5	O
prolactin	3	O
greater	5	O
than	5	O
20	9	O
ng	0	O
.	9	O
/	9	O
ml	0	O
.	9	O
in	5	O
1	9	O
.	9	O
86	7	O
%	9	O
of	5	O
1	9	O
,	9	O
821	7	O
patients	5	O
,	9	O
prolactinomas	5	B-Disease
in	5	O
7	9	O
,	9	O
0	7	O
.	9	O
38	7	O
%	9	O
)	9	O
.	9	O

Bromocriptine	0	B-Chemical
was	9	O
definitely	5	O
effective	5	O
in	5	O
cases	5	O
with	5	O
prolactin	3	O
greater	5	O
than	5	O
35	9	O
ng	0	O
.	9	O
/	9	O
ml	0	O
.	9	O

(	9	O
8	9	O
of	5	O
12	9	O
compared	9	O
to	5	O
only	9	O
9	7	O
of	5	O
22	7	O
cases	5	O
with	5	O
prolactin	3	O
between	5	O
20	9	O
and	5	O
35	9	O
ng	0	O
.	9	O
/	9	O
ml	0	O
.	9	O
)	9	O
.	9	O

Testosterone	0	B-Chemical
was	9	O
low	9	O
in	5	O
less	5	O
than	5	O
50	0	O
%	9	O
of	5	O
cases	5	O
with	5	O
prolactin	3	O
greater	5	O
than	5	O
35	9	O
ng	0	O
.	9	O
/	9	O
ml	0	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Low	9	O
prevalences	5	O
and	5	O
effects	9	O
of	5	O
low	9	O
testosterone	9	B-Chemical
and	5	O
high	9	O
prolactin	3	O
in	5	O
erectile	5	B-Disease
dysfunction	9	I-Disease
cannot	5	O
justify	5	O
their	5	O
routine	5	O
determination	9	O
.	9	O

However	9	O
,	9	O
cost	5	O
-	7	O
effective	5	O
screening	5	O
strategies	5	O
recommended	5	O
so	5	O
far	5	O
missed	5	O
40	9	O
to	5	O
50	0	O
%	9	O
of	5	O
cases	5	O
improved	5	O
with	5	O
endocrine	9	O
therapy	5	O
and	5	O
the	5	O
pituitary	3	B-Disease
tumors	3	I-Disease
.	9	O

We	9	O
now	5	O
advocate	5	O
that	5	O
before	9	O
age	5	O
50	0	O
years	5	O
testosterone	9	B-Chemical
be	5	O
determined	9	O
only	9	O
in	5	O
cases	5	O
of	5	O
low	9	B-Disease
sexual	5	I-Disease
desire	5	I-Disease
and	5	O
abnormal	9	O
physical	5	O
examination	5	O
but	9	O
that	5	O
it	5	O
be	5	O
measured	9	O
in	5	O
all	5	O
men	5	O
older	5	O
than	5	O
50	0	O
years	5	O
.	9	O

Prolactin	9	O
should	5	O
be	5	O
determined	9	O
only	9	O
in	5	O
cases	5	O
of	5	O
low	9	B-Disease
sexual	5	I-Disease
desire	5	I-Disease
,	9	O
gynecomastia	5	B-Disease
and	5	O
/	9	O
or	5	O
testosterone	9	B-Chemical
less	5	O
than	5	O
4	9	O
ng	0	O
.	9	O
/	9	O
ml	0	O
.	9	O

Extrapyramidal	5	O
side	5	O
effects	9	O
with	5	O
risperidone	5	B-Chemical
and	5	O
haloperidol	5	B-Chemical
at	9	O
comparable	9	O
D2	9	O
receptor	3	O
occupancy	9	O
levels	3	O
.	9	O

Risperidone	7	B-Chemical
is	5	O
an	5	O
antipsychotic	5	O
drug	5	O
with	5	O
high	9	O
affinity	0	O
at	9	O
dopamine	5	B-Chemical
D2	9	O
and	5	O
serotonin	9	B-Chemical
5	9	I-Chemical
-	7	I-Chemical
HT2	3	I-Chemical
receptors	3	O
.	9	O

Previous	9	O
clinical	5	O
studies	9	O
have	5	O
proposed	5	O
that	5	O
risperidone	5	B-Chemical
'	9	O
s	9	O
pharmacologic	9	O
profile	9	O
may	5	O
produce	9	O
improved	5	O
efficacy	9	O
for	5	O
negative	9	O
psychotic	5	B-Disease
symptoms	5	I-Disease
and	5	O
decreased	9	O
propensity	5	O
for	5	O
extrapyramidal	5	O
side	5	O
effects	9	O
;	9	O
features	5	O
shared	5	O
by	9	O
so	5	O
-	7	O
called	5	O
'	9	O
atypical	5	O
'	9	O
neuroleptics	5	O
.	9	O

To	9	O
determine	9	O
if	5	O
routine	5	O
risperidone	5	B-Chemical
treatment	9	O
is	5	O
associated	9	O
with	5	O
a	5	O
unique	9	O
degree	5	O
of	5	O
D2	9	O
receptor	3	O
occupancy	9	O
and	5	O
pattern	9	O
of	5	O
clinical	5	O
effects	9	O
,	9	O
we	5	O
used	5	O
[	9	O
123I	0	O
]	9	O
IBZM	0	O
SPECT	5	O
to	5	O
determine	9	O
D2	9	O
occupancy	9	O
in	5	O
subjects	5	O
treated	3	O
with	5	O
routine	5	O
clinical	5	O
doses	0	O
of	5	O
risperidone	5	B-Chemical
(	9	O
n	9	O
=	7	O
12	9	O
)	9	O
or	5	O
haloperidol	5	B-Chemical
(	9	O
n	9	O
=	7	O
7	9	O
)	9	O
.	9	O

Both	9	O
risperidone	5	B-Chemical
and	5	O
haloperidol	5	B-Chemical
produced	9	O
D2	9	O
occupancy	9	O
levels	3	O
between	5	O
approximately	9	O
60	9	O
and	5	O
90	9	O
%	9	O
at	9	O
standard	5	O
clinical	5	O
doses	0	O
.	9	O

There	5	O
was	9	O
no	9	O
significant	9	O
difference	9	O
between	5	O
occupancy	9	O
levels	3	O
obtained	9	O
with	5	O
haloperidol	5	B-Chemical
or	5	O
risperidone	5	B-Chemical
.	9	O

Drug	5	B-Disease
-	7	I-Disease
induced	3	I-Disease
parkinsonism	5	I-Disease
was	9	O
observed	9	O
in	5	O
subjects	5	O
treated	3	O
with	5	O
risperidone	5	B-Chemical
(	9	O
42	7	O
%	9	O
)	9	O
and	5	O
haloperidol	5	B-Chemical
(	9	O
29	7	O
%	9	O
)	9	O
and	5	O
was	9	O
observed	9	O
at	9	O
occupancy	9	O
levels	3	O
above	9	O
60	9	O
%	9	O
.	9	O

Based	9	O
on	5	O
these	5	O
observations	9	O
,	9	O
it	5	O
is	5	O
concluded	9	O
that	5	O
5	9	O
-	7	O
HT2	3	O
blockade	3	O
obtained	9	O
with	5	O
risperidone	5	B-Chemical
at	9	O
D2	9	O
occupancy	9	O
rates	5	O
of	5	O
60	9	O
%	9	O
and	5	O
above	9	O
does	9	O
not	5	O
appear	9	O
to	5	O
protect	9	O
against	9	O
the	5	O
risk	5	O
for	5	O
extrapyramidal	5	O
side	5	O
effects	9	O
.	9	O

Treatment	9	O
of	5	O
previously	9	O
treated	3	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
by	9	O
mitoxantrone	0	B-Chemical
and	5	O
48	9	O
-	7	O
hour	0	O
continuous	5	O
infusion	0	O
of	5	O
high	9	O
-	7	O
dose	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
and	5	O
leucovorin	0	B-Chemical
(	9	O
MFL	7	B-Chemical
)	9	O
:	9	O
low	9	O
palliative	5	O
benefit	5	O
and	5	O
high	9	O
treatment	9	O
-	7	O
related	9	O
toxicity	9	B-Disease
.	9	O

For	9	O
previously	9	O
treated	3	O
advanced	5	O
breast	3	B-Disease
cancer	3	I-Disease
,	9	O
there	5	O
is	5	O
no	9	O
standard	5	O
second	9	O
-	7	O
line	9	O
therapy	5	O
.	9	O

Combination	9	O
chemotherapy	5	O
with	5	O
mitoxantrone	0	B-Chemical
,	9	O
high	9	O
-	7	O
dose	9	O
5	9	B-Chemical
-	7	I-Chemical
fluorouracil	0	I-Chemical
(	9	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
)	9	O
and	5	O
leucovorin	0	B-Chemical
(	9	O
MFL	7	B-Chemical
regimen	5	I-Chemical
)	9	O
had	9	O
been	9	O
reported	9	O
as	5	O
an	5	O
effective	5	O
and	5	O
well	9	O
tolerated	9	O
regimen	5	O
.	9	O

From	5	O
October	2	O
1993	2	O
to	5	O
November	2	O
1995	2	O
,	9	O
we	5	O
treated	3	O
13	7	O
patients	5	O
with	5	O
previously	9	O
chemotherapy	5	O
-	7	O
treated	3	O
metastatic	3	O
breast	3	B-Disease
cancer	3	I-Disease
by	9	O
mitoxantrone	0	B-Chemical
,	9	O
12	9	O
mg	0	O
/	9	O
m2	7	O
,	9	O
on	5	O
day	9	O
1	9	O
and	5	O
continuous	5	O
infusion	0	O
of	5	O
5	9	B-Chemical
-	7	I-Chemical
FU	9	I-Chemical
,	9	O
3000	0	O
mg	0	O
/	9	O
m2	7	O
,	9	O
together	9	O
with	5	O
leucovorin	0	B-Chemical
,	9	O
300	0	O
mg	0	O
/	9	O
m2	7	O
,	9	O
for	5	O
48	9	O
h	0	O
from	9	O
day	9	O
1	9	O
to	5	O
2	9	O
.	9	O

Each	5	O
course	5	O
of	5	O
chemotherapy	5	O
was	9	O
given	5	O
every	5	O
4	9	O
weeks	9	O
.	9	O

Most	5	O
of	5	O
these	5	O
patients	5	O
had	9	O
more	5	O
than	5	O
two	5	O
metastatic	3	O
sites	9	O
,	9	O
with	5	O
lung	9	O
metastasis	3	O
predominant	9	O
.	9	O

Seven	9	O
patients	5	O
had	9	O
been	9	O
treated	3	O
with	5	O
anthracycline	9	B-Chemical
.	9	O

Seven	9	O
patients	5	O
had	9	O
previously	9	O
received	9	O
radiotherapy	5	O
and	5	O
seven	9	O
had	9	O
received	9	O
hormone	9	O
therapy	5	O
.	9	O

Median	7	O
number	9	O
of	5	O
courses	5	O
of	5	O
MFL	7	B-Chemical
regimen	5	I-Chemical
given	5	O
was	9	O
six	9	O
and	5	O
the	5	O
median	9	O
cumulative	5	O
dose	9	O
of	5	O
mitoxantrone	0	B-Chemical
was	9	O
68	7	O
.	9	O
35	9	O
mg	0	O
/	9	O
m2	7	O
.	9	O

One	5	O
patient	5	O
had	9	O
complete	9	O
response	9	O
,	9	O
seven	9	O
had	9	O
stable	9	O
disease	5	O
,	9	O
none	9	O
had	9	O
partial	9	O
response	9	O
and	5	O
five	9	O
had	9	O
progressive	5	O
disease	5	O
.	9	O

The	5	O
overall	5	O
objective	5	O
response	9	O
rate	9	O
was	9	O
7	9	O
.	9	O
6	9	O
%	9	O
.	9	O

The	5	O
median	9	O
follow	5	O
-	7	O
up	5	O
period	5	O
was	9	O
14	7	O
months	5	O
.	9	O

Median	7	O
survival	9	O
was	9	O
16	9	O
months	5	O
.	9	O

Median	7	O
progression	9	O
-	7	O
free	9	O
survival	9	O
was	9	O
5	9	O
months	5	O
.	9	O

A	9	O
complete	9	O
responder	9	O
had	9	O
relapse	5	O
-	7	O
free	9	O
survival	9	O
up	5	O
to	5	O
17	7	O
months	5	O
.	9	O

Major	9	O
toxicities	5	B-Disease
were	9	O
cardiotoxicity	9	B-Disease
and	5	O
leukopenia	9	B-Disease
.	9	O

Eight	9	O
patients	5	O
were	9	O
dead	9	O
in	5	O
the	5	O
last	5	O
follow	5	O
-	7	O
up	5	O
;	9	O
two	5	O
of	5	O
them	5	O
died	9	O
of	5	O
treatment	9	O
-	7	O
related	9	O
toxicity	9	B-Disease
.	9	O

The	5	O
MFL	7	B-Chemical
regimen	5	I-Chemical
achieves	5	O
little	9	O
palliative	5	O
benefit	5	O
and	5	O
induces	3	O
severe	5	O
toxicity	9	B-Disease
at	9	O
a	5	O
fairly	5	O
high	9	O
rate	9	O
.	9	O

Administration	2	O
of	5	O
this	5	O
regimen	5	O
to	5	O
breast	3	B-Disease
cancer	3	I-Disease
patients	5	O
who	5	O
have	5	O
been	9	O
treated	3	O
by	9	O
chemotherapy	5	O
and	5	O
those	5	O
with	5	O
impaired	9	B-Disease
heart	5	I-Disease
function	9	I-Disease
requires	5	O
careful	5	O
attention	5	O
.	9	O

Ticlopidine	0	B-Chemical
-	7	O
induced	3	O
aplastic	5	B-Disease
anemia	9	I-Disease
:	9	O
report	5	O
of	5	O
three	9	O
Chinese	9	O
patients	5	O
and	5	O
review	5	O
of	5	O
the	5	O
literature	5	O
.	9	O

In	9	O
this	5	O
study	9	O
,	9	O
three	9	O
Chinese	9	O
patients	5	O
with	5	O
ticlopidine	0	B-Chemical
-	7	O
induced	3	O
aplastic	5	B-Disease
anemia	9	I-Disease
were	9	O
reported	9	O
and	5	O
another	9	O
13	7	O
patients	5	O
in	5	O
the	5	O
English	5	O
literature	5	O
were	9	O
reviewed	9	O
.	9	O

We	9	O
attempted	5	O
to	5	O
find	5	O
underlying	5	O
similarities	9	O
,	9	O
evaluate	9	O
the	5	O
risk	5	O
factors	9	O
,	9	O
and	5	O
identify	9	O
appropriate	5	O
treatment	9	O
for	5	O
this	5	O
complication	5	O
.	9	O

All	9	O
but	9	O
one	5	O
of	5	O
the	5	O
patients	5	O
were	9	O
over	5	O
60	9	O
years	5	O
old	5	O
,	9	O
and	5	O
the	5	O
6	9	O
who	5	O
died	9	O
were	9	O
all	5	O
older	5	O
than	5	O
65	7	O
.	9	O

Therefore	9	O
,	9	O
old	5	O
age	5	O
may	5	O
be	5	O
a	5	O
risk	5	O
factor	9	O
for	5	O
developing	5	O
this	5	O
complication	5	O
.	9	O

Agranulocytosis	5	B-Disease
occurred	9	O
3	9	O
-	7	O
20	9	O
weeks	9	O
after	9	O
initiation	9	O
of	5	O
ticlopidine	0	B-Chemical
,	9	O
so	5	O
frequent	5	O
examination	5	O
of	5	O
white	9	O
cell	3	O
count	9	O
during	5	O
treatment	9	O
is	5	O
recommended	5	O
.	9	O

There	5	O
seemed	9	O
to	5	O
be	5	O
no	9	O
direct	9	O
correlation	9	O
between	5	O
the	5	O
dose	9	O
or	5	O
duration	5	O
used	5	O
and	5	O
the	5	O
severity	5	O
of	5	O
bone	5	B-Disease
marrow	3	I-Disease
suppression	9	I-Disease
.	9	O

Treatment	9	O
for	5	O
ticlopidine	0	B-Chemical
-	7	O
induced	3	O
aplastic	5	B-Disease
anemia	9	I-Disease
with	5	O
colony	9	O
-	7	O
stimulating	9	O
factors	9	O
seemed	9	O
to	5	O
have	5	O
little	9	O
effect	9	O
.	9	O

The	5	O
fact	9	O
that	5	O
5	9	O
of	5	O
the	5	O
6	9	O
patients	5	O
who	5	O
received	9	O
concurrent	5	O
calcium	0	B-Chemical
channel	9	O
blockers	9	O
died	9	O
,	9	O
should	5	O
alert	5	O
clinicians	5	O
to	5	O
be	5	O
more	5	O
cautious	5	O
when	5	O
using	9	O
these	5	O
two	5	O
drugs	5	O
simultaneously	5	O
.	9	O

Upregulation	3	O
of	5	O
the	5	O
expression	3	O
of	5	O
vasopressin	9	B-Chemical
gene	1	O
in	5	O
the	5	O
paraventricular	9	O
and	5	O
supraoptic	9	O
nuclei	3	O
of	5	O
the	5	O
lithium	0	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
insipidus	5	I-Disease
rat	3	O
.	9	O

The	5	O
expression	3	O
of	5	O
arginine	0	B-Chemical
vasopressin	9	I-Chemical
(	9	O
AVP	9	B-Chemical
)	9	O
gene	1	O
in	5	O
the	5	O
paraventricular	9	O
(	9	O
PVN	3	O
)	9	O
and	5	O
supraoptic	9	O
nuclei	3	O
(	9	O
SON	9	O
)	9	O
was	9	O
investigated	9	O
in	5	O
rats	9	O
with	5	O
lithium	0	B-Chemical
(	9	O
Li	6	B-Chemical
)	9	O
-	7	O
induced	3	O
polyuria	5	B-Disease
,	9	O
using	9	O
in	5	O
situ	9	O
hybridization	9	O
histochemistry	9	O
and	5	O
radioimmunoassay	0	O
.	9	O

The	5	O
male	9	O
Wistar	9	O
rats	9	O
consuming	5	O
a	5	O
diet	9	O
that	5	O
contained	9	O
LiCl	0	B-Chemical
(	9	O
60	9	O
mmol	0	O
/	9	O
kg	0	O
)	9	O
for	5	O
4	9	O
weeks	9	O
developed	5	O
marked	9	O
polyuria	5	B-Disease
.	9	O

The	5	O
Li	6	B-Chemical
-	7	O
treated	3	O
rats	9	O
produced	9	O
a	5	O
large	5	O
volume	9	O
of	5	O
hypotonic	0	O
urine	9	O
with	5	O
low	9	O
ionic	0	O
concentrations	0	O
.	9	O

Plasma	0	O
sodium	0	B-Chemical
concentrations	0	O
were	9	O
found	9	O
to	5	O
be	5	O
slightly	9	O
increased	9	O
in	5	O
the	5	O
Li	6	B-Chemical
-	7	O
treated	3	O
rats	9	O
compared	9	O
with	5	O
those	5	O
in	5	O
controls	9	O
.	9	O

Plasma	0	O
concentration	0	O
of	5	O
AVP	9	B-Chemical
and	5	O
transcripts	1	O
of	5	O
AVP	9	B-Chemical
gene	1	O
in	5	O
the	5	O
PVN	3	O
and	5	O
SON	9	O
were	9	O
significantly	9	O
increased	9	O
in	5	O
the	5	O
Li	6	B-Chemical
-	7	O
treated	3	O
rats	9	O
compared	9	O
with	5	O
controls	9	O
.	9	O

These	5	O
results	9	O
suggest	9	O
that	5	O
dehydration	9	B-Disease
and	5	O
/	9	O
or	5	O
the	5	O
activation	3	O
of	5	O
visceral	9	O
afferent	5	O
inputs	5	O
may	5	O
contribute	9	O
to	5	O
the	5	O
elevation	9	O
of	5	O
plasma	9	O
AVP	9	B-Chemical
and	5	O
the	5	O
upregulation	3	O
of	5	O
AVP	9	B-Chemical
gene	1	O
expression	3	O
in	5	O
the	5	O
PVN	3	O
and	5	O
the	5	O
SON	9	O
of	5	O
the	5	O
Li	6	B-Chemical
-	7	O
induced	3	O
diabetes	5	B-Disease
insipidus	5	I-Disease
rat	3	O
.	9	O

Antinociceptive	0	O
and	5	O
antiamnesic	0	O
properties	9	O
of	5	O
the	5	O
presynaptic	3	O
cholinergic	3	O
amplifier	5	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
.	9	O

The	5	O
antinociceptive	0	O
effect	9	O
of	5	O
3	9	B-Chemical
alpha	9	I-Chemical
-	7	I-Chemical
tropyl	_	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
p	7	I-Chemical
-	7	I-Chemical
bromophenyl	0	I-Chemical
)	9	I-Chemical
propionate	0	I-Chemical
[	9	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
]	9	O
(	9	O
10	9	O
-	7	O
40	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
s	9	O
.	9	O
c	9	O
.	9	O
;	9	O
30	9	O
-	7	O
60	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
p	7	O
.	9	O
o	9	O
.	9	O
;	9	O
10	9	O
-	7	O
30	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
v	0	O
.	9	O
;	9	O
10	9	O
-	7	O
30	9	O
micrograms	0	O
/	9	O
mouse	3	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
was	9	O
examined	9	O
in	5	O
mice	3	O
,	9	O
rats	9	O
and	5	O
guinea	9	O
pigs	9	O
by	9	O
use	5	O
of	5	O
the	5	O
hot	5	O
-	7	O
plate	0	O
,	9	O
abdominal	5	O
-	7	O
constriction	5	O
,	9	O
tail	9	O
-	7	O
flick	5	O
and	5	O
paw	5	O
-	7	O
pressure	5	O
tests	5	O
.	9	O

(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
antinociception	3	O
peaked	9	O
15	9	O
min	0	O
after	9	O
injection	9	O
and	5	O
then	9	O
slowly	5	O
diminished	9	O
.	9	O

The	5	O
antinociception	3	O
produced	9	O
by	9	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
was	9	O
prevented	9	O
by	9	O
the	5	O
unselective	0	O
muscarinic	3	O
antagonist	3	O
atropine	0	B-Chemical
,	9	O
the	5	O
M1	9	O
-	7	O
selective	9	O
antagonists	3	O
pirenzepine	0	B-Chemical
and	5	O
dicyclomine	0	B-Chemical
and	5	O
the	5	O
acetylcholine	0	B-Chemical
depletor	0	O
hemicholinium	0	B-Chemical
-	7	I-Chemical
3	9	I-Chemical
,	9	O
but	9	O
not	5	O
by	9	O
the	5	O
opioid	5	O
antagonist	3	O
naloxone	0	B-Chemical
,	9	O
the	5	O
gamma	9	B-Chemical
-	7	I-Chemical
aminobutyric	0	I-Chemical
acidB	9	I-Chemical
antagonist	3	O
3	9	B-Chemical
-	7	I-Chemical
aminopropyl	0	I-Chemical
-	7	I-Chemical
diethoxy	0	I-Chemical
-	7	I-Chemical
methyl	0	I-Chemical
-	7	I-Chemical
phosphinic	0	I-Chemical
acid	0	I-Chemical
,	9	O
the	5	O
H3	1	O
agonist	3	O
R	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
alpha	9	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
methylhistamine	0	I-Chemical
,	9	O
the	5	O
D2	9	O
antagonist	3	O
quinpirole	3	B-Chemical
,	9	O
the	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptamine4	_	I-Chemical
antagonist	3	O
2	9	B-Chemical
-	7	I-Chemical
methoxy	0	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
amino	1	I-Chemical
-	7	I-Chemical
5	9	I-Chemical
-	7	I-Chemical
chlorobenzoic	0	I-Chemical
acid	0	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
diethylamino	0	I-Chemical
)	9	I-Chemical
ethyl	0	I-Chemical
ester	0	I-Chemical
hydrochloride	0	O
,	9	O
the	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptamin1A	_	I-Chemical
antagonist	3	O
1	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
methoxyphenyl	0	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
[	9	I-Chemical
4	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
phthalimido	0	I-Chemical
)	9	I-Chemical
butyl	0	I-Chemical
]	9	I-Chemical
piperazine	0	I-Chemical
hydrobromide	0	O
and	5	O
the	5	O
polyamines	0	O
depletor	0	O
reserpine	0	B-Chemical
.	9	O

Based	9	O
on	5	O
these	5	O
data	5	O
,	9	O
it	5	O
can	5	O
be	5	O
postulated	9	O
that	5	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
exerted	9	O
an	5	O
antinociceptive	0	O
effect	9	O
mediated	3	O
by	9	O
a	5	O
central	5	O
potentiation	3	O
of	5	O
cholinergic	3	O
transmission	5	O
.	9	O

(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
(	9	O
10	9	O
-	7	O
40	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
was	9	O
able	9	O
to	5	O
prevent	5	O
amnesia	5	B-Disease
induced	3	O
by	9	O
scopolamine	0	B-Chemical
(	9	O
1	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
and	5	O
dicyclomine	0	B-Chemical
(	9	O
2	9	O
mg	0	O
kg	0	O
-	7	O
1	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
in	5	O
the	5	O
mouse	3	O
passive	5	O
-	7	O
avoidance	5	O
test	5	O
.	9	O

Affinity	0	O
profiles	9	O
of	5	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
for	5	O
muscarinic	3	O
receptor	3	O
subtypes	9	O
,	9	O
determined	9	O
by	9	O
functional	9	O
studies	9	O
(	9	O
rabbit	3	O
vas	9	O
deferens	9	O
for	5	O
M1	9	O
,	9	O
guinea	9	O
pig	9	O
atrium	5	O
for	5	O
M2	9	O
,	9	O
guinea	9	O
pig	9	O
ileum	9	O
for	5	O
M3	9	O
and	5	O
immature	3	O
guinea	9	O
pig	9	O
uterus	9	O
for	5	O
putative	1	O
M4	9	O
)	9	O
,	9	O
have	5	O
shown	9	O
an	5	O
M4	9	O
/	9	O
M1	9	O
selectivity	9	O
ratio	9	O
of	5	O
10	9	O
.	9	O
2	9	O
that	5	O
might	9	O
be	5	O
responsible	9	O
for	5	O
the	5	O
antinociception	3	O
and	5	O
the	5	O
anti	3	O
-	7	O
amnesic	5	B-Disease
effect	9	O
induced	3	O
by	9	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
through	9	O
an	5	O
increase	9	O
in	5	O
acetylcholine	0	B-Chemical
extracellular	9	O
levels	3	O
.	9	O

In	9	O
the	5	O
antinociceptive	0	O
and	5	O
antiamnesic	0	O
dose	9	O
range	9	O
,	9	O
(	9	O
+	9	O
/	9	O
-	7	O
)	9	O
-	7	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
did	9	O
not	5	O
impair	9	O
mouse	3	O
performance	5	O
evaluated	9	O
by	9	O
the	5	O
rota	5	O
-	7	O
rod	9	O
test	5	O
and	5	O
Animex	9	O
apparatus	9	O
.	9	O

The	5	O
effect	9	O
of	5	O
different	9	O
anaesthetic	5	O
agents	5	O
in	5	O
hearing	5	B-Disease
loss	9	I-Disease
following	9	O
spinal	5	O
anaesthesia	5	O
.	9	O

The	5	O
cause	5	O
of	5	O
hearing	5	B-Disease
loss	9	I-Disease
after	9	O
spinal	5	O
anaesthesia	5	O
is	5	O
unknown	9	O
.	9	O

Up	7	O
until	5	O
now	5	O
,	9	O
the	5	O
only	9	O
factor	9	O
studied	9	O
has	9	O
been	9	O
the	5	O
effect	9	O
of	5	O
the	5	O
diameter	9	O
of	5	O
the	5	O
spinal	5	O
needle	5	O
on	5	O
post	9	O
-	7	O
operative	5	O
sensorineural	5	B-Disease
hearing	5	I-Disease
loss	9	I-Disease
.	9	O

The	5	O
aim	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
describe	5	O
this	5	O
hearing	5	B-Disease
loss	9	I-Disease
and	5	O
to	5	O
investigate	9	O
other	5	O
factors	9	O
influencing	5	O
the	5	O
degree	5	O
of	5	O
hearing	5	B-Disease
loss	9	I-Disease
.	9	O

Two	9	O
groups	9	O
of	5	O
22	7	O
similar	9	O
patients	5	O
were	9	O
studied	9	O
:	9	O
one	5	O
group	9	O
received	9	O
6	9	O
mL	0	O
prilocaine	0	B-Chemical
2	9	O
%	9	O
;	9	O
and	5	O
the	5	O
other	5	O
received	9	O
3	9	O
mL	0	O
bupivacaine	0	B-Chemical
0	7	O
.	9	O
5	9	O
%	9	O
.	9	O

Patients	5	O
given	5	O
prilocaine	0	B-Chemical
were	9	O
more	5	O
likely	5	O
to	5	O
develop	5	O
hearing	5	B-Disease
loss	9	I-Disease
(	9	O
10	9	O
out	9	O
of	5	O
22	7	O
)	9	O
than	5	O
those	5	O
given	5	O
bupivacaine	0	B-Chemical
(	9	O
4	9	O
out	9	O
of	5	O
22	7	O
)	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

The	5	O
average	5	O
hearing	5	B-Disease
loss	9	I-Disease
for	5	O
speech	5	O
frequencies	9	O
was	9	O
about	5	O
10	9	O
dB	5	O
after	9	O
prilocaine	0	B-Chemical
and	5	O
15	9	O
dB	5	O
after	9	O
bupivacaine	0	B-Chemical
.	9	O

None	9	O
of	5	O
the	5	O
patients	5	O
complained	5	O
of	5	O
subjective	5	O
hearing	5	B-Disease
loss	9	I-Disease
.	9	O

Long	9	O
-	7	O
term	5	O
follow	5	O
-	7	O
up	5	O
of	5	O
the	5	O
patients	5	O
was	9	O
not	5	O
possible	5	O
.	9	O

A	9	O
transient	9	O
neurological	5	B-Disease
deficit	5	I-Disease
following	9	O
intrathecal	3	O
injection	9	O
of	5	O
1	9	O
%	9	O
hyperbaric	5	O
bupivacaine	0	B-Chemical
for	5	O
unilateral	5	O
spinal	5	O
anaesthesia	5	O
.	9	O

We	9	O
describe	5	O
a	5	O
case	5	O
of	5	O
transient	9	O
neurological	5	B-Disease
deficit	5	I-Disease
that	5	O
occurred	9	O
after	9	O
unilateral	5	O
spinal	5	O
anaesthesia	5	O
with	5	O
8	9	O
mg	0	O
of	5	O
1	9	O
%	9	O
hyperbaric	5	O
bupivacaine	0	B-Chemical
slowly	5	O
injected	3	O
through	9	O
a	5	O
25	9	O
-	7	O
gauge	5	O
pencil	5	O
-	7	O
point	5	O
spinal	5	O
needle	5	O
.	9	O

The	5	O
surgery	5	O
and	5	O
anaesthesia	5	O
were	9	O
uneventful	5	O
,	9	O
but	9	O
3	9	O
days	9	O
after	9	O
surgery	5	O
,	9	O
the	5	O
patient	5	O
reported	9	O
an	5	O
area	5	O
of	5	O
hypoaesthesia	5	O
over	5	O
L3	9	O
-	7	O
L4	9	O
dermatomes	5	O
of	5	O
the	5	O
leg	5	O
which	5	O
had	9	O
been	9	O
operated	5	O
on	5	O
(	9	O
loss	9	B-Disease
of	5	I-Disease
pinprick	5	I-Disease
sensation	5	I-Disease
)	9	O
without	9	O
reduction	9	O
in	5	O
muscular	5	O
strength	5	O
.	9	O

Sensation	5	O
in	5	O
this	5	O
area	5	O
returned	5	O
to	5	O
normal	9	O
over	5	O
the	5	O
following	9	O
2	9	O
weeks	9	O
.	9	O

Prospective	5	O
multicentre	5	O
studies	9	O
with	5	O
a	5	O
large	5	O
population	5	O
and	5	O
a	5	O
long	5	O
follow	5	O
-	7	O
up	5	O
should	5	O
be	5	O
performed	9	O
in	5	O
order	5	O
to	5	O
evaluate	9	O
the	5	O
incidence	5	O
of	5	O
this	5	O
unusual	9	O
side	5	O
effect	9	O
.	9	O

However	9	O
,	9	O
we	5	O
suggest	9	O
that	5	O
a	5	O
low	9	O
solution	0	O
concentration	0	O
should	5	O
be	5	O
preferred	5	O
for	5	O
unilateral	5	O
spinal	5	O
anaesthesia	5	O
with	5	O
a	5	O
hyperbaric	5	O
anaesthetic	5	O
solution	0	O
(	9	O
if	5	O
pencil	5	O
-	7	O
point	5	O
needle	5	O
and	5	O
slow	5	O
injection	9	O
rate	9	O
are	5	O
employed	5	O
)	9	O
,	9	O
in	5	O
order	5	O
to	5	O
minimize	5	O
the	5	O
risk	5	O
of	5	O
a	5	O
localized	9	O
high	9	O
peak	9	O
anaesthetic	5	O
concentration	0	O
,	9	O
which	5	O
might	9	O
lead	5	O
to	5	O
a	5	O
transient	9	O
neurological	5	B-Disease
deficit	5	I-Disease
.	9	O

Transient	9	B-Disease
neurologic	5	I-Disease
symptoms	5	I-Disease
after	9	O
spinal	5	O
anesthesia	5	O
:	9	O
a	5	O
lower	9	O
incidence	5	O
with	5	O
prilocaine	0	B-Chemical
and	5	O
bupivacaine	0	B-Chemical
than	5	O
with	5	O
lidocaine	0	B-Chemical
.	9	O

BACKGROUND	2	O
:	9	O
Recent	9	O
evidence	9	O
suggests	9	O
that	5	O
transient	9	B-Disease
neurologic	5	I-Disease
symptoms	5	I-Disease
(	9	O
TNSs	5	B-Disease
)	9	O
frequently	5	O
follow	5	O
lidocaine	0	B-Chemical
spinal	5	O
anesthesia	5	O
but	9	O
are	5	O
infrequent	5	O
with	5	O
bupivacaine	0	B-Chemical
.	9	O

However	9	O
,	9	O
identification	9	O
of	5	O
a	5	O
short	5	O
-	7	O
acting	9	O
local	5	O
anesthetic	5	O
to	5	O
substitute	9	O
for	5	O
lidocaine	0	B-Chemical
for	5	O
brief	5	O
surgical	5	O
procedures	5	O
remains	9	O
an	5	O
important	9	O
goal	5	O
.	9	O

Prilocaine	0	B-Chemical
is	5	O
an	5	O
amide	0	O
local	5	O
anesthetic	5	O
with	5	O
a	5	O
duration	5	O
of	5	O
action	5	O
similar	9	O
to	5	O
that	5	O
of	5	O
lidocaine	0	B-Chemical
.	9	O

Accordingly	9	O
,	9	O
the	5	O
present	9	O
,	9	O
prospective	5	O
double	9	O
-	7	O
blind	5	O
study	9	O
compares	5	O
prilocaine	0	B-Chemical
with	5	O
lidocaine	0	B-Chemical
and	5	O
bupivacaine	0	B-Chemical
with	5	O
respect	9	O
to	5	O
duration	5	O
of	5	O
action	5	O
and	5	O
relative	9	O
risk	5	O
of	5	O
TNSs	5	B-Disease
.	9	O

METHODS	2	O
:	9	O
Ninety	5	O
patients	5	O
classified	5	O
as	5	O
American	9	O
Society	2	O
of	5	O
Anesthesiologists	5	O
physical	5	O
status	9	O
I	9	O
or	5	O
II	9	O
who	5	O
were	9	O
scheduled	5	O
for	5	O
short	5	O
gynecologic	5	O
procedures	5	O
under	9	O
spinal	5	O
anesthesia	5	O
were	9	O
randomly	5	O
allocated	5	O
to	5	O
receive	5	O
2	9	O
.	9	O
5	9	O
ml	0	O
2	9	O
%	9	O
lidocaine	0	B-Chemical
in	5	O
7	9	O
.	9	O
5	9	O
%	9	O
glucose	0	B-Chemical
,	9	O
2	9	O
%	9	O
prilocaine	0	B-Chemical
in	5	O
7	9	O
.	9	O
5	9	O
%	9	O
glucose	0	B-Chemical
,	9	O
or	5	O
0	7	O
.	9	O
5	9	O
%	9	O
bupivacaine	0	B-Chemical
in	5	O
7	9	O
.	9	O
5	9	O
%	9	O
glucose	0	B-Chemical
.	9	O

All	9	O
solutions	0	O
were	9	O
provided	9	O
in	5	O
blinded	5	O
vials	0	O
by	9	O
the	5	O
hospital	5	O
pharmacy	5	O
.	9	O

Details	5	O
of	5	O
spinal	5	O
puncture	5	O
,	9	O
extension	9	O
and	5	O
regression	5	O
of	5	O
spinal	5	O
block	9	O
,	9	O
and	5	O
the	5	O
times	5	O
to	5	O
reach	5	O
discharge	5	O
criteria	5	O
were	9	O
noted	9	O
.	9	O

In	9	O
the	5	O
evening	5	O
of	5	O
postoperative	5	O
day	9	O
1	9	O
,	9	O
patients	5	O
were	9	O
evaluated	9	O
for	5	O
TNSs	5	B-Disease
by	9	O
a	5	O
physician	5	O
unaware	5	O
of	5	O
the	5	O
drug	5	O
administered	9	O
and	5	O
the	5	O
details	5	O
of	5	O
the	5	O
anesthetic	5	O
procedure	5	O
.	9	O

RESULTS	9	O
:	9	O
Nine	9	O
of	5	O
30	9	O
patients	5	O
receiving	9	O
lidocaine	0	B-Chemical
experienced	5	O
TNSs	5	B-Disease
,	9	O
1	9	O
of	5	O
30	9	O
patients	5	O
receiving	9	O
prilocaine	0	B-Chemical
(	9	O
P	9	O
=	7	O
0	7	O
.	9	O
03	7	O
)	9	O
had	9	O
them	5	O
,	9	O
and	5	O
none	9	O
of	5	O
30	9	O
patients	5	O
receiving	9	O
bupivacaine	0	B-Chemical
had	9	O
TNSs	5	B-Disease
.	9	O

Times	5	O
to	5	O
ambulate	5	O
and	5	O
to	5	O
void	5	O
were	9	O
similar	9	O
after	9	O
lidocaine	0	B-Chemical
and	5	O
prilocaine	0	B-Chemical
(	9	O
150	0	O
vs	7	O
.	9	O
165	7	O
min	0	O
and	5	O
238	7	O
vs	7	O
.	9	O
253	7	O
min	0	O
,	9	O
respectively	9	O
)	9	O
but	9	O
prolonged	9	O
after	9	O
bupivacaine	0	B-Chemical
(	9	O
200	0	O
and	5	O
299	7	O
min	0	O
,	9	O
respectively	9	O
;	9	O
P	9	O
<	0	O
0	7	O
.	9	O
05	7	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
Prilocaine	0	B-Chemical
may	5	O
be	5	O
preferable	5	O
to	5	O
lidocaine	0	B-Chemical
for	5	O
short	5	O
surgical	5	O
procedures	5	O
because	5	O
it	5	O
has	9	O
a	5	O
similar	9	O
duration	5	O
of	5	O
action	5	O
but	9	O
a	5	O
lower	9	O
incidence	5	O
of	5	O
TNSs	5	B-Disease
.	9	O

Suxamethonium	0	B-Chemical
-	7	O
induced	3	O
cardiac	5	B-Disease
arrest	3	I-Disease
and	5	O
death	9	B-Disease
following	9	O
5	9	O
days	9	O
of	5	O
immobilization	0	O
.	9	O

The	5	O
present	9	O
report	5	O
describes	5	O
a	5	O
case	5	O
of	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
and	5	O
subsequent	9	O
death	9	B-Disease
as	5	O
a	5	O
result	9	O
of	5	O
hyperkalaemia	5	B-Disease
following	9	O
the	5	O
use	5	O
of	5	O
suxamethonium	5	B-Chemical
in	5	O
a	5	O
23	7	O
-	7	O
year	5	O
-	7	O
old	5	O
Malawian	5	O
woman	5	O
.	9	O

Five	9	O
days	9	O
after	9	O
the	5	O
onset	5	O
of	5	O
the	5	O
symptoms	5	O
of	5	O
meningitis	5	B-Disease
,	9	O
the	5	O
patient	5	O
aspirated	9	O
stomach	9	O
contents	9	O
and	5	O
needed	5	O
endotracheal	5	O
intubation	5	O
.	9	O

Forty	9	O
seconds	5	O
after	9	O
injection	9	O
of	5	O
suxamethonium	5	B-Chemical
,	9	O
bradycardia	5	B-Disease
and	5	O
cardiac	5	B-Disease
arrest	3	I-Disease
occurred	9	O
.	9	O

Attempts	9	O
to	5	O
resuscitate	5	O
the	5	O
patient	5	O
were	9	O
not	5	O
successful	5	O
.	9	O

The	5	O
serum	9	O
level	9	O
of	5	O
potassium	0	B-Chemical
was	9	O
observed	9	O
to	5	O
be	5	O
8	9	O
.	9	O
4	9	O
mequiv	0	O
L	0	O
-	7	O
1	9	O
.	9	O

Apart	9	O
from	9	O
the	5	O
reduction	9	O
in	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
level	9	O
of	5	O
consciousness	5	O
,	9	O
there	5	O
were	9	O
no	9	O
signs	5	O
of	5	O
motor	5	O
neurone	5	O
damage	9	O
or	5	O
of	5	O
any	5	O
of	5	O
the	5	O
other	5	O
known	9	O
predisposing	5	O
conditions	9	O
for	5	O
hyperkalaemia	5	B-Disease
following	9	O
the	5	O
administration	9	O
of	5	O
suxamethonium	5	B-Chemical
.	9	O

It	5	O
is	5	O
postulated	9	O
that	5	O
her	5	O
death	9	B-Disease
was	9	O
caused	9	O
by	9	O
hypersensitivity	9	B-Disease
to	5	O
suxamethonium	5	B-Chemical
,	9	O
associated	9	O
with	5	O
her	5	O
5	9	O
-	7	O
day	9	O
immobilization	0	O
.	9	O

Acute	5	O
hepatitis	9	B-Disease
,	9	O
autoimmune	3	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
,	9	O
and	5	O
erythroblastocytopenia	_	B-Disease
induced	3	O
by	9	O
ceftriaxone	0	B-Chemical
.	9	O

An	5	O
80	9	O
-	7	O
yr	7	O
-	7	O
old	5	O
man	5	O
developed	5	O
acute	9	O
hepatitis	9	B-Disease
shortly	9	O
after	9	O
ingesting	5	O
oral	9	O
ceftriaxone	0	B-Chemical
.	9	O

Although	9	O
the	5	O
transaminases	9	O
gradually	9	O
returned	5	O
to	5	O
baseline	5	O
after	9	O
withholding	5	O
the	5	O
beta	9	B-Chemical
lactam	0	I-Chemical
antibiotic	5	O
,	9	O
there	5	O
was	9	O
a	5	O
gradual	9	O
increase	9	O
in	5	O
serum	9	O
bilirubin	0	B-Chemical
and	5	O
a	5	O
decrease	9	O
in	5	O
hemoglobin	0	O
concentration	0	O
caused	9	O
by	9	O
an	5	O
autoimmune	3	B-Disease
hemolytic	0	I-Disease
anemia	9	I-Disease
and	5	O
erythroblastocytopenia	_	B-Disease
.	9	O

These	5	O
responded	9	O
to	5	O
systemic	9	O
steroids	9	B-Chemical
and	5	O
immunoglobulins	3	O
.	9	O

Despite	5	O
the	5	O
widespread	5	O
use	5	O
of	5	O
these	5	O
agents	5	O
this	5	O
triad	9	O
of	5	O
side	5	O
effects	9	O
has	9	O
not	5	O
previously	9	O
been	9	O
reported	9	O
in	5	O
connection	5	O
with	5	O
beta	9	B-Chemical
lactam	0	I-Chemical
antibiotics	5	O
.	9	O

Thyroxine	0	B-Chemical
abuse	5	O
:	9	O
an	5	O
unusual	9	O
case	5	O
of	5	O
thyrotoxicosis	5	B-Disease
in	5	O
pregnancy	5	O
.	9	O

Eating	5	B-Disease
disorders	5	I-Disease
and	5	O
the	5	O
associated	9	O
behavioural	5	O
problems	5	O
and	5	O
drug	5	B-Disease
abuse	5	I-Disease
are	5	O
uncommon	5	O
in	5	O
pregnancy	5	O
.	9	O

When	9	O
they	5	O
do	5	O
occur	5	O
they	5	O
are	5	O
often	5	O
unrecognized	9	O
because	5	O
of	5	O
denial	5	O
but	9	O
when	5	O
significant	9	O
may	5	O
pose	5	O
a	5	O
risk	5	O
to	5	O
both	9	O
the	5	O
mother	5	O
and	5	O
her	5	O
fetus	5	O
.	9	O

This	5	O
case	5	O
illustrates	5	O
a	5	O
number	9	O
of	5	O
problems	5	O
that	5	O
may	5	O
be	5	O
encountered	5	O
in	5	O
women	5	O
with	5	O
eating	5	B-Disease
disorders	5	I-Disease
in	5	O
pregnancy	5	O
,	9	O
including	9	O
prolonged	9	O
and	5	O
recurrent	5	O
metabolic	9	O
disturbances	5	O
and	5	O
diuretic	5	O
abuse	5	O
.	9	O

In	9	O
particular	5	O
it	5	O
illustrates	5	O
the	5	O
derangements	5	O
of	5	O
thyroid	9	O
function	9	O
seen	9	O
in	5	O
pregnant	5	O
women	5	O
with	5	O
eating	5	B-Disease
disorders	5	I-Disease
and	5	O
reminds	5	O
us	5	O
that	5	O
when	5	O
a	5	O
cause	5	O
for	5	O
thyrotoxicosis	5	B-Disease
remains	9	O
obscure	5	O
,	9	O
thyroxine	0	B-Chemical
abuse	5	O
should	5	O
be	5	O
considered	5	O
and	5	O
explored	9	O
.	9	O

Repeated	5	O
trimipramine	0	B-Chemical
induces	3	O
dopamine	5	B-Chemical
D2	9	O
/	9	O
D3	9	O
and	5	O
alpha1	9	O
-	7	O
adrenergic	9	O
up	5	O
-	7	O
regulation	9	O
.	9	O

Trimipramine	7	B-Chemical
(	9	O
TRI	9	B-Chemical
)	9	O
,	9	O
which	5	O
shows	9	O
a	5	O
clinical	5	O
antidepressant	5	B-Chemical
activity	9	O
,	9	O
is	5	O
chemically	0	O
related	9	O
to	5	O
imipramine	0	B-Chemical
but	9	O
does	9	O
not	5	O
inhibit	3	O
the	5	O
reuptake	0	O
of	5	O
noradrenaline	0	B-Chemical
and	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptamine	0	I-Chemical
,	9	O
nor	9	O
does	9	O
it	5	O
induce	3	O
beta	9	O
-	7	O
adrenergic	9	O
down	9	O
-	7	O
regulation	9	O
.	9	O

The	5	O
mechanism	9	O
of	5	O
its	9	O
antidepressant	5	B-Chemical
activity	9	O
is	5	O
still	5	O
unknown	9	O
.	9	O

The	5	O
aim	5	O
of	5	O
the	5	O
present	9	O
study	9	O
was	9	O
to	5	O
find	5	O
out	9	O
whether	9	O
TRI	9	B-Chemical
given	5	O
repeatedly	5	O
was	9	O
able	9	O
to	5	O
induce	3	O
adaptive	5	O
changes	9	O
in	5	O
the	5	O
dopaminergic	5	O
and	5	O
alpha1	9	O
-	7	O
adrenergic	9	O
systems	5	O
,	9	O
demonstrated	9	O
by	9	O
us	5	O
previously	9	O
for	5	O
various	9	O
antidepressants	5	B-Chemical
.	9	O

TRI	9	B-Chemical
was	9	O
given	5	O
to	5	O
male	9	O
Wistar	9	O
rats	9	O
and	5	O
male	9	O
Albino	2	O
Swiss	2	O
mice	3	O
perorally	0	O
twice	9	O
daily	5	O
for	5	O
14	7	O
days	9	O
.	9	O

In	9	O
the	5	O
acute	9	O
experiment	9	O
TRI	9	B-Chemical
(	9	O
given	5	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
does	9	O
not	5	O
antagonize	3	O
the	5	O
reserpine	0	B-Chemical
hypothermia	5	B-Disease
in	5	O
mice	3	O
and	5	O
does	9	O
not	5	O
potentiate	3	O
the	5	O
5	9	B-Chemical
-	7	I-Chemical
hydroxytryptophan	0	I-Chemical
head	5	O
twitches	5	O
in	5	O
rats	9	O
.	9	O

TRI	9	B-Chemical
given	5	O
repeatedly	5	O
to	5	O
rats	9	O
increases	9	O
the	5	O
locomotor	5	O
hyperactivity	5	B-Disease
induced	3	O
by	9	O
d	9	B-Chemical
-	7	I-Chemical
amphetamine	5	I-Chemical
,	9	O
quinpirole	3	B-Chemical
and	5	O
(	9	O
+	9	O
)	9	O
-	7	O
7	9	O
-	7	O
hydroxy	0	O
-	7	O
dipropyloaminotetralin	_	O
(	9	O
dopamine	5	B-Chemical
D2	9	O
and	5	O
D3	9	O
effects	9	O
)	9	O
.	9	O

The	5	O
stereotypies	5	O
induced	3	O
by	9	O
d	9	B-Chemical
-	7	I-Chemical
amphetamine	5	I-Chemical
or	5	O
apomorphine	0	B-Chemical
are	5	O
not	5	O
potentiated	3	O
by	9	O
TRI	9	B-Chemical
.	9	O

It	5	O
increases	9	O
the	5	O
behaviour	5	O
stimulation	3	O
evoked	5	O
by	9	O
phenylephrine	0	B-Chemical
(	9	O
given	5	O
intraventricularly	3	O
)	9	O
in	5	O
rats	9	O
,	9	O
evaluated	9	O
in	5	O
the	5	O
open	5	O
field	5	O
test	5	O
as	5	O
well	9	O
as	5	O
the	5	O
aggressiveness	5	B-Disease
evoked	5	O
by	9	O
clonidine	0	B-Chemical
in	5	O
mice	3	O
,	9	O
both	9	O
these	5	O
effects	9	O
being	5	O
mediated	3	O
by	9	O
an	5	O
alpha1	9	O
-	7	O
adrenergic	9	O
receptor	3	O
.	9	O

It	5	O
may	5	O
be	5	O
concluded	9	O
that	5	O
,	9	O
like	9	O
other	5	O
tricyclic	0	O
antidepressants	5	B-Chemical
studied	9	O
previously	9	O
,	9	O
TRI	9	B-Chemical
given	5	O
repeatedly	5	O
increases	9	O
the	5	O
responsiveness	9	O
of	5	O
brain	5	O
dopamine	5	B-Chemical
D2	9	O
and	5	O
D3	9	O
(	9	O
locomotor	5	O
activity	9	O
but	9	O
not	5	O
stereotypy	5	O
)	9	O
as	5	O
well	9	O
as	5	O
alpha1	9	O
-	7	O
adrenergic	9	O
receptors	3	O
to	5	O
their	5	O
agonists	3	O
.	9	O

A	9	O
question	5	O
arises	5	O
whether	9	O
the	5	O
reuptake	0	O
inhibition	3	O
is	5	O
of	5	O
any	5	O
importance	5	O
to	5	O
the	5	O
adaptive	5	O
changes	9	O
induced	3	O
by	9	O
repeated	5	O
antidepressants	5	B-Chemical
,	9	O
suggested	9	O
to	5	O
be	5	O
responsible	9	O
for	5	O
the	5	O
antidepressant	5	B-Chemical
activity	9	O
.	9	O

Pethidine	0	B-Chemical
-	7	O
associated	9	O
seizure	5	B-Disease
in	5	O
a	5	O
healthy	5	O
adolescent	5	O
receiving	9	O
pethidine	5	B-Chemical
for	5	O
postoperative	5	B-Disease
pain	5	I-Disease
control	9	O
.	9	O

A	9	O
healthy	5	O
17	7	O
-	7	O
year	5	O
-	7	O
old	5	O
male	9	O
received	9	O
standard	5	O
intermittent	5	O
doses	0	O
of	5	O
pethidine	5	B-Chemical
via	9	O
a	5	O
patient	5	O
-	7	O
controlled	5	O
analgesia	5	O
(	9	O
PCA	5	O
)	9	O
pump	0	O
for	5	O
management	5	O
of	5	O
postoperative	5	B-Disease
pain	5	I-Disease
control	9	O
.	9	O

Twenty	9	O
-	7	O
three	9	O
h	0	O
postoperatively	5	O
he	5	O
developed	5	O
a	5	O
brief	5	O
self	5	O
-	7	O
limited	5	O
seizure	5	B-Disease
.	9	O

Both	9	O
plasma	9	O
pethidine	5	B-Chemical
and	5	O
norpethidine	0	B-Chemical
were	9	O
elevated	9	O
in	5	O
the	5	O
range	9	O
associated	9	O
with	5	O
clinical	5	O
manifestations	5	O
of	5	O
central	5	O
nervous	5	O
system	5	O
excitation	0	O
.	9	O

No	9	O
other	5	O
risk	5	O
factors	9	O
for	5	O
CNS	9	O
toxicity	9	B-Disease
were	9	O
identified	9	O
.	9	O

This	5	O
method	5	O
allowed	9	O
frequent	5	O
self	5	O
-	7	O
dosing	9	O
of	5	O
pethidine	5	B-Chemical
at	9	O
short	5	O
time	5	O
intervals	5	O
and	5	O
rapid	5	O
accumulation	9	O
of	5	O
pethidine	5	B-Chemical
and	5	O
norpethidine	0	B-Chemical
.	9	O

The	5	O
routine	5	O
use	5	O
of	5	O
pethidine	5	B-Chemical
via	9	O
PCA	5	O
even	5	O
for	5	O
a	5	O
brief	5	O
postoperative	5	O
analgesia	5	O
should	5	O
be	5	O
reconsidered	5	O
.	9	O

An	5	O
unusual	9	O
toxic	0	O
reaction	9	O
to	5	O
axillary	5	O
block	9	O
by	9	O
mepivacaine	0	B-Chemical
with	5	O
adrenaline	0	B-Chemical
.	9	O

An	5	O
increase	9	B-Disease
in	5	I-Disease
blood	9	I-Disease
pressure	5	I-Disease
,	9	O
accompanied	9	O
by	9	O
atrial	5	B-Disease
fibrillation	5	I-Disease
,	9	O
agitation	5	B-Disease
,	9	O
incomprehensible	5	B-Disease
shouts	5	I-Disease
and	5	O
loss	9	B-Disease
of	5	I-Disease
consciousness	5	I-Disease
,	9	O
was	9	O
observed	9	O
in	5	O
an	5	O
elderly	5	O
,	9	O
ASA	9	O
classification	5	O
group	9	O
II	9	O
,	9	O
cardiovascularly	5	O
medicated	5	O
male	9	O
,	9	O
12	9	O
min	0	O
after	9	O
performance	5	O
of	5	O
axillary	5	O
block	9	O
with	5	O
mepivacaine	0	B-Chemical
850	9	O
mg	0	O
containing	0	O
adrenaline	0	B-Chemical
0	7	O
.	9	O
225	9	O
mg	0	O
,	9	O
for	5	O
correction	5	O
of	5	O
Dupuytren	5	B-Disease
'	9	I-Disease
s	9	I-Disease
contracture	5	I-Disease
.	9	O

After	9	O
intravenous	0	O
administration	9	O
of	5	O
labetalol	0	B-Chemical
,	9	O
metoprolol	0	B-Chemical
and	5	O
midazolam	0	B-Chemical
the	5	O
patient	5	O
'	9	O
s	9	O
condition	5	O
improved	5	O
,	9	O
and	5	O
15	9	O
min	0	O
later	9	O
he	5	O
woke	5	O
up	5	O
.	9	O

The	5	O
block	9	O
was	9	O
successful	5	O
and	5	O
surgery	5	O
was	9	O
conducted	9	O
as	5	O
scheduled	5	O
despite	9	O
persisting	9	O
atrial	5	B-Disease
fibrillation	5	I-Disease
.	9	O

Postoperatively	5	O
,	9	O
the	5	O
patient	5	O
refused	5	O
DC	3	O
cardioversion	5	O
and	5	O
was	9	O
treated	3	O
medically	5	O
.	9	O

Both	9	O
the	5	O
temporal	5	O
relationship	5	O
of	5	O
events	5	O
and	5	O
the	5	O
response	9	O
to	5	O
treatment	9	O
suggest	9	O
that	5	O
a	5	O
rapid	5	O
systemic	9	O
absorption	0	O
of	5	O
mepivacaine	0	B-Chemical
with	5	O
adrenaline	0	B-Chemical
and	5	O
/	9	O
or	5	O
interaction	9	O
of	5	O
these	5	O
drugs	5	O
with	5	O
the	5	O
patient	5	O
'	9	O
s	9	O
cardiovascular	5	O
medications	5	O
were	9	O
responsible	9	O
for	5	O
the	5	O
perioperative	5	O
complications	5	O
.	9	O

Drug	5	O
-	7	O
associated	9	O
acute	9	O
-	7	O
onset	5	O
vanishing	5	B-Disease
bile	0	I-Disease
duct	5	I-Disease
and	5	O
Stevens	6	B-Disease
-	7	I-Disease
Johnson	6	I-Disease
syndromes	5	I-Disease
in	5	O
a	5	O
child	5	O
.	9	O

Acute	5	O
vanishing	5	B-Disease
bile	0	I-Disease
duct	5	I-Disease
syndrome	5	O
is	5	O
a	5	O
rare	5	O
but	9	O
established	9	O
cause	5	O
of	5	O
progressive	5	O
cholestasis	5	B-Disease
in	5	O
adults	5	O
,	9	O
is	5	O
most	9	O
often	5	O
drug	5	O
or	5	O
toxin	1	O
related	9	O
,	9	O
and	5	O
is	5	O
of	5	O
unknown	9	O
pathogenesis	9	O
.	9	O

It	5	O
has	9	O
not	5	O
been	9	O
reported	9	O
previously	9	O
in	5	O
children	5	O
.	9	O

Stevens	6	B-Disease
-	7	I-Disease
Johnson	6	I-Disease
syndrome	5	I-Disease
is	5	O
a	5	O
well	9	O
-	7	O
recognized	9	O
immune	3	O
complex	9	O
-	7	O
mediated	3	O
hypersensitivity	9	B-Disease
reaction	9	O
that	5	O
affects	9	O
all	5	O
age	5	O
groups	9	O
,	9	O
is	5	O
drug	5	O
or	5	O
infection	9	B-Disease
induced	3	O
,	9	O
and	5	O
has	9	O
classic	5	O
systemic	9	O
,	9	O
mucosal	9	O
,	9	O
and	5	O
dermatologic	5	O
manifestations	5	O
.	9	O

A	9	O
previously	9	O
healthy	5	O
child	5	O
who	5	O
developed	5	O
acute	9	O
,	9	O
severe	5	O
,	9	O
rapidly	9	O
progressive	5	O
vanishing	5	B-Disease
bile	0	I-Disease
duct	5	I-Disease
syndrome	5	I-Disease
shortly	9	O
after	9	O
Stevens	6	B-Disease
-	7	I-Disease
Johnson	6	I-Disease
syndrome	5	I-Disease
is	5	O
described	9	O
;	9	O
this	5	O
was	9	O
temporally	5	O
associated	9	O
with	5	O
ibuprofen	0	B-Chemical
use	5	O
.	9	O

Despite	5	O
therapy	5	O
with	5	O
ursodeoxycholic	0	B-Chemical
acid	0	I-Chemical
,	9	O
prednisone	0	B-Chemical
,	9	O
and	5	O
then	9	O
tacrolimus	0	B-Chemical
,	9	O
her	5	O
cholestatic	5	B-Disease
disease	5	I-Disease
was	9	O
unrelenting	5	O
,	9	O
with	5	O
cirrhosis	5	B-Disease
shown	9	O
by	9	O
biopsy	5	O
6	9	O
months	5	O
after	9	O
presentation	5	O
.	9	O

This	5	O
case	5	O
documents	5	O
acute	9	O
drug	5	O
-	7	O
related	9	O
vanishing	5	B-Disease
bile	0	I-Disease
duct	5	I-Disease
syndrome	5	I-Disease
in	5	O
the	5	O
pediatric	5	O
age	5	O
group	9	O
and	5	O
suggests	9	O
shared	5	O
immune	3	O
mechanisms	9	O
in	5	O
the	5	O
pathogenesis	9	O
of	5	O
both	9	O
Stevens	6	B-Disease
-	7	I-Disease
Johnson	6	I-Disease
syndrome	5	I-Disease
and	5	O
vanishing	5	B-Disease
bile	0	I-Disease
duct	5	I-Disease
syndrome	5	I-Disease
.	9	O

High	9	O
incidence	5	O
of	5	O
primary	9	B-Disease
pulmonary	5	I-Disease
hypertension	5	I-Disease
associated	9	O
with	5	O
appetite	5	B-Chemical
suppressants	5	I-Chemical
in	5	O
Belgium	2	O
.	9	O

Primary	9	B-Disease
pulmonary	5	I-Disease
hypertension	5	I-Disease
is	5	O
a	5	O
rare	5	O
,	9	O
progressive	5	O
and	5	O
incurable	5	O
disease	5	O
,	9	O
which	5	O
has	9	O
been	9	O
associated	9	O
with	5	O
the	5	O
intake	5	O
of	5	O
appetite	5	B-Chemical
suppressant	5	I-Chemical
drugs	5	O
.	9	O

The	5	O
importance	5	O
of	5	O
this	5	O
association	9	O
was	9	O
evaluated	9	O
in	5	O
Belgium	2	O
while	9	O
this	5	O
country	5	O
still	5	O
had	9	O
no	9	O
restriction	9	O
on	5	O
the	5	O
prescription	5	O
of	5	O
appetite	5	B-Chemical
suppressants	5	I-Chemical
.	9	O

Thirty	9	O
-	7	O
five	9	O
patients	5	O
with	5	O
primary	9	B-Disease
pulmonary	5	I-Disease
hypertension	5	I-Disease
and	5	O
85	9	O
matched	9	O
controls	9	O
were	9	O
recruited	9	O
over	5	O
32	7	O
months	5	O
(	9	O
1992	2	O
-	7	O
1994	2	O
)	9	O
in	5	O
Belgium	2	O
.	9	O

Exposure	9	O
to	5	O
appetite	5	B-Chemical
-	7	I-Chemical
suppressants	5	I-Chemical
was	9	O
assessed	9	O
on	5	O
the	5	O
basis	5	O
of	5	O
hospital	5	O
records	5	O
and	5	O
standardized	5	O
interview	5	O
.	9	O

Twenty	9	O
-	7	O
three	9	O
of	5	O
the	5	O
patients	5	O
had	9	O
previously	9	O
taken	5	O
appetite	5	B-Chemical
suppressants	5	I-Chemical
,	9	O
mainly	9	O
fenfluramines	5	B-Chemical
,	9	O
as	5	O
compared	9	O
with	5	O
only	9	O
5	9	O
of	5	O
the	5	O
controls	9	O
(	9	O
66	7	O
versus	9	O
6	9	O
%	9	O
,	9	O
p	7	O
<	0	O
0	7	O
.	9	O
0001	7	O
)	9	O
.	9	O

Five	9	O
patients	5	O
died	9	O
before	9	O
the	5	O
interview	5	O
,	9	O
all	5	O
of	5	O
them	5	O
had	9	O
taken	5	O
appetite	5	B-Chemical
suppressants	5	I-Chemical
.	9	O

In	9	O
8	9	O
patients	5	O
the	5	O
diagnosis	5	O
of	5	O
primary	9	B-Disease
pulmonary	5	I-Disease
hypertension	5	I-Disease
was	9	O
uncertain	5	O
,	9	O
5	9	O
of	5	O
them	5	O
had	9	O
taken	5	O
appetite	5	B-Chemical
suppressants	5	I-Chemical
.	9	O

The	5	O
patients	5	O
who	5	O
had	9	O
been	9	O
exposed	9	O
to	5	O
appetite	5	B-Chemical
suppressants	5	I-Chemical
tended	5	O
to	5	O
be	5	O
on	5	O
average	5	O
more	5	O
severely	9	O
ill	5	O
,	9	O
and	5	O
to	5	O
have	5	O
a	5	O
shorter	9	O
median	9	O
delay	5	O
between	5	O
onset	5	O
of	5	O
symptoms	5	O
and	5	O
diagnosis	5	O
.	9	O

A	9	O
policy	5	O
of	5	O
unrestricted	5	O
prescription	5	O
of	5	O
appetite	5	B-Chemical
suppressants	5	I-Chemical
may	5	O
lead	5	O
to	5	O
a	5	O
high	9	O
incidence	5	O
of	5	O
associated	9	O
primary	9	B-Disease
pulmonary	5	I-Disease
hypertension	5	I-Disease
.	9	O

Intake	5	O
of	5	O
appetite	5	B-Chemical
suppressants	5	I-Chemical
may	5	O
accelerate	9	O
the	5	O
progression	9	O
of	5	O
the	5	O
disease	5	O
.	9	O

Inappropriate	5	O
use	5	O
of	5	O
carbamazepine	0	B-Chemical
and	5	O
vigabatrin	0	B-Chemical
in	5	O
typical	9	O
absence	3	B-Disease
seizures	5	I-Disease
.	9	O

Carbamazepine	0	B-Chemical
and	5	O
vigabatrin	0	B-Chemical
are	5	O
contraindicated	5	O
in	5	O
typical	9	O
absence	3	B-Disease
seizures	5	I-Disease
.	9	O

Of	9	O
18	7	O
consecutive	5	O
referrals	5	O
of	5	O
children	5	O
with	5	O
resistant	9	O
typical	9	O
absences	5	O
only	9	O
,	9	O
eight	9	O
were	9	O
erroneously	5	O
treated	3	O
with	5	O
carbamazepine	0	B-Chemical
either	9	O
as	5	O
monotherapy	5	O
or	5	O
as	5	O
an	5	O
add	5	O
-	7	O
on	5	O
.	9	O

Vigabatrin	0	B-Chemical
was	9	O
also	9	O
used	5	O
in	5	O
the	5	O
treatment	9	O
of	5	O
two	5	O
children	5	O
.	9	O

Frequency	5	O
of	5	O
absences	5	O
increased	9	O
in	5	O
four	9	O
children	5	O
treated	3	O
with	5	O
carbamazepine	0	B-Chemical
and	5	O
two	5	O
of	5	O
these	5	O
developed	5	O
myoclonic	5	B-Disease
jerks	5	I-Disease
,	9	O
which	5	O
resolved	9	O
on	5	O
withdrawal	5	O
of	5	O
carbamazepine	0	B-Chemical
.	9	O

Absences	5	O
were	9	O
aggravated	9	O
in	5	O
both	9	O
cases	5	O
where	5	O
vigabatrin	0	B-Chemical
was	9	O
added	0	O
on	5	O
to	5	O
concurrent	5	O
treatment	9	O
.	9	O

Optimal	5	O
control	9	O
of	5	O
the	5	O
absences	5	O
was	9	O
achieved	5	O
with	5	O
sodium	0	B-Chemical
valproate	0	I-Chemical
,	9	O
lamotrigine	0	B-Chemical
,	9	O
or	5	O
ethosuximide	0	B-Chemical
alone	9	O
or	5	O
in	5	O
combination	9	O
.	9	O

Choreoathetoid	5	B-Disease
movements	5	I-Disease
associated	9	O
with	5	O
rapid	5	O
adjustment	5	O
to	5	O
methadone	5	B-Chemical
.	9	O

Choreatiform	_	B-Disease
hyperkinesias	5	I-Disease
are	5	O
known	9	O
to	5	O
be	5	O
occasional	5	O
movement	5	B-Disease
abnormalities	9	I-Disease
during	5	O
intoxications	5	O
with	5	O
cocaine	5	B-Chemical
but	9	O
not	5	O
opiates	5	O
.	9	O

This	5	O
is	5	O
a	5	O
case	5	O
report	5	O
of	5	O
euphoria	5	O
and	5	O
choreoathetoid	5	B-Disease
movements	5	I-Disease
both	9	O
transiently	3	O
induced	3	O
by	9	O
rapid	5	O
adjustment	5	O
to	5	O
the	5	O
selective	9	O
mu	9	O
-	7	O
opioid	5	O
receptor	3	O
agonist	3	O
methadone	5	B-Chemical
in	5	O
an	5	O
inpatient	5	O
previously	9	O
abusing	5	O
heroine	5	B-Chemical
and	5	O
cocaine	5	B-Chemical
.	9	O

In	9	O
addition	9	O
,	9	O
minor	9	O
EEG	5	O
abnormalities	9	O
occurred	9	O
.	9	O

Possible	9	O
underlying	5	O
neurobiological	5	O
phenomena	5	O
are	5	O
discussed	5	O
.	9	O

Adverse	5	O
effects	9	O
of	5	O
the	5	O
atypical	5	O
antipsychotics	5	O
.	9	O

Collaborative	2	O
Working	5	O
Group	9	O
on	5	O
Clinical	5	O
Trial	5	O
Evaluations	5	O
.	9	O

Adverse	5	O
effects	9	O
of	5	O
antipsychotics	5	O
often	5	O
lead	5	O
to	5	O
noncompliance	5	O
.	9	O

Thus	9	O
,	9	O
clinicians	5	O
should	5	O
address	5	O
patients	5	O
'	9	O
concerns	5	O
about	5	O
adverse	5	O
effects	9	O
and	5	O
attempt	5	O
to	5	O
choose	5	O
medications	5	O
that	5	O
will	5	O
improve	5	O
their	5	O
patients	5	O
'	9	O
quality	5	O
of	5	O
life	5	O
as	5	O
well	9	O
as	5	O
overall	5	O
health	5	O
.	9	O

The	5	O
side	5	O
effect	9	O
profiles	9	O
of	5	O
the	5	O
atypical	5	O
antipsychotics	5	O
are	5	O
more	5	O
advantageous	5	O
than	5	O
those	5	O
of	5	O
the	5	O
conventional	5	O
neuroleptics	5	O
.	9	O

Conventional	5	O
agents	5	O
are	5	O
associated	9	O
with	5	O
unwanted	5	O
central	5	O
nervous	5	O
system	5	O
effects	9	O
,	9	O
including	9	O
extrapyramidal	5	B-Disease
symptoms	5	I-Disease
(	9	O
EPS	9	B-Disease
)	9	O
,	9	O
tardive	5	B-Disease
dyskinesia	5	I-Disease
,	9	O
sedation	5	O
,	9	O
and	5	O
possible	5	O
impairment	5	O
of	5	O
some	5	O
cognitive	5	O
measures	5	O
,	9	O
as	5	O
well	9	O
as	5	O
cardiac	5	O
effects	9	O
,	9	O
orthostatic	5	B-Disease
hypotension	5	I-Disease
,	9	O
hepatic	9	O
changes	9	O
,	9	O
anticholinergic	5	O
side	5	O
effects	9	O
,	9	O
sexual	5	B-Disease
dysfunction	9	I-Disease
,	9	O
and	5	O
weight	9	B-Disease
gain	5	I-Disease
.	9	O

The	5	O
newer	5	O
atypical	5	O
agents	5	O
have	5	O
a	5	O
lower	9	O
risk	5	O
of	5	O
EPS	9	B-Disease
,	9	O
but	9	O
are	5	O
associated	9	O
in	5	O
varying	5	O
degrees	5	O
with	5	O
sedation	5	O
,	9	O
cardiovascular	5	O
effects	9	O
,	9	O
anticholinergic	5	O
effects	9	O
,	9	O
weight	9	B-Disease
gain	5	I-Disease
,	9	O
sexual	5	B-Disease
dysfunction	9	I-Disease
,	9	O
hepatic	9	O
effects	9	O
,	9	O
lowered	9	O
seizure	5	B-Disease
threshold	5	O
(	9	O
primarily	9	O
clozapine	5	B-Chemical
)	9	O
,	9	O
and	5	O
agranulocytosis	5	B-Disease
(	9	O
clozapine	5	B-Chemical
only	9	O
)	9	O
.	9	O

Since	9	O
the	5	O
incidence	5	O
and	5	O
severity	5	O
of	5	O
specific	9	O
adverse	5	O
effects	9	O
differ	9	O
among	5	O
the	5	O
various	9	O
atypicals	5	O
,	9	O
the	5	O
clinician	5	O
should	5	O
carefully	5	O
consider	5	O
which	5	O
side	5	O
effects	9	O
are	5	O
most	9	O
likely	5	O
to	5	O
lead	5	O
to	5	O
the	5	O
individual	5	O
'	9	O
s	9	O
dissatisfaction	5	O
and	5	O
noncompliance	5	O
before	9	O
choosing	5	O
an	5	O
antipsychotic	5	O
for	5	O
a	5	O
particular	5	O
patient	5	O
.	9	O

A	9	O
randomized	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
dose	9	O
-	7	O
comparison	9	O
trial	5	O
of	5	O
haloperidol	5	B-Chemical
for	5	O
psychosis	5	B-Disease
and	5	O
disruptive	5	B-Disease
behaviors	5	I-Disease
in	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

OBJECTIVE	2	O
:	9	O
The	5	O
goal	5	O
of	5	O
this	5	O
study	9	O
was	9	O
to	5	O
compare	9	O
the	5	O
efficacy	9	O
and	5	O
side	5	O
effects	9	O
of	5	O
two	5	O
doses	0	O
of	5	O
haloperidol	5	B-Chemical
and	5	O
placebo	9	O
in	5	O
the	5	O
treatment	9	O
of	5	O
psychosis	5	B-Disease
and	5	O
disruptive	5	B-Disease
behaviors	5	I-Disease
in	5	O
patients	5	O
with	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

METHOD	2	O
:	9	O
In	9	O
a	5	O
6	9	O
-	7	O
week	9	O
random	5	O
-	7	O
assignment	5	O
,	9	O
double	9	O
-	7	O
blind	5	O
,	9	O
placebo	9	O
-	7	O
controlled	5	O
trial	5	O
(	9	O
phase	5	O
A	9	O
)	9	O
,	9	O
haloperidol	5	B-Chemical
,	9	O
2	9	O
-	7	O
3	9	O
mg	0	O
/	9	O
day	9	O
(	9	O
standard	5	O
dose	9	O
)	9	O
,	9	O
and	5	O
haloperidol	5	B-Chemical
,	9	O
0	7	O
.	9	O
50	0	O
-	7	O
0	7	O
.	9	O
75	9	O
mg	0	O
/	9	O
day	9	O
(	9	O
low	9	O
dose	9	O
)	9	O
,	9	O
were	9	O
compared	9	O
in	5	O
71	7	O
outpatients	5	O
with	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
.	9	O

For	9	O
the	5	O
subsequent	9	O
6	9	O
-	7	O
week	9	O
double	9	O
-	7	O
blind	5	O
crossover	5	O
phase	5	O
(	9	O
phase	5	O
B	9	O
)	9	O
,	9	O
patients	5	O
taking	5	O
standard	5	O
-	7	O
or	5	O
low	9	O
-	7	O
dose	9	O
haloperidol	5	B-Chemical
were	9	O
switched	9	O
to	5	O
placebo	9	O
,	9	O
and	5	O
patients	5	O
taking	5	O
placebo	9	O
were	9	O
randomly	5	O
assigned	5	O
to	5	O
standard	5	O
-	7	O
or	5	O
low	9	O
-	7	O
dose	9	O
haloperidol	5	B-Chemical
.	9	O

RESULTS	9	O
:	9	O
For	9	O
the	5	O
60	9	O
patients	5	O
who	5	O
completed	5	O
phase	5	O
A	9	O
,	9	O
standard	5	O
-	7	O
dose	9	O
haloperidol	5	B-Chemical
was	9	O
efficacious	5	O
and	5	O
superior	5	O
to	5	O
both	9	O
low	9	O
-	7	O
dose	9	O
haloperidol	5	B-Chemical
and	5	O
placebo	9	O
for	5	O
scores	5	O
on	5	O
the	5	O
Brief	5	O
Psychiatric	5	O
Rating	5	O
Scale	5	O
psychosis	5	B-Disease
factor	9	O
and	5	O
on	5	O
psychomotor	5	B-Disease
agitation	5	I-Disease
.	9	O

Response	5	O
rates	5	O
according	9	O
to	5	O
three	9	O
sets	5	O
of	5	O
criteria	5	O
were	9	O
greater	5	O
with	5	O
the	5	O
standard	5	O
dose	9	O
(	9	O
55	7	O
%	9	O
-	7	O
60	9	O
%	9	O
)	9	O
than	5	O
the	5	O
low	9	O
dose	9	O
(	9	O
25	9	O
%	9	O
-	7	O
35	9	O
%	9	O
)	9	O
and	5	O
placebo	9	O
(	9	O
25	9	O
%	9	O
-	7	O
30	9	O
%	9	O
)	9	O
.	9	O

The	5	O
advantage	5	O
of	5	O
standard	5	O
dose	9	O
over	5	O
low	9	O
dose	9	O
was	9	O
replicated	9	O
in	5	O
phase	5	O
B	9	O
.	9	O

In	9	O
phase	5	O
A	9	O
,	9	O
extrapyramidal	5	B-Disease
signs	5	I-Disease
tended	5	O
to	5	O
be	5	O
greater	5	O
with	5	O
the	5	O
standard	5	O
dose	9	O
than	5	O
in	5	O
the	5	O
other	5	O
two	5	O
conditions	9	O
,	9	O
primarily	9	O
because	5	O
of	5	O
a	5	O
subgroup	9	O
(	9	O
20	9	O
%	9	O
)	9	O
who	5	O
developed	5	O
moderate	9	O
to	5	O
severe	5	O
signs	5	O
.	9	O

Low	9	O
-	7	O
dose	9	O
haloperidol	5	B-Chemical
did	9	O
not	5	O
differ	9	O
from	9	O
placebo	9	O
on	5	O
any	5	O
measure	5	O
of	5	O
efficacy	9	O
or	5	O
side	5	O
effects	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
The	5	O
results	9	O
indicated	9	O
a	5	O
favorable	5	O
therapeutic	5	O
profile	9	O
for	5	O
haloperidol	5	B-Chemical
in	5	O
doses	0	O
of	5	O
2	9	O
-	7	O
3	9	O
mg	0	O
/	9	O
day	9	O
,	9	O
although	9	O
a	5	O
subgroup	9	O
developed	5	O
moderate	9	O
to	5	O
severe	5	O
extrapyramidal	5	B-Disease
signs	5	I-Disease
.	9	O

A	9	O
starting	9	O
dose	9	O
of	5	O
1	9	O
mg	0	O
/	9	O
day	9	O
with	5	O
gradual	9	O
,	9	O
upward	5	O
dose	9	O
titration	0	O
is	5	O
recommended	5	O
.	9	O

The	5	O
narrow	5	O
therapeutic	5	O
window	5	O
observed	9	O
with	5	O
haloperidol	5	B-Chemical
may	5	O
also	9	O
apply	5	O
to	5	O
other	5	O
neuroleptics	5	O
used	5	O
in	5	O
Alzheimer	5	B-Disease
'	9	I-Disease
s	9	I-Disease
disease	5	I-Disease
patients	5	O
with	5	O
psychosis	5	B-Disease
and	5	O
disruptive	5	B-Disease
behaviors	5	I-Disease
.	9	O

Effects	9	O
of	5	O
acetylsalicylic	0	B-Chemical
acid	0	I-Chemical
,	9	O
dipyridamole	0	B-Chemical
,	9	O
and	5	O
hydrocortisone	0	B-Chemical
on	5	O
epinephrine	0	B-Chemical
-	7	O
induced	3	O
myocardial	9	B-Disease
injury	9	I-Disease
in	5	O
dogs	5	O
.	9	O

A	9	O
reproducible	5	O
model	5	O
for	5	O
producing	9	O
diffuse	5	O
myocardial	9	B-Disease
injury	9	I-Disease
(	9	O
epinephrine	0	B-Chemical
infusion	0	O
)	9	O
has	9	O
been	9	O
developed	5	O
to	5	O
study	9	O
the	5	O
cardioprotective	9	O
effects	9	O
of	5	O
agents	5	O
or	5	O
maneuvers	5	O
which	5	O
might	9	O
alter	9	O
the	5	O
evolution	5	O
of	5	O
acute	9	O
myocardial	9	B-Disease
infarction	5	I-Disease
.	9	O

Infusions	0	O
of	5	O
epinephrine	0	B-Chemical
(	9	O
4	9	O
mug	5	O
per	9	O
kilogram	0	O
per	9	O
minute	5	O
for	5	O
6	9	O
hours	9	O
)	9	O
increased	9	O
radiocalcium	0	B-Chemical
uptakes	0	O
into	9	O
intact	9	O
myocardium	9	O
and	5	O
each	5	O
of	5	O
its	9	O
subcellular	3	O
components	5	O
with	5	O
the	5	O
mitochondrial	9	O
fraction	9	O
showing	9	O
the	5	O
most	9	O
consistent	9	O
changes	9	O
when	5	O
compared	9	O
to	5	O
saline	0	O
-	7	O
infused	9	O
control	9	O
animals	9	O
(	9	O
4	9	O
,	9	O
957	7	O
vs	7	O
.	9	O
827	7	O
counts	9	O
per	9	O
minute	5	O
per	9	O
gram	9	O
of	5	O
dried	0	O
tissue	9	O
or	5	O
fraction	9	O
)	9	O
.	9	O

Myocardial	9	O
concentrations	0	O
of	5	O
calcium	0	B-Chemical
also	9	O
increased	9	O
significantly	9	O
(	9	O
12	9	O
.	9	O
0	7	O
vs	7	O
.	9	O
5	9	O
.	9	O
0	7	O
mg	0	O
.	9	O
per	9	O
100	0	O
Gm	9	O
.	9	O
of	5	O
fat	9	O
-	7	O
free	9	O
dry	0	O
weight	9	O
)	9	O
.	9	O

Infusions	0	O
of	5	O
calcium	0	B-Chemical
chloride	0	I-Chemical
sufficient	9	O
to	5	O
raise	9	O
serum	9	O
calcium	0	B-Chemical
concentrations	0	O
2	9	O
mEq	0	O
.	9	O
per	9	O
liter	0	O
failed	9	O
to	5	O
increase	9	O
calcium	0	B-Chemical
influx	9	O
into	9	O
the	5	O
myocardial	9	O
cell	3	O
.	9	O

Mitochondrial	9	O
radiocalcium	0	B-Chemical
uptakes	0	O
were	9	O
significantly	9	O
decreased	9	O
in	5	O
animals	9	O
pretreated	3	O
with	5	O
acetylsalicylic	0	B-Chemical
acid	0	I-Chemical
or	5	O
dipyridamole	0	B-Chemical
or	5	O
when	5	O
hydrocortisone	0	B-Chemical
was	9	O
added	0	O
to	5	O
the	5	O
epinephrine	0	B-Chemical
infusion	0	O
(	9	O
2	9	O
,	9	O
682	7	O
,	9	O
2	9	O
,	9	O
803	7	O
,	9	O
and	5	O
3	9	O
,	9	O
424	7	O
counts	9	O
per	9	O
minute	5	O
per	9	O
gram	9	O
of	5	O
dried	0	O
fraction	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Myocardial	9	O
calcium	0	B-Chemical
concentrations	0	O
also	9	O
were	9	O
decreased	9	O
(	9	O
11	7	O
.	9	O
2	9	O
,	9	O
8	9	O
.	9	O
3	9	O
,	9	O
and	5	O
8	9	O
.	9	O
9	7	O
mg	0	O
.	9	O
per	9	O
100	0	O
Gm	9	O
.	9	O
of	5	O
fat	9	O
-	7	O
free	9	O
dry	0	O
weight	9	O
,	9	O
respectively	9	O
)	9	O
in	5	O
the	5	O
three	9	O
treatment	9	O
groups	9	O
,	9	O
being	5	O
significantly	9	O
decreased	9	O
only	9	O
in	5	O
the	5	O
last	5	O
two	5	O
.	9	O

Evidence	9	O
of	5	O
microscopic	9	O
damage	9	O
was	9	O
graded	5	O
as	5	O
less	5	O
severe	5	O
in	5	O
the	5	O
three	9	O
treatment	9	O
groups	9	O
.	9	O

Acetylsalicylic	0	B-Chemical
acid	0	I-Chemical
,	9	O
dipyridamole	0	B-Chemical
,	9	O
and	5	O
hydrocortisone	0	B-Chemical
all	5	O
appear	9	O
to	5	O
have	5	O
cardioprotective	9	O
effects	9	O
when	5	O
tested	9	O
in	5	O
this	5	O
model	5	O
.	9	O

Clinical	5	O
and	5	O
histopathologic	9	O
examination	5	O
of	5	O
renal	9	O
allografts	5	O
treated	3	O
with	5	O
tacrolimus	0	B-Chemical
(	9	O
FK506	3	B-Chemical
)	9	O
for	5	O
at	9	O
least	9	O
one	5	O
year	5	O
.	9	O

BACKGROUND	2	O
:	9	O
We	9	O
clinically	5	O
and	5	O
pathologically	5	O
analyzed	9	O
renal	9	O
allografts	5	O
from	9	O
1	9	O
9	7	O
renal	9	O
transplant	9	O
patients	5	O
treated	3	O
with	5	O
tacrolimus	0	B-Chemical
(	9	O
FK506	3	B-Chemical
)	9	O
for	5	O
more	5	O
than	5	O
1	9	O
year	5	O
.	9	O

METHODS	2	O
:	9	O
Twenty	9	O
-	7	O
six	9	O
renal	9	O
allograft	5	O
biopsy	5	O
specimens	9	O
from	9	O
1	9	O
9	7	O
renal	9	O
transplant	9	O
patients	5	O
who	5	O
underwent	5	O
transplantations	5	O
between	5	O
1991	2	O
and	5	O
1993	2	O
were	9	O
evaluated	9	O
.	9	O

Thirteen	9	O
biopsies	9	O
were	9	O
performed	9	O
from	9	O
stable	9	O
functioning	5	O
renal	9	O
allografts	5	O
with	5	O
informed	5	O
consent	5	O
(	9	O
nonepisode	_	O
biopsy	5	O
)	9	O
and	5	O
the	5	O
other	5	O
13	7	O
were	9	O
from	9	O
dysfunctional	9	O
renal	9	O
allografts	5	O
with	5	O
a	5	O
clinical	5	O
indication	5	O
for	5	O
biopsy	5	O
(	9	O
episode	5	O
biopsy	5	O
)	9	O
.	9	O

RESULTS	9	O
:	9	O
The	5	O
main	5	O
pathologic	5	O
diagnoses	5	O
(	9	O
some	5	O
overlap	9	O
)	9	O
were	9	O
acute	9	O
rejection	5	O
(	9	O
AR	9	O
;	9	O
n	9	O
=	7	O
4	9	O
)	9	O
,	9	O
chronic	5	O
rejection	5	O
(	9	O
CR	9	O
;	9	O
n	9	O
=	7	O
5	9	O
)	9	O
,	9	O
AR	9	O
+	9	O
CR	9	O
(	9	O
n	9	O
=	7	O
4	9	O
)	9	O
,	9	O
recurrent	5	O
IgA	3	B-Disease
nephropathy	9	I-Disease
(	9	O
n	9	O
=	7	O
5	9	O
)	9	O
,	9	O
normal	9	O
findings	9	O
(	9	O
n	9	O
=	7	O
2	9	O
)	9	O
,	9	O
minimal	9	O
-	7	O
type	9	O
chronic	5	O
FK506	3	B-Chemical
nephropathy	9	B-Disease
(	9	O
n	9	O
=	7	O
9	7	O
)	9	O
,	9	O
and	5	O
mild	9	O
-	7	O
type	9	O
FK506	3	B-Chemical
nephropathy	9	B-Disease
(	9	O
n	9	O
=	7	O
11	7	O
)	9	O
.	9	O

Of	9	O
the	5	O
nonepisode	_	O
biopsies	9	O
,	9	O
7	9	O
and	5	O
4	9	O
biopsies	9	O
showed	9	O
minimal	9	O
-	7	O
type	9	O
and	5	O
mild	9	O
-	7	O
type	9	O
chronic	5	O
FK506	3	B-Chemical
nephropathy	9	B-Disease
,	9	O
respectively	9	O
.	9	O

Chronic	9	O
FK506	3	B-Chemical
nephropathy	9	B-Disease
consisted	5	O
of	5	O
rough	5	O
and	5	O
foamy	3	O
tubular	9	O
vacuolization	3	O
(	9	O
5	9	O
biopsies	9	O
)	9	O
,	9	O
arteriolopathy	5	O
(	9	O
angiodegeneration	_	O
of	5	O
the	5	O
arteriolar	5	O
wall	5	O
;	9	O
20	9	O
biopsies	9	O
)	9	O
,	9	O
focal	5	B-Disease
segmental	5	I-Disease
glomerulosclerosis	3	I-Disease
(	9	O
4	9	O
biopsies	9	O
)	9	O
and	5	O
the	5	O
striped	4	O
form	9	O
of	5	O
interstitial	9	B-Disease
fibrosis	9	I-Disease
(	9	O
11	7	O
biopsies	9	O
)	9	O
.	9	O

The	5	O
serum	9	O
creatinine	0	B-Chemical
levels	3	O
of	5	O
patients	5	O
in	5	O
the	5	O
mild	9	O
-	7	O
type	9	O
chronic	5	O
FK506	3	B-Chemical
nephropathy	9	B-Disease
group	9	O
,	9	O
which	5	O
included	5	O
7	9	O
episode	5	O
biopsies	9	O
,	9	O
were	9	O
statistically	9	O
higher	9	O
than	5	O
those	5	O
in	5	O
the	5	O
minimum	5	O
-	7	O
type	9	O
chronic	5	O
FK506	3	B-Chemical
-	7	O
nephropathy	9	B-Disease
group	9	O
(	9	O
P	9	O
<	0	O
0	7	O
.	9	O
001	9	O
)	9	O
.	9	O

CONCLUSIONS	5	O
:	9	O
This	5	O
study	9	O
demonstrates	9	O
that	5	O
chronic	5	O
FK506	3	B-Chemical
nephropathy	9	B-Disease
consists	5	O
primarily	9	O
of	5	O
arteriolopathy	5	O
manifesting	5	O
as	5	O
insudative	_	O
hyalinosis	5	O
of	5	O
the	5	O
arteriolar	5	O
wall	5	O
,	9	O
and	5	O
suggests	9	O
that	5	O
mild	9	O
-	7	O
type	9	O
chronic	5	O
FK506	3	B-Chemical
nephropathy	9	B-Disease
is	5	O
a	5	O
condition	5	O
which	5	O
may	5	O
lead	5	O
to	5	O
deterioration	5	O
of	5	O
renal	9	O
allograft	5	O
function	9	O
.	9	O

Different	9	O
lobular	5	O
distributions	5	O
of	5	O
altered	9	O
hepatocyte	3	O
tight	9	O
junctions	9	O
in	5	O
rat	3	O
models	5	O
of	5	O
intrahepatic	9	B-Disease
and	5	I-Disease
extrahepatic	5	I-Disease
cholestasis	5	I-Disease
.	9	O

Hepatocyte	3	O
tight	9	O
junctions	9	O
(	9	O
TJs	3	O
)	9	O
,	9	O
the	5	O
only	9	O
intercellular	3	O
barrier	5	O
between	5	O
the	5	O
sinusoidal	5	O
and	5	O
the	5	O
canalicular	0	O
spaces	5	O
,	9	O
play	9	O
a	5	O
key	9	O
role	9	O
in	5	O
bile	0	O
formation	9	O
.	9	O

Although	9	O
hepatocyte	3	O
TJs	3	O
are	5	O
impaired	9	O
in	5	O
cholestasis	5	B-Disease
,	9	O
attempts	5	O
to	5	O
localize	9	O
the	5	O
precise	5	O
site	9	O
of	5	O
hepatocyte	3	O
TJ	9	O
damage	9	O
by	9	O
freeze	9	O
-	7	O
fracture	5	O
electron	0	O
microscopy	9	O
have	5	O
produced	9	O
limited	5	O
information	5	O
.	9	O

Recently	9	O
,	9	O
several	9	O
TJ	9	O
-	7	O
associated	9	O
proteins	1	O
like	9	O
ZO	9	O
-	7	O
1	9	O
and	5	O
7H6	3	O
have	5	O
been	9	O
identified	9	O
and	5	O
characterized	9	O
.	9	O

Immunolocalization	3	O
of	5	O
7H6	3	O
appears	9	O
to	5	O
closely	9	O
correlate	9	O
with	5	O
paracellular	0	O
permeability	0	O
.	9	O

We	9	O
used	5	O
rat	3	O
models	5	O
of	5	O
intrahepatic	9	B-Disease
cholestasis	5	I-Disease
by	9	O
ethinyl	0	B-Chemical
estradiol	0	I-Chemical
(	9	O
EE	9	B-Chemical
)	9	O
treatment	9	O
and	5	O
extrahepatic	5	B-Disease
cholestasis	5	I-Disease
by	9	O
bile	0	O
duct	5	O
ligation	9	O
(	9	O
BDL	9	O
)	9	O
to	5	O
precisely	5	O
determine	9	O
the	5	O
site	9	O
of	5	O
TJ	9	O
damage	9	O
.	9	O

Alterations	9	O
in	5	O
hepatocyte	3	O
TJs	3	O
were	9	O
assessed	9	O
by	9	O
double	9	O
-	7	O
immunolabeling	3	O
for	5	O
7H6	3	O
and	5	O
ZO	9	O
-	7	O
1	9	O
using	9	O
a	5	O
confocal	3	O
laser	5	O
scanning	5	O
microscope	0	O
.	9	O

In	9	O
control	9	O
rats	9	O
,	9	O
immunostaining	3	O
for	5	O
7H6	3	O
and	5	O
ZO	9	O
-	7	O
1	9	O
colocalized	3	O
to	5	O
outline	5	O
bile	0	O
canaliculi	5	O
in	5	O
a	5	O
continuous	5	O
fashion	5	O
.	9	O

In	9	O
contrast	9	O
,	9	O
7H6	3	O
and	5	O
ZO	9	O
-	7	O
1	9	O
immunostaining	3	O
was	9	O
more	5	O
discontinuous	5	O
,	9	O
outlining	5	O
the	5	O
bile	0	O
canaliculi	5	O
after	9	O
BDL	9	O
.	9	O

Immunostaining	3	O
for	5	O
7H6	3	O
,	9	O
not	5	O
ZO	9	O
-	7	O
1	9	O
,	9	O
decreased	9	O
and	5	O
predominantly	9	O
appeared	9	O
as	5	O
discrete	5	O
signals	9	O
in	5	O
the	5	O
submembranous	3	O
cytoplasm	3	O
of	5	O
periportal	5	O
hepatocytes	3	O
after	9	O
BDL	9	O
.	9	O

After	9	O
EE	9	B-Chemical
treatment	9	O
,	9	O
changes	9	O
in	5	O
immunostaining	3	O
for	5	O
7H6	3	O
and	5	O
ZO	9	O
-	7	O
1	9	O
were	9	O
similar	9	O
to	5	O
those	5	O
seen	9	O
in	5	O
periportal	5	O
hepatocytes	3	O
after	9	O
BDL	9	O
,	9	O
but	9	O
distributed	5	O
more	5	O
diffusely	3	O
throughout	9	O
the	5	O
lobule	5	O
.	9	O

This	5	O
study	9	O
is	5	O
the	5	O
first	9	O
to	5	O
demonstrate	9	O
that	5	O
impairment	5	O
of	5	O
hepatocyte	3	O
TJs	3	O
occurs	9	O
heterogenously	3	O
in	5	O
the	5	O
liver	9	O
lobule	5	O
after	9	O
BDL	9	O
and	5	O
suggests	9	O
that	5	O
BDL	9	O
and	5	O
EE	9	B-Chemical
treatments	9	O
produce	9	O
different	9	O
lobular	5	O
distributions	5	O
of	5	O
increased	9	O
paracellular	0	O
permeability	0	O
.	9	O

Memory	5	O
facilitation	5	O
and	5	O
stimulation	3	O
of	5	O
endogenous	3	O
nerve	5	O
growth	3	O
factor	9	O
synthesis	9	O
by	9	O
the	5	O
acetylcholine	0	B-Chemical
releaser	0	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
.	9	O

The	5	O
effects	9	O
of	5	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
(	9	O
3alpha	1	B-Chemical
-	7	I-Chemical
tropyl	_	I-Chemical
2	9	I-Chemical
-	7	I-Chemical
(	9	I-Chemical
p	7	I-Chemical
-	7	I-Chemical
bromophenyl	0	I-Chemical
)	9	I-Chemical
propionate	0	I-Chemical
)	9	O
,	9	O
the	5	O
acetylcholine	0	B-Chemical
releaser	0	O
,	9	O
on	5	O
memory	5	O
processes	5	O
and	5	O
nerve	5	O
growth	3	O
factor	9	O
(	9	O
NGF	3	O
)	9	O
synthesis	9	O
were	9	O
evaluated	9	O
.	9	O

In	9	O
the	5	O
mouse	3	O
passive	5	O
-	7	O
avoidance	5	O
test	5	O
,	9	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
(	9	O
10	9	O
-	7	O
30	9	O
mg	0	O
/	9	O
kg	0	O
,	9	O
i	9	O
.	9	O
p	7	O
.	9	O
)	9	O
,	9	O
administered	9	O
20	9	O
min	0	O
before	9	O
the	5	O
training	5	O
session	5	O
,	9	O
prevented	9	O
amnesia	5	B-Disease
induced	3	O
by	9	O
both	9	O
the	5	O
non	9	O
selective	9	O
antimuscarinic	5	O
drug	5	O
scopolamine	0	B-Chemical
and	5	O
the	5	O
M1	9	O
-	7	O
selective	9	O
antagonist	3	O
S	9	B-Chemical
-	7	I-Chemical
(	9	I-Chemical
-	7	I-Chemical
)	9	I-Chemical
-	7	I-Chemical
ET	9	I-Chemical
-	7	I-Chemical
126	7	I-Chemical
.	9	O

In	9	O
the	5	O
same	9	O
experimental	5	O
conditions	9	O
,	9	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
(	9	O
5	9	O
-	7	O
20	9	O
microg	0	O
per	9	O
mouse	3	O
,	9	O
i	9	O
.	9	O
c	9	O
.	9	O
v	0	O
.	9	O
)	9	O
was	9	O
also	9	O
able	9	O
to	5	O
prevent	5	O
antimuscarine	_	O
-	7	O
induced	3	O
amnesia	5	B-Disease
,	9	O
demonstrating	9	O
a	5	O
central	5	O
localization	3	O
of	5	O
the	5	O
activity	9	O
.	9	O

At	9	O
the	5	O
highest	9	O
effective	5	O
doses	0	O
,	9	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
did	9	O
not	5	O
produce	9	O
any	5	O
collateral	5	O
symptoms	5	O
as	5	O
revealed	9	O
by	9	O
the	5	O
Irwin	6	O
test	5	O
,	9	O
and	5	O
it	5	O
did	9	O
not	5	O
modify	9	O
spontaneous	5	O
motility	9	O
and	5	O
inspection	5	O
activity	9	O
,	9	O
as	5	O
revealed	9	O
by	9	O
the	5	O
hole	5	O
-	7	O
board	5	O
test	5	O
.	9	O

PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
was	9	O
also	9	O
able	9	O
to	5	O
increase	9	O
the	5	O
amount	9	O
of	5	O
NGF	3	O
secreted	3	O
in	5	O
vitro	3	O
by	9	O
astrocytes	3	O
in	5	O
a	5	O
dose	9	O
-	7	O
dependent	9	O
manner	9	O
.	9	O

The	5	O
maximal	9	O
NGF	3	O
contents	9	O
obtained	9	O
by	9	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
were	9	O
17	7	O
.	9	O
6	9	O
-	7	O
fold	9	O
of	5	O
the	5	O
control	9	O
value	9	O
.	9	O

During	5	O
culture	9	O
,	9	O
no	9	O
morphological	9	O
changes	9	O
were	9	O
found	9	O
at	9	O
effective	5	O
concentrations	0	O
of	5	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
.	9	O

The	5	O
current	5	O
work	5	O
indicates	9	O
the	5	O
ability	9	O
of	5	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
to	5	O
induce	3	O
beneficial	9	O
effects	9	O
on	5	O
cognitive	5	O
processes	5	O
and	5	O
stimulate	3	O
activity	9	O
of	5	O
NGF	3	O
synthesis	9	O
in	5	O
astroglial	3	O
cells	3	O
.	9	O

Therefore	9	O
,	9	O
PG	9	B-Chemical
-	7	I-Chemical
9	7	I-Chemical
could	9	O
represent	9	O
a	5	O
potential	9	O
useful	5	O
drug	5	O
able	9	O
to	5	O
improve	5	O
the	5	O
function	9	O
of	5	O
impaired	9	O
cognitive	5	O
processes	5	O
.	9	O

Mechanisms	9	O
of	5	O
FK	9	B-Chemical
506	7	I-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
the	5	O
rat	3	O
.	9	O

-	7	O
Tacrolimus	0	B-Chemical
(	9	O
FK	9	B-Chemical
506	7	I-Chemical
)	9	O
is	5	O
a	5	O
powerful	5	O
,	9	O
widely	5	O
used	5	O
immunosuppressant	9	O
.	9	O

The	5	O
clinical	5	O
utility	5	O
of	5	O
FK	9	B-Chemical
506	7	I-Chemical
is	5	O
complicated	5	O
by	9	O
substantial	9	O
hypertension	5	B-Disease
and	5	O
nephrotoxicity	9	B-Disease
.	9	O

To	9	O
clarify	9	O
the	5	O
mechanisms	9	O
of	5	O
FK	9	B-Chemical
506	7	I-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
,	9	O
we	5	O
studied	9	O
the	5	O
chronic	5	O
effects	9	O
of	5	O
FK	9	B-Chemical
506	7	I-Chemical
on	5	O
the	5	O
synthesis	9	O
of	5	O
endothelin	3	O
-	7	O
1	9	O
(	9	O
ET	9	O
-	7	O
1	9	O
)	9	O
,	9	O
the	5	O
expression	3	O
of	5	O
mRNA	3	O
of	5	O
ET	9	O
-	7	O
1	9	O
and	5	O
endothelin	3	O
-	7	O
converting	9	O
enzyme	0	O
-	7	O
1	9	O
(	9	O
ECE	9	O
-	7	O
1	9	O
)	9	O
,	9	O
the	5	O
endothelial	3	O
nitric	0	B-Chemical
oxide	0	I-Chemical
synthase	1	O
(	9	O
eNOS	3	O
)	9	O
activity	9	O
,	9	O
and	5	O
the	5	O
expression	3	O
of	5	O
mRNA	3	O
of	5	O
eNOS	3	O
and	5	O
C	9	O
-	7	O
type	9	O
natriuretic	9	O
peptide	9	O
(	9	O
CNP	9	O
)	9	O
in	5	O
rat	3	O
blood	9	O
vessels	5	O
.	9	O

In	9	O
addition	9	O
,	9	O
the	5	O
effect	9	O
of	5	O
the	5	O
specific	9	O
endothelin	3	O
type	9	O
A	9	O
receptor	3	O
antagonist	3	O
FR	9	B-Chemical
139317	_	I-Chemical
on	5	O
FK	9	B-Chemical
506	7	I-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
rats	9	O
was	9	O
studied	9	O
.	9	O

FK	9	B-Chemical
506	7	I-Chemical
,	9	O
5	9	O
mg	0	O
.	9	O

kg	0	O
-	7	O
1	9	O
.	9	O

d	9	O
-	7	O
1	9	O
given	5	O
for	5	O
4	9	O
weeks	9	O
,	9	O
elevated	9	O
blood	9	O
pressure	5	O
from	9	O
102	7	O
+	9	O
/	9	O
-	7	O
13	7	O
to	5	O
152	7	O
+	9	O
/	9	O
-	7	O
15	9	O
mm	9	O
Hg	0	O
and	5	O
increased	9	O
the	5	O
synthesis	9	O
of	5	O
ET	9	O
-	7	O
1	9	O
and	5	O
the	5	O
levels	3	O
of	5	O
ET	9	O
-	7	O
1	9	O
mRNA	3	O
in	5	O
the	5	O
mesenteric	9	O
artery	5	O
(	9	O
240	9	O
%	9	O
and	5	O
230	9	O
%	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

Little	9	O
change	9	O
was	9	O
observed	9	O
in	5	O
the	5	O
expression	3	O
of	5	O
ECE	9	O
-	7	O
1	9	O
mRNA	3	O
and	5	O
CNP	9	O
mRNA	3	O
.	9	O

FK	9	B-Chemical
506	7	I-Chemical
decreased	9	O
eNOS	3	O
activity	9	O
and	5	O
the	5	O
levels	3	O
of	5	O
eNOS	3	O
mRNA	3	O
in	5	O
the	5	O
aorta	9	O
(	9	O
48	9	O
%	9	O
and	5	O
55	7	O
%	9	O
,	9	O
respectively	9	O
)	9	O
.	9	O

The	5	O
administration	9	O
of	5	O
FR	9	B-Chemical
139317	_	I-Chemical
(	9	O
10	9	O
mg	0	O
.	9	O
kg	0	O
-	7	O
1	9	O
.	9	O
d	9	O
-	7	O
1	9	O
)	9	O
prevented	9	O
FK	9	B-Chemical
506	7	I-Chemical
-	7	O
induced	3	O
hypertension	5	B-Disease
in	5	O
rats	9	O
.	9	O

These	5	O
results	9	O
indicate	9	O
that	5	O
FK	9	B-Chemical
506	7	I-Chemical
may	5	O
increase	9	O
blood	9	O
pressure	5	O
not	5	O
only	9	O
by	9	O
increasing	9	O
ET	9	O
-	7	O
1	9	O
production	9	O
but	9	O
also	9	O
by	9	O
decreasing	9	O
NO	9	B-Chemical
synthesis	9	O
in	5	O
the	5	O
vasculature	5	O
.	9	O

